<SEC-DOCUMENT>0001641172-25-007878.txt : 20250430
<SEC-HEADER>0001641172-25-007878.hdr.sgml : 20250430
<ACCEPTANCE-DATETIME>20250430171030
ACCESSION NUMBER:		0001641172-25-007878
CONFORMED SUBMISSION TYPE:	POS AM
PUBLIC DOCUMENT COUNT:		90
FILED AS OF DATE:		20250430
DATE AS OF CHANGE:		20250430

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Tevogen Bio Holdings Inc.
		CENTRAL INDEX KEY:			0001860871
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				981597194
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		POS AM
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-280414
		FILM NUMBER:		25897407

	BUSINESS ADDRESS:	
		STREET 1:		15 INDEPENDENCE BOULEVARD, SUITE 410
		CITY:			WARREN
		STATE:			NJ
		ZIP:			07059
		BUSINESS PHONE:		646-807-8832

	MAIL ADDRESS:	
		STREET 1:		15 INDEPENDENCE BOULEVARD, SUITE 410
		CITY:			WARREN
		STATE:			NJ
		ZIP:			07059

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Semper Paratus Acquisition Corp
		DATE OF NAME CHANGE:	20210505
</SEC-HEADER>
<DOCUMENT>
<TYPE>POS AM
<SEQUENCE>1
<FILENAME>formposam.htm
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:TVGN="http://tevogen.com/20241231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_030_TVGN_tevogen.com_20241231 -->
<!-- Field: Set; Name: xdx; ID: xdx_04C_20240101_20241231 -->
<!-- Field: Set; Name: xdx; ID: xdx_055_edei%2D%2DAmendmentFlag_true -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DEntityCentralIndexKey_0001860871 -->
<!-- Field: Set; Name: xdx; ID: xdx_073_XDX_formposam.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_061_Integer_0_Integer -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_Segment_0_Segment -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000003" name="dei:AmendmentFlag">true</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000004" name="dei:EntityCentralIndexKey">0001860871</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0013" name="dei:DocumentType">POS AM</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:OtherReceivablesNetCurrent" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="xdx2ixbrl0054" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredCosts" contextRef="AsOf2024-12-31" id="xdx2ixbrl0065" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl0090" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2024-12-31" id="xdx2ixbrl0092" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="xdx2ixbrl0096" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConvertibleLongTermNotesPayable" contextRef="AsOf2024-12-31" id="xdx2ixbrl0101" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl0111" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0120" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0133" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0146" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0198" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0201" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:LossOnIssuanceOfCommitmentShares" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0207" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0236" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0237" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0238" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0244" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0246" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0248" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0252" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0253" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0254" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0255" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0256" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0260" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0261" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0262" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0268" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0270" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0272" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0276" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0277" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0278" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0284" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0286" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0288" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0293" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0294" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0295" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0296" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0297" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueNewIssuesTwo" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0302" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueNewIssuesTwo" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0303" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueNewIssuesTwo" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0305" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueNewIssuesTwo" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0306" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueNewIssuesTwo" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0307" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueNewIssuesOne" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0312" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueNewIssuesOne" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0314" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueNewIssuesOne" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0315" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueNewIssuesOne" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0316" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueNewIssuesOne" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0317" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0322" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0323" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0324" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0327" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:MergerNetOfRedemptionsAndTransactionCosts" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0332" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:MergerNetOfRedemptionsAndTransactionCosts" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0333" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:MergerNetOfRedemptionsAndTransactionCosts" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0334" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:MergerNetOfRedemptionsAndTransactionCosts" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0337" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0342" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0343" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0344" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0347" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0348" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0352" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0353" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0354" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0357" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0362" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0363" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0364" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0367" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0372" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0373" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0374" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0377" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0378" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueContributionFromRelatedParty" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0382" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueContributionFromRelatedParty" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0384" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueContributionFromRelatedParty" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0385" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueContributionFromRelatedParty" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0387" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueContributionFromRelatedParty" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0388" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0392" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0393" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0394" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0395" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0397" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0400" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0401" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0402" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0405" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0406" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0410" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0411" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0412" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0413" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0415" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0418" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0419" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0420" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0421" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0422" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0427" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0436" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0443" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0452" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0471" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NoncashMergerRelatedCosts" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0477" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:LossOnPreferredStockIssuance" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0483" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:LossOnIssuanceOfCommitmentShares" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0486" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0489" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0518" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0521" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:CashAcquiredInConnectionWithReverseRecapitalization" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0528" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0531" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:ProceedsFromIssuanceOfSeriesCPreferredStock" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0534" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0537" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0540" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0542" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0545" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:ReverseRecapitalizationTransactionFeesIncludedInAccruedExpensesAndOtherLiabilities" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0563" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtConversionOriginalDebtAmount1" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0567" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:RepurchaseOfSeriesBPreferredStock" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0570" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssued1" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0573" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0630" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="AsOf2024-02-14_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" id="xdx2ixbrl0648" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="AsOf2024-02-14_us-gaap_FairValueInputsLevel3Member_us-gaap_CallOptionMember" id="xdx2ixbrl0650" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_CallOptionMember" id="xdx2ixbrl0662" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0666" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0668" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2022-12-31_custom_ServiceBasedRestrictedStockMember" id="xdx2ixbrl0938" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2022-12-31_custom_ServiceBasedRestrictedStockMember" id="xdx2ixbrl0940" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2023-01-012023-12-31_custom_ServiceBasedRestrictedStockMember" id="xdx2ixbrl0942" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31_custom_ServiceBasedRestrictedStockMember" id="xdx2ixbrl0944" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2023-01-012023-12-31_custom_ServiceBasedRestrictedStockMember" id="xdx2ixbrl0946" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31_custom_ServiceBasedRestrictedStockMember" id="xdx2ixbrl0948" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2023-01-012023-12-31_custom_ServiceBasedRestrictedStockMember" id="xdx2ixbrl0950" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31_custom_ServiceBasedRestrictedStockMember" id="xdx2ixbrl0952" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2023-12-31_custom_ServiceBasedRestrictedStockMember" id="xdx2ixbrl0954" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2023-12-31_custom_ServiceBasedRestrictedStockMember" id="xdx2ixbrl0956" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2024-01-012024-12-31_custom_ServiceBasedRestrictedStockMember" id="xdx2ixbrl0966" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-12-31_custom_ServiceBasedRestrictedStockMember" id="xdx2ixbrl0968" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2023-01-012023-12-31_custom_PerformanceBasedRSUsMember" id="xdx2ixbrl0982" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31_custom_PerformanceBasedRSUsMember" id="xdx2ixbrl0984" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2024-01-012024-12-31_custom_PerformanceBasedRSUsMember" id="xdx2ixbrl0994" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-12-31_custom_PerformanceBasedRSUsMember" id="xdx2ixbrl0996" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2024-01-012024-12-31_custom_PerformanceBasedRSUsMember" id="xdx2ixbrl1002" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-12-31_custom_PerformanceBasedRSUsMember" id="xdx2ixbrl1004" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="From2023-01-012023-12-31_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1136" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:StockRepurchase" contextRef="From2023-01-012023-12-31_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl1139" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:StockRepurchase" contextRef="From2023-01-012023-12-31_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl1142" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="From2023-01-012023-12-31_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl1145" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="From2023-01-012023-12-31_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl1148" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockMember" id="xdx2ixbrl1159" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="xdx2ixbrl1162" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_ConvertibleDebtSecuritiesMember" id="xdx2ixbrl1164" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_custom_EarnoutSharesMember" id="xdx2ixbrl1168" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1186" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1199" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1202" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1204" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1207" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1208" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:DeferredTaxAssetsFixedAssets" contextRef="AsOf2023-12-31" id="xdx2ixbrl1228" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2023-12-31" id="xdx2ixbrl1231" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2024-12-31" id="xdx2ixbrl1257" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2023-12-31" id="xdx2ixbrl1258" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="tvgn-20241231.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2024-01-01to2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_dei_BusinessContactMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-14_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TevogenBioMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">TVGN:TevogenBioMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SemperParatusMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">TVGN:SemperParatusMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-012024-06-30_custom_LoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:LoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_LoanAgreementMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputDiscountRateMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputDiscountRateMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ProbabilityOfFutureLiquidityMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">TVGN:ProbabilityOfFutureLiquidityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ProbabilityOfFutureLiquidityMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">TVGN:ProbabilityOfFutureLiquidityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputOptionVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputDiscountRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-14_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-14_us-gaap_FairValueInputsLevel3Member_us-gaap_CallOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:CallOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-152024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-15</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-152024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_CallOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:CallOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-15</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_CallOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:CallOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-14">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-142024-02-14">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-14</xbrli:startDate>
        <xbrli:endDate>2024-02-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-14_custom_EarnoutSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TevogenBioCommonStockMember_custom_EarnoutSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:TevogenBioCommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember_custom_EarnoutSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:TevogenBioCommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_custom_EarnoutSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:TevogenBioCommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_custom_EarnoutSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:TevogenBioCommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:TevogenBioCommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:TevogenBioCommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:TevogenBioCommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SponsorMember_custom_EarnoutSharesMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SponsorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SponsorMember_custom_EarnoutSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SponsorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ComputerAndSoftwareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">TVGN:ComputerAndSoftwareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ComputerAndSoftwareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">TVGN:ComputerAndSoftwareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-142024-02-14_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-14</xbrli:startDate>
        <xbrli:endDate>2024-02-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-012024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_ThePatelFamilyLLPMember_custom_LoanAgreementMember_us-gaap_UnsecuredDebtMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-28_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-012024-06-30_custom_ThePatelFamilyLLPMember_custom_LoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:LoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-012024-06-30_custom_ThePatelFamilyLLPMember_custom_LoanAgreementMember_custom_AdditionalAmountPurchaseOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">TVGN:AdditionalAmountPurchaseOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_custom_AdditionalAmountPurchaseOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">TVGN:AdditionalAmountPurchaseOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PolarMultiStrategyMasterFundMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:PolarMultiStrategyMasterFundMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentArrangementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TwoThousandTwentyFourPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">TVGN:TwoThousandTwentyFourPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-142024-02-14_custom_TwoThousandTwentyFourPlanMember_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">TVGN:TwoThousandTwentyFourPlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-14</xbrli:startDate>
        <xbrli:endDate>2024-02-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_PerformanceBasedRSUsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:PerformanceBasedRSUsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-01_us-gaap_SubsequentEventMember_custom_PerformanceBasedRSUsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:PerformanceBasedRSUsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-01_us-gaap_SubsequentEventMember_custom_ServiceBasedRestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:ServiceBasedRestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ServiceBasedRestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:ServiceBasedRestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PerformanceBasedRSUsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:PerformanceBasedRSUsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ServiceBasedRestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:ServiceBasedRestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ServiceBasedRestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:ServiceBasedRestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ServiceBasedRestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:ServiceBasedRestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ServiceBasedRestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:ServiceBasedRestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_PerformanceBasedRSUsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:PerformanceBasedRSUsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_PerformanceBasedRSUsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:PerformanceBasedRSUsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_PerformanceBasedRSUsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:PerformanceBasedRSUsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-012024-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-262024-03-27_custom_SeriesAOnePreferredStockMember_custom_ThePatelFamilyLLPMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TVGN:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-26</xbrli:startDate>
        <xbrli:endDate>2024-03-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-27_custom_SeriesAOnePreferredStockMember_custom_ThePatelFamilyLLPMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TVGN:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SeriesAOnePreferredStockMember_custom_ThePatelFamilyLLPMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TVGN:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-012024-03-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-212024-08-21_us-gaap_SeriesCPreferredStockMember_custom_ThePatelFamilyLLPMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-21</xbrli:startDate>
        <xbrli:endDate>2024-08-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-21_us-gaap_SeriesCPreferredStockMember_custom_ThePatelFamilyLLPMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-30_custom_SemperParatusMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SemperParatusMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-30_custom_SemperParatusMember_custom_PublicWarrantsMember_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SemperParatusMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TVGN:PublicWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-30_custom_SemperParatusMember_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SemperParatusMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-30_custom_SemperParatusMember_custom_PublicWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SemperParatusMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TVGN:PublicWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-012021-11-30_custom_SemperParatusMember_custom_PublicWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SemperParatusMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TVGN:PublicWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-11-01</xbrli:startDate>
        <xbrli:endDate>2021-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SemperParatusMember_custom_PublicWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SemperParatusMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TVGN:PublicWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SemperParatusMember_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SemperParatusMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RestrictedStockMember74469375">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_WarrantMember74469375">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_ConvertibleDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_ConvertibleDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_EarnoutSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_EarnoutSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember74469500">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SponsorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SponsorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SponsorAdvisoryServicesFeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:SponsorAdvisoryServicesFeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-01-31_custom_PerformanceBasedRSUsMember_custom_WifeOfChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:PerformanceBasedRSUsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:WifeOfChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-01-31_custom_MehtaphoricConsultingIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:MehtaphoricConsultingIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DrManmohanPatelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:DrManmohanPatelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DrManmohanPatelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:DrManmohanPatelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DrManmohanPatelMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:DrManmohanPatelMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-28_us-gaap_RestrictedStockUnitsRSUMember_custom_DrManmohanPatelMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:DrManmohanPatelMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-31_us-gaap_SubsequentEventMember_custom_KRHPLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:KRHPLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-28_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-02_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Integer">
      <xbrli:measure>TVGN:Integer</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Segment">
      <xbrli:measure>TVGN:Segment</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="Fact001049" toRefs="Footnote001054"/>
  <ix:relationship fromRefs="Fact001051" toRefs="Footnote001055"/>
  <ix:relationship fromRefs="Fact001155" toRefs="Footnote001172"/>
  <ix:relationship fromRefs="Fact001156" toRefs="Footnote001172"/>
  <ix:relationship fromRefs="xdx2ixbrl1164" toRefs="Footnote001175"/>
  <ix:relationship fromRefs="Fact001165" toRefs="Footnote001175"/>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As
filed with the Securities and Exchange Commission on April 30, 2025</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registration
No. 333-280414</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>WASHINGTON,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 14pt"><b>POST-EFFECTIVE
AMENDMENT NO. 1</b></span></p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 14pt"><b>TO</b></span></p>

<p style="text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-size: 14pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_909_edei--DocumentType_dxL_c20240101__20241231_zhcAHo9zwDP6" title="::XDX::POS%20AM"><span style="-sec-ix-hidden: xdx2ixbrl0013">S-1</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REGISTRATION
STATEMENT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>UNDER</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>THE
SECURITIES ACT OF 1933</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_90D_edei--EntityRegistrantName_c20240101__20241231_zqU8tDtnMM5j"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000014" name="dei:EntityRegistrantName">Tevogen
Bio Holdings Inc.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90A_edei--EntityIncorporationStateCountryCode_c20240101__20241231_zKRwfkqHU8hj"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:stateprovnameen" id="Fact000015" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2836</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_909_edei--EntityTaxIdentificationNumber_c20240101__20241231_z4yPprsxFZjj"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000016" name="dei:EntityTaxIdentificationNumber">98-1597194</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
    or other jurisdiction of<br/>
    incorporation or organization)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Primary
    Standard Industrial<br/>
    Classification Code Number)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
    Employer<br/>
    Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_909_edei--EntityAddressAddressLine1_c20240101__20241231_zS7CziGsl5tc"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000017" name="dei:EntityAddressAddressLine1">15
Independence Boulevard</ix:nonNumeric></span>, <span id="xdx_90F_edei--EntityAddressAddressLine2_c20240101__20241231_zWBJK46lOgs5"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000018" name="dei:EntityAddressAddressLine2">Suite #410</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_907_edei--EntityAddressCityOrTown_c20240101__20241231_zeGDrzPwlrR7"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000019" name="dei:EntityAddressCityOrTown">Warren</ix:nonNumeric></span>,
<span id="xdx_903_edei--EntityAddressStateOrProvince_c20240101__20241231_zbYL6RyhNhyj"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:stateprovnameen" id="Fact000020" name="dei:EntityAddressStateOrProvince">New Jersey</ix:nonNumeric></span> <span id="xdx_907_edei--EntityAddressPostalZipCode_c20240101__20241231_zpeK3YIJJpU"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000021" name="dei:EntityAddressPostalZipCode">07059</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(<span id="xdx_905_edei--CityAreaCode_c20240101__20241231_zHZ9d1TUmnLe"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000022" name="dei:CityAreaCode">877</ix:nonNumeric></span>)
<span id="xdx_90C_edei--LocalPhoneNumber_c20240101__20241231_zJDagqtarr7d"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000023" name="dei:LocalPhoneNumber">838-6436</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address,
including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90C_edei--ContactPersonnelName_c20240101__20241231__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zwtdvlibnTb2"><ix:nonNumeric contextRef="From2024-01-012024-12-31_dei_BusinessContactMember" id="Fact000024" name="dei:ContactPersonnelName">Ryan
Saadi</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Chief
Executive Officer</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Tevogen
Bio Holdings Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--EntityAddressAddressLine1_c20240101__20241231__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zs8GVFIQCWul"><ix:nonNumeric contextRef="From2024-01-012024-12-31_dei_BusinessContactMember" id="Fact000025" name="dei:EntityAddressAddressLine1">15
Independence Boulevard</ix:nonNumeric></span>, <span id="xdx_909_edei--EntityAddressAddressLine2_c20240101__20241231__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zyJ74b3j4tO4"><ix:nonNumeric contextRef="From2024-01-012024-12-31_dei_BusinessContactMember" id="Fact000026" name="dei:EntityAddressAddressLine2">Suite #410</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90A_edei--EntityAddressCityOrTown_c20240101__20241231__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zccVHU0JsZG6"><ix:nonNumeric contextRef="From2024-01-012024-12-31_dei_BusinessContactMember" id="Fact000027" name="dei:EntityAddressCityOrTown">Warren</ix:nonNumeric></span>,
<span id="xdx_900_edei--EntityAddressStateOrProvince_c20240101__20241231__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_z1NvcC7R2dce"><ix:nonNumeric contextRef="From2024-01-012024-12-31_dei_BusinessContactMember" format="ixt-sec:stateprovnameen" id="Fact000028" name="dei:EntityAddressStateOrProvince">New Jersey</ix:nonNumeric></span> <span id="xdx_90C_edei--EntityAddressPostalZipCode_c20240101__20241231__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zwcUhFlMW4t3"><ix:nonNumeric contextRef="From2024-01-012024-12-31_dei_BusinessContactMember" id="Fact000029" name="dei:EntityAddressPostalZipCode">07059</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(<span id="xdx_90D_edei--CityAreaCode_c20240101__20241231__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zp0eON5E76e3"><ix:nonNumeric contextRef="From2024-01-012024-12-31_dei_BusinessContactMember" id="Fact000030" name="dei:CityAreaCode">877</ix:nonNumeric></span>)
<span id="xdx_906_edei--LocalPhoneNumber_c20240101__20241231__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zNfgNpFhleS2"><ix:nonNumeric contextRef="From2024-01-012024-12-31_dei_BusinessContactMember" id="Fact000031" name="dei:LocalPhoneNumber">838-6436</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name,
address, including zip code, and telephone number, including area code, of agent for service)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Copies
to:</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>William
I. Intner<br/>
J. Nicholas Hoover<br/>
Hogan Lovells US LLP<br/>
100 International Drive, Suite 2000</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Baltimore,
Maryland 21202</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(410)
659-2700</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approximate
date of commencement of proposed sale to the public: From time to time after this registration statement becomes effective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933, check the following box. &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following
box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.
&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 44%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 44%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--EntityFilerCategory_c20240101__20241231_zRrqS1VDnXY8"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:entityfilercategoryen" id="Fact000032" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--EntitySmallBusiness_c20240101__20241231_znDpjbqR4lg1"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000033" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--EntityEmergingGrowthCompany_c20240101__20241231_zqwbFxGb2LMj"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000034" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></span></td>
    </tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. <span id="xdx_900_edei--EntityExTransitionPeriod_c20240101__20241231_zT0p0lmL3AHe"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000035" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>This
post-effective</b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> amendment will become
effective in accordance with the provisions of Section 8(c) of the&#160;Securities Act of 1933, as amended.</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXPLANATORY
NOTE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p id="xdx_984_edei--AmendmentDescription_c20240101__20241231_gBFAD-FAYG_zTwis0KI8hob" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" continuedAt="ConU000039-01" id="Fact000039" name="dei:AmendmentDescription">On
June 21, 2024, the registrant filed a Registration Statement on Form S-1 (Registration No. 333-280414), which was subsequently amended
on July 23, 2024, and August 1, 2024, and declared effective by the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) on
August 2, 2024 (the &#8220;Registration Statement&#8221;).</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C0A_gBFAD-FAYG_zZHx4ifBma2c"><ix:continuation continuedAt="ConU000039-02" id="ConU000039-01">&#160;</ix:continuation></span></span></p>

<div id="xdx_C0F_gBFAD-FAYG_zIp1GGzm4VC5"><ix:continuation continuedAt="ConU000039-03" id="ConU000039-02"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Registration Statement registered the issuance by the registrant (i) up to 17,974,978 shares of common stock, par value $0.001 per share
(the &#8220;Common Stock&#8221;), upon the exercise of outstanding warrants to purchase Common Stock (the &#8220;Warrants&#8221;) originally
issued by Semper Paratus Acquisition Corporation (&#8220;Semper Paratus&#8221;), a Cayman Islands exempted company (n/k/a Tevogen Bio Holdings Inc., a Delaware corporation), as part of Semper Paratus&#8217;
(a) initial public offering and (b) concurrent private placement (the &#8220;Private Placement&#8221;) of units at a price of $10.00
per unit, with each unit consisting of one Class A ordinary share of Semper Paratus and one-half of a warrant, and (ii) up to 24,500,000
shares of Common Stock issuable upon the achievement of certain earnout triggering events as described in prospectus below. The Registration
Statement also registered for resale by the securityholders identified in this prospectus (each a &#8220;Registered Holder&#8221; and,
collectively, the &#8220;Registered Holders&#8221;) up to 24,551,308 shares of Common Stock (the &#8220;Total Resale Shares&#8221;) and
725,000 of our outstanding Warrants, originally issued as part of units sold in the Private Placement (the &#8220;Private Placement Warrants&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
post-effective amendment is being filed to update the Registration Statement to include information contained in the
registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the SEC on April 2, 2025 (the
&#8220;2024 Form 10-K&#8221;), and update certain other information in the Registration Statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information included in this filing amends the Registration Statement and the prospectus contained therein. No additional securities
are being registered under this post-effective amendment. All applicable registration fees were paid at the time of the original filing
of the Registration Statement.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"></p>

</ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span id="xdx_C06_gBFAD-FAYG_zT33jwyOX3Lj"><ix:continuation id="ConU000039-03"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></ix:continuation></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><b>The
information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration
statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities
and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><b>Subject
to Completion, dated April 30, 2025.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><b>PRELIMINARY
PROSPECTUS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="forms-1_001.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Tevogen
Bio Holdings Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>42,474,978
</b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares of Common Stock </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5,329,590
Shares of Common Stock Offered by the Registered Holders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>663,398
Warrants Offered by the Registered Holders</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus relates to the issuance by us of up to (i) 17,974,000 shares of Common Stock upon the exercise of the Warrants originally
issued by Semper Paratus as part of Semper Paratus&#8217; (a) initial public offering and (b) Private Placement of units at a price of
$10.00 per unit, with each unit consisting of one Class A ordinary share of Semper Paratus and one-half of a warrant and (ii) 24,500,000
shares of Common Stock issuable upon the achievement of certain earnout triggering events, as described in the prospectus contained herein.
This prospectus also relates to the resale by the Registered Holders of up to (i) 5,329,590 of the Total Resale Shares and (ii) 663,398
Private Placement Warrants.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Total Resale Shares consist of (i) 500,000 shares of Common Stock underlying Private Placement Warrants that were purchased by SSVK Associates,
LLC (&#8220;SSVK&#8221;), which was Semper Paratus&#8217; sponsor, from Semper Paratus Sponsor LLC (the &#8220;Original Sponsor&#8221;),
which was Semper Paratus&#8217; original sponsor, in a transaction in which SSVK acquired 7,988,889 Class A ordinary shares
of Semper Paratus and 1,000,000 Private Placement units for an aggregate purchase price of $1.00, (ii) 174,000 shares of Common Stock
issued pursuant to the Conversion Agreements (as defined elsewhere in this prospectus) at an effective price of $10.00 per share, (iii)
500,000 shares of Common Stock issuable upon the conversion of shares of Series A Preferred Stock at a conversion price of $4.00 per
share, (iv) 655,590 shares of Common Stock issued upon assumption and subsequent conversion of the Tevogen Bio Convertible Notes
(as defined elsewhere in this prospectus) that had an aggregate principal amount totaling approximately $24.0 million and accrued interest
totaling approximately $2.9 million at the time of the Business Combination (as defined elsewhere in this prospectus), (v) 300,000
shares of Common Stock issuable upon the conversion of shares of Series A-1 Preferred Stock at a conversion price of $10.00 per share,
and (vi) 1,000,000 shares of Common Stock issued pursuant to the Loan Agreement (as defined elsewhere in this prospectus) as a
commitment fee in consideration for providing us with a credit facility.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may receive up to an aggregate of approximately $207 million from the cash exercise of the Warrants. The exercise price of each of our
Warrants is $11.50 per warrant. However, the last reported sales price of our Common Stock on April 29, 2025 was $1.01.
The likelihood that holders of Warrants will exercise their Warrants, and therefore any amount of cash proceeds that we may receive,
is dependent upon the trading price of our Common Stock. If the trading price for our Common Stock continues to be less than $11.50 per
share, we do not expect holders to exercise their Warrants. Additionally, under certain circumstances, the Warrants may be exercised
on a cashless basis and we would not receive any proceeds from such exercise. Accordingly, we have not included the net proceeds from
any exercise of the Warrants in our assessment of our&#160;liquidity and operational funding needs<span style="background-color: white">.
See &#8220;<i>Risk Factors - Risks Related to Being a Public Company and Ownership of Securities -</i></span><i> Any amount
of cash proceeds that we may receive is dependent upon the trading price of our Common Stock relative to the exercise price of the Warrants</i><span style="background-color: white">.&#8221;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to use the net proceeds from the exercise of such securities, if any, for general corporate and working capital purposes. We will
have broad discretion over the use of any proceeds from the exercise of such securities. Any proceeds from the exercise of such securities
would increase our liquidity and provide additional funds for operations, but we are not currently budgeting for any cash proceeds from
the exercise of Warrants when planning for our operational funding needs. For further information regarding our operational funding needs,
see the section of this prospectus titled &#8220;<i>Risk Factors - Risks Related to Our Financial Position and Need for Additional
Capital - Our management has concluded that due to cash on hand, there is substantial doubt about our ability to continue as a
going concern</i>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are registering the securities for resale including pursuant to certain of the Registered Holders&#8217; registration rights under certain
agreements between us and the Registered Holders and to facilitate the Company&#8217;s call right with respect to the Series A Preferred
Stock and Series A-1 Preferred Stock. Our registration of the securities covered by this prospectus does not mean that the Registered
Holders will offer or sell any of the shares of Common Stock or Warrants. The Registered Holders may offer, sell or distribute all or
a portion of their shares of Common Stock or Warrants publicly or through private transactions at prevailing market prices or at negotiated
prices. We provide more information about how the Registered Holders may sell the shares of Common Stock or Warrants in the section titled
&#8220;<i>Plan of Distribution</i>.&#8221; See the section of this prospectus titled &#8220;<i>Prospectus Summary-Background</i>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
sale of securities being offered in this prospectus could result in adverse effects on the market for our Common Stock, including increasing
volatility, limiting the availability of an active market, or resulting in a significant decline in the public trading price of our Common
Stock. Even if the prevailing trading price of our Common Stock is at or significantly below the price at which the units were issued
in Semper Paratus&#8217; initial public offering, some of the Registered Holders may still be able to profit on sales due to the
lower price at which they purchased their shares compared to public investors, or because they acquired or may acquire their shares as
compensation for services rendered, in consideration of the extension of loans, or in other circumstances, and therefore may still have
an incentive to sell securities held by them and being offered in this prospectus. Public securityholders may not experience a similar
rate of return on the securities they purchase due to differences in the purchase prices and the current trading price. See &#8220;<i>Risk
Factors - Risks Related to Being a Public Company and Ownership of Securities - Sales of a substantial number of our securities
in the public market by the Registered Holders or by our other existing securityholders could cause the price of our Common Stock and
Warrants to fall</i>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &#8220;emerging growth company&#8221; and &#8220;smaller reporting company&#8221; for purposes of federal securities laws and
are subject to reduced public company reporting requirements. Accordingly, the information in this prospectus may not be comparable to
information provided by companies that are not emerging growth companies or smaller reporting companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Common Stock and public Warrants are listed on The Nasdaq Stock Market LLC under the symbols &#8220;TVGN&#8221; and &#8220;TVGNW,&#8221;
respectively. On April 29, 2025, the closing price of our Common Stock was $1.01 and the closing price for our Warrants
was $0.0464.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will bear all costs, expenses and fees in connection with the registration of the shares of Common Stock and Private Placement Warrants.
The Registered Holders will bear all commissions and discounts, if any, attributable to their sales of the shares of Common Stock or
Private Placement Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
business and investment in our Common Stock and Warrants involve significant risks. These risks are described in the section titled &#8220;Risk
Factors&#8221; beginning on page 8 of this prospectus.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed
upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
date of this prospectus is &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TABLE
OF CONTENTS<sup></sup></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Su_001">ABOUT THIS PROSPECTUS</a></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Su_002">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Su_003">PROSPECTUS SUMMARY</a></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Su_004">THE OFFERING</a></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">7</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Su_005">RISK FACTORS</a></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_001">USE OF PROCEEDS</a></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_002">DIVIDEND POLICY</a></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_004">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#as_002">BUSINESS</a></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#as_003">MANAGEMENT</a></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">93</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#as_004">EXECUTIVE AND DIRECTOR COMPENSATION</a></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">98</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#as_005">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</a></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">107</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#as_006">PRINCIPAL STOCKHOLDERS</a></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">111</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#as_007">REGISTERED HOLDERS</a></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">112</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#as_008">DESCRIPTION OF OUR SECURITIES</a></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">114</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#as_009">PLAN OF DISTRIBUTION</a></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">125</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#as_010">LEGAL MATTERS</a></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">128</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#as_011">EXPERTS</a></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">129</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#as_012">WHERE YOU CAN FIND MORE INFORMATION</a></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">130</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#as_013">INDEX TO FINANCIAL STATEMENTS</a></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Su_001"></span>ABOUT
THIS PROSPECTUS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus is part of a registration statement that we filed with the SEC
using a &#8220;shelf&#8221; registration process. We will not receive any proceeds from the sale by the Registered Holders of the securities
offered by them described in this prospectus. This prospectus also relates to the issuance by us of the shares of Common Stock issuable
upon the exercise of the Warrants. We will not receive any proceeds from the sale of shares of Common Stock underlying the Warrants pursuant
to this prospectus, except with respect to amounts received by us upon the exercise of the Warrants for cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also file a prospectus supplement or post-effective amendment to the registration statement of which this prospectus forms a part
that may contain material information relating to these offerings. The prospectus supplement or post-effective amendment may also add,
update or change information contained in this prospectus with respect to that offering. If there is any inconsistency between the information
in this prospectus and the applicable prospectus supplement or post-effective amendment, you should rely on the prospectus supplement
or post-effective amendment, as applicable. Before purchasing any securities, you should carefully read this prospectus, any post-effective
amendment, and any applicable prospectus supplement, together with the additional information described under the heading &#8220;<i>Where
You Can Find More Information</i>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
we nor the Registered Holders have authorized anyone to provide you with any information or to make any representations other than those
contained in this prospectus, any post-effective amendment, or any applicable prospectus supplement prepared by or on behalf of us or
to which we have referred you. We and the Registered Holders take no responsibility for and can provide no assurance as to the reliability
of any other information that others may give you. We and the Registered Holders will not make an offer to sell these securities in any
jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus, any post-effective
amendment and any applicable prospectus supplement to this prospectus is accurate only as of the date on its respective cover. Our business,
financial condition, results of operations and prospects may have changed since those dates. This prospectus contains, and any post-effective
amendment or any prospectus supplement may contain, market data and industry statistics that are based on independent industry
publications and other publicly available information. We believe this information is reliable as of the applicable date of its publication;
however, we have not independently verified the accuracy or completeness of the information included in or assumptions relied on in these
third-party publications. In addition, the market and industry data and forecasts that may be included in this prospectus, any post-effective
amendment or any prospectus supplement may involve estimates, assumptions and other risks and uncertainties and are subject to change
based on various factors, including those discussed under the heading &#8220;<i>Risk Factors</i>&#8221; contained in this prospectus,
any post-effective amendment and the applicable prospectus supplement. Accordingly, investors should not place undue reliance on this
information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
own or have rights to trademarks, trade names and service marks that we use in connection with the operation of our business. In addition,
our name, logos and website name and address are our trademarks or service marks. Solely for convenience, in some cases, the trademarks,
trade names and service marks referred to in this prospectus are listed without the applicable &#174;, &#8482; and SM symbols, but we
will assert, to the fullest extent under applicable law, our rights to these trademarks, trade names and service marks. Other trademarks,
trade names and service marks appearing in this prospectus are the property of their respective owners.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">On February 14,
2024 (the &#8220;Closing Date&#8221;), we consummated the previously announced business combination pursuant to that certain Agreement
and Plan of Merger, dated June 28, 2023 (the &#8220;Merger Agreement&#8221;), by and among Semper Paratus, Semper Merger Sub, Inc., a
Delaware corporation and a wholly owned subsidiary of Semper Paratus (&#8220;Merger Sub&#8221;), SSVK, in its capacity as purchaser representative,
Tevogen Bio Inc (n/k/a Tevogen Bio Inc.), a Delaware corporation (&#8220;Tevogen Bio&#8221;), and Dr. Saadi, in his capacity as seller
representative, pursuant to which Merger Sub merged with and into Tevogen Bio, with Tevogen Bio being the surviving company and a wholly
owned subsidiary of Semper Paratus (the &#8220;Merger&#8221; or the &#8220;Business Combination&#8221;). On the Closing Date,
and in connection with the closing of the Business Combination (the &#8220;Closing&#8221;), we changed our name to Tevogen Bio
Holdings Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Unless otherwise
stated, in this prospectus, when we refer to &#8220;Tevogen,&#8221; the &#8220;Company,&#8221; &#8220;we&#8221; or &#8220;us&#8221; we
mean the entity that remains following the Business Combination. Additionally, unless otherwise stated, in this prospectus, when
we refer to &#8220;Tevogen Bio&#8221; or &#8220;Semper Paratus&#8221;, we are referring to each respective entity before the consummation
of the Business Combination.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Su_002"></span>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus contains statements that constitute &#8220;forward-looking statements&#8221; for purposes of the federal securities laws.
Forward-looking statements include, but are not limited to, statements that discuss future events, hopes, expectations, beliefs, intentions,
or strategies regarding the future, projections of results of operations or financial condition, changes in the markets in which we compete,
and trends in our business. In addition, any statements that refer to projections, forecasts, or other characterizations of future events
or circumstances, including any underlying assumptions, are forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221;
&#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intends,&#8221;
&#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221;
&#8220;should,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; and similar expressions or their opposites may identify forward-looking
statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this
prospectus may include, for example, statements about:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            development of, potential benefits of, and patient access to our product candidates for the
                                            treatment of infectious diseases, cancer, and neurological disorders, including TVGN 489
                                            for the treatment of COVID-19 and Long COVID;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to develop additional product candidates, including through the use of our ExacTcell<sup>TM
                                            </sup>technology;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            anticipated benefits of ExacTcell;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            expectations regarding our future clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            manufacturing plans;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to generate revenue in the future;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to manage, grow, and diversify our business and execute our business initiatives
                                            and strategy;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expectations
                                            regarding the healthcare and biopharmaceutical industries;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            potential liquidity and trading of our securities; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            future business, operations, and financial performance of our company.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
forward-looking statements contained in this prospectus are based on management&#8217;s current expectations, assumptions, and beliefs
concerning future developments and their potential effects on us. There can be no assurance that future developments affecting us will
be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond
our control), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied
by these forward-looking statements. These risks and uncertainties include, among others:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            in the markets in which we compete, including with respect to its competitive landscape,
                                            technology evolution, or regulatory changes;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            in domestic and global general economic conditions;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            may not be able to execute our growth strategies or may experience difficulties in managing
                                            our growth and expanding operations;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            may not be able to develop and maintain effective internal controls;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            may fail to achieve our commercialization and development plans and identify and realize
                                            additional opportunities, which may be affected by, among other things, competition and our
                                            ability to grow and manage growth economically and hire and retain key employees;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">we may fail to keep pace with rapid technological developments to
    provide new and innovative products and services or make substantial investments in unsuccessful new products and services;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">risks related to our ability to develop, license, or acquire new
    therapeutics;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">we will need to raise additional capital, which may not be available
    on acceptable terms or at all, in order to execute our business plan;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the risk of regulatory lawsuits or proceedings relating to our business;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">uncertainties inherent in the execution, cost, and completion of
    preclinical studies and clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">risks related to regulatory review and approval and commercial development;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">risks associated with intellectual property protection;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">increasing use of artificial intelligence (&#8220;AI&#8221;) could
    lead to liability, violation of data security and privacy laws, or reputational damage;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">computer systems may fail or suffer security breaches; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our limited operating history.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward-looking
statements should be considered in light of these factors and the factors described elsewhere in this prospectus, including in the sections
titled &#8220;<i>Risk Factors</i>&#8221; and &#8220;<i>Management&#8217;s Discussion and Analysis of Financial Condition and Results
of Operations</i>.&#8221; You should read these factors and the other cautionary statements made in this prospectus as being applicable
to all related forward-looking statements wherever they appear in this prospectus. These risks are not exhaustive. New risks emerge from
time to time and it is not possible to predict or identify all such risks, nor can we assess the impact of all such risks on our business
or the extent to which any risk or combination of risks may cause actual results to differ materially from those contained in any forward-looking
statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future
events, or otherwise, except as may be required under applicable law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, statements of belief and similar statements reflect our beliefs and opinions on the relevant subject. These statements are
based upon information currently available to us, and while we believe such information forms a reasonable basis for such statements,
such information may be limited or incomplete, and statements should not be read to indicate that we have conducted an exhaustive inquiry
into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not
to unduly rely upon these statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<div style="border: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 0.1in; padding-left: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Su_003"></span>PROSPECTUS
SUMMARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>This
summary highlights, and is qualified in its entirety by, the more detailed information and financial statements included elsewhere in
this prospectus. This summary does not contain all of the information that may be important to you in making your investment decision.
You should read this entire prospectus carefully, especially the &#8220;Risk Factors&#8221; section beginning on page 8 and
our consolidated financial statements and the related notes appearing at the end of this prospectus, before deciding to invest in our
Common Stock or Warrants.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4pt; text-align: justify; text-indent: 17.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage specialty immunotherapy company harnessing one of nature&#8217;s most powerful immunological weapons, CD8+ cytotoxic
T lymphocytes (&#8220;CTLs&#8221;), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers,
and other disorders, with the aim of addressing the significant unmet needs of large patient populations. We believe that sustainability
and commercial success in the forthcoming era of medicine will rely on ensuring patient accessibility through advanced science, innovative
business models and engagement across the development lifecycle and healthcare system. We believe the full potential of T cell therapies
remains largely untapped and aspire to be the first biotechnology company offering commercially attractive, economically viable, and
cost-effective personalized T cell therapies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4pt; text-align: justify; text-indent: 17.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4pt; text-align: justify; text-indent: 17.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe our allogeneic, precision T cell technology, ExacTcell<sup>TM</sup>, represents a significant scientific breakthrough
with the potential to mainstream cell therapy with a new class of off-the-shelf &#8211; manufactured and stored for immediate
use &#8211; T cell therapies with diverse applications across virology, oncology, and other areas. ExacTcell is a set of processes
and methodologies to develop, enrich, and expand single human leukocyte antigen (&#8220;HLA&#8221;) restricted CTL therapies with proactively
selected, precisely defined targets. HLA molecules are proteins that play an important role in the immune system&#8217;s ability to recognize
&#8220;self&#8221; versus &#8220;foreign.&#8221; There are numerous HLA types that vary from person to person. CD8+ CTLs, also known
as killer T cells, are white blood cells that are part of the immune system and destroy infected, malignant, or otherwise damaged cells.
We are focused on using ExacTcell to develop allogeneic therapeutics, meaning therapeutics that are intended to be infused in patients
other than the original donor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4pt; text-align: justify; text-indent: 17.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4pt; text-align: justify; text-indent: 17.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ExacTcell
therapies are based on carefully selected, naturally occurring CTLs that are designed to recognize targets of interest from the
body&#8217;s native T cell receptor pool, unlike genetically engineered T cell therapies. CD8+ CTLs in ExacTcell-based products target
multiple and distinct antigens, with the aim to circumvent the impact of mutations in viruses and cancer cells, which can render
existing treatments focused on a single target ineffective. ExacTcell is designed to maximize the immunologic specificity of our
products in order to eliminate malignant and virally infected cells while allowing healthy cells to remain intact. We believe this high
degree of specificity has the potential to significantly reduce the chances of cross-reactivity or adverse impact on healthy cells. Our
confidence in ExacTcell is reflected in our development pipeline, which has been carefully tailored to address the unmet needs of large
patient populations grappling with life-threatening viral diseases, cancers, and other disorders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4pt; text-align: justify; text-indent: 17.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4pt; text-align: justify; text-indent: 17.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for
the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering
symptoms of the disease (&#8220;Long COVID&#8221;). Viruses, including COVID-19, hijack cellular machinery to transform infected cells
into virus production plants. Elimination of infected cells is necessary to allow them to be replaced by healthy, uninfected counterparts.
TVGN 489 consists of CTLs designed to be active against multiple precise, well defined, and well characterized targets spread
across the SARS-CoV-2 genome. The product progressed from pre-discovery to the clinic in less than 18 months, and in January 2023,
we completed the Phase 1 proof-of-concept clinical trial of TVGN 489 for the treatment of ambulatory, high-risk adult COVID-19 patients.
No dose-limiting toxicities or significant treatment-related adverse events were observed in the treatment arm. Secondary endpoints showed
a rapid reduction of viral load and that infusion of TVGN 489 did not prevent the development of the patients&#8217; own T
cell-related (cellular) or antibody-related (humoral) anti-COVID-19 immunity. None of the patients reported progression of infection,
reinfection, or the development of Long COVID during the six-month follow-up period. These clinical observations were mirrored by laboratory
evidence of the persistence of TVGN 489 cells for at least six months after treatment. We believe these findings validate our initiative
to develop off-the-shelf T cell therapies for outpatient administration, targeting diseases that affect large patient populations &#8211;
for the very first time. We are planning a pivotal trial of TVGN 489 in COVID-19 patients with B cell malignancies, with studies
of other highly vulnerable populations thereafter. TVGN 489 is also in preclinical development for treatment and prevention of Long COVID.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4pt; text-align: justify; text-indent: 17.6pt">In addition, through our
Tevogen.AI artificial intelligence initiative, we are focused on harnessing the potential of AI to expedite drug development, optimize
laboratory processes and clinical trials, unravel complex biological data, improve patient outcomes, and pass on related savings to patients.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 9; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<div style="border: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 0.1in; padding-left: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Background</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were incorporated as Semper Paratus Acquisition Corporation on April 21, 2021. On February 14, 2024, we closed the Business Combination
with Tevogen Bio, as a result of which Tevogen Bio became a wholly owned subsidiary of ours, and we changed our name to Tevogen Bio Holdings
Inc. Although we are the legal acquirer of Tevogen Bio in the Business Combination, we are treated as the &#8220;acquired&#8221; entity
for financial reporting purposes and Tevogen Bio has been deemed to be the accounting acquirer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Convertible
Promissory Notes</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the consummation of the Business Combination, Semper Paratus
assumed all obligations of Tevogen Bio under pre-existing convertible promissory notes issued by Tevogen Bio (the &#8220;Tevogen Bio Convertible
Notes&#8221;) with an aggregate principal amount totaling approximately $24.0 million and aggregate accrued interest of approximately
$2.8 million as of the consummation of the Business Combination. The Tevogen Bio Convertible Notes converted pursuant to their terms immediately
following the Closing into shares of Common Stock, resulting in the issuance of 10,337,419 shares of our Common Stock, on the Closing
Date. The holders of the convertible notes included The Patel Family, LLP and HMP Partners, LLC, both of which are associated with Dr.
Manmohan Patel, an existing investor in the Company and beneficial owner of more than 5% of the Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Series
A Preferred Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4pt; text-align: justify; text-indent: 17.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 14, 2024, we entered into a securities purchase agreement with an investor pursuant to which the investor agreed to purchase
shares of our Series A Preferred Stock for an aggregate purchase price of $8.0 million. On March 27, 2024, we entered into an amended
and restated securities purchase agreement pursuant to which that amount was reduced to $2.0 million (as amended and restated, the &#8220;Preferred
Purchase Agreement&#8221;). The shares of Series A Preferred Stock are convertible into a total of 500,000 shares of Common Stock
(the &#8220;Series A Conversion Shares&#8221;) at the election of the holder. The Series A Preferred Stock is subject to a call right
providing us the right to call the stock if the volume weighted average price of the Common Stock for the 20 days prior to delivery of
the call notice is greater than $5.00 per share and in each case there is an effective resale registration statement on file covering
the underlying Common Stock. The investor in the Series A Preferred Stock is an entity associated with Dr. Manmohan Patel, who is a beneficial
owner of more than 5% of the Common Stock. This prospectus relates to the resale of the Series A Conversion Shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4pt; text-align: justify; text-indent: 17.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4pt; text-align: justify; text-indent: 17.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<div style="border: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 0.1in; padding-left: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Series
A-1 Preferred Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Preferred Purchase Agreement, the investor agreed to purchase shares of our Series A-1 Preferred Stock for an
aggregate purchase price of $6.0 million. The shares of Series A-1 Preferred Stock will be convertible into a total of 600,000
shares of Common Stock (the &#8220;Series A-1 Conversion Shares&#8221; and, together with the Series A Conversion Shares, the
&#8220;Conversion Shares&#8221;) at the election of the holder. The Series A-1 Preferred Stock will be subject to a call right
providing us the right to call the stock if the volume weighted average price of the Common Stock for the 20 days prior to delivery
of the call notice is greater than $5.00 per share and in each case there is an effective resale registration statement on file
covering the underlying Common Stock. The investor in the Series A-1 Preferred Stock is an entity associated with Dr. Manmohan
Patel, who is a beneficial owner of more than 5% of the Common Stock. This prospectus relates to the resale of 300,000 of the
Series A-1 Conversion Shares. We expect that we will register the resale of the remaining 300,000 Series A-1 Conversion Shares on a future registration statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Conversion
Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 14, 2024, we entered into agreements (the &#8220;Conversion Agreements&#8221;) with SSVK and Mr. Ajjarapu pursuant to
which we issued an aggregate of 174,000 shares of Common Stock in relation to services that were to have been provided to us and
Tevogen Bio, at an effective price of $10.00 per share of Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Loan
Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 6, 2024, we entered into a Loan Agreement (the &#8220;Loan Agreement&#8221;) with The Patel Family, LLP (the &#8220;Lender&#8221;)
providing for (i) an unsecured line of credit facility (the &#8220;Facility&#8221;), pursuant to which the Lender agreed to lend the
Company up to $36.0 million (the &#8220;Maximum Loan Amount&#8221;), and (ii) a contingent option for the Lender to purchase at least
$14.0 million of Common Stock in a future private placement (the &#8220;Optional PIPE&#8221;). Pursuant to the terms of the Loan Agreement,
the Company issued to the Lender 1,000,000 shares of Common Stock as a commitment fee (the &#8220;Commitment Shares&#8221;), subject
to forfeiture by the Lender of the Commitment Shares or an equal number of shares of Common Stock in the event the Lender fails to (i)
make a deposit under the Facility when due or (ii) pay the purchase price for the Optional PIPE within 30 days after the Threshold Price
Notice Date (as defined below) in the event the Company has satisfied all applicable closing conditions. The Lender is an entity
associated with Dr. Manmohan Patel, who is a beneficial owner of more than 5% of the Common Stock. This prospectus relates to the resale
of the Commitment Shares. The Loan Agreement is described in more detail under &#8220;<i>Management&#8217;s Discussion and Analysis of
Financial Condition and Results of Operations-Liquidity and Capital Resources-Funding Requirements-Loan Agreement</i>&#8221;
below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<div style="border: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 0.1in; padding-left: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sale
to SSVK</i></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 30, 2023, the Original Sponsor, holding all of the issued and outstanding Class B ordinary shares of Semper Paratus elected to
convert its Class B ordinary shares into Class A ordinary shares on a one-for-one basis. As a result, 11,983,333 of the Company&#8217;s
Class B ordinary shares were cancelled and 11,983,333 Class A ordinary shares were issued to the Original Sponsor. The Original Sponsor
agreed that all of the terms and conditions applicable to the founder shares (as defined elsewhere in this prospectus) set forth in the
Letter Agreement would continue to apply to the Class A ordinary shares that the founder shares converted into.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 4, 2023, Semper Paratus, the Original Sponsor, and SSVK entered into
a Sponsor Purchase Agreement (the &#8220;Sponsor Share Purchase Agreement&#8221;), pursuant to which SSVK agreed to purchase from the
Original Sponsor 7,988,889 Class A ordinary shares and 1,000,000 private placement units for an aggregate purchase price of $1.00. Additionally
SSVK agreed to assume the responsibilities and obligations of the Original Sponsor related to Semper Paratus. The transactions contemplated
by the Sponsor Share Purchase Agreement closed June 7, 2023, and the Original Sponsor transferred the Class A ordinary shares and the
private placement units to SSVK.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b><i>Earnout Shares</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Former
holders of Tevogen Bio common stock and SSVK are eligible to receive up to an aggregate of 24,500,000 shares of Common Stock
(&#8220;Earnout Shares&#8221;) if the volume-weighted average price (the &#8220;VWAP&#8221;) of the Common Stock reaches specified
threshold levels during the three-year period commencing on the Closing Date. Following the Closing, former holders of Tevogen Bio
common stock may receive up to 20,000,000 Earnout Shares in tranches of 6,666,667, 6,666,667, and 6,666,666 shares of Common Stock
per tranche, respectively. The first, second, and third tranches are issuable if the VWAP per share of the Common Stock is greater
or equal to $15.00, $17.50, and $20.00, respectively, over any twenty trading days within any thirty consecutive day trading period
during the three-year period after the Closing. SSVK received the right to Earnout Shares with the same terms above, except
that each of SSVK&#8217;s three earnout tranches are for 1,500,000 shares of Common Stock, for an aggregate of 4,500,000
shares across the entire SSVK earnout.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Developments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Master
Services and Facilities</i></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 17, 2025, we entered into a Master Services and Facilities Agreement (the &#8220;MSA&#8221;) with CD 8 Technology Services LLC
(&#8220;CD8&#8221;). The MSA establishes the general terms and conditions under which CD8 would provide us with access to specialized
manufacturing facilities, including clean rooms and laboratories, as well as related operational services, to support the production
of our cell therapy products. The MSA provides that the specific details of these facilities and services, including scope of work, costs,
and timelines, will be set out in one or more individual project work orders. The MSA has an initial term of twelve months and will automatically
renew for additional 12-month periods unless it is terminated in accordance with the terms set forth therein. CD8 is associated with
Dr. Manmohan Patel, who beneficially owns more than 5% our Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risk
Factor Summary</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to a variety of risks and uncertainties, including risks that could have a material adverse effect on our business, financial
condition, results of operations, and cash flows. The following summary of the principal factors that make an investment in our securities
speculative or risky should not be relied upon as an exhaustive summary of the material risks facing us. You should read the following
summary together with the more detailed description of risks under &#8220;Risk Factors&#8221; this prospectus and the other information
contained in this prospectus before investing in our securities. Capitalized terms not otherwise defined below have been defined elsewhere
in this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Our Financial Position and Need for Additional Capital</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            have a limited operating history, no products approved for commercial sale, have never generated
                                            revenue from product sales, and have a history of significant losses.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">We
                                            are relying in part on an additional $8.0 million of grant funding that we have not yet received
                                            to meet our liquidity needs.</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            will require substantial additional financing to achieve our business objectives.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Development, Regulatory Review, and Product Approval</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulation
                                            of cellular therapy product candidates is rigorous, complex, uncertain, and subject to change.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            have limited experience designing and implementing preclinical and clinical trials, which
                                            are complex, expensive, time-consuming, difficult to design and implement, and involve uncertain
                                            outcomes.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may be unable to develop, receive regulatory approval for, and commercialize our product
                                            candidates.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may encounter substantial delays and disruptions in the development of our product candidates.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Food and Drug Administration (&#8220;FDA&#8221;) regulatory approval process is lengthy
                                            and time-consuming.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may never receive regenerative medicine advanced therapy (&#8220;RMAT&#8221;) designation
                                            for any product candidate, and this designation may not lead to a faster development or regulatory
                                            review or approval process.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            business is highly dependent on our first product candidate, TVGN 489.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Results
                                            from our clinical trials may change and are subject to audit, validation, and verification
                                            procedures.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial
                                            results and results of earlier trials may not be predictive of future results.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            TVGN 489 proof-of-concept clinical trial results may be less reliable than results in larger
                                            clinical trials.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
                                            in product candidate manufacturing or formulation may result in additional costs or delay.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ExacTcell
                                            is unproven and may not result in marketable products.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may fail to demonstrate the safety and efficacy of our product candidates, or serious adverse
                                            or unacceptable side effects may be identified during development.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may encounter difficulties enrolling patients in our clinical trials.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<div style="border: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 0.1in; padding-left: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may be required to suspend, repeat, or terminate our clinical trials if they are not conducted
                                            in accordance with regulatory requirements, the results are negative or inconclusive, or
                                            the trials are not well designed.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may not achieve our projected development goals in the time frames we announce and expect.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disruptions
                                            at government agencies could hinder or prevent product development and commercialization.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Development
                                            of product candidates in combination with other therapies presents additional regulatory
                                            risks.</span></td></tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">We
                                            could fail utilizing new and evolving technologies, such as AI, in our business.</td></tr>
                                                                   </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Business Development and Commercialization</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            commercial success depends upon attaining significant market acceptance of our product candidates.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulated
                                            biologics may be subject to biosimilar competition.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            incidence and prevalence of target patient populations are based on estimates and third-party
                                            sources.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            will face extensive ongoing regulatory requirements and regulatory review after regulatory
                                            approval.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may be unable to establish sales and marketing capabilities.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
                                            to comply with or adapt to changes in data protection, privacy, and similar laws could materially
                                            and adversely harm our business.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Increasing
                                            use of AI could lead to liability, violation of data security and privacy laws, or reputational
                                            damage.</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer
                                            systems may fail or suffer security breaches.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Coverage
                                            and reimbursement may be limited or unavailable in certain market segments.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare
                                            reform may negatively impact our ability to sell our product candidates profitably.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            could violate healthcare fraud and abuse, false claims, and health information privacy and
                                            security laws.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            could fail to comply with environmental, health and safety laws and regulations.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Manufacturing and Reliance on Third Parties</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            manufacture of cell therapies is subject to a multitude of manufacturing risks.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            efforts to establish manufacturing capabilities will involve time and expense and may not
                                            be successful.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            loss of suppliers or their inability to supply us with adequate materials could harm our
                                            business.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may not obtain marketing approval for or successfully commercialize product candidates as
                                            a result of failures by third parties.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may not be able to establish collaborations on commercially reasonable terms.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Intellectual Property</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may be unable to obtain and maintain sufficient patent protection for our product candidates
                                            or ExacTcell.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            patent protection could be reduced or eliminated for non-compliance with patent agency requirements.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may not be able to protect our intellectual property rights throughout the world.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
                                            in patent law could diminish the value of patents in general.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may become involved in lawsuits to protect or enforce our intellectual property.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued
                                            patents covering our product candidates could be found invalid or unenforceable if challenged
                                            in court.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
                                            parties may initiate legal proceedings alleging that we are infringing their intellectual
                                            property rights.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Others
                                            may claim an ownership interest in our intellectual property and our product candidates.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may be unable to protect the confidentiality of our proprietary information.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may be subject to claims asserting that our agents have wrongfully used or disclosed alleged
                                            trade secrets.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            trademarks and trade names may be inadequately protected.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intellectual
                                            property rights do not necessarily address all potential threats.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Our Business</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            are highly dependent on our key personnel.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may face substantial competition.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            will need to grow the size of our organization.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product
                                            liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may be limited in our ability to use our net operating loss (&#8220;NOL&#8221;) carryforwards.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Being a Public Company and Ownership of Securities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            price of our Common Stock or Warrants may fluctuate significantly.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">We
                                            have previously failed to timely file certain periodic reports with the SEC and could fail
                                            to timely file such reports in the future.</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may not have the funds necessary to satisfy our future obligations under the terms of our
                                            outstanding preferred stock (the &#8220;Preferred Stock&#8221;).</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<div style="border: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 0.1in; padding-left: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            incur increased costs due to operating as a public company, and our management devotes substantial
                                            time to compliance initiatives and corporate governance practices.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may issue additional shares of our Common Stock or other equity securities without your approval.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company&#8221;.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            management team has limited experience managing a public company.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Analysts
                                            may not publish research about us or may change their recommendation regarding our Common
                                            Stock.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            could become subject to securities litigation or stockholder activism.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may be required to take write-downs or write-offs, restructuring and impairment or other
                                            charges.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            could fail to maintain proper and effective internal control over financial reporting.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Sales
                                            of a substantial number of our securities by existing securityholders could cause their price
                                            to fall.</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
                                            individuals have substantial control over us.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may redeem warrants at a time that is disadvantageous to warrant holders.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            warrant holder exercising warrants on a &#8220;cashless basis&#8221; will receive fewer shares
                                            of Common Stock from such exercise than through a cash exercise.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            public warrants may never be in the money and they may expire worthless.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tevogen
Bio was incorporated June 1, 2020, as a Delaware corporation. Semper Paratus was incorporated on April 21, 2021 as a Cayman Islands exempted
company under the name Semper Paratus Acquisition Corporation. In connection with the closing of the Business Combination, Semper Paratus
became a Delaware corporation and we changed our name to Tevogen Bio Holdings Inc. Our Common Stock and public Warrants are listed on
The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) under the symbols &#8220;TVGN&#8221; and &#8220;TVGNW,&#8221; respectively.
Our principal executive offices are located at 15 Independence Boulevard, Suite #410, Warren, New Jersey 07059, and our telephone number
is (877) 838-6436. Our website address is <i>www.tevogen.com</i>. The information contained in, or accessible through, our website does
not constitute a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Emerging
Growth Company and Smaller Reporting Company Status</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;).
As such, we are eligible for and intend to take advantage of certain exemptions from various reporting requirements applicable to other
public companies that are not emerging growth companies for as long as we continue to be an emerging growth company, including, but not
limited to, (a) not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, (b)
reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and (c) exemptions from
the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments
not previously approved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private
companies are required to comply with the standards. Semper Paratus previously elected to avail itself of the extended transition period
and we will take advantage of the benefits of the extended transition period emerging growth company status permits. During the extended
transition period, it may be difficult or impossible to compare our financial results with the financial results of another public company
that complies with public company effective dates for accounting standard updates because of the potential differences in accounting
standards used.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will remain an emerging growth company under the JOBS Act until the earliest of (a) December 31, 2026 (the last day of the fiscal year
following the fifth anniversary of the consummation of Semper Paratus&#8217; initial public offering (the &#8220;IPO&#8221;)),
(b) the last date of our fiscal year in which we have a total annual gross revenue of at least $1.235 billion, (c) the date on which
we are deemed to be a &#8220;large accelerated filer&#8221; under the rules of the SEC with at least $700.0 million of outstanding securities
held by non-affiliates, and (d) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the
previous three years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also a &#8220;smaller reporting company&#8221; as defined in the Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).
We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain
of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for
so long as the market value of our voting and non-voting common stock held by non-affiliates is less than $250.0 million measured on
the last business day of our second fiscal quarter, or our annual revenue is less than $100.0 million during the most recently completed
fiscal year and the market value of our voting and non-voting common stock held by non-affiliates is less than $700.0 million measured
on the last business day of our second fiscal quarter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<div style="border: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 0.1in; padding-left: 0.1in">



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Su_004"></span>THE
OFFERING</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            of Common Stock offered by us</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42,474,978
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            of Common Stock offered by the Registered Holders</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,329,590
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            of Common Stock outstanding prior to the exercise of Warrants and issuance of Earnout
                                            Shares and Conversion Shares</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">183,893,433
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares (as of April 29, 2025)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
                                            offered by the Registered Holders</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">663,398
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
                                            outstanding</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,974,978
    Warrants (as of April 30, 2025)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise
                                            price per share pursuant to the Warrants</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$11.50</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use
                                            of proceeds</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    will not receive any proceeds from the sale of shares by the Registered Holders. We will receive the proceeds from any exercise of
    the Warrants or options for cash, which we intend to use for general corporate and working capital purposes if there are any such
    exercises. We may receive up to an aggregate of approximately $207 million from the cash exercise of the Warrants. The exercise price
    of each of our Warrants is $11.50 per Warrant. However, the last reported sales price of our Common Stock on April 29, 2025
    was $1.01. The likelihood that holders of Warrants will exercise their Warrants, and therefore any amount of cash proceeds
    that we may receive, is dependent upon the trading price of our Common Stock. If the trading price for our Common Stock continues
    to be less than $11.50 per share, we do not expect holders to exercise their Warrants. Additionally, under certain circumstances,
    the Warrants may be exercised on a cashless basis and we will not receive any proceeds from such exercise, even if the Private Placement
    Warrants are in-the-money. See &#8220;<i>Use of Proceeds</i>&#8221; on page 49 for additional information. <span style="letter-spacing: 0.2pt">Accordingly,
    we have not included the net proceeds from any exercise of the Warrants in our assessment of our liquidity and our ability to fund
    operations on a prospective basis. Our future capital requirements and the adequacy of available funds will depend on many factors,
    including those set forth under &#8220;Risk Factors&#8221; elsewhere in this prospectus.</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
                                            factors</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
    should carefully read the &#8220;<i>Risk Factors</i>&#8221; beginning on page 8 and the other information included
    in this prospectus for a discussion of factors you should consider carefully before deciding to invest in our Common Stock or Warrants.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq
                                            symbol for our Common Stock</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;TVGN&#8221;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; border-left-width: 0in; text-align: left; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq
                                            symbol for our Warrants</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;TVGNW&#8221;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Su_005"></span>RISK
FACTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Investing
in our Common Stock or Warrants involves a high degree of risk. Before making an investment, you should carefully consider the following
risks and uncertainties, as well as general economic and business risks, and the other information contained in this prospectus. These
risk factors are not exhaustive, and investors are encouraged to perform their own investigation with respect to our business, financial
condition and prospects. Our business, financial condition, results of operations, or prospects could be materially and adversely affected
if any of these risks occurs, and as a result, the market price of our Common Stock and Warrants could decline and you could lose all
or part of your investment.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Financial Position and Need for Additional Capital</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have a limited operating history and no products approved for commercial sale and have never generated revenue from product sales. We
have a history of significant losses, expect to continue to incur significant losses for the foreseeable future and may never achieve
or maintain profitability.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage specialty immunotherapy company with a limited operating history. Investment in immunotherapy product development
entails substantial upfront capital expenditures and significant risk that product candidates will fail to prove safe or effective, gain
regulatory approval or become commercially viable. Since our founding in 2020, we have incurred significant net losses. We have funded
our operations to date primarily with proceeds from offerings of convertible notes and preferred stock and have devoted substantially
all of our efforts and financial resources to organizing and staffing our Company, conducting discovery, research, and development
activities, securing intellectual property rights related to our product candidates and ExacTcell technology, raising capital,
and the Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that it could be years, if ever, before we have a commercialized product. We expect to continue to incur significant expenses
and operating losses for the foreseeable future. The net losses we incur may fluctuate significantly from year to year. We anticipate
that our expenses will increase substantially if, and as, we:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have not generated revenue. To become and remain profitable, we, whether on our own or jointly with a collaborator, must develop
and commercialize products with significant market potential. Our ability to generate revenue from product sales and achieve profitability
depends on our ability, alone or with collaboration partners, to successfully complete the development of, and obtain the regulatory
approvals necessary to commercialize, our product candidates. We do not anticipate generating revenue from product sales for some time,
if ever. Our ability to generate future revenue from product sales depends heavily on our, or our potential future collaborators&#8217;,
success in:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completing
                                            preclinical studies and clinical trials of our product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seeking
                                            and obtaining marketing approvals for any product candidates that we or our collaborators
                                            develop;</span></td></tr>
                                                                     </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">receiving
                                            authorization of Investigational New Drug applications (&#8220;INDs&#8221;) for future
                                            product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying
                                            and developing new product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing
                                            current Good Manufacturing Practice (&#8220;cGMP&#8221;) supply of our product candidates
                                            for clinical trials and, if approved, commercial sales;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">launching
                                            and commercializing products for which we obtain marketing approval by establishing a marketing,
                                            sales, distribution, and medical affairs infrastructure or, alternatively, collaborating
                                            with a commercialization partner;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">achieving
                                            coverage and adequate reimbursement by hospitals and third-party payors, including governmental
                                            authorities, such as Medicare and Medicaid, private insurers, and managed care organizations,
                                            for product candidates, if approved, that we or our collaborators develop;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
                                            market acceptance of product candidates, if approved, that we develop as viable treatment
                                            options;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">addressing
                                            any competing technological and market developments;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">negotiating
                                            favorable terms in any collaboration, licensing, or other arrangements into which we may
                                            enter and performing our obligations under such arrangements;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining,
                                            protecting, and expanding our portfolio of intellectual property rights, including patents,
                                            trade secrets and know-how;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">defending
                                            against third-party interference or infringement claims, if any; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">attracting,
                                            hiring, and retaining qualified personnel.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may never succeed in any or all of these activities and, even if we do, we may never generate revenue that is significant or large enough
to achieve profitability and may need to obtain additional funding to continue operations. If we do achieve profitability, we may not
be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease
the value of our Company and could impair our ability to raise capital, maintain our research and development efforts, expand
our business, or continue our operations. A decline in the value of our Company could also cause you to lose all or part of your
investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are relying in part on an additional $8.0 million of grant funding that we have not yet received to meet our liquidity needs.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
primary sources of funds to meet our near-term liquidity and capital requirements include cash on hand, amounts available under the
Loan Agreement, and an additional $8.0 million of grant funding we expect to receive in the second quarter of 2025 from KRHP LLC,
a New Jersey limited liability company (&#8220;KRHP&#8221;). In January 2025, we received a grant of $2.0 million from KRHP to
further our development of off-the-shelf, genetically unmodified precision T cell therapeutics to treat infectious diseases and cancers.
KRHP also committed to provide an additional $8.0 million of grant funding to the Company to be used towards the Company&#8217;s
ongoing operational expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are relying in part on the additional grant funding to help meet our liquidity needs. Even if we receive all of such proceeds,
we will still need additional capital to fully implement our business, operating, and development plans. At this time, we have not
secured any additional financing. There can be no assurance that additional capital will be available to us, or that, if available, it
will be on terms satisfactory to us. If we do not obtain additional capital on terms satisfactory to us, or at all, it may cause us to
delay, curtail, scale back or forgo some or all of our research and development or business operations, which could have a material adverse
effect on our business and financial results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will require substantial additional financing to pursue our business objectives, which may not be available on acceptable terms, or at
all. A failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development,
commercialization efforts or other operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to spend substantial amounts of cash to continue the preclinical and clinical development of our current and future programs.
If we receive marketing approval for any product candidates, including TVGN 489, we will require significant additional amounts of cash
in order to launch and commercialize such product candidates. In addition, other unanticipated costs may arise. Because the designs and
outcomes of our planned and anticipated clinical trials are highly uncertain, we cannot reasonably estimate the actual amounts necessary
to successfully complete the development of and commercialize any product candidate we develop.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future capital requirements depend on many factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            scope, progress, timing, results, and costs of researching and developing TVGN 489 and our
                                            other product candidates, including product candidates developed with our ExacTcell technology,
                                            and of conducting preclinical studies and clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            timing of, and the costs involved in, obtaining marketing approval for TVGN 489 and any future
                                            product candidates we develop, if clinical trials are successful;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            costs of manufacturing TVGN 489 and any future product candidates for preclinical studies
                                            and clinical trials and in preparation for marketing approval and commercialization;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            costs of commercialization activities, including marketing, sales, and distribution costs,
                                            for TVGN 489 and any future product candidates we develop if any of these product candidates
                                            are approved for sale;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to establish and maintain strategic collaborations, licensing, or other arrangements
                                            on favorable terms, if at all;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            costs involved in preparing, filing, prosecuting, maintaining, expanding, defending, and
                                            enforcing patent claims, including litigation costs and the outcome of any such litigation;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            timing, receipt, and amount of sales of, or royalties on, our future products, if any; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            emergence of competing therapies and other developments in the markets we intend to address.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
we can generate sufficient product and royalty revenue to finance our cash requirements, which we may never do, we expect to finance
our future cash needs through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances,
and licensing arrangements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the terms of the Preferred Stock and our Loan Agreement may negatively impact our ability
to raise additional capital through equity or debt financings, due to the potential substantial dilution to our stockholders that could
occur as a result of the conversion of our convertible Preferred Stock or our issuance of shares under the Loan Agreement and due to
the other terms of our Preferred Stock and the Loan Agreement, or may negatively affect our ability to obtain favorable or acceptable
terms in connection with any such financing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
if we raise additional capital through marketing, sales, and distribution arrangements or other collaborations, strategic alliances,
or licensing arrangements with third parties, we may have to relinquish certain valuable rights to our product candidates, future revenue
streams, research programs, or technologies or grant licenses on terms that may not be favorable to us. If we raise additional capital
through public or private equity offerings, the terms of these securities may include liquidation or other preferences that adversely
affect our stockholders&#8217; rights. Further, to the extent that we raise additional capital through the sale of Common Stock
or securities convertible or exchangeable into Common Stock, your ownership interest will be diluted. If we raise additional capital
through debt financing, we would be subject to fixed payment obligations and may be subject to covenants limiting or restricting our
ability to take specific actions, such as incurring additional debt, making capital expenditures, engaging in acquisition, merger, or
collaboration transactions, selling or licensing our assets, making capital expenditures, redeeming our stock, making certain investments,
declaring dividends, or other operating restrictions that could adversely impact our ability to conduct our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
future debt financing or other financing of securities senior to our Common Stock will likely include financial and other covenants
that will restrict our flexibility. Any failure to comply with these covenants may cause an event of default and acceleration of the
obligation to pay the debt, which would have a material adverse effect on our business, prospects, financial condition, and results of
operations and we could lose our existing sources of funding and impair our ability to secure new sources of funding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adequate
additional financing may not be available to us on acceptable terms, or at all, and may be impacted by the economic climate and market
conditions. If we are unable to obtain additional financing on favorable terms when needed, we may be required to delay, limit, reduce,
or terminate preclinical studies, clinical trials, or other research and development activities or one or more of our development programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Development, Regulatory Review, and Product Approval</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
regulatory landscape that applies to cellular therapy product candidates is rigorous, complex, uncertain, and subject to change. Our
allogeneic T cell therapy product candidates represent new therapeutic approaches that could result in heightened regulatory scrutiny,
delays in clinical development or delays in or our ability to achieve regulatory approval, if at all, and commercialization or payor
coverage and reimbursement of our product candidates, if approved.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future success is dependent on our unique approach to T cell therapy. Because these programs, particularly our pipeline of allogeneic
T cell product candidates that are developed from donors, represent a novel approach to immunotherapy for the treatment of virus-infected
cells in order to produce T cell immunity, developing and commercializing our product candidates subjects us to a number of challenges,
including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
                                            regulatory approval from FDA, which has relatively limited experience with regulating the
                                            development and commercialization of T cell immunotherapies;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing
                                            and deploying consistent and reliable processes for procuring blood from consenting third-party
                                            donors, isolating T cells from the blood of such donors, activating the isolated T cells
                                            against specific antigens, characterizing and storing the resulting activated T cells for
                                            future therapeutic use, selecting and delivering a sufficient supply and breadth of appropriate
                                            human leukocyte antigen-matched (&#8220;HLA-matched&#8221;) cells from among the available
                                            T cell lines, and finally infusing these activated T cells into patients to eliminate virus-infected
                                            cells in the patient and induce anti-disease benefit;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">relying
                                            on healthcare provider site availability and accessibility to patients for receipt of T cell
                                            infusions;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">utilizing
                                            these product candidates in combination with other therapies currently used to treat patients
                                            in our target population, which may increase the risk of adverse side effects;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">educating
                                            medical personnel regarding the potential side effect profile of each of our product candidates,
                                            particularly those that may be unique to our allogeneic T cell therapy product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">understanding
                                            and addressing variability in the quality of a donor&#8217;s T cells, which could ultimately
                                            affect our ability to manufacture product in a reliable and consistent manner;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing
                                            processes for the safe administration of these products, including long-term follow-up and
                                            registries, as applicable, for all patients who receive these product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing
                                            our product candidates to our specifications and in a timely manner to support our clinical
                                            trials and, if approved, commercialization;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sourcing
                                            clinical and, if approved by FDA, commercial supplies for the materials used to manufacture
                                            and process these product candidates that are free from viruses and other pathogens that
                                            may increase the risk of adverse side effects;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing
                                            a manufacturing process and distribution network that can provide a stable supply with a
                                            cost of goods that allows for an attractive return on investment;</span></td></tr></table>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
                                            sales and marketing capabilities ahead of and after obtaining any regulatory approval to
                                            gain market acceptance, and obtaining adequate coverage, reimbursement and pricing by third-party
                                            payors and government authorities; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing
                                            therapies for types of diseases beyond those initially addressed by our current product candidates.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adverse
developments in preclinical studies or clinical trials conducted by others in cellular therapy products may cause FDA and other regulatory
bodies to amend the requirements for approval of any product candidates we may develop or limit the use of products utilizing cellular
therapy technologies, either of which could harm our business. In addition, FDA&#8217;s clinical trial requirements and its criteria
for determining the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty, and intended
use and market of the potential products. The regulatory approval process for product candidates such as ours could be more expensive
and take longer than for other, better known, or more extensively studied pharmaceutical or other product candidates. Further, as we
are developing novel potential treatments for diseases in which in some cases there is relatively little clinical experience with new
endpoints and methodologies, there is heightened risk that FDA or other regulatory bodies may not consider the clinical trial endpoints
to provide clinically meaningful results, and the resulting clinical data and results may be more difficult to analyze. Regulatory agencies
administering existing or future regulations or legislation may not allow production and marketing of products utilizing cellular therapy
technology in a timely manner or under technically or commercially feasible conditions. In addition, regulatory action or private litigation
could result in expenses, delays, or other impediments to our research programs or the commercialization of resulting products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot be sure that the manufacturing processes used in connection with our T cell immunotherapy product candidates will yield a sufficient
supply of satisfactory products that are safe, pure, and potent, scalable, or profitable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
actual or perceived safety issues, including adoption of new therapeutics or novel approaches to treatment, may adversely influence the
willingness of patients to participate in clinical trials, or if approved by FDA, of physicians to subscribe to the novel treatment mechanics.
FDA may ask for specific post-market requirements, such as establishment of a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;),
and additional information informing benefits or risks of our products may emerge at any time prior to or after regulatory approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA&#8217;s
policies may change and additional government regulations may be enacted that could prevent, limit, or delay regulatory approval of any
current or future product candidate. We cannot predict the likelihood, nature or extent of government regulation that may arise from
future legislation or administrative action. If we are slow or unable to adapt to changes in existing requirements or to the adoption
of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we
may have obtained. In addition, the regulatory landscape applicable to AI is immature and changes to existing regulations or new
regulations could impede our use of AI, which could impair our ability to achieve our goals for our AI initiative and result
in an adverse effect on our business, results of operations and financial condition. For example, FDA&#8217;s Center for Biologics
Evaluation and Research, in coordination with others in FDA, has recently developed a regulatory framework for the safe and responsible
use of AI throughout the biological product lifecycle, which is outlined in a draft guidance document issued by FDA. If and when finalized,
this and other guidance documents, as well as other new FDA regulations and requirements, could present substantial and increasing costs
for our compliance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>As
an organization, we have limited experience designing and implementing preclinical and clinical trials, which is a complex, expensive,
and time-consuming process and involves uncertain outcomes, and we have never conducted pivotal clinical trials. We may fail to adequately
design a trial, which could adversely affect the ability to initiate the trial, enroll patients, complete the trial, or obtain regulatory
approval on the basis of the trial results, as well as lead to increased or unexpected costs and in delayed timelines.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have limited experience designing and implementing preclinical and clinical trials, which is a complex, expensive, and time-consuming
process and involves uncertain outcomes. All of our product candidates are in preclinical or clinical development and their risk of failure
is high. The clinical trials and manufacturing of our product candidates are, and the manufacturing and marketing of our products, if
approved, will be, subject to extensive and rigorous review and regulation by numerous government authorities in the United States and
in other countries where we intend to test and market our product candidates. Before obtaining regulatory approvals for the commercial
sale of any of our product candidates, we must demonstrate through lengthy, complex, and expensive preclinical studies and clinical trials
that our product candidates are both safe and effective for use in each target indication. In particular, because our product candidates
are subject to regulation as biological products, we will need to demonstrate that they are safe, pure, and potent for use in their target
indications. Each product candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for
its intended use. We cannot be certain of the timely completion or outcome of our preclinical studies and clinical trials and cannot
predict if FDA will accept our proposed clinical programs or if the outcome of our preclinical studies and clinical trials will ultimately
support the further development of our current or future product candidates. As a result, we cannot be sure that we will be able to submit
INDs or similar applications for our preclinical programs on the timelines we expect, if at all, and we cannot be sure that such submission
will result in FDA allowing clinical trials to begin.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
we may not successfully or cost-effectively design and implement preclinical and clinical trials that achieve our desired clinical endpoints
efficiently, or at all. A clinical trial that is not well designed may delay or prevent initiation or completion of the trial, can lead
to increased difficulty in enrolling patients, may make it more difficult to obtain regulatory approval for the product candidate on
the basis of the study results, or, even if a product candidate is approved, could make it more difficult to commercialize the product
successfully or obtain reimbursement from third-party payors. Additionally, a trial that is not well-designed could be inefficient or
more expensive than it otherwise would have been, or we may incorrectly estimate the costs to implement the clinical trial, which could
lead to a shortfall in funding. We also expect to continue to rely on third parties to conduct our pivotal clinical trials. See &#8220;&#8212;
<i>Risks Related to Reliance on Manufacturing and Third Parties</i>.&#8221; If these third parties do not successfully carry out their
contractual duties, comply with regulatory requirements or meet expected deadlines, we may not be able to obtain marketing approval for
or commercialize TVGN 489 any future product candidates we develop, and our business could be materially harmed. We may require more
time and incur greater costs than our competitors and may not succeed in obtaining regulatory approvals of product candidates that we
develop.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to successfully develop, receive regulatory approval for, and commercialize our product candidates, our business will be
harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of our product candidates are still in preclinical and clinical development and, with the exception of TVGN 489, we are early in our
development efforts. FDA permitted our IND for TVGN 489 to proceed in May 2021,
and we began enrolling subjects in October 2021. Each of our programs and product candidates will require additional preclinical and/or
clinical development, regulatory approval, obtaining manufacturing supply, capacity, and expertise, building a commercial organization
or successfully outsourcing commercialization, substantial investment, and significant marketing efforts, before we generate any revenue
from product sales. We do not have any products that are approved for commercial sale, and we may never be able to develop or commercialize
marketable products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to generate revenue from our product candidates, which could take years to develop, if it ever does, will depend heavily on the
successful development, regulatory approval, and eventual commercialization of our product candidates. The success of our product candidates
or any other product candidates that we develop or otherwise may acquire will depend on several factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">timely
                                            and successful completion of preclinical studies and clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">effective
                                            INDs submitted to FDA that allow commencement of our clinical trials for our product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sufficiency
                                            of our financial and other resources to complete the necessary preclinical studies and clinical
                                            trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successful
                                            development of, or making arrangements with third-party manufacturers for, our commercial
                                            manufacturing processes for our clinical trials and any of our product candidates that receive
                                            regulatory approval at an acceptable cost and on a timely basis;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">receipt
                                            of timely marketing approvals from FDA;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">launching
                                            commercial sales of products, if approved;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acceptance
                                            of the benefits and use of our products, if approved, by patients, the medical community,
                                            and third-party payors, for their approved indications;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            prevalence and severity of adverse events or other safety issues experienced with our product
                                            candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            availability, perceived advantages, cost, safety, and efficacy of alternative therapies for
                                            any product candidate, and any indications for such product candidate, that we develop;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to produce any product candidates we develop on a commercial scale;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
                                            and maintaining patent, trademark and trade secret protection and regulatory exclusivity
                                            for our product candidates and otherwise protecting our rights in our intellectual property
                                            portfolio;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining
                                            compliance with regulatory requirements, including cGMP requirements;</span></td></tr></table>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
                                            and maintaining coverage and adequate reimbursement by third-party payors, including government
                                            payors, for our products, if approved by FDA;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining
                                            a continued acceptable safety, tolerability and efficacy profile of the products following
                                            approval; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining
                                            and growing an organization of scientists and functional experts who can develop and commercialize
                                            our products and technology.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we do not succeed with respect to one or more of these factors in a timely manner or at all, we could experience significant delays or
an inability to successfully commercialize the product candidates we develop, which would materially harm our business. If we do not
receive marketing approvals for any product candidate we develop, we may not be able to continue our operations. Even if regulatory approvals
are obtained, we could experience significant delays or an inability to successfully commercialize our current and any future product
candidates we develop, which would materially harm our business. If we are not able to generate sufficient revenue through the sale of
any current or future product candidate, we may not be able to continue our business operations or achieve profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may encounter substantial delays and disruptions in completing the development of our product candidates that could impair our ability
to successfully commercialize our product candidates and may harm our business and results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may experience delays in completing planned clinical trials for a variety of reasons, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            extensive research and development required because our product candidates are based on new
                                            technologies;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            availability of financial resources to commence and complete the planned trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reaching
                                            agreement on acceptable terms with prospective clinical research organizations (&#8220;CROs&#8221;)
                                            and clinical trial sites, the terms of which can be subject to extensive negotiation and
                                            may vary significantly among different CROs and trial sites;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
                                            or independent institutional review boards (&#8220;IRBs&#8221;) may not authorize us or our
                                            investigators to commence a clinical trial or conduct a clinical trial at a prospective trial
                                            site;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recruiting
                                            suitable patients to participate in a trial or sufficient patients to complete a trial;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">having
                                            patients complete a trial or return for post-treatment follow-up;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
                                            trial sites deviating from trial protocol or dropping out of a trial, which may require that
                                            we add new clinical trial sites or investigators;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing
                                            the necessary product for use in the clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
                                            trials of any product candidate may fail to show safety, purity, or potency, or may produce
                                            negative or inconclusive results, which may cause us to decide, or regulators to require
                                            us, to conduct additional nonclinical trials or clinical trials or which may cause us to
                                            decide to abandon product candidate development programs;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            of our product candidates could cause undesirable side effects that could result in significant
                                            negative consequences, including the inability to enter clinical development or receive regulatory
                                            approval; and/or</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competition
                                            from other clinical trial programs for similar indications and clinical trial patients.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
clinical trial may also be suspended or terminated by us, the IRB for the institutions in which such trials are being conducted, the
data and safety monitoring board (&#8220;DSMB&#8221;) for such trial, or by FDA due to a number of factors. Those factors could include
failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical
trial operations or trial site by FDA, resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects,
failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack
of adequate funding to continue the clinical trial. In addition, FDA may order the temporary or permanent discontinuation of our clinical
trials at any time if it believes that the clinical trials are not being conducted in accordance with applicable regulatory requirements
or that they present an unacceptable safety risk to the patients enrolled in our clinical trials, or that the applicable INDs do not
contain sufficient information to assess the risks to patients in the proposed trials. For example, in November 2020, FDA placed a clinical
hold on our IND for TVGN 489 for the treatment of patients with COVID-19 infection, requested certain information regarding the manufacture
of TVGN 489, and asked us to revise our sterility testing approach so that such testing is performed on the final drug product, as opposed
to testing before harvesting the cells for cryopreservation. In May 2021, FDA found that we sufficiently addressed all of these issues
and lifted the clinical hold, permitting us to initiate our Phase 1 trial, which we completed in January 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may experience regulatory delays or rejections as a result of many reasons. For example, we believe based on precedential industry examples,
including in areas with high unmet needs or strong early phase clinical trial results, that we may be able to commence pivotal trials
of TVGN 489 on the basis of the results of our completed Phase 1 trial. However, the clinical trial process usually includes three phases,
and our current plan to move TVGN 489 from its recently completed Phase 1 trial directly into pivotal trials may be rejected by FDA or
may be otherwise unfeasible. We may have to conduct additional Phase 1 testing or other Phase 2 trials, or may experience other delays,
prior to escalating TVGN 489 into a pivotal trial. At this stage, we cannot be certain whether we will be permitted to move from a Phase
1 trial directly to pivotal trials until FDA reviews and concurs with or rejects our proposed plans, and FDA may require us to conduct
further trials to generate additional safety and efficacy data. If regulatory inspectors conclude that we or our clinical trial sites
are not in compliance with applicable regulatory requirements for conducting clinical trials, we may receive reports of observations
or warning letters detailing deficiencies, and we will be required to implement corrective actions. If regulatory agencies deem our responses
to be inadequate, or are dissatisfied with corrective actions, our clinical trials may be temporarily or permanently discontinued, we
or our investigators may be precluded from conducting any ongoing or any future clinical trials, the government may refuse to approve
our marketing applications or allow us to manufacture or market our products, we may face civil enforcement actions from FDA, and we
may be criminally prosecuted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we experience termination of, or delays in the completion of, any clinical trial of our product candidates, the commercial prospects
for our product candidates will be harmed, and our ability to generate product revenue will be delayed. In addition, any delays in completing
our clinical trials will increase our costs, slow down our product development and approval process, and jeopardize our ability to commence
product sales and generate revenue. Significant clinical trial delays could also allow our competitors to bring products to market before
we do or shorten any periods during which we have the exclusive right to commercialize our product candidates. In addition, many of the
factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of
regulatory approval of our product candidates or result in the development of our product candidates stopping early.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
FDA regulatory approval process is lengthy and time-consuming and may lead to significant delays in the clinical development and regulatory
approval of our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
time required to obtain approval from FDA is unpredictable but typically takes many years following the commencement of clinical trials
and depends upon numerous factors, including the substantial discretion of FDA. Any delay in obtaining FDA and/or other necessary regulatory
approvals in the United States for any investigational new drug and failure to receive such approvals would have an adverse effect on
the investigational new drug&#8217;s potential commercial success and on our business, prospects, financial condition, and results of
operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not obtained regulatory approval for any product candidate. We have not previously submitted a Biologics License Application (&#8220;BLA&#8221;)
to FDA. It is possible that none of our current or future product candidates will ever obtain regulatory approval from FDA. The novel
nature of our product candidates may create further challenges in obtaining regulatory approval. The regulatory approval pathway for
our product candidates may be uncertain, complex, expensive, and lengthy, and approval may not be obtained. In addition, factors outside
our control, such as government shutdowns, natural disasters, and public health emergencies, could disrupt business at FDA, which could
result in delays of reviews, approvals and communications with FDA related to our clinical trials and product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current and future product candidates could fail to receive regulatory approval for many reasons, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
                                            may disagree with the design or implementation of our clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            may be unable to demonstrate to the satisfaction of FDA that a product candidate is safe,
                                            pure, and potent for its proposed indication;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            results of clinical trials may not meet the level of statistical significance required by
                                            FDA for approval;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits
                                            outweigh its safety risks;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
                                            may disagree with our interpretation of data from clinical trials or preclinical studies;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            data collected from clinical trials of our product candidates may not be sufficient to support
                                            the submission of a BLA to FDA to obtain regulatory approval in the United States; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
                                            may find deficiencies with or fail to approve our manufacturing processes or facility or
                                            the manufacturing processes or facilities of third-party manufacturers with which we contract
                                            for clinical and commercial supplies.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
lengthy approval process as well as the unpredictability of clinical trial results may result in our failing to obtain regulatory approval
to market any product candidate we develop, which would significantly harm our business, results of operations and prospects. Even if
we believe the data collected from current or future clinical trials of our product candidates are promising, such data may not be sufficient
to support approval by FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we obtain approval, FDA may approve any of our product candidates for fewer or more limited indications, or a more limited patient
population, than we request; may grant approval contingent on the performance of costly post-approval clinical trials or other post-marketing
requirements; or may approve a product candidate with labeling that does not include the claims we believe are necessary or desirable
for the successful commercialization of such product candidates. Moreover, if we modify TVGN 489 and our other product candidates so
that they recognize and target new or more prevalent variants of COVID-19 and other viruses, we may have to either file a supplemental
BLA with FDA or receive FDA approval for a comparability protocol or obtain other regulatory approval. These requirements may be costly
and time-consuming and FDA ultimately may not approve of such changes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
may also change its policies, promulgate additional regulations, revise existing regulations, or take other actions that may prevent
or delay approval of our future products under development on a timely basis. Such policy or regulatory changes could impose additional
requirements upon us that could delay our ability to obtain approvals, increase the costs of compliance or restrict our ability to maintain
any marketing authorizations we may have obtained.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may never receive RMAT designation for TVGN 489 or any other product candidate,
and receiving this designation may not lead to a faster development or regulatory review or approval process, and will not increase the
likelihood that such product candidates will receive marketing approval.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may seek RMAT designation from FDA for TVGN 489 for the treatment of COVID-19, or for our other product candidates. FDA may find that
TVGN 489 or our other product candidates do not meet the criteria for RMAT designation or may otherwise deny our requests for RMAT designation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RMAT
designation provides potential benefits that include more frequent meetings with FDA to discuss the development plan for the product
candidate, and potential eligibility for rolling review and priority review. Products granted RMAT designation may also be eligible for
accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or
reliance upon data obtained from a meaningful number of sites, including through expansion to additional sites post-approval, if appropriate.
RMAT-designated products that receive accelerated approval may, as appropriate, fulfill their post-approval requirements through the
submission of clinical evidence, clinical studies, patient registries, or other sources of real world evidence; through the collection
of larger confirmatory data sets; or via post-approval monitoring of all patients treated with such therapy prior to approval of the
therapy. Under the Food and Drug Omnibus Reform Act of 2022 (&#8220;FDORA&#8221;), FDA is permitted to require that a post-approval confirmatory
study or studies be underway prior to approval or within a specified time period after the date of approval for a product granted accelerated
approval. FDORA also requires sponsors to send updates to FDA on the status of such studies and FDA must promptly post this information
publicly. FDORA also gives FDA increased authority to withdraw approval of a drug or biologic granted accelerated approval on an expedited
basis if the sponsor fails to conduct such studies in a timely manner, send the necessary updates to FDA, or if such post-approval studies
fail to verify the drug&#8217;s predicted clinical benefit. Under FDORA, FDA is empowered to take action, such as issuing fines, against
companies that fail to conduct with due diligence any post-approval confirmatory study or submit timely reports to the agency on their
progress. In addition, for products being considered for accelerated approval, FDA generally requires, unless otherwise informed by the
agency, that all advertising and promotional materials intended for dissemination or publication within 120 days of marketing approval
be submitted to the agency for review during the pre-approval review period. There can be no assurance that FDA would allow any of the
product candidates we may develop to proceed on an accelerated approval pathway, and even if FDA did allow such pathway, there can be
no assurance that such submission or application will be accepted or that any expedited development, review or approval will be granted
on a timely basis, or at all. Moreover, even if we received accelerated approval, any post-approval studies required to confirm and verify
clinical benefit may not show such benefit, which could lead to withdrawal of any approvals we have obtained. Receiving accelerated approval
does not assure that the product&#8217;s accelerated approval will eventually be converted to a traditional approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RMAT
designation does not change the standards for product approval, and there is no assurance that any such designation or eligibility will
result in expedited review or approval or that the approved indication will not be narrower than the indication covered by the RMAT designation.
Additionally, RMAT designation can be revoked if the criteria for eligibility cease to be met as clinical data emerges.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business is highly dependent on our first product candidate, TVGN 489, and we must conduct clinical testing before we can obtain regulatory
approval and begin commercialization of any of our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we have limited financial and personnel resources and are placing significant focus on the development of TVGN 489, we may forgo or delay
pursuit of opportunities with other future product candidates that later prove to have greater commercial potential. Our resource allocation
decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current
and future research and development programs and other future product candidates for specific indications may not yield any commercially
viable future product candidates. If we do not accurately evaluate the commercial potential or target market for a particular future
product candidate, we may relinquish valuable rights to those future product candidates through collaboration, licensing, or other royalty
arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to
such future product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Interim
and preliminary results from our clinical trials that we announce or publish from time to time may change as more patient data become
available and are subject to audit, validation, and verification procedures that could result in material changes in the final data.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may publish interim data, including interim top-line results or preliminary results from our clinical trials. Interim
data and results from our clinical trials are subject to the risk that one or more of the clinical outcomes may materially change as
patient enrollment continues and more patient data become available. Preliminary or top-line results also remain subject to audit, validation,
and verification procedures that may result in the final data being materially different from the interim and preliminary data we previously
published. As a result, interim and preliminary data may not be predictive of final results and should be viewed with caution until the
final data are available. Differences between preliminary or interim data and final data could significantly harm our business prospects
and may cause the trading price of our Common Stock to fluctuate significantly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
results of earlier preclinical and clinical trials may not be predictive of future clinical trial results. Initial positive results in
any of our clinical trials may not be indicative of results obtained when the trial is completed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
can occur at any time during the clinical trial process. Preclinical studies and early-stage clinical trials are primarily designed to
test safety, to study pharmacokinetics and pharmacodynamics, and to understand the side effects of product candidates at various doses
and schedules, and the results of preclinical studies and early clinical trials of our product candidates may not be predictive of the
results of larger, later-stage controlled clinical trials. For example, our current or future product candidates may demonstrate different
chemical, biological and pharmacological properties in patients than they do in laboratory studies or may interact with human biological
systems in unforeseen or harmful ways. Product candidates in later stages of clinical trials may fail to show desired pharmacological
properties or produce the necessary safety and efficacy results despite having progressed through preclinical studies and initial clinical
trials. In addition, initial success in clinical trials may not be indicative of results obtained when such trials are completed. Product
candidates that have shown promising results in early-stage clinical trials may still suffer significant setbacks in subsequent clinical
trials. Our sole clinical trial to date was conducted on a small number of patients in a single academic clinical site for a limited
number of indications. We will have to conduct larger, well-controlled trials in our proposed indications at multiple sites to verify
the results obtained to date and to support any regulatory submissions for further clinical development of our product candidates. Our
assumptions related to our product candidates, such as with respect to lack of toxicity, are based on an early limited clinical trial
and may prove to be incorrect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even
after achieving promising results in earlier, smaller clinical trials, and any such setbacks in our clinical development could have a
material adverse effect on our business and operating results. Moreover, clinical data are often susceptible to varying interpretations
and analyses that may delay, limit, or prevent regulatory approval. We do not know whether any later stage clinical trials of TVGN 489
or other clinical trials we may conduct will demonstrate consistent or adequate efficacy and safety with respect to the proposed indication
for use sufficient to receive regulatory approval or market our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Because
the number of patients in our proof-of-concept clinical trial of TVGN 489 was small, the results from this trial may be less reliable
than results achieved in larger clinical trials.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
trial design that is considered appropriate includes a sufficiently large sample size with appropriate statistical power, as well as
proper control of bias, to allow a meaningful interpretation of the results. The preliminary results of studies with smaller sample sizes,
such as our proof-of-concept clinical trial of TVGN 489, can be disproportionately influenced by the impact the product had on a few
individuals, which limits the ability to generalize the results across a broader community, thus making the study results less reliable
than studies with a larger number of patients and making it difficult to predict final results from preliminary results. Our proof-of-concept
clinical trial only tested TVGN 489 in the most common HLA type, and while we intend to treat patients with the six most common HLA types
in our next clinical trial of TVGN 489, our results in our proof-of-concept clinical trial may not be predictive of results in other
HLA types. As a result, there may be less certainty that TVGN 489 would achieve a statistically significant effect in any future clinical
trials. If we conduct any future clinical trials of TVGN 489, we may not achieve a statistically significant result. Similarly, if we
conduct a clinical trial of any other product candidate we develop with a small sample size, the results of any such trial may be less
reliable than results achieved in larger clinical trials and may provide less certainty of achieving statistically significant effects
in any future clinical trials. Such results could negatively impact our business, financial condition, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in methods of product candidate manufacturing or formulation may result in additional costs or delay.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
product candidates proceed through preclinical studies to late-stage clinical trials towards potential approval and commercialization,
it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way
in an effort to optimize processes and results. Such changes carry the risk that they will not achieve these intended objectives. Any
of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other
future clinical trials conducted with the materials manufactured using altered processes. Such changes may also require additional testing,
FDA notification, or FDA approval. This could delay completion of clinical trials, require the conduct of bridging clinical trials or
the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates, and jeopardize
our ability to commence sales and generate revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
approach to the discovery and development of product candidates using our ExacTcell technology is unproven and may not result
in marketable products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
success of our business depends in part upon our ability to develop and commercialize cell therapies based on our proprietary ExacTcell
technology. We have only conducted one Phase 1 trial based on a product developed using ExacTcell. Our approach to the development
of cell therapies using ExacTcell is novel. We may not continue to have access to effective HLA-typing diagnostics and may have difficulties
in obtaining or manufacturing significant quantities and breadth of single HLA-restricted cell lines to use in clinical trials or sufficient
to cover desired patient populations. We cannot assure the product candidates we develop with ExacTcell will be found to be safe and
effective in treating any disease so as to achieve marketing approval. If we uncover any previously unknown risks related to ExacTcell,
or if we experience unanticipated problems or delays in developing our ExacTcell product candidates, we may be unable to achieve our
strategy of building a broad pipeline of cell therapy product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
preclinical studies and clinical trials may fail to demonstrate the safety and efficacy of our product candidates, or serious adverse
or unacceptable side effects may be identified during the development of our product candidates, which could prevent or delay regulatory
approval and commercialization, increase our costs, or necessitate the abandonment or limitation of the development of some of our product
candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
obtaining regulatory approvals for the commercial sale of our product candidates, we must demonstrate through lengthy, complex, and expensive
preclinical studies and clinical trials that our product candidates are safe, pure, and effective for use in each target indication,
and failures can occur at any stage of testing. Preclinical studies and clinical trials often fail to demonstrate safety or efficacy
of the product candidate studied for the target indication. The use of our current or future product candidates could be associated with
side effects or adverse events, which could vary in severity from minor reactions to death and in frequency from infrequent to prevalent.
In addition, if one or more of our product candidates or our T cell technology proves to be unsafe it would also materially
harm our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to side effects caused by the product candidate, the administration process or related procedures also can cause adverse side
effects. If any such adverse events occur, our clinical trials could be suspended or terminated. If we cannot demonstrate that any adverse
events were not caused by the drug or administration process or related procedures, FDA could order us to cease further development of,
or deny approval of, our product candidates for any or all targeted indications. Even if we are able to demonstrate that all future serious
adverse events are not product-related, such occurrences could affect patient recruitment or the ability of enrolled patients to complete
the trial. Moreover, if we elect, or are required, to not initiate, delay, suspend or terminate any future clinical trial of any of our
product candidates, the commercial prospects of such product candidates may be harmed and our ability to generate product revenues from
any of these product candidates may be delayed or eliminated. In addition, these side effects may not be appropriately recognized or
managed by the treating medical staff.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
our current and future product candidates have undergone and will undergo extensive safety testing and, where applicable, under such
conditions discussed with FDA, not all adverse effects of drugs can be predicted or anticipated. Immunotherapy and its method of action
of harnessing the body&#8217;s immune system are powerful and could lead to serious side effects that we only discover in clinical trials
or during commercial marketing. Unforeseen side effects could arise either during clinical development or after our product candidates
have been approved by FDA and the approved product has been marketed, resulting in the exposure of additional patients. If our product
candidates are associated with side effects in clinical trials or have characteristics that are unexpected, we may need to abandon their
development or limit development to more narrow uses in which the side effects or other characteristics are less prevalent, less severe,
or more acceptable from a risk-benefit perspective. So far, we have not demonstrated that TVGN 489 or any other product candidate is
safe in humans, and we cannot predict if ongoing or future clinical trials will do so. If any of our current or future product candidates
fail to demonstrate safety and efficacy in clinical trials or do not gain marketing approval, we will not be able to generate revenue
and our business will be harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
or an IRB may also require that we suspend, discontinue, or limit our clinical trials based on safety information, or that we conduct
additional preclinical studies regarding the safety and efficacy of our product candidates that we have not planned or anticipated. Such
findings could further result in FDA failing to provide marketing authorization for our product candidates or limiting the scope of the
approved indication, if approved. Many product candidates that initially showed promise in early-stage testing have later been found
to cause side effects that prevented further development of the product candidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
if one or more of our product candidates receives marketing approval, and we or others identify undesirable side effects caused by such
products, a number of potentially significant negative consequences could result, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
                                            may withdraw approvals of such product;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
                                            may require additional warnings on the labels such as a &#8220;black box&#8221; warning or
                                            a contraindication;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            may be required to create a medication guide outlining the risks of such side effects for
                                            distribution to patients or other requirements subject to a REMS;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            could be sued and held liable for harm caused to patients;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            may not be able to achieve or maintain third-party payor coverage and adequate reimbursement;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            may be required to recall a product or change the way such product is administered to patients;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional
                                            restrictions may be imposed on the marketing of the particular product or the manufacturing
                                            processes for the product or any component thereof; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            reputation and physician or patient acceptance of our products may suffer.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
can be no assurance that we will resolve any issues related to any product-related adverse events to the satisfaction of FDA in a timely
manner or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise
be adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
successful and timely completion of clinical trials in accordance with their protocols depends on, among other things, our ability to
enroll a sufficient number of patients who remain in the trial until the trial&#8217;s conclusion, including any follow-up period. We
may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The enrollment of patients depends
on many factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            patient eligibility criteria defined in the protocol;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            nature and size of the patient population required for analysis of the trial&#8217;s primary
                                            endpoints and the process for identifying patients;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            number and location of participating clinical sites or patients;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            design of the trial;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinicians&#8217;
                                            and patients&#8217; perceptions as to the potential advantages and risks of the product candidate
                                            being studied in relation to other available therapies, including any new products that may
                                            be approved for the indications we are investigating;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            availability of competing commercially available therapies and other competing drug candidates&#8217;
                                            clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to obtain and maintain patient informed consents for participation in our clinical
                                            trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            risk that patients enrolled in clinical trials will drop out of the trials before completion;
                                            and/or</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">factors
                                            outside of our control, including as a result of business interruptions resulting from natural
                                            disasters and public health emergencies, such as the coronavirus.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may experience difficulties in patient enrollment in our future clinical trials for a variety of reasons. A decrease in cases
may reduce the number of eligible candidates for trials testing COVID-19 therapeutics, such as TVGN 489. Additionally, as time passes,
treating COVID-19 is becoming a less critical issue in the eyes of the public, further limiting the potential patient population
for COVID-19 therapeutics. Moreover, TVGN 489 may represent a departure from more commonly used methods for COVID-19 treatment, and potential
patients and their doctors may be inclined to use more conventional therapies for the treatment of COVID-19 rather than enroll in any
future clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient
number of patients who remain in the study until its conclusion. In addition, our clinical trials may compete with existing therapies
and other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition
may reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead
opt to enroll in a trial being conducted by one of our competitors. Accordingly, we cannot guarantee that our clinical trials will progress
as planned or as scheduled. Delays from difficulties in patient enrollment in a clinical trial may result in increased costs or affect
the timing, outcome, or completion of the trial, which could delay or prevent our receipt of regulatory approval of the applicable product
candidate or to abandon the trial altogether.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be required to suspend, repeat, or terminate our clinical trials if they are not conducted in accordance with regulatory requirements,
the results are negative or inconclusive, or the trials are not well designed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials must be conducted in accordance with FDA&#8217;s Good Clinical Practice (&#8220;GCP&#8221;) requirements. Clinical trials
are subject to oversight by FDA and IRBs or ethical committees at the study sites where the clinical trials are conducted. In addition,
clinical trials must be conducted with product candidates manufactured in accordance with applicable cGMP requirements. Clinical trials
may be suspended by FDA, us, a DSMB, or by an IRB with respect to a particular clinical trial site, for various reasons, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">deficiencies
                                            in the conduct of the clinical trials, including failure to conduct the clinical trial in
                                            accordance with regulatory requirements or study protocols;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">deficiencies
                                            in the clinical trial operations or trial sites;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unforeseen
                                            adverse side effects or the emergence of undue risks to study subjects;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">deficiencies
                                            in the trial design necessary to demonstrate efficacy;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            product candidate may not appear to offer benefits over current therapies; or</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            quality or stability of the product candidate may fall below acceptable standards.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
such suspension or delay may result in us failing to obtain regulatory approval for our product candidates, which would materially harm
our business, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we do not achieve our projected development goals in the time frames we announce and expect, the commercialization of our products may
be delayed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may estimate the timing of the accomplishment of various scientific, clinical, regulatory, manufacturing, and other
product development goals, which we may refer to as milestones. These milestones may include the commencement or completion of preclinical
studies and clinical trials and the submission of regulatory filings, including IND submissions. From time to time, we may announce the
expected timing of some of these milestones. All of these milestones are, and will be, based on a variety of assumptions. The actual
timing of these milestones can vary significantly compared to our estimates, in some cases for reasons beyond our control, including
with respect to challenges related to enrollment, manufacturing, and our reliance on third parties to conduct, supervise or monitor some
or all aspects of our clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Disruptions
at FDA and other government agencies, such as those that may be caused by funding shortages, could hinder their ability to hire, retain
or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved, or commercialized
in a timely manner or at all, which could negatively impact our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ability of FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels,
statutory, regulatory, and policy changes, FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees,
and other events that may otherwise affect FDA&#8217;s ability to perform routine functions. Average review times at the agency have
fluctuated in recent years as a result.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disruptions
at FDA and other agencies may also increase the time necessary to meet with and provide feedback to entities developing drug products,
review and/or approve our submissions, conduct inspections, issue regulatory guidance, or otherwise authorize our actions requiring regulatory
approval, which would adversely affect our business. In addition, government funding of FDA and other government agencies on which our
operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently
fluid and unpredictable. For example, the Trump Administration recently established the Department of Government Efficiency, which implemented
a federal government hiring freeze and large scale layoffs of current federal employees, and also announced additional efforts to reduce
federal government employee headcount and the size of the federal government. The Trump Administration has also, for example, rescinded
a previous executive order tasking the Center for Medicare and Medicaid Innovation to consider new payment and healthcare models to limit
drug spending and eliminated a previous executive order that directed the Department of Health and Human Services (&#8220;HHS&#8221;) to establish an AI task force and develop
a strategic plan.&#160;It is unclear how these executive actions or other potential actions by the Trump Administration will impact the
regulatory authorities that oversee our business. These budgetary pressures may reduce FDA&#8217;s ability to perform its responsibilities.
If a significant reduction in FDA&#8217;s workforce occurs, FDA&#8217;s budget is significantly reduced, or there are other disruptions
at FDA and other agencies, more time may be </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">necessary
for biological products, or biologics, or modifications to approved biologics to be reviewed and/or approved by necessary government
agencies, which could increase our costs and would adversely affect our business. In addition, if a prolonged government
shutdown occurs, it could significantly impact the ability of FDA to timely review and process our regulatory submissions, which could
have a material adverse effect on our business. For example, over the last several years, the United States government has shut down
several times and certain regulatory agencies, such as FDA, have had to furlough critical FDA employees and stop critical activities.
Additionally, Congress may introduce and ultimately pass healthcare related legislation that could impact the drug approval process.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may develop future product candidates in combination with other therapies, which exposes us to additional regulatory risks.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may develop future product candidates in combination with one or more currently approved therapies. These combinations may, among other
things, fail to demonstrate synergistic activity, may fail to achieve superior outcomes relative to the use of single agents or other
combination therapies, or may fail to demonstrate sufficient safety or efficacy traits in clinical trials to enable us to complete those
clinical trials or obtain marketing approval for the combination therapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, even if any product candidate we develop were to receive marketing approval or be commercialized for use in combination with
other existing therapies, we would continue to be subject to the risk that FDA or a comparable foreign regulatory authorities could revoke
approval of the therapy used in combination with our product candidate or that safety, efficacy, manufacturing, or supply issues could
arise with these existing therapies. This could result in our own products being removed from the market or being less successful commercially.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also evaluate future product candidates in combination with one or more other therapies that have not yet been approved for marketing
by FDA or comparable foreign regulatory authorities. We will not be able to market and sell TVGN 489 or any product candidate we develop
in combination with any such unapproved therapies that do not ultimately obtain marketing approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
regulatory authorities do not approve these other biological products or revoke their approval of, or if safety, efficacy, manufacturing,
or supply issues arise with, the biologics we choose to evaluate in combination with any product candidate we develop, we may be unable
to obtain approval of or market any such product candidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
use of AI in our business may require us to spend material resources and presents risks that could adversely
impact our business, including by posing security and other risks to our confidential and/or proprietary
information.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to use AI in and integrate AI into our business processes, and this innovation presents risks and challenges that could affect
its adoption, and therefore our business. If we enable or offer solutions that draw controversy due to perceived or actual negative societal
impact, we may experience brand or reputational harm, competitive harm or legal liability. The use of certain AI technology can give
rise to intellectual property risks, including compromises to proprietary intellectual property and intellectual property infringement.
Additionally, we expect to see increasing government and supranational regulation related to AI use and ethics, which may also significantly
increase the burden and cost of research, development and compliance in this area. For example, the new Artificial Intelligence Act (the
&#8220;AI Act&#8221;) in the European Union (the &#8220;EU&#8221;) imposes significant obligations on providers and deployers of high-risk
AI systems and encourages such providers and deployers to account for specified ethical principles in the development and use of these
systems. If we develop or use AI systems that are governed by the AI Act or similar regulations, it may necessitate ensuring higher standards
of data quality, transparency, and human oversight, as well as adhering to specific and potentially burdensome and costly ethical, accountability,
and administrative requirements. The rapid evolution of AI will require the application of significant resources to design, develop,
test and maintain our products and services to help ensure that AI is implemented in accordance with applicable law and regulation and
in a socially responsible manner and to minimize any real or perceived unintended harmful impacts. Our vendors may also incorporate AI
tools into their offerings, and may not meet existing or rapidly evolving regulatory or industry standards, including with respect to
privacy and data security. Further, bad actors around the world use increasingly sophisticated methods, including the use of AI, to engage
in illegal activities involving the theft and misuse of personal information, confidential information and intellectual property. Any
of these effects could damage our reputation, result in the loss of valuable property and information, cause us to breach applicable
laws and regulations, and adversely impact our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Business Development and Commercialization</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
commercial success depends upon attaining significant market acceptance of our product candidates, if approved, among physicians, patients,
healthcare payors and the medical community, including hospitals and outpatient clinics.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we obtain regulatory approval for any of our product candidates that we may develop or acquire in the future, the product may not
gain market acceptance among physicians, healthcare payors, patients or the medical community that supports our product development efforts,
including hospitals and outpatient clinics. Market acceptance of any of our product candidates for which we receive approval depends
on a number of factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            efficacy and safety of the product candidates as demonstrated in clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            clinical indications and patient populations for which the product candidate is approved;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acceptance
                                            by physicians and patients of the drug as a safe and effective treatment;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            administrative and logistical burden of treating patients, including the availability and
                                            accessibility of healthcare provider sites for administering infusions to patients;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            adoption of novel cellular therapies by physicians, hospitals, and third-party payors;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            potential and perceived advantages of product candidates over alternative treatments;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            safety of product candidates seen in a broader patient group, including its use outside the
                                            approved indications should physicians choose to prescribe for such uses;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            restrictions on use together with other medications;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            prevalence and severity of any side effects;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA&#8217;s
                                            product labeling or package insert requirements;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            timing of market introduction of our products as well as competitive products;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            development of manufacturing and distribution processes for our product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            cost of treatment in relation to alternative treatments;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            availability of coverage and adequate reimbursement from, and our ability to negotiate pricing
                                            with, third-party payors, providers, and government authorities;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">relative
                                            convenience and ease of administration; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            effectiveness of our sales and marketing efforts.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
expect the product candidates we develop will be regulated biologics and therefore they may be subject to biosimilar competition.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Biologics Price Competition and Innovation Act of 2009 (&#8220;BPCIA&#8221;) created an abbreviated pathway for the approval of for biological
product candidates shown to be highly similar to or interchangeable with an FDA licensed biological product. Under the BPCIA, an application
for a biosimilar product cannot be approved by FDA until 12 years after the reference product was approved under a BLA. The law is complex
and is still being interpreted and implemented by FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty.
Although it is uncertain when processes intended to implement BPCIA may be fully adopted by FDA, any of these processes could have a
material adverse effect on the future commercial prospects for our biological products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that any of the product candidates we develop that is approved in the United States as a biological product under a BLA should
qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened, potentially creating
the opportunity for competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, will be substituted
for any one of the reference products in a way that is similar to traditional generic substitution for non-biological products is not
yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. Additionally, the increased likelihood
of biosimilar competition has increased the risk of loss of innovators&#8217; market exclusivity. Due to these risks, and uncertainties
regarding patent protection, if one of our product candidates are approved for marketing, it is not possible to predict the length of
market exclusivity for any particular product with certainty based solely on the expiration of the relevant patent(s) or the current
forms of regulatory exclusivity. The loss of market exclusivity for a product would likely materially and negatively affect revenues
from product sales of that product and thus our financial results and condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the approval of a biologic product that is a biosimilar to one of our products could have a material adverse impact on our
business as it may be significantly less costly to bring to market and may be priced significantly lower than our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
incidence and prevalence of the target patient population for TVGN 489 are based on estimates and third-party sources. If the market
opportunity for TVGN 489 or our other product candidates is smaller than we estimate or if any approval that we obtain is based on a
narrower definition of the patient population, our revenue and ability to achieve profitability might be materially and adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Periodically,
we make estimates regarding the incidence and prevalence of target patient populations based on various third-party sources and internally
generated analysis. These estimates may be inaccurate or based on imprecise data. For example, the total addressable market opportunity
for TVGN 489 will depend on, among other things, acceptance of TVGN 489 by the medical community, patient access, drug pricing and reimbursement,
and the number of eligible patients with COVID-19, which may decrease. The number of patients in the addressable markets may turn out
to be lower than expected, patients may not be otherwise amenable to treatment with TVGN 489, or new patients may become increasingly
difficult to identify or gain access to or may not have the requisite HLA-typing to receive the drug, all of which may significantly
harm our business, financial condition, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if our product candidates receive regulatory approval, we will still face extensive ongoing regulatory requirements and continued regulatory
review, which may result in significant additional expense, and our products may still face future development and regulatory difficulties.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we obtain regulatory approval for a product candidate, it would be subject to ongoing requirements by FDA governing the manufacture,
materials and facilities, qualification testing, quality control, further development, labeling, packaging, storage, distribution, post-approval
clinical data, adverse event reporting, safety surveillance, import, export, advertising, promotion, recordkeeping and reporting of safety
and other post-marketing information. These requirements include submissions of safety and other post-marketing information and reports,
establishment registration and product listing, as well as continued compliance by us and/or our contract manufacturing organizations
(&#8220;CMOs&#8221;) and CROs for any post-approval clinical trials that we conduct. The safety profile of any product will continue
to be closely monitored by FDA after approval. If FDA become aware of new safety information after approval of any of our product candidates,
they may require labeling changes or establishment of a REMS, impose significant restrictions on a product&#8217;s indicated uses or
marketing or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, manufacturers of cell therapies and their facilities are subject to initial and continual review and periodic inspections by
FDA for compliance with cGMP, GCP, Good Laboratory Practice (&#8220;GLP&#8221;), Good Tissue Practice (&#8220;GTP&#8221;)
and other regulations. For certain commercial prescription biological products, manufacturers, and other parties involved in the supply
chain must also meet chain of distribution requirements and build electronic, interoperable systems for product tracking and tracing
and for notifying FDA of counterfeit, diverted, stolen, and intentionally adulterated products or other products that are otherwise unfit
for distribution in the United States. If we or a regulatory agency discover previously unknown problems with a product, such as adverse
events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may
impose restrictions on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the
market or suspension of manufacturing. If we, our product candidates, or the manufacturing facilities for our product candidates fail
to comply with applicable regulatory requirements, a regulatory agency may:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue
                                            warning letters or untitled letters;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">mandate
                                            modifications to promotional materials or require us to provide corrective information to
                                            healthcare practitioners, or require other restrictions on the labeling or marketing of such
                                            products;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">require
                                            us to enter into a consent decree, which can include imposition of various fines, reimbursements
                                            for inspection costs, required due dates for specific actions and penalties for noncompliance;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
                                            an injunction or impose civil or criminal penalties or monetary fines;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend,
                                            withdraw, or modify regulatory approval;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend
                                            or modify any ongoing clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse
                                            to approve pending applications or supplements to applications filed by us;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend
                                            or impose restrictions on operations, including costly new manufacturing requirements; or</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seize
                                            or detain products, refuse to permit the import or export of products, or require us to initiate
                                            a product recall.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
occurrence of any of the foregoing may inhibit our ability to successfully commercialize our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advertising
and promotion of any product candidate that obtains approval in the United States will be heavily scrutinized by FDA, the Federal Trade
Commission (the &#8220;FTC&#8221;), the Department of Justice, the Office of Inspector General of the Department of Health and
Human Services, state attorneys general, members of the U.S. Congress and the public. Violations, including actual or alleged promotion
of our products for unapproved or off-label uses, are subject to enforcement letters, inquiries and investigations, and potential civil
and criminal sanctions by FDA. Any actual or alleged failure to comply with labeling and promotion requirements may result in fines,
warning letters, mandates to corrective information to healthcare practitioners, injunctions, or civil or criminal penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our product
candidates, we may be unable to generate any revenue.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are at an early stage of establishing an organization that will be responsible for the sale, marketing and distribution of cell therapy
products and the cost of establishing and maintaining such an organization may exceed the cost-effectiveness of doing so. In order to
market any products that may be approved by FDA, we must build our sales, marketing, managerial and other non-technical capabilities
or make arrangements with third parties to perform these services. There are significant risks involved in building and managing a sales
organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate
training to sales and marketing personnel, and effectively manage a geographically dispersed sales and marketing team. Any failure or
delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization
of these products. We may be competing with many companies that currently have extensive and well-funded sales and marketing operations.
Without a sufficiently scaled, appropriately timed, and trained internal commercial organization or the support of a third party to perform
sales and marketing functions, we may be unable to compete successfully against these more established companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Data
protection, privacy and similar laws restrict access, use, and disclosure of information, and failure to comply with or adapt to changes
in these laws could materially and adversely harm our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to federal and state data privacy and security laws and regulations, state data breach notification laws, state health
information and/or genetic privacy laws, and federal and state consumer protection and consumer privacy laws (such as Section 5 of the
FTC Act, the FTC Health Breach Notification Rule, and the California Consumer Privacy Act, as amended by the California Privacy Rights
Act (the &#8220;CCPA&#8221;)). Laws and expectations relating to privacy continue to evolve. Changes in these laws may limit our
data access, use, and disclosure, and may require increased expenditures. In addition, data protection, privacy and similar laws protect
more than patient information and, although they vary by jurisdiction, these laws can extend to employee information, business contact
information, provider information, and other information relating to identifiable individuals. For example, the CCPA requires
covered businesses to, among other things, provide disclosures to California consumers regarding the collection, use and disclosure of
such consumers&#8217; personal information and afford such consumers new rights with respect to their personal information, including
the right to opt out of certain sales of personal information. Comprehensive and sensitive data laws in a number of states have gone
into or will go into effect during the next few years. We believe that further increased regulation in additional jurisdictions is likely
in the area of data privacy. Any of the foregoing may have a material adverse effect on our ability to provide services to patients and,
in turn, our results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
to comply with these laws may result in, among other things, civil and criminal liability, negative publicity, damage to our reputation,
and liability under contractual provisions. In addition, compliance with such laws may require increased costs to us or may dictate that
wet not offer certain types of services in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Increasing
use of AI could give rise to liability, breaches of data security and privacy laws, or reputational damage.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AI-based
solutions, including generative AI, are increasingly being used in the biopharmaceutical industry. There is a global trend towards more
regulation (e.g., the AI Act and AI laws passed in certain states) to ensure the ethical use, privacy, and security of AI and the data
that it processes. AI solutions that we may employ and rely upon may lead to the impermissible use or disclosure of confidential information
(including personal data and proprietary information) in contravention of our internal policies, data protection laws, other applicable
laws, or contractual requirements. The misuse of AI solutions may give rise to liability, lead to the loss of trade secrets or other
intellectual property, result in reputational harm, or lead to outcomes with unintended biases or other consequences. The misuse of AI
solutions could also result in unauthorized access and use of personal data of our employees, clinical trial participants, collaborators,
or other third parties. Any of these events could have a material adverse effect on our business, prospects, operating results, and financial
condition and could adversely affect the price of our Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
internal computer systems, or those used by our contractors or consultants, may fail, or suffer security breaches.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
internal computer systems and the systems of our contractors and consultants are vulnerable to damage from cyber-attacks and unauthorized
access. While we have not experienced any such material system failure or security breach to date, if such an event were to occur and
cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations.
For example, the loss of clinical trial data from future clinical trials could result in delays in our regulatory approval efforts and
significantly increase our costs to recover or reproduce the data. Despite our efforts and given the ever-changing threat landscape,
the possibility of these events occurring cannot be eliminated entirely and there can be no assurance that any measures we take will
prevent cyber-attacks or unauthorized access that could adversely affect our business. To the extent that any disruption or security
breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary
information, we could incur liability and the further development and commercialization of our product candidates could be delayed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Coverage
and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult
for us to sell our product candidates, if approved, profitably.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Successful
sales of our product candidates, if approved, depend on the availability of coverage and adequate reimbursement from third-party payors
including governmental healthcare programs, such as Medicare and Medicaid, managed care organizations and commercial payors, among others.
Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients
who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated
with their treatment. Obtaining coverage and adequate reimbursement from third-party payors is critical to new product acceptance. Third-party
payors decide which drugs and treatments they will cover and the amount of reimbursement. Reimbursement by a third-party payor may depend
upon a number of factors, including, but not limited to, the third-party payor&#8217;s determination that use of a product is a covered
benefit under its health plan, safe, effective, and medically necessary, appropriate for the specific patient, cost-effective, and neither
experimental nor investigational.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
coverage and reimbursement of a product from a government or other third-party payor is a time consuming and costly process that could
require us to provide to the payor supporting scientific, clinical and cost-effectiveness data for the use of our products. Even if we
obtain coverage for a given product, if the resulting reimbursement rates are insufficient, hospitals may not approve our product for
use in their facility or third-party payors may require co-payments that patients find unacceptably high. Separate reimbursement for
the product itself may or may not be available. Instead, the hospital or administering physician may be reimbursed only for providing
the treatment or procedure in which our product is used. Further, at least annually, the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;)
revises the reimbursement systems used to reimburse health care providers, which may result in reduced Medicare payments. In some
cases, private third-party payers rely on all or portions of Medicare payment systems to determine payment rates. Changes to government
healthcare programs that reduce payments under these programs may negatively impact payments from private third-party payers and reduce
the willingness of physicians and providers to use our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. Therefore, coverage
and reimbursement for products can differ significantly from payor to payor. Further, one payor&#8217;s determination to provide coverage
for a product does not assure that other payors will also provide coverage for the product. Adequate third-party reimbursement may not
be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.
Because our product candidate may have a higher cost of goods than conventional therapies, and may require long-term follow-up evaluations,
the risk that coverage and reimbursement rates may be inadequate for us to achieve profitability may be greater. There is significant
uncertainty related to insurance coverage and reimbursement of newly approved products. It is difficult to predict at this time what
third-party payors will decide with respect to the coverage and reimbursement for our product candidate. Moreover, payment methodologies
may be subject to changes in healthcare legislation and regulatory initiatives. Additional state and federal healthcare reform measures
are expected to be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare
products and services, which could result in reduced demand for certain pharmaceutical products or additional pricing pressures. We expect
to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed healthcare,
the increasing influence of health maintenance organizations, cost containment initiatives and additional legislative changes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by
any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in
the United States. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from
list prices and are challenging the prices charged for medical products. In addition, many pharmaceutical manufacturers must calculate
and report certain price reporting metrics to the government, such as average sales price and best price. Penalties may apply in some
cases when such metrics are not submitted accurately and timely. Further, these prices for drugs may be reduced by mandatory discounts
or rebates required by government healthcare programs. Payment methodologies may be subject to changes in healthcare legislation and
regulatory initiatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to seek approval to market our product candidates in both the United States and in selected foreign jurisdictions. Increased efforts
by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations
to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate
payment for our product candidate. If we obtain approval in one or more foreign jurisdictions for our product candidates, we will be
subject to rules and regulations in those jurisdictions. In some foreign countries, particularly those in Europe, the pricing of biologics
is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time
after obtaining marketing approval of a product candidate. Some of these countries may require the completion of clinical trials that
compare the cost-effectiveness of a particular product candidate to currently available therapies. Other EU member states allow
companies to fix their own prices for medicines but monitor and control company profits. In addition, in some countries, cross-border
imports from low-priced markets exert a commercial pressure on pricing within a country.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if government and other
third-party payors fail to provide coverage and adequate reimbursement. We expect downward pressure on pharmaceutical pricing to continue.
Further, coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status
is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates
may be implemented in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
advancement of healthcare reform may negatively impact our ability to sell our product candidates, if approved, profitably.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third-party
payors, whether domestic or foreign, or governmental or commercial, are developing increasingly sophisticated methods of controlling
healthcare costs. In both the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory
changes to the health care system that could impact our ability to sell our product candidates, if approved, profitably.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal, and state levels directed at
broadening the availability of healthcare and containing or lowering the cost of healthcare. The implementation of cost containment measures
or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products.
Such reforms could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which
we may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
there has been heightened governmental scrutiny in the United States of pharmaceutical and biologics pricing practices in light of the
rising cost of prescription drugs and biologics. This scrutiny has resulted in various Congressional inquiries and proposed and enacted
federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between
pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that
the U.S. federal government will pay for healthcare drugs and services, which could result in reduced demand for our drug candidates
or additional pricing pressures. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction
in payments from private payors, which may adversely affect our future profitability. Individual states in the United States have also
become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product
pricing, including price or patient reimbursement constraints, discounts, restrictions on certain drug access and marketing cost disclosure
and transparency measures, and designed to encourage importation from other countries and bulk purchasing. Additionally, some individual
states have begun establishing Prescription Drug Affordability Boards to review high-cost drugs and, in some cases, set upper payment
limits. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, financial
condition, results of operations and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly
using bidding procedures to determine what drug products and which suppliers will be included in their prescription drug and other healthcare
programs. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services
to contain or reduce costs of healthcare and/or impose price controls may adversely affect our business, financial condition, results
of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, and health information
privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we obtain FDA approval for any of our product candidates and begin commercializing those products in the United States, our operations
may be subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute, the
federal False Claims Act, and federal and state transparency laws and regulations. These laws may impact, among other things, our proposed
sales, marketing, and education programs. In addition, we may be subject to patient privacy regulation by both the federal government
and the states in which we conduct our business. These laws, described in further detail in &#8220;<i>Regulatory Environment &#8211;
Healthcare Regulation &#8211; Other Healthcare Laws and Compliance Requirements</i>,&#8221; include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly
                                            and willfully soliciting, receiving, offering, or paying remuneration, directly or indirectly,
                                            to induce, or in return for, the purchase or recommendation of an item or service reimbursable
                                            under a federal healthcare program, such as the Medicare and Medicaid programs;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            federal civil False Claims Act, which prohibits, among other things, individuals or entities
                                            from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment
                                            of government funds, or knowingly making, using or causing to be made or used, a false record
                                            or statement material to an obligation to pay money to the government or knowingly concealing
                                            or knowingly and improperly avoiding, decreasing or concealing an obligation to pay money
                                            to the federal government;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Health
                                            Insurance Portability and Accountability Act (&#8220;HIPAA&#8221;), which created new federal
                                            criminal statutes that prohibit executing a scheme to defraud any healthcare benefit program
                                            and making false statements relating to healthcare matters;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA,
                                            as amended by the Health Information Technology for Economic and Clinical Health Act, and
                                            its implementing regulations, which imposes specified requirements relating to the privacy,
                                            security, and transmission of individually identifiable health information;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            U.S. federal Physician Payment Sunshine Act, which requires manufacturers of drugs, devices,
                                            biologics, and medical supplies for which payment is available under Medicare, Medicaid or
                                            the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually
                                            to the CMS information related to direct or indirect payments and other transfers of value
                                            to physicians and teaching hospitals (and certain other practitioners), as well as ownership
                                            and investment interests held in the company by physicians and their immediate family members;
                                            and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">state
                                            law equivalents of each of the above federal laws, such as anti-kickback and false claims
                                            laws that may apply to items or services reimbursed by any third-party payor, including governmental
                                            and private payors, laws that require manufacturers to comply with the pharmaceutical industry&#8217;s
                                            voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal
                                            government, or otherwise restrict payments that may be made to healthcare providers and other
                                            potential referral sources, state laws that require drug manufacturers to report information
                                            related to payments and other transfers of value to physicians and other healthcare providers
                                            or marketing expenditures, and state laws governing the privacy and security of health information
                                            in specified circumstances, many of which differ from each other in significant ways and
                                            may not have the same scope or application, thus complicating compliance efforts.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Efforts
to ensure that our collaborations with third parties, and our business generally, will comply with applicable United States and healthcare
laws and regulations will involve substantial costs. Governmental authorities could conclude that our business practices may not comply
with statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations
are found to violate any of these laws or any other governmental laws and regulations that may apply to us, we may be subject to significant
civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion of products from government funded healthcare programs,
contractual damages, reputational harm, disgorgement or curtailment or restricting of our operations, any of which could substantially
disrupt our operations and diminish our profits and future earnings. If any of the physicians or other providers or entities with whom
we expect to do business is found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative
sanctions, including exclusions from government funded healthcare programs. The risk of our being found in violation of these laws is
increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions
are open to a variety of interpretations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
relationships with customers, physicians including clinical investigators, CROs and third-party payors are subject, directly or indirectly,
to federal and state healthcare fraud and abuse laws, false claims laws, health information privacy and security laws, transparency laws,
government price reporting and other healthcare laws and regulations. If we or our employees, independent contractors, consultants, commercial
partners, vendors, or other agents violate these laws, we could face substantial penalties.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
laws may impact, among other things, our clinical research programs as well as our proposed and future sales, marketing, and education
programs. In particular, the promotion, sales and marketing of healthcare items and services is subject to extensive laws and regulations
designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a
wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive and other business arrangements. We
may also be subject to federal, state, and foreign laws governing the privacy and security of identifiable patient information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform.
Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare
providers, which has led to a number of investigations, prosecutions, convictions, and settlements in the healthcare industry. Because
of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that
some of our business activities, or our arrangements with physicians, could be subject to challenge under one or more of such laws. If
we or our employees, independent contractors, consultants, commercial partners, and vendors violate these laws, we may be subject to
investigations, enforcement actions and/or significant penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is not always possible to identify and deter employee misconduct or business noncompliance, and the precautions we take to detect and
prevent inappropriate conduct may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental
investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Efforts to ensure
that our business arrangements will comply with applicable healthcare laws may involve substantial costs. It is possible that governmental
and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or
case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against
us, and we are not successful in defending themselves or asserting our rights, those actions could have a significant impact on our business,
including the imposition of civil, criminal and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from
participation in federal healthcare programs, reputational harm, diminished profits and future earnings, additional reporting requirements
and/or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance
with these laws, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results
of operations. In addition, the approval and commercialization of any of our product candidates outside the United States will also likely
subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur
costs that could have a material adverse effect on the success of our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the
handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable
materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We cannot eliminate the
risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials,
we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs
associated with civil or criminal fines and penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Manufacturing and Reliance on Third Parties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
manufacture of cell therapies is subject to a multitude of manufacturing risks, any of which could substantially increase our costs and
limit supply of our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process of manufacturing cell therapies is complex, highly regulated, subject to multiple risks, and requires significant expertise.
Manufacturers of cell therapy products often encounter difficulties in production, particularly in scaling out and validating initial
production and ensuring the absence of contamination. These include difficulties with production costs and yields, quality control, shortages
of qualified personnel, and compliance with strictly enforced regulations. Cell therapy manufacturing facilities also require appropriate
commissioning and validation activities to demonstrate that they operate as designed. There are limited numbers of CMOs that operate
under cGMP regulations and that are capable of manufacturing cell therapies, and transferring manufacturing processes and know-how is
complex and may require utilization of new or different processes to meet the specific requirements of a given facility.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cell
therapy manufacturing is susceptible to product loss due to contamination, equipment failure, and vendor or operator error. The facilities
in which our product candidates will be made could also be adversely affected by pandemics, natural disasters, equipment failures, labor
shortages, power failures, supply chain problems, changes in laws and regulations, and numerous other factors. Even minor deviations
from normal manufacturing and distribution for any of our product candidates could result in reduced production yields, impact to product
quality, and other supply disruptions. Manufacturing cell therapies is susceptible to risks associated with the need to maintain aseptic
conditions throughout the manufacturing process. Contamination with pathogens or ingress of microbiological material may result in unusable
product and could also delay the manufacture of product candidates, resulting in delays in development. If contamination is discovered,
the facilities in which our product candidates are made may need to be closed for an extended period of time for investigation and remediation.
Because our cell therapy product candidates are manufactured from the cells of third-party donors, the manufacturing process is also
susceptible to insufficient quantity or inadequate quality of third-party donor material.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturing
is also subject to FDA and comparable foreign regulation. For example, FDA will not approve a cellular product if the manufacturer is
not in compliance with cGMPs and GTPs, to the extent applicable. If we are unable to reliably produce products in accordance with specifications
acceptable to authorities, we may not obtain or maintain the approvals we need to commercialize our product candidates. Failure to comply
with manufacturing regulations may lead to regulatory enforcement actions against our third-party manufacturers or us that result in
fines and civil and criminal penalties, imprisonment, suspension, delay, or restriction of production, injunctions, delay or denial of
product approval, clinical holds or termination of clinical trials, warning or untitled letters, regulatory authority communications
warning the public about safety issues with the cell therapies, refusal to permit import or export, product seizure, detention, or recall,
lawsuits under the civil False Claims Act, or consent decrees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
efforts to establish manufacturing capabilities, either on our own or through a contract relationship, will involve significant time
and expense and may not be successful.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
manufacturing experience as an organization and with our contractors is limited. We relied on a Clinical Trial Services and Materials
Agreement with Thomas Jefferson University for the manufacture of TVGN 489 for our Phase 1 proof-of-concept trial. However, we will need
to establish manufacturing capabilities, either on our own or through a contract relationship, in order to meet our projected supply
needs for clinical and commercial materials to support our activities through regulatory approval and commercial manufacturing of our
product candidates, if approved. Our efforts to develop manufacturing capability are currently focused on acquiring existing manufacturing
facilities or constructing one or more new manufacturing facilities, including through collaboration with a potential facility development
partner. Securing a manufacturing facility will involve considerable time and expense, and may not be successful. In addition, we cannot
ensure that we can successfully manufacture our products in compliance with cGMP, GTP, and any other applicable laws, regulations, and
standards in sufficient quantities for clinical trials or for commercial sale. We have no prior experience in establishing a manufacturing
facility and we may encounter challenges given the complexity of manufacturing cell therapies. We must also compete for the small number
of individuals with expertise in cell therapy manufacturing. Even if we are able to establish manufacturing operations, given the complexities
of manufacturing cell therapy products, there is no assurance that we will be able to successfully produce sufficient amounts, or sufficient
quality, of TVGN 489 in order to move forward with our clinical development plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
depend on third-party suppliers for key materials used in our manufacturing processes, and the loss of these third-party suppliers or
their inability to supply us with adequate materials could harm our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on third-party suppliers for certain materials and components required for the production of our product candidates. Our dependence
on these suppliers and the challenges we may face in obtaining adequate supplies of materials involve several risks, including limited
control over pricing, availability, and quality and delivery schedules. We also face competition for supplies from other cell therapy
companies. Such competition may make it difficult for us to secure raw materials or the testing of such materials on commercially reasonable
terms or in a timely manner. Our negotiation leverage is limited, and we are likely to get lower priority than our competitors that are
larger than we are. In addition, the biotechnology market has recently experienced supply chain disruptions. We cannot be certain that
our suppliers will continue to provide us with the quantities of the raw materials that we require or satisfy our anticipated specifications
and quality requirements whether due to our size or otherwise. Any supply interruption in limited or sole sourced raw materials could
materially harm our ability to manufacture our product candidates until a new source of supply, if any, could be identified and qualified.
We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reasonable terms. Significant
changes in global economic conditions, and an increase in the costs of goods and services, including as a result of tariffs, could negatively
impact testing volumes, the demand for biopharma laboratory services, cash collections, profitability, and the availability and cost
of credit. Any performance failure on the part of our suppliers could delay the development and potential commercialization of our
product candidates, including limiting supplies necessary for clinical trials and regulatory approvals, which would have a material adverse
effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
the third parties we rely on to help conduct our preclinical studies and clinical trials do not successfully carry out their contractual
duties, comply with regulatory requirements, or meet expected deadlines, we may not be able to obtain marketing approval for or commercialize
TVGN 489 and any future product candidates we develop, and our business could be materially harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
outsource some of the conduct and management of our clinical trials to third parties. Agreements with clinical investigators and medical
institutions for clinical testing and with other third parties for data management services and clinical trial management services place
substantial responsibilities on these parties that, if unmet, could result in delays in, or termination of, our clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on universities, medical institutions, clinical investigators, contract laboratories and other third parties to conduct or help
us conduct GLP-compliant preclinical studies and GCP-compliant clinical trials on our product candidates properly and on time. While
we have agreements governing their activities, we control only certain aspects of their activities and have limited influence over their
actual performance. The third parties with whom we contract play a significant role in the conduct of these studies and trials and the
subsequent collection and analysis of data. These third parties are not our employees and, except for restrictions imposed by our contracts
with such third parties, we have limited ability to control the amount or timing of resources that they devote to our current or future
product candidates. Although we rely on these third parties to conduct our GLP-compliant preclinical studies and GCP-compliant clinical
trials, we remain responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with its
investigational plan and protocol and applicable laws and regulations, and our reliance on the CROs does not relieve us of our regulatory
responsibilities. If any of our clinical trial sites fail to comply with GCP, we may be unable to use the data gathered at those sites.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for
whom they may also be conducting clinical trials or other drug development activities that could harm our competitive position. Some
of our agreements may also be terminated by these third parties under certain other circumstances. If the third parties conducting our
preclinical studies or our clinical trials do not adequately perform their contractual duties or obligations, experience significant
business challenges, disruptions or failures, do not meet expected deadlines, terminate their agreements with us or need to be replaced,
or if the quality or accuracy of the data they obtain is compromised due to their failure to adhere to our protocols or to GLP and GCP,
or for any other reason, we may need to enter into new arrangements with alternative third parties. This could be difficult, costly,
or impossible, and our preclinical studies or clinical trials may need to be extended, delayed, terminated, or repeated. As a result,
we may not be able to obtain regulatory approval in a timely fashion, or at all, for the applicable product candidate, our financial
results and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate
revenues could be delayed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may depend on third-party collaborators for the development and commercialization of certain of our current and future product candidates.
If our collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the future, we may form or seek strategic alliances, joint ventures, or collaborations, or enter into licensing arrangements with third
parties that we believe will complement or augment our development and commercialization efforts with respect to product candidates we
develop. Potential future collaborations involving our product candidates may pose the following risks to us:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    may have significant discretion in determining the efforts and resources that they will apply to these collaborations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product
    candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    may not properly enforce, maintain, or defend our intellectual property rights or may use our proprietary information in a way that
    gives rise to actual or threatened litigation or that could jeopardize or invalidate our intellectual property or proprietary information,
    exposing us to potential litigation or other intellectual property proceedings;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disputes
    may arise between a collaborator and us that cause the delay or termination of the research, development, or commercialization of
    the product candidate, or that result in costly litigation or arbitration that diverts management attention and resources;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient
    resources to the marketing and distribution of such products;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 74pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 74pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    a present or future collaborator were to be involved in a business combination, the continued pursuit and emphasis on our product
    development or commercialization program under such collaboration could be delayed, diminished, or terminated; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaboration
    agreements may restrict our right to independently pursue new product candidates.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 41.75pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we enter into collaboration agreements and strategic partnerships or license our intellectual property, products, or businesses, we may
not be able to realize the expected benefit of such transactions if we are unable to successfully integrate them with our existing operations,
which could delay our timelines or otherwise adversely affect our business. We also cannot be certain that, following a strategic transaction
or license, we will achieve the revenue or net income that justifies such transaction. Any of the factors set forth above and any delays
in entering into new collaborations or strategic partnership agreements related to any product candidate we develop could delay the development
and commercialization of our product candidates, which would harm our business prospects, financial condition, and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event a present or future collaborator terminates their agreement with us, we would be prevented from receiving the benefits of any
such agreement, which could have a materially adverse effect on our results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may have to alter our development and commercialization plans if we seek to establish collaborations and are not able to establish them
on commercially reasonable terms.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
advancement of our product candidates and development programs and the potential commercialization of our current and future product
candidates will require substantial additional cash to fund expenses. For some of our current or future product candidates, we may decide
to collaborate with third parties with respect to development and potential commercialization. Any of these relationships may require
us to incur non-recurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing
stockholders, or disrupt our management and business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Whether
we reach a definitive agreement for other collaborations will depend, among other things, upon our assessment of the collaborator&#8217;s
resources and expertise, the terms and conditions of the proposed collaboration and the collaborator&#8217;s evaluation of a number of
factors. Those factors may include the design or results of clinical trials, the progress of our clinical trials, the likelihood of approval
by FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs
and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence
of uncertainty with respect to our ownership of technology and market conditions generally. The collaborator may also consider alternative
product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could
be more attractive than the one with us for our product candidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also be restricted under collaboration agreements from entering into future agreements on certain terms with potential collaborators.
Such exclusivity could limit our ability to enter into strategic collaborations with future collaborators. In addition, there have been
a significant number of business combinations among large pharmaceutical and biotechnology companies that have resulted in a reduced
number of potential future collaborators.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have
to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program
or one or more of our other development programs, delay its potential commercialization or reduce the scope of any marketing or sales
activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to
increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which
may not be available to us on acceptable terms or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Intellectual Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to obtain and maintain adequate patent protection for our product candidates or ExacTcell, our competitors could develop
and commercialize products similar or identical to ours, and our ability to successfully commercialize our product candidates may be
adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success depends, in large part, on our ability to obtain and maintain patent protection in the United States and other countries with
respect to our product candidates. We have sought, and intend to seek, to protect our proprietary position by filing patent applications
in the United States and abroad related to our product candidates and technology that are important to our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions
and has, in recent years, been the subject of much litigation. As a result, the issuance, scope, validity, enforceability, and commercial
value of our patent rights are highly uncertain. Our issued patents may not, and our pending and future patent applications may not result
in patents being issued that adequately protect our technology or product candidates or prevent others from commercializing similar or
alternative competitive technologies and product candidates. There is no assurance that all potentially relevant prior art relating to
our patents and patent applications is known to us or has been found. We may be unaware of prior art that could be used to invalidate
an issued patent or prevent a pending patent application from issuing as a patent. Because patent applications in the United States and
most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we
were the first to file a patent application relating to any particular aspect of a product candidate. Furthermore, if third parties have
filed such patent applications, we may challenge their ownership, for example in a derivation proceeding before the U.S. Patent and Trademark
Office (the &#8220;USPTO&#8221;) to determine who has the right to the claimed subject matter in the applications. Similarly, if our
patent applications are challenged in a derivation proceeding, the USPTO may hold that a third party is entitled to certain patent ownership
rights instead of us. We may then be forced to seek a license from the third party that may not be available on commercially favorable
terms, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent prosecution process is expensive, time-consuming, and complex, and we may not be able to file, prosecute, maintain, enforce, or
license all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail
to identify patentable aspects of our research and development output before it is too late to obtain patent protection.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Obtaining
and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements
imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Periodic
maintenance fees, renewal fees, annuity fees and various other government fees on patents or applications will be due to be paid to the
USPTO and various government patent agencies outside of the United States over the lifetime of our patents or applications and any patent
rights we own or may own in the future. The USPTO and various non-U.S. government patent agencies require compliance with several procedural,
documentary, fee payment and other similar provisions during the patent application process. In many cases, an inadvertent lapse can
be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which
non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent
rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market and this circumstance
could have a material adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to protect our intellectual property rights throughout the world.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing,
prosecuting, and enforcing patents on product candidates in all countries throughout the world would be prohibitively expensive, and
our intellectual property rights in some countries outside the United States may be less extensive than those in the United States. In
addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws
in the United States. Consequently, we may be less likely to be able to prevent third parties from infringing our patents in all countries
outside the United States, or from selling or importing products that infringe our patents in and into the United States or other jurisdictions.
Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and,
further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as
that in the United States. These products may compete with our products and our patents or other intellectual property rights may not
be effective or sufficient to prevent them from competing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition,
many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent
owner may have limited remedies, which could materially diminish the value of such patent. If we are forced to grant a license to third
parties with respect to any patents relevant to our business, our competitive position may be impaired and our business, financial condition,
results of operations and prospects may be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs surrounding
the prosecution of patent applications and the enforcement or defense of issued patents. After March 2013, under the Leahy-Smith America
Invents Act (the &#8220;America Invents Act&#8221;), the United States transitioned to a first inventor to file system in which, assuming
that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on
an invention regardless of whether a third party was the first to invent the claimed invention. The America Invents Act also included
a number of significant changes that affected the way patent applications are prosecuted and also may affect patent litigation. These
include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity
or ownership of a patent by USPTO administered post-grant proceedings, including post-grant review, <i>inter partes</i> review and derivation
proceedings. Additional changes in patent law could increase the uncertainties and costs surrounding the prosecution of our patent applications
and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition,
results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly
uncertain. Rulings from the U.S. Court of Appeals for the Federal Circuit and the U.S. Supreme Court have narrowed the scope of patent
protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events
has created uncertainty with respect to the validity and enforceability of patents. Depending on future actions by the U.S. Congress,
the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material
adverse effect on our existing patent portfolio and our ability to protect and enforce our intellectual property in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time-consuming, and unsuccessful.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitors
may infringe our intellectual property rights, or we may be required to defend against claims of infringement. Countering infringement
or unauthorized use claims or defending against claims of infringement can be expensive and time-consuming. Even if resolved in our favor,
litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract
our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results
of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to
be negative, it could have a substantial adverse effect on the price of our Common Stock. Such litigation or proceedings could
substantially increase our operating losses and reduce the resources available for development activities or any future marketing, sales,
or distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings.
Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their
greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation
and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions.
The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets
and other intellectual property, particularly those relating to biotechnology products, which could make it difficult for us to stop
the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce
our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects
of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not
issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages
or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property
rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we own, develop
or license.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Issued
patents covering our product candidates could be found invalid or unenforceable if challenged in court. We may not be able to protect
our trade secrets in court.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we initiate legal proceedings against a third party to enforce any patent that is issued covering one of our product candidates, the
defendant could counterclaim that the patent covering our product candidate is invalid or unenforceable. In patent litigation in the
United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could
be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, written description, or
non-enablement. In addition, patent validity challenges may, under certain circumstances, be based upon non-statutory obviousness-type
double patenting, which, if successful, could result in a finding that the claims are invalid for obviousness-type double patenting or
the loss of patent term, including a patent term adjustment granted by the USPTO, if a terminal disclaimer is filed to obviate a finding
of obviousness-type double patenting. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution
of the patent withheld information material to patentability from the USPTO, or made a misleading statement, during prosecution. Third
parties also may raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation.
Such mechanisms include re-examination, post grant review, <i>inter partes</i> review and equivalent proceedings in foreign jurisdictions.
Such proceedings could result in the revocation or cancellation of or amendment to our patents in such a way that they no longer cover
our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. We cannot be certain
that there is no invalidating prior art of which the patent examiner and we were unaware during prosecution. If a defendant were to prevail
on a legal assertion of invalidity or unenforceability, we could lose part, and perhaps all, of the patent protection on one or more
of our product candidates. Such a loss of patent protection could have a material adverse impact on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary
know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements
of our product candidate discovery and development processes that involve proprietary know-how, information or technology that is not
covered by patents, including portions of our ExacTcell technology. However, trade secrets can be difficult to protect, and some
courts inside and outside the United States are less willing or unwilling to protect trade secrets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Third
parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would
be uncertain and could have a material adverse effect on the success of our business and financial condition.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success depends upon our ability and the ability of any collaborators to develop, manufacture, market and sell our product
candidates and use our proprietary technologies without infringing the proprietary rights and intellectual property of third parties.
We cannot provide any assurances that third-party patents do not exist which might be enforced against our current manufacturing methods,
product candidates or future methods or products, resulting in either an injunction prohibiting our manufacture or sales, or, with respect
to our sales, an obligation on our part to pay royalties or other forms of compensation to third parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
biotechnology and pharmaceutical industries are characterized by extensive and complex litigation regarding patents and other intellectual
property rights. We may in the future become party to, or be threatened with, adversarial proceedings or litigation regarding intellectual
property rights with respect to our product candidates and technology, including post grant review and <i>inter partes</i> review before
the USPTO. The risks of being involved in such litigation and proceedings may also increase as our product candidates approach commercialization
and as we gain greater visibility as a public company. Third parties may assert infringement claims against us based on existing patents
or patents that may be granted in the future, regardless of their merit. There is a risk that third parties may choose to engage in litigation
with us to enforce or to otherwise assert their patent rights against us. Even if we believe such claims are without merit, a court of
competent jurisdiction could hold that these third-party patents are valid, enforceable, and infringed, which could materially and adversely
affect our ability to commercialize any of our product candidates or technologies covered by the asserted third-party patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are found to infringe a third party&#8217;s valid and enforceable intellectual property rights, we could be required to obtain a license
from such third party to continue developing, manufacturing, and marketing our product candidates and technology. However, we may not
be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could
be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could
require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease developing, manufacturing,
and commercializing the infringing technology or product candidates. In addition, we could be found liable for monetary damages, including
treble damages and attorneys&#8217; fees, if we are found to have willfully infringed a patent or other intellectual property right.
A finding of infringement could prevent us from manufacturing and commercializing our product candidates or force us to cease some of
our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or
trade secrets of third parties could have a similar negative impact on our business, financial condition, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Others
may claim an ownership interest in our intellectual property and our product candidates, which could expose us to litigation and have
a significant adverse effect on our prospects.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we are presently unaware of any claims or assertions by third parties with respect to our patents or other intellectual property, we
cannot guarantee that a third party will not assert a claim or an interest in any of such patents or intellectual property. For example,
a third party may claim an ownership interest in one or more of our patents or other proprietary or intellectual property rights. A third
party could bring legal actions against us to seek monetary damages or enjoin clinical testing, manufacturing, or marketing of the affected
product candidate or product. If we become involved in any litigation, it could consume a substantial portion of our resources and cause
a significant diversion of effort by our technical and management personnel. If any such action is successful, in addition to any potential
liability for damages, we could be required to obtain a license to continue to manufacture or market the affected product candidate or
product, in which case we could be required to pay substantial royalties or grant cross-licenses to patents. We cannot, however, assure
you that any such license would be available on acceptable terms, if at all. Ultimately, we could be prevented from commercializing a
product, or forced to cease some aspect of our business operations as a result of claims of patent infringement or violation of other
intellectual property rights. Further, the outcome of intellectual property litigation is subject to uncertainties that cannot be adequately
quantified in advance, including the demeanor and credibility of witnesses and the identity of any adverse party. This is especially
true in intellectual property cases, which may turn on the testimony of experts as to technical facts upon which experts may reasonably
disagree. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations or prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to protect the confidentiality of our proprietary information, the value of our technology and products could be adversely
affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
secrets and know-how can be difficult to protect. To maintain the confidentiality of trade secrets and proprietary information, we enter
into confidentiality agreements with our employees, consultants, collaborators, and others upon the commencement of their relationships
with us. These agreements require that all confidential information developed by the individual or made known to the individual by us
during the course of the individual&#8217;s relationship with us be kept confidential and not disclosed to third parties. Our agreements
with employees and consultants also provide that any inventions conceived by the individual in the course of rendering services to us
shall be our exclusive property. However, we cannot guarantee that we have entered into such agreements with each party that may have
or have had access to our trade secrets or proprietary technology and processes, and individuals with whom we have these agreements may
not comply with their terms. Thus, despite such agreement, there can be no assurance that such inventions will not be assigned to third
parties. In the event of unauthorized use or disclosure of our trade secrets or proprietary information, these agreements, even if obtained,
may not provide meaningful protection, particularly for our trade secrets or other confidential information. To the extent that our employees,
consultants, or contractors use technology or know-how owned by third parties in their work for us, disputes may arise between us and
those third parties as to the rights in related inventions. We also seek to preserve the integrity and confidentiality of our trade secrets
by other means, including maintaining physical security of our premises and physical and electronic security of our information technology
systems. However, these security measures may be breached, and we may be forced to bring claims against third parties, or defend claims
that they may bring against us, to determine the ownership of what we regard as our intellectual property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adequate
remedies may not exist in the event of unauthorized use or disclosure of our proprietary information. The disclosure of our trade secrets
would impair our competitive position and may materially harm our business, financial condition, and results of operations. Costly and
time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to maintain trade
secret protection could adversely affect our competitive business position. In addition, others may independently discover or develop
our trade secrets and proprietary information, and the existence of our own trade secrets affords no protection against such independent
discovery. For example, a public presentation in the scientific or popular press on the properties of our product candidates could motivate
a third party, despite any perceived difficulty, to assemble a team of scientists having backgrounds similar to those of our employees
to attempt to independently reverse engineer or otherwise duplicate our cell therapy technologies to replicate our success.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject to claims asserting that our employees, consultants, or advisors have wrongfully used or disclosed alleged trade secrets
of their current or former employers.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of our employees, consultants or advisors are currently, or were previously, employed at universities or other biotechnology or pharmaceutical
companies. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how
of others in their work for us, we may be subject to claims that these individuals, or we, have used or disclosed intellectual property,
including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer, or that patents
and applications we have filed to protect inventions of these employees, even those related to one or more of our product candidates,
are rightfully owned by their former or current employer. Litigation may be necessary to defend against these claims. If we fail in defending
claims of misappropriation and similar claims, in addition to paying monetary damages, we may lose valuable intellectual property rights
or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction
to management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest
and our business may be adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
registered trademarks or trade names may be challenged, circumvented, or declared generic or determined to be infringing on other marks.
We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential
partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby
impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name
or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered
or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks
and trade names, then we may not be able to compete effectively, and our business may be adversely affected. Our efforts to enforce or
protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective
and could result in substantial costs and diversion of resources and could adversely impact our financial condition or results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Intellectual
property rights do not necessarily address all potential threats.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations,
and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">others
                                            may be able to make products that are similar to our product candidates but that are not
                                            covered by the claims of the patents that we own or may own in the future;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we,
    or any partners or collaborators, might not have been the first to make the inventions covered by the issued patents or pending patent
    applications that we own or may own in the future;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we,
    or any partners or collaborators, might not have been the first to file patent applications covering certain of our or their inventions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">others
    may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or
    licensed intellectual property rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">it
    is possible that our pending patent applications or those that we may own in the future will not lead to issued patents;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issued
    patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    competitors might conduct research and development activities in countries where we do not have patent rights and then use the information
    learned from such activities to develop competitive products for sale in our major commercial markets;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may not develop additional proprietary technologies that are patentable;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    patents of others may have an adverse effect on our business; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may choose not to file a patent for certain trade secrets or know-how, and a third party may subsequently file a patent covering
    such intellectual property.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Should
any of these events occur, they could significantly harm our business, financial condition, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are highly dependent on our key personnel, and if we are not successful in attracting, motivating, and retaining highly qualified personnel,
we may not be able to successfully implement our business strategy.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are highly dependent on members of our executive team. The loss of the services of any of them may adversely impact the achievement of
our objectives. Any of our executive officers could leave our employment at any time, as all of our employees are &#8220;at-will&#8221;
employees, and we do not have &#8220;key person&#8221; insurance on them. The loss of the services of our Chief Executive Officer Ryan
Saadi, Chief Scientific Officer Neal Flomenberg, or one or more of our other executive officers or key employees could impede the achievement
of our research, development, and commercialization objectives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recruiting
and retaining qualified employees, consultants, and advisors for our business, including scientific and technical personnel, will also
be critical to our success. Competition for skilled personnel is intense and the turnover rate can be high. We may not be able to attract
and retain personnel on acceptable terms given the competition among numerous biotechnology and pharmaceutical companies and academic
institutions for skilled individuals. In addition, failure to succeed in preclinical studies, clinical trials or applications for marketing
approval may make it more challenging to recruit and retain qualified personnel. The inability to recruit, or the loss of services of
certain executives, key employees, consultants, or advisors, may impede the progress of our research, development and commercialization
objectives and have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may face substantial competition, which may result in others discovering, developing, or commercializing products before or more successfully
than we do.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
biotechnology and pharmaceutical industries, and in particular the immunotherapy sector, are characterized by the rapid evolution of
technologies and understanding of disease etiology, intense competition, and strong pursuit and defense of intellectual property. We
may face substantial competition from multiple sources, including major pharmaceutical, specialty pharmaceutical and existing or emerging
biotechnology companies, governmental agencies, academic institutions, public and private research institutions, technology companies
active in the AI space, and others. Our commercial opportunities will be significantly impacted if our competitors develop and
commercialize products that are safer, more effective, have fewer side effects, are less expensive or obtain more significant acceptance
in the market than any product candidates that we develop. Additionally, our commercial opportunities will be significantly impacted
if novel upstream products or changes in treatment protocols reduce the overall incidence or prevalence of diseases in our current or
future target population. Competition could result in reduced sales and pricing pressure on our product candidates, if approved by FDA.
In addition, significant delays in the development of our product candidates could allow our competitors to bring products to market
before us and impair any ability to commercialize our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 46; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of the approved or commonly used drugs and therapies for certain of our target diseases are well established and are widely accepted
by physicians, patients, and third-party payors. Some of these drugs are branded and subject to patent protection, and other drugs and
nutritional supplements are available on a generic basis. Insurers and other third-party payors may encourage the use of generic products
or specific branded products. If any of our product candidates are approved, although we expect they may be priced at a discount to existing
cell therapies, we also expect they will be priced at a significant premium over any competitive generic products. Absent differentiated
and compelling clinical evidence, pricing premiums may impede the adoption of our products over currently approved or commonly used therapies,
which may adversely impact our business. In addition, many companies are developing new therapeutics, and we cannot predict what the
standard of care will become as our products continue in clinical development. We anticipate that we could face intense and increasing
competition as new therapies enter the market and advanced technologies become available from time to time. We expect that any treatments
which we develop and commercialize will need to compete on, among other things, efficacy, safety, convenience of administration and delivery,
and price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of our competitors or potential competitors, either alone or through collaborations, have significantly greater market presence, financial
resources and expertise in research and development, preclinical studies, conducting clinical trials, manufacturing, obtaining regulatory
approvals and marketing approved products than we do, and as a result may have a competitive advantage over us. Smaller or early-stage
companies may also prove to be significant competitors, including through collaborative arrangements or mergers with large and established
companies. These third parties compete with us in establishing clinical trial sites and patient enrollment for clinical trials, as well
as in acquiring technologies and technology licenses complementary to our programs or advantageous to our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also face substantial competition for our AI initiatives and our computational approaches to drug discovery. Our competitors may
have significantly greater experience and expertise in using AI, algorithmic tool development, predictive analytics, and data
science to expedite drug development, optimize laboratory processes and clinical trials, unravel complex biological data, and improve
patient outcomes than we do, and significantly greater financial and other resources with which to do so. AI technologies are
changing rapidly and we must adapt and develop these technologies in a timely and effective manner at an acceptable cost in order to
compete. There can be no assurance that we will be able to develop, acquire, or integrate AI technologies, tools, and processes
successfully or as quickly or cost-effectively as our competitors, or that these technologies, tools, and processes will meet our needs
or achieve our goals. In addition, if the technologies, tools, or processes that we develop are incorrectly designed, do not operate
properly, or are otherwise deficient, or if we do not have the rights to use the data on which they rely, we may not achieve our goals
for this initiative, our performance and reputation could suffer or we could incur liability through the violation of laws, privacy rights,
or contracts. Even with the successful use of AI, we may fail to allocate resources efficiently, which could adversely impact
our pipeline and ability to compete effectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to attract and retain highly skilled personnel is critical to our operations and expansion. We also face competition for these
types of personnel from biotechnology and other companies and organizations, many of which have significantly larger operations and greater
financial, technical, human, and other resources than us. We may not be successful in attracting and retaining qualified personnel on
a timely basis, on competitive terms, or at all. If we are not successful in attracting and retaining these personnel, or integrating
them into our operations, our business, prospects, financial condition, and results of operations will be materially adversely affected.
In such circumstances, we may be unable to conduct certain research and development programs, unable to adequately manage our clinical
trials and development of our product candidates, and unable to adequately address our management needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of these factors, these competitors may obtain regulatory approval of their products before we are able to, which could result
in our competitors obtaining a head start and establishing a frontrunner position before we are ready to commercialize and will limit
our ability to develop or commercialize our product candidates. Our ability to commercialize our proprietary cell products could also
be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have a better safety profile,
are more convenient or are less expensive than our products. Our competitors also may be more successful than us in manufacturing and
marketing their products. These appreciable advantages could render our product candidates obsolete or noncompetitive before we can recover
the expenses of development and commercialization. If we are not able to compete effectively against our existing and potential competitors,
our business, financial condition, results of operations and growth prospects may be materially and adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will need to grow the size of our organization, and we may experience difficulties in managing this growth.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
our development plans and strategies develop, we expect to need additional managerial, operational, marketing, sales, financial and other
personnel. Future growth would impose significant added responsibilities on members of management, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying,
    recruiting, integrating, maintaining, and motivating additional employees;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">managing
    our internal development efforts effectively, including the clinical and FDA review process for TVGN 489 and any future product candidates
    we develop, while complying with our contractual obligations to contractors and other third parties; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">improving
    our operational, financial and management controls, reporting systems and procedures.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future financial performance and our ability to advance development of and, if approved, commercialize TVGN 489 and any future product
candidates we develop will depend, in part, on our ability to effectively manage any future growth, and our management may have to divert
a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing
these growth activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors
and consultants to provide certain services. We cannot assure you that the services of independent organizations, advisors and consultants
will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are
unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised
for any reason, our clinical trials may be extended, delayed, or terminated, and we may not be able to obtain marketing approval of any
current or future product candidates or otherwise advance our business. We cannot assure you that we will be able to manage our existing
consultants or find other competent outside contractors and consultants on economically reasonable terms, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors,
we may not be able to successfully implement the tasks necessary to further develop and commercialize TVGN 489 and any future product
candidates we develop and, accordingly, may not achieve our research, development, and commercialization goals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Product
liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
face an inherent risk of product liability exposure related to the testing of our product candidates in human trials and may face greater
risk if we commercialize any products that we develop. Product liability claims may be brought against us by subjects enrolled in our
trials, patients, healthcare providers or others using, administering, or selling our products. If we cannot successfully defend ourselves
against such claims, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">decreased
    demand for any product candidate we may develop;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal
    of trial participants;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">termination
    of clinical trial sites or entire trial programs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injury
    to our reputation and significant negative media attention;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">initiation
    of investigations by regulators;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    time and costs to defend the related litigation;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">substantial
    monetary awards to trial subjects or patients;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">diversion
    of management and scientific resources from our business operations; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inability to commercialize any product candidates that we may develop.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 41.75pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we currently hold liability insurance coverage consistent with industry standards, the amount of coverage may not adequately cover
all liabilities that we may incur. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to
satisfy any liability that may arise. We intend to expand our insurance coverage for products to include the sale of commercial products
if we obtain marketing approval for our product candidates, but we may be unable to obtain commercially reasonable product liability
insurance. A successful product liability claim or series of claims brought against us, particularly if judgments exceed our insurance
coverage, could decrease our cash and adversely affect our business and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
ability to use our NOL carryforwards to offset future taxable income may be subject to certain limitations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">We have incurred
substantial losses during our history and do not expect to become profitable in the near future, and we may never achieve profitability.
To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any,
until such unused losses expire. Limitations imposed by the applicable jurisdictions on our ability to utilize NOL carryforwards
could cause income taxes to be paid earlier than would be paid if such limitations were not in effect and could cause such NOL
carryforwards to expire unused, in each case reducing or eliminating the benefit of such NOL carryforwards. Furthermore, we may
not be able to generate sufficient taxable income to utilize our NOL carryforwards before they expire. If any of these events
occur, we may not derive some or all of the expected benefits from our NOL carryforwards. In addition, we may experience ownership
changes in the future as a result of subsequent shifts in our stock ownership, some of which may be outside of our control. As a result,
even if we earn net taxable income, our ability to use our NOL and tax credit carryforwards may be materially limited, which could
harm our future operating results by effectively increasing our future tax obligations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Being a Public Company and Ownership of Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
price of our Common Stock and Warrants may fluctuate significantly and you could lose all or part of your investment as a result.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market price of our Common Stock and Warrants has been and is likely to continue to be volatile. The stock market in general, and the
market for biopharmaceutical companies in particular, have experienced extreme volatility that has often been unrelated to the operating
performance or prospects of particular companies. As a result of this volatility, you could lose all or part of your investment. Many
factors may have a material adverse effect on the market price of our securities, including, but not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    commencement, enrollment, delay, or  results of our ongoing or future clinical trials, or changes in the development status of our
    product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    decision to initiate, not to initiate, or to terminate a clinical trial;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unanticipated
    serious safety concerns related to the use of our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    delay in our regulatory filings for our product candidates and any adverse or perceived adverse development with respect to the applicable
    regulatory authority&#8217;s review of such filings;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    actions, including failure to receive regulatory approval, with respect to our product candidates or our competitors&#8217; products
    or product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    failure to commercialize our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">our failure to utilize AI technologies in the development
    of our product candidates;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    success of competitive products or technologies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    by us or our competitors of significant acquisitions, strategic collaborations, joint ventures, collaborations, capital commitments,
    significant development milestones, or product approvals;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    failure to obtain new commercial partners;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    failure to obtain adequate manufacturing capacity or product supply for any approved product or inability to do so at acceptable
    cost;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    failure to achieve expected product sales and profitability;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 49; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    or legal developments applicable to our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    level of expenses related to our product candidates or clinical development programs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    lawsuits, including without limitation patent or stockholder litigation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    impact of the incidence and development of COVID-19 on our business and product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    changes in our Board of Directors (the &#8220;Board&#8221;) or senior management;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
    or anticipated fluctuations in our cash position or operating results;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in financial estimates or recommendations by securities analysts;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fluctuations
    in the valuation or financial results of companies perceived by investors to be comparable to us;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inconsistent
    trading volume levels of our shares;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcement
    or expectation of additional financing efforts;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales
    of Common Stock by us, our executive officers or directors, or our stockholders;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fluctuations
    and market conditions in the U.S. equity markets generally and in the biotechnology sector;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
    economic, political and social conditions; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    events or factors, many of which are beyond our control, or unrelated to our operating performance or prospects.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
recent years, the stock market in general has experienced significant price and volume fluctuations that have often been unrelated or
disproportionate to changes in the operating performance of the companies whose stock is experiencing those price and volume fluctuations.
Broad market and industry factors may seriously affect the market price of our Common Stock and Warrants, regardless of actual operating
performance. Following periods of such volatility in the market price of a company&#8217;s securities, securities class action litigation
has often been brought against that company. Because of the potential volatility of our Common Stock and warrant price, we may become
the target of securities litigation in the future. Securities litigation could result in substantial costs and divert management&#8217;s
attention and resources from our business. The realization of any of the above risks or any of a broad range of other risks, including
those described in this &#8220;<i>Risk Factors</i>&#8221; section, could have a dramatic and material adverse impact on the market price
of our Common Stock following the Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b><i>We have previously failed to
timely file certain periodic reports with the SEC. Potential future delays in the filing of our reports with the SEC pose significant
risks to our business, and could materially and adversely affect our financial condition and results of operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">We did not
timely file our 2024 Form 10-K for the fiscal year ended December 31, 2023 or our Form 10-Q for the quarterly period ended
March 31, 2024 and missed the initial deadline for the filing of our Form 10-Q for the quarterly period ended September 30, 2024
and our 2024 Form 10-K for the fiscal year ended December 31, 2024. While we are now current in our filing of periodic reports
under the Exchange Act, there is no assurance that in the future our reporting will always be timely. Our access to financing may be
impaired by any untimely filing of our periodic reports. For example, we will not be eligible to register the offer and sale of our
securities using a short-form registration statement on Form S-3 until we have timely filed all periodic reports required under
the&#160;Exchange Act for a period of twelve calendar months and any portion of a month immediately preceding the filing of such
registration statement. In addition, in the event the filing of our periodic reporting is delayed in the future, we may experience a
material adverse effect on our ability to grow our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Future failures
to timely file periodic reports with the SEC could subject us to enforcement action by the SEC and stockholder lawsuits, and result in
the delisting of our Common Stock and Warrants from Nasdaq, regulatory sanctions from the SEC, or breach of covenants in any future credit
facilities or of any preferred equity or debt securities that we may issue in the future, any of which could have a material adverse
impact on our operations, your investment in our Common Stock and Warrants, and our ability to register with the SEC public offerings
of our securities for our benefit or the benefit of our security holders. Additionally, any potential failure to timely file future periodic
reports could result in investors not receiving access to current or timely information regarding our business and operations with which
to make investment decisions.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sales
of a substantial number of our securities in the public market by the Registered Holders or by our other existing securityholders could
cause the price of our Common Stock and Warrants to fall.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of a substantial number of shares of our Common Stock in the public market could occur at any time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Registered Holders can sell, under this prospectus, up to 5,329,590 resale shares, representing approximately a 2.9% beneficial
ownership interest of our Common Stock as of April 30, 2025. Sales of a substantial number of our shares of Common Stock
or Warrants in the public market by the Registered Holders or by our other existing security holders, or the perception that those sales
might occur, could depress the market price of our Common Stock and Warrants and could impair our ability to raise capital through the
sale of additional equity securities. We are unable to predict the effect that such sales may have on the prevailing market price of
our Common Stock and Warrants. The sale of all the securities being offered in this prospectus could result in a significant decline
in the public trading price of our securities. Despite such a decline in the public trading price, which at $1.01 per share
as of April 29, 2025 is significantly below the price for the Semper Paratus common shares upon closing of Semper Paratus&#8217;
initial public offering, some of the Registered Holders may still experience a positive rate of return on the securities they purchased
due to the differences in the purchase prices described elsewhere in this prospectus. Other securityholders may not be able to experience
positive rates of return on securities they purchased due to the lower closing price at which our shares of Common Stock are trading
as of April 29, 2025. In addition, the registration of these shares of Common Stock for resale creates the possibility of a significant
increase in the supply of our Common Stock in the market. The increased supply, coupled with the potential disparity in purchase prices,
may lead to heightened selling pressure, which could negatively affect the public trading price of our Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we have a substantial number of restricted stock units and we expect that tax obligations with respect to vesting and settlement
of many of these restricted stock units will be satisfied through sell to cover arrangements. Sales, or the perception in the market
that the holders of a large number of shares intend to sell shares, could reduce the market price of our Common Stock.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<!-- Field: Page; Sequence: 50; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Certain
existing stockholders of Tevogen acquired such securities at a price below the current trading price of such securities, and may experience
a positive rate of return based on the current trading price or at lower trading prices. Future investors in Tevogen may not experience
a similar rate of return.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to consummation of the Business Combination, certain existing stockholders of Tevogen acquired shares of Common Stock or Warrants at
prices below, and in some cases considerably below, the current trading price of our Common Stock or for no cash consideration at all.
It is possible that these stockholders may experience a positive rate of return based on the current trading price or at lower trading
prices.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the relatively lower purchase prices that some of our stockholders paid
to acquire some of their securities compared to the current trading price of our shares of Common Stock and the fact that some of our
stockholders received securities for services rendered, these stockholders, including some of the Registered Holders, in some instances
may earn a positive rate of return on their investment, which may be a significant positive rate of return, depending on the market price
of our shares of Common Stock at the time that such stockholders choose to sell their shares of Common Stock. Investors who purchased
units in Semper Paratus&#8217; initial public offering (at a public offering price of $10.00 per unit), who purchased shares on Nasdaq
following Semper Paratus&#8217; initial public offering, or who purchased our Common Stock on Nasdaq following consummation of the Business
Combination may not experience a similar rate of return on the securities they purchased due to differences in the purchase prices and
the prevailing trading price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not have the funds necessary to satisfy our future obligations under the terms of our Preferred Stock and uncertainties with respect
to our obligations under the terms of our Preferred Stock could materially and adversely affect our ability to raise capital, our liquidity
position, our ability to operate our business and execute our business strategy, and the trading volatility and price of our securities.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Uncertainty
regarding our ability to satisfy our future obligations under the terms of our Preferred Stock could materially and adversely affect
our business. Our Series A Preferred Stock, which has an aggregate face value of $2.0 million, carries an annual 5% cumulative
dividend, increasing by 2% each year. The Series A Preferred Stock is callable if the volume weighted average price of the Common Stock
for the 20 days prior to delivery of the call notice is greater than $5.00 per share and there is an effective resale registration statement
on file covering the underlying Common Stock. Our Series C Preferred Stock, which has an aggregate face value of $6.0 million, carries
an annual 7.5% cumulative dividend, compounded annually, payable in shares of Series C Preferred Stock, or at our election, in cash.
The Series C Preferred Stock is callable at any time after the fifth anniversary of the issuance date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not have sufficient funds or be able to obtain financing from third parties to pay the dividends applicable to our Preferred Stock
or to redeem the Preferred Stock pursuant to our call rights, and the amount of dividend we may be required to pay on the Preferred Stock
is uncertain. These uncertainties could materially and adversely affect our ability to raise capital, our liquidity position, our ability
to operate our business and execute our business strategy, and the trading volatility and price of our securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<!-- Field: Page; Sequence: 51; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
incur increased costs as a result of operating as a public company, and our management devotes substantial time to compliance initiatives
and corporate governance practices.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public company, we incur significant legal, accounting, and other expenses that we did not incur as a private company. The Sarbanes-Oxley
Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of Nasdaq, and other applicable securities
rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure
and financial controls and corporate governance practices. We expect that we will need to hire additional accounting, finance, and other
personnel in connection with our efforts to comply with the requirements of being, a public company, and our management and other personnel
devote a substantial amount of time towards maintaining compliance with these requirements. These requirements contribute significantly
to our legal and financial compliance costs. These rules and regulations are often subject to varying interpretations, in many cases
due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by
regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated
by ongoing revisions to disclosure and governance practices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may issue additional shares of our Common Stock or other equity securities without your approval, which would dilute your ownership interests
and may depress the market price of your shares.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue additional shares of our Common Stock or other equity securities of equal or senior rank in the future in connection with,
among other things, raising additional capital, future acquisitions, repayment of outstanding indebtedness, or award issuances under
the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan (the &#8220;2024 Plan&#8221;), without stockholder approval, in a number
of circumstances. The additional shares or other securities convertible into or exchangeable for our public shares may be offered at
price that may not be the same as the price per share in this offering. We may sell shares or other securities in any other offering
at a price per share that is less than the price per share paid by the investors in this offering, and investors purchasing shares or
other securities in the future could have rights superior to existing stockholders. The price per share at which the additional
shares or securities convertible or exchangeable into public shares, will be sold in future transactions may be higher or lower than
the price per share paid by investors in this offering. If any of the above should occur, our stockholders, including investors who purchased
public shares in this offering, will experience additional dilution, and any such issuances may result in downward pressure on the price
of our Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
issuance of additional shares of Common Stock or other equity securities of equal or senior rank could have the following effects:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">your
                                            proportionate ownership interest in Tevogen will decrease;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 74.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            relative voting strength of each previously outstanding share of Common Stock may be diminished;
                                            or</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 74.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            market price of your shares of Common Stock may decline.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company&#8221;, and certain exemptions from disclosure requirements
available to us could make our securities less attractive to investors and may make it more difficult to compare our performance to the
performance of other public companies.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
qualify as an &#8220;emerging growth company&#8221; as defined in Section 2(a)(19) of the Securities Act of 1933, as amended (the &#8220;Securities
Act&#8221;), as modified by the JOBS Act. As such, we are eligible for and intend to take advantage of certain exemptions from various
reporting requirements applicable to other public companies that are not emerging growth companies for as long as we continue to be an
emerging growth company, including, but not limited to, (a) not being required to comply with the auditor attestation requirements of
Section 404 of the Sarbanes-Oxley Act, (b) reduced disclosure obligations regarding executive compensation in our periodic reports and
proxy statements and (c) exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder
approval of any golden parachute payments not previously approved. As a result, our stockholders may not have access to certain information
they may deem important. We cannot predict whether investors will find our securities less attractive because we rely on these exemptions.
If some investors find our securities less attractive as a result of our reliance on these exemptions, the trading prices of our securities
may be lower than they otherwise would be, there may be a less active trading market for our securities and the trading prices of our
securities may be more volatile.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 52; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will remain an emerging growth company until the earliest of : (i) the last day of the fiscal year (a) following the fifth anniversary
of the closing of Semper Paratus&#8217; initial public offering, or December 31, 2026, (b) in which we have total annual gross revenue
of at least $1.235 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of our common
equity that is held by non-affiliates exceeds $700 million as of the last business day of its most recently completed second fiscal quarter;
and (ii) the date on which we have issued more than $1.00 billion in non-convertible debt securities during the prior three-year period.
In addition, the JOBS Act also provides that an emerging growth company can delay the adoption of certain accounting standards until
those standards would otherwise apply to private companies. We have elected not to opt out of such extended transition period and, therefore,
we may not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.
This may make comparison of our financial statements with the financial statements of other companies who comply with public company
adoption dates difficult or impossible because of the potential differences in accounting standards used. Investors may find our Common
Stock less attractive because it will rely on these exemptions, which may result in a less active trading market for our Common Stock
and its price may be more volatile.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
we qualify as a &#8220;smaller reporting company&#8221; as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may
take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial
statements. We will remain a smaller reporting company and may take advantage of certain scaled disclosures available to smaller reporting
companies for so long as the market value of our voting and non-voting common equity held by non-affiliates is less than $250.0 million,
measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0 million during the most recently
completed fiscal year and the market value of our common equity held by non-affiliates is less than $700.0 million, measured on the last
business day of our second fiscal quarter. To the extent we take advantage of such reduced disclosure obligations, it may also make comparison
of its financial statements with other public companies difficult or impossible.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
management team has limited experience managing a public company.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Members
of our management team have limited experience managing a publicly traded company, interacting with public company investors, and complying
with the increasingly complex laws pertaining to public companies. Our management team may not successfully or efficiently manage our
transition to being a public company that is subject to significant regulatory oversight and reporting obligations under the federal
securities laws and the continuous scrutiny of securities analysts and investors. These new obligations and constituents require significant
attention from our senior management and could divert their attention away from the day-to-day management of our business, which could
harm our business, financial condition, and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
securities or industry analysts do not publish research or reports about our business, if they adversely change their recommendation
regarding our Common Stock or if our results of operations do not meet their expectations, including projections in those reports that
differ from our actual results, our share price and trading volume could decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our Common Stock may be influenced by research and reports that industry or securities analysts may
publish about us or our business. We do not have any control over these analysts. We have limited analyst coverage and we may continue
to have limited analyst coverage in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
securities or industry analysts fail to commence coverage of us, the trading price of our Common Stock may be negatively
impacted. In the event securities or industry analysts initiate coverage, and one or more of these analysts cease coverage of us or fail
to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause the price of our Common
Stock or trading volume to decline. Moreover, if one or more of the analysts who cover us publish negative reports, downgrade our stock,
or if our results of operations do not meet their expectations, the price of our Common Stock could decline. Securities research analysts
may establish and publish their own periodic projections for us. These projections may vary widely and may not accurately predict the
results we actually achieve. Our share price may decline if our actual results do not match the projections of these securities research
analysts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 53; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business and operations could be negatively affected we become subject to any securities litigation or stockholder activism, which
could cause us to incur significant expense, hinder execution of business and growth strategy and impact its stock price.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the past, following periods of volatility in the market price of a company&#8217;s securities, securities class action litigation has
often been brought against that company. Stockholder activism, which could take many forms or arise in a variety of situations, has been
increasing recently. Volatility in the stock price of our Common Stock or other reasons may in the future cause it to become the target
of securities litigation or stockholder activism. Securities litigation and stockholder activism, including potential proxy contests,
could result in substantial costs and divert management&#8217;s and Board&#8217;s attention and resources from our business. Additionally,
such securities litigation and stockholder activism could give rise to perceived uncertainties as to our future, adversely affect its
relationships with service providers and make it more difficult to attract and retain qualified personnel. Also, we may be required to
incur significant legal fees and other expenses related to any securities litigation and activist stockholder matters. Further, its stock
price could be subject to significant fluctuation or otherwise be adversely affected by the events, risks and uncertainties of any securities
litigation and stockholder activism.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be required to take write-downs or write-offs, restructuring and impairment or other charges that could have a significant negative
effect on its financial condition, results of operations and the share price of our securities, which could cause you to lose some or
all of your investment.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be forced to write-down or write-off assets, restructure our operations, or incur impairment or other charges that could result in
our reporting losses. In addition, unexpected risks may arise and previously known risks may materialize in a manner not consistent
with prior risk analysis. If any of these risks materialize, this could have a material adverse effect on our financial condition
and results of operations and could contribute to negative market perceptions about our securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have identified material weaknesses in our internal control over financial reporting. If we are unable to develop and maintain proper
and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired,
investors may lose confidence in our financial reporting and the trading price of our Common Stock may decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management previously concluded that we had material weaknesses in our internal controls over financial reporting related to our
not maintaining a sufficient complement of personnel commensurate with its accounting and reporting requirements resulting in inadequate
segregation of duties over the preparation, review, and posting of manual journal entries to the general ledger and in not having a sufficient
risk assessment process to identify and analyze risks of misstatement due to error and/or fraud. A material weakness is a deficiency,
or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material
misstatement of our annual or interim financial statements will not be prevented or detected and corrected on a timely basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we continue to evaluate steps to remediate these material weaknesses, the material weaknesses will not be considered remediated until
our plan has been fully implemented, the applicable controls are fully operational for a sufficient period of time, and we have concluded,
through testing, that the newly implemented and enhanced controls are operating effectively. At this time, we cannot predict the success
of such efforts or the outcome of future assessments of the remediation efforts. If the material weaknesses are not remediated, or if
we generally fail to establish and maintain effective internal controls appropriate for a public company, we may be unable to produce
timely and accurate financial statements, and we may conclude that our internal control over financial reporting is not effective, which
could adversely impact our investors&#8217; confidence and our stock price. In addition, these remediation measures may be time consuming
and costly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 54; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we identify any new material weaknesses in the future, any such newly identified material weakness could limit our ability to prevent
or detect a misstatement of our accounts or disclosures that could result in a material misstatement of our annual or interim financial
statements. In such case, we may be unable to maintain compliance with securities law requirements regarding timely filing of periodic
reports in addition to applicable stock exchange listing requirements, investors may lose confidence in our financial reporting and our
stock price may decline as a result. We cannot assure you that the measures we have taken to date, or any measures we may take in the
future, will be sufficient to avoid potential future material weaknesses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
address these material weaknesses, we intend to hire additional accounting personnel with appropriate expertise in accounting and reporting
under U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) and SEC regulations in order to better align with segregation of duties and perform appropriate risk assessment procedures to evaluate risks
of material misstatement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also cannot assure you that there will not be material weaknesses in our internal control over financial reporting in the future. Our
independent registered public accounting firm is not required to provide an attestation report on the effectiveness of our internal control
over financial reporting so long as we qualify as an &#8220;emerging growth company,&#8221; which may increase the risk that material
weaknesses or significant deficiencies in our internal control over financial reporting go undetected. Any failure to maintain internal
control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations
or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered
public accounting firm determines we have a material weakness in our internal control over financial reporting, investors may lose confidence
in the accuracy and completeness of our financial reports, the market price of our Common Stock could decline, and we could be
subject to sanctions or investigations by Nasdaq, the SEC, or other regulatory authorities. Failure to remedy any material weakness in
our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies,
could also restrict our future access to the capital markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 55; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
directors, executive officers, and principal stockholders, and Dr. Ryan Saadi in particular, have substantial control over our Company,
which could limit your ability to influence the outcome of key transactions, including a change of control.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
executive officers, directors, and principal stockholders and their affiliates beneficially own approximately 90% of the outstanding
shares of Common Stock and our Chief Executive Officer, Dr. Ryan Saadi, beneficially owns approximately 70% of the outstanding shares
of Common Stock. As a result, these stockholders exercise a significant level of control over all matters requiring stockholder approval,
including the election of directors and the approval of mergers, acquisitions or other extraordinary transactions. They may also have
interests that differ from our investors and may vote in a way with which our investors disagree. This concentration
of ownership may also have the effect of delaying, preventing or deterring a change of control, could deprive our stockholders of an
opportunity to receive a premium for their Common Stock as part of a sale, and might ultimately affect the market price of our Common
Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are a &#8220;controlled company&#8221; for purposes of the Nasdaq rules and, as a result, our stockholders do not have certain corporate
governance protections that are available to stockholders of companies that are not controlled companies.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Nasdaq rules, a company of which more than 50% of the voting power is held by an individual, group or another company is a &#8220;controlled
company&#8221; and need not comply with certain requirements, including the requirement that a majority of the board of directors consist
of independent directors and the requirements that we have compensation and nominating and governance committees composed entirely
of independent directors. For so long as we qualify as a &#8220;controlled company,&#8221; we maintain the option to rely on some
or all of these exemptions. We do not currently have a compensation committee or a nominating and governance committee.
Accordingly, our stockholders do not have the same protections afforded to stockholders of companies that are subject to all
of the corporate governance requirements of Nasdaq.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may redeem a warrant holder&#8217;s unexpired warrants prior to their exercise at a time that may be disadvantageous to such warrant
holder, thereby making its warrants worthless.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have the ability to redeem outstanding public warrants at any time after they become exercisable and prior to their expiration, at a
price of $0.01 per warrant, provided that the last reported sales price of Common Stock equals or exceeds $18.00 per share (as adjusted
for stock splits, stock capitalizations, reorganizations, recapitalizations and the like for certain issuances of public shares and equity-linked
securities for capital raising purposes in connection with the closing of its initial business combination) for any 20 trading days within
a 30 trading-day period ending on the third trading day prior to the date we send the notice of redemption to the warrant holders. We
may exercise our redemption right even if we are unable to register or qualify the underlying securities for sale under all applicable
state securities laws. Redemption of the outstanding warrants could force a warrant holder to: (i) exercise its warrants and pay the
exercise price at a time when it may be disadvantageous for such warrant holder to do so; (ii) sell its warrants at the then-current
market price when a warrant holder might otherwise wish to hold its warrants; or (iii) accept the nominal redemption price which, at
the time the outstanding warrants are called for redemption, is likely to be substantially less than the market value of a warrant holder&#8217;s
warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
value received upon exercise of the warrants (1) may be less than the value the holders would have received if they had exercised their
warrants at a later time where the underlying share price is higher and (2) may not compensate the holders for the value of the warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>A
warrant holder may only be able to exercise its public warrants on a &#8220;cashless basis&#8221; under certain circumstances, and if
a warrant holder does so, such warrant holder will receive fewer shares of Common Stock from such exercise than if a warrant holder were
to exercise such warrants for cash.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrant agreement, dated November 3, 2021, between Semper Paratus and Continental Stock Transfer &amp; Trust Company, as warrant agent
(the &#8220;warrant agreement&#8221;), provides that in the following circumstances holders of public warrants who seek to exercise
their warrants will not be permitted to do for cash and will, instead, be required to do so on a cashless basis in accordance with Section
3(a)(9) of the Securities Act: (i) if the Common Stock issuable upon exercise of the warrants is not registered under the Securities
Act in accordance with the terms of the warrant agreement; (ii) if we have so elected and the Common Stock is at the time of any exercise
of a warrant not listed on a national securities exchange such that it satisfies the definition of &#8220;covered securities&#8221; under
Section 18(b)(1) of the Securities Act; and (iii) if we have so elected and we call the public warrants for redemption. In addition,
the Private Placement Warrants may be exercised on a cashless basis so long as they are held by the initial purchasers or their
respective permitted transferees. If you exercise your warrants on a cashless basis, you would pay the warrant exercise price by surrendering
all of the warrants for that number of Common Stock equal to the quotient obtained by dividing (x) the product of the number of Common
Stock underlying the warrants, multiplied by the excess of the &#8220;fair market value&#8221; of the Common Stock (as defined in the
next sentence) over the exercise price of the warrants by (y) the fair market value. The &#8220;fair market value&#8221; is the average
reported closing price of the Common Stock for the 10 trading days ending on the third trading day prior to the date on which the notice
of redemption is sent to the holders of the warrants. As a result, you would receive fewer shares of Common Stock from such exercise
than if you were to exercise such warrants for cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our warrants may never be in the money and they may expire worthless.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise price for our outstanding warrants is $11.50 per share. Such warrants may never be in the money prior to their expiration, and
as such, the warrants may expire worthless. As such, it is possible that we may never generate any cash proceeds from the exercise of our Warrants. Accordingly,
as of the date of this prospectus, we have neither included nor intend to include any potential cash proceeds from the exercise of our
Warrants in our assessment of our liquidity and operational funding needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Any
amount of cash proceeds that we may receive is dependent upon the trading price of our Common Stock relative to the exercise price of
the Warrants.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may receive up to an aggregate of approximately $207 million from the cash exercise of the Warrants. The exercise price of each of our
Warrants is $11.50 per warrant. However, the last reported sales price of our Common Stock on April 29, 2025 was $1.01.
The likelihood that holders of Warrants will exercise their Warrants, and therefore any amount of cash proceeds that we may receive,
is dependent upon the trading price of our Common Stock. If the trading price for our Common Stock continues to be less than $11.50 per
share, we do not expect holders to exercise their Warrants. Accordingly, as of the date of this prospectus, we have neither included
nor intend to include any potential cash proceeds from the exercise of our Warrants in our assessment of our liquidity and operational
funding needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 56; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_001"></span>USE
OF PROCEEDS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will not receive any proceeds from the sale of shares of Common Stock or Warrants by the Registered Holders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Registered Holders will pay all incremental selling expenses relating to the sale of their shares of Common Stock and Warrants,
including underwriters&#8217; commissions and discounts, brokerage fees, underwriting marketing costs, and all reasonable fees and
expenses of any legal counsel representing the Registered Holders, except that we will pay the reasonable fees and expenses of one
U.S. legal counsel and local counsel in any other applicable jurisdiction(s) for the Registered Holders party to the A&amp;R
Registration Rights Agreement (as defined below) in the event of a demanded underwritten offering of their securities. We
will bear all other costs, fees and expenses incurred in effecting the registration of the securities covered by this prospectus,
including, without limitation, all registration and filing fees, printing and delivery fees, Nasdaq listing fees and fees and
expenses of our counsel and our accountants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will receive the proceeds from any exercise of Warrants for cash. The exercise price of each of our Warrants is $11.50 per warrant. However,
the last reported sales price of our Common Stock on April 29, 2025 was $1.01. The likelihood that holders of Warrants
will exercise their Warrants, and therefore any amount of cash proceeds that we may receive, is dependent upon the trading price of our
Common Stock. If the trading price for our Common Stock continues to be less than $11.50 per share, we do not expect holders to exercise
their Warrants. The Private Placement Warrants may be exercised on a cashless basis and we will not receive any proceeds from such exercise,
even if the Private Placement Warrants are in-the-money.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
we inform you otherwise in a prospectus supplement, the Company intends to use the net proceeds from the exercise of Warrants for
general corporate and working capital purposes. Any proceeds from the exercise of Warrants would increase our liquidity, but as
of the date of this prospectus, we have not included any potential cash proceeds from the exercise of our Warrants in our assessment of our liquidity and operational funding needs. The
Company will have broad discretion over the use of any such proceeds. There is no assurance that the holders of the Warrants will
elect to exercise any or all of such Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 57; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_002"></span>DIVIDEND
POLICY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not paid any cash dividends on our Common Stock to date and do not intend to pay cash dividends in the foreseeable future.
The payment of cash dividends in the future will be dependent upon our revenues and earnings, if any, capital requirements, and general
financial condition. The payment of any cash dividends will be within the discretion of our Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 58; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<!-- Field: Split-Segment; Name: 01 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_004"></span>MANAGEMENT&#8217;S
DISCUSSION AND ANALYSIS OF</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FINANCIAL
CONDITION AND RESULTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
following discussion and analysis of our results of operations and our liquidity and capital resources should be read together with our
unaudited consolidated financial statements and the related notes and our audited consolidated financial statements and the related notes
appearing elsewhere in this prospectus. Certain of the information contained in this discussion and analysis or set forth elsewhere in
this prospectus, including information with respect to plans and strategies for Tevogen&#8217;s business, includes forward-looking statements
intended to be covered by the safe harbor provisions for forward-looking statements in Section 21E of the Exchange Act. Forward-looking statements should be considered in light of these factors and the
factors described elsewhere in this prospectus, including in the &#8220;Risk Factors&#8221; section, and in our various filings with
the SEC. It is important that you read these factors and the other cautionary
statements made in this prospectus as being applicable to all related forward-looking statements wherever they appear in this prospectus.
Please also see the section entitled &#8220;Cautionary Note Regarding Forward-Looking Statements.&#8221;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>References
in this section to &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; &#8220;Tevogen,&#8221; &#8220;the Company&#8221; and similar
terms refer to Tevogen Bio Holdings Inc. and its subsidiaries collectively unless the context indicates otherwise.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage specialty immunotherapy company harnessing one of nature&#8217;s most powerful immunological weapons, CD8+ CTLs,
to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders, with
the aim of addressing the significant unmet needs of large patient populations. We believe the full potential of T cell therapies remains
largely untapped, and aspire to be the first biotechnology company offering commercially attractive, economically viable, and cost-effective
personalized T cell therapies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe our allogeneic, precision T cell technology, ExacTcell<sup>TM</sup>, has the potential to mainstream cell therapy with
a new class of off-the-shelf T cell therapies with diverse applications across virology, oncology, and other areas. ExacTcell
is a set of processes and methodologies to develop, enrich, and expand single human HLA restricted CTL therapies with proactively
selected, precisely defined targets. We are focused on using ExacTcell to develop therapeutics that are intended to be infused in patients
other than the original donor.&#160;ExacTcell is designed to maximize the immunologic specificity of our products in order
to eliminate malignant and virally infected cells while allowing healthy cells to remain intact. In addition, through our Tevogen.AI
artificial intelligence initiative, we are exploring ways to deploy artificial intelligence-powered target detection to further
accelerate our product development pace.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for
the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of Long COVID. We have
completed a Phase 1 proof-of-concept clinical trial of TVGN 489 for the treatment of ambulatory, high-risk adult COVID-19 patients.
No dose-limiting toxicities or significant treatment-related adverse events were observed in the treatment arm of the trial. Secondary
endpoints showing a rapid reduction of viral load and that infusion of TVGN 489 did not prevent development of the patients&#8217; own
T cell-related (cellular) or antibody-related (humoral) anti-COVID-19 immunity were also met. None of the patients who participated in
the trial reported progression of infection, reinfection, or the development of Long COVID during the six-month follow-up period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 59; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success depends in part on our ability to obtain and maintain patent and other protection for our products and methods, preserve
the confidentiality of our trade secrets, operate without infringing, misappropriating, or otherwise violating the valid, enforceable
proprietary rights of others, and prevent others from infringing, misappropriating, or otherwise violating our proprietary rights. We
rely on a combination of patents, patent applications, trademarks, and trade secrets to establish and protect our intellectual property
rights. Our ability to stop third parties from making, using, selling, offering to sell, or importing our products without the right
to do so may depend on the extent to which we have rights under valid and enforceable patents, trademarks or trade secrets that cover
these activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
our patents were developed internally, historical expenditures related to their development were all expensed as incurred per GAAP. We
believe these patents have significant value as the basis of our product pipeline. Our continued investment in our pipeline highlights
our belief in future commercial viability of these products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the Closing Date, pursuant to the Merger Agreement by and among Semper Paratus, Merger Sub, SSVK Associates, LLC, Tevogen Bio, and
Dr. Ryan Saadi, in his capacity as seller representative, Merger Sub merged with and into Tevogen Bio, with Tevogen Bio being the
surviving company and a wholly owned subsidiary of Semper Paratus. See Note 4 to our consolidated financial statements appearing
elsewhere in this prospectus for additional information regarding the net assets acquired through the Merger. The Merger was accounted
for as a reverse recapitalization under GAAP because the Company was determined to be the accounting acquirer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
commencing operations in June 2020, we have devoted substantially all our efforts and financial resources to establishing corporate governance,
recruiting essential staff, establishing research and development capability including securing laboratory space and equipment, conducting
scientific research, securing intellectual property rights to our inventions related to our product candidates and ExacTcell, carrying
out drug discovery including pre-clinical studies and our Phase 1 clinical trial of TVGN 489, raising capital, and pursuing the Business
Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have not generated any revenue. Our net loss for the years ended December 31, 2024 and 2023 was $13.7 million
and $60.5 million, respectively. Net loss for the year ended December 31, 2024 was primarily attributable to a $53.6
million loss from operations that primarily resulted from non-cash, stock-based compensation expense recognized with the liquidity
event condition contained in certain stock awards was satisfied upon the closing of the Business Combination as well as $7.5 million
in transaction costs in connection with the Business Combination, partially offset by the change in fair value of convertible promissory
notes of $48.5 million. As of December 31, 2024, we had cash of $1.3 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 14, 2024, we entered into a securities purchase agreement with The Patel Family, LLP (the &#8220;Patel Family&#8221;)
pursuant to which the Patel Family purchased 500 shares of our Series A Preferred Stock for an aggregate purchase price of $2.0
million. On March 27, 2024, we entered into an Amended and Restated Securities Purchase Agreement with the Patel Family pursuant
to which we amended and restated the original agreement and the Patel Family agreed to purchase 600 shares of our Series A-1 Preferred
Stock for an aggregate purchase price of $6.0 million, of which $3.0 million has been received through the date of this prospectus.
On August 21, 2024, we entered into a securities purchase agreement with the Patel Family, pursuant to which the investor purchased 600
shares of our Series C Preferred Stock for an aggregate purchase price of $6.0 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described in more detail in &#8220;&#8212;<i>Liquidity and Capital Resources&#8212;Funding Requirements</i>&#8221; below, on June
6, 2024, we entered into the Loan Agreement with the Patel Family providing for (i) the Facility, pursuant to which
the Patel Family agreed to lend us the Maximum Loan Amount of term loans in $1.0 million increments on a monthly basis, over
a draw period of thirty-six months, and (ii) a contingent option for the Patel Family to purchase at least $14.0 million of
our Common Stock in the Optional PIPE. The Loan Agreement also contains a contingent option for the Patel Family to purchase at least
$14.0 million of our Common Stock plus up to the then-remaining available amount under the Facility, in a future private placement
if the ten-day trailing volume weighted average price per share of the Common Stock (the &#8220;Trailing VWAP&#8221;) reaches $10.00
per share. Pursuant to the terms of the Loan Agreement, we also issued to the Patel Family the Commitment Shares, subject to forfeiture
by the Patel Family of the Commitment Shares or an equal number of shares of Common Stock in the event the Patel Family fails to (i)
make a deposit under the Facility when due or (ii) pay the purchase price for the Optional PIPE within 30 days after the Threshold Price
Notice Date in the event we have satisfied all applicable closing conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 60; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">In addition,
in January 2025, we received a grant of $2.0 million from KRHP to further our development of off-the-shelf, genetically unmodified precision
T cell therapeutics to treat infectious diseases and cancers. KRHP is affiliated with the Patel Family.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on cash on hand as of the date of this prospectus of approximately $1.3 million, the amounts available under our Loan Agreement, and
the $8.0 million of additional committed grant funding from KRHP, we have concluded that we have sufficient cash to fund our operations
for at least the next 12 months from the issuance date of our consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not expect to generate product revenue unless and until we obtain marketing approval or other authorization for and successfully
commercialize TVGN 489 or another product candidate. We expect to incur expenses related to expanding our research and development capability,
building our manufacturing infrastructure including through acquisitions, and developing our commercialization organization, including
reimbursement, marketing, managed market, and distribution functions, and training and deploying a specialty medical science liaison
team.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Components
of our Results of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenue</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have not generated any revenue, and we do not expect to generate any revenue from the sale of products unless and until we obtain
marketing approval or other authorization for and commercialize TVGN 489 or another product candidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Operating
Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses consist primarily of costs incurred for our research activities, including staffing, discovery efforts, preclinical
studies, and clinical development of TVGN 489, and preclinical studies of other product candidates, and include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acquisition
    of supplies and equipment and leasing lab spaces;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses
    incurred to conduct the necessary pre-clinical studies required by FDA to obtain the regulatory approval necessary to conduct TVGN
    489 clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">salaries,
    benefits, and other related costs for personnel engaged in research and development functions&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    of funding research performed by third parties, including pursuant to agreements with CROs,
    and investigative site costs to conduct our pre-clinical studies and clinical trials&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing
    costs, including expenses incurred under agreements with CMOs, including manufacturing
    scale-up expenses, and the cost of acquiring and manufacturing pre-clinical study and clinical trial materials&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    of outside consultants, including their fees, stock-based compensation, and related travel expenses&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    of laboratory supplies and acquiring materials for pre-clinical studies and clinical trials&#894; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">facility-related
    expenses, which include direct depreciation costs of equipment and expenses for rent and maintenance of facilities and other operating
    costs.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 61; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development activities are central to the biotechnology business model. Product candidates in later stages of clinical development
generally have higher development costs than those in earlier stages, primarily due to the increased study sizes, which also leads generally
to longer patient enrollment times in later-stage clinical trials. We expect our research and development expenses to increase significantly
over the next several years as we increase manufacturing, shipping, and storage of clinical batches required for clinical trials, incur
increased personnel costs, including stock-based compensation, conduct planned clinical trials for TVGN 489 and other clinical and
pre-clinical activities for other product candidates, and prepare regulatory filings for any of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
successful development of our current or future product candidates is highly uncertain. At this time, we cannot reasonably estimate or
know the nature, timing, and costs of the efforts that will be necessary to complete the development of any product candidates. The success
of TVGN 489 and our other product candidates will depend on several factors, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
    respect to products other than TVGN 489, successfully completing pre-clinical studies&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully
    initiating future clinical trials&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully
    enrolling patients in and completing clinical trials&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">applying
    for and receiving marketing approvals from applicable regulatory authorities&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
    and maintaining intellectual property protection and regulatory exclusivity for TVGN 489 and any other product candidates we are
    developing or may develop in the future and enforcing, defending, and protecting these rights&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">making
    arrangements with third-party manufacturers, or establishing adequate commercial manufacturing capabilities&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    sales, marketing, and distribution capabilities and launching sales of our products, if and when approved, whether alone or in collaboration
    with others&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">market
    adoption of TVGN 489 and any other product candidates, if and when approved, by patients and the medical community&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competing
    effectively with potential therapeutic alternatives in our target disease areas; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adequate
    reimbursement by private and public payors including health technology appraisal entities in non-U.S. countries.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
change in the outcome of any of these variables concerning the development, manufacturing, or commercialization activities of a product
candidate could result in a significant change in the costs and timing associated with the development of that product candidate. For
example, if we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently
contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of
these trials or tests are not positive or are only modestly positive, if there are safety concerns, or if we determine that the
observed safety or efficacy profile would not be competitive in the marketplace, we could be required to expend significant additional
financial resources and time on the completion of clinical development. We anticipate that product commercialization may
take several years, and we expect to spend a significant amount in development costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and Administrative Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses primarily consist of personnel expenses, which include salaries, benefits, and stock-based long term incentive
compensation for employees. These expenses also encompass corporate facility costs such as rent, utilities, depreciation, and maintenance,
as well as costs not classified under research and development expenses. Legal fees pertaining to intellectual property and corporate
matters, as well as fees for accounting and consulting services, are also included in general and administrative expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 62; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that our general and administrative expenses will increase in the future to support our continued research and development activities,
potential commercialization efforts, and increased costs of operating as a public company. These increases will likely include increased
costs related to the hiring of additional personnel and fees to outside consultants, lawyers, accountants, and recruitment firms, among
other expenses. Increased costs associated with being a public company will also include expenses related to services associated with
maintaining compliance with SEC and Nasdaq requirements, insurance, and investor relations costs. If any of our current
or future product candidates obtains marketing approval, we expect that we would incur significantly increased expenses associated with
sales and marketing efforts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Interest
Expense, Net</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
expense, net consists primarily of interest on our former convertible promissory notes and Loan Agreement, partially offset
by interest earned on bank deposits. (See &#8220;&#8212;<i>Liquidity and Capital Resources</i>&#8212;<i>Sources of Liquidity</i>&#8221;
below.)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Merger
Transaction Costs</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transaction
costs we incurred in relation to the Business Combination were initially capitalized as deferred transaction costs up through
the Closing Date, at which time such costs were charged to expense in our statements of operations less the amount of cash received in
the Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Change
in Fair Value of Convertible Promissory Notes</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
accounting standards provide entities with an option to measure many financial instruments and certain other items at fair value. As
a result of us electing this option, we recorded all convertible promissory notes at fair value with changes in fair value reported in
our statements of operations at each balance sheet date through the settlement of the convertible promissory notes in connection with
the Closing, at which time the convertible promissory notes were converted into our Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Loss
on Issuance of Commitment Shares</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
other expenses consist of losses on the issuance of the Commitment Shares for the year ended December 31, 2024 associated with the Loan
Agreement. Since we intend to elect the fair value option for future draws under the Loan Agreement, we expense all issuance costs associated
with the Loan Agreement, which are comprised of the fair value of the Commitment Shares as well as the issuance date fair value of the
$14 million Purchase Option and Additional Amount Purchase Option. For more information about the Loan Agreement, see &#8220;&#8212;<i>Liquidity
and Capital Resources&#8212;Funding Requirements</i>&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Income
Tax Provision</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Since inception,
we have incurred significant net losses. As of December 31, 2024, we had NOL carryforwards for federal
and state income tax purposes of $25.6 million and $27.8 million, respectively. We have provided a valuation allowance
against the full amount of our net deferred tax assets since, in the opinion of our management, based upon our historical and anticipated
future losses, it is more likely than not that the benefits will not be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
utilization of our NOL carryforwards may be subject to a substantial annual limitation in the event of certain cumulative
changes in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections
382 and 383 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), respectively, as well as similar state
provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Results
of Operations</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Comparison
of the years ended December 31, 2024 and 2023</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our results of operations for the years ended December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Year ended December 31,</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">31,033,276</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">4,403,526</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1pt; text-align: left">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">22,531,212</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,439,499</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; padding-bottom: 1pt; text-align: left">Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">53,564,488</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">8,843,025</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; padding-bottom: 1pt; text-align: left">Loss from operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(53,564,488</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(8,843,025</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest expense, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(184,037</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,206,352</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Merger transaction costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,499,353</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in fair value of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(58,180</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in fair value of convertible promissory notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48,468,678</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(50,428,303</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">Loss on issuance of commitment shares</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(890,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(13,727,380</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(60,477,680</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 63; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not track our internal research and development costs on a program-by-program basis. The following table summarizes our research and
development expenses for the years ended December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December
    31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Personnel costs</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">466,955</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">2,263,711</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,012,127</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other clinical and pre-clinical development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,584,651</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,226,402</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Facilities and other expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">969,543</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">913,413</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total research and development expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">31,033,276</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,403,526</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses for the year ended December 31, 2024 were $31.0 million, compared to $4.4 million
for the year ended December 31, 2024. The increase was primarily attributable to an increase in stock-based
compensation due to stock compensation expense related to the restricted stock units (&#8220;RSUs&#8221;) granted to
Dr. Saadi on the Closing Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and Administrative Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our general and administrative expenses for the years ended December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December
    31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Personnel costs</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,725,326</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,095,468</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,752,010</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Legal and professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,636,232</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,616,925</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Facilities and other expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">417,644</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">727,106</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total general and administrative expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,531,212</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,439,499</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses for the year ended December 31, 2024 were $22.5 million compared to $4.4 million
for the year ended December 31, 2023. The increase was primarily attributable to stock-based compensation expense of
$13.8 million, of which $7.7 million was recognized as a non-cash stock-based compensation expense from certain stock-based awards
that continue to vest through satisfaction of service conditions subsequent to the satisfaction of the liquidity condition
upon the Closing, and $2.3 million was recognized as restricted stock compensation expense related to the RSUs granted. The increase
of $0.6 million in personnel costs was primarily attributable to an increase in headcount and an increase in premium for our director
and officer insurance policy. The increase of $4.0 million in legal and professional fees was primarily attributable to the additional
services incurred as a result of the Merger.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Interest
Expense, Net</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognized $0.2 million and $1.2 million in interest expense for the years ended December 31, 2024 and 2023, respectively,
which was attributable primarily to the outstanding principal balance associated with our convertible promissory notes that converted
into Common Stock in connection with the Closing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Merger
Transaction Costs</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Merger
transaction costs in excess of cash received from the Business Combination of $7.5 million were recognized as period expenses
for the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 64; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Change
in Fair Value of Convertible Promissory Notes</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognized a non-cash gain of $48.5 million and a non-cash loss of $50.4 million for the change in fair value of the convertible
promissory notes for the years ended December 31, 2024 and 2023, respectively. The change was primarily a result of the
increase in the underlying estimated fair value of our Common Stock during the year ended December 31, 2023 compared
to a decrease in the underlying estimated fair value of our Common Stock from January 1, 2024 to the settlement of the convertible
promissory notes upon the Closing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Loss on Issuance</i><i> of Commitment
Shares</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">We incurred losses
on the issuance of Commitment Shares during the year ended December 31, 2024, associated with the Loan Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sources
of Liquidity</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, we had $1.3 million in cash, as compared to $1.1 million in cash as of December 31, 2023.
To date, we have not yet commercialized any products or generated any revenue from product sales and have financed our operations primarily
with proceeds from the sale of convertible promissory notes and preferred stock, funds drawn on the Loan Agreement, and grant funding.
Since January 2021, we have raised aggregate gross proceeds of $24.0 million from the sale of convertible promissory notes, $2.0 million
from the sale of our Series A Preferred Stock, $3.0 million from deposits related to the future sale of our Series A-1 Preferred Stock,
and $6.0 million from the sale of our Series C Preferred Stock. In June 2024, we entered into the Loan Agreement, which provided up to
$36.0 million of term loans that can be drawn in $1.0 million increments each month over thirty-six months, as described below. As of
December 31, 2024, we had drawn $1.0 million with a remaining $30.0 million&#160;available for future financing over the remaining&#160;30&#160;months.
We drew an additional $1.0 million on February 10, 2025. In addition, in January 2025, we received a grant of $2.0 million from KRHP.
We expect to receive an additional $8.0 million grant from KRHP during the second quarter of 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
Flows</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our cash flows for the years ended December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Year ended December 31,</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash provided by (used in)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Operating activities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(11,998,730</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(8,171,118</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(133,000</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,229,328</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,872,250</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net change in cash</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">230,598</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(4,431,868</td><td style="text-align: left">)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cash
Flows from Operating Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, we used $12.0 million of net cash in operating activities. Cash used in operating
activities reflected our net loss of $13.7 million offset by $1.7 million of non-cash charges related to the change in
the fair value of the convertible promissory notes, depreciation expense, reductions in the operating right of use (&#8220;ROU&#8221;)
assets, non-cash interest on the convertible promissory notes, and the net change in our operating assets and liabilities attributable
to the timing of our payments to our vendors for research and development activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, we used $8.2 million of net cash in operating activities. Cash used in operating activities reflected
our net loss of $60.5 million offset by $52.0 million of non-cash charges related to the change in the fair value of the convertible
promissory notes, depreciation expense, reductions in the ROU assets, non-cash interest on the
convertible promissory notes, and a $0.3 million net change in our operating assets and liabilities attributable to the timing of our
payments to our vendors for research and development activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cash
Flows from Investing Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2024 and 2023, we used $0.0 million and $0.1 million respectively, for the
purchase of property and equipment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 65; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cash
Flows from Financing Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, we received $12.3 million of net cash from financing activities attributable to $2.0 million in proceeds
from the sale of Series A Preferred Stock, $6.0 million in proceeds from the sale of Series C Preferred Stock, $3.0 million of non-refundable
prepaid proceeds towards the anticipated issuance of Series A-1 Preferred Stock, $1.0 million drawn under the Loan Agreement, and $0.2
million of cash in connection with the Merger.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">During the year
ended December 31, 2023, we received $4.0 million of net cash from financing activities attributable to the proceeds from the convertible
promissory notes, less $0.1 million related to payments of deferred transaction costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Funding
Requirements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
primary sources of funds to meet our near-term liquidity and capital requirements include cash on hand, including the funding we have
received from the sale of our Series A and Series C Preferred Stock and the funding we expect to receive from the sale of our
Series A-1 Preferred Stock, our access to an unsecured line of credit (limited to a $1.0 million monthly draw) under the Loan Agreement
described below, and the $8.0 million of grant funding that KRHP has committed to provide to be used towards the Company&#8217;s ongoing
operational expenses. On February 14, 2024, we entered into a securities purchase agreement with an investor pursuant to which the
investor agreed to purchase shares of our Series A Preferred Stock for an aggregate purchase price of $8.0 million. On March 27, 2024,
we entered into an agreement pursuant to which that amount was reduced to $2.0 million and the investor agreed to purchase shares of
our Series A-1 Preferred Stock for an aggregate purchase price of $6.0 million. We have not yet received $3.0 million of the $6.0 million
purchase price for the Series A-1 Preferred Stock. Even if we receive such proceeds, we will still need additional capital to fully implement
our business, operating, and development plans. On August 21, 2024, we entered into a securities purchase agreement with an investor
pursuant to which the investor agreed to purchase shares of our Series C Preferred Stock for an aggregate purchase price of $6.0 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><i>Loan Agreement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 6, 2024, we entered into the Loan Agreement, pursuant to which the Patel Family agreed to provide to us up to the
Maximum Loan Amount of $36.0 million under the Facility. The Patel Family is also the investor in our Series A, Series A-1,
and Series C Preferred Stock. The Facility permits us to borrow up to $1.0 million monthly in a single monthly draw over a period
of up to three years. Draws accrue interest at a fixed annual rate of the lower of (i) the daily secured overnight financing rate, measured
on the date we receive the draw (the &#8220;Deposit Date&#8221;), plus 2.00% and (ii) 7.00%, accruing quarterly beginning on the Deposit
Date and payable quarterly beginning on the three-month anniversary of the Deposit Date. Interest will be payable in shares of Common
Stock with an effective purchase price of $1.50 per share, and each draw will mature 48 months after the Deposit Date. Prepayment will
be permitted without penalty. We may repay or prepay any amount of outstanding principal balance under the Facility at our
election in cash or in shares of Common Stock with an effective purchase price of the greater of $1.50 per share and the Trailing VWAP
as of the trading day prior to payment, subject to certain requirements related to resale registration. Pursuant to the Loan Agreement,
we also agreed to provide the Patel Family an option to purchase $14.0 million of shares of our Common Stock plus an additional
amount up to the total then-remaining available and undrawn portion of the Maximum Loan Amount (which amount would thereafter no longer
be available under the Facility). The Optional PIPE would be priced at a 30% discount to the Trailing VWAP on the date such price first
reaches at least $10.00 per share (the &#8220;Threshold Price Date&#8221;) and will be exercisable by the Patel Family by written
notice within three business days after we have notified the Patel Family of the Threshold Price Date (the date of such
notice, the &#8220;Threshold Price Notice Date&#8221;). Pursuant to the terms of the Loan Agreement, we issued to the Patel Family
the Commitment Shares, subject to forfeiture by the Patel Family of the Commitment Shares or an equal number of shares of Common
Stock in the event the Patel Family fails to (i) make a deposit under the Facility when due or (ii) pay the purchase price for the Optional
PIPE within 30 days after the Threshold Price Notice Date in the event we have satisfied all applicable closing conditions. There
is no assurance as to the amount of proceeds we will ultimately receive under the Loan Agreement. As of December 31, 2024, we have
drawn an aggregate of $1.0 million under the Loan Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><i>Sales by Registered
Holders</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will not receive any proceeds from the sale of shares by the Registered Holders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Warrant Proceeds</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will receive the proceeds from any exercise of the Warrants or options for cash, which we intend to use for general corporate and working
capital purposes. We may receive up to an aggregate of approximately $207 million from the cash exercise of the Warrants. The exercise
price of each of our Warrants is $11.50 per Warrant. However, the last reported sales price of our Common Stock on April 29, 2025
was $1.01. The likelihood that holders of Warrants will exercise their Warrants, and therefore any amount of cash proceeds
that we may receive, is dependent upon the trading price of our Common Stock. If the trading price for our Common Stock continues to
be less than $11.50 per share, we do not expect holders to exercise their Warrants. Additionally, under certain circumstances, the Warrants
may be exercised on a cashless basis and we will not receive any proceeds from such exercise, even if the Private Placement Warrants
are in-the-money. Furthermore, to the extent Warrants are exercised, additional Common Stock will be issued, which will result in dilution
to the holders of our Common Stock and increase the number of Common Stock eligible for resale in the public market. Sales of substantial
numbers of such shares in the public market could adversely affect the market price of our Common Stock, which increases the likelihood
of periods when our Warrants will not be in the money prior to their expiration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
proceeds from the exercise of Warrants would increase our liquidity, but we are not currently including any cash proceeds from
the exercise of Warrants in our assessment of our liquidity and when planning for our operational funding needs. We will continue to evaluate the probability of Warrant exercise over the life of our Warrants and the merit of including
potential cash proceeds from the exercise thereof in our liquidity sources and capital resources planning. <span style="letter-spacing: 0.2pt">Our
future capital requirements and the adequacy of available funds will depend on many factors, including those described below and set forth
under &#8220;<i>Risk Factors</i>&#8221; elsewhere in this prospectus.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Increasing Expenses</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to devote considerable financial resources to our ongoing and planned activities, particularly as we conduct our planned
clinical trials of TVGN 489 and other product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identifying
potential product candidates and conducting pre-clinical testing and clinical trials is a time-consuming, expensive, and uncertain process
that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve
product sales. In addition, our product candidates, if approved, may not achieve commercial success.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 66; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect our expenses to increase in connection with our ongoing activities, particularly as we advance our pre-clinical studies and clinical
trials. In addition, if we obtain marketing approval for TVGN 489 in any indication or for any other product candidate we are developing
or develop in the future, we expect to incur commercialization expenses related to product manufacturing, sales, marketing, and distribution.
Furthermore, we expect to continue to incur increased costs associated with operating as a public company. Accordingly, we will need
additional funding to fully implement our business plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future capital requirements will depend on many factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    progress, costs, and results of our planned clinical trials of TVGN 489 and other planned and future clinical trials&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope, progress, costs, and results of our pre-clinical testing and clinical trials of TVGN 489 for additional combinations, targets,
    and indications&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number of and development requirements for additional indications for TVGN 489 or for any other product candidates&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to scale up our manufacturing processes and capabilities to support clinical trials of TVGN 489 and other product candidates
    we are developing and may develop in the future&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs, timing, and outcome of regulatory review of TVGN 489 and other product candidates we are developing and may develop in the
    future&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    changes in the regulatory environment and enforcement rules&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to establish and maintain strategic collaboration, licensing, or other arrangements and the financial terms of such arrangements&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs and timing of future commercialization activities, including product manufacturing, sales, marketing, and distribution, for
    TVGN 489 and other product candidates we are developing and may develop in the future for which we may receive marketing approval&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain and maintain acceptance of any approved products by patients, the medical community, and third-party payors&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    amount and timing of revenue, if any, received from commercial sales of TVGN 489 and any other product candidates we are developing
    or develop in the future for which we receive marketing approval&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    changes in pharmaceutical pricing and reimbursement infrastructure&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    availability of raw materials for use in production of our product candidates&#894; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs and timing of preparing, filing, and prosecuting patent applications, maintaining and enforcing our intellectual property and
    proprietary rights, and defending any intellectual property-related claims.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, we had cash of $1.3 million. We believe that our cash balance and amounts available under the Loan Agreement, which
allows us to draw down term loans of $1.0 million per month over thirty-six months, will allow us to have adequate cash and financial
resources, to operate for at least the next 12 months from the date of issuance of our consolidated financial statements included in
this prospectus. In addition, KRHP has committed to provide an additional $8.0 million of grant funding to the Company to be used towards
the Company&#8217;s ongoing operational expenses. The grant funding will be used to satisfy the Company&#8217;s obligations as they come
due through March 31, 2026. The Company does not plan to initiate a clinical trial until additional funding is received.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 67; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
regularly evaluate different strategies to obtain funding for operations for subsequent periods. These strategies may include but are
not limited to private placements of securities, licensing and/or marketing arrangements, partnerships with other pharmaceutical or biotechnology
companies, and public offerings of securities. We may not be able to obtain financing on acceptable terms and may not be able to enter
into strategic alliances or other arrangements on favorable terms. The terms of any financing may adversely affect the holdings or the
rights of our stockholders. If we are unable to obtain sufficient funding, we could be required to delay, reduce or eliminate research
and development programs, product portfolio expansion, or future commercialization efforts, which could adversely affect our business
prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Contractual
Obligations and Commitments</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our contractual obligations and commitments as of December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Total</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Less than 1 Year</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">1 to 3 Years</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Contractual obligations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease commitments&#160;<sup>(1)</sup></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">244,446</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">230,471</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">13,975</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes payable&#160;<sup>(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,651,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,651,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loan Agreement repayment&#160;<sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,028,270</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,270</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,000,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total contractual obligations</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">2,923,716</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">1,909,741</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">1,013,975</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="margin: 0"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; padding-bottom: 1.45pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reflects
    obligations pursuant to our office and laboratory leases in Philadelphia, Pennsylvania and Warren, New Jersey.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.45pt; text-align: left">(2)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.45pt; text-align: justify">Reflects notes payable obligations
    assumed as part of the Merger.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.45pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reflects
    obligations to settle outstanding balances on our Loan Agreement, if paid in cash at time of settlement, as well as accrued interest.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
commitment amounts in the table above are associated with contracts that are enforceable and legally binding and that specify all significant
terms, including fixed or minimum services to be used, fixed, minimum, or variable price provisions, and the approximate timing of the
actions under the contracts. Our contracts with CROs, CMOs, and other third parties for the manufacture of our product candidates and
to support pre-clinical research studies and clinical testing are generally cancelable by us upon prior notice and do not contain any
minimum purchase commitments. Payments due upon cancellation consisting only of payments for services provided or expenses incurred,
including noncancelable obligations of our service providers, up to the date of cancellation are not included in the table above as the
amount and timing of such payments are not known.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 68; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Policies and Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements,
which have been prepared in accordance with GAAP. The preparation of the consolidated financial statements requires us to make
estimates and judgments that affect the reported amounts of assets, liabilities, and expenses and the disclosure of contingent assets
and liabilities in our consolidated financial statements. On an ongoing basis, we evaluate our estimates and judgments, including
those related to accrued expenses, the fair value of our Common Stock, the fair value of our convertible promissory notes, and stock-based
compensation. We base our estimates on historical experience, known trends and events, and various other factors that are believed to
be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and
liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions
or conditions, including those factors set out in the &#8220;<i>Risk Factors</i>&#8221; section and elsewhere in this prospectus,
including the section entitled &#8220;<i>Cautionary Note Regarding Forward-Looking Statements</i>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
our significant accounting policies are described in more detail in Note 3 to our consolidated financial statements, we believe
the following accounting policies are the most critical to the judgments and estimates used in the preparation of our consolidated
financial statements or involve a significant level of estimation uncertainty and have had or are reasonably likely to have a material
impact on our financial condition or results of operation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and Development Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development activities are expensed as incurred. As part of the process of preparing our consolidated financial statements,
we are required to estimate our accrued research and development expenses, including those related to clinical trials and product candidate
manufacturing. This process involves reviewing open contracts and purchase orders, communicating with our applicable personnel to identify
services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the
services when we have not yet been invoiced or otherwise notified of actual costs. Our service providers invoice us in arrears or require
prepayments for services performed, as well as on a pre-determined schedule or when contractual milestones are met. We make estimates
of our accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances
known to us at that time. We periodically confirm the accuracy of the estimates with the service providers and make adjustments if necessary.
Examples of estimated accrued research and development expenses include fees paid to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">vendors
    in connection with preclinical and clinical development activities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CROs
    in connection with clinical trials; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CMOs
    in connection with the process development and scale-up activities and the production of preclinical and clinical trial materials.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
for clinical trials and manufacturing activities are recognized based on an evaluation of our vendors&#8217; progress towards completion
of specific tasks, using data such as participant enrollment, clinical site activations, or information provided to us by our vendors
regarding their actual costs incurred. Payments for these activities are based on the terms of individual contracts and payment timing
may differ significantly from the period in which the services were performed. We determine accrual estimates through reports from and
discussions with applicable personnel and outside service providers as to the progress or state of completion of studies, or the services
completed. Our estimates of accrued expenses as of each balance sheet date are based on the facts and circumstances known at the time.
Costs that are paid in advance of performance are deferred as a prepaid expense and amortized over the service period as the services
are provided.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing
of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that
are too high or too low in any particular period. To date, there have not been any material adjustments to our prior estimates of accrued
research and development expenses. However, due to the nature of estimates, we cannot assure you that we will not make changes to our
estimates in the future as we become aware of additional information about the status or conduct of our clinical trials and other research
activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 69; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fair
Value Measurements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
recurring fair value measurements primarily consist of the convertible promissory notes prior to the Merger, for which we elected the
fair value option, the freestanding $14 million purchase option under the Loan Agreement, and the bifurcated purchase option that
is embedded within the loan commitment under the Loan Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
used the Probability Weighted Expected Return Method (&#8220;PWERM&#8221;) valuation methodology to determine the fair value of the convertible
promissory notes prior to the Merger for all the periods presented. The PWERM is a scenario-based methodology that estimates the fair
value based upon an analysis of future values for the company, assuming various outcomes. The value is based on the probability-weighted
present value of expected future investment returns considering each of the possible outcomes available. The future value under each
outcome is discounted back to the valuation date at an appropriate risk-adjusted discount rate and probability weighted to arrive at
an indication of value. Significant assumptions used in determining the fair value of convertible promissory notes include volatility,
discount rate, and probability of a future liquidity event. In February 2024, concurrent with the Merger, we converted our outstanding
convertible promissory notes into 10,337,419 shares of Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">We used a Monte
Carlo Simulation (&#8220;MCS&#8221;) valuation methodology to determine the fair value of the freestanding $14 million purchase option
and embedded purchase option associated with the Loan Agreement at inception and as of December 31, 2024. The MCS methodology simulates
our future stock price to estimate if and when the Trailing VWAP will reach $10.00 per share, and discounts the resulting payoff back
to each valuation date using a present value factor. Significant assumptions used in determining the fair value of these options include
volatility and discount rate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock-Based
Compensation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Awards under
our compensation plans are accounted for in accordance with Accounting Standards Codification 718, Compensation &#8211;&#160;<i>Stock
Compensation</i>. Compensation cost is measured at the grant date fair value of the award and is recognized over the vesting period of
the award. We use the straight-line method to record compensation expense of awards with service-based vesting conditions. We account
for forfeitures of stock-based awards as they occur. We recognize share-based compensation expense for awards with performance conditions
when it is probable that the condition will be met, and the award will vest. Prior to the Merger, we estimated the fair value of our
Common Stock in accordance with the guidance outlined in the American Institute of Certified Public Accountants&#8217;&#160;<i>Accounting
and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation</i>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Accounting Pronouncements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 3 to our consolidated financial statements found in this prospectus for a description of recent accounting pronouncements
applicable to our financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 70; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="as_002"></span>BUSINESS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage specialty immunotherapy company harnessing one of nature&#8217;s most powerful immunological weapons, CD8+ CTLs,
to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders, with
the aim of addressing the significant unmet needs of large patient populations. We believe that sustainability and commercial success
in the forthcoming era of medicine will rely on ensuring patient accessibility through advanced science, innovative business models and
engagement across the development lifecycle and healthcare system. We believe the full potential of T cell therapies remains largely
untapped and aspire to be the first biotechnology company offering commercially attractive, economically viable, and cost-effective
personalized T cell therapies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe our allogeneic, precision T cell technology, ExacTcell<sup>TM</sup>, represents a significant scientific breakthrough with the
potential to mainstream cell therapy with a new class of off-the-shelf &#8211; manufactured and stored for immediate use &#8211; T cell
therapies with diverse applications across virology, oncology, and other areas. ExacTcell is a set of processes and methodologies
to develop, enrich, and expand single HLA restricted CTL therapies with proactively selected, precisely defined targets. HLA molecules
are proteins that play an important role in the immune system&#8217;s ability to recognize &#8220;self&#8221; versus &#8220;foreign.&#8221;
There are numerous HLA types that vary from person to person. CD8+ CTLs, also known as killer T cells, are white blood cells that are
part of the immune system and destroy infected, malignant, or otherwise damaged cells. We are focused on using ExacTcell to develop allogeneic
therapeutics, meaning therapeutics that are intended to be infused in patients other than the original donor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">ExacTcell therapies
are based on carefully selected, naturally occurring CTLs that are designed to recognize targets of interest from the body&#8217;s native
T cell receptor pool, unlike genetically engineered T cell therapies. CD8+ CTLs in ExacTcell-based products target multiple and distinct
antigens, with the aim to circumvent the impact of mutations in viruses and cancer cells, which can render existing treatments focused
on a single target ineffective. ExacTcell is designed to maximize the immunologic specificity of our products in order to eliminate
malignant and virally infected cells while allowing healthy cells to remain intact. We believe this high degree of specificity has the
potential to significantly reduce the chances of cross-reactivity or adverse impact on healthy cells. Our confidence in ExacTcell is
reflected in our development pipeline, which has been carefully tailored to address the unmet needs of large patient populations grappling
with life-threatening viral diseases, cancers, and other disorders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for
the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, Long
COVID. Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants. Elimination of
infected cells is necessary to allow them to be replaced by healthy, uninfected counterparts. TVGN 489 consists of CTLs designed to be
active against multiple precise, well defined, and well characterized targets spread across the SARS-CoV-2 genome. The product progressed
from pre-discovery to the clinic in less than 18 months, and in January 2023, we completed the Phase 1 proof-of-concept clinical trial
of TVGN 489 for the treatment of ambulatory, high-risk adult COVID-19 patients. No dose-limiting toxicities or significant treatment-related
adverse events were observed in the treatment arm. Secondary endpoints showed a rapid reduction of viral load and that infusion
of TVGN 489 did not prevent the development of the patients&#8217; own T cell-related (cellular) or antibody-related (humoral)
anti-COVID-19 immunity. None of the patients reported progression of infection, reinfection, or the development of Long COVID during
the six-month follow-up period. These clinical observations were mirrored by laboratory evidence of the persistence of TVGN 489 cells
for at least six months after treatment. The results of the trial were published in&#160;<i>Blood Advances</i>&#160;in June 2024 following
peer review. We believe these findings validate our initiative to develop off-the-shelf T cell therapies for outpatient administration,
targeting diseases that affect large patient populations &#8211; for the very first time. We are planning a pivotal trial of TVGN
489 in COVID-19 patients with B cell malignancies, with studies of other highly vulnerable populations thereafter. TVGN 489 is also in
preclinical development for treatment and prevention of Long COVID based on evidence of a persistent viral reservoir in Long COVID
patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 71; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business
Combination</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 14, 2024, Tevogen Bio Tevogen Bio completed the previously announced Business Combination with Semper Paratus, a special
purpose acquisition company formed for the purpose of effecting a merger, stock purchase, reorganization or similar acquisition or business
combination with one or more businesses, pursuant to which Tevogen Bio became a wholly owned subsidiary of Semper Paratus. In connection
with the closing of the Business Combination, Semper Paratus changed its name from &#8220;Semper Paratus Acquisition Corporation&#8221;
to &#8220;Tevogen Bio Holdings Inc.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Pipeline</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are leveraging our understanding of immunotherapy and our ExacTcell technology to discover, validate, and build a proprietary
pipeline of T cell therapies with diverse targets in infectious disease, cancer, and other disorders. The figure below details
our pipeline of product candidates and their targets:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<img src="posam_001.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>1</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    1 clinical trials are designed in part to generate proof of concept data and safety-related data on tolerability and side effects.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>2</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    pivotal trial is a trial designed to generate data sufficient to support the filing of an application for regulatory approval. A
    pivotal trial may not necessarily be denoted as a Phase 3 clinical trial and instead may be a Phase 2 or Phase 2/3 clinical trial.
    We believe that Phase 2, Phase 2/3, or Phase 3 clinical trials may serve as pivotal trials for TVGN 489.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>&#160;</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>3</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    believe that the safety data from our completed Phase 1 clinical trial should be sufficient to serve as the basis for one
    or more later stage, potentially pivotal trials in acute SARS-CoV-2 patients with B-cell cancer immune suppression, other
    B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, and for Long COVID prevention and
    treatment. We cannot be certain whether we will be permitted to move from a Phase 1 trial directly to a pivotal trial covering any
    specific target population until FDA reviews and concurs with or rejects our proposed plans, and FDA may require us to conduct further
    trials to generate additional safety and efficacy data prior to approval.</span></td></tr>
  </table>
<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Strategy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
goal is to have a positive impact on patients&#8217; health and treatment equity by developing and commercializing personalized cell
therapies to treat infectious disease, cancer, and other diseases. Our strategy is to target large patient populations for each pipeline
product. Key elements of our strategy to advance toward this goal include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Advancing
    the clinical development of TVGN 489 for the treatment of COVID-19 and Long COVID</i></b>. We completed a Phase 1 proof-of-concept
    trial of TVGN 489 for the treatment of high-risk ambulatory adult COVID-19 patients in January 2023 and plan to launch a pivotal
    trial in COVID-19 patients with B cell malignancies. TVGN 489 is also in development for other highly vulnerable COVID-19 patients
    and sufferers of Long COVID. A Phase 2 treatment trial examining the safety and efficacy of TVGN 489 in individuals with Long
    COVID is currently under development.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Leveraging
    our ExacTcell technology to develop therapies for additional indications</i></b>. In addition to TVGN 489, we are leveraging
    our ExacTcell technology to advance product candidates in virology, oncology, and other conditions. For example, early
    work is underway that leverages our expertise in the selection of viral peptide targets to be used preventatively
    in the form of a T cell vaccination.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Developing
    manufacturing capabilities, including through acquisitions</i></b>. We will need to develop manufacturing capabilities for clinical
    and, if approved, commercial supply of our cell therapy products. Our efforts to develop manufacturing capability are currently focused
    on acquiring a manufacturing and research and development facility, including through collaboration with a potential
    facility development partner.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Forming
    strategic alliances and collaborating with partners to augment our capabilities</i></b>. We may pursue strategic alliances with other
    biopharmaceutical companies with well-established presences in the specialties we aim to target for our indications. This may include
    co-marketing, co-promotion, and co-development relationships, or a partnership with a diagnostics company to help improve availability
    of HLA testing (rapid testing in acute illnesses and prompt testing in more chronic conditions). We also intend to explore
    options to work with partners to augment the study and treatment of patients and the impact of our product candidates, including
    medical professionals, healthcare professional networks, pharmacy benefit managers, insurance companies, and AI companies.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 73; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">We believe that
positive data from studies and clinical trials can help pave the way for positive regulatory discussions, strategic partnerships, and
future label expansions, furthering our ability to meet our goal.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
ExacTcell Technology</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ExacTcell technology and our therapies harness one of nature&#8217;s own approaches to eradicating cancer and other diseases:
the cytotoxic or killer T cell. We believe that our patented ExacTcell precision allogeneic T cell development technology has
the potential to be a broadly applicable approach for developing convenient and reasonably priced cellular immunotherapies for the treatment
of acute viral infections, long-term consequences of viral infections such as Long COVID, viral- and non-viral-induced cancers, and other
disorders. Although our initial product development has been in the area of infectious disease, we believe our technology also holds
promise for applications in cancers and autoimmune diseases, which would increase our total addressable market. We also believe that
ExacTcell can enable us to deliver products faster, at a greater scale, and at lower cost than future competing cell therapies, if any.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ExacTcell
focuses on the selection and expansion of naturally occurring, genetically unmodified CD8+ CTLs to target multiple, distinct, preselected
antigens present only on virus-infected or malignant cells and to kill those cells. We believe that by relying on CD8+ CTLs, ExacTcell
has the potential to produce an entirely new class of drugs that could present numerous benefits over existing platforms. In contrast
to other approaches, ExacTcell enables a single, specific HLA molecule to be targeted in a clinical product and the specific target peptides
to be known with certainty and precision. HLA molecules are proteins present on the cell surface that play an important role in the immune
system&#8217;s ability to recognize &#8220;self&#8221; versus &#8220;foreign.&#8221; Specifically, HLA molecules present foreign antigens
to T cells for eradication. There are numerous HLA types that vary from person to person.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Killer
T cells are white blood cells that play a vital role in the immune system&#8217;s defense against diseases, including viruses and cancer. CTLs, including those developed with ExacTcell, express T cell receptors (&#8220;TCRs&#8221;), which are surface proteins that provide
each T cell with its unique immune specificity to recognize and react against specific foreign antigenic peptides of infected or malignant
cells. These foreign antigenic peptides are presented in conjunction with an HLA molecule. The CTLs destroy their infected or malignant
cell targets by inducing them to undergo apoptosis, or programmed cell death, by releasing cytolytic granules that produce pores in the
target cell&#8217;s membrane. CTLs also possess a protein that spans the entirety of the cell membrane, known as Cluster Differentiation
8 (which makes them CD8+), that aids in the reaction. CD8+ T cells work in conjunction with HLA-class I molecules, and CD4+ T cells work
in conjunction with HLA-class II molecules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="formposam_011.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 74; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently
available cell-based immunotherapy approaches include genetically unmodified T cells applied to the treatment of viruses early after
transplant and genetically modified chimeric antigen receptor (&#8220;CAR&#8221;) T cells used to treat a selected subset of malignancies.
We believe that to date, cellular therapy has not been harnessed to its full potential for clinical application. We believe that our
proprietary approach will allow T cell products to be generated with a much higher target-specific CD8+ content and better-defined target
specificity than existing commercially available approaches. Contrasted with our approach, the genetically unmodified T cells used after
hematopoietic stem cell transplantation for the treatment of viral infections have used large viral proteins, pools of peptides, or infected
cells to stimulate CTLs. These broader targets may stimulate both CD4+ and CD8+ T cell responses, resulting in more heterogeneous T cell
products with little information regarding the specific peptide targets recognized by the T cells. By stimulating with only carefully
selected smaller peptides that are known to bind to a single HLA-class I molecule and to be recognized by CTLs,
our approach elicits a high degree of target-specific CD8+ responses, which we believe may result in improved outcomes as compared to
these other approaches. Knowing the specific peptide targets also allows rapid identification of the impact of mutations on our CTL products.
Having multiple targets within a product also blunts the impact of any one mutation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the targeted nature of the cells ExacTcell can produce, we also believe we may be able to avoid some of the unwanted corollary effects
observed in other T cell immunotherapies. For example, we believe products developed through ExacTcell could potentially avoid the high
incidence of adverse events, some life-threatening, such as cytokine release syndrome and neurotoxicity, that have been observed with
autologous and allogeneic CAR-T platforms. Data from our Phase 1 trial strongly supports this belief. Autologous cell therapies
are derived from a donor&#8217;s own cells, as contrasted with allogenic therapies such as ours, where cells are from third party donors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to select candidate peptides for ExacTcell products, we rely on computer-facilitated prediction of the ability of specific peptide
candidates to bind to specific HLA molecules. Once candidates are selected and used to stimulate T cells in the laboratory,
we use tetramer staining to assess whether T cells recognize the target peptides and assess cytotoxicity against individual peptide-pulsed
and non-pulsed targets. This allows us to rapidly and proactively select multiple, precise, candidate T cell targets and then quickly
experimentally confirm their effectiveness.&#160;Through our Tevogen. AI artificial intelligence initiative, we are exploring
ways to deploy artificial intelligence-powered target detection to accelerate our product development pace, either internally or in collaboration
with leading entities in the field of artificial intelligence, such as through our enrollment in the Microsoft for Startups program
and use of Microsoft Azure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
illustrated in the figure below, we begin the ExacTcell process by collecting cells from a healthy donor. T cells from the donor are
exposed to the preselected targeted peptides and through a repetitive process of selection and expansion. CD8+ CTLs specific for the
targeted, antigenic peptides become the major cellular component of the final product. The expansion of the antigen specific CTLs is
extensive enough to produce over 100, and up to hundreds, of doses from a single donor. Those doses can then be used to treat hundreds
of patients who share the same HLA type.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="formposam_012.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 75; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ExacTcell
stands in contrast with both autologous and allogeneic CAR-T platforms, which target antigens present on both healthy and diseased cells
and require genetic modification of the T cells. In autologous CAR-T approaches, the quantity and health of desired T cells in patient
blood samples used to manufacture the CAR-T product have been among the largest obstacles for T cell therapies to date. Much of this
is due to the chemotherapy treatments the patients have already received. Some existing CAR-T therapies may take weeks to manufacture,
may require patients to receive pre-infusion lymphodepleting (<i>i.e.</i>, immunosuppressing) chemotherapy as part of a lengthy preparation
process, and be hospitalized in many cases during the CAR-T cell infusion or afterwards due to the frequency of side effects from the
therapy such as cytokine release syndrome. These treatments may also require lifelong monitoring for the development and treatment of
infections due to eradication of normal parts of the immune system along with the cancer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
November 2023, FDA announced that it had &#8220;received reports of T-cell malignancies&#8221; in patients who received certain
autologous CAR T cell immunotherapies. In January 2024, FDA required a class-wide black box warning be added to the label of these
CAR T products regarding this risk. Currently approved autologous CAR-T platforms utilize the patient&#8217;s own T cells to manufacture
their products. These cells have previously been exposed to cancer therapy and are genetically altered and subsequently expanded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
contrast, CTLs generated using the ExacTcell technology come from a healthy donor with a normal immune system. ExacTcell CTLs
are not genetically altered in the manufacturing process and although they expand during manufacture, this is the expected response of
a T-lymphocyte when encountering its target antigen. The genetic modifications necessary to make CAR-T cells, which may be associated
with the recent reports of T cell malignancies, are not utilized in the manufacture of our products made on the ExacTcell technology.
Moreover, secondary malignancies have not been described in the unmodified T cell products given to hundreds of post-transplant patients.
Although products from our ExacTcell technology are not designed to be genetically modified, they are still in the early
stages of testing, and only limited human and laboratory study data are available regarding the risk profiles of our products. Allogeneic
CAR-T approaches are in early-stage development, but concerns exist regarding side effects similar to autologous CAR-T, and additionally,
the development of graft versus host disease with allogeneic CAR-T products, both of which we believe will be of lower risk with our
technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="formposam_013.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hundreds
of doses per donor can be obtained using the ExacTcell approach, which is expected to facilitate off-the-shelf use and the ability to
administer doses within hours of diagnosis when rapid therapeutic intervention is crucial.
Use of TVGN 489, for example, is expected to begin with a confirmatory COVID-19 test and rapid HLA typing for which results would be
available in six to eight hours, allowing selection of the proper product based on HLA type. After confirmation of HLA type, thawing
takes minutes, and cells are infused within ten minutes of thawing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
convenience of &#8220;off-the-shelf&#8221; &#8211; manufactured and stored for immediate use &#8211; therapy has the potential to offer timely and
cost-efficient therapeutics by potentially eliminating the need for specialized medical facilities, unlike existing platforms. By producing
products in which the active CD8+ T cell components are present at high concentrations, we believe relatively small volumes will be required,
allowing our therapies to be easily and promptly delivered in the ambulatory setting as a very brief intravenous administration such
as in a physician&#8217;s office.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 76; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are working to further advance ExacTcell with a new, proprietary T cell receptor-engineered process, which we believe
may substantially increase the number of doses that can be produced from a single donor. Available technology can be used to allow us
to interrogate over a thousand individual T cells to determine which one kills peptide-pulsed targets fastest or kills the most in a
given timeframe. This highest performing T cell can then be isolated, and its T cell receptor sequenced, allowing us to make an artificial
TCR gene that can be introduced into CD8+ T cells collected from healthy donors. We believe this could allow at least a several-fold
increase in the number of desired CTLs as compared to our current approach. We expect efforts to produce second generation products based
on this process may begin shortly after and if initial regulatory approval of the first-generation product is obtained.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
First Product Candidate</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
first product candidate, TVGN 489, is an off-the-shelf, allogeneic cytotoxic CD8+ T cell therapy designed to fill a critical remaining
gap in COVID-19 therapeutic solutions for the immunocompromised and the high-risk elderly, who remain at substantial risk for poor
outcomes, with potential applications in both treatment and prevention of Long COVID. Treatment for these groups represents an area
of unmet or incompletely met need which we believe TVGN 489 can significantly address. We rapidly progressed TVGN 489 from pre-discovery
to the clinic in only 18 months. TVGN 489 cells are derived from healthy donors who recovered from a prior COVID-19 infection, and TVGN
489 is active against multiple, precise targets spread across the SARS-CoV-2 genome.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2023, we completed a Phase 1 proof-of-concept trial of TVGN 489 for the treatment of ambulatory high-risk adult COVID-19 patients.
No dose-limiting toxicities or significant TVGN 489-related adverse events were observed in this trial at any of the four dosing levels
tested. Secondary endpoint analysis showed a rapid reduction in COVID-19 viral load and that the infusion of TVGN
489 did not prevent the development of the patient&#8217;s own T cell-related (cellular) and antibody-related (humoral) anti-COVID-19
immunity. In addition, none of the patients in the treatment arm reported progression of infection, reinfection, or the development
of Long COVID during the six-month follow-up period. The TVGN 489 in the Phase 1 trial was formulated to match patients expressing HLA-A*02:01,
the most common HLA type in the population.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that TVGN 489 targets are less susceptible to viral mutations due to their small size than monoclonal antibody
targets and less susceptible to drug resistance than antivirals. As evidence of this, despite selection of T cell targets
in 2020, more than 95% of the targets for the HLA-A*02:01 TVGN 489 product targets have remained intact through the first
quarter of 2025. In contrast, most monoclonal antibodies were withdrawn from the market for lack of efficacy related to the
lack of recognition of new variants, providing what we believe to be evidence of decreased susceptibility of TVGN 489 to viral
mutation. In addition, knowing the precise peptide targets of our therapy helps allow rapid assessment regarding their preservation or
loss as soon as new variants are sequenced. We check emerging COVID-19 variants against TVGN 489 targets on an ongoing basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>COVID-19
Background</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COVID-19,
caused by the SARS-CoV-2 virus, has killed millions and infected hundreds of millions since its emergence in late 2019. Groups most at
risk for poor outcomes due to COVID-19 are immunocompromised individuals unable to mount an adequate immune response, such as those with
immune system cancers, immunodeficiency disorders, transplant recipients, patients with immune-mediated disorders requiring immunosuppressive
therapy, or high doses of corticosteroids, the elderly and the unvaccinated. Data shows that the majority of COVID-19 deaths occur
in people over the age of 65. The risk of severe illness from COVID-19 for an individual tends to escalate with an increase in their
number of underlying medical conditions. In addition to the acute impacts of infection, a significant portion of those who have been
infected by COVID-19 in the past develop more chronic and potentially debilitating symptoms afterwards, a condition termed Long COVID.
Despite the availability of vaccines and emergence of initial therapeutics, significant gaps and shortcomings in treatment remain both
for vulnerable patients experiencing an acute infection and for Long Covid sufferers for whom there are no treatment options approved
for the indication or its underlying causes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 77; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Like
other viruses that have RNA as their genetic material, SARS-CoV-2 is constantly evolving through random mutations. New mutations can
potentially increase or decrease infectiousness and virulence. In addition, mutations can increase the virus&#8217; ability to evade
adaptive immune responses from past SARS-CoV-2 infection or vaccination. New variants of the SARS-CoV-2 virus continue to emerge, and
many people continue to be adversely affected by COVID-19, particularly those at the highest risk and sufferers of Long COVID. Moreover,
a growing body of scientific data suggests new immune-evasive variants are more likely to arise in immunocompromised patients because
they are less able to eradicate the virus. The longer duration of infection within the host affords the virus more opportunity to mutate
so as to evade the immune system. The potential rise of immune-evasive variants in immunocompromised patients provides a public health
rationale for the treatment of immunocompromised patients in order to more rapidly and aggressively eliminate the virus and avoid generation
of new variants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
large number of Americans remain highly vulnerable to COVID-19 infection, including immunocompromised and elderly patients. For example,
the rate of hospitalization in cancer patients with COVID-19 infection remains high, specifically for those under active chemotherapy
or immunosuppression. There is therefore a high unmet need to have an effective treatment available for these populations. Classic herd
immunity leading to eradication of COVID-19 is unlikely, much as is the case for influenza, respiratory syncytial virus (RSV), and other
endemic respiratory viruses. This contrasts with smallpox, for example, where both natural infection and vaccination eliminated virus
transmission. SARS-CoV-2 infection and vaccination produce a steadily waning natural and vaccine-induced immunity, respectively, but
do not eliminate transmission. Although the number of daily reported cases and deaths has declined, the emergence of more transmissible
variants has led to spikes in cases and mortality, and variants are expected to continue to evolve over time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
current COVID-19 landscape is also characterized by continued vaccine hesitancy among a significant portion of the population, unequal
access to vaccines and treatment, lack of response in some immunocompromised and other high-risk groups, and breakthrough cases among
the vaccinated due in part to increased immune evasion by current and emerging variants and the relatively short duration of protection
by booster shots. We expect these circumstances to continue, which could adversely impact long-term community-level protective immunity.
In addition, we believe that the expiration of the U.S. federal Public Health Emergency and U.S. government funding for COVID-19 testing,
and treatment could lead to higher pricing for diagnostics and therapeutics.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Only
two anti-viral agents, Nirmatrelvir with Ritonavir (Paxlovid) and Veklury (remdesivir), have been FDA-approved for the
treatment of COVID-19. While Paxlovid is indicated for treatment in individuals at high risk for viral progression, neither drug has
been specifically authorized for use in immunocompromised patients, creating a need for the development of novel therapies in this area.
Both drugs also present challenges for subsets of patients. Paxlovid is associated with many drug-drug interactions, resulting in the
need to temporarily stop ongoing medications or seek alternative therapy and thereby making it difficult for some patients to take. This
is especially true for patients on multiple medications, which is often true of high-risk patients requiring anti-COVID-19 treatment.
Paxlovid is also known to be associated with COVID-19 rebound, which has been calculated as high as 21% in ambulatory patients, according
to a study published in the Annals of Internal Medicine in November 2023. Although the rate of rebound in high-risk subgroups is less
well-documented, we anticipate it may be as high or higher in this group. Paxlovid also must be started within five days of symptom development
to be effective. Remdesivir must be given within seven days and is only available in intravenous form, requiring three daily infusions
in a treatment center. Remdesivir has also been associated with liver enzyme abnormalities and gastrointestinal side effects. Monoclonal
antibodies to the viral spike protein were introduced early in the pandemic for treatment of COVID-19 but typically have been rendered
ineffective over time as the virus continues to evolve. One prophylactic monoclonal antibody for COVID-19 prevention, Pemgarda (Pemivibart),
has received emergency use authorization for moderate to severely immune compromised patients. Whether this monoclonal antibody will
remain more durable than other monoclonal antibody remains to be seen, although resistance to the drug has already been observed in some
variants. No therapies have been approved to treat the underlying causes of the symptoms of Long COVID, and significant research
is ongoing to determine why some patients fully recover while others develop long-term complications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 78; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Key
Advantages of TVGN 489</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the ongoing spread of COVID-19 and its effects and continued gaps in treatment, there is a clear need for alternatives to current therapeutic
options for COVID-19 We have shown that TVGN 489 is less susceptible to viral mutations than monoclonal antibodies and
thus able to overcome the increased immune evasion of current and emerging COVID-19 variants. We also believe TVGN 489 has the potential
to be less susceptible to drug resistance than antivirals. As contrasted with existing therapies, TVGN 489 is designed to recognize multiple
specific target peptides from distinct COVID-19 proteins, versus one or two targets typically derived only from the spike protein. Whereas
other viral therapies buy time for natural immunity to emerge and definitively control the virus, TVGN 489 provides natural immunity
directly and immediately to patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><img src="formposam_014.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TVGN
489&#8217;s targets have also persisted in studied COVID-19 variants. We have observed TVGN 489&#8217;s targets to be generally retained,
in nearly all cases at greater than a 95% level of retention, in the genome of all of the isolates of SARS-CoV-2 variants that we have
studied to date. This is in significant contrast with the target loss of anti-spike monoclonal antibody therapies, which has led
to the withdrawal of emergency use authorizations (&#8220;EUAs&#8221;) that had been granted during the now-expired COVID-19 National
Public Health Emergency.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COVID-19
variants have demonstrated how this virus is able to escape our immune system through mutation. However, we believe our proprietary approach
to manufacturing TVGN 489 may allow us to monitor the sequences of emerging variants and, if necessary, to proactively adjust or fine
tune our products to ensure that they continue to recognize and treat current and future variants of this and other viruses. For example,
with our approach, if a product contains T cells that recognize and target seven different peptides and one is lost through mutation,
that peptide can be dropped from future product batches. Similarly, if the mutation generates a new peptide target, that target can be
added to future batches. However, making these types of changes to TVGN 489 may require additional regulatory approvals, and there is
no guarantee that we will receive such approvals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TVGN
489 is also designed to be fast acting, as the cells are fully mature and crafted to be primed to act as soon as they find their way
to infected cells. All patients in the interventional arm of our Phase 1 clinical trial noted improved symptoms within two to three days,
which is shorter than the average noted by patients in the observational arm, and 83% of patients in the interventional arm had negative
nasal swab polymerase chain reaction tests and there was a 99% viral load reduction in all patients within 14 days. The consistency
of the resolution was suggestive of a treatment effect and the rapidity of nasal swab COVID-19 resolution was shown in a population
where five individuals were on active immunosuppression for cancer (three with hematological malignancy, two with solid tumors)
and one for lupus at the time of COVID-19 infection. Moreover, a more recent study showed that the median time to SARS-CoV-2 nasal
swab PCR negativity was 72 days for patients with a hematologic malignancy highlighting the rapidity of response in the Tevogen phase
I study. Two patients on the trial went on to stem cell transplantation, an immunosuppressive procedure, within a month of treatment.
Neither experienced COVID-19 reactivation, which we believe further attests to the rapid acting nature of this product. When immunocompromised
patients get sick from COVID-19, their current treatment regimens for existing conditions are often stopped. For oncology patients, this
can be especially disruptive or even harmful to the curative potential of their treatment. Given TVGN 489&#8217;s design and these
results, we believe TVGN 489 may allow immunocompromised patients to recover and be able to return to their pre-COVID-19 treatment regimen
with minimal delays.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Production
of TVGN 489 and Mechanism of Action</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TVGN
489 cells are sourced from healthy donors who have recovered from a previous COVID-19 infection. These donor cells are subsequently expanded
by 600-fold or more by restimulating them toward specific peptide targets. This is accomplished by exposing them to antigen-presenting
cells and selectively isolating the T cells that recognize the specific targets. TVGN 489 is formulated to precisely target multiple
peptide targets spread across the SARS-CoV-2 genome, rather than focusing solely on the mutation-susceptible spike protein, which is
the primary target of most vaccines and monoclonal antibodies. Upon completion of the manufacturing process, the cells are frozen and
stored for future intravenous infusion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 79; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Administration
of TVGN 489 infuses the body with killer T cells that have been designed to attack COVID-19 infected cells. These highly purified, multi-target
CD8+ CTLs are intended to bind to and eliminate infected cells expressing the targeted peptides against which the CTLs were manufactured.
Peptides are presented in conjunction with the HLA molecule and the CTLs eradicate diseased cells expressing these viral or malignant
targets. To be clinically effective, a T cell therapy must be compatible with the patient&#8217;s specific HLA type. Therefore, a panel
of HLA-specific CTL products is necessary to broadly cover and treat the population. In our next clinical trial of TVGN 489, we expect
to treat patients with the six most common HLA types, which we believe would represent between 60% and 65% of the COVID-19 infected population.
We plan to continue expansion into additional HLA types until we are confident that between 90% and 95% of the population could be treated
based on our research.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that once bound to infected cells, TVGN 489 cells then destroy the infected cells through formation of an immunological synapse
between the killer cell and target and the release of cytotoxic granules from TVGN 489 into the target. These both produce pores in the
target cell&#8217;s membrane and also trigger a process known as apoptosis, or programmed cell death, which is built into all our cells.
Then, once the infected cells die, new, healthy cells are able to grow in their place.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><img src="posam_002.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Discovery
and Preclinical Data</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
approach to identifying CTL targets starts with computer-based prediction and then tests candidate peptides functionally with T cells. We use a technique known as tetramer staining to assess whether T cells recognized these target peptides, assessed cytotoxicity against
individual peptide-pulsed and non-pulsed targets, and selected final peptides for use in TVGN 489 on that basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted multiple in-vitro studies of TVGN 489 in preparation for filing the IND with FDA and observed strong antiviral activity against SARS-CoV-2 in these laboratory studies. In preclinical studies, we observed that
TVGN 489 cells kill target cells that are exposed to SARS-CoV-2 peptides, but not cells that are not exposed to those peptides. This
is illustrated in the figure below, which shows the percentage of cells killed over a four-hour period when targets were pulsed with
the peptides and when they were not, with the x-axis showing the lysis rates based on the ratio of CTLs to target cells.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 80; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><img src="formposam_016.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
of appropriate COVID-19 peptide targets for additional HLA molecules remains ongoing, and we plan to continue this testing until we are
confident that between 90% and 95% of the COVID-19 infected population could be treated based on our research. We believe generating
these CTLs can provide treatment for SARS-CoV-2 or, with the appropriate targets, for other viral infections. Immunizing an individual
to these specific targets should form the basis of helping to prevent a subsequent infection through a T cell vaccine. Target identification
thus has the potential to assist with prevention as well as treatment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
Development for COVID-19 Patients</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
permitted our IND for TVGN 489 to proceed in May 2021, and we began enrolling patients in the Phase 1 proof-of-concept trial of TVGN
489 for the treatment of high-risk ambulatory adult COVID-19 patients in October 2021. Patients in the trial were newly diagnosed with
COVID-19 and were deemed to be at high risk for complications due to the presence of one or more underlying medical conditions defined
as high risk by the Centers for Disease Control and Prevention, including among others cancer, hypertension, obesity, diabetes,
cardiovascular disease, and old age. The trial, which was conducted at Thomas Jefferson University Hospital in Philadelphia, was completed
in January 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trial included two arms, with 12 patients in the treatment, or interventional, arm and 18 patients in the observational arm. Assignment
to the interventional arm versus the observational arm was based on each patient&#8217;s HLA type. Patients expressing HLA-A*02:01, the
most common HLA type in the population, matched the CTLs and were enrolled in the interventional arm. Patients in the treatment arm had
been infected with either the delta variant or one of three omicron variants of COVID-19. Patients on the interventional arm had a higher
median number of comorbid conditions, a higher incidence of immune compromise, and a higher number of patients who were unvaccinated
or failed to respond to vaccination versus patients on the observational arm.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
patient in the treatment arm received a single intravenous infusion of TVGN 489 within four days of diagnosis. Analysis of COVID-19 viral
load showed that the patients were early in their COVID-19 disease course. Patients were treated with TVGN 489 at one of four dose levels:
1 x 10<sup>5</sup>/kg; 3 x 10<sup>5</sup>/kg; 1 x 10<sup>6</sup>/kg; or 3 x 10<sup>6</sup>/kg. Patients treated on the first dosing
level had the high-risk delta variant of COVID-19. These dose levels were chosen based on data regarding antiviral T cell therapy
in hematopoietic transplant patients involving the administration of similar cell numbers. Three patients were enrolled at each dosing
level with the option to enroll three more if a significant side effect was observed. Each dose level concluded with three patients rather
than six and the treatment arm concluded with a total of 12 patients rather than 24, due to the absence of appreciable toxicities
across all dose levels. The comparative arm, which was designed to end enrollment when treatment arm enrollment was completed, concluded
with 18 patients, appreciably less than what would have occurred if the treatment group required additional enrollment. Observational
arm patients received standard of care treatment, including monoclonal antibodies. Interventional arm patients were monitored in the
hospital for four days before being discharged and then were observed daily at home for ten additional days and again at the one, two,
three, and six-month anniversary of the initial infusion. Observational arm patients were monitored at home over the same interval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary endpoints of the trial, which were safety-related, were met. No dose-limiting toxicities or significant adverse events related
to TVGN 489, including acute infusion reactions, cytokine release syndrome, neurotoxicity, or instances of graft versus host disease,
were observed in any patient at any dose level of our Phase 1 trial of TVGN 489.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 81; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Secondary
endpoints showing a rapid reduction of COVID-19 viral load and showing that infusion of TVGN 489 did not prevent development of the patient&#8217;s
own T cell-related (cellular) and antibody-related (humoral) anti-COVID-19 immunity were also met. In other words, observations indicate
that TVGN 489 did not prevent the body from responding to the infection and generating its own CTLs and antibodies to COVID-19.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
treatment arm patients reported returning to their baseline level of health without COVID-19 symptoms within 14 days of treatment. All
such patients also reported symptom improvement within two to three days of treatment, which corresponded with a decrease in the COVID-19
viral load on PCR testing in the majority of patients. None of the patients who participated in the trial reported progression of their
COVID-19 infection and none developed recurrent COVID-19 or Long COVID during the six-month follow-up period. These clinical observations
were mirrored by laboratory evidence of the persistence of infused TVGN 489 cells for at least six months after treatment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><img src="formposam_017.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Persistence
of infused therapeutic cells remains a significant issue in the T cell therapy space, leading to challenges in controlling viral infections,
preventing viral recurrence, and managing cancer relapse. The shorter the CTLs persist in the recipient, the less opportunity they have
to perform their intended therapeutic tasks. Genetic differences between donor and recipient in allogeneic cell products and new genes
introduced into autologous products can be recognized by the patient&#8217;s immune system, which can encourage elimination of the administered
cells. This is one of the reasons why lymphodepleting therapy is commonly administered prior to CAR-T treatments. Maximizing the percentage
of CTLs in the products is also useful as the CTLs may receive re-stimulation from the virus infecting the patient and have a better
ability to protect themselves against elimination by the patient&#8217;s immune system. Most studies of genetically unmodified CTLs have
suggested that they are eliminated within weeks, with three months, in highly immune-suppressed hematopoietic blood and marrow transplant
(&#8220;HSCT&#8221;) patients, being the longest that they typically are reported to persist. The highly immune-suppressed nature of
the HSCT patient group is thought to allow for longer than typical persistence.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
our Phase 1 clinical trial for TVGN 489, following infusion, peripheral blood of five patients was collected at various timepoints throughout
the six-month follow-up period. These samples were sent to Adaptive Biotechnologies (&#8220;Adaptive&#8221;) to evaluate the persistence
of infused TVGN 489 in the patients following treatment, and Adaptive conducted analyses by sequencing protein chains of TCRs in the
samples. As seen in the figure below, Adaptive&#8217;s data showed persistence of T cells present in the TVGN 489 product but absent
from the recipients prior to administration of TVGN 489. This subset of CTLs was found in all samples tested, including at the final
study assessment at six months. The TCRs used to recognize TVGN 489&#8217;s peptides were also shown to be largely distinct from person
to person, making it highly unlikely that the cells from later timepoints derive from anything other than the product in these five different
patients. Taken together, we believe this data shows the persistence of TVGN 489 cells six months after administration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 82; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TVGN
489 COVID-19 Reactive CD8+ T Cells Detected Throughout the Six-Month Follow Up Period</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><img src="formposam_018.jpg" alt=""/></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expansion
and persistence of allogeneic T cells has been associated with disease control in many settings. Whether the prolonged persistence of
the CTLs used in this study is of benefit in the treatment of COVID-19, Long COVID, or alternate future viral or oncologic targets for
these CTLs merits further examination. However, the evidence of their prolonged persistence provides us with encouragement for future
applications of the ExacTcell technology, particularly in oncology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe based on precedential industry examples, including in areas with high unmet needs or strong early phase clinical trial results,
that we may be able to commence pivotal trials of TVGN 489 on the basis of the results of our completed Phase 1 trial. A pivotal trial
is a trial designed to generate data sufficient to support the filing of an application for regulatory approval. Although the clinical
trial process usually includes three phases, a pivotal trial may not necessarily be denoted as a Phase 3 clinical trial and instead may
be a Phase 2 or Phase 2/3 clinical trial. We hope to begin a pivotal trial of TVGN 489 for the treatment of COVID-19 in select vulnerable
populations with humoral immune suppression due to B cell malignancy or the treatment thereof. Patients with hematological malignancies
continue to experience higher rates of hospitalization and death as compared to the general population and those with solid tumors. Increased
mortality, hospitalization, and incidence of Long COVID are higher in patients with B cell malignancies due to inadequate vaccination
response and the immunosuppressive consequences of treatment received for B cell cancers. While the major acute outcomes of patients
with hematological malignancies and COVID-19 have improved with increasing experience, for cancer patients who contract COVID-19,
uninterrupted treatment is critical, as delays can impact long-term outcomes. Whereas treatment arm patients
in our Phase 1 proof-of-concept clinical trial all had a single HLA type, we expect to treat patients in this pivotal trial who have
any of the six most common HLA types, which we believe would represent between 60% and 65% of the population. The primary endpoint of
this trial is planned to be reduction in SARS-CoV-2 viral load and reduction in the delays of cancer treatment. Secondary endpoints
include the incidence and duration of hospitalization, intensive care unit admissions, hours on supplemental oxygen, mortality, COVID-19
recurrence, and Long COVID diagnosis. At this stage, however, we cannot be certain whether we will be permitted to move from a
Phase 1 trial directly to a pivotal trial until FDA reviews and concurs with or rejects our proposed plans, and FDA may require us to
conduct further trials to generate additional safety and efficacy data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
development of TVGN 489 continues, we may also seek FDA&#8217;s RMAT designation
for TVGN 489, which as explained in &#8220;Regulatory Environment &#8211; Expedited Development and Review Programs&#8221; below, is intended
to facilitate efficient development and expedited review.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 83; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Target Patient Populations and Indications for TVGN 489</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Although the
majority of younger and healthier adults with COVID-19 avoid poor outcomes after infection without treatment, there remain subsets of
the population (such as humorally suppressed patients with B cell malignancies, as described above) who are vulnerable to significant
complications from COVID-19 because of a weak immune system or suboptimal responses to vaccines. Treatment of these individuals is an
area of unmet need that we believe TVGN 489 therapy has the opportunity to fill. These target populations also include COVID-19 patients
with a non-B-cell cancer indication, elderly and infirm acute COVID-19 patients, and those with immune suppression due solid organ or
hematopoietic transplantation or autoimmunity or its treatment. Regardless of age or comorbidity, individuals with Long COVID represent
another critical area of unmet need. As noted above, these patients are among those with the greatest need for effective treatment.
We believe that the safety and the clinical benefit data from our completed Phase 1 clinical trial in ambulatory, high-risk adult patients
should be sufficient to serve as the basis for later-stage and potentially pivotal trials in these patient groups as well as for the
prevention of Long COVID. However, whether such trials may serve as pivotal trials, the phase of these trials, and the dose level to
be selected in each trial remains subject to discussions with and agreement by FDA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Recent studies have detected persistent viral spike
and nucleocapsid proteins in some Long COVID patients, suggesting a persistent viral reservoir in those patients. If that is correct,
we believe that TVGN 489 may circumvent Long COVID by preventing such a reservoir from being established or by minimizing its size. No
treated patients in our Phase 1 proof-of-concept trial developed Long COVID. We expect considerable additional information on Long COVID
prevention to be obtained from our planned acute COVID-19 treatment trials in which patients treated with TVGN 489 are expected to be
compared to patients receiving standard of care treatment. We believe that the comparative data with respect to patients in these trial
arms going on to develop Long COVID should provide sufficient information to obviate a separate Phase 1 Long COVID prevention trial, and
that the significant unmet need for treatment in vulnerable patients as well as the efficacy data in preventing Long COVID generated in
these studies will lend further support for a streamlined development pathway. However, we cannot be certain whether FDA will require
us to conduct a separate prevention trial until FDA reviews and concurs with or rejects our proposed plans.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Recent studies
have indicated that there is not an HLA class I-based predisposition to Long COVID. Therefore, it was not necessary for us to undertake
a genetic prediction study to determine optimal class I HLA types for CTL donor selection. Instead, a Phase 2 study is in development
that will examine the effect of treatment with TVGN 489 on specific categories of Long COVID sufferers such as those with fatigue or
brain fog based on the existence of a SARS-CoV-2 reservoir which may cause these symptoms. This protocol is in a very early stage of
development.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 84; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
Discovery Programs, Product Candidates and Indications</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to TVGN 489, we have several product candidates under early-stage development in virology, neurology, and oncology using our
ExacTcell technology. For example, investigative work is also underway to develop product candidates targeted at human papilloma
virus (&#8220;HPV&#8221;)-related diseases, including TVGN 920 in cervical cancer and TVGN 960 in oropharyngeal cancer, which is a type
of mouth and throat cancer. Cervical cancer and oropharyngeal cancer are both commonly caused by HPV. According to the WHO, HPV is responsible
for 99% of cervical cancers. Mouth and throat cancers are more diverse, but the WHO estimates that about 70% of oropharyngeal cancers
are due to HPV. Although a vaccine for HPV exists, the National Cancer Institute estimates that as of 2022, only 58.6% of adolescents
between the ages of 13 and 15 had received the recommended doses, estimated vaccination among older populations is lower, and the COVID
pandemic has shown that significant portions of the population will avoid vaccination. We believe that as with other viral infections,
the availability of both a preventative strategy and a treatment strategy is important to reduce incidence and impact of disease and
is investigating peptide candidates for HPV to further the development of TVGN 920 and TVGN 960. We are also beginning investigative
work to develop TVGN 116, a product candidate targeted at hepatitis B. We are also developing Epstein-Barr virus (&#8220;EBV&#8221;)
specific CTLs for potential use in multiple sclerosis (&#8220;MS&#8221;) and EBV-associated lymphomas. Our TVGN 601 is being developed
for MS, and our TVGN 930 is being developed for EBV-associated lymphomas. EBV is a common virus that infects over 90% of the world&#8217;s
adult population, according to the World Health Organization (the &#8220;WHO&#8221;), and is mainly transmitted through saliva, but also
through other body fluids such as blood and semen. EBV is the leading cause of infectious mononucleosis, and infects B-cells, a type
of immune cell. Recent studies have suggested a potential link between infection with EBV and later onset of inflammation that causes
MS, and EBV infection can lead to a variety of cancers and cancer-like disorders, including lymphomas, nasopharyngeal cancers, Post-Transplant
Lymphoproliferative Disorder, and others. Given the widespread nature of EBV and the serious health problems it can cause, investigative
work is underway to identify effective peptide targets for this virus to further the development of TVGN 601 and TVGN 930.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our ExacTcell approach also presents a novel and highly specific technique to combating cancers with T cell therapy. Unlike
CAR-T or Bispecific T-cell Engager (BiTE) antibody approaches, which recruit a heterogeneous group of T cells to the tumor, our approach
would instead focus a highly purified population of CTLs on the tumor, which we believe may provide more potential to accomplish the
task of eradicating the cancer. Cancer cells may not always express an ideal T cell target on their own. However, it is possible to coat
a cancer cell with a well-recognized target peptide using monoclonal antibodies or liposomes. We believe this would allow our target
specific CTLs to then attack the cancer cells. We also believe that our approach has the potential to eventually bring the benefits of
cell therapies to first-line options in oncology, as well as to create products that may overcome current limitations of checkpoint inhibitors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">T
cells can lose their ability to fight viruses and tumors in prolonged infections and cancer in a state called T cell exhaustion that
is characterized by the presence of certain biomarkers. Expression of these markers, which include PD-1, PDL-1, and LAG-3, has been observed
to be low level to absent in TVGN 489 cells. Moreover, TVGN 489 cells are functionally tested after generation, and have been observed
to remain strongly cytolytic at very low ratios of CTLs to target cells, which shows that they are not displaying the functional limitations
associated with T cell exhaustion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Manufacturing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
relied on a Clinical Trial Services and Materials Agreement with Thomas Jefferson University for the manufacture of TVGN 489 for our
Phase 1 proof-of-concept trial. However, we will need to develop manufacturing capabilities for clinical and, if approved, commercial
supply of our cell therapy products. Our efforts to develop manufacturing capability are currently focused on finding a manufacturing
and research and development facility, including through collaboration with a potential facility development partner.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Commercialization Plans</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
approved, we plan to globally commercialize TVGN 489 and our other product candidates aimed at serving a large patient population suffering
from infectious diseases, cancer, and other disorders. Our commercial and market access team has been diligently working alongside
our research and development team and external experts to better understand market dynamics, identify segments with high unmet needs,
map the patient journey, understand the competition within each segment, and identify opportunities for our product candidates. The same
team continues to offer input in portfolio planning and target prioritization for our research pipeline. We are also proactive in identifying
potential collaboration and service partners, including distribution partners for our sophisticated, cryopreserved cell therapy products
like TVGN 489. As part of our Company&#8217;s mission of patient centricity, we aim to collaborate with all stakeholders, including
patients, healthcare professionals, sales channel partners, public and private payers, and service providers. Essential commercial capabilities,
such as market analytics, pricing, and commercial operations functions, are continuously being developed as we progress toward the later-stage
development of TVGN 489.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the U.S. opportunity for our key pipeline products includes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TVGN
    489:&#160;</b>Approximately 750,000 patients with B cell hematologic cancer, 2,175,000 addressable patients with other cancers, including
    lung, breast, colon, pancreatic and liver, and 18 million addressable patients with Long COVID.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TVGN
    920:&#160;</b>Approximately 5.5 million patients with high-risk HPV infections, of which 200,000 are diagnosed with high grade dysplasia
    per year.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TVGN
    930:&#160;</b>Approximately 92,000 patients with the main EBV-associated lymphomas.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TVGN
    960:&#160;</b>Approximately 110,000 patients with HPV-related mouth and throat cancer.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TVGN
    601:&#160;</b>Approximately 1 million patients with EBV-related multiple sclerosis.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TVGN
    116:&#160;</b>Approximately 500,000 to 1 million patients with high-risk chronic Hepatitis B for prevention of liver cancer.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 85; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Artificial
Intelligence</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2023, we announced Tevogen.AI, a new early-stage initiative focused on harnessing the potential of AI to expedite
drug development, optimize laboratory processes and clinical trials, unravel complex biological data, improve patient outcomes, and pass
on related savings to patients. We intend to assemble a team of research scientists, physicians, data scientists, and AI and machine
learning engineers to help accomplish these goals by leveraging tools and techniques that might include large, curated data sets, algorithmic
models, pattern recognition, data analyses, automation, and artificial intelligence-powered software such as chatbots. As an initial
part of this initiative, we are specifically exploring ways to deploy artificial intelligence-powered target detection to further accelerate
our product development pace, either internally or in collaboration with leading entities in the field of artificial intelligence. We
also intend to explore the potential use of AI to power tools that could anticipate potential adverse reactions, efficacy
concerns, and identify patients who would be most likely to respond to an investigational therapy. The ability to search the human
genome for specific peptide sequences might, for example, eliminate some peptide targets simplifying the peptide screening/selection
process. We have filed patents for algorithms to be trained against a curated dataset to predict immunologically active HLA-peptide complexes
and additionally to predict T cell receptor engagement tied to specific HLA-peptide complexes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Since its inception,
Tevogen.AI has begun investigating individual viral isolates with a keen focus on target selection of peptides for our pipeline of products.
We continue curating a highly refined dataset across 14 isolates, with more targets planned, to train future machine learning and predictive
AI foundational models. Further, we are investigating the human genome to understand immunologically active HLA-peptide
complexes related to our first patent filing. We intend to create an interface we call PredicTcell to take inputs in the form of proteins
and suggest a viable T cell receptor design to bind to the given protein. To aid this effort, we have entered into agreements with leading
AI and technology companies. The collaborative nature of these agreements affords Tevogen.AI access to experts and
other resources to fulfill its mission of creating foundational algorithmic models of T cell interactions with proteins. Tevogen.AI is
also exploring how we can leverage datasets from partners and enrich them with internal insights to drive clinical trial recruitment
and monitoring to ensure efficacy of a given T cell product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
History and Team</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tevogen
Bio was established in June 2020 as a Delaware corporation, and Semper Paratus was incorporated as a Cayman Islands exempted company
in April 2021. Our senior leadership team is composed of accomplished scientists and biopharmaceutical leaders. The team brings
together diverse experience across the entire life sciences spectrum, including biotechnology, pharmaceuticals, hospitals, public and
private insurance, education, and health policy. Additionally, our team holds substantial expertise in drug development, global product
launches, and commercialization and ensuring patient access across a range of therapeutic areas.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
biotechnology industry, and in particular the cell therapy sector, are characterized by the rapid evolution of technologies and understanding
of disease etiology, and strong pursuit and defense of intellectual property. We believe that our approach, strategy, scientific development
capabilities, know-how, access to global experts, and experience provide us with competitive advantages. However, we expect future competition
in some of the indications we are targeting and from existing or emerging pharmaceutical and biotechnology companies as well as possibly
from governmental agencies, academic institutions, and public and private research institutions, among others. Some of our competitors,
either alone or through collaborations, have greater financial resources and expertise in research and development, conducting clinical
trials, manufacturing, obtaining regulatory approvals, and marketing approved products than we do. Smaller or early-stage companies may
also prove to be competitors, particularly through collaborative arrangements with large and established companies. Entities in the biotechnology
industry also compete with us in recruiting and retaining qualified scientific, clinical, and management personnel and may compete with
us in establishing clinical trial sites and enrolling patients in clinical trials as well as in acquiring technologies complementary
to, or necessary for, our programs. As a result, our competitors may discover, develop, license, or commercialize products before or
more successfully than we do.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TVGN
489 is being developed to fill the critical gaps that exist in COVID-19 therapeutics for the immunocompromised, the high-risk elderly,
and Long COVID. Only one product has been FDA approved to date for treatment of COVID-19 in the immunocompromised population. This
treatment provides passive immunity in the form of high-titer COVID-19 convalescent plasma (&#8220;CCP&#8221;) treatment, available from
the non-profit blood donation center, OneBlood, serving the southeastern United States. Blood banks nationwide can request CCP from OneBlood,
but it is unclear how long it takes to transport the therapy. In one trial, CCP was administered to young (median age 43 years) patients
with few comorbidities other than multiple sclerosis or neuromyelitis optica, for which they were receiving anti-CD 20 therapy. Treated
patients with persistent symptoms before therapy had resolution of fever in seven days and the majority had reduction of viremia after
CCP treatment. In another trial of immune compromised patients with mild COVID-19 within seven days of infection, CCP did not prevent
the evolution of SARS-CoV-2 mutations in either the treated or untreated groups, and only two of 117 patients studied had B cell deficiency.
While the majority of patients had undergone solid organ transplantation, only one patient in the treatment group underwent allogeneic
hematopoietic stem cell transplant, and there were minimal differences in outcomes between CCP-treated and non-treated groups. The only
significant finding was a reduced rate of hospitalization in the CCP treatment group versus the non-treated group, with zero hospitalizations
out of 59 patients versus five out of 58. In both of these studies, CCP was dosed multiple times. This therapy is an FDA licensed treatment
through a blood donation center and is not marketed. We believe more data is needed regarding this therapy, especially in humorally suppressed
individuals, and that questions remain about widespread availability and effectiveness in specific subgroups.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 86; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Clinical trial
data of other approved treatments in immunocompromised patients is limited. The National Institutes of Health&#8217;s COVID-19 Treatment
Guidelines Panel, a group of clinical experts that developed guidance on COVID-19 care (the &#8220;NIH Panel Guidelines&#8221;), recommended
prompt treatment of COVID-19 in non-hospitalized immunocompromised patients with antiviral drugs, but acknowledged the limitations
of these drugs and related research in such patients. Two antivirals are currently FDA-approved for COVID-19 treatment: Gilead Science&#8217;s
Veklury<sup>&#174;</sup>&#160;(Remdesivir) for the treatment of mild-to-moderate COVID-19 in hospitalized or non-hospitalized adults who
are at high risk for progression to severe COVID-19, and Pfizer&#8217;s Paxlovid (Nirmatrelvir/Ritonavir tablets) for the treatment of
mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19. The NIH Panel Guidelines highlight the limitation
of the insights that clinical trials conducted for Remdesivir and for Nirmatrelvir/Ritonavir tablets in broader populations can provide
with respect to immunocompromised patients, as each trial enrolled only limited numbers of such patients. For example, a retrospective
study examining the use of Nirmatrelvir/Ritonavir tablets in vulnerable individuals with COVID-19 included only 13.2% highly immunocompromised
and 10.6% moderately immunocompromised patients with cancer, with cancer type and type immunosuppressive medications not otherwise specified.
Although the NIH Panel Guidelines acknowledge observation in retrospective studies of &#8220;some potential benefits&#8221; of the use
of Paxlovid for patients with &#8220;various immunocompromising conditions,&#8221; they also note that because the pivotal trial of Nirmatrelvir/Ritonavir
tablets did not enroll many immunocompromised participants, &#8220;efficacy ... was not established for this population.&#8221; Based
on our target product profile, therefore, we anticipate that these products may not be direct competitors in our target patient population.
Moreover, we believe that TVGN 489&#8217;s anticipated single outpatient infusion may be easier to administer than Veklury&#8217;s multiple
infusions over a number of days. Additionally, Paxlovid requires daily doses, has a significant number of drug interaction issues, as
discussed in &#8220;COVID-19 Background&#8221; and noted by the NIH Panel Guidelines, and has experienced numerous patient reports of
disease relapse or rebound, which in each case we do not anticipate for TVGN 489 based on its design and our Phase 1 proof of concept
trial results. We do expect that these products may present direct competition in high-risk elderly patients, but we are initially targeting
immunocompromised indications. There remains no documented effective treatments for Long COVID, with a recent study showing no benefit
from the use of Paxlovid (Nirmatrelvir/Ritonavir tablets) in patients with Long COVID.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Monoclonal antibodies
have also previously been considered promising as an effective therapeutic option for COVID-19, including in immunocompromised patients,
and several had been granted EUAs. Most of these treatments have had their EUAs revoked by FDA due to lack of efficacy stemming
from viral mutations. There are nonetheless ongoing efforts to develop additional anti-COVID monoclonal antibodies for treatment and
prevention of COVID-19 infection. For example, in March 2024, Invivyd received an EUA of its product, Pemgarda (pemivibart), a
broadly neutralizing monoclonal antibody used for COVID-19 prevention in immunocompromised individuals who have not either been exposed
to or developed active COVID infection.&#160;While recent press releases from Invivyd confirm continued activity of Pemivibart against
circulating strains of SARS-CoV-2, third-party research showed that inhibitory concentrations needed for neutralization of the JN.1 sublineages
increased for Pemivibart, and that activity was substantially adversely impacted by the currently highest circulating variant at the
time of the research.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Pemivibart and
other monoclonal antibodies remain vulnerable to novel viral mutations. Antibodies, unlike T-cells, recognize intact molecules. Consequently,
even remote mutations, not directly where the antibodies bind, may alter how the target molecule folds and its overall shape and therefore
prevent antibody binding. T-cells, in contrast, recognize small peptide breakdown products of proteins and are only affected if the mutation
is directly within the target peptide.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">More broadly, known
companies developing virus-specific T cell therapies include Atara Biotherapeutics (&#8220;Atara Bio&#8221;), whose Ebvallo (tabelecleucel)
has received approval in Europe for treating a rare hematologic cancer caused by EBV. AlloVir, Inc. (&#8220;AlloVir&#8221;) is another
company developing allogeneic T cell therapies for viral diseases. Neither Atara Bio nor AlloVir has an active development program for
the treatment of COVID-19. AlloVir conducted a Phase 1b trial of an allogeneic, partially HLA-matched product candidate in COVID-19 and
reported results of the trial in 2021 but has not continued clinical development. One patient in the trial experienced a recurrence of
the disease and died four weeks after treatment. Atara Bio paused development of its T cell therapy, ATA188, after announcing
in November 2023 that the Phase 2 trial of ATA188 targeting EBV-infected B cells and plasma cells in progressive forms of multiple
sclerosis failed to meet efficacy or biomarker endpoints. ATA188 targets only three latent EBV proteins, whereas our CTL peptide
targets are selected from all proteins expressed at the appropriate point in the viral life cycle, whether unique to that point in the
viral life cycle or not. This approach provides far more immunologic targets and thus more opportunities for viral control. In addition,
ATA188 is generated against targets restricted by several HLA alleles, which is likely to reduce the functional dose of drug targeting
any one HLA allele, as contrasted with CTLs developed with ExacTcell, which are generated against a single HLA specificity and therefore
allow a more precise understanding and control of dosage.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">We anticipate that
we will continue to face competition as new therapies enter the market and advanced technologies become available from time to
time. We expect that any treatments which we develop and commercialize will need to compete on, among other things, efficacy, safety,
convenience of administration and delivery, and price. Commercialization of any treatments we develop will be affected by the level of
competition from original and biosimilars products and the availability of reimbursement from government and other third-party payors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Our ability to commercialize our proprietary cell products could be significantly
and adversely affected if our competitors develop and commercialize products that are more effective, have a better safety profile, are
more convenient or are less expensive than our products. Our competitors also may obtain relevant regulatory approvals for their products
more rapidly than we may be able to obtain approval for ours, which could result in our competitors obtaining a head start and establishing
a frontrunner position before we are ready to commercialize. If we are not able to compete effectively against our existing and potential
competitors, our business, financial condition, results of operations and growth prospects may be materially and adversely affected.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 87; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual
Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Our commercial success
depends in part on our ability to obtain and maintain patent and other proprietary protection for our products and methods, preserve
the confidentiality of our trade secrets, operate without infringing, misappropriating, or otherwise violating the valid, enforceable
proprietary rights of others, and prevent others from infringing, misappropriating, or otherwise violating our proprietary rights. We
rely on a combination of patents, patent applications, trademarks, and trade secrets to establish and protect our intellectual
property rights. Our ability to stop third parties from making, using, selling, offering to sell, or importing our products without the
right to do so may depend on the extent to which we have rights under valid and enforceable patents, trademarks or trade secrets
that cover these activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
continue to build our intellectual property portfolio and seek to protect our proprietary position by, among other things, filing patent
applications. Our patent estate includes patents and patent applications with claims relating to our product candidates, methods of use,
and methods of preparing the product candidates. As of April 23, 2025, our U.S. intellectual property portfolio includes three
U.S. patents relating to TVGN 489 for the treatment of COVID-19, nine pending U.S. patent applications, including two
patent applications relating to the treatment of COVID-19, six relating to the treatment of other viruses or cancer, and one
related to artificial intelligence-driven T cell target identification and receptor engagement, as well as thirteen ex-U.S.
patent applications, including applications in Australia, Canada, Europe, Japan, Qatar, United Arab Emirates, and the Patent Cooperation
Treaty (PCT) directed at viral specific T cells, methods of treating and preventing viral infections, methods for developing CD3+CD+
cells against multiple viral epitopes for the treatment of viral infections, and systems for predicting immunologically active peptides
with machine learning models, which have anticipated expiration dates through December 16, 2044.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, our three issued utility patents, all of which will expire on December 9, 2040, are U.S. Patent No. 11,191,827
covering methods of treating COVID-19 infection using COVID-19 peptide specific CTLs, U.S. Patent No. 11,207,401 covering COVID-19 peptide-specific
CTLs, and U.S. Patent No. 11,219,684 covering methods of manufacturing COVID-19 peptide specific CTLs. A pending utility patent application
in the United States directed at viral specific T cells and methods of treating and preventing viral infections has an anticipated expiration
of December 9, 2041.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
determine strategy for claim scope for our patent applications on a case-by-case basis, taking into account advice of counsel and our
business model and needs. We file patents containing claims for protection of useful applications of our proprietary technologies and
any product candidates, including new applications or uses we discover for existing technologies and product candidates, based on our
assessment of their strategic value. We continuously reassess the number and type of patent applications, as well as our pending and
issued patent claims, to ensure maximum coverage and value are obtained for our processes and compositions, given existing patent office
rules and regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">In addition,
we own a registered trademark for &#8220;Tevogen Bio&#8221; (and design), and have applied for a registered trademark protection for
&#8220;ExacTcell&#8221; and &#8220;Tevogen.AI&#8221; (and logo) with the USPTO.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Human
Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success depends on our ability to attract and retain highly qualified management and personnel. As of April 30, 2025, we had 19
full-time and no part-time employees. We value a work culture that encourages employees, contractors, and vendors to contribute their
unique and diverse perspectives, to harness optimism and creativity, and to be ready to learn and develop solutions towards a common
and greater purpose of developing accessible immunotherapies. Our work culture is centered around four &#8220;CORE&#8221; values: Curiosity,
Optimism, Respect, and Equality. We believe it is essential and necessary that these values are instilled and maintained in each of our
employees to foster a collaborative culture. At our current size, ensuring this culture is primarily achieved through the recruitment
process. Talent recruitment at our current stage is setting the foundation for further company growth. When attracting talent, we ensure
that every job description mentions our core values, and the importance of these values in achieving our mission. Beyond evaluating experience,
job applicants are also evaluated based on their values and passions. We believe it is necessary that each employee represents our four
core values. As our employee numbers increase, we plan to create more defined programs to further enhance our company culture and retention
of personnel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b>Facilities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Our corporate
headquarters are located in Warren, New Jersey, and consist of 6,708 square feet dedicated to corporate, operational, and pre-commercial
activities under a lease that expires February 14, 2026. We also have two research and development facilities located in Philadelphia:
our 3,620 square foot research and development center under a lease that expires June 30, 2025; and a shared facility with laboratory
space dedicated to us that is focused on preclinical and pharmacodynamic activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate expansion of both our corporate office and research and development facilities and intend to facilitate both in-house clinical
and commercial manufacturing and are currently engaged in active discussions regarding such expansion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 88; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">On April 17,
2025, we entered into the MSA with CD 8, establishing the general terms and conditions under which CD8 would provide us with access to
specialized manufacturing facilities, including clean rooms and laboratories, as well as related operational services, to support the
production of our cell therapy products. The MSA provides that the specific details of these facilities and services, including scope
of work, costs, and timelines, will be set out in one or more individual project work orders. The MSA has an initial term of twelve months
and will automatically renew for additional 12-month periods unless it is terminated in accordance with the terms set forth therein.
CD8 is associated with Dr. Manmohan Patel, who beneficially owns more than 5% our Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Regulatory
Environment</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Government
Regulation and Product Approval</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, biological products are subject to regulation under the Federal Food, Drug, and Cosmetic Act (the &#8220;FDCA&#8221;),
and the Public Health Service Act (the &#8220;PHSA&#8221;), and other federal, state, and local statutes and regulations. Both the FDCA
and PHSA and their corresponding regulations govern, among other things, the research, development, clinical trials, testing, manufacturing,
quality control, safety, purity and potency (efficacy), labelling, packaging, storage, record keeping, distribution, reporting,
marketing, promotion, advertising, post-approval monitoring, and post-approval reporting involving biological products. Along with third-party
contractors, we will be required to navigate the various preclinical and clinical regulatory obligations and the commercial approval
requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure
of our product candidates. The processes for obtaining regulatory approvals in the United States, along with subsequent compliance with
applicable laws and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Government
policies may change and additional government regulations may be enacted that could prevent, delay, or present significant
new challenges and costs for further development or regulatory approval of any product candidates, product or manufacturing changes,
additional disease indications or label changes. We cannot predict the likelihood, nature or extent of government regulation that might
arise from future legislative or administrative action.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Review
and Approval for Licensing Biologics in the United States</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, FDA regulates our current product candidates as biological products, or biologics, under the FDCA, the PHSA, and associated
implementing regulations. Biologics, like other drugs, are used for the diagnosis, cure, mitigation, treatment, or prevention of disease
in humans. In contrast to low molecular weight drugs, which have a well-defined structure and can be thoroughly characterized, biologics
are generally derived from living material (human, animal, or microorganism), are complex in structure, and thus are usually not fully
characterized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biologics
are also subject to other federal, state, and local statutes and regulations. The failure to comply with applicable statutory and regulatory
requirements at any time during the product development process, approval process, or after approval may subject a sponsor or applicant
to administrative or judicial enforcement actions. These actions could include the suspension or termination of clinical trials by FDA,
FDA&#8217;s refusal to approve pending applications or supplemental applications, suspension or withdrawal of an approval, issuance
of warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, import
detention, injunctions, fines, refusals of government contracts, restitution, disgorgement of profits, or civil or criminal investigations
and penalties brought by FDA, the Department of Justice (&#8220;DOJ&#8221;), and other governmental entities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
applicant seeking approval to market and distribute a biologic in the United States must typically undertake the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion
    of non-clinical laboratory tests and studies performed in accordance with FDA&#8217;s GLP regulations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacture,
    labeling and distribution of investigational drugs in compliance with FDA&#8217;s cGMP requirements;</span></td></tr>
  </table>

<p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 89; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to FDA of an IND, which must become effective before clinical trials may begin and must be updated annually and when significant
    changes are made;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval
    by an IRB for each clinical site before each clinical trial may be initiated;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance
    of adequate and well-controlled human clinical trials in accordance with FDA&#8217;s GCP requirements to establish the safety,
    purity, and potency of the proposed biological product candidate for its intended purpose;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">after
    completion of all pivotal clinical trials, preparation of and submission to FDA of a BLA requesting marketing approval, which includes providing sufficient evidence to establish the efficacy, safety, purity, and potency
    of the proposed biological product for its intended use, including from results of nonclinical testing and clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of an FDA advisory committee review, when appropriate, as may be requested by FDA to assist with its review;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of one or more FDA inspections of the manufacturing facility or facilities at which the proposed product, or certain components
    thereof, are produced to assess compliance with cGMP and data integrity requirements to assure that the facilities, methods, and
    controls are adequate to preserve the biological product&#8217;s identity, strength, quality, and purity and, if applicable, FDA&#8217;s
    GTP requirements for certain human cellular and tissue products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of FDA inspections of selected clinical investigation sites to assure compliance with GCP requirements and the integrity
    of the clinical data;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of an FDA sponsor GCP inspection, often conducted at the applicant&#8217;s headquarters facility;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">payment
    of user fees (unless there is a waiver, exemption, or reduction) under the Prescription Drug User Fee Act (&#8220;PDUFA&#8221;) for
    the relevant year;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA&#8217;s
    review and approval of the BLA to permit commercial marketing of the licensed biologic for particular indications for use in the
    United States; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance
    with post-approval requirements, including the potential requirements to implement a REMS to report adverse events and biological
    product deviations, and to complete any post-approval studies such as confirmatory trials or pediatric studies.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, legislation is drafted, introduced, and passed in Congress that could significantly change the statutory provisions governing
the testing, approval, manufacturing, and marketing of biological products regulated by FDA. In addition to new legislation, FDA regulations,
guidance documents, and policies are often revised or interpreted by the agency in ways that may significantly affect the regulation
of biological products in the United States. It is impossible to predict whether further legislative changes will be enacted or whether
FDA regulations, guidance, policies, or interpretations will change, and the effects of any such changes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<!-- Field: Page; Sequence: 90; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preclinical
and Clinical Development</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
an applicant can begin testing the potential product candidate in human subjects, the applicant must first conduct preclinical studies.
Preclinical studies may include laboratory evaluations of product chemistry, toxicity, and formulation, as well as in vitro and animal
studies to assess the potential safety and activity of the drug for initial testing in humans and to establish a rationale for therapeutic
use. Preclinical studies are subject to federal regulations and requirements, including GLP regulations, which govern the conduct of
animal studies designed to test a product&#8217;s safety. None of our preclinical studies to date have been animal studies. The results
of an applicant&#8217;s preclinical studies are submitted to FDA as part of an IND.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
IND is a request for authorization from FDA to administer an investigational new drug product to humans. An IND is an exemption from
the FDCA that allows an unapproved drug to be shipped in interstate commerce for use in a clinical trial. Such authorization must be
secured prior to interstate shipment and administration of a biological drug that is not subject of an approved BLA. In support of an
IND, applicants must submit a protocol for each clinical trial, which details, among other things, the objectives of the trial, the parameters
to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made
for each successive clinical trial conducted during product development and for any subsequent protocol amendments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human
clinical trials may not begin until an IND is effective. The IND automatically becomes effective 30 days after receipt by FDA, unless
FDA raises safety concerns or questions about the proposed clinical trial within the 30-day time period. In such a case, FDA may place
the IND on clinical hold and the IND sponsor must resolve any of FDA&#8217;s outstanding concerns or questions before the clinical trial
can begin. Submission of an IND therefore may or may not result in regulatory authorization to begin a clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
may also place a clinical hold or partial clinical hold on a clinical trial following commencement of the trial under an IND. A clinical
hold is an order issued by FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. A partial
clinical hold is a delay or suspension of only part of the clinical work requested under the IND. For example, under a partial clinical
hold, FDA may instruct a sponsor not to enroll any new patients into a study, but permit the previously enrolled patients to continue
in the study. No more than 30 days after imposition of a clinical hold or partial clinical hold, FDA will provide the sponsor a written
explanation of the basis for the hold. Following issuance of a clinical hold or partial clinical hold, an investigation may only resume
after FDA has notified the sponsor that the investigation may proceed. FDA will base that determination on information provided by the
sponsor addressing the deficiencies previously cited or otherwise satisfying FDA that the investigation can proceed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in
accordance with GCP regulations, which include the requirement that all research subjects provide their informed consent for their participation
in any clinical trial. If a sponsor chooses to conduct a foreign clinical study under an IND, all FDA IND requirements must be met unless
waived. When the foreign clinical study is not conducted under an IND, the sponsor must ensure that the study complies with GCP regulations
in order to use the study as support for an IND or application for marketing approval, including review and approval by an IRB and informed
consent from subjects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
an independent IRB for all sites participating in a clinical trial must review and approve the plan for any clinical trial and its informed
consent form before the clinical trial begins at each site, and must monitor the trial until completed. Regulatory authorities, the IRB,
or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to
an unacceptable health risk or that the trial is unlikely to meet its stated objectives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
trials also include oversight by an independent group of qualified experts organized by the clinical trial sponsor, known as a DSMB. DSMBs review unblinded study data at pre-specified times during the course of the study. If the
DSMB determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy, the DSMB
can make a recommendation to the sponsor to modify or stop the trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
grounds for a sponsor&#8217;s decision to suspend or terminate a study may be made based on evolving business objectives or competitive
climate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 91; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of BLA approval, clinical trials are typically conducted in the following sequential phases:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                            1: The investigational product is initially introduced into a small group of healthy human
                                            subjects or patients with the target disease or condition. These trials are designed to test
                                            the safety, dosage tolerance, absorption, metabolism and distribution of the investigational
                                            product in humans and the side effects associated with increasing doses. These trials may
                                            also yield early evidence of effectiveness.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                            2: The investigational product is administered to a slightly larger patient population with
                                            a specified disease or condition to evaluate the preliminary efficacy, optimal dosages, and
                                            dosing schedule and to identify possible adverse side effects and safety risks. Multiple
                                            Phase 2 clinical trials may be conducted to obtain information prior to beginning larger
                                            and more expensive Phase 3 clinical trials.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                            3: The investigational product is administered to an expanded patient population to further
                                            evaluate dosage, to provide statistically significant evidence of clinical efficacy and to
                                            further test for safety, generally at multiple geographically dispersed clinical trial sites.
                                            These clinical trials are intended to generate sufficient data to statistically demonstrate
                                            the efficacy and safety of the product, to establish the overall risk/benefit ratio of the
                                            investigational product, and to provide an adequate basis for product approval by FDA.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
phases may overlap or be combined. In some cases, FDA may require, or companies may voluntarily pursue, additional clinical trials after
a product is approved to gain more information about the product, referred to as Phase 4 trials.
Such post-approval trials are conducted following initial approval, often to develop additional data and information relating to the
use of the product in new indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Progress
reports detailing the results of the clinical trials must be submitted at least annually to FDA. In addition, IND safety reports must
be submitted to FDA for any of the following: serious and unexpected suspected adverse reactions in study subjects; findings from epidemiological
studies, pooled analysis of multiple studies, animal or in vitro testing, or other clinical studies, whether or not conducted under an
IND, and whether or not conducted by the sponsor, that suggest a significant risk in humans exposed to the drug; and any clinically important
increase in the rate of a serious suspected adverse reaction over such rate listed in the protocol or investigator brochure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
sponsor&#8217;s planned clinical trials may not be completed successfully within any specified period, or at all. Furthermore, FDA or
the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects
are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution,
or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the
drug has been associated with unexpected serious harm to patients. FDA will typically inspect one or more clinical sites to assure compliance
with GCP and the integrity of the clinical data submitted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
clinical development, the sponsor often refines the indication and endpoints on which the BLA will be based. For endpoints based on patient-reported
outcomes (&#8220;PROs&#8221;), the process typically is an iterative one. FDA has issued guidance on the framework it uses to evaluate
PRO instruments. Although the agency may offer advice on optimizing PRO instruments during the clinical development process, FDA usually
reserves final judgment until it reviews the BLA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrent
with clinical trials, companies often complete additional animal studies, and develop additional information about the chemistry and
physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance with
cGMP. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things,
must develop methods for testing the identity, strength, quality, purity and potency of the final drug. Additionally, appropriate packaging
must be selected and tested, and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable
deterioration over its shelf life.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>BLA
Submission and Review</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assuming
successful completion of all required clinical testing in accordance with all applicable regulatory requirements, an applicant may submit
a BLA requesting licensing to market the biologic for one or more indications in the United States. The BLA must include the results
of nonclinical studies and clinical trials; detailed information on the product&#8217;s chemistry, manufacture, controls; and proposed
labeling. Under the PDUFA, a BLA submission is subject to an application user fee, unless a waiver, reduction, or exemption applies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 92; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
will initially review the BLA for completeness before accepting it for filing. Under FDA&#8217;s procedures, the agency has 60 days from
its receipt of a BLA to determine whether the application will be accepted for filing and substantive review. If the agency determines
that the application does not meet this initial threshold standard, FDA may refuse to file the application and request additional information,
in which case the application must be resubmitted with the requested information and review of the application delayed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
the BLA is accepted for filing, FDA reviews the BLA to determine, among other things, whether a product is safe, pure, and potent and
if the facility in which it is manufactured, processed, packed, or held meets standards designed to assure the product&#8217;s continued
identity, strength, quality, safety, purity, and potency. To ensure cGMP, GLP, GCP, GTP, and other regulatory compliance, an applicant
must incur significant expenditure of time, money, and effort in the areas of training, record keeping, production and quality control.
In addition, FDA expects that all data be reliable and accurate, and requires sponsors to implement meaningful and effective strategies
to manage data integrity risks. Data integrity is an important component of the sponsor&#8217;s responsibility to ensure the safety,
efficacy and quality of its product or products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
cellular products, FDA will not approve the product if the manufacturer is not in compliance with the GTPs, to the extent applicable.
GTPs are FDA regulations and guidance documents that govern the methods used in, and the facilities and controls used for, the manufacture
of human cells, tissue, and cellular and tissue-based products (&#8220;HCT/Ps&#8221;), which are human cells or tissue intended for implantation,
transplant, infusion, or transfer into a human recipient. The primary intent of the GTP requirements is to ensure that HCT/Ps
are manufactured in a manner designed to prevent the introduction, transmission and spread of communicable disease. FDA regulations also
specify how HCT/P establishments must register and list their HCT/Ps with FDA and how they must evaluate donors through screening and
testing, where applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies
in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional
information, FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
performance goals and policies implemented by FDA under the PDUFA generally provide for FDA action on an original BLA within 10 months
of filing, which (as discussed above) typically occurs within 60 days of submission, but that deadline is extended in certain circumstances.
Furthermore, the review process is often significantly extended by FDA&#8217;s requests for additional information or clarification.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
may refer applications for novel products or products that present difficult questions of safety or efficacy to an advisory committee.
Typically, an advisory committee consists of a panel that includes clinicians and other experts who will review, evaluate, and provide
a recommendation as to whether the application should be approved and, if so, under what conditions. FDA is not bound by the recommendations
of an advisory committee, but it considers such recommendations carefully when making decisions and usually has followed such recommendations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its components will
be produced, FDA may issue an approval letter or a Complete Response Letter (&#8220;CRL&#8221;).
An approval letter authorizes commercial marketing of the biologic with specific prescribing information for specific indications. A
CRL will describe all of the deficiencies that FDA has identified in the BLA, except that where FDA determines that the data supporting
the application are inadequate to support approval, FDA may issue the CRL without first conducting required inspections, testing submitted
product lots and/or reviewing proposed labeling. If and when the deficiencies have been addressed to FDA&#8217;s satisfaction in a resubmission
of the BLA, FDA will issue an approval letter. In issuing the CRL, FDA may recommend actions that the applicant might take to place the
BLA in condition for approval, including requests for additional data, information, or clarification. FDA may delay or refuse approval
of a BLA if applicable regulatory criteria are not satisfied, and may require additional testing or information and/or require new clinical
trials. Even with submission of this additional information, FDA ultimately may decide that the application does not satisfy the regulatory
criteria for approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 93; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the approval process, FDA will determine whether a REMS is necessary to help ensure the benefits outweigh the risks of the biologic.
A REMS is a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued
access to such medicines by managing their safe use, and could include medication guides, physician communication plans or elements to
assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. If FDA concludes that
a REMS is needed, the BLA sponsor must submit a proposed REMS and FDA will not approve the BLA without a REMS that the agency has determined
is acceptable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
FDA approves a product, it may limit the approved indications for use for the product, or require that contraindications, warnings, or
precautions be included in the product labeling. FDA may also require that post-approval studies, including Phase
4 clinical trials, be conducted to further assess the drug&#8217;s safety after approval. FDA may prevent or limit further marketing
of a product based on the results of post-market studies or surveillance programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
may also require testing and surveillance programs to monitor the product after commercialization. For biologics, such testing may include
official lot release, which requires the manufacturer to perform certain tests on each lot of the product before it is released for distribution.
The manufacturer then typically must submit samples of each lot of product to FDA, together with a release protocol showing a summary
of the history of manufacture of the lot and the results of all of the manufacturer&#8217;s tests performed on the lot. FDA may also
perform certain confirmatory tests on lots of some products itself, before releasing the lots for distribution by the manufacturer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, an approved BLA only allows the sponsor to market the biologic as approved, without modification. If, for example, a sponsor
modifies an approved T cell product to target different peptides or in our case to target another HLA type, the sponsor would be required
to either file a supplemental BLA with FDA or receive FDA approval for a comparability protocol in order to implement this change into
the final product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after
the product reaches the marketplace.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Post-Approval
Requirements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
products manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by FDA, including,
among other things, requirements relating to recordkeeping, periodic reporting, reporting of certain deviations and adverse experiences,
product sampling and distribution, and advertising and promotion of the product. After approval, many types of changes to the approved
product, such as adding new indications, manufacturing changes and additional labeling claims, are often subject to further testing requirements
and FDA review and approval, depending on the nature of the post-approval change. There also are continuing user fee requirements, under
which FDA assesses an annual program fee for each product identified in an approved BLA. Biologic manufacturers and their third-party
contractors are required to register their facilities with FDA and certain state agencies. These facilities are subject to routine and
periodic unannounced inspections by FDA and certain state agencies for compliance with cGMP, post-marketing safety reporting and data
integrity requirements, which impose certain procedural and documentation requirements to assure quality of manufacturing and product.
FDA has increasingly observed cGMP violations involving data integrity during site inspections and is a significant focus of its oversight.
Requirements with respect to data integrity include, among other things, controls ensuring complete and secure data; activities documented
at the time of performance; audit trail functionality; authorized access and limitations; validated computer systems; and review of records
for accuracy, completeness, and compliance with established standards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-approval
changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require FDA approval
before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting
requirements upon the sponsor and any third-party manufacturers that the sponsor may use. Accordingly, manufacturers must continue to
expend time, money, and effort in the area of production and quality control to maintain compliance with cGMP, data integrity, pharmacovigilance,
and other aspects of regulatory compliance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 94; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product
reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity
or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved
labeling to add new safety information; imposition of post-approval studies to assess new safety risks; or imposition of distribution
or other restrictions under a REMS. Other potential consequences include, for example:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on the marketing or manufacturing of a product, complete withdrawal of the product from the market, or product recalls;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines,
    warning or untitled letters, or holds on post-approval clinical studies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    of FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    seizure or detention, or refusal of FDA to permit the import or export of products; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">permanent
    injunctions and consent decrees, including the imposition of civil or criminal penalties.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
strictly regulates the marketing, labeling, advertising, and promotion of prescription drug products placed on the market. A company
can make only those claims relating to safety and efficacy, purity and potency that are approved by FDA and in accordance with the provisions
of the approved labeling. FDA&#8217;s regulation includes, among other things, standards and regulations for direct-to-consumer advertising,
communications regarding unapproved uses, industry-sponsored scientific and educational activities and promotional activities involving
the Internet and social media. Promotional claims relating to a product&#8217;s safety or effectiveness are prohibited before the drug
is approved. After approval, a product generally may not be promoted for uses that are not approved by FDA, as reflected in the product&#8217;s
prescribing information. In the United States, healthcare professionals are generally permitted to prescribe drugs for such uses not
described in the drug&#8217;s labeling, known as off-label uses, because FDA does not regulate the practice of medicine. However, FDA
regulations impose rigorous restrictions on manufacturers&#8217; communications and prohibit the promotion of off-label uses. It may
be permissible, under very specific, narrow conditions, for a manufacturer to engage in non-promotional, non-misleading communication
regarding off-label information, such as distributing scientific or medical journal information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a company is found to have promoted off-label uses, it may become subject to adverse public relations and administrative and judicial
enforcement by FDA, the DOJ, or the Office of the Inspector General of HHS, as well as other federal and state authorities. This
could subject a company to a range of penalties that could have a significant commercial impact, including civil, administrative, and
criminal fines, penalties, and agreements that materially restrict the manner in which a company promotes or distributes products. The
federal government has levied large civil, administrative, and criminal fines and penalties against companies for alleged improper promotion,
and has also requested that companies enter into Corporate Integrity Agreements and Consent Decrees of Permanent Injunction under which
specified promotional conduct is changed or curtailed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
distribution of prescription drugs and biologics are subject to the Drug Supply Chain Security Act (&#8220;DSCSA&#8221;), which requires
manufacturers and other stakeholders to comply with product identification, tracing, verification, detection and response, notification,
and licensing requirements. In addition, the Prescription Drug Marketing Act and its implementing regulations and state laws limit the
distribution of prescription pharmaceutical product samples, and the DSCSA imposes requirements to ensure accountability in distribution
and to identify and remove prescription drug and biological products that may be counterfeit, stolen, contaminated, or otherwise harmful
from the market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 95; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Expedited
Development and Review Programs</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
offers a number of expedited development and review programs for qualifying product candidates. The fast-track program is intended to
expedite or facilitate the process for reviewing new products that meet certain criteria. Specifically, new products are eligible for
fast-track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential
to address unmet medical needs for the disease or condition. A product intended to treat a serious or life-threatening disease or condition
may also be eligible for breakthrough therapy designation to expedite its development and review. Any marketing application for a biologic
submitted to FDA for approval, including a product with a fast-track designation and/or breakthrough therapy designation, may be eligible
for other types of FDA programs intended to expedite FDA review and approval process, such as priority review and accelerated approval.
FDA also may grant accelerated approval to certain products studied for their safety and effectiveness in treating serious or life-threatening
diseases or conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
RMAT designation, which we are currently planning to seek for some of our therapies, is intended to facilitate an efficient development
program for, and expedite review of, any drug that meets the following criteria: (1) the drug is a cell therapy, therapeutic tissue engineering
product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions; (2) the
drug is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and (3) preliminary clinical
evidence indicates that the drug has the potential to address unmet medical needs for such a disease or condition. Like breakthrough
therapy designation, RMAT designation provides potential benefits that include more frequent meetings with FDA to discuss the development
plan for the product candidate and eligibility for rolling review and priority review. Products granted RMAT designation may also be
eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical
benefit, or reliance upon data obtained from a meaningful number of sites (including through expansion to additional sites) so as to
remove any likelihood of site-specific or investigator-specific bias on the evidence of effectiveness. Once approved, when appropriate,
FDA can permit fulfillment of post-approval requirements for RMATs receiving accelerated approval through the submission of clinical
evidence, clinical studies, patient registries, or other sources of real-world evidence such as electronic health records; through the
collection of larger confirmatory datasets; or through post-approval monitoring of all patients treated with the therapy prior to approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fast
track designation, breakthrough therapy designation, priority review, accelerated approval, and RMAT designation do not change the standards
for approval but may expedite the development or approval process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Patent
Term Restoration and Marketing Exclusivity</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
approval, owners of relevant drug or biological product patents may apply for up to a five year term patent extension to restore a portion
of patent term lost during product development and FDA review of a BLA if approval of the application is the first permitted commercial
marketing or use of a drug or biologic containing the active ingredient under the Drug Price Competition and Patent Term Restoration
Act of 1984, referred to as the Hatch-Waxman Act. The allowable patent term extension is
calculated as one-half of the product&#8217;s testing phase, which is the time between the effective date of an IND and initial BLA submission,
and all of the approval phase, which is the time between BLA submission and approval, up to a maximum of five years. The time can be
shortened if FDA determines that the applicant did not pursue approval with due diligence. The total patent term after the extension
may not exceed 14 years from the date of FDA approval of the product. Only one patent claiming each approved product is eligible for
restoration and the patent holder must apply for restoration within 60 days of approval, even if the product cannot be commercially marketed
at that time. The USPTO, in consultation with FDA, reviews and approves the application for patent term restoration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
patents that might expire during the BLA application phase, the patent owner may request an interim patent extension. An interim patent
extension increases the patent term by one year and may be renewed up to four times. For each interim patent extension granted, the post-approval
patent extension is reduced by one year. The director of the USPTO must determine that approval of the product candidate covered by the
patent for which a patent extension is being sought is likely. Interim patent extensions are not available for a product candidate for
which a BLA has not been submitted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 96; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Biosimilars
and Marketing Exclusivities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The BPCIA created an abbreviated approval
pathway for biological product candidates shown to be highly similar to or interchangeable with an FDA licensed biological product. A
biological product on which another biological product candidate&#8217;s BLA relies to establish biosimilarity is known as a reference
product. Biosimilarity sufficient to reference a prior FDA-approved product requires that there be no differences in conditions of use,
route of administration, dosage form and strength, and no clinically meaningful differences between the biological product candidate
and the reference product in terms of safety, purity, and potency. Biosimilarity must be shown through analytical trials, animal trials
and at least one clinical trial, unless the Secretary of HHS waives a required element. A biosimilar product candidate may be deemed
interchangeable with a prior approved product if it meets the higher hurdle of demonstrating that it can be expected to produce the same
clinical results as the reference product and, for products administered multiple times, the biological product candidate and the reference
biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative
to exclusive use of the reference biologic. Complexities associated with the larger, and often more complex, structures of biologics,
as well as the process by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval
pathway that are still being resolved by FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reference biologic is granted 12 years of exclusivity from the time of first licensure of the reference product, and no application for
a biosimilar can be submitted for four years from the date of licensure of the reference product. The first biological product candidate
submitted under the abbreviated approval pathway that is determined to be interchangeable with the reference product has exclusivity
against a finding of interchangeability for other biologics for the same condition of use for the lesser of (i) one year after first
commercial marketing of the first interchangeable biosimilar, (ii) 18 months after the first interchangeable biosimilar is approved if
there is no patent challenge, (iii) 18 months after resolution of a lawsuit over the patents of the reference biologic in favor of the
first interchangeable biosimilar applicant, or (iv) 42 months after the first interchangeable biosimilar&#8217;s application has been
approved if a patent lawsuit is ongoing within the 42 month period. At this time, it is unclear whether products deemed &#8220;interchangeable&#8221;
by FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy laws and regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Healthcare
Regulation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Coverage,
Pricing, and Reimbursement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to successfully commercialize any products for which we receive regulatory approval for commercial sale will depend, in part,
on the extent to which third-party payors provide coverage and establish adequate reimbursement levels for such products, and significant
uncertainty exists as to the coverage and reimbursement status of any products for which may we obtain regulatory approval. In the United
States, third-party payors include federal and state health care programs, private managed care providers, health insurers and other
organizations. The process for determining whether a third-party payor will provide coverage for a product may be separate from the process
for setting the price of a product or for establishing the reimbursement rate that such a payor will pay for the product. Third-party
payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the FDA-approved
products for a particular indication. Third-party payors are increasingly challenging the price, examining the medical necessity, and
reviewing the cost-effectiveness of medical products, therapies, and services, in addition to questioning their safety and efficacy.
We may need to conduct expensive pharmaco-economic studies in order to demonstrate the medical necessity and cost-effectiveness of our
products, in addition to the costs required to obtain FDA approvals. Our product candidates may not be considered medically necessary
or cost-effective. A payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will
be approved. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide
coverage for the product. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to
realize an appropriate return on our investment in product development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if the government and
third-party payors fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care in the United States has
increased and we expect will continue to increase the pressure on healthcare pricing. Coverage policies and third-party reimbursement
rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive
regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Healthcare Laws and Compliance Requirements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we currently do not have any commercialized products, our current and future business operations may be subject to additional healthcare
regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which we conduct our
business. Such laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, privacy and security,
price reporting and physician sunshine laws. Some of our pre-commercial activities are subject to some of these laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 97; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal Anti-Kickback Statute makes it illegal for any person or entity, including
a prescription drug manufacturer or a party acting on its behalf to knowingly and willfully, directly or indirectly, solicit, receive,
offer, or pay any remuneration in cash or in kind that is intended to induce or reward the referral of business, including the purchase,
order, or lease of any item or service for which payment may be made under a federal healthcare program, such as Medicare or Medicaid.
The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. The Anti-Kickback
Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, formulary
managers and beneficiaries on the other.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, the exceptions
and safe harbors are drawn narrowly. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases
or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements
of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback
Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all its facts
and circumstances. Several courts have found that the Anti-Kickback Statute may be
violated if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare program business. In
addition, liability may be established without actual knowledge of the statute or specific intent to violate it. Violations of this law
are punishable by up to ten years in prison, and can also result in criminal fines, civil money penalties and exclusion from participation
in federal healthcare programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
a claim including items or services resulting from a violation of the federal Anti-Kickback
Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal civil False Claims Act prohibits, among other things, individuals or entities from knowingly presenting, or causing to be presented,
a false or fraudulent claim for payment of government funds or knowingly making, using, or causing to be made or used, a false record
or statement material to an obligation to pay money to the government or knowingly concealing or knowingly and improperly avoiding, decreasing,
or concealing an obligation to pay money to the federal government. Persons and entities can be held liable under these laws if they
are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims by, for example, providing inaccurate billing or coding
information to customers or promoting a product off-label. Many pharmaceutical and other healthcare companies have been investigated
and have reached substantial financial settlements with the federal government under the civil False Claims Act for a variety of alleged
improper marketing activities, including: providing free product to customers with the expectation that the customers would bill federal
programs for the product; providing sham consulting fees, grants, free travel and other benefits to physicians to induce them to prescribe
our products; and inflating prices reported to private price publication services, which are used to set drug payment rates under
government healthcare programs. Penalties for federal civil False Claims Act violations may include up to three times the actual damages
sustained by the government, plus mandatory per claim civil penalties, and the potential for exclusion from participation in federal
healthcare programs. In addition, although the federal False Claims Act is a civil statute, False Claims Act violations may also implicate
various federal criminal statutes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
healthcare fraud provisions of HIPAA prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud
any healthcare benefit program, including private third- party payors, knowingly and willfully embezzling or stealing from a healthcare
benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing
or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of
or payment for healthcare benefits, items or services. Like the federal Anti-Kickback Statute, a person or entity does not need to have
actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 98; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
states have analogous laws and regulations, such as: state anti-kickback and false claims laws that may apply to sales or marketing arrangements
and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; laws
that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant
compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to certain healthcare providers;
laws that require drug manufacturers to report information related to clinical trials or information related to payments and other transfers
of value to physicians and other healthcare providers or marketing expenditures; laws that restrict the ability of manufacturers to offer
co-pay support to patients for certain prescription drugs; and laws and local ordinances that require identification or licensing of
sales representatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA,
as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;), and their implementing regulations,
mandates, among other things, the adoption of uniform standards for the electronic exchange of information in common healthcare transactions,
as well as standards relating to the privacy and security of individually identifiable health information, which require the adoption
of administrative, physical and technical safeguards to protect such information. Among other things, HITECH makes HIPAA&#8217;s security
standards directly applicable to business associates, defined as independent contractors or agents of covered entities that create, receive,
or obtain protected health information in connection with providing a service for or on behalf of a covered entity. HITECH also increased
the civil and criminal penalties that may be imposed against covered entities and business associates, and gave state attorneys general
new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#8217;s
fees and costs associated with pursuing federal civil actions. In addition, certain state laws govern the privacy and security of health
information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant
ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with these laws, where applicable, can
result in the imposition of significant civil and/or criminal penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. federal Physician Payment Sunshine Act, implemented as the Open Payments Program, requires manufacturers of drugs, devices, biologics,
and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program
(with certain exceptions) to report annually to the CMS information related to direct or indirect payments and other transfers of value
to physicians and teaching hospitals (and certain other practitioners as of 2022), as well as ownership and investment interests held
in the Company by physicians and their immediate family members.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we intend to commercialize products that could be reimbursed under a federal health care program and other governmental healthcare programs,
we intend to develop a comprehensive compliance program that establishes internal control to facilitate adherence to the rules and program
requirements to which we will or may become subject. Although the development and implementation of compliance programs designed to establish
internal control and facilitate compliance can mitigate the risk of investigation, prosecution, and penalties assessed for violations
of these laws, the risks cannot be entirely eliminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our operations are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be subject
to penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, disgorgement, contractual
damages, reputational harm, diminished profits and future earnings, the curtailment or restructuring of our operations, exclusion from
participation in federal and state healthcare programs and individual imprisonment, any of which could adversely affect our ability to
operate our business and our financial results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Health
Care Reform</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States and some foreign jurisdictions, there have been, and continue to be, legislative and regulatory changes and proposed
changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval
activities, and affect the ability to profitably sell product candidates for which marketing approval is obtained. Among policy makers
and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated
goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has
been a particular focus of these efforts and has been significantly affected by major legislative initiatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
example, the Affordable Care Act (&#8220;ACA&#8221;)
substantially changed the way healthcare is financed by both the government and private insurers, and significantly impacts the U.S.
pharmaceutical industry. The ACA contains provisions that may reduce the profitability of drug products through increased rebates for
drugs reimbursed by Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain
Medicare Part D beneficiaries, and annual fees based on
pharmaceutical companies&#8217; share of sales to federal health care programs. The ACA made several changes to the Medicaid
Drug Rebate Program, including increasing pharmaceutical manufacturers&#8217; rebate liability by raising the minimum basic Medicaid
rebate. The ACA also expanded the universe of Medicaid utilization subject to drug rebates by requiring pharmaceutical manufacturers
to pay rebates on Medicaid managed care utilization and by enlarging the population potentially eligible for Medicaid drug benefits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 99; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been judicial challenges to certain aspects of the ACA, as well as efforts by Congress to modify, and by agencies to alter the implementation
of, certain aspects of the ACA. For example, Congress eliminated the tax penalty for failure to comply with the ACA&#8217;s individual
mandate to carry health insurance. Further, the Bipartisan Budget Act of 2018, among other things, amended the ACA to increase from 50
percent to 70 percent the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare
Part D to close the coverage gap in most Medicare drug plans, commonly referred to as the donut
hole (this existing coverage gap program will be sunset by the Inflation Reduction Act beginning in 2025 and replaced with a new manufacturer
discount program).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is possible that the ACA, as currently enacted or as may be amended in the future, as well as other healthcare reform measures, including
those that may be adopted in the future, may result in more rigorous coverage criteria, and less favorable payment methodologies, or
other downward pressure on coverage and payment and the price that we receive for any approved product. Any reduction in reimbursement
or restriction on coverage under Medicare or other federal health care programs may result in a similar reduction or restriction by private
payors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
legislative changes have been proposed and adopted in the U.S. since the ACA was enacted. For example, the Inflation Reduction Act introduces
several changes to the Medicare Part D benefit, including
a limit on annual out-of-pocket costs and a change in manufacturer liability under the program which could negatively affect the profitability
of our product candidates. The IRA sunsets the current Part D coverage gap discount program starting
in 2025 and replaces it with a new manufacturer discount program. Failure to pay a discount under this new program will be subject to
a civil monetary penalty. In addition, the IRA establishes a Medicare Part
B inflation rebate scheme effective January 2023 and a Medicare Part
D inflation rebate scheme effective October 2022, under which, generally speaking, manufacturers will owe rebates if the price of a Part
B or Part D drug increases faster than the pace of inflation. Failure to timely pay a Part
B or D inflation rebate is subject to a civil monetary penalty. The IRA also creates a drug price negotiation
program under which the prices for Medicare units of certain high Medicare spend drugs and biologicals without generic or biosimilar
competition will be capped by reference to, among other things, a specified non-federal average manufacturer price starting in 2026.
Failure to comply with requirements under the drug price negotiation program is subject to an excise tax and/or a civil monetary penalty.
Congress continues to examine various policy proposals that may result in pressure on the prices of prescription drugs with respect to
the government health benefit programs and otherwise. The IRA or other legislative changes could impact the market conditions for our
product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, there has been heightened governmental scrutiny over the manner in which drug manufacturers set prices for their commercial
products, which has resulted in several Congressional inquiries and proposed and enacted
federal and state legislation designed to, among other things, bring more transparency to drug product pricing, review the relationship
between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. At the
state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological
product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing
cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Privacy</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also be subject to federal, state, national and international laws and regulations governing the privacy and security of health-related
and other personal data we collect and maintain (e.g., Section 5 of the FTC Act, the CCPA, and the EU&#8217;s General Data
Protection Regulation). These laws and regulations are evolving and subject to interpretation and may impose limitations on our
activities or otherwise adversely affect our business. In addition, state laws govern the privacy and security of health information
in specified circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating
compliance efforts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we or our third party partners fail to comply or are alleged to have failed to comply with these or other applicable data protection
and privacy laws and regulations, or if we were to experience a data breach involving personal data, we could be subject to government
enforcement actions or private lawsuits. Any associated claims, inquiries, or investigations or other government actions could lead to
unfavorable outcomes that have a material impact on our business including through significant penalties or fines, monetary judgments
or settlements including criminal and civil liability for us and our officers and directors, increased compliance costs, delays or impediments
in the development of new products, negative publicity, increased operating costs, diversion of management time and attention, or other
remedies that harm our business, including orders that we modify or cease existing business practices.</span></p>






<p style="margin: 0"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 100; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="as_003"></span>MANAGEMENT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
of Directors and Management</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth, as of April 30, 2025, the name, age, and position of each our executive officers and directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 26%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: top; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: top; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Executive
    Officers</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Ryan Saadi</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer, Chairperson and Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kirti
    Desai</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Neal Flomenberg</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Scientific Officer and Global R&amp;D Lead</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sadiq
    Khan</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Commercial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Non-Employee
    Directors</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey
    Feike</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Keow Lin Goh</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Curtis Patton</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">89</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Susan
    Podlogar</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Victor
    Sordillo</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Executive
Officers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dr.
Ryan Saadi</i></b> has served as our Chief Executive Officer and Chairperson since February 2024, and served as Chief Executive Officer
and Chairperson of Tevogen Bio beginning in June 2020. Dr. Saadi has been a member of the Leadership Council of the Yale School of Public
Health since 2021. Prior to founding Tevogen Bio, Dr. Saadi was the Global Vice President of Evidence, Market Access, and Strategic Pricing
for CSL Behring, a biopharmaceutical company that manufactures plasma-derived and recombination therapeutic products, from 2018 to 2019.
Before CSL Behring, Dr. Saadi served as Global Head, Market Access and Policy, Oncology for Janssen from 2012 to 2018 and Worldwide Vice
President, Health Policy, Reimbursement, Strategic Pricing and Market Access for Johnson &amp; Johnson&#8217;s Cordis business from 2008
to 2012. Earlier, Dr. Saadi was Global Vice President, Health Outcomes &amp; Pricing for Genzyme and Global Head, Health Outcomes and
Market Access for Sanofi-Aventis&#8217; oncology, bone and arthritis product portfolio. From 2010 through 2019, Dr. Saadi served as a
Voting Member of the CMS Medicare Evidence Development &amp; Coverage Advisory Committee, which provides independent guidance and expert
advice to CMS on clinical topics. We believe Dr. Saadi is qualified to serve on our Board based on his extensive business and
leadership experience in the healthcare industry.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Kirti
Desai</i></b>  has served as our Chief Financial Officer since February  2024, and served as Chief Financial Officer of
Tevogen Bio beginning in June 2020. Mr. Desai previously served as President of Star Accounting Services Inc., an accounting firm providing
accounting and tax services to businesses and individuals, from January 2005 to December 2021. Mr. Desai is a certified public accountant.
Mr. Desai also serves as the Treasurer of Shrimad Rajchandra Mission Dharampur (USA) Inc., a community outreach and development nonprofit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dr.
Neal Flomenberg</i></b>  has served as our Chief Scientific Officer and Global R&amp;D Lead since February  2024, and served
as Chief Scientific Officer and Global R&amp;D Lead of Tevogen Bio beginning in July 2022. Prior to joining Tevogen Bio, Dr. Flomenberg
served as professor and Chair of the Department of Medical Oncology at Sidney Kimmel Medical College of Thomas Jefferson University from
2008 to July 2022 and Deputy Director of Thomas Jefferson University&#8217;s Sidney Kimmel Cancer Center from 2015 to July 2022. Prior
to those positions, Dr. Flomenberg held a number of leadership roles in the academia, hospital, and research settings. Dr. Flomenberg&#8217;s
career has focused on blood cancers, particularly those requiring bone marrow or peripheral blood stem cell transplants, and he has authored
over 175 peer reviewed publications. At Jefferson, Dr. Flomenberg also maintained an active medical practice and was continually listed
in Philadelphia Magazine&#8217;s &#8220;Top Doctors in Philadelphia&#8221; for more than 15 years prior to joining Tevogen Bio.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 101; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sadiq
Khan</i></b>  has served as our Chief Commercial Officer since February  2024, and served as Chief Commercial Officer of
Tevogen Bio beginning in April 2022. Previously, Mr. Khan held several roles at the New Jersey Institute of Technology (&#8220;NJIT&#8221;),
a public research university, and its subsidiaries from 2014 to March 2022. Most recently, Mr. Khan served as Senior Director and then
Executive Director of Operations &amp; Business Planning at BioCentriq, a for-profit cell and gene therapy contract development and manufacturing
organization owned by New Jersey Innovation Institute (&#8220;NJII&#8221;), which was itself a non-profit subsidiary of NJIT, from September
2018 to March 2022. While at BioCentriq, Mr. Khan was part of the leadership team that prepared BioCentriq for its spin-off from NJII.
Mr. Khan held several roles at NJII from 2014 to February 2020, including Director of Business Development, Biopharma Innovation beginning
in 2018, where he worked to facilitate academic, government, and industry collaboration in the biopharmaceutical field. From 2008 to
March 2018, Mr. Khan also acted as Founder and Chief Strategist for Pharmique Health LLC, where he advised corporations on strategic
commercial planning and other matters. Previously, Mr. Khan co-founded Tegelix Therapeutics, a now-defunct pharmaceutical company, and
held various regional and global commercialization and alliance management roles at Hoechst Marion Roussel, Aventis, and then Sanofi-Aventis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-Employee
Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Jeffrey
Feike</i></b> has served on our Board since February</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
2024, and served on the board of directors of Tevogen Bio beginning in August 2022. Mr. Feike served as the Hospital President of Covenant
Health&#8217;s Fort Loudoun Medical Center from September 2004 to June 2022. Throughout his career, Mr. Feike has overseen the development
of hospitals, outpatient clinics, and emergency medical services (&#8220;EMS&#8221;) systems. Mr. Feike represents East Tennessee on
the state EMS Board&#8217;s Clinical Issues Committee and serves on the board of Regional Medical Communications Center for East Tennessee.
We believe Mr. Feike is qualified to serve on our Board based on his dedication to public health and healthcare industry experience.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dr.
Keow Lin Goh</i></b>  has served on our Board since February  2024, and served on the board of directors of Tevogen Bio
beginning in August 2022. Dr. Goh is a Partner at Tapestry Networks, a company that brings together leaders in different sectors in order
to facilitate economic, social, and organizational change. Dr. Goh has served as a Partner at Tapestry Networks since 2009 and focuses
on global healthcare policy with the goal of improving patient outcomes. Previously, Dr. Goh was a Senior Project Leader at Boston Consulting
Group from 2003 through 2009, where she worked with senior biotech and pharmaceutical executives in product development, research and
development restructuring, organizational and operational change initiatives, post-merger acquisition synergies, and regulatory issues.
We believe Dr. Goh is qualified to serve on our Board based on her experience in the healthcare sector.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 102; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dr.
Curtis Patton</i></b>  has served on our Board since February  2024, and served on the board of directors of Tevogen
Bio beginning in July 2020. Dr. Patton is Professor Emeritus at Yale School of Public Health, where he worked for 36 years. Dr. Patton
served in a variety of administrative capacities during his time at Yale, including as Division Head, Epidemiology of Microbial Diseases
and Acting Head of Global Health. While at Yale, Dr. Patton also served as the Director of International Medical Studies and was the
Chair of the Committee on International Health. We believe Mr. Patton is qualified to serve on our Board based on his work on and experience
with public health issues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Susan
Podlogar</i></b> has served on our Board since February 2024, and served on the board of directors of Tevogen Bio beginning in
August 2022. Ms. Podlogar most recently oversaw global human resources strategies and practices at MetLife, Inc ., a financial services company providing insurance, annuities, employee benefits, and asset management (&#8220;MetLife&#8221;), as MetLife&#8217;s Executive Vice President and Chief Human Resources Officer from 2017 until her retirement
in June 2024. At MetLife, Ms. Podlogar among other things established a &#8220;Workforce of the Future Development
Fund&#8221; to prepare employees for future work needs. Ms. Podlogar also served on the board of directors of MetLife
Foundation, a philanthropic organization. Ms. Podlogar has also served on the board of directors of LivaNova PLC (Nasdaq:
LIVN), a global medical technology company, since October 2024. Prior to her time at MetLife, Ms. Podlogar held a series of human
resources roles at Johnson &amp; Johnson from 2003 to 2017, including Global Vice President of Human Resources and member of the
Human Resources Executive Committee. We believe Ms. Podlogar is qualified to serve on our Board based on her extensive human
resources and healthcare industry experience.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Victor
Sordillo</i></b> has served on our Board since February 2024, and served on the board of directors of Tevogen Bio beginning in July 2023.
Mr. Sordillo has served as Director of Risk Advisory Services at Verita CSG, Inc. (&#8220;Verita&#8221;), a provider of holistic insurance
and risk management solutions for commercial line clients, since March 2024. Before joining Verita, Mr. Sordillo served as the Executive
Vice President, Director of Risk Control Services of Sompo International, a global specialty provider of property and casualty insurance
and reinsurance, from 2017 to March 2024, and as Senior Vice President - Risk Solutions of QBE North America (&#8220;QBE&#8221;) from
2016 to 2017. Prior to QBE, Mr. Sordillo served as Vice President and Global Technical Services Manager at Chubb NA, where
he worked from 2000 through 2016. Mr. Sordillo is a registered professional civil and fire protection engineer and Certified Safety
Professional. Mr. Sordillo served as the mayor of Warren, New Jersey for more than 22 years. We believe Mr. Sordillo is qualified to
serve on our Board based on his extensive business and leadership experience.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
Governance</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We have structured our corporate
governance in a manner that we believe closely aligns our interests with those of our stockholders. Our Audit Committee, our only
current standing committee, is composed solely of independent directors. Our independent directors are responsible for certain determinations
relating to executive compensation and meet regularly in executive sessions without the presence of our corporate officers or non-independent
directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Our Board has
adopted Corporate Governance Guidelines that address, among other topics, the role and responsibilities of our directors, the structure
and composition of our Board, and corporate governance policies and standards applicable to us in general. The Corporate Governance Guidelines
are subject to periodic review and changes by our Board. Our Corporate Governance Guidelines are available on our website.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Composition
of the Board</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business and affairs are managed under the direction of the Board. The Board is divided into three classes, designated as Class I, Class
II, and Class III. Each class currently consists of one third of the total number of directors constituting the whole Board. The
term of the current Class I directors, Dr. Curtis Patton and Jeffrey Feike, expires at the Annual Meeting; the term of the current
Class II directors, Victor Sordillo and Dr. Keow Lin Goh, expires at the 2026 annual meeting of the stockholders; and the term
of the current Class III directors, Dr. Ryan Saadi and Susan Podlogar, expires at the 2027 annual meeting of the stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b><i>Director Qualifications</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">The Board strives
in its membership profile to have a range of backgrounds and expertise that enhances the ability of the directors collectively to understand
the issues facing the Company and to fulfill the Board&#8217;s responsibilities. Among the qualifications the Board considers are character,
ability to exercise sound judgment, demonstrated leadership, skills, experience, tenure, education, independence, and certain other criteria
set forth in our Corporate Governance Guidelines.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b><i>Director Independence</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Under our Corporate Governance
Guidelines and the Nasdaq rules, a director will not be independent unless our Board affirmatively determines that the
director does not have a relationship with the Company that would interfere with the exercise of independent judgment in carrying
out the responsibilities of a director. In addition, the director must not be precluded from qualifying as independent under the per
se bars set forth by the Nasdaq rules.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Our Board undertook a review
of its composition, the composition of its Audit Committee, and the independence of directors and considered whether
any director has a relationship with us that could compromise the director&#8217;s ability to exercise independent judgment in carrying
out the director&#8217;s responsibilities. Based upon information requested from and provided by each director concerning the director&#8217;s
background, employment, and affiliations, including family relationships, our Board has determined that none of Jeffrey Feike, Dr. Keow
Lin Goh, Dr. Curtis Patton, Susan Podlogar, and Victor Sordillo has a relationship that would interfere with the exercise of independent
judgment in carrying out the responsibilities of a director and that each of these directors qualifies as &#8220;independent&#8221; as
that term is defined under the Nasdaq rules. In making these determinations, our Board considered all facts and circumstances our Board
deemed relevant in determining their independence.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">There are no family relationships
between the Board and any of our executive officers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>


<!-- Field: Page; Sequence: 103; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Board Leadership Structure</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Dr. Saadi, our Chief Executive
Officer and majority stockholder, also serves as Chairperson of the Board. The Board believes that our stockholders are best served at
this time by having Dr. Saadi as Chairperson of the Board. Dr. Saadi has served as Chairperson since the Closing, and previously served
as the Chairperson of Tevogen Bio. Dr. Saadi brings considerable skills and experience. The Board does not have a lead independent director.
The Board believes that this structure is appropriate in light of the size of our Company and corresponding size of our Board and the
complexity of our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Role of Board in Risk Oversight</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Our Board has extensive involvement
in the oversight of risk management related to our Company and its business and accomplishes this oversight in part through regular reporting
to the Board by the Audit Committee. The Audit Committee represents the Board by periodically reviewing our accounting, reporting, and
financial practices, including the integrity of our financial statements, our administrative and financial controls,
and our compliance with legal and regulatory requirements. Through its regular meetings with management, the Audit Committee reviews
and discusses all significant areas of our business and summarizes for the Board all areas of risk and the appropriate mitigating factors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Our executive officers regularly
report to the non-executive directors and the Audit Committee to ensure effective and efficient oversight of our activities and to assist
in proper risk management and the ongoing evaluation of management controls. We believe that the leadership structure of our Board provides
appropriate risk oversight.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Controlled
Company Status</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a &#8220;controlled company&#8221; for purposes of the corporate governance rules of Nasdaq. Controlled companies under those rules
are companies of which more than 50% of the voting power for the election of directors is held by an individual, a group or another company.
Dr. Saadi owns more than 50% of our voting power. Accordingly, we are eligible for certain exemptions from the corporate governance requirements
of Nasdaq. Specifically, we are not required to (1) have a majority of independent directors, (2) have a compensation committee
composed entirely of independent directors, or (3)&#160;have all director nominees selected, or recommended for selection by the board
of directors, either by independent directors constituting a majority of the independent directors of the board in a vote in which only
independent directors participate, or a nominations committee composed entirely of independent directors. We do not have a compensation
committee composed entirely of independent directors or have director nominees selected or recommended by independent directors or a
nominations committee composed entirely of independent directors. We do not currently rely on the exemption from the requirement to have
a majority of independent directors but may choose to rely on such exemption in the future. In the event we elect to rely on such
exemption in the future, stockholders would not have the same protections afforded to stockholders of companies that are subject
to the requirement to have a majority of independent directors or that do not rely on an exemption from such requirement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
Meetings and Committees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The Board currently maintains
an Audit Committee. The Board may, from time to time, establish other committees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We do not currently have
a compensation committee or a nominating committee, or a committee performing similar functions. As described under <i>&#8220;&#8212;Controlled
Company Status</i>&#8221; above, we are not required to have a compensation committee and are not subject to certain Nasdaq requirements
relating to the nomination of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In April 2025, our Board
disbanded our previously existing compensation committee and nominating and corporate governance committee. The functions
that would be performed by a compensation committee are performed by the Board or, in the case of certain responsibilities relating
to executive compensation, the independent directors of the Board. Each member of the Board is independent other than Dr. Saadi, who
is not independent under the general Nasdaq independence standards or the heightened standards applicable to members of compensation
committees under Nasdaq rules. Our director nomination process is described below under &#8220;<i>Nomination of
Directors</i>.&#8221; We believe these arrangements are appropriate in the interest of the efficiency of the discharge of the
Board&#8217;s duties, in light of the size and the stage of development of the Company, to further a goal of keeping the entire
Board informed of all Board activities, and because such committees are not required for a controlled company. However,
notwithstanding the absence of a compensation committee or a committee performing similar functions, we continue to believe that
independent director oversight of executive compensation is important and that it facilitates impartial decision-making and furthers
alignment of the interests of our executive leadership with those of our stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Audit Committee</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The Audit Committee consists
of Victor Sordillo, who serves as the chairperson, Jeffrey Feike, and Susan Podlogar. Each of the members of the Audit Committee
satisfies the requirements for independence and financial literacy under the applicable rules and regulations of the SEC and rules of
Nasdaq.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The Board has determined
that Mr. Feike qualifies as an Audit Committee financial expert, having acquired the attributes of an Audit Committee financial
expert through his decades of experience overseeing chief financial officers and the preparation and analysis of financial statements
as a hospital and hospital system chief executive officer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The functions of the Audit
Committee include, among other things:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluating
    the performance, independence, and qualifications of our independent auditors and determining whether to retain our existing
    independent auditors or engage new independent auditors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    our financial reporting processes and disclosure controls;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and approving the engagement of our independent auditors to perform audit services and any permissible non-audit services;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    the adequacy and effectiveness of our internal control policies and procedures;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    with the independent auditors the annual audit plan, including the scope of audit activities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
    and reviewing at least annually a report by our independent auditors describing the independent auditors&#8217; internal quality
    control procedures and any material issues raised by the most recent internal quality-control review;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 74.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 104; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<!-- Field: Split-Segment; Name: 02 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 74.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and evaluating our independent auditor&#8217;s lead audit partner and the rotation of audit partners as required by law;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">prior
    to engagement of any independent auditor, and at least annually thereafter, reviewing relationships that may reasonably be thought
    to bear on their independence, and assessing and otherwise taking the appropriate action to oversee the independence of our independent
    auditor;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    our annual and quarterly financial statements and reports, including the disclosures contained in the section titled &#8220;<i>Management&#8217;s
    Discussion and Analysis of Financial Condition and Results of Operations</i>&#8221; in such reports, and discussing
    the statements and reports with our independent auditors and management;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    with our independent auditors and management significant issues that arise regarding accounting principles and financial statement
    presentation and matters concerning the scope, adequacy, and effectiveness of our financial controls and critical accounting policies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    with management and our auditors any earnings announcements and other public announcements regarding material developments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    procedures for the receipt, retention and treatment of complaints we receive regarding accounting, internal accounting controls,
    auditing or other matters;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">preparing
    the report required by the SEC that appears under &#8220;<i>Audit Committee Report</i>&#8221;;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and discussing our major financial risk exposures, including the guidelines and policies to govern the process by which risk assessment
    and risk management is implemented; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and evaluating the Audit Committee charter annually and recommending any proposed changes to the Board.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
composition and function of the Audit Committee complies with all applicable requirements of the Sarbanes-Oxley Act of 2002
and all applicable SEC and Nasdaq rules and regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board adopted a written charter for the Audit Committee, which is available on our website at <i>ir.tevogen.com/governance/governance-documents/default.aspx</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Board and Committee Meetings</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">In 2024, the
Board met three times and the Audit Committee met five times. The former compensation committee and the former nominating and corporate governance committee did not hold any meetings in 2024. Each of our directors attended at least 75% of the total number of meetings of
the Board and committees on which the director served during 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Nomination of Directors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">The Board is
responsible for identifying director nominees for election or re-election at the Company&#8217;s annual meeting of stockholders in each
fiscal year, nominating individuals for election, and filling vacancies and newly created directorships. The Board will evaluate individuals
nominated, or recommended for nomination, by stockholders for election to the Board. In evaluating potential nominees, the Board considers
Nasdaq rules and our Corporate Governance Guidelines, including the criteria set forth therein. Our Corporate Governance Guidelines are
available on our website at <i>ir.tevogen.com/governance/governance-documents/default.aspx</i>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Code of Business Conduct and Ethics</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">We have adopted
a code of business conduct and ethics that applies to all of our directors, officers, and employees, including those officers
responsible for financial reporting. A current copy of the code of business conduct and ethics is available under the Governance Documents
section of our website. We intend to disclose future amendments to the code or any waivers of its requirements on our website at <i>ir.tevogen.com/governance/governance-documents/default.aspx</i>.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>


<!-- Field: Page; Sequence: 105; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="as_004"></span>EXECUTIVE
AND DIRECTOR COMPENSATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables and accompanying narrative set forth information about the 2024 and 2023 compensation provided to our principal
executive officer and the two most highly compensated executive officers (other than our principal executive officer) who were serving
as executive officers as of December 31, 2024. These executive officers consist of Dr. Ryan Saadi, our Chief Executive Officer,
Kirti Desai, our Chief Financial Officer, and Dr. Neal Flomenberg, our Chief Scientific Officer and Global R&amp;D Lead, and are referred
to in this section as our &#8220;named executive officers&#8221; or &#8220;NEOs.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
discussion may contain forward-looking statements that are based on our current plans, considerations, expectations, and determinations
regarding future compensation practices. Actual compensation practices in the future may differ materially from the forward-looking statements
included in this discussion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
Compensation Table</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents summary information regarding the total compensation for services rendered in all capacities that was awarded
to, earned by, or paid to our named executive officers for the last two completed fiscal years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold">Name and Principal Position</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Salary</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Awards<sup>(1)</sup></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>All Other</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 38%; text-align: left"><i>Ryan Saadi, M.D., M.P.H. <br/>
    Chief Executive Officer</i></td><td style="width: 1%">&#160;</td>
    <td style="width: 8%; text-align: center">2024</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">501,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">87,263,783<sup></sup></td><td style="width: 1%; text-align: left"><sup>(2)</sup></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">87,764,783</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">501,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">501,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left">Kirti Desai <br/>
Chief Financial Officer</td><td>&#160;</td>
    <td style="text-align: center">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left">Neal Flomenberg, M.D.<br/>
Chief Scientific Officer and Global R&amp;D Lead</td><td>&#160;</td>
    <td style="text-align: center">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">350,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">350,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">350,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,576,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,926,000</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    amounts in this column reflect the full grant date fair value of RSUs computed in accordance with ASC 718, Compensation
    - <i>Stock Compensation</i> (&#8220;ASC 718&#8221;), excluding estimates of forfeitures related to service-based vesting
    conditions. See our discussion of &#8220;<i>Stock-Based Compensation</i>&#8221; under Note 11 to our audited consolidated financial
    statements included in the 2024 Form 10-K for a discussion of all assumptions made by us in determining the grant date fair values
    of our equity awards. See also our discussion of stock-based compensation under &#8220;<i>Management&#8217;s Discussion and Analysis
    of Financial Condition and Results of Operations&#8212;Critical Accounting Policies and Estimates</i>&#8221; in the 2024 Form 10-K.
    The amount reported reflects the accounting cost for the RSUs and does not correspond to the actual value that may be recognized
    by the applicable grantee in connection with each award.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 12pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">(2)</span></td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">As a condition to the
    Closing and pursuant to the Merger Agreement, on the Closing Date, the Company issued an aggregate of
    19,348,954 RSUs under the 2024 Plan to Dr. Saadi (the &#8220;Special
    RSU Award&#8221;), the terms of which are described below under &#8220;<i>&#8212;Narrative Disclosure to Summary Compensation Table&#8212;Equity Compensation</i>.&#8221; The fair value per share for the Special RSU Award was
    determined to be $4.51 per share, equivalent to the Company&#8217;s stock price on the Closing Date, resulting in a total grant date
    fair value of $87,263,783.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Narrative
Disclosure to Summary Compensation Table</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Base
Salary</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
named executive officers receive base salaries to compensate them for services rendered to us. The base salary payable to each named
executive officer is intended to provide a fixed component of compensation reflecting the executive&#8217;s skill set, experience, role,
and responsibilities. The annual base salaries for Dr. Saadi, Mr. Desai, and Dr. Flomenberg for 2024 were $501,000, $300,000,
and $350,000, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Equity
Compensation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Further to a
condition to the Closing, the Company granted the Special RSU Award to Dr. Saadi on the Closing Date. The
19,348,954 shares underlying the Special RSU Award represented approximately 10% of our Common Stock, calculated on a fully diluted basis,
at the time of the grant. Upon grant, the RSUs immediately settled in shares of restricted Common Stock (&#8220;Restricted Stock&#8221;),
the restrictions on which are not scheduled to begin to lapse until seven years after grant. They will lapse in four equal annual installments
beginning on February 14, 2031, subject to Dr. Saadi&#8217;s continuous service through the applicable vesting date. The Restricted Stock
is also subject to accelerated vesting in the event of a Change in Control (as defined in the 2024 Plan) in which the Restricted Stock
is not assumed or continued. Pursuant to the terms of the Special RSU Award, Dr. Saadi will be entitled to vote the Restricted Stock,
but such shares may not be sold, assigned, transferred, pledged, hypothecated, or otherwise encumbered prior to vesting, subject to automatic
forfeit. Dr. Saadi will automatically forfeit all unvested Restricted Stock in the event his service terminates for any reason prior
to vesting or he is determined to have engaged in Conduct Detrimental to the Company (as defined in the Special RSU Award agreement)
during his service to the Company. In addition, in the event Dr. Saadi is determined to have engaged in Conduct Detrimental to the Company
during his service with the Company or in the 12-month period thereafter, he will owe the Company a cash payment or forfeiture of shares
of Common Stock with respect to shares that vested in the 12-months prior to the conduct, regardless of whether he still owns the shares
at the time of the determination.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">From time to
time, we grant equity awards as incentives to attract, retain, and motivate our named executive officers. Prior to the Closing, we
granted equity awards under the Tevogen Bio Inc 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;). In connection with the
consummation of the Business Combination, we adopted the 2024 Plan and no longer grant awards pursuant to the 2020 Plan. Each RSU
award granted under the 2020 Plan that was outstanding and unvested as of the Closing Date was automatically canceled in
connection with the Closing and converted into an award under the 2024 Plan with respect to our Common Stock. Such
converted awards remained subject to the same terms and conditions as set forth under the applicable award agreement prior to
the Closing. Other than the Special RSU Award to Dr. Saadi, no new equity awards were granted to our named executive
officers in 2024.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 106; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>2025 Executive Compensation Program</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Executive officer
salaries have not been increased for 2025, and the independent directors have determined to grant equity awards to executive officers
in the form of Restricted Stock awards that will vest in three equal installments beginning on the fifth anniversary of the grant date,
and that will be subject to forfeiture in most cases in the event the executive&#8217;s service with the Company terminates prior to
vesting. We believe that awarding Restricted Stock awards that vest over a significant period of time incentivizes retention and value
creation while still providing executive officers with an important incident of stock ownership.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding
Equity Awards at Fiscal Year-End</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides information regarding equity awards held by our named executive officers that were outstanding as of December
31, 2024. Our named executive officers did not hold any outstanding stock options as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock Awards</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Name</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Equity Incentive Plan Awards: Market Value of Unearned Shares, Units or Other Rights That Have Not Vested ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Ryan Saadi</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Kirti Desai</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 50%; text-align: left">Neal Flomenberg</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 20%; text-align: right">363,607</td><td style="padding-bottom: 0.05in; width: 2%; text-align: left"><sup>(1)</sup></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">374,515</td><td style="padding-bottom: 0.05in; width: 2%; text-align: left"><sup>(2)</sup></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reflects <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an award of 100,000 RSUs of Tevogen
Bio originally granted on July 14, 2023 (the &#8220;2023 Flomenberg Award&#8221;), 75% of which remained unvested as of December 31, 2024,
adjusted to reflect the Exchange Ratio and expressed in shares of Common Stock. Under the terms of the Merger Agreement, each RSU with
respect to shares of Tevogen Bio common stock that was unvested at the time of the Closing was canceleed and converted into an award under
the 2024 Plan with respect to a number of RSUs (&#8220;Rollover RSUs&#8221;) to be settled in our Common Stock equal to the product, rounded
up to the nearest whole number, of (i)&#160;the number of shares of the common stock of Tevogen Bio subject to the Tevogen Bio RSU as
of immediately prior to the effective time of the Merger, multiplied by (ii) approximately 4.84 (the &#8220;Exchange Ratio&#8221;). The
vesting of the 2023 Flomenberg Award required the satisfaction of both a service-based condition and a performance-based condition (the
&#8220;Liquidity Event Condition&#8221;). The Liquidity Event Condition was satisfied by the consummation of the Business Combination.
The 2023 Flomenberg Award vested with respect to 25% of the RSUs on July 14, 2024 and will vest with respect to additional tranches of
25% on each anniversary thereof, subject to continued service. In addition, as of December 31, 2024, Mr. Flomenberg held 1,333,225 RSUs
that had vested but had not yet been settled into shares of Common Stock.</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computed
    by multiplying the closing price of $1.03</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> per
    share of the Common Stock on December 31, 2024 by the number of RSUs.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Anti-Hedging and Anti-Pledging Policy</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Under our Insider
Trading Policy, our directors, officers, and employees are prohibited from engaging in the following transactions at any time: (i)&#160;short-term
trading of our securities; (ii)&#160;short sales of our securities; (iii)&#160;transactions in put options, call options, or other derivative
securities, on an exchange or in any other organized market; (iv)&#160;hedging or monetization transactions, including through the use
of financial instruments such as prepaid variable forward contracts, equity swaps, collars, and exchange funds or other transactions
which hedge or offset, or are designed to hedge or offset, any decrease in the market value of our securities; (v)&#160;holding our securities
in a margin account or otherwise pledging our securities as collateral for a loan; and (vi)&#160;standing and limit orders, unless the
order is limited to a short duration and otherwise complies with certain other restrictions and procedures outlined in our Insider Trading
Policy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Policies and Practices Related to the Grant
of Certain Equity Awards</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">While we do
not have any formal policy or practice with respect to the timing of awards of stock options, stock appreciation rights (&#8220;SARs&#8221;), or similar
option-like instruments, we have never granted such awards. We have not timed the disclosure of material non-public information for
the purpose of affecting the value of executive compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Equity</b><b> Compensation Plan Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">The following
table provides information as of December 31, 2024 with respect to the shares of the Company&#8217;s Common Stock that may be
issued under the Company&#8217;s existing compensation plans.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Plan category</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of securities to be issued
    upon exercise of outstanding options, warrants and rights</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-average exercise price
    of outstanding options, warrants and rights</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of securities remaining available
    for future issuance under equity compensation plans (1)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Equity compensation plans approved by security holders</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">10,670,118</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Equity compensation plans not approved by security holders</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Totals</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,670,118</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Consists of shares available for future issuance under
    our 2024 Plan. The number of shares available for issuance under the 2024 Plan increases annually on January 1 of each calendar year
    (beginning in 2025 and ending in 2034) by an amount equal to the lesser of (i) a number of shares of Common Stock equal to 5.0% of
    the total number of shares of Common Stock outstanding as of the last day of the immediately preceding calendar year, or (ii) such
    lesser number of shares of Common Stock as determined by the Board.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"/></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Director Compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">The following
table provides information regarding compensation granted to our directors during the fiscal year ended December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-size: 10pt"><b>Name <sup>(1)</sup></b></span></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Stock
    Awards ($) <sup>(2) (3)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Jeffrey Feike</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">239,040</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">239,040</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Keow Lin Goh</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">239,040</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">239,040</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Curtis Patton</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">239,040</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">239,040</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Susan Podlogar</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">239,040</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">239,040</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Victor Sordillo</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">478,080</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">478,080</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Dr. Saadi receives no
    additional compensation for his service as a director. Suren Ajjarapu, who served as a non-employee director until August 21, 2024, was not granted any compensation for the fiscal year ended December 31, 2024.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Reflects, with respect to
    each non-employee director, an award of 240,000 RSUs granted on December 21, 2024, which vest ratably in four equal annual
    installments beginning on January 1, 2025 subject to each grantee&#8217;s continued service, except that Mr. Sordillo was granted an
    additional 240,000 RSUs on December 20, 2024, which vested immediately, in recognition of the value of his past service on the Board
    (collectively, the &#8220;December RSUs&#8221;). Amounts in this column represent grant date fair value computed in accordance with
    ASC 718 based on the closing price of our Common Stock on the applicable grant date. See our discussion of &#8220;<i>Stock-Based
Compensation</i>&#8221; under Note 11 to our audited consolidated financial statements included in the 2024 Form 10-K for a discussion
of all assumptions made by us in determining the grant date fair values of our equity awards. See also our discussion of stock-based compensation
under &#8220;<i>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Critical Accounting
Policies and Estimates</i>&#8221; in the 2024 Form 10-K.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">The following table provides
    information regarding the stock awards granted to our non-employee directors that were outstanding as of December 31, 2024:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Name</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>RSUs
    (#) <sup>(1)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Jeffrey Feike</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">240,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dr. Keow Lin Goh</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">240,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dr. Curtis Patton</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">240,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Susan Podlogar</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">240,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Victor Sordillo</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">286,058</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">The numbers in the table
    above reflect, with respect to each non-employee director, the December RSUs, and, with respect to Mr. Sordillo, an award of 19,000
    RSUs of Tevogen Bio granted on January 5, 2023, of which 38,382, adjusted to reflect the Exchange Ratio and expressed in shares of
    Common Stock, remained unvested and 7,676 had vested but not yet been settled into shares of Common Stock as of December 31,
    2024. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 107; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity
Incentive Plan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described in more detail below, certain notable features of the 2024 Plan include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">granting
    of options and SARs only at a per share exercise price at least equal to the fair market value of a share of our Common Stock
    on the grant date;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">granting
    of options with a ten-year maximum term;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">awards
    are subject to potential clawback, forfeiture, repayment or other similar action pursuant to any clawback policy adopted by us or
    an affiliate or applicable law;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    liberal share recycling;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    payment of dividends or dividend equivalent rights on options or SARs, and no current payment of dividends or dividend equivalent
    rights on unvested performance-based awards; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    repricing of options or SARs without prior stockholder approval.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
of the Material Terms of the 2024 Plan </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Purpose
and Eligibility</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purpose of the 2024 Plan is (i) to provide eligible persons with an incentive to contribute to our success and to operate and manage
our business in a manner that will provide for our long-term growth and profitability and that will benefit our stockholders and other
important stakeholders, including our employees and customers, and (ii) to provide a means of recruiting, rewarding, and retaining key
personnel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity
awards may be granted under the 2024 Plan to officers, directors, including non-employee directors, other employees, advisors, consultants
or other service providers of the Company or our subsidiaries or other affiliates, and to any other individuals who are approved by the
Committee (as defined below) as eligible to participate in the 2024 Plan. Only our employees or employees of our corporate subsidiaries
are eligible to receive incentive stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Administration,
Amendment and Termination</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2024 Plan generally is administered by a committee composed of not fewer than two directors designated by the Board, each of whom must
be a &#8220;non-employee director&#8221; and satisfy the composition requirements under the listing rules of Nasdaq (the &#8220;Committee&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
where the authority to act on such matters is specifically reserved to the Board under the 2024 Plan or applicable law, the Committee
has full power and authority to interpret and construe all provisions of the 2024 Plan, any award, and any award agreement, and take
all actions and to make all determinations required or provided for under the 2024 Plan, any award, and any award agreement, including
the authority to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">designate
    grantees of awards;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determine
    the type or types of awards to be made to a grantee;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determine
    the number of shares of our Common Stock subject to an award or to which an award relates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish
    the terms and conditions of each award;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">prescribe
    the form of each award agreement;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject
    to limitations in the 2024 Plan (including the prohibition on repricing of options or share appreciation rights without stockholder
    approval), amend, modify, or supplement the terms of any outstanding award; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">make
    substitute awards.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 108; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board also is authorized to appoint one or more committees of the Board consisting of one or more directors who need not meet the independence
requirements above for certain limited purposes permitted by the 2024 Plan, and to the extent permitted by applicable law, the Committee
is authorized to delegate authority to our Chief Executive Officer and/or any other officers for certain limited purposes permitted
by the 2024 Plan. The Board will retain the authority under the 2024 Plan to exercise any or all of the powers and authorities related
to the administration and implementation of the 2024 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board may amend, suspend, or terminate the 2024 Plan at any time; provided that with respect to awards that are granted under the 2024
Plan, no amendment, suspension or termination may materially impair the rights of the award holder without such holder&#8217;s consent.
No such action may amend the 2024 Plan without the approval of stockholders if the amendment is required to be submitted for stockholder
approval by the Board, the terms of the 2024 Plan, or applicable law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Awards</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Awards
under the 2024 Plan may be made in the form of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">stock
    options, which may be either incentive stock options or nonqualified stock options;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SARs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restricted
    stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">RSUs;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">deferred
    stock units;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unrestricted
    stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">dividend
    equivalent rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance
    awards, including performance shares;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    equity-based awards; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cash.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
incentive stock option is an option that meets the requirements of Section 422 of the  Code,  and a nonqualified stock option is an option that does not meet those requirements. A SAR is a right to receive
upon exercise, in the form of stock, cash or a combination of stock and cash, the excess of the fair market value of one share of Common
Stock on the exercise date over the exercise price of the SAR. Restricted Stock is an award of Common Stock subject to restrictions
over restricted periods that subject the shares of Common Stock to a substantial risk of forfeiture, as defined in Section 83 of the
Code. An RSU or deferred stock unit is an award that represents a conditional right to receive shares of Common Stock in the future
and that may be made subject to the same types of restrictions and risk of forfeiture as restricted stock. Unrestricted shares are shares
of Common Stock free of restrictions other than those imposed under federal or state securities law. Dividend equivalent rights are awards
entitling the grantee to receive cash, shares of Common Stock, other awards under the 2024 Plan or other property equal in value to dividends
or other periodic payments paid or made with respect to a specified number of shares of Common Stock. Performance awards are awards made
subject to the achievement of one or more performance goals over a performance period established by the Committee. Other equity-based
awards are awards representing a right or other interest that may be denominated or payable in, valued in whole or in part by reference
to, or otherwise based on or related to stock, other than an option, SAR, restricted stock, RSU, unrestricted stock, dividend
equivalent right, or a performance award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2024 Plan provides that each award will be evidenced by an award agreement, which may specify terms and conditions of the award that
differ from the terms and conditions that would otherwise apply under the 2024 Plan in the absence of the different terms and conditions
in the award agreement. In the event of any inconsistency between the 2024 Plan and an award agreement, the provisions of the 2024 Plan
will control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 109; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Awards
under the 2024 Plan may be granted alone or in addition to, in tandem with, or in substitution or exchange for any other award under
the 2024 Plan, other awards under another compensatory plan of the Company or any of our affiliates (or any business entity that has
been a party to a transaction with us or any of our affiliates), or other rights to payment from us or any of our affiliates. Awards
granted in addition to or in tandem with other awards may be granted either at the same time or at different times.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Committee may permit or require the deferral of any payment pursuant to any award into a deferred compensation arrangement, which may
include provisions for the payment or crediting of interest or dividend equivalent rights, in accordance with rules and procedures established
by the Committee. Awards under the 2024 Plan generally will be granted for no consideration other than past services by the grantee of
the award or, if provided for in the award agreement or in a separate agreement, the grantee&#8217;s promise to perform future services
to us or one of our subsidiaries or other affiliates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Forfeiture;
Clawback</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may reserve the right in an award agreement to cause a forfeiture of the gain realized by a grantee with respect to an award on account
of actions taken by, or failed to be taken by, such grantee in violation or breach of, or in conflict with, any employment agreement,
non-competition agreement, agreement prohibiting solicitation of our employees or clients or employees or clients of any affiliate, confidentiality
obligations with respect to us or any affiliate, or otherwise in competition with us or any affiliate, to the extent specified in such
award agreement. If the grantee is an employee and is terminated for &#8220;Cause&#8221; (as defined in the 2024 Plan), the Committee
may annul the grantee&#8217;s award as of the date of the grantee&#8217;s termination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, any award granted pursuant to the 2024 Plan will be subject to mandatory repayment by the grantee to us to the extent (i) set
forth in the 2024 Plan or in an award agreement, or (ii) the grantee is or becomes subject to any clawback policy or compensation recovery
policy or such other similar policy of us or an affiliate, or any applicable laws which impose mandatory recoupment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Shares
Subject to the 2024 Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to adjustment as described below,  the maximum number of shares of Common Stock reserved for issuance under the 2024 Plan is equal
to the sum of (a) 40,000,000 shares of Common Stock plus (b) an annual increase as of the first business day of each calendar year, for
a period of not more than ten (10) years and starting with the 2025 calendar year, in an amount equal to the lesser of (i) a number of
shares of Common Stock equal to 5.0% of the total number of shares of Common Stock outstanding as of the last day of the immediately
preceding calendar year, or (ii) such lesser number of shares of Common Stock as determined by the Committee. In addition, in connection with mergers, reorganizations, separations, and certain other transactions in which awards
previously granted under a compensatory plan of another business entity that is a party to such transaction are assumed or replaced with
substitute awards, the maximum number of shares of Common Stock reserved for issuance under the 2024 Plan will increase by the number
of shares of Common Stock subject to such assumed awards and substitute awards, including the 10,900,128 shares subject to the Rollover
RSU awards. The maximum number
of shares of Common Stock available for issuance pursuant to incentive stock options granted under the 2024 Plan is the same as the total
number of shares of Common Stock reserved for issuance under the 2024 Plan. Shares of Common Stock issued under the 2024 Plan may be
authorized and unissued shares of Common Stock, or treasury shares of Common Stock, or a combination of the foregoing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
shares of Common Stock covered by an award, or portion of an award, granted under the 2024 Plan that are not purchased or forfeited or
canceled, or expire or otherwise terminate without the issuance of shares of Common Stock or are settled in cash in lieu of shares of
Common Stock, will again be available for issuance under the 2024 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
of Common Stock subject to an award granted under the 2024 Plan are counted against the maximum number of shares of Common Stock reserved
for issuance under the 2024 Plan as one share for every one share subject to such an award. In addition, at least the target number of
shares of Common Stock issuable under a performance award is counted against the maximum number of shares of Common Stock reserved for
issuance under the 2024 Plan as of the grant date, but such number is adjusted to equal the actual number of shares of Common Stock issued
upon settlement of the performance award to the extent different from such number initially counted against the share reserve.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares of Common Stock available for issuance under the 2024 Plan is not increased by the number of shares of Common Stock:
(i) tendered or withheld or subject to an award surrendered in connection with the purchase of shares of Common Stock upon exercise of
an option; (ii) that were not issued upon the net settlement or net exercise of a stock-settled SAR; (iii) deducted or delivered from
payment of an award in connection with our tax withholding obligations; or (iv) purchased by us with proceeds from option exercises.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 110; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Options</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2024 Plan authorizes the Committee to grant incentive stock options (under Section 422 of the Code) and options that do not qualify as
incentive stock options. An option granted under the 2024 Plan is exercisable only to the extent that it is vested. Each option becomes
vested and exercisable at such times and under such conditions as the Committee may approve consistent with the terms of the 2024 Plan.
No option may be exercisable more than ten years after the option grant date, or five years after the option grant date in the case of
an incentive stock option granted to a &#8220;ten percent stockholder&#8221; (as defined in the 2024 Plan); provided that, to the extent
deemed necessary or appropriate by the Committee to reflect differences in local law, tax policy, or custom with respect to any option
granted to a grantee who is a foreign national or is a natural person who is employed outside of the United States, such option may terminate,
and all rights to purchase shares of Common Stock thereunder may cease, upon the expiration of a period longer than ten (10)
years from the date of grant of such option as the Committee shall determine. The Committee may include in the option agreement provisions
specifying the period during which an option may be exercised following termination of the grantee&#8217;s service. The exercise price
of each option is determined by the Committee, provided that the per share exercise price will be equal to or greater than 100% of the
fair market value of a share of Common Stock on the grant date (other than as permitted for substitute awards). If we were to grant incentive
stock options to any ten percent stockholder, the per share exercise price would not be less than 110% of the fair market value of a
share of Common Stock on the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incentive
stock options and nonqualified stock options are generally non-transferable, except for transfers by will or the laws of descent and
distribution. The Committee may, in its discretion, determine that a nonqualified stock option may be transferred to family members by
gift or other transfers deemed not to be for value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Share
Appreciation Rights</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2024 Plan authorizes the Committee to grant SARs that provide the recipient with the right to receive, upon exercise of the SAR, cash,
Common Stock, or a combination of the two. The amount that the recipient receives upon exercise of the SAR generally equals the excess
of the fair market value of shares of Common Stock on the date of exercise over the fair market value of shares of Common Stock on the
grant date. SARs become exercisable in accordance with terms determined by the Committee. SARs may be granted in tandem with an option
grant or independently from an option grant. The term of a SAR cannot exceed ten (10) years from the date of grant. The per share exercise
price of a SAR is no less than the fair market value of one share of Common Stock on the grant date of such SAR.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SARs
are nontransferable, except for transfers by will or the laws of descent and distribution. The Committee may determine that all or part
of a SAR may be transferred to certain family members of the grantee by gift or other transfers deemed not to be for value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fair
Market Value</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
so long as the Common Stock remains listed on Nasdaq, the fair market value of the Common Stock on an award&#8217;s grant date, or on
any other date for which fair market value is required to be established under the 2024 Plan, is the closing price of the Common Stock
as reported on Nasdaq on such date. If there is no such reported closing price on such date, the fair market value of the Common Stock
will be the closing price of the Common Stock as reported on such market on the next preceding date on which any sale of Common Stock
will have been reported.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Common Stock ceases to be listed on Nasdaq and is listed on another established national or regional stock exchange, or traded on
another established securities market, fair market value will similarly be determined by reference to the closing price of the Common
Stock on the applicable date as reported on such other stock exchange or established securities market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Common Stock ceases to be listed on Nasdaq or another established national or regional stock exchange, or traded on another established
securities market, the Committee will determine the fair market value of the Common Stock by the reasonable application of a reasonable
valuation method in a manner consistent with Section 409A of the Code.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 111; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>No
Repricing</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
in connection with a corporate transaction involving us (including, without limitation, any stock dividend, distribution (whether in
the form of cash, shares of common stock, other securities or other property), stock split, extraordinary dividend, recapitalization,
change in control, reorganization, merger, consolidation, split-up, spin-off, combination, repurchase or exchange of shares of common
stock or other securities or similar transaction), we may not, without obtaining stockholder approval, (a) amend the terms of outstanding
options or SARs to reduce the exercise price of such outstanding options or SARs, (b) cancel outstanding options or SARs in exchange
for, or in substitution of, options or SARs with an exercise price that is less than the exercise price of the original options or SARs,
or (c) cancel outstanding options or SARs with an exercise price above the current price of Common Stock in exchange for cash or other
securities, in each case, unless such action is (i) subject to and approved by our stockholders, or (ii) would not be deemed to be a
repricing under the rules of any stock exchange or securities market on which the Common Stock is listed or publicly traded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Restricted
Stock, Restricted Stock Units, and Deferred Stock Units</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2024 Plan authorizes the Committee to grant restricted stock, RSUs, and deferred stock units. Subject to the provisions of the
2024 Plan, the Committee determines the terms and conditions of each award of restricted stock, RSUs, and deferred stock units,
including the restricted period for all or a portion of the award, the restrictions applicable to the award, and the purchase price,
if any, for the shares of Common Stock subject to the award. The restrictions, if any, may lapse over a specified period of time or through
the satisfaction of conditions, in installments or otherwise, as the Committee may determine. A grantee of restricted stock has all of
the rights of a stockholder as to those shares of Common Stock, including, without limitation, the right to vote the shares of Common
Stock and receive dividends or distributions on the shares of Common Stock, except to the extent limited by the Committee. The Committee
may provide in an award agreement evidencing a grant of restricted stock that (a) cash dividend payments or distributions paid on restricted
stock will be reinvested in shares of Common Stock, which may or may not be subject to the same vesting conditions and restrictions as
applicable to such shares of restricted stock, or (b) any dividend payments or distributions declared or paid on shares of restricted
stock will only be made or paid upon satisfaction of the vesting conditions and restrictions applicable to such shares of restricted
stock. Dividend payments or distributions declared or paid on shares of restricted stock which vest or are earned based on the achievement
of performance goals do not vest unless such performance goals for such shares of restricted stock are achieved, and if such performance
goals are not achieved, the grantee of such shares of restricted stock promptly forfeits and, to the extent already paid or distributed,
repay to us such dividend payments or distributions. Grantees of RSUs and deferred stock units have no voting or dividend rights
or other rights associated with share ownership, although the Committee may award dividend equivalent rights on such units.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the restricted period, if any, when restricted stock, RSUs, and deferred stock units are non-transferable or forfeitable, a grantee
is prohibited from selling, transferring, assigning, pledging, exchanging, hypothecating, or otherwise encumbering or disposing of the
grantees&#8217; restricted stock, RSUs, and deferred stock units.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Unrestricted
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2024 Plan authorizes the Committee to grant unrestricted stock, free of any restrictions such as vesting requirements, in such amounts
and upon such terms as the Committee may determine. Unrestricted stock awards may be granted or sold in respect of past services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dividend
Equivalent Rights</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2024 Plan authorizes the Committee to grant dividend equivalent rights. Dividend equivalent rights may be granted independently or in
connection with the grant of any equity-based award, except that no dividend equivalent right may be granted in connection with, or related
to an option or SAR. Dividend equivalent rights may be paid currently (with or without being subject to forfeiture or a repayment obligation)
or may be deemed to be reinvested in additional shares of Common Stock or awards which may thereafter accrue additional dividend equivalent
rights (with or without being subject to forfeiture or a repayment obligation) and may be payable in cash, shares of Common Stock, or
a combination of the two. Dividend equivalent rights granted as a component of another award may (a) provide that such dividend equivalent
right will be settled upon exercise, settlement, or payment of, or lase of restriction on, such other award and that such dividend equivalent
will expire or be forfeited or annulled under the same conditions as such award or (b) contain terms and conditions which are different
from the terms and conditions of such other award, provided that dividend equivalent rights credited pursuant to a dividend equivalent
right granted as a component of another award which vests or is earned based on the achievement of performance goals will not vest unless
such performance goals for such underlying award are achieved, and if such performance goals are not achieved, the grantee of such dividend
equivalent right will promptly forfeit and, to the extent already paid or distributed, repay to us payments or distributions made in
connection with such dividend equivalent rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 112; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Performance
Awards</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2024 Plan authorizes the Committee to grant performance awards. The Committee determines the applicable performance period, the performance
goals, and such other conditions that apply to the performance award. Any performance measures may be used to measure the performance
of the Company and its subsidiaries and other affiliates as a whole or any business unit of us, our subsidiaries, and/or our affiliates
or any combination thereof, as the Committee may deem appropriate, or any performance measures as compared to the performance of a group
of comparable companies, or published or special index that the Committee deems appropriate. Performance goals may relate to our financial
performance or the financial performance of our operating units, the grantee&#8217;s performance, or such other criteria determined by
the Committee. If the performance goals are met, performance awards will be paid in cash, shares of Common Stock, other awards, or a
combination thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Equity-Based Awards</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2024 Plan authorizes the Committee to grant other types of stock-based awards under the 2024 Plan. The terms and conditions that apply
to other equity-based awards are determined by the Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Forms
of Payment</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise price for any option or the purchase price (if any) for restricted stock, vested RSUs, and/or vested deferred stock units
is generally payable (i) in cash or in cash equivalents acceptable to us, (ii) to the extent the award agreement provides, by the tender
(or attestation of ownership) of shares of Common Stock having a fair market value on the date of tender (or attestation) equal to the
exercise price or purchase price, (iii) to the extent permitted by law and to the extent permitted by the award agreement, through a
broker-assisted cashless exercise, or (iv) to the extent the award agreement provides and/or unless otherwise specified in an award agreement,
any other form permissible by applicable law, including net exercise or net settlement and service rendered to us or our affiliates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Change
in Capitalization</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Committee may adjust the terms of outstanding awards under the 2024 Plan to preserve the proportionate interests of the holders in such
awards on account of any recapitalization, reclassification, share split, reverse share split, spin-off, combination of shares, exchange
of shares, share dividend or other distribution payable in capital shares, or other increase or decrease in such shares effected without
receipt of consideration by us. The adjustments will include proportionate adjustments to (i) the number and kind of shares subject to
outstanding awards and (ii) the per share exercise price of outstanding options or SARs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Transaction
not Constituting a Change in Control</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are the surviving entity in any reorganization, merger, or consolidation of us with one or more other entities which does not constitute
a &#8220;change in control&#8221; (as defined in the 2024 Plan), any awards will be adjusted to pertain to and apply to the securities
to which a holder of the number of shares of Common Stock subject to such award would have been entitled immediately after such transaction,
with a corresponding proportionate adjustment to the per share price of options and SARs so that the aggregate price per share of each
option or SAR thereafter is the same as the aggregate price per share of each option or SAR subject to the option or SAR immediately
prior to such transaction. Further, in the event of any such transaction, performance awards (and the related performance measures if
deemed appropriate by the Committee) will be adjusted to apply to the securities that a holder of the number of Common Stock subject
to such performance awards would have been entitled to receive following such transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 113; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Effect
of a Change in Control in which Awards are not Assumed</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise provided in the applicable award agreement, in another agreement with the grantee, or as otherwise set forth in writing,
upon the occurrence of a change in control in which outstanding awards are not being assumed or continued, the following provisions will
apply to such awards, to the extent not assumed or continued:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immediately
                                            prior to the occurrence of such change in control, in each case with the exception of performance
                                            awards, all outstanding shares of restricted stock and all RSUs, deferred stock units,
                                            and dividend equivalent rights will be deemed to have vested, and all shares of Common Stock
                                            and/or cash subject to such awards will be delivered; and either or both of the following
                                            two actions will be taken:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 38.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
                                            least fifteen (15) days prior to the scheduled consummation of such change in control, all
                                            options and SARs outstanding will become immediately exercisable and will remain exercisable
                                            for a period of fifteen (15) days. Any exercise of an option or SAR during this fifteen (15)
                                            day period will be conditioned on the consummation of the applicable change in control and
                                            will be effective only immediately before the consummation thereof, and upon consummation
                                            of such change in control, the 2024 Plan and all outstanding but unexercised options and
                                            SARs will terminate, with or without consideration as determined by the Committee in its
                                            sole discretion; and/or</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Committee may elect, in its sole discretion, to cancel any outstanding awards of options,
                                            SARs, restricted stock, RSUs, deferred stock units, and/or dividend equivalent rights
                                            and pay or deliver, or cause to be paid or delivered, to the holder thereof an amount in
                                            cash or capital stock having a value (as determined by the Committee acting in good faith),
                                            in the case of restricted stock, RSUs, deferred stock units, and dividend equivalent
                                            rights (for shares of Common Stock subject thereto), equal to the formula or fixed price
                                            per share paid to holders of shares of Common Stock pursuant to such change in control and,
                                            in the case of options or SARs, equal to the product of the number of shares of Common Stock
                                            such subject to such options or SARs multiplied by the amount, if any, which (i) the formula
                                            or fixed price per share paid to holders of shares of Common Stock pursuant to such change
                                            in control exceeds (ii) the option price or SAR price applicable to such options or SARs.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 38.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
                                            performance awards, if less than half of the performance period has lapsed, such awards will
                                            be treated as though the target performance thereunder has been achieved. If at least half
                                            of the performance period has lapsed, such performance awards will be earned, as of immediately
                                            prior to but contingent on the occurrence of such change in control, based on the greater
                                            of (i) deemed achievement of target performance or (ii) determination of actual performance
                                            as of a date reasonably proximate to the date of consummation of the change in control as
                                            determined by the Committee, in its sole discretion.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
                                            Equity-Based Awards will be governed by the terms of the applicable award agreement.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Effect
of a Change in Control in which Awards are Assumed</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise provided in the applicable award agreement, in another agreement with the grantee, or as otherwise set forth in writing,
upon the occurrence of a change in control in which outstanding awards are being assumed or continued, the following provisions will
apply to such awards, to the extent not assumed or continued: The 2024 Plan and the options, SARs, restricted stock, RSUs, deferred
stock units, dividend equivalent rights, and other equity-based equity awards granted under the 2024 Plan will continue in the manner
and under the terms so provided in the event of any change in control to the extent that provision is made in writing in connection with
such change in control for the assumption or continuation of such awards, or for the substitution for such awards of new options, SARs,
restricted stock, RSUs, deferred stock units, dividend equivalent rights, and other equity-based awards relating to the capital
stock of a successor entity, or a parent or subsidiary thereof, with appropriate adjustment as to the number of shares of Common Stock
and exercise price of options and SARs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, a &#8220;change in control&#8221; means:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9675;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    transaction or series of related transactions whereby a person or group (with certain exceptions) becomes the beneficial owner of
    50% or more of the total voting power of our voting stock on a fully diluted basis;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9675;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">individuals
    who, as of the Effective Date, constitute the Board (together with any new directors whose election was approved by at least a majority
    of the members of the Board then in office), cease to constitute a majority of the members of the Board then in office;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9675;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    merger or consolidation involving us, other than any such transaction in which the holders of our voting stock immediately prior
    to the transaction own directly or indirectly at least a majority of the voting power of the surviving entity immediately after the
    transaction;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9675;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    sale of substantially all of our assets to another person or entity; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9675;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    consummation of a plan or proposal for the dissolution or liquidation of the Company.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 114; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="as_005"></span>CERTAIN
RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Our Related Person Transactions
Policy applies to any transaction where we are a participant, the aggregate amount involved may exceed $120,000, and a Related Person
has a direct or indirect material interest, other than transactions not required to be reported pursuant to Item 404(a) of Regulation
S-K. For this purpose, a &#8220;Related Person&#8221; is any director, executive officer, any beneficial owners of five percent or more
of our voting securities, and their immediate family members, as well as entities in which a Related Person is a partner or has a 5%
or greater beneficial interest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Under our Related Person
Transactions Policy, the Audit Committee (or any independent body) serves as the approval authority for related person transactions.
Any transaction that we intend to undertake with a related person will be submitted to either our Chief Financial Officer, who serves
as the compliance officer under the Related Person Transactions Policy, the Audit Committee (or any independent body), or the full Board.
If the compliance officer, the Audit Committee (or any independent body), or the Board becomes aware of a transaction with a related
person that has not been previously approved or previously ratified under the Related Person Transactions Policy that required such approval,
the transaction will be submitted promptly to the approval authority for review. The Audit Committee (or any independent body) will consider
all relevant available facts and circumstances, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">the
                                            materiality and character of the Related Person&#8217;s direct or indirect interest;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">the
                                            commercial reasonableness of the terms;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">any
                                            Company contractual obligations;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">the
                                            benefit or perceived benefit, or lack thereof, to the Company;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">the
                                            opportunity cost of alternate transactions; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">the
                                            actual or apparent conflict of interest of the Related Person.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Related Person Transactions</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><i><span style="text-decoration: underline">Lock-Up Agreements with the
Original Sponsor and SSVK</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">On November 3, 2021, Semper
Paratus entered into a letter agreement (the &#8220;Letter Agreement&#8221;) with the Original Sponsor and certain individuals party
thereto (the &#8220;Insiders&#8221;), pursuant to which, among other things, the Original Sponsor and each Insider agreed that the Class
B ordinary shares of Semper Paratus then held by the Original Sponsor would not be transferable or salable until the earlier of (A) one
year after the completion of the Business Combination or (B) the occurrence of certain events (the &#8220;Letter Agreement Lock-Up&#8221;)
and that the private placement units then held by the Original Sponsor would not be transferable or salable until 30 days after completion
of the Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">On January 30, 2023, the
Original Sponsor, holding all of the issued and outstanding Class B ordinary shares of Semper Paratus, elected to convert its Class B ordinary shares into Class A ordinary shares on a one-for-one basis.
As a result, 11,983,333 of the Company&#8217;s Class B ordinary shares were cancelled and 11,983,333 Class A ordinary shares were issued
to the Original Sponsor. The Original Sponsor agreed that all of the terms and conditions applicable to these shares set forth in the Letter Agreement would continue to apply to the Class A ordinary shares that these shares converted into,
including the Letter Agreement Lock-Up.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">On February 13, 2024, Semper
Paratus, the Original Sponsor, SSVK, and certain individuals party thereto entered into an Amendment to the Letter Agreement, which,
among other things, replaced the reference to &#8220;one year after completion of the initial business combination&#8221; in the Letter
Agreement Lock-Up with &#8220;six months after the completion of the initial business combination.&#8221; At the time of this transaction, SSVK was the beneficial owner of more than 5% of Semper Paratus&#8217;s common shares.
Suren Ajjarapu, managing member of SSVK, was a member of our Board until August 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 115; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Sale to SSVK</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">On May 4, 2023, Semper
Paratus, the Original Sponsor, and SSVK entered into the Sponsor Share Purchase Agreement, pursuant to which SSVK agreed
to purchase from the Original Sponsor 7,988,889 Class A ordinary shares and 1,000,000 private placement units, each consisting of
one Class A ordinary share and one-half of one redeemable warrant that was exercisable for one Class A ordinary share, for an aggregate
purchase price of $1.00. Additionally, SSVK agreed to assume the responsibilities and obligations of the Original Sponsor related
to Semper Paratus. Consequently, the parties to the Letter Agreement were updated to include SSVK and Semper Paratus&#8217;s officers
and directors. The transactions contemplated by the Sponsor Share Purchase Agreement closed on June 7, 2023, and the Original
Sponsor transferred the Class A ordinary shares and the private placement units to SSVK. We estimated the aggregate
fair values of the Class A non-redeemable ordinary shares, the private placement shares, and the 500,000 public warrants transferred
to be $3,515,111, $440,000, and $20,000, respectively, or $0.44 per share and $0.04 per warrant.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Subscription
Agreement Loans</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 3, 2023, Semper Paratus entered into a subscription agreement with the Original Sponsor and Polar Multi-Strategy
Master Fund (&#8220;Polar&#8221;) pursuant to which Polar agreed to make a cash contribution of $151,000 to the Original Sponsor
(the &#8220;Initial Capital Contribution&#8221;) on or prior to May 3, 2023, which was in turn loaned to Semper Paratus
to cover working capital expenses. In consideration for the Initial Capital Contribution, we issued 151,000 shares of Common Stock to
Polar at the Closing and Semper Paratus agreed to repay the cash contribution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 20, 2023, Semper Paratus entered into a second subscription agreement with SSVK and Polar, pursuant to which Polar
agreed to lend to SSVK, which would in turn be lent to Semper Paratus, an aggregate of $1,500,000 (the &#8220;Additional Capital
Commitment&#8221;) to cover working capital expenses. In consideration for the Additional Capital Commitment, we issued 1,500,000
shares of Common Stock to Polar at the Closing, and Semper Paratus agreed to repay the cash contribution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Sponsor
Advisory Services Fee</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">In June 2023, pursuant
to the Merger Agreement, Tevogen Bio agreed that at the Closing, it would pay $2.0 million to SSVK for advisory services (the &#8220;Sponsor
Advisory Services Fee&#8221;). Thereafter, in connection with the Closing and the Conversion Agreements (as described below), the Sponsor
Advisory Services Fee was reduced to $500,000. This amount was further reduced to $250,000 by reducing a repayment obligation of SSVK.
That repayment obligation arose from transactions in 2023 pursuant to which Semper Paratus transferred $250,000 to an affiliate of Mr.
Ajjarapu.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Consulting
Agreement with Judy Akhtar</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Judy
Akhtar, wife of our Chairperson and Chief Executive Officer and majority stockholder Ryan Saadi, entered into a consulting agreement
with Tevogen Bio pursuant to which she received a compensatory grant of RSUs in 2023 with an aggregate grant date fair value of $533,600
for advisory services provided to Tevogen Bio.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Consulting
with Mehtaphoric Consulting Inc</span>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mehtaphoric
Consulting Inc. (&#8220;Mehtaphoric&#8221;), a company controlled by Puja Mehta, daughter of our Chief Financial Officer and 5% stockholder
Kirti Desai, entered into a consulting agreement with Tevogen Bio pursuant to which Mehtaphoric received a compensatory grant of RSUs
in 2023 with an aggregate grant date fair value of $266,800 for information technology services provided to Tevogen Bio.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Sordillo
Equity Grant</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2023, Tevogen Bio granted Victor Sordillo, who is currently a member of the Board, RSUs for 19,000 shares of non-voting common stock
with a grant date fair value of $253,460 in anticipation of Mr. Sordillo&#8217;s joining the Tevogen Bio board of directors.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 116; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Conversion
Agreements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 14, 2024, Semper Paratus entered into Conversion Agreements with SSVK and Mr. Ajjarapu pursuant to which we issued an
aggregate of 174,000 shares of Common Stock in relation to services that were to have been provided to us and Tevogen Bio, at an effective
price of $10.00 per share of Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Amended
and Restated Registration Rights Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 3, 2021, Semper Paratus entered into a Registration and Shareholder Rights Agreement, pursuant to which the Original Sponsor,
Cantor Fitzgerald &amp; Co. (&#8220;Cantor&#8221;), and their permitted transferees, if any, were entitled to certain registration rights.
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 14, 2024, in connection with the Closing,
we entered into an amended and restated registration rights agreement (the &#8220;A&amp;R Registration Rights Agreement&#8221;)
with SSVK, the Original Sponsor, Dr. Saadi, Mr. Desai, Dr. Neal Flomenberg, our Chief Scientific Officer and Global R&amp;D Lead,
the Sponsor Holders (as defined therein), and Cantor. Pursuant to the A&amp;R Registration Rights Agreement, we agreed to use commercially
reasonable efforts to file a registration statement registering the resale of certain shares of Common Stock and warrants (the &#8220;Registrable
Securities&#8221;). In addition, at any time (after the expiration of any lock-up period) and from time to time after the shelf registration
statement has been declared effective, the Special Holders (as defined therein) holding at least a majority in interest of Registrable
Securities may request to sell all or any portion of their Registrable Securities in an underwritten offering that is registered pursuant
to the shelf registration statement (each, an &#8220;Underwritten Shelf Takedown&#8221;); provided that such Underwritten Shelf Takedown
meets certain requirements and that we shall not be obligated to effect more than one Underwritten Shelf Takedown during any twelve-month
period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>New
</i></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Lock-Up Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 14, 2024, in connection with the Closing, we entered into a lock-up agreement (the &#8220; Lock-Up Agreement&#8221;)
with SSVK, Mr. Ajjarapu, and Dr. Saadi (the &#8220;Locked-Up Parties&#8221;), pursuant to which each Locked-Up Party agreed
subject to specified exceptions not to transfer any securities they held until the earlier of (A) six months after the Closing
Date and (B)&#160;subsequent to the Business Combination, (x) if the closing price of the Common Stock equalled or exceeded
$12.00 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) for
any 20 trading days within any 30-trading day period commencing at least 150 days after the Business Combination, or (y) the date on
which we completed a liquidation, merger, share exchange, or other similar transaction that resulted in all of our stockholders
having the right to exchange their Common Stock for cash, securities, or other property. The Lock-Up Agreement has expired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 117; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Mittul Mehta Employment</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Mittul Mehta, son-in-law
of Mr. Desai, is employed as our Chief Information Officer and Head of Tevogen.AI. In 2024, Mr. Mehta had a base salary of $250,000 and
was awarded compensatory grants of RSUs with a grant date fair value of $505,763.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Series A Preferred Stock</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4pt; text-align: justify; text-indent: 17.6pt">On February 14, 2024,
we entered into that certain securities purchase agreement with the Patel Family,
pursuant to which the Patel Family agreed to purchase shares of our Series A Preferred Stock for an aggregate purchase price of
$8.0 million. On March 27, 2024, we entered into the Preferred Purchase Agreement. The shares of Series A Preferred Stock are convertible
into a total of 500,000 shares of Common Stock at the election of the holder. The Series A Preferred Stock is subject to a call right
providing us the right to call the stock if the volume weighted average price of the Common Stock for the 20 days prior to delivery of
the call notice is greater than $5.00 per share and in each case there is an effective resale registration statement on file covering
the underlying Common Stock. The Patel Family is associated with Dr. Manmohan Patel, who is a beneficial owner of more than 5% of the
Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Series A-1 Preferred Stock</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Pursuant to the Preferred
Purchase Agreement, the Patel Family agreed to purchase shares of our Series A-1 Preferred Stock for an aggregate purchase price
of $6.0 million. The shares of Series A-1 Preferred Stock will be convertible into a total of 600,000 shares of Common Stock at
the election of the holder. The Series A-1 Preferred Stock will be subject to a call right providing us the right to call the
stock if the volume weighted average price of the Common Stock for the 20 days prior to delivery of the call notice is greater than $5.00
per share and in each case there is an effective resale registration statement on file covering the underlying Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Series B Preferred Stock and Assignment and
Assumption Agreement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">In connection with the Closing,
Semper Paratus entered into an agreement as of February 14, 2024 with SSVK (the &#8220;Assignment and Assumption Agreement&#8221;), pursuant
to which Semper Paratus assigned to SSVK and SSVK agreed to assume certain liabilities and obligations, including liabilities and obligations
that would become liabilities and obligations of the Company as a result of the Business Combination, in the aggregate initial amount
of approximately $4.2 million, which amount was later reduced to approximately $3.6 million, in consideration for the issuance of Series
B Preferred Stock of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">On June 15, 2024, we entered
into that certain repurchase agreement with SSVK (the &#8220;Repurchase Agreement&#8221;), pursuant to which we repurchased and cancelled,
with immediate effect, the outstanding shares of our Series B Preferred Stock in exchange for (i) the reassignment to and reassumption
by us of the liabilities assigned under the Assignment and Assumption Agreement <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
(ii) the termination of the Assignment and Assumption Agreement, and SSVK released us from certain claims relating to the Repurchase
Agreement.</span></p>

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Series C Preferred Stock</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">On August 21, 2024, we entered
into a securities purchase agreement with the Patel Family, pursuant to which the Patel Family purchased 600 shares of our
Series C Preferred Stock  for an aggregate purchase price of $6.0 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">The shares of&#160;Series&#160;C
Preferred Stock are convertible at the election of the Patel Family, beginning six months after the date of issuance, into shares of
the Common Stock at a conversion price equal to the volume-weighted average price of the Common Stock for the 30 trading days immediately
prior to the exercise of the holder&#8217;s conversion option, subject to a floor price of $0.6172 and a beneficial ownership limitation
of 9.99% following conversion. The Series C Preferred Stock are subject to a call right providing us the right to call the stock at any
time after the fifth anniversary of the date of issuance. The Series C Preferred Stock are non-voting. The Series C Preferred Stock
carry an annual 7.5% cumulative dividend, compounded annually, beginning on October 25, 2024 and ending on the last business
day of the calendar quarter ending September 30, 2034. Dividends are payable in shares of Series C Preferred Stock
or, at our election, in cash. So long as the Series C Preferred Stock is outstanding, we will not, without the written
consent of the holders of 50.1% of the Series C Preferred Stock, amend, alter, or repeal any provision of our certificate of incorporation,
as amended (the &#8220;Charter&#8221;) or our bylaws (the &#8220;Bylaws&#8221;) in a manner adverse to the Series C Preferred
Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Loan Agreement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">On June 6, 2024, we entered
into the Loan Agreement, providing for (i) the Facility, pursuant to which the Patel Family agreed to lend the Company up to $36.0
million, and (ii) a contingent option for the Patel Family to purchase at least $14.0 million of Common Stock in the Optional
PIPE. Pursuant to the terms of the Loan Agreement, the Company issued to the Patel Family the Commitment Shares, subject to forfeiture
by the Patel Family of the Commitment Shares or an equal number of shares of Common Stock in the event the Patel Family fails to (i)
make a deposit under the Facility when due or (ii) pay the purchase price for the Optional PIPE within 30 days after the Threshold Price
Notice Date in the event the Company has satisfied all applicable closing conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Consulting Agreement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In December 2024, the Company
contracted with Dr. Manmohan Patel to provide advisory services to the Company in support of the Company&#8217;s manufacturing development,
including but not limited to identifying and developing real estate, establishing quality management processes, attracting and hiring
an executive to lead operations, providing medical advice, and addressing government affairs and regulatory matters. In exchange for
his consultation services, Dr. Patel was granted 6,000,000 RSUs, of which 2,000,000 vested immediately and 2,000,000 RSUs vested in each
of January 2025 and February 2025, with an aggregate grant date fair value of $5,976,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Grant from KRHP </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In January 2025, KRHP&#160;
granted the Company $2,000,000 to further the Company&#8217;s development of off-the-shelf, genetically unmodified precision T cell therapeutics
to treat infectious diseases and cancers.&#160;KRHP&#160;is affiliated with Dr. Patel&#8217;s spouse. KRHP has also committed to granting
the Company an additional $8,000,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>CD8 Agreement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">On April 16, 2025, we entered
into the MSA with CD8. Under the MSA, CD8 will provide us with access to specialized manufacturing facilities, including clean rooms
and laboratories, as well as related operational services to support the production of our cell therapy products. The specific details
for each project&#8212;including scope of work, costs, and timelines&#8212;will be set out in individual project work orders. CD8 is
associated with Dr. Patel.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 118; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="as_006"></span>PRINCIPAL
STOCKHOLDERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information regarding the beneficial ownership of Common Stock as of April 30, 2025, by:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
                                            person known by us to be the beneficial owner of more than 5% of the outstanding shares of
                                            Common Stock;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
                                            of our named executive officers and directors; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
                                            of our executive officers and directors as a group.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security
if they possess sole or shared voting or investment power over that security. Under those rules, beneficial ownership includes securities
that the individual or entity has the right to acquire, such as through the vesting of RSUs, within 60 days of April 30, 2025.
Shares subject to RSUs that vest within 60 days of April 30, 2025, are considered outstanding and beneficially owned by the person
holding such RSUs for the purpose of computing the percentage ownership of that person but are not treated as outstanding for the purpose
of computing the percentage ownership of any other person. Except as noted by footnote, and subject to community property laws where
applicable, based on the information provided to us, we believe that the persons and entities named in the table below have sole voting
and investment power with respect to all shares shown as beneficially owned by them.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
beneficial ownership of the Common Stock is based on 183,893,433 shares issued and outstanding as of April 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Name and Address of Beneficial Owner</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br/> Shares of<br/> Tevogen<br/> Common<br/> Stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic">5% Holders</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Manmohan Patel, MD</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">18,927,981</td><td style="width: 2%; text-align: left"><sup>(1)</sup></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">9.99</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Tevogen Directors and Named Executive Officers<sup>(2)</sup></i></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Ryan Saadi</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">118,446,583.322</td><td style="text-align: left"><sup>(3)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">64.41</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Kirti Desai</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,699,186</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.27</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Neal Flomenberg</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,232,003</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.76</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Jeffrey Feike</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">641,771</td><td style="text-align: left"><sup>(4)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Keow Lin Goh</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">313,923</td><td style="text-align: left"><sup>(4)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Curtis Patton</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,029,618</td><td style="text-align: left"><sup>(4)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Susan Podlogar</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">253,924</td><td style="text-align: left"><sup>(4)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Victor Sordillo</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">373,933</td><td style="text-align: left"><sup>(5)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">All Tevogen directors and executive officers as a group (9 individuals)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">134,960,559.322</td><td style="text-align: left"><sup>(6)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73.24</td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Less than 1%</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    500,000 shares issuable upon conversion of Series A Preferred Stock, 600,000 shares issuable upon conversion of Series A-1 Preferred
    Stock, and 4,475,851 shares issuable upon conversion of Series C Preferred Stock (after operation of a 9.99% beneficial ownership
    limitation) that is held by the Patel Family or that the Patel Family has the right to acquire within 60 days of April 30, 2025.
    Dr. Patel may be deemed to beneficially own the shares of Common Stock issuable upon conversion of the Preferred Stock as well as
    1,655,590 shares of Common Stock held by the Patel Family. The business address of the Patel Family and Dr. Patel is 5 Jennie Court,
    Cedar Grove, New Jersey 07009. Dr. Patel is the spouse of the managing member of the Patel Family.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    address of each of these individuals is c/o Tevogen Bio Holdings Inc., 15 Independence Boulevard, Suite #410, Warren, New
    Jersey 07059.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    193,923 shares of Common Stock held by Dr. Saadi&#8217;s wife.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    60,000 shares of Common Stock underlying RSUs that have vested but remain subject to settlement.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    67,676 shares of Common Stock underlying RSUs that have vested but remain subject to settlement.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    307,676 shares of Common Stock underlying RSUs that have vested but remain subject to settlement.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span>&#160;</p>


<!-- Field: Page; Sequence: 119; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="as_007"></span>REGISTERED
HOLDERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Registered Holders listed in the table below may from time to time offer and sell any or all of the shares of our Common Stock and Warrants
set forth below pursuant to this prospectus. When we refer to the &#8220;Registered Holders&#8221; in this prospectus, we refer to the
persons listed in the table below, and the pledgees, donees, transferees, assignees, successors, and other permitted transferees that
hold any of the Registered Holders&#8217; interest in the shares of Common Stock and Warrants after the date of this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth certain information provided by or on behalf of the Registered Holders concerning the Common Stock and Warrants
that may be offered from time to time by each Registered Holder pursuant to this prospectus. The Registered Holders identified below
may have sold, transferred, or otherwise disposed of all or a portion of their securities after the date on which they provided us with
information regarding their securities. Any changed or new information given to us by the Registered Holders, including regarding the
identity of, and the securities held by, each Registered Holder, will be set forth in a prospectus supplement or amendments to the registration
statement of which this prospectus is a part, if and when necessary. A Registered Holder may sell all, some or none of such securities
in this offering. See &#8220;<i>Plan of Distribution</i>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Percentage
ownership is based on 183,893,433 shares of Common Stock outstanding as of April 29, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than as described below or elsewhere in this prospectus, none of the Registered Holders has any material relationship with us or any
of our predecessors or affiliates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Beneficially<br/>
                                            Owned Prior to this<br/> Offering</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Securities <br/> to be <br/> Sold
    in <br/> this Offering</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Securities <br/> Beneficially <br/>
    Owned After this <br/> Offering (1)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Name of Registered Holder</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares of <br/> Common <br/> Stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares of <br/> Common <br/> Stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares of <br/> Common <br/> Stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Percentage</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Percentage</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left">Ian Adelson (2)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">16,150</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">16,150</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">16,150</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Ajjarapu Sandhya Revocable Trust (3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,874,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,874,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Estate of Basil Ben Baldanza (4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">169,264</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,758</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,758</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">163,506</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cantor Fitzgerald &amp; Co. (5)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Corbin ERISA Opportunity Fund, Ltd. (6)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">868,507</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">868,507</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,107</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">858,400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">858,400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Corbin Opportunity Fund, L.P. (7)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">305,151</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">305,151</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,551</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">301,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">301,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">FourWorld Event Opportunities, L.P. (8)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48,919</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48,919</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">569</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48,350</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48,350</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">FourWorld Global Opportunities Fund, Ltd. (9)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">244,495</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">244,495</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,845</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">241,650</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">241,650</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Game Boy Partners LLC (10)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,884</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,884</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,884</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Gregory Gooding (11)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,094</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">853</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">853</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,241</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Pouria Paul Jebely (12)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">76,039</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,303</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,303</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73,736</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Philippe J. Kurzweil (13)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,303</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,303</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,303</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">David Michael Magruder (14)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,015</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,015</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,015</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Marblegate Special Opportunities Master Fund, L.P. (15)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">334,598</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,382</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,382</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">323,216</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Millennium Trust Co LLC Custodian FBO Hooman Yazhari Traditional IRA (16)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,312</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">691</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">691</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,621</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Harold A Neu (17)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">206,433</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,150</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,150</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">190,283</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Parizad June Olver (18)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">76,039</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,303</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,303</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73,736</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Richard Peretz (19)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,455</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,455</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,455</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Jeffrey Rogers (20)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">921</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">921</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">921</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Sabona Investments Limited SA (21)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,884</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,884</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,884</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Peter Schwaikert (22)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">576</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">576</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">576</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Semper Paratus Sponsor LLC (23)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">SSVK Associates, LLC (24)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Bradley John Stewart (25)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">691</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">691</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">691</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">The Patel Family, LLP (26)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,250,288</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,455,590</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,794,698</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.6</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Less than 1%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumes
                                            that the Registered Holders sell all of their shares of Common Stock and Warrants offered
                                            pursuant to this prospectus.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 120; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Shares
                                            beneficially owned prior to this offering consist of 16,150 shares underlying
                                            warrants.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Sandhya
                                            and Suren Ajjarapu may be deemed to beneficially own these shares. Mr. Ajjarapu is the spouse
                                            of Sandjya Ajjarapu, Trustee of the trust, and is the managing member of SSVK and may be
                                            deemed to have beneficial ownership of the shares of Common Stock held directly by the trust
                                            and the Warrants held directly by SSVK. Mr. Ajjarapu disclaims
                                            any beneficial ownership of the reported shares other than to the extent of any pecuniary
                                            interest he may have therein, directly or indirectly.</td></tr>
                                                                                                           </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Shares
                                            beneficially owned prior to this offering include 5,758 shares underlying warrants. Mr. Baldanza
                                            was the Chief Executive Officer of Semper Paratus from April 2021 to June 2023.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            beneficially owned prior to this offering consist of 75,000 shares underlying warrants. Cantor
                                            Fitzgerald &amp; Co. (&#8220;CF&amp;CO&#8221;) is the record owner of the securities. The
                                            business address of CF&amp;CO is 110 East 59th Street, New York, NY 10022. Cantor Fitzgerald
                                            Securities (&#8220;CFS&#8221;) controls the managing general partner of CF&amp;CO. Cantor
                                            Fitzgerald, L.P. (&#8220;CFLP&#8221;) indirectly controls each of CFS and CF&amp;CO. CFLP
                                            is controlled by CF Group Management, Inc. (&#8220;CFGM&#8221;), which is its managing general
                                            partner. Mr. Howard Lutnick is the Chairman and Chief Executive Officer of CFGM and also
                                            the trustee of CFGM&#8217;s sole stockholder and therefore controls CFGM. As such, each of
                                            CFS, CFLP, CFGM and Mr. Lutnick may be deemed to have beneficial ownership of the securities
                                            directly held by CF&amp;CO. Each such entity or person disclaims any beneficial ownership
                                            of the reported shares other than to the extent of any pecuniary interest they may have therein,
                                            directly or indirectly.</span></p>
</td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    beneficially owned prior to this offering consist of 868,507 shares underlying warrants.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    beneficially owned prior to this offering consist of 305,151 shares underlying warrants.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    beneficially owned prior to this offering consist of 48,919 shares underlying warrants.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    beneficially owned prior to this offering consist of 244,495 shares underlying warrants.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    beneficially owned prior to this offering consist of 2,884 shares underlying warrants.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    beneficially owned prior to this offering include 853 shares underlying warrants.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    beneficially owned prior to this offering include 2,303 shares underlying warrants. Former director of Semper Paratus from
    April 2021 to June 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    beneficially owned prior to this offering consist of 2,303 shares underlying warrants. Former Chief Financial Officer of Semper Paratus
    from April 2021 to April 2022.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    beneficially owned prior to this offering consist of 2,015 shares underlying warrants.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    beneficially owned prior to this offering include 11,382 shares underlying warrants.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(16)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares beneficially owned prior to this offering include
    691 shares underlying warrants. Hooman Yazhari may be deemed to beneficially own these shares and also directly owns 10,000 shares
    of Common Stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(17)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares beneficially owned prior to this offering include
    16,150 shares underlying warrants.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(18)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    beneficially owned prior to this offering include 2,303 shares underlying warrants. Former director of Semper Paratus from November
    2021 to June 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(19)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    beneficially owned prior to this offering consist of 3,455 shares underlying warrants. Former Executive Chairman of Semper Paratus
    from April 2021 to June 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(20)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    beneficially owned prior to this offering consist of 921 shares underlying warrants. Former President of Semper Paratus from November
    2021 to April 2022 and Chief Financial Officer and President from April 2022 to June 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(21)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    beneficially owned prior to this offering consist of 2,884 shares underlying warrants.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(22)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    beneficially owned prior to this offering consist of 576 shares underlying warrants.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(23)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    beneficially owned prior to this offering consist of 7 shares underlying warrants. Former sponsor of Semper Paratus.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(24)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    beneficially owned prior to this offering consist of 500,000 shares underlying warrants. Mr. Ajjarapu is the managing member of SSVK
    and may be deemed to have beneficial ownership of the Warrants held directly by SSVK and the shares of Common Stock held directly
    by the trust. Mr. Ajjarapu disclaims any beneficial ownership of the reported shares other than to the extent of any pecuniary interest
    he may have therein, directly or indirectly.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(25)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    beneficially owned prior to this offering consist of 691 shares underlying warrants. Former director of Semper Paratus from November
    2021 to June 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(26)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    beneficially owned prior to this offering include 5,575,851 shares issuable upon conversion of Preferred Stock. Dr. Patel
    is the spouse of the managing member of The Patel Family, LLP. Dr. Patel also owns 11,677,693 shares of Common Stock directly.</span></td></tr>
  </table>

<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 121; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="as_008"></span>DESCRIPTION
OF OUR SECURITIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
following sets forth a summary of the material terms of our securities registered under Section 12 of the Securities Act, including certain
provisions of the law of the State of Delaware and the Company&#8217;s Charter, Bylaws, and certain warrant-related documents.
This summary is qualified by reference to the full text of the Charter, Bylaws, and warrant-related documents described herein, which
are exhibits to the report to which this exhibit is attached. We urge you to read each of the Charter, the Bylaws, and the warrant-related
documents described herein in their entirety for a complete description of the rights and preferences of our securities. The summary
below is also qualified by reference to the provisions of the General Corporation Law of the State of Delaware (the &#8220;DGCL&#8221;),
as applicable.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Charter authorizes the issuance of a total of 820,000,000 shares of capital stock, each with par value $0.0001 per share, consisting
of (a) 800,000,000 shares of Common Stock and (b) 20,000,000 shares of preferred stock. As of April 29, 2025, there were 183,893,433
shares of Common Stock outstanding held by approximately 78 stockholders of record.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Voting
Power</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise required by law or as otherwise provided in any preferred stock designation, the holders of Common Stock will possess all
voting power for the election of directors and all other matters submitted to a vote of stockholders. Generally, each holder of Common
Stock is entitled to one vote per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise required by law, holders of Common Stock, as such, will not be entitled to vote on any amendment to the Charter (including
any preferred stock designation) that relates solely to the rights, powers, preferences (or the qualifications, limitations or restrictions
thereof) or other terms of one or more outstanding series of preferred stock of the Company if the holders of such affected series of
preferred stock are entitled to vote on such amendment pursuant to the Charter (including any preferred stock designation) or pursuant
to the DGCL.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dividends</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to applicable law and the rights and preferences of any holders of any outstanding class or series of preferred stock of the
Company, holders of Common Stock will be entitled to receive dividends when, as and if declared by the Board, payable either in
cash, in property, or in shares of capital stock. All shares of Common Stock shall be of equal rank and shall be identical
with respect to rights to such dividends.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Liquidation,
Dissolution, and Winding Up</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
our voluntary or involuntary liquidation, dissolution, or winding up and after payment in full of our debts and other liabilities and
to any holders of preferred stock of the Company having liquidation preferences, if any, the holders of the shares of the Common Stock
shall be entitled to receive all the remaining assets of the Company available for distribution to our stockholders, ratably in
proportion to the number of shares of the Common Stock then issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preemptive
or Other Rights</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to applicable law and the preferential rights of any other class or series of stock, all shares of Common Stock will have equal dividend,
distribution, liquidation, and other rights, and will have no preference or appraisal rights, except for any appraisal rights provided
by the DGCL. Furthermore, subject to applicable law, holders of Common Stock will have no preemptive rights and there are no conversion,
sinking fund, or redemption rights, or rights to subscribe for any of our securities. The rights, powers, preferences, and privileges
of holders of Common Stock will be subject to those of the holders of any shares of preferred stock that the Board may authorize and
issue in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Election
of Directors</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board is divided into three classes, each of which generally serves for a term of three years with only one class of directors being
elected in each year. Directors are generally elected by a plurality of votes cast at a meeting of the stockholders at which a
quorum is present, and there is no cumulative voting with respect to the election of directors, with the result that the holders of more
than 50% of the shares voted for the election of directors can elect all of the directors and that the director nominees receiving the
highest number of votes will be elected at such a meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 122; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Charter provides that shares of preferred stock may be issued from time to time in one or more classes or series. The Board is authorized
to establish the voting rights, if any, designations, preferences, and relative, participating, optional, or other special rights of
the shares of such series, and the qualifications, limitations or restrictions thereof, applicable to the shares of each series of preferred
stock. The Board may, without stockholder approval, issue preferred stock with voting and other rights that could adversely affect
the voting power and other rights of the holders of Common Stock and could have anti-takeover effects. The ability of the Board to issue
preferred stock without stockholder approval could have the effect of delaying, deferring, or preventing a change of control of
the Company or the removal of existing management. We currently have 500 shares of Series A Preferred Stock and 600 shares of Series
C Preferred Stock issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="text-decoration: underline">Series
A Preferred Stock</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><b><i>Voting</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in">The
Series A Preferred Stock does not have any voting rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><b><i>Dividends</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in">Holders
of Series A Preferred Stock are entitled to receive dividends accruing daily on a cumulative basis at a fixed rate of 5% per annum per
share on the Series A Original Issue Price (as defined in the Certificate of Designation of Series A Preferred Stock of the Company),
automatically increasing by 2% every year that the Series A Preferred Stock remains outstanding (the &#8220;Series A Accruing Dividends&#8221;).
The Series A Accruing Dividends become payable when and if declared by the Board. The Series A Preferred Stock will also participate
on an as-converted basis in any regular or special dividends paid to holders of the Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><b><i>Liquidation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in">The
Series A Preferred Stock ranks senior to the Common Stock in liquidation priority. In the event of a liquidation of the Company, or certain
deemed liquidation events, the Series A is redeemable for a price equal to the greater of the Series A Original Issue Price plus all
Series A Accruing Dividends that are unpaid through the redemption date, or such amount that would have been payable had the Series A
converted into shares of Common Stock immediately before the liquidation or deemed liquidation event.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><b><i>Redemption</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in">Holders
of Series A Preferred Stock are not entitled to redeem their shares outside of the liquidation of the Company or the occurrence of a
deemed liquidation event. The Company is entitled to redeem that Series A Preferred Stock at a price equal to the Series A Original Issue
Price plus any Series A Accruing Dividends accrued but unpaid thereon, if the volume-weighted average price of the Common Stock exceeds
$5.00 per share for the twenty days immediately prior to our call election.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><b><i>Conversion</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in">Holders
of Series A Preferred Stock have the option to convert the Series A Preferred Stock into shares of Common Stock at a ratio equal to the
Series A Original Issue Price divided by the Series A Conversion Price, which is initially $4.00 per share and is subject to standard
antidilution adjustments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Series
C Preferred Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Voting</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series C Preferred Stock does not have any voting rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dividends</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series C Preferred Stock carries an annual&#160;7.5% cumulative dividend, compounded annually, beginning on October 25, 2024 and ending
on the last business day of the calendar quarter ending September 30, 2034 (the &#8220;Series C Accruing Dividends&#8221;). The Series
C Accruing Dividends are payable in shares of Series C Preferred Stock or, at the election of the Company, in cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Liquidation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series C Preferred Stock ranks subordinate to the Series A Preferred Stock and ranks senior to Common Stock in liquidation priority.
In the event of a liquidation of the Company, or certain deemed liquidation events, the Series C Preferred Stock is redeemable for a
price equal to the greater of the Series C Original Issue Price (as defined in the Certificate of Designation of Series C Preferred Stock
of the Company) plus all Series C Accruing Dividends that are unpaid through the redemption date, or such amount as would have been payable
had the Series C Preferred Stock converted into shares of Common Stock immediately before the liquidation or deemed liquidation event.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Redemption</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of Series C Preferred Stock are not entitled to redeem their shares outside of the liquidation of the Company or the occurrence
of a deemed liquidation event. The Company is entitled to redeem that Series C Preferred Stock at any time after the fifth anniversary
of issuance at a price equal to the Series C Original Issue Price plus any Series C Accruing Dividends accrued but unpaid thereon, subject
to the conversion right described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Conversion</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of Series C Preferred Stock will be convertible at the election of the holder, beginning six months after the date of issuance,
into shares of Common Stock at a conversion price equal to the volume-weighted average price of the Common Stock for the 30 trading days
immediately prior to the exercise of the holder&#8217;s conversion option, subject to a floor price of $0.6172 and a beneficial ownership limitation of 9.99% following conversion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"></p>

<!-- Field: Page; Sequence: 123; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dividends</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not paid any cash dividends on the Common Stock to date and do not intend to pay cash dividends in the foreseeable future. The payment
of cash dividends in the future will be dependent upon our revenue and earnings, if any, capital requirements, and general financial
condition. The payment of any cash dividends is within the discretion of the Board. Our ability to declare dividends may also be limited
by restrictive covenants pursuant to any debt financing agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain
Anti-Takeover Provisions of Delaware Law</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Classified
Board</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Charter provides that the Board is divided into three classes of directors, with the classes to be as nearly equal in number as possible,
and with each director serving a three-year term. As a result, approximately one-third of the Board is elected each year. The classification
of directors will have the effect of making it more difficult for stockholders to change the composition of the Board. Amending
the classified Board provisions requires approval by two-thirds (2/3) of the then-outstanding voting power.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Authorized
but Unissued Shares</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
authorized but unissued shares of Common Stock and preferred stock are available for future issuance without stockholder approval,
subject to any limitations imposed by the listing standards of Nasdaq. These additional shares may be used for a variety of corporate
finance transactions, acquisitions, and employee benefit plans. The existence of authorized but unissued and unreserved, Common Stock
and preferred stock could make more difficult or discourage an attempt to obtain control of the Company by means of a proxy contest,
tender offer, merger, or otherwise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stockholders</i></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>
Action; Special Meetings of Stockholders</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Charter provides that, subject to the rights of the holders of any series of preferred stock, any action required or permitted to be
taken by the stockholders must be effected at a duly called annual or special meeting of the stockholders and may not be
effected by any consent by such stockholders. As a result, a holder controlling a majority of our capital stock cannot amend the
Bylaws or remove directors without holding a meeting of stockholders called in accordance with the Bylaws. This restriction does
not apply to actions taken by the holders of any series of preferred stock to the extent expressly provided in the applicable preferred
stock designation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
the Charter provides that, subject to any special rights of the holders of preferred stock, special meetings of the stockholders
may only be called by the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<!-- Field: Page; Sequence: 124; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Advance
Notice Requirements for Stockholders Proposals and Director Nominations</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Bylaws provide that stockholders seeking to bring business before our annual meeting of stockholders, or to nominate candidates
for election as directors at our annual meeting of stockholders, must provide timely notice. To be timely, a stockholder&#8217;s
notice must be received by the Secretary at our principal executive offices not later than the close of business on the 90<sup>th</sup>
day nor earlier than the close of business on the 120<sup>th</sup> day before the anniversary date of the immediately preceding annual
meeting of stockholders. However, in the event that the annual meeting is more than 30 days before or more than 60 days after
such anniversary date (or if there has been no prior annual meeting), notice by the stockholder to be timely must be so delivered
not earlier than the close of business on the 120<sup>th</sup> day before the meeting and not later than the later of (x) the close of
business on the 90<sup>th</sup> day before the meeting or (y) the close of business on the 10<sup>th</sup> day following the day on which
public announcement of the date of the annual meeting is first made by us. The Bylaws also specify certain requirements as to the form
and content of a stockholders&#8217; notice. These provisions may preclude our stockholders from bringing matters before
our annual meeting of stockholders or from making nominations for directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Amendment
of Charter or Bylaws</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Bylaws may be amended or repealed by the Board or by the affirmative vote of the holders of a majority of the voting power of all of
the shares of our capital stock entitled to vote in the election of directors, voting as one class. The affirmative vote of the holders
of at least two-thirds (2/3) of the voting power of the then-outstanding shares of our capital stock entitled to vote generally in the
election of directors, voting together as a single class, is required to amend certain provisions of the Charter related to the classified
Board and limitation of liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Board
Vacancies</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
vacancy on the Board may be filled by a majority vote of the directors then in office, although less than a quorum, or by a sole remaining
director, subject to any special rights of the holders of preferred stock. Any director chosen to fill a vacancy will hold office until
the expiration of the term of the class for which he or she was elected and until the director&#8217;s successor is duly elected and
qualified or until their earlier resignation, removal from office, death, or incapacity. Except as otherwise provided by law, in the
event of a vacancy on the Board, the remaining directors may exercise the powers of the full Board until the vacancy is filled.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preferred
Directors</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Charter, during any period when the holders of one or more series of preferred stock have the separate right to elect additional
directors, the then-otherwise total authorized number of directors will automatically be increased by such number of directors that the
holders of any series of preferred stock have a right to elect. Whenever the holders of one or more series of preferred stock having
a separate right to elect additional directors cease to have such right, the terms of office of all preferred stock directors elected
by the holders of such series of preferred stock, and the total authorized number of directors, will be automatically reduced accordingly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Exclusive
Forum Selection</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Charter provides that (A) (i) any derivative action or proceeding brought on behalf of the Company, (ii) any action asserting a claim
of breach of a fiduciary duty owed by any current or former director, officer, other employee, or stockholder of the Company to
the Company or our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the DGCL, the Charter,
or the Bylaws (as either may be amended or restated) or as to which the DGCL confers jurisdiction on the Court of Chancery of the State
of Delaware or (iv) any action asserting a claim governed by the internal affairs doctrine of the law of the State of Delaware shall,
to the fullest extent permitted by law, be exclusively brought in the Court of Chancery of the State of Delaware or, if such court does
not have subject matter jurisdiction thereof, the federal district court of the State of Delaware; and (B) the federal district courts
of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities
Act. Under the Charter, these provisions may be waived by us at our discretion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 125; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exclusive forum provision in the Charter does not apply to suits brought to enforce any duty or liability created by the Exchange Act
or any other claim for which the federal courts have exclusive jurisdiction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we believe that these provisions benefit the Company by providing increased consistency in the application of Delaware law in the types
of lawsuits to which it applies, a court may determine that these provisions are unenforceable, and to the extent they are enforceable,
the provisions may have the effect of discouraging lawsuits against our directors and officers, although our stockholders will not be
deemed to have waived our compliance with federal securities laws and the rules and regulations thereunder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Section
203 of the DGCL</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to the provisions of Section 203 of the DGCL until the election to opt-out of Section 203 of the DGCL in the Charter becomes
effective 12 months from the date the Charter first became effective under the DGCL. In general, Section 203 prohibits a Delaware corporation
that is listed on a national securities exchange or held of record by more than 2,000 stockholders from engaging in a &#8220;business
combination&#8221; with an &#8220;interested stockholder&#8221; for a three-year period following the time that such stockholder
becomes an interested stockholder, unless the business combination is approved in a prescribed manner. A &#8220;business combination&#8221;
includes, among other things, certain mergers, asset or stock sales, or other transactions resulting in a financial benefit to the interested
stockholder. An &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns, or
did own within three years prior to the determination of interested stockholder status, 15% or more of the corporation&#8217;s
outstanding voting stock. Under Section 203, a business combination between a corporation and an interested stockholder is prohibited
unless it satisfies one of the following conditions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">before
    the stockholder became interested, the board of directors approved either the business combination or the transaction which
    resulted in the stockholder becoming an interested stockholder;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon
    consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested
    stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding
    for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee
    stock plans, in some instances; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
    or after the time the stockholder became interested, the business combination was approved by the board of directors of the
    corporation and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least two thirds
    (2/3) of the outstanding voting stock which is not owned by the interested stockholder.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
certain circumstances, Section 203 of the DGCL would make it more difficult for a person who would be an &#8220;interested stockholder&#8221;
to effect various business combinations with a corporation for a three-year period. This provision may encourage companies interested
in acquiring us to negotiate in advance with the Board because the stockholder approval requirement would be avoided if the Board
approves either the business combination or the transaction which results in the stockholder becoming an interested stockholder.
Section 203 of the DGCL also may have the effect of preventing changes in the Board and may make it more difficult to accomplish transactions
which stockholders may otherwise deem to be in their best interests.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Limitation
on Liability</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Charter provides that a director or officer shall not be personally liable to us or our stockholders for monetary damages for
breach of fiduciary duty as a director, except to the extent such exemption from liability or limitation thereof is not permitted under
the DGCL as the same exists or may hereafter be amended.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 126; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Indemnification
and Advancement of Expenses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Bylaws provide that our directors and officers are indemnified and advanced expenses by us to the fullest extent authorized or permitted
by the DGCL as it now exists or may in the future be amended. In addition, the Bylaws provide that our directors are not personally liable
to us or our stockholders for monetary damages for breaches of their fiduciary duty as directors to the fullest extent permitted
by the DGCL.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Bylaws also permit us to purchase and maintain insurance on behalf of any officer, director, employee, or agent of the Company for any
liability arising out of such person&#8217;s status as such, regardless of whether the DGCL would permit indemnification.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
provisions may discourage stockholders from bringing a lawsuit against our directors for breach of their fiduciary duty. These
provisions also may have the effect of reducing the likelihood of derivative litigation against directors and officers, even though such
an action, if successful, might otherwise benefit us and our stockholders. Furthermore, a stockholder&#8217;s investment
may be adversely affected to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these
indemnification provisions. We believe that these provisions, the insurance, and the indemnity agreements are necessary to attract and
retain talented and experienced directors and officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers, and controlling persons
pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the SEC such indemnification is
against public policy as expressed in the Securities Act and is, therefore, unenforceable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of April 29, 2025,
there were 17,974,978 warrants to purchase Common Stock outstanding held by 23 holders of record.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Public
Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
whole warrant entitles the registered holder to purchase one share of Common Stock at a price of $11.50 per share, subject to adjustment
as discussed below, at any time. Warrant holders may, until such time as there is an effective registration statement and during
any period when we shall have failed to maintain an effective registration statement, exercise warrants on a cashless basis pursuant
to the exemption provided by Section 3(a)(9) of the Securities Act, provided that such exemption is available. If that exemption, or
another exemption, is not available, holders will not be able to exercise their warrants on a cashless basis. In the event of such cashless
exercise, each holder would pay the exercise price by surrendering the warrants for that number of shares of Common Stock equal to the
quotient obtained by dividing (x) the product of the number of shares of Common Stock underlying the warrants, multiplied by the difference
between the exercise price of the warrants and the &#8220;fair market value&#8221; by (y) the fair market value. The
&#8220;fair market value&#8221; for this purpose means the average reported last sale price of the shares of Common Stock for the 10
trading days ending on the third trading day prior to the date on which the notice of exercise is sent to the warrant agent. The warrants
will expire five years after the completion of the Business Combination on February 14, 2029, at 5:00 p.m., New York City time,
or earlier upon redemption or liquidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Redemption
of warrants when the price per share of Common Stock equals or exceeds $18.00.</i> Once the warrants become exercisable, we may redeem
the outstanding warrants except as described herein with respect to the Private Placement Warrants:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    whole and not in part;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
    a price of $0.01 per warrant;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon
    a minimum of 30 days&#8217; prior written notice of redemption to each warrant holder; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if,
    and only if, the closing price of the Common Stock equals or exceeds $18.00 per share (as adjusted for adjustments to the number
    of shares issuable upon exercise or the exercise price of a warrant as described under &#8220;-<i>Anti-Dilution</i><i> Adjustments</i>&#8221;
    below) for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which we send
    the notice of redemption to the warrant holders.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 127; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will not redeem the warrants as described above unless a registration statement under the Securities Act covering the issuance of the
Common Stock issuable upon exercise of the warrants is then effective and a current prospectus relating to those shares of Common Stock
is available throughout the 30-day redemption period. If and when the warrants become redeemable by us, we may exercise our redemption
right even if we are unable to register or qualify the underlying securities for sale under all applicable state securities laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have established the last of the redemption criterion discussed above to prevent a redemption call unless there is at the time of the
call a significant premium to the warrant exercise price. If the foregoing conditions are satisfied and we issue a notice of redemption
of the warrants, each warrant holder will be entitled to their warrant prior to the scheduled redemption date. However, the price of
the Common Stock may fall below the $18.00 redemption trigger price (as adjusted for adjustments to the number of shares issuable upon
exercise or the exercise price of a warrant as described under &#8220;-Anti-dilution <i>Adjustments</i>&#8221; below) as well as
the $11.50 (for whole shares) warrant exercise price after the redemption notice is issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we call the warrants for redemption as described above, our management has the option to require all holders that wish to exercise warrants
to do so on a &#8220;cashless basis.&#8221; In determining whether to require all holders to exercise their warrants on a &#8220;cashless
basis,&#8221; our management would consider, among other factors, our cash position, the number of warrants that are outstanding and
the dilutive effect on our stockholders of issuing the maximum number of Common Stock issuable upon the exercise of our warrants.
In such event, each holder would pay the exercise price by surrendering the warrants for that number shares of Common Stock equal to
the lesser of (A) the quotient obtained by dividing (x) the product of the number of shares of Common Stock underlying the warrants,
multiplied by the excess of the fair market value of our shares of Common Stock over the exercise price of the warrants by (y) the fair
market value and (B) 0.361 per warrant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Redemption
of warrants when the price per share of Common Stock equals or exceeds $10.00.</i> Once the warrants become exercisable, we may redeem
the outstanding warrants except as described herein with respect to the Private Placement Warrants:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    whole and not in part;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
    a price of $0.10 per warrant upon a minimum of 30 days&#8217; prior written notice of redemption; provided that holders will be able
    to exercise their warrants on a cashless basis prior to redemption and receive that number of shares determined by reference to the
    table below, based on the redemption date and the &#8220;fair market value&#8221; of our Class A ordinary shares, except as otherwise
    described below; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if,
    and only if, the closing price of the Common Stock equals or exceeds $10.00 per public share (as adjusted for adjustments to the
    number of shares issuable upon exercise or the exercise price of a warrant as described under &#8220;-<i>Anti-dilution</i><i>
    Adjustments</i>&#8221; below) on the trading day prior to the date on which we send the notice of redemption to the warrant holders.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beginning
on the date the notice of redemption is given until the warrants are redeemed or exercised, holders may elect to exercise their warrants
on a cashless basis. The numbers in the table below represent the number of shares of Common Stock that a warrant holder will receive
upon such cashless exercise in connection with a redemption by us pursuant to this redemption feature, based on the &#8220;fair market
value&#8221; of the Common Stock on the corresponding redemption date (assuming holders elect to exercise their warrants and such warrants
are not redeemed for $0.10 per warrant), determined for these purposes based on volume weighted average price of the Common Stock for
the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants,
and the number of months that the corresponding redemption date precedes the expiration date of the warrants, each as set forth in the
table below. We will provide our warrant holders with the final fair market value no later than one business day after the 10-trading
day period described above ends.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 128; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="34" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair
    Market Value of Common Stock</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Redemption
    Date</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#8804;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#8805;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(period
    to expiration of warrants)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$10.00</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$11.00</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$12.00</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$13.00</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$14.00</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$15.00</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$16.00</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$17.00</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$18.00</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60
    months</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.261</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.281</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.297</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.311</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.324</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.337</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.348</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.358</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.361</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57
    months</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.257</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.277</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.294</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.310</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.324</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.337</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.348</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.358</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.361</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54
    months</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.252</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.272</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.291</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.307</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.322</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.335</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.347</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.357</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.361</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51
    months</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.246</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.268</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.287</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.304</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.320</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.333</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.346</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.357</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.361</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48
    months</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.241</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.263</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.283</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.301</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.317</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.332</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.344</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.356</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.361</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45
    months</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.235</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.258</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.279</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.298</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.315</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.330</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.343</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.356</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.361</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42
    months</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.228</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.252</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.274</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.294</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.312</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.328</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.342</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.355</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.361</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39
    months</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.221</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.246</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.269</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.290</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.309</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.325</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.340</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.354</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.361</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36
    months</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.213</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.239</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.263</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.285</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.305</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.323</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.339</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.353</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.361</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33
    months</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.205</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.232</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.257</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.280</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.301</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.320</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.337</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.352</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.361</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30
    months</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.196</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.224</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.250</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.274</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.297</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.316</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.335</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.351</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.361</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27
    months</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.185</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.214</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.242</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.268</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.291</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.313</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.332</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.350</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.361</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24
    months</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.173</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.204</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.233</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.260</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.285</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.308</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.329</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.348</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.361</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21
    months</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.161</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.193</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.223</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.252</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.279</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.304</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.326</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.347</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.361</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18
    months</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.146</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.179</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.211</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.242</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.271</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.298</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.322</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.345</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.361</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15
    months</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.130</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.164</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.197</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.230</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.262</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.291</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.317</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.342</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.361</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12
    months</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.111</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.146</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.181</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.216</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.250</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.282</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.312</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.339</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.361</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9
    months</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.090</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.125</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.162</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.199</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.237</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.272</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.305</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.336</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.361</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6
    months</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.065</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.099</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.137</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.178</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.219</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.259</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.296</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.331</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.361</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3
    months</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.034</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.065</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.150</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.197</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.243</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.286</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.326</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.361</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0
    months</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.042</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.115</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.179</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.233</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.281</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.323</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.361</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exact fair market value and redemption date may not be set forth in the table above, in which case, if the fair market value is between
two values in the table or the redemption date is between two redemption dates in the table, the number of shares of Common Stock to
be issued for each warrant exercised will be determined by a straight-line interpolation between the number of shares set forth for the
higher and lower fair market values and the earlier and later redemption dates, as applicable, based on a 365- or 366-day year, as applicable.
For example, if the volume weighted average price of the Common Stock for the 10 trading days ending on the third trading day prior to
the date on which the notice of redemption is sent to the holders of the warrants is $11.00 per share, and at such time there are 57
months until the expiration of the warrants, holders may choose to, in connection with this redemption feature, exercise their warrants
for 0.277 shares of Common Stock for each whole warrant. For an example where the exact fair market value and redemption date are not
as set forth in the table above, if the volume weighted average price of the Common Stock for the 10 trading days ending on the third
trading day prior to the date on which the notice of redemption is sent to the holders of the warrants is $13.50 per share, and at such
time there are 38 months until the expiration of the warrants, holders may choose to, in connection with this redemption feature, exercise
their warrants for 0.298 shares of Common Stock for each whole warrant. In no event will the warrants be exercisable on a cashless basis
in connection with this redemption feature for more than 0.361 shares of Common Stock per warrant (subject to adjustment). Finally, as
reflected in the table above, if the warrants are out of the money and about to expire, they cannot be exercised on a cashless basis
in connection with a redemption by us pursuant to this redemption feature, since they will not be exercisable for any shares of Common
Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
redemption feature differs from the typical warrant redemption features established by many other blank check companies, which typically
only provide for a redemption of warrants for cash when the trading price for their shares exceeds $18.00 per share for a specified period
of time. This redemption feature is structured to allow for all of the outstanding warrants to be redeemed when the shares of Common
Stock are trading at or above $10.00 per public share, which may be at a time when the trading price of Common Stock is below the exercise
price of the warrants. We have established this redemption feature to provide us with the flexibility to redeem the warrants without
the warrants having to reach the $18.00 per share threshold described above under &#8220;-<i>Redemption</i><i> of warrants when
the price per share of Common Stock equals or exceeds $18.00</i>&#8221; above. Holders choosing to exercise their warrants in connection
with a redemption pursuant to this feature will, in effect, receive a number of shares for their warrants based on an option pricing
model with a fixed volatility input as of the date of this prospectus. This redemption right provides us with an additional mechanism
by which to redeem all of the outstanding warrants, and therefore have certainty as to our capital structure as the warrants would no
longer be outstanding and would have been exercised or redeemed. We will be required to pay the applicable redemption price to warrant
holders if we choose to exercise this redemption right and it will allow us to quickly proceed with a redemption of the warrants if we
determine it is in our best interest to do so. As such, we would redeem the warrants in this manner when we believe it is in our best
interest to update our capital structure to remove the warrants and pay the redemption price to the warrant holders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 129; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
stated above, we can redeem the warrants when the shares of Common Stock are trading at a price starting at $10.00, which is below the
exercise price of $11.50, because it will provide certainty with respect to our capital structure and cash position while providing warrant
holders with the opportunity to exercise their warrants on a cashless basis for the applicable number of shares. If we choose to redeem
the warrants when the shares of Common Stock are trading at a price below the exercise price of the warrants, this could result in the
warrant holders receiving fewer shares of Common Stock than they would have received if they had chosen to wait to exercise their warrants
for shares of Common Stock if and when such shares of Common Stock were trading at a price higher than the exercise price of $11.50.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
fractional shares of Common Stock will be issued upon exercise. If, upon exercise, a holder would be entitled to receive a fractional
interest in a share, we will round down to the nearest whole number of the number of shares of Common Stock to be issued to the holder.
If, at the time of redemption, the warrants are exercisable for a security other than the shares of Common Stock pursuant to the warrant
agreement, the warrants may be exercised for such security. At such time as the warrants become exercisable for a security other than
the shares of Common Stock, the company (or surviving company) will use its commercially reasonable efforts to register under the Securities
Act the security issuable upon the exercise of the warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Redemption
Procedures</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
holder of a warrant may notify us in writing in the event it elects to be subject to a requirement that such holder will not have the
right to exercise such warrant, to the extent that after giving effect to such exercise, such person (together with such person&#8217;s
affiliates), to the warrant agent&#8217;s actual knowledge, would beneficially own in excess of 9.8% (or such other amount as a holder
may specify) of the Common Stock issued and outstanding immediately after giving effect to such exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Anti-dilution
Adjustments</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the number of outstanding shares of Common Stock is increased by a capitalization or share dividend payable in shares of Common Stock,
or by a split-up of shares or other similar event, then, on the effective date of such capitalization or share dividend, split-up or
similar event, the number of shares of Common Stock issuable on exercise of each warrant will be increased in proportion to such increase
in the outstanding shares of Common Stock. A rights offering made to all or substantially all holders of ordinary shares entitling holders
to purchase shares of Common Stock at a price less than the &#8220;historical fair market value&#8221; will be deemed
a share dividend of a number of shares of Common Stock equal to the product of (i) the number of shares of Common Stock actually sold
in such rights offering (or issuable under any other equity securities sold in such rights offering that are convertible into or exercisable
for shares of Common Stock) and (ii) one minus the quotient of (x) the price per shares of Common Stock paid in such rights offering
and (y) the historical fair market value. For these purposes, (i) if the rights offering is for securities convertible into or exercisable
for shares of Common Stock, in determining the price payable for shares of Common Stock, there will be taken into account any consideration
received for such rights, as well as any additional amount payable upon exercise or conversion and (ii) &#8220;historical fair market
value&#8221; means the volume weighted average price of shares of Common Stock as reported during the 10 trading day period ending on
the trading day prior to the first date on which the shares of Common Stock trade on the applicable exchange or in the applicable market,
regular way, without the right to receive such rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if we, at any time while the warrants are outstanding and unexpired, pay a dividend or make a distribution in cash, securities
or other assets to all or substantially all of the holders of shares of Common Stock, other than (a) as described above or (b) any cash
dividends or cash distributions which, when combined on a per share basis with all other cash dividends and cash distributions paid on
the shares of Common Stock during the 365-day period ending on the date of declaration of such dividend or distribution does not exceed
$0.50 (as adjusted to appropriately reflect any other adjustments and excluding cash dividends or cash distributions that resulted in
an adjustment to the exercise price or to the number of shares of Common Stock issuable on exercise of each warrant) but only with respect
to the amount of the aggregate cash dividends or cash distributions equal to or less than $0.50 per share, then the warrant exercise
price will be decreased, effective immediately after the effective date of such event, by the amount of cash and/or the fair market value
of any securities or other assets paid on each share of Common Stock in respect of such event.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 130; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the number of outstanding shares of Common Stock is decreased by a consolidation, combination, reverse share sub-division, or reclassification
of the shares of Common Stock or other similar event, then, on the effective date of such consolidation, combination, reverse share sub-division,
reclassification, or similar event, the number of shares of Common Stock issuable on exercise of each warrant will be decreased in proportion
to such decrease in outstanding shares of Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whenever
the number of shares of Common Stock purchasable upon the exercise of the warrants is adjusted, as described above, the warrant exercise
price will be adjusted by multiplying the warrant exercise price immediately prior to such adjustment by a fraction (x) the numerator
of which will be the number of shares of Common Stock purchasable upon the exercise of the warrants immediately prior to such adjustment
and (y) the denominator of which will be the number of shares of Common Stock so purchasable immediately thereafter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if (x) we issued additional shares of Common Stock or equity-linked securities for capital raising purposes in connection with
the Business Combination at an issue price or effective issue price of less than $9.20 per share (with such issue price or effective
issue price to be determined in good faith by the Board and, in the case of any such issuance to our initial shareholders or their affiliates,
without taking into account any founder shares held by our initial shareholders or such affiliates, as applicable, prior to such issuance)
(the &#8220;Newly Issued Price&#8221;), (y) the aggregate gross proceeds from such issuances represented more than 60% of the total equity
proceeds, and interest thereon, available for the funding of the Business Combination as of the Closing (net of redemptions), and (z)
the volume weighted average trading price of our Common Stock during the 20 trading day period starting on the trading day prior to the
Closing (such price, the &#8220;Market Value&#8221;) was below $9.20 per share, the exercise price of the warrants would be adjusted
(to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption
trigger price described above under &#8220;-<i>Redemption</i><i> of warrants when the price per shares of Common Stock equals
or exceeds $18.00</i>&#8221; would be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly
Issued Price, and the $10.00 per share redemption trigger price described above under <i>&#8220;-Redemption</i><i> of warrants
when the price per share of Common Stock equals or exceeds $10.00</i>&#8221; would be adjusted (to the nearest cent) to be equal
to the higher of the Market Value and the Newly Issued Price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
case of any reclassification or reorganization of the outstanding shares of Common Stock (other than those described above or that solely
affects the par value of such shares of Common Stock), or in the case of any merger or consolidation of us with or into another corporation
or entity (other than a consolidation or merger in which we are the continuing corporation and that does not result in any reclassification
or reorganization of our outstanding shares of Common Stock), or in the case of any sale or conveyance to another corporation or entity
of the assets or other property of us as an entirety or substantially as an entirety in connection with which we are dissolved, the holders
of the warrants will thereafter have the right to purchase and receive, upon the basis and upon the terms and conditions specified in
the warrants and in lieu of the shares of Common Stock immediately theretofore purchasable and receivable upon the exercise of the rights
represented thereby, the kind and amount of shares of Common Stock or other securities or property (including cash) receivable upon such
reclassification, reorganization, merger or consolidation, or upon a dissolution following any such sale or transfer, that the holder
of the warrants would have received if such holder had exercised their warrants immediately prior to such event. However, if such holders
were entitled to exercise a right of election as to the kind or amount of securities, cash, or other assets receivable upon such consolidation
or merger, then the kind and amount of securities, cash, or other assets for which each warrant will become exercisable will be deemed
to be the weighted average of the kind and amount received per share by such holders in such consolidation or merger that affirmatively
make such election, and if a tender, exchange, or redemption offer has been made to and accepted by such holders under circumstances
in which, upon completion of such tender or exchange offer, the maker thereof, together with members of any group (within the meaning
of Rule 13d-5(b)(1) under the Exchange Act) of which such maker is a part, and together with any affiliate or associate of such maker
(within the meaning of Rule 12b-2 under the Exchange Act) and any members of any such group of which any such affiliate or associate
is a part, own beneficially (within the meaning of Rule 13d-3 under the Exchange Act) more than 50% of the issued and outstanding shares
of Common Stock, the holder of a warrant will be entitled to receive the highest amount of cash, securities, or other property to which
such holder would actually have been entitled as a stockholder if such warrant holder had exercised the warrant prior to the expiration
of such tender or exchange offer, accepted such offer and all of the shares of Common Stock held by such holder had been purchased pursuant
to such tender or exchange offer, subject to adjustment (from and after the consummation of such tender or exchange offer) as nearly
equivalent as possible to the adjustments provided for in the warrant agreement. If less than 70% of the consideration receivable by
the holders of shares of Common Stock in such a transaction is payable in the form of shares in the successor entity that is listed for
trading on a national securities exchange or is quoted in an established over-the-counter market, or is to be so listed for trading or
quoted immediately following such event, and if the registered holder of the warrant properly exercises the warrant within thirty days
following public disclosure of such transaction, the warrant exercise price will be reduced as specified in the warrant agreement based
on the Black-Scholes value (as defined in the warrant agreement) of the warrant. The purpose of such exercise price reduction is to provide
additional value to holders of the warrants when an extraordinary transaction occurs during the exercise period of the warrants pursuant
to which the holders of the warrants otherwise do not receive the full potential value of the warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 131; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Private
Placement Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as described below, the Private Placement Warrants have terms and provisions that are identical to those of the public warrants described
above. The Private Placement Warrants (including the shares of Common Stock issuable upon exercise of the Private Placement Warrants)
are not redeemable by us so long as they are held by <span style="background-color: white">SSVK, the Original Sponsor, Cantor,</span> or their permitted transferees. <span style="background-color: white">SSVK, the Original Sponsor, Cantor,
or</span> their permitted transferees have the option to exercise the Private Placement Warrants on a cashless basis. If the Private Placement
Warrants are held by holders other than <span style="background-color: white">SSVK, the Original Sponsor, Cantor,</span> and their permitted transferees, the Private Placement
Warrants would be redeemable by us and exercisable by the holders on the same basis as the public warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
holders of the Private Placement Warrants elect to exercise them on a cashless basis, they would pay the exercise price by surrendering
their warrants for that number of shares of Common Stock equal to the quotient obtained by dividing (x) the product of the number of
shares of Common Stock underlying the warrants, multiplied by the excess of the &#8220;fair market value&#8221; over
the exercise price of the warrants by (y) the Sponsor fair market value. For these purposes, the &#8220;fair market value&#8221; shall
mean the average reported closing price of the shares of Common Stock for the 10 trading days ending on the third trading day prior to
the date on which the notice of warrant exercise is sent to the warrant agent. We have agreed that these warrants will be exercisable
on a cashless basis so long as they are held by <span style="background-color: white">SSVK, Original Sponsor, Cantor,</span> or their permitted transferees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Listing
of Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Common Stock and public warrants are currently listed on Nasdaq, under the symbols &#8220;TVGN&#8221; and &#8220;TVGNW,&#8221;
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>






<!-- Field: Page; Sequence: 132; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="as_009"></span>PLAN
OF DISTRIBUTION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Registered Holders will pay all incremental selling expenses relating to the sale of their shares of Common Stock and Warrants, including
underwriter&#8217;s commissions and discounts, brokerage fees, underwriting marketing costs, and all reasonable fees and expenses of
any legal counsel representing the Registered Holders, except that we will pay reasonable fees and expenses of one U.S. legal counsel
and local counsel in any other applicable jurisdiction(s) for the Registered Holders party to the A&amp;R Registration Rights
Agreement in the event of a demanded underwritten offering of their securities. We will bear all other costs, fees, and expenses
incurred in effecting the registration of the shares of Common Stock and Warrants covered by this prospectus, including, without limitation,
all registration and filing fees, printing and delivery fees, Nasdaq listing fees, and fees and expenses of our counsel and our accountants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of Common Stock and Warrants beneficially owned by the Registered Holders covered by this prospectus may be offered and sold from
time to time by the Registered Holders. The term &#8220;Registered Holders&#8221; includes donees, pledgees, transferees, or other successors
in interest selling securities received after the date of this prospectus from a Registered Holder as a gift, pledge, partnership distribution,
or other transfer. The Registered Holders will act independently of us in making decisions with respect to the timing, manner, and size
of each sale. Such sales may be made on one or more exchanges, including any exchange, market or trading facility on which the Common
Stock or Warrants are traded, including Nasdaq, or in the over-the-counter market or otherwise, at prices and under terms then prevailing
or at prices related to the then-current market price or in negotiated transactions. The Registered Holders may sell their shares of
Common Stock and Warrants by one or more of, or a combination of, the following methods:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">purchases
                                            by a broker-dealer as principal and resale by such broker-dealer for its own account pursuant
                                            to this prospectus;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ordinary
                                            brokerage transactions and transactions in which the broker solicits purchasers;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">block
                                            trades in which the broker-dealer so engaged will attempt to sell the shares as agent but
                                            may position and resell a portion of the block as principal to facilitate the transaction;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
                                            over-the-counter distribution in accordance with the rules of Nasdaq;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">through
                                            trading plans entered into by a Registered Holder pursuant to Rule 10b5-1 under the Exchange
                                            Act, that are in place at the time of an offering pursuant to this prospectus and any applicable
                                            prospectus supplement hereto that provide for periodic sales of their securities on the basis
                                            of parameters described in such trading plans;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            or through underwriters or broker-dealers;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            &#8220;at the market&#8221; offerings, as defined in Rule 415 under the Securities Act, at
                                            negotiated prices, at prices prevailing at the time of sale, or at prices related to such
                                            prevailing market prices, including sales made directly on a national securities exchange
                                            or sales made through a market maker other than on an exchange or other similar offerings
                                            through sales agents;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            privately negotiated transactions;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            options transactions;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">through
                                            a combination of any of the above methods of sale; or</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            other method permitted pursuant to applicable law.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, any shares that qualify for sale pursuant to Rule 144 may be sold under Rule 144 rather than pursuant to this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
Registered Holder that is an entity may elect to make an in-kind distribution of Common Stock to its members, partners, stockholders,
or other equityholders pursuant to the registration statement of which this prospectus forms a part by delivering a prospectus. To the
extent that such members, partners, stockholders, or other equityholders are not affiliates of ours, such members, partners, stockholders,
or other equityholders would thereby receive freely tradable shares of Common Stock pursuant to a distribution pursuant to the registration
statement of which this prospectus forms a part.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 133; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent required, this prospectus may be amended or supplemented from time to time to describe a specific plan of distribution. In
connection with distributions of the shares or otherwise, the Registered Holders may enter into hedging transactions with broker-dealers
or other financial institutions. In connection with such transactions, broker-dealers or other financial institutions may engage in short
sales of shares of Common Stock in the course of hedging the positions they assume with Registered Holders. The Registered Holders may
also sell shares of Common Stock short and redeliver the shares to close out such short positions. The Registered Holders may also enter
into option or other transactions with broker-dealers or other financial institutions that require the delivery to such broker-dealer
or other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial institution may
resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). The Registered Holders may also pledge shares
to a broker-dealer or other financial institution, and, upon a default, such broker-dealer or other financial institution, may effect
sales of the pledged shares pursuant to this prospectus (as supplemented or amended to reflect such transaction).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
Registered Holder may enter into derivative transactions with third parties, or sell securities not covered by this prospectus to third
parties in privately negotiated transactions. If the applicable prospectus supplement so indicates, in connection with those derivatives,
the third parties may sell securities covered by this prospectus and the applicable prospectus supplement, including in short sale transactions.
If so, the third party may use securities pledged by any Registered Holder or borrowed from any Registered Holder or others to settle
those sales or to close out any related open borrowings of stock, and may use securities received from any Registered Holder in settlement
of those derivatives to close out any related open borrowings of stock. The third party in such sale transactions will be an underwriter
and will be identified in the applicable prospectus supplement (or a post-effective amendment). In addition, any Registered Holder may
otherwise loan or pledge securities to a financial institution or other third party that in turn may sell the securities short using
this prospectus. Such financial institution or other third party may transfer its economic short position to investors in our securities
or in connection with a concurrent offering of other securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
effecting sales, broker-dealers or agents engaged by the Registered Holders may arrange for other broker-dealers to participate. Broker-dealers
or agents may receive commissions, discounts, or concessions from the Registered Holders in amounts to be negotiated immediately prior
to the sale.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
offering the securities covered by this prospectus, the Registered Holders and any broker-dealers who execute sales for the Registered
Holders may be deemed to be &#8220;underwriters&#8221; within the meaning of the Securities Act in connection with such sales. Any profits
realized by the Registered Holders and the compensation of any broker-dealer may be deemed to be underwriting discounts and commissions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to comply with the securities laws of certain states, if applicable, the securities must be sold in such jurisdictions only through
registered or licensed brokers or dealers. In addition, in certain states the securities may not be sold unless they have been registered
or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is
complied with.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have advised the Registered Holders that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of securities
in the market and to the activities of the Registered Holders and their affiliates. In addition, we will make copies of this prospectus
available to the Registered Holders for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The Registered
Holders may indemnify any broker-dealer that participates in transactions involving the sale of the securities against certain liabilities,
including liabilities arising under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 134; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the time a particular offer of securities is made, if required, a prospectus supplement will be distributed that will set forth the number
of securities being offered and the terms of the offering, including the name of any underwriter, dealer or agent, the purchase price
paid by any underwriter, any discount, commission and other item constituting compensation, any discount, commission or concession allowed
or reallowed or paid to any dealer, and the proposed selling price to the public.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
holder of Warrants may exercise its Warrants in accordance with the warrant agreement on or before the expiration date by surrendering,
at the office of the warrant agent, Continental Stock Transfer &amp; Trust Company, the certificate evidencing such Warrant, an election
to purchase, properly completed and duly executed, accompanied by full payment of the exercise price and any and all applicable taxes
due in connection with the exercise of the Warrant, subject to any applicable provisions relating to cashless exercises in accordance
with the warrant agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the A&amp;R Registration Rights Agreement, we have agreed to indemnify the Registered Holders party thereto against certain liabilities
that they may incur in connection with the sale of the securities registered hereunder, including liabilities under the Securities Act,
and to contribute to payments that the Registered Holders may be required to make with respect thereto. In addition, we and the Registered
Holders party to the A&amp;R Registration Rights Agreement have agreed to indemnify any underwriter against certain liabilities
related to the selling of the securities, including liabilities arising under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to maintain the effectiveness of the registration statement of which this prospectus is a part until (i) with respect to the shares of Common Stock issuable upon exercise of the Warrants, until the expiration of the Warrants
in accordance with the provisions of the warrant agreement, and (ii) with respect to the Registrable Securities under the A&amp;R
Registration Rights Agreement, the earlier of such time that (A) a registration statement with respect to the sale of such Registrable
Securities has become effective under the Securities Act and such Registrable Securities have been sold, transferred, disposed of or
exchanged in accordance with the plan of distribution set forth in such registration statement, (B) such Registrable Securities shall
have ceased to be issuable or outstanding, (C) such Registrable Securities have been sold to, or through, a broker, dealer or underwriter
in a public distribution or other public securities transaction, (D) such Registrable Securities shall have been otherwise transferred,
new certificates for them not bearing a legend restricting further transfer shall have been delivered by Company and subsequent public
distribution of them shall not require registration under the Securities Act and (E) the first date on which such Common Stock is able
to be sold without any volume restrictions under Rule 144 of the Securities Act .</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 135; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->127<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="as_010"></span>LEGAL
MATTERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
validity of the shares of Common Stock and Warrants offered hereby will be passed upon for us by Hogan Lovells US LLP, Baltimore, Maryland.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 136; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->128<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="as_011"></span>EXPERTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">The consolidated
financial statements of Tevogen Bio Holdings Inc., as of December 31, 2024 and 2023, and for the years then ended, have been
included herein and in the registration statement in reliance upon the report of KPMG LLP, independent registered public accounting
firm, appearing elsewhere herein, and upon the authority of said firm as experts in accounting and auditing. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 137; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->129<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="as_012"></span>WHERE
YOU CAN FIND MORE INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the shares of Common Stock and
Warrants offered hereby. This prospectus, which constitutes a part of the registration statement, does not contain all of the information
set forth in the registration statement or the exhibits and schedules filed therewith. For further information about us and the shares
of Common Stock and Warrants offered hereby, we refer you to the registration statement and the exhibits and schedules filed thereto.
Statements contained in this prospectus regarding the contents of any contract or any other document that is filed as an exhibit to the
registration statement are not necessarily complete, and each such statement is qualified in all respects by reference to the full text
of such contract or other document filed as an exhibit to the registration statement. We file periodic reports, proxy statements, and
other information with the SEC pursuant to the Exchange Act. The SEC maintains an Internet website that contains reports, proxy statements
and other information about registrants, like us, that file electronically with the SEC. The address of that site is <i>www.sec.gov</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 138; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->130<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="fin_001"></span>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="as_013"></span><b>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: justify; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 0.5in; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin_002">Report
    of Independent Registered Public Accounting Firm (KPMG LLP, Philadelphia, PA, Auditor Firm ID:</a> 185</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="#fin_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    Balance Sheets, December 31, 2024 and 2023</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="#fin_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    Statements of Operations, Years ended December 31, 2024 and 2023</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="#fin_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    Statements of Changes in Stockholders&#8217; Deficit, Years ended December 31, 2024 and 2023</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="#fin_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    Statements of Cash Flows, Years ended December 31, 2024 and 2023</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="#fin_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
    to Consolidated Financial Statements</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 139; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="fin_002"></span>Report
of Independent Registered Public Accounting Firm</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Stockholders and Board of Directors</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tevogen
Bio Holdings Inc.:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Opinion
on the Consolidated Financial Statements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of Tevogen Bio Holdings Inc. and subsidiaries (the Company) as of December
31, 2024 and 2023, the related consolidated statements of operations, changes in stockholders&#8217; deficit, and cash flows for the
years then ended, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial
statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the
results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Basis
for Opinion</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion
on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting
Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.
The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part
of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing
an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether
due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles
used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.
We believe that our audits provide a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
KPMG LLP</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Philadelphia,
Pennsylvania</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
2, 2025</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 140; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="fin_003"></span>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
BALANCE SHEETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_111_zNOiVjVr2Vjh" summary="xdx: Statement - Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: center; text-indent: 0pt">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20241231_zRixDaXw3Bzh" style="font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20231231_zgTL37f9Hirb" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: center; text-indent: 0pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AssetsAbstract_iB_zXKYkENpCu4e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; font-weight: bold; padding-left: 0pt">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AssetsCurrentAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; text-align: left; padding-left: 0pt">Current assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--Cash_i02I_pp0p0_maACzVF6_zWQi3aP8kOrc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-indent: 0pt; padding-left: 0.125in">Cash</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2024-12-31" id="Fact000047" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,282,995</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2023-12-31" id="Fact000048" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,052,397</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_pp0p0_maACzVF6_zyCHvau8Amd1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.125in">Prepaid expenses and other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000050" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">919,088</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000051" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">670,582</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OtherReceivablesNetCurrent_i02I_pp0p0_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_maACzW0w_maACzVF6_ziMFuhLyEgu7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 0pt; padding-left: 0.125in">Due from related party</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherReceivablesNetCurrent" contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember" id="Fact000053" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">158,819</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0054">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AssetsCurrent_i02TI_pp0p0_mtACzVF6_maAzJRK_zwX9rerrYStk" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; text-align: left; padding-left: 0pt">Total current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000056" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,360,902</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000057" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,722,979</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentNet_i01I_pp0p0_maAzJRK_zRNKJ8zuHbl3" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; text-align: left; padding-left: 0pt">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-12-31" id="Fact000059" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">296,442</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact000060" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">458,651</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_pp0p0_maAzJRK_z1CBk68BbuEg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; text-align: left; padding-left: 0pt">Right-of-use assets - operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-12-31" id="Fact000062" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">228,490</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-12-31" id="Fact000063" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">469,862</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredCosts_i01I_pp0p0_maAzJRK_zJvvHFFsWdhg" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; text-align: left; padding-left: 0pt">Deferred transaction costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0065">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredCosts" contextRef="AsOf2023-12-31" id="Fact000066" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,582,870</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OtherAssetsNoncurrent_i01I_pp0p0_maAzJRK_zVYKRunC6yO7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; text-align: left; padding-bottom: 1pt; padding-left: 0pt">Other assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2024-12-31" id="Fact000068" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">575,841</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2023-12-31" id="Fact000069" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">271,141</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--Assets_i01TI_pp0p0_mtAzJRK_z3hfZDMJ8in1" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt">Total assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31" id="Fact000071" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,461,675</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31" id="Fact000072" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,505,503</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; font-weight: bold; text-align: left; padding-left: 0pt">Liabilities and stockholders&#8217; deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesCurrentAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; text-align: left; padding-left: 0pt">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccountsPayableCurrent_i02I_pp0p0_maLCzRlS_zd5VkggZqIU" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.125in">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-12-31" id="Fact000080" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,200,245</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-12-31" id="Fact000081" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,418,378</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccruedLiabilitiesCurrent_i02I_pp0p0_maLCzRlS_z2PdMrCg00Lg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.125in">Accrued expenses and other liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000083" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,712,396</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000084" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,096,450</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_pp0p0_maLCzRlS_zTa67oIPUnac" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.125in">Operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-12-31" id="Fact000086" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">229,063</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-12-31" id="Fact000087" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">252,714</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NotesPayableCurrent_i02I_pp0p0_maLCzRlS_zMei7LPD0EQa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.125in">Notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2024-12-31" id="Fact000089" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,651,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0090">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ConvertibleNotesPayableCurrent_i02I_pp0p0_maLCzRlS_zUOC4Px1Y0B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.125in">Convertible promissory notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0092">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2023-12-31" id="Fact000093" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">80,712,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OtherLiabilitiesCurrent_i02I_pp0p0_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_maLCzRlS_zdguIIy88Peb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 0pt; padding-left: 0.125in">Due to related party</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember" id="Fact000095" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">250,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0096">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesCurrent_i02TI_pp0p0_mtLCzRlS_maLzUvu_zPIhUQ9htrR2" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; text-align: left; padding-left: 0pt">Total current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000098" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,042,704</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000099" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">85,479,542</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ConvertibleLongTermNotesPayable_i01I_pp0p0_maLzUvu_zNKuFSI49bAj" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; text-align: left; padding-left: 0pt">Convertible promissory notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0101">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ConvertibleLongTermNotesPayable" contextRef="AsOf2023-12-31" id="Fact000102" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">14,220,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--LoanAgreementNoncurrent_i01I_pp0p0_maLzUvu_zFaUxXlfhOvc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; text-align: left; padding-left: 0pt">Loan agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:LoanAgreementNoncurrent" contextRef="AsOf2024-12-31" id="Fact000104" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_pp0p0_maLzUvu_z9htFgx9Gxa3" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; text-align: left; padding-left: 0pt">Operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-12-31" id="Fact000107" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,796</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-12-31" id="Fact000108" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">234,858</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DerivativeLiabilitiesNoncurrent_i01I_pp0p0_maLzUvu_zbdnH2nKfKyf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; text-align: left; padding-bottom: 1pt; padding-left: 0pt">Derivative warrant liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="AsOf2024-12-31" id="Fact000110" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">87,180</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0111">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--Liabilities_i01TI_pp0p0_mtLzUvu_maLASEzTUz_zaj7FwVUcMKl" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; text-align: left; padding-bottom: 1pt; padding-left: 0pt">Total liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2024-12-31" id="Fact000113" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,135,680</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-12-31" id="Fact000114" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">99,934,400</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquityAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; text-align: left; padding-left: 0pt">Stockholders&#8217; deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PreferredStockValue_i02I_pp0p0_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zAUBRU0i5cXa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 0.125in">Series A Preferred Stock, $<span id="xdx_908_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zyV6Hj1u8NNc" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact000122" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction>
    </span>par value; <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zm0wI2x4iqBh" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact000124" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,000</ix:nonFraction>
    </span>shares authorized; <span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zLo5rrBtLcY5" title="Preferred stock, shares issued"><span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z4Euz4vtsmce" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact000126" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact000128" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500</ix:nonFraction></ix:nonFraction></span>
    </span>shares issued and outstanding as of December 31, 2024 (liquidation value of $<span id="xdx_903_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zNtjwUjxyTPi" title="Preferred stock, liquidation preference, value"><ix:nonFraction name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact000130" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,076,712</ix:nonFraction>
    </span>at December 31, 2024)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact000119" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,799,990</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0120">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PreferredStockValue_i02I_pp0p0_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z6knxXlf9W2h" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; padding-left: 0.125in">Series C Preferred Stock, $<span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zYmDGrx6i7na" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember" id="Fact000135" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction>
    </span>par value; <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zMuEX5djjlq2" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember" id="Fact000137" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">600</ix:nonFraction>
    </span>shares authorized; <span id="xdx_909_eus-gaap--PreferredStockSharesIssued_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zEUpkTrR81U2" title="Preferred stock, shares issued"><span id="xdx_90B_eus-gaap--PreferredStockSharesOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zf0hJ09PZ1Dl" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember" id="Fact000139" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember" id="Fact000141" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">600</ix:nonFraction></ix:nonFraction></span>
    </span>shares issued and outstanding as of December 31, 2024 (liquidation value of $<span id="xdx_90F_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zylDOhUUzzT6" title="Preferred stock, liquidation preference, value"><ix:nonFraction name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember" id="Fact000143" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,082,603</ix:nonFraction>
    </span>at December 31, 2024)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember" id="Fact000132" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0133">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--PreferredStockValue_i02I_pp0p0_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_maSEzG1Y_z8RuUGYjw1N1" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 0.125in">Preferred Stock, value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember" id="Fact000145" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0146">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--CommonStockValue_i02I_pp0p0_maSEzG1Y_zGBwZPX3Cz05" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 0.125in">Common stock, $<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20241231_zdEV54TbKVLe" title="Common shares, par value"><span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231231_zW70Uy4B5mLf" title="Common shares, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000151" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000153" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span>
    </span>par value; <span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_c20241231_zeEHk2xbkFpi" title="Common shares, shares authorized"><span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_c20231231_zLPS63IBjXr5" title="Common shares, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000155" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000157" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">800,000,000</ix:nonFraction></ix:nonFraction></span></span>
    shares authorized; <span id="xdx_903_eus-gaap--CommonStockSharesIssued_iI_c20241231_zZhNCwZb3Ti6" title="Common shares, shares issued"><span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_iI_c20241231_zmDM57EV5bVc" title="Common shares, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact000159" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000161" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">177,991,365</ix:nonFraction></ix:nonFraction></span></span>
    and <span id="xdx_906_eus-gaap--CommonStockSharesIssued_iI_c20231231_z7N5aciF27Xe" title="Common shares, shares issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_c20231231_z40746z8ji8k" title="Common shares, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact000163" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact000165" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">119,999,989</ix:nonFraction></ix:nonFraction></span></span> shares issued and
    outstanding at December 31, 2024 and December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-12-31" id="Fact000148" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">17,800</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31" id="Fact000149" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AdditionalPaidInCapital_i02I_pp0p0_maSEzG1Y_zozQ7hV1DASh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.125in">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-12-31" id="Fact000167" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">97,893,322</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-12-31" id="Fact000168" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,216,840</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_pp0p0_maSEzG1Y_zK2uclp2RPS4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 0pt; padding-left: 0.125in">Accumulated deficit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-12-31" id="Fact000170" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">113,385,117</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31" id="Fact000171" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">99,657,737</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--StockholdersEquity_i02TI_pp0p0_maLASEzTUz_mtSEzG1Y_zQ3Zj9pU8Jm7" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; text-align: left; padding-bottom: 1pt; padding-left: 0pt">Total stockholders&#8217; deficit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000173" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">6,674,005</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000174" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">94,428,897</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_pp0p0_mtLASEzTUz_z3TSwgHzdUAd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt">Total liabilities and stockholders&#8217;
    deficit</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000176" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,461,675</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000177" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,505,503</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>See
accompanying notes to the consolidated financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<!-- Field: Page; Sequence: 141; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="fin_004"></span>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_303_113_zC7e2KJDBRt9" summary="xdx: Statement - Consolidated Statements of Operations" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-left: 0pt; text-indent: 0pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49D_20240101__20241231_zSVAB9Lo6za9" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20230101__20231231_zhKSeQR4KGPc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-indent: 0pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-indent: 0pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingExpensesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; text-align: left; padding-left: 0pt">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ResearchAndDevelopmentExpense_i01_pp0p0_maOEzkfw_zXuxbuhCzVNd" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; text-indent: 0pt; padding-left: 0.125in">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000182" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">31,033,276</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31" id="Fact000183" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,403,526</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--GeneralAndAdministrativeExpense_i01_pp0p0_maOEzkfw_zKffAuRKmkg1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.125in">General and administrative</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000185" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">22,531,212</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-12-31" id="Fact000186" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,439,499</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingExpenses_i01T_pp0p0_mtOEzkfw_msOILzXle_zhCCYoGp8Ofc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.25in">Total operating expenses</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-01-01to2024-12-31" id="Fact000188" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">53,564,488</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-01-012023-12-31" id="Fact000189" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,843,025</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingIncomeLoss_iT_pp0p0_mtOILzXle_maNILz4Z0_z3Ee51mzwkGc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.25in">Loss from operations</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000191" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">53,564,488</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000192" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">8,843,025</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--InterestExpense_iN_di_msNILz4Z0_zXwshujxaOy2" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; text-align: left; padding-left: 0pt">Interest expense, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000194" format="ixt:numdotdecimal" decimals="0" unitRef="USD">184,037</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-01-012023-12-31" id="Fact000195" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,206,352</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--BusinessCombinationAcquisitionRelatedCosts_iN_pp0p0_di_msNILz4Z0_zYsbEGjtzBee" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; text-align: left; padding-left: 0pt">Merger transaction costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" contextRef="From2024-01-01to2024-12-31" id="Fact000197" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,499,353</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0198">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FairValueAdjustmentOfWarrants_iN_pp0p0_di_msNILz4Z0_zUFpF2OrWayd" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; text-align: left; padding-left: 0pt">Change in fair value of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-01to2024-12-31" id="Fact000200" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">58,180</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0201">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--ChangeInFairValueOfConvertiblePromissoryNotes_maNILz4Z0_zNT4RNMigU4g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; text-align: left; padding-left: 0pt">Change in fair value of convertible promissory notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:ChangeInFairValueOfConvertiblePromissoryNotes" contextRef="From2024-01-01to2024-12-31" id="Fact000203" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,468,678</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="TVGN:ChangeInFairValueOfConvertiblePromissoryNotes" contextRef="From2023-01-012023-12-31" id="Fact000204" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">50,428,303</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_ecustom--LossOnIssuanceOfCommitmentShares_iN_pp0p0_di_msNILz4Z0_ze3deK75mdn8" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; text-align: left; padding-left: 0pt">Loss on issuance of commitment shares</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="TVGN:LossOnIssuanceOfCommitmentShares" contextRef="From2024-01-01to2024-12-31" id="Fact000206" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">890,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0207">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetIncomeLoss_iT_pp0p0_mtNILz4Z0_zwTwWNSz91Ra" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; text-align: left; padding-left: 0pt">Net loss</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000209" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">13,727,380</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000210" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">60,477,680</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; text-align: left; padding-left: 0pt">Net loss attributable to common stockholders, basic and diluted</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_" id="xdx_904_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20240101__20241231_zMQx9VeVVR9f" title="Net loss attributable to common stockholders, basic"><span id="xdx_90D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20240101__20241231_zKo9eHDBfYwg" title="Net loss attributable to common stockholders, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2024-01-01to2024-12-31" id="Fact000212" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="From2024-01-01to2024-12-31" id="Fact000214" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,273,695</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_" id="xdx_90A_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20230101__20231231_zb95VIjkgnL9" title="Net loss attributable to common stockholders, basic"><span id="xdx_90A_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20230101__20231231_z0JL071ZT6M3" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_" title="Net loss attributable to common stockholders, diluted">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-01-012023-12-31" id="Fact000216" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="From2023-01-012023-12-31" id="Fact000218" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">60,477,680</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; text-align: left; padding-left: 0pt">Net loss per share attributable to common stockholders, basic
    and diluted</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_" id="xdx_90B_eus-gaap--EarningsPerShareBasic_pid_c20240101__20241231_z9BTrt9ySen1" title="Net loss per share attributable to common stockholders, basic"><span id="xdx_90E_eus-gaap--EarningsPerShareDiluted_pid_c20240101__20241231_zfhLOhRLjIWh" title="Net loss per share attributable to common stockholders, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-01to2024-12-31" id="Fact000220" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-01to2024-12-31" id="Fact000222" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.07</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_" id="xdx_903_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231_z4MJT1jo7E61" title="Net loss per share attributable to common stockholders, basic"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231_zCZH0YdPS959" title="Net loss per share attributable to common stockholders, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-012023-12-31" id="Fact000224" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-12-31" id="Fact000226" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">2.44</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; text-align: left; padding-left: 0pt">Weighted-average common stock outstanding, basic and diluted</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_" id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20241231_zo9T6pXIOdzi" title="Weighted-average common stock outstanding, basic"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20241231_zsJIkF5TFFd4" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_" title="Weighted-average common stock outstanding, diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-01to2024-12-31" id="Fact000228" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-01to2024-12-31" id="Fact000230" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">146,672,534</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_" id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231_zOVAfibaoSqf" title="Weighted-average common stock outstanding, basic"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_zWs93qxnMJO6" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_" title="Weighted-average common stock outstanding, diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-12-31" id="Fact000232" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-12-31" id="Fact000234" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,752,000</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>See
accompanying notes to the consolidated financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<!-- Field: Page; Sequence: 142; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="fin_005"></span>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; DEFICIT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_302_114_zvSF79Gy9oii" summary="xdx: Statement - Consolidated Statements of Changes in Stockholders' Deficit" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_us-gaap--SeriesAPreferredStockMember_z5HX93Wk2ZCj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B6_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_us-gaap--SeriesBPreferredStockMember_z6A0cAHsiOP" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B9_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_us-gaap--SeriesCPreferredStockMember_zhgqpPcbosIc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B0_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zCpMH27dp1Oi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_z52axlCh4sG5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Capital</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zF7U3L1pNzd3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B6_zrRe45TqNXIb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Series
                                            A</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Preferred
                                            Stock</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Series
                                            B</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Preferred
                                            Stock</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Series
                                            C</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Preferred
                                            Stock</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Additional</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Paid-in</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Total</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Stockholders&#8217;</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Deficit</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Capital</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_43A_c20230101__20231231_eus-gaap--StockholdersEquity_iS_zXvVuLsxixfb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-left: 0pt; width: 12%">Balance at January 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zbBFDen1wXwl" title="Balance, shares" style="width: 4%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0244">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0236">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zWTLEbpMF3I7" title="Balance, shares" style="width: 4%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0246">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0237">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zuyDIDFLc53d" title="Balance, shares" style="width: 4%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0248">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0238">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRHIbQbQT9K9" title="Balance, shares" style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000250" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">119,999,989</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000239" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000240" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,216,840</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact000241" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">39,180,057</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right">&#160;&#160;(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000242" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">33,951,217</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLoss_zwHf3oQmmLZk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0252">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0253">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0254">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0255">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0256">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="Fact000257" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">60,477,680</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000258" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">60,477,680</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_43B_c20240101__20241231_eus-gaap--StockholdersEquity_iS_zvNKwGW5M6Fi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-left: 0pt">Balance at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zLPtHyGazW8h" title="Balance, shares" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0268">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0260">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z5RFajpCH4h3" title="Balance, shares" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0270">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0261">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zQpvEh9xIG5b" title="Balance, shares" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0272">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0262">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zN5d1eVqYi5g" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000274" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">119,999,989</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000263" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000264" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,216,840</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000265" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">99,657,737</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000266" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">94,428,897</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_437_c20240101__20241231_eus-gaap--StockholdersEquity_iS_zhXVLPBv5Lg6" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-left: 0pt">Balance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zVkzo3LhIcN8" title="Balance, shares" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0284">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0276">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zERJZIrYtif9" title="Balance, shares" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0286">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0277">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zbwFqnC3RGKe" title="Balance, shares" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0288">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0278">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6ycK5fFPVSb" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000290" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">119,999,989</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000279" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000280" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,216,840</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000281" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">99,657,737</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000282" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">94,428,897</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_40E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zsxd73DFowC7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Issuance of Series A preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zwEQ6yOhpXQl" title="Issuance of preferred stock, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="Fact000300" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="Fact000292" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,799,990</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0293">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0294">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0295">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0296">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0297">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-01to2024-12-31" id="Fact000298" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,799,990</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--StockIssuedDuringPeriodValueNewIssuesTwo_zXbi3BOK6gz7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Issuance of Series C preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0302">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0303">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--StockIssuedDuringPeriodSharesNewIssuesTwo_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zQGKXvenqkz3" title="Issuance of preferred stock, shares" style="text-align: right"><ix:nonFraction name="TVGN:StockIssuedDuringPeriodSharesNewIssuesTwo" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="Fact000310" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">600</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueNewIssuesTwo" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="Fact000304" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0305">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0306">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0307">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueNewIssuesTwo" contextRef="From2024-01-01to2024-12-31" id="Fact000308" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--StockIssuedDuringPeriodValueNewIssuesOne_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Issuance of Series B preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0312">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--StockIssuedDuringPeriodSharesNewIssuesOne_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zghjOCcLgGd5" title="Issuance of Series B preferred stock, shares" style="text-align: right"><ix:nonFraction name="TVGN:StockIssuedDuringPeriodSharesNewIssuesOne" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="Fact000320" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,613</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueNewIssuesOne" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="Fact000313" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,613,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0314">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0315">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0316">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0317">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueNewIssuesOne" contextRef="From2024-01-01to2024-12-31" id="Fact000318" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,613,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_zMkU9xlh4ZMd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Conversion of convertible promissory notes into common stock in connection with
    merger</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0322">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0323">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0324">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCCTwb4E2pZ7" title="Conversion of convertible promissory notes into common stock in connection with merger, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000330" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,337,419</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000325" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,034</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000326" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,621,593</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0327">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-01to2024-12-31" id="Fact000328" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,622,627</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--MergerNetOfRedemptionsAndTransactionCosts_iN_di_zqQFLfiT6dYi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Merger, net of redemptions and transaction costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0332">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0333">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0334">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuCHXY2lgye4" title="Merger, net of redemptions and transaction costs, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000340" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,778,056</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:MergerNetOfRedemptionsAndTransactionCosts" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000335" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,478</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="TVGN:MergerNetOfRedemptionsAndTransactionCosts" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000336" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,885,459</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0337">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="TVGN:MergerNetOfRedemptionsAndTransactionCosts" contextRef="From2024-01-01to2024-12-31" id="Fact000338" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,883,981</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Issuance of restricted common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0342">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0343">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0344">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zESOWQzBVUs9" title="Issuance of restricted common stock, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000350" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">19,348,954</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000345" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,935</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000346" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,935</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0347">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0348">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Issuance of common stock for Sponsor advisory service fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0352">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0353">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0354">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zchUxVDsD7Cf" title="Issuance of common stock for Sponsor advisory service fee, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000360" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000355" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000356" format="ixt:numdotdecimal" decimals="0" unitRef="USD">676,485</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0357">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-01to2024-12-31" id="Fact000358" format="ixt:numdotdecimal" decimals="0" unitRef="USD">676,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement_zP0UXqbFsY77" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Issuance of commitment shares in connection with the loan agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0362">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0363">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0364">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithLoanAgreement_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJpjxcl7bjX4" title="Issuance of commitment shares in connection with the loan agreement, shares" style="text-align: right"><ix:nonFraction name="TVGN:StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithLoanAgreement" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000370" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000365" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000366" format="ixt:numdotdecimal" decimals="0" unitRef="USD">889,900</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0367">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement" contextRef="From2024-01-01to2024-12-31" id="Fact000368" format="ixt:numdotdecimal" decimals="0" unitRef="USD">890,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValueOther_zl68YESCLWBe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Issuance of common stock in connection with Polar note</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0372">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0373">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0374">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zznPsufHQzvl" title="Issuance of common stock in connection with Polar Note, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000380" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000375" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000376" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">150</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0377">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0378">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--StockIssuedDuringPeriodValueContributionFromRelatedParty_zjhZVuboDyVa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Contribution from related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0382">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--StockIssuedDuringPeriodSharesContributionFromRelatedParty_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z6cOGE3vx0ej" title="Contribution from related party, shares" style="text-align: right">(<ix:nonFraction name="TVGN:StockIssuedDuringPeriodSharesContributionFromRelatedParty" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="Fact000390" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">3,613</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueContributionFromRelatedParty" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="Fact000383" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,613,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0384">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0385">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueContributionFromRelatedParty" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000386" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,613,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0387">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0388">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AdjustmentsToAdditionalPaidInCapitalMarkToMarket_zzOasmd24BI5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Nonrefundable prepaid proceeds towards anticipated Series A-1 preferred stock
    issuance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0392">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0393">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0394">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0395">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000396" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0397">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket" contextRef="From2024-01-01to2024-12-31" id="Fact000398" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits_zSfDUvz8ft0k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Issuance of common stock in settlement of vested restricted stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0400">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0401">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0402">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVRjoxV5BFr9" title="Issuance of common stock in settlement of vested restricted stock units, shares" style="text-align: right"><ix:nonFraction name="TVGN:StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000408" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,876,947</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000403" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,088</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000404" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,088</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0405">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0406">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zV5xtDxf3Kl6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0410">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0411">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0412">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0413">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000414" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,764,136</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0415">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-01to2024-12-31" id="Fact000416" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,764,136</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetIncomeLoss_z0hylcIgvjYc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0418">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0419">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0420">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0421">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0422">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="Fact000423" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,727,380</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000424" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,727,380</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_434_c20240101__20241231_eus-gaap--StockholdersEquity_iE_zFl21CcfBvy4" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 0pt">Balance at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zQqUUZGlE0lf" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="Fact000434" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="Fact000426" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,799,990</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zkCrzQTv29v2" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0436">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0427">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zjgGzYvKuAo6" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="Fact000438" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">600</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="Fact000428" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,000,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zvr38ygbl703" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000440" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">177,991,365</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000429" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,800</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000430" format="ixt:numdotdecimal" decimals="0" unitRef="USD">97,893,322</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000431" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">113,385,117</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000432" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,674,005</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_439_c20240101__20241231_eus-gaap--StockholdersEquity_iE_zEPZhvnOTmZh" style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; font-weight: bold; padding-bottom: 2.5pt; padding-left: 0pt">Balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zLJEIVCw388" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="Fact000450" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="Fact000442" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,799,990</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zwJPx88OuRDg" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0452">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0443">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zBpSUNJkfeT9" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="Fact000454" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">600</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="Fact000444" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,000,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUFs6HHcFWc4" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000456" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">177,991,365</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000445" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,800</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000446" format="ixt:numdotdecimal" decimals="0" unitRef="USD">97,893,322</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000447" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">113,385,117</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000448" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,674,005</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>See
accompanying notes to the consolidated financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<!-- Field: Page; Sequence: 143; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="fin_006"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_308_112_zzfFYKEa7Wz9" summary="xdx: Statement -  Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20240101__20241231_zNnQU2Ad9sK8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20230101__20231231_zsKrBJB6zMFa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the year ended December&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: 0pt; padding-left: 0pt">Cash flows from operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLoss_i01_pp0p0_maNCPBUzsTD_zcsVHsZN3le8" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; text-indent: 0pt; padding-left: 0.125in">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000461" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">13,727,380</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000462" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">60,477,680</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.125in">Adjustments to reconcile net loss to net cash used in operating
    activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--Depreciation_i02_pp0p0_maNCPBUzsTD_z4hYBT4KqAge" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.25in">Depreciation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-01-01to2024-12-31" id="Fact000467" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">162,209</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-01-012023-12-31" id="Fact000468" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">163,300</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ShareBasedCompensation_i02_pp0p0_maNCPBUzsTD_z6i10VkPNJD1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.25in">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-01to2024-12-31" id="Fact000470" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">40,764,136</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0471">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PaidInKindInterest_i02_pp0p0_maNCPBUzsTD_z8AqUDFvUxt7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.25in">Non-cash interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PaidInKindInterest" contextRef="From2024-01-01to2024-12-31" id="Fact000473" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">187,575</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PaidInKindInterest" contextRef="From2023-01-012023-12-31" id="Fact000474" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,206,697</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NoncashMergerRelatedCosts_i02_pp0p0_maNCPBUzsTD_zAEqJE0RUCDl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.25in">Merger transaction costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NoncashMergerRelatedCosts" contextRef="From2024-01-01to2024-12-31" id="Fact000476" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,099,353</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0477">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--ChangeInFairValueOfConvertiblePromissoryNotes_i02N_pp0p0_di_msNCPBUzsTD_zPzKmMsqDm4d" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.25in">Change in fair value of convertible promissory notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="TVGN:ChangeInFairValueOfConvertiblePromissoryNotes" contextRef="From2024-01-01to2024-12-31" id="Fact000479" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">48,468,678</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:ChangeInFairValueOfConvertiblePromissoryNotes" contextRef="From2023-01-012023-12-31" id="Fact000480" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">50,428,303</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--LossOnPreferredStockIssuance_i02_pp0p0_maNCPBUzsTD_zk0EGdLI8153" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.25in">Loss on Series A Preferred Stock issuance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:LossOnPreferredStockIssuance" contextRef="From2024-01-01to2024-12-31" id="Fact000482" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">799,990</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0483">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--LossOnIssuanceOfCommitmentShares_i02_pp0p0_maNCPBUzsTD_z0Xl8rMRLqX2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.25in">Loss on issuance of commitment shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:LossOnIssuanceOfCommitmentShares" contextRef="From2024-01-01to2024-12-31" id="Fact000485" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">890,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0486">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FairValueAdjustmentOfWarrants_i02_pp0p0_maNCPBUzsTD_zdHyOVK5vk1c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.25in">Change in fair value of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-01to2024-12-31" id="Fact000488" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">58,180</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0489">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_i02_pp0p0_maNCPBUzsTD_zfbUJAN6fBo7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.25in">Amortization of right-of-use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="From2024-01-01to2024-12-31" id="Fact000491" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">241,372</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="From2023-01-012023-12-31" id="Fact000492" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">215,057</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.25in">Change in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_pp0p0_di_msNCPBUzsTD_zyPIbfcEk5yc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.375in">Prepaid expenses and other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2024-01-01to2024-12-31" id="Fact000497" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">246,005</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2023-01-012023-12-31" id="Fact000498" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">317,605</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--IncreaseDecreaseInOtherOperatingAssets_i03N_pp0p0_di_msNCPBUzsTD_zLquE0HeUrui" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.375in">Other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="From2024-01-01to2024-12-31" id="Fact000500" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">511,011</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="From2023-01-012023-12-31" id="Fact000501" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">323,742</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncreaseDecreaseInAccountsPayableTrade_i03_pp0p0_maNCPBUzsTD_zFKwCFzaSz6e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.375in">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="From2024-01-01to2024-12-31" id="Fact000503" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,685,692</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="From2023-01-012023-12-31" id="Fact000504" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,114,261</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i03_pp0p0_maNCPBUzsTD_zFKQsjCvFwWh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.375in">Accrued expenses and other liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2024-01-01to2024-12-31" id="Fact000506" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">681,450</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2023-01-012023-12-31" id="Fact000507" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">603,832</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i03_pp0p0_maNCPBUzsTD_zpL7HGeTck78" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 0pt; padding-left: 0.375in">Operating lease liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2024-01-01to2024-12-31" id="Fact000509" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">252,713</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2023-01-012023-12-31" id="Fact000510" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">223,361</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_pp0p0_mtNCPBUzsTD_maCCERCzjKL_zBB9V6DID5Re" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 0pt; padding-left: 0.5in">Net cash used in operating activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000512" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">11,998,730</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-012023-12-31" id="Fact000513" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">8,171,118</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; text-indent: 0pt; padding-left: 0pt">Cash flows from investing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_pp0p0_di_msNCPBUzU3Z_zsEFXQ7tF9f4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 0pt; padding-left: 0.25in">Purchases of property and equipment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0518">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2023-01-012023-12-31" id="Fact000519" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">133,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_pp0p0_mtNCPBUzU3Z_maCCERCzjKL_zW9Op6YT7MBk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 0pt; padding-left: 0.5in">Net cash used in investing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0521">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-01-012023-12-31" id="Fact000522" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">133,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: 0pt; padding-left: 0pt">Cash flows from financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--CashAcquiredInConnectionWithReverseRecapitalization_i01_pp0p0_maNCPBUz0HS_zKnvhrCKYvc1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.125in">Cash acquired in connection with the reverse recapitalization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:CashAcquiredInConnectionWithReverseRecapitalization" contextRef="From2024-01-01to2024-12-31" id="Fact000527" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">229,328</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0528">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_i01_pp0p0_maNCPBUz0HS_zff7wySakpu" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.125in">Proceeds from issuance of Series A Preferred Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="From2024-01-01to2024-12-31" id="Fact000530" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0531">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--ProceedsFromIssuanceOfSeriesCPreferredStock_i01_pp0p0_maNCPBUz0HS_zXLrBcUNgo9a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.125in">Proceeds from issuance of Series C Preferred Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:ProceedsFromIssuanceOfSeriesCPreferredStock" contextRef="From2024-01-01to2024-12-31" id="Fact000533" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0534">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ProceedsFromLinesOfCredit_i01_pp0p0_maNCPBUz0HS_zen2S1Ln3yj9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.125in">Proceeds from loan agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2024-01-01to2024-12-31" id="Fact000536" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0537">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance_i01_pp0p0_maNCPBUz0HS_zbDUbhdRHZz9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.125in">Nonrefundable prepaid proceeds towards anticipated Series
    A-1 Preferred Stock Issuance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance" contextRef="From2024-01-01to2024-12-31" id="Fact000539" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0540">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PaymentOfFinancingAndStockIssuanceCosts_i01N_pp0p0_di_msNCPBUz0HS_zvWOBiWDxMJ6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.125in">Payments of deferred transaction costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0542">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" contextRef="From2023-01-012023-12-31" id="Fact000543" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">127,750</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--ProceedsFromConvertibleDebt_i01_pp0p0_maNCPBUz0HS_zGFvFEoWIVA4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 0pt; padding-left: 0.125in">Proceeds from issuance of convertible
    promissory notes</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0545">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2023-01-012023-12-31" id="Fact000546" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,000,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_pp0p0_mtNCPBUz0HS_maCCERCzjKL_zBAm8S8BbSyf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 0pt; padding-left: 0.5in">Net cash provided by financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000548" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,229,328</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-012023-12-31" id="Fact000549" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,872,250</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_pp0p0_mtCCERCzjKL_zq4ViZlNAACe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Net increase (decrease) in cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2024-01-01to2024-12-31" id="Fact000551" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">230,598</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-01-012023-12-31" id="Fact000552" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">4,431,868</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-indent: 0pt; padding-left: 0.125in">Cash &#8211; beginning of period</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-12-31" id="Fact000554" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,052,397</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-12-31" id="Fact000555" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,484,265</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-indent: 0pt; padding-left: 0.125in">Cash &#8211; end of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-12-31" id="Fact000557" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,282,995</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-12-31" id="Fact000558" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,052,397</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: 0pt; padding-left: 0pt">Supplementary disclosure of noncash investing
    and financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--ReverseRecapitalizationTransactionFeesIncludedInAccruedExpensesAndOtherLiabilities_i01_pp0p0_zlor4JTtnj4e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.125in">Reverse recapitalization transaction fees included in accrued
    expenses and other liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0563">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:ReverseRecapitalizationTransactionFeesIncludedInAccruedExpensesAndOtherLiabilities" contextRef="From2023-01-012023-12-31" id="Fact000564" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,455,120</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DebtConversionOriginalDebtAmount1_i01_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.125in">Conversion of convertible promissory notes into common stock
    in connection with Merger</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DebtConversionOriginalDebtAmount1" contextRef="From2024-01-01to2024-12-31" id="Fact000566" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">46,622,627</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0567">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--RepurchaseOfSeriesBPreferredStock_i01_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.125in">Repurchase of Series B preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:RepurchaseOfSeriesBPreferredStock" contextRef="From2024-01-01to2024-12-31" id="Fact000569" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,613,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0570">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--StockIssued1_i01_pp0p0_zg54kNlaiiA8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.125in">Issuance of common stock for net liabilities upon reverse
    recapitalization, net of transaction costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssued1" contextRef="From2024-01-01to2024-12-31" id="Fact000572" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,113,309</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0573">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>See
accompanying notes to the consolidated financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<!-- Field: Page; Sequence: 144; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b><span id="fin_007"></span>TEVOGEN
BIO HOLDINGS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000575" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock"><p id="xdx_804_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zCNaGI6GbMM7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1. <span id="xdx_82B_zN9tcoyn3jBc">NATURE OF BUSINESS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tevogen
Bio Holdings Inc., a Delaware corporation (the &#8220;Company&#8221;), is a clinical-stage specialty immunotherapy company harnessing
the power of CD8+ cytotoxic T lymphocytes to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases,
cancers, and other disorders. The Company&#8217;s precision T cell technology, ExacTcell, is a set of processes and methodologies to
develop, enrich, and expand single human leukocyte antigen-restricted CTL therapies with proactively selected, precisely defined targets.
The Company has completed a Phase 1 proof-of-concept trial for the first clinical product of ExacTcell, TVGN 489, for the treatment of
ambulatory, high-risk adult COVID-19 patients, and has other product candidates in its pipeline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 14, 2024 (the &#8220;Closing Date&#8221;), pursuant to the Agreement and Plan of Merger dated June 28, 2023 (the &#8220;Merger
Agreement&#8221;) by and among Semper Paratus Acquisition Corporation (&#8220;Semper Paratus&#8221;), Semper Merger Sub, Inc., a wholly
owned subsidiary of Semper Paratus (&#8220;Merger Sub&#8221;), SSVK Associates, LLC (the &#8220;Sponsor&#8221;), Tevogen Bio Inc (n/k/a
Tevogen Bio Inc.) (&#8220;Tevogen Bio&#8221;), and Dr. Ryan Saadi, in his capacity as seller representative, Merger Sub merged with and
into Tevogen Bio, with Tevogen Bio being the surviving entity and a wholly owned subsidiary of Semper Paratus (the &#8220;Merger&#8221;
and together with the other transactions contemplated by the Merger Agreement, the &#8220;Business Combination&#8221;) and Semper Paratus
was renamed Tevogen Bio Holdings Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the closing of the Business Combination (the &#8220;Closing&#8221;), the then-outstanding shares of common stock of Tevogen
Bio, were converted into shares of the common stock of the Company at an exchange ratio of approximately&#160;<span id="xdx_908_ecustom--BusinessCombinationSharesExchangeRatio_iI_c20240214__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXBingLPzREg" title="Business combination shares"><ix:nonFraction name="TVGN:BusinessCombinationSharesExchangeRatio" contextRef="AsOf2024-02-14_us-gaap_CommonStockMember" id="Fact000577" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.85</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;shares
of Company common stock for each share of Tevogen Bio common stock (the &#8220;Exchange Ratio&#8221;). See Note 4 for more information
on the Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed in Note 4, the Merger was accounted for as a reverse recapitalization under which the historical financial statements of the
Company prior to the Merger are those of Tevogen Bio. All information related to the common stock of Tevogen Bio prior to the Closing
and presented in the consolidated financial statements and notes thereto has been retroactively adjusted to reflect the Exchange Ratio.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the Merger, the former equity holders and holders of convertible promissory notes of Tevogen Bio held&#160;<span id="xdx_904_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TevogenBioMember_z8YaQSRt0PL"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2024-12-31_custom_TevogenBioMember" id="Fact000578" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">91.0</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the outstanding shares of common stock of the Company and the former shareholders, creditors, and other contractual counterparties
of Semper Paratus held&#160;<span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SemperParatusMember_zwafqri8gW67" title="Equity ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2024-12-31_custom_SemperParatusMember" id="Fact000580" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9.0</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the Company.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000582" name="TVGN:DevelopmentStageRisksAndLiquidityTextBlock"><p id="xdx_80E_ecustom--DevelopmentStageRisksAndLiquidityTextBlock_zSEL1kYFLT55" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2. <span id="xdx_825_zdaGSlgqJht8">DEVELOPMENT-STAGE RISKS AND LIQUIDITY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has generally incurred losses and negative cash flows from operations since inception. The Company anticipates incurring additional
losses until such time, if ever, that it can generate significant sales from its product candidates currently in development. Management
believes that cash of $<span id="xdx_90E_eus-gaap--Cash_iI_c20241231_z54gFr7yqmm9" title="Cash"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2024-12-31" id="Fact000584" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,282,995</ix:nonFraction></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
of December 31, 2024, the amounts available under the Loan Agreement entered into in June 2024 (as defined in Note 8), and the commitment
for an $<span id="xdx_906_eus-gaap--ProceedsFromRelatedPartyDebt_c20240601__20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zz9m7Wc2CT43" title="Grant received"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2024-06-012024-06-30_custom_LoanAgreementMember" id="Fact000586" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,000,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">grant from KRHP LLC, a New Jersey limited
liability company (&#8220;KRHP&#8221;), will allow the Company to have adequate cash and financial resources to operate for at least
the next 12 months from the date of issuance of these consolidated financial statements. Subsequent to December 31, 2024, the Company
received a grant of $<span id="xdx_90F_eus-gaap--ProceedsFromRelatedPartyDebt_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z3YVJ23ouYca" title="Grant received"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2025-01-012025-03-31_custom_LoanAgreementMember_us-gaap_SubsequentEventMember" id="Fact000588" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">from KRHP and drew $<span id="xdx_907_ecustom--GrantDrewFromRelatedParty_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zHn5lQn3Qp5b" title="Grant drew from related party"><ix:nonFraction name="TVGN:GrantDrewFromRelatedParty" contextRef="From2025-01-012025-03-31_custom_LoanAgreementMember_us-gaap_SubsequentEventMember" id="Fact000590" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in each of February 2025 and in March
2025 under the Loan Agreement. The grant funding may not be used for repayment of existing debt obligations and does not include any
requirement to repay the investor or to issue equity in consideration of the funding. KRHP has committed to provide an additional $<span id="xdx_90D_eus-gaap--ProceedsFromRelatedPartyDebt_c20240601__20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zy6KwBSPcvhf" title="Grant received"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2024-06-012024-06-30_custom_LoanAgreementMember" id="Fact000592" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,000,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of grant funding to the Company to be
used towards the Company&#8217;s ongoing operational expenses. The grant funding will be used to satisfy the Company&#8217;s obligations
as they come due through March 31, 2026. The Company does not plan to initiate a clinical trial until additional funding is received.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
regularly evaluates different strategies to obtain funding for operations for subsequent periods. These strategies may include but are
not limited to private placements of securities, licensing and/or marketing arrangements, partnerships with other pharmaceutical or biotechnology
companies, and public offerings of securities. The Company may not be able to obtain financing on acceptable terms and the Company may
not be able to enter into strategic alliances or other arrangements on favorable terms. The terms of any financing may adversely affect
the holdings or the rights of the Company&#8217;s stockholders. If the Company is unable to obtain sufficient funding, the Company could
be required to delay, reduce or eliminate research and development programs, product portfolio expansion, or future commercialization
efforts, which could adversely affect its business prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operations
since inception have consisted primarily of organizing the Company, securing financing, developing licensed technologies, performing
research, conducting pre-clinical studies and a clinical trial, and pursuing and completing the Business Combination. The Company is
subject to risks associated with any specialty biotechnology company that requires considerable expenditures for research and development.
The Company&#8217;s research and development projects may not be successful, products developed may not obtain necessary regulatory approval,
and any approved product may not be commercially viable. In addition, the Company operates in an environment of rapid technological change
and is largely dependent on the services of its employees and consultants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 145; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS
INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000594" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_804_eus-gaap--SignificantAccountingPoliciesTextBlock_zFtpcnRqHCDf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3. <span id="xdx_82D_zIoAw2Lo0PA">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000596" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zEjozw92zT9b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_869_z6zGIDk7hIo2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
of Presentation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (&#8220;GAAP&#8221;).
Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;)
and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000598" name="us-gaap:UseOfEstimates"><p id="xdx_84E_eus-gaap--UseOfEstimates_zh4v7xeUIyE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_86C_z9OsFUUKNFM7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use
of Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preparing the consolidated financial statements in conformity with GAAP, management is required to make estimates and assumptions that
affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts of
expenses. Actual results could differ from those estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions
are reflected in the consolidated financial statements in the period they are determined to be necessary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
areas that require management&#8217;s estimates include the fair value of the common stock and convertible promissory notes prior to
the Merger, the fair value of the Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock, fair value of the
purchase options under the Loan Agreement, stock-based compensation assumptions, and accrued research and development expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000600" name="TVGN:FreestandingAndEmbeddedCommonStockOptionsPolicyTextBlock"><p id="xdx_84C_ecustom--FreestandingAndEmbeddedCommonStockOptionsPolicyTextBlock_zU1Yg00Ynoqa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_86B_zjZOTYXrYvW1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Freestanding
and Embedded Common Stock Purchase Options</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity-linked
purchase options issued in connection with the Company&#8217;s debt agreements are assessed to determine whether they are freestanding
or embedded with the host instrument under ASC 815,&#160;<i>Derivatives and Hedging Contracts in Entity&#8217;s Own Equity&#160;</i>(&#8220;ASC
815&#8221;). Each type of purchase option is then assessed for equity or liability classification under ASC 815. The Company&#8217;s
embedded and freestanding purchase options were determined to be liability-classified derivative instruments and are measured at fair
value both on the date of issuance and at each subsequent balance sheet date, with changes in fair value recorded to &#8216;Change in
fair value of written call option derivative liabilities&#8217; within the consolidated statements of operations and consolidated statements
of cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000602" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_zaVX69hJqaGj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_860_zBYIf29m4TMl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Concentrations
of Credit Risk</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash. The Company
maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced
any losses in such accounts and believes it is not exposed to significant risk on its cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000604" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zGavjTbsGjld" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_86B_zqy1DxfGgale" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Segment
Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are defined as components of an entity for which discrete financial information is both available and regularly reviewed by
its chief operating decision maker or decision-making group. The Company views its operations and manages its business in <span id="xdx_905_eus-gaap--NumberOfOperatingSegments_pid_dc_uSegment_c20240101__20241231_zQCkR43qaf21" title="Number of operating segments"><ix:nonFraction name="us-gaap:NumberOfOperatingSegments" contextRef="From2024-01-01to2024-12-31" id="Fact000606" format="ixt-sec:numwordsen" decimals="INF" unitRef="Segment">one
</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">segment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 146; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS
INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000608" name="us-gaap:DerivativesPolicyTextBlock"><p id="xdx_84C_eus-gaap--DerivativesPolicyTextBlock_zD1xmE1CP1Z1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_860_zTyoPxhDqOEb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the result of the Merger, the Company accounts for its warrants originally sold as part of Semper Paratus&#8217;s initial public offering
(the &#8220;IPO&#8221;) in accordance with ASC 815, <i>Derivatives and Hedging Contracts in Entity&#8217;s Own Equity </i>(&#8220;ASC
815&#8221;) and ASC 480,&#160;<i>Distinguishing Liabilities from Equity</i>&#160;(&#8220;ASC 480&#8221;). The assessment considers whether
the warrants are freestanding financial instruments and meet the definition of a liability pursuant to ASC 480 and meet all of the conditions
for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s own shares of common stock,
among other conditions. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance
and as of each subsequent quarterly period end date while the warrants are outstanding. For issued or modified warrants that meet all
of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the
time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required
to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter until settlement. Changes
in the estimated fair value of the warrants are recognized as a non-cash loss on the consolidated statements of operations. Under these
standards, the Company&#8217;s private placement warrants sold at the time of the IPO do not meet the criteria for equity classification
and must be recorded as liabilities while the public warrants sold in connection with the IPO do meet the criteria for equity classification
and must be recorded as equity.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000610" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_840_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zrhlYragtHG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_867_zPsHFdIWiME8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair
Value Measurements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
assets and liabilities are carried at fair value under GAAP. Fair value is defined as the price that would be received for an asset or
paid to transfer a liability (exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction
between market participants on the measurement date. The Company utilizes valuation techniques that maximize the use of observable inputs
and minimize the use of unobservable inputs to the extent possible. When considering market participant assumptions in fair value measurements,
the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following
levels:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 0.5in; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unadjusted
    quoted prices in active markets for identical assets or liabilities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Observable
    inputs other than Level 1 prices, such as quoted prices for similar, but not identical, assets or liabilities in active markets;
    quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable
    or can be corroborated by observable market data;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unobservable
    inputs in which there is little or no market data available and which require the Company to develop its own assumptions that market
    participants would use in pricing an asset or liability.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments recognized at historical amounts in the balance sheets consist of accounts payable and notes payable. The Company believes
that the carrying value of accounts payable and notes payable approximates their fair values due to the short-term nature of these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s recurring fair value measurements consist of the convertible promissory notes prior to the Merger, for which the Company
elected the fair value option to reduce accounting complexity, and private warrants after the Merger. Such fair value measurements are
Level 3 inputs. The following table provides a roll-forward of the aggregate fair values of the Company&#8217;s convertible promissory
notes.</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000612" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"><p id="xdx_89D_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zvQIcfKfBw7b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B4_zLwMSvweVTPg" style="display: none">SCHEDULE
OF FAIR VALUE MEASUREMENT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; font-weight: bold">Balance at January 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zmPdTyoWTo8e" title="Fair value beginning balance" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact000614" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,297,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Initial fair value at issuance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zn2RHV15r6Be" title="Initial fair value at issuance" style="text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact000616" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Accrued interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zPFQwSUZCOQj" title="Accrued interest expense" style="text-align: right"><ix:nonFraction name="TVGN:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact000618" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,206,697</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Change in fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zNzncNEjVShd" title="Change in fair value" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact000620" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,428,303</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z4rCEr5QVgp4" title="Fair value beginning balance" style="text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact000622" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,932,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Accrued interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zt6aGeiPKPWa" title="Accrued interest expense" style="text-align: right"><ix:nonFraction name="TVGN:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest" contextRef="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact000624" format="ixt:numdotdecimal" decimals="0" unitRef="USD">159,305</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Change in fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zyjBGFf91vbi" title="Change in fair value" style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" contextRef="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact000626" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">48,468,678</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Derecognition upon conversion of convertible promissory
    notes</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5YwVfhmAdXj" title="Derecognition upon conversion of convertible promissory notes" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="TVGN:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable" contextRef="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact000628" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">46,622,627</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2ME1DbWt72e" title="Fair value beginning balance" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0630">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zqcgjNCAyIG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 147; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS
INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no transfers between levels during the years ended December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company used the probability weighted expected return method valuation methodology to determine the fair value of the convertible promissory
notes prior to the Merger. Significant assumptions and ranges used in determining the fair value of convertible promissory notes prior
to the Merger include volatility (<span id="xdx_903_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zF3lzBx4NxE3" title="Volatility"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember" id="Fact000632" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">80</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%),
discount rate (<span id="xdx_90D_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember__srt--RangeAxis__srt--MinimumMember_zI7cdoSRgYZf" title="Volatility"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputDiscountRateMember_srt_MinimumMember" id="Fact000634" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">35</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
- <span id="xdx_90C_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember__srt--RangeAxis__srt--MaximumMember_z3CE1sVwC9l8" title="Volatility"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputDiscountRateMember_srt_MaximumMember" id="Fact000636" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">36</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%),
and probability of a future liquidity event (<span id="xdx_90F_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__custom--ProbabilityOfFutureLiquidityMember__srt--RangeAxis__srt--MinimumMember_zWLtQzBOBiyb" title="Volatility"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-12-31_custom_ProbabilityOfFutureLiquidityMember_srt_MinimumMember" id="Fact000638" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">85</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
- <span id="xdx_906_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__custom--ProbabilityOfFutureLiquidityMember__srt--RangeAxis__srt--MaximumMember_ztX9pqLKBk9j" title="Volatility"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-12-31_custom_ProbabilityOfFutureLiquidityMember_srt_MaximumMember" id="Fact000640" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">95</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%).
The Company used its stock price on the Closing Date to determine the fair value for the derecognition of the convertible promissory
notes upon conversion on the Closing Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the Closing, the Company acquired private warrants, the fair value of which increased by $<span id="xdx_900_eus-gaap--FairValueAdjustmentOfWarrants_iN_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCyhs8Yly2tg" title="Fair value adjustment of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember" id="Fact000642" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">58,180</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;between
the Closing Date and December 31, 2024 primarily due to changes in the market value of the Company&#8217;s common shares. In June 2024,
the Company issued written call options in connection with the Loan Agreement, the fair value of which decreased by $<span id="xdx_903_eus-gaap--FairValueAdjustmentOfWarrants_iN_di_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zK0pZpXRMYP3" title="Fair value adjustment of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact000644" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">375,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;between
the issuance and December 31, 2024. Such fair value measurements are Level 3 inputs. The following table provides a roll-forward of the
aggregate fair values of the warrants and the written call option derivative liabilities.</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000646" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"><p id="xdx_89E_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zVFlWWOtgvBk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BC_zKxxJeSEy77b" style="display: none">SCHEDULE
OF FAIR VALUES OF WARRANTS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Derivative</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>warrant
                                            liabilities</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Written
                                            call option</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>derivative
                                            liabilities</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance at February 15, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--DerivativeLiabilitiesNoncurrent_iS_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHBI9UhFXWzg" title="Derivative warrant liabilities, Balance" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0648">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeLiabilitiesNoncurrent_iS_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zNojA057WR65" title="Derivative warrant liabilities, Balance" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0650">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-left: 10pt">Initial fair value at issuance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_ecustom--DerivativeLiabilitiesFairValueIssuance_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziWiAcw0clR" title="Initial fair value at issuance" style="width: 16%; text-align: right"><ix:nonFraction name="TVGN:DerivativeLiabilitiesFairValueIssuance" contextRef="From2024-02-152024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" id="Fact000652" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_ecustom--DerivativeLiabilitiesFairValueIssuance_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zh8O4BbAP9Vc" title="Initial fair value at issuance" style="width: 16%; text-align: right"><ix:nonFraction name="TVGN:DerivativeLiabilitiesFairValueIssuance" contextRef="From2024-02-152024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_CallOptionMember" id="Fact000654" format="ixt:numdotdecimal" decimals="0" unitRef="USD">375,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Change in fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FairValueAdjustmentOfWarrants_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQUdk6IQWDg1" title="Change in fair value" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-02-152024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" id="Fact000656" format="ixt:numdotdecimal" decimals="0" unitRef="USD">58,180</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FairValueAdjustmentOfWarrants_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zhTcXjj4WLil" title="Change in fair value" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-02-152024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_CallOptionMember" id="Fact000658" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">375,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--DerivativeLiabilitiesNoncurrent_iE_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeYQcoChW2m" title="Derivative warrant liabilities, Balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" id="Fact000660" format="ixt:numdotdecimal" decimals="0" unitRef="USD">87,180</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--DerivativeLiabilitiesNoncurrent_iE_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zfSJPgabLkfk" title="Derivative warrant liabilities, Balance" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0662">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zoiLz4vJKfVi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000664" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zUKPgDAmlig6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information about the Company&#8217;s liabilities that are measured at fair value on a recurring basis at December
31, 2024, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B2_zMdNzDoPK375" style="display: none">SCHEDULE
OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Quoted Prices
    in <br/> Active Markets <br/> (Level 1)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Significant
    Other <br/> Observable Inputs <br/> (Level 2)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Significant
    Other <br/> Unobservable <br/> Inputs (Level 3)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 44%; text-align: left">Derivative warrant liabilities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">3</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zTFE3aAAK2o2" title="Derivative warrant liabilities" style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0666">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zI5XpHzeno74" title="Derivative warrant liabilities" style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0668">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zT3vY3M4tuw6" title="Derivative warrant liabilities" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact000670" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">87,180</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zfdgPue2UFzb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s nonrecurring fair value measurements consist of Series A Preferred Stock. Such fair value measurements are Level 3 inputs.
The Company determined the fair value of Series A Preferred Stock using a Monte Carlo Simulation (&#8220;MCS&#8221;). Key inputs utilized
in the MCS to estimate fair value of Series A Preferred Stock included a range of volatility between&#160;<span id="xdx_90E_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zBQCgsFYWXy" title="Stock, measurement input"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNiMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember" id="Fact000672" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">75</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
to&#160;<span id="xdx_90B_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zY07bkVh1tTi"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNiMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember" id="Fact000673" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">85</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%,
a holding period to a deemed liquidation event, as defined in the Series A Preferred Stock agreement, ranging from&#160;<span id="xdx_900_ecustom--EquitySecuritiesTerm_dtY_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--RangeAxis__srt--MinimumMember_zJ7WOdTcTrch" title="Holding period"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact000675" name="TVGN:EquitySecuritiesTerm">0.5</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;to&#160;<span id="xdx_900_ecustom--EquitySecuritiesTerm_dtY_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--RangeAxis__srt--MaximumMember_zx3jOtbTc9Kk" title="Range in years"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact000677" name="TVGN:EquitySecuritiesTerm">10.0</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;years,
and a risk-free interest rate between&#160;<span id="xdx_90D_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zIZeBBxGPA83" title="Risk-free interest rate percentage"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNiMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember" id="Fact000679" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.3</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
and&#160;<span id="xdx_90B_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zBXxOkIGk7N7" title="Stock, measurement input"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNiMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember" id="Fact000681" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">5.3</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%.
The difference between the cash received of $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zgMvkcSAG6bc" title="Cash received upon issuance of preferred stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact000683" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;upon
issuance of the Series A Preferred Stock and its estimated fair value was recognized as general and administrative expense on the consolidated
statements of operations during the three months ended March 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company used a MCS valuation methodology to determine the fair value of the freestanding $<span id="xdx_905_ecustom--FreeStandingPurchaseOptions_c20240101__20241231_zMcIwfI14nab" title="Free standing purchase options"><ix:nonFraction name="TVGN:FreeStandingPurchaseOptions" contextRef="From2024-01-01to2024-12-31" id="Fact000685" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,000,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;purchase
option and remaining embedded $<span id="xdx_90A_ecustom--EmbeddedOptions_c20240101__20241231_zJt3WvksQt6c" title="Embedded options shares"><ix:nonFraction name="TVGN:EmbeddedOptions" contextRef="From2024-01-01to2024-12-31" id="Fact000687" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,000,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;purchase
option associated with the Loan Agreement as of December 31, 2024. The MCS methodology simulates the Company&#8217;s future stock price
to estimate if and when the Trailing VWAP (as defined below) will reach $<span id="xdx_90A_eus-gaap--SharePrice_iI_uUSDPShares_c20241231_zDGajU2DphH" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-12-31" id="Fact000689" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;per
share, and discounts the resulting payoff back to each valuation date using a present value factor. Significant assumptions used in determining
the fair value of these options include volatility of&#160;<span id="xdx_905_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zO4ZtR8xaGD7"><ix:nonFraction name="us-gaap:AlternativeInvestmentMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputOptionVolatilityMember" id="Fact000690" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">78.3</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
and discount rate of&#160;<span id="xdx_900_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember_zA5hPt9cSmoa" title="Discount rate"><ix:nonFraction name="us-gaap:AlternativeInvestmentMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputDiscountRateMember" id="Fact000692" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.3</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%.
At December 31, 2024, the MCS produced a fair value of $<span id="xdx_901_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20241231_zCSBpPO94ljd" title="Fair value"><ix:nonFraction name="us-gaap:DerivativeFairValueOfDerivativeNet" contextRef="AsOf2024-12-31" id="Fact000694" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">relating to these freestanding and embedded
options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 148; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS
INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000696" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zDD1mMrYTiic" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_863_zfPQfeKGxXZ1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid financial instruments with a maturity date of 90 days or less when purchased to be cash equivalents.
There were <span id="xdx_900_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_do_c20241231_zjoGF4P7HdTl" title="Cash equivalents"><span id="xdx_902_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_do_c20231231_zSAdcokKBeoe" title="Cash equivalents"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-12-31" id="Fact000698" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31" id="Fact000700" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cash
equivalents as of December 31, 2024 and 2023 as all amounts consisted of bank deposits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000702" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_84C_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zdqI5jkunLD6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_864_zoqVO2hfbssd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Property
and Equipment, Net</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000704" name="TVGN:PropertyAndEquipmentUsefulLifeTableTextBlock"><p id="xdx_893_ecustom--PropertyAndEquipmentUsefulLifeTableTextBlock_zHN0wr1ikGj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment is recorded at cost. Depreciation and amortization is provided using straight-line methods over their respective estimated
useful lives. Repairs and maintenance, which do not extend the useful lives of the related assets, are expensed as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B5_zJYD2SpYrHLa" style="display: none">SCHEDULE
OF PROPERTY AND EQUIPMENT USEFUL LIFE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify">Estimated Useful Lives</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 83%; text-align: justify">Computer software</td><td style="width: 2%">&#160;</td>
    <td style="width: 14%; text-align: center"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zYycrtiHNlDj" title="Property, plant and equipment, useful life"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_ComputerEquipmentMember" format="ixt-sec:duryear" id="Fact000706" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_zDnZQPBSz9v3" title="Property, plant and equipment, useful life" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact000708" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zLHnEO71cT9d" title="Property, plant and equipment, useful life"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact000710" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">4</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Office equipment</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zSUqkMCooCEj" title="Property, plant and equipment, useful life"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_OfficeEquipmentMember" format="ixt-sec:duryear" id="Fact000712" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zSoNNhiJr9od" title="Property, plant and equipment, useful life"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember" format="ixt-sec:duryear" id="Fact000714" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">7</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zl5Ugxi1eSE3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews the carrying value of property and equipment whenever events and circumstances indicate that the carrying value of an
asset may not be recoverable from the estimated future cash flows expected to result from its eventual use and disposition. Based on
this assessment, management has determined that there was no impairment during the years ended December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000716" name="us-gaap:LesseeLeasesPolicyTextBlock"><p id="xdx_84A_eus-gaap--LesseeLeasesPolicyTextBlock_zfKTy2QrYHCk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_862_z4mqZGMPTzPj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Leases</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines whether an arrangement is or contains a lease, its classification, and its term at the lease commencement date. Leases
with a term greater than one year will be recognized on the balance sheet as right-of-use (&#8220;ROU&#8221;) assets, current lease liabilities,
and if applicable, long-term lease liabilities. The Company includes renewal options to extend the lease term where it is reasonably
certain that it will exercise these options. Lease liabilities and the corresponding ROU assets are recorded based on the present values
of lease payments over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such,
the Company utilizes the appropriate incremental borrowing rates, which are the rates that would be incurred to borrow on a collateralized
basis, over similar terms, amounts equal to the lease payments in a similar economic environment. If significant events, changes in circumstances,
or other events indicate that the lease term or other inputs have changed, the Company would reassess lease classification, remeasure
the lease liability using revised inputs as of the reassessment date, and adjust the ROU assets. Lease expense is recognized on a straight-line
basis over the expected lease term for operating classified leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases
with an initial term of <span id="xdx_902_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dc_c20241231_zDnUbmG7pY6j" title="Leases initial term"><ix:nonNumeric contextRef="AsOf2024-12-31" format="ixt-sec:durwordsen" id="Fact000718" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm">12 months</ix:nonNumeric></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">or less and without a purchase option that the Company is reasonably
certain of exercising are not included within the lease ROU assets and lease liabilities on the balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000720" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_zIdxFuVgTZNh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_868_z51STCTlamK2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and Development Expenses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development activities are expensed as incurred. Costs for clinical trials and manufacturing activities are recognized based on an
evaluation of our vendors&#8217; progress towards completion of specific tasks, using data such as participant enrollment, clinical site
activations, or information provided to us by vendors regarding their actual costs incurred. Payments for these activities are based
on the terms of individual contracts and payment timing may differ significantly from the period in which the services were performed.
The Company determines accrual estimates through reports from and discussions with applicable personnel and outside service providers
as to the progress or state of completion of studies, or the services completed. The Company estimates accrued expenses as of each balance
sheet date based on the facts and circumstances known at the time. Costs that are paid in advance of performance are deferred as a prepaid
expense and amortized over the service period as the services are provided.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 149; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS
INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000722" name="us-gaap:CompensationRelatedCostsPolicyTextBlock"><p id="xdx_840_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zlWE40LQEnBa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_867_zN8KNyRNRiS1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock-Based
Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation
cost is measured at the grant date fair value of the award and is recognized over the vesting period of the award. The Company uses the
straight-line method to record compensation expense of awards with service-based vesting conditions. The Company accounts for forfeitures
of awards as they occur rather than applying an estimated forfeiture rate to stock-based compensation expense. The Company recognizes
compensation expense for awards with performance conditions when it is probable that the condition will be met, and the award will vest.
Prior to the Merger, the Company estimated the fair value of the Company&#8217;s common stock on the date of grant in accordance with
the guidance outlined in the American Institute of Certified Public Accountants&#8217; <i>Accounting and Valuation Guide, Valuation of
Privately-Held-Company Equity Securities Issued as Compensation</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000724" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zoWCJBw0vlYh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_866_zldsYnnmPWEb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Income
Taxes</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes using the asset and liability method in accordance with ASC Topic 740, <i>Income Taxes </i>(&#8220;ASC
740&#8221;), which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events
that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities
are determined on the basis of the differences between the financial statement and tax basis of assets and liabilities using enacted
tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are
recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future
taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all
or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense.
Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent
and feasible tax planning strategies. At December 31, 2024 and 2023, the Company has concluded that a full valuation allowance is necessary
for its net deferred tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000726" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_84B_eus-gaap--EarningsPerSharePolicyTextBlock_zPrUSe34nzZ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_869_znCeJn71YSG1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net
Loss Per Share</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company computes basic net loss per share by dividing net loss by the weighted-average common stock outstanding during the period. Given
the Company&#8217;s net loss, basic and diluted net loss per share for the years ended December 31, 2024 and 2023 are the same.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000728" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zWIqaAo2igS8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_862_zOYer4WwVUw5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recently
Issued Accounting Standards</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, the FASB issued ASU No. 2020-06, <i>Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and
Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815 -40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s
Own Equity </i>(&#8220;ASU 2020-06&#8221;), which simplifies the accounting for convertible instruments by reducing the number of accounting
models available for convertible debt instruments. ASU 2020-06 also eliminates the treasury stock method to calculate diluted earnings
per share for convertible instruments and requires the use of the if-converted method. Effective January 1, 2024, the Company adopted
ASU 2020-06 and that adoption did not have an impact on its consolidated financial statements and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the FASB issued ASU No. 2023-07,&#160;<i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&#160;</i>(&#8220;ASU
2023-07&#8221;). ASU 2023-07 enhances reportable segment disclosures by requiring disclosures such as significant segment expenses. The
main provisions of this update require companies to disclose, on an annual and interim basis, significant segment expenses, segment profit
and loss, and other segments items that are regularly provided to the chief operating decision maker (&#8220;CODM&#8221;). This update
also requires companies to disclose the title and position of the CODM and to explain how the CODM uses the reported segment measures
in assessing segment performance and deciding how to allocate resources. The update also requires companies with a single reportable
segment to provide all required segment reporting disclosures. This new standard is effective for fiscal years beginning after December
15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company adopted this standard on January 1,
2024 for annual reporting and interim periods beginning in 2025. See Note 16 for additional disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 150; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS
INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU 2024-03, <i>Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures,
(Subtopic 220-40) </i>(&#8220;ASU 2024-03&#8221;). ASU 2024-03 improves disclosures regarding the types of expenses included in commonly
presented expense captions, including disaggregating the amounts of employee compensation, depreciation and amortization included within
each income statement expense caption. This standard is effective for fiscal years beginning after December 15, 2026, and interim periods
within fiscal years beginning after December 15, 2027. The Company is currently evaluating the impact of the standard on its consolidated
financial statements and disclosures.</span></p>

</ix:nonNumeric><p id="xdx_853_znCRnm9LZro" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000730" name="us-gaap:BusinessCombinationDisclosureTextBlock"><p id="xdx_802_eus-gaap--BusinessCombinationDisclosureTextBlock_zqNIOxtWAU41" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4.&#160;<span id="xdx_82A_zDbQ2iMDygAd">BUSINESS COMBINATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the Closing Date, the Company completed the Business Combination described in Note 1. The Merger was accounted for as a reverse recapitalization
under GAAP because Tevogen Bio was determined to be the accounting acquirer based upon the terms of the Merger and other factors, including
that following the Merger, former Tevogen Bio (i) equity holders and holders of convertible promissory notes owned approximately&#160;<span id="xdx_90A_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TevogenBioMember_zpb728IdYnI5" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2024-12-31_custom_TevogenBioMember" id="Fact000732" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">91.0</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the Company, (ii) directors constituted the majority (six of seven) of the directors of the Company, and (iii) management held all
key positions of management of the Company. Accordingly, the Merger was treated as the equivalent of Tevogen Bio issuing stock to acquire
the net assets of Semper Paratus. As a result of the Merger, the net liabilities of Semper Paratus were recorded at their acquisition-date
fair value in the consolidated financial statements and the reported operating results prior to the Merger are those of Tevogen Bio.
Immediately after the Merger, there were&#160;<span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_c20240214_zm7oVlVJKBmh" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-02-14" id="Fact000734" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">164,614,418</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;shares
of the Company&#8217;s common stock outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000736" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_zJzX1OzWkW2l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the net liabilities acquired in the Merger:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8BF_zCTQj89vyov1" style="display: none">SCHEDULE OF NET LIABILITIES
ACQUIRED IN MERGER</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240214_zbcnrScvqKR1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">February&#160;14,&#160;2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_maBCRIAzgn3_z9Io3A3mnHy3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Cash</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" contextRef="AsOf2024-02-14" id="Fact000738" format="ixt:numdotdecimal" decimals="0" unitRef="USD">229,328</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_iI_maBCRIAzgn3_z0mQ6Jgtmb0h" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Due from Sponsor</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" contextRef="AsOf2024-02-14" id="Fact000740" format="ixt:numdotdecimal" decimals="0" unitRef="USD">158,819</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_iI_maBCRIAzgn3_zl4ektKvznGj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid expenses and other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" contextRef="AsOf2024-02-14" id="Fact000742" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,501</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iNI_di_msBCRIAzgn3_zQnadgn4rRHk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" contextRef="AsOf2024-02-14" id="Fact000744" format="ixt:numdotdecimal" decimals="0" unitRef="USD">96,175</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_iNI_di_msBCRIAzgn3_zY1HfC6433le" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="TVGN:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" contextRef="AsOf2024-02-14" id="Fact000746" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,269,126</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_iNI_di_msBCRIAzgn3_zZRAK9OX6HM8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" contextRef="AsOf2024-02-14" id="Fact000748" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,651,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_iNI_di_msBCRIAzgn3_zPRMCGucTFN8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Derivative warrant liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" contextRef="AsOf2024-02-14" id="Fact000750" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iTI_mtBCRIAzgn3_maBCRIAzidu_ztgwK4PBMIHb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total net liabilities acquired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" contextRef="AsOf2024-02-14" id="Fact000752" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,654,653</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--MergerTransactionCostsLimitedToCashAcquired_iI_maBCRIAzidu_z4zGz7PO8Sa4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Plus: Merger transaction costs limited to cash acquired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="TVGN:MergerTransactionCostsLimitedToCashAcquired" contextRef="AsOf2024-02-14" id="Fact000754" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">229,328</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts_iTI_mtBCRIAzidu_z3Z0rZNtOiEc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total net liabilities acquired plus transaction costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="TVGN:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts" contextRef="AsOf2024-02-14" id="Fact000756" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,883,981</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zqlUY39z45fd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
transaction costs of $<span id="xdx_906_eus-gaap--BusinessCombinationAcquisitionRelatedCosts_c20240214__20240214_zcK3LwHoWqu5" title="Transaction costs"><ix:nonFraction name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" contextRef="From2024-02-142024-02-14" id="Fact000758" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,728,681</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;were
incurred in relation to the Business Combination through the Closing Date, of which $<span id="xdx_903_eus-gaap--BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_iI_c20240214_z0JxgTGn9CSj" title="Transaction costs charged to equity"><ix:nonFraction name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" contextRef="AsOf2024-02-14" id="Fact000760" format="ixt:numdotdecimal" decimals="0" unitRef="USD">229,328</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;were
charged directly to equity to the extent of the cash received from the Business Combination, with the balance of $<span id="xdx_909_eus-gaap--BusinessCombinationAcquisitionRelatedCosts_c20240101__20241231_zOJEgRME5SF6" title="Merger transaction costs"><ix:nonFraction name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" contextRef="From2024-01-01to2024-12-31" id="Fact000762" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,499,353</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;charged
to Merger transaction costs for the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Former
holders of Tevogen Bio common stock and the Sponsor are eligible to receive up to an aggregate of&#160;<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20240214__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_ztQMKkaGXToh" title="Earnout shares issuable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-02-14_custom_EarnoutSharesMember" id="Fact000764" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,500,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;shares
of common stock (&#8220;Earnout Shares&#8221;) if the volume-weighted average price (the &#8220;VWAP&#8221;) of the Company&#8217;s common
stock reaches specified threshold levels during the three-year period commencing on the Closing Date. Refer to Note 5, Earnout Shares,
for further details of the earnout arrangement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Merger, the Company issued Series B Preferred Stock to the Sponsor in return for the Sponsor assuming $<span id="xdx_90B_ecustom--StockIssuedDuringPeriodValueNewIssuesOne_c20240214__20240214_zhmT0tkR4K6g" title="New issuance value"><ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueNewIssuesOne" contextRef="From2024-02-142024-02-14" id="Fact000766" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,613,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;of
liabilities and obligations (&#8220;Assumed Liabilities&#8221;) of Semper Paratus and Tevogen Bio. The issuance date fair value of the
Series B Preferred Stock was recorded to Merger transaction costs within the consolidated statements of operations. All of the issued
Series B Preferred Stock was repurchased by the Company during the three months ended June 30, 2024 in exchange for the Sponsor being
released from their obligation to repay the Assumed Liabilities. See Note 12 for additional information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 151; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS
INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000768" name="TVGN:EarnoutSharesDisclosureTextBlock"><p id="xdx_806_ecustom--EarnoutSharesDisclosureTextBlock_zagX6b1RQoS5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5.&#160;<span id="xdx_82B_znlZKg6laZk7">EARNOUT SHARES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the Closing, former holders of Tevogen Bio common stock may receive up to&#160;<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20241231__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_zt67oQ3JkOM2" title="Earnout shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-12-31_custom_TevogenBioCommonStockMember_custom_EarnoutSharesMember" id="Fact000770" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Earnout
Shares in tranches of&#160;<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20241231__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_zRX8DRXnEewa" title="Earnout shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-12-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember_custom_EarnoutSharesMember" id="Fact000772" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,666,667</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,&#160;<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20241231__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_zAC3jlxHCxN5" title="Earnout shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-12-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_custom_EarnoutSharesMember" id="Fact000774" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,666,667</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
and&#160;<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20241231__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_zuvEsTKHrt37" title="Earnout shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-12-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_custom_EarnoutSharesMember" id="Fact000776" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,666,666</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;shares
of common stock per tranche, respectively. The first, second, and third tranches are issuable if the VWAP per share of the Company&#8217;s
common stock is greater or equal to $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241231__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQfktJPCqMR7" title="Shares issued, price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-12-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember_us-gaap_CommonStockMember" id="Fact000778" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">15.00</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
$<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241231__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zslYvEivslpf" title="Shares issued, price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-12-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_us-gaap_CommonStockMember" id="Fact000780" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">17.50</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
and $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241231__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLC8ZTppmgR3" title="Shares issued, price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-12-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_us-gaap_CommonStockMember" id="Fact000782" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.00</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively, over any twenty trading days within any thirty consecutive day trading period during the three-year period after the Closing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Sponsor received the right to Earnout Shares with the same terms above, except that each of the Sponsor&#8217;s three earnout tranches
are for&#160;<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20241231__srt--TitleOfIndividualAxis__custom--SponsorMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember_zZt0gzpM7SQf" title="Earnout shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-12-31_custom_SponsorMember_custom_EarnoutSharesMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" id="Fact000784" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;shares
of common stock, for an aggregate of&#160;<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20241231__srt--TitleOfIndividualAxis__custom--SponsorMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_ziei3aO7tYy8" title="Earnout shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-12-31_custom_SponsorMember_custom_EarnoutSharesMember" id="Fact000786" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,500,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;shares
of common stock across the entire Sponsor earnout. The Earnout Shares are a form of dividend for holders of Tevogen Bio common stock,
and the Earnout Shares earnable by the Sponsor are treated as contingent consideration in a reverse recapitalization. In accordance with
ASC 815, the Earnout Shares were considered to be indexed to the Company&#8217;s common stock and are classified within permanent equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000788" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_805_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_z8VPehfYwEia" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6. <span id="xdx_823_zklmFykksWod">PROPERTY AND EQUIPMENT, NET</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000790" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_895_eus-gaap--PropertyPlantAndEquipmentTextBlock_zyTLeod1iAYg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B7_zL4gRjUr8gL8" style="display: none">SCHEDULE
OF PROPERTY AND EQUIPMENT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20241231_z2fTAjjPcK87" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20231231_zafoUtjWTt3c" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerAndSoftwareMember_zLcF9UHhLe03" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Computer software</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_custom_ComputerAndSoftwareMember" id="Fact000792" format="ixt:numdotdecimal" decimals="0" unitRef="USD">292,341</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_custom_ComputerAndSoftwareMember" id="Fact000793" format="ixt:numdotdecimal" decimals="0" unitRef="USD">292,341</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zWEzRTWh31K3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember" id="Fact000795" format="ixt:numdotdecimal" decimals="0" unitRef="USD">263,217</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember" id="Fact000796" format="ixt:numdotdecimal" decimals="0" unitRef="USD">263,217</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zOA54W6JoE32" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_us-gaap_OfficeEquipmentMember" id="Fact000798" format="ixt:numdotdecimal" decimals="0" unitRef="USD">132,468</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_us-gaap_OfficeEquipmentMember" id="Fact000799" format="ixt:numdotdecimal" decimals="0" unitRef="USD">132,468</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zAxeUorRM0F7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Furniture and fixtures</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember" id="Fact000801" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,743</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember" id="Fact000802" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,743</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzFLE_z9CL68pLllfg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31" id="Fact000804" format="ixt:numdotdecimal" decimals="0" unitRef="USD">721,769</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31" id="Fact000805" format="ixt:numdotdecimal" decimals="0" unitRef="USD">721,769</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzFLE_zDXDRLq09mIh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Less: accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2024-12-31" id="Fact000807" format="ixt:numdotdecimal" decimals="0" unitRef="USD">425,327</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2023-12-31" id="Fact000808" format="ixt:numdotdecimal" decimals="0" unitRef="USD">263,118</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzFLE_zd2iNvK6JHzf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total property and
    equipment, net</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-12-31" id="Fact000810" format="ixt:numdotdecimal" decimals="0" unitRef="USD">296,442</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact000811" format="ixt:numdotdecimal" decimals="0" unitRef="USD">458,651</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zsRWGRsOH3c1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense for the years ended December 31, 2024 and 2023 was $<span id="xdx_905_eus-gaap--Depreciation_c20240101__20241231_zi2l51PiBoSk" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-01-01to2024-12-31" id="Fact000813" format="ixt:numdotdecimal" decimals="0" unitRef="USD">162,209</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_900_eus-gaap--Depreciation_c20230101__20231231_zpc6SRupOUdg" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-01-012023-12-31" id="Fact000815" format="ixt:numdotdecimal" decimals="0" unitRef="USD">163,300</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000817" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"><p id="xdx_804_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_z6RfvuWeYq5f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
7. <span id="xdx_827_zRrSDVU9XqN4">ACCRUED EXPENSES AND OTHER LIABILITIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000819" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zRlUj4VqPk4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses and other liabilities consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BE_zB2Az3kYPDPi" style="display: none">SCHEDULE
OF ACCRUED EXPENSES AND OTHER LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_496_20241231_zjOO0oCsnLwg" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20231231_z9WXnm6jsJTl" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
    31,</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--AccruedProfessionalFeesCurrent_iI_maALCzC3I_zGgDsihN9oXg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 62%; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Professional
    services</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 16%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2024-12-31" id="Fact000821" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,309,163</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 16%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2023-12-31" id="Fact000822" format="ixt:numdotdecimal" decimals="0" unitRef="USD">976,301</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maALCzC3I_zrCYjFa3Avbi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000824" format="ixt:numdotdecimal" decimals="0" unitRef="USD">403,233</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000825" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,149</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzC3I_zmG7bIjIJOo2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000827" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,712,396</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000828" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,096,450</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A2_z7WvcneI6UYf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000830" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_800_eus-gaap--DebtDisclosureTextBlock_zw2kLZQBNkj1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
8.&#160;<span id="xdx_823_zgdJfRsQOU48">DEBT</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 14, 2024, in connection with the consummation of the Business Combination, previously issued promissory notes and accrued interest
were automatically converted into an aggregate of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20240214__20240214__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlWQrcXAraJ8" title="Converted shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2024-02-142024-02-14_us-gaap_CommonStockMember" id="Fact000832" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,337,419</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock. These debt obligations
were retired upon conversion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 152; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS
INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Loan
Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2024, the Company entered into a Loan Agreement (the &#8220;Loan Agreement&#8221;) with The Patel Family, LLP (the &#8220;Patel
Family&#8221;), a related party of the Company, providing for an unsecured line of credit facility (the &#8220;Facility&#8221;) for term
loans of up to an initial total of $<span id="xdx_90B_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_z3rwGeRKyp6c" title="Line of credit maximum borrowing capacity"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember" id="Fact000834" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,000,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
Under the Facility, the Company may draw up to $<span id="xdx_903_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_ztPZbIxcq55h" title="Line of credit borrowing capacity"><ix:nonFraction name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" contextRef="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember" id="Fact000836" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;in
term loans per calendar month over a draw period of 36 months. Each term loan draw will have a maturity date of&#160;<span id="xdx_90C_eus-gaap--DebtInstrumentTerm_dtM_c20240601__20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zJMa7xPDymH5" title="Debt maturity date"><ix:nonNumeric contextRef="From2024-06-012024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember" format="ixt-sec:durmonth" id="Fact000838" name="us-gaap:DebtInstrumentTerm">48</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;months
and will accrue interest at the lower of (i) daily SOFR plus&#160;<span id="xdx_903_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zhr7Tpjltdag" title="Debt instrument variable rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember" id="Fact000840" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.00</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
and (ii)&#160;<span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zc06Lxl0USuj" title="Debt instrument interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember" id="Fact000842" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.00</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%.
Interest accrues quarterly and is payable on the three-month anniversary of the draw date. Interest is payable in shares of common stock
at an effective price of $<span id="xdx_90F_eus-gaap--SharePrice_iI_c20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zrMQbfykxT5d" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember" id="Fact000844" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.50</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;per
share. Interest payable through December 31, 2024 relating to the first two draws on the Facility were settled in February 2025 through
issuance of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zKfL1dDXu1S2" title="Shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-12-31_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember" id="Fact000846" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,847</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock. Principal may
be prepaid at any time without penalty, and repayments or prepayments may be made in cash or common stock at the Company&#8217;s election.
Payments of principal in common stock would be made at an effective price of the greater of $<span id="xdx_90F_eus-gaap--SharePrice_iI_c20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember__srt--RangeAxis__srt--MaximumMember_zK5gCn2eQJfc" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-06-30_custom_ThePatelFamilyLLPMember_custom_LoanAgreementMember_us-gaap_UnsecuredDebtMember_srt_MaximumMember" id="Fact000848" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.50</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;per
share and the ten-day trailing volume weighted average price per share of the common stock (the &#8220;Trailing VWAP&#8221;) as of the
trading day prior to payment. As an inducement to enter into the Loan Agreement, the Company issued&#160;<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240601__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zhosEAWuDlCb" title="Issuance of shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-06-012024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember" id="Fact000850" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;shares
of common stock to the Patel Family during June 2024. As of December 31, 2024, the Company has drawn $<span id="xdx_907_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zhqC3Y2o57Ij" title="Line of credit borrowing capacity"><ix:nonFraction name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" contextRef="AsOf2024-12-31_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember" id="Fact000852" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;from
the Facility, with maturity dates in July and August 2028, with a remaining $<span id="xdx_900_eus-gaap--LineOfCreditFacilityRemainingBorrowingCapacity_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zKEoY04aRsli" title="Line of credit remaining capacity"><ix:nonFraction name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" contextRef="AsOf2024-12-31_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember" id="Fact000854" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,000,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;available
for future financing over the remaining&#160;<span id="xdx_908_eus-gaap--DebtInstrumentTerm_dtM_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zPMZFpcBxoJi" title="Debt maturity date"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember" format="ixt-sec:durmonth" id="Fact000856" name="us-gaap:DebtInstrumentTerm">30</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;months.
The Company drew an additional $<span id="xdx_90A_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20250228__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zHXGIGQ17x75" title="Line of credit borrowing capacity"><span id="xdx_905_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20250331__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zYqwI2uqfct5" title="Line of credit borrowing capacity"><ix:nonFraction name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" contextRef="AsOf2025-02-28_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember_us-gaap_SubsequentEventMember" id="Fact000858" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" contextRef="AsOf2025-03-31_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember_us-gaap_SubsequentEventMember" id="Fact000860" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,000</ix:nonFraction></ix:nonFraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in each of February and March 2025, with
maturity dates in February and March 2029, respectively (see Note 17).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Loan Agreement includes a purchase option whereby the Patel Family has the option to purchase up to $<span id="xdx_909_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensationGross_c20240601__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zN5WdCriU1oh" title="Option to purchase common stock, value"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross" contextRef="From2024-06-012024-06-30_custom_ThePatelFamilyLLPMember_custom_LoanAgreementMember" id="Fact000862" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,000,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;of
shares of common stock at a purchase price equal to&#160;<span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_pid_dp_uPure_c20240601__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zs03c8p9FpJ1" title="Percentage of price of common stock purchased"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="From2024-06-012024-06-30_custom_ThePatelFamilyLLPMember_custom_LoanAgreementMember" id="Fact000864" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">70</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the Trailing VWAP per share (the &#8220;$<span id="xdx_905_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensationGross_pn6n6_c20240601__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zNZq2yLBs2Ic" title="Option to purchase common stock, value"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross" contextRef="From2024-06-012024-06-30_custom_ThePatelFamilyLLPMember_custom_LoanAgreementMember" id="Fact000866" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">14</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;million
Purchase Option&#8221;). The $<span id="xdx_900_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensationGross_pn6n6_c20240601__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zbmPytDfLmsj" title="Option to purchase common stock, value"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross" contextRef="From2024-06-012024-06-30_custom_ThePatelFamilyLLPMember_custom_LoanAgreementMember" id="Fact000868" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">14</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;million
Purchase Option only becomes exercisable once Trailing VWAP reaches $<span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_c20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_zoP8P3O1Mj0h" title="Purchase, price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember" id="Fact000870" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;per
share. The $<span id="xdx_90A_eus-gaap--DerivativeLiabilities_iI_pn6n6_c20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zvcNqi4vgof3" title="Derivative liability"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember" id="Fact000872" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">14</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;million
Purchase Option was determined to be a freestanding derivative liability under ASC 815 and is carried at fair value, with changes in
fair value recorded to change in fair value of written call option derivatives liabilities within the consolidated statements of operations
and consolidated statements of cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Loan Agreement also includes a purchase option (the &#8220;Additional Amount Purchase Option&#8221;) that is identical to the $<span id="xdx_90E_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensationGross_pn6n6_c20240601__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AdditionalAmountPurchaseOptionMember_zztYjOylm645" title="Option to purchase common stock, value"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross" contextRef="From2024-06-012024-06-30_custom_ThePatelFamilyLLPMember_custom_LoanAgreementMember_custom_AdditionalAmountPurchaseOptionMember" id="Fact000874" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">14</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;million
Purchase Option, except that the option is exercisable for an amount up to the then-remaining undrawn term loan amount under the Loan
Agreement at the time Trailing VWAP reaches $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_c20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AdditionalAmountPurchaseOptionMember_zVJdG09Z1zMj" title="Purchase, price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_custom_AdditionalAmountPurchaseOptionMember" id="Fact000876" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;per
share. The Additional Amount Purchase Option was determined to be an embedded derivative within the written loan commitment that requires
bifurcation under ASC 815, and thus is carried at fair value with changes in fair value recorded to change in fair value of written call
option derivatives liabilities within the consolidated statements of operations and consolidated statements of cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
$<span id="xdx_909_eus-gaap--DerivativeLiabilities_iI_pn6n6_c20240630_zFmdl79XH6Bg" title="Derivative liability"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2024-06-30" id="Fact000878" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">14</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;million
Purchase Option and the Additional Amount Purchase Option are recorded to written call option derivative liabilities within the consolidated
balance sheet and have a fair value of $<span id="xdx_906_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20241231_zSuuARFpSgrh" title="Derivative liabilities"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000880" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Loan Agreement is a written loan commitment that is not eligible for the fair value option under ASC 825,&#160;<i>Financial Instruments</i>.
However, management intends to elect the fair value option for future draws under this commitment, and therefore has expensed all issuance
costs associated with the Loan Agreement, which are comprised of the fair value of the&#160;<span id="xdx_90C_ecustom--StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility_c20240601__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_z2m85ELBeYTc" title="Line of credit facility shares"><ix:nonFraction name="TVGN:StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility" contextRef="From2024-06-012024-06-30_custom_ThePatelFamilyLLPMember_custom_LoanAgreementMember" id="Fact000882" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;shares
of common stock issued to the Patel Family as well as the issuance date fair value of the $<span id="xdx_90F_eus-gaap--DerivativeLiabilities_iI_pn6n6_c20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zqXtJwOpLcnc" title="Derivative liability"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember" id="Fact000884" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">14</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;million
Purchase Option and Additional Amount Purchase Option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Notes
Payable</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the Merger, the Company assumed notes payable held by Polar Multi-Strategy Master Fund (&#8220;Polar&#8221;) for which the
proceeds were to be used for working capital purposes by Semper Paratus with an outstanding balance of $<span id="xdx_902_eus-gaap--NotesPayableCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PolarMultiStrategyMasterFundMember_z3rY3o5uyHX6" title="Notes payable"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2024-12-31_custom_PolarMultiStrategyMasterFundMember" id="Fact000886" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,651,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;on
the Closing Date and remain outstanding at December 31, 2024. The notes payable do not accrue interest. The outstanding balance of the
notes was required to be repaid in full within five business days of the Merger, and the Company is therefore in default of its obligations
at December 31, 2024. The notes&#8217; default provisions do not require the Company to transfer any shares or pay any amounts to Polar.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 153; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS
INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000888" name="us-gaap:OperatingLeasesOfLessorDisclosureTextBlock"><p id="xdx_80E_eus-gaap--OperatingLeasesOfLessorDisclosureTextBlock_zc3CeCOj6qU6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9. <span id="xdx_82C_zArk9wUoyvf7">LEASES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2022, the Company entered into leases for office and laboratory space in Warren Township, New Jersey and Philadelphia, Pennsylvania under
operating leases expiring in February 2026 and July 2025, respectively. The leases require fixed monthly payments of rent, as well as
a share of operating costs. The leases are classified as operating leases and the lease liabilities were calculated using incremental
borrowing rates ranging from <span id="xdx_901_ecustom--OperatingLeasesIncrementalBorrowingRates_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_zM9BKtznH8Yg" title="Operating leases incremental borrowing rates"><ix:nonFraction name="TVGN:OperatingLeasesIncrementalBorrowingRates" contextRef="From2024-01-012024-12-31_srt_MinimumMember" id="Fact000890" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">11.0</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
to <span id="xdx_902_ecustom--OperatingLeasesIncrementalBorrowingRates_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zWk0ioLAECGb" title="Operating leases incremental borrowing rates"><ix:nonFraction name="TVGN:OperatingLeasesIncrementalBorrowingRates" contextRef="From2024-01-012024-12-31_srt_MaximumMember" id="Fact000892" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">11.2</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%,
which was determined using a synthetic credit rating model. Lease expense for the year ended December 31, 2024 was $<span id="xdx_907_eus-gaap--OperatingLeaseExpense_c20240101__20241231_z0wILeVXmThd" title="Operating lease expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000894" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,065,784</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
which consisted of $<span id="xdx_908_eus-gaap--OperatingLeaseExpense_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentArrangementMember_zZO81HfiBvi3" title="Operating lease expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentArrangementMember" id="Fact000896" format="ixt:numdotdecimal" decimals="0" unitRef="USD">897,958</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_906_eus-gaap--OperatingLeaseExpense_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zKHxjj4OAQvc" title="Operating lease expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact000898" format="ixt:numdotdecimal" decimals="0" unitRef="USD">167,826</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recognized as a component of research
and development expense and general and administrative expense, respectively. This amount included $<span id="xdx_903_eus-gaap--ShortTermLeasePayments_c20240101__20241231_zyfKBUXNg9Tg" title="Short term lease"><ix:nonFraction name="us-gaap:ShortTermLeasePayments" contextRef="From2024-01-01to2024-12-31" id="Fact000900" format="ixt:numdotdecimal" decimals="0" unitRef="USD">785,424</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of expense under short-term leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average remaining lease term for the Company&#8217;s operating leases as of December 31, 2024 was <span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_zflP0svOdGRa" title="Operating leases weighted average remaining lease term"><ix:nonNumeric contextRef="AsOf2024-12-31" format="ixt-sec:duryear" id="Fact000902" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">0.93</ix:nonNumeric>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years. The weighted average discount rate
for the Company&#8217;s operating leases for the year ended December 31, 2024 was <span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20241231_zZUuLFURavl6" title="Operating leases weighted average discount rate"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2024-12-31" id="Fact000904" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">11.1</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000906" name="TVGN:ScheduleOfCompanyLeaseLiabilitiesTableTextBlock"><p id="xdx_895_ecustom--ScheduleOfCompanyLeaseLiabilitiesTableTextBlock_z5Amd0mc7FH6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
aggregate minimum rental payments under the operating leases as of December 31, 2024 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B5_z56qhGR4fHig" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF MINIMUM RENTAL PAYMENTS UNDER THE OPERATING LEASES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">Years Ending December 31,</td><td>&#160;</td>
    <td colspan="2" id="xdx_49D_20241231_ziRvYQE54ivl" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maOLLzALR_zmGsqaMQdUM" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2024-12-31" id="Fact000908" format="ixt:numdotdecimal" decimals="0" unitRef="USD">230,471</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maOLLzALR_zGr95ElDsClh" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">2026</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2024-12-31" id="Fact000910" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,975</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtOLLzALR_zrMvbdd8G9Lh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2024-12-31" id="Fact000912" format="ixt:numdotdecimal" decimals="0" unitRef="USD">244,446</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zS0rZ8shQAB6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2024-12-31" id="Fact000914" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,587</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiability_iTI_zj9oIpfMdBmb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Operating lease liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2024-12-31" id="Fact000916" format="ixt:numdotdecimal" decimals="0" unitRef="USD">234,859</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zNODONkrSBx2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
cash payments related to leases for the years ended December 31, 2024 and 2023 were $<span id="xdx_90F_eus-gaap--OperatingLeasePayments_c20240101__20241231_zbQfrmSDpMK" title="Cash payments"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2024-01-01to2024-12-31" id="Fact000918" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,077,127</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_909_eus-gaap--OperatingLeasePayments_c20230101__20231231_zj7JgaiK49mk" title="Cash payments"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2023-01-012023-12-31" id="Fact000920" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,058,754</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000922" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_80E_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zHq3GNNa6Zf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10. <span id="xdx_821_zsWcklDknXOc">COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employment
contracts</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered into employment contracts with its officers and certain employees that provide for severance and continuation of
benefits in the event of termination of employment either by the Company without cause or by the employee for good reason, both as defined
in the applicable agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contingencies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities
for loss contingencies arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is probable
that a liability has been incurred and the amount of the assessment and/or remediation can be reasonably estimated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000924" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_808_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zyMCODyWWnya" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
11. <span id="xdx_827_z4dAxgKik4m6">STOCK-BASED COMPENSATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Closing, the Company adopted the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan (the &#8220;2024 Plan&#8221;)
and no longer grants awards pursuant to the 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;). Each RSU award granted under the
2020 Plan that was outstanding and unvested as of the Closing Date was automatically canceled and converted into an award under the 2024
Plan with respect to the common stock of the Company (the &#8220;Rollover RSUs&#8221;). Such Rollover RSUs remain subject to the same
terms and conditions as set forth under the applicable award agreement prior to the Closing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to covering the Rollover RSUs, under the 2024 Plan, the Company is authorized to grant awards up to an aggregate&#160;<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourPlanMember_zkaAUew16Z37" title="Granted shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2024-12-31_custom_TwoThousandTwentyFourPlanMember" id="Fact000926" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,000,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;shares
of common stock. The 2024 Plan provides for the grant of options, stock appreciation rights, Restricted Stock, RSUs, and other equity-based
awards. As of December 31, 2024, awards for <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourPlanMember_z7HKfBKy4zE6" title="Shares available for granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2024-12-31_custom_TwoThousandTwentyFourPlanMember" id="Fact000928" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,670,118</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares remained available to be granted
under the 2024 Plan.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has issued RSUs that are subject to either service-based vesting conditions or service-based and performance-based vesting conditions.
Compensation expense for service-based RSUs are recognized on a straight-line basis over the vesting period of the award. Compensation
expense for service-based and performance-based RSUs (&#8220;Performance-Based RSUs&#8221;) are recognized when the performance condition,
which is based on a liquidity event condition being satisfied, is deemed probable of achievement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 154; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS
INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the Closing Date, the Company issued an aggregate of&#160;<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240214__20240214__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourPlanMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z84ak8g02yQ4" title="Number of shares issued for RSUs"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2024-02-142024-02-14_custom_TwoThousandTwentyFourPlanMember_srt_ChiefExecutiveOfficerMember" id="Fact000930" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">19,348,954</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;RSUs
under the 2024 Plan to the Company&#8217;s Chief Executive Officer, Dr. Ryan Saadi (the &#8220;Special RSU Award&#8221;). Such RSUs immediately
converted into shares of Restricted Stock, the restrictions on which lapse in four equal annual installments beginning on February 14,
2031 (&#8220;Vesting Period&#8221;). Pursuant to the terms of the Special RSU Award, Dr. Saadi will be entitled to vote the Restricted
Stock, but the shares may not be sold, assigned, transferred, pledged, hypothecated, or otherwise encumbered, subject to forfeit. Dr.
Saadi will automatically forfeit all unvested Restricted Stock in the event he departs the Company. The fair value per share for the
Special RSU Award was determined to be $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20240214__20240214__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourPlanMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_ziRYnY7CEYVf" title="Fair value per share for award"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-02-142024-02-14_custom_TwoThousandTwentyFourPlanMember_srt_ChiefExecutiveOfficerMember" id="Fact000932" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.51</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;per
share, equivalent to the Company&#8217;s stock price on the Closing Date, resulting in a total grant date fair value of $<span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20240214__20240214__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourPlanMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zs7oTBLqaQu3" title="Grant date fair value of shares"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="From2024-02-142024-02-14_custom_TwoThousandTwentyFourPlanMember_srt_ChiefExecutiveOfficerMember" id="Fact000934" format="ixt:numdotdecimal" decimals="0" unitRef="USD">87,263,783</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
In accordance with ASC 718,&#160;<i>Compensation - Stock Compensation&#160;</i>(&#8220;ASC 718&#8221;), the Company will recognize compensation
expense on a straight-line basis from the Closing Date until the completion of the Vesting Period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000936" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zg71PxSY1j3d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
Stock and RSU activity was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BB_zKiyxUa8Uqya" style="display: none">SCHEDULE
OF RESTRICTED STOCK AND RSU ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Service-Based Restricted Stock and
    RSUs</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average grant-date fair
    value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Nonvested as of January 1, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zYkbcEwtskV6" title="Nonvested Shares, Beginning" style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0938">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zTw0SUr5swm" title="Nonvested weighted average grant-date fair value, Beginning" style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0940">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zSMKKQsYVatk" title="Nonvested Shares, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0942">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zfQCmYSGg127" title="Nonvested weighted average grant-date fair value, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0944">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zYGORBC0qyr8" title="Nonvested Shares, Vested" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0946">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zgzleRueiFa5" title="Nonvested weighted average grant-date fair value, Vested" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0948">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_z0nVoVud6em5" title="Nonvested Shares, Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0950">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zxUFVKPP1Mf5" title="Nonvested weighted average grant-date fair value, Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0952">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Nonvested as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zl7TdslQqUz7" title="Nonvested Shares, Beginning" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0954">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zVjv6BEq74j5" title="Nonvested weighted average grant-date fair value, Beginning" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0956">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%">Granted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zmhyAJn6R25k" title="Nonvested Shares, Granted" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2024-01-012024-12-31_custom_ServiceBasedRestrictedStockMember" id="Fact000958" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">29,329,882</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zIVhFVfiUd26" title="Nonvested weighted average grant-date fair value, Granted" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-12-31_custom_ServiceBasedRestrictedStockMember" id="Fact000960" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.31</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zb4N3FdAt0F4" title="Nonvested Shares, Vested" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2024-01-012024-12-31_custom_ServiceBasedRestrictedStockMember" id="Fact000962" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,639,628</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zjmY3Ryy46re" title="Nonvested weighted average grant-date fair value, Vested" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-12-31_custom_ServiceBasedRestrictedStockMember" id="Fact000964" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.96</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zOT6oxpXsWYh" title="Nonvested Shares, Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0966">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zVr3GW8f4fFg" title="Nonvested weighted average grant-date fair value, Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0968">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Nonvested as of December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zAbeEL3jQWA2" title="Nonvested Shares, Beginning" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-12-31_custom_ServiceBasedRestrictedStockMember" id="Fact000970" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">26,690,254</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zpPP7ynEpTU" title="Nonvested weighted average grant-date fair value, Beginning" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2024-12-31_custom_ServiceBasedRestrictedStockMember" id="Fact000972" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.54</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Performance-Based RSUs</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average grant-date fair
    value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Nonvested as of January 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z1rlz6ZIH2E1" title="Nonvested Shares, Beginning" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2022-12-31_custom_PerformanceBasedRSUsMember" id="Fact000974" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,894,958</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zYEBRUUa4fS6" title="Nonvested weighted average grant-date fair value, Beginning" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2022-12-31_custom_PerformanceBasedRSUsMember" id="Fact000976" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.85</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zXzXs5LuVewk" title="Nonvested Shares, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2023-01-012023-12-31_custom_PerformanceBasedRSUsMember" id="Fact000978" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,027,796</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zU5QwhOVtKKh" title="Nonvested weighted average grant-date fair value, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31_custom_PerformanceBasedRSUsMember" id="Fact000980" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.16</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zNihbNDgoJlj" title="Nonvested Shares, Vested" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0982">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zRtEuhMXxxY2" title="Nonvested weighted average grant-date fair value, Vested" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0984">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z4WNux4psgFf" title="Nonvested Shares, Forfeited" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2023-01-012023-12-31_custom_PerformanceBasedRSUsMember" id="Fact000986" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">22,626</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zCwJ89xod5X9" title="Nonvested weighted average grant-date fair value, Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31_custom_PerformanceBasedRSUsMember" id="Fact000988" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.39</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Nonvested as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zVTTQ5j3Vxe1" title="Nonvested Shares, Beginning" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2023-12-31_custom_PerformanceBasedRSUsMember" id="Fact000990" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,900,128</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z4tOtcsDbQrk" title="Nonvested weighted average grant-date fair value, Ending" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2023-12-31_custom_PerformanceBasedRSUsMember" id="Fact000992" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.97</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zmsRkYvAG8l3" title="Nonvested Shares, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0994">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zf55dHhm3mC2" title="Nonvested weighted average grant-date fair value, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0996">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zaPBEe7jGmH7" title="Nonvested Shares, Vested" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2024-01-012024-12-31_custom_PerformanceBasedRSUsMember" id="Fact000998" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,610,540</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z3qi8eJlnIoj" title="Nonvested weighted average grant-date fair value, Vested" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-12-31_custom_PerformanceBasedRSUsMember" id="Fact001000" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.87</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zDVaCo8Kj5x6" title="Nonvested Shares, Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1002">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zZJSQQVnys22" title="Nonvested weighted average grant-date fair value, Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1004">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Nonvested as of December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z6DRsiRRodBh" title="Nonvested Shares, Beginning" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-12-31_custom_PerformanceBasedRSUsMember" id="Fact001006" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,289,578</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_znTBbMTO9Iii" title="Nonvested weighted average grant-date fair value, Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2024-12-31_custom_PerformanceBasedRSUsMember" id="Fact001008" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.70</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_z4eThjaJVWS9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the Merger, the liquidity event performance condition was achieved and therefore compensation cost of $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zf9pjdTt3KNe" title="Compensation cost recognized"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-12-31_custom_PerformanceBasedRSUsMember" id="Fact001010" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,233,487</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;for
the year ended December 31, 2024 was recognized for the Performance-Based RSUs, of which&#160;<span id="xdx_907_ecustom--StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zSX8nT5zA3p8" title="Number of shares issued and outstading RSU"><ix:nonFraction name="TVGN:StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits" contextRef="From2024-01-012024-12-31_custom_PerformanceBasedRSUsMember" id="Fact001012" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,237,319</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares were issued and outstanding as
of December 31, 2024, and&#160;<span id="xdx_90C_ecustom--VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing_iI_c20250101__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zX2rnjABA6Je" title="Number of shares issuable"><ix:nonFraction name="TVGN:VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing" contextRef="AsOf2025-01-01_us-gaap_SubsequentEventMember_custom_PerformanceBasedRSUsMember" id="Fact001014" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,373,221</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;shares
will be issued subsequent to December 31, 2024. There was $<span id="xdx_90C_eus-gaap--EmployeeStockOwnershipPlanESOPCompensationExpense_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z83Wk1gYbvT1" title="Compensation cost"><ix:nonFraction name="us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockMember" id="Fact001016" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,410,921</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">compensation cost related to Service-Based
Restricted Stock and RSUs, for the year ended December 31, 2024, and <span id="xdx_90D_ecustom--VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing_iI_c20250101__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zRLZER3wPQl7" title="Number of shares issuable"><ix:nonFraction name="TVGN:VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing" contextRef="AsOf2025-01-01_us-gaap_SubsequentEventMember_custom_ServiceBasedRestrictedStockMember" id="Fact001018" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,639,628</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares were issued and outstanding. There
was $<span id="xdx_902_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zCzwJ6CqfhDd" title="Unrecognized compensation cost"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2024-12-31_custom_ServiceBasedRestrictedStockMember" id="Fact001020" format="ixt:numdotdecimal" decimals="0" unitRef="USD">85,601,786</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;of
unrecognized compensation cost related to Service-Based Restricted Stock and RSUs as of December 31, 2024, which will be expensed over
a weighted average period of&#160;<span id="xdx_901_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zQygHX4CHgMl" title="Weighted average period"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockMember" format="ixt-sec:duryear" id="Fact001022" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">7.0</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;years.
There was $<span id="xdx_906_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zapiN8fpwYak" title="Unrecognized compensation cost"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2024-12-31_custom_PerformanceBasedRSUsMember" id="Fact001024" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,984,909</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;of
unrecognized compensation cost related to Performance-Based RSUs as of December 31, 2024, which will be expensed over a weighted average
period of&#160;<span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zO72HDdRqff6" title="Weighted average period for recognition"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_PerformanceBasedRSUsMember" format="ixt-sec:duryear" id="Fact001026" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">1.1</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 155; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS
INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001028" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zqQ6C3RkJXLh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded stock-based compensation expense in the following expense categories in the accompanying consolidated statements of
operations:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8B4_z0T6x9S9R0nc" style="display: none">SCHEDULE OF STOCK-BASED
COMPENSATION EXPENSE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20240101__20241231_zDU36E9nUsml" style="font-weight: bold; text-align: center">Year ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zYTqU2Y6qIUa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact001030" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,019,781</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z2XZFhW9Nmak" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001032" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,744,355</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AllocatedShareBasedCompensationExpense_zwdTtZqbiUNb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-01to2024-12-31" id="Fact001034" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,764,136</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zolbzGpD9Gyc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_do_c20230101__20231231_ze91l903pZjd"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="From2023-01-012023-12-31" id="Fact001035" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">No
</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">stock-based compensation expense was recognized
in 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001037" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_800_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zqa4HQO38Ad3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
12.&#160;<span id="xdx_823_zPEUk6aDyaG5">STOCKHOLDERS&#8217; DEFICIT</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;Common
Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of February 15, 2024, the Company&#8217;s common stock and warrants began trading on The Nasdaq Stock Market LLC under the symbols &#8220;TVGN&#8221;
and &#8220;TVGNW&#8221;, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the Company had&#160;<span id="xdx_90C_eus-gaap--CommonStockSharesIssued_iI_c20241231_zMwByKIdp1T5" title="Common shares, shares issued"><span id="xdx_905_eus-gaap--CommonStockSharesOutstanding_iI_c20241231_z3wxrw4IG9ql" title="Common shares, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact001039" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact001041" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">177,991,365</ix:nonFraction></ix:nonFraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;shares
of common stock issued and outstanding. For accounting purposes related to earnings per share, only shares that are fully vested are
considered issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001043" name="us-gaap:ScheduleOfStockholdersEquityTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfStockholdersEquityTableTextBlock_zSOL5mLD6Ex8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below
is a reconciliation of shares of common stock issued and outstanding:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8BF_zBobVkOAVlrc" style="display: none">SCHEDULE OF RECONCILIATION
OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Total shares of common stock issued and outstanding</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_c20241231_zyN8CCKLMVr8" title="Total shares of common stock legally issued"><span id="xdx_909_eus-gaap--CommonStockSharesOutstanding_iI_c20241231_z5LoyIQAfSeg" title="Total shares of common stock legally outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact001045" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact001047" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">177,991,365</ix:nonFraction></ix:nonFraction></span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Plus: shares to be issued:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Vested RSUs not yet legally settled into common stock (a)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing_iI_c20241231_fKGEp_zCbHItSD0oN5" title="Vested Performance-Based RSUs from satisfaction of liquidity condition upon the Closing" style="text-align: right"><ix:nonFraction name="TVGN:VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing" contextRef="AsOf2024-12-31" id="Fact001049" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,373,221</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: Shares subject to future vesting:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Issuance of restricted common stock subject to forfeiture
    (b)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture_iI_c20241231_fKGIp_zAWe8GbZVlj2" title="Issuance of restricted common stock subject to forfeiture" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="TVGN:SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture" contextRef="AsOf2024-12-31" id="Fact001051" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">19,348,954</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total shares, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_ecustom--CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture_iI_c20241231_zTEH5atUDVxk" title="Total shares issued and outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="TVGN:CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture" contextRef="AsOf2024-12-31" id="Fact001053" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">160,015,632</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_F0C_zk3ugD4zYWK3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_F1B_z37YHzlQJlp4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001054" xml:lang="en-US">As
    of December 31, 2024, there were RSUs that had vested but had not been legally settled into common stock. See Note 11 for additional
    information.</ix:footnote></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_F03_zRtXAoAo4a1b" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_F1E_zYoDAP8O7hp2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001055" xml:lang="en-US">Dr.
    Saadi will automatically forfeit all unvested Restricted Stock granted pursuant to the Special RSU Award in the event he departs
    the Company. See Note 11 for additional information on the Special RSU Award.</ix:footnote></span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A5_zFXyPlOcKyif" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the Merger, Tevogen Bio had outstanding shares of voting and non-voting common stock. Upon the Closing, Tevogen Bio&#8217;s common
stockholders received shares of the Company&#8217;s common stock in an amount determined by application of the Exchange Ratio, as discussed
in Note 1.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 156; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS
INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Preferred
Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue up to&#160;<span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_c20241231_zeKFUrWx9AP2" title="Preferred shares, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact001057" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;shares
of preferred stock, par value $<span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20241231_zoEeMt6zvnV4" title="Preferred shares, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact001059" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;per
share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Series
A Preferred Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2024, the Company authorized and issued&#160;<span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zOLmDBCk46lb" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember" id="Fact001061" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;and&#160;<span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zbMqeQf9Qm6a" title="Preferred stock, shares issued"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_InvestorMember" id="Fact001063" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;shares,
respectively, of Series A Preferred Stock (the &#8220;Series A&#8221;) to the Patel Family at a price of $<span id="xdx_908_eus-gaap--SharePrice_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_z3XSZLyE1g57" title="Original issue price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_InvestorMember" id="Fact001065" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;per
share (the &#8220;Series A Original Issue Price&#8221;), for gross proceeds of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20240301__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zfEFg1tPo3j9" title="Proceeds from issuance of preferred stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="From2024-03-012024-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_InvestorMember" id="Fact001067" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The Company recorded an expense of $<span id="xdx_900_ecustom--LossOnPreferredStockIssuance_c20240301__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zsNErM7B6u37" title="Loss on preferred stock issuance"><ix:nonFraction name="TVGN:LossOnPreferredStockIssuance" contextRef="From2024-03-012024-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_InvestorMember" id="Fact001069" format="ixt:numdotdecimal" decimals="0" unitRef="USD">799,990</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;in
its consolidated statements of operations related to issuance of the Series A equal to the fair value of the Series A when issued of
$<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zJiiIEZtR32" title="Price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_InvestorMember" id="Fact001071" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5,600</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;per
share less the purchase price of $<span id="xdx_90A_eus-gaap--SharePrice_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zQ5BTtvcEdja" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_InvestorMember" id="Fact001073" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;per
share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dividends</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of Series A are entitled to receive dividends accruing daily on a cumulative basis payable at a fixed rate of&#160;<span id="xdx_903_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zEXAZXeTMRm2" title="Dividend rate, percentage"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact001075" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
per annum per share on&#160;<span id="xdx_90A_eus-gaap--PreferredStockDividendPaymentRateVariable_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zRwbc71eB8U1" title="Dividend variable rate, description"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact001077" name="us-gaap:PreferredStockDividendPaymentRateVariable">the
Series A Original Issue Price, which rate will automatically increase by 2% every year that the Series A remains outstanding (the &#8220;Series
A Accruing Dividends&#8221;). These dividends become payable when and if declared by the Company. The Series A Preferred Stock will also
participate on an as-converted basis in any regular or special dividends paid to holders of the common stock</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series A ranks senior to common stock and Series C Preferred Stock in liquidation priority. In the event of a liquidation of the Company,
or certain deemed liquidation events, the Series A is redeemable for a price equal to the greater of the Series A Original Issue Price
plus all Series A Accruing Dividends that are unpaid through the redemption date, or such amount that would have been payable had the
Series A converted into shares of common stock immediately before the liquidation or deemed liquidation event.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Voting</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series A does not have any voting rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Redemption</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of Series A are not entitled to redeem their shares outside of the liquidation of the Company or the occurrence of a deemed liquidation
event. The Company is entitled to redeem the Series A at a price equal to the Series A Original Issue Price plus any Series A Accruing
Dividends accrued but unpaid thereon, if the VWAP of the Company&#8217;s common stock exceeds $<span id="xdx_904_eus-gaap--PreferredStockRedemptionPricePerShare_iI_pid_uUSDPShares_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zuAfldtfHc62" title="Redemption price per share"><ix:nonFraction name="us-gaap:PreferredStockRedemptionPricePerShare" contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact001079" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.00</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;per
share for&#160;<span id="xdx_907_eus-gaap--PreferredStockRedemptionTerms_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zf3mfbHmCfG8" title="Redemption term"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact001081" name="us-gaap:PreferredStockRedemptionTerms">the
twenty days immediately prior to the Company&#8217;s call election</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<i>Conversion</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of Series A have the option to convert the Series A into shares of common stock at a ratio equal to the Series A Original Issue
Price divided by the Series A Conversion Price, which is initially $<span id="xdx_902_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_uUSDPShares_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zQIYF4ixkDGa" title="Conversion price per share"><ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionPrice" contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact001083" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.00</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;per
share and is subject to standard antidilution adjustments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="text-decoration: underline">Series
A-1 Preferred Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 27, 2024, the Company entered into an Amended and Restated Securities Purchase Agreement with the Patel Family covering the issuance
of&#160;<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240326__20240327__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_zoxKHXWMgXH3"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-03-262024-03-27_custom_SeriesAOnePreferredStockMember_custom_ThePatelFamilyLLPMember" id="Fact001084" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">600</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;shares
of Series A-1 Preferred Stock for a gross purchase price of $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240326__20240327__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_zil4uC88XYqb"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-03-262024-03-27_custom_SeriesAOnePreferredStockMember_custom_ThePatelFamilyLLPMember" id="Fact001085" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,000,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.&#160;<span id="xdx_900_eus-gaap--PreferredStockDividendPaymentRateVariable_c20240326__20240327__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_z0EexvHdNfP4" title="Dividend variable rate, description"><ix:nonNumeric contextRef="From2024-03-262024-03-27_custom_SeriesAOnePreferredStockMember_custom_ThePatelFamilyLLPMember" id="Fact001087" name="us-gaap:PreferredStockDividendPaymentRateVariable">The
terms of the Series A-1 Preferred Stock are identical to the Series A, except that the cumulative dividends are capped at 15% per annum,
and the Series A-1 Issuance Price is defined as $<span id="xdx_90C_eus-gaap--SharePrice_iI_c20240327__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_zNLrJD98P3cf" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-03-27_custom_SeriesAOnePreferredStockMember_custom_ThePatelFamilyLLPMember" id="Fact001089" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10,000</ix:nonFraction></span>&#160;per share</ix:nonNumeric></span>. As of December 31, 2024, the investor had paid a non-refundable
deposit of $<span id="xdx_903_eus-gaap--Deposits_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_zGLhxcx8NeVb" title="Non refundable deposist paid"><ix:nonFraction name="us-gaap:Deposits" contextRef="AsOf2024-12-31_custom_SeriesAOnePreferredStockMember_custom_ThePatelFamilyLLPMember" id="Fact001091" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;towards
the Series A-1 purchase price, and no shares of Series A-1 Preferred Stock were issued or outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 157; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS
INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Series
B Preferred Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Closing, the Company entered into an agreement to issue shares of Series B to the Sponsor in return for the Sponsor
assuming certain liabilities and obligations of Semper Paratus and Tevogen Bio. In March 2024,&#160;<span id="xdx_90C_ecustom--StockIssuedDuringPeriodSharesConversionOfLiabilities_c20240301__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zzKEiMAM1kA" title="Conversion of certain liabilities into Series B preferred stock, shares"><ix:nonFraction name="TVGN:StockIssuedDuringPeriodSharesConversionOfLiabilities" contextRef="From2024-03-012024-03-31_us-gaap_SeriesBPreferredStockMember" id="Fact001093" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,613</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;shares
of Series B were issued in return for the assumption of the Assumed Liabilities. The issuance date fair value of the Series B was determined
to be $<span id="xdx_90E_ecustom--StockIssuedDuringPeriodValueConversionOfLiabilities_c20240301__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z0w4NNJx0206" title="Conversion of certain liabilities into Series B preferred stock"><ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueConversionOfLiabilities" contextRef="From2024-03-012024-03-31_us-gaap_SeriesBPreferredStockMember" id="Fact001095" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,613,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;and
was recorded within Merger transaction costs in the consolidated statements of operations. The Series B was classified as permanent equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 15, 2024, the Company and the Sponsor entered into the Preferred Stock Repurchase Agreement, pursuant to which the Company repurchased
all outstanding Series B in exchange for the release of the Sponsor from its obligations related to the Assumed Liabilities, but no cash
consideration. The repurchase was recorded as a deemed contribution from a related party and recorded to additional paid-in capital.
As of June 30, 2024, there were&#160;<span id="xdx_909_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20240630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zjMKJrpQOGJ7" title="Preferred stock shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-06-30_us-gaap_SeriesBPreferredStockMember" id="Fact001097" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;shares
of Series B outstanding, and on August 9, 2024, the Company filed a Certificate of Elimination to eliminate the Series B. Although the
Company was not legally released by the creditors, the Company has made payments towards the Assumed Liabilities and approximately $<span id="xdx_901_eus-gaap--LiabilitiesAssumed1_pn5n6_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zyMnhtgkwDqa" title="Liabilities assumed"><ix:nonFraction name="us-gaap:LiabilitiesAssumed1" contextRef="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact001099" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.6</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;million
remains on the Company&#8217;s balance sheet at December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="text-decoration: underline">Series
C Preferred Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 21, 2024, the Company entered into a securities purchase agreement (the &#8220;Series C Agreement&#8221;) with an investor, pursuant
to which the Patel Family purchased&#160;<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240821__20240821__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_zSPnuzVFW8I3"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-08-212024-08-21_us-gaap_SeriesCPreferredStockMember_custom_ThePatelFamilyLLPMember" id="Fact001100" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">600</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;shares
of Series C Preferred Stock (the &#8220;Series C&#8221;) of the Company at a price of $<span id="xdx_909_eus-gaap--SharePrice_iI_c20240821__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_zDTaVGWAeBdf" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-08-21_us-gaap_SeriesCPreferredStockMember_custom_ThePatelFamilyLLPMember" id="Fact001102" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;per
share (the &#8220;Series C Original Issue Price&#8221;), for gross proceeds of $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20240821__20240821__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_zAEFpmxITdxc" title="Gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="From2024-08-212024-08-21_us-gaap_SeriesCPreferredStockMember_custom_ThePatelFamilyLLPMember" id="Fact001104" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,000,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series C is subject to a call right providing the Company the right to call the stock at any time after the fifth anniversary of the
date of issuance. The Company also agreed that so long as the Series C is outstanding, the Company will not, without the written consent
of the holders of 50.1% of the Series C, amend, alter, or repeal any provision of the Company&#8217;s certificate of incorporation or
bylaws in a manner adverse to the Series C. Assessed under accounting guidance within ASC 480 and ASC 815, as the Series C is unregistered
and without mandatory redemption features, the Series C is classified within equity at issued face value as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dividends</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series C carries an annual&#160;<span id="xdx_90E_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zOfmBzQmYJh5" title="Dividend rate, percentage"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2024-01-012024-12-31_us-gaap_SeriesCPreferredStockMember" id="Fact001106" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.5</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
cumulative dividend, compounded annually, beginning on the later of (1) September 30, 2024 and (2)&#160;the date on which the investor
has paid the entirety of the purchase price under the Series C Agreement and ending on the last business day of the calendar quarter
ending September 30, 2034 (the &#8220;Series C Accruing Dividends&#8221;). Dividends will be payable in shares of Series C or, at the
election of the Company, in cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series C ranks subordinate to the Series A and Series A-1 Preferred Stock and ranks senior to common stock in liquidation priority. In
<span id="xdx_90E_eus-gaap--PreferredStockDividendPaymentRateVariable_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zLJfTgOGcgV4" title="Dividend variable rate, description"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_SeriesCPreferredStockMember" id="Fact001108" name="us-gaap:PreferredStockDividendPaymentRateVariable">the
event of a liquidation of the Company, or certain deemed liquidation events, the Series C is redeemable for a price equal to the greater
of the Series C Original Issue Price plus all Series C Accruing Dividends that are unpaid through the redemption date, or such asset
amount as would have been payable had the Series C converted into shares of common stock immediately before the liquidation or deemed
liquidation event</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Voting</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series C does not have any voting rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 158; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS
INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Redemption</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of Series C are not entitled to redeem their shares outside of the liquidation of the Company or the occurrence of a deemed liquidation
event. The Company is entitled to redeem that Series C at a price equal to the Series C Original Issue Price plus any Series C Accruing
Dividends accrued but unpaid thereon, subject to the conversion right described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Conversion</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of Series C will be convertible at the election of the holder, beginning six months after the date of issuance, into shares of
common stock at a conversion price equal to the volume-weighted average price of the Common Stock for the 30 trading days immediately
prior to the exercise of the holder&#8217;s conversion option, subject to a floor price of $<span id="xdx_903_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_uUSDPShares_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zv0yGDL9ogud" title="Floor price"><ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionPrice" contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember" id="Fact001110" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.6172</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Warrants</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the Closing,&#160;<span id="xdx_907_ecustom--ClassOfWarrantOrRightIssued_iI_c20211130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SemperParatusMember_zzjSEoZrAQV6" title="Number of warrants issued"><ix:nonFraction name="TVGN:ClassOfWarrantOrRightIssued" contextRef="AsOf2021-11-30_custom_SemperParatusMember" id="Fact001112" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">17,975,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;warrants
initially issued by Semper Paratus in November 2021, comprising&#160;<span id="xdx_901_ecustom--ClassOfWarrantOrRightIssued_iI_c20211130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SemperParatusMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zC20OblgOKeb" title="Number of warrants issued"><ix:nonFraction name="TVGN:ClassOfWarrantOrRightIssued" contextRef="AsOf2021-11-30_custom_SemperParatusMember_custom_PublicWarrantsMember_us-gaap_IPOMember" id="Fact001114" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">17,250,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;public
warrants sold in the IPO and&#160;<span id="xdx_90C_ecustom--ClassOfWarrantOrRightIssued_iI_c20211130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SemperParatusMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zTabAw0W3unb" title="Number of warrants issued"><ix:nonFraction name="TVGN:ClassOfWarrantOrRightIssued" contextRef="AsOf2021-11-30_custom_SemperParatusMember_us-gaap_PrivatePlacementMember" id="Fact001116" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">725,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;warrants
issued in a concurrent private placement, were assumed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Public
Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
public warrants have an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SemperParatusMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_z9sHJ50LAX11" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2021-11-30_custom_SemperParatusMember_custom_PublicWarrantsMember" id="Fact001118" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.50</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;per
share, became exercisable on&#160;<span id="xdx_901_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20211101__20211130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SemperParatusMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zjAflArab5ke" title="Exercisable date"><ix:nonNumeric contextRef="From2021-11-012021-11-30_custom_SemperParatusMember_custom_PublicWarrantsMember" format="ixt:datemonthdayyearen" id="Fact001120" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">March
15, 2024</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, and will expire at 5:00 p.m.,
New York City time, on February 14, 2029, or earlier upon redemption or liquidation. Warrant holders may, until such time as there is
an effective registration statement and during any period when the Company has failed to maintain an effective registration statement
covering the shares of the Company&#8217;s common stock issuable upon exercise of the warrants, exercise warrants on a &#8220;cashless
basis&#8221; in accordance with Section 3(a)(9) of the Securities Act of 1933, as amended, or another exception.&#160;<span id="xdx_900_ecustom--WarrantsRedemptionDescription_c20211101__20211130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SemperParatusMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_za1vBJ9LJ5e" title="Warrants redemption description"><ix:nonNumeric contextRef="From2021-11-012021-11-30_custom_SemperParatusMember_custom_PublicWarrantsMember" id="Fact001122" name="TVGN:WarrantsRedemptionDescription">The
Company may redeem the public warrants if the Company&#8217;s common stock equals or exceeds $18.00 per share for 20 trading days within
a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the
holders of public warrants</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.&#160;As of
December 31, 2024, there are&#160;<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SemperParatusMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zwCbzd7uy8J7" title="Number of warrants outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_SemperParatusMember_custom_PublicWarrantsMember" id="Fact001124" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">17,386,580</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;public
warrants outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<i>Private
Placement Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
private placement warrant is identical to the public warrants, except that the private placement warrants, so long as they are held by
the initial purchasers or their permitted transferees, (i) will not be redeemable by the Company and (ii) may be exercised by the holders
on a cashless basis. As of December 31, 2024, there are&#160;<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SemperParatusMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zDLTpTVdl9I7" title="Number of warrants outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_SemperParatusMember_us-gaap_PrivatePlacementMember" id="Fact001126" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">588,398</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">private placement warrants outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 3 for additional information on the Company&#8217;s warrant accounting policy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 159; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS
INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001128" name="us-gaap:EarningsPerShareTextBlock"><p id="xdx_80D_eus-gaap--EarningsPerShareTextBlock_ze736zl6POZi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
13.&#160;<span id="xdx_825_zqPN9q60Q2sd">NET LOSS PER SHARE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001130" name="us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_zrMhznhcADK1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
below table is a reconciliation of net loss to net loss attributable to common stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span id="xdx_8B2_zqvjlw0tPPPc" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF RECONCILIATION OF NET LOSS</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20240101__20241231_zewavYKYmcO9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_493_20230101__20231231_z5LV02lxoR03" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Year ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_maNILATzLnk_z0EjB95kvWd5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact001132" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,727,380</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact001133" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">60,477,680</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--PreferredStockDividendsIncomeStatementImpact_iN_di_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_msNILATzLnk_ziuy4AAZlZpa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Series A cumulative preferred stock dividend</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact001135" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,712</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1136">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--StockRepurchase_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_msNILATzLnk_zMbcnuDaiYHe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Series B stock repurchase</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:StockRepurchase" contextRef="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact001138" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,613,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1139">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--StockRepurchase_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zsFxVRhsUdRd" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock repurchase</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:StockRepurchase" contextRef="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact001141" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,613,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1142">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--PreferredStockDividendsIncomeStatementImpact_iN_di_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_msNILATzLnk_zXXqhExT8Qp9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Series C cumulative preferred stock dividend</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="From2024-01-012024-12-31_us-gaap_SeriesCPreferredStockMember" id="Fact001144" format="ixt:numdotdecimal" decimals="0" unitRef="USD">82,603</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1145">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PreferredStockDividendsIncomeStatementImpact_iN_di_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zYSKuDF6E6f7" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cumulative preferred stock dividend</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="From2024-01-012024-12-31_us-gaap_SeriesCPreferredStockMember" id="Fact001147" format="ixt:numdotdecimal" decimals="0" unitRef="USD">82,603</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1148">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iT_mtNILATzLnk_zCi7OAkiAonl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss attributable to common stockholders</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2024-01-01to2024-12-31" id="Fact001150" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,273,695</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-01-012023-12-31" id="Fact001151" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">60,477,680</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zG3z9K9LYeO2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company excluded the following potential shares from the computation of diluted net loss per share because including them would have
had an anti-dilutive effect:</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001153" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zMKW3hz6iji8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B5_zdSENhIO9rV3" style="display: none">SCHEDULE
OF ANTI-DILUTIVE NET LOSS PER SHARE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20240101__20241231_zsfIgTckdztj" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20230101__20231231_z3pWLbJFR0Ba" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zF2EpHKswSyc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Outstanding RSUs <span id="xdx_F4D_z07FvddSvL6a">(a)</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001155" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,623,225</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001156" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,900,128</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_z059N4sxVyL8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockMember74469375" id="Fact001158" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">19,348,954</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1159">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zs04JFRW2k1j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember74469375" id="Fact001161" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">17,974,978</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1162">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zvxNYvig3f4k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Convertible promissory notes <span id="xdx_F41_zy3oX7MkW0ga">(b)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1164">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_ConvertibleDebtSecuritiesMember" id="Fact001165" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">891,298</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--EarnoutSharesMember_zQdxAkjI4TOe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Earnout Shares</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_custom_EarnoutSharesMember" id="Fact001167" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,500,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1168">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zQ4P6OqK2bi6" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-01to2024-12-31" id="Fact001170" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">70,447,157</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31" id="Fact001171" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,791,426</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 0.25in; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_F0D_zlr7PY4CNPL7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_F18_zLgqOEX8aBr1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001172" xml:lang="en-US">As
    of December 31, 2024 there were an additional&#160;</ix:footnote></span><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFOVEktRElMVVRJVkUgTkVUIExPU1MgUEVSIFNIQVJFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8EyIlRCBIqc" title="Stock option vested" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember74469500" id="Fact001174" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,373,221</ix:nonFraction></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;RSUs
    that had vested but had not been legally settled into common stock and therefore were included in the basic net income per share.
    See Note 11 for additional information.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_F0D_zYhkL5W3VIKi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_F17_zDwYlBaiVt58" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001175" xml:lang="en-US">The
    numbers of shares were determined based on the conversion upon maturity provisions in the convertible promissory note agreements,
    dividing the conversion amount (principal plus accrued interest) by three times the estimated fair value of the Company&#8217;s common
    stock derived from the Company&#8217;s most recently completed convertible promissory notes valuation as of the balance sheet date.</ix:footnote></span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A5_ztzzjDJRdhf4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
above table excludes any potentially anti-dilutive shares as a result of the $<span id="xdx_90E_eus-gaap--DerivativeLiabilities_iI_pn6n6_c20241231_zSEHCi9gIi7b" title="Derivative liability"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2024-12-31" id="Fact001177" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">14</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;million
Purchase Option and the Additional Amount Purchase Option (see Note 8). These are excluded as the number of shares issuable cannot be
determined until the conditions for issuance are met and the share prices are known upon exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001179" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_80B_eus-gaap--IncomeTaxDisclosureTextBlock_zOH3qqx6CUEg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
14. <span id="xdx_82E_zVru2JBQBEJ">INCOME TAXES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the Company&#8217;s net losses for 2024 and 2023, as well as the full valuation allowance on its net deferred tax assets as discussed
below, the Company did not record any income tax expense or benefit for the years ended December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001181" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zzuUunQjL2f1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of income tax benefit at the federal statutory income tax rate to the income tax expense at the Company&#8217;s effective
income tax rate is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B0_zfqHypT5TS0f" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF RECONCILIATION OF INCOME TAX BENEFIT AT THE FEDERAL STATUTORY INCOME TAX RATE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20240101__20241231_zFaKKRbw9Jgg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20230101__20231231_zNiY81lgme86" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_uPure_ma123_zUDNJ7EwY67a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Federal benefit at statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2024-01-01to2024-12-31" id="Fact001183" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2023-01-012023-12-31" id="Fact001184" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_40A_ecustom--IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest_dp_uPure_ma123_zW5cTaPDNid4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Convertible note interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1186">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="TVGN:IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest" contextRef="From2023-01-012023-12-31" id="Fact001187" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">0.4</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_dp_uPure_ma123_z5fy4lkgWl6j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" contextRef="From2024-01-01to2024-12-31" id="Fact001189" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">29.2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" contextRef="From2023-01-012023-12-31" id="Fact001190" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">17.4</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_uPure_ma123_z93Oyuc8PpGh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State taxes, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2024-01-01to2024-12-31" id="Fact001192" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12.3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2023-01-012023-12-31" id="Fact001193" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.2</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_uPure_ma123_z8l8k4IRndd6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2024-01-01to2024-12-31" id="Fact001195" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">66.5</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2023-01-012023-12-31" id="Fact001196" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">5.4</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_dp_uPure_ma123_zdjWGnsqB8jb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="From2024-01-01to2024-12-31" id="Fact001198" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.6</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1199">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_iN_dpi_uPure_ms123_zV87CPJluAad" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther" contextRef="From2024-01-01to2024-12-31" id="Fact001201" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.6</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1202">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_dp_ms123_zZEC2coYO4Ze" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Tax credits</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1204">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="From2023-01-012023-12-31" id="Fact001205" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.1</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_dp_uPure_mt123_zpKTAJJeo2Ik" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Income Tax Expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1207">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1208">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zI1V4O0T35ek" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
income taxes reflect the net tax effects of temporary differences between carrying amounts of assets and liabilities for financial reporting
purposes and the amounts used for income tax purposes. Realization of net deferred tax assets is dependent upon future earnings, if any,
the timing and amount of which are uncertain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 160; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS
INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001210" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zVwD84JmqhR9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following items comprise the Company&#8217;s net deferred tax assets and liabilities as of December&#160;31, 2024 and December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zDJj32uxJhO7" style="display: none">SCHEDULE
OF DEFERRED TAX ASSETS AND LIABILITIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20241231_zGc3SqzUGCkk" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20231231_zhmEz9hnVLok" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsGrossAbstract_iB_z6v0y1kTSMR1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzJ64_zOmUptAXUjeg" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-left: 10pt">Net operating loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2024-12-31" id="Fact001215" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,808,826</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2023-12-31" id="Fact001216" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,755,008</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DeferredTaxAssetsAccruedExpensesAndOther_iI_maDTAGzJ64_zbnWptSsezM2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Accrued expenses and other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:DeferredTaxAssetsAccruedExpensesAndOther" contextRef="AsOf2024-12-31" id="Fact001218" format="ixt:numdotdecimal" decimals="0" unitRef="USD">385,801</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:DeferredTaxAssetsAccruedExpensesAndOther" contextRef="AsOf2023-12-31" id="Fact001219" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,330</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--DeferredTaxAssetsOperatingLeaseLiabilities_iI_maDTAGzJ64_zbPtKvCafCgc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:DeferredTaxAssetsOperatingLeaseLiabilities" contextRef="AsOf2024-12-31" id="Fact001221" format="ixt:numdotdecimal" decimals="0" unitRef="USD">61,380</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:DeferredTaxAssetsOperatingLeaseLiabilities" contextRef="AsOf2023-12-31" id="Fact001222" format="ixt:numdotdecimal" decimals="0" unitRef="USD">127,427</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGzJ64_z4vJKSUIuMtd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2024-12-31" id="Fact001224" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,110,942</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2023-12-31" id="Fact001225" format="ixt:numdotdecimal" decimals="0" unitRef="USD">718,425</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DeferredTaxAssetsFixedAssets_iI_maDTAGzJ64_z9o5LRtyj6Wf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Fixed assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:DeferredTaxAssetsFixedAssets" contextRef="AsOf2024-12-31" id="Fact001227" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,834</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1228">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsOther_iI_maDTAGzJ64_zRoN4unq5yVf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2024-12-31" id="Fact001230" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,823</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1231">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures_iI_maDTAGzJ64_zzXlwd8COPvd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Capitalized research and development expenditures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures" contextRef="AsOf2024-12-31" id="Fact001233" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,944,801</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures" contextRef="AsOf2023-12-31" id="Fact001234" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,589,105</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTAGzJ64_zTLvRLdgkjH8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Research and development credits</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2024-12-31" id="Fact001236" format="ixt:numdotdecimal" decimals="0" unitRef="USD">234,478</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2023-12-31" id="Fact001237" format="ixt:numdotdecimal" decimals="0" unitRef="USD">317,455</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzJ64_maDTANz2Fd_zCuir0pCfzL2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2024-12-31" id="Fact001239" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,610,885</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2023-12-31" id="Fact001240" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,549,750</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANz2Fd_zxaKCulwpvQ7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2024-12-31" id="Fact001242" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,551,169</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-12-31" id="Fact001243" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,426,952</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANz2Fd_maDTALNz6fV_zBQC16G4WuN8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Deferred tax assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2024-12-31" id="Fact001245" format="ixt:numdotdecimal" decimals="0" unitRef="USD">59,716</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2023-12-31" id="Fact001246" format="ixt:numdotdecimal" decimals="0" unitRef="USD">122,798</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_zwH9JPsFaUL4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--DeferredTaxLiabilitiesRightOfUseAsset_iNI_di_maDITLzmly_zrkAHcCoXP54" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Right of use asset</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="TVGN:DeferredTaxLiabilitiesRightOfUseAsset" contextRef="AsOf2024-12-31" id="Fact001251" format="ixt:numdotdecimal" decimals="0" unitRef="USD">59,716</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="TVGN:DeferredTaxLiabilitiesRightOfUseAsset" contextRef="AsOf2023-12-31" id="Fact001252" format="ixt:numdotdecimal" decimals="0" unitRef="USD">122,798</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_di_mtDITLzmly_msDTALNz6fV_zHWdAIwKT5s5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Total deferred tax liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2024-12-31" id="Fact001254" format="ixt:numdotdecimal" decimals="0" unitRef="USD">59,716</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2023-12-31" id="Fact001255" format="ixt:numdotdecimal" decimals="0" unitRef="USD">122,798</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNz6fV_zsuFt7LrE58b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1257">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1258">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zlBeaG0lqf3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company continually evaluates the likelihood of the realization of deferred tax assets and adjusts the carrying amount of the deferred
tax assets by the valuation allowance to the extent the future realization of the deferred tax assets is more likely than not. The Company
considers many factors when assessing the likelihood of future realization of its deferred tax assets, including its recent cumulative
earnings experience by taxing jurisdiction, expectation of future taxable income or loss, the carryforward periods available to the Company
for tax reporting purposes, and other relevant factors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, based on the Company&#8217;s history of earnings and its assessment of future earnings, management believes that
it is more likely than not that future taxable income will not be sufficient to realize the deferred tax assets. Therefore, a valuation
allowance has been applied to deferred tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the year ended December 31, 2024, the Company has federal and state net operating loss carryforwards of approximately $<span id="xdx_905_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn5n6_c20241231_zcC2rR17KDnk" title="Federal  net operating loss carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" contextRef="AsOf2024-12-31" id="Fact001260" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">25.6</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and $<span id="xdx_90A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pn5n6_c20241231_zjbEu68R0teg" title="State net operating loss carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="AsOf2024-12-31" id="Fact001262" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">27.8</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal
net operating loss (&#8220;NOL&#8221;) carryforwards in the amount of $<span id="xdx_902_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn5n6_c20241231_zSWtVs0fo31a" title="Federal  net operating loss carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" contextRef="AsOf2024-12-31" id="Fact001264" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">25.6</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million have an indefinite life. Federal
NOL carryforwards generated after tax year 2017 are subject to an <span id="xdx_907_ecustom--TaxableIncomeLimitationPercentage_dp_uPure_c20240101__20241231_zK3J71d5c3v2" title="Limitation percentage"><ix:nonFraction name="TVGN:TaxableIncomeLimitationPercentage" contextRef="From2024-01-01to2024-12-31" id="Fact001266" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">80</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
limitation on taxable income, do not expire and will carryforward indefinitely.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
net operating loss carryforwards in the amount of $<span id="xdx_90B_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pn5n6_c20241231_zqE47Zt8h4jl" title="State net operating loss carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="AsOf2024-12-31" id="Fact001268" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">27.8</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million begin expiring in 2040.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
utilization of the Company&#8217;s net operating losses may be subject to a U.S. federal limitation due to the &#8220;change in ownership
provisions&#8221; under Section 382 of the Internal Revenue Code and other similar limitations in various state jurisdictions. Such limitations
may result in a reduction of the amount of net operating loss carryforwards in future years and possibly the expiration of certain net
operating loss carryforwards before their utilization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business,
the Company is subject to examinations by federal, state and local jurisdictions, where applicable. There are currently no pending tax
examinations. The Company&#8217;s tax years are still open under statute from 2021 to the present in the United States. To the extent
the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination
by the Internal Revenue Service and state and local tax authorities to the extent utilized in a future period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
required by the uncertain tax position guidance in ASC No. 740, Income Tax, the Company recognizes the financial statement benefit of
a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit.
For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit
that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company applied
the uncertain tax position guidance in ASC No. 740 to all tax positions for which the statute of limitations remained open. Any estimates
of tax contingencies contain assumptions and judgments about potential actions by taxing jurisdictions. Any interest and penalties related
to uncertain tax positions would be included as part of the income tax provision.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 161; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS
INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001270" name="TVGN:ScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock"><p id="xdx_89A_ecustom--ScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock_zWnNsTHpLs3g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of changes in the valuation allowance for net deferred tax assets during the year ended December 31, 2024 and 2023 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zf0aPlttrYT4" style="display: none">SCHEDULE
OF VALUATION ALLOWANCE FOR NET DEFERRED TAX ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240101__20241231_z9U4XQUAmYQd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20231231_zSNRXftI7Xx" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsValuationAllowance_iS_zdHNImCfERul" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Valuation allowance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-12-31" id="Fact001272" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,426,952</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2022-12-31" id="Fact001273" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,175,241</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--IncreasesRecordedToIncomeTaxProvision_zSpem9g5uypc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Increases recorded to income tax provision</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="TVGN:IncreasesRecordedToIncomeTaxProvision" contextRef="From2024-01-01to2024-12-31" id="Fact001275" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,124,217</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="TVGN:IncreasesRecordedToIncomeTaxProvision" contextRef="From2023-01-012023-12-31" id="Fact001276" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,251,711</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsValuationAllowance_iE_z3yEnVjWbsEh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Valuation allowance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2024-12-31" id="Fact001278" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,551,169</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-12-31" id="Fact001279" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,426,952</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zp0wzhbf7Lr4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company applies the authoritative guidance on accounting for and disclosure of uncertainty in tax positions, which requires the Company
to determine whether a tax position of the Company is more likely than not to be sustained upon examination, including resolution of
any related appeals of litigation processes, based on the technical merits of the position. For tax positions meeting the more likely
than not threshold, the tax amount recognized in the consolidated financial statements is reduced by the largest benefit that has a greater
than 50% likelihood of being realized upon the ultimate settlement with the relevant taxing authority. There were no material uncertain
tax positions as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes interest and penalties related to uncertain tax positions in income tax expense when in a taxable income position.
As of December 31, 2024, the Company had <span id="xdx_90F_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestAccrued_iI_do_c20241231_zBNPAu47Q8Q6" title="Income tax penalties and interest accrued"><ix:nonFraction name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" contextRef="AsOf2024-12-31" id="Fact001281" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no
</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">accrued interest or penalties related
to uncertain tax positions and no amounts have been recognized in the Company&#8217;s statements of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001283" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zrerlloKSUG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
15. <span id="xdx_826_zuwxRamozzMf">RELATED PARTY TRANSACTIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Transactions
with Sponsor</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Merger Agreement, the Company incurred $<span id="xdx_90F_eus-gaap--SponsorFees_c20240101__20241231_zFnqLSQtv1d" title="Sponsor advisory service fee"><ix:nonFraction name="us-gaap:SponsorFees" contextRef="From2024-01-01to2024-12-31" id="Fact001285" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;in
fees to the Sponsor for advisory services (the &#8220;Sponsor Advisory Service Fee&#8221;). In connection with the Merger and thereafter,
the Company and Sponsor agreed that $<span id="xdx_906_ecustom--SponsorFeesPayable_iI_c20241231_ztCWpzk26Dm6" title="Sponsor advisory services fee payable"><ix:nonFraction name="TVGN:SponsorFeesPayable" contextRef="AsOf2024-12-31" id="Fact001287" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;of
the Sponsor Advisory Service Fee is payable in cash, $<span id="xdx_900_eus-gaap--OtherLiabilities_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zLCUmLigY3f7" title="Sponsor fee payable offset"><ix:nonFraction name="us-gaap:OtherLiabilities" contextRef="AsOf2024-12-31_custom_SponsorMember" id="Fact001289" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;would
be offset against amounts due from the Sponsor, and the remainder of the Sponsor Advisory Service Fee was paid with the issuance of&#160;<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--SponsorAdvisoryServicesFeeMember_zCMhICFCUQWh" title="Number of shares issued for sponsor fees"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2024-01-012024-12-31_custom_SponsorAdvisoryServicesFeeMember" id="Fact001291" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;shares
of the Company&#8217;s common stock at Closing. The Sponsor Advisory Service Fee payable in cash is presented on the consolidated balance
sheets under the line item &#8220;Due to related party.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the Sponsor owes the Company $<span id="xdx_906_eus-gaap--OtherReceivables_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zjPvxlc8Yh34" title="Due from related party"><ix:nonFraction name="us-gaap:OtherReceivables" contextRef="AsOf2024-12-31_custom_SponsorMember" id="Fact001293" format="ixt:numdotdecimal" decimals="0" unitRef="USD">158,819</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;to
cover working capital expenses, which is presented on the consolidated balance sheets under the line item &#8220;Due from related party.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 12 for additional information on the Series B issued to the Sponsor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock-Based
Compensation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2023, the Company issued&#160;<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20230131__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember__srt--TitleOfIndividualAxis__custom--WifeOfChiefExecutiveOfficerMember_zydIjts291zk" title="Isssued shares to related party"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2023-01-012023-01-31_custom_PerformanceBasedRSUsMember_custom_WifeOfChiefExecutiveOfficerMember" id="Fact001295" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Performance-Based
RSUs to the wife of the Company&#8217;s chair and chief executive officer for advisory services provided to the Company, and&#160;<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20230131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MehtaphoricConsultingIncMember_zQFiNPfzRHKj" title="Shares issued to related party"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2023-01-012023-01-31_custom_MehtaphoricConsultingIncMember" id="Fact001297" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Performance-Based
RSUs to Mehtaphoric Consulting Inc, a company controlled by the daughter of the Company&#8217;s chief financial officer, for information
technology services provided to the Company. In connection with the Closing, the performance condition was achieved and therefore compensation
cost of $<span id="xdx_904_eus-gaap--EmployeeStockOwnershipPlanESOPCompensationExpense_c20240101__20241231_zZgPukrSpgSj" title="Compensation cost recognized"><ix:nonFraction name="us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense" contextRef="From2024-01-01to2024-12-31" id="Fact001299" format="ixt:numdotdecimal" decimals="0" unitRef="USD">800,396</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;has
been recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Loan
Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 8 for additional information on the Loan Agreement with the Patel Family, which provides for an unsecured line of credit facility
for term loans of up to an initial amount of $<span id="xdx_906_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_z17ANZk39xOl" title="Line of credit maximum borrowing capacity"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember" id="Fact001301" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,000,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in the aggregate. As of December 31, 2024,
the facility has remaining available capacity of $<span id="xdx_905_eus-gaap--LineOfCreditFacilityRemainingBorrowingCapacity_iI_c20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zqzsSLMY6ME8" title="Line of credit remaining borrowing capacity"><ix:nonFraction name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" contextRef="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember" id="Fact001303" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,000,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Preferred
Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 12 for additional information on the Series A, Series A-1, and Series C Preferred Stock, which were purchased by the Patel Family.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 162; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS
INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Consulting
Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2024, the Company contracted with Dr. Manmohan Patel of The Patel Family LLP to provide advisory services to the Company in
support of the Company&#8217;s manufacturing development, including but not limited to identifying and developing real estate, establishing
quality management processes, attracting and hiring an executive to lead operations, providing medical advice, and addressing government
affairs and regulatory matters. In exchange for his consultation services, Dr. Patel was granted <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrManmohanPatelMember_zhI5kz6Iu5r4" title="Granted, shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DrManmohanPatelMember" id="Fact001305" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,000,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RSUs, of which <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrManmohanPatelMember_zZbyZm2qdgt3" title="Vested shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DrManmohanPatelMember" id="Fact001307" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,000,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">immediately vested, and <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20250131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrManmohanPatelMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zXrgChRsVMTb" title="Vested shares"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20250228__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrManmohanPatelMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zBB0HEnVRZH4"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2025-01-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DrManmohanPatelMember_us-gaap_SubsequentEventMember" id="Fact001309" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2025-02-28_us-gaap_RestrictedStockUnitsRSUMember_custom_DrManmohanPatelMember_us-gaap_SubsequentEventMember" id="Fact001310" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,000,000</ix:nonFraction></ix:nonFraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RSUs vested in both January 2025 and February
2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001312" name="us-gaap:SegmentReportingDisclosureTextBlock"><p id="xdx_805_eus-gaap--SegmentReportingDisclosureTextBlock_zjViOtEdXFwc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
16. <span id="xdx_824_zz8eWF3pcbLk">SEGMENT REPORTING</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates in one operating segment, and therefore one reportable segment, and is focused on the global discovery, development
and commercialization of proprietary therapeutics. The Company&#8217;s business activities are managed on a consolidated basis through
the development and potential commercialization of pharmaceutical products, which are aimed at the global market in the event that products
are successful in receiving regulatory approvals. Our determination that we operate as a single operating segment is consistent with
the financial information regularly reviewed by the chief operating decision maker for purposes of evaluating performance, allocating
resources, setting incentive compensation targets, and planning and forecasting for future periods. Our chief operating decision maker
is the Chief Executive Officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accounting policies for our single operating segment are the same as those described in the summary of significant accounting policies.
Our single operating segment incurs expenses from the development of TVGN 489, which is developed by our research and development department,
designed to target various disease indications. The Company has not yet generated revenue in its operating history.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the segment, the chief operating decision maker uses net loss, which is reported on the consolidated statements of operations as consolidated
net income (loss), to allocate resources (including employees, property, and financial resources), predominantly during the annual budget
and forecasting process. The chief operating decision maker also uses consolidated net loss, along with non-financial inputs and qualitative
information, to evaluate our performance, establish compensation, monitor budget versus actual results, and decide the level of investment
in our various research activities. The measure of segment assets is reported on the consolidated balance sheet as total consolidated
assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001314" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_800_eus-gaap--SubsequentEventsTextBlock_zcq2drwDeQt5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
17. <span id="xdx_823_zySUOK5HYSp2">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated subsequent events and transactions for potential recognition or disclosure from the balance sheet date through
April 2, 2025, the issuance date of these the consolidated financial statements, and has not identified any additional items requiring
disclosure except as noted below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2025, the Company executed an agreement with KRHP to receive a grant for $<span id="xdx_90C_eus-gaap--OtherReceivablesNetCurrent_iI_c20250131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KRHPLLCMember_zotOYpqGdIo8" title="Grant"><ix:nonFraction name="us-gaap:OtherReceivablesNetCurrent" contextRef="AsOf2025-01-31_us-gaap_SubsequentEventMember_custom_KRHPLLCMember" id="Fact001316" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
KRHP is affiliated with the Patel Family. The grant is specified for use toward the Company&#8217;s ongoing operational expenses, may
not be used for repayment of existing debt obligations, and does not include any requirement to repay the investor or to issue equity
in response. Cash payment was received by the Company in January 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2025, the Company executed a draw on the Loan Agreement for an additional $<span id="xdx_907_eus-gaap--LineOfCredit_iI_c20250228__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zajpY7rBcYEg" title="Line of credit Facility additional"><ix:nonFraction name="us-gaap:LineOfCredit" contextRef="AsOf2025-02-28_us-gaap_SubsequentEventMember" id="Fact001318" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to be utilized for operational expenses.
An additional draw of $<span id="xdx_909_eus-gaap--LineOfCredit_iI_c20250331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zYH65LGJr0Ak" title="Line of credit Facility additional"><ix:nonFraction name="us-gaap:LineOfCredit" contextRef="AsOf2025-03-31_us-gaap_SubsequentEventMember" id="Fact001320" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">was completed in March 2025. As of the
date of filing, the facility has a remaining capacity of $<span id="xdx_90B_eus-gaap--LineOfCreditFacilityRemainingBorrowingCapacity_iI_c20250402__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zTexk7tGogP7" title="Line of credit Facility remaining capacity"><ix:nonFraction name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" contextRef="AsOf2025-04-02_us-gaap_SubsequentEventMember" id="Fact001322" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,000,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and remains effective for the next 26
months.</span></p>

</ix:nonNumeric><p id="xdx_81D_zQZ1kJRva8Tb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 163; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Part
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INFORMATION
NOT REQUIRED IN PROSPECTUS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
13. Other Expenses of Issuance and Distribution.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table indicates the expenses to be incurred in connection with the offering described in this registration statement, other
than underwriting discounts and commissions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Registered Holders will pay all incremental selling expenses relating to the sale of their shares of Common Stock and Warrants, including
underwriters&#8217; commissions and discounts, brokerage fees, underwriter marketing costs, and all reasonable fees and expenses of any
legal counsel representing the Registered Holders, except that we will pay the reasonable fees and expenses of one U.S. legal counsel
and local counsel in any other applicable jurisdiction(s) for the Registered Holders party to the A&amp;R Registration Rights
Agreement in the event of a demanded underwritten offering of their securities. We will bear all other costs, fees and expenses
incurred in effecting the registration of the securities covered by this prospectus, including, without limitation, all registration
and filing fees, printing and delivery fees, and fees and expenses of our counsel and our accountants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10.5pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 84%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
    and Exchange Commission registration fee</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33,310.10</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">*<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting
    fees and expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,000.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
    fees and expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">250,000.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    printing and miscellaneous expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,834.90</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">336,145.00</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">* Previously
paid.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
14. Indemnification of Directors and Officers.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a Delaware corporation, the Company is subject to the provisions of the DGCL.
Section 145(a) of the DGCL provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party
to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than
an action by or in the right of the corporation) by reason of the fact that such person is or was a director, officer, employee or agent
of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation,
partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#8217; fees), judgments, fines and amounts
paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding if such person
acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the corporation,
and, with respect to any criminal action or proceeding, had no reasonable cause to believe such person&#8217;s conduct was unlawful.
The termination of any action, suit or proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendere or its
equivalent, shall not, of itself, create a presumption that the person did not act in good faith and in a manner which such person reasonably
believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had
reasonable cause to believe that such person&#8217;s conduct was unlawful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
145(b) of the DGCL provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party to
any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason
of the fact that such person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request
of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise
against expenses (including attorneys&#8217; fees) actually and reasonably incurred by such person in connection with the defense or
settlement of such action or suit if such person acted in good faith and in a manner such person reasonably believed to be in or not
opposed to the best interests of the corporation and except that no indemnification shall be made in respect of any claim, issue or matter
as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Delaware Court
of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of
liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses
which the Delaware Court of Chancery or such other court shall deem proper.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 164; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
145(c) of the DGCL provides that to the extent that a present or former director or officer of a corporation has been successful on the
merits or otherwise in defense of any action, suit or proceeding referred to in Section 145(a) and (b), or in defense of any claim, issue
or matter therein, such person shall be indemnified against expenses (including attorneys&#8217; fees) actually and reasonably incurred
by such person in connection therewith, and the corporation may indemnify any other person who is not a present or former director or
officer of the corporation against expenses (including attorneys&#8217; fees) actually and reasonably incurred by such person to the
extent he or she has been successful on the merits or otherwise in defense of any action, suit or proceeding referred to in Section 145(a)
and (b), or in defense of any claim, issue or matter therein. For indemnification with respect to any act or omission occurring after
December 31, 2020, references to &#8220;officer&#8221; for purposes of Section 145(c) shall mean only a person who at the time of such
act or omission is deemed to have consented to service by the delivery of process to the registered agent of the corporation pursuant
to section 3114(b) of title 10 (for purposes of this sentence only, treating residents of the State of Delaware as if they were nonresidents
to apply section 3114(b) of title 10 to this sentence).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
145(d) of the DGCL provides that any indemnification under Section 145(a) and (b) (unless ordered by a court) shall be made by the
corporation only as authorized in the specific case upon a determination that indemnification of the present or former director,
officer, employee or agent is proper in the circumstances because such person has met the applicable standard of conduct set forth
in Section 145(a) and (b). Such determination shall be made, with respect to a person who is a director or officer of the
corporation at the time of such determination, (1) by a majority vote of the directors who were not parties to such action, suit or
proceeding, even though less than a quorum; or (2) by a committee of such directors designated by majority vote of such directors,
even though less than a quorum; or (3) if there are no such directors, or if such directors so direct, by independent legal counsel
in a written opinion; or (4) by the stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
145(e) of the DGCL provides that expenses (including attorneys&#8217; fees) incurred by an officer or director of the corporation in
defending any civil, criminal, administrative or investigative action, suit or proceeding may be paid by the corporation in advance of
the final disposition of such action, suit or proceeding upon receipt of an undertaking by or on behalf of such director or officer to
repay such amount if it shall ultimately be determined that such person is not entitled to be indemnified by the corporation as authorized
in Section 145. Such expenses (including attorneys&#8217; fees) incurred by former directors and officers or other employees and agents
of the corporation or by persons serving at the request of the corporation as directors, officers, employees or agents of another corporation,
partnership, joint venture, trust or other enterprise may be so paid upon such terms and conditions, if any, as the board of directors
deems appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
145(f) of the DGCL provides that the indemnification and advancement of expenses provided by, or granted pursuant to, Section 145 shall
not be deemed exclusive of any other rights to which those seeking indemnification or advancement of expenses may be entitled under any
bylaw, agreement, vote of stockholders or disinterested directors or otherwise, both as to action in such person&#8217;s official capacity
and as to action in another capacity while holding such office. A right to indemnification or to advancement of expenses arising under
a provision of the certificate of incorporation or a bylaw shall not be eliminated or impaired by an amendment to the certificate of
incorporation or the bylaws after the occurrence of the act or omission that is the subject of the civil, criminal, administrative or
investigative action, suit or proceeding for which indemnification or advancement of expenses is sought, unless the provision in effect
at the time of such act or omission explicitly authorizes such elimination or impairment after such action or omission has occurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
145(g) of the DGCL provides that a corporation shall have the power to purchase and maintain insurance on behalf of any person who is
or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director,
officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted
against such person and incurred by such person in any such capacity, or arising out of such person&#8217;s status as such, whether or
not the corporation would have the power to indemnify such person against such liability under Section 145.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
145(j) of the DGCL states that the indemnification and advancement of expenses provided by, or granted pursuant to, Section 145 shall,
unless otherwise provided when authorized or ratified, continue as to a person who has ceased to be a director, officer, employee or
agent and shall inure to the benefit of the heirs, executors and administrators of such a person.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 165; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
174 of the DGCL provides, among other things, that a director, who willfully or negligently approves of an unlawful payment of dividends
or an unlawful stock purchase or redemption, may be held liable for such actions. A director who was either absent when the unlawful
actions were approved or dissented at the time, may avoid liability by causing his or her dissent to such actions to be entered in the
books containing the minutes of the meetings of the board of directors at the time such action occurred or immediately after such absent
director receives notice of the unlawful acts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Certificate
of Incorporation. </i>The Charter provides that the Company to fullest extent permitted by the DGCL as it presently exists or
may hereafter be amended, may indemnify and advance expenses to any person made or threatened to any person threatened to be made a party
to an action, suit, or proceeding, whether criminal, civil, administrative, or investigative, by reason of the fact that such person,
or such person&#8217;s testator or intestate, is or was a director or officer of the Company or any predecessor of the Company,
or serves or served at any other enterprise as a director, employee, or agent at the request of the Company or any predecessor
to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Charter also provides that to the fullest extent permitted by the DGCL as it presently exists or may hereafter be amended, a director
or officer of the Company shall not be personally liable to the Company or to its stockholders for monetary damages for
any breach of fiduciary duty as a director or officer. No amendment to, modification of, or repeal of the Charter shall apply to or have
any effect on the liability or alleged liability of any director or officer of the Company for or with respect to any acts or
omissions of such director or officer occurring prior to such amendment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Bylaws.
</i>The Bylaws provide that the Company shall indemnify and advance expenses to any person who was or is a party or is threatened
to be made a party to any threatened, pending, or completed action, suit, or proceeding, whether civil, criminal, administrative or investigative
(other than an action by or in the right of the Company) by reason of the fact that they are or were a director or officer of
the Company, or are or were serving at the request of the Company as a director, officer, employee, or agent of another
corporation, partnership, joint venture, trust, or other enterprise, against expenses (including attorneys&#8217; fees), judgments, fines
and amounts paid in settlement (if such settlement is approved in advance by the Company, which approval shall not be unreasonably
withheld) actually and reasonably incurred by them in connection with such action, suit, or proceeding if such person acted in good faith
and in a manner such person reasonably believed to be in or not opposed to the best interests of the Company, and, with respect
to any criminal action or proceeding, had no reasonable cause to believe their conduct was unlawful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Bylaws provide that the Company shall indemnify and advance expenses to any person who was or is a party or is threatened to be
made a party to any threatened, pending or completed action or suit by or in the right of the Company to procure a judgment in
its favor by reason of the fact that they are or were a director, officer, employee or agent of the Company, or is or was serving
at the request of the Company as a director, officer, employee, or agent of another corporation, partnership, joint venture, trust,
or other enterprise against expenses (including attorneys&#8217; fees) actually and reasonably incurred by them in connection with the
defense or settlement of such action or suit, if such person acted in good faith and in a manner such person reasonably believed to be
in or not opposed to the best interests of the Company, except that no indemnification shall be made in respect of any claim,
issue or matter as to which such person shall have been adjudged to be liable to the Company unless and only to the extent that
the Delaware Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the
adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity
for such expenses which the Delaware Court of Chancery or such other court shall deem proper; provided that no person shall be indemnified
hereunder for any expenses or amounts paid in settlement with respect to any action to recover short-swing profits under Section 16(b)
of the Securities Exchange Act of 1934, as amended.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Indemnification
Agreements</i>. The Company has entered into indemnification agreements with each of its directors and executive officers, which
generally provide indemnity to the fullest extent permitted by applicable law against liabilities and expenses incurred in connection
with the defense or disposition of certain actions, suits or proceedings in which such person may be involved or to which such person
was, is or is threatened to be made, a party by reason of the service of such person as a director or an officer of the Company
or in certain other representative or fiduciary capacities on behalf thereof and which establish processes and procedures for indemnification
claims.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liability
Insurance</i>. The Company also maintains standard policies of insurance that provide coverage (a) to its directors and officers
against losses arising from claims made by reason of breach of duty or other wrongful act and (b) to the Company with respect
to indemnification payments that the Company may make to such directors and officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 166; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
15. Recent Sales of Unregistered Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">The following
sets forth information as to all of the registrant&#8217;s securities sold in the last three years that were not registered under the
Securities Act. Capitalized terms used and not defined in this Item 15 have the meanings assigned to them in the prospectus that forms
a part of this registration statement. Unless stated otherwise, each of the following issuances was made pursuant to the exemption from
registration contained in Section 4(a)(2) of the Securities Act as transactions not involving a public offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">On May 3,
2023 and June 20, 2023, Semper Paratus entered into the Subscription Agreements. Pursuant to the Subscription Agreements, we issued
an aggregate of 1,651,000 shares of Common Stock to Polar in consideration for Polar making capital contributions to SSVK, which were in turn to be lent to us, in the amount of $1,651,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">On June 28, 2023,
Semper Paratus and Cantor entered into a fee reduction agreement, pursuant to which Cantor agreed to forfeit a portion of the
deferred underwriting commission owed to Cantor as underwriter of the IPO, resulting in a remainder of $5.0 million of deferred underwriting
fees (the &#8220;Reduced Deferred Fee&#8221;) payable to Cantor upon the closing of the Business Combination in the form of 500,000
shares of common stock. We issued the 500,000 shares of common stock to Cantor in payment of the Reduced Deferred Fee in
connection with the closing of the Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">On February
14, 2024, pursuant to the Conversion Agreements, we issued an aggregate of 174,000 shares of Common Stock to an entity affiliated
with Suren Ajjarapu in relation to services that were to have been provided to us and Tevogen Bio, at an effective price of $10.00
per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">On February 14,
2024, in connection with the consummation of the Business Combination, the Company and Tevogen Bio entered into an Assignment and Assumption
Agreement, pursuant to which the Company assumed all obligations of Tevogen Bio under convertible promissory notes that were outstanding as of the Closing Date (the &#8220;Assumed Notes&#8221;). The Assumed Notes were automatically
converted immediately following Closing, at which time they had an aggregate principal amount totaling approximately $24.0 million and
accrued interest totaling approximately $2.9 million, in accordance with their terms into an aggregate of 10,337,419 shares of Common
Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">On February 14,
2024, the Company issued an aggregate of 19,348,954 RSUs under the 2024 Plan to Dr. Saadi. The Special RSUs were immediately vested into
shares of restricted Common Stock (&#8220;Restricted Stock&#8221;) that vest in four equal annual installments beginning on February
14, 2031. Pursuant to the terms of the Special RSU Award, Dr. Saadi will be entitled to vote the Restricted Stock, but it may not be
sold, assigned, transferred, pledged, hypothecated, or otherwise encumbered, subject to forfeit. Dr. Saadi will automatically forfeit
all unvested Restricted Stock in the event he departs the Company for any reason, unless termination of his service triggers accelerated
vesting pursuant to the terms of the Special RSU Award or the 2024 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">In connection
with the consummation of the Business Combination, Semper Paratus entered into an agreement as of February 14, 2024 with SSVK, pursuant
to which, as amended, we issued 3,613 shares of Series B Preferred Stock to SSVK in consideration of the assumption by SSVK of certain liabilities
and obligations in the amount of approximately $3.6 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">On February 14,
2024, we entered into a securities purchase agreement, pursuant to which an investor agreed to purchase shares of our Series
A Preferred Stock for an aggregate purchase price of $8.0 million. On March 27, 2024, we entered into the Preferred Purchase
Agreement,  pursuant to which that amount was reduced to $2.0 million and the investor agreed to purchase
shares of our Series A-1 Preferred Stock for an aggregate purchase price of $6.0 million. Pursuant to the Preferred Purchase
Agreement, we issued shares of Series A Preferred Stock convertible into a total of 500,000 shares of Common Stock at a conversion
price of $4.00 per share and agreed to sell shares of Series A-1 Preferred Stock convertible into a total of 600,000 shares of
Common Stock at a conversion price of $10.00 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">On June 6, 2024,
we entered into the Loan Agreement. Pursuant to the Loan Agreement, we issued the Commitment Shares to The Patel Family, LLP as a commitment
fee in consideration of the extension of credit. Interest payable through December 31, 2024 relating to the first two draws on the
Facility was settled in February 2025 through issuance of 18,847 shares of Common Stock (the &#8220;Interest Shares&#8221;). The Commitment
Shares and Interest Shares were issued pursuant to the exemption from registration under Section 4(a)(2) and/or Rule 506 of Regulation
D under the Securities Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;On August 21, 2024, we entered into a securities purchase agreement pursuant to which an investor purchased 600 shares of Series C Preferred
Stock of our Series C Preferred Stock for an aggregate purchase price of $6.0 million. The Series C Preferred Stock was issued pursuant
to the exemption from registration under Section 4(a)(2) of the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 167; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
16. Exhibits and Financial Statements Schedules.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tr>
    <td style="font: 10.5pt Arial, Helvetica, Sans-Serif; white-space: nowrap; width: 0.85in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10.5pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibits.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><p style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description
    </b></span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315223022852/ex2-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement and Plan of Merger, dated June 28, 2023, by and among the Company, Semper Merger Sub, Inc., SSVK Associates, LLC, Tevogen Bio Inc, and Ryan Saadi, in his capacity as seller representative (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed with the SEC on June 29, 2023 (File No. 001-41002))</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315224006751/ex3-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the SEC on February 14, 2024 (File No. 001-41002))</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000164117225006227/ex3-1.htm" style="-sec-extract: exhibit">Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the SEC on April 25, 2025 (File No. 001-41002))</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315224010806/ex3-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Designation of Series A Preferred Stock of the Company (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the SEC on March 21, 2024 (File No. 001-41002))</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315224012650/ex3-1.htm" style="-sec-extract: exhibit">Certificate
    of Designation of Series A-1 Preferred Stock of the Company (incorporated by reference to Exhibit 3.1 to the Current Report on Form
    8-K filed with the SEC on April 2, 2024 (File No. 001-41002))</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315224033756/ex3-1.htm" style="-sec-extract: exhibit">Certificate of Designation of Series C Preferred Stock of Tevogen Bio Holdings Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the SEC on August 23, 2024 (File No. 001-41002))</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000110465921135566/tm2132195d1_ex4-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant Agreement, dated November 3, 2021, by and between the Company and Continental Stock Transfer &amp; Trust Company, as warrant agent (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed with the SEC on November 8, 2021 (File No. 001-41002))</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000110465921124178/tm2126753d1_ex4-3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specimen Warrant Certificate (incorporated by reference to Exhibit 4.3 to the Registration Statement on Form S-1 (Registration Statement No. 333-260113) filed with the SEC on October 7, 2021)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315224029808/ex5-1.htm" style="-sec-extract: exhibit">Opinion
    of Hogan Lovells US LLP (incorporated by reference to Exhibit 5.1 to Amendment No. 2 to the Registration Statement on Form S-1
    (Registration No. 333-280414) filed with the SEC on August 1. 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315223042391/ex10-15.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Service Agreement, dated as of April 15, 2022, between Tevogen Bio Inc and CIC Innovation Communities, LLC (incorporated by reference to Exhibit 10.15 to Amendment No. 2 to the Registration Statement on Form S-4 (Registration No. 333-274519) filed with the SEC on November 22, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315223042391/ex10-16.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease Agreement, dated as of June 9, 2022, between Tevogen Bio Inc and Wanamaker Office Lease, LP (incorporated by reference to Exhibit 10.16 to Amendment No. 2 to the Registration Statement on Form S-4 (Registration No. 333-274519) filed with the SEC on November 22, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315223042391/ex10-17.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease Agreement, dated as of February 14, 2022, between Tevogen Bio Inc and Mitsui Sumitomo Insurance Company of America (incorporated by reference to Exhibit 10.17 to Amendment No. 2 to the Registration Statement on Form S-4 (Registration No. 333-274519) filed with the SEC on November 22, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000110465923057818/tm2315115d1_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscription Agreement, dated May 3, 2023, by and among Semper Paratus Acquisition Corporation, Semper Paratus Sponsor LLC and Polar Multi-Strategy Master Fund (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on May 9, 2023 (File No. 001-41002))</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000110465923057818/tm2315115d1_ex10-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchase Agreement, dated May 4, 2023, by and among SSVK Associates, LLC, Semper Paratus Acquisition Corporation and Semper Paratus Sponsor LLC (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the SEC on May 9, 2023 (File No. 001-41002))</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315223029606/ex10-3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscription Agreement, dated June 20, 2023, by and among Semper Paratus Acquisition Corporation, Semper Paratus Sponsor LLC and Polar Multi-Strategy Master Fund (incorporated by reference to Exhibit 10.3 to the Quarterly Report on Form 10-Q filed with the SEC on August 21, 2023 (File No. 001-41002))</span></a></td></tr>

<tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><span style="font-size: 10pt">10.7</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315224016796/ex10-6.htm" style="-sec-extract: exhibit">Amended and Restated Registration Rights Agreement, dated February 14, 2024, by and among the Company, SSVK Associates, LLC, Semper Paratus Sponsor LLC, Cantor Fitzgerald &amp; Co., and the other signatories thereto (incorporated by reference to Exhibit 10.6 to the Annual Report on Form 10-K filed with the SEC on April 29, 2024 (File No. 001-41002))</a></span></td></tr>
</table>

<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 168; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify; width: 0.75in"><span style="font-size: 10pt">10.8+</span></td>
    <td style="text-align: justify; width: 0.1in">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315224016796/ex10-8.htm" style="-sec-extract: exhibit">Non-Competition and Non-Solicitation Agreement, effective as of February 14, 2024, by and between the Company and Ryan Saadi (incorporated by reference to Exhibit 10.8 to the Annual Report on Form 10-K filed with the SEC on April 29, 2024 (File No. 001-41002))</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><span style="font-size: 10pt">10.9+</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315224006751/ex10-8.htm" style="-sec-extract: exhibit">Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.8 to the Current Report on Form 8-K filed with the SEC on February 14, 2024 (File No. 001-41002))</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.10+</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315224023230/ex99-2.htm" style="-sec-extract: exhibit">Form of Restricted Stock Unit Agreement (incorporated by reference to Exhibit 99.2 to the Registration Statement on Form S-8 (Registration No. 333-280075) filed with the SEC on June 10, 2024)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><span style="font-size: 10pt">10.11+</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315224016796/ex10-14.htm" style="-sec-extract: exhibit">Restricted Stock Unit Agreement, dated as of February 14, 2024, by and between the Company and Ryan Saadi (incorporated by reference to Exhibit 10.14 to the Annual Report on Form 10-K filed with the SEC on April 29, 2024 (File No. 001-41002))</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.12+</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315224006751/ex10-10.htm" style="-sec-extract: exhibit">Form of Indemnification Agreement (incorporated by reference to Exhibit 10.10 to the Current Report on Form 8-K filed with the SEC on February 14, 2024 (File No. 001-41002))</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><span style="font-size: 10pt">10.13</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315224012650/ex10-1.htm" style="-sec-extract: exhibit">Amended and Restated Securities Purchase Agreement, dated as of March 27, 2024, by and between Tevogen Bio Holdings Inc. and The Patel Family, LLP (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on April 2, 2024 (File No. 001-41002))</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.14</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315224023483/ex10-1.htm" style="-sec-extract: exhibit">Loan Agreement, dated as of June 6, 2023, by and between Tevogen Bio Holdings Inc. and The Patel Family, LLP (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on June 11, 2024 (File No. 001-41002))</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><span style="font-size: 10pt">10.15</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315224033756/ex10-1.htm" style="-sec-extract: exhibit">Securities Purchase Agreement, dated as of August 21, 2024, by and between Tevogen Bio Holdings Inc. and The Patel Family, LLP (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on August 23, 2024 (File No. 001-41002))</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">23.1*</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="ex23-1.htm">Consent of KPMG LLP</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><span style="font-size: 10pt">23.2**</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315224029808/ex5-1.htm" style="-sec-extract: exhibit">Consent of Hogan Lovells US LLP (included in Exhibit 5.1) (incorporated by reference to Exhibit 5.1 to Amendment No. 2 to the Registration Statement on Form S-1 (Registration No. 333-280414) filed with the SEC on August 1. 2024)</a></span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315224024790/forms-1.htm#as_001" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power of Attorney (included on signature page of the initial filing of this Registration Statement)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EX-101.INS*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within
    the Inline XBRL document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EX-101.SCH*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EX-101.CAL*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EX-101.DEF*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EX-101.LAB*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Label Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EX-101.PRE*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">107.1**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315224029808/ex107-1.htm" style="-sec-extract: exhibit">Filing
    Fee Table (incorporated by reference to Exhibit 107.1 to Amendment No. 2 to the Registration Statement on Form S-1 (Registration
    No. 333-280414) filed with the SEC on August 1. 2024)</a></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    herewith.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">**</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Previously filed.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedules
    and exhibits to this Exhibit omitted pursuant to Regulation S-K Item 601(a)(5). The Registrant agrees to furnish supplementally a
    copy of any omitted schedule or exhibit to the SEC upon request.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates
    management contract or compensatory plan.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
    Statement Schedules.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedules
not listed above have been omitted because the information required to be set forth therein is not applicable or is shown in the financial
statements or notes thereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 169; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
17. Undertakings.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The undersigned registrant hereby undertakes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933&#894;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration
statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range
may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume
and price represent no more than 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Filing Fee
Tables&#8221; table in the effective registration statement&#894; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or
any material change to such information in the registration statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed
to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall
be deemed to be the initial bona fide offering thereof&#894;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the
termination of the offering&#894;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser, each prospectus filed pursuant
to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or
other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of
the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that
is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement
or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first
use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement
or made in any such document immediately prior to such date of first use&#894;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)
That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution
of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant
to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities
are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to
the purchaser and will be considered to offer or sell such securities to such purchaser:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to
Rule 424&#894;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to
by the undersigned registrant&#894;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
The portion of any other free writing prospectus relating to the offering containing material information about the undersigned
registrant or its securities provided by or on behalf of the undersigned registrant&#894; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling
persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of
the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable.
In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred
or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is
asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless
in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the
question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication
of such issue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 170; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, the registrant has duly caused this Registration Statement on Form S-1 to be signed
on its behalf by the undersigned, thereunto duly authorized in the City of Warren, State of New Jersey on the 30th day of April,
2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
    BIO HOLDINGS INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Ryan Saadi</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ryan
    Saadi</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="POA_001"></span>Pursuant
to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities
held on the dates indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Ryan Saadi</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">April 30, 2025</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and <br/>
    Chairperson of the Board of Directors</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ryan
    Saadi</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Kirti Desai</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">April 30, 2025</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kirti
    Desai</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial Officer and <br/>
    Principal Accounting Officer)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>*</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">April 30, 2025</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey
    Feike</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>*</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">April 30, 2025</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Keow Lin Goh</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>*</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">April 30, 2025</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Curtis Patton</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>*</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">April 30, 2025</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Susan
    Podlogar</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>*</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">April 30, 2025</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Victor
    Sordillo</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
    By: </span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Ryan Saadi</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ryan
    Saadi</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attorney-in-fact</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 171; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>ex23-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consent
of Independent Registered Public Accounting Firm</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the use of our report dated April 2, 2025, with respect to the consolidated financial statements of Tevogen Bio Holdings Inc.,
incorporated herein by reference, and to the reference to our firm under the heading &ldquo;Experts&rdquo; in the prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
KPMG LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Philadelphia,
Pennsylvania<BR>
April 30, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>forms-1_001.jpg
<TEXT>
begin 644 forms-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  _ 3T# 2(  A$! Q$!_\0
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MW=I?R^'O&&A:=X@TAKZQD,EG>BQU.WN;=+NV9G\FY1%FC625%<)+(K?RW_\
M!0OX#?!7P!_P5)_8Q^&/@CX5> O"?P[\8VW[.K>*_!/A_P ,:3I7ACQ$WB']
MHCQKX?UUM8T:SMHK'4#J^AV5II&H&YAD-UI]M#:S;X8T4?SH?W&?T#_LW?MX
M?LQ?M9^(?$7A7X&>/;WQ3K_A;1H?$&L:??>#_&'AIH=(FO8M.%Y#<>(M#TVT
MN5CO;BV@EAAN'N%-Q&ZPM&)7CW/VD/VS_P!F_P#9,@T=OCE\1;7PMJ/B*&>Y
MT'P]9Z7K/B+Q'JMK;2>3/>V^C:!I^H7<.GI/F ZC?):6!N \*W)E1T7O?AA^
MSE\ _@IJ.IZO\(O@W\-OAKJNLV4>FZMJ7@KP?HGAV^U'3XIUNH[&[NM,L[>:
M>T6Y1)Q;NYB\Y(Y"I=$(_FN_:NU;X/:Q_P %OX;+]IBX\*K\$O"EEX0L?$/_
M  G+>9X26P@_9^7Q=H=KK<-PSVTEE<^.M7LT^QR1FRNY[E(KJWF2XN%E /V-
M^%G_  5N_8@^+_COPI\-_"WQ#\2V_BWQOKVC^%_"UAK/PZ\:6D.J^(=?OH=-
MTK2Q?6ND7UG9275]<06YN]2FL]-@,@EN+V*!))4^G_VD?VK_ ('_ +)GAWP]
MXK^.?BB_\*Z%XHUJ7P]HUY9>&?$GB7[1JT-C-J3VTL7AS2]3EM?]#MYI4DND
MBCD\MUC9F5@/E_X3^*_^"3.N?$3P;I7P;TS]BZ3XH2:S:R^!/^$-^'WPQT_Q
M<GB'3PU_87'A[4;/PW:ZA;:S;-:FYL;FSNHKT7$2-;2&X*9K?\%?/A OQ<_8
M1^++6]M-<ZU\+9-%^+^B+$ RQ-X.N9(?$US.HCD=H8/ .K^+WRAB,<JQ2R2>
M1'*C@'Z,>%O$^@^-O#'ASQGX6U*'6?#'B[0='\3^'-7MEF2WU70=?T^WU71]
M2@2XCAN$AOM/N[>ZB6>&*94E42QQN&4?.EI^VE^SK??M)7'[)5GXWN[GXZ6I
MG2;PM;>%/%=U81RVOA,>-;J&7Q3;:+-X8MI+7P[ONK@W6JP1Q74;:6[C5'BL
MY/FK_@D7\8+;XC?L!_"N[U75(I+[X5)XG^&7B.ZGG41:;;>"]0GN] @GD=V\
MB*Q^'^I>%682E5CA =56 Q@?FK_P1[TR7]H/]N/]L#]KW4;::YTZ.]\2GP[<
MW2LBV>H_%_QIJ6L:?#:+,_G!](\'>&[K2?) D%E9:C!#.R--;^8 ?T3_ !/^
M*WPW^"_@_4?'WQ5\::!X#\'Z5M6[UWQ%?QV5J9W262&QLXVW7.I:G=)#-]CT
MK38+O4KUHW2TM9G4J/@WPU_P6!_X)^>)_%$/A:W^.!TB6[N(K2QUSQ+X'\=^
M'_"]S<S3"%5FU[4_#L%GH]NN3++J7B$Z/I4$*EYKY. ?S0_X+$:EK/QQ_;A_
M8]_8\DUV^L/ WB.?X=W>KVUML2&VUWXJ?$O5? UYK;(ZQ_;+[1?"^D"6P9I)
M8X$U&\@M0D]U>I)]Z_M:_P#!-#]CV+]D?XM:?X"^!W@SP3XH^'OPO\7^+O _
MC'0;*YB\7P:_X/\ #M_KFG1ZUXFDNY-<\46FJ2:?_9NI0>);[6(WM[V6ZBB6
M_@M+B$ _6*PO['5;&RU32[VTU+3-2M+:_P!.U&PN8;RQO[&\A2XM+VRN[=Y+
M>ZM+JWDCGMKF"22&>&1)8G9&5CX_\<_VB_@G^S5X33QK\;_B'HG@'0)YI+:P
M?4?ME[JFL742QM-:Z%X?T>UU'7]<N(%EB>YBTG3+QK6.6.6Y\F)@]?F+_P $
M*/BGXB\>_L<ZOX3\1ZE/J7_"I?BGKW@_PR]S(TLUGX/U#0O#?BK3M-::1FFD
MBL=9UOQ#%9*[&.TTW[#I]L([6SABC^%/VA/#=O\ MH?\%L]"^ OQ.$^J_"CX
M<0V.B+X=%W<VD$_A[PQ\+'^*.MV+O:>5,A\2^+[N:QU&XAD@NI-)EM[9+Q/L
MEL\8!^F^G_\ !:?_ ()\WMSY%S\5/$^DQ>>\/VS4/A;\0Y+;RU+ 76W2O#VI
MW?D2 !D7[+]J =0]NC!U3]3[*]M-2LK/4;"XBN[&_M;>]LKJ!P\%S:7423VU
MQ"Z\/%-"Z21L.&1@>AKY;F_82_8LG@6V?]E']GM8UC$8:'X1^![><J-HRUU;
MZ+%<M(0HS*TQE)+$N2S$_3,L<&B:))%IMM;VMMI&EO'I]G%&(K2W@L+0K:VT
M4,1C$=O#'%'$D410)$H1"H P ?!OQN_X*C?L5? #QEJOP]\<_%:6\\::#<_8
MM>T'PAX6\2>*GT2\5MDUGJ6IZ9IKZ'!?6IS]LTY=4?4+4@QSVJ2XC/H'[,W[
M>G[,O[7.M:_X:^"/C74]=\1^&-'CU_6M%U;PAXI\.W-KH\MY!IRWR76KZ7;Z
M7<HM[<P6[P6M_-=*TJR&#R=TH_FW_P""3?B/]BB?7?VBO&G[;-Q\%;_Q'K.I
M>"+GP6GQLTO0M<T^>75;KQQJGC>^T72?$-CJ-@]W-??\(^-0NFA>>&(VT,3Q
MQW-P+C^DC]E_7/V$?$.K>+;G]D*Q_9RAUW3M.TR#QG<?!/PGX)\.:LND7]S=
M2:7#K4OAG1]+O+K3I;RPN7@CG::VCNH0Q5)6C+ &[^TK^VI^SE^R,_A*'X[^
M.I_"=UXY76)?#-G9>&/%'B:ZOK?0#IR:K<RQ^&M(U46,%O)JMA$CW[6QNI)V
M6T6?[-=F#W'X:?$GP3\8? 7A7XG?#C7K?Q/X'\:Z1;ZYX;URUAN[9+_3[@LH
M,EG?V]IJ%A=V\\<UI?Z=J%K:W^GWL%Q97UM;W4$T*?SM_P#!>#PHWCOXX?L2
M>!UOAI;>,I_&'A1=3:V-XNG-XB\7?#K2%OC9B>U-T+0WGV@VPN;<SB/RA/#N
M\Q?4O^")_P 9/$?@+5OCA^P-\6I6TSQW\'/%/B+7_!^E7,TDD:V=KK;Z-\2=
M!TR>18H7L]-\2OIWBC24M@[:O;>*-=UB!/L=G-,0#]>O@1^UK\!_VE->^)GA
MGX/>,+GQ-K?P@U>ST7Q]9W'AKQ-H2Z1>ZA>:]I]B(+O7-(T^RU:&YN_#.MQ)
M+I5S>+&++S9A%%<V<EQ](U_.[_P1 _Y+A_P44_[*%X$_]2_X[5_1%0!YQ\7/
MBSX!^!?PY\4_%CXH:Z/#?@3P9907^OZR;'4-3:UBN[^TTJRCAT_2K6]U"[N;
M[4]0LK"U@M;6622XNHE(5-SK^<L'_!:W_@G[-<K!)\2?%]K$Q4&]G^&'CAK9
M =N69+72+F\(7)W!+1V.UMJME=W<_P#!7W_E'5^T;_UZ_#'_ -71\.:_.O\
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M%_&*UTC3B)$6VT%_'VN7?AX1";#O;RZ'<:?/;,P)D@DC<,P<,=;P1=Q'R<D
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MC+#SHUY_T_\ [#'C71M>^"&D^%[:\MCK7@^^UFTU#3Q(HO%M-2U:[UBQOV@
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MHZ)>Z5X?\+^%=%FU"W+1JLD)UN+6--:2*25!<:9/$=DD4@/R9XPUS3OV=/\
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M6LT#/^#BC_CR_9$_Z^OCO_Z)^#U?LM^R+^PS\!OV+?#^L:7\(]'U.YUWQ/\
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=110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>posam_001.jpg
<TEXT>
begin 644 posam_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" *2 M@# 2(  A$! Q$!_\0
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M?D\0> =1T>/P]J=GI>KRQ7]O<+:O<?=?Y?O*OR_]]UZGX/\ BK9^,?B!XO\
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M[4<H<Q=WT;ZI?:O:C[5[4<H<Q=WT;ZI?:O:C[5[4<H<Q=WUE^(/^0->?[O\
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M<]6K_0OC=J.E>,+&/3O$$<>LWUS?W4$WE);[&^QM#]E??YJMO6XW)OV;5?\
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MZG\H_P"T,)_S]B>G?:9=WW6_[YH^TR_W&_[XKSS_ (; ^%__ $'+C_P G_\
MB*7_ (:]^&7_ $&[G_P!E_\ B:/9U/Y1?VAA/^?T3T+[3+_<;_OBC[3+_<;_
M +XKSW_AK[X9?]!NX_\  &7_ .(I?^&OOAE_T&[C_P  9?\ XBG[.I_*1_:&
M$_Y_Q/0?M,O]QO\ OBC[3+_<;_OBN _X:[^&?_0;N/\ P!F_^(H_X:[^&?\
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M".[^TR_W&_[XH^TR_P!QO^^*X3_AK#X:?]!N?_P!E_\ B:/^&L/AI_T&Y_\
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MYPY3E?M+?W6_[YH^TM_=;_OFNJP*,"CG#E.5^TR_W&_[XIZ7+?W6_P"^:Z?
MHP*7,'*84,S?W6_[YJW#-OK2(XK"AF^=_P#>I!\)L(]%10O1048]^];&G?\
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MJ//)^*T =/J?QF\ Z)XDN/#^H>,]!LM=@5I9-,GU");F-5B\UF9-V[_5?/\
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M^><=/V0>T.HWT;ZY?_A([K_GG'1_PD=U_P \XZ/9,/:'4;Z-]<O_ ,)'=?\
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MG_GE'4_6*Y/^KV7_ -[_ ,"/D;_AB?QO_P!!/1/^_P#+_P#$4_\ X8G\;_\
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M14>WJB_U;RW^]_X$?)O_  Q;XU_Z">B?]_Y?_B*/^&+?&O\ T$]$_P"_\O\
M\17UE_PDEU_SRBH_X22Z_P">451[>J/_ %;RW^]_X$?)O_#%OC7_ *">B?\
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M2)U-%<M_PDMW_P \H_SH_P"$EN_^>4?YT<D@]I$ZFBN6_P"$EN_^>4?YT?\
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M_P"$P\#?]!W0_P#P.B_^*I?^$Q\$?]!W0_\ P.B_^*I?]NB]S^<I;Z-]7?\
MA,?!'_0=T/\ \#HO_BJ/^$Q\$?\ 0=T/_P #HO\ XJC_ +=#GA_.4M]&^KO_
M  F/@C_H.Z'_ .!T7_Q5)_PEO@G_ *#>B_\ @=%_\51_VZ'-#^<I[Z-]7/\
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M_'5*YU7P/;6&GM9Z?:32Q6;?\?&]W:7[/]R5-B?\M?G^^W_?-3S?W2I8=?\
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MK]-O^$G@_P">4E'_  D\'_/.2K_M;$?RG-_8&&_FD?F9_P ,R_%/_H1=4_\
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M_"3P?\\Y:/\ A)X/^><M3];J_P HO]5\-_S\E^!^?7_#/?Q'_P"A/U'\T_\
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MUFK_ "D_ZJX3_GY+\#X$_P"&?_B)_P!"C?\ _CG_ ,71_P ,_P#Q$_Z%&_\
M_'/_ (NOOO\ X2:W_P">4E'_  DUO_SRDH^LU?Y0_P!5<)_S\E^!\"?\,_\
MQ$_Z%&__ /'/_BZ/^&?_ (B?]"C?_P#CG_Q=???_  DUO_SSEH_X2:W_ .><
MM1[>?\H?ZJX3_GY+\#X(L_V>?B->7"Q)X5NDW=7E>)$_]#KZ%^$'[-Y^'&FW
MWB#7Y8;K7_LDJPQ1#=':[E^;YOXFKW(>)K<?\LI/RJAKWB2!]$U!?*E^:!O_
M $"IG4J3/0P6083!5/:_%(ZS<-N:-P]*P/\ A)[?_GE+3O\ A)[?_GE+7-R2
M/I^8W=P]*-P]*PO^$GM_^>4M'_"3V_\ SREHY)!S&[N'I1N'I6%_PD]O_P \
MI:/^$GM_^>4M')(.8W=P]*-P]*PO^$GM_P#GE+1_PD]O_P \I:.20<QN[AZ4
M;AZ5A?\ "3V__/*6GIXD@?\ Y924<D@YC9D.(G^E<,D/R5TW]MQ.C_*U8GDU
M<2)>\;WA\;--7_>:O&'^)OQ M[(HOAR_OM4NGD26$:7+#'8R_=\I)=KK*JK^
M]\UOE?9L7YFVIZS9ZHMG:I$T3/3W\21)_P L)/\ OJIE$N)YEIOQ \9OJC8\
M#,K+=+#<WCPRQ.\2OM_N?,VS;)N^[\^W^!JR?%/Q-^)-IXHUG3](\-W>I6%I
MXALHOMBZ1*BII[)#YH3<Z^>VYI?WB?=V?=^[7L'_  D\?_/&7_ONF?\ "5)_
MSPD_[ZI<D@YCQ/X<?$_XH:SXWT./7M#GMO"=Q%/+<:K<:)+:W$3++=>3',CG
M]WNB2)G==RJP1/\ EKNK4OOB#\29O!_@S5M$T.YOD\0ZTDU[-);(SZ9I<LZK
M$IBWHV[RG5]WS;=C[J]9_P"$JB_YXM_WU1_PE47_ #Q;_OJGR2'SQ/!9/%OQ
MQT[2+.^LK3^VK]K"2]DTV[TC[,K;[U8[6)G5_DE\@N\O]S;7<W?B[Q_K/A?P
ML_AVW3^V+B^2WU)M1L)+=(4^RO*_FHW^J_>[5^7?_=W[J]!_X2J+_GBW_?5)
M_P )7'_SPE_[ZI<D@YXGF>G_ !?\=WMA<77_  KV[BBMWG4I<QRQ2RA5?RF5
M-G^RN[_>^6GW?Q;\>6ES;@>!+B^LI7N?])@@G#[(D1E;RF3<K/N?:C[?N[=V
MZO2?^$KC_P">$O\ WU1_PE<?_/"7_OJCDD'/$\KTWXM>/KB)+NY\'W-H&CB;
M[.;*=S K>4&9]BLS?-YIV)\WR_-6%\3_ (E?%CPYXS\0VWAWPW+J^DI]A:SN
M(--E=(HV7]\N[;^]E9_E79N5%;Y]M>X_\)7'_P \)?\ OJE_X2J+_GBW_?5'
M)(.>)X_I7Q-^(5WX3UZ/7M,;0O$EWK,6C:$L=DVWRI7VK=;F^5F5?-=D_A\K
M_:J#XL^,OB]X=\5ZL_A73WU?086MHH$;2#*_GO%+)L3:WS1;D@C:7^'SV_N5
M[/\ \)5%_P \6_[ZH_X2J+_GBW_?5')(.>)X_P##GXI_$?5M&UJ#Q/H#:;XE
M2RO+JSLCI\R(?+6+R&5ON/O9WW)O5DV[?F^]6M?_ !8\:6TVIR:9X(U+5[ I
M]HL[B6"6W^58(BZ^4Z*WWY?E7[S;)?[M>D_\)6G_ #PE_P"^J/\ A*T_YX2_
M]]4<DA<\3S/QM\0_B+#\+]4UO1?#GV?Q)#<VL5GIRV=Q=/.K)$\OR;$_B=EW
M?*OR_,R?P\?X3^+'QIU7QI86FN>"Y],T*;59[>]NET]W^S0>;$L6SGYC\S*S
M_,OS,Z[E2O??^$JB_P">+?\ ?5)_PE<?_/"7_OJCDD/GB>1>+_B+\1(O"E[K
MWA?3'UQ+KQ,UE9V<=MN>#3XE:-G^[]Z6>)_G?Y%65?NK\]9WA7XG_%V^^(=C
MIFH^&I$\+2:Q<PW&J_V7*LB6J^5]G^5MGWW9T9MORXW?,GS5[C_PDZ_\^LO_
M 'U3T\21/_RPD_[ZHY)"YC?W5S5LG[U_]ZKT.MJ__+)JAMD^>G$)&A:]Z*?#
M10!2NNU9DU7;R:IX=)MKF&.1@VYE_O4%\IS<SK51WKKV\-6C]?,_[[J/_A$K
M+TD_[[JN<.2)R6^C?76_\(E9>DG_ 'W3?^$3LO\ IM_WW1SARQ.4WT;ZZO\
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M?^FW_?=/G#E@<IOHWUU?_"*6/K+_ -]T?\(G9?\ 3;_ONESARP.4WT;ZZO\
MX1.R_P"FW_?='_")V7_3;_ONCG#EB<IOHWUU?_")V7_3;_ONC_A$[+_IM_WW
M1SARQ.,U)_\ B6W?_7)ZL;ZW]:\+6*:1>,OF96)OXJN_\(G8_P#3;_ONCG#W
M#D]]&^NK_P"$3LO^FW_?='_")V7_ $V_[[HYPY8G*;Z-]=7_ ,(G9?\ 3;_O
MNC_A$[+_ *;?]]T<X<L3E-]&^NK_ .$3LO\ IM_WW1_PB=E_TV_[[HYPY8G*
M;Z-]=7_PB=E_TV_[[H_X1.R_Z;?]]T<X<L3E-]5-8?\ XE-[_P!<G_\ 0*[?
M_A$['_IM_P!]U1UWPO8IHFH,OF96!_XO]FCF#W#!WT;ZZQ?"=D%_Y;?]]TG_
M  B=E_TV_P"^Z.<.6)RF^C?75_\ ")V7_3;_ +[H_P"$3LO^FW_?='.'+$Y3
M?1OKJ_\ A$[+_IM_WW1_PB=E_P!-O^^Z.<.6)RF^C?76?\(G8_\ 3;_ONC_A
M$['_ *;?]]T<X>Z<KOJQ"ZUT?_")67I)_P!]TJ^%K).TG_?='.'+$R87IV^M
MD:';0ABOF9_WJYE+FC<.4L.]5W>M#?IECH,VIZI<1VEI;HSS7%Q/Y44:K_$S
M?PU4N=>\%6^@1ZY-XATR'0YVVQ:FVHHMNS?[,N_;VHYP*6Y:9OKJ(?#VFW,:
M2Q;GA9=RLDGRLM8>L:QX-\/7$MOJ>M:?IDT0W21W=\L;*-KO_$_]Q6;_ '5]
M*.<.6)3WT;ZWM-T_1-:MVFL)DN[=9'B\RWGWKN5RK+_P%A5W_A%K#^[)_P!_
M*.<.6)RF^C?75_\ "+6']V3_ +^4?\(M8?W9/^_E'.'+$Y3?1OKJ_P#A%K#^
M[)_W\H_X1:P_NR?]_*.<.6)RF^C?75_\(M8?W9/^_E'_  BUA_=D_P"_E'.'
M+$Y3?1OKJ_\ A%K#^[)_W\JII^D:1J<,DMI(D\:2O"S1S;@KH^UE_P!Y65EH
MYPY8G/[Z-]=7_P (M8?W9/\ OY5*[L=$TYG6[GBMG6![AA+<[=L2_>?_ '5W
M?>HYPY8F#OHWUH6VH^$=0U"6PMM8T^YOXI/(:UBOU:5)?F^0KO\ O?(_R_[+
M58*>'1':2?;[79>3?9[9S=K^_E_N+_>;Y6^7G[O2CG#EB96^I4=:LRW?A2*#
M5)VU.V":6^R^VW.[[,WHW/RM2W&I>$+*V^TSZUI\%M]I:S\Y[]47S_\ GENW
M?>_V:.<.6));.M:MKWJPFAVB?=5O^^JS[:;YMM0'*;$-%,A>BI Q;]ZW=*_Y
M!]O_ +E<YJ7W*Z+3/^0=;_\ 7):IER+6ZC=7R=K-K\19_'WQ6T3P_P#$77GN
MM TFUU'2+22*S96GE69_*?\ T?[O[I%7\:Q[[]H3Q'\1([;6- \1MX>\(ZOJ
M&C^'!?B./%G//$T]Y*KNA_>_-#;KN^57YK3V)JJ,F?9).:48KXKF^*7CFUL]
M,TOPEJGB.?7=,\2WEM>Z;XE-G<W%TL&G_:GM1) NUE?^%_O[FKN/!?Q2\6_%
M7]GWQ]XE\'7SWFMS:M?1:&\JQ1/%!YJ[(QN^7>J,P7?_ !8HE1D@E1E$^G,B
MC(KX<G^*'BJX^&7BNQ/BWQ5I?B.Q\0RZ/X7@FGLVU"^G:WB=(KID1T=8G=F=
ME^ZGW^E;]_\ $SQO:?$=)KGQ9*+G2O$VA>''T2U2/[)?175JCW$NW;N9G9W=
M&W?*J4_8R']7D?8M%(.@I:P.8**** "BBD/2@!N"3FJMU=165K+/.ZQ6\:L[
MNWW55>M6L\BO'/VM+^[TW]GCQI-:,R3/:K$SKU6-Y41__'&:KIP]I4C$PKU?
M94I5/Y3Y@^+?[;7BCQ5XA?1_AXW]D:5Y_P!G@O4C5[J\;?M##?\ <1O^^JX>
M^^*'Q;@U273[#XB7VM7L#-%>0V,S?N'1MGSNR(OWFV?)]YJ\4L)I[:]MY[9F
M2[BE1XG3[ZOO^2O2+;QMKUA?ZQ?0>%[2P>ZEEBU/ROM$7FSJZ2O\_F_*R;-V
MQ/[[U]Q]5HTH\L8'YO+'5<1+FJ2D;S_%?XUP6"7TGB/Q EHR[][R?P^;Y7W/
MO?>^3_>JU<_$WXTVJS.WBC7F6")9;C]YL\K[_P GS??;Y7^Y_=KB=$\<ZY#J
M7_"1P6=M>)I%G]EG^T?.FV65W1W^?<S>:^[_ ( E7=$U[7O&>FIHL&AVWB%+
M**)U1U??$R[T27[Z;F?S=FQ_]CY*4J4/Y8G/[>?_ #]D=9-\5/B]9Z5J-[?>
M,M8LTMHHI51YT?S5>7ROE9?[K58N_BC\4K.&T23XA7G]J7,45PFE^>WFI%*N
M]&9]FS[OS_?^ZU<9XP\?ZOK%F]G?:?;:;;SQ;/)B5_D5;C>_R,_R_.FW9_#5
MA/$^JVWB"TL[GP]8WGB.RVZ;YSJSROM3RD3Y7V[D78F]/F^1*Q]DOY8D2KSY
MOXLO_)CJ9/B7\:8K>[G?7_$"PV>Y9W\S[NQ4=O\ QUD?_=:I?^%D?&K[5]E_
MM_7OM&Q6\GSTW_/]U/\ >_V/O5C6WB?Q?XJU**\L](6:66*Z>+R5;[C6\5G+
M]Y_X-B?\">GIXS\1Z5J^JRKX>6PN[]?[2O$A\^)W>)W_ -(_UNY?G>7Y/NUA
MR+^2)'MI_P#/V7XFWI_Q)^+MWJ^B:?-XLU?3WUEXEM7N)OE=7^Z_]_;\U7M0
M\=_&"W"26WBK6-3M'CBF6XMV9?\ 6NRHKHZ(RO\ (WRUYP_B?5;#Q#H6O2P1
M0W=K!;O9[U^258/E1_\ QRK</B?7O#RVES/*LUQ=7EOJ\5Q<2^;*SQ;TB=_G
MW;?G?[]1*G_=B8?69_:G+_P([&;XF_&"V""7Q#KF)&V(R2(R,VUG^]_NHW_?
M#58A^(/QDN9=D6N:\[>4TO\ K$^14V[MW]S[Z_?_ +ZUR/\ PL75[E-8\BV7
MRKBP^SRINEE^RIO?]ZCL[[6_>NG_ &UJQXA^)&M7\NIVU]%&DMU$]O=)YLK_
M #L\3NZ(S[4;]TGW*CD7\H2Q3_Y^R.NN/'WQ=LM/BN[GQ1JL"2QSS*GG;I?W
M4OE,KI_#\U">._C.;K[,=:U[SMN_9YB?=W[?_0_EKCG^)VIS3O<K!:)=[KAU
MN$5MZ>;*EP_\>W[R5%?^.9[RUEMHM/LK.TE;S6BA5_O-*DKO\[O_ !Q)67LE
M_*92QC_Y^R_\".KL/BE\6-2G>"V\0:Y<SK/]F>%#\ZR;';9_O?*__?-7],\>
M?%G5+)IK?Q/J@V02W&R6;9NB6)9=^YO]EUKA]*\?ZGH^J:Q?6RP)<:BWFL^W
M_5-OW;T_VOG=/]UWJW>?$B^U*ZO9;JSM'BNFG=K=%9$598DBV+\_RJB(FRHE
M!?RD1QK^U5D==XG^(GQ1\*/$USXLU=[258GBN_,^1]T*2[?_ !ZL.7XX?$"X
MB:*3Q;J;(WWD:2N=U7Q;>:W9RVT\4")+/%<-L7^.*W\I/_'*QZ/9P.:KC*O-
M^ZJR_P# F=[_ ,+U^(?_ $.&J?\ ?^G?\+U^(7_0X:G_ -_JX.BCV<.QA]<Q
M/_/V7_@4CO/^%Z_$+_H<-3_[_4?\+U^(7_0X:G_W^KA:$J>2!'U[$_\ /V7_
M (%(]0\/_M(_$'P_?+-_;\FHPK]ZWOU616_]GK[(^#?Q:T_XO^%SJ-O%]DO8
M6\J[LV8,8G_^);M7YU5]"?L3W<\7Q'UBV5F^SRZ9OE4_WEE7;_Z&]<M>E'EY
MCZC(<TQ,<7&A.7-&1]K"EHHKS#]7"BBB@#/US_D#7W_7!_\ T&K_ &JAKG_(
M&OO^N#_^@U?[4 +1110 4444 %%%% !1110 5F^(?^0%J?\ U[2_^@5I5F^(
M?^0%J?\ U[2_^@4 :*_=%+2+]T4M !1110 4444 %%%% !1110!%+_JV^E><
MI-\E>BR_ZIO]VO,$^Y5Q-8&IXB\++XZ^%NL:$UI;Z@FI6TMNUM=32V\4F[^%
MWB^9?]Y*\PU#X*_$'4_A%;>%-0U+2M8U.RE:\L=4FU"\@ELKEI;@ILE1=\JV
M\4L2*S\R[6W[:]1U36K_ ,.?#34-2TRVEN[^UAE>"**V:X=WW'CRE9=__?5>
M7:+\7?BSJ%BFH2^%8=L5KM;3QIEPDMU/_IOSH[/\B_Z+!\NUO^/C[WW:B1E(
ML_$G]G_Q9XYU+PO<GQ?<;=+TNTL[EX[V>R:ZG6]MY9[@K P7+P13IC_IK7GO
MB+]COQUX@T=K*[\66=\%MI[6#[9//-Y2/9W5NOWE_P"FT7_?%>A^'O'7CNT\
M#:UJ=UY]]>S^)5@AU"?0[I([6P:*+]^MEO\ -95;>NT-]YMU0V6K?$V]\(?$
MCQ')+=6&OG1X'T73%T^5XH)4M?-?RHF;YV9W;Y?O?P?PT <Z_P"S1\21K5M.
MGCJ-;<74\Z2B]NE>S5KVXGVQ)]V3S8I8HGW_ '%B^7=74>#/@/XQ\)?#GQ)H
MJ>+7EU>X73[G2[JXO+FX2"\@@@\QG9CO\N6>)F9!_"]5;[Q[\4O#7]NW-E8C
MQ!8W,\KV32Z3<*]JBM9KYNW?\RLMQ.ZQ?*W[K[S?-4-_\8_BI8VK(?#MM<7<
MEI9RB6RTVZ>WM=[*LLLKOM9F^;Y(D5O]IOD>@ ;]GSQY%H*:>?%PU*XB:6U@
MN[B^NHG@BV*MO=?+]^>)O-?8WRMO^]6E9?L^>);/4)-1B\5SQZD\[3"[%]=/
ML9KJY9F\IGV_ZB6*+_ME6WXS^(EU+\#==U*2+6)?$EA:117=EX2BD>[CO&2-
M_*BW1-M_UJ;FV'8K-_=KY\UCQ?\ 'JPL[9=-U+Q#K>O0:5 K/;Z*RV5U:_V:
MSW%TN^)/]*^V?*J/M;[G[K:U 'K'A[]G?Q?96>G_ -I>*)7O+))GC/\ :L\J
M)=-+9,LJ[8HOX8)_E;?\T[_>WM6AX[^$WC?QKX]\376EZO\ \(]9RP^59ZD;
MZ7SG+69C:)(E^5(O-979_O;D^[7#WOQ#\7?\*]@T(:KXL-W%KDMQ-J$&EROK
M": TMTEK<,GD??>2*-/N;]GS;?XJXW2/&7Q[GA5]=;Q5::B\42ZW!::;F*SL
M/^)=_I%KMB^:Y^>_W(FYOE?Y/D2@#Z(^%WP:U/PQ>M<:_J,]_G3?L44']IRW
M'V=VGN'EV-LB79LDB5?DW+LKAM$^"'Q"O)/#&J:EXGO%N;:]E^UP-?M _E13
M1):R_*LJLS00?.OR[FG?YOF:M/3/'OQ4\/\ P@\'7<>B3Z]X@OGNK24W]JWV
MB-!*[6L]PJ[-FZ"/Y_E^^RTQOC+\39%%S%X4^R^98O>6VE3:5=/,\;P3RQ,\
MJML5HML$31??9G;[GRT :OPM^"7BS0=;M=0\6ZS;:DEO>3WL5K8W=P85D:*W
M17V-M_BBE;8^_;O^\[?-6=XA_9]\4KI>OQ>'M8M;:[UFYO+BZ6:ZG5&\V_:>
M)E^5U5TB;9]S_P"*J'5?B;\8?#T>HB70;+6&26XMXI[72IXDB6.XM5^T.OFO
MN5HKB5MB?\\/O?>KJ?!WC?XB:IXJT5-9TNRAT:[VV\Z6]A.KQ2?8EG\_S6?[
MGF[HMFS_ (%0!R^N? 7QWJ6G7D"^+3)M^R_9HC=RQ>;N56O4EEV/]^5%=6VM
MC[M;?CSX":GXXT:QM7UJXCN;?PG=:"9WOY=\US+Y'SRNBKYJ?NFW;E^;^Y7'
M6_QZ^)FJZ%>7^D:':WR->/;+=#2KI(;/;+=1[7^=O/W>1!^]3Y5\VO1YO'GC
M#1? /BKQ7K-I:0KI%VTRZ?#;2JWV"!_W[[V?]ZS1!V1MB?P_+0!SH_9UO;+1
M]9U&PU:.7QJ^IW&HZ1<W0_T2QW7KW*KM5=WS*VU_O??;;\M=/XF^%E]!X;\
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M  %J%S1=Q2ASKE9^6'Q3^"/B?X(^*!#JUC/<Z4L^^VU6*/\ =3Q*W]_^%_\
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MJY%&165_PD&G_P#/U_XZU'_"0:?_ ,_7_CK4!RFKD5F^(?\ D!ZG_P!>\O\
MZ!3/^$@T_P#Y^O\ QUJS]=UZR;1-05;GYO(?^%O[M <ITB?<I<BLK_A(-/\
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M9O\ GK'^5',+F,/R4H\E*W?[ F_YZ1_D:/[ F_YZ1_D:?,/G,+R4H\E*W?[
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M  C\_P#STC_*C_A'Y_\ GI'^5'-(.8Q/)2CR4K;_ .$?G_YZ1_E1_P (_/\
M\](_RHYI!S&)Y*4>2E;?_"/S_P#/2/\ *C_A'Y_^>D?Y4<T@YC$\E*/)2MO_
M (1^?_GI'^5'_"/S_P#/2/\ *CFD',8GDI1Y*5M_\(_/_P ](_RH_P"$?G_Y
MZ1_E1S2#F,3R4H\E*V_^$?G_ .>D?Y4?\(_/_P ](_RHYI!S&)Y*4>2E;?\
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M>(/\+M>ANI8)UL8?*5GEE>^B\J+;+Y3H[[_O([HFRK<WPKUQ+6T:"!;F[?\
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M]K<W4$OAC2#)X;OHK/Q0\-Y+AO,U1M.1K+Y/F^9&D_>_[O7FOKP<B@!:***
M"BBB@ HHHH **** "BBB@!HZUC0O\[ULCK6'#]Y_]ZHD-&G#11#10(S[E*T[
M3_CVC_W15&Z[5=MVS G^[1$IF;;^&+"VUW4=75&^U:A%%!/N;*LJ;MOR_P#
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M:K<VLMM+%I_V*6)(EM/L,7E6^W?L>)/X6_>O\_\ MU]S?\,2?"[_ )\M1_\
M!@_^-._X8F^&/_/GJ'_@>_\ C4_VCA_Y2)9)C_YO_)CXG?XM>)9K5X&O(]CS
M_:-_D)OW^:DO_H:;Z/\ A9VO;;=5EMH?LL_VBU\F!$^SMYOF[$_V=_\ !7VW
M_P ,5?#'_GSU#_P/?_&C_ABWX8_\^>H?^![_ .-9?7L-_*3_ &)F/\__ ),?
M#\WCG59M6LM07[-;7%E UO EO:I%%$C;_P"!?^NKU:U+XA:G?VNF6R-Y,5EI
MT6FKO^?<BRI+O_[Z1/\ @*)7VQ_PQE\,O^?&_P#_  8/2_\ #&GPR_Y\K_\
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MN3[N+YZ7UNF3_JOC?[I\/45]W?\ #(7PZ_Y]+_\ \#7H_P"&0OAU_P ^E_\
M^!KT?6Z9/^J^-_N_>?"="5]V?\,A?#K_ )];_P#\#7_QH_X9$^'7_/K?_P#@
M:_\ C4?68!_JMC?[I\+5]5?L:_#6[LI;SQA?0M;V\\'V2S5E_P!8N[YI/I\H
M6O3]!_9A^'NAWJ7*:,UY(K;U%[,TJ _[I.W]*]61$AC$<85$7Y55>U8U*W/'
MEB>[E/#TL)7]OB)?"7**AW_[5&__ &JX3[TFHJ'?_M4;_P#:H JZY_R!K[_K
M@_\ Z#5_M69K3_\ $FO?F_Y8/_Z#5[?_ +5 $U%0[_\ :HW_ .U0!-14._\
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M/[,U+_GTDJ>4.8DW_P"U1O\ ]JH_[,U+_GTDI?[,U+_GTDI<H<P_?_M4;_\
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MK&YNXO,A7<O^_4+Z'J/\,*?]]T<I',0[_P#:IF__ &F_[ZJ3^P-4_P">"_\
M?Q:;_P (_JG_ #[K_P!_%HY1\PWS1_>?_OJCS1_>?_OJG?\ "/ZI_P ^Z_\
M?Q:/^$?U3_GW7_OXM'*',-\T?WG_ .^J/-']Y_\ OJG?\(_JG_/NO_?Q:/\
MA']4_P"?=?\ OXM'*',-\T?WG_[ZH\T?WG_[ZIW_  C^J?\ /NO_ '\6C_A'
M]4_Y]U_[^+1RAS#?-']Y_P#OJCS1_>?_ +ZIW_"/ZI_S[K_W\6C_ (1_5/\
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MC[TG1!_WT5IQ7-+EB9SE&$>:1R?Q?_:;\$?!^7['JM[+=ZN4W#3M/3S90/\
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MG?\ #=>A_P#0K:G_ -_H_P#&OEBS\ :Y>-<*MFJ>0TL4KS3Q1(CKLW_,S_\
M35/^^ZJ:EX8U/1TNVO+;R4M?*\W>R_)YOW/_ $!_^^*GZM0"6>YI#WO_ &T^
MLO\ ANC1?^A6U/\ [_1?XU!J'[;FB7UC+"/#.HJS#'^OB_QKY4MO#VIW-U%
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M6*U:X?S=[^4B(C_?^5MJ)]S_ &ZMV?Q=U>SU1]0BMK3[0R[/G5]G_'U]J_\
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M84LO^AQN?_ %/_BZKZC^Q!96-E+-_P )=<N%&=OV%/\ XJI]O0*_LC-OY?\
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MCO/^?6?_ +]4?8[S_GUG_P"_5 $O]M:E_P _<E']LZD?^7N2HOL=Y_SZS_\
M?JC['>?\^L__ 'ZH E_MG4O^?N2C^VM2_P"?N2HOL=Y_SZS_ /?JC['>?\^L
M_P#WZH E_MK4O^?N2C^VM2_Y^Y*B^QWG_/K/_P!^J/L=Y_SZS_\ ?J@"'6]8
MU#^R;W_2Y/\ 5-5[^V-1_P"?R2LG6[.Y32;UFMI?]4__ "RJ]]CO/^?6?_OU
M0!+_ &UJ7_/W)1_;6I?\_<E1?8[S_GUG_P"_5'V.\_Y]9_\ OU0!+_;6I?\
M/W)1_;6I?\_<E1?8[S_GUG_[]4?8[S_GUG_[]4 2_P!M:E_S]R4?VUJ7_/W)
M47V.\_Y]9_\ OU1]CO/^?6?_ +]4 2_VUJ7_ #]R4?VUJ7_/W)47V.\_Y]9_
M^_5'V.\_Y]9_^_5 $O\ ;6I?\_<E4=>UC4/[#U#_ $N3_4/_ .@59^QWG_/K
M/_WZK/UZSN4T34-UM+_J'_A_V* -7^V-1_Y_):/[:U+_ )^Y*B^QWG_/K/\
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MR657?:K_ .QMVK_ M'L*9']N8W>,H_U\SZ3_ .&P/AW_ ,]]3_\  %_\*/\
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M &ILHV5-10!#LHV5-10!#LHV5-10!#LHV5-10!#LHV5-3'H 8Z?NF_W:\_\
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M7]Z+_OBC^W=2_O1?]\5>^QT?8Z */]N:EZQ?]\4?V[J7]Z+_ +XJ]]CH^QT
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M6U/^R^],#,AEN;.+RXV^7_=ICZCJ0Z2)_P!\5K?9?>C[&M!)C?VGJG_/1/\
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ML_T67[Y5U^7Y?FKI=&_:/\,>)O _B;Q+H\=W/::#I:ZE<K<1&+#M$\OV?/\
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M?Q+ZUVUE^VAJE]J>D>9X'2TTV671(+]I-4W74$FI++Y7E1+%MEVM%_?7<K4
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MYBM%T^^MM2N[JSM;I4A;8D7FR[?GW?P_+]^H]AAOY2/KN9?S2/6O^&\/'/\
MT!-"_P"_<O\ \73O^&\/&_\ T!="_P"_<O\ \77CUG\*-5OU26"^TM[>7[.D
M%Q]J?9<-*\J(B?)][?$Z?/5+0?!D^O:2]Y%/!;>5+*DLMW+LB1(HO-?_ &JG
MV.&_E,OK^8_\_)'N'_#=WC?_ * VA_\ ?$O_ ,73O^&[/&__ $!=#_[XF_\
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MR-GW/[]1["C_ "F/]HYC+_EY(]A_X;E\:?\ 0'T3_OU+_P#%T[_AN3QI_P!
M?1/^_<O_ ,77EEA\)=3O+"56E@_MAVM_(TY)?GV2NZ;Y?[J_)69K'@#4/#UK
M=W-Y/:(EOY2+^]??+YJ;DV)LW?P/]_;4^SH?RA+'YG&/-[21[/\ \-Q>-?\
MH#Z+_P!^Y?\ XNG?\-P^-?\ H#Z+_P!^Y?\ XNO(W^&]R\44MMJ=E<[K.UNF
M3<R.CSOL2+[GS-NJQ_PI_P 0_P!MQ:5MMOM<JL\2;FV.ZOMV?<^7Y_X_N_[=
M+V5 /[0S3^:1ZI_PV_XU_P"@/HG_ '[E_P#BZ?\ \-O>-?\ H#Z+_P!^Y?\
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MPTZW#7$JH^^5?N?)]W^&OT%_X8F^%7_0(O?_  93_P#Q=._X8J^%?_0'O/\
MP93_ /Q=']I8;^0B618V7VO_ "8_/VY\6ZK>:X^KM/$FH.K(TT,"1;]R.K_=
M3^/>]2OXVUJ;[1NU"3_2MWF_*OS;HO*?_P <^2OOS_AB[X5_] :\_P#!G/\
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M_%5/U^CV,O[!QW\T?O/AK1_'^I:/=:Q>+Y=S?:C;):RS7$2MMVO$WW&3:_\
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M1?VWE_\ /_Y*?3']CZK_ ,]6_P"_M']CZK_SU;_O[7S3_P -QZ__ -"QI?\
MW_EH_P"&X-?_ .A9TO\ [_RT>PJ?RA_;F7_S2_\  3Z6_L?5?^>K?]_:/['U
M7_GJW_?VOFS_ (;=U_\ Z%G2_P#O_+1_PV[K_P#T+.E_]_Y:7L*O8/[<R_\
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MS[:I_P"#!Z]<Q>?\]Y?^^J,7G_/>7_OJE]8K_P#/T/J6$_Y]Q/)?^&&OA?\
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M7%;+S_GYG_[Z:C9>?\_,_P#WTU'*',=KD49%<5LO/^?F?_OIJ-EY_P _,_\
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MX'Z!_P#"*P_\_$WYT?\ "*P_\_$WYU^?_P#POCXA?]#?J?\ W\H_X7Q\0O\
MH;]3_P"_E'U:7\P?ZUX3_GW+\#] /^$5A_Y[S?G1_P (K#_SWF_.OS__ .%Z
M_$+_ *'#4_\ OY1_PO7XA?\ 0WZG_P!_*GZM+^8/]:\)_P ^Y?@??_\ PBT)
M_P"7B8_0U2UWPO NB:@WGR@K _\ Z#7PC:_'SXAV-PLJ>++YG7^&4(R_]\LE
M?0WP=_:3?XA:??\ AWQ#%#;ZY]DE:":([4NMJ\KM_A;VJ)T90._!9_A,;5]E
MR\LCWA?"D 7_ %\WYTG_  BD'_/S-^=;HQ@<TN!ZUS<S/J.2)@_\(I!_S\S?
MG1_PBD'_ #\S?G6]@>M&!ZT<S#D1@_\ "*0?\_,WYT?\(I!_S\S?G6]@>M&!
MZT<S#D1@_P#"*0?\_,WYT?\ "*0?\_,WYUO8'K1@>M',PY$87_")V_\ SWEI
MZ>&8$_Y;25M8'K1@>M+F8<D3+30HT_Y:R5S_ -LKM"<J:\S^U>U:0(E[IUFF
M:?'J%KYK2,OS;?DJPWAF%^LT@_&F^$WWZ3N_Z:M6T3FHN7&)B?\ "+V__/:;
M\Z;_ ,(G;?\ /:;\ZW<#UHP/6CF8<D3"_P"$3MO^>TWYT?\ ")VW_/:;\ZW<
M#UHP/6CF8<D3"_X1.V_Y[3?G1_PB=M_SVF_.MW ]:,#UHYF')$PO^$3MO^>T
MWYT?\(G;?\]IOSK=P/6C ]:.9AR1,+_A$[;_ )[3?G1_PB=M_P ]IOSK=P/6
MC ]:.9AR1,+_ (1.V_Y[3?G1_P (G;?\]IOSK=P/6C ]:.9AR1,+_A$[;_GM
M-^='_")VW_/:;\ZW<#UHP/6CF8<D3"_X1.V_Y[3?G1_PB=M_SVF_.MW ]:,#
MUHYF')$Q/^$4MO\ GM-^=/3PU G_ "WF_.MC ]:,#UI<S#DB9J:%$O262J<,
MVR5U_N-LK?'2N22;_3;C_KJ]-!(Z"%Z*BMGHJ0,34JZ'2_\ D&6W_7)?Y5@W
MZ5T&E?\ (/M_]RKD1$^<M6C^($OC3XCZ7I/CO5);C0M.@O\ 3[::WM=DLLJR
MN(V_=?=^0+6=>?'+7O'/D:GH&K?V'X<U.\TS08]0,2/]EN)(GN+J7YOXE_=0
M?-\NZOI6#1K&VU2ZU*.T@34+I42>X5 'D5,[%9O]G<:RC\._#">'I]"70-/&
MC3NTLNG_ &9/)=F;<S%,?>[UTQKP^U$Y)X6I]F1\[WGQ+\7VL%C9>'-3UR\U
M;3]?NK>[T_Q#%:O<3I!9?:&M=\'RLK_PO]_YJ[/P3\=)[_X/>+/'3/)K%O;Z
ME=C3XA%AQ%O58(W"_P!W=\WXUZEX?^&_A;PM#!'H^A6&FQV\[7$0MX539*R[
M&?C^(K\M:NB^'=,\-VKV^EV%OI]N\C3/%:QJB,[?>; IU*U.7V14\/6A+XCX
M\G^-/C36?",5I8>*[S6]6M]5U59O[*MXK6XN(((-\3KYL6SRD?&Y?OLKK75P
M_$7Q[#XK\%ZC)JMY?:-K%YI=K9RVD4":??6\MO\ Z0S(W[])]^]_]E4KWW6_
MA;X/\3VHM]4\-Z=?0_:7O=DT"G]^WWWZ?>;^+UJ6T^&OA73_ !#%KMOH%A%J
M\4:017J0*'B15V*JG^'Y?EXK26)HV^ QCA:]_P"(=8.0*6DI:\X]@**** "B
MBB@!M>6_M,ZA=:7\!O&US9,4N%TUTW+_  JWRN?^^6:O4JS=;T:U\0:+?:7>
MQB:SO87MYX_[Z,NUA^1JZ<N6<9&-6//3E$_&.%_)='VJ^QM^Q_N/7L6O>&/#
M^L7]E$RVV@H]MHR*^GJB)YMY%NEEEW?PIL^Y5/XV_LX^)_@QKMTLEC/?^'-W
M^AZM%%O5E_@27^ZU>6;T_O5^AJ<,1#FI3/RR<)T)RIU('M5G\#=,O_$=QIT6
MH7R6\47S2RKL>"5GEV?(T7S+^Z^_\J_/]^F6WPT\,:K>V3.VI:;:746DQ1.D
ML3[Y;J)_-E^;^%&3[G_H->-;_P#:J7?_ +59>SE_.1[6'\AZ]IOPE\/7^G/J
M:ZO=I:2V<%Q%;^5YMQ%N\W>[I$C[E1XO]G[_ -^I='^&_AK[;#$S:AJ4OD;)
M;=)53S99=/>Z3RO]QDV?[5>/HZ_WJ>C_ .U4R@_YR/:P_D/0/!/@"S\2:)<7
MES/=P[)Y;=GBV;+)%B\WS;C=_"_W?^ /6Q<Z#H^J^/'TK3-,_P!'BT!G@M_O
MNUQ]B\U'^7[[;WKRS>G]ZGH_^U424OYS+G48\O(>JZ)\(K.\L-,:^N;VPEN/
MLOFW#JOE;I;KRGMTW?-YJ+\__ *T-'^$6AZK8/JJWVI?V?\ 94E6W3:]PC;[
MA/X4?=\]NGR?[?\ L5XXCK_>K8T?Q;JOAZ*6/3[YK9)6\UMBH_S?=WIN^ZWS
MO\Z5E)3_ )@C5I?:@=1HFCJ_@.*^L=(@U6[EO+B+4975Y7LHE1-GR*_R_?E;
M?_L5V=YX>T'3=1O5U?1;:PT2+4X++3+Z+?ONK>5'5Y=^_P#>[%V2[_\ XNO%
M$=?[U/1U_O5,H$QJJ/V#W#P]X#T6SU&'1;ZQM+S4].OK*UO'W;_-EEBNI94_
MVO\ EDG_  "N?U5]*\/:,G]H:1'8:WJFDLD^G0P)LMY?-?RI?F?]TVW9\E>9
M(Z_WJ?O3^]4<GF1*NN7W8$M.J+>G]ZG[T_O5=T>?9]B5*?4*.O\ >I^]/[U1
M=$VEV'TY*;OIR.O]ZHNB.5]A]/IF^G[T_O5-T1ROL.H2C<M"/470<K[#TI],
M1U_O4_>G]ZIN1ROL.H2F[T_O4_>G]ZHN'*^PZBC>G]ZC>G]ZC0GE?8>E%,WI
M_>HWI_>J+AROL/H2C>G]ZA'7^]1<CE?8=12[T_O4;T_O5(<K[")3Z8CK_>I=
MZ?WJ@.5]AU:OA6YGL_$^CSVS,DJWD6W9_OUE)^^?:OSNW\"5]"? ;X!ZK--)
MXL\0V<MC9V<#36EI<)MEFDV?(Y7^!5J*LN6!ZF6X.MB<5%4T?:J?<7Z4ZFK]
MT4ZO%/W1;!1110,**** "BBB@ HHI* &_P )KRJO5?X37F7D_?K2!C4.Q\&_
M\@7_ +:M7)>+/AYX@UWQG9ZY8_$'6]"L(7A\[1;2"!K>>*-][)\Z%E9VVY?^
MZ"O\5=?X179I&/\ IHU;>.#4RW-(?"?G5XW^('C.]^$FO6>E:]XVN;F/QW?>
M1J&K0:G:[[!K65K7=+!$DJHTJ_NEB7;YNQ&VK7MWQ2\=_%?0?A?X'G\'KJ5O
MJ8\'WFKZB=5TC[;=R75M;VKQ6\H3Y$EE9Y5;_@6WI7U314E'P=\5=:^+&NZ9
MKFDZE!JFJ7%E%JUO!J6G:=/:^:G_ !*YXODB?;_RUG3?\W^J_P!^K-]XN^(W
M@+5M:O-,M-5MK=KK45GU66QGO/L-K+XE='N%@^[+LM7WHNW[OS?<K[HHH ^+
MM$^+_P <-4&E7867^S;);&5I&\.NCZW!+KDMGYKK_P L-]GLGVK]W[WRI7VC
M110 4444 %%%% !1110 4444 %%%% !1110 5QB?\?\ <?\ 75J[.N11/]-N
M/^NK542)&Q9_<HI]FE%,"E>0U?L[ZVAM8E:55VK2S0U1FLZ0%_\ MBR7K<)^
M=)_;5A_S\Q_G6(]A47]FK3Y2.:1T']N:?_S\Q_G1_;FG_P#/S'^=<_\ V=_L
MT?V=_LU?)$.:1T']N:?_ ,_4?YT?VYI__/U'^=<__9W^S1_9W^S2Y(AS2.@_
MMS3_ /GZC_.C^W-/_P"?J/\ .N?_ +._V:/[._V:?)$.:1T']N:?_P _4?YT
M?VYI_P#S]1_G7/\ ]G?[-']G?[-')$.:1T']N:?_ ,_4?YT?VYI__/U'^=<_
M_9W^S1_9W^S1R1#FD=!_;FG_ //U'^=']N:?_P _4?YUS_\ 9W^S1_9W^S1R
M1#FD;KZQI\@(>YB8-_"U9GV+PO\ \^.F_P#@*G_Q-5?[._V:/[._V:6P61:^
MP^%O^?'3O_ 9?_B:/L/A;_GQT[_P&7_XFJO]G?[-']G?[-&O<BR_D+7V'PM_
MSXZ=_P" R_\ Q-'V'PM_SXZ=_P" R_\ Q-5?[._V:/[._P!FC7N%E_(6OL/A
M;_GQT[_P&7_XFC['X8_Y\M._\!T_^)JK_9W^S1_9W^S1J%E_(6OL?AC_ )\M
M._\  =/_ (FC['X8_P"?+3O_  '3_P")JK_9W^S1_9W^S1J%E_(6OL?AC_GR
MT[_P'3_XFC[+X8_Y\]/_ / =?_B:J_V=_LT?V=_LT:A9?R%S[)X8_P"?/3__
M  '7_P")H^R^&?\ GST[_OPO_P 35/\ L[_9H_L[_9HU[A9?R%S[+X9_Y\].
M_P"_"_\ Q-'V7PS_ ,^>G?\ ?A?_ (FJ?]G?[-']G?[- N5?R%S[+X9_Y\].
M_P"_"_\ Q-4]7T_0)M,GCAM-/>5A\NR!*/[._P!FC^SO]F@?*OY"W]D\-?\
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M //U'^=']N:?_P _4?YUS_\ 9W^S1_9W^S3Y(AS2.@_MS3_^?J/\Z/[<T_\
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M_P!O:?\ \_*4?V]I_P#S\I7/?V=_LT?V=_LT<H<TCH?[>T__ )^4H_M[3_\
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MC[+[U=V4;* *7V7WH^R^]7=E&R@"E]E]Z/LOO5W91LH I?9?>C[+[U=V4;*
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M2O$7C$26^N:ZTFK-I[]+"&5RT5N/]V+9_P "W4 >JT4S?6=X@;&@ZA_UP?\
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MI>1/!I]W?17<+Q+YNV7>DTK-.^_=*S[?OHO\%?1.^@!]%,WT;Z 'T4S?1OH
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ME:+9O=Z@UE86R?>FN2L:+]6:N7/Q@^&Q;'_"7>&__!A!_P#%5^9?Q<^,NO\
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M3+*RQ,Z1+O9T7[E3]2C_ #&?^M-?_GW'\3],O^%H_#__ *&7P]_X&1?XT?\
M"T? '_0R^'__  ,BK\S43_9JQ;6TMY<+!!$TTK_(J(N]WI?4X_S$_P"M-?\
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M0!6_L^V_Y]X_^^:SO$%C;'0=0_<1_P"H?^'_ &:VJS?$/_("U/\ Z]I?_0*
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MR0_\\8_^^!4U% $/V2'_ )XQ_P#? H^R0_\ /&/_ +X%344 0_9(?^>,?_?
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*M%% #Z***"S_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>formposam_011.jpg
<TEXT>
begin 644 formposam_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &# 80# 2(  A$! Q$!_\0
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MC\:/9T_Y1_VECO\ G_+_ ,"E_F>3?\,K_"'_ *)SX<_\%Z?X4O\ PRQ\(?\
MHG/AS_P7Q_X5ZQ^-'XTO94_Y0_M+'?\ /^7_ (%+_,\I_P"&7/A)_P!$\\/?
M^ "4[_AF'X2_]$]\/?\ @"G^%>J?C1^-/V=/^47]I8[_ )_R_P# I?YGEO\
MPS'\*/\ HGWA_P#\ $_PI?\ AF;X5?\ 0@:!_P" *5ZC^-'XT>SI_P H?VCC
MO^?\O_ I?YGF'_#-7PL_Z$+0?_ %*=_PS;\+O^A#T'_P!2O3?QH_&CV=/^4/
M[1QO_/\ E_X%+_,\T_X9R^&'_0BZ%_X!)2_\,[?#+_H1]$_\ UKTK\:/QH]G
M3_E#^T<;_P _Y?\ @4O\SS;_ (9V^&?_ $(^B?\ @&M+_P ,\?#/_H2-$_\
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MU1M=M;>755C;[1/I\LFYY7_AVLW_ *#7%Z-X4B^(&M76J:HRFSC?S]0O6_\
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MUC_V?[R_\"^O1[2I3]Y^]$QY8RVW.QI::CAU!'2G5WHP"BBBF 4444 %%%%
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MI2K2C(^8ABZ52K&K'X3R--8_VJL)JO\ M51UWP)KFBROY4#7]O\ PRV_S?\
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MK[^0/NPZE!Y^WZ.K(W_?>ZO2<'UI?QKAQ&$H8K^+$VI5ZE+X)'DY\"^+4?\
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MBWL5B_YYF)O_ $+=70:5\?0"%UC3&A!_Y:VK[O\ QUJ^6H<;9+B*GLO:\O\
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M-,;2C7P]"4HR/M\8QUHXKXD3_@JA\/7_ .93\3?]\6__ ,=IZ?\ !4OX>O\
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MY4ZB@=QNQ3_"/RHV+_='Y4ZB@+C=B_W1^5.HHH$%%%% 'Y6_\%5?^2[^&O\
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M=[K7RMBK*T4>WY69%7^+TKC/BOX[C^)/CW4?$<=HUE%>>5F!I-SKMB5?O?\
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MKG_B_P#=+_>T>?\ ]&Q5^@=ZRQ6D[-]T(?Y5^;G[$6JK'^T191_\_-A<Q?\
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M79=ORK_LUS5K\7O&,/A1_&%Y9Z-<^'(M0EM9[2W25;M(EN/*WHV_:U='X/\
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M,S+]U?\ =K\<XMX=S',\TCRQY8JT?>[ZGL\/YUA,#@I\^LM9?D='\"K*6S\
MVQE&PS222J/]G<:]$/%0PQI;1+&BA4484"I">2.V*_3LOP?U'"4L-_+&Q\-B
M\2\5B)U_YF4=8T*R\0V4EGJ%LEQ;OPR-T-<LWP:\)J?^08?^_P!)_P#%5VW+
M=@13E'U%3B,NP6+ES5Z492\T*CB\10CRTJDH^C.)_P"%->$O^@7_ .3$G_Q5
M'_"FO"7_ $"__)B3_P"*KN,T9KF_L/+/^@6/_@*.C^TL;_S_ )?^!,X?_A37
MA+_H%_\ DQ)_\51_PIKPD?\ F%_^3$G_ ,57<9HS1_8>5_\ 0-'_ ,!0?VEC
M?^?\O_ F<MX<^'N@^&[PW6GV2Q7!7;YA9F./Q-=548.#V'T%/XVCGBO2PV&H
MX6/LZ$%&/D<56M4K2YJLN:0^BBBNLS"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ I*6B@ HHHH **** "BBB@ HHHH **** $[5\6?\ !2#X@:AI7A_P
MMX/L;M[:UUAY[G4%B?:TL46Q5B;_ &'>7_QROM,<BOSG_P""D5Y!-\7O"ULD
MFZXM=#=Y4_NK+<?+_P"BGKW,DI1JXZ"D<F*ER4)'R@B;%VK3D1IGVJK._P#L
M4VM+0;R*VN'65MF_^.OUF6A\KN3:5H,]Y+NE7R4_VZZJS\,0?WI*BMM2MD^[
MN?\ W*ZC2G6\BW+7GU:D@*5GX87=\TOR?[M;5MX>MMO^JK3L[:M6VLZ\V5>1
M!Q]SX&T^YN/M/V.![A/XY8D=_P#ONHIM'9/E9=E>AI84RYT=9HON_/6*Q$E\
M07-/]G#XV1_ _7M3MM8BNI/"^K,LLTEI'YK65POR>=L7YG5EV*VT%OD2OJ'P
M[^T1\-O$/Q >&S\8Z<)[FRB2!+EFM][[W^3]X%^;YE^7K7Q1>:5LW_+7.ZQI
M2S1/%+$LT3_>1U^1J\K&93AL?5C5<N61Z^'S&I1CR.)^LW'K2\5\X?L1_$"^
M\5?#.\T74KF6\O/#MW]BCEE?>[6S(K1;F]5^=/\ @%?1N>M?&XBC+#U94I_9
M/>A+GCS#L4M)2UB6%%%% !1110 F**6B@ HHHH **** "BBB@ HHHH ****
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MFTJU);_MDM>/G&54\NC!TYWYCJPF(EB.;F.JHHHKYT] **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#YU_;(\$?$3XA?#JWT/P% MU#<W6W5[9+D
M6\T\&SY55G*KMW?>7<,\?[5?GUX[^!/C[X7Z%#J_BGPQ-H^FS7*V:2RW%N_[
MQD9D78CNW\+5^QG3Z5^:G[>?Q@_X3WXG)X1L91_9'A5W67'_ "UOW3YO^^$^
M3_>9J^QX?QE=3^JPC'E^*1Y>-IT^7VDCYEJO>)\B5*DT3NZK*KNGWD1J>Z;J
M_1]SP8^X<O-#LE=:96KJ6F_)YL7\'\%8[O0>K2ESQ#?\]/IB)0_WZ"@>GI\E
M%,^Y0 ]YFWI3O.>HDI]  _SU;TJ:6VO8O*;9O^1JHN]:>CVS/+YK?<2HE&,H
M\LB)RY(\QT#W\J+N:6OHCX(_L<>/OB9J=E=^(K.X\(>%RRRS3W9V7=PO]R*+
M[R;O[[;?^!UXW\*M>TOPQ\4_!VKZVJ/I%AJ]K<7>]=^Q5;[_ /P#[_\ P"OV
M6C=;B)&C<,K<JR]&KXO/,0L%RTZ5./O?:L7@H^U]^4CS./\ 9@^%D<2+_P (
M5IH"KM^96_\ BJ=_PS%\+?\ H2M+_P"^6_\ BJ]2I:_/CVSS?1OV?OAWX=U6
MTU/3?"6GV>H6LGFP7"(V^-_[PYK\POVBO^2\>/\ _L,W7_H5?L&>17SW\3?V
M)O 'Q.\77GB2\EU73M0O#ONET^X58I7_ +^QD;YJ][)<?3P%:4ZOVC@Q=&5:
M-HGY\_ WQ]:?##XK^'O$E_#)+86<[^>L7WO*9'B9U_W-^ZO3OA)?_#;X-_&#
M1/$%O\0TUK2V6\MY=ND3Q-:HT#+$[?WOF;9\M?1__#N;X<8_Y"_B3_P)@_\
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MT%\)UX3#RH\W,7J***^6/2"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MVJYERJ<>51/H*.&CA_A%HHHKQSJ"BBB@!,4M%% "8HQ2T4 )BEHHH 2EHHH
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/ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>formposam_012.jpg
<TEXT>
begin 644 formposam_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #N G # 2(  A$! Q$!_\0
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MAN;E]/EFT^6V(*ROL.QE/\77.<U^??[0/P%UP>.KE].L[K7-0U*_F GAS/\
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MMB*2J16B6F]T_NT_$Z2YLM$M/!EW:0VUOI6@/9R$Q0QB*.*%T)8A5QC@D_\
MZZ^!_C#\.[GQ1J.EIH%C+J%S<100Q_V?;,\4H<?NF) _=NRX)5\$9!Z5]T?$
M#6--\/Z.(]<TN\O[66:*$6-G;F=GRWR_*O&SCD].@[T[PYI5AX&TG7=0C@N;
M:TEEEU.\F>U=-JA>FWJ0JK@ ?05ZV7YQ4RZLY1UOW[]SAK8&C7H\^JG?W;6M
M;L]=SE?V6_A5>?![X:)I^J.PU6^F^UW5N2I6!MH4(".IV@9]_I70_'/0(?$/
M@NWDD:T!T^^BNDAO) D<YY01 L0NX[N,]^*W?#_BW2?$VBVNKZ;?PW&G7/\
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M2 #E8Y)F'U( _D:[J,8C4>U>?Z.PU?QC=SI\T$&VVC/7(7@G\3FO01P*^J/
M%KG?&[&#2HKD#/V>=)"?09YKHJH:Y8C4M*NK4C/FQE1QW[4 <_!<B'771#]_
M<P].H(KPSQMX7_X1O6+BU\/6BH7N9;J6V$A)D,K;MX)[DYX]N*]+&JLFG:=J
M#X6:U?[/<9YP5^0_^.E3^%4?"O@[7K#QY+J.MW=KJEE(9)()U)5URH",5Z9
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M2"4DK'E&N:%>Z=X<=5=\JI EG&S=(64@8[ @8SZD5REI/J=G:/>:HL6F:=&
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M* "BBB@ HHHH S-?T*W\0:=):W R#]UNZFO&M;T2?2+@:=J ;"G]Q<K^G/\
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MF17U.]GO&!R?-D)'Y5ZQBC'/6@#F]%\!Z9HR+Y4"@CT%=%%$L2X50H]J?10
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M+BYTJSGGD.YY7A!9CZDTUYDN_0U]Z>H_.C>GJ/SK"_X0'PY_T!;+_ORM'_"
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M:V%G9V-O<6X>[NQMPCSM"T;#=\K93()QP1@<C.MXM^(E[X3U*9YK6&32(Y3
MS(DC3*WV9YMY X*_+MQ[]10!Z-FC(]:\9T/XP:E>:S))J)T^STR*!U(W8$CI
M=B)Y5DR05"$,0"0!SG%/7XTWTL.L7/V2SAM[6=;6TD;<RSR%Y@"6)550K#US
MU8=>,@'L>:6O'X/B?J5NZZS>(5T@6:W=S XP+>-GAW."!DE [''< ^E>F^&K
MZYU/0-/O+R!+:ZN(5EDA1BP0L,XR?3- &G1110 4444 %%%% !29'J*J:I:O
M>6,\23RVK,IQ- 0)$]U)!&?PKR#POXL\2V4>@S2W;ZI%/HD%[>)>KAVEDN%0
ME"H&" QP#G^M 'M61ZT9KS#P]\2-<U[PMKVI)IEA'/9HKVJ2W2I&[$$NDAW'
M85QU;;G/05SNH?&C5M4MM2ATFSC"II;727AQ'(&,4C>8D3-DA70+@!@>3F@#
MW'(]:,@=Z\8@^,6KRR3J^EVEC;K=)9F[O)U'V8F4H7F0-G:5&X$A1R!GFI]>
M^*>M>']3GLE@T_4YI+V2*$*XB$:+"CHK%F S(6.UB>QX.* /8,CUHR/6O,_"
M7B_4O$_CJ^L)KB""S339&-I:G,EM*+AHP9&/\>T9 QCZ]:9HNO:CX?\  >KZ
MM=7EUK%S%J4]LAOF 6*-;IH5<[5&%5<,Q]LT >GYHR/6O%O$WQ7UQ)];TZP@
MMF^QP(1J5O(I+9C1_.1"Q+(2VW@'USP:UOA_\0M3O]>@T?5FA+7(NGMY?O32
M;)Y%*NHQY8557!(PPS@Y&* /5**** "BBB@ HHKE?B9K%YI'A28:;Y_]I7<L
M=G;&V0/(KR, 64-\N57<PSQQ0!U.X>HHR/6O$+/QUXHFBN+J2[BL1::=9).E
M]%A8IC>2PW#OCC.(P>N #GWK1T7XLZYK.II;1:/:P13:D+(222Y:$;Y0=Z*Q
M;)6,,"0H^;% 'KV: P/<5YSXB\;:QIGBZYTRQM89HEADN7>Z9\;42(E4VC@G
MS#U]*R-)^(^HZ3?WD&JF&<W%W>_9I)"8QB.ZCACA08Y^1BW&2<9Z9H ]=W#U
M%&:\;NOBW?+?Q1/!";F">XM[D1,3;08:(+([C.]0'+$@C&"" :N>'_BIK&KZ
ME$K:=:"P6Z@LI)86<F4RR2H)8R1C9^[5N<\-UZ4 >L9'K1D>M<GIUE=Q^.=2
MWZI?36D=O'(EI(RF(,[2 _PYX"C'/%<8/B_JTUCH<MO8:;<7.HR2A[<3[/LY
M1D'DNSL,288GUXX4T >OY [T=:\8L_B9K.D6TEW?RQ360OU@EDG3YXHRTH!C
MC&#(<JH(&2!DX->RQG*T /HHHH **** (W0!6.,G&*XBW^(7AZ]M/$%Q';M,
MVC[9[N*.))6;(.UUVDAC\IYSD;:[H]..M<IHOPTT7P[9ZA;Z=#<6J7T8AD9+
MN3>B L55&)R@&]L8QC- &#>?%[1X;B1)["XO%4)-%';0K*R@0M,9"=VT@(N0
M5)/..M.OOBSI']JFVMK.26>W<!KJ5%$:QF9(Y2""7!!?."!G!K6L/A/X:TR-
M4MM-VJJ-&-TSL2&C:-LDG))5VY]\U5TKX2Z=IFJZC=%S-;7LGG26A7"LX=75
MF.?FVE0!TX)SF@ TGXI:#>Z%>:C:17"6UIY(%NL2[Y/.(\GRPK8.\D8&0<]<
M5E:=\8-)-M<?VEI<]E);W4J3A8E>.W9995B\PY^^_DG&,\D#/-=19?#K1K#0
M;G18X)SIMP0QBDNG8QXQM\MB<IMP"-I&"!BJ%O\ !_PS T7^A3/L5P_F74C^
M<6+G?)EOG8&1R&;)&XXH S8OBOX<= CZ;>6\D;^=<12VB!K4$1GSWPV-O[Y.
M1D\GT-=1X=U6P\;:.FIPVT\,-P'B1YT$<K)D@D$$D*2,CD'O5&\^%GAZ\N$G
M>P;S X=]L[@286-0K@'YTQ%'\IX)4'K6UHGANR\/I'%8Q-#%'$L*H96954%B
M, GKECSUH MZ7I=KHMA#964*V]K"NV.->BBK=%% !1110 4444 <?XA^)VE>
M&-8_LV]6<W)A>9!"JON"J6(QNR"0#C( /K6/JOQ?%C=ZG;G1;R*6PS\DX'[]
MOLCW(52"=I 7!W>O%;^J?#G0M5UJ75;NU=[F5<28F<(QV;-Q0'!;;\N<9Q7.
M>+I_ >FSZEJFHSPW-X9X[6XMX;H-(9GB:!4V;@ QC=AVXY[4 2^'/B6OB*T6
M"ZT>Y%VX'FVJVX*PKY4<A9\L1MS*,8)SZ9S3%^*VDA[6*WMUEU6ZLX+K*J K
M1L\(()R64KYZD*PI=4C\!:-JQCGU&*PU"S\J69(KYHW1&18D\W##]V1&@(/'
M -2:7X'\#0ZQ"EG+ ;Z2W66&UCO2V8\QD2+'N[^3%E@.=HH T]"\<Z;J>H6]
MIY#0:M<ML=$CXXB\P,6[KMX!]>*RM+^+^A3WD4$&F:A:I<LS)<26Z1Q2',O)
M.[C<8).2!TYQFK$.G>'O#_BVWUL7<3236G]GVZ1NNR&)2SL[G//*$;NV,4R3
MPQX"?2(7DDL'TT1E4D>\_=%0)6/S;L'B:4D^C>PH QH_B7H&E^'E30-$FEM1
M=JDT9A58("URL;N[ G)RY88SG':M[3/B+H'B#2=5O[6UEE@A6*2:,P*7G23_
M %3  D,&Z '!&.0*I2>#O <>EZ5>37B&P>=9+>ZFU)]EV[,K*&8MB4;D4A3D
M9%6AX=\)6/A+7M+M=66RTM6VWD@OR19D8^0,6/E8QP.,4 1+\5]"-[/'!IM]
M+?0E+9DCMD#B5I'C6W!+?>W1.<9V@#.:IK\:-!\^YF&F7?DQ>2\5PL*9G:2)
MW;;E@0R+&P;/ICGBICH7P]BL;Z :A:1'RX9[FX&I%9D^=GBF,F[<K%I&._.3
MO[YHN?#'P_EACC6^MK59+2*XA:WU$QMY,2L%F0AN@5F!;ODYS0!>3XN:9'>)
M#)%<R1R*L_VB*'$<4+,B*\A8@C+.. #Q]*Z+PQXJM_%E@UY9PS10B0QXG"AL
M@X(*@DJ01C!P:Q(?#O@_69V$4MM?7%Y:*QV77F-+ '5P_!Y&Y0=WK6SX=\)V
M/AAKUK)9C)?3_:+F:>=I7D?  RS$G    ]J -VBBB@ HHHH 0G )KF?$_P 0
M=,\)ZE96-YYTEQ=#<!"@;RTWJF]N1QN<#C)Z\<5TQK U[PIIFK:C9:G=1RI>
M6 +136\K1MMR&*MM(W*2H.#QQ0!S/_"Z]#^PW%T;/4E$85Q"\2*\L;"4AURX
M&/W$G!(/'3D4U?BKX:@N4@2TD6XBM8[J"-(HU;9*R*%&6 1B9$R&(Z\UA>(=
M#\ WV@6T[:M9Z(EK;0WC)<2AWBA42>673=D%3<,0?4CK4^J>!_ M_;7Q;6[9
M+EDBEN[B:^#HRM)&^YXRP4"1TC)QC)QB@#;T'XM>&_$NKZ=!:PW*75TH2.2:
MW4&-V5G$;<E@2J%LCY>1SR*SO^%OP6^OW-L_AZ]@LX)+R.ZO%1&8?9FB7S>&
MY3$O.>1C !JYHNF>#_#T\6JMX@BEO;!4L[F[>_"*[D8194!VE@N%7(R  .U$
M%CX"U)/$>JQW=K+ LEQ::G,;PB*%WV"93SA"VQ"2/8B@#2TKX@:#KIU5;:"6
M2"RC>YED>%=DRHS*67GDAD/# 'H>E4[CXO:-#-+:SV6HQ7$4;//!) "T0_=!
M0WS8RYGB"@$_>YP :6WM?!>@VNLQVVM6MC%J, :96U$&.)9<A716;"!BY((Z
MDU&G@?P7I)ATVYEC>\U"!H$-Y?%KBY7*,2"6W,1Y2$,.FP8Z4 17/Q;T:&?R
M)M%OECC@"@R0QC;(TQ@^SX+<-N4_[.!UI(_C%H=P JV5W>V\BF2-+>UW-&B1
MK([.&(^[D?=STXSUJ-]%\ W5E$IOHYK06L@-\E^Q0*DJN[O,&_U@D;.XG.2:
MFO+;X>^'(7OK_4[1!'8-.\]Q?>8[6S(L1D)R2P*JJ[J +^J>*- USP]K[ZA;
MS/I>FNT5VDAP9"I(VA0VX[N, XW!AVINC_$=M<\66>CV6FW$5O\ 9YVNI+B,
M!K>2-U3RR W7Y@<C(Y&/9JV'@E%\123:A:S+>0HVI-<ZAO*0D9CY+?(F&RN,
M=>.U:'@31/#_ /9EAK&AK)+#/ YBNYI7>29'8,S.S$EB2H.3SB@#KJ*** "B
MBB@ KG/&?CG3O!%O;27WFN]PSB**$ LP1"[GD@8"@GKGTS71U@>,?#6D^(["
M+^U=T4=HYG2YCF,+PX!#,'!! VYSVQ0!@GXPZ/).T,$5[<SK+#"T,5MAM\W,
M(^8@#>OS#V].E-N/B]H=JR(T-[(\MG]L2*.)=Y7Y!LV[LJ^7 PV.<\U@:MHO
M@;Q)K^CZ59:A(=1U _VH+O3+S+SQQ.&R\@;/WCM4CD $# S5V#2?AQ#>WACO
MK2(6OE6UQB_(@21B%53EMOF'R5![X ]: +4/Q.TR]N8++3M*GDEN+V.UOTF@
M5%MV>5XCYN#RQ,;8QD'CGFGW'Q,TS3]1U*UFT._\[3+A[6)HH$<RJL*RNT?/
M"JI7(X[8!IMQHO@*TU>347U"UM;K3;D3W/\ Q,2B+,[LZ&9-V"=SMM##C/%2
MZGX;\%Z]JNJM/=PO>IMN[R.WU!E,6$VEG"L-JLF W0, ,T 7M=\:Z+HTMU%-
M"7N98(I1B .)U??M]V V,3Z"N='Q;T+4%@BM[-+FYFD@0M+"%A<[XE?!Y(,?
MFY&X#D$ TX7O@WQK<:7XHGU>VM[&SL[B&WAN)4B!BD)B,C'=]PXPN<=?7BK$
M&A_#_3-5:V34K.WN'>!38'4\(74HT1\LMC<=B'.,G\>0"&?XKF+3/%.J6>A2
M*-.ALYXDG CENUF) ) )[#Y<GOVK>LOB1H^I-?0^5<Q/9[1=0S0C,3-*T6UL
M$@G*DGM@@UERZ#X*\.1:QIC.9YKQ89;K3VO&EG\M& CVJS;E12PP!@#-$NF_
M#^:YN]9_M2R40SE[R:+4ML1D8[P)<-@\Y8*>F3B@"I=?%S3(?#\^I:9H%_)>
MQV+7$%M);+&?)$7FARV["QX*]#G)QBK,'QB\.3SVLDEM<0S3YC,KP*"L8F\K
M?UW>69 0, G@D@ 5$^B^ ?$EE!IWVE88T<:7 $O6@><1QJOEH0PWJ49<XR&X
MJ[=^'O!.CZC:B6\MM-O-*C>Y\L7OE%(FD+L9%W<Q[V)PW')]: (-,^,UK>:\
M]A-IEY;1S- MD\B*IE$B%]SY;" @?*"<GTS7HR,6SFO,;'P/X(NKW^S[47$Z
MSS1W(1+R5X)/+0/$H^;!10054<"O3E!Y)&#0 ZBBB@#GO&'C:Q\%6D$]ZLTG
MGR,D<4"AG.U"['D@8"J3U]!WKG_^%RZ&]O-.8K]+96:.*=X J7+JZ(5CRW7=
M(@^;:.?:NG\2^%+'Q9:);WZ2[8I!+%);S-%(C8(RK*01P2/QKE/'G@;PK;^$
MKQM6FCTK3XY&N9;NYD+*&>5'<OD\AF10>A]"* %N/C%X;6VM7OQ/:0W44K!9
MT1B @D+*RJS'D1/@\@^M,L_BYX?>\B1;"]M[B><0MF&,[?F1%9F5B",NH&TD
M@ Y Q6';>#_ NK:5J*3:\)KJPA>WN;R2]">0N)$1VC)VX5961"P/RXY/6MGP
MQX \-6D>FF'5/MDEM<,+-[6Z,2J"JOY"!6.Y, /M)/WB>!Q0!>U_XE/HNNRZ
M;'H5]=M!-;QO+$$(E65)&_=C<"67R^0<=Z=X?^*7A_Q;K-I8V7G22R+N@G>(
M!-WE+(R==RL$<9R .V36C>:7X>N]2&L3S1&5Q'AS<XC8H'"$#.-V&D&?3/I6
M-H&G>!O#D]OJNEZI:VL3VI$>S4<P211J$+[2V"5"J"WMSS0 EU\4] L=.EGA
MAD^R11-<742VV'QB3*;>F\F)L@]B/6K"_$K31JZ:-% \6I(8B;:7:-D;.BD?
M*6PR[URIQ^55=4TOP#9V@6^N+*"V\1W;21LUT0MS,Z'(0YP 5SP,#)/<U']@
M\!VFKWFN6US!>:B4DOC%;WOF,1N5G>./=CEHU)(ZD4 :&L_%;2=%OKVUGM-1
MEDMIQ:!H8 PFF(C.Q#NY.)D/.!UYXK-O?BKHJ21Q6^CW=Y--?111A88P)2T_
MD-,A)Y"/P3P?3@TR7PYX(.L^(-:OM8M[J;[5'<7"S7X$5BX$87Y0V$8F%<D\
MGD4]]%\#0^)X])29)-8U1OML4$5VSM$(W$^] &/DH7P_& Q/>@!;CXP:#-:3
MW;07$EM9%I7,MMN9U <AHL$\Y0\-@^H&16OIOQ+TZ^UF#2([6]@OY7>-HKB-
M5,3)C<"=V&.&5L*2<')K$TS1?AWJ%M/9VVHVMU;7UU+ EJ=0+)YPW+)'$A;Y
M<;CE5]16]J/PST35KUKMH[F*X\][K=!<NBB=E"^:%!QO  P>U '7CH*6F0Q"
M&)(UR510HR<GCWI] !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ )0,"EHZ44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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1. 3Z ]/H.*N44 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>formposam_013.jpg
<TEXT>
begin 644 formposam_013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #E G # 2(  A$! Q$!_\0
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M_BJ/^$AU;_H*WW_@7)_\51_94_YD']M1_P"??XG]$7XFC\37\[O_  D.K?\
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M+.\!RWS8%5&#DTCFQ>8X;!QE.I*ZCO:\FO-I7:7FT>+45VVH>!;/7O$T&D^
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ME&I%4^1Z';B,KG+,ECX-/W5&S3TLV[JSZWMJ?5WQ/75]6^$&LZ/8WMM=>/\
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M]INN$AC?SKBS64,(_,1>=VWGOR*Y+3/AMXNU\-%IF@7QE +-)<0&)$P/XBV
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M&F?#5M6\5^)=#MM3A?\ L2WNK@W6T[9Q!]X+WYQQ70Z=\"6GT,:O?^([/2[
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MCZ=S7B?C/PQ%X0\07.EQWAOWA(#2FW>W9&[JRO@Y%=;J'QMOM:EVZEHFG7\
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M1" $2QO$S32@-D[)!EOK6?IW[._@F_\ #KWMUJ;:9LU!%\T:G%.AMC=&':7
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M+=WJ[GU,+.":CRKMV\A****0PHHHH **** "BBB@"6&2..XA>6,2Q*ZL\9)
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M-OP02RG@C#$ =ACGBJ^D?#;3/#]Q:36\\X-M<17($A7&Z.W:#D^A#$GWZ<4
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MBY<VJL14]GRVNSFATK]R_P!BW_DU/X7?]@.#^1K\-!TK]R_V+?\ DU/X7?\
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M].M8/AS2;?1+06]G:PV5N.?)@C"+GUP*V6;'3FM)<K?NF%=4XU6J*?+TOO\
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M=5_Z^I?_ $(U[66QTF?.YK*2E!KS.<^SR%0N]M@_AR<5HM$L^F(_66W^1O\
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MBF%SK[K6+2UN+6WDF59;IF2+NI*KN8%AP,#UJ/4=:LM,L&O;N\AM[-,!IY'
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M76\MGBE_[Y(S^E>T_!+]G+XMQ^(;+Q+;^!-730XT=[BXN8A"/*VDL0K$,QP
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M20.,L:]+=P3[9.*8Q!Z\TA.>],!2XS7GOQ?U@:?HL460IN)T7Z@<D?E7?LV
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M,\!MB)9"QV&1Y"/;YI&Y^E84?P9\.06ZI&^HK-&HBCNQ='SHXPK)Y2-V0JS
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MJX6$\0E3VZ_,@76&NKB67)!8[A@_I6SIVMLA4$]/>O-M/UC( /0<5NVFH[L
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M_/U+^0HHHYGW#E0O_"#V_P#S]3?D*/\ A![?_GZF_(444<S[ARKL'_"#V_\
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MHH^N5_YV']GX7_GV@_X=&^"/^A^\2_\ ?JV_^(H_X=&^"/\ H?O$O_?JV_\
MB***/KE?^=A_9^%_Y]H/^'1O@C_H?O$O_?JV_P#B*/\ AT;X(_Z'[Q+_ -^K
M;_XBBBCZY7_G8?V?A?\ GV@_X=&^"/\ H?O$O_?JV_\ B*/^'1O@C_H?O$O_
M 'ZMO_B***/KE?\ G8?V?A?^?:#_ (=&^"/^A^\2_P#?JV_^(H_X=&^"/^A^
M\2_]^K;_ .(HHH^N5_YV']GX7_GV@_X=&^"/^A^\2_\ ?JV_^(H_X=&^"/\
MH?O$O_?JV_\ B***/KE?^=A_9^%_Y]H/^'1O@C_H?O$O_?JV_P#B*/\ AT;X
M(_Z'[Q+_ -^K;_XBBBCZY7_G8?V?A?\ GV@_X=&^"/\ H?O$O_?JV_\ B*/^
M'1O@C_H?O$O_ 'ZMO_B***/KE?\ G8?V?A?^?: _\$C?!';Q]XE_&&V/_LE?
M87PC^'5K\)/AUX>\&V-Y/?VFB62645S<A1)*J]&;: ,\]A117/6KU:ME.5S>
)EAJ-%WIQL?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>formposam_014.jpg
<TEXT>
begin 644 formposam_014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (B G # 2(  A$! Q$!_\0
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MMOL/A^_OM0GU$Z6+&VFA?][Y7F*1)NVE2O?/'-+V%3>QL\WP*:3J+7U_R/;
M0>G- ;J!7A^F?M!WWB/Q9X/LM(\-RR:;K<%R\[3RHLUN\+E7&-V"%(Y]01BI
M;/\ :AT.2?7HKC2[J&72K5KK$4T,WFJ)!'MRC$(VYAP3T.:/85.PO[8P6[GI
M\^U_R/;-QI,\D\8KPR;]JC2K+27NKW0KJSN?[0DTV&UDNH-LDD:!Y&\W=L"J
M".<\DX%=C-\:M$7X76?C=+:[EL;P1K!9J@\]Y'?8L8&<9W<9SBI=&:W1I3S7
M!5;\E5:+F?DNYZ$&'MBF[E;(Z\=J^=OB!\<M=U2PL],T+2[_ $'73KUOI6H1
M2&%YK=9%\Q=A)*-O7H>@P<UW'CGXF7G@?QCX>L)(S<Z;-I5]?W@5-UR[0(I
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M<SPR1W.&<3MF6-^/F0],<?6N-\2_LLZ;;^%]5M?#5]<1:C<V?V"W34IRUO%
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M7=(A39Y9 3&W'MG/.<U/9_ G0=.\11:O8W>I:>X\CSK6WN<0W!B4*A<$$YP
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M +GJK9)]17T)$ZN$*_=8 CZ8J)0<-SKPN.I8S^%V3^3O;\B:BBBLST HHHH
M*\8^//Q;U+X;ZMX?M;&[TNPAU!+IYKO5HW>-#$@95&P@Y.<5[/7'>+_AWI/B
M_P 0:5JNI!Y)--AN($@X\J5)D".'&,G@<8-:TG%37.M#S<PIXBKAW#"NT]+,
M\YG_ &H]+\->'] N/$>F7%KJ=[IRZE=VL#)BVB+$!OG92V<9"C+8K3U;]HFU
M2/Q<ND:)=ZC-H%HUPSR.D:2,%5NA;>%PV=V,'!QS2O\ LXZ&(=(\C5M6M[C3
MK/\ L];I'B:26 /N6-]R$?+T#  @5?O/@+HVH>(;_6;[4-2O;BZLIK%8Y9%"
MP12@!U4A03TXW$X[5T?N'JKG@*&=\MFU;2VW\O\ \E9F?I_QW;4U\/V<OAS4
MH-9U?3/[2*0!'CMH<X,K'=]T<,.Y! QFJ_@GXZ)J>DZ!I\%AJ_BO5KJQ6^N9
MK:VBA:*)I&17==P R5/RKDX&371>'/@UIGAV_P!.O%U'4+^YL])DT>*2Y=?^
M/=G# '"CD8 !]*S=$^ .E^'+G1+C2M8U?3;C3K=+*22WG5?M<*NSJD@*\@%C
M]W!P<5-Z70U5/-4XMM/H]O[MWVON_0YG1?CQJ/B;3=!OKNVN/#"S>(9-,*QQ
MQW$=W&GF94L3NCQLY.,YZ9K?L/VE-$N8C=2Z1JEI836-S?Z?>SQJ([^. ;G\
MO!R#CD!L9JY9? 30K26)%OM2ELX-7;68+2213'%(V[>B_+G82Y."<^]5;+]G
M#P_:6\ML=2U:YM%L[FPLK2XG4QV$4XQ)Y0V]<< MG IWH]M#*G2SFFE[T6[)
M._>Z^Y6O:WD;OP[^,]C\0M3N+"/2[_2;J.SBU"-+]%7SK>3(21=I/<8P:]"1
M@Z@BN)\-_"_2_"NOQZO:S73SKI,&C!)&!7RHF)5NF=Q[FNTA7;&!7-/EO[I]
M%@OK"I6Q33EKM^ \C(KG?B!X+A\?>#=6\/374EG#J$)A:>)060$CD \=JZ.B
MI3:=T==2G&K!PFKIJS^9YKXL^!/A_P 0^";3P[;Q1:/#:31W4,]G;1\3(,;V
M0C:V02"#US7":O\  +7$\1^%8-*UM[*RLK2^CN=5MK6")D,P4!1 %VX(!&0,
MC -?0;>G7VII4$\C\*U5:<>IY-?*<'7?-*&NBTNM$[I?>>3VW[/&G:=+8G2]
M8N["VAT.30IX-BR"YB8'#,3R&#,6XZGVK+NOV7;1[#[#9^*-2L+&:QL[.]@C
MBC8736V/*D8L"5/ R%ZU[>HP *6CVT^Y3R? 2M>DM/7_ #/)M._9]L-)^(,W
MB:TU-D2>[^W364EE#(3*1@[9F&]5)YP#US4GB_\ 9X\/>-?&3>(M1/F7+-:,
MT9B4AO(8G!/7YP0#[**]5HI>UG>]S3^R\%R.G[-6;O\ /N,2(1H%7A0, >E#
M1[NY%/HK(].RV.$T'X1:-H?C/Q!XF=([[4M6N5N%DG@0M:X0+M1L9P<9KSV]
M_9IC\.Z1XI_L&]^UF_LKR*UT^>UA5EDF5L W&-Y4%C@$]^:]\-1L,G'4>E:Q
MJSB[W/*JY9A*L5&4-KM6Z-[L\.T/]FL:AX/O;;Q%K][=:KJ.CVVEF79&/L,<
M95PB;1AL..IZXK6UC]GB+7I]0O;WQ)>OJUW'8D7R0QJT4]JQ9)0O3DGE>G%>
MO(,*!C%.I^VG>]S*.2X",%#V=TN[?GY[ZOTN>(7W[+MCJ-C)]H\0W5SJK:G)
MJ8O[FTAE&]XU1U:)AL*D*#C Q7>)\/[FQ\"6OA_3-<ETRY@"@:C#:0DMALL#
M$5V8.2, 5V=%)U9RW9T4LMPE!MTH6NK;O_/\=SQ6U_9HM])BL[G2O$]_IFNP
MS7,TNIQ6\1\[[1CS5\HC8HX!&.AJ/5OV7--N=-AT_3/$6HZ/:_V2='NEB2.0
MW4.\OEBP^4[B22N,YKVZBFZU1]3!Y-@''D]GIZO_ #_X<\MN?@#I5_IWBZSN
MM1NI4\0I;*[(%5K<P1JB,A]<H&YK)\1_LXOXK72[K5/%=S>ZW8K)"NHW&G6\
M@>%L$(8BNP%2H(;&>M>T44O:S[ESRG!5(\LJ>GJ^]^^]]GNNA2T73$T72+.P
MC;>EM$L08($S@8S@<#Z#BKM%%9MWU/6BE%)+H%%%%(84444 (PW"F>3SG/'I
M4E% K7/%]._9MCLM62ZD\47L]K;W]SJEG:?98D$%S-N^<N!N8+O.%)Q4NB_L
MR:#X;G\.7VE:A>V>M:1(TDFH[R[7>Y"LBNK$JH8G=\H'(KV.BMG6F]V>1'*,
M##X:2_'R\_)'D_BKX)ZKXL7PPUSXXO1<:%*MU'.;*%FFN%W 2MQQ\K8P.*]4
M@C:*-%9_,8* SD8W'UJ2BLW)R23Z'=1PU*A*4Z:LY6OJW>VBW84445)U!111
M0 A&:JZGIXU/3KJT9RBSQ/$6 R0&!&?UJW103**DG%['A.G?LL0VFE?8[CQ;
M?W)@TN32+&5;:*(VT$A'F?='SL0,9;IGBMRS_9UTGPWJR:EX3U.\\,W7]GR:
M>[0'S]X;:5?]X3@J5R ..3Q7K5%;.M-[L\B&38"%N6DKK9ZW7H[W7WGE"_!+
M48_B$WBU?&5V]VR10&*>QAD"PKC=&C'E Y!+%<9)KU95"@ =*6BHE.4[<QWT
M,-2PW-[)6N[O5O7YL****@Z@HHHH *IZQ93ZCI=U;6MX^GW$L96.ZC4,T3$<
M, >#CWJY103**DG%]3R?PY^SQI&@QZ/'+J%QJ$=C9W]I.LR*/M9NW#RNV.!R
M. ..:M> /@O-\.["ULM.\4W\ELE[/>7"31(QNO,7:J.3R F 01UQS7IU%:NK
M-[L\Z&6X2G)2A"S6VK\O/R7]-GF_PX^$E[X!\1:[JLWBFYUG^V9OM-U!-:1Q
M*9L ;P5Y'R@#%>D445$I.3NSKP^'IX:'LZ2LO5O??>X4445)T#"A/>O+?$OP
M!L/$/B/5M?75[JQUB[N+6ZM;N!%WV4D((^7^\'!(8'CFO5:*N,Y0=XLY,1A:
M.*2C6CS):_,X/PA\(-(\*>(=>US$=]JNJWC7?VN:W020;E *(W7;QG\:Y[Q1
M\#=3\33^'+FZ\<W[W6B/)+$\UE#(DDK,2LC1D;=R*=J\<8SUKUVF.H(H]I*]
M[F$\NPTZ/L''W=[7:UO?H^YYI\4/!FJZ[H?AE[)QJ6KZ'JMK?%I=L7VG8=LA
M..%)5B<#TQ4]C\%-+L](\867V@R3>)+F[N)+MX$\VW$ZA61#U(&.YKT(J/QJ
M6G[1VLAO 4)U76DKM^O:S^]'DNE_ BXMK;PW;ZAXLN]4BT"1FLE>TBBVHT#0
M[#LQGALYZ\5-X"^ .G?#W5- O].U*<3Z=8O87)\I%&H(6W*9<?Q*2<'W->J4
M4_:SM:YG#*\'"49QAK&UM6]K6W?DCQ;Q1\';NR^$MUX*T24WZZCJIGN+BZ(0
MQ12W7G2D#OM' '4U['%$L:HH& BA0/I3V0'G'/K0 ..:ARON=%'"T\/)RIJV
MB279*_\ FQ]%%%2=H4R1=ZXYQ['%/HH K_8TQP9!_P!M#2?8D]7_ ._AJS10
M!7^Q)ZO_ -_#2?8D]7_[^&K-% %;[$G^W_W\-'V)/5_^_AJS10!6^PI_M_\
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MOE^P\.R^(/"-U;6=J?(M+FW33[FWTZ:(ZA=30['5UE<E9(B 3/T')P2*]/\
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M!YP>: .A^QK_ 'G_ ._AI/L2>K_]]FK-% "*,#%+110 4444 %%%% !1110
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MTA*XP.IZUX(W[3DT4=Q*^DV+"2">:VMHKXF>W\JX2!OMB[?W(_>*Y(S@ ^E
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M%;%K=:;?3W<-N\,TMI((IU0 ^6Y ;:??!!_&@#0WK_>'YT;U_O#\ZB^Q0_\
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MF^OE?%R3 81&SJ)%55(R5V.NUNXP>]2:;X$\,:1%:QV]E $MI99XS([2$RR
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M_/<_]\"K%% %?R9O^>Y_[X%'DS?\_!_[X%6*:_W30!!Y,I!'GG'^X*/(E/\
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M>=QZ;!7B?P=\7:Q-J^OZ9JU_>&""VLO*DUF[AF9;^17WQI)&<%255@N<@=
M0*Y_P?XH\4-JNJ:/K&J:E+,^C"XO9!J=ND:WOV@*BVLX)$2R+N 5L'CCG)H
M^C/L\@_Y;?\ C@I1!*.DY_[X%?,>F>+/%]WX6\-ZY%K,M_>VU[=6 L);G,DD
ML4[$JQ0;;A1$NUI!Q@;N]>Q?!;Q2OBCPKO+W4]U;R 7%Q=R*YE>2-9=R[3@#
M$@&W^'&WM0!W7DS?\]S_ -\"CR9O^>Y_[X%6** *_DS?\]S_ -\"CR9O^>Y_
M[X%6** *YAF[SG_O@4GV>7C]]_XX*EF7< />OE__ (23XA1ZMJ&DPZK=2:R^
MGW5Q?,][;FV0K=1B,VK<B$F)I%4.!R!GIF@#Z;^SR9_UW/\ N"C[/+_SV_\
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MG^%'_"8V?_/M?_\ @')_A6[10!A?\)C9_P#/M?\ _@')_A1_PF-G_P ^U_\
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M#^\PH '1CG)QBMC1_BEX;UE=#":G#;W&LVT=U9VMR=DSHZ[E!4]"1VSD\XH
MT?\ A,;/_GVO_P#P#D_PH_X3&S_Y]K__ , Y/\*VP<FG4 87_"8V?_/M?_\
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MR^,+-1C[-?\ _@')_A2_\)C9_P#/M?\ _@')_A6XIS2T 87_  F-G_S[7_\
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M16E//[L*(G+!N0-G]X5Z6&R: ,3_ (3&S_Y]K_\ \ Y/\*/^$QL_^?:__P#
M.3_"MVB@#"_X3&S_ .?:_P#_  #D_P */^$QL_\ GVO_ /P#D_PK=HH P&\7
MV;?\N]^/^W.3_"LE7\,QP7D*>'PD-X<W,:Z20L_^^-GS=>^:[*239CISZUY7
M_P -$Z&EO)<RZ=J4-I+$\VG3M$I&HA9EA(B ;(.]TQOQP<]* .HBO]"@CMXH
M](ECBMT:."--+(6)6X8*-O (X('454-OX2^P&P'AF,6!D\TVO]C?NB_]XKLQ
MGWQFIM+^*>F7GA?7-:OH+G2%T.26+4K6Z4&2!HU#D?*2&RK*00><BL(_'O38
M(IH;S1]1L-92:&%-)N1&DLGFHTB.&W; NU'))/R[2#S0!T<>I:'!:_9X=)EA
MA\D6XC33&"B(=$QMQMY/R].35JQ\2:9IUK';6]C=V\$8PD4-@Z(H]  ,"N4O
MOCMI^E:P=/O]-N+1TMEF=C(CL)6C\Q8@JDEB00H89!8X%>AZ3=SW^G6]Q<6Q
MM)I45V@+!C&2,[21P2.F10!G?\)C9_\ /M?_ /@')_A2'QE9@?\ 'M?_ /@'
M)_A6]10 R.02(K $9 .",&GTE+0 4444 %%%% !1110 4444 %%%% !1110!
M7M?^6W_74U8JC#!O:8^8X_>GA6P*E^R'_GM-_P!]T 6:*K?9#_SVF_[[H^R'
M_GM-_P!]T <W\3/#-_XS\':GH>G7EKI\M_"T#SW4#3*$(P<*K+S^-;FB6]W:
M:=:P7TL,]U%&J226\91&('4 DD#\34_V7_IM-_WW0+8$X\^;/^_0!:HJM]D/
M_/:;_ONC[(?^>TW_ 'W0!9ILAPA.,^U0?9#_ ,]IO^^Z#:8&?.F_[[H \PU7
MX0:C?1^)-*MM=BM?#'B*\-[?6C66^Y5GV^<D<F_ 63;_ !*2-QQ3(?@7;6/B
MNX\16E[%!JESJ-U//.+?YI;6>$1FV8YYVE496[;<8YKU'[,#_P MYO\ ONC[
M.,X\^;/IOH \QA^"%KI7PTL?"FEV^B%5@CBOFO\ 33)%>E4V[V174AL\YS69
M'\!M2CU3PH\OBZ>]T_0C9/'!=1,7+6X;)&'"_/N&2RL0% !KV$6P/2>8_P#
MZ7[(?^>TW_?= $R#!)_SUI]5OLA_Y[3?]]T?9#_SVF_[[H LT56^R'_GM-_W
MW1]D/_/:;_ON@"S15;[(?^>TW_?='V0_\]IO^^Z +-%5OLA_Y[3?]]T?9#_S
MVF_[[H LT56^R'_GM-_WW1]D/_/:;_ON@"S15;[(?^>TW_?='V0_\]IO^^Z
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M\A_%?\: +-%5_M$G_/O)_P!]+_C0;F3_ )]W_-?\: +%%(IR!D8-+0 4444
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M#6[J*2&WN[6P@A^S*[AG.T#$CG:H+-G@5J1>!M1B^(EQXG;79'CEL_L"Z?\
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MFZ,H6&UQ:7$ZR.+@7)VX3$9)() Y&.>* /I;[);8/[L=<4T6UL2 (LY[C_\
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M %;?<_W(_P#OH_X4;[G^Y'_WT?\ "K-% %;?<_W(_P#OH_X4;[G^Y'_WT?\
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M$@ MGI7LWA#5X]<\-V-ZE[#J!DCQ)<0(41G'#X5N5PP(P>1CF@#0WW/]R/\
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M:,QJB2XBCRJ(61.BDK'&I([(*Z?[/'_<7_OD4?9X_P"XO_?(H %GB _UB?\
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MM'H*,#TH ^8])^!7BC3?"\]E<V\>J3WVA"Q*W5RA^P.MT)&@3C!BD4DG.<%
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MH FW4;J@:SB49P__ '\;_&FFUB'9_3_6-_C0!9W4;JJ>3"3@+(?^VC?XT&&
M $A^?21O\: +>ZC=5*86MO&TDKF*-?O.\I55^I)Q3T@@=@N3NQG E8\>O7I0
M!:W4;JA^Q1>C_P#?QO\ &C[%%Z/_ -_&_P : )MU&ZH?L47H_P#W\;_&C[%%
MZ/\ ]_&_QH FW4;JA^Q1>C_]_&_QJ-K>-3C8Y]/WC?XT 6MU&ZJ;11*&RKC'
MK(V*<MO$V?E?_OXW^- %K=1NJG,MM;JK2MY2LP4%YB,D]!R>M)L@+NBY+KC*
MB5LC/KSQ0!=W4;JA^Q1>C_\ ?QO\:/L47H__ '\;_&@";=1NJ'[%%Z/_ -_&
M_P :/L47H_\ W\;_ !H FW4;J@-G$ 3\_'_31O\ &H ;0SF .#<!0YA$QW[2
M<9QG./>@"]NHW50MVM+I"\,@F4-M)CG+ 'N.#UIL<UC)',ZSH4@)$K"X_P!6
M0,D-SQ^- &CNHW5DMJ&FI-:0FZB$MWG[.ANL&; R=@W?-@=<58M#9WJLT$GG
M*KLA:.8L P.".#U!X/O0!>W4;JA^Q1>C_P#?QO\ &C[%%Z/_ -_&_P : )MU
M&ZH?L47H_P#W\;_&C[%%Z/\ ]_&_QH FW4;JKM:1+V?_ +^-_C5:.6SE>55E
M4O%_K5%P28_]X9X_&@#1W4;JHP?9;J)98'\Z)AD21S%E(]CG%1-=Z<MJUS]J
MB^S@X,WVGY,YQC=G% &GNHW5EF]T[[:;/[3']K">8;?[3^\"9QNVYSCWZ59M
MH[:[@2:%S)$XRKI*65AV((/(H M[J-PJ'[%%Z/\ ]_&_QI#91?[?_?QO\: )
MP<TM(!@ >E+0 TDXHSCKUH)^6N(\3?&CP/X,UF32M<\6:3I.H1HKM:WERL<B
MAN0<'L:<(RG\*N93J0I+FF[+S.WW?7\J-WU_*O-/^&D?A?\ ]#]H'_@:M'_#
M2/PO_P"A^T#_ ,#5K7V%7^1_B8?7,-_S\C_X$O\ ,]+W?7\J-WU_*O-/^&D?
MA?\ ]#]H'_@:M'_#2/PO_P"A^T#_ ,#5H]A5_D?XA]<PW_/R/_@2_P STO=]
M?RHW?7\J\T_X:1^%_P#T/V@?^!JT?\-(_"__ *'[0/\ P-6CV%7^1_B'US#?
M\_(_^!+_ #/2]WU_*C=]?RKS3_AI'X7_ /0_:!_X&K1_PTC\+_\ H?M _P#
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M6N^[O[<Q1,JQOY(1B'9\@JFX<!LCGT__ (:1^%Y_YG[0/_ U*/\ AI'X7_\
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MS#?\_(_^!+_,]*9N/6O"OVD=(N+N2QGADCOY7L+FUL]*ECN"WVIMGEW$!B!
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M%KJ&F'2UM9/+@5H6B>12JLY96))82%U+_P 1&>]0']I#X7'KX^\/GZWJ4O\
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MUS"_\_(_^!+_ #/))/A?XDT[PMHQBBO9=;@T;S-2A"C:JK'Y0MU<?,69/E*
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M?,_0.#OBK_+]2T?NFORX_;W_ .3D]8_Z\++_ -%U^HY^Z:_+C]O?_DY/6/\
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MM$$!)^289)('S8KXU(1R[. S,V]ACAB222?SI, G.,G.<^_K67]EW2DZFO\
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MH?IQ6BDUCH\OQ9/@C6?"\EQXBU#2M8TJ/6)H&B"2;WG7;)E0ZY?@],]J^(0
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M4E%%(!0<=LT9]J2BBR ****8!2KUI*5>M #H_P#6P_[Z_P Z_<+1/^0-8_\
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MD]8_Z\++_P!%U^HY^Z:_+C]O;_DY/6/^O"R_]%UYW#_^^O\ PL];BS_D7_\
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M\)5K?_08U#_P*?\ QH]\/W7F)_PC.L_] 74__ .3_"C_ (1G6?\ H"ZG_P"
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M  I?^$JUO_H,:A_X%/\ XT?\)5K?_08U#_P*?_&G[Y/[KS$_X1G6?^@+J?\
MX!R?X4?\(SK/_0%U/_P#D_PI?^$JUO\ Z#&H?^!3_P"-'_"5:W_T&-0_\"G_
M ,:/?'^Z\Q/^$9UG_H"ZG_X!R?X4'PQK)&#HFI$?]><G^%+_ ,)5K?\ T&-0
M_P# I_\ &@^*]; )_MC4/_ I_P#&CWP_=>9T>L^(?B)XBT^RL-3NO$U_8V;*
M]O;W"SND3+]TJ".W:K\/Q ^*MM?7=Y#K'BZ*YNMGVB56N TNP87<>^!Q6G)\
M//%ZWN@6'_"6$ZEK20/!;>== *LL9D5FD*;#\HY"L2">G%86D:)XPUK2](OK
M;6+EDU356T:WC-Y)O$ZJK%F'9,,.?8UP<U%J_N_<>G;$+1.=_7T_1HK0:SX^
MM+*TLX)O$D-M:71OK>)$G"PSDDF11CAB2>1ZUHKX[^*@U(:@-7\5_;O+:(7!
M\_>$9@S*#C@$@''L*H^)=-\7^%_&DWAB74[V^U2*98(UL[J21;DL 4:(YRP;
M<"..0:670_B'!]O\RWU]#8#_ $K<[_N<J& 89Z[>2!R!@FM.6G)*3Y?NL9.5
M5-Q<I:>?5'/S:!KMQ/+/-I.JS3R.7DD>TE+.QZDDCDG-1_\ ",ZS_P! 74__
M  #D_P *W(;+QW<W\EG!'K\EU'<+:O KR%DE92RH>>"5!/T&:U;;PKXYFL]6
M62YUJ#5["YM;8:47D,TYGWE649Z )G(R",\UJJMM+HR]C[1_"SCO^$9UG_H"
MZG_X!R?X4?\ ",ZS_P! 74__  #D_P *W6L_':6%I?/'KOV.[D6*"97E*RNQ
M(55P<Y)X&>N.,UH>--#\6^ =*T&YU?5=3M+O589IOL4\KH\ CE*<G=SNQFCV
MVJ2:U)>'LFW%Z?\ #')?\(SK/_0%U/\ \ Y/\*/^$9UG_H"ZG_X!R?X4D?B_
M5W!VZW?-C_I[;_&NQUCPKXZT;2/#%^U_?77_  D*YM+6VNY'F5L K&ZYX=E(
M8#N"*N4W"R;6I,:*G?E3=CC_ /A&=9_Z NI_^ <G^%'_  C.L_\ 0%U/_P
MY/\ "NG/ASXDC5$T[[#XC%\\'VM;<M)N,(./,Z_=S@$]CP<&CPOI/BKQ3I^N
MW=MXA:!=&M7NIXKK4'2254&66-0<L0 >>![U/M='+F5D-4$Y*-G=G,?\(SK/
M_0%U/_P#D_PH_P"$9UG_ * NI_\ @')_A75ZIHWB?1O"5EKU]XCGM5O8UGM;
M)I[@RRQ,Q57W!?+&<$[2P.!]*H>%Y=7\2Z@MG)XO&BLY5$FU"[F".[,%51L#
M$DDCMQ256Z;3V*^KVE&+3N_0P_\ A&=9_P"@+J?_ (!R?X4?\(SK/_0%U/\
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M]S"QCDAE0JZ,#@J5/((J$,I&=P/L#FJ>$HN,58GZ[B8R;3UOKIU=O\CV6/\
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M@N@S-X>TW2=0L)5DUK2XCMMGCN!)""-@",T>^,XR2.IK'7Q_\,9M*GU8:7H
MO(;/7IK+1[JV+1I-YJ?8D*8P<HN1]37S NUB4&,]2*!CGID5?]FPT7/*Q']K
M3;;5-+Y'U3XB\4?"3Q!?QVZ6WA;2+:WU71[F*[MM/R'1X2;X2+_'&LF%V]!V
MS70R>,/AII'B+Q%!H6K>$K7^T_#,%K(]W:L=-EO4O"Q\R-5 /[L*3@ <"OC4
M' / YZT( ,#;G'3 S6;RM./+SLTCG,E+F5)7.R^,MQX;N?B?X@E\(I GAYI@
M;86R%(ONC>44\A2V['M7&4^-#*ZI&A=F.$1!DDGV'7\*83D^XX(/8]Z]>G%4
MXJ"=['@U9NI-SM:X444I4KP00?<$?I6I@)103@9/ H!R* "BBE*E>2"!U&1R
M?>@!**&&T$G@#@GMD].>E(S#KD ?44AV%HHW*!DLN#TYI PSC<,_6F(6BC(/
M0@T9 ZD#ZT %%(6&2-R_G3AAL8P=W0#DT )12FDH **** "BBB@ HHHH ***
M* "BBB@ HHHH *.M%'ZT >@?!G6WT;Q!J"FYTF&UO;,VMW%JUT]LLL)=21'+
M&"T;J5!!]O>O4[VT\$Z5X26\-SI-[X>O9-;#W6J0,^JZAM_X]FADV[BPD/WL
M@]SP:^;69<98X'O4DEW--!#"TSO!#N,418E8]WWMHZ#/'2O/JX7VL^?FL>I0
MQOLJ?*XW/HJ^\3^ ;KP[XBTR.\T[[?-<1S:4]PC/;0R#3HDD9UQR6(D16Y"N
M<UR?QSUCP==^&[.#PIINC06R2JUK=6ER3>+#Y.&65/+7&6Y)9F.1P:\< R,A
M01P.G!]J7@#Z\U,,'"$KJ3-:F82J1Y7%:GT]X@@\$^'=<TRSUR'PS#:+=:++
M!:6]KMNH4,(>[:Z(7F-@P)Y.<C&.:YKPQXF\'ZMI"7NJQ^&;6%Y[_P#MNSEL
M0ES)%LVV2V85>,?[)!SR<UX7<W4UY*9;F:2XE8!2\K%B0!@#)[   5%N)S[]
M:F.!TM*;N#S'WKQ@K'TI8>-?"6M:G;:EJTGAJ^NU\-6%OIL=T%MTAG38MTDS
M>4P#84[<@_+D#&:Y>]\4^$+*PGOK"QT5+^"SU=[?3G0W-O#.]U%]G50X&_\
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M3[Y",$?<SP*TM.\2^ [9=3LKZYT@:K=6FGK-+;6Y.F'5%\[,_E@#="A:/?C
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MX2N;+1/A+J)G\2P7L^L(MG=:*;QE>PL5F5W$<14JT\A7Y<8"CGO7D/0YV^U
M<$Y&#4?55R\O,6\=*4W-15[6/>/B7J>A_%_P[X7M_#5])"='M]1G>TU&-(XM
M/LH]K(A*D\G:%7^\22>M<Y\(;Y="\->(=:3Q+8VFI_9I[*QT2^O&AB=Y8BDE
MQ*N"& 1B%4<ENI %>5K(ZA]KLHD&&VG&X<'!]1P/RI,JS'D;AUH6%M3=/FT"
M6,O555QUL?0^K>*=(U73]4CM?&%I86>N6>C6&F6[RR!](E@"^?-(@7]WMVL,
MK][?39M0TZ_^)FE;_&EI;^'_  YID,-G-%J;B?5?)D+)'+*%^5FD8L<YV)QU
MKYY+1LHQ@+]WV^E!93P6&X]O6L_J4>DC59A*Z?+L;'C'4)]6\6ZU?74EK+<W
M5Y+/(]D<P%F8L?+.!E>>#BLA>M)^E*O6O1BN5*/8\B3YI-CH_P#6P_[Z_P Z
M_<+1/^0-8_\ 7"/_ -!%?A['_K8?]]?YU^X6B?\ (&L?^N$?_H(KXOB3:E\S
M]+X.^*O\OU+1^Z:_+C]O?_DY/6/^O"R_]%U^HY^Z:_+C]O?_ ).3UC_KPLO_
M $77G</_ .^/_#_D>MQ9_P B_P#[>7Y,^=Z]_P#@YX=<?!G4M>\,^$-/\;^,
M?[;2RN;2_MQ<FTL]F0RQ%AP[$J7[?A7@%6K2_N;,[H+J:SRNPO Y0L/0D'G\
M:^\Q-*5:'+%VU1^58.M&C4;DKJS]5Z'TS+^R_HS_  [TKQ!?Q:KI>J75U8_:
MH+2:.X1DN)BDB0Q@  H/NC<Q'>MJ[_9S\/:7J=[X7BN+^#1;[7M%@_?2127'
ME3B7<V\H'C.%'RX'N#7R<=1O/+2$WESY"G*1^<V!SG(&>N>]*VIWS2M(;VZ,
MK.KF0RL69AT8G/4<X/:O/^J8B5_WNFOYGJ+'816M05].I]'Z-\+/!OC+PQI>
MD:?-J5A:W_B#5-+TT7LL'F_;(K53$TCA,E'<%=F<#<*U],^ GAB:.'PG)J5V
MUK#XCBT_4Y(S%O\ M"Z<\T_EOMR%#J$ SMXKY32\N(]FV>9?+<R1A7(PYX+#
MT8^HYIZWUS&I*W<X9F,C$2L"S]"QYZ^_6J>#K7TK/[AK'X=+6BK['T+K7P0^
M'U[X3^V>'W\00ZG<Z!#XAMDO;F%HTC-P(6A;"CYCDL#VXKTK1_V=M ^''C'3
M6M+;4YSJNE:S97.FSSQ32EDMP5:%RBJ&;=P<$9P037Q:+V?&UKB;9L\O:)#C
M;UV]>F><=*F;5;^1D,FH7;.GRJSSL=H(YQSQQVI3P>(DG'VS*AF.$B^9T5?3
M_@GT;'\.=)^"OB_6?%EDMY;V>A>%X]5AT_561[FSU*Y#106\A4;2RDM)C'0"
MM:\^#7@77(]-U/6+>^M8HM'\/1&#1Y8XC/<7K.DDCE@<G.UB:^:6\7ZNWAN\
MT)KV1]-O+I+V>.3YGEE12J,S'D@ G Z5F_VA=[<"[GV@* OF-_"<KW[=O3M2
M^I5M'[1I[">88974:2<7K9]_^&/IU?V:O VJZS;)I=YKTMG;7.L6%S9230FY
MU">R4%1 < +O)( (["NX\2?L^>%?B%XOEEU%=5TZ'2]#T:TBTFV=/M</F1'=
M),$4[F0@*V, G<217Q6NH7(D5A=W"E7,BLLK95CU8'/4]SWIZ:O>I,\RWMTL
M[#:9%G8,5R>"<Y(YJ7@<0VI.L]/(J&8X11Y?JZM=7U\O\]3Z/T'X"^%+&P\/
M>+H-8NY=/N;ZTTNV1WC+G4_MIBEW*RD&,1IO"D?Q $\&KU[\#OA[)<7]QK$^
MO2:G-;ZQK#/83010^7:73Q^6$V\%P![#MUKY<2\N$B2-;B4(C>8B"1MJO_>
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M[W-Q*1C=([%F(]!DU1)R:]BE&481C+=+_(\.O.,ZLY1V;?YB4445L<X4444
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M$H&TK[YK;^&?B>#P=XB?4+C4=4TMA$4232XHI3("1NCE23Y71@,8/I7K-_\
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MFXO[>YTF25EW0P+/%--;R>J,T.Y?0L>U77J5XM.G$SH4L+--3E9VT^X\5O\
MP_J^F'%YI5_9XA^T?Z1:O'B+@;^0/ER0,].:?I?AVZU+4EL))+?2I#'YIEU2
M7[-&J8R"68=P1CUSQ7L+_'/P_'J$-I)'K>N>'KZ]OI]775)$,YM[I KV\..
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M(6W-NP#D9)8\\4ECD]8P=A_V=9I2FDSP8\#.?K[<XJ1H)8XHY'1TBD+!'92
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M )?+[F?BN9H3G]Y&<\'D<U;TG69]!U.WU'3KUK"_MVWPW-O)MD1O4$5^SO\
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MT9^*WFQ*1\\8QT^84>=#_P ](_S%?M2?A-X*_P"A2T3_ , (O\*3_A4O@O\
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M&:$]7C/XBOVH_P"%2^"_^A2T3_P B_PH_P"%2^"_^A2T3_P B_PH_P!8Z?\
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M!?\ T*6B?^ $?^%'^L</^?;^\/\ 4ZK_ ,_E]S/Q8^T1?\](_P#OH4?:(O\
MGI'_ -]"OVG_ .%2^"_^A2T3_P  (O\ "C_A4O@O_H4M$_\  "+_  I_ZQP_
MY]O[P_U.J_\ /Y?<S\6/M$7_ #TC_P"^A1]HB_YZ1_\ ?0K]I_\ A4O@O_H4
MM$_\ (O\*/\ A4O@O_H4M$_\ (O\*/\ 6.'_ #[?WA_J=5_Y_+[F?BP9XF&#
M)&?JPJQ/K$MS96EG->^;:VA8P0L^4BW$%MH[9(!/TK]G_P#A4O@O_H4M$_\
M "+_  H_X5+X+_Z%+1/_   C_P *E\14WK[-_>AK@^JE95E]S/Q7,T)_Y:1_
MF*/.APP\R/#<'D<U^U'_  J7P7_T*6B?^ $7^%'_  J7P7_T*6B?^ $7^%/_
M %CI_P#/M_>A?ZG5?^?R^YGXPZGK,VLW;75_>_;+ET5#+,^YBJ@*H)/H  /8
M55,T).3)&3[D5^U'_"I?!?\ T*6B?^ $7^%'_"I?!?\ T*6B?^ $?^%+_6*F
MM%3?WH?^IU5_\OE]S/Q6\V _QQ^O44HGB7I)&/HPK]J/^%2^"_\ H4M$_P#
M"+_"C_A4O@O_ *%+1/\ P B_PI_ZQT_^?;^]"_U.J_\ /Y?<S\5Q/$!Q)&/^
M!"E^T1?\]8_^^A7[3_\ "I?!?_0I:)_X 1?X4?\ "I?!?_0I:)_X 1?X4?ZQ
MT_\ GV_O#_4ZK_S^7W,_%C[1%_STC_[Z%'VB+_GI'_WT*_:?_A4O@O\ Z%+1
M/_ "+_"C_A4O@O\ Z%+1/_ "/_"G_K'#_GV_O#_4ZK_S^7W,_%C[1%_STC_[
MZ%'VB+_GI'_WT*_:?_A4O@O_ *%+1/\ P B_PH_X5+X+_P"A2T3_ , (O\*/
M]8X?\^W]X?ZG5?\ G\ON9^+'VB+_ )Z1_P#?0H^T1?\ /2/_ +Z%?M/_ ,*E
M\%_]"EHG_@!%_A1_PJ7P7_T*6B?^ $7^%'^L</\ GV_O#_4ZK_S^7W,_%?SH
M<Y\R//U%"S0KTDC'.>"*_:C_ (5+X+_Z%+1/_ "+_"C_ (5+X+_Z%+1/_ "+
M_"E_K%3_ .?;^]#_ -3JO_/Y?<S\6!/$,XDCYZ_,*/M$60?,CR.GS#BOVG_X
M5+X+_P"A2T3_ , (O\*/^%2^"_\ H4M$_P# "+_"C_6.'_/M_>+_ %.J_P#/
MY?<S\5_/A_YZ1_F*/.AQCS(\>F17[4?\*E\%_P#0I:)_X 1?X4?\*E\%_P#0
MI:)_X 1_X4?ZQP_Y]O[T'^IU7_G\ON9^*_G0YSYD>>1U%"SQ+TDC'_ A7[4?
M\*E\%_\ 0I:)_P" $7^%'_"I?!?_ $*6B?\ @!%_A1_K'#_GV_O'_J=5_P"?
MR^YGXKF>(C'F1D9S]X4>;".CQ_F*_:C_ (5+X+_Z%+1/_ "+_"C_ (5+X+_Z
M%+1/_ "+_"C_ %CI_P#/M_>@_P!3JO\ S^7W,_%C[1$,_O4Y_P!H4WS8,8WQ
MX/N*_:G_ (5+X+_Z%+1/_ "+_"C_ (5+X+_Z%+1/_ "/_"C_ %BI_P#/M_>@
M_P!3JO\ S^7W,_%QM0W6\=NUUFWC8LD1D^52>I S@$XJ+SH?^>D?YBOVH_X5
M+X+_ .A2T3_P B_PH_X5+X+_ .A2T3_P B_PI?ZQ4_\ GV_O0?ZGU7O67W,_
M%?SH?^>D?YBE$\0.1+&"/<5^T_\ PJ7P7_T*6B?^ $7^%'_"I?!?_0I:)_X
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
0BB@ HHHH *;)]TT44 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>posam_002.jpg
<TEXT>
begin 644 posam_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $^ W$# 2(  A$! Q$!_\0
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M=S_O?EH_M&@:_P"HN;?W?_ O^ ?J/GVH)!K\N8_^"DWQ5?\ Y=/#G_@'+_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY%JC:3=*RPWL;07.KRSQK]HB:-O+5D_=[-U?9_\ PR3\)]Q_XH^#_P ")O\
MXN@?LE_"CI_PB,&3W^T3?_%UK'#5X?;(GQ1D<Y<TL-+K_P"3?]O'Y\^./&4G
MCO7(M1DM%M&BLK:T\I6W_P"KC6/=_P".U]O_ +#?'P9E/_44GS_WRE=4?V3O
MA3SCPE!_X$3?_%UZ%X8\+Z9X,T:UTG1;*+3]+@7$<$(PJUUT*$XRYI,\3/N)
M,'F&7QP6%I2A9HZ"L[1/^/27_KZN/_1KUH#H*S]$_P"/27_KZN/_ $:]=9^>
M&C1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJ7E9'B?XA:3X,\+7OB'5+O9HUFGFSW$$;3[5^[]U-U=2J<IPRPLIRLBYX/\
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MZ^KC_P!&O0!HT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MY?6NC&Y5B<#'GJ+W3.GB(U?=/5****\@Z@HHHH **** "BBB@ HHHH ****
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MU/$:2ES'D?Q0>6SO+*[V_P"CLOE;_P#:KC$U[_:KV35?(GM);;5M-N[:)O\
M6Q75FVS_ +[7Y/\ @6ZO/;_P!X=FWM:>(%L_]B65'2OS:O@I\_-8]+"8^E[+
MED9":]_M5836_P#:IR?#W3_^ANT__P <_P#BZOV/@31$?_2/%,$W^Q;NB?\
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MG10!F?\ "-Z3_P! NR_[\)_A1_PC>D_] NR_[\)_A6G10!F?\(WI/_0+LO\
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M;]:Q_$_B?3/"&@7^MZU=QV&F6,+W%Q<2G"1QJ,LQ_"OGG_AXU\##]WQ%??\
M@JN#_P"R5^MSK4Z7QR/F<+EV+QL>;#4I2_PH^G]A/<4;#ZC\J^8O^'CGP/\
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MI2TAZ4 ?GM^V_P#M,P^*;B^^&WASY]*L[I?[5O?^>\\3[_)3_81T^9O[R_\
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M"]O_ +9;*]RRQ>7$NU'55V_-_O,U=$8K^0J.86G"=7&QE_V]'^;_ .1N>9_
M;_DLW@K'7^U(/_0J_4P5\$_!C]EWXB:#\3_#>J:MI,>FV.GW:W4TLMQ&_P J
M_P *JC-\U?>@.0#GBO1PT)0A[Q\'QKC*&+QE.="<9+E^SZD@Z5GZ)_QZ2_\
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M_OC\Z_'\67Q1M]>M]&F_X2N'5IXO-CLVFNO-9?[^W^[6@B_$A--O]0:7Q/\
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MUL+>6Y:+9*C)MKZJ%>/-RGYC6J>^>:VW^M2O3? WA6Y\6WD5G;,L/_/69_\
M51+_ 'W>J0^%'B.XL]!O6\-WDD6O.PTMK:-G^U[6VMM1*[+P?XMG^'MY=Z5=
MV<FE7MFS175O,NQXF7[^Y*PQ-6,X_NG[P2K.$?A/8+/P3IG@/1GL[:?SO[TS
M_P 3?WZ]+_9/NX;>7XC:S:P2OJMGIZ>5+Y#,GE;6?9_O;T^Y7'^ /A#XV^.6
MB'5]/^SZ7I$AVQ7NH,Z^;_>9$V?,O^U7W%X1\+6/@OPWI^C:?"D=I9PI$@1
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MM)L(_*L[2(1Q+[5]5E]./+[2/PGQO$N=_P!H>Y]K_P!M-?%+117MGYZ%%%%
M!1110!@>)\)!97+#$=O=I)(V[[B_,N[_ ,>IUS<U$TUSK8E6"=(;+<8S)Y?F
M/)SM;;N^7;_WU6-_PA;VDRO!KNI0HO\ R[I]G\K_ +Y\KY?^ UY&)YOBB=M'
ME^T7+B:L^:3>U.N-+OTW;;^)SM^5);;_ -"VM68\6JVY^>WM+@;?F>*5E?\
M[X9?_9J^:K\W\I[-)Q*/B35=H:O/-4O_ +S-7>:I:F^A;[397,+*OWXMK_\
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M=;->7&]V:7Y%;'S-Q\QK>^+'PB\*?%73(U\3:5'J/V!))+=BS(T3,OS89?\
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MS7;[8NU?X:M^9MKD/$-_]^OG<=B?94CV,+0YZAS^L7F]FKFX-=;2]=M9E?\
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M72_;[&S9%EEV._\ !M^Y7RK9PQ([[?O5U6@^,]5\-SO*LJWEI*NR6WN/G_\
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MU)<=H(-G_?3?_85\[Z%-+KWB.RLT^=?-W2_[JU]0^!;'[/HXNF4![MO,_P"
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M?NK7L<2+ B(J[57Y56I?QI<9KZ#!8*C@H\M(\C$XNIBY<U46BBBO1.,****
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M!]C? W]KGPMX]\"VMWXKU*R\,^(;9_L]Y:W,NQ9755_>Q?[#?^._,O:O2/\
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M;I37"G3_ #GBEOG3^/SY8OEE_P!EV^?^]7L-% !1110 4444 %%%% !1110
M5\X^+/A;XQU#X?'0[/3+*X>XU_5KJ<3^1)-%!//.\#Q-*K*OWTW_ ,?]VO=O
M$FNV_AGPYJFLW2L\&G6LMW*L?WF6--S!?^^:\AMOC]KCM!ILGA.VB\0W=Y8P
MQ6C:KNMQ%=QW$L3M*L7WE^SNK)M^C-0!YSXR^'OB#PMX'OM4U;3EDUB?4- C
M>\N6^U(\4%M:I<>?MW?NO-B?=N^]^59VC_!G5O&VC>%M1T%=5MM%3[5%*L/V
M6UN+6Z:]:5[J+S4=?*Z*C1?/LC2O;OB?\:=4^'^N365IX?MM5BM=/@U*ZD?4
M6@=%DN/("HOE/O\ F_W:P]=_:.U#0O#D][<:!9_VCITU^NI::M_*S[;1E\U[
M<I;MO7YD^:7RE^:@#8TOX<WNDWOQ9BL]#M;(^(/WMCJ$#QIY[-9)$4?'S+^]
M5F_[:UPEI\!O$1ET>YO-+MI;VUD\.1-,\ZLRP6T6R]3_ '?_ $*M*X^.FK^&
M]9\0W6H23:AING:CK&VTC6*/=!:V4$JQ9V?WG?Y]W_?5:&D_'_Q-K$L4%KX3
MTZ:[NM373;.5=4F6TG_T*6Z=O->U5OD\K;]S^.@#@]:_9M\1R>'_  Q96=H]
MI!;?VD+NQTF:UBEBDGNMT5PCRHZ;EB55W+\Z_+76ZK\&-9UCPM\2=!N]#M-0
MU35O/N+'Q)=3Q,UUN96BB=?O1LFW;_<^2K]I^TRE^WA.[@TFWEL]96U2ZB2\
ME:[L)9]VS<GE>5M^3O*K-_=K$N_VEO%%YX"GU:U\,Z98WL^A1Z]8"74'G0P>
M:L;;_P!TOS[G7:G_ (]0 MG\%_%+?%O2?$3VUSI5@L%JUM#975KLTORK7RFM
MW^7<R;V=ML7R/_%6_P# WX8:WX-\3)>:KH5II MM$BTJ>\AN5F;4[I9=SW7]
M[YO]OYJ[/Q/X_P!9T+4/"NAVFC6FH>(];CED,,M\\5K (%5ICYHB=V^^H7Y/
MF_V:\_U[X_ZUJ6A^/'TK0KC3XM+L-6>QUA-TJI/9EX_WJM%Y7S.K,NUWX3Y]
MM 'T)17GWPF\2ZEXEM_$K:E/Y[V>LRVL&%5=L2Q1,J_+_OM7H- !1110 444
M4 %%%% &)XNLI]5\*:W8VZAKFYLIX8USMRS(RKS7@7BSX5^.]0A\!6MGIULB
MZ/IVF))=Q- +B*>"53.K2M\X39]WRF^;Y]W:O:OB+XRD\#^'/ML%D=0O;B[M
M["TM3)Y:O//*L2;FQ\J[F^]7C]G^T!XHT&"XL]0T#^W=>.HZF[6-A*S+%;6T
ML4?E1%+??*W[U=NY5_VGH \^^*O@RZ\%Z+X<M[W2XHC<S:[+J+>4MPDOFR[H
MMO\ #Y_E-^ZW?=KKO"'P/U:7XD:5KS_VD/#306LMKYS6Z/%;)9I$UK=1.GF?
M/\VY$^7YJZ_Q%\;]>@?Q]9VVA66F7^A:=+?V46JW,J37D2[?WXC\K:T?+<H[
M?-M5ME);?'7Q!;VUQ]M\.V#+8)H\=W-#J+?-+?/$OR)Y7W5\W^]_#0!YI??L
M[^+;K1O#EE#IDFG66F_;;:2#2;FU64M)<+)%>()4VK\HV_PRKMKOO#'PK\0Z
M7\5=/U.]T>WF6SU;4+^3Q*URK37<$\3)%%M^\K)N5=OW?DKH(OC+JNI^+V\.
M:1X?MI]2&I7EH7N[]HXO(ME@+2Y6%OF;[0N$_P!G[U<T?C1XEM/$<T&M6MK9
MV%KXEN-,_P");/YIE@BL&N&5]\7LGW=OWO\ 9^8 C\9?"7Q-K,7Q%M+3381J
M&MW"WEEX@^TIO: -!_H#;OF7_5-_L5AR_ SQ4? LMA;6MR\LNAZ[:K;:A<VN
M^WENF@\J)?*VQ(O[ION_*M=3IW[0^M:I%IL,7A2U74]4?3VL[=]5/E-!>07$
ML;L_E91E^S/N3:WWN&KU#X;^,)/'7A&VU:6S%C<-+/;SP++YJI+%*\3[6_B7
M<C<T ='8PM!96\;\ND:JWY59HHH **** "BBB@#D_B=HMWXC^&_BK2=/C66_
MO]*NK6!&;;NE>)E7YOJ:\8UGX7^.KSQ%\/6AT^T6QT2+2!)=6S0+*AB=?M22
MRL/-9=OW5B;:WS;J]C^(_BV\\%:#;WEA81:E=W.H6=A';RS_ &==T\Z1;F?8
MV/O?W:\PU+]I:XT[PQ#JCZ'8M=V\U\NJ:8E]*]Q$EK/Y$LL&VW^=<_Q2^50!
MY'\0? ES\/O"'@;2=4TN*%6T+4DU9%B2X:6=F@W-$WW?M.W=L;_>KT+PO\$-
M6E^*HUR]AO;SPY.OF0?:'MT1;9K-8EM+J)E\UMO]S[O\7WJZSPC\9?$5[XDN
MK#6-(L$MG\5R>'K66TN6W*JVLL^]MR?-_JEZ8^__ +/S4M#_ &BKK7;*\O3H
MVGZ=9V>EK?SW-[J;*BLUQ+!%$=D3M\S0]?\ :^ZU 'GS_L^^+9M)\#6HL9--
MM]*TT:=/;Z5>6JO%<I+N^VHSI_RTV[MR?O:[[P!\*?$&A_%J+6-1TNV,5M+J
MLLVO&Z5I;]+F6)K=-GWE\I4V[&^5?X:YKQ-^T%XCU"QO;G3PNA7-GI&L>?:[
M?-5;RVG@1'5Y8D?;\[?*ZK_M+7I7AOXRW'B#Q['X7&CI'?17>H07I^U;OLT5
MMY7E2XV_-YOGQ?[OS4 <-XK^$7BC5-'\<Z=;:7"FIZCJ@U&+Q ES'OOK7[4L
MOV)MWS+MB79M;]U\J_WFK'O/@9XJE\-:-9V5E.[6^C7]J\6H7D'FQ2RZC:SI
M%^Z^3;MB;[GRKMVUVFM_'W4M/N=3AA\-0W,JZ]+H.GDW<N9WC5Y9'DVQ,R+L
M5=NT/ENNVIKK]H#4HKF&<^$9;;3+>ST^[U0WMR\5[:?:Y7B55@\KY]C1_-\R
MT 7OAKX'UGPM\3?%U\=-CM-!OI))X[F[DCENY9WDWOLE7YO(_P!B7YE/W?EK
MRC4/@I\0=<U_7)]3TNRAM-1:U2Y@L9((+>7R[]96953:SKY6[YI?G^]ZUU?A
M_P#:$U+3?#7ARXU6*TUJ:Y;_ (F312LEW DEXT$3^4D7E[?N_>=-VVMV_P#C
MSJUMH":S'X:MY+2_U=M&TA/M\K/-*CSJSW"I;MY2_N';Y/-;E: ,KPM\&M>T
M#X[7GB.YEN3I0NYKBUN+26!8O(:)8TM95*^;\G\*I\OR+7T+7SMXP^/OB*;0
M+<:/X??0[Y8-/O=2?4Y=DMDL]]]GVI$T7[S[C?,VSY65JUOB+\6O$'@+XFZF
ML5E#JGA?3O#]MJE];O.L4L6ZYE1Y8OD_>-M1?D9U'R^] 'N=%>5^"_C"WB[Q
M=#X?&C_9KR(:A_:(\_?]E\BX\E/X/F\W[W\./]JO5* "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ I*6B@#PW]L675$_9R\9II%O+<32PK%,(C\ZV[2H
M)6^FS=_P&ORQL--OM5M9;FQT^[O[2#_6W%I \L47^^Z_=K]O1^=016T,">7'
M$B)_=5:^BRW.?[.IRIJGS7.&MA/;RYN8_$.VA:\N+>"!?.EN'2*)-WWV;Y$K
MK_B3\(?&'P?U"WM/%VARZ4UQ_J+A&66WN/\ 825?EW?[/WJ^O?BS_P $]H_%
MOCB35/"6M6?AW0]2E,MYIL]JS&U9OO\ D;?X7_NMMV_3Y:^J-5^'.@>)_ L'
MA37K)=?TF*".!DU$;VDVKM5RW]__ &E]:^CK\148^RE2][^;^8X(9?\ %S'X
M]^'/"VL^,M632M!TB[UK4F7>MI90-*^S^_\ ["_[=:'BSX:^+O *;_$OAC5M
M"A_Y[7MFRP_]_?N_^/U^M7PR^#7@[X06%Q:^$M"ATN.Y;?-*'>6:4_[<CLS-
M^==I+ D\;)*JNC=58=:XJO%$O:_NJ7NFL<NCR^](_#SSEV[MR[/[]?97[,'[
M&'A[XE_"^/Q3XS&K0SZG*SV$5O/Y'E6Z_(DOW?FW_,WS9^797V%)\"/AQ/J:
M:DW@7P\UZG*S'3(<_P#H-=RD8C4*@VJ.U<^.XAGB::A0CR%T,#"E+FE[QY7\
M"OV>?#7[/MAJL&@37][-J<B27-WJ$BN[;-^Q?D5555WMCC^(UZQ33QU-.!XK
MY&I4G6E[2H^:1Z<8Q@N6(ZBBBI*"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *SM$_X])?^OJX_]&O6C5.QLC:Q,I;?NE>7_OIMU %RBBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"":"*YB>*1%>)EVL
MC+E66N5T/X6>$_#L<,>F^'[&S2*Z6\C$47W9U0HCC_=5F6NQHH Y_5_!6A^(
M;F>?4M+M[N6>!;61I5SNB23S53Z;_FK)USX2^#O$BO\ VEX=L;OS9)Y7WI]]
MI2OF[O\ ?V+N_P!VNVHH X7Q/\(O#7B/2-8L6T^.QEU2*Z22]M4594>>)8I7
M7_:947_OFLOX>?!FT\%))]MO$U=TN5NK.(0>1;6+")HCY$6YMFY7?=S\VZO3
MJ* .%A^#7@BVN;&XB\,:<DMB(EMF6+_5"/.S'^[N:KA^%_A3^SX]/_L&R-BE
MC_9:V_E_*MKN#>5_N[E7CVKKJ* .9U?P#X?\0:?I]KJ&E17D&G<V8E+;H/EV
M_*WWA\M5!\*O"0N=5N/[ LO,U:.6&^VI\MPLO^MW+_M_Q5V-% &7I>AV&A+<
M)86D5HEU.UQ+Y2\-(W5C_P!\K6I110 4444 %%%% !1110!D^(/#^F>*=*FT
MW5[.&_L)]HDMYUW(V#NKG)?@WX*FL+6T;PW9>3;22RQ83YE:4_O?F^]\_P#%
M7<T4 <HOPT\,/J&HZ@^BVCWFHP2V]U*R;C+%+_K$_P!UJ8GPP\*KI=YI7]A6
MCV%[%%#<P,FY94B_U0;_ '?X:ZZB@#A8_@[X,@LX+>+P[9QQ07#746Q-K+*Q
M7>^[[V6VKN_W:TO^%>>&O[7EU/\ L:U%_+=?;6F*<F?RC%YO^]L;;7444 <7
MHWPI\(>&C#_9OAZPLO+NDO%\J(+ME171'_X"KLJ_[U=!HVCV6AV@M-/M8[*U
M\R6;R8EPNYW9W;_@3,S5J44 %%%% !1110 4444 9FK:39ZU%'%?6T=S#!/%
M=1K+T66)PZ-_P%E5JYC4O@[X(UA56\\-Z?,I>=OFB^\97\R7_OI_FI/BWX0F
M\=^&K+2HK:"\A.KV$]S!</\ (T$=U&\N?[WR*WRUX9J_[/WBV;2$TV+3;.\M
ME.LVMA;RWOE1Z5]INC):WD7R?>11]U?F6@#W[4OA;X2U4WHN]!LIS>7*7D^Z
M/[\ZIL67_>V_+NID'PI\'66DSZ9;^';"#3Y[=+26!(AL:)79U3_@+,S?C7E5
MY\ +O5+R*2]TC3[O[1XUDU:_>9E;S[#RI57?_>^9E^2L/2/@1XH\*^$6M=-T
M?2VGN-$TJUU&W>2-A/<Q3RM<.NY73S-C1[7=6H ]9M?!7P^@UZZ\+0>'[(7J
MV#W4L'V?Y6@N92KG=_MM%\W^[5;X9^%M(OO%&M_$2SOUU";7!]DBE6S6U\J"
M*5EV-_$[;LC?_%L6N>^ WPN\0^!]2M9M<BC5(-%^P8$ZR.CB]N957Y?^F4J5
MPEQ^S9XG&BW%MIL5EI=W=Z3<17TD,RI]KG.HI.B-\G.Z)77>RM]^@#Z'U+X;
M>%]7L+BRN]%M)K:ZO&U&5'3[URW_ "U_WJX#2_"7P_O?B)>:C--9SW=M+;:)
M8Z?=KM\BYM%>7$6YOWK;95;_ &=E>;^(O@'XPN/AMI^A:;IPD#'4)6@U"[LW
MGL)Y=OE&*7[/M2+<K-MB56^;[]=2OP9UU?$>BZS/I=CJ#V?BN35)$DE4O]ED
MM5BW[F_B65=VW_9H [CPQX$^''C[0M(UW3M T^ZLL'['*]OM^[,S_=_ZZ;FK
M:N/A)X/NH]0CD\/63P7TWVJY0I\KR[M^_K\K;OFW+BO I/@%JWA+P/I<\&GQ
MVFKVFEWCW,VF*TLL^H+>03V6Y8D9G_U3KN_AW5W%K\._$6O_ +/+Z>]M]G\2
MZS<_VSJ&GW4K1>8\MUY\MJ[?P_)^Z_X#0!Z+?_"CPAJATYKG0+*X;3XTBM2Z
M9V(K;E7W56^:N>CF^'7Q7\502OIEMJVL16AD26ZMGSY,5U+'CIAML\3?*?\
M>KSVZ^!^NZA\2_#WB Z2VC:9$+1HK'2]1@0Z4\4K,Z_-"VY'W?=B9-WS;JIW
M?P%\0W.EW\-[I8NHY=/>%([;4%A8S?VM/<KRRLC+MD5MKKM;[M 'LO@;X70^
M$?%/BCQ+-=I>ZOK\D?G31VRP*L46_P I=J_>;Y_F;^*N_KD/ACI&I:!X!T33
M]9MK"TU*WA"SQ:6FRW5L_P *_P"?FKKZ "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *3%+10 E+110 4444 %%%% "44M% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
E10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>formposam_016.jpg
<TEXT>
begin 644 formposam_016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #[ 9@# 2(  A$! Q$!_\0
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MBB@ HHHH **S=8U.+2-+NM0E5GAMHFE947YCMJA_PD%Y_P!"YJ__ )*__':
M.AHKGO\ A(+S_H7-7_\ )7_X[1_PD%Y_T+FK_P#DK_\ ': .AHKGO^$@O/\
MH7-7_P#)7_X[1_PD%Y_T+FK_ /DK_P#': .AHKGO^$@O/^A<U?\ \E?_ ([1
M_P )!>?]"YJ__DK_ /': .AHKGO^$@O/^A<U?_R5_P#CM'_"07G_ $+FK_\
MDK_\=H Z&BN>_P"$@O/^A<U?_P E?_CM'_"07G_0N:O_ .2O_P =H Z&BN>_
MX2"\_P"A<U?_ ,E?_CM'_"07G_0N:O\ ^2O_ ,=H Z&BN>_X2"\_Z%S5_P#R
M5_\ CM'_  D%Y_T+FK_^2O\ \=H Z&BN>_X2"\_Z%S5__)7_ ..T?\)!>?\
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M)!KFN6&CZ'M5_P"T+Z=8H?F^[\[4S_A8WA9O!O\ PE7_  DVE_\ "->5YO\
M;/VR+[)L_O>;]VOF?Q_ID'BKXL_LR^'M4M8[O0GTZXU!K2X7?%+<162^5N3^
M+;7B5SI5L/C?=?#);:,^ &^+MO*^DJG^C_-I_P!H\K;_ '?-^?90!^A7@SQ[
MX>^(.CKJOAC7++Q#IC-M^UZ?.LJ;OJM=+7R+X0%S\-/VG_C9IW@WP_%=Q/H6
MG:O%H-HZVL4M[]S_ '5WUUO@;]HOQUJ7Q:T#P5XT^%DG@A]<MKJXM+O^V(KO
M?Y";G7:B_P"U0!]&T444 %%%% !1110 4444 %%%<[XP\5KX0T.;4FTW4M46
M+[UOI5O]HN/^^* .BHKBOAM\2+3XFZ/_ &I9:7K&G6C?ZI]6L_L_FK_>6NUH
M **** "BBB@ HHHH **** "BDI: "BBB@ HI*,T +129I: "BBB@ HHHH *Y
M[P[_ ,ACQ-_U_P 7_I+;UT-<]X=_Y#'B;_K_ (O_ $EMZ .AHHHH **** "B
MBB@ HHHH **** "BBB@#G?'G_(E:[_UXR_\ H%9GQ7^'-M\6?AYKWA&\NY["
MUU:U^SR7%M]^/_=K3\>?\B5KO_7C+_Z!714 >,_$[]GVT^(/ACPA;6?B#4?#
M?B'PD\4NC^(;!8VN+=UB\I]RO\KJZ_>2N83]CO05^&4_A^3Q+K+^(I=;_P"$
ME?QB6B_M'^U/^?C[NW[OR;/N[:^C:* /(?@E\#H_A9>>(-:U#Q!J'B_Q5X@E
M274=;U-(D>5$7:D2I%\JJM>6>)=(\76'[;OPXN=>\1VFL:+=6>L_V3I]OI_V
M>6R3RHOOR[OWM?6-?&$MGX!M_P!O_P (3^&/$:ZKXEEMM9_MS3DU/[1]B;R4
MV?NO^65 'V?1110 5Y5\8M=\2^&/[#GT;7M)T>WO+Z+3Y5U.VW_-*WWD;>E>
MJU^=W_!4?]G+XF?&G6OA]?>#9?M>FP2_8)+$3^5Y=U*_R2T ?H#IL-U%8P)>
M3+<W2IB69%V*[?[M:%?)_@[]F;XLV?AC2+36OVA/$T<\%K%%/;V5A:A5?;]U
M9?O-73K^REK4W_(0^-OQ NO^N-^EO_Z"M 'T34;NJ?>:OGQOV,?#]U_R$/'7
MQ U+^]]H\12U7D_8)^%ER/\ 35\0ZB?^GG7[H_\ L] 'O=UK^FV7^OU*TB_Z
MZSHM>;?&;]H;P)\(_ &L>(=>\0V7V*U@9?)M)TEN)7;[J(E<Q;_L&_!* ?-X
M-^T_]?.HW4O_ *%+6#\2?V O@EXP\!:OI<'@RST.XE@8Q:G9(WVBW=?XEW4
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MTG[^"66X^5)?N[]DJ-7V([(BM3TVNN[^[6GL(HXUFE9;QC]G\#XXU#X,>/\
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M'PW7Q _:K^-MWX4UY+%5\/Z=I2ZW:1+.D%Y\[_[K,JUGP^!O&W@_]KOX3?\
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MJ:F^B2:5HE7_ %7]W[M?H;;0>1;Q1_=VKMJS10 4444 %%%% !1110 4444
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MND>"OVR/AE967Q(UOQQJ,6G:O%>6>MZPMZ]E^Z3^!?\ 54 ?;5%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !7/>'?^0QXF_Z_XO\ TEMZZ&N>\._\ACQ-_P!?\7_I+;T
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M_K973^'YZXOPOX/^#W@3]MOP%H?PQTRTTS6;.PU:+6K:T\WY/W2;-_F_^R4
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MX_#U_P"%=+UBXLI])2*6*[^SQ7'E;TEW[=W_  "JE4C'X@P^"JXKFY?\)]H
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M HHHH **** "BBB@#G?'G_(E:[_UXR_^@5T5<[X\_P"1*UW_ *\9?_0*Z*@
MKY]_:K\:^(M(M_ /@[PKJDFA:MXTU^+2&U:%-TMK!L>65T_VMJ5]!5X/^T]\
M/_$OBBT\%>)/!VF0ZWXE\':[%K$&E33I;_;HMK)+$LK_ "HVUOXJ .;^#'CS
M5_AM\3_B/\.?&WBR;Q!I7ARSM=:L=>UME6X2UE^^DK_Q[&_CKS'7O%WPN\/_
M +9O@#Q=I_Q"2^AU&TU9KY[[7?M%I9MY2;5B1FVQ;O\ 9KU3X-_#GQ)XU^)/
MQ!^('Q%\(P>'8?$MM:Z5:>&;Z>*]=;6#^*?9NB^=OX:]-?\ 9P^%;LK?\*Y\
M+[T^[_Q*8/\ XB@!G_#1WPL_Z*'H'_@=%1_PT=\+/^BAZ!_X'158_P"&=OA;
M_P!$Z\,?^"F#_P")H_X9V^%O_1.O#'_@I@_^)H K_P##1WPL_P"BAZ!_X'15
M2O\ X[_!_55B6^\9^&;Q8FW+]HNHGV-6G_PSM\+?^B<^%O\ P4P?_$5Y=\<O
MV6_"OB#1?#<7ACX=>'?/M_$EA=WABL;>+_14?]]_O?[M 'I?_#1GPL_Z*%X?
M_P# Z*C_ (:.^%G_ $4/0/\ P.BJQ_PSM\+?^B=>&/\ P4P?_$TW_AG;X6_]
M$Y\+?^"F#_XB@"'_ (:,^%O_ $4+0/\ P/BH_P"&COA9_P!%#T#_ ,#HJF_X
M9V^%O_1.?"W_ (*8/_B*/^&=OA;_ -$Y\+?^"F#_ .(H A_X:.^%G_10] _\
M#HJ\\^,WB#X#_'3P;)X<\2^.-#^SM*MQ#=VFIQ17$$J_<E1_[U>D_P##.OPN
M_P"B<^&/_!3;_P#Q-8WC']F_X=7GAC5X-.^'GAC[?+:2I!LTN!?WNSY/X: /
M(?@CX1_9N^!VB:A8Z?XOT+Q!<7[JUYJ&O7]O=W$NW[B_[M=9JMS^RYK?_']%
M\-[S_KM!:_\ Q-6?@7^S%X/\._![PEIGBKX=^'?^$BM;"**^\W3X)6\WW?\
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MHWC[XJ7>O?#OP^=*U+6XI]$\ZQ@E3[+]GB5]J_P?/NKUG_AG;X6_]$Y\+?\
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M_P"&C/A;_P!%"T#_ ,#XJF_X9V^%O_1.?"W_ (*8/_B*=_PSM\+?^B=>&/\
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MBV1$BB:7S6MU3^&#=_RRKZ=VT;: .?\ ^$V\/_\ 0PZ;_P"!D5'_  FWA_\
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J1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>formposam_017.jpg
<TEXT>
begin 644 formposam_017.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %1 G # 2(  A$! Q$!_\0
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MS$CG/:N*^'=AI_BK]M?XJ2^((8K[4-,L;6+2X+Q XB@*KO*!NG..1_>->X_
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M5\.X-3257UI]&2[^W)X>?4G.FB;.=WD_49QFHIXO#QLFM5:^BU2<K_?=&M3
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M#O;P)"67H2J@9_2@"]1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MP.,V<8H&D:>1_P ><=*\4'++N8W]JC^]^M)_:H_O?K6S_9&GXS]C3/I0=(L
M,_8D_*B\049/J8_]JC^]^M']JC^]^M;']DV&0/L2<TC:7IRL%-G'DT7CM8.6
M7<R/[5'][]:/[5'][]:V3I&GCK9H.W2C^R-/YQ:1_E1S1'R2[F+_ &J/[WZT
MO]JC^]^M; TG3S_RYQTX:/IY./LD?Y47CV%RR[F+_:H_O?K1_:H_O?K6XNB6
M#?\ +I'^(H_L*P_Y](_RHO$.27<P_P"U1_>_6C^U1_>_6MW^PK#_ )](_P J
M/["L/^?2/\J=X]@Y9=S"_M4?WOUH_M4?WOUK=_L*P_Y](_RH_L*P_P"?2/\
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M,MA(CBV@#H $81C*@=,'&15QQ<$DG"__  YE4RVI-N2JVOT_IK^D?*6B:O\
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M;N![5/%\1OB+=_$W3="T#6[CQ+'#8:+=2RV^GP&QNHYV;[5/-+PT0**60+W
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M=-^''A;1K"WL;#P_IEI:6]RMY%#%;(JI<+]V4<??'9NM6[;P7H=DUN]OHUA
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M.Y$](F])U-96H?=-:LG4UE:A]TTEN#,W1/\ D/#_ *YM_2NKKE-$_P"0Z/\
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M *!7_DTO^% &KBEK)^W:G_T"O_)I?\*/MVI_] K_ ,FE_P * -:BLG[=J?\
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M(QLIQ?K?_)$5_P#%K2H+SR;8B_C_ ++N=2:6.0801!"8W')5B'';(]*R;/\
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M\,?\AR/_ '6_E7H*=!55?B(H?"/IGE+[T^BLCH&H@08%.HHH **** "BBB@
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M.I(V!8CD\\ 'T)@^M&#ZU\_ZG\<OB%HVIW?F>"[;4[&-3)#!8&?[3+N6[,:
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MG'_\51_;%S_T"+S\X_\ XJM2B@#+_MBY_P"@1>?G'_\ %4?VQ<_] B\_./\
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M>I?]_P ?X4 :FSKSUJG<Z'87LTDMQ96\\LD2PN\D09F0-N"DD= ><>O-5_\
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M5GG5"D><;V!/"YXR>,UD=!?HIL<B31K)&RNC ,K*<@@]"#3J "BBB@ HHHH
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M0 R[D==RY&5-<@O[._A@6D\,MQJEU+<H@N;B:Y!DG=;O[7YC$+C<9>N!C'
MK:^&GP=T/X7W>I3:1YQ-[U$ZQDHN]GVAPH=AESC<3BG)8?E?*W<FG+&.:]HH
M\O6S.]ZTM%%<IZ(5Q?CG_C_L_P#KFW\Q7:5Q?CG_ (_[/_KFW\Q5T_B,JGPF
M?X8_Y#D?^ZW\JN_&+Q?9^!/A?X@UJ_BN)[:"V\HI:[1(6E81+@MPHW."6/"@
M$G@52\,?\AR/_=;^5=^$#J P!'H:JK\1%#X3YU_8OMM,M?"GB>VL+N^O/LFJ
M^4J7-ZM]#:QM#&ZQ6]R"1(F""W3#9&T8Y[;XD_ @_$/Q;)K?]MIIN_2DTTPC
M3XYBS)=)<QR.S'YU#Q@&,C:0S>M>K+$J#"@*/0<4^LCH.;\/^!K7P_X;T?1H
MKR]>'3+.*SCD%PR,ZHH4%MI )XJ]_P (W!_S]W__ (&2?XUK44 9/_"-P?\
M/W?_ /@9)_C1_P (W!_S]W__ (&2?XUK44 9/_"-P?\ /W?_ /@9)_C1_P (
MW!_S]W__ (&2?XUK44 9/_"-P?\ /W?_ /@9)_C1_P (W!_S]W__ (&2?XUK
M44 9/_"-P?\ /W?_ /@9)_C1_P (W!_S]W__ (&2?XUK44 9/_"-P?\ /W?_
M /@9)_C1_P (W!_S]W__ (&2?XUK44 9/_"-P?\ /W?_ /@9)_C1_P (W!_S
M]W__ (&2?XUK44 9/_"-P?\ /W?_ /@9)_C1_P (W!_S]W__ (&2?XUK44 9
M/_"-P?\ /W?_ /@9)_C1_P (W!_S]W__ (&2?XUK44 9/_"-P?\ /W?_ /@9
M)_C1_P (W!_S]W__ (&2?XUK44 9/_"-P?\ /W?_ /@9)_C1_P (W!_S]W__
M (&2?XUK44 9/_"-P?\ /W?_ /@9)_C1_P (W!_S]W__ (&2?XUK53U>]GT_
M3I[BVLI=1GC&5M8&17D.>@+D*/Q(H J_\(W!_P _=_\ ^!DG^-'_  C<'_/W
M?_\ @9)_C7)ZE\4-3TFXL(+GP1K,<E_/]FMP+BT.^3:SX_UW'RHQR?2M_0?$
MNJZK?F"]\,:AH\6PM]HN9[=TS_=Q'(QSU[8XH N_\(W!_P _=_\ ^!DG^-'_
M  C<'_/W?_\ @9)_C6K2T 9/_"-P?\_=_P#^!DG^-'_"-P?\_=__ .!DG^-:
MU% &3_PC<'_/W?\ _@9)_C1_PC<'_/W?_P#@9)_C6M10!F0Z#%;S)*MS>L5.
M0'NG93]03S6?XHXN+/Z-71&N=\4_\?%G]&_I51W,Y_";\G4UE:A]TUJR=365
MJ'W326XV9FB\Z[_VS;^E=#<37$3XCMC,N/O"0+^AKG]$_P"0\/\ KFW]*ZK%
M5+<4-F4?M5W_ ,^#?]_UH^U7?_/@W_?]:MI(KLRJX9E.& .2/K4=S>0VTL$4
MD\<<L[%8D=P#(0,D*#U..>*@T(/M5W_SX-_W_6C[5=_\^#?]_P!:N@9'6EQ[
MF@"C]JN_^?!O^_ZT?:[O_GP;_O\ +5['N::2!_$/SH I_:KO_GP;_O\ K1]J
MN_\ GP;_ +_K5[''6HWF6,J&=5+'"ACC)]!0!5^U7?\ SX-_W_6C[5=_\^#?
M]_UJY&ZR*2KAL$@E3GFG8]S0!1^U7?\ SX-_W_6C[5=_\^#?]_UJ]CW-&/<T
M 4?M5W_SX-_W_6C[5=_\^#?]_P!:O8]S1CW- %'[5=_\^#?]_P!:/M5W_P ^
M#?\ ?]:O8]S1CW- %'[5=_\ /@W_ '_6C[5=_P#/@W_?]:O8]S1CW- %'[5=
M_P#/@W_?]:/M5W_SX-_W_6KV/<T8]S0!1^U7?_/@W_?]:/M5W_SX-_W_ %J]
MCW-&/<T 4?M5W_SX-_W_ %H^U7?_ #X-_P!_UJ]CW-&/<T 4?M5W_P ^#?\
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M]\+_ /%4?VL__0/O/^^%_P#BJ -"BL_^UG_Z!]Y_WPO_ ,51_:S_ /0/O/\
MOA?_ (J@#0HK/_M9_P#H'WG_ 'PO_P 51_:S_P#0/O/^^%_^*H T*1N!5#^U
MG_Z!]Y_WPO\ \536U9\<:?=_BB__ !5)@6;F\ALH&FN)4@A09:21@JJ/<FL[
M_A,-!_Z#6G_^!4?^->>?M'ZI<K\$?%S6^DW5S.+0;(69(PQWKP6)P.]?G?\
MV]XC_P"A);_P:05])E>50S"E*I.;C9VTC<^.SG/*N5UHTJ=.,KJ^LE'KYGZ1
M^//%&CSZYX):/5K&18]9W.5N4(4?9IQD\\#D?G78'QAH6/\ D-:?_P"!2?XU
M^5G]O^).?^**;!Z_\32#_"@Z_P"(\<>"6/\ W%8*]E\-T?\ G]+_ , 9\_\
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M%-$\66\4&N:/I^LP1/YD<6H6J3JC8QN <$ X[UA?\*9^'_\ T(OAK_P46_\
M\17=2JX:$;5:;;[\S7X6/+KT,9.IS4:_+'MRI_C<^7_^&L?"O]O*3\1O$/\
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MP5"RD9 +,H'^\/45NGX??,5_X2CQ)D=O[1'_ ,30!V9 /;]*.*XL_#\ $_\
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M_M _\Q1/_ 1?\:#_ &@/^8HG_@(O^-%@YD:RZ98I<27"V5N)Y&#/*(EW.0"
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M#L>>M3:;H&EZ/<W5Q8:9:64]TV^>6W@6-I3DG+$ %CDGKZUG?\3#_H*)_P"
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MZA2[L/[7K?RH_8?_ (;=^#/_ $/^G?\ ?$O_ ,11_P -M_!G_H?]._[XE_\
MB*_'?/'04@8$9&,4U@*?=A_:];^5'[$_\-N_!K_H?]._[XE_^(H_X;=^#/\
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M_OW+_P#$U^.F?8?E1GZ?E1_9U+NP_M>M_*C]B_\ AMSX,?\ 0_Z=_P!^Y?\
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M^$3'_/-::Q\NJ0?V5'NS\<?^&:OBH?\ F0=8_P"_(_QH'[-/Q5/_ #(6L_\
M?D?XU^QW_")C_GFM'_"*#_GF*?U]]D']E1[L_'+_ (9G^*O_ $(6L_\ ?D?X
MT?\ #,_Q5_Z$+6?^_(_QK]C?^$4'_/,4?\(H/^>8J?K\^R#^RH]V?CE_PS/\
M5?\ H0M9_P"_(_QI#^S1\51_S(6L_P#?D?XU^QW_  B@_P">8H_X10?\\Q1]
M?GV0?V5'NS\<1^S1\5#_ ,R%K/\ WY'^-+_PS/\ %7_H0M9_[\C_ !K]C?\
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MM9_[\C_&OV/_ .$57'^K H_X15?[@-/Z_+LA_P!DP[L_'#_AF;XK=O .L_\
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M(_\ "+I_SS%'_"+I_P \Q1]?EV0?V5#NS\;O^&9_BI_T(6L_]^1_C1_PS/\
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M7A\MA1FIIO0ZRJ\O>BBO(1](BO)T-9\O4T451D]B%^U-HHJT9A1115 %%%%
M!1110 4444 %%%%3(3"D]***A;B%HHHK4H**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ H'6BBDQHGCJ9.WUHHK,I;,?)UJ!^IHHIH1">M,HHJT2
M%%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
C*** "BBB@ HHHH **** "G#I1128T30U=@ZFBBLV5'<__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>formposam_018.jpg
<TEXT>
begin 644 formposam_018.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (/ @X# 2(  A$! Q$!_\0
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MHIF^C?0 ^BF;Z-] #Z*9OHWT /HIF^C?0 ^BF;Z-] #Z*9OHWT /HIF^C?0
M^BF;Z-] #Z*9OHWT /HIF^C?0 ^BF;Z-] #Z*9OHWT /HIF^C?0 ^BF;Z-]
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MDW_Z'7Q-_P"!,?\ \11_PI-_^AU\3?\ @3'_ /$5Z?10!YA_PI-_^AU\3?\
M@3'_ /$4?\*3?_H=?$W_ ($Q_P#Q%>GT4 >8?\*3?_H=?$W_ ($Q_P#Q%'_"
MDW_Z'7Q-_P"!,?\ \17I]% 'F'_"DW_Z'7Q-_P"!,?\ \11_PI-_^AU\3?\
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M>UQ!/#8C$^WP<>6F:-%,W-3Z]<^8"BBB@ HHHH **** "BBB@ HHHH ****
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M*E+ED.HHHJR0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MI#2U5N;E+:&265UBB1=S.W\*T 3!Q3S7QU\,?VZ[/QQ^TOK'@J>W@M?"4LS6
M&BZF[X\VZB.UO^ R[UV5]A(^2U!C"K"K\))7EU__ ,E]TK_L'2UZAVKR^_\
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MT;: *_F7']R/_OJCS+C^Y'_WU5C;1MH K^9<?W(_^^J/,N/[D?\ WU4U&U:
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MV)+I?Q \6Z9IOC?PWX47P>_D2Z5JVX7&K3JF]T7Y&VIM;Y67^*OJKX5^,_\
MA8_PY\->*?LQLSK&GP7IM_\ GEO7=M_6@#KZ*** "BBB@ HHHH X[XH#0O\
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M & =*\V^+,WVE=-TM/OW$^ZO2&)W"O,-<7^V?BCI\/WELTWM7'B?AY3NP/\
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M\W\9,WQ#^*.GZ#'N?3],_?77^R]>Q11JBJJCY1]VO-?@EX;EM-'N-;OAOO\
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M[-.DMCLBNK%N6B;Y_P"]L_[XK[QL/B#9-*(-2@:PN/\ ;7Y:ZJQMQ:V4$/\
M<15J#5-$LM53R[FV69/>N#"X.>#HQIT9&]6M[67-4)K:Y@O(TE@:.9/[Z5:\
MI3_"*X6Y\!7.FRO/HFH2VK_\\F^Y4<7C75="=(=;T]MG_/Q#TKK^L3A_$B9>
MS_E.^\I1_"*/*7^ZM96D^)+#6EW6URKM_=KG;SXN>$;3Q%KN@MKMK_;.B6L=
M[J-GO^>WB?=L=O\ OFNR-2,H\YERRYN4U_%/B2#PY8[MN^Y?Y(HO[U9G@OPM
M+"7U74_GU*?YOF_@KR3]G'XTZ'^T9K7B+4H[>YMKK0[S[*MI=[?WJ?PRI_LU
M]&*@Q7%3C]8E[27PFLOW7N1%V)_=6E\I?[HI"56J[:A GW[F-/\ >D6O3.7G
M'3VT<\;QLJLC+M*UY=8;O /C)K:4D:3?M^ZW?=1Z^4_VK_VT/$/A/XY:1IG@
M74%DT+PK+OU]5^[>NWRRV_\ P!/F_P!ZO>[[XJM\</"NGW'@K2)+R*]B6Z@N
MY?X*YZU.2CSQ^(O"YA14Y4.8]]N;RUL+1IYY(X8%^;>YKQOXK?M*Z)X)TN6+
M28&UC6)?W5M#"OR,]<[X;T*?6["]N?'GB"57TQ?WMNC;/DIWPG\ 6WC_ ,63
M>*[G34LM#MFV6%O_ ,]?]ZNBA*-6'M#&M3K1J<OPF5\*_@]XU\0K-XA\1WG]
MEW>J?O7$?^N16KV_PM\)O#_AH^:EHMU=$?-<7'S%J[;9BE)QUYJY2YS.-&,?
M>D,2%438JJJ?W:CFMHIXMLD:NG]UEJU25C.//N=2T.*U7X=VSSFZTJ1K"Z_V
M/NU17Q/J_AF58M;M/M-O_P _,*UZ"%QUJ*:%)@RR*K)Z-7%+"Z\U)\IK&I_,
M<]-XYT.UT"_UN:\BBTZP@>ZN9&_Y9Q*N]FKS7X2?M0>'?B]X0U#5],M+BTU"
MSNGM9=,N5VRIS^Z;_<=-K?\  J\&_;G\>:'H7B'P_P" U>^TNTU#_B8:O<VM
MG/*KQ1?<B^1&^]\U>2^!?CCX5^'?QH\->)=,-]<6MXRZ1J=HFE76Q(&^Y<?<
M^\FQ4KRZF,KPQ,<+R?%]H[:>'IRI>UYC]!?#WA6?6+W^V=;^>5O]5;M_!7=K
M"O\ =6DA*/ K+]QEW5,1FO;I48TCSY2YAGE+_=6EV+_=6GT5TDD?E+_=6CRE
M_NK4E% $?E+_ '5KS*]3;\?=*_[!TM>HUY=?_P#)?=*_[!TM 'J"]*;OIR_=
M%?G+_P %I-6O=&^%?P[?3[ZXL'DUJ?>;:5HR_P"X_P!F@#]%_-]UI4^=*_#W
M_@E#XFU;5/VP])@O=4O;R'^R;\^7<7+.OW/1J_<+^.@!LCK"K,[*B_WFJO;:
MK:7DFR"YAE?^ZC5Y;^U26/P(\4*A^9TB7&[;O_>K\M>(Z!H^L_"7P#HVKP>%
M]"\.:GJTMAHUKJME<3L]NEU\C2MYK,NY?EH ^S,48KY8M_B3XM\ >/[#P3<Z
M_)XC@3Q!9V1U:]"_:&BEMVE=)=OR[MWW?]FI-9^)GC3Q;X[7PKHVO6NE12^,
MKS2'NU3?*MK!9)/M7_;W;J".8^I**IV4+6]M%$\K7+HBJ97^\_\ M&KE!844
M44 >8_M(:IJ>B? _QC?:-J:Z/J=O9;[?4&D\KR&W+\^_M7R=\/M;^&U_XFT%
MK?QK^T)<W4LZ[5U1;_[(S;O^6NZ+;MKZW^/^CZ9XA^#?B_3]<U"VT?2KBQ9+
MB^O6_<P+N^^U?-GP[_:3EO=6T/19?VB?A_XAE>1('BMEB2:Z_P!E%V_>H ^V
M$^^U/IB?Q4^@ HHHH **** "BBB@#RCQ7_R7?PA_U[2_^@O7JR]*\I\5_P#)
M=_"'_7M+_P"@O7JR]* %HHHH **** "BBD- $*2[A]VL[Q!?_8](NI?N;8F-
M?#/[5&L>*-5_:3&@V'BS4]!TN#1&N/L]C*R[GW+\WWJ/V9_%7B.+4OB5H.K^
M);W7K>WMH'M?MS;W3=+LK6OAJD</[?[)X^$SC#5\U_LO_EX?7OPDMF7P])<O
M]^XDWUWX'2L'PE8K8>'+&#;TB7=6]ZUQ48\E,]_$RYZ\F-;[U<"G_%0?$1OX
M[>P7_P ?KM=4O%L+">Y;Y0B[C7*_#:T9[&ZU*4?O;R5GKDQ#YZD:84_=C*1V
MV*;3LTM>F8$;#*U%- DT7ERJKJW\+U,&K@O'/Q5T_P */]CMQ_:6L/\ *EI%
MU_X%4<M_B,I5(P]XY+]H#Q'X6^"GP[UCQGJ$XTV2RB_T-4;;YMPWRQ)M_B^?
M;7Y&:MXGU"YU6[\8WNN2_P!NZBTK:[Y4_P ]Q:R_\?%O_N[/E6OU;UGX"#X]
MP0R?%"![K3$;S8-(1V38W^WMJ9_V'O@YM^;PE&__ &V>LG0IVE'^8X,1'$XJ
M=.K2ER\I\1Z+\:+/P'JGAKX@> 1<W+V<":?/;16+RQ75@WWXEV?\M4;9\W^Q
M7WI#I'Q,UN)9I=3MK!)55E$/\-=AX0^%GA'P-X?L]%T;0+"ST^SW""$0*VS^
M*NOC18TVH<"N/ 8/ZC3]GS<QZV*E]:ES2]T\G7X4>++K_C[\;73C^)45JJZW
M^S])?Z#J$4&O7/\ :\L#):W%S\\43_WG3^*O:,>]&/>O4./ZO3/S;L/^"8WQ
M#L+7RG^(FB7+NSO+,^E-OE9O[_SU]/\ [(OP&\6?L\>#=3\->(?$MCXATY[E
MKJQ6TM?L_P!EW?>3[W*_=KZ#//%>2_&KX@7&EPP^&-#'G:_J?[H(GWXE;O5Q
M]^7*9TL'1P\Y5:<?>D>3_&*YE\?_ !#2V\/^;_8M@W_$VN(ON-7TQX5.GQ:!
M91Z5&L=DD>V)$_A%<[\//AI9>#/"']FR(LUW=+ONY6_Y:O6/X4NY/!'B270K
MJ3_19_FMFKEJ2C2J<L?A/?BOK5&WVHGJJMFGU"G^]4U;GG!1110 4444 1[3
M1M8?=VBI**BP#$^1*?115@%%%% !1110 5Y=?_\ )?=*_P"P=+7J->77_P#R
M7W2O^P=+0!Z@OW17$_$;X.^"OC#9V5IXT\,Z;XFM;.5I[:+4X%F2)V7:64?2
MNV7[HI: /+O W[,_PJ^&?B&+7O"G@#0O#^M11/$E[I]FD<JHWWEW"O4%^Z*6
MB@#&\2^&-/\ %FCW.EZK;I=V$^SS(7_BVMNJCX@\"Z-XH\+_ /"/:C917.E>
M4L:PLO$>W[C+_=9:Z>B@#RJW_9X\(1>$KO06@NIC=3K=2:K-<;K\SHNQ)?-Q
M]Y4^5?1:UO"WP8\)>"WM9=-TI$G@O)=0^TS'=,]S+%Y3RNW\3,GRUW]% !11
M10 4444 <WXUOY++P_>BVBLKF_E39:VE^ZHD\G]WYOO5\P^*M$\<_$^\T_PG
M/X?\!^$M06\M[U[M'4W<"QS(_P"Z1'W;F5=E7_VEM7T?PO\ M!>"?$?CNQU+
M4/ ^FZ-<2V*V]I+=6\6L^<GE.Z)_'Y6_:U>(OX&TU/AUX:\7WF@W/_"__&^N
MP:U8W'V5O[3M8OM"+*KO_P LHOLZ/_WW0!^CR??:GTQ/OM3Z "BBB@ HHHH
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M%C:6B[%NK-OF1_\ @&Y5:O:-)^'^O?$:Z35/%\S6UENW1:8C<"O2/.^L<_\
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MK?+_ '*A,OB5/@AXT^#3> ]53Q5XBU6]33)Q;.]I<1/=-+YLL^S;%_P.OO\
MV?+2;1]W<U 'P%\3/AQJ_C?3?B?9Z-+J4MWHGBBWNKF+2I_*NWB5;?<T3_WU
M56:G#X4-\2M'\:>(/"<'Q!UV>V@MI;:Z\>7;HVHF+?OM4@EB1D_N[Z^S/ 7P
MP\/_  XDUR31()DGUB\:_O9;B=I7EE8!?O,?]FNPV4 ?(GB?QA>_'?X5^*M
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M 6-PHR*K_8_^F\W_ 'W1]C_Z;S?]]T 6-U&ZJ_V/_IO-_P!]T?8_^F\W_?=
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M^ BK5%% 'E'BO_DN_A#_ *]I?_07KU9>E>4^*_\ DN_A#_KVE_\ 07KU9>E
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MA=2^5!.ZNX=O^ J:P? _[6'PG^(OB:W\.^'?&5KJ>M7"[HK1()5=_P#OI*\
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MK^M?!6TM=%M[Z)#>'6+JXM]+>5D5'V2RMN^9]OW&H _0=*?3$^^U/H ****
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M!>O5EZ4 +4<JY%24QZ /&?C3+_:OB#0M*_ORUQOC9Y/%7C+3]#MF^>5D1O\
M9VUN^,[];GXI/*[?NK"#?O\ [KTSX$Z:WB3Q5K'B>=?D5O*B#_WO[U>=4_?8
MCE_E,ML/_BD>Y6%K%86L5M$JI%$NQ5KPSX@:Q=?&/QK#X*T>5H]%LY=^HW"?
MQ;?X*Z;XT_$*?0K6'P_HS>=XBU3]TB)_RR7^_71?"CX<P?#WPTMLW[S49QON
M[@?QO7JQ]V/,5_=.HT/1+3P]IEKI]E&L-M NU$6M*BBL2PHHHJ@"BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "O+K_ /Y+[I7_ &#I:]1KRZ__ .2^Z5_V#I: /4%^Z*6D7[HI
M: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#RCQ7
M_P EW\(?]>TO_H+UZLO2O*?%G_)=_"'_ %[2_P#H+UZJ.E  !@&HIG$<>YOX
M:E)S63XEO%L-!OIVZ) __H-!$O=B?+GCGQ"WV_Q'<Q?ZVZG^RQ?[C5[!I5_9
M?!CX3P7-\0\XBW*G\4LK?=6O#/ =LOBWXAVGGRJFGZ=NO;IW^Y\OS5Z/I=G/
M\>?'YOYU9/!NC-M@B_Y^'KGPU+WI59'/&?/R_P!TV_@OX(O-4OI_'/B-&;5[
M]MUM$_\ RQ2O:%Z4V)5C 10JHO15J:NJ4N8Z0HHHJ2@HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *\NO_P#DONE?]@Z6O4:\NO\ _DONE?\ 8.EH ]07[HI:1?NBEH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **XGXL>*;GPEX
M*O;ZQ*K?R%;>V9AN"RMPK5RO@+5=8\.>.'\-:IJ4FJ03Z5_:JW$WWXFRBNO_
M 'TU %CQ;Q\=/!__ %[S?^@/7J>XGMQ7SQH_QE\&?%3X_:!!X5UZVUF:PM9?
MM*6[;O*^5ZX7]J7X^_$7P=\8-!\(>"-5L-*M9[&6[NI;FR6Y9OE^3[WW:NG3
ME5ERQ.'%XNG@J,J^(ERQB?79F2%&:2143NS_ "UPOQPUD:-\.-5N"VQMB[:_
M,OX^_'SXR>,KBU\"Z[XQA2QE3^TOM>CVWV.;>C?ZK>K_ ':W=7_:F^)7QZ\'
M36ESJMAX8BT=6@O+=;9;AKIU3=YK-_!OK+%RC@OXX994CQ#^ZR^7-*4>;Y'N
MGPNAOO%J2^'M(;9<:O+NO+C=_JHE^_7V5X5\,V7A+0K32K%1%;VR[<+QN:OR
M,T?QGX^^&?A%_C/I-\NG>(H($LH-,F_>V4MJW_+7;]UG9:GM_P#@I?\ 'BWN
MM)ENK[1)K6>YB22)-,5'9&J,'6CCZ<OJWPQ.N6$E@.6E5^(_8=*?5"WOHS;Q
M/(ZH[(K-4WV^V_YZK6I99HJM]OMO^>JT?;[;_GJM %FBJWV^V_YZK1]OMO\
MGJM %FBJWV^V_P">JT?;[;_GJM %FBJWV^V_YZK1]OMO^>JT 6:*K?;[;_GJ
MM'V^V_YZK0!9HJM]OMO^>JT?;[;_ )ZK0!9HJM]OMO\ GJM'V^V_YZK0!9HJ
MM]OMO^>JT?;[;_GJM %FBJWV^V_YZK1]OMO^>JT 6:*K?;[;_GJM'V^V_P">
MJT 6:*K?;[;_ )ZK1]OMO^>JT 6:*K?;[;_GJM'V^V_YZK0!9HJM]OMO^>JT
M?;[;_GJM %FBJWV^V_YZK1]OMO\ GJM %FBJWV^V_P">JT?;[;_GJM %FBJW
MV^V_YZK1]OMO^>JT 6:*K?;[;_GJM'V^V_YZK0!9KRZ__P"2^Z5_V#I:])^W
MP?\ /5:\RO95?X^:9M;_ )ALO_H- 'JB_=%+2+]T4M !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% '/>-O"D'C7PWJ&D3R- +B/:LR?>B;
M^%EKGO GP]N]"U2XU;6M1_M34W@6RBDV[4BMTV_+_P "*[J]"I#0!XOJOA[2
M]!^.GA5]-TRRL'EM9O->TMEBW?*_WMM<1^T1^RSX@^+7Q"TKQ7X=\51Z#<VM
MF]I+%-$KHZM_P&O2/%0Q\=?" _Z=9O\ T%Z]0PLG ZU<)2A+FB<V(H4\72E2
MJQYHGPH?^";^J^+/$BZMXL^)-RDT%MY$!TNUB_O?Q;UK%\0?\$O-0AU*9O#O
MQ+OH["^BBBO_ +=;QK+L5]WR;$_]"K]!A$IZ4XQKBHK?O_XOO$X'#T\ME&6%
MCR\I\8^-O^">=UXN\"7'A\_%36GA:)$BCEL;58OE^[]U*\>L/^"1VLM?:=_:
M'Q':2R@GBEE2*W7>VW_@-?I@%5*..U8X>G'"1E&A[O,=U24JTN>9#;VJ01)'
MMW;$5=WK4WE)_<7_ +YJ2BMB"/RD_N+_ -\T>4G]Q?\ OFI** (_*3^XO_?-
M'E)_<7_OFI** (_*3^XO_?-'E)_<7_OFI** (_*3^XO_ 'S1Y2?W%_[YJ2B@
M"/RD_N+_ -\T>4G]Q?\ OFI** (_*3^XO_?-'E)_<7_OFI** (_*3^XO_?-'
ME)_<7_OFI** (_*3^XO_ 'S1Y2?W%_[YJ2B@"/RD_N+_ -\T>4G]Q?\ OFI*
M* (_*3^XO_?-'E)_<7_OFI** (_*3^XO_?-'E)_<7_OFI** (_*3^XO_ 'S1
MY2?W%_[YJ2B@"/RD_N+_ -\T>4G]Q?\ OFI** (_*3^XO_?-'E)_<7_OFI**
M (_*3^XO_?-'E)_<7_OFI** (_*3^XO_ 'S1Y2?W%_[YJ2B@"/RD_N+_ -\T
M>4G]Q?\ OFI** (_*3^XO_?->97B[?C]IGOITM>HUY=?_P#)?=*_[!TM 'J"
M_=%+2+]T4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M2-TI:* /*?BA\-O%'BKQ'HNN^$_%MMX5U#3U=)6NM+6]6564_P!YUV_>K&_X
M5[\;_P#HKND_^$M%_P#':]OHH \1_P"%>_'#_HKND_\ A+1?_':X+Q_?_&SP
M%XM\$:&/B1I>HMXGOY;+S_\ A'(D^R[(O,W??^:OJKM7(^-O&/AOP9':W7B&
M\M;3YV\AYEW.K8^;;_=^6@#@/^%>_'#_ **[I/\ X2T7_P =H_X5]\</^BNZ
M3_X2T7_QVO7=(U:TUS2[74=/G6[LKF-989X_NNK?Q5HT >(_\*^^.'_17=)_
M\):+_P".T?\ "OOCA_T5W2?_  EHO_CM>W44 ?,7Q:'QN^%?PXUWQ9_PLO2]
M7?3(//%@GAB)/-^=5V[O-_VJZ+2O!OQNU33+6[_X6QI,)GB279_PC$3;=W_;
M6NU^*_Q(MO!NF&RM]+;Q!K%U'OBTI%W[XMV&=O\ 9KM-$U&#5=)M+R KY,\:
MNNV@#R/_ (5]\</^BNZ3_P"$M%_\=H_X5]\</^BNZ3_X2T7_ ,=KVZB@#Q'_
M (5]\</^BNZ3_P"$M%_\=IR?#WXV[_F^+NE[?^Q6B_\ CM>V51U.^_LS3[FY
M\MI?)C:38O\ %0!\K_ WQ#\;/C5X/NM<_P"%@:7H31:C=6'V=O#B2[O*E>+?
M]_\ BV[J](_X5]\</^BNZ3_X2T7_ ,=KK?A5\2/#_C[199](MO[+EAN'BN=-
MFC2*:&7=_$B_WOO5Z#0!XC_PK[XX?]%=TG_PEHO_ ([1_P *^^.'_17=)_\
M"6B_^.U[=10!XC_PK[XX?]%=TG_PEHO_ ([7G7A_6OC?K?QJ\5_#]_B%I,*Z
M'8VM[_:7_"/)_I'GJ_R[-_\ #MKZJNKB.RMY9YW"11JS,_\ =6O,]"^+N@ZI
MXOAM)-(N=(?4T9M/U6[CB5-11,?<9&W;?F_BH QO^%??'#_HKND_^$M%_P#'
M:/\ A7WQP_Z*[I/_ (2T7_QVO:D?<U24 >(_\*^^.'_17=)_\):+_P".T?\
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MWUO$WE,8?X6K:H \1_X5]\</^BNZ3_X2T7_QVC_A7WQP_P"BNZ3_ .$M%_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7(_$'X>:-\3O#DVC:Y:)<0-\\;_ ,<$G\+I_=;FNNHH \X\!?#?4]'OFU?Q
M3K2>(M=1?L\%PD'E100^BK_>_P!JO1$I]% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
K 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>13
<FILENAME>tvgn-20241231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaaPGbP9z5Z86ekhvWB4bfla7ysh4N7NOioTMGG2wcYM -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:TVGN="http://tevogen.com/20241231" elementFormDefault="qualified" targetNamespace="http://tevogen.com/20241231">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://tevogen.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/StatementsOfOperations" id="StatementsOfOperations">
          <link:definition>00000004 - Statement - Consolidated Statements of Operations</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit" id="StatementsOfChangesInStockholdersDeficit">
          <link:definition>00000005 - Statement - Consolidated Statements of Changes in Stockholders' Deficit</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
          <link:definition>00000006 - Statement -  Consolidated Statements of Cash Flows</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/NatureOfBusiness" id="NatureOfBusiness">
          <link:definition>999007 - Disclosure - NATURE OF BUSINESS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/Development-stageRisksAndLiquidity" id="Development-stageRisksAndLiquidity">
          <link:definition>999008 - Disclosure - DEVELOPMENT-STAGE RISKS AND LIQUIDITY</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
          <link:definition>999009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/BusinessCombination" id="BusinessCombination">
          <link:definition>999010 - Disclosure - BUSINESS COMBINATION</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/EarnoutShares" id="EarnoutShares">
          <link:definition>999011 - Disclosure - EARNOUT SHARES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/PropertyAndEquipmentNet" id="PropertyAndEquipmentNet">
          <link:definition>999012 - Disclosure - PROPERTY AND EQUIPMENT, NET</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/AccruedExpensesAndOtherLiabilities" id="AccruedExpensesAndOtherLiabilities">
          <link:definition>999013 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/Debt" id="Debt">
          <link:definition>999014 - Disclosure - DEBT</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/Leases" id="Leases">
          <link:definition>999015 - Disclosure - LEASES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>999016 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/Stock-basedCompensation" id="Stock-basedCompensation">
          <link:definition>999017 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/StockholdersDeficit" id="StockholdersDeficit">
          <link:definition>999018 - Disclosure - STOCKHOLDERS&#8217; DEFICIT</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/NetLossPerShare" id="NetLossPerShare">
          <link:definition>999019 - Disclosure - NET LOSS PER SHARE</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>999020 - Disclosure - INCOME TAXES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
          <link:definition>999021 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/SegmentReporting" id="SegmentReporting">
          <link:definition>999022 - Disclosure - SEGMENT REPORTING</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>999023 - Disclosure - SUBSEQUENT EVENTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>999024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
          <link:definition>999025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/BusinessCombinationTables" id="BusinessCombinationTables">
          <link:definition>999026 - Disclosure - BUSINESS COMBINATION (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/PropertyAndEquipmentNetTables" id="PropertyAndEquipmentNetTables">
          <link:definition>999027 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/AccruedExpensesAndOtherLiabilitiesTables" id="AccruedExpensesAndOtherLiabilitiesTables">
          <link:definition>999028 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/LeasesTables" id="LeasesTables">
          <link:definition>999029 - Disclosure - LEASES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/Stock-basedCompensationTables" id="Stock-basedCompensationTables">
          <link:definition>999030 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/StockholdersDeficitTables" id="StockholdersDeficitTables">
          <link:definition>999031 - Disclosure - STOCKHOLDERS&#8217; DEFICIT (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/NetLossPerShareTables" id="NetLossPerShareTables">
          <link:definition>999032 - Disclosure - NET LOSS PER SHARE (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
          <link:definition>999033 - Disclosure - INCOME TAXES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/NatureOfBusinessDetailsNarrative" id="NatureOfBusinessDetailsNarrative">
          <link:definition>999034 - Disclosure - NATURE OF BUSINESS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative" id="Development-stageRisksAndLiquidityDetailsNarrative">
          <link:definition>999035 - Disclosure - DEVELOPMENT-STAGE RISKS AND LIQUIDITY (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails" id="ScheduleOfFairValueMeasurementDetails">
          <link:definition>999036 - Disclosure - SCHEDULE OF FAIR VALUE MEASUREMENT (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails" id="ScheduleOfFairValuesOfWarrantsDetails">
          <link:definition>999037 - Disclosure - SCHEDULE OF FAIR VALUES OF WARRANTS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" id="ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
          <link:definition>999038 - Disclosure - SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails" id="ScheduleOfPropertyAndEquipmentUsefulLifeDetails">
          <link:definition>999039 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>999040 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails" id="ScheduleOfNetLiabilitiesAcquiredInMergerDetails">
          <link:definition>999041 - Disclosure - SCHEDULE OF NET LIABILITIES ACQUIRED IN MERGER (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/BusinessCombinationDetailsNarrative" id="BusinessCombinationDetailsNarrative">
          <link:definition>999042 - Disclosure - BUSINESS COMBINATION (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/EarnoutSharesDetailsNarrative" id="EarnoutSharesDetailsNarrative">
          <link:definition>999043 - Disclosure - EARNOUT SHARES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ScheduleOfPropertyAndEquipmentDetails" id="ScheduleOfPropertyAndEquipmentDetails">
          <link:definition>999044 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/PropertyAndEquipmentNetDetailsNarrative" id="PropertyAndEquipmentNetDetailsNarrative">
          <link:definition>999045 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" id="ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails">
          <link:definition>999046 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/DebtDetailsNarrative" id="DebtDetailsNarrative">
          <link:definition>999047 - Disclosure - DEBT (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ScheduleOfMinimumRentalPaymentsUnderOperatingLeasesDetails" id="ScheduleOfMinimumRentalPaymentsUnderOperatingLeasesDetails">
          <link:definition>999048 - Disclosure - SCHEDULE OF MINIMUM RENTAL PAYMENTS UNDER THE OPERATING LEASES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
          <link:definition>999049 - Disclosure - LEASES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails" id="ScheduleOfRestrictedStockAndRsuActivityDetails">
          <link:definition>999050 - Disclosure - SCHEDULE OF RESTRICTED STOCK AND RSU ACTIVITY (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ScheduleOfStock-basedCompensationExpenseDetails" id="ScheduleOfStock-basedCompensationExpenseDetails">
          <link:definition>999051 - Disclosure - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/Stock-basedCompensationDetailsNarrative" id="Stock-basedCompensationDetailsNarrative">
          <link:definition>999052 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails" id="ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails">
          <link:definition>999053 - Disclosure - SCHEDULE OF RECONCILIATION OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/StockholdersDeficitDetailsNarrative" id="StockholdersDeficitDetailsNarrative">
          <link:definition>999054 - Disclosure - STOCKHOLDERS&#8217; DEFICIT (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ScheduleOfReconciliationOfNetLossDetails" id="ScheduleOfReconciliationOfNetLossDetails">
          <link:definition>999055 - Disclosure - SCHEDULE OF RECONCILIATION OF NET LOSS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails" id="ScheduleOfAnti-dilutiveNetLossPerShareDetails">
          <link:definition>999056 - Disclosure - SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical" id="ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical">
          <link:definition>999057 - Disclosure - SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details) (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/NetLossPerShareDetailsNarrative" id="NetLossPerShareDetailsNarrative">
          <link:definition>999058 - Disclosure - NET LOSS PER SHARE (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails" id="ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails">
          <link:definition>999059 - Disclosure - SCHEDULE OF RECONCILIATION OF INCOME TAX BENEFIT AT THE FEDERAL STATUTORY INCOME TAX RATE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" id="ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
          <link:definition>999060 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ScheduleOfValuationAllowanceForNetDeferredTaxAssetsDetails" id="ScheduleOfValuationAllowanceForNetDeferredTaxAssetsDetails">
          <link:definition>999061 - Disclosure - SCHEDULE OF VALUATION ALLOWANCE FOR NET DEFERRED TAX ASSETS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
          <link:definition>999062 - Disclosure - INCOME TAXES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
          <link:definition>999063 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>999064 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="tvgn-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="tvgn-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="tvgn-20241231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="tvgn-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
    <element id="TVGN_TevogenBioMember" name="TevogenBioMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_SemperParatusMember" name="SemperParatusMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_LoanAgreementMember" name="LoanAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_ProbabilityOfFutureLiquidityMember" name="ProbabilityOfFutureLiquidityMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_EarnoutSharesMember" name="EarnoutSharesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_TevogenBioCommonStockMember" name="TevogenBioCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_SponsorMember" name="SponsorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_ComputerAndSoftwareMember" name="ComputerAndSoftwareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_ThePatelFamilyLLPMember" name="ThePatelFamilyLLPMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_AdditionalAmountPurchaseOptionMember" name="AdditionalAmountPurchaseOptionMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_PolarMultiStrategyMasterFundMember" name="PolarMultiStrategyMasterFundMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_TwoThousandTwentyFourPlanMember" name="TwoThousandTwentyFourPlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_PerformanceBasedRSUsMember" name="PerformanceBasedRSUsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_ServiceBasedRestrictedStockMember" name="ServiceBasedRestrictedStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_SeriesAOnePreferredStockMember" name="SeriesAOnePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_PublicWarrantsMember" name="PublicWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_SponsorAdvisoryServicesFeeMember" name="SponsorAdvisoryServicesFeeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_WifeOfChiefExecutiveOfficerMember" name="WifeOfChiefExecutiveOfficerMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_MehtaphoricConsultingIncMember" name="MehtaphoricConsultingIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_DrManmohanPatelMember" name="DrManmohanPatelMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_KRHPLLCMember" name="KRHPLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_LoanAgreementNoncurrent" name="LoanAgreementNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_ChangeInFairValueOfConvertiblePromissoryNotes" name="ChangeInFairValueOfConvertiblePromissoryNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_LossOnIssuanceOfCommitmentShares" name="LossOnIssuanceOfCommitmentShares" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_StockIssuedDuringPeriodValueNewIssuesTwo" name="StockIssuedDuringPeriodValueNewIssuesTwo" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_StockIssuedDuringPeriodSharesNewIssuesTwo" name="StockIssuedDuringPeriodSharesNewIssuesTwo" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_StockIssuedDuringPeriodValueNewIssuesOne" name="StockIssuedDuringPeriodValueNewIssuesOne" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_StockIssuedDuringPeriodSharesNewIssuesOne" name="StockIssuedDuringPeriodSharesNewIssuesOne" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_MergerNetOfRedemptionsAndTransactionCosts" name="MergerNetOfRedemptionsAndTransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement" name="StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithLoanAgreement" name="StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithLoanAgreement" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_StockIssuedDuringPeriodValueContributionFromRelatedParty" name="StockIssuedDuringPeriodValueContributionFromRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_StockIssuedDuringPeriodSharesContributionFromRelatedParty" name="StockIssuedDuringPeriodSharesContributionFromRelatedParty" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits" name="StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits" name="StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_LossOnPreferredStockIssuance" name="LossOnPreferredStockIssuance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_CashAcquiredInConnectionWithReverseRecapitalization" name="CashAcquiredInConnectionWithReverseRecapitalization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_ProceedsFromIssuanceOfSeriesCPreferredStock" name="ProceedsFromIssuanceOfSeriesCPreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance" name="NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_ReverseRecapitalizationTransactionFeesIncludedInAccruedExpensesAndOtherLiabilities" name="ReverseRecapitalizationTransactionFeesIncludedInAccruedExpensesAndOtherLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_RepurchaseOfSeriesBPreferredStock" name="RepurchaseOfSeriesBPreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_DisclosureDevelopmentstageRisksAndLiquidityAbstract" name="DisclosureDevelopmentstageRisksAndLiquidityAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_DevelopmentStageRisksAndLiquidityTextBlock" name="DevelopmentStageRisksAndLiquidityTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_DisclosureEarnoutSharesAbstract" name="DisclosureEarnoutSharesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_EarnoutSharesDisclosureTextBlock" name="EarnoutSharesDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_DisclosureLeasesAbstract" name="DisclosureLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_FreestandingAndEmbeddedCommonStockOptionsPolicyTextBlock" name="FreestandingAndEmbeddedCommonStockOptionsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_PropertyAndEquipmentUsefulLifeTableTextBlock" name="PropertyAndEquipmentUsefulLifeTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_ScheduleOfCompanyLeaseLiabilitiesTableTextBlock" name="ScheduleOfCompanyLeaseLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_ScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock" name="ScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_BusinessCombinationSharesExchangeRatio" name="BusinessCombinationSharesExchangeRatio" nillable="true" xbrli:periodType="instant" type="xbrli:pureItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_GrantDrewFromRelatedParty" name="GrantDrewFromRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_DerivativeLiabilitiesFairValueIssuance" name="DerivativeLiabilitiesFairValueIssuance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_EquitySecuritiesTerm" name="EquitySecuritiesTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_FreeStandingPurchaseOptions" name="FreeStandingPurchaseOptions" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_EmbeddedOptions" name="EmbeddedOptions" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_MergerTransactionCostsLimitedToCashAcquired" name="MergerTransactionCostsLimitedToCashAcquired" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility" name="StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_OperatingLeasesIncrementalBorrowingRates" name="OperatingLeasesIncrementalBorrowingRates" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing" name="VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture" name="SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture" name="CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_StockIssuedDuringPeriodSharesConversionOfLiabilities" name="StockIssuedDuringPeriodSharesConversionOfLiabilities" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_StockIssuedDuringPeriodValueConversionOfLiabilities" name="StockIssuedDuringPeriodValueConversionOfLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_ClassOfWarrantOrRightIssued" name="ClassOfWarrantOrRightIssued" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_WarrantsRedemptionDescription" name="WarrantsRedemptionDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_StockRepurchase" name="StockRepurchase" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest" name="IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_DeferredTaxAssetsAccruedExpensesAndOther" name="DeferredTaxAssetsAccruedExpensesAndOther" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_DeferredTaxAssetsOperatingLeaseLiabilities" name="DeferredTaxAssetsOperatingLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_DeferredTaxAssetsFixedAssets" name="DeferredTaxAssetsFixedAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures" name="DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_DeferredTaxLiabilitiesRightOfUseAsset" name="DeferredTaxLiabilitiesRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_IncreasesRecordedToIncomeTaxProvision" name="IncreasesRecordedToIncomeTaxProvision" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_TaxableIncomeLimitationPercentage" name="TaxableIncomeLimitationPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_SponsorFeesPayable" name="SponsorFeesPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_CommonStock0.0001ParValuePerShareMember" name="CommonStock0.0001ParValuePerShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_WarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember" name="WarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility" name="StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_PrivateInvestorMember" name="PrivateInvestorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_PrivateWarrantsMember" name="PrivateWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_LinesOfCreditNoncurrent" name="LinesOfCreditNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_LoanAgreement" name="LoanAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>14
<FILENAME>tvgn-20241231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://tevogen.com/role/Cover" xlink:href="tvgn-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/BalanceSheets" xlink:href="tvgn-20241231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/BalanceSheetsParenthetical" xlink:href="tvgn-20241231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/StatementsOfOperations" xlink:href="tvgn-20241231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit" xlink:href="tvgn-20241231.xsd#StatementsOfChangesInStockholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="tvgn-20241231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/NatureOfBusiness" xlink:href="tvgn-20241231.xsd#NatureOfBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Development-stageRisksAndLiquidity" xlink:href="tvgn-20241231.xsd#Development-stageRisksAndLiquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="tvgn-20241231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/BusinessCombination" xlink:href="tvgn-20241231.xsd#BusinessCombination" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/EarnoutShares" xlink:href="tvgn-20241231.xsd#EarnoutShares" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/PropertyAndEquipmentNet" xlink:href="tvgn-20241231.xsd#PropertyAndEquipmentNet" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/AccruedExpensesAndOtherLiabilities" xlink:href="tvgn-20241231.xsd#AccruedExpensesAndOtherLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Debt" xlink:href="tvgn-20241231.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Leases" xlink:href="tvgn-20241231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/CommitmentsAndContingencies" xlink:href="tvgn-20241231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Stock-basedCompensation" xlink:href="tvgn-20241231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/StockholdersDeficit" xlink:href="tvgn-20241231.xsd#StockholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/NetLossPerShare" xlink:href="tvgn-20241231.xsd#NetLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/IncomeTaxes" xlink:href="tvgn-20241231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/RelatedPartyTransactions" xlink:href="tvgn-20241231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SegmentReporting" xlink:href="tvgn-20241231.xsd#SegmentReporting" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SubsequentEvents" xlink:href="tvgn-20241231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="tvgn-20241231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="tvgn-20241231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/BusinessCombinationTables" xlink:href="tvgn-20241231.xsd#BusinessCombinationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/PropertyAndEquipmentNetTables" xlink:href="tvgn-20241231.xsd#PropertyAndEquipmentNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/AccruedExpensesAndOtherLiabilitiesTables" xlink:href="tvgn-20241231.xsd#AccruedExpensesAndOtherLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/LeasesTables" xlink:href="tvgn-20241231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Stock-basedCompensationTables" xlink:href="tvgn-20241231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/StockholdersDeficitTables" xlink:href="tvgn-20241231.xsd#StockholdersDeficitTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/NetLossPerShareTables" xlink:href="tvgn-20241231.xsd#NetLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/IncomeTaxesTables" xlink:href="tvgn-20241231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/NatureOfBusinessDetailsNarrative" xlink:href="tvgn-20241231.xsd#NatureOfBusinessDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative" xlink:href="tvgn-20241231.xsd#Development-stageRisksAndLiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfFairValueMeasurementDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfFairValuesOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfPropertyAndEquipmentUsefulLifeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="tvgn-20241231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfNetLiabilitiesAcquiredInMergerDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/BusinessCombinationDetailsNarrative" xlink:href="tvgn-20241231.xsd#BusinessCombinationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/EarnoutSharesDetailsNarrative" xlink:href="tvgn-20241231.xsd#EarnoutSharesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:href="tvgn-20241231.xsd#PropertyAndEquipmentNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/DebtDetailsNarrative" xlink:href="tvgn-20241231.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfMinimumRentalPaymentsUnderOperatingLeasesDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfMinimumRentalPaymentsUnderOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/LeasesDetailsNarrative" xlink:href="tvgn-20241231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfRestrictedStockAndRsuActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfStock-basedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="tvgn-20241231.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/StockholdersDeficitDetailsNarrative" xlink:href="tvgn-20241231.xsd#StockholdersDeficitDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfReconciliationOfNetLossDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfReconciliationOfNetLossDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfAnti-dilutiveNetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical" xlink:href="tvgn-20241231.xsd#ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/NetLossPerShareDetailsNarrative" xlink:href="tvgn-20241231.xsd#NetLossPerShareDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfValuationAllowanceForNetDeferredTaxAssetsDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfValuationAllowanceForNetDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/IncomeTaxesDetailsNarrative" xlink:href="tvgn-20241231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="tvgn-20241231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SubsequentEventsDetailsNarrative" xlink:href="tvgn-20241231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapOtherReceivablesNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaapDeferredCosts" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapDeferredCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaapConvertibleLongTermNotesPayable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapConvertibleLongTermNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_LoanAgreementNoncurrent" xlink:label="loc_TVGNLoanAgreementNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_TVGNLoanAgreementNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="loc_us-gaapBusinessCombinationAcquisitionRelatedCosts" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapBusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ChangeInFairValueOfConvertiblePromissoryNotes" xlink:label="loc_TVGNChangeInFairValueOfConvertiblePromissoryNotes" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_TVGNChangeInFairValueOfConvertiblePromissoryNotes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_LossOnIssuanceOfCommitmentShares" xlink:label="loc_TVGNLossOnIssuanceOfCommitmentShares" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_TVGNLossOnIssuanceOfCommitmentShares" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Deficit" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement -  Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaapPaidInKindInterest" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapPaidInKindInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashMergerRelatedCosts" xlink:label="loc_us-gaapNoncashMergerRelatedCosts" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNoncashMergerRelatedCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ChangeInFairValueOfConvertiblePromissoryNotes" xlink:label="loc_TVGNChangeInFairValueOfConvertiblePromissoryNotes" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_TVGNChangeInFairValueOfConvertiblePromissoryNotes" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_LossOnPreferredStockIssuance" xlink:label="loc_TVGNLossOnPreferredStockIssuance" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_TVGNLossOnPreferredStockIssuance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_LossOnIssuanceOfCommitmentShares" xlink:label="loc_TVGNLossOnIssuanceOfCommitmentShares" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_TVGNLossOnIssuanceOfCommitmentShares" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_CashAcquiredInConnectionWithReverseRecapitalization" xlink:label="loc_TVGNCashAcquiredInConnectionWithReverseRecapitalization" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_TVGNCashAcquiredInConnectionWithReverseRecapitalization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ProceedsFromIssuanceOfSeriesCPreferredStock" xlink:label="loc_TVGNProceedsFromIssuanceOfSeriesCPreferredStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_TVGNProceedsFromIssuanceOfSeriesCPreferredStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaapProceedsFromLinesOfCredit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromLinesOfCredit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance" xlink:label="loc_TVGNNonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_TVGNNonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="loc_us-gaapPaymentOfFinancingAndStockIssuanceCosts" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentOfFinancingAndStockIssuanceCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/NatureOfBusiness" xlink:title="999007 - Disclosure - NATURE OF BUSINESS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/Development-stageRisksAndLiquidity" xlink:title="999008 - Disclosure - DEVELOPMENT-STAGE RISKS AND LIQUIDITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/BusinessCombination" xlink:title="999010 - Disclosure - BUSINESS COMBINATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/EarnoutShares" xlink:title="999011 - Disclosure - EARNOUT SHARES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/PropertyAndEquipmentNet" xlink:title="999012 - Disclosure - PROPERTY AND EQUIPMENT, NET" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/AccruedExpensesAndOtherLiabilities" xlink:title="999013 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/Debt" xlink:title="999014 - Disclosure - DEBT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/Leases" xlink:title="999015 - Disclosure - LEASES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/CommitmentsAndContingencies" xlink:title="999016 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/Stock-basedCompensation" xlink:title="999017 - Disclosure - STOCK-BASED COMPENSATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/StockholdersDeficit" xlink:title="999018 - Disclosure - STOCKHOLDERS&#8217; DEFICIT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/NetLossPerShare" xlink:title="999019 - Disclosure - NET LOSS PER SHARE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/IncomeTaxes" xlink:title="999020 - Disclosure - INCOME TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/RelatedPartyTransactions" xlink:title="999021 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/SegmentReporting" xlink:title="999022 - Disclosure - SEGMENT REPORTING" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/SubsequentEvents" xlink:title="999023 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/BusinessCombinationTables" xlink:title="999026 - Disclosure - BUSINESS COMBINATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/PropertyAndEquipmentNetTables" xlink:title="999027 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/AccruedExpensesAndOtherLiabilitiesTables" xlink:title="999028 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/LeasesTables" xlink:title="999029 - Disclosure - LEASES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/Stock-basedCompensationTables" xlink:title="999030 - Disclosure - STOCK-BASED COMPENSATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/StockholdersDeficitTables" xlink:title="999031 - Disclosure - STOCKHOLDERS&#8217; DEFICIT (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/NetLossPerShareTables" xlink:title="999032 - Disclosure - NET LOSS PER SHARE (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/IncomeTaxesTables" xlink:title="999033 - Disclosure - INCOME TAXES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/NatureOfBusinessDetailsNarrative" xlink:title="999034 - Disclosure - NATURE OF BUSINESS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative" xlink:title="999035 - Disclosure - DEVELOPMENT-STAGE RISKS AND LIQUIDITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails" xlink:title="999036 - Disclosure - SCHEDULE OF FAIR VALUE MEASUREMENT (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails" xlink:title="999037 - Disclosure - SCHEDULE OF FAIR VALUES OF WARRANTS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="999038 - Disclosure - SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails" xlink:title="999039 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999040 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails" xlink:title="999041 - Disclosure - SCHEDULE OF NET LIABILITIES ACQUIRED IN MERGER (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:label="loc_TVGNBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="loc_TVGNBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts" xlink:label="loc_TVGNBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_TVGNBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_MergerTransactionCostsLimitedToCashAcquired" xlink:label="loc_TVGNMergerTransactionCostsLimitedToCashAcquired" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_TVGNBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts" xlink:to="loc_TVGNMergerTransactionCostsLimitedToCashAcquired" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/BusinessCombinationDetailsNarrative" xlink:title="999042 - Disclosure - BUSINESS COMBINATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/EarnoutSharesDetailsNarrative" xlink:title="999043 - Disclosure - EARNOUT SHARES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="999044 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:title="999045 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" xlink:title="999046 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/DebtDetailsNarrative" xlink:title="999047 - Disclosure - DEBT (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfMinimumRentalPaymentsUnderOperatingLeasesDetails" xlink:title="999048 - Disclosure - SCHEDULE OF MINIMUM RENTAL PAYMENTS UNDER THE OPERATING LEASES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/LeasesDetailsNarrative" xlink:title="999049 - Disclosure - LEASES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails" xlink:title="999050 - Disclosure - SCHEDULE OF RESTRICTED STOCK AND RSU ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:title="999051 - Disclosure - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="999052 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails" xlink:title="999053 - Disclosure - SCHEDULE OF RECONCILIATION OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/StockholdersDeficitDetailsNarrative" xlink:title="999054 - Disclosure - STOCKHOLDERS&#8217; DEFICIT (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfReconciliationOfNetLossDetails" xlink:title="999055 - Disclosure - SCHEDULE OF RECONCILIATION OF NET LOSS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockRepurchase" xlink:label="loc_TVGNStockRepurchase" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_TVGNStockRepurchase" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails" xlink:title="999056 - Disclosure - SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical" xlink:title="999057 - Disclosure - SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/NetLossPerShareDetailsNarrative" xlink:title="999058 - Disclosure - NET LOSS PER SHARE (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails" xlink:title="999059 - Disclosure - SCHEDULE OF RECONCILIATION OF INCOME TAX BENEFIT AT THE FEDERAL STATUTORY INCOME TAX RATE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest" xlink:label="loc_TVGNIncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_TVGNIncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsOther" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCredits" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="999060 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DeferredTaxAssetsAccruedExpensesAndOther" xlink:label="loc_TVGNDeferredTaxAssetsAccruedExpensesAndOther" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_TVGNDeferredTaxAssetsAccruedExpensesAndOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="loc_TVGNDeferredTaxAssetsOperatingLeaseLiabilities" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_TVGNDeferredTaxAssetsOperatingLeaseLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DeferredTaxAssetsFixedAssets" xlink:label="loc_TVGNDeferredTaxAssetsFixedAssets" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_TVGNDeferredTaxAssetsFixedAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures" xlink:label="loc_TVGNDeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_TVGNDeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilities" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="loc_TVGNDeferredTaxLiabilitiesRightOfUseAsset" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:to="loc_TVGNDeferredTaxLiabilitiesRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfValuationAllowanceForNetDeferredTaxAssetsDetails" xlink:title="999061 - Disclosure - SCHEDULE OF VALUATION ALLOWANCE FOR NET DEFERRED TAX ASSETS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/IncomeTaxesDetailsNarrative" xlink:title="999062 - Disclosure - INCOME TAXES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="999063 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/SubsequentEventsDetailsNarrative" xlink:title="999064 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>15
<FILENAME>tvgn-20241231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://tevogen.com/role/Cover" xlink:href="tvgn-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/BalanceSheets" xlink:href="tvgn-20241231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/BalanceSheetsParenthetical" xlink:href="tvgn-20241231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/StatementsOfOperations" xlink:href="tvgn-20241231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit" xlink:href="tvgn-20241231.xsd#StatementsOfChangesInStockholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="tvgn-20241231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/NatureOfBusiness" xlink:href="tvgn-20241231.xsd#NatureOfBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Development-stageRisksAndLiquidity" xlink:href="tvgn-20241231.xsd#Development-stageRisksAndLiquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="tvgn-20241231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/BusinessCombination" xlink:href="tvgn-20241231.xsd#BusinessCombination" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/EarnoutShares" xlink:href="tvgn-20241231.xsd#EarnoutShares" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/PropertyAndEquipmentNet" xlink:href="tvgn-20241231.xsd#PropertyAndEquipmentNet" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/AccruedExpensesAndOtherLiabilities" xlink:href="tvgn-20241231.xsd#AccruedExpensesAndOtherLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Debt" xlink:href="tvgn-20241231.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Leases" xlink:href="tvgn-20241231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/CommitmentsAndContingencies" xlink:href="tvgn-20241231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Stock-basedCompensation" xlink:href="tvgn-20241231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/StockholdersDeficit" xlink:href="tvgn-20241231.xsd#StockholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/NetLossPerShare" xlink:href="tvgn-20241231.xsd#NetLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/IncomeTaxes" xlink:href="tvgn-20241231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/RelatedPartyTransactions" xlink:href="tvgn-20241231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SegmentReporting" xlink:href="tvgn-20241231.xsd#SegmentReporting" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SubsequentEvents" xlink:href="tvgn-20241231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="tvgn-20241231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="tvgn-20241231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/BusinessCombinationTables" xlink:href="tvgn-20241231.xsd#BusinessCombinationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/PropertyAndEquipmentNetTables" xlink:href="tvgn-20241231.xsd#PropertyAndEquipmentNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/AccruedExpensesAndOtherLiabilitiesTables" xlink:href="tvgn-20241231.xsd#AccruedExpensesAndOtherLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/LeasesTables" xlink:href="tvgn-20241231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Stock-basedCompensationTables" xlink:href="tvgn-20241231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/StockholdersDeficitTables" xlink:href="tvgn-20241231.xsd#StockholdersDeficitTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/NetLossPerShareTables" xlink:href="tvgn-20241231.xsd#NetLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/IncomeTaxesTables" xlink:href="tvgn-20241231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/NatureOfBusinessDetailsNarrative" xlink:href="tvgn-20241231.xsd#NatureOfBusinessDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative" xlink:href="tvgn-20241231.xsd#Development-stageRisksAndLiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfFairValueMeasurementDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfFairValuesOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfPropertyAndEquipmentUsefulLifeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="tvgn-20241231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfNetLiabilitiesAcquiredInMergerDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/BusinessCombinationDetailsNarrative" xlink:href="tvgn-20241231.xsd#BusinessCombinationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/EarnoutSharesDetailsNarrative" xlink:href="tvgn-20241231.xsd#EarnoutSharesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:href="tvgn-20241231.xsd#PropertyAndEquipmentNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/DebtDetailsNarrative" xlink:href="tvgn-20241231.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfMinimumRentalPaymentsUnderOperatingLeasesDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfMinimumRentalPaymentsUnderOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/LeasesDetailsNarrative" xlink:href="tvgn-20241231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfRestrictedStockAndRsuActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfStock-basedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="tvgn-20241231.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/StockholdersDeficitDetailsNarrative" xlink:href="tvgn-20241231.xsd#StockholdersDeficitDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfReconciliationOfNetLossDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfReconciliationOfNetLossDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfAnti-dilutiveNetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical" xlink:href="tvgn-20241231.xsd#ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/NetLossPerShareDetailsNarrative" xlink:href="tvgn-20241231.xsd#NetLossPerShareDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfValuationAllowanceForNetDeferredTaxAssetsDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfValuationAllowanceForNetDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/IncomeTaxesDetailsNarrative" xlink:href="tvgn-20241231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="tvgn-20241231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SubsequentEventsDetailsNarrative" xlink:href="tvgn-20241231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesLineItems" xlink:label="loc_deiEntityAddressesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesTable" xlink:label="loc_deiEntityAddressesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_deiEntityAddressesAddressTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesAddressTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember" xlink:label="loc_deiBusinessContactMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiAddressTypeDomain" xlink:to="loc_deiBusinessContactMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentType_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentFlag_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentDescription_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentRegistrationStatement_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAnnualReport_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentQuarterlyReport_30" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentTransitionReport_30" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyReport_30" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_30" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodStartDate_30" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodEndDate_30" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_30" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_30" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_30" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFileNumber_30" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityRegistrantName_30" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCentralIndexKey_30" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPrimarySicNumber_30" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_30" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_30" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine1_30" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine2_30" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine3_30" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCityOrTown_30" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_30" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCountry_30" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_30" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCountryRegion_30" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCityAreaCode_30" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiLocalPhoneNumber_30" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiExtension_30" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiWrittenCommunications_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSolicitingMaterial_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementTenderOffer_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_30" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12bTitle_30" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiNoTradingSymbolFlag_30" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiTradingSymbol_30" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityExchangeName_30" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12gTitle_30" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityReportingObligation_30" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAnnualInformationForm_30" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_30" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_30" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityVoluntaryFilers_30" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_30" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_30" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFilerCategory_30" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntitySmallBusiness_30" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_30" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityExTransitionPeriod_30" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAccountingStandard_30" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_30" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityShellCompany_30" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPublicFloat_30" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_30" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_30" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_30" xlink:type="arc" order="57" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName" xlink:label="loc_deiContactPersonnelName_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiContactPersonnelName_30" xlink:type="arc" order="58" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_90" xlink:to="loc_us-gaapAssetsCurrentAbstract_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_90" xlink:to="loc_us-gaapCash_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_90" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_90" xlink:to="loc_us-gaapOtherReceivablesNetCurrent_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_90" xlink:to="loc_us-gaapAssetsCurrent_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_90" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_90" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaapDeferredCosts_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_90" xlink:to="loc_us-gaapDeferredCosts_90" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_90" xlink:to="loc_us-gaapOtherAssetsNoncurrent_90" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_90" xlink:to="loc_us-gaapAssets_90" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_90" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_90" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_90" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_90" xlink:to="loc_us-gaapAccountsPayableCurrent_90" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_90" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_90" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_90" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_90" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_90" xlink:to="loc_us-gaapNotesPayableCurrent_90" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_90" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent_90" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_90" xlink:to="loc_us-gaapOtherLiabilitiesCurrent_90" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_90" xlink:to="loc_us-gaapLiabilitiesCurrent_90" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaapConvertibleLongTermNotesPayable_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_90" xlink:to="loc_us-gaapConvertibleLongTermNotesPayable_90" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_LoanAgreementNoncurrent" xlink:label="loc_TVGNLoanAgreementNoncurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_90" xlink:to="loc_TVGNLoanAgreementNoncurrent_90" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_90" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_90" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_90" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent_90" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_90" xlink:to="loc_us-gaapLiabilities_90" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_90" xlink:to="loc_us-gaapStockholdersEquityAbstract_90" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_90" xlink:to="loc_us-gaapPreferredStockValue_90" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_90" xlink:to="loc_us-gaapCommonStockValue_90" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_90" xlink:to="loc_us-gaapAdditionalPaidInCapital_90" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_90" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_90" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_90" xlink:to="loc_us-gaapStockholdersEquity_90" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_90" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_90" xlink:type="arc" order="31" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="loc_us-gaapPreferredStockLiquidationPreferenceValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockLiquidationPreferenceValue_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_50" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Deficit">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodValueNewIssuesTwo" xlink:label="loc_TVGNStockIssuedDuringPeriodValueNewIssuesTwo_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodValueNewIssuesTwo_80" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodSharesNewIssuesTwo" xlink:label="loc_TVGNStockIssuedDuringPeriodSharesNewIssuesTwo_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodSharesNewIssuesTwo_80" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodValueNewIssuesOne" xlink:label="loc_TVGNStockIssuedDuringPeriodValueNewIssuesOne_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodValueNewIssuesOne_80" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodSharesNewIssuesOne" xlink:label="loc_TVGNStockIssuedDuringPeriodSharesNewIssuesOne_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodSharesNewIssuesOne_80" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_80" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_80" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_MergerNetOfRedemptionsAndTransactionCosts" xlink:label="loc_TVGNMergerNetOfRedemptionsAndTransactionCosts_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNMergerNetOfRedemptionsAndTransactionCosts_80" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_80" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_80" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_80" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_80" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_80" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement" xlink:label="loc_TVGNStockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement_80" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithLoanAgreement" xlink:label="loc_TVGNStockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithLoanAgreement_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithLoanAgreement_80" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_80" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_80" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodValueContributionFromRelatedParty" xlink:label="loc_TVGNStockIssuedDuringPeriodValueContributionFromRelatedParty_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodValueContributionFromRelatedParty_80" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodSharesContributionFromRelatedParty" xlink:label="loc_TVGNStockIssuedDuringPeriodSharesContributionFromRelatedParty_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodSharesContributionFromRelatedParty_80" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalMarkToMarket_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalMarkToMarket_80" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits" xlink:label="loc_TVGNStockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits_80" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits" xlink:label="loc_TVGNStockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits_80" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_80" xlink:type="arc" order="27" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement -  Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/NatureOfBusiness" xlink:title="999007 - Disclosure - NATURE OF BUSINESS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/Development-stageRisksAndLiquidity" xlink:title="999008 - Disclosure - DEVELOPMENT-STAGE RISKS AND LIQUIDITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/BusinessCombination" xlink:title="999010 - Disclosure - BUSINESS COMBINATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/EarnoutShares" xlink:title="999011 - Disclosure - EARNOUT SHARES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/PropertyAndEquipmentNet" xlink:title="999012 - Disclosure - PROPERTY AND EQUIPMENT, NET" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/AccruedExpensesAndOtherLiabilities" xlink:title="999013 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/Debt" xlink:title="999014 - Disclosure - DEBT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/Leases" xlink:title="999015 - Disclosure - LEASES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/CommitmentsAndContingencies" xlink:title="999016 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/Stock-basedCompensation" xlink:title="999017 - Disclosure - STOCK-BASED COMPENSATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/StockholdersDeficit" xlink:title="999018 - Disclosure - STOCKHOLDERS&#8217; DEFICIT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/NetLossPerShare" xlink:title="999019 - Disclosure - NET LOSS PER SHARE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/IncomeTaxes" xlink:title="999020 - Disclosure - INCOME TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/RelatedPartyTransactions" xlink:title="999021 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/SegmentReporting" xlink:title="999022 - Disclosure - SEGMENT REPORTING" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/SubsequentEvents" xlink:title="999023 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/BusinessCombinationTables" xlink:title="999026 - Disclosure - BUSINESS COMBINATION (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/PropertyAndEquipmentNetTables" xlink:title="999027 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/AccruedExpensesAndOtherLiabilitiesTables" xlink:title="999028 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/LeasesTables" xlink:title="999029 - Disclosure - LEASES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/Stock-basedCompensationTables" xlink:title="999030 - Disclosure - STOCK-BASED COMPENSATION (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/StockholdersDeficitTables" xlink:title="999031 - Disclosure - STOCKHOLDERS&#8217; DEFICIT (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/NetLossPerShareTables" xlink:title="999032 - Disclosure - NET LOSS PER SHARE (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/IncomeTaxesTables" xlink:title="999033 - Disclosure - INCOME TAXES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/NatureOfBusinessDetailsNarrative" xlink:title="999034 - Disclosure - NATURE OF BUSINESS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_TevogenBioMember" xlink:label="loc_TVGNTevogenBioMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_TVGNTevogenBioMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_SemperParatusMember" xlink:label="loc_TVGNSemperParatusMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_TVGNSemperParatusMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_BusinessCombinationSharesExchangeRatio" xlink:label="loc_TVGNBusinessCombinationSharesExchangeRatio_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNBusinessCombinationSharesExchangeRatio_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_40" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative" xlink:title="999035 - Disclosure - DEVELOPMENT-STAGE RISKS AND LIQUIDITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_LoanAgreementMember" xlink:label="loc_TVGNLoanAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_TVGNLoanAgreementMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCash_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_GrantDrewFromRelatedParty" xlink:label="loc_TVGNGrantDrewFromRelatedParty_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_TVGNGrantDrewFromRelatedParty_40" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails" xlink:title="999036 - Disclosure - SCHEDULE OF FAIR VALUE MEASUREMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest" xlink:label="loc_TVGNFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_TVGNFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable" xlink:label="loc_TVGNFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_TVGNFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable_60" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails" xlink:title="999037 - Disclosure - SCHEDULE OF FAIR VALUES OF WARRANTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CallOptionMember" xlink:label="loc_us-gaapCallOptionMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_us-gaapCallOptionMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DerivativeLiabilitiesFairValueIssuance" xlink:label="loc_TVGNDerivativeLiabilitiesFairValueIssuance_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_TVGNDerivativeLiabilitiesFairValueIssuance_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_70" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="999038 - Disclosure - SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails" xlink:title="999039 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_60" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999040 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaapMeasurementInputDiscountRateMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputDiscountRateMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ProbabilityOfFutureLiquidityMember" xlink:label="loc_TVGNProbabilityOfFutureLiquidityMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_TVGNProbabilityOfFutureLiquidityMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="loc_us-gaapMeasurementInputOptionVolatilityMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputOptionVolatilityMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaapNumberOfOperatingSegments_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapNumberOfOperatingSegments_200" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="loc_us-gaapDebtInstrumentMeasurementInput_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDebtInstrumentMeasurementInput_200" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_200" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:label="loc_us-gaapEquitySecuritiesFvNiMeasurementInput_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapEquitySecuritiesFvNiMeasurementInput_200" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_EquitySecuritiesTerm" xlink:label="loc_TVGNEquitySecuritiesTerm_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_TVGNEquitySecuritiesTerm_200" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock_200" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_FreeStandingPurchaseOptions" xlink:label="loc_TVGNFreeStandingPurchaseOptions_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_TVGNFreeStandingPurchaseOptions_200" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_EmbeddedOptions" xlink:label="loc_TVGNEmbeddedOptions_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_TVGNEmbeddedOptions_200" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapSharePrice_200" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:label="loc_us-gaapAlternativeInvestmentMeasurementInput_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAlternativeInvestmentMeasurementInput_200" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeNet" xlink:label="loc_us-gaapDerivativeFairValueOfDerivativeNet_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDerivativeFairValueOfDerivativeNet_200" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_200" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm_200" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails" xlink:title="999041 - Disclosure - SCHEDULE OF NET LIABILITIES ACQUIRED IN MERGER (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/BusinessCombinationDetailsNarrative" xlink:title="999042 - Disclosure - BUSINESS COMBINATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_TevogenBioMember" xlink:label="loc_TVGNTevogenBioMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_TVGNTevogenBioMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_EarnoutSharesMember" xlink:label="loc_TVGNEarnoutSharesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_TVGNEarnoutSharesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="loc_us-gaapBusinessCombinationAcquisitionRelatedCosts_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationAcquisitionRelatedCosts_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="loc_us-gaapBusinessAcquisitionCostOfAcquiredEntityTransactionCosts_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessAcquisitionCostOfAcquiredEntityTransactionCosts_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodValueNewIssuesOne" xlink:label="loc_TVGNStockIssuedDuringPeriodValueNewIssuesOne_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodValueNewIssuesOne_60" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/EarnoutSharesDetailsNarrative" xlink:title="999043 - Disclosure - EARNOUT SHARES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_TevogenBioCommonStockMember" xlink:label="loc_TVGNTevogenBioCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_TVGNTevogenBioCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_SponsorMember" xlink:label="loc_TVGNSponsorMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_TVGNSponsorMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_EarnoutSharesMember" xlink:label="loc_TVGNEarnoutSharesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_TVGNEarnoutSharesMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapVestingAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheOneMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheOneMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheThreeMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheThreeMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_100" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="999044 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ComputerAndSoftwareMember" xlink:label="loc_TVGNComputerAndSoftwareMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_TVGNComputerAndSoftwareMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_110" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:title="999045 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" xlink:title="999046 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/DebtDetailsNarrative" xlink:title="999047 - Disclosure - DEBT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_LoanAgreementMember" xlink:label="loc_TVGNLoanAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_TVGNLoanAgreementMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ThePatelFamilyLLPMember" xlink:label="loc_TVGNThePatelFamilyLLPMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_TVGNThePatelFamilyLLPMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_PolarMultiStrategyMasterFundMember" xlink:label="loc_TVGNPolarMultiStrategyMasterFundMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_TVGNPolarMultiStrategyMasterFundMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaapUnsecuredDebtMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_us-gaapUnsecuredDebtMember_10" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_40" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_60" xlink:type="arc" order="64" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_AdditionalAmountPurchaseOptionMember" xlink:label="loc_TVGNAdditionalAmountPurchaseOptionMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_TVGNAdditionalAmountPurchaseOptionMember_100" xlink:type="arc" order="103" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_160" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_160" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityCurrentBorrowingCapacity_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityCurrentBorrowingCapacity_160" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaapDebtInstrumentTerm_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTerm_160" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_160" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_160" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapSharePrice_160" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_160" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityRemainingBorrowingCapacity_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityRemainingBorrowingCapacity_160" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:label="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensationGross_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensationGross_160" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_160" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_160" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaapDerivativeLiabilities_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDerivativeLiabilities_160" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent_160" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility" xlink:label="loc_TVGNStockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility_160" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapNotesPayableCurrent_160" xlink:type="arc" order="15" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfMinimumRentalPaymentsUnderOperatingLeasesDetails" xlink:title="999048 - Disclosure - SCHEDULE OF MINIMUM RENTAL PAYMENTS UNDER THE OPERATING LEASES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/LeasesDetailsNarrative" xlink:title="999049 - Disclosure - LEASES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_OperatingLeasesIncrementalBorrowingRates" xlink:label="loc_TVGNOperatingLeasesIncrementalBorrowingRates_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNOperatingLeasesIncrementalBorrowingRates_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeasePayments" xlink:label="loc_us-gaapShortTermLeasePayments_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShortTermLeasePayments_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeasePayments_80" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails" xlink:title="999050 - Disclosure - SCHEDULE OF RESTRICTED STOCK AND RSU ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ServiceBasedRestrictedStockMember" xlink:label="loc_TVGNServiceBasedRestrictedStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_TVGNServiceBasedRestrictedStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_PerformanceBasedRSUsMember" xlink:label="loc_TVGNPerformanceBasedRSUsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_TVGNPerformanceBasedRSUsMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_110" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:title="999051 - Disclosure - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="999052 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_TwoThousandTwentyFourPlanMember" xlink:label="loc_TVGNTwoThousandTwentyFourPlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_TVGNTwoThousandTwentyFourPlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_PerformanceBasedRSUsMember" xlink:label="loc_TVGNPerformanceBasedRSUsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_TVGNPerformanceBasedRSUsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ServiceBasedRestrictedStockMember" xlink:label="loc_TVGNServiceBasedRestrictedStockMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_TVGNServiceBasedRestrictedStockMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits" xlink:label="loc_TVGNStockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing" xlink:label="loc_TVGNVestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_TVGNVestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing_100" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPCompensationExpense_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPCompensationExpense_100" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_100" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_100" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_100" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails" xlink:title="999053 - Disclosure - SCHEDULE OF RECONCILIATION OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/StockholdersDeficitDetailsNarrative" xlink:title="999054 - Disclosure - STOCKHOLDERS&#8217; DEFICIT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_SeriesAOnePreferredStockMember" xlink:label="loc_TVGNSeriesAOnePreferredStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_TVGNSeriesAOnePreferredStockMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapInvestorMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ThePatelFamilyLLPMember" xlink:label="loc_TVGNThePatelFamilyLLPMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_TVGNThePatelFamilyLLPMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_SemperParatusMember" xlink:label="loc_TVGNSemperParatusMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_TVGNSemperParatusMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_PublicWarrantsMember" xlink:label="loc_TVGNPublicWarrantsMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_TVGNPublicWarrantsMember_170" xlink:type="arc" order="172" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_170" xlink:type="arc" order="173" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_180" xlink:type="arc" order="182" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_240" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_240" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_240" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_240" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_240" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharePrice_240" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock_240" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_LossOnPreferredStockIssuance" xlink:label="loc_TVGNLossOnPreferredStockIssuance_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNLossOnPreferredStockIssuance_240" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_240" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage_240" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendPaymentRateVariable" xlink:label="loc_us-gaapPreferredStockDividendPaymentRateVariable_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockDividendPaymentRateVariable_240" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="loc_us-gaapPreferredStockRedemptionPricePerShare_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockRedemptionPricePerShare_240" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockRedemptionTerms" xlink:label="loc_us-gaapPreferredStockRedemptionTerms_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockRedemptionTerms_240" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice_240" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_240" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_240" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Deposits" xlink:label="loc_us-gaapDeposits_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDeposits_240" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodSharesConversionOfLiabilities" xlink:label="loc_TVGNStockIssuedDuringPeriodSharesConversionOfLiabilities_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodSharesConversionOfLiabilities_240" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodValueConversionOfLiabilities" xlink:label="loc_TVGNStockIssuedDuringPeriodValueConversionOfLiabilities_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodValueConversionOfLiabilities_240" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_240" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="loc_us-gaapLiabilitiesAssumed1_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapLiabilitiesAssumed1_240" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ClassOfWarrantOrRightIssued" xlink:label="loc_TVGNClassOfWarrantOrRightIssued_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNClassOfWarrantOrRightIssued_240" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_240" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_240" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_WarrantsRedemptionDescription" xlink:label="loc_TVGNWarrantsRedemptionDescription_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNWarrantsRedemptionDescription_240" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_240" xlink:type="arc" order="25" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfReconciliationOfNetLossDetails" xlink:title="999055 - Disclosure - SCHEDULE OF RECONCILIATION OF NET LOSS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="loc_us-gaapEarningsPerShareBasicLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapNetIncomeLoss_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaapPreferredStockDividendsIncomeStatementImpact_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapPreferredStockDividendsIncomeStatementImpact_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockRepurchase" xlink:label="loc_TVGNStockRepurchase_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_TVGNStockRepurchase_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_90" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails" xlink:title="999056 - Disclosure - SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaapConvertibleDebtSecuritiesMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapConvertibleDebtSecuritiesMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_EarnoutSharesMember" xlink:label="loc_TVGNEarnoutSharesMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_TVGNEarnoutSharesMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_130" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical" xlink:title="999057 - Disclosure - SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_20" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/NetLossPerShareDetailsNarrative" xlink:title="999058 - Disclosure - NET LOSS PER SHARE (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails" xlink:title="999059 - Disclosure - SCHEDULE OF RECONCILIATION OF INCOME TAX BENEFIT AT THE FEDERAL STATUTORY INCOME TAX RATE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="999060 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfValuationAllowanceForNetDeferredTaxAssetsDetails" xlink:title="999061 - Disclosure - SCHEDULE OF VALUATION ALLOWANCE FOR NET DEFERRED TAX ASSETS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/IncomeTaxesDetailsNarrative" xlink:title="999062 - Disclosure - INCOME TAXES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="999063 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_SponsorMember" xlink:label="loc_TVGNSponsorMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_TVGNSponsorMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_MehtaphoricConsultingIncMember" xlink:label="loc_TVGNMehtaphoricConsultingIncMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_TVGNMehtaphoricConsultingIncMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ThePatelFamilyLLPMember" xlink:label="loc_TVGNThePatelFamilyLLPMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_TVGNThePatelFamilyLLPMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DrManmohanPatelMember" xlink:label="loc_TVGNDrManmohanPatelMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_TVGNDrManmohanPatelMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_SponsorAdvisoryServicesFeeMember" xlink:label="loc_TVGNSponsorAdvisoryServicesFeeMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_TVGNSponsorAdvisoryServicesFeeMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_LoanAgreementMember" xlink:label="loc_TVGNLoanAgreementMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_TVGNLoanAgreementMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_PerformanceBasedRSUsMember" xlink:label="loc_TVGNPerformanceBasedRSUsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_TVGNPerformanceBasedRSUsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_WifeOfChiefExecutiveOfficerMember" xlink:label="loc_TVGNWifeOfChiefExecutiveOfficerMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_TVGNWifeOfChiefExecutiveOfficerMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaapUnsecuredDebtMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_us-gaapUnsecuredDebtMember_60" xlink:type="arc" order="63" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_90" xlink:type="arc" order="93" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SponsorFees" xlink:label="loc_us-gaapSponsorFees_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSponsorFees_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_SponsorFeesPayable" xlink:label="loc_TVGNSponsorFeesPayable_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_TVGNSponsorFeesPayable_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaapOtherLiabilities_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOtherLiabilities_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaapOtherReceivables_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOtherReceivables_120" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPCompensationExpense_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPCompensationExpense_120" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_120" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityRemainingBorrowingCapacity_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityRemainingBorrowingCapacity_120" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_120" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_120" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/SubsequentEventsDetailsNarrative" xlink:title="999064 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_KRHPLLCMember" xlink:label="loc_TVGNKRHPLLCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_TVGNKRHPLLCMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapOtherReceivablesNetCurrent_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaapLineOfCredit_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapLineOfCredit_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityRemainingBorrowingCapacity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityRemainingBorrowingCapacity_50" xlink:type="arc" order="2" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>16
<FILENAME>tvgn-20241231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember" xlink:label="dei_BusinessContactMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US">Business Contact [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xml:lang="en-US">Series C Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US">Investment, Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_TevogenBioMember" xlink:label="TVGN_TevogenBioMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_TevogenBioMember" xlink:to="TVGN_TevogenBioMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_TevogenBioMember_lbl" xml:lang="en-US">Tevogen Bio [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_SemperParatusMember" xlink:label="TVGN_SemperParatusMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SemperParatusMember" xlink:to="TVGN_SemperParatusMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_SemperParatusMember_lbl" xml:lang="en-US">Semper Paratus [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_LoanAgreementMember" xlink:label="TVGN_LoanAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_LoanAgreementMember" xlink:to="TVGN_LoanAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_LoanAgreementMember_lbl" xml:lang="en-US">Loan Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputDiscountRateMember" xlink:to="us-gaap_MeasurementInputDiscountRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ProbabilityOfFutureLiquidityMember" xlink:label="TVGN_ProbabilityOfFutureLiquidityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ProbabilityOfFutureLiquidityMember" xlink:to="TVGN_ProbabilityOfFutureLiquidityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_ProbabilityOfFutureLiquidityMember_lbl" xml:lang="en-US">Probability of Future Liquidity [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputOptionVolatilityMember" xlink:to="us-gaap_MeasurementInputOptionVolatilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Option Volatility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CallOptionMember" xlink:label="us-gaap_CallOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CallOptionMember" xlink:to="us-gaap_CallOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CallOptionMember_lbl" xml:lang="en-US">Call Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_EarnoutSharesMember" xlink:label="TVGN_EarnoutSharesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_EarnoutSharesMember" xlink:to="TVGN_EarnoutSharesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_EarnoutSharesMember_lbl" xml:lang="en-US">Earnout Shares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_TevogenBioCommonStockMember" xlink:label="TVGN_TevogenBioCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_TevogenBioCommonStockMember" xlink:to="TVGN_TevogenBioCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_TevogenBioCommonStockMember_lbl" xml:lang="en-US">Tevogen Bio Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US">Vesting [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_SponsorMember" xlink:label="TVGN_SponsorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SponsorMember" xlink:to="TVGN_SponsorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_SponsorMember_lbl" xml:lang="en-US">Sponsor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ComputerAndSoftwareMember" xlink:label="TVGN_ComputerAndSoftwareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ComputerAndSoftwareMember" xlink:to="TVGN_ComputerAndSoftwareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_ComputerAndSoftwareMember_lbl" xml:lang="en-US">Computer And Software [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ThePatelFamilyLLPMember" xlink:label="TVGN_ThePatelFamilyLLPMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ThePatelFamilyLLPMember" xlink:to="TVGN_ThePatelFamilyLLPMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_ThePatelFamilyLLPMember_lbl" xml:lang="en-US">The Patel Family LLP [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnsecuredDebtMember" xlink:label="us-gaap_UnsecuredDebtMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnsecuredDebtMember" xlink:to="us-gaap_UnsecuredDebtMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnsecuredDebtMember_lbl" xml:lang="en-US">Unsecured Debt [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_AdditionalAmountPurchaseOptionMember" xlink:label="TVGN_AdditionalAmountPurchaseOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_AdditionalAmountPurchaseOptionMember" xlink:to="TVGN_AdditionalAmountPurchaseOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_AdditionalAmountPurchaseOptionMember_lbl" xml:lang="en-US">Additional Amount Purchase Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_PolarMultiStrategyMasterFundMember" xlink:label="TVGN_PolarMultiStrategyMasterFundMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PolarMultiStrategyMasterFundMember" xlink:to="TVGN_PolarMultiStrategyMasterFundMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_PolarMultiStrategyMasterFundMember_lbl" xml:lang="en-US">Polar Multi-Strategy Master Fund [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementMember" xlink:to="us-gaap_ResearchAndDevelopmentArrangementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember_lbl" xml:lang="en-US">Research and Development Arrangement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_TwoThousandTwentyFourPlanMember" xlink:label="TVGN_TwoThousandTwentyFourPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_TwoThousandTwentyFourPlanMember" xlink:to="TVGN_TwoThousandTwentyFourPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_TwoThousandTwentyFourPlanMember_lbl" xml:lang="en-US">2024 Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_PerformanceBasedRSUsMember" xlink:label="TVGN_PerformanceBasedRSUsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PerformanceBasedRSUsMember" xlink:to="TVGN_PerformanceBasedRSUsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_PerformanceBasedRSUsMember_lbl" xml:lang="en-US">Performance-Based RSUs [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ServiceBasedRestrictedStockMember" xlink:label="TVGN_ServiceBasedRestrictedStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ServiceBasedRestrictedStockMember" xlink:to="TVGN_ServiceBasedRestrictedStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_ServiceBasedRestrictedStockMember_lbl" xml:lang="en-US">Service-Based Restricted Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember" xlink:label="us-gaap_InvestorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestorMember_lbl" xml:lang="en-US">Investor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_SeriesAOnePreferredStockMember" xlink:label="TVGN_SeriesAOnePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SeriesAOnePreferredStockMember" xlink:to="TVGN_SeriesAOnePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_SeriesAOnePreferredStockMember_lbl" xml:lang="en-US">Series A1 Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_PublicWarrantsMember" xlink:label="TVGN_PublicWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PublicWarrantsMember" xlink:to="TVGN_PublicWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_PublicWarrantsMember_lbl" xml:lang="en-US">Public Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_SponsorAdvisoryServicesFeeMember" xlink:label="TVGN_SponsorAdvisoryServicesFeeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SponsorAdvisoryServicesFeeMember" xlink:to="TVGN_SponsorAdvisoryServicesFeeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_SponsorAdvisoryServicesFeeMember_lbl" xml:lang="en-US">Sponsor Advisory Services Fee [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_WifeOfChiefExecutiveOfficerMember" xlink:label="TVGN_WifeOfChiefExecutiveOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_WifeOfChiefExecutiveOfficerMember" xlink:to="TVGN_WifeOfChiefExecutiveOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_WifeOfChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Wife of Chief Executive Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_MehtaphoricConsultingIncMember" xlink:label="TVGN_MehtaphoricConsultingIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_MehtaphoricConsultingIncMember" xlink:to="TVGN_MehtaphoricConsultingIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_MehtaphoricConsultingIncMember_lbl" xml:lang="en-US">Mehtaphoric Consulting Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DrManmohanPatelMember" xlink:label="TVGN_DrManmohanPatelMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DrManmohanPatelMember" xlink:to="TVGN_DrManmohanPatelMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_DrManmohanPatelMember_lbl" xml:lang="en-US">Dr. Manmohan Patel [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_KRHPLLCMember" xlink:label="TVGN_KRHPLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_KRHPLLCMember" xlink:to="TVGN_KRHPLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_KRHPLLCMember_lbl" xml:lang="en-US">KRHP LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesTable" xlink:label="dei_EntityAddressesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesTable" xlink:to="dei_EntityAddressesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesTable_lbl" xml:lang="en-US">Entity Addresses [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesLineItems" xlink:label="dei_EntityAddressesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesLineItems" xlink:to="dei_EntityAddressesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesLineItems_lbl" xml:lang="en-US">Entity Addresses [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName" xlink:label="dei_ContactPersonnelName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelName_lbl" xml:lang="en-US">Contact Personnel Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Due from related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use assets - operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCosts" xlink:to="us-gaap_DeferredCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCosts_lbl" xml:lang="en-US">Deferred transaction costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and stockholders&#8217; deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl" xml:lang="en-US">Convertible promissory notes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Due to related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="us-gaap_ConvertibleLongTermNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_lbl" xml:lang="en-US">Convertible promissory notes</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_LoanAgreementNoncurrent" xlink:label="TVGN_LoanAgreementNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_LoanAgreementNoncurrent" xlink:to="TVGN_LoanAgreementNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_LoanAgreementNoncurrent_lbl" xml:lang="en-US">Loan agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xml:lang="en-US">Derivative warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.0001 par value; 800,000,000 shares authorized; 177,991,365 and 119,999,989 shares issued and outstanding at December 31, 2024 and December 31, 2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreferenceValue" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue_lbl" xml:lang="en-US">Preferred stock, liquidation preference, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common shares, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common shares, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common shares, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common shares, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xml:lang="en-US">Merger transaction costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Change in fair value of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ChangeInFairValueOfConvertiblePromissoryNotes" xlink:label="TVGN_ChangeInFairValueOfConvertiblePromissoryNotes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ChangeInFairValueOfConvertiblePromissoryNotes" xlink:to="TVGN_ChangeInFairValueOfConvertiblePromissoryNotes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_ChangeInFairValueOfConvertiblePromissoryNotes_lbl" xml:lang="en-US">Change in fair value of convertible promissory notes</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_LossOnIssuanceOfCommitmentShares" xlink:label="TVGN_LossOnIssuanceOfCommitmentShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_LossOnIssuanceOfCommitmentShares" xlink:to="TVGN_LossOnIssuanceOfCommitmentShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="TVGN_LossOnIssuanceOfCommitmentShares_lbl" xml:lang="en-US">Loss on issuance of commitment shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss attributable to common stockholders, basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US">Net loss attributable to common stockholders, diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per share attributable to common stockholders, basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per share attributable to common stockholders, diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted-average common stock outstanding, basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted-average common stock outstanding, diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of Series A preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of preferred stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodValueNewIssuesTwo" xlink:label="TVGN_StockIssuedDuringPeriodValueNewIssuesTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodValueNewIssuesTwo" xlink:to="TVGN_StockIssuedDuringPeriodValueNewIssuesTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_StockIssuedDuringPeriodValueNewIssuesTwo_lbl" xml:lang="en-US">Issuance of Series C preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodSharesNewIssuesTwo" xlink:label="TVGN_StockIssuedDuringPeriodSharesNewIssuesTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodSharesNewIssuesTwo" xlink:to="TVGN_StockIssuedDuringPeriodSharesNewIssuesTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TVGN_StockIssuedDuringPeriodSharesNewIssuesTwo_lbl" xml:lang="en-US">Issuance of preferred stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodValueNewIssuesOne" xlink:label="TVGN_StockIssuedDuringPeriodValueNewIssuesOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodValueNewIssuesOne" xlink:to="TVGN_StockIssuedDuringPeriodValueNewIssuesOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_StockIssuedDuringPeriodValueNewIssuesOne_lbl" xml:lang="en-US">Issuance of Series B preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodSharesNewIssuesOne" xlink:label="TVGN_StockIssuedDuringPeriodSharesNewIssuesOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodSharesNewIssuesOne" xlink:to="TVGN_StockIssuedDuringPeriodSharesNewIssuesOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_StockIssuedDuringPeriodSharesNewIssuesOne_lbl" xml:lang="en-US">Issuance of Series B preferred stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of convertible promissory notes into common stock in connection with merger</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of convertible promissory notes into common stock in connection with merger, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_MergerNetOfRedemptionsAndTransactionCosts" xlink:label="TVGN_MergerNetOfRedemptionsAndTransactionCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_MergerNetOfRedemptionsAndTransactionCosts" xlink:to="TVGN_MergerNetOfRedemptionsAndTransactionCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="TVGN_MergerNetOfRedemptionsAndTransactionCosts_lbl" xml:lang="en-US">Merger, net of redemptions and transaction costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US">Merger, net of redemptions and transaction costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Issuance of restricted common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Issuance of restricted common stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Issuance of common stock for Sponsor advisory service fee</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Issuance of common stock for Sponsor advisory service fee, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement" xlink:label="TVGN_StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement" xlink:to="TVGN_StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement_lbl" xml:lang="en-US">Issuance of commitment shares in connection with the loan agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithLoanAgreement" xlink:label="TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithLoanAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithLoanAgreement" xlink:to="TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithLoanAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithLoanAgreement_lbl" xml:lang="en-US">Issuance of commitment shares in connection with the loan agreement, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Issuance of common stock in connection with Polar note</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Issuance of common stock in connection with Polar Note, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodValueContributionFromRelatedParty" xlink:label="TVGN_StockIssuedDuringPeriodValueContributionFromRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodValueContributionFromRelatedParty" xlink:to="TVGN_StockIssuedDuringPeriodValueContributionFromRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_StockIssuedDuringPeriodValueContributionFromRelatedParty_lbl" xml:lang="en-US">Contribution from related party</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodSharesContributionFromRelatedParty" xlink:label="TVGN_StockIssuedDuringPeriodSharesContributionFromRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodSharesContributionFromRelatedParty" xlink:to="TVGN_StockIssuedDuringPeriodSharesContributionFromRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_StockIssuedDuringPeriodSharesContributionFromRelatedParty_lbl" xml:lang="en-US">Contribution from related party, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket_lbl" xml:lang="en-US">Nonrefundable prepaid proceeds towards anticipated Series A-1 preferred stock issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits" xlink:label="TVGN_StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits" xlink:to="TVGN_StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits_lbl" xml:lang="en-US">Issuance of common stock in settlement of vested restricted stock units</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits" xlink:label="TVGN_StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits" xlink:to="TVGN_StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits_lbl" xml:lang="en-US">Issuance of common stock in settlement of vested restricted stock units, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaidInKindInterest" xlink:to="us-gaap_PaidInKindInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaidInKindInterest_lbl" xml:lang="en-US">Non-cash interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashMergerRelatedCosts" xlink:label="us-gaap_NoncashMergerRelatedCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashMergerRelatedCosts" xlink:to="us-gaap_NoncashMergerRelatedCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashMergerRelatedCosts_lbl" xml:lang="en-US">Merger transaction costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ChangeInFairValueOfConvertiblePromissoryNotes" xlink:to="TVGN_ChangeInFairValueOfConvertiblePromissoryNotes_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="TVGN_ChangeInFairValueOfConvertiblePromissoryNotes_2_lbl" xml:lang="en-US">Change in fair value of convertible promissory notes</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_LossOnPreferredStockIssuance" xlink:label="TVGN_LossOnPreferredStockIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_LossOnPreferredStockIssuance" xlink:to="TVGN_LossOnPreferredStockIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_LossOnPreferredStockIssuance_lbl" xml:lang="en-US">Loss on Series A Preferred Stock issuance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_LossOnIssuanceOfCommitmentShares" xlink:to="TVGN_LossOnIssuanceOfCommitmentShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_LossOnIssuanceOfCommitmentShares_2_lbl" xml:lang="en-US">Loss on issuance of commitment shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xml:lang="en-US">Change in fair value of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US">Amortization of right-of-use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Change in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_CashAcquiredInConnectionWithReverseRecapitalization" xlink:label="TVGN_CashAcquiredInConnectionWithReverseRecapitalization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_CashAcquiredInConnectionWithReverseRecapitalization" xlink:to="TVGN_CashAcquiredInConnectionWithReverseRecapitalization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_CashAcquiredInConnectionWithReverseRecapitalization_lbl" xml:lang="en-US">Cash acquired in connection with the reverse recapitalization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US">Proceeds from issuance of Series A Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ProceedsFromIssuanceOfSeriesCPreferredStock" xlink:label="TVGN_ProceedsFromIssuanceOfSeriesCPreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ProceedsFromIssuanceOfSeriesCPreferredStock" xlink:to="TVGN_ProceedsFromIssuanceOfSeriesCPreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_ProceedsFromIssuanceOfSeriesCPreferredStock_lbl" xml:lang="en-US">Proceeds from issuance of Series C Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xml:lang="en-US">Proceeds from loan agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance" xlink:label="TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance" xlink:to="TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance_lbl" xml:lang="en-US">Nonrefundable prepaid proceeds towards anticipated Series A-1 Preferred Stock Issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xml:lang="en-US">Payments of deferred transaction costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Proceeds from issuance of convertible promissory notes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase (decrease) in cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash &#8211; beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash &#8211; end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Supplementary disclosure of noncash investing and financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ReverseRecapitalizationTransactionFeesIncludedInAccruedExpensesAndOtherLiabilities" xlink:label="TVGN_ReverseRecapitalizationTransactionFeesIncludedInAccruedExpensesAndOtherLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ReverseRecapitalizationTransactionFeesIncludedInAccruedExpensesAndOtherLiabilities" xlink:to="TVGN_ReverseRecapitalizationTransactionFeesIncludedInAccruedExpensesAndOtherLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_ReverseRecapitalizationTransactionFeesIncludedInAccruedExpensesAndOtherLiabilities_lbl" xml:lang="en-US">Reverse recapitalization transaction fees included in accrued expenses and other liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xml:lang="en-US">Conversion of convertible promissory notes into common stock in connection with Merger</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_RepurchaseOfSeriesBPreferredStock" xlink:label="TVGN_RepurchaseOfSeriesBPreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_RepurchaseOfSeriesBPreferredStock" xlink:to="TVGN_RepurchaseOfSeriesBPreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_RepurchaseOfSeriesBPreferredStock_lbl" xml:lang="en-US">Repurchase of Series B preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Issuance of common stock for net liabilities upon reverse recapitalization, net of transaction costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US">NATURE OF BUSINESS</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DisclosureDevelopmentstageRisksAndLiquidityAbstract" xlink:label="TVGN_DisclosureDevelopmentstageRisksAndLiquidityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DisclosureDevelopmentstageRisksAndLiquidityAbstract" xlink:to="TVGN_DisclosureDevelopmentstageRisksAndLiquidityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_DisclosureDevelopmentstageRisksAndLiquidityAbstract_lbl" xml:lang="en-US">Development-stage Risks And Liquidity</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DevelopmentStageRisksAndLiquidityTextBlock" xlink:label="TVGN_DevelopmentStageRisksAndLiquidityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DevelopmentStageRisksAndLiquidityTextBlock" xlink:to="TVGN_DevelopmentStageRisksAndLiquidityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_DevelopmentStageRisksAndLiquidityTextBlock_lbl" xml:lang="en-US">DEVELOPMENT-STAGE RISKS AND LIQUIDITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl" xml:lang="en-US">Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US">BUSINESS COMBINATION</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DisclosureEarnoutSharesAbstract" xlink:label="TVGN_DisclosureEarnoutSharesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DisclosureEarnoutSharesAbstract" xlink:to="TVGN_DisclosureEarnoutSharesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_DisclosureEarnoutSharesAbstract_lbl" xml:lang="en-US">Earnout Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_EarnoutSharesDisclosureTextBlock" xlink:label="TVGN_EarnoutSharesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_EarnoutSharesDisclosureTextBlock" xlink:to="TVGN_EarnoutSharesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_EarnoutSharesDisclosureTextBlock_lbl" xml:lang="en-US">EARNOUT SHARES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">ACCRUED EXPENSES AND OTHER LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">DEBT</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DisclosureLeasesAbstract" xlink:label="TVGN_DisclosureLeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DisclosureLeasesAbstract" xlink:to="TVGN_DisclosureLeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_DisclosureLeasesAbstract_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:label="us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:to="us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_lbl" xml:lang="en-US">LEASES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; DEFICIT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">NET LOSS PER SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">SEGMENT REPORTING</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_FreestandingAndEmbeddedCommonStockOptionsPolicyTextBlock" xlink:label="TVGN_FreestandingAndEmbeddedCommonStockOptionsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_FreestandingAndEmbeddedCommonStockOptionsPolicyTextBlock" xlink:to="TVGN_FreestandingAndEmbeddedCommonStockOptionsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_FreestandingAndEmbeddedCommonStockOptionsPolicyTextBlock_lbl" xml:lang="en-US">Freestanding and Embedded Common Stock Purchase Options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentrations of Credit Risk</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Reporting</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xml:lang="en-US">Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment, Net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Standards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FAIR VALUE MEASUREMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FAIR VALUES OF WARRANTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_PropertyAndEquipmentUsefulLifeTableTextBlock" xlink:label="TVGN_PropertyAndEquipmentUsefulLifeTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PropertyAndEquipmentUsefulLifeTableTextBlock" xlink:to="TVGN_PropertyAndEquipmentUsefulLifeTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_PropertyAndEquipmentUsefulLifeTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl" xml:lang="en-US">SCHEDULE OF NET LIABILITIES ACQUIRED IN MERGER</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">SCHEDULE OF PROPERTY AND EQUIPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ScheduleOfCompanyLeaseLiabilitiesTableTextBlock" xlink:label="TVGN_ScheduleOfCompanyLeaseLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ScheduleOfCompanyLeaseLiabilitiesTableTextBlock" xlink:to="TVGN_ScheduleOfCompanyLeaseLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_ScheduleOfCompanyLeaseLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF MINIMUM RENTAL PAYMENTS UNDER THE OPERATING LEASES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF RESTRICTED STOCK AND RSU ACTIVITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF RECONCILIATION OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_lbl" xml:lang="en-US">SCHEDULE OF RECONCILIATION OF NET LOSS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF RECONCILIATION OF INCOME TAX BENEFIT AT THE FEDERAL STATUTORY INCOME TAX RATE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock" xlink:label="TVGN_ScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock" xlink:to="TVGN_ScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_ScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF VALUATION ALLOWANCE FOR NET DEFERRED TAX ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_BusinessCombinationSharesExchangeRatio" xlink:label="TVGN_BusinessCombinationSharesExchangeRatio" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_BusinessCombinationSharesExchangeRatio" xlink:to="TVGN_BusinessCombinationSharesExchangeRatio_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_BusinessCombinationSharesExchangeRatio_lbl" xml:lang="en-US">Business combination shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Equity ownership percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US">Grant received</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_GrantDrewFromRelatedParty" xlink:label="TVGN_GrantDrewFromRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_GrantDrewFromRelatedParty" xlink:to="TVGN_GrantDrewFromRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_GrantDrewFromRelatedParty_lbl" xml:lang="en-US">Grant drew from related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="srt_PlatformOperatorCryptoAssetTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PlatformOperatorCryptoAssetTable" xlink:to="srt_PlatformOperatorCryptoAssetTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_PlatformOperatorCryptoAssetTable_lbl" xml:lang="en-US">Platform Operator, Crypto Asset [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="srt_PlatformOperatorCryptoAssetLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PlatformOperatorCryptoAssetLineItems" xlink:to="srt_PlatformOperatorCryptoAssetLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_PlatformOperatorCryptoAssetLineItems_lbl" xml:lang="en-US">Platform Operator, Crypto Asset [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US">Fair value beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xml:lang="en-US">Initial fair value at issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest" xlink:label="TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest" xlink:to="TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_lbl" xml:lang="en-US">Accrued interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xml:lang="en-US">Change in fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable" xlink:label="TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable" xlink:to="TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable_lbl" xml:lang="en-US">Derecognition upon conversion of convertible promissory notes</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2_lbl" xml:lang="en-US">Fair value beginning balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_2_lbl" xml:lang="en-US">Derivative warrant liabilities, Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DerivativeLiabilitiesFairValueIssuance" xlink:label="TVGN_DerivativeLiabilitiesFairValueIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DerivativeLiabilitiesFairValueIssuance" xlink:to="TVGN_DerivativeLiabilitiesFairValueIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TVGN_DerivativeLiabilitiesFairValueIssuance_lbl" xml:lang="en-US">Initial fair value at issuance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_3_lbl" xml:lang="en-US">Change in fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_3_lbl" xml:lang="en-US">Derivative warrant liabilities, Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property, plant and equipment, useful life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of operating segments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMeasurementInput" xlink:to="us-gaap_DebtInstrumentMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMeasurementInput_lbl" xml:lang="en-US">Volatility</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_4_lbl" xml:lang="en-US">Fair value adjustment of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:label="us-gaap_EquitySecuritiesFvNiMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:to="us-gaap_EquitySecuritiesFvNiMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquitySecuritiesFvNiMeasurementInput_lbl" xml:lang="en-US">Stock, measurement input</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_EquitySecuritiesTerm" xlink:label="TVGN_EquitySecuritiesTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_EquitySecuritiesTerm" xlink:to="TVGN_EquitySecuritiesTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_EquitySecuritiesTerm_lbl" xml:lang="en-US">Range in years</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_2_lbl" xml:lang="en-US">Cash received upon issuance of preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_FreeStandingPurchaseOptions" xlink:label="TVGN_FreeStandingPurchaseOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_FreeStandingPurchaseOptions" xlink:to="TVGN_FreeStandingPurchaseOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_FreeStandingPurchaseOptions_lbl" xml:lang="en-US">Free standing purchase options</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_EmbeddedOptions" xlink:label="TVGN_EmbeddedOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_EmbeddedOptions" xlink:to="TVGN_EmbeddedOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_EmbeddedOptions_lbl" xml:lang="en-US">Embedded options shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:label="us-gaap_AlternativeInvestmentMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AlternativeInvestmentMeasurementInput" xlink:to="us-gaap_AlternativeInvestmentMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AlternativeInvestmentMeasurementInput_lbl" xml:lang="en-US">Discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeNet" xlink:label="us-gaap_DerivativeFairValueOfDerivativeNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFairValueOfDerivativeNet" xlink:to="us-gaap_DerivativeFairValueOfDerivativeNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeFairValueOfDerivativeNet_lbl" xml:lang="en-US">Fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xml:lang="en-US">Leases initial term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl" xml:lang="en-US">Due from Sponsor</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:label="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:to="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_lbl" xml:lang="en-US">Notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_lbl" xml:lang="en-US">Derivative warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xml:lang="en-US">Total net liabilities acquired</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_MergerTransactionCostsLimitedToCashAcquired" xlink:label="TVGN_MergerTransactionCostsLimitedToCashAcquired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_MergerTransactionCostsLimitedToCashAcquired" xlink:to="TVGN_MergerTransactionCostsLimitedToCashAcquired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_MergerTransactionCostsLimitedToCashAcquired_lbl" xml:lang="en-US">Plus: Merger transaction costs limited to cash acquired</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts" xlink:label="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts" xlink:to="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts_lbl" xml:lang="en-US">Total net liabilities acquired plus transaction costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_2_lbl" xml:lang="en-US">Ownership percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_2_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_2_lbl" xml:lang="en-US">Merger transaction costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" xml:lang="en-US">Transaction costs charged to equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Earnout shares issuable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodValueNewIssuesOne" xlink:to="TVGN_StockIssuedDuringPeriodValueNewIssuesOne_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TVGN_StockIssuedDuringPeriodValueNewIssuesOne_2_lbl" xml:lang="en-US">New issuance value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Earnout shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares issued, price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and equipment, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Total property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Professional services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2_lbl" xml:lang="en-US">Converted shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US">Line of credit maximum borrowing capacity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_lbl" xml:lang="en-US">Line of credit borrowing capacity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US">Debt maturity date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US">Debt instrument variable rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt instrument interest rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Issuance of shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xml:lang="en-US">Line of credit remaining capacity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:to="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross_lbl" xml:lang="en-US">Option to purchase common stock, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US">Percentage of price of common stock purchased</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_2_lbl" xml:lang="en-US">Purchase, price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilities_lbl" xml:lang="en-US">Derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl" xml:lang="en-US">Derivative liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility" xlink:label="TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility" xlink:to="TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility_lbl" xml:lang="en-US">Line of credit facility shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DisclosureLeasesAbstract" xlink:to="TVGN_DisclosureLeasesAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TVGN_DisclosureLeasesAbstract_2_lbl" xml:lang="en-US">Schedule Of Minimum Rental Payments Under Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_OperatingLeasesIncrementalBorrowingRates" xlink:label="TVGN_OperatingLeasesIncrementalBorrowingRates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_OperatingLeasesIncrementalBorrowingRates" xlink:to="TVGN_OperatingLeasesIncrementalBorrowingRates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_OperatingLeasesIncrementalBorrowingRates_lbl" xml:lang="en-US">Operating leases incremental borrowing rates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating lease expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeasePayments" xlink:label="us-gaap_ShortTermLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeasePayments" xlink:to="us-gaap_ShortTermLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermLeasePayments_lbl" xml:lang="en-US">Short term lease</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating leases weighted average remaining lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Operating leases weighted average discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Cash payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Nonvested Shares, Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Nonvested weighted average grant-date fair value, Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Nonvested Shares, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Nonvested weighted average grant-date fair value, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Nonvested Shares, Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Nonvested weighted average grant-date fair value, Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Nonvested Shares, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Nonvested weighted average grant-date fair value, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4_lbl" xml:lang="en-US">Nonvested Shares, Beginning</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Nonvested weighted average grant-date fair value, Ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2_lbl" xml:lang="en-US">Nonvested Shares, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Granted shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Shares available for granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_2_lbl" xml:lang="en-US">Number of shares issued for RSUs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Fair value per share for award</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US">Grant date fair value of shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Compensation cost recognized</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits" xlink:to="TVGN_StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TVGN_StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits_2_lbl" xml:lang="en-US">Number of shares issued and outstading RSU</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing" xlink:label="TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing" xlink:to="TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing_lbl" xml:lang="en-US">Number of shares issuable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_lbl" xml:lang="en-US">Compensation cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized compensation cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted average period for recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Amount Capitalized</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_2_lbl" xml:lang="en-US">Total shares of common stock legally issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_3_lbl" xml:lang="en-US">Total shares of common stock legally outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing" xlink:to="TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing_2_lbl" xml:lang="en-US">Vested Performance-Based RSUs from satisfaction of liquidity condition upon the Closing</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture" xlink:label="TVGN_SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture" xlink:to="TVGN_SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture_lbl" xml:lang="en-US">Issuance of restricted common stock subject to forfeiture</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture" xlink:label="TVGN_CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture" xlink:to="TVGN_CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture_lbl" xml:lang="en-US">Total shares issued and outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_2_lbl" xml:lang="en-US">Preferred shares, par value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_3_lbl" xml:lang="en-US">Gross proceeds</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_LossOnPreferredStockIssuance" xlink:to="TVGN_LossOnPreferredStockIssuance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TVGN_LossOnPreferredStockIssuance_2_lbl" xml:lang="en-US">Loss on preferred stock issuance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_3_lbl" xml:lang="en-US">Price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US">Dividend rate, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendPaymentRateVariable" xlink:label="us-gaap_PreferredStockDividendPaymentRateVariable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendPaymentRateVariable" xlink:to="us-gaap_PreferredStockDividendPaymentRateVariable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendPaymentRateVariable_lbl" xml:lang="en-US">Dividend variable rate, description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockRedemptionPricePerShare" xlink:to="us-gaap_PreferredStockRedemptionPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare_lbl" xml:lang="en-US">Redemption price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockRedemptionTerms" xlink:label="us-gaap_PreferredStockRedemptionTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockRedemptionTerms" xlink:to="us-gaap_PreferredStockRedemptionTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockRedemptionTerms_lbl" xml:lang="en-US">Redemption term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xml:lang="en-US">Floor price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Deposits" xlink:label="us-gaap_Deposits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Deposits" xlink:to="us-gaap_Deposits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Deposits_lbl" xml:lang="en-US">Non refundable deposist paid</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodSharesConversionOfLiabilities" xlink:label="TVGN_StockIssuedDuringPeriodSharesConversionOfLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodSharesConversionOfLiabilities" xlink:to="TVGN_StockIssuedDuringPeriodSharesConversionOfLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_StockIssuedDuringPeriodSharesConversionOfLiabilities_lbl" xml:lang="en-US">Conversion of certain liabilities into Series B preferred stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodValueConversionOfLiabilities" xlink:label="TVGN_StockIssuedDuringPeriodValueConversionOfLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodValueConversionOfLiabilities" xlink:to="TVGN_StockIssuedDuringPeriodValueConversionOfLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_StockIssuedDuringPeriodValueConversionOfLiabilities_lbl" xml:lang="en-US">Conversion of certain liabilities into Series B preferred stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_2_lbl" xml:lang="en-US">Preferred stock shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="us-gaap_LiabilitiesAssumed1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAssumed1" xlink:to="us-gaap_LiabilitiesAssumed1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAssumed1_lbl" xml:lang="en-US">Liabilities assumed</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ClassOfWarrantOrRightIssued" xlink:label="TVGN_ClassOfWarrantOrRightIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ClassOfWarrantOrRightIssued" xlink:to="TVGN_ClassOfWarrantOrRightIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_ClassOfWarrantOrRightIssued_lbl" xml:lang="en-US">Number of warrants issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xml:lang="en-US">Exercisable date</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_WarrantsRedemptionDescription" xlink:label="TVGN_WarrantsRedemptionDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_WarrantsRedemptionDescription" xlink:to="TVGN_WarrantsRedemptionDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_WarrantsRedemptionDescription_lbl" xml:lang="en-US">Warrants redemption description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Number of warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareBasicLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xml:lang="en-US">Cumulative preferred stock dividend</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockRepurchase" xlink:label="TVGN_StockRepurchase" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockRepurchase" xlink:to="TVGN_StockRepurchase_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_StockRepurchase_lbl" xml:lang="en-US">Stock repurchase</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xml:lang="en-US">Stock option vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal benefit at statutory rate</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest" xlink:label="TVGN_IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest" xlink:to="TVGN_IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest_lbl" xml:lang="en-US">Convertible note interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">Permanent differences</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State taxes, net of federal benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xml:lang="en-US">Tax credits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Income Tax Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xml:lang="en-US">Deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DeferredTaxAssetsAccruedExpensesAndOther" xlink:label="TVGN_DeferredTaxAssetsAccruedExpensesAndOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DeferredTaxAssetsAccruedExpensesAndOther" xlink:to="TVGN_DeferredTaxAssetsAccruedExpensesAndOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_DeferredTaxAssetsAccruedExpensesAndOther_lbl" xml:lang="en-US">Accrued expenses and other</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="TVGN_DeferredTaxAssetsOperatingLeaseLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="TVGN_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xml:lang="en-US">Lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DeferredTaxAssetsFixedAssets" xlink:label="TVGN_DeferredTaxAssetsFixedAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DeferredTaxAssetsFixedAssets" xlink:to="TVGN_DeferredTaxAssetsFixedAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_DeferredTaxAssetsFixedAssets_lbl" xml:lang="en-US">Fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures" xlink:label="TVGN_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures" xlink:to="TVGN_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures_lbl" xml:lang="en-US">Capitalized research and development expenditures</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Research and development credits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US">Deferred tax liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="TVGN_DeferredTaxLiabilitiesRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="TVGN_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="TVGN_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xml:lang="en-US">Right of use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Total deferred tax liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Net deferred tax assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_IncreasesRecordedToIncomeTaxProvision" xlink:label="TVGN_IncreasesRecordedToIncomeTaxProvision" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_IncreasesRecordedToIncomeTaxProvision" xlink:to="TVGN_IncreasesRecordedToIncomeTaxProvision_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_IncreasesRecordedToIncomeTaxProvision_lbl" xml:lang="en-US">Increases recorded to income tax provision</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_3_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xml:lang="en-US">Federal net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US">State net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_TaxableIncomeLimitationPercentage" xlink:label="TVGN_TaxableIncomeLimitationPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_TaxableIncomeLimitationPercentage" xlink:to="TVGN_TaxableIncomeLimitationPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_TaxableIncomeLimitationPercentage_lbl" xml:lang="en-US">Limitation percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xml:lang="en-US">Income tax penalties and interest accrued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Related Party Transaction [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SponsorFees" xlink:label="us-gaap_SponsorFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SponsorFees" xlink:to="us-gaap_SponsorFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SponsorFees_lbl" xml:lang="en-US">Sponsor advisory service fee</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_SponsorFeesPayable" xlink:label="TVGN_SponsorFeesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SponsorFeesPayable" xlink:to="TVGN_SponsorFeesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_SponsorFeesPayable_lbl" xml:lang="en-US">Sponsor advisory services fee payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilities_lbl" xml:lang="en-US">Sponsor fee payable offset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2_lbl" xml:lang="en-US">Shares issued to related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherReceivables_lbl" xml:lang="en-US">Due from related party</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_2_lbl" xml:lang="en-US">Compensation cost recognized</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_2_lbl" xml:lang="en-US">Line of credit remaining borrowing capacity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Granted, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Vested shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherReceivablesNetCurrent_2_lbl" xml:lang="en-US">Grant</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCredit_lbl" xml:lang="en-US">Line of credit Facility additional</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_3_lbl" xml:lang="en-US">Line of credit Facility remaining capacity</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_CommonStock0.0001ParValuePerShareMember" xlink:label="TVGN_CommonStock0.0001ParValuePerShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_CommonStock0.0001ParValuePerShareMember" xlink:to="TVGN_CommonStock0.0001ParValuePerShareMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_CommonStock0.0001ParValuePerShareMember_doc" xml:lang="en-US">Common Stock, $0.0001 par value per share.</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_WarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember" xlink:label="TVGN_WarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_WarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember" xlink:to="TVGN_WarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_WarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember_doc" xml:lang="en-US">Warrants, each exercisable for one share of Common Stock for $11.50 per share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ChangeInFairValueOfConvertiblePromissoryNotes" xlink:to="TVGN_ChangeInFairValueOfConvertiblePromissoryNotes_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_ChangeInFairValueOfConvertiblePromissoryNotes_doc" xml:lang="en-US">Change in fair value of convertible promissory notes.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_LossOnIssuanceOfCommitmentShares" xlink:to="TVGN_LossOnIssuanceOfCommitmentShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_LossOnIssuanceOfCommitmentShares_doc" xml:lang="en-US">Loss on issuance of commitment shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodValueNewIssuesOne" xlink:to="TVGN_StockIssuedDuringPeriodValueNewIssuesOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_StockIssuedDuringPeriodValueNewIssuesOne_doc" xml:lang="en-US">Stock issued during period value new issues one.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodSharesNewIssuesOne" xlink:to="TVGN_StockIssuedDuringPeriodSharesNewIssuesOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_StockIssuedDuringPeriodSharesNewIssuesOne_doc" xml:lang="en-US">Number of new stock issued during the period.</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility" xlink:label="TVGN_StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility" xlink:to="TVGN_StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility_doc" xml:lang="en-US">Stock issued during period value commitment shares in connection with unsecured equity line of credit facility.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility" xlink:to="TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility_doc" xml:lang="en-US">Stock issued during period shares commitment shares in connection with unsecured equity line of credit facility.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodValueContributionFromRelatedParty" xlink:to="TVGN_StockIssuedDuringPeriodValueContributionFromRelatedParty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_StockIssuedDuringPeriodValueContributionFromRelatedParty_doc" xml:lang="en-US">Stock issued during period value contribution from related party</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodSharesContributionFromRelatedParty" xlink:to="TVGN_StockIssuedDuringPeriodSharesContributionFromRelatedParty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_StockIssuedDuringPeriodSharesContributionFromRelatedParty_doc" xml:lang="en-US">Stock issued during period shares contribution from related party</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits" xlink:to="TVGN_StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits_doc" xml:lang="en-US">Stock issued during period value settlement of vested restricted stock units.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_LossOnPreferredStockIssuance" xlink:to="TVGN_LossOnPreferredStockIssuance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_LossOnPreferredStockIssuance_doc" xml:lang="en-US">Loss on preferred stock issuance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_CashAcquiredInConnectionWithReverseRecapitalization" xlink:to="TVGN_CashAcquiredInConnectionWithReverseRecapitalization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_CashAcquiredInConnectionWithReverseRecapitalization_doc" xml:lang="en-US">Cash acquired in connection with the reverse recapitalization.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ProceedsFromIssuanceOfSeriesCPreferredStock" xlink:to="TVGN_ProceedsFromIssuanceOfSeriesCPreferredStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_ProceedsFromIssuanceOfSeriesCPreferredStock_doc" xml:lang="en-US">Proceeds from issuance of series c preferred stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance" xlink:to="TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance_doc" xml:lang="en-US">Nonrefundable prepaid proceeds towards anticipated Series A-1 Preferred Stock Issuance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_RepurchaseOfSeriesBPreferredStock" xlink:to="TVGN_RepurchaseOfSeriesBPreferredStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_RepurchaseOfSeriesBPreferredStock_doc" xml:lang="en-US">Repurchase of series B preferred stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ReverseRecapitalizationTransactionFeesIncludedInAccruedExpensesAndOtherLiabilities" xlink:to="TVGN_ReverseRecapitalizationTransactionFeesIncludedInAccruedExpensesAndOtherLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_ReverseRecapitalizationTransactionFeesIncludedInAccruedExpensesAndOtherLiabilities_doc" xml:lang="en-US">Reverse recapitalization transaction fees included in accrued expenses and other liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_BusinessCombinationSharesExchangeRatio" xlink:to="TVGN_BusinessCombinationSharesExchangeRatio_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_BusinessCombinationSharesExchangeRatio_doc" xml:lang="en-US">Business combination shares exchange ratio.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_TevogenBioMember" xlink:to="TVGN_TevogenBioMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_TevogenBioMember_doc" xml:lang="en-US">Tevogen Bio [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SemperParatusMember" xlink:to="TVGN_SemperParatusMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_SemperParatusMember_doc" xml:lang="en-US">Semper Paratus [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DevelopmentStageRisksAndLiquidityTextBlock" xlink:to="TVGN_DevelopmentStageRisksAndLiquidityTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_DevelopmentStageRisksAndLiquidityTextBlock_doc" xml:lang="en-US">Development Stage Risks And Liquidity [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_FreestandingAndEmbeddedCommonStockOptionsPolicyTextBlock" xlink:to="TVGN_FreestandingAndEmbeddedCommonStockOptionsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_FreestandingAndEmbeddedCommonStockOptionsPolicyTextBlock_doc" xml:lang="en-US">Freestanding And Embedded Common Stock Options [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest" xlink:to="TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_doc" xml:lang="en-US">Fair value measurement with unobservable inputs reconciliation recurring basis liability accrued interest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable" xlink:to="TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable_doc" xml:lang="en-US">Fair value measurement with unobservable inputs reconciliation recurring basis liability derecognition upon conversion of note payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ProbabilityOfFutureLiquidityMember" xlink:to="TVGN_ProbabilityOfFutureLiquidityMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_ProbabilityOfFutureLiquidityMember_doc" xml:lang="en-US">Probability of Future Liquidity [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DerivativeLiabilitiesFairValueIssuance" xlink:to="TVGN_DerivativeLiabilitiesFairValueIssuance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_DerivativeLiabilitiesFairValueIssuance_doc" xml:lang="en-US">Derivative liabilities fair value issuance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_EquitySecuritiesTerm" xlink:to="TVGN_EquitySecuritiesTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_EquitySecuritiesTerm_doc" xml:lang="en-US">Equity securities term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_FreeStandingPurchaseOptions" xlink:to="TVGN_FreeStandingPurchaseOptions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_FreeStandingPurchaseOptions_doc" xml:lang="en-US">Free standing purchase options.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_EmbeddedOptions" xlink:to="TVGN_EmbeddedOptions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_EmbeddedOptions_doc" xml:lang="en-US">Embedded options.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PropertyAndEquipmentUsefulLifeTableTextBlock" xlink:to="TVGN_PropertyAndEquipmentUsefulLifeTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_PropertyAndEquipmentUsefulLifeTableTextBlock_doc" xml:lang="en-US">Property And Equipment Useful Life [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:to="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_doc" xml:lang="en-US">Business combination recognized identifiable assets acquired and liabilities assumed current liabilities accrued expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_MergerTransactionCostsLimitedToCashAcquired" xlink:to="TVGN_MergerTransactionCostsLimitedToCashAcquired_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_MergerTransactionCostsLimitedToCashAcquired_doc" xml:lang="en-US">Merger transaction costs limited to cash acquired.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts" xlink:to="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts_doc" xml:lang="en-US">Business combination recognized identifiable assets acquired and liabilities assumed net plus transaction costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_EarnoutSharesMember" xlink:to="TVGN_EarnoutSharesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_EarnoutSharesMember_doc" xml:lang="en-US">Earnout Shares [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_EarnoutSharesDisclosureTextBlock" xlink:to="TVGN_EarnoutSharesDisclosureTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_EarnoutSharesDisclosureTextBlock_doc" xml:lang="en-US">Earnout Shares [Disclosure Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_TevogenBioCommonStockMember" xlink:to="TVGN_TevogenBioCommonStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_TevogenBioCommonStockMember_doc" xml:lang="en-US">Tevogen Bio Common Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SponsorMember" xlink:to="TVGN_SponsorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_SponsorMember_doc" xml:lang="en-US">Sponsor [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_LoanAgreementMember" xlink:to="TVGN_LoanAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_LoanAgreementMember_doc" xml:lang="en-US">Loan Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ThePatelFamilyLLPMember" xlink:to="TVGN_ThePatelFamilyLLPMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_ThePatelFamilyLLPMember_doc" xml:lang="en-US">The Patel Family LLP [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_AdditionalAmountPurchaseOptionMember" xlink:to="TVGN_AdditionalAmountPurchaseOptionMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_AdditionalAmountPurchaseOptionMember_doc" xml:lang="en-US">Additional Amount Purchase Option [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PolarMultiStrategyMasterFundMember" xlink:to="TVGN_PolarMultiStrategyMasterFundMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_PolarMultiStrategyMasterFundMember_doc" xml:lang="en-US">Polar Multi-Strategy Master Fund [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_TwoThousandTwentyFourPlanMember" xlink:to="TVGN_TwoThousandTwentyFourPlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_TwoThousandTwentyFourPlanMember_doc" xml:lang="en-US">2024 Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ServiceBasedRestrictedStockMember" xlink:to="TVGN_ServiceBasedRestrictedStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_ServiceBasedRestrictedStockMember_doc" xml:lang="en-US">Service-Based Restricted Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PerformanceBasedRSUsMember" xlink:to="TVGN_PerformanceBasedRSUsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_PerformanceBasedRSUsMember_doc" xml:lang="en-US">Performance-Based RSUs [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits" xlink:to="TVGN_StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits_doc" xml:lang="en-US">Stock issued during period shares settlement of vested restricted stock units.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing" xlink:to="TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing_doc" xml:lang="en-US">Vested performance based restricted stock units from satisfaction of liquidity condition upon closing.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture" xlink:to="TVGN_SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture_doc" xml:lang="en-US">Shares subject to future vesting issuance of restricted common stock subject to forfeiture.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture" xlink:to="TVGN_CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture_doc" xml:lang="en-US">Common stock shares issued and outstanding inclusion of shares to be issued and exclusion of shares subject to forfeiture.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SeriesAOnePreferredStockMember" xlink:to="TVGN_SeriesAOnePreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_SeriesAOnePreferredStockMember_doc" xml:lang="en-US">Series A1 Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodSharesConversionOfLiabilities" xlink:to="TVGN_StockIssuedDuringPeriodSharesConversionOfLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_StockIssuedDuringPeriodSharesConversionOfLiabilities_doc" xml:lang="en-US">Stock issued during period shares conversion of liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodValueConversionOfLiabilities" xlink:to="TVGN_StockIssuedDuringPeriodValueConversionOfLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_StockIssuedDuringPeriodValueConversionOfLiabilities_doc" xml:lang="en-US">Stock issued during period value conversion of liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ClassOfWarrantOrRightIssued" xlink:to="TVGN_ClassOfWarrantOrRightIssued_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_ClassOfWarrantOrRightIssued_doc" xml:lang="en-US">Class of warrant or right issued.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PublicWarrantsMember" xlink:to="TVGN_PublicWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_PublicWarrantsMember_doc" xml:lang="en-US">Public Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_WarrantsRedemptionDescription" xlink:to="TVGN_WarrantsRedemptionDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_WarrantsRedemptionDescription_doc" xml:lang="en-US">Warrants redemption description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SponsorFeesPayable" xlink:to="TVGN_SponsorFeesPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_SponsorFeesPayable_doc" xml:lang="en-US">Sponsor advisory services fee payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SponsorAdvisoryServicesFeeMember" xlink:to="TVGN_SponsorAdvisoryServicesFeeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_SponsorAdvisoryServicesFeeMember_doc" xml:lang="en-US">Sponsor Advisory Services Fee [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_WifeOfChiefExecutiveOfficerMember" xlink:to="TVGN_WifeOfChiefExecutiveOfficerMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_WifeOfChiefExecutiveOfficerMember_doc" xml:lang="en-US">Wife of Chief Executive Officer [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_MehtaphoricConsultingIncMember" xlink:to="TVGN_MehtaphoricConsultingIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_MehtaphoricConsultingIncMember_doc" xml:lang="en-US">Mehtaphoric Consulting Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_PrivateInvestorMember" xlink:label="TVGN_PrivateInvestorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PrivateInvestorMember" xlink:to="TVGN_PrivateInvestorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_PrivateInvestorMember_doc" xml:lang="en-US">Private Investor [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DrManmohanPatelMember" xlink:to="TVGN_DrManmohanPatelMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_DrManmohanPatelMember_doc" xml:lang="en-US">Dr Manmohan Patel [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ScheduleOfCompanyLeaseLiabilitiesTableTextBlock" xlink:to="TVGN_ScheduleOfCompanyLeaseLiabilitiesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_ScheduleOfCompanyLeaseLiabilitiesTableTextBlock_doc" xml:lang="en-US">Schedule Of Company Lease Liabilities [TableTextBlock]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_OperatingLeasesIncrementalBorrowingRates" xlink:to="TVGN_OperatingLeasesIncrementalBorrowingRates_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_OperatingLeasesIncrementalBorrowingRates_doc" xml:lang="en-US">Operating leases incremental borrowing rates.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest" xlink:to="TVGN_IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest_doc" xml:lang="en-US">Income tax reconciliation income tax expense benefit convertible noteinterest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="TVGN_DeferredTaxAssetsOperatingLeaseLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_DeferredTaxAssetsOperatingLeaseLiabilities_doc" xml:lang="en-US">Deferred tax assets operating lease liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DeferredTaxAssetsAccruedExpensesAndOther" xlink:to="TVGN_DeferredTaxAssetsAccruedExpensesAndOther_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_DeferredTaxAssetsAccruedExpensesAndOther_doc" xml:lang="en-US">Deferred tax assets accrued expenses and other.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DeferredTaxAssetsFixedAssets" xlink:to="TVGN_DeferredTaxAssetsFixedAssets_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_DeferredTaxAssetsFixedAssets_doc" xml:lang="en-US">Deferred tax assets fixed assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures" xlink:to="TVGN_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures_doc" xml:lang="en-US">Deferred tax assets capitalized research and development expenditures.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="TVGN_DeferredTaxLiabilitiesRightOfUseAsset_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_DeferredTaxLiabilitiesRightOfUseAsset_doc" xml:lang="en-US">Deferred tax liabilities right of use asset.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_IncreasesRecordedToIncomeTaxProvision" xlink:to="TVGN_IncreasesRecordedToIncomeTaxProvision_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_IncreasesRecordedToIncomeTaxProvision_doc" xml:lang="en-US">Increases recorded to income tax provision.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock" xlink:to="TVGN_ScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_ScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock_doc" xml:lang="en-US">Schedule Of Valuation Allowance For Net Deferred Tax Assets [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_TaxableIncomeLimitationPercentage" xlink:to="TVGN_TaxableIncomeLimitationPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_TaxableIncomeLimitationPercentage_doc" xml:lang="en-US">Taxable income limitation percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_GrantDrewFromRelatedParty" xlink:to="TVGN_GrantDrewFromRelatedParty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_GrantDrewFromRelatedParty_doc" xml:lang="en-US">Grant drew from related party.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodValueNewIssuesTwo" xlink:to="TVGN_StockIssuedDuringPeriodValueNewIssuesTwo_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_StockIssuedDuringPeriodValueNewIssuesTwo_doc" xml:lang="en-US">Stock issued during period value new issues two.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodSharesNewIssuesTwo" xlink:to="TVGN_StockIssuedDuringPeriodSharesNewIssuesTwo_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_StockIssuedDuringPeriodSharesNewIssuesTwo_doc" xml:lang="en-US">Stock issued during period shares new issues two.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ComputerAndSoftwareMember" xlink:to="TVGN_ComputerAndSoftwareMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_ComputerAndSoftwareMember_doc" xml:lang="en-US">Computer And Software [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_PrivateWarrantsMember" xlink:label="TVGN_PrivateWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PrivateWarrantsMember" xlink:to="TVGN_PrivateWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_PrivateWarrantsMember_doc" xml:lang="en-US">Private Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_MergerNetOfRedemptionsAndTransactionCosts" xlink:to="TVGN_MergerNetOfRedemptionsAndTransactionCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_MergerNetOfRedemptionsAndTransactionCosts_doc" xml:lang="en-US">Merger net of redemptions and transaction costs.</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_LinesOfCreditNoncurrent" xlink:label="TVGN_LinesOfCreditNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_LinesOfCreditNoncurrent" xlink:to="TVGN_LinesOfCreditNoncurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_LinesOfCreditNoncurrent_doc" xml:lang="en-US">Lines of credit non current.</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_LoanAgreement" xlink:label="TVGN_LoanAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_LoanAgreement" xlink:to="TVGN_LoanAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_LoanAgreement_doc" xml:lang="en-US">Loan agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement" xlink:to="TVGN_StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement_doc" xml:lang="en-US">Stock issued during period value commitment shares in connection with loan agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithLoanAgreement" xlink:to="TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithLoanAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithLoanAgreement_doc" xml:lang="en-US">Stock issued during period shares commitment shares in connection with loan agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_LoanAgreementNoncurrent" xlink:to="TVGN_LoanAgreementNoncurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_LoanAgreementNoncurrent_doc" xml:lang="en-US">Loan agreement non current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockRepurchase" xlink:to="TVGN_StockRepurchase_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_StockRepurchase_doc" xml:lang="en-US">Stock repurchase.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_KRHPLLCMember" xlink:to="TVGN_KRHPLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_KRHPLLCMember_doc" xml:lang="en-US">KRHP LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="us-gaap_ConvertibleLongTermNotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_2_lbl" xml:lang="en-US">Convertible Notes Payable, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest Expense, Operating and Nonoperating</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_3_lbl" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodSharesNewIssuesTwo" xlink:to="TVGN_StockIssuedDuringPeriodSharesNewIssuesTwo_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_StockIssuedDuringPeriodSharesNewIssuesTwo_3_lbl" xml:lang="en-US">StockIssuedDuringPeriodSharesNewIssuesTwo</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_MergerNetOfRedemptionsAndTransactionCosts" xlink:to="TVGN_MergerNetOfRedemptionsAndTransactionCosts_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_MergerNetOfRedemptionsAndTransactionCosts_3_lbl" xml:lang="en-US">MergerNetOfRedemptionsAndTransactionCosts</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_2_lbl" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_2_lbl" xml:lang="en-US">Payment of Financing and Stock Issuance Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_2_lbl" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3_lbl" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DerivativeLiabilitiesFairValueIssuance" xlink:to="TVGN_DerivativeLiabilitiesFairValueIssuance_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_DerivativeLiabilitiesFairValueIssuance_3_lbl" xml:lang="en-US">DerivativeLiabilitiesFairValueIssuance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_2_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:to="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_3_lbl" xml:lang="en-US">BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_2_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-Term Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_2_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_2_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts" xlink:to="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts_3_lbl" xml:lang="en-US">BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_2_lbl" xml:lang="en-US">Operating Lease, Liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_2_lbl" xml:lang="en-US">Preferred Stock Dividends, Income Statement Impact</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_2_lbl" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_4_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="TVGN_DeferredTaxLiabilitiesRightOfUseAsset_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_DeferredTaxLiabilitiesRightOfUseAsset_3_lbl" xml:lang="en-US">DeferredTaxLiabilitiesRightOfUseAsset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivables_2_lbl" xml:lang="en-US">Other Receivables</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>17
<FILENAME>tvgn-20241231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://tevogen.com/role/Cover" xlink:href="tvgn-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/BalanceSheets" xlink:href="tvgn-20241231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/BalanceSheetsParenthetical" xlink:href="tvgn-20241231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/StatementsOfOperations" xlink:href="tvgn-20241231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit" xlink:href="tvgn-20241231.xsd#StatementsOfChangesInStockholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="tvgn-20241231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/NatureOfBusiness" xlink:href="tvgn-20241231.xsd#NatureOfBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Development-stageRisksAndLiquidity" xlink:href="tvgn-20241231.xsd#Development-stageRisksAndLiquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="tvgn-20241231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/BusinessCombination" xlink:href="tvgn-20241231.xsd#BusinessCombination" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/EarnoutShares" xlink:href="tvgn-20241231.xsd#EarnoutShares" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/PropertyAndEquipmentNet" xlink:href="tvgn-20241231.xsd#PropertyAndEquipmentNet" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/AccruedExpensesAndOtherLiabilities" xlink:href="tvgn-20241231.xsd#AccruedExpensesAndOtherLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Debt" xlink:href="tvgn-20241231.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Leases" xlink:href="tvgn-20241231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/CommitmentsAndContingencies" xlink:href="tvgn-20241231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Stock-basedCompensation" xlink:href="tvgn-20241231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/StockholdersDeficit" xlink:href="tvgn-20241231.xsd#StockholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/NetLossPerShare" xlink:href="tvgn-20241231.xsd#NetLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/IncomeTaxes" xlink:href="tvgn-20241231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/RelatedPartyTransactions" xlink:href="tvgn-20241231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SegmentReporting" xlink:href="tvgn-20241231.xsd#SegmentReporting" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SubsequentEvents" xlink:href="tvgn-20241231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="tvgn-20241231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="tvgn-20241231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/BusinessCombinationTables" xlink:href="tvgn-20241231.xsd#BusinessCombinationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/PropertyAndEquipmentNetTables" xlink:href="tvgn-20241231.xsd#PropertyAndEquipmentNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/AccruedExpensesAndOtherLiabilitiesTables" xlink:href="tvgn-20241231.xsd#AccruedExpensesAndOtherLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/LeasesTables" xlink:href="tvgn-20241231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Stock-basedCompensationTables" xlink:href="tvgn-20241231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/StockholdersDeficitTables" xlink:href="tvgn-20241231.xsd#StockholdersDeficitTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/NetLossPerShareTables" xlink:href="tvgn-20241231.xsd#NetLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/IncomeTaxesTables" xlink:href="tvgn-20241231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/NatureOfBusinessDetailsNarrative" xlink:href="tvgn-20241231.xsd#NatureOfBusinessDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative" xlink:href="tvgn-20241231.xsd#Development-stageRisksAndLiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfFairValueMeasurementDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfFairValuesOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfPropertyAndEquipmentUsefulLifeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="tvgn-20241231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfNetLiabilitiesAcquiredInMergerDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/BusinessCombinationDetailsNarrative" xlink:href="tvgn-20241231.xsd#BusinessCombinationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/EarnoutSharesDetailsNarrative" xlink:href="tvgn-20241231.xsd#EarnoutSharesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:href="tvgn-20241231.xsd#PropertyAndEquipmentNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/DebtDetailsNarrative" xlink:href="tvgn-20241231.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfMinimumRentalPaymentsUnderOperatingLeasesDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfMinimumRentalPaymentsUnderOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/LeasesDetailsNarrative" xlink:href="tvgn-20241231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfRestrictedStockAndRsuActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfStock-basedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="tvgn-20241231.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/StockholdersDeficitDetailsNarrative" xlink:href="tvgn-20241231.xsd#StockholdersDeficitDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfReconciliationOfNetLossDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfReconciliationOfNetLossDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfAnti-dilutiveNetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical" xlink:href="tvgn-20241231.xsd#ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/NetLossPerShareDetailsNarrative" xlink:href="tvgn-20241231.xsd#NetLossPerShareDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfValuationAllowanceForNetDeferredTaxAssetsDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfValuationAllowanceForNetDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/IncomeTaxesDetailsNarrative" xlink:href="tvgn-20241231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="tvgn-20241231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SubsequentEventsDetailsNarrative" xlink:href="tvgn-20241231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesTable" xlink:label="loc_deiEntityAddressesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesLineItems" xlink:label="loc_deiEntityAddressesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_deiEntityAddressesAddressTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesAddressTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember" xlink:label="loc_deiBusinessContactMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiAddressTypeDomain" xlink:to="loc_deiBusinessContactMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName" xlink:label="loc_deiContactPersonnelName" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiContactPersonnelName" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOtherReceivablesNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaapDeferredCosts" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapDeferredCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaapConvertibleLongTermNotesPayable" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapConvertibleLongTermNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_LoanAgreementNoncurrent" xlink:label="loc_TVGNLoanAgreementNoncurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_TVGNLoanAgreementNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="loc_us-gaapPreferredStockLiquidationPreferenceValue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockLiquidationPreferenceValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="loc_us-gaapBusinessCombinationAcquisitionRelatedCosts" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapBusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ChangeInFairValueOfConvertiblePromissoryNotes" xlink:label="loc_TVGNChangeInFairValueOfConvertiblePromissoryNotes" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_TVGNChangeInFairValueOfConvertiblePromissoryNotes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_LossOnIssuanceOfCommitmentShares" xlink:label="loc_TVGNLossOnIssuanceOfCommitmentShares" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_TVGNLossOnIssuanceOfCommitmentShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Deficit">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapSeriesCPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodValueNewIssuesTwo" xlink:label="loc_TVGNStockIssuedDuringPeriodValueNewIssuesTwo" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodValueNewIssuesTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodSharesNewIssuesTwo" xlink:label="loc_TVGNStockIssuedDuringPeriodSharesNewIssuesTwo" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodSharesNewIssuesTwo" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodValueNewIssuesOne" xlink:label="loc_TVGNStockIssuedDuringPeriodValueNewIssuesOne" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodValueNewIssuesOne" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodSharesNewIssuesOne" xlink:label="loc_TVGNStockIssuedDuringPeriodSharesNewIssuesOne" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodSharesNewIssuesOne" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_MergerNetOfRedemptionsAndTransactionCosts" xlink:label="loc_TVGNMergerNetOfRedemptionsAndTransactionCosts" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNMergerNetOfRedemptionsAndTransactionCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement" xlink:label="loc_TVGNStockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithLoanAgreement" xlink:label="loc_TVGNStockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithLoanAgreement" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithLoanAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodValueContributionFromRelatedParty" xlink:label="loc_TVGNStockIssuedDuringPeriodValueContributionFromRelatedParty" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodValueContributionFromRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodSharesContributionFromRelatedParty" xlink:label="loc_TVGNStockIssuedDuringPeriodSharesContributionFromRelatedParty" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodSharesContributionFromRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalMarkToMarket" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalMarkToMarket" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits" xlink:label="loc_TVGNStockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits" xlink:label="loc_TVGNStockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement -  Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaapPaidInKindInterest" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapPaidInKindInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashMergerRelatedCosts" xlink:label="loc_us-gaapNoncashMergerRelatedCosts" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNoncashMergerRelatedCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ChangeInFairValueOfConvertiblePromissoryNotes" xlink:label="loc_TVGNChangeInFairValueOfConvertiblePromissoryNotes" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_TVGNChangeInFairValueOfConvertiblePromissoryNotes" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_LossOnPreferredStockIssuance" xlink:label="loc_TVGNLossOnPreferredStockIssuance" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_TVGNLossOnPreferredStockIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_LossOnIssuanceOfCommitmentShares" xlink:label="loc_TVGNLossOnIssuanceOfCommitmentShares" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_TVGNLossOnIssuanceOfCommitmentShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_CashAcquiredInConnectionWithReverseRecapitalization" xlink:label="loc_TVGNCashAcquiredInConnectionWithReverseRecapitalization" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_TVGNCashAcquiredInConnectionWithReverseRecapitalization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ProceedsFromIssuanceOfSeriesCPreferredStock" xlink:label="loc_TVGNProceedsFromIssuanceOfSeriesCPreferredStock" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_TVGNProceedsFromIssuanceOfSeriesCPreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaapProceedsFromLinesOfCredit" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromLinesOfCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance" xlink:label="loc_TVGNNonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_TVGNNonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="loc_us-gaapPaymentOfFinancingAndStockIssuanceCosts" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentOfFinancingAndStockIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ReverseRecapitalizationTransactionFeesIncludedInAccruedExpensesAndOtherLiabilities" xlink:label="loc_TVGNReverseRecapitalizationTransactionFeesIncludedInAccruedExpensesAndOtherLiabilities" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_TVGNReverseRecapitalizationTransactionFeesIncludedInAccruedExpensesAndOtherLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaapDebtConversionOriginalDebtAmount1" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapDebtConversionOriginalDebtAmount1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_RepurchaseOfSeriesBPreferredStock" xlink:label="loc_TVGNRepurchaseOfSeriesBPreferredStock" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_TVGNRepurchaseOfSeriesBPreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaapStockIssued1" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapStockIssued1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/NatureOfBusiness" xlink:title="999007 - Disclosure - NATURE OF BUSINESS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/Development-stageRisksAndLiquidity" xlink:title="999008 - Disclosure - DEVELOPMENT-STAGE RISKS AND LIQUIDITY">
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DisclosureDevelopmentstageRisksAndLiquidityAbstract" xlink:label="loc_TVGNDisclosureDevelopmentstageRisksAndLiquidityAbstract" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DevelopmentStageRisksAndLiquidityTextBlock" xlink:label="loc_TVGNDevelopmentStageRisksAndLiquidityTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TVGNDisclosureDevelopmentstageRisksAndLiquidityAbstract" xlink:to="loc_TVGNDevelopmentStageRisksAndLiquidityTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/BusinessCombination" xlink:title="999010 - Disclosure - BUSINESS COMBINATION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaapBusinessCombinationDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapBusinessCombinationDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/EarnoutShares" xlink:title="999011 - Disclosure - EARNOUT SHARES">
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DisclosureEarnoutSharesAbstract" xlink:label="loc_TVGNDisclosureEarnoutSharesAbstract" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_EarnoutSharesDisclosureTextBlock" xlink:label="loc_TVGNEarnoutSharesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TVGNDisclosureEarnoutSharesAbstract" xlink:to="loc_TVGNEarnoutSharesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/PropertyAndEquipmentNet" xlink:title="999012 - Disclosure - PROPERTY AND EQUIPMENT, NET">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/AccruedExpensesAndOtherLiabilities" xlink:title="999013 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/Debt" xlink:title="999014 - Disclosure - DEBT">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/Leases" xlink:title="999015 - Disclosure - LEASES">
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DisclosureLeasesAbstract" xlink:label="loc_TVGNDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:label="loc_us-gaapOperatingLeasesOfLessorDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TVGNDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeasesOfLessorDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/CommitmentsAndContingencies" xlink:title="999016 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/Stock-basedCompensation" xlink:title="999017 - Disclosure - STOCK-BASED COMPENSATION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/StockholdersDeficit" xlink:title="999018 - Disclosure - STOCKHOLDERS&#8217; DEFICIT">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/NetLossPerShare" xlink:title="999019 - Disclosure - NET LOSS PER SHARE">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/IncomeTaxes" xlink:title="999020 - Disclosure - INCOME TAXES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/RelatedPartyTransactions" xlink:title="999021 - Disclosure - RELATED PARTY TRANSACTIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/SegmentReporting" xlink:title="999022 - Disclosure - SEGMENT REPORTING">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaapSegmentReportingDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapSegmentReportingDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/SubsequentEvents" xlink:title="999023 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_FreestandingAndEmbeddedCommonStockOptionsPolicyTextBlock" xlink:label="loc_TVGNFreestandingAndEmbeddedCommonStockOptionsPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_TVGNFreestandingAndEmbeddedCommonStockOptionsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaapDerivativesPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDerivativesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_PropertyAndEquipmentUsefulLifeTableTextBlock" xlink:label="loc_TVGNPropertyAndEquipmentUsefulLifeTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_TVGNPropertyAndEquipmentUsefulLifeTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/BusinessCombinationTables" xlink:title="999026 - Disclosure - BUSINESS COMBINATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/PropertyAndEquipmentNetTables" xlink:title="999027 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/AccruedExpensesAndOtherLiabilitiesTables" xlink:title="999028 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/LeasesTables" xlink:title="999029 - Disclosure - LEASES (Tables)">
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DisclosureLeasesAbstract" xlink:label="loc_TVGNDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ScheduleOfCompanyLeaseLiabilitiesTableTextBlock" xlink:label="loc_TVGNScheduleOfCompanyLeaseLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TVGNDisclosureLeasesAbstract" xlink:to="loc_TVGNScheduleOfCompanyLeaseLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/Stock-basedCompensationTables" xlink:title="999030 - Disclosure - STOCK-BASED COMPENSATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/StockholdersDeficitTables" xlink:title="999031 - Disclosure - STOCKHOLDERS&#8217; DEFICIT (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/NetLossPerShareTables" xlink:title="999032 - Disclosure - NET LOSS PER SHARE (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/IncomeTaxesTables" xlink:title="999033 - Disclosure - INCOME TAXES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock" xlink:label="loc_TVGNScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_TVGNScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/NatureOfBusinessDetailsNarrative" xlink:title="999034 - Disclosure - NATURE OF BUSINESS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_TevogenBioMember" xlink:label="loc_TVGNTevogenBioMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_TVGNTevogenBioMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_SemperParatusMember" xlink:label="loc_TVGNSemperParatusMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_TVGNSemperParatusMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_BusinessCombinationSharesExchangeRatio" xlink:label="loc_TVGNBusinessCombinationSharesExchangeRatio" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNBusinessCombinationSharesExchangeRatio" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative" xlink:title="999035 - Disclosure - DEVELOPMENT-STAGE RISKS AND LIQUIDITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DisclosureDevelopmentstageRisksAndLiquidityAbstract" xlink:label="loc_TVGNDisclosureDevelopmentstageRisksAndLiquidityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TVGNDisclosureDevelopmentstageRisksAndLiquidityAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_LoanAgreementMember" xlink:label="loc_TVGNLoanAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_TVGNLoanAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_GrantDrewFromRelatedParty" xlink:label="loc_TVGNGrantDrewFromRelatedParty" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_TVGNGrantDrewFromRelatedParty" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails" xlink:title="999036 - Disclosure - SCHEDULE OF FAIR VALUE MEASUREMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_srtPlatformOperatorCryptoAssetLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest" xlink:label="loc_TVGNFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_TVGNFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable" xlink:label="loc_TVGNFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_TVGNFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails" xlink:title="999037 - Disclosure - SCHEDULE OF FAIR VALUES OF WARRANTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_srtPlatformOperatorCryptoAssetLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CallOptionMember" xlink:label="loc_us-gaapCallOptionMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_us-gaapCallOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DerivativeLiabilitiesFairValueIssuance" xlink:label="loc_TVGNDerivativeLiabilitiesFairValueIssuance" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_TVGNDerivativeLiabilitiesFairValueIssuance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="999038 - Disclosure - SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_srtPlatformOperatorCryptoAssetLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails" xlink:title="999039 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999040 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaapMeasurementInputDiscountRateMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputDiscountRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ProbabilityOfFutureLiquidityMember" xlink:label="loc_TVGNProbabilityOfFutureLiquidityMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_TVGNProbabilityOfFutureLiquidityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="loc_us-gaapMeasurementInputOptionVolatilityMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputOptionVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaapNumberOfOperatingSegments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapNumberOfOperatingSegments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="loc_us-gaapDebtInstrumentMeasurementInput" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDebtInstrumentMeasurementInput" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:label="loc_us-gaapEquitySecuritiesFvNiMeasurementInput" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapEquitySecuritiesFvNiMeasurementInput" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_EquitySecuritiesTerm" xlink:label="loc_TVGNEquitySecuritiesTerm" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_TVGNEquitySecuritiesTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_FreeStandingPurchaseOptions" xlink:label="loc_TVGNFreeStandingPurchaseOptions" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_TVGNFreeStandingPurchaseOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_EmbeddedOptions" xlink:label="loc_TVGNEmbeddedOptions" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_TVGNEmbeddedOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:label="loc_us-gaapAlternativeInvestmentMeasurementInput" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAlternativeInvestmentMeasurementInput" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeNet" xlink:label="loc_us-gaapDerivativeFairValueOfDerivativeNet" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDerivativeFairValueOfDerivativeNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails" xlink:title="999041 - Disclosure - SCHEDULE OF NET LIABILITIES ACQUIRED IN MERGER (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:label="loc_TVGNBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_TVGNBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_MergerTransactionCostsLimitedToCashAcquired" xlink:label="loc_TVGNMergerTransactionCostsLimitedToCashAcquired" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_TVGNMergerTransactionCostsLimitedToCashAcquired" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts" xlink:label="loc_TVGNBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_TVGNBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/BusinessCombinationDetailsNarrative" xlink:title="999042 - Disclosure - BUSINESS COMBINATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_TevogenBioMember" xlink:label="loc_TVGNTevogenBioMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_TVGNTevogenBioMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_EarnoutSharesMember" xlink:label="loc_TVGNEarnoutSharesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_TVGNEarnoutSharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="loc_us-gaapBusinessCombinationAcquisitionRelatedCosts" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="loc_us-gaapBusinessAcquisitionCostOfAcquiredEntityTransactionCosts" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodValueNewIssuesOne" xlink:label="loc_TVGNStockIssuedDuringPeriodValueNewIssuesOne" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodValueNewIssuesOne" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/EarnoutSharesDetailsNarrative" xlink:title="999043 - Disclosure - EARNOUT SHARES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DisclosureEarnoutSharesAbstract" xlink:label="loc_TVGNDisclosureEarnoutSharesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TVGNDisclosureEarnoutSharesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_TevogenBioCommonStockMember" xlink:label="loc_TVGNTevogenBioCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_TVGNTevogenBioCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_SponsorMember" xlink:label="loc_TVGNSponsorMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_TVGNSponsorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_EarnoutSharesMember" xlink:label="loc_TVGNEarnoutSharesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_TVGNEarnoutSharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapVestingAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheOneMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheThreeMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="999044 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ComputerAndSoftwareMember" xlink:label="loc_TVGNComputerAndSoftwareMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_TVGNComputerAndSoftwareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:title="999045 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" xlink:title="999046 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/DebtDetailsNarrative" xlink:title="999047 - Disclosure - DEBT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_LoanAgreementMember" xlink:label="loc_TVGNLoanAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_TVGNLoanAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ThePatelFamilyLLPMember" xlink:label="loc_TVGNThePatelFamilyLLPMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_TVGNThePatelFamilyLLPMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_PolarMultiStrategyMasterFundMember" xlink:label="loc_TVGNPolarMultiStrategyMasterFundMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_TVGNPolarMultiStrategyMasterFundMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaapUnsecuredDebtMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_us-gaapUnsecuredDebtMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtRangeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_AdditionalAmountPurchaseOptionMember" xlink:label="loc_TVGNAdditionalAmountPurchaseOptionMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_TVGNAdditionalAmountPurchaseOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityCurrentBorrowingCapacity" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityCurrentBorrowingCapacity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaapDebtInstrumentTerm" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityRemainingBorrowingCapacity" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:label="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensationGross" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaapDerivativeLiabilities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDerivativeLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility" xlink:label="loc_TVGNStockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfMinimumRentalPaymentsUnderOperatingLeasesDetails" xlink:title="999048 - Disclosure - SCHEDULE OF MINIMUM RENTAL PAYMENTS UNDER THE OPERATING LEASES (Details)">
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DisclosureLeasesAbstract" xlink:label="loc_TVGNDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TVGNDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TVGNDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TVGNDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TVGNDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TVGNDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/LeasesDetailsNarrative" xlink:title="999049 - Disclosure - LEASES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DisclosureLeasesAbstract" xlink:label="loc_TVGNDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TVGNDisclosureLeasesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_OperatingLeasesIncrementalBorrowingRates" xlink:label="loc_TVGNOperatingLeasesIncrementalBorrowingRates" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNOperatingLeasesIncrementalBorrowingRates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeasePayments" xlink:label="loc_us-gaapShortTermLeasePayments" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShortTermLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails" xlink:title="999050 - Disclosure - SCHEDULE OF RESTRICTED STOCK AND RSU ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ServiceBasedRestrictedStockMember" xlink:label="loc_TVGNServiceBasedRestrictedStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_TVGNServiceBasedRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_PerformanceBasedRSUsMember" xlink:label="loc_TVGNPerformanceBasedRSUsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_TVGNPerformanceBasedRSUsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:title="999051 - Disclosure - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="999052 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_TwoThousandTwentyFourPlanMember" xlink:label="loc_TVGNTwoThousandTwentyFourPlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_TVGNTwoThousandTwentyFourPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_PerformanceBasedRSUsMember" xlink:label="loc_TVGNPerformanceBasedRSUsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_TVGNPerformanceBasedRSUsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ServiceBasedRestrictedStockMember" xlink:label="loc_TVGNServiceBasedRestrictedStockMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_TVGNServiceBasedRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits" xlink:label="loc_TVGNStockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing" xlink:label="loc_TVGNVestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_TVGNVestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPCompensationExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails" xlink:title="999053 - Disclosure - SCHEDULE OF RECONCILIATION OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing" xlink:label="loc_TVGNVestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_TVGNVestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture" xlink:label="loc_TVGNSharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_TVGNSharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture" xlink:label="loc_TVGNCommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_TVGNCommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/StockholdersDeficitDetailsNarrative" xlink:title="999054 - Disclosure - STOCKHOLDERS&#8217; DEFICIT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_SeriesAOnePreferredStockMember" xlink:label="loc_TVGNSeriesAOnePreferredStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_TVGNSeriesAOnePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapInvestorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ThePatelFamilyLLPMember" xlink:label="loc_TVGNThePatelFamilyLLPMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_TVGNThePatelFamilyLLPMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_SemperParatusMember" xlink:label="loc_TVGNSemperParatusMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_TVGNSemperParatusMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_PublicWarrantsMember" xlink:label="loc_TVGNPublicWarrantsMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_TVGNPublicWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_LossOnPreferredStockIssuance" xlink:label="loc_TVGNLossOnPreferredStockIssuance" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNLossOnPreferredStockIssuance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendPaymentRateVariable" xlink:label="loc_us-gaapPreferredStockDividendPaymentRateVariable" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockDividendPaymentRateVariable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="loc_us-gaapPreferredStockRedemptionPricePerShare" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockRedemptionPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockRedemptionTerms" xlink:label="loc_us-gaapPreferredStockRedemptionTerms" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockRedemptionTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Deposits" xlink:label="loc_us-gaapDeposits" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDeposits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodSharesConversionOfLiabilities" xlink:label="loc_TVGNStockIssuedDuringPeriodSharesConversionOfLiabilities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodSharesConversionOfLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodValueConversionOfLiabilities" xlink:label="loc_TVGNStockIssuedDuringPeriodValueConversionOfLiabilities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodValueConversionOfLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="loc_us-gaapLiabilitiesAssumed1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapLiabilitiesAssumed1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ClassOfWarrantOrRightIssued" xlink:label="loc_TVGNClassOfWarrantOrRightIssued" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNClassOfWarrantOrRightIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_WarrantsRedemptionDescription" xlink:label="loc_TVGNWarrantsRedemptionDescription" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNWarrantsRedemptionDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfReconciliationOfNetLossDetails" xlink:title="999055 - Disclosure - SCHEDULE OF RECONCILIATION OF NET LOSS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="loc_us-gaapEarningsPerShareBasicLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="loc_us-gaapEarningsPerShareBasicLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockRepurchase" xlink:label="loc_TVGNStockRepurchase" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_TVGNStockRepurchase" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails" xlink:title="999056 - Disclosure - SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaapConvertibleDebtSecuritiesMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapConvertibleDebtSecuritiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_EarnoutSharesMember" xlink:label="loc_TVGNEarnoutSharesMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_TVGNEarnoutSharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical" xlink:title="999057 - Disclosure - SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/NetLossPerShareDetailsNarrative" xlink:title="999058 - Disclosure - NET LOSS PER SHARE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaapDerivativeLiabilities" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapDerivativeLiabilities" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails" xlink:title="999059 - Disclosure - SCHEDULE OF RECONCILIATION OF INCOME TAX BENEFIT AT THE FEDERAL STATUTORY INCOME TAX RATE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest" xlink:label="loc_TVGNIncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_TVGNIncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsOther" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCredits" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="999060 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="loc_us-gaapDeferredTaxAssetsGrossAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DeferredTaxAssetsAccruedExpensesAndOther" xlink:label="loc_TVGNDeferredTaxAssetsAccruedExpensesAndOther" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_TVGNDeferredTaxAssetsAccruedExpensesAndOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="loc_TVGNDeferredTaxAssetsOperatingLeaseLiabilities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_TVGNDeferredTaxAssetsOperatingLeaseLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DeferredTaxAssetsFixedAssets" xlink:label="loc_TVGNDeferredTaxAssetsFixedAssets" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_TVGNDeferredTaxAssetsFixedAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures" xlink:label="loc_TVGNDeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_TVGNDeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaapDeferredTaxLiabilitiesAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="loc_TVGNDeferredTaxLiabilitiesRightOfUseAsset" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_TVGNDeferredTaxLiabilitiesRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfValuationAllowanceForNetDeferredTaxAssetsDetails" xlink:title="999061 - Disclosure - SCHEDULE OF VALUATION ALLOWANCE FOR NET DEFERRED TAX ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_IncreasesRecordedToIncomeTaxProvision" xlink:label="loc_TVGNIncreasesRecordedToIncomeTaxProvision" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_TVGNIncreasesRecordedToIncomeTaxProvision" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance_2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/IncomeTaxesDetailsNarrative" xlink:title="999062 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_TaxableIncomeLimitationPercentage" xlink:label="loc_TVGNTaxableIncomeLimitationPercentage" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_TVGNTaxableIncomeLimitationPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaapIncomeTaxExaminationPenaltiesAndInterestAccrued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="999063 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_SponsorMember" xlink:label="loc_TVGNSponsorMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_TVGNSponsorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_MehtaphoricConsultingIncMember" xlink:label="loc_TVGNMehtaphoricConsultingIncMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_TVGNMehtaphoricConsultingIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ThePatelFamilyLLPMember" xlink:label="loc_TVGNThePatelFamilyLLPMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_TVGNThePatelFamilyLLPMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DrManmohanPatelMember" xlink:label="loc_TVGNDrManmohanPatelMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_TVGNDrManmohanPatelMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_SponsorAdvisoryServicesFeeMember" xlink:label="loc_TVGNSponsorAdvisoryServicesFeeMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_TVGNSponsorAdvisoryServicesFeeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_LoanAgreementMember" xlink:label="loc_TVGNLoanAgreementMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_TVGNLoanAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapAwardTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_PerformanceBasedRSUsMember" xlink:label="loc_TVGNPerformanceBasedRSUsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_TVGNPerformanceBasedRSUsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtTitleOfIndividualAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_WifeOfChiefExecutiveOfficerMember" xlink:label="loc_TVGNWifeOfChiefExecutiveOfficerMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_TVGNWifeOfChiefExecutiveOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaapUnsecuredDebtMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_us-gaapUnsecuredDebtMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SponsorFees" xlink:label="loc_us-gaapSponsorFees" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSponsorFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_SponsorFeesPayable" xlink:label="loc_TVGNSponsorFeesPayable" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_TVGNSponsorFeesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaapOtherLiabilities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOtherLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaapOtherReceivables" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOtherReceivables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPCompensationExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityRemainingBorrowingCapacity" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/SubsequentEventsDetailsNarrative" xlink:title="999064 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_KRHPLLCMember" xlink:label="loc_TVGNKRHPLLCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_TVGNKRHPLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapOtherReceivablesNetCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaapLineOfCredit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapLineOfCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityRemainingBorrowingCapacity" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>83
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( $V)GEI&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( $V)GEK/$Y=>\@   "L"   1
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MNIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#
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M"CS<_N\-L,+$CN'MB[\!4$L#!!0    ( $V)GEJ:UL'UDP@  #@>   8
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MCYU=D>/=0..'Z&J4AG':<%!FP>&KAEPXO3Z;?[N]HJ\?Z?S;[-/UU6QV/ S
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M!K^][9%+=\#T$FP=[UT+&W"+BX\%KLW*\09\7UJ0WKZP@NU%_/3_4$L#!!0
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M@ ZW7_3BX+AS\/JX\_KH6+V,D)V)1;.>5$C8'4\Y<9:NS),<!BQ0U._COR/
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M\/LLSTO_!UU0OP[_X?\ 4$L#!!0    ( $V)GEKDW"PDF <  !D1   9
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MV(FYQ>C3+BEOQP>=5;G\N'(#-)=*=#AT!:Y@L-,.B]0XWW_OWVUVOUMV D\
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M&GJ6N&%.[T!4=@-]7TII=A/KH'U93OX'4$L#!!0    ( $V)GEKSW)Y770,
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MH/KABYXO"OKA^/W;E9RKL2J^KAYR?#OVJ\1ZJ5*CLU3D:O;N8-!]\^&4QO.
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M6+R?2N.6A$#*:0GR2<U-5*>^32431>660 &8XQ2!JG)_^Q3]TQ=0<D\WKS8
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M73&6*YDG&CHM5WS3TJ,6'C4 PUO4<^"E1)(C2IG8=& YO7$UM#8!'7DVL^_
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MN:#2$27V)&9; ._A(.Z':9*&_5$$A_8\C,)!FH9#>P[FJ#AJ&%-#E8U@=@X
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M=V]R:W-H965T<R]S:&5E=#(P+GAM;*U:76_;N!)]UZ\@LMU%"ZB.+7_$Z4<
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MNU P2T_NKV82X,31>Z3P+^+C%%IQPU/IDOK>G\36Y''4+ DR!%P60*B6V1U
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M60#?EP;5WTSX@-UK_.)O4$L#!!0    ( $V)GEJVQ:5_8@4  %L,   9
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MV+PP264Z)9ZQ%8R2=9%KCLL0_NRL+)*=M4P\2E>^D=^&^]:: OFN^+)4B7'
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MU?%K #INWNCYT6GGZ-5IY]7)J7@1(((T&LUR4B#-L33E=,.4,_=2&+!PHL$
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M#>7V,:*O()1&@-XO!=7C=F$,[+^K>O\ 4$L#!!0    ( $V)GEKWN<ZH3P,
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MNQ0:KX$52SR_($T ^@LA]%XQ!0X'/?D+4$L#!!0    ( $V)GEHXT_F(PP(
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M['5]4/5#5#M&EF[X)])0+YVYI;<;E0V@_;4D<7O'%CC\&QC]!U!+ P04
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M<!N:4LF<:RW5$Q324+Y<K([1A/X@]*-!W[.MB[ZJ==?2$'7\+E$Y3;:E-$Q
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M-6R@BU9W>>^EU+Z'RQ&%'5I2D@F_4\PA0FM,^;=&TUMY!YMN-_S$;#1=9]A
M%ZTPW=P[%,B KM1I#$,AV>2\.!^H[E8G/A-USF'^[%X<%XGWVU62,Y3"4DBM
MH[YPAA8G,$6#D[4Z8E@0SDFF+F/ $5#903Q?$L)O&S) =0[F_0!02P,$%
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MEW8[W.OF"X4QT.^W7%^":F(VJ-NYT7=02P,$%     @ 38F>6F"0(BN>!
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M$ 91\A_]3(78"W#;1P)@&@!/#6BD 8VW <TC <TT();:3DJ)=?"10,,^HSO
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MO8G#1?KPM:<PCD,_?3GG;,)%4D!^/PW#^/U-TL#Z@7_]_P!02P,$%     @
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M*G"SWU,FI.@CUB"%1TD,A]XH&KEGM'KL@CCV0_^,E#$S?:K>B JG,+'4L2F
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M8_+,SE$F?@@1]VF$&$S[UCD^&[I)0/+$=Q]6O#1&BLJ8TB=U\FW2MQPU(PC
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MQO4#]^"S"#HFA=(8E,:A-(&BF6XU$85GCR@.W0J37!7CY,?=@F8+->W K?'
M^'$.58-&"% :@](XE"90-%.U)D+PK/WA4]?NL%=W%FM+F^SO&ET,#T6"!@%0
M&H/2.)0F4#13I+VK#]F#@$]9MI;)]ARVXU&]'=+9IY:O%[3ND[<M.)GX!Z>W
M4>C:,2B-0VD"13-E:9KYGKV9?W \=]YW2>W,SNZ\;^I[@W9YSEV20M>006D<
M2A,HFNE/T[;W_L]M^^*53I=TL*]?9Q>A+7THC4)I#$KC4)I T4RGFY:^AVWI
M>]"6/I060&D42F-0&H?2!(IF*MBT]+U.+?WSVJQV9F</H1=+@M(HE,:\]Z%%
MZ\XK/W=!@5H_TYZF2>^=:-+_!9/R?9TJ6>=B:)\?2@N@- JE,2B-0VD"13-5
M;A(##WN=)0^:'4!I 91&H30&I7$H3:!HYB5UFWS!M^<+IRZJ"TT3:IJ],0<=
MDD)I#$KC4)I T4R1FC#!MX<)=]O3<1^K+Y3:YE$[I[-2T"\H0&D42F-0&H?2
M!(IFNM>D"S[V"PH^-&Z T@(HC4)I#$KC4)I T4P%FUS"M^<2=VFR43HOCBV.
MIQ)^6X[@>6/?N33GP#O[8)V5.G=<"AV706D<2A,HVE:7_M[]7V*EGZM[ 65D
M7GY[;WLKF-VSN_L-W51WV>DWBV]O5G0O]7.89"123T7IX&)<')#K[?U_M@_R
M=%7=36:6YGD:5[\NE5PH72Y0O/Z4IOG;@W* W5V8IO\#4$L#!!0    ( $V)
MGEJ=U.E0> (  .\%   9    >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;(64
M;6_:,!2%_XJ535,G;4W(:\M")%K2@004$=BTCR9<P*H39[:!]M_/=FB$VI3Q
M(;$=G_.<BU_B(^-/8@<@T7-!2]&S=E)67=L6^0X*+*Y9!:7ZLF&\P%)U^=86
M%0>\-J*"VJ[CA':!26DEL1F;\21F>TE)"3..Q+XH,'^Y \J./:MCO0[,R78G
M]8"=Q!7>0@9R6<VXZMF-RYH44 K"2L1AT[/ZG>Y=I.>;";\(',59&^E*5HP]
MZ<YHW;,<'0@HY%([8/4ZP#U0JHU4C+\G3ZM!:N%Y^]7]P=2N:EEA ?>,_B9K
MN>M9-Q9:PP;OJ9RSXQ!.]03:+V=4F"<ZUG,CST+Y7DA6G,0J04'*^HV?3__#
MF<!U/Q"X)X%K<M<@DW* )4YBSHZ(Z]G*33=,J4:MPI%2+THFN?I*E$XFV?TP
M'2S'*7I\0)/1=#193M \G2[Z8S3K_YFH5H:6TT$Z1XNAFC1+Y_W%:/H3C=-^
MEF;H:@ 2$RJ^QK94:;2GG9_(=S79_8 \@/P:>9UOR'5<'RVS ;KZ_,;&5L4T
M%;E-1:[Q]3[P'8-:)-&6I];Y[3J]^[NBPCGT++6]!? #6,F73YW0^7$AE=>D
M\BZY)ZK(H"U3K0J,2A^@0^)ZCA]U8OO00O,;FO\_6MA&JU7A&:WCW49!.RQH
M8,%%V())3-MHP3N:ZZM?V(X+&UQX$3<&(;J(%-5>PAJ14H):+=G&#]_QO]\&
M-U$[/FKPT47\8P4<2U)N$=4;#5&"5X02^=*6(&I97?\FN'T3P3X[O_HJG&"^
M):50A(T2.M>1<N#U]5)W)*O,D5XQJ2X(T]RI&QFXGJ"^;QB3KQU]2S1W?/(/
M4$L#!!0    ( $V)GEHOO5;ULP,  '\/   9    >&PO=V]R:W-H965T<R]S
M:&5E=#0Y+GAM;+576X_B-A3^*U9:5;O2=A('0L(4D+A,+U)I1X.V?:CZ8)(#
MB3:)4]O S+]?7S(!THR[4/8%XLOY?+[S^7+.Z$#9)YX""/1<Y"4?.ZD0U;WK
M\CB%@O [6D$I1S:4%43()MNZO&) $FU4Y*[O>0.W(%GI3$:Z[Y%-1G0G\JR$
M1X;XKB@(>YE!3@]C!SNO'4_9-A6JPYV,*K*%%8B/U2.3+;=!2;("2I[1$C'8
MC)TIOI_C0!GH&7]D<. GWTA165/Z235^2<:.ISR"'&*A((C\V\,<\EPA23_^
MJ4&=9DUE>/K]BOZC)B_)K F'.<W_S!*1CIW(00ELR"X73_3P,]2$M(,QS;G^
M10<S-P@<%.^XH$5M+#THLM+\D^<Z$"<&.'S#P*\-_+9!_PV#7FW0TT2-9YK6
M@@@R&3%Z0$S-EFCJ0\=&6TLV6:ED7 DF1S-I)R:_/DQ7#ROT;@&"9#E'OQ'&
MB(KL>_0]^KA:H'??OA^Y0JZDYKMQC3HSJ/X;J-A'2UJ*E*.',H'D',"5+C9^
M^J]^SGPKX@+B.]3#'Y#O^?T.A^9?;MZSN--KPM;3>/TW\'ZO0(6IW*(<Y"9"
M\"S/%8>N2!F@0 .I0[6?8&\0A)%DL3\E8%U0G>9[7I$8QHX\KAS8'IS)=]_@
M@?>#A4Z_H=.WTEFEE DD@!6&3Q>/_K]XA%'0]]LTK M=22-H: 27J,+109]B
M2!#9RY$MR(M'76U'W13E+K+V=3!&A=G>?920%]ZU'ZT(5\9AT,1A\#_CD&0\
MIKM2(#FO4VVS /9/Y/;N,,8MM:U^7,DR;%B&5I9SPE-4D1?YJ(@N"69AQ\D+
M0^R'+1)=\X(H#(Y;^\R_J/$OLOKW)!D3%J>(E E:P%X^F97R%4WE%5MN07__
MM81B#>SO+O^M\%\>7$/R1F!GD1@VD1C>ZK8T0(,3+:)A. RBEF36]:YD@[WC
MF^E9^?P$I224:V&GB7R5,R[,JXD>##6KKG;T2X6]%=IY+$[R!WPK;6NDLX,V
M""-_T!+7ON*UC/PC(]_*:"GU+':%74(KQ,42W@CMG/ QE\$7)3,<967,]/4D
M]_B:,@FH!M53T7G/UO##UEO15O5K)#CXF.%@>XJS),__K>J-DI>:\-=(A? Q
M%\(7)D.7JAITIP!^6]>;9CKN22E3 -OJ"H\CG:R8:J'I-57D3%61JA1J]<OJ
M<JIK*O<(8TK3)6';K.0R+!L)Z=V%D@ SU9YI"%KI@FE-A2R_]&<J*V1@:H(<
MWU J7AMJ@:;FGGP&4$L#!!0    ( $V)GEI<&P,X_@0  )$;   9    >&PO
M=V]R:W-H965T<R]S:&5E=#4P+GAM;,59;8^C-A#^*Q:MJE;:#=@0 MLD4E[V
M>JO>WJV2W:VJ4S]X$R=!!SAGG.3VW]<8%@(A+FR0^B4!XGEFGO%X_!#W#Y1]
MBS:$</ C\,-HH&TXW][H>K38D !'';HEH?AE15F N;AE:SW:,H*7TBCP=608
MMAY@+]2&??GL@0W[=,=]+R0/#$2[(,#L=4Q\>AAH4'M[,//6&QX_T(?]+5Z3
M.>%/VP<F[O0,9>D%)(P\&@)&5@-M!&\FR(D-Y(AGCQRBHVL04WFA]%M\<[<<
M:$8<$?')@L<06'SMR83X?HPDXOB>@FJ9S]CP^/H-_8,D+\B\X(A,J/^7M^2;
M@>9H8$E6>.?S&3U\)"FA;HRWH'XD/\$A&=MS-;#819P&J;&((/#"Y!O_2!-Q
M9 #M,P8H-4!E ^N,@9D:F))H$IFD-<4<#_N,'@"+1PNT^$+F1EH+-EX83^.<
M,_&K)^SX<#[Y>#M]^G0+OGP L]OYX^QN\G@[!?/'+Y,_P>CS%,SF3V T>;Q[
MOGO\&_PZ)1Q[?O0;N 8_ QU$&\Q(U->YB"3&TQ>IUW'B%9WQ"A&XIR'?1. V
M7))E$4 7%#(>Z(W'&"D1IV31 2:\ LA 5D5 D_KFIB(<,TNK*?&L<VDE;.\M
MR/585-@2S$C$F;?@XG+.Z>(;^'I/@A?"_JG*G!(X7M4WT18OR$ 3RS82;H@V
M_.4G:!N_5[%N":R0 RO+@271S7,YB(LCS<"$!J+Q1%@NW1%C.%P3T0PX>'D%
MQ^,>\*M\/#I@M@1?/PE(<,=)$%6FRFHS52V!%5+5S5+559;+9QKN18W$]2%7
MU!48D[47AEZXKN*M!*L.%511OARGP-;.V-HUV1YDEQ47>$^8V#7 6E0&OUYB
M3L *>PSLL;\C5W&7.),*I:<&J;@<IY"*7I:*7L.)_R/.0+DE)EP3*%M"Q=OS
M?HA<$[F.@_KZ_IB,TF=S,DY&QFEY7A5D$U?.$5FS8\(2464\S8FZ&5&WX:P]
MR]LJ'N[)I%TCVW1MY)2X*%TVYP*-7 $8+4_;>;:IJ^-I,SJN7:*J#N@=7(_4
M#FPX<T(,KHAWCHX2K4%[:0&HR!CEC%'+LZO.B-);DXQ<#E3,2"[-H%J;-=QL
M4[1"V[5MUT!=JUS6[U!;2DJYTH)*==+JCIJZ*G;>4Z[OD$M*KKE4@DVUDKI@
MVQ)++0 5&>=R":KUT@-A\GT]S%\HYD^1\B5"C=A4&K>%5N2?:R38^Y]?). [
M%),B72VA%=.5JS!85X;5ZV_.27^#AFL8\$2A5(QT'==RN_G 8LBYGH)U!54+
M_<L]Z5^HX_;*7*I&.=UJ(BC74JBNEJJAY]58#5I3"E2<0M3K'0FO(I]<+Z&Z
M>JD%2:_VU80O/)D\JP//D<VE$JHKE?Y;UJ=0!5WOVM#H6D:ITM1.F^\;*!<Z
MJ*[0N5S8IZY*ZZ6\JM0!O8-KKH!070542Q6HT9J4HG6J#I&-SM5BKG)07973
MBFQ7>VO"MUNQ]$SW#-U<XJ"Z?PG5VK-2M$+#0X[;[96WK*J!Y<VM&'*N2E#=
MOVXNW[-25T7-?;*X3@<5-K8BCUPNH*9R05U)E__GDM(Y51/754M'/SK<" A;
MRS.?""SH+N3)^4#V-#E7&L.;B3Q^*3T?P9N1/&71<YCDL.H>,U%L$?#)2D :
MG9XH<I:<_R0WG&[E$<H+Y9P&\G)#\)*P>(#X?44I?[N)'62G<,-_ 5!+ P04
M    " !-B9Y:=6J38>H"  #M"   &0   'AL+W=O<FMS:&5E=',O<VAE970U
M,2YX;6S%5FUOFS 0_BL6FZ96:LM+""1=@I07NE9KFJBTVZ1J'QRX!%3 S':2
M=K]^MB$TFU(T1:KZ!?QRS_/<'6<?O0VACRP&X.@I2W/6UV+.BW-=9V$,&69G
MI(!<["P(S3 74[K464$!1PJ4I;IE&(Z>X237O)Y:FU&O1U8\37*84<1668;I
M\Q!2LNEKIK9=N$V6,9<+NM<K\!("X/?%C(J97K-$208Y2TB.*"SZVL \'YJ&
M!"B+;PELV,X8R5#FA#S*R574UPSI$:00<DF!Q6L-(TA3R23\^%61:K6F!.Z.
MM^P7*G@1S!PS&)'T>Q+QN*]U-!3! J]2?DLVEU %U)9\(4F9>J)-:>MV-12N
M&"=9!18>9$E>OO%3E8@=@&6] K J@*7\+H64EV/,L=>C9(.HM!9L<J!"56CA
M7)++KQ)P*G83@>->,+KTQ_?7/II>H.!N.OIZ.AP$_AB-II.9?Q,,[JZF-\C_
M(<<^.AH#QTG*CGLZ%]J200\KG6&I8[VB8UIH0G(>,^3G$41_$^C"Z=IS:^OY
MT&ID'$-XAEKF";(,RT;WP1@=?3QNX&W5&6DIWM9K&8DQA=.A^-(1FN%G48$<
M#2C%^1+D^ 3Y3^)(R%V<1VB$BX3C-/D-T0D:9&0EK!^N!26ZXI"QG_LR5>K;
M^_7E,3QG!0ZAKXESQH"N0?,^?3 =XW-#='8=G=W$[MT1X>T^ITI86\'D45Y[
MMN$ZMMER>OIZCV"[%FPW"MZ*$# -8Y6M,:S%/5"HG%9I1 \3R.9 ]V:JD?K
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M@6Y8EC$M_QOT#CV,1^BG']Z<MZ2*K0FMZ3;.J(A#3L3!!%VGB5P(Y"<!#TQ
M2W5ZUW/RW/,AL1(IGS01;K]%Q"'MJ@[9FX_XM(E<?+*Y__+F;D5S:F_^&TN:
MR"F:=RS)<'<RNCG//27C@F7\W96ZQ (T3&,U[@B67[F72KQDSM58(-'D">WO
M=\>>\LV7&Y8%Z/$/A43O)8_%IXKC&1;QV]7Q]?AW)I9LRB\::H 3/%OSQN#'
M[['G_%PE#23,AX11()@A8GLG8MM&'QC"35,AU= ]3>=)^-?A!5-(8J75E:2
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MTAB4%D!I(93&4313S]I+<NQFTN>5JHN5H!^5^Y^6-B?)SNJL9JB7!*51I\D
MNA@-][I5#!HW@-)"*(VC:*92M>GDV%VG ZT(\E\RR>.'J!1DDLCH"Y&6]B8&
MU(F"TGPHC4)I#$H+H+002N,HFBET;7TY'K2) 76]H#0?2J-0&H/2 B@MA-(X
MBF;J63MDCMTBZ];$@#ID4)H/I=&:9@R(N4T-#&34 $H+H32.HIDZU4Z98[?*
M&G3:DM-B!W86*]0_@](HE,9JVK;TA^-Q_V*\.Z8&]=&@-(ZBF6+55IIC]](L
MK>'5;1)/R>_/&K:VA:&&&Y3F0VD42F-06@"EA5 :1]',Q'WMT+D]9%O8A9IS
M4)H/I5$HC4%I 9060FD<13/UK'T\U^[CT>\BG\:%)2/'#N@L8:A1!Z71FC;>
M'F-S7N]DMC)HS !*"Z$TCJ*9TM0NG6MWZ6II1K>)(+.H;!8GU)Z#TGPHC;9<
MK&I2ES,\(X=F-C'HX0106@BE<13-U*UVY%RK0W*U:>CF8B8;Q=7<VIDHIGE<
MO6Z4,=25@])\*(VV7+MO<W%RG2V64?I$%M%3=0G%@I1S>8-:=R/TD,U=]7&]
M=SV'M"#3>BY(U3P3?ZVB1#;7<B*^5SE^Y$=G_+K7(ZJK4N5'DSNYT>V1,H]4
MIUI6-$\%>8S+>9R>1*3?>[6U096*LQD15?];Y6FI Y"[YC-B[";WRDF959M5
MS:5V?9S'T_GV$9-"<HKJDS0KY<U7M2JW)+,N?S+/DIG(JR;GSA5H_)%#;4HH
M+832.(IF_LBU3>EVMBE;QF;LP,Z_<:A7":51*(VY3<YG?^P-Q[L93]"X(93&
M4313KMJK=%_L51X8G9&;^.2+=;#&'K.SHJ'&)91&H30&I0506@BE<13-5+TV
M+EVH<>E"C4LHS8?2*)3&H+0 2@NA-(ZBF7K6QJ4+-"[MK,YJAAJ74!IU]XU+
M9^U<[EJ7T+@!E!9":1Q%,Y6JK4NW99:?["F)@KPGD\U,EKH.MK4GH.XEE.9#
M:11*8U!: *6%4!I'T4Q5:X_3O8"V)Z!F)I3F0VD42F-06@"EA5 :1]',Q:>T
MF=FW3S><O&A1"SNTJZRA-+^_/ZG/W6L&4&A,=E3, !HSA-(XBF;*4'N0?;L'
M.>FV9(6=UEE_4$,22J-0&JMIK>M60*.&4!I'T4RE:DNR;W?9#E68AWMA=F!G
ML4(-2BB-0FFLIAD9>?MU*M2$A-(XBF8J=6MA2;N1UKZTA1W069G8Y22QZTEB
M%Y1<T]K7MX"&#:$TCJ*9ZM3N6=_NGOGQ0SP3Z8SD42G.E*\Z%6D9W3??[Z'&
M&93F0VD42F,U[<*\W^\NU >-&4)I'$4S5:I-L[[=--NH]"'*XRH-:2W7EF0.
M.[6S7J&V&)1&H336\FVH9(C-L.*7/+Z/TRA9+S"B)EQ.Y1>SSK%07Q)YC)-$
M]6.S153&TRA)GDB<3G,1%8+</A'W)R(>1/Y$GH3L:I3SJ*P2,3;\7*@%^PU/
MG_RL]E!Y)F[O[7K'D_?D_72:K]369[$4U1[.VU]>DV]S>=)D]KR!W(IIMA"R
M<_-4B>EQ+E(BV2J392:F2:3:E?+8MG)$*H8^JMW!U/5))D5V(CM,\C3C99UL
M$LG_BE?3+)7G6"IJ5,2RE:HVJ)R:^Y4,IK)BBJ68QO(JZF-<1O%,I9YLI9VH
MX]G.JFD:9($J(832.(IFUB+:A.S;5P[]JE-ZJAQ;G7O46'E /4@HS8?2*)3&
M:MIVJVSO3@<U%J$TCJ*9&M7&8M]N+&YIM!3YHE&84#L12O.A- JEL98KK^YJ
MY:-L_#ZM4P_CQ4+,8EF-)SMYA'MYCO*>1IZ?W=)8)4/=22B-HVBFW+4[V;>[
MDRS)Y(4]../!7KJSU*$^))1&H336WU^(=+!;!T/-12B-HVBF*+6YV+=/H-P9
M6SQR%7L[M+-6H1XCE$:A-%;36L87H=8AE,91-/.)']HZ'-BMP]8$#Y4_*KL?
M4LNY->G#'J>K@*$T'TJC4!J#T@(H+832.(IF*EV[DP,'F?0Q@+J34)H/I5$H
MC4%I 9060FD<13/UK#W, =K#M ,[2QKJ80Z.\ DI-"2#T@(H+832.(IF*E5[
MF .[A]GRJ A[Z<ZRA!J8@WV3<+"?AP2-R:"T $H+H32.HIFZW'K<G=V];/?6
M[8#.TH1:EC6MU;^FT+ ,2@N@M!!*XRB:J4[M6@[L/ME+GB%A1W;6*]2RK&G;
M>FU:[YY"HS(H+8#20BB-HVBF7+4]-FA[L%ZK)V8G=%8GU!,;-/A.WGY5"O6Z
MH+0 2@NA-(ZBF=K4MMC ;LX\#W(YME$NY=!/E&%#6+2(DR?R\>/$/N(%==*@
M-!]*HU :@]("*"V$TCB*9LI>VV.#,73$"VJ706D^E$:A- :E!5!:"*5Q%,W4
MLW;6!BU+D[:,(T MM,'^X^^<_<Z5#PU*H30&I0506@BE<13-?&JY-M&&=A/M
MA0FF=FI7P;8<HUJ12^4$;5(!GQM%K_9;1>IGIDZHRKA\3EQYWO^L6H-K6>IL
MR^EJL4JB,G[83I)4C&FT7$JHW,T9_E3U#:(T72W.3E2VY,XQ\+I;N\X!E;U<
M>?7NY#G(XFJUK]Z9_.VM3][6Q_"AUY1":0Q*"Z"T$$KC*)KY>]16W_#E#S6\
MJ:<FVI]J: _0^:?I[)D;>WU+'QJ20FD,2@N@M!!*XRB:J5QMZ@U;GFCX=Q_'
M:>=W%JZ[UPCRFL:8?6A8"J4Q*"V TD(HC:-HIGBUSS>T^WR?LY3(EL0JG:W7
M^A7+K(B+LIJ+T*A5J/$'I?E0&H72V'#?E.PWSER$A@VA-(ZBF5K5WM_0[OW5
M+<\/G18VLC,["Q9J!T)I%$IC4%H I850&D?13%5KSW X1([X#:%V(93F0VD4
M2F-06@"EA5 :1]%,/6M3<6@W%:^KF8^%FL\D13T5>1G%*4GBZ#9.XE)5X'%:
M9F13F2^;<^(:M0\U(Z$TOZ9M]Q?[GM/?,2.A,1F4%D!I(93&4313T]J,'-K-
MR+^IZ48M0YU(*,VO:<,=+>^G*4'#,B@M@-)"*(VC:*:<M<DXM,_!F[QHNI,=
MVEFQ4*\12J-0&H/2 B@M'.X_?''G-\Y1 4VM:@-Q:#<0/VY5LK*AO%HTY\G;
M*9W%"9V+!Z51*(T-]RU3UVL<EX!:B5 :1]$,B7K:2O2.FH]WW6E<PL[L*E@H
MS8?2*)3&H+0 2@NA-(ZBF:K6AIP'G7OG0=TW*,V'TBB4QJ"T $H+H32.HIEZ
MUC:=][*Y=_8%E^W0SK*&SK^#TBB4QKS]N8%[]GD #1E":1Q%,]6J?3G/[LM-
MNJW+;*=UEBG4EH/2*)3&:EKKNLS0J"&4QE$T4ZG:E?/LKMRA>O7PG&8[L+-8
MH98<E$:A-%;36NI4J-,&I7$4S52J=MJ\(]<4/6;E6SNKLTBA/AN41J$T5M,<
MUZQ21[LK D*CAE :1]%,G6H'S;,[:"],3;93.RL6ZHY!:11*8RW?AEHE4#S(
MBD+UA2.2Q'^MXEE4UE[0UO* 9VI5UV=O2#TZ6=X2M_>N(+(AMY5$?:URIM?/
M6:Z^9_5 Y*A>JK1Z?O)S(O=]+J0$\A,S#_RZ<2U>LDQ6LEN3)'JW_95RUYG@
M*N%[E:[7G9WGV>I^_93D[8=G5\I3R]6NIG,U "O*DVB1K>3EB KRF*V2&9E'
M#X+<"I%NEM>=1S/S./5RN)51]FPXW)F/C-Y>@/%6R(LA*HIQR?/ZTI[L7=K&
M_C#4TX32.(IFUC+:T_3LGF;+0HSVTIUK$Z@_":51*(W5-+-'X3DC=_?^![4G
MH32.HIG*U/:D]_^P)^W0SH*%VI-0&H72F+=O 3;T*J"N(Y3&4313K=J@]%IF
M.+:Y/R^9IVZ/V5G,4#L32J-0&H/2 B@MA-(XBF:H?J0]SU$/Z0Z-H&XGE.9#
M:11*8U!: *6%4!I'T4P]:[=SU#+]T#Y/O2[=,K/\VAZDLS"AMB64QJ"T $H+
MH32.HIG"U+;ER&Y;MB]X-SIRPM^U/5)G=4+=1RB-06D!E!9":1Q%,]6I;<I1
MRS*A?WO6=AW VOVXMA]%9^5"#4DHC4%I 9060FD<15LK][R8"U'Z41E=72Y$
M?B^N19(49*I&*E4K=NM3-=]5JL!Y0YW3\[W/F?,F:/K\O?/FO:L^/]?XJ\ME
M="\^1?F]>EY9(NYDJ-[KD:R)\_A^OGE39LMWI_(N<IN59;:H7LY%-!.YVD%N
MO\NR\OF-"O"8Y7]6IW/U/U!+ P04    " !-B9Y:@5R@X;,#  "J#P  &0
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MR&B^.MR#)"*#<N]=*AD/64IBE,:90B0,90:D& >6\,?G/5H\@"E@(LT2\,'
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M2=AEH2G\[EC&V9 F.?_HAMK7X9[(#>4*&*X-*!B\,VC93%SC:%&[2[L4VHR
M,TOS2*&T 69_+80^.'8.NF<O^P-02P,$%     @ 38F>6F9F Z&N P  /PP
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M4'3DH1&)+X$-?P?(0HXB?79ZNJU(CTY/1X?IIE"OE1"U$J(*SSZ*MR1E21+
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MA0Q*W5S*JPR9*I#S<TK%MJ,^4%^._A]02P,$%     @ 38F>6NA5K6^> @
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M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ 38F>6L\3EU[R    *P(  !$
M             ( !PP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
M38F>6IE<G",0!@  G"<  !,              ( !Y $  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    " !-B9Y:FM;!]9,(   X'@  &
M    @($E"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
M38F>6CDRI@G$!@  V2$  !@              ("![A   'AL+W=O<FMS:&5E
M=',O<VAE970R+GAM;%!+ 0(4 Q0    ( $V)GEI$9L;_G0,  &L2   8
M          " @>@7  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M    " !-B9Y:H)RDV9<$   N$0  &               @(&[&P  >&PO=V]R
M:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ 38F>6A[G$=L'"0  J$T
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M965T.2YX;6Q02P$"% ,4    " !-B9Y:Y-PL))@'   9$0  &0
M    @('&5P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    (
M $V)GEHQ-B'Q  0  !\)   9              " @95?  !X;"]W;W)K<VAE
M971S+W-H965T,3$N>&UL4$L! A0#%     @ 38F>6B^;KE@^ P  ^ 8  !D
M             ("!S&,  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"
M% ,4    " !-B9Y:HRXH=K "  #V!0  &0              @(%!9P  >&PO
M=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( $V)GEHC#M0)'@D
M /$7   9              " @2AJ  !X;"]W;W)K<VAE971S+W-H965T,30N
M>&UL4$L! A0#%     @ 38F>6F",,K3-!   90H  !D              ("!
M?7,  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " !-B9Y:
M\]R>5UT#  !6!P  &0              @(&!>   >&PO=V]R:W-H965T<R]S
M:&5E=#$V+GAM;%!+ 0(4 Q0    ( $V)GEK3EOB(60D  ,L7   9
M      " @15\  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%
M  @ 38F>6@+0,-AL$   23   !D              ("!I84  'AL+W=O<FMS
M:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " !-B9Y:M'Q1/Z4%  "%#
M&0              @(%(E@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+
M 0(4 Q0    ( $V)GEJ24!TK>PP  .(@   9              " @22<  !X
M;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ 38F>6J0XLB.=
M!@  F0\  !D              ("!UJ@  'AL+W=O<FMS:&5E=',O<VAE970R
M,2YX;6Q02P$"% ,4    " !-B9Y:ML6E?V(%  !;#   &0
M@(&JKP  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( $V)
MGEHO<;%Q$@0  -8(   9              " @4.U  !X;"]W;W)K<VAE971S
M+W-H965T,C,N>&UL4$L! A0#%     @ 38F>6JT?,>;,%P  N4<  !D
M         ("!C+D  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
M    " !-B9Y:?A%%5WH%  !C#0  &0              @(&/T0  >&PO=V]R
M:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( $V)GEKWN<ZH3P,  / &
M   9              " @4#7  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL
M4$L! A0#%     @ 38F>6KM(#B$' P  = 8  !D              ("!QMH
M 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " !-B9Y:7JB=
MW; "  #<!0  &0              @($$W@  >&PO=V]R:W-H965T<R]S:&5E
M=#(X+GAM;%!+ 0(4 Q0    ( $V)GEHXT_F(PP(  .H%   9
M  " @>O@  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @
M38F>6@]]GC G!   $PH  !D              ("!Y>,  'AL+W=O<FMS:&5E
M=',O<VAE970S,"YX;6Q02P$"% ,4    " !-B9Y:?<OTL[X#   9"   &0
M            @(%#Z   >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4
M Q0    ( $V)GEK5:+=%W 0  ",+   9              " @3CL  !X;"]W
M;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ 38F>6AQYJ$Z!!0
MO@T  !D              ("!2_$  'AL+W=O<FMS:&5E=',O<VAE970S,RYX
M;6Q02P$"% ,4    " !-B9Y:B<)3&Y,"  ";"   &0              @($#
M]P  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( $V)GEI?
M8Z1NG ,  !,3   9              " @<WY  !X;"]W;W)K<VAE971S+W-H
M965T,S4N>&UL4$L! A0#%     @ 38F>6C?A>OEK P  V@D  !D
M     ("!H/T  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4
M" !-B9Y:8) B*YX$  #D'P  &0              @(%" 0$ >&PO=V]R:W-H
M965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( $V)GEI 0+?1,@,  +,.   9
M              " @1<& 0!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L!
M A0#%     @ 38F>6O@KH?S_ @  <@T  !D              ("!@ D! 'AL
M+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " !-B9Y: B&&\L4(
M  #\3P  &0              @(&V# $ >&PO=V]R:W-H965T<R]S:&5E=#0P
M+GAM;%!+ 0(4 Q0    ( $V)GEJ=TOB05 ,  !L)   9              "
M@;(5 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ 38F>
M6EZ>,S>) P  &0T  !D              ("!/1D! 'AL+W=O<FMS:&5E=',O
M<VAE970T,BYX;6Q02P$"% ,4    " !-B9Y:E9BKE-0#  "A%P  &0
M        @(']' $ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0
M   ( $V)GEI#L8T-M0,  %<1   9              " @0@A 0!X;"]W;W)K
M<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ 38F>6E;=#'UR @  M04
M !D              ("!]"0! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q0
M2P$"% ,4    " !-B9Y:SO(9\84"  !%!@  &0              @(&=)P$
M>&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( $V)GEJ"@:5M
M @D  )%I   9              " @5DJ 0!X;"]W;W)K<VAE971S+W-H965T
M-#<N>&UL4$L! A0#%     @ 38F>6IW4Z5!X @  [P4  !D
M ("!DC,! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " !-
MB9Y:+[U6];,#  !_#P  &0              @(%!-@$ >&PO=V]R:W-H965T
M<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( $V)GEI<&P,X_@0  )$;   9
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M970U-"YX;6Q02P$"% ,4    " !-B9Y:@5R@X;,#  "J#P  &0
M    @('Z7P$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    (
M $V)GEJW58IN(@4  %,7   9              " @>1C 0!X;"]W;W)K<VAE
M971S+W-H965T-38N>&UL4$L! A0#%     @ 38F>6A3O)L6. @  J04  !D
M             ("!/6D! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"
M% ,4    " !-B9Y:GP!.NB\"   "!0  &0              @($"; $ >&PO
M=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( $V)GEIF9@.AK@,
M #\,   9              " @6AN 0!X;"]W;W)K<VAE971S+W-H965T-3DN
M>&UL4$L! A0#%     @ 38F>6CM<%25S!   4A0  !D              ("!
M37(! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    " !-B9Y:
M539 P]<"   H!P  &0              @('W=@$ >&PO=V]R:W-H965T<R]S
M:&5E=#8Q+GAM;%!+ 0(4 Q0    ( $V)GEKH5:UOG@(  %(&   9
M      " @05Z 0!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%
M  @ 38F>6H):N>%@!P   TD  !D              ("!VGP! 'AL+W=O<FMS
M:&5E=',O<VAE970V,RYX;6Q02P$"% ,4    " !-B9Y:"(BWU.X"   K#0
M&0              @(%QA $ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+
M 0(4 Q0    ( $V)GEH>J&)]/0,  ,X3   -              "  9:' 0!X
M;"]S='EL97,N>&UL4$L! A0#%     @ 38F>6I>*NQS     $P(   L
M         ( !_HH! %]R96QS+RYR96QS4$L! A0#%     @ 38F>6GOWZQ=H
M!0  12H   \              ( !YXL! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4
M Q0    ( $V)GEK22;QM$0(  !<F   :              "  7R1 0!X;"]?
M<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( $V)GEK B&UTZ0$
M 'XE   3              "  <63 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%
3!@    !( $@ KQ,  -^5 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>90
<FILENAME>0001641172-25-007878-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001641172-25-007878-xbrl.zip
M4$L#!!0    ( $R)GEH[+SH(M (  &,.   *    97@R,RTQ+FAT;>U77V^;
M,!!_CY3O<(NT/H629MH>@$8*3=I&HRU*T:8^.F# FV-3V[3-/OW.$+).FC1-
MZC*E&A(8GWU_?G?GLQU<)E?1I-\++N?3&;9@GR!9)-%\$KAMBZ/N=C@(;V9W
M<)O<1?/302Z%\>!D5!E(V)IJN*:/L)1K(H8M80BW5+%\@(S(&O\IGP]KH@HF
M/+!3=Z\/ACX9AW!6X)!B16E\6)'T:Z%D+3(GE5PJ#QY+9NA@$IS?7"?/-3LY
M63.^\7ZGNYFKV3?:FCJ8'(F5KOS M0+1-_'K0!6$D_E3R5;,]'OC=\<G@1M.
M]H/Q2ZT-RS<O#*:+TKY0I%08JEX8Q)D4&N7V>S*'A<AH1?$C#"QIP32JHQG$
M]8JS%*9IBNEAF"C@G*GU_^C]<Q2?:;^7MO$#(\&4%&I- 2,I:P6*5E(9R(C!
M&$XKQ3B,AS >C=\/X9&9$B?HBJ8[5BM)<M;.SYD@(F6$@S9(6*,*;04G]$$6
M5$#()%Q*GF$V:,R;]'C8[S&12H4Z&P$EI@X3L-J@FAS_14J'0$36:=M1+<&:
MFV-. 98?JIKQDA(K'(YX=E]+?_Y4467TD6IZ@)+MI$K)!D*MCP\VB/NL]7_!
M?%>[_=['^.H"HB@^6!0''H2X9)QDE%<E([@08RJ$WO '(A@)PB6":9?_NU&[
M_@\6YX&'Z=48_L9Q\ Q >>9!3 KJ(^-];8LY,OAP4QF&>XD'$=$&'&=[U@]F
MBT^=-2T,9R6-D6L//E3V!"H5%O\=+>1X(H43Q-?L2FA$,@VC.9S-L=!,9[/%
M]<7I8#1H^K?Q]*SK;S5LI>%9EI-*HV'=GX^;7V9*"VWT]E=8DV4GXP&W')82
MWGG6R.IG5W.:-QRSCN.9Z!_9FLSL_69I/Q8!MNB)SBG/7.E:7[;^.N#DV(OQ
M72*Z]I+8WAKMY?([4$L#!!0    ( $R)GEHU=HU*B-,$ (BI*  -    9F]R
M;7!O<V%M+FAT;>R]:7?;QK(H^AV_ E=G[W/L]2B9DR8GT5VT!EN)IB?*=O;Y
MX@4"31(Q"# 8)#&__E95=P,-$*1(&1P-K\262 S5W36/O_[?YX&C/S(_L#WW
MM_^I[57_1V>NZ5FVV_OM?UKMT\O+__F_)]JO_1 N@TO=X+>=?A@.W[][]_3T
MM/?4V//\WKO:\?'QNV>\9H=?]/XY][IZM5I[]^?U5=OLLX&Q:[M!:+@FBV]R
M;/?[Y.?CM_&E'=^Q4Y?B)_(EC7=CCX9OK>0&]>*#=_S+U*5A[J7[_-)07FH'
M7K->.YP&![\BON%YTK4UA!E6R/[\<'^57![F7Y]<^B[T#3?H>O[ ".$(\4G[
MN]7Z;OU ><ANP,S4@^#WO9[W^.)SCG8;-?F<L<-)KQ2_[AA!O.,6RVRW?"=\
M 7?4F_+"*-CM&<8POKAK!!UZK/@B>['O.2S(O9J^25UNA?YN.!JR(!]P^/H=
M?HWWU'>K#66UIA>YH3_*7X+X,O6JP _'@8(/4Q<]?/EX$U\5LD>OQ]P]TQO0
M1;4ZO!YIC1G6B:;CGU]#.W38R:_O^+_:KP,6&CK>O\O^CNS'WW9./3=D;KC[
M ,O8T4W^VV\[(7L.WQ%!OH.[WO%'_OI_=G?U"YLYUGN]S<)?]!MCP-[KS];S
M+_KE&?WPK5H_^_:Y_>_ZV<=6ZP[^0<#TW=T9;VY4O^$2ORE+^R:7-OM3FJ=T
M4[56K;WB[OW];PQP#&"'_UH#YEKP?WCA&+UOH1^Q.1YTKCSHW(4C&)W"DWS#
MN70M]OP'&WVK D,[.J@>'<X!WV'CVY]G?WY#4AMZ@3'8@T]GO_O@ QS/V;?:
M-\%9.'3PT1R/J']K]PV?!=_JWXB/\F<$]-D<CT%$.;L3CVJ, ?1#SZY]NP1,
M[C'_6U7^-,?=Q]_N(I]]:ZH@#.&3N;:YS7J(. " ^(G?W?&LD1Z$(X?]MM,%
M<GNOUZK#4'^P![# &_:DWWL#PZWP#RKP!M_N(E5;]J.\S;*#H6.,WNNNYS+\
MSGY^CQ3*?"![^L6V+.8B#\#?X*J;: #/,3E]/X?WK/O;SH7O#9 Z=JLU^"_T
MZ.=:G7B8;<'WAAE6\4]C1W=AB?!>9K]/$<3."5+$K^]2+RGJM4WUM;GDLW.2
MT$^Q0, 9UFT\?'A^:OEGGAGAZHE=GMS=MO76]>177_BP&)"&X@%"(+V_#?O,
MOV<FLQ^-#HB<&Q:>1KX/C]U)0=D*;KL 68-#]DW<_NV>.4;(K#O##T?7;-!A
M_AC0^[!YD6OSQP M@?P(WKNV XP=#FSG1((L 7P9YC/690"B=>H%89 +YJ0-
M/-@O&I8;+V3!G3'"S9MAX\8@.JX6#1%(4="!0QL FA6X2=MU7"\:.$*W*]OH
MV(X=VBPH&->.#Q:XFU>>VWM@_D#=U7FV$U2 XBG!![H-[4>F[.F-YYKS8V*M
M5CAT=[X@U';HF=^_&$Z4OU_9@T8YPX)6^O;\$Z_5"Z>?'X/Z=":H&XU-A+I9
M.'5]B *PV8+@U!MT;)>LM98)QD!@XX^"X'/8O)"9#2XSIR#U\5'1(%\8MD_;
MV[+^BH(0!?!M]ZOA@\GY6BCKQ3$&M%C>7WE!<.M>!D&$;H/;+NSNP"9(N8+[
M6B@/B]Y+0K:^YX"V&)S#L8>C7)RM9W V#UE?PSSJC<(1>G$K^C#;BC;HC&9B
M.O5&X13,B> V"M&MAL[!Y2)=4]6')4&N[9IF0[N49%C[-<V&>,VC!:P)S*M+
MU_0&#'GT;'RX> S<+URM7_"R9D/"_<*5J@4O:S8\+-Y^_I%EH2[AN5/A+=[&
M_@%X6Y9%NJ3AW!FV=>F>&D,[-)Q)L*]*(5@8K1\4;A\M;D6SD?E!X7;JXE8T
M&X4?%,Z/9Q.=BT.Z18C.A:UI-K0[K&[2FF9#O,/Z(M:T8HYWN$$\?$;46Y51
MMSC$6Y%1MS"D.UJ=4;<PM#M:G5&W,,0[6HADPA>BNXU99Y$/:[H#B#R+O(0W
M[(F^R==;F['>VES4*1X7;A6M:+FS'?!QX=;2(I;[LA5U7+@5M8AUS&==%1^=
M6\2:[EEHV"ZSS@W?A2<&DQ93F% FG_U,*WEX\HJGJYD$7*-:F(VRXN7.Q#4;
MU<*XYB*7^R(;:50+8R.+7,=<;*11+8R-+')-L[&11G%!M=D7<^NR5;&1V@K8
MR$*6.Y,VTJ@5IHTL<KDOLY':"MC(_.N8CXW45L!&YE_3C&RDMA@7P83U\*0H
M++/ Y((X0:K-3+@24Y!6Q5[JQ7M2UVL;9M->ZDNU^5:P#;-QW_I2;<&BMV%&
MRJ\7JT!<,[_'_!L6WG;OF<4&0[P@:+G6 ];4\.LG)V0M@<0;Q6H0*USO;+1<
M7*K@JM<[&]$VBE69%K7>&:ES0?E8$UC0/0M"WS9#L<.M)\.W/OJ3@N9+(-;F
M4N7Q$I<_&^TVERJ'E[C\V4BYN53Y6]3R9Z3LYOI3]K1:HD:S^!#<%/CYQQ>>
M#_CS:)NKLQ"*SWU;\;)GXT3%Y\:M>-FS<:#B<^<6N>P9.<_^\ER&V<J!2]"5
M7)?1,[[:8?_*,]Q6SV=L,%9MM#R2+BY]:MWW8S9:/UA>[&+%^S$;$SA8GA-V
MD?LQ(W<X6*I>0O6<JR+\PZ7*\@4M=3::/ERJ_%[04F<CU\.ERNS7+'5&2EQ0
MVMYK%S+5&B@N(6\&'NF"*=.)\!Z$4"WK7A4G.5JF"K',Y<]&<D?+E)"%+?_E
ML.71\L*6!:YK1O9RM$PSX'6+F\IRC@IW0"05V<&#-RD8;/C?'SS\FZW,8"F^
MK<;J5SZ;&E-\,NKJ5SX;BRT^+W7!*W^9NQ:?HKK@)<W(6)>8V=EF8>@PWD/B
M"PN IV8<O9\!CE7Y2IO5PFH'UW8C9F);S8+[<ZSC1LS$Q9I+S )>R$;,Q@&:
M2\R:_?%E3E.RFL7ERL[#H\GYA0U4+9 B0^8&U-GGGO'./DRXQ_DNW#/3Z[GT
ME)RN1<MC=K7""Z4W;Z=FXX;%-PK;O)V:C5T6E^V\ICOUHI+8K*U$XU_B%LPH
M4HK+H);[\')7C&5PS<*-^ 4O:T86=[QARYJ-'Q7?+/%'EO4R\Z@7+FE^!-ZY
MR@N:"TI%?[EH?V%$45RF<;RBF8K!%[:@QD(*W%=\2@O(.5SM*:4RM@IM0_ A
MJR"\KC%F\[!X-N6YIA'T>?+RC[=!;187BE0:C*9/3[8;?26$1\4FK2RF!6KS
MJ'!S>@'M9)M'A6LO=\9(*MS8GM=G=[XW9'XXNG, SI9K(:<;OI34,LU3L;\0
M3?(4B A ?;0M9GT8?09ROW0OW4<6A,#&6G#3XXN5.5.!+DY!(:Q%<,4&6]G4
MH7N&U44,K!6N=MC__ #+VJ\7OMNPS29C5H @)'27YA& */P#!E_2)Z\$OU'L
MON?#GJM9OQ;@PL,_*LQ7V$0;F!P :>=3X P0%BLB0(+!OD6NA5WR80N'H#)+
MD!\\3%\/6FYHF_:0(LD%BI+]9O$MX3G[N^U>V"X AKS#38/Z8@G15#92?)F,
MBAU*,>(9Z[R>0S>+]8I/8&A*7=8%PPQ*TXDL9(<MTX376.?/J*XQ+.'*#I-X
M]<J*RYB5^X\;K12$^G8/,,?!3UL#'+A5>R5N%Y?=*<Y@&/EF'_1@R>X^%,+N
M#A?3=93'4%Z[=\7G4,;*VS4S@LBG, [*ZL^NUPF83Q-U+MTA6$[H9 3&X=B$
MX_AKY&,D"$P0.Y H/)H\MB%K7<5OYH^_ EIR&OD&U$&C\,-XS=B1)D[RJS5G
M64%\C="#)ZRK^ JF9:WKU'"<6ZI$G;"T_34YLIF1;O:E%=_L=E%+JV66ED?M
M"25/6F[A%N.BEELO9+F+:>PYYJEI(6/H$4P?1LDE0E&C\DCN?+MT W@SP4[J
MPD/?<#E^XIX]4L3])N)KR=DX.5W !-O<&WP3@2-Z5R9.G[\AQXV%M4)>[)Y\
M97:O#_^V0(4Q>NPC\N$S4-5CK%C,=F5U][OUWS+:&M!3>31QQO;TK]^@Y7E#
MB]^<.9%J ;O7W#CTXDE!2T.OA?7\7<+FK!Z]CC8.O2X\O\OL)6+8_L+ZZ"]R
M?T#_"5:.7MG>!1N 7K/H6#^^+PMKOKZ..M:/;]?!QJ'1;%QJ/'7CU7MTL%ER
M\(>Y5)%;MWE"\$=T++BGZ_D## +P36I_GI #>'RT6;K[0I6K>;9M\Y3V&6S"
MB10WQ\X<;Y;@*\(8+&3;?CH!.//FU*K5S6)2BY-\\^S9HCA4.AAW9F,BBVL%
M/(6U'<+B<%,N!T.X>\[!B+-G>==JQ<U)3NJADM#CJP"?)7<0 "\L$VK)@"\B
M(V#!J#1+"CHLK/ ZB'596/'M#-S0MFPGPE!/TD7Z_)DG1/#,CL$P"HF7WG9E
M 0KP+6(_/-%@SA7/HN+7:OO'"Y 1JUCNM !SK7:P"%&XN&5.J[1(90 EKYVT
M\$7HE<L\7R'"\1E>)%)^)ZVUR  =20G.>1Z,YW321_RQR&#ZP%S6M4/E;&Z\
MD-FP.@#AM5E:M5HJ1?D.]*(?/[GS;A?S4!]9LC+@JNG5W7@NG&)DTD+$"O.U
M/DR5>U4&3ZUV?+R2M<&'/+4RF-QDZT7@ZRG%>A7 OQ:EZBGU=I&08Y\AVXV
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M3&SEC-NK:)D6L[]]B *L00B0%P+""%UK)=N>["7KH>67?"Z^L0"2YZ%CF[:
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MN[5FR>C7@M'362R>QL60F ?VZ/68^\'V-O>H S]\WP8HK,AAMUU^SM<L['O
MMW'6<'+ZZJ>,W1@#T=.<QD5DMV)[R3TSXW8 #[LS?".,-IC#%X0$.;NQ=7B0
M.'\/I/,7?FI4)49<>8;;ZOF,V.;F8H1D[3BZX+:KC-M4CCMGJ:MT]1[,[^JE
MDUM<A& _CA# 3PV%;>3L7.*NB#H!^SM"BGLL4>A'G1/IS4P&<4RX8,58O/^*
M@(5 K>4%+*Z9$40^'XWI#J/PSK=-]L5SC! '"FU!I_WL L>Q9J8MV#K1-R,^
MG-F!B0,7<<"9X&V@7WR[MEU[$ U^1O08WY%"F!QJ;??(5/G;\=?4)I<(F$9
MX[E$P(4CH+K)VXZ <MR[[W7X-+W1;?<BPHGR5S982U8L"GX6!D@ZW<O;47*_
MY2/?]C._52/?5G.^%W/>TO/0-QC!9O1YI]:[2K?'&F6XO8@D%X;M?S&<B!'I
M!E?LD3F-S4>9>%D?1O&/G^ MAF_V1[3(-.Y,V882DUXYU6T^]\1V*60+3F-<
M1]])J2&NC&JV19,LJ:94;6?26J;13RE'BJ6(=>+9:ZP?_3C.EEQ\*SGF&N-L
M@=K)O1U\O_ 9V$\A\UFPM:&F-4#NUZLHDP]IZR3%IFGW+]%/*1Q^3OHI]?QM
M+K9=^R+7S5->LC1[.\2ZEY\[&2I_#[:.G;PZ&>7GPH97I)YL*"9D)RN6P:YU
M"G8M99[@BXU62YQ8)YQ8X]ZK$R;8E/BS3OBSS%E&92K%AF#"TBN.IVS!]F5G
M+1,_7F5DKVG6V'*KI.='T%/#<;CA6.+HHG"4[^^E:[%G9CUXET$0,3_@"#MN
MR&5/9.NP-?$'P@OVYQ.Q)6,M&6N.#2%P:4U\EH4@>,F82\:\$=@^OYU4,O&2
MB:_"?"N9\#KBZ.8PX77#UEH&6^-KE%A0<,_,R/=MMU=BL+)GA6*P I>R\Q<^
M]3<Q1Q. FG)(/S-2UTNDGANIZR52KS=29_6*$JE7HVN42/WZ-MIP,,Q'M6R(
M"]E\'+WS/=B@<'3GP-:U7"M>VH<\M3-__3_+\5\!!;"^YUB7@Z'O/7)2V,;$
M_[F08LJN%,*URDS[&;%O6]+FUQ[[MCI/?0+VW7:[MLE^5L&7N_J?Y>@O(M^U
ML941[-*%_8P_;7"SZ5>=_^0MV%XDH,#W:DYX,X+VS4W<IIP06KQ1L[:M5N]9
M1 B-Y^^(#G,XQ\.+PG;?V JVTWHR?"O3-2YGB5N7[O+2"(NQ(1Y;=OZH.#[8
M(0XXN'0M^]&V(L/)G6 Q_SB3;<*_Y;:OG(9_<5TF;LL'L#(L='_ ?AH8=^/[
MZ!LN8-:MRTJ<72#.?F%!:+N]3-'H[,=2$M":$]##DU<2T/H14'PL)0&M.P'U
M?5;*H'4DH>1@2B):<R)*U#@EWK?YTQ0WG((6H\5MW&C)322H1*TK"6I]"&HQ
M6EU)4$M6\TJ26B.26I"65Q+5]/&WL!N!Y[]H][R.PK:1CE([MI8&R9I1Z\]%
M*"7*ES;X:W%,YH:V7*OM=4/8FPWFHW,EB=#!3US^MAY_HSS^-3[^I3>$FI*'
MN?484$0NZH9S@1(-UAD-%LX-LFA09@NO2[;PTH^^S!9>OVSAQ2'!I(38[7)/
M;I(_;B,2? ]V&U5I.5QYAMOJ^8PEO#+VFO?9';S;N3 &MC.ZNKK+^/,^NP$6
MHC+KC'6V0,@@)[GMMK +38]V0S$P<G:I4&?&/7-@IZT[0) 1^LD"PT2_6?!A
MI'ZCNN3SSZ90H*X\MP=&U0"/=YS-YIS^RM1LPNB%\M<#.36D))Z2>#:>>+)2
MZF#^62LIDEO&<,.2Y$J2VR*26\?Q1BG9-HF:IM#A%$+;KAKYM43_5?*#XDEO
MEK>O;7> 1>FC^;&_4B2N PFL)4]8:Y&XS$C)/KI5ZD>+(9DDPRGJ!-3&*SQ_
MW K'>TE0:R'H8@]H&K_& <A%P!71M""YA=)T8V%BL*3IDJ9+FLZAZ<:B0UGY
MKM;YS=%-IM&UI).B&<?/X= L*NRVR>C\4XB<37,F%,]QY5<MR[)QCPVG-<#Q
MSW>1;_:-@&W+%(N?@CO/J\/8EFWXH[:!I0"4?*&\?Q:$*,5%L5D:/PDM_A2B
M99MI<;F.<WK!YO2+7&%4X<YS#/\Z<D*['?J M+W1M1& F7P1N=;FLXVY2??E
M[=@ZU_G$5(RMZ+:_3HWMUS@Y8#H2;'I ?YTBR)N(!-))?L\"AG-U6O!.G)OC
M47:^HI5M+HI(B7'IFMZ Q3GH5Y[)2]M3OMH9]Z%$J]G0ZB-SF0^*JFNUK $P
MYP!%K_W(SI^QM< 6E+C.A%0S[4*)4M/Z_SQY#WTO"@S7>GB"E8XNO,C'8J+-
MQR!<Q8TQ4*NA7UCM%NNIF2JHV4Z?-)G3OLVZY\_,C)"R> FA7V+'#R3F3>@*
M@E]-V>Q5LK$UJM5Z*0O^COE=SQ\8KLF;[=RW/V]!F6=>2Y?)*RTE7B89!H&:
MGK:RW>BSH$R*[<#@=!*'BK_+\!@I=F+HVV;(K"VI2<X<N&('CJ^S9%BO9EAM
MYC_:DGZV#8?6E&^]N.=;Q[XFM._;9MS;I(-?=D^][=22-D)%6?A1UTL:7TL:
MKR_:2]2(==-&B0+K@P(I?;7Q"GVUL6A]M427-4*7)7?7RG?"E2BP-AQC+2W<
M>JE.KHDZN3JMHCST4H^8JD>4"/(S:0[3\Z5^KK26&?:@U"<RV>L-%8E ';-9
MT+KS69?Y_M9HGC':G#I&$*0*&.)+)J]\90ZK115&SW_X\367[B-HZ=X6Y+$L
M&"?F 66>RH&$'ZH'L74HFHB[1EQ)6B)KB:P_*H(;KRC+;"Q&!*LH7C^(?SI4
M?$%XH+<NRT7R[2WMGX+LTF<T96-6ANSK4ND_CO+U@_E1OGZX8*VS1/02T8M5
M1!*4748"1XFR)<K^&,HNWE4T57?^\--:^;DK+[72O&8A)<JL"<HLN7_3!"=S
MB09KQCG6R*6<(,_1;KV6_)1!GM-28\K'K=R-^>DUIBS"(T;-*RK5>Q8B*DLT
M+]&\2/&N(NSRQ7ON"96X^9.+=\'M:KNUFM)%L,T&\# @*".,MB#)9&[6D;/^
M%;$-<3"+<X&]?/)Q E+4@85_-;!'C1R4G03E[FY+/"E<Y@G.)O;\UK^W>WVU
M;V7>D10*P)0>D7$44)[\3TPAD@KN?/L1\.3.,<PM:6:U=B0Q T;FG\)/C)Y3
M&'B)F^O.KC<-+84Y0B\@<Z1$T!)!7V,H"0R:RU#*H/7"^\65R%PB\SI4J<^
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MHV<$7N2;+(!/Z(,^,RSDO;^^ XP_T33MUZ$>A",'Y$L7V-Y[O58=AOH#\/Y
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M@J/^1':"@1>J&,LAYYBEA'T@:!Y=$:DOG*FTO_RAMX+ ,VW$VHIV=76:9*O
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M-1(CECRJ1P&-Q:&KE$EDJ6*K\<Z9:?>!EC]%5\(6]]V3<SU1[\H9)94:Y33
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MSXMS'NK09?#1E436< W=H D?STO[+^M6R8EY*%%#-C4; X=W!./!X&D,0SQ
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M98F5>DY9==PPG'<_$^EDJ,51!V]C:,BA6R4&;2<&71BV$_GSH5'H\<81(^&
MPQ[CQE#I<T*..M#S#=3\0V;R4A.:9V:.1&\4H=,YQI/T'LO>M,[\Q:HB <W!
M(?/^(.L86B_$75?_W:5K^LS 23YS;7\4D++5NA2G*(LL,>,>>0><]R.H]X9L
M"4QH(3KRCH361GA!J%#A=9C#*#2XZW8N6"QC8%"7G34YZI)'%9.+#\PF"N>L
MTPA&0<@&09+QBOFJ4;?+_ 3[.F( VMKQB!)Q"D(</AMO;GGB,WO0B4"BD+]9
MEA+)WK64N?P(.,7'N[FZZ'@D'6 !ZY%&7Z+5=J+5)V8X8=\TYE2;?$S='(@>
M"CP]"!06>S T3-[\50A,RGG"')]\URE^U+51;R_K@K84P5X52N5:%M/[,79B
M9D_$F\D8H ZS"@A"!]0UTS'L02!:7=/5ZHR%6!^#K^>3N%*LHB)7HF:)FGHJ
MRI^Q&IG[:/L>I1$93D7B(9F&O Z)+$/%)X:.V[)_\<J!GQ"HOTZ5N>*QW6/1
M-;GB7?V!QN/>&7[>T,8-VX R4E_RU_4)@ UBNF.R=[&2"V<'Z8E: ZR,"R.+
MKAVD2'9"KELIM;<!J^;-_V!='/ 8I$,$:7Q1@P,\W"4[ (< 2YQ![@9,+5+_
M?^R]:Y/;5I8M^!V_ M&W9Z(J@LJ69+MLW^KIB/2K2G7+98?DZHKY- &2ATFT
M0("%1Z98OW[VVH_S ,&4*$MRBH+CQJU6)A,$#O;99S_67NL\6( S],EFF%M8
M%VJ:YSH\J.^P(L^PWX-/B%DRR..5&+2),VC\_A!T;-?NGX/P<4B7P6/6M6'P
M5H1NLU%>IE&^Y?1-LXS*@!P'1]344H V=T:FF;)43Q1ZBC-',XP!!"1:TM;K
M\N5!$"VL<33W<6>+32V6CMAC+ "/V;-8-X.EFCHRU0K E*)K%$( !<TY*?_-
M;_Y$4OZL[BD?@#8I5"];B.[UASG]GM/OV8V^)T"51@"2\92L5<Q=YW(E&%3:
MF3(5J:@8"0PF^SSGLBEY,K'YB+],VSPWB3\V-LEXF%Z!C$U:V0YM[9I/#-AB
MW=2/N$Q?!M8#O1 /^Z:8U=G4+M/4?GTTJ5;'OJV,PY"]AB$Y4^ATE)VTS7"S
M;8:>&0GNFK::22TNU*S>EE15_$]5W*D'6Y>LBK)EB[D%:QG/B_/'&'LJFA3S
M27BA=O1641KTY:Q&O1;RY[MN**7*[=T5'8B 0JS<:<\U6]5E6M6SKAO.'%PT
ME[,"T)#YG:<A6S[PVC2#:"5"@D&0A&IO@B7< $%?0;/I?+(J^I)VYNNY4.-D
M!,69MLD%7_9^)<LX]*##OS%Y(H="29?#VFYB07L Q\IZ W.6'TMK)3C"<R5"
MXG!O-L_+-,^?@#DX+[!CJ1H@$7.ZA^:. K9N6^[9TEK7]4;P,IT\H, R,PM\
M2A;V:RMS%N$A95@U]4:XQ0MN%P>:BGU;NKYH#S$@=K:HV:*"1<6B[HRCSHNN
MPYNU(Y21_#<<%K+0]UW;U#?2\1TZJ;FMRVY5-?@'G[YGAGI]6ZP=T-:MFP_4
M2S7.<XN];!0 'BB+!=M(S<2>)J90&P:F.I@WG/EC+]5^GKVC@#U?-US:K1V
M*T5+-P-BQ1:44.2\\GW3RSF*0JXKIAS2C 9X&&@ <BF>3V\& <P@@-EWOIO
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M31X3V(0)D@<:+CW  _U3O*L'91.7&D)C\YX50ZN'F./G7W6K_V\S\+UU6V4
MI]!FH!.=O'@AGCL<AK%_C4_")<7/=<VL=7HF?N7]OO TQ&QF=IZI9S]B%>/#
ME.<VAZ[3"6U]UQ '\W=*IU+),8>_91E)HI-D5<IAT=#U;S&6K^?@*5GO"?+6
M![+;'Z!)?HIW]:!LXE)/@+\Q.>199X#01DXF09_2N?#NU7''+)P/=C,\P'?S
M*=[5@[*)V4&><I!SV^V=.L=_W.<=C<W]XYZ\_B D%+\IW\07,]^$_,5[X9OX
M\J/FFWA?=O^N?=)_+OU3?:Q4 L=D"5]XLH3GSU[\G^R'ZV]_^>GYBX_W"2^/
MZ.P_R_]ZQ@46\%Z^IL:"4DQ3W6*>*-^6-]M\[6Y :-=L\K;L7E[EWTCU9E>\
M%*HIK=V@C;!("C^^WN-+0,R8:/R)&2XGC8>AUH842/46PNQ<5?A?Z[6"6*K9
ME2O^N*>>XBLL[JEAQ8S\QWSZOX" C&_#%ZX\!?6K;8&7@T:@\&+C&>T3Y!II
M"8L;(3_<NQ;?J(VWYLY6Q.1AF=9011"8 IM6WQYA$7A3,W!GE9XZV6Y4>S<3
M?Y#[/UC$G*NA&<1D9/XZ7M0V1P.Y+=$/%(GV-4;&6"& 65?=.BN%HMF3M,FK
M:E:KH=7U9LD-^=9%3$=VNO.+O_)&)O>R=JN*GHI_!<N1GU9H'='=9;A[U4(X
MX'+!T*Y0UIPI[G\390)4E[OLN:L*)42&>?[@C?+GI@M&_#<'^D]ZCZ$)G7\K
M[<=9I. W>X-T'/S#94H,:Q3XZC;(I9.;[,'O+BR"<"#K825$_LS#+B@9J*NW
M_,89K(,/2RN<);;$;^.ZQH#(37"]EJ!$@'JQN[#O!.:'GKS<4$A<]W %'1Y&
MX0[,1AT8,LMZ!=+!H\_S#<I9 [%XIRUL;G[C/H,26+':EO1_9*P@'Q1T-V2@
MTF971S.;ZH.)98RT-<?1P8E3QX2B..3(&OM#7NYV@_".%_N#YTL5<N'3Y@ZE
M)SM>$"VD5S'#79.U5,V> 2H.]E)UB:#JL"<[IPL8Q@*&BT-ZL 'MV%HY\F#L
MD5U^A<D5831GL(7)._/&HUVS<3C2/3GZ(K\!8VOK;@;RQKQGO<A":_+U8:?2
M"7];8C-<Y2]*GC<'**099%:=GEFDN>Z"S-#0 FP7WS. +;++@AX1T"%@!QW:
M&(E"M\VLRQ01D/F41KF?HF*,\9HCEYAIF9;>F80%!(KX/GP<P5]+[Z)AR%E8
M_^J0T?]GX0>MDQ?"2.CIZ9?@@T<LUMX4=?DO(TVEZVPVW""5Z&7/PB&(L^CM
MX.=H=T(L]\ AERM:B*G@+V/#8(&E4F)9(8OFY>TIID7D"7 @JW23K3(K(*BX
M_6G*4A['YH#O^/Y5L?H%I0C:8ZMMW53-#>ZC$"5.-;E%9N'PE";9Q9.Q?MQ/
M1,[-CCK6X.U#T,Z$X@O Y01ZJ4WTP/ >]CE=<&TVQ+OT38]/]E:TM=F$@H=\
M[:DJJ,W@&@0WBZOCJ-U4 ZR>7$'T7>0.V $PI3'=#/Z7[Q4;&=IPO1.9"-[(
M>E_B%.G*K2LZEVY\6AG+3.#"_O<EF<7[>9:3HJ.CYWDT[]S7/]$O309'O4@@
MH4=1,&V4QLYEV*K*65C(6?'? WSNN)312*D&)07:>__3E+QO-)+A6O,2 /2&
MW,%NZ'QTPMLW<0<AB.<_CO>\Y>VFF"+EA@AE:@]Q3R0O^TYBZ31^S@0NVMFC
MZ(]IIU:08J2GXAL*S\+R-)3TTW?2:H-G?F 11:LD"2.Z:#J$(Y=.?%5Z7'(,
M+V)6%A5E%A5UY*-P,>ATB+)-6*+%B9.7G9*BKH-OLE41^:*3ZP*7V>%E]V0]
MBTR=]^DEUB3EGBO:>FY=<8N82M;5T\X'X1L#^T968K(CBTP7E5SI1?G)^VEN
MWZ"A\^9/G?1WDM;2<8\CZ??\VG;[KV&YU15_*\7Q\44^/0%R=3XH79_3VJ?\
MQ5)5NHUA;0(9_H<]:K&=)2W''FBB;3W;TP78$\70+\\UIG#&X>21LYN35W_"
MB9+G82J'M#$G/2N2H^&LN]"3=Q)/\0[^\Y",CZ6M>S:6X0\SEN$]8AF^FK$,
MOXW1S\'6?#B^H]N4(=*SC\>AWS9M^:_"9!>?Q9UXBK5P ]^UPXVI4DNI^G<F
MM?BW[VP@\?=\D$H2=6:X-\=OGX:)EDACZ9IO$\-I!(70K:8OG(WF4S$:^LP
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M'J7VPP>C.\--5<)5H:'^0O[-683C<$'XJ4)Q1?4C4'I_9!S*H(/;2Y9WE;\
M%QJ/1\IRC&*C]0A>>+_T4EYVF:0'M0P8=YZ^4,,N XUR5G+3& II&J,@XQ6T
M:QH?%)Z1J67W))!)^6K:.'2&!/3Q$RT/7K"8,]1"J7'//K/SW#<!K1\CY_U\
M)#[H)X+V']M\_NSY-\<@%W/=&D<NQ'U+ZW(1G,%4ON+;K&J2D9;$PK/5!NAM
M%KO$B3I*ZVZ *S$ ^#E56O]5W@$8J&A\8@+Q Z*>-<O_R+%BN4M #K+V55!/
M-NSK"94^KWLU79+@!?2/M6KVGL1A@L4WJ-G<XG9_G-1D]MI&/,D/J.VVN9.S
M:E=:P2L,T%O (OR:/$#&)QFW4[F)RZGL\8FNI6>W/I'>32?5LS]XT$^4D#MG
M;UQ;TW&];O(DT1/2SOW.NA\'CH95_?=4989#94,#T;7B(0Z#;8[@Y 8*YY$@
M[1_:;@[L7TH)][\OJ ]Q5L_XS1\P:2$GW>OC+FK24G[SKYAH/O_;?V51K_GL
MN]6M\1__]0XN\DY?V]=_^/+K\-[0T7Z;&WS/UH6P(#_C/P0.1U)/1T6A]+'1
MR,]F:_E$K64"1GU7M#4'7LK,S?KRG4?-%[F*O2T94;-L7JG@F_TARG3GW$8A
MPYM%B*]F [U, [US9]OG,I37N3C/_.P\T^N5,FX&A"S-T%?2-[>1BDAG+XYI
M-F>:YYIE'I>#M:Y\KR#0?,?RDC$E:_[\^Q]?S,8\&S/]%_4-M?NR!7>^#GQN
ME #/(N[(SF;[F>U'G>&H!N@QQ4"8ES6K O3;LET_ NK_0!9T:%H!?Z/"P,-=
M1A73NG*W'-J.O=9L8K.)Y9/G;>M6W/SRQ8:FC<6WH,2;M)O+SL,53#WUM!\S
M^/"OR??OR8 #7/AU4/(O9RCY^X22?SU#R3\ E'RN1,U'R?L[2D)]X*PCQ4;7
MO&K4DAF,&NU)R3BXE:JM5Q&DG*)31SX:S=&==1]A(-]@NM&E5;]JW]3<10=8
MI*$UH'AICHLNTIB!JCO/BO>#SEH(9?JA*U=E(6+D$MX8&*)>C?LSRH7-U)U7
M[R4&&ATSD,E\DZ[5H[D1]T9CUJJN,"GV;N@,J )6MX+I+.DC+AE C?K#!F =
M(XYUI+DC:^HV@@B#':''70:==, ?:W3=O$[Z):WU!? W/-M (Y/"VV9 ])R,
MA2O<F-EWBY1T\X@,Y"2=+DSC5@;&?44I0MQR0?*N[%RV]+!W\+IP[7/6;WEX
M-A_1.!B44[;Z_80T[!16*TH2V1<9MT[)IT[?4+(86""8PV@'WB(I5_=;='<6
M(_1W)M:9\'-.,37>;;WZ6!G+!'F%+?FWQZV"J[ :.IMT5 $XQKXWX.=\-.R!
M%"R;-4@(,IR5T6Q^LG^"'DFLL#:]A53, ;103L#^F+'DX01,8T5_'S^<+EG&
M+&6X1=IN3=O-.(4Y.YP#ZGMN$SBYL](QV\:Q KU)TZ_=AE5.C"5?'=I<I)YM
M!__5!0.QF>*>];2M:C!FM0F%;)E9 ]U_Z9D!TU-*U,P.9]T(G13[IC3V8C55
M'LW#]QFX+@[W9A.>39A-6,(JF(UIR$L8TBH(.IF9$4FH4&J8S6@V(_Y/F?=C
MAS:;QF6:QKD5RVBJ5T>@QS/&97V+B8,;$(Q$Q/6Q\ (R4-=3'N;%,7UB-MO9
M9=J9&$E9U)V&1N=971U&Z?7OD=NS(A-SN_LZ9T3UO+XM:A'T9*YD ^Y-3JV<
M=3<B8&[T+&4M%5E%\4DIQ*M_!][(<96BIK7SE7R3BCKS/L*@JG6?8OE')4D(
M&Y*^>MY?E[F_SCWBU4 ]8X6XY'0T&_7=8SL6@@<9\/5_Q)0B85[H;?;XJ,XV
M&^IE&NJO"#B$P4SI<166:-FY3)^"R!8S8;7 L>/$IZG'!=VS;F,VRDLVRG.]
M9Q!6\!5^3_DS,8TO/  4_F*8($FKP"JQ:8)J-F94SHV,_J-I9[.\2+/4+M%9
M!D$6QE,I1C31L'Q=$GP&82XABE9>!Y:P:P<OQFWT)DS!P<71,WWFNNP*P'55
M>VE85N4JW[JBHI3048QQ(QE@T$T1\JFVJ8O;LAVZ&=3RL36=?TV?]02'RNEV
MZW6^=DIP"Y]+_]ME,GE(.97 R$.;61I"E1LSSAG-J)(D?/O3?S_[[M&3KS7<
M907ER$"-1H:^/)ZC9]NEE:&G Q1PD7GV,'^]$IZ>G+PPLHN,6EN*]B3C>CR+
MT,&%-)6WS,+S+R1<$B'3/>Y0L.CNY+/$E'.>%$=6;0_J)2!!T*VFP EO0V@]
M]8#:,<$3CQ&9IE'Z/7CJ'=/Z\(:W&\P2-49!$ZP;=FT>NEGCO0NH"6P4^I4U
M,$RJP>/S#\^':E^'Y?(WT1:*18" DB /1'9N6DAHQCD]Z"<"B@4[ZQW"5DY@
M5HYT3"9@*]D;P59$O%1@*V4? U5&9(53Z)*=*D:Y7I_"O2H[V_.R ;(H 9]P
MEJ?X8J04I&# G8N] GY7=)'"[*3T4R_*5CL3GCKA;/FCD !-=5A#(0$[? %O
M*+PSS<ZEJ[DK;[:]:KWL%>@8=C+N,%JKLJ8(HUAG],GT<X6IP3@I:IA>S/(@
ME"<6'LGCD"LBG\X&!'F4PR*B_+H9BK:@V,@%,NK) )]EX*"V2>L8$Q!U>;?:
MTC)5H/3Y3I0_V*^^V=EX)!V:RAP:R?LZJ!P**$]H1L&3>0-3Z^E1A=(IW4@^
M%4D)GH5L/I*J%]G8E2OWO9S"$[KM&ZOT*QWB,=4= ^X3_CE]* H*FQL6NK]T
MCWS_Q-A7\\38>YP8>_IXGAB;V VS^,AK'D7SFM$,JR?-@QAC(;3-@85YZIPH
M-Z+$:>33X5B:B%\B%QL302RR1%4=5S(^+*"#:@LW;MTB]Y&RB#GKM[+"O?3X
M9^3VPSLSODTES$5C8^GN-Y8?OKOVF+,_-<TZMZOD/X.#M:3/_4[I=?[T[<]*
MK//[Q+"NPM\H7R\+; 3:$62-'0=G$5WNL^??<-!!9S?_*?+$LJ=HJ<M%=U;C
M80$;"6$RUWG&2N-M](1IH)P=!<E'*\)K,$D='@G!3BQ;%*NL_O3CSZ]9#_4!
M@:!?UF'! 6V1?_?BQV]XSRT/1KBI&YGI:H6Y)1I"',5U6*$%A_"F.:RECM\(
M)?Z;I*LS='PNGK^;VP3:&UD[2LQGE:TU28[$F"?\55Q05PDAT7B0/SK^"_K\
M>8V=-XL&6*",':PO=,Q-RMF@)PUZI 6R=R+\PC84CJ#9?B[4?@:OKG">(XHT
MCF*.?VY6:!>/ZVD#N3XCR$-V)&&?A(^S45VH4?U:IR1^1P'GHDP):;F1ZH%Q
MP,]6=)E6=/:8WY%PA['844+G"JXQ-^#%R%4SI./DU<MN^%[*'_,9/#/;%/_W
MSZ$0,"S>?82,G1;G%(GA"OVEJKF+%6OHC^MUT:X_#'QEKJ^=_437]2$3]EZN
MXW3<"#-YY;2Y-G2Q$(CB3Z=:7Z<U0*RM)FJC06B465FS6%AGX8NZ:$Z&Z)RQ
M%*;#]R&[8Q^U&;TO"A:55?(4J?+2_X=94!)"E9M&<0G:AP68IL#W8BRCKIL!
M8;,-/T'T,95>-'69"<ZG+%"SS-7[A^9=?FB;'4-6>"*I1,]=Q=< ,=N9Z+HT
MYGW+?,5-^;+;&I[)2L = T^@?++P"?PB<D&+E+MN$:8SO+SGD5%ZE^34W2%0
M0G&:K*NLZ#8;<D=,9P(DEO^)XBU0]7+!6,F*33@N!19$(D_9?6+9-N-.F>*N
M[#K]Z\C);M@!)Q6W9W_[+OH\W2M6/9]<=;_5$ ^8(%ZT_*9FWX^>]BJ_KJJI
M7Z!3L0A"D4OZAY?"2H"*8/3:[56X]A=^R_V MD[\ZM-+@PZ,I;4CN1N%/A7:
M=(0S,$OB-9$G8/@C'T/:-* ;.S0JW78, L[&C8G5E@XE5V-:+N(7"TB4:3MC
M3$A5"CF=<D1+A\-U43D4 $HZSVZA3L5:0S40-WSCF<K]%D%F=J)Q>NF8D(_'
M8<M1^%W9&5 \*WK?"Q10V@U2K5I(Q28@WDWG_+@C-_&\%-1F8&$VZ)FU/+BY
M4##2MF1550'T11 ],C<'9XBP3+2F]U5SR%^Z PN6NK;;EOOHSB <V=2UJQ8)
MI9G'.&$DD^US37LOJ'\J7$N09.I-(:IIPY>&JO(GMUMG$;<>=D["K9<BK:Q[
M3Q\L:9NO^K'Z_*4=\+_R]G\[(&J4%,+B>03^MJ1+, &^&$,ZUJOTCL:2QXWA
M^(@XI@&+=\]R6-\X$S"6K5'!^KH%':A%/\CY'\<" KNNRM5!R=2[18(,&.T=
M&8SF[<.;QN\/>2+.:94#YV"!"6W6-M\XH-S#QC*N2=O686NI;/J)FZ OQ-A>
MWC9#3^:.QUSI@7FMX@*ZQ#V_+T44L%LY,$0TVU0#CM7>)K&!%<L/KFB[>-#E
M'1X@EW%H_#9/<>^Y88=%4"DU;&M(H9(*\<[1[A 8AZ3(+--)MKE> A7)\4LO
ME);JM?VHLA<<S,(6_@\X:-W%<,%1@+GPC=VR%NEA@67PX$84JD(Q",'0Z'PQ
MO5"Y;K&R"2NT<7%+X0I9I,\;E0W&A)OI$9&BRB,'8EY#'=:]1S3B-_E*3.A&
MY0=)$0")#DXJ.L7Q'=ADM.-6\B*F646Q6C&82$98*AV!48(K>^H2B3.@0@A_
ML<5+4;89:M5?1AF-HG[@CEX5R#HD??ZEI8@[OU:A"'D"]0D5)V#T=Y1D.<DX
MON,Q%W-L?PIK\KT"_E<'?T/XCAVKH68%F1C%%G37T3)NY4UN6N?^)7ZUHJT&
MQ=>B@M+9H=EL.+JU$K1=P^T0LS@#V;/=6\ZRCM73W(9<I1#Z"N@^F[@-NQK&
M[-;,%1ORJXC3[/@O)4.97#]HG^.V!)ODUYO>^0J> @N" (K35??*K0;%(G+(
M5G0O;6#I6T;Q\D5^9)$M/8#D'_2&G]%CWQ9&I(%![A+7X!-5#R"1-\($(?\Y
M16I0D*-/\VA4QGN;P5G"LK'&W)?@,=?Y?;<)2U[3B2C)X9%M_%F&%G'!/T,6
M' [NMH3JJ('J_OSG%QY4!\=CI@8@V/4S7@<\N99\=(O0RDF#ZZ9<\<C E;CY
M9ZQW0A90H9>Q;>XT4PRW;3[$2X5%O"?Z*XHU3FX)SEPUVD1>')<TQ5=)!L?S
M#NQZW,CE2'% (A2X8PR/=4/KS%_P5,AK3GVT99""XD7S;^D[KS((I2=RKWPQ
M&^"/+WG7M"]E39L5;:M1K*/1$[Q.DDS+O:T-'-L*28JLXOI-SJ>%3*?Q>:0Y
MC)W+[^R@].<<3_(MRZ9J;LQ1JE)N]'/YEZ0M1OZ">HZ1P_C/X:=+BZE$+2PZ
M]3@^#2=L< Y9>/0X<_''L]08.AWP.__(@N@UGJQJ*&1=QU_<;8=^W=S5_@V#
M;XJOG[[48,OY<92N:5@4K!N?HA0PO.TG)W[TI!D/(Q6^>A\XUO71ZM'3)0<3
M=QY%[[+K\\[=LNOE$%5.K;_7)=S.BYXAJ_&A@MDA6H$<2Y#97VHHC%*::X\Z
M$D<9-P-4^0&V!1=U-D-;-</--@R@8IW\.20$F'VS#[\/I_A5E@Z^?DMO##M?
M:X,]6Z?X.,PU8<&J X_%QF[;*DP5.;[.J)/@:]2NPLMDA^Z[+/K:DF#^MRD&
M74(=:JZI/9 :23)CHJ&!C<-/8-HQ[-[LEHAJY"RGR,2&63W7F'@O]PJ*.!WZ
MF#@/0C 9HTD!V+K ,M-';M&_SAQJ+;1CJ$(2CNH0CGEO)Q;'11=@5Y[,2&<V
M(XU6^!B9U1UJ1VO6\12Q'!/<DSKX3UNGE%L )??)>195&PV(9C4=Q#@P.C*8
MP)4B3R2&F\4/&1DZ:U0>IN\MZ UTQ<8)ML.@9#F$H44H8]R1XL(!8SD&[6)P
M7\M)VGLTC8([%&1 4)Q*@ ':*QO=_>'2FQKW#[I^/0^ZOL]!UR?SH.O$;O@0
MTH@?]SY^5F<A+T-9GY.S(#,50>  AM'3Z<[)^ L3!-RZ*4>(=-6-NF3L'0?E
M[QF=89EV%H[H+[BS+SDF^MIE/3A-:T?5Q4#2AOR&:82DD6["V Z8XQ.E#\E$
M*&5L7KILS'"@#ERH<";/WRDHF!0<"CN,%OXH.NJMHS<^[/>5E_R2++1H44PV
M;A.N!XT7!P=Z&>[><&RX'V31OC$EO<R6#DLFCV7TA)=,E'<E[:8.15NO(A1S
M@U[Z\?61/Y'&CUQ/=F2[+,[]]E'D*,$00^:J M!P!X=Y7'(6"1^Q]P*9S@LK
M1NB-=B!$FZ1..1(G5QOE*@4&V3V+E0INWN>HLJG'Q!]QL62HCR-D+0T+Z"\J
M:9R,^.9M\:"?Z-GF5+';@)W: 10/*V8_47_-&6F%T\%@*>&,8 =.Q^;K_'QV
MY.>#AY?*8"C<@HYHVW#7+=K/I\SYOCW@D7&TIP9.<[*(6S<ZZ?P.#CODZ+JS
MM3_,ZN('JED!%:-9^_4S"S0\H:AT@GA663-I;LV%,CK$38=VY0SC[H2Y64<(
M0T'8]Q*R"814W)>F<V;?=(PA<RO:9/TAZM_XR42%1&Y$2:FHK TB A7<S\J$
M3YJWU7NHC7V(UV/6_$%K>A\BK %/;>V9(L7N\);Q\QLN_/#/]$5[:_1*W1&;
M71DZSB/KX_9*P,3&QBCL:J@=%>MF+YF2-ME;(7,>M;HV.4NW<@"#8A$/IG5-
M-6BGCB.,MKA3G"YL_9"O):UAE8OR5JGD&$ <^'ZZ9@5SK71;!*1YX%]=MKP!
MVDAJFJZ V9-%X/+CWE"[P\<JNG:55Z5VT006H%O<VDWH9[O5ML;9=&",VPU=
M(N.SJV_X/="ZR;UB3]&?:9DYWJOX=LH[RDZ@PM'F.W$%>\?'OZ'-B@.5 1KC
M#A66_I6AG-''UJ[E"&O'X>2PI]4JTA*Y($@\(IJ>':O!T (PWOA2NP^VD\9D
MED"8ED.[=F*L:)<*SEV0,XL4-L.?P$0 0ZMYB*1DY'DQ@7H!0.*ZY2$!>+-G
MO$:ES&5?TX/_#BU^Q2G0_=.//%1!QU.^'["4]"+_7N-Y\0>Y_L'W?P\?WDDW
M(6[.-\N*E448C% ;"$LIGP6/BW_1DV[+F^TC6$%&]] =NM[M5/P'HL8M"[58
MD#%Y#:XE"Z8%V05P6 +3->HALI]Z5=*R^+&;\9JJ(7-LE^D]V :U6H:6)**;
M]/298B_2)\?E93$Y72_)G15M9#32J^:Q5.ZHEST/,M<=QWZ\&JX-PX(9W18%
M5(6-(2Y0GZX[P/X9AL3 %X:>>!8FIAUF+B\ =-9T.9U3TY59I2R\%&6*_?&\
M@-D@8%&R? M;7=WZ@N\L(N#(K:<_4WXD^ :D2?0*;M6=:2B@VN5R]D>DD/:1
M%-]A40#7[_$KOQL6&9B94\F'9!Q*TD %XP#6ZJJ]K++BTW 6=#%^ZS4T4%5Q
MI[!8O_WIGX+GAK_EA?2HE<H9NKN0(PFKM2O_)8+MM%VY\!6<^%#+Z47_)SPN
M:BKBNVDU?Z+GNJ7?&2VR02";=M_HL4:1>L-#95+B*O4PD?:,+)*,03,TTI>'
MX/[QFO"RZ47=IIA#H8U;TP$."(099.RJ1\,B&6VT6[10>'_":"W:(N<D5-68
MB0&"F#F>B[89%(1VU[356DM^YH;IKKIFO^4>$KM9)9=. 8?^%+I^MI .S0VY
M#+P7,C4^M"(%\[*VQ]1RW49MJ.ST*@)U9EH>'^@MTJ@P^LWIL^<JQSBIG^4Q
M?@PE42UVJ&@+RL2.WT54EV-42--U,O%%.9V2IL8'7GQ[S)@KH32J\ZO8<C.R
MW&YDN@8J]%B<Z0F#.:S]L-W^YXB%LN<AJOC&@M3O1@?6M^-YT(_XP2\ HT$N
M.@LU<*N,&[-X/NSA*GJ<4IR#1H><55*$)T 9<TY-C*/EXF>+I!._WQXZT<];
M>+;L119AJO;%H6G#-.6.0;52L:=#IT_@V]NFVU,\HL.7S= ;\[2TMF<TR(-+
M>[^GP" K.4Y]#0L!XHZ3IB4AD6:)4<!;K"12TR-)V@2+A/I"(XOL)I2]8VL^
MMM(CVPR&:_111T:J_;%AOV>H>_P0<2BO4/A%=H9)YS].[<#[5POKZ4>EK;?I
M5UMW?<9SOT$9X'BFZT.2=L[\G#,_SV7R\WC@%J=\BN<Z0<_#LW\1%&Q*E6WF
M$IOM"O]YLXBE<R/!X4A6*3X1IFFA4*33R&VVK\NTKQ! G"?6?(BBHT30VKR8
MS#I@9AG>34JC7$Y@B*R)7<UF=9EF=:[;&A5F>>*T$2 V5(^DTP#+,BDZGS6.
MRFJ)$C1*G6?=!2? 91BYBJ-^K>,K]3\G)WK34JHNZPW+8DG_1V]OMN_9OL6^
MI;<*HZKI/*TXR6#=A #.2ISJ(B2!OL7;KA]ACO>@*>AL7+-QX;]H6AH'L6_/
M%.O;HF;J(6$P.THK>):3/)QKZR(]EV?;FFV+_PNIZ83]@'U=1/V6;0.&*I]E
MW+3-L(_/9@!,N%FE@LYG.U##LL9Y3;?EQE04B094(1 PJ[9<.FFO,R*VF^4
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M..QRYJ5=XZ;<JU4U=$QB>Y7_N;E#HW*A*@$EGTB>4Y )&:+/JW]'/ GY,LI
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MLFV).7?P0Z'N2%Q4.Z+H(N(-?J)2/M;%4"S!L?1_#R6F[59_^_OS9_WQ(*&
M4E?HE&E.DNO^&<6GF+(6,AMD0K(: ]H0Q.8AMD6,$Q5#16&-ZY5+('$IKIX#
M"662.9$YJJG,T,NP\ +\!6?7.R3B5(7H2$FSOFY&Q'(6F:OY#PDVV.1=%'CM
MEHX$:99"R6JA^IU9=R[B5T)T3;8<ER>%]#$/I%ECV&_@G%\.\PO;< _@/9I:
M,]4Z[D)9+O:#HJD:^Y0^&..2-#R(&$^7AZ8-V[+_9]$LS9FT4[4W5Z"LI%*+
M<'D*KZ_?0#MF1[3VF =H>R[ =OICY^^PN/:W8#&E*"AV_AW(?4<E*H0#>>PE
M08T=C(/^R.<OXY&T;FAOG=\:K% --M?67QX:<?@O?;HO.UY)V^P;]?'@RGSK
MW"&>WO+-Q.1)WVVTX&F)$6EAB;0EW$D>.P^\.:N]&;]V]2Y?:];4Y5E0WMWS
M0[B.JK=R+O$\02GO*,%^JW<RW+MKR+PH0[@PA_LO)$8LB_]MVNNB%I*^+M,N
M\XOOON]"DYD(_7[XOHLU-/LVIS)DD@&)]#C'-_)<*%VI H55K,!55;@-"6@V
M54,9BP_L2F]4L>/++=Z@6X$\#_\L04EQ1[*X.XI:Y*K)0T\^?2^75IX%R(72
MPH:1#NZ $RM8^O:HV/+#7[][G0OW\)@W-AE("QX@2 #+Y*,CQE%\?Q8-""DG
M?^>L-\ K2JKW7&!)WUC7#]N2%V[,,]EG3SW\.=^2_6QIR7[,ENP?EI;LTI+]
M5\O;)L1AHG9L',.Q(<EYV9J(9PRPH1J<L"G(\4.=CRBX+449S.P=7%"HSW#@
M:/]3#ESN(GW[W:M\]>T+_+^FV:[^7JS!@8VH[Q4.7P"^](S]]N^O](B5WWY#
M<CHSO_DF_*8)6 Q=,I=4%!"4P&]H-IX926;EV)/'F-O !8TRIYS4L8W-RC^9
M/_Q J#F Y1R$W\3<S?\(2G@[431)I]9#Z6-;!T[JUI_NFYS+392*PR4J@?VN
MB4<R8I>W&LGA+VA)4SQ+O5K8'WY*<EV8)!CPC3M7]@A%X?A0#_'1:>4$<T4X
M*>VL^BARP*@*H^>,5E)2%C:-VEA%&>I=2<V^]*;GFOY*V4]A_UC\'"E=1Q,0
M5,Y#=<ZO:ZC?UJ* YY_,7NI)(62(<ND21&<41--^&&K3A3?#RWY#M.QRCU3>
M2;^:8%R\88Z E@D/OKZ&LK,6 YK?F1OQT5(F0<HXV+&=QWR4JN#]A4N3G('E
ME6 KXC]MJ [$X_M0((D2A[I.E0;45C Q0T#&IY.:>W)9>3'Y269C)7Z=6VMY
M=E2.%'XS5>,]3GC[3Y0=3C[8A91U(65=!B[&RZ2#\V$#7P572RK7]Q1 M 0E
M[BO@:OC?EJ&NIVDL>TB%] \SE[V/ K50IKI/7&GR9T\LL)%@E56.D^E![_W;
M5B@Q;36B;QZTBH2E$$$BOH3B-G-AC0['!Z]+R"A,16%'0<3[T%LL6^2);A&Q
MI0?9!!L\%0E8Z0>ZU37$Z;C7Z;15 N4U+9]2F!B $-J5WJ%YEZ?MUH?QK^QH
M3$5S-BJ#T1?2;6U)I2YRY4?AJ8WI!#J_M4-P5S=US/46JW^:5M\Y]_9A ^PP
MY)^&6NA90FEV4]Z6E*#XW'M?XHB(UD3*U#4+!I*=+];T1*V)\LUM_F > F2T
M.=O)%B"*F=;A8C-/VF8>9#+14'@J@KM"BVK$K\)@6K<;N@=RC#5!+!ZV1C75
M.(/;K53=70JV_.OQQ^C?;KF]O!C5TS2J]_1")TJ^$6&7RBA38QI=^K2JFM B
M^J]=;.QIVICS?WFHA6T=-;AB]XK=GPB.[TN> V.$$,$R?N8_[<Q')B4:;@(^
ML!X485O<C5@862ZX]X AE&;#<WF)?AXUNQH?7U/(!)!/6=^4Z[(?DXN)8B83
M)VR,N*G[9--'C_KM?G2HP/.("LP$/\?EVC'T+&I@46N2T9I=!(C-#F_K6/*-
M*WRB?UQUFW;HO1_Y'T.G@4]]X[;^[*M6;]IBZS*(XC)4,%&J_^;-BX@#P+]_
M[=![5R39_\43V\B@Q/< _9(%O^3BEO=FW])\1NB II_^&U6,21_G;R3#_EI$
MQ]$,QUT7O?^.VAT[GH0&7'KO,(L0])W^>?7Z:O7"YQ4M3?3)S,-A6/N8\&KU
M7V5334_W@M6FT>B&RK4S+R ;#Q;NJ/42QGX;$@=_1K5JPK_E8]2&0P%]P[PF
MTJK!M:D]',97;@%FO=:5)8KR7)XALPCUF:ZH [I#F%PPU36Y#71S2:,];>B&
MRGIJ:PGR(46(<XDS&[6A"(\ADJ?-Z:;!F49 K$?Q67>F%/74,7Z/Q__RB,/+
M'<:^\$Z',)<3@*6S='";XL"'E!06;?'=;U<Q/,%UE.TV@'K2.=L.R"FS)S,+
M?1#5W;5=E8Z$D2>5"<5E".'2ML2/+B-"!;SDE2M:'%00":)!-;4K=EH)#%P0
MW(&4KCMX9T)3;<I  EO,C1U.2*13.-XQ"\Y>CP]E#AZM \;MS5>%R G;-%H<
MC-']O'$N?M&S"7_BE@*ZKKGRY^2*D+-HM0:3/XX076+@(VXQMGT@W!BP%D@9
MS:V3P_;/M%48(7=?01[2N\T-E^#L-LVH]_H6^[P%?/S<%O4Y#;R^<&YT<G(3
MH+YE1Y'@RL')D<#U:-GQP=8THT$ZC14M)#Y5>W:/0E^_*(=$BS(O/EN!!/;'
MB@]^98!$U'INR^U *F;!/W0# A8:JF3_5;EBVP52W4#RF_6MO',$VS.>SC^*
MKJEK5^6IP"218=3$&>ROVEQ[:[OA&5H8)#X%[-O,%_:NV/,AKT=ZTV9;5U$.
MP!.'*6TZ'HM.Q4[,8+H#$M?,PSQQ"EO8$MA^8S)1:'P4.-@XJUC]&'RP,+OX
M*Y+)[&'+^#?_)IT8L_"/^,O0@&6<=".>&K\KG^T&(HB;>RRQ6'.5_5B"<:Z'
MP8372,&N_QR0?]@MAQ:I,R@<O"_:YHK.],%-G"&V@-1D*ZLW8=UT'IN(F^!H
MMD VM]9=#'3F#BE^5"[-W0J,HW:]/.$].#6#"Y(!&GJ42R;WR<*@KXN^R"QM
MD+>QVR"@+20E57'7A4IC&-@>=+824-JJZ08>!3+!<RXS<+-1/"E]%@=*,F2X
M)V-GT#F^(I.@G&17F,P?+T'1A09%)IW<29).YD4Y,<824ZMSWJGB/"0C,).X
M['W,IS"7XH,6 J3K7"4^I+_$B5LV&@/$C![.S)ZX>?BZ_"FRULD"@:L9]@Q,
MEVVB,PSZ[_%+5K]1C/AK^=4_2FJ???/F!4AFI5CA_R+E@K_P7?S#WL4/0^7R
M$+^]P+G?^-RU0&F +_I*+DK?"$CZGHE(A7#!?$1_\P?PE709>&YM1>3%BU>!
MXO:W5ZN_ZT-G8@/I0S$U.T<,>KLZ0DB9$\5!5ZL7,J67;F2<%E6YYTI?1J_N
MC!/) QV1EHXCHQK-=&]+P.$["C?CB(K8T3MX,OFE;,\DS][6E8MB9"F@0! >
M6!I,O 6,Q#_@G[Q]=MMR$ZB?@L<B0@A0PM)#\<ZN.3J7NL1 UX3GYP.3+/EI
MT$.>N%&.=>T*[4L1$HB2SF,3'L[P?^"%ZZ/M,AJ"@-W(LB@8GJ?XT#@ROBH*
MG(VIZ988$ZA@?$Y?"UH(DU,CHUT3/J[4>!R(4F$PG>0M0,V^7:6?HOY62U;.
M1PRR*?$[/)PT]WTF&L^8L ^T/A@ /\!>>TZO>-@G<+K-?=$5L4NW[L9$@!W^
M3#4E,D\RDC)E+.RXRDGAXW53@\&)F3LH)[QNN,(@U+];;ML1#XHW-.^M[IB+
MF<+6A$)3Q\CCYHENE-80F1*L/1,'$S/?94J*XC]/>9[QU!S-SU;U3[&61?;B
M4=*C=J4YEU7ZIFU("QG:6DF:9OA$GGIY[?P([>^7$=J/.4+[^3)".[,;EA':
M^^[H&\Y\Q@-IH\@HM"GF3UWN*23]DZH4[YD'-E)I$=&_;8L]WCU.$7*7AT'H
M[ZD+$SXL[,=*53'PI.IMV?&0:Q)<C4=OZ> U=S".TP@"3JSZG9)0X7S1SE]V
MYWIBI6K\F1!G:7N_#9G80T^"TE+=/W4?_VGNZ%^_]"_5L0D,:-G &D_/7TJ-
MX)K8J$H&IYC=P0DBVQ1%+R&WY-:A3?X:NU6(+@>[Z"/4%'Z)QZ76]8O60CX^
MSN#E,Z(YS'S8,DS:X%('ARD\?\E];$N:)[HB0Q>GZ]=E<T 5J=BX@0(-9$[^
M7MJCEOV)KO>Z:M:$[>6\[LXG-AU5,S,34?_&75U?<8+ES?*Y4#W[/W+*671R
MW9!*4-C_6VZQ4Q9$U-<]%=0Y+1;[S-.J"-N]E@9@U1DS"_=11^0*OQ(>4B )
MHFX.):525L',^T':/&@62*:$DCD07L+\3;NM'97Y_+&QXZ0SS8*RW\0W$K(D
M3OFY6^_OBN<QS(=^2T^&#J);Y@F8- $.#8XW6,<HT=?M2X=FG/7.PJZV!YS%
M"#!7DK_+Z$WB(\,3.>55[)-22G&PW".#\?9FN R0RSE*?>5T]4\$WQ"1"8G+
M@2W2DO4*/OT$SY*DLT,=Y&;69<%D17+?-/O%8>G,?<7](OZ22"3B(H9:U!4!
MJ1'V2&*;YR](7Z.\&"UN($))T.]"^E[Z30\$((7]PLO1Y5E8<=)_L]FD<I/=
M1X*=II.1@S*02N::'A+.E7)&*?$I2V466"JEH)<VCH3>G9D.! F$:P%:Y#_R
MNF\V;S]@3/)DSX4/'PI\/_#6TH:7WT/>I(3)1 @D@(XF9[\^)I1L#<^?4]6H
MZME(L=O1IL@9CT]!:7"X&D0L[85+BP?.FD$X(O7OLGNM'80R/AL"Q0RW0U4+
M-8[WP))+$</)YKAV[;.B[XO-6W&0QG%F[#BO5C_>@'3/'[?DN9#EH&K=DD3I
MEO 0E#T%A\;K,YWQL>GQ.HBJ<A=@&LS?>.>XL4: 6P(>;@IX;7HJ[7"0BA[[
MR&0VH!=W%T\!XV/]42\?UJ=F^_/>PUZWA3QAZWR3AO:D[JQ'Y>BXH$.%GJ\*
MFHTH#L?K)-Q N*DYJD\1[J3GD0H9:(8JEB!)*M@K007$*0 ! 5R(KJY67[ON
M +YD.O;B5U-\((HEMRAUH??!U5GP._NXI-YVF^+@B-90A%2"_')RTC%>FD%F
MJKWG*LKV 81%2$3!6M"GI$[#&M:U\I'ET%)F'I23]OX6J3I_![[_MTS(FQU:
MMIG4C!D/.CG^&=PP?R F/=?5FR91&M(U6!.*%IV)1:O=6NL3^R ?'$H87/+E
MP*--9J-R%D<TP(AS$2I3+VGLF?9<B#X3=^JMPU\L%DC4@\PPLHKK&,%)SJCM
M!.4G,E_2!/ATCO@/C[R6\>$CBA>BAIY-F.<5ZT(-3(9,^PW#8NK4:PLIG3)[
MNNM(#WJ*XTK(&03AX+>H=\B!99H(SGA>9HP63;X$<AA!O4O%*:KC$JA<6J#R
M.J"BLM!"?*>7&D7.J!''5A?.D(T8K0!C&-TWLE[A9HO"$X?BZ$.?S-1-B,R:
M1%*K%.O.QWRDO?N.5!Q:OA[_I=PJ*-.[0^+JLQ3'(R\IUT[JW#Y2>&UPE4:%
MU1\I)0[HHM-D.[G?]#913AFZD_,FO!EYTYVE"5]JS!=]1Z^D+9S=W30K,5+T
MCK=!821J:PA^NFRC&$68NZF.7/VBC37>&QR8B'6MA/T0OZ#];@X<?>#5;$@"
M.M.VCK]6N/[5ZONU8JO_A8U*,LD^=.*;:U@?1,7D@N8*:C[ADYE\<NL@6R-6
M#TD/R8ETA1VC6H0/' &P!CQ^?PX,Q$W6>+7Z(5FRSZR+Z9)%<(6&FJFZ:-$.
M(L)HZK9 Q' S2$]81'TD5#/^YL#9O74]ZI.U0=!+K2J.BE+I5M MV=J_=G\Z
M2LL+4M'LZ%:'"E8'ZO(\XIQ5)UH$@OPSA_?V<6."PXT ?64T$M!"/L+)YZ(;
M6%))D)-!<;<UQ;!F?&KQ0!=^1V%39V=.H\00:6,7YIA=I4709.^0U0+>+; F
MA;LKM3Q7^$UZELU3X,F)R5\JF&^:TB!@.:S5U&WU J/1#L[,Q<AE?R4#N"LH
M;ZQ(>2.3(S4\%);;X!0Y4-"6*N>)K(_KLO:QM4&7M*PC"CY?W31(P%$+4#4C
MY=2P092_8L:UCY2*^LCUP(ECM9WK3>-_=E2G6/01?[0KN<[#KG8-W'%Y?7/E
M[<-_V8P7]XM(*'Q['\'OZ%I&C&D=8KG*H=/>]:[8LM/3>V5\M'__/@9R5!HX
MW!P[_T2*6C.2<&4$B-51&9S]^U<L6SP,^4<;MQWHZ<JA8!\?9.X[* A_P]EN
MCEFFRA7@G*Y!U:V2N"\(5\,1U6Q$&,9>5U'AXG7@U ;=,J$,;\;/3@MU5+5-
MSF!QUAMSXK?=O!B0]_8#ZFQA9?I>"='0-7N7;0H:=*7V6C\Y9AB]R+&!GOW8
M/*(Y,O[>L&H4Z>18BC]LF8E:8;&8Y@MN()N)M=GX^!["RN74"G,J_)MD2U&+
M5J9<PF=$B_;D+;+3PG7(4A $>*O1D:Y@:T&HBY\Y0SK<B>3EJ1]=YT%X?UA
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M!37907H:,H'0O=4(_Z1!MB,I6'WNL71\0K68/W&-R-"U!N=DK"ZS53B:,N&
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M6II>U=(0U#/T T7-= <]4>S1915]-TGA+!-'0I4LQ_M*.Z243&3RFZ?'50+
MP(QF4D;A+2C0'*Q2F@-SG.I5?WU0OD=^1Q%"4!VI]4SQ6,?AV(T#A:5#PII$
ME2*<<YPO.Q/J,\G,J8&D%4O36H<$BI!S5426*02W+2D !2^ G'_3ECP#',=/
MPC?2S$H75X7U<U694UO5IU8UG%((-ZWT#+L^&JO'F'0!EY9-,0VVQ;-U0+K(
MF,D<X=J:_!F3P[9%W:$V66^4J9+VB3P+$+G<EOZE,999JL@WY<&_A_[.OXI,
M'QIOT]@&#(RS<<B.G3JEBJ8Z(S\?0ZB21I?%D2W[]J+OZ$>726F,!^4CJ(.$
MG^X' 06ED'\5^<-->'M18W4G<#]F%[\'Z(<&^:EE'TZ9[%Z@SW/2O(%I"VWM
MS-!<@.2'V&&Z@<:*4$6@A [?#I;9>?A\S.%UWF"6$T%P%4FH@4Q;R9BUZS#K
M?CF^J+HF6SMP/J59?J'"5,0DQAI6*=@LQ%@\5A-[6L;?A4[%&4<?H0U9\'*&
MT8MYD*+_2E\'.DPD2 %2G=#6SR<JI5I?(',PA%-&; F'2.1SR'APT7ACW1#"
M'FYNTO_8OPVD.-Q2X6=$+U3)LK1913<^5&]7AZ'=W-##MO \0%$Z?A?Z#C-+
MU[SVC[E.575>V4/O:]S><Z*JUJ#K+PVQQQ%ZE8X.8$J?\=WJYC*](IY4Z9R/
M=P\'1N32Z CM:;\]_NZN:4)1A,RV\H+D/=.SULZK;GXBB)\4^L/625Z5AKXC
MH85\CD)+6<U&Q,QZ3#,GUZ@GYNU4F,],CF%:E]Q_#_LGSH&-R?VR@3;%NMR*
MF<JHTV@LYR[ AA($(^]KTF$N71M]+-M]<+(@$!_'-(::/<5'"C3ES8W35 X+
M4_H8&22V4!X+KI5^Y+VC]0E,.TW5U$%GLNVQW2*.@,$#D^3NWZ.P\,B03CJ]
M&9M836TB.V<33^F ?P+=C!_="/&<2[6@.C+ECOXMGQ?T,":U:XMA*TGG()S'
MWE#\#@;-4U'Z8SDJ;T@]V'))GI0%4;1(JM_'),N4W0?NK: BB[WM76M*7VS(
M?WQH3G?<@0JL'$DW+@V6B]IE+-XH99%OOGZ>MK[/8[H9%GE-N/!8 >(25F.$
MP&;#M'Q$I#8S&Z!IZW1CS.\&0X1P)QI@=+H705TD?-5S;YC/_E^Y>;M&D1XK
M&GH&&86<]QO:6R]X;[$VS*RH31)+S0GMT-%E:<JY(3.?,LNCIE0\FZKV47+N
M'RI'8O%P3&*!J"IF'F9,D]D1&,)='\>$#M8TA<D"^U^(N4-_'L?3,.4Q"[<+
MVAV<\FL^^2/[5P\TA/\7F6KVOO*'6)+[:WU;M@TG'32,]=E7V=^B*_PAKEQ^
M*J D\SM!>^=%I%O_P3#6P@_E,DBMP<E_/"&G]* NTKO?8-)42OI9T[Y*TF1Z
M]TO,M*/^[3\STWUZ\&K%:?[[?WZ +_F@K^W+/WWQ97QOZ'&]SP(_LG7!):X>
M\#_W>%AV'=YQD5Y]-^\$F2992@=OZ^:.,Y.'+(.2$9]\<-#2$22HET(C,$7T
M1]),X#]1[,\)_WZHY5 Z&:X]:"DT[H=<07@6=:S2'[ ":^64V7%606<I<M"@
M^KXJT=$G[D?*1$*I@-BY'[(4IC\HYJIC<I;$00BL;)Z40H^=U'9M?_87#HM^
M[S?GX:.W21>?NOC43^M36<!F&IB^DU,U4G:BN<["S@]:2.*0=;Y-/2BF)P1_
MNG;Z0U+7E4050"U$[D-%)4[< ;=<I!;WD*4T"?06TL#,8QM7MR_>TLIX49/U
M[2$S0"/>=HGPO^WV82L1$+R,Y OQ,\;&O?]>5T)')I0#@+N[XW0 +5VZCZLW
M&,FOKQ^ZDO@=4LHFI00"\S<EYT9;%T9KF;U=+G5FO0\][^8SB4]W7BQ'PW(T
M/(ZCX<T#CP:]GP^V $ZB'[2&EZ'>_@I-(D/Y_7Q#'2+])Q+,E93_;R]?/0]J
MN:'W25P:6Z+F%/_QH)4$7;>.\XTPA\TG(R9_-@-/9:VZS8UWV=S5T'K2T4;$
MRG0IX>Z#TP\^?^1<"2=$J@!L+N=/#I#!+4'UXCD7S_D^C@L.Y6&9^53L6X3$
M7QJ1Y#=N<U.CH\\8CK_Z@*G9EQNN+NH0IGQ.R\0/6@4X=$]A#M0Q<BNQ4X)<
MPD?&:F;B4F10EO3.'K0.;0N)6CK*VB1<QF6(F#Y@Y,9J9$^[3;\N'W9^:N"/
MR]3 QYP:^&*9&OA$4P/+R;V<W)^F')9@+5\%+F?EKGD] #E<.UL;D].R&S$(
M*0L3BB(,PGS00@( .Z&Y5_B3G656Z!A&H .K E?CM<:>QP)[TSZLX (JZ9NR
MVK:N#N25(9()N9G@GW]#N W%#;J?P<:-4..W#*4C_B2EJ7Z?NL^+[U[;6,"R
M'G+_Q/92(DPT@K H\MC)ZP&CX\.L W6KE'.YAU 6HJ.(>ON-G<T4[!>A\;%D
M?^G?$C?+'68D_7^;._S;37EX< Z8<&;Z(\]U))A0!;2Q,EVLCY-5$TRNW,.J
M"/- NTMH-[JO'KJ47U5(MAQ.R^'T@99)A9L';;:JN%OAN/&NBSR;]V*DU"=(
MU6(-N04]OA@E$\CGT#1_JTUSPAL9A-]#5R'5K\A1ATXT"WB&7G)GM0^@0E//
M@)H3;7 S!_5@=S@> XB+5**C]'P.2,1(-WI"9ES/O0<MZ;:I4)UL%=5(Y^3U
MX+/;BNB)%/GDCS!W6Q J/_FU@HE2F_U07=,9)U6$]RE=6@"S0LCO2NI("75D
M*JLA""_J8J6%Q"@Q$ EI'K*20P/]R9(TOOTQ#"OMFJ&E$149 IN\-@)P3]Z=
M1!,6A_J0A9C(X9W"A)FC?S( &Q[.0QMK<: "8T= 9<>9"?-4^#4:ULLIZC:R
MV+[O@\%00R@$;<IV,^P[$J_JA#8SS"T)#SKU;=D)T0/!%QBIN#NHP#ZT;*5,
M=80/9B+@O?]_F^;@1@*C0+D,G6R>32%3*6$G"9+_ZI>(4*[\(?8N4<JS)X!G
M_^C8X;\*12--"AG&>Q($5JWZ2*N7Z-3SQDDDCX.@7*YS^]'SBS4AJ)MRK)AQ
MD3G\+7^;C\2;ZC;%I0N#R[<G^?X(SHX..?"A\>["DN,$;^1MQ*)9QDZ;4'FR
M&@(B,#Y6%B4L@7J#8W#SW!S_/,[XY6X,JJ;1@69@,L];GZXR2;K13:9O4JCW
M:.1/XI/) YV&%4-W G9LN? )OI+')ATSG[$P$Q8,AGV=%,A%N)BG88B39N^]
M:=?($>GSUFK0VG0D#X.?&\%"$G+Q."6<J7KY0,K9<BU_8@V,%P<ZSD<:-'QW
MW;373E$:WHL#O:Q_#5->S$LY5@>?F2(U%N@M1=2=1Q_D4;R2GDT0EP(5(@>%
M/![I"CII^,7'EVK/P& [,2@PV!_>6W<WS1Y# #I.Z_/T)IIXV8D!P;H9.<.
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M4![2=_&F@6A86%HG5/'2%XB-?%5HL$6K4;4\Q_[,Z%I!;$&GKV3#)2SS$33
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M\O1(1OB-JE$^/2#YRYH';<E^@@G0"4[BIN[MBNDCKC$]4G$^X+_OI\:?,)B
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MZC9D?IH(#FF\"^0AZ"$)9WHTU0^9HY0PC0'(7+TM]@6ZI"8>9DC("OP 6XS
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M[\3YK4C5$;!U5#S3>8ZAG:L68I7SM<*GY*.?0O1R;B)<,CR-ZDO8_W9+U3]
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MSW^WC$I^NC+=$]C/2]WQTU?OEKKC+W"PQ^X#BX<W-7-P%'=%NZ637?)O;;>
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MA;^K%*&J6.C\=6AW:T$+(VS<C\LDD^Y%3E7T8_Z-PC=%EA4W,ONT2"J#1.&
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M%4@=46#1HEL"QK'/@KZ7I62D<A@0;>\JX/+H<EG0E7N%/D).'UJ6V+$X'8(
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MZ?,VHJ!#V8RK6H>+HF0$J'2*OK^DZV)!$7=)4SBKY!*,6)J)=J9SR/+O=C@
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ME;2A4#M'0<W&/ =4)@'[[/:$@0)EZY5>'%FT6LU[E2<N8A$BS6G*.UU[-%S
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MNG(U=44O,UT4?E.PA\"GG/2U6S'H &ZY*&$QLSQ0OD*;E^:^-[@B\1=%LT$
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M3=V9S_UP; WBU1[PWS&5$+2%)+(ML;AI$G$TZ/"G]HX2]-LE,=$X4/<QAO_
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ML31B9$<?$*HXNFX(ZX-5 L2!2#P'X-D6"6DDKG02Y0/G(B\9H9 ++]E<R:_
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MY56<RP\.^$90JG0Q 2]1%(198_QG'F.E"?\JTDP6G'JB56[RJ3,$='9SRRF
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M@Z_W8"3U;]$: 'G2'/41/*$>>.IW[(XQNZ3T+N6JULZ<Z]_!V4_ELQCQ03U
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MI+3:H-&!0:6BQ,_@_4_;Q/U$#*8@?Z9O\F3TPRING;ZET8KB%-C28GK S -
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MRVJ!<-QAB9(T:XB"3][ER&!G+W$U#.8[M<(9#\C[' CU5:IQ R6:(;[$LIF
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M-I,A>TQ=MW$K%RY1<@^/<N#\N<VC'/;S*'\B8C7W+1J:7!XLI$*K?H[F"9P
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M_^R]ZY+;1K(M_!]/@9@X$V&?S>Y12[YI]B6B=9FQ]A[;^B39_GD"),%NC$"
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MNO!<9;QL)1=D7V<I.RS0N,AY:O\4SJB_RCWED/LI+8D_5YVR>G?R;5DO3UP
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MM_XYL72X=+9EEZ),]+#U5L((,6-VR1!J<$]DDNV;.A!>XAA@W>HGDA@A"YQ
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ME>\0@78EFIEB6!WB$TMP3S*R?0QE(!2B! 67NQHF:G$(\S9V62)@?Y8_+]?
M+15R.,D#7%5S64N?SS),?>#9*X-71.H(,_5%4*-;MTL5HJ#("FK:=.?H@1XR
M_CBN5&N$B_O0>-&GG5F&AB$B_% F9P":4]?YT.\\/:)K7 PM:M:^=U-,G[YH
M/]$"Z>E8Z<@<^!"1GHI92,ZBA++5C^E @:]H@DE%U3W04,4>I;;5]4_#$IQF
M1;>XS+CE]"R9M!7N)@<"]>J\VP"VM#8%MZ Z-?:P8W?'77<ZWU[N_>98[OV
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M)=S6JN?I?L[O'&LZMWH]!D\RNH>]N&6!6_D XZ$Q$^W1'JK\X,%3]15C&U-
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M)*">2@Z%)D-6B&>J3EHU7B#L/][K!K9@M/*NK43 M8"KB6QSGP $[](.N@/
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M0LNB#A*43K&1R[)V3]\4BU>:OO58<S>SBMY0.T3;Y3+NNLO\B3]10K 9 .+
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MK^1'>"EZX8GWH>\.V@1;I-[BM)A&.5T=]:@F:SNLZ(.:F/0JM0%J'H@[#3A
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MJM9G3 F QU1N9W; ;QDF>%-MJ&<RKD\P2F=*LFK"Z+$^HNT?'PV:V^;9[@?
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MP@?:8G$0(BY3T12$G=3]44T'BX7":_/3ZZ8&MYF3P[/E=R02+?<9=?7.3.$
MWSP@.&USHJU ?&/69CBB/VGP9I>MS,$:+!8=WV)2.HCO"2+1WAMV9>K/H]D:
M2\,?F"JLR8X':AJPLB>1\Y.X;DFP^G22?!VMHRS(EG-H.ASKW!IZG6A&9;YD
MN]*G[!^RDY5)*&[.69ARG[S&\W ;-J(WI3<W[D8WR_1FX1'2MV?A85\Y::[$
MF#(IB=?!WT[J)>F^ -?( @("C"53^Z:Y#^Z1;B?^WPSO;\12/_,.0Q+Y:M[>
M---GTP7/QUH:^^_,E^5,/,4%[.#,I(J2=M2PE+0H#.IW)I/Z@19,XG\NA;#,
M[M+9=@=/:^![T%Q\@,S1Y+OTC';-J8MB8Z4*G@)8J%%5)3K,02')TGE8<F+A
MQ10NE<DU H),OVN6C16-)9@"'6,;F\QB,S$T,H)M0W(&=G\L*S+1G#\XDHD
M==5G\?=VS/8L0K(KU@6^)JE /HAL)C&DX89BT*\*8YE%=K5?%X&7\_'CYX&8
M,]&E,][56L662<4*V3.TEHIKHFR2R];X914B,I,9*A_ADUGH^"9;(5"G:$1!
M;?#'AMJQ+[?:8\ROY_.B>=WG>K%KXU:E8 G2F#) />;#U3/P7BI7F<172 8S
MQX;V;?P9>=+><L=-3TD5<K)YY>A9P[=H"C&X/&)M*&$WT(8PZ1Q*_^6?K<ME
M)8/!0?3% [8-])]/!.%6LKJC?!H)SHP@L3C(B$K[.,@3[<J:@#-4LA>%5J&T
MK8$<0M>J#.C"/8A 3QX_D<@^*8*I*% V!K<ERDXN6N'6,<KCD8XC<5I7\,XH
M'P7<FRSA71_X)H,DHO[,Y<OE5U<2QJ^K0GF7,LQE(B?T#!&NS45G97UG"$U7
M_6CP8C>6<>5:/WLRIH2>M-&WMQ3_&UQ+AMCC6AWYXXG(QWIP2C6<E54@LG1U
M)6BJ-/X?*K/FC.(X1JY;4C*??1T'K?2F2TZ-=72)TTX5H\7N-/OYLJK+\23&
M#O">OV)T<($EF0K]373]C#::YL<2!;;QHXU0AD,E^&0FH:[)?E@M)IJ!U&?4
M,"?<)7! =Z6N/,IM45>=@BM,T5!9R\0MG:]57L&)SQAUR<1,C&=0TT08?Y8R
M2#M5#'>?43(O<_:][\O7^]..EI@],3)-@R:6]FYN]:5_RMZ;7K+/0 LNM_HR
M2C+ZM58PL?[Q-US*9)X.Y0ECM8WV8\E,6MCN6YQS)A7CFXYJECPLS)U9QD<)
M%+[%8>/JK,!8Z.I00UTQ"?Z4#9UJ5#T9)*C0#:5'M<-Q'& )1RF7U2R9UD.2
MHEDB >DK0\Y86F1N'R-/4VKUA+!VQ-=M*O=*+0ND#^V+EY'[86[KXRYY,+\:
M=/K5$73Z(4&GWQQ!I^\=='I;XH['HX UH_5#$D53)L$A=QM+\W/ ZPXA<*^L
MC+"LKU)UAR#K0/=#R=P#L4OP58*6<?;700PBL!*]K$0)V(&(#/3#(<H.M$&P
MK#',N9 ?%V3E3$(9\KJDC/'?/_M6KYW'FT4*^409 A@D\0%O#D5P9,:3L5R^
M;89,H%7,.5$E*(#T1D._0.ZP+I<7)DZ1\EN&4Y,_L"R( B62[)A"_"*2\M5U
M&^_53RCGY!0]"6^8HG5[6II_SO]:D?/]I5:8 FW_3^7K>NAV_R'''9;RUU]@
M*>N_95E_]J)< R$AM_T\1(VCV8.+*CO_!! !NBOI=(ZF$J[^='I=/?RRI>H(
M-!K0J<S84QM/E-+&T(74QXFWT,/X^4HNU84E^+QX4R,\S#_[OH)HIDRNC/Y/
M+ZJM+%_Y5T[SMNT//T_VUN>)P\W_%\.UC71@L2I$B&C3\7+)0N[7T0X$(DYR
M4Y:CM)<?7YEFA>5/;Y\)/-F\:XNI(@H"3PNULZG0Z<W[@B3/B<RQIM=*BQK,
MIN3-L)X#Y"'/-UGI(Q4BN,);B10WZC9EJK*H2HH>4AMH\Y>?,9$RW1/U3MXR
MT;XVW+,'I_?_Z "NO6=F5N3L'L1K?+D<^MK$9 0MHO@?U(Q0SQ+_T"L$Y7,X
MM&7,_</KI56_1O+:/$@QTUG0Z=G>M,P2PV3LOR&>&,VS>_285[.Q"O\,@%>G
M 3<SZS4*>1=8LF$/<E.,GMXN!]4)$-I-)HN)6EG-E6;R_>I*(XR4,O33=1/,
MRR!(.5;IOGDQ9+X8/$K6M8F\\N'7UBG4EZO:!AX00Z>GIT&(-,V5!Y&()('E
MS_&HP*IIFX3+/230F$VJ517>M4[95!#@QD[_U">)7J>ZGX/RH5.IYIA KL9W
M*J9,@Z=9))6^2< Z&-8X$O%2Y475# IC +X::/<P(AE-6?05X=-),DFS0';B
M1#(X"Q,SOX0IS11F)"A"5.SZ*3(A+#)3\Y77*N'6SM6?+AE)IS%V<CF %1(,
MFW@[_<!J5I^9!KL"5CPOZ-;AD>P@."_-TE^I1OG;6 ,]M/&<>;M/BH6T@1*)
M#WUX,5VY(>DLQ%*M* K78-.7*BX\QXTCV[A:V06^QG2^B>N&]8*5& @J@_ K
MP'\&>G32RA$W+]TRY>;-'$F'\H0"MY>M%RQO6HVFBS%=CF9F]E++R;D!URF
M4MG(@#23ESBS_0V:5$1-(MA"<>Q*&>IBP*E>)G%WZO]B>F)*>^9HX"XJ]>Q(
M90Z;U+1N\;08FIP[[^YO5-/&VQ&)T-T,]S_Q)_KMG^6[0ZHAJK'M,C17E;-"
MENB;:4#;VFEAV8[4@LFV9!<DZ"G5Z1B%#2GH[*U1HM:%7+42^5N.X:(KN.V>
M_GA.W8)^&W.%R0;D0^!'J@2!;T-=O7VMQA2Y09,A9)H'ZB]^^")INPX$N1J
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M\WRZ!9)-"3$(< !2,N?7WU[[I7LW",HOQW(HF>?#G%@D@4:C>_=^67LMMCG
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MY!.!CS[%3P_2T-IZ&=N%N6@WXW.7.]R8\T3JD<J32<1,X=$^Y6GRIT)*?SA
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M9(.1Z&SL"(R0&GKN)R1\5*(XHNHFY=9$TY1$VU$U++=AQ JP%1$6-:#F(.,
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M!-?X9A5ICS3G1_A57!HRN0(=DP95(B&@#OUV(FVGE,4HK;!Q]#A!BM+G7UH
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MG.21EWXW'9TY8C?3)[WW@+_WV38%C S^!K?W 5)P@!3<7H]C.U$=00:[G(H
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M$&@;YKW9H\6_2.BQLL$E9(F0 I9^T3>57F'=N,&<.<K/LQ;1;HEH>J-\A8[
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MOB??FX(JD*'_#\8 @B.(,(/&$ /VH;\ <D-92NLY4OOE&4$0V'*UK2?+< D
MAL2<_)I>]3)?X%_ :^/IU+.#%?@<DWANH1$6W/X\4!7E36J'JL CK&6!\=ZR
M1Q)T+[,6\17Z& G_QJ0:R*PL'T:&1>8@DP@,WLK(LNJD'15*AO=RG >C-Y-\
M+&1\I S8SP:%56A=>H!'Y>I<#[?J.EP!-4580E0/ZHC(0:7[5+"B1)JJ3BX&
M!^H;#L1)  <45=X2[0C*OC=>B_P&,ORK6 (XC:E.(3-O+L/U%^ J58<&[E5D
M]@.%VF4E/^4S131 +I,:JV0<@D6Q:R4F*C6/K$N":#,;)#7E[86\$^EQ9O/!
M=Q+%U2T'%(/E2:RDJD%9L0*,2Z:BUUOF.9SK' R),:8VDI7QA!3PW2&>Q;GI
MP^'(J&RE,P=F\4D8@M<*U]'ZI5,"6J8$;!KOK^U;(!>\IIE)VG-+<#@5_'7'
M<EP77ZH] JDEHJJH]A9F?CS=F$#/*8(T5#K$,&(P!_=\NTB</&Q<)6[?R,E7
MQO.F6F?PE;Z4MUH;(!$ 1!#;]#28Z=TP%/JA')NT7T\0H/0XU K(0%;=. QF
MG %ZP?1N#H0F<7X](V4,D:S2J90BI)NH*><$KPB$7QC.%6R>+F;WZI/!K937
M,PNXM+):B(',D\TN+)GB:VKFE!HCP;_BQIQ?"WRC7C\M)*7<Q)FHG7?I4*6F
M-[(3C&[3PH"R1J--E=^UB2(9B2ZFZ!--M8D9A9 SH>JI')MZZ$?9*8([HNB$
MY,H4DS:$VA_I%1H15W>8J8R*6\Y$UI.DCJKB-HD RX!+"%!+:QB]Z5,1)TI=
M+2&_90ID!)]&R#M6D0$M@7W&4J=XS$CQ,6^O<@+4; @O:;G.L"=B#)JV:A;#
M4U#W='LRJ 1#]512]W&M=>E X5#7&N5Z0W1DQZ77]S<NN5UXV6XD@#)EX/@)
MA29\V?N&.)'I#(39#]5N0++XA9YC*ZK5*Z<*+F\%480EQ*^43#685I[G\/,4
M0H>YWLZR4&;+BI<A\/&"LIP8UH-6J0S&Z8>)\"=+W9])SSF\T"$<0PE:R!'2
M.Y>IY_[,%!)-*,,:11@'+2/B8F2.6#C7S$!-0RG5^2I-8\S$E/!+*A_J-@(+
M8!: &>N'R#&O9S6\G-E.,Y*V#BVQ O"4M*6GI_^]IFH1IU;S,6K$[4Q$&VM6
M\N 5\\XM=!S.SM(%14Z0:M1>6?(.-F,8D@#7"53T"78O3!+]N0C%Y)K^DK8F
M_3U;+G"[8QP(/Q;0=D!"$NZ /BGI@L.I4AV5Y*0R>V-SC;>S;1[+/K7;#;+B
MUMF;+>,WF]J;=0WQ5)M(U.,*NI)$YM-ZE=TIU5,@V3)1/*4R0E;-J,:5K<L[
MC)<_*N0T=#]!'09,%9?PUKFF$M4BNX]#QR@>C5$H+=EY8Y27KB#E23",9KUT
M92O82OV#7=U T0>G#DU(6]G4KL!J6:K\/<KD1YL[BINIJRG *+W/LWJ,.@QZ
M)*LM..RPSO#(.)'!!QC7'@,&)=H_<B4H7F0,<KN%1$+9-!J%2$,*[3O2GB^'
M"8IN 875AAE$S7"&S$R-JX!23[ETWQ^/DUS8SZF934<.^)Z&1EJ>GCS5,/:N
M9L"(H]Q4JK1BD72KLU3"[\:1QGNRVY4A/>B_,157"JBA<4(,S+Z$G"JU!C=X
M59[LC2NAINAC*/&R+&'K4M33)!!*7Y1J+=U(#=%A0#"Y=$%C97+;B+"0UTS^
MH"+8!(MQV>^(8XK -K"BHM9'+/-^$ZL/J;.ZZ:F.99JQE0O75]B_W'VJU/7
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M"O*13<T1W9CU-^B[ _@]MFQ"FS_3/@HS,EDE.?,KCF#;;H$,/1GQI(!8 0F
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M?FHXJXR?Q]H/I^&L+GXVZQH_-9P5QL^F;J*@X:PP?NHXQK86871T[&*+X-P
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MB,2=.?1G"7,(Y#QJ$(3 /2>,;;##)@@RO"I(D,&,W1@6DW1.WV40,T@ M?S
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M89*E@"*9@.7/FAD)YT))]H.E1('5K8"5@L3+0NFI5P*_%L7L]$-4'WP>M0I
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M*J#:<LPU>6-^(CZ>BT=-&S%1BT\(#EB3L-+7LR@)AF"$B3+]C+!C&)W YOK
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M-(EL%)$OG7V:4HPQTGSGR]I\F?JX#"1BC&XJM[)'KKI3UL@*T$>Z"#O8U_Q
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M#V<?K[=>I%5%L%U3GJM/+ T=BT9:22$-<Y),U\YM -:C^=H-R+M*-2[G?N^
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M[:>B0RAO8P'P%=%OB1>D!^C@A)GE7KQZNZ^>I#C#7\WKR1@@. F!U?5^-2^
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MZ_JWX.CL<&/\9!9T>7XR!=_I__ZH_=W_<-5I%ZB0.\I/YB@PC46-J4?E)O.
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MLH7]:ARB*.3<,H<^H-_LKN>E+F==S@UM*#36B7)9O,LC*[))/ADO'&V;Y.U
MN(KYKQ-T"@1@BD_M9JA=R9M^4_(V2PZBO:R4B#^]MAK?*XFC8>64#(/&2QP%
M2?H#>3/BS*U1!!B$6Y^GC7DN\>7;173#6)R):32QXP;C7AV,<Z0;0521+_Y^
MK-3>'C^,W#%(I(:J7!!]16+[/@H:6 3GAOB_3IO#(-Z:S_&9W.IX_E$*IY"
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MS8G\*_'U;YZ3=/RUOBPI1)1B30F+!7V"0&\R9IPT'D\5XNP6)C..J5W<2-"
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MG(.XLN_0N(>T[OQ'"89OM.8/U>$7#O,#N&$+_'T'^"E$E@:@PATB((DPGKS
M9V);[2[LU&.?ADTOK#=J#A]Z:ZJA+]_2EWF_E$)&3_2OB*F5 B\&2CM#FX5
M"1+Z(PID!X(2IN5ZU$D%)E@Y E>3&"[Q7A#74+&VFR8KCU4-1C]3>.&SQB /
M)X#*SDSQ )LOZC'(S9OJK$4SO3O>*19!H ETBA_XVE68Q(JE=E!?38SR(GQK
MA,TBL@Q6,K!90"P+/T<]8VHQ$SLGF@3VA>K< F F-L!T+WY><D5LS3GP"^^&
M2G8K3.#+? ENNU[$N#K1(YCR0P$2*MA ]  6G\ :!\*+@G'30PAV9#A,.D&$
M2Z0;U-  [#OR"C<]G4GA )NO82U4?3=='13S*"$ >F$L1$3"<5A;!5<#-6'9
MSZL2G#RH-T*RZ"^7G:Y**E'OB.N!9@B3[B183=;TD31I(0V<T<(0@6R>2&)7
MG'2G(&>HH$XD4XEN5]<,+*3[(X0M<=0<^*^Y^"E"$/N@,MQ4%-@)\ %,"9Y_
M$>[;#T:\=;LJAAWZ+,OR_-E.NMZ-> 1TV/QP(J!9N/LBN2"K"XE+OYR1W<CJ
M?\>8;A=.B71I@6#ZV%A*OL3PDN?ZI,&<ZG:7 83A0%/,Q"A?UR:"!CD2L46;
M*QA72T>,J_00[ PFNKX+@]^:E!\^9W.6PDF7(\8GV2G4X9BHN$^<]MFP&ZWS
M8;O+KD+K0V UP]7+DQ802V(*_W%%P;Y%'A3+)[\XK9T*]3X#NK4!P1XD_172
MHV\EC)*8WF=!D;"J;?:%7Z,[;U=O$Z\OM=L.E!*>SFV1 %AR,0"6Z<Y%X:HM
M#W]_'QGY+]\JU:?J;;,%$=B+=J=X5>4>ZNV;-E=L5+C;^OUCO5+OO)Q^3.RD
MB:_C,!% M\;R'VD"^ TEI3\E.;!8A3?C-0H:$M\E;=3C&#'!YCJ")Q#K^WTP
M3B$@ N:G,W3D:&ZILQ>0HB11)$YE08ZQEV'A*6%+8 JV#CX STD##@PC4!P%
M@Y-(3(-M%EM6T!E &F!;2#$X'7-HLR,91#H68R#D7(I!SFB&U(!>+[D[0<$D
M"S_'>DB6\*]T^D)R7LQT_^45UE5/]9GESR&B=YY)#VM:;O9[/"Y8HA$>"U/S
M%[XT,[]&Z47X@DRG[.*BPSB!:$,5U"?"F$LE: "$F@0"R?7'R/8F2#+)AZ)F
M+_SN%EH.VT$/DC!B.O?P1=)8!PFE8#PVXWFF[9UGWGK3>I6(4A$C9K>R>*W9
M@.Y]#]0.QOJ$,2/M^ZCO+AO':A;]*15W>.<@[:DY*&H:V*#P0K<V!2>R#F1J
M4_/"./?<3Y8[T-N0H<R5!IBM89AAXA/7Z:OFW7!0HFN65O:0G_ 1F/;DLT$/
MYJU17N$=2QG4:2VV*[5I2*!(.,/-PW4+@D00@H(%OH//9<;)$D8,),;,]&8[
M8F^&@>"+MH_Z79)E3@#[UF4Z$#\%YI*"B&U;X$^$?3@*,;&!@"T0=8HU61+7
MI^P342^00::"&\1<5O!-<8DDAZT48\2X&GP.C(Q$\AV)VOAS/4P&)P2<=))C
M1T*) 93(SA(SD0X#BL+/CPO6UB&73#S!R"433X%]L@VY.#SFUJFJ;_@_L);'
M5^YYPB2XU,O3]V1*G;[TA7T17,8JI<,_I1SFBM\130>Z[_8]Y+A&#7?8 1D[
M(T>;$($R1 U_<0&Q<K9B3:ZD@I_R0ODHD>I:R<CW2NI^DNEYD(H<E)S==*J"
MDV"V- P3>/:]8E=AC4$L8?OA[PR[L. G\1?,KJQD"X (03;\RSM!ZX]BY),@
M%8.JKDQJ3*GO:"P0WR/70W3\(G!L:'L^,W.K$$8/,HM1Q,3/J3VLN3/%F&"Y
MB@\!WV=%TAQEL61HU9@Q9+(<V0XMY,=OH YU8/;(=)?2*DY=$IGB;;JOV$8O
M*66QS"4LU9ASG#77!*7'UKH7Z:YR./UGEKUY+[5;_;?1X/CUG\(:%4 'UW\P
MAKB1V0S2V&I+#\4(6IO#"!R_MM+^5&6HDLB^:?-A!#)K^_U(ABA))KU (!Y_
M21_,_->VZ24FD-<3%0PK/%,(56GJ=#BBI&NJ*UFW@6D1V 3RH8AE@)$<M"4[
M29.EZ5$;TT$%YH8EW4*U<\3H )MW6.$:&DYE0<.F.GH3Y"DQWT5I0(:*85/?
M *V9Y8YBW#$$S!7-6P3.['!+P#]U6_&E;:$HOF*MV;$2<'B3._>F!@1)8X!0
MS#:@3%1Z Y3".-:WHZTZ5E4T4A+)XX?[F!Z(;T,1_P,1>T%[171&K\T-\8,@
M^YECFV6JLM3-D8"Y2A]-284."(">I-KYM3%JEY!WD=CJ%!-.'_*"D4:RH5S[
M<9.(0X01"]L!.JM-C$I:=Z )K4G"AO98M\QGQSHQSSK$)F?I-@RB?;"/)+!1
M=#@%/9T3!O"N@?"F:O:KZ'[I6R'O1G$V@H;M"R()DD/@E_2@)+;2R,P$8WFT
MI'Y1]X1U+$Y#8CXLGG/)U=VQ'PD\4![@Z-/!0.I#GJV)8BY#"2(^LACK0>2>
M3<XD"=NR,./Q1^(4C#2-0X!&"B /1,,)(R-Z@>V% A&-&>@8D(/YKB:J9@RP
M4:?25&B=U-3BQ0938ZI1?P;2P,QCN0(Q-,#H#NA%TP7(UA: 1MQC/3-C!+\+
MLM9)A=])<HV39GE-BU'%//Y3ZDD@JAY)<,"\!V]1DDD>IZH-,1.8FXF@#!5Y
M1OK !$VRX4T4@T\I=P(,-1D*821X#Z#+0*C>1$X>W@PX"%^;:.C"DJ&Z,14E
MYA;VBE:3)VGZE+% ,WW>W*EOHI*+2TD8$M/>+Y+(@75BB*)P@IGA:V7*SARE
M%BX&:3ENB/N6D:1NJ\Q VT1IP=)_JK%"B2"2=%4#6!QD&0'#OG4GI]6G?:A[
M&$QEBZQU\TOX..:3C-<H"!X&DX4*0,C_I^F'6 KR))N&>-/))P0I**-PO-!F
M"AA5WB0X,&9SMM;O9E[, 47J R#W47F3-%4Q;1HHI' B"UPTS:LA6\'<4H:R
M"5)& 2 E7Z,Y/CK2WJ0^C;8#OX$<876&&.+ =4QE0U#.;&>=S5L5@NB#Z"G?
MEI<O9\[ERSLM7\Z=<ODR,3]-//HTM<RL8IES5BS'SA7+N^1ZN\_6**2])<QM
M.^Y;I*FTF,^T,-?">KH>IFPYW +=><V8])6'W]?ERN#D,C52BYD:E>Z\KA;?
MD[=JO%7\\JW]>'=7?'B!4N5V_:I1K]7+Q4:'*Y;+S<=&!],.U\+(6JY7/W<%
M<^3XFETHN:?U\!Y4F]'_!N!KVCE)+MP"W7GUESI_+R3GG4)O+_AJ[39;Z,ZS
M\ZMZY34WJJO)+U'=&3DX) XX>PE\3C0\F3,0UUEL=18_L6!)TCX9>JM9K6&Q
M$DB"U\28>[QL7W)75OI1D;B?\*,VKN.[QV:Q-('\'C,>?U4L6O'XRUA1 8N)
M> >)#<UBXE:+(VPP84(ABNIP*M&78^MEC 0S]#) )-0"RT(]Q@!:KIGU"HZ=
MM"&7F'C(RZI(!(BK$+;8+IN;(A:2[S<?)S0=R?[2HU4 R9Q6-0N<OBN45/R7
M]?U:L5VR0'&B*.5G3>U<K<A[V?0C]%NLXL-!J9_N8<?.C"_W@]WY*/V6^T"/
M]5DUN6>V6^[."TV]]OAXTZAYVJELPZ/P 8'I6D<\86[U&3AN78E1%FKZT58S
M7QHG)GX]8T8Y+3 W'I_ C++0@)?MM!X+KXA#YI53#Y^N3\<3&DD!CUJ,N9")
MGQV!?QJ)5O(>N.QU';'Z+4>K2.IS<C>M!_K%IR%M#'R_9,4=?-X3L^..15IW
M@;6#J6SHS.5-0T5FVA04NEG'NK21>N&$4!=' T3@7Y!!IKQ)Z!TZAIB;0>3\
MY*SP2YU&+#5D5I^M4^7&'J1OI#%/6$E$$ &A74D@,FM[!3\3=S^9S3M,1;AH
M07>YEAWD9#F(;1(RXXDD04.0- Z"F<BW%IVY18-KWLSZRL5RNH6%64/C(F<U
M#>9(_35OMSI>^ UMO4!^6U[\[<([8G8#948\0=DT/#W@14^ R .XYS'E4K7)
M07MT VQL0+"+W:+[$T6F ^@YV7C<5>Q2P_=BEL05%;$Z[B%11**C3+])KV2Y
M=5JV,_0V7;$[?TR\#./Q%T7]+>Q9;RIUY[]^-CLO/[27M^=$9'J3$Q3$ C"!
MP5%H4'KB6B;Q,,"<L&IRTKR=EAQ>R)+RBL1%ED82[T2_P0E^F04D\4\PV1[5
M)D"UT74S)X#)=>Y]1!OK6")_X$0;R!8PL<9Z&59B('E0Q^1-&"'EMMC>Y/*)
M#,\N0?I6021%17ICVLTU$H>@,Y99B2I1.JJD6Y"U[^8[_H@ PNZ2ZS!H8_@%
M=D.**N16&K,)D0,>@($^"9U;[%.3;ABL(M2>^C+C^C)^Q#:?78?Q[3D7LR!"
MLND=X/)N0J=-8!:4*.OE%^;+$8@6$UP.V#*]$&0[EO93D()8WH,$C%$)V%,A
M74?Q3\@GWS58#Q [[Z@GR.37^@@A@WR+M7:B\51R+PXAJR%PDM#-$QADOY9I
M0P-)B;F%\;L&29XP)%B6S8MPG,NA43-@DO?Z*:GN)A*.'"HS9.OS)%B)=E'8
M62RO(9:37O=#&;H) IT"U*%^M$RJS>$GC_"-.ZO/@K_5G0M//[*%T???PM6O
M/0O8>'=>>JD/DH5QNG,G1R9@7:>E;7C(<3DX[PF+T<_@I;"\EC$G,R76T@2;
M,%CJ$*/:2N]QIR [:SG[KELF[@)ZRZ0+)DN*<J=$ 1-RB8[86) 4R*H!R3Q1
M=8D*OP$2K4)7RMQMVQRV+1E3)OQ)*S#(5<*K+WZ+I(5Z,BPAZQ[2<,!*P984
M/H,8@\]9<2M))@2CAOIT*5^UZDTEXH]A7U?-G&D'4,C95=K'DYSV1-'D(,QV
M,82,AH"?#\2Y%#(BYYKN$N;[W?F5\/:KT].O?LGB_BV<W[-$Y6-P-11D%!D#
M9N>.60<_88;U&9@NRR#%=H-.;T9G3D1:!\TZ&-,>@C2IVNP6"LHYS1,&SZR&
MH [5P0KM)F"8+1&5UR[.!L9EI^B;7E*N-XL1YC22D*4_DHHHUBX:',RDJ,G\
MY )_ D_ B*.)FY?"DCKA=1Y%E#K<='<6,V:MWE*FC(-8,2/I(:TYL(#%L%BG
MO7/ZW2G[@-4UF36%K)K_OOSZD$[]%@;)A%6:1)=T*,K08(BMNJI0*7 [&XTC
MRL;=Q=@PJP<*DMZQ!:$C);B'(GOKEV\8.V)[:V+#@+0CZ75B[&']I,[L.:ES
MITF=^7-2YSFI\YS4N7N-?"'[PN&[7!EZ< ST#?I2=UY)?(RKB7(K\3,1E>[M
MZ^?HS-36QZCRNUGM1:9F/Y-2.6.'D8$3DY3[:-U+LPT@D<",I#KCK%8O*]-\
M!P4:M-!W=E=8LZ73B\')H<I$^88ZS\7.^Y;OG58IR]XZSIBS-W2]U;3RPWSR
MY\P8 +>U^Y];XODGR\&KTOFX(]Q >QY,)7T$KW%,$J>Y%W1=6)9^Q;$X+&2'
M%4#SIU$#$MTPR[5T,U1"KL:"LS=DXG'A.-WX8W"W$T<]&$22V3%!< 0CG/,U
MV,;LKQ*GNAFN5V@)E1YSQ#66A3)XE@! JN'MF(_[(#"7]<-NL;Q0&?^N!#0N
MY6-T6(?5A)3M#J IZ0YPFN6@5C4<O&=*NS]/-'4 $XE((?ROJ3BD7Y!TLP"0
M1C](4WY,/R3@0'=OA3QH61K9GC?J\7N*T1^!C<B27!#$\R%D@G<DHT5@.-JU
M7G(UH"\:@B.]ST4:M+&^0#R+YBV9K3'[FH3?* E<X!WQBZ]U9D'U'-$7TIG;
MLI\)XMAM R:")%Y ;)#VZV9@BIE@,L$3\ARB2GQ_%M)M?9:8]RQD>Y)F\1QG
M&,D_F,7&,,&E+L:O:&MN80"5WZQM'S*P:4P[J-!HE1YC<28S)4;TR5;Q[+ZO
M#A7,EAGPL<YQ0>)+X$,U]QDJ:G7)/9H9*3J*Z6;R+.]+90N5_?:N*"=WDP#\
MC-FRZ]+"71@AEC&67EX\<V:^V<3!Y()[,P'Q:+:A*#9#GSZWE]U0MTW$O;IM
M#6,],=OO:$@94"R,Q]D9Z N]1G>NC>0731@:UU=[=CKGNO.6?ET3Z\_2734?
M75H-!-_)V3G'X4\Y;>8S:,QEI$%\+1:4OPLM*C#CDNP$"L;XJ9($Z<A8.-H?
M2[K3;4W8'Z9'1.7C.TGLI7R*-B9D/3S)V[%@C8$\)EH4S*>"]%^GDO<7^I ,
MNM[?5N(M+2NA;5;&D& CB&\":3$.(Q)IZQ9K/)_Y'L>BM&B>>+^PBN.8BQ7K
M(>,="E_8&J0=/+R*]3V!]<8V(A-YZG9_3[% Q:#6.=K^!A@]J<.7L&)E:C["
MAS3&SSC5.;4'A??$>2<I$ZQ,41:/1;[WR:FR\*RI@F*L(>T,L,252/N 9TCJ
M,75RVHO%>RQ7'K4[E\5Q4)V/T=;Z;#2$\[&1A"6WUA_-(!QA6A4(IGY04#JV
M"V?RV;^IYU+$,] 0VV-SFK^%]3>K49HUET*&Q%+]GQ.E/C_A;+MMG6Y:KQMW
M[0.ZO+B!WMXOX)ATN'3#K^_C_/W"O)RVOS?\<NRL#B\>.T#\,B,I]N])HR#V
MA/F9V]$7V67= JJ1$R6L&S/$2,_H@VX'.>JC8@[E(:?[/559^YH^:S-"9O<P
M%L*<*- YA'078:+$P66Q)/GJ!!EQP!\MHAT WAX^L!56+<6A(SOE&1$">4SR
ML_.8IB7ZR>F8^L+&DX[P2P@LR*1F8#L\R[O2/=R(] ;$FI$L:#SI^4<ZM)K,
MB/?G1HL\[*L/HW.S-?L]P6N:#)'H=J#"P&;HB[[:'?1,3<U\2'5# C\' Q)(
M'RA-4WLPJ9<.9G5H2TQ[PTJG<*:H?;'6XR6F,VM=@[6F/CLV/"JJ+W/%',J:
M0:D16QVS+D,FS2T5U<E3/'EBKMB#-^F7U?;1/*]W9:'>F*U+-N(RHJD[ &Q9
M22$\ES8<]+'2+WTQFV5PG+B]=S*;]T\-=SK[#>=@4[/2FSEJ7,$'W<K_AG",
M&8N="#,+XUB]+/W$[58QLZUC!+F(EUS0M!D@CQ636+VF<R*TSJ(JMB=#ITVK
MJ2]%'ZF:<0&U2)PB&*SVG78G<4#B,Z5RG\SF'2.P'+T]S=E4 0XL)_*Q4-3J
MDFU7*H&==NL<MX)8\P!O03>MYR(M:D@K8<'N!T-;JWY@%L?ZKK(8EAU/([$Y
M^]TP 0:_-NADT/":ZLTIQO0I[=C>.NI>8J,$R-!B_*L+?"!H&F]"1!@.-1@7
MAEPD$="-V1]\,0(^#U%$'J19J+^R BR./ 86;A";RH.)&J0EE5-,U@%8^-<J
MYG!8[,"-!<1S"A6_>$Z$K^O.W^[K_<'-H/2>VW,'L%*Z.[]]OVN_O:.G3FMH
MO5R4](DL8/K$MX>^?&N7KZN5Q]MJK%GC:L7Z _=4O'VL<G?58OOQ@:3+[6AP
M>Y"G-$2":WCXA4N%]7I*O2HS5>WP:D+_%5+C%1%65+5_.&W8^RL93_/)5)Y/
M9C)_+VK6[#5Y*^'V'5'EL:?*XI=O)29*L?3[+BAD.@J=IY"B^M'"0LE_VP#T
M47G-4_W;+UOW7]::5EI^OKHBHODL&:,%;-?=Z*Z[B<.DGQE9JRNU219_RLKB
M3]%QN(NO+<VL'Z_-Z /A@)Y9/]93=#/DD90YMV3<$CLS];FCYI%5'. (:O40
M)B@%N"?38KYX09?UP(XH^ZM*"'8".M_)@TDV6-<<&+0$&!X&N_%TPE2!3Q9R
MOD-2 K#4'_\<>.MCTH:GNN>19*!%4O.^T+;-X%]V[Z:%=!O!3IXRS[.,QI8?
MS$5=Z0BH*P!#ZI#!I.^5M)3DP_53(J-E2S9I+0?G%S^8[92@ED++MYXG98WI
M2FU,6AN/7TP'CA_R4M;NR&FU$ M'6476+4@B$T%UJSM0Q#3E['03+9*P ]39
M_O=*6ZW:_7O[\6>Y>?_+HJT@@*Y/5;33T$ZAM3/:VGB68H)/QK-\MI [(&VM
M+:I,-V)B$D!E5M\1!\OUGL=GL:5:XZHBM36HL[ [B=<B.<MUI0]=WU %T;_W
M2J6-N=)O5'\]M4>B/4?:YT*\M7BA('L(N>@/TUW1<G+CR969.)].YOE4/+62
MF'TIZ9#2<[G9YYW[FXI87&;V9>!YR[1W18-IK5S5,O=/PTEZ/0/OB(VZS2EJ
MX\&7A31?2"4/K'IN9<GM2=\L[E7?W!<5&5GA"DFMF]:S\(GTS;0EH](;4]3&
M;I)$IH %5.836'++=,R(J*IV$#UQ7]0U^U6ZJ@T*B;>>%$Y/]*&LOXY5$8R"
MR-9PF$#/K?]]N5CPG.3Y=#;/9W/Y#0CN[V.T["J(!>!IY>I$55@\3F=5L@'1
M.=@!B= =D1F8WYG0=$'I$0.I;,&H.6A@,+1H4L!>Z3WS\OXT&(V+X@_;>[/A
M==*KW,: #& <NY#)82]C9WQD#>=0$!_)\EB+QG]6NXE"6I81,)<-C,I%1I.\
MS #!+[$UTZM.R)98EV>0KW&B.L57'S80F=R]G5K=*T](WE43E=ZSD4NN&8A<
M$Z2F(NZ,ST//L0OIXV(DB2+"SV 0)Z6/GB;'LRG2/2B?3"3=.:8KD""L"\5,
MY%NLZG7D7133W?GO_O!7HUR<U?=3$WNJZ55KMB/+G=N1[;0=6>'<CNS<CNS<
MCNRDLDHU%",S"!2[%MTN8Z9%QYPXM69YS9" ?P_CT\5%A8ED=H+#]IPB?-@4
M8:@U$%G; +5G=@"@"C'^!7@N20*OAHRIIG!C9(Q4T5&]3S_ VO9PYAX&$C0;
M*C@QUB^O^))SS*ER#S6#7KUTQ@0Y@J18+S<QT/WZU2G-,=>KK2E7;ZHL&*S=
M@K<;;\K5LZ]GU*WD=X?*3;3:KE0G77FG+?PI5: ]:K/W&R!!/8JR]Y$65.4]
M6?LS5>9:2IZ7/M*-CVK*4IGMIU:%:Y:?PS?NXC4\0^W3;8*FPD9@W,U^ 9I?
MON7]@B^[Z?/[[[_Y&#26AG1U#LH0%Y&B<EBDJ+#=/>#-,8SHZIIQ<?$ Y$*_
M3/Y]!_TSIF,3:^JYOJBV'X8O/P?'@34^!\'[[KJV[4&BL$$'/R1*^84<=H1$
ML8N%QM[E4\$:Z,]B8TVJ7$WH3^_E@IP_;JQQ;MN#-6&]Z+Y8D]TKZZ$5,;:D
M)DT?!U-2@B5+OZ>2")]B90QSIP7&5-L+BID.ZY:]S>:@1K9X:^YP';[T?&O<
MSTO-DC3K[1?#Z$&Z(<ZQBBV%=:_ZRK;#LJ7LB>",FRL9/PJ3W[<WI=?"KZ/&
MF6"FE Z;X^6',X4]XLS?ES%7AR^BC$-/1S(2DK8Z8[W!RK*J@W)>(7TVEU@+
M9G,RT17["6-#+,2'%M]\-CD/L'D(:L4<-^'M/<T:U7J+/?U& =,J4XF%V$D7
MD']YN99O@\DB:> $=-P<F(W(NU*C*THK AIMLQ<K;?Q<MB;/>'0JMJC)A,JS
MD9Y_D6=)8^@7N1"L[3C:#Z\<LK+T-&O&!UW[];"?-1+B B*"F3R?V*-A1LF#
M^:-B"^P&%*=%-Y0]:XT5MSOF5I)NAK3_@\N'L5CL2YM7DV[6EUQ=X;Y/,4N#
M]6E?0!/+6;-DG\F6>E#S6^_,Z2!J$-$R:DA%2@W1AO=NXI.?DQ\/=R^MU'$2
M2>@@>GJ-C+< DDGE,@&9I/NB&=? UP5Z65UJSVU?:A];6FIOMP%0J-\R_*#8
M'5?>I[,;5MX7%;&A*IHKYMX!0 65V_L6&V_[CN[\J28_/S>-X5OI=<\U]F7,
M!SX^OJ-V=99S%/B'JK%O<_B?S\6'AR*) 9V+["&&9B>Z>'/+ULUIPYN L__O
M2W*C7"H:\G,&72/%*&OY*#M8V^-&/%VLN5,Z!6.4Y"+#_L_!+#U'7Q=_SJ@6
M;AX2%5YK79)#T)TR?MHR^E H>LARM1KJ:;1-2<:=0KA>78!?!F#1=XZ80SW
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M=0,"AS-JW6.UMQ#'/\YT3M6P^--UZMHQ?5 DNZK'PE[(QG<2(],01R9R+S/
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M\%Z,*5VK#-H;<>^WICW,:KDBO7'\!LO:_J_TC7UJ=LMYLNSS*_PZQ#L^4 <
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M(IDI(>J;!,[,!83UJ% DFL]P2)9>D2R-5%4TDUATWPTXLWOPEN&FP8M*T0<
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M!P#6/UK4A^\M/Y_3/J_%YMUTG.G9?G[5NSDC0AG 62"DH7HF;58= -:A\X+
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M1S][]K-:+K3*K>,?_?H=3F8DQIE HL$NF7\E8Y[%9R2UWX=B#_ %91Y96-Z
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M"E=ZX;8([/46VY6G2OLE)M_@B%%R%C1UXQ<E4&SP&UE8T)J^%"@GXP]'+XR
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M_:M_*J*F#Z5Q0^:5<JO><)O4,ADCOYY"MC]? *N3XY[?F,%+]Z/-+/8&5KD
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M"82+]R57!:WO<+=:+T<AX"*L,\X"\-NR,(0]<@=,C-GU81M/*+(]2AO3FW<
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M^'OHEX2KX1.G&Q(N0<^G^#[@*V%@;:F/749%@FP!KTU-<YH0S."'E<#QXC<
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M6_Y\R62CP'1OVEEJKM7M7#D.%;@^Q]%NN(6-B59%E0N+4(^3@V9H[YQUQ?:
M%Q +,Q<; M3_^\_>J16E3[FUDK@[V*=%U>56G;;SQA[2V!^7R5'FDLBMJ[H>
MPJU6AFA.V3RG>VV^4:I)0FI771XD.6<NZ$#Z-G(;0M'']@(+T-0PAO16."*2
M[*Q5+>Z2G7FT-2)$R8LH/:++)G 4UC32Q2&4H524LL)#+<@BVYSN3U/RV^!9
MSNRJQ[$A(CHK,!-<D-![:#!L=[\-C]')&=&BYK>DJ?,74:9E[%/,8R+Y"O'.
MKU4('D*\F>S6Y3NYIGQCY-Z"(E15M%S[.E&?D_ \5Y].>KG&^'H8*XJZ@0.2
ML 0:1_W5OAW -%WO@Q?R132-)N;YL).T5H@YPUY$ 4 ^@"[,K=-\E9QOZZBR
ML5Y="2&UC@(LF?DS=%$!9\^>K'Q;P4JWS4E]3LZ]I2I-11"B-#)%L>MDM5 D
M%I ./!YK$X+8$=7!6AV_(8Q0)G,1&][R<>_%*C6Q%C12B)U(;]T;N%Q35=14
MB!Y/>O@T9!Z3@NO3BVK H5EX?;Y6]/?+W&LW7A\!2C!)W6G/M::#-U+KD3>B
M?E@+G&BQ\4I=K&Y>.W"$DWP<\$3KBA3ZL(ATCV2V9^!Y)V/)DAL=R\U3+EML
MW,J3 B]LU<K^Q(\\?$7MHU$DQF>3:_5L+F;\9"3&/Y#9D8@X,?!\.C+/@XDP
MF?QWN<CVU)=ZZG<4Z(R0QF%!E@TMB.J1%7U_Z 2D"V* 3CA.BFU1-45P$=ED
M5&=]3B<%-<7% X?!K!3V(J*#I$S0P^IC4<-DTF&BC^,.&ECBQW?MPNVMJ+*5
M*$A9JP^/*Y+>P?K !$4@+T2!8C =L>^ IA!6063751 +80GFDJG?F6QK0]*L
M(MMZHW!*G5F%>4K5DVTN+;Y%J,Q;IYK2(O!Q%39;1WU772KZO2;V9:3'2 >-
M:) *5ZS:2)N=.!JK&J]-W:DDJBL:G]#[V^,U;0J]AZ39$/_"JCY7!+LS2C+K
MW/N2PB/SP<LP3E=%RDX9),83;:SJHFYWV5BWFL 1%O?C.&6TUL475%-$A)K9
M%;Z+:N E'7T\AE)UQ2"-.OV),8'F(1,/A::D/I2^TPEXMB&-\-N@I9CMD^C>
MGT.I-\3]/A/T\IK!2\IN:]MWRFYVP;O97O7SO_]W?DY=2:(L_* :_ "IB9;X
M/@$^@.H-=!^(&,'?U/FYJ;\$Z2.L8T+6YFH8-C^P?I#!W2!K5>.&J[$-:CI9
M7,&'UA>DJA9XVZ2DS%?2>W7NIJ1%PW\H &CX014T)"J]?Z@:\L((G6LJ$)1E
MW;_ZC_4S^,I1DY:._.]_$.4#]D 3^;?S+FZ__X&,/NRAF^Z9 +H3@MC,YF(A
M-S^Z'^A>)JR?+-'%2%MDWLUE(FB[5O&BU9G4+C_5K\LUZK)2IV[JU5*E=MU*
M5&K%"]*LM(\E09=8BVK7<05]L5YKU:N54J%=+B6N*K5"K5@Q"^K+]^5:N[79
M.A?L2+P#XK;=@L,RR<4M.'-!<4B>.;9L:?=-*;#[9JT[=F9/GZ5<ZG;T/FSF
M8W9EMMN][8S DY#C@+$!QIJDBPN;X +[UGR> ^GWMZJV"7-XNLW\/6C</GIK
MMLCXOEX=IC,KW;YR[.3K=EA?,+?9VVY3*E^5F\UR";?,%%JM<KM%%6HEJEHI
M7%:JE7;%U2)Z:GI9L[^CY&IUN>YQK??9XW7Q[2UT.?KWG>3&NOI=AJ/R+#]4
MGJIJ>,J<^EVV1Z13D\NIR67732Y9#[J*S^&YUF!V<U<W($;;D2X[L\Q'<LJ\
MM5OW369']3.E>6\CYM34Z@MWF!N.LIB5.:^YC3;CWLH AG47(4"$SIV R8?!
M=49\J5VXGMUF4IU9??0X-@J_'E_%P?:R7LLZE1P1A']97A=,NU>M16-8AAB:
M8.8&I6_4_[(&T4/C"[%,V(1,<F[R.9U+YNA<"$C?_8RF.RSB!V;#F+ %4W/$
MY^AL.DTGDW%/D;MRVHKF3[,$5,[,%L'AUBSH\ I\5WD>&RU=G-VS.]'XP?)N
M+M;"<2 '3G4'U2!+VG+"4G0-:0Y;ZS3/4+DTDN?52=6#JH?>G(K!8AFVCV2.
MBBF6YKC577[1K.]"0714D<CK?F [CR@VC+N/(M\O#J*,HEV[XL0M?WAI#FK>
M ;'+0NJ%%SLV;*75O!%E:"ZW*<,<(1D#Y8X-V]@Q1T:&S=(I=O4\B0B"M_1\
M [!SYF>FNO% 5BN"V5*I+ZD9]LEHZN/VKO58F=P;VRU]7$]<<47Q^8%5%,=!
M_C6$/&P?>("GS,#8W]3!-A4>"-F#E4+D TJ6R2&E$*658Z52*"^QQE?2ERB0
M/_VRG5?3U:8Q?<T\]W=M?_&J=A/^6,=JN(BUAB2&[2J?]W(Y.L<=^Y1AEEU9
M=K5A&?^\<0\ZV#756FJBO*>G3U&X.?SH/S<;[Z)^?]U P'I'-"YLS_0\\R;I
M''NX':LAF1?18_O,NTP?%_FQ9$#=F"@T15WDM=X0F:B2^"'*ZA@@];$-$R2H
M$)O3V+-?\J>0*]8;'U&\L8TTMFO=@'".%XZC%H*S=!+.,-=^0&I]+9JO(3MA
M^Y#G9(=%[E?JNP0X-J=NH*?%179P63J=R]-,,A9?ZVJ98:HH#4WMB;H>3 B_
M.+>K'\VJ,'A[O<GM^'#ER;,%B7MSD8A_@S:=]0SJBCU=0UU$#J\C6:!3(2;:
MG]J&MK:#P2HINJ?/9.E4>K5"VE:34')E&KPCM9$R,FQEA/52;<9>"9U9<2)I
MR7&Q/ZM&R9%$=#/8I#TM-Z@D[["\;$S"-40_<@B?R= 9!GG:N4V-V>%3+E#D
M4I'/)UDZG<K3V70L^8_2,OD*P&V1:I6.('5&NB-D7_Q=<2)_CC\>LOLS_F<_
MGQ:CN!RA95C1[+XVTL@RH4Y%SP]DZ'2:H9E,?EL&X>_3GH53)Y&/;)#1R=#Y
M].JH^7I;MGYQ4TTT'.--E DVWM7:+--_ZLPN'XI,YCKU/*E%.55LTL@??)18
M4O%VA-RZ)K.BS5I#HT1.+J21I6/6GV9^.B LW:1@%1+Y&,>P+)W-QW*,6R=4
MX4J&>VIA/V_RMPW]BG^L1H%4WK@6UM5N\^, BU /:C&!VUT,C#J[=KL)#ZSW
M'W41L[WME/*E2KLZ&\G3SDQ[*]STBNJO1CI&6.T%GBA>'K1936"P$:SPB#70
M,OSK4+L3WFJD(Y?[;-=J?$,?=,/M"K0?Z0W*BK9J/Y8YH$%E1C;&C*>DK]8F
M2L2PE0@^Y%K.Z,VS4*A\WK73>OK00MP!H2:7#?I^S.QW?X+V<PVM$SD]<](Z
M<6U4L+Z)?*C8H;XI+#OPNE[;<_:U=(P^N3*R5:V<SL4(:[H J6IQ.\^2&/8B
MPL6$Q337>A(O#%-Z>^A5X0ZBWX1LVT.O"CHJA(.P*G9F\J7(7R?E]SYW-+ /
M 6 =QP.X )@5UCCD'D'NXV5Y2HD$7UTD YAEZ4V4_W][7[:<N)(M^JZO4.S;
M?:+JF+(1,[W[[ C,8+ Q8#">7BH$2D!&2%@#&'_]72LS-3$9V^"I>.C>91"I
MS)5K'M6!82BT(Q9\8H:[3ZWJ8B$KN&>VR%RK+'<E]Z="X*>=&?UJV<AG/HT6
MH(+Y &PZ-.UG-;>CX-)S_;!&ALF/A*\!0.J&?2A>^@TZ!("$I0*UP;,(F!Z(
M'@/^F Z(3M>Q+#S'(F26;P5'5"_92@3[>FF.PIJ%8!^R+DUQ<$:.)M/QN6Z+
M+IK99*JT[1&"1G[$W]P[IFHI*I6*$?I(U_;>R7<"C]*.%KR#F&'2ZLZ(?Q^\
M3D_$]0T%+FTBJQK]27APMT!'7^,<7[=OF=>*+.*7C\&W&F .G(*#[#N-P/XR
MF\]90J!=C#>7/,*;H@."+&M&,U M.JT0?NKA'5ZL2@>I(\[3#!P?M_P&<K I
MN4_HUQV@!C*A;$.V!=5>16_T^Q58.E4UC3[3(:+E]'IJ5Z6T;G#"(JN(FQ*Q
M2;M\ 5+Z[$/PV<= QMY]2,;C,>Q4P567K?1%K_X;X"W>[0QGU9*%6;4<C0/8
M2^_3G0"$V&K1"4'Z0D%[B-NQ+HWCL6D\@O5A(U[^*]QS*/O:"O\"(#  IHO)
M=F,]J:=^=_UF.=U\S&Q*Z;."/OQ+M%4;(>9.#GUVSULLRG8WN;F]G=HT$>)7
MTNM4G%I()$LN:9XNS/5AVAHVP:\TJCH 5BS<[EJ+;S7@0G.$EE[Q?:?HI#+-
MJ(T='?@5MS;"R2W>;VB;+[CD37V#:R\Y?;AHL^_ZDB.8%#YFS:BUV9YY?\#F
M.1\3EJ#Y#]0Q8M&_:_4J_9?T]\\Y=JSJ@<:WR)P7"#:V W;<NK:OK&C/B$OR
M5V/'F[H_/Q\['L@3N&BX6I#N/14VA*IACQR*+@(!ELQA1Y_H"#HLV>O9A)DA
M5$.(1:4T;4ML.9U[VL+9P*7G<2?MAR8OF:;)?)I5=:0RBZE!3+2]0(GUV]13
M1(E*4>EWH-W=6?PT+2G);GP2\U#&7P:M*+[.VB*&9W?QNADGJ=>.G)J;)["T
M!G\W6/%O0?.AAX9)R!*(B(I!#0$P;E634%%.C8.0Z>ICTI[U?\CFJ;JQC/&_
ME,FO+[M\@U;V4$RD[^S,('&O?3VM;-,V-I].*P-#&["1$2]U<NG L1/1/8U^
MD)_7L=5Y#^FRCL1A<B#H YTQ5XPO9,7V8>O0,[P#/%QQ/,\AU_JZWLA.8PIR
MW!JH8P$L[XEJX608KA "NL)2L'M&8_%,S-UA!=LVZO"2)ID0W<$M*R3@<;3@
MW1KH OX>+#8>U%0-Q^+^@*"KU#H46TYW$/R!@"<$"\+1;/RM#/^F<_A\./E,
M:Q,VQ]U:J*,P']H8'E,[VHR[KH$>O%O@\Q1P76'MNJQ[/:Z@FF+@*O?D],%A
MDYZJH;^3^L;AWG7:KWL,Z-0UU0XHK3R803,\Y*GEHE0()Q%KV)0-U44OG/%1
M82)31_8/6H_AF!;!WW<<2]6)9;&9'>Y&5"M(H^01SJ9SBH ]<&*-<)*@/<91
M$H4W$L$@!ZI:Z![MHB[&G:I4S^XZ(.MT&Q!9-T1:5HMA$/E1"+XL%$KQ.(NK
MM%M,8;=1C8.#ZISR<5,.;*L'NBZZ^227BR @T?O+M8<VZGF*2&4IOBD8#1+F
M'8/4GVO;< VX=(B<(MZ=L$UY\*?4[OUF*@?-#V03;.? #EEH"SZE0U4" !#X
MA2]P+D"FB=HE 3^E?PETJXX],$S6\CT<YF+D3A3&G3A[82&;/?E_C*?:) ^.
M:OKD[4W&86-Z#$NE'+[OJ H-/, 7N59>K!F'8CH1C8C^B+&P0]LD7:.OP[M8
MT-0?&$0QAL=8:$<A8 2"''Z;H0-I,B-9(?#_@)(L4"G;/&K+PW-!=)N)4\/1
ME.5A&@N )W/:\U[C#SF IV1'4>U#H<3C@^Y#H#808KMA4ES[%UO[%Z[]BX6
M@+8'AJ9$@C+6 X#BTOP2&- X+HV_POT3RX.)0(^*M"^+?9/(U%V 9TE&_ST7
MJ^T0W!R/*'$J!@6 !@1$T.3!2*#0GJKV8 WP0MS.C2H)+\<(JE9IVAP,,>KJ
M\R672<+N@^J.24;P%HSL 3\]%'.P#_0GX4%81 7G6]+8/K"R+G(7_ LW)EN6
M,QJS59 7W3M*GX%7[AB.#1M!]H.0E[N>(%D2?K;86U7D>'@;5.<AP/LH+P/
M(?L4X(3+86)Q#.P0'A*GW9G$L6QZ60+!$5BN\KB?0>7.H)+V,Z@6\^:V.8,J
MOI]!M9]!M9]!M?495&EO!A5UC/OCHA;+;$'!J!%[2?_%-:.H<K[G_\U+_WZZ
MUFO697E<M>+]+Y.<F!- PH]DEM?#7#&>)W99>ATJ'*O&4BF.Z>ISZQ(TJ/3'
M?'!Q2NU&B^N+UO<:2A7[_=2+R@T-;,7;R\0F0ZFN<M5V[K)2KXFY:K5^#0RA
M*);J3;%6O%PVL&H_H.JU8YBBOY?%[K+MQ,U%.S>ZO5#^G.$Y/E"R=#:5!Q0^
MI:I5:][T[$KZYO%3#]KY)%.7MCZDZA;Y:'&!CVX-;OMY5?MY56L*GS(O;234
M^OVDE&N54;Y7;#K:3FHJUXTOVJAAT.<?E_.6'C+I5Q?P;MY#YEO.*-H0Z+&E
M0']UXYY$1$HG(Z""['@V4<RW="IZU\2Q$U:3=)$'*9>&5\/9<'UG(/G'9)3M
M)YW9^%WFGSQ;$.UMFWJ <=_H$EWF]_O"-;=KDL(VNK;7)8:E7UV$FXU(,6#6
MTO/31/[LYCYOO,$XN\&5//\-H]%B22F2EIYG/]MJ^Y-ZJ4I1_/T4GQ7UJ_OK
MCE4<?%";!E[$^XIVA)^\_/?]&A*F7SUN[0T-";]W[?8[:I6O;A'[^LZ$NRD@
M'T>G3X-.+UTU$U_&2?NE<R&"J5 L_,TB\VZ$7,:B'#_JC;RUV\5(/_J2T=U,
M>[RK5E<S+$QKP19<;I38GHGSH>((CX?S_ LK5*1,BSE9W@/!1"::(3B?(Q'*
M?%Q=GVJPG$>:_K DRR=8O0W;,#2'KRZP+ Z-%2R,QP3HAD7L;;7/RP180W"$
M:J@DUR;=@8Y"3T3<MKU4,7?OA^+S61;\($*@T#:494']^:LR+;#N'34?NO=5
M:1<T.=)/?)G+P! 7,S"$%V1@T,2)3;,P: 9**!$#SD^##KHAX@HF[M[#)B$,
M.9G"=R%\L4^H^F F$LB 6I]0(JY)*%'UH.G(!]VR!@XTAVZNY-RC,"&W'"OF
MJXZ5A2JC8+]+3^TO^@RCX6X_IRL5?BX^G15K%A0C6+!P7&ODG$3Z(G.1\@H6
M*@%3V ,%K=#WH,26>TYS>.'N-E<!,^%>@-AN!C6)*6@_%M'7JA&Z(;Q;T1$'
MDP\W8*HORE9"H .'86S48B5MM*G (D>=3X,-L%) ,Y[P[:Z)PR5- CAJH<C$
M'/#OQ(SF%;=MYQ)DXG_-(7J3765#-NW9I2GK%L]B*WC:QHK$@6@V0,PO6.7W
MDTE,T+[/6NV3+Z-]\L0504H>SC&U3"SU^\F9/C8!TY^>SGM__=,L5C&?16SD
MFI>WXF4S5VOE\AC2]J/5G7^^$<Y^F<W_5_TGB)L"U9=:8]3G3*"\_9U\P.8;
MCFDY,M8EL&3^<P*:LBGF0"VF(B"L4X FXM",FX6RR*!FP:^T1(BUO$*YI#]4
M6Q?V1%+\2D?V&U%6)JJ%+7XL7HC0(ROKE%T6&GC?ZWS/F5?[GF.1:#2*_WLW
MQ8!A&Q@* !BO!,.%7F\)!"WQ1Z#2S7TRYS[E%GP ]-S&![2F!^"H\THWSZ[A
MR(%J %JMA&;QA^M[\#OO+A&)%&9L+2!,*I#VYM]?0YZARHO*9D#3M//7XZ=A
M+%48I9Y%&&RU [HR6V>M*WSQM2_0(E\]YRJ6_ A\ 9,_B"?+;A_-9@XV5 R[
MLC6(+%Y;<&P6':0::G4<O+7?SRHGQ[/@-[E'U?K]>PXGSJF%\_NIFF^/JFK_
M-MY++V! X+Y!7^UAJ^EG&,;\QM?=.]_1[]"&YI#AU8[)CT$&6L@@=%QH 9V"
M^8"F&;<5L#Z6UK@%4";B4CVOY,!Z..[Y68M44UHCH2H^$U$M%#CH9>LM2UH,
M]SVB8^TK\ NB%&AF9X,6E-$YY1;[O&28_(7+I8V/AY@_7^_E3!,S3%&X+44Y
M]QCNHG *%POSYX-*OI1O7UP//"P$VZ##8&'13='SH6<*(&+Y&/ILD?[+3KI.
MSJW$W94G"Z-S=M-N^;1%AX?0;*=__2-]"$XSX LK2L;!:!T9^#J L0C2* \V
M$8"8U46MQ=\YCDB9)*OV]%VB(8]D1]80NP5K0# ?F56.LBZ<.BP#AK4KB@NL
M#-UU%&$ET>R0R^ OJDU^:55X94O*(),SIF%W_E+%)BPAF["B.D$LVJ6$O&],
M'K5NYG: 4X$Y;RJXC#R$8QM)Q\"FWR@=LZ_.2Y*2F4A&6A9PW24GL0VA:TP
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M$ _]VXS@>R9JUT-W9TR[1P/UR[BX#I82JX/'A !&RH 6V)MF(FMT 6N T76
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MV #-1\T+>;I3+W7;S\;W[4)@65[/!DVV;*J[$G%&9).+/J\M0. *F,V)+H"
MB0F6Y:&8E\>J#:?!O&A6Q>F@=P8%(ZX!2CHMS77'A^.-BU+23_7'WB]4'9<M
M; C@.79&[B;]*;UL>WAR;*N.JK776V7Y5/)#P"/J6Z&?*,$".5>/L(,@IEUT
MF*L"'254_PADC7.W#$^BHZJ*$'HQ3SACQW4-] 3H0M@18=%$1\L<;P^NRG+3
MV1!FS/B@/CUX/:CC7=&=H+R-V0LKYBU\.+;7=?$<-*UX1(A%8W&*0:>.3D1L
M-82?X)M&V.JC(9NTN"1D\%+8.AT<5\^NQS>7#\7&W"6N>#"" [JIKT^A;>7[
M\$V?5QM*D512PHEFJT:7P](-0Y--;JYB=QYW\BSHJ>RK$:N&[S*:H?ABJAW'
MRV1LM:[.W+@9)4.D <?47?\A3X!D ZM9I2$KCX?-_,O;X;L,Z-CID)*W81'#
MF@S'&F$.:Q"O\H +AAE&(!D=YI@DZW3#'I-(B >PR^$+T&<HQX([[A&5-C<#
M#NT7K5+_N>FQ4.P>PD;/>T.*C2E;P5W2"DVKYURCTJACORT+6Q_0FF-XD4G0
M2%/80_]*'D9%D,,:?_72UPIT^.(/7)!WZVKB<>&I@OMXB1#>NNLG6D2NOYIO
MCKJ(J0L7S#9_H+MXC.FZR&B!(CINC2?'4.37^%PR2@<""C[Y=!GYT)0A.@:>
MD1[]%7]:7/YT8$NJ'DR'QI\N.Q.&E9;U.M[@''\Z-95(QW1D<R9("4I1B<B"
M3,P;.M@:UDIF*BXPTW3B&58*OZ"^?TRJ[JD:)E@KS/77<DP"[[F_!WH>.RQF
MH\FNXYQ[UH*JC-L8CD9D?.<^LE'*#"[)Q.C#5\>J$6$YFSPE#)UH8Y/[Z?XE
MX2Q+8<QRR4RR,TG\!5!!!%00&"JLZ"&. M 9C>0 )UQ*7.$Y.'.W,<>?X=*I
MBCAR*^3@3SX8PO>-+V/6X=@M_ 8Q$O5E4*WZLNTFX 7?S/3=+L5K6T4F"(B#
M'-N TX..%D(PP[&IDXQJ;'X(DK.6 N)\D.?F^!9JN(S+;)D++O05#VL[8$G*
MU([79@+?$<(D4'?@*[#\I12/^>&Q>($&RS%K)$2(.->SJXXQS81I$3;.":2G
MP)R=1[?)SK]BB8!P@8,*<K=K.NQB:-QU]2\/L^X/*:[ #PU3H8Y#%U=4D]L-
M[BV'.44T$H^G(PDIN\ L!,HL]G1(Z3"(XZN8;C823V0BV61";+;:EF_34:XN
M-C29<M"">0AVN*RH#"5;V-</4(3^A.FD <R;L#8D>'4!P8XH 7P3OPGQ]1^>
MUN%]3[_P- Y*4Q,6T0>L=D!%>W 0/W4=_X,.8R #YJ;M@.6ET^(>8T%(Q:5%
MG9\AF6N%^:<2<U/95"+^N6D]5JA/"ZQ V[$P[2*\]P@+?=O42\R2VP2TL2.>
M01MA%AY31B(X&0=3 B+B8#9&@Q2+210_P8]6'A.]ZV"S5?PB,!F,*YF'\WL-
M\0CW*8&VRM+Y#<UOV]7.L*\>;7.K$#2HK8449OPO<\#[_4'"\X-86U$6T()W
M]/N8^@V$3C0T@$!LTVQ/#&"_Z$;<K 8/.?\X2J\LCWMN+EO7V<MRP,+A4BO(
M5AC8F<)%C=)@[ULJ68+)!$%=+QY)2?$ LT9HP+^.<8PD5\@]+0^77K27W28Z
MGGC'(!!]-!#;#82-:=9F4)@OV,9S4BE^F'*ETEZ[7Q E4S)O& ?<AWY+EG4:
MEZSS).^0C>S]UD<.9/$,083< H(P]A-46-P%?*T\XVLFAR+U(,$C8BSMFBKS
MAT&\\-_3X L&]<>E"B2:!0R;T#%H<@L3'@ -)Z0:T1>L.;NP[.QB[I?TJM.G
M@J>?%WCKC^D3[ *I+MY$4!'F.$$UOH!=O\J6X\U^7 -1\#</2F54].PIWNO0
MA9=%-&W)SI; :=W>4O-[$];M;=[8$[=J['UE+D$]:BE.4\(RFJH:<L#X7T3&
M\/=!].,*QTBUJ2AJL:N"GZ'VV4".+99HA"DB5JL-EB/3]9Y'E]9*"4*SD-P.
M<EW8+^I.%==F\=Q; YH0*<YWN$]PQP*6C_/L)M5$6V=JB(J)"=K,&2:4Y"Y+
M@F0IQ#;5&=4 ;X7%DMYKW!@#5<DSD4PBO8IT@D:CMVL&G[#9Z(-/X.!#8IK[
M"5?>&=#71S7"X91POJ$;SH W' &':CH:.NM2N/DFZ3O,$R,4 M;%7,3H2R<5
M?+^L('8BH/&<T\>^8C%IE>A\1@]X1@UP?Z @4U[D['F?KS.[?DY"YM\N'ZDU
MNVHU)-TYVA!>31M+0WW?-3WHF=R:]#ZW9K>Y-8EOG5OS3>>'[2R7)G4H%A\'
M:@<S+U$)**DZ*!OH6&FY61&6V.H.P(+1"*8LOF="S5;/ZU[6ESW XM9]+A;D
M6O-<C;\^Q*I6LK2_D"Z!;W'R]-F1"YW#)!PV9ZI8JETFVH0@6X-]R[KUBV\>
MA+E-?N&68&'=F)KRV&-=T<,,*"2[A15(50].P-'><)(=WZA+>6&R<IDP7@3G
MPU\:2_=;_SCF]B(.L?DA7\9+7K[^O+;$E(B_%DAY3AGLS"N#+SC16IZ5WCG/
M\KG!/"]8Q;XVOJ7HH?0.NU^"@6_;_.*%P'O&V[_YS6WK+4.L0+R<0@:F,/6&
M!<$VJ(C:'!T 5-\TP!!%BC7,_XAFO_,C%DU$8O%,))9,_EPDLS>2T2XQ+W8H
M4=]6XN_MH-T[F@M;VZ>/GK(X,$GO__X:V/;8^L_1T70Z/;1(][!O3(YR9G>
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MTOY.F<<.^'#\4-HE0?Y9O",1C:;220EX1_R]>4<^/.NG$A[$$^['LAF%QM]
MH8N9$9^&2M]5VN^$8&-[@MVR+OH6TD\E)"D=BR6!]&.Q].:DGV.90$S.$EYP
MQ1M9O3N]YL:FJHFQ9(2%7E<0J[S<1[,7J?,4&O\2:/]%1*H4S413GT"D%O@
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M_0C>?K@'-%B+UC%T$,RJ$EB4"_F]'OAA&!SG:N ('=U4/P@A#ZCT(R+KM%G
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M,;Y?(5@CY&4FKL.,5V&M2V==JG\JC@;B7V;.YM4]>$/=/7CU&#.T496Q+=>
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M.V''5;A^IVN[XF']477>+]/^:=F_9]B]_U^6_9=A_VW7 +!CPSKH\#;L 1"
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MTQ@4VN2M)/\?)*M0I"<L0:.8&?J 4(>N&OX-/YI.C69"T-JODD-96"5MF/Z
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M^6VE);4!8Q(&>)!ZE;95 !]);-]IW11]J%O7X--\I&_4:_=!+*@>=>KFV[$
MFE/VG<I%,<OH"V.,)@\[*%9ZP?2I0<12[;&O75BEI)W47%@Z1F_<V?F&6U<D
M/0C;;R8;^0>/&&-R4)+$AL6Q=HNAF(E?B<@,Q/V&UKW:7AV).M8IK\?*6-#@
M%T];R0M&[HSYL'_G%9D8>"Y8S[4/CU.)A._9C<2M9CN:1SL%5D&R<T(J@BR(
M76MI8XLPN?4W=?Y\FJ</TPXKYZBLMK&"LT<),:SMRTQX;!7*>!OO+B_D89#I
MGJ ?*[Z<;V<4NA(T>P\+#U;%@)Q;RA"%,Q(@77@[<G=Q4^(CC[WTJUX<;LT_
M$M-3CZNCN15WX6Q(B_-6GZOOC_E=')V0 C$!3>.5,M-!!XW PW= =ICGDB=^
M!6.X*J2%)_L0-$"KH%:9^"<9AD920(L0!.'Y$;WARRWTN961.I/H7K1EW/SZ
M06??M;H?YAD"VI<GE9;@6CR6)LDQTQ*4BQIARA,93>BX>:II2!$ZS]7PDUX6
M*C@=/E\U03[.W97(0]83Y"L[#Q :=K*MZZP&1)Q4DL\2F4B7^$DZV8X$T<RK
MQ$:ZG/Y.9+-EP_!.GD52/K9=]VVZW=1B&^N&U]#XB3!W*1#FIWGJXWQK5T'R
M\WS-%G>.:5@^SP*5,>P3W7$'IA3=15,DNN YV,3LS]Z9"RH=2Z\N%-P('N)G
MW]$-9.U:V1DQQF\.U8<_S.HM?#/=&[MP);W--[( E6RH*R>FU[8$B],FC+T;
M%AZNF:[4<3)B(FV](W!:[9N:T#=F>,<EO8[][HE%H7%C7^F$ M:P+Z@94:>%
M,>L.#;2(3\L,/NWO1,-GB!A["]I5G3].M]HGH;M)9TL0]]./3[@O-$/I]L(R
M<;,@HM[8N^G@<2G0@#*.#,DP5GR7E9SQVL^&H%"AH]$6E);F,H$I")MLN;A>
MH#$BTF"I[J^7 O261([+6'1%$7/&*,OHX8W:>\-8G^<^IX,MCW-2QYWH\>;7
M9J)W"=+(/Z8=,X:5>)N:E-VJ^W6O^MH59JARF-&3_.SE$JWV7)-W=YOO-48<
M.*_=VV3A2A]&OLH !\-;Z&-TI5E"!?TO>Q'6GD9CK-36JL1@7[-"5*W>7H+P
MV+2+$F*CB5J$8G*KY;L>B@Q!'NTSD):<]K8S-/M&R\^T;*_/*$2C^TF3TSQC
M&YE+75OB3"QJHC/O]*4_/I*F]4SCYKPG+KLV:X8"VQL9U&O6N5J':+*79,UH
M_Z"S+[2+IFASQ!G:"G8[E75@%_K]?GO7]SHV)R.Z,YK;>:8(V??3E;)QJKOZ
MR+1_N*%#+\N9& 5MSL$7^BG/#C"_HIT=QI\$,Y=PF _H*BFP(WJ_VW!HNVM%
MW.6:;Y7Q.F]Q.*_>@NKRI<,I@<E+XCG6L>WTQD5'V8:DB);H[7'-QV9H<KRG
M2FC)EQ"[F2R+3/#OTM(O[55.5>55,V0V;'>D.08V _[&];X?>6XTT<;BY-@3
MAGZU)]%/(O18I-;-M88,E3Z\LQBY99-5Z&>VM]7)E."N\8Q*?G2GD3N-/X.?
M,E3=R&V+=*WJUF]'*/A4A5\*<>23@S1QCSR&-J^ LV,3F*SW^ 2=($PL1B;H
M<PO\=?F'GE>W^5G:OJO-4B"YBM627Y;!GL]DFUJBXR[TI=I]/[2H-VY\@I-#
MJ&D?QX'*J:W&B$2Q\VL!]E(%U^BA3F"'#-+%J=?-V-'7TVM(AQXBR*),\ U-
M=YC"/!(?7.Q]1*_K@ B6,&(EPZ,#1^\EBQAKO%=2X)/6%T(/1"J_81=[+ 3G
MQMR0]I3*N(9PZIWV0\747KNF1'#I. <MN?+N(;._?K^H*Z](O%F;O"/+[$1R
MV5YLS9Y",VQ ](.:HWFUG6U;/QS0TT0.35!E5Q,E9)/?1(;#ON'1M;@W,^$E
M8AN3X*SK:L8M*OX3>C/ T(+X"#624.\ JD*+%[ AW/\!_XN"I(?6_)ZA\RKB
MA^M]_9;NI$C3;5;'S5C[6M$GR?'RX/:7W!4I,&'/,Y+P?G7WG88*JK4@7 HL
M:0JRP5]OQ(]18&Z-$"_H TG>B.6=\$9Q9]7)_ 1!"6+D32Y $*:90%0G$BK=
MO+9,Q$CA/YNH%Z&F7W=SVC"_QIXD%/>W28%GOM&PB:B<Y@.HEL_0,B>X*E+@
M2PD;+IJ $%:R0XP4N/<T=#^DCA-/2;+T2QU-R9VX)1F)XU?"E#(F3DC\DV>I
ML*A,J+<TV0UIJ(N5 OP.NA0X0-H&S2?+A93X0B%+ =;O!%Y@5'#<TI:UDN?0
M=NC399?,*MG)VC\A5!-J>9\PY=I'.(H0U"!&1U5W2H&7 6[B%U* /;7&D)V0
M7<&<DOY?G7UW7%/9VFYF1@?K( (RBI*Q@$B+!<2"Q(8HJ!$10DU&,4 2 464
MT++'@@R@9E#* $*DA"*$2(VT9" 4!1$!(?00>@U)@"20]FW.^<ZYY][[M7O_
M6+]?LI.5M?:[UON^S[.SGW=#WOYMKC>3CJ - %:-!3C3LSP09X=:*2'U]DSN
MD.5JMT!W)82Q!^SXCE%LO1RNR/>"_MU N8^R S2%_0"=_=0)W!-,*DGJI07B
M&O19 JQ^!7@I,_,HP%[%%%8_MU4OFML7$C7U? 0>GHHZ8M P)ABOOW[/TE;^
M-J"L#?">*(=.EYZRW!B^#$0&-G!6-CB:O!CQ\>):1_J:A6UPZCWPQ7=Q^<L>
M$#1%^HGRVH [*>:SJ-U\DP_1GX)F;P,%C6CYVCR6S)7 L&?'.0@=7L/O?-(X
MLO/=4P-6DD55D1)"OQVB2ZKW>\8I:8Q:9*XC%/_E?RG/+3_U2EWE]EL&^:UE
M#I@8RXE?#0LJY7&,S:&'.^9E5Q6;7#O;W[X29%2DVN8;X5S'G-UHN.4%D651
MM+T\/3V&'>(\%7B$)C6.1<A39N;A:E."F1T_4FY/B ./MM>"]$?7T/5:]@:!
MJ)A4%>JUY8NSCN6Q39M=_@!#OO>"[9R?!&J$ \J>S*S@>B7FK(FK/U7>JOAF
M0S(&>B(1<'%G4*_5'NR)N*6!SPD)XI.4U&''Y;%@ >F[EM%T*SGG5?4YUTYB
M(]<0W+N>Y:?R)S))'3FCDLNY0NY>+YALW8JKR+HMM6,HK+/_R7BGGPF/.71<
MF+#X\L.OW725;\AJF4Z;%@M0L3CTJ\;W26YW1N1E5T!/)ZFC+4%.7>XBBZ[[
M4PFI<)5RTI9Y"-<9IUEWI(BB $9#V'_Y+6^%S_$0$ZB7)Y')LC5*2(RV8C!3
M\6#JAU)B'HLIU&<!X=!4$$/,@TY7=^28M,ZC0V,(C!;KX.%>^"0Y*<)(9\$N
MQ6?H:CX^QN\%0]-#"8':>_1N \$QKV[\SYT:U:E[2CQ@\T?BGZFJ_TXRV^ ?
M,WE2Y:TLI_<4W&8(S@TD(!5$\/>9FZUE)O,;E)#6?HZ8FT>2_]H$3.K!@]KD
M<7\"K8EAC4!),#'V#G0 &G<7RJ^L F$T_#[ >9:AT H,!R9X?E+A-R6D:V>V
MXK&'.$+D>%,)L<2(=TVNT7G"?_MNA!<U9G%<L/^<P(I;\OZ#WH3OO,EYS$<9
MGFK9.7U3$' H5EZ@$]HF//:N+>^L6YQ'\^ZS^@JU9;M"H )N\$"S^^:]HT^Z
MB3>2M:09PFR[RS_.HGFDIA?1\K9E^YRW@=I_^]I1V%M9[K=KNRFKUI'E=&=(
MK,>NIC_J]ZV'UZY^*EY]^]N'@;_W2G^T>CLM-([)=T OFRAV*"&%P3#Y@52&
M-;\L+VMR\)?"ZB[3!X(?D]<D9W=@RO$/4H#*<=IG)G_'RHAB0]ZF7 &3I5YT
M*'QQS7D_KA']B"]4LH)L./"5W>#!',P$[.Z6! D-#BIF_BX8Q4;#(G2V\N>?
MS%D<XD\;;[PNV!^1O]214U!X_VY7EJ,/W^AZ61<Z8=X!H4JX_Q=YL^4& KJ!
M:,!_.FC>:6$?%+BVNACGWWT&NVGM-3J/X>GI"4T)$M?3HHXJ(>H)-7C-ITF!
MLKT*G=*O?:')5>+(9#%S5CY?Z8Y\JCA$<)G@$N.&R#J2JU)4<1ML?T4[K:3:
M=O95_8020HVD&QJ:C&4DJ>?MMEX?E?&(LGWATD+(H+BZ>3ZLP(^_=#1TE]1D
MAKG%] K,N?#;XHL=?EOD[\(VGJ[^$)-=&:7G(:PH^,8]6S#NWH=OL_PY]&=^
M02&7$VZ^X^7OK]UF'"WWOI)9%-&2==_[[9<PW$M;)&A107&'Q?H,@N=T<WWP
MG1,'/CS^5'5\6+5HWWO3_(^O:?%]B>8^_:6V->B2./HS4_(/SLUI_0/T9]0E
M B9A[H B3M2)<90R308X?(->RUH5LLOQP=U759>K!Y"L9I,J#A<,3Q'$ID%(
M6VA8V,B!)=)/+<-E;8OKS;2O&*P?C>1E(]TCI<SD/D&!N)Y3_%QG+[G67P)8
M^T&F7>+)0;FX7KUB0GM!XII-9.98: N5R9L;:"&P:VA1>'Y18X-=M//$!W;)
MI8 _Q^CD)KRG)WIP-=M-*7;)<]?&EW+G'BHAY\LKV&_;,%_-0B2PJD@_*G,L
M]EU?H/6).2FG_FIL3HC)I62/'$]^PXVZFT1H,4T,Q(LDC$#Z.5-BRTJO)+Z]
MUAA]*>'2A_:)+BV4\1X7ZANT47Y3\[BAX9;*AYVD3;*-K^O4IL5EJ89M !?:
MD?GXQ\X!3^%8JE5_C,$RT7-^/K240/P:["73?;:4'VJ=/\D^<:J+!/@5X-'8
ME RRY\3C*\Q*:9[,S.LO],Y%] ].^-YM<13)XV;6RG.^^P51<$5-V)IWE:[B
M:)TNQ[^6'[9]BAC?F>?%:.:*Y8,QH'4K9*Y P&-HSXA=8;*[>TC="?-G[$O?
M;K6GVC;$Q3N/7FOSZ:4*B\A52Q0O_@;V53ZY;KW,>E@_("6$I=[WERCU!FGK
M,DUXTH<TOH#DS2HACQS'R'6P=3/033+GP.&-8?8WGDW4/7S=-]4Q_8[=OO:W
MK(F8A'$$5\JL*VUQ"[U'%VR47;@2<C'5%M JS8\J,S?4[C7=+*554<N)X],%
MERTVW70]47=?"7EH-P7EH1/&6H":&!RY6%&<Z4U_799+:<F?6B%\FR]9EWDS
M!'^'4Z>$F'#BM@>:\#H3!'#N&^;&TH!VWR7J2?MOC$61B.@IT<(5\?KSQ'0D
M,E_Q=<=#ZD_TO$9NSQY!07FFR>L<'"*P@MW4G6=HI<.)2]0$HML_M$8I3I*&
M$:0'4+5&[RX[5)#SH\S^F3)==+42\AVUE]+,VW7,(+%*H+;" 1F&K\P%&*WL
MH]U/>L8\IX1XM4()?C7P8O%C5S3;R/3,O9TSZZM3;FV-2Q3[#+"5$!HZ=0M[
M2FNV+<UIFEPL?O(C);MO<.WC"S<J'Z$]I]#%R(?JPY8>))>5<)B ^%S(Z94.
M9S^6.0^%;?)F[&TO=96ZNQP__S#ADF%^R&U'OS'T<1QC?_$WJJCFOL:7O(4[
MN)4GHM&V@!>JW,VQ72[N<;&D?-?<HZ+I%RE%0 "R3IS4C[K0V4N&\6^,Z.IX
M9#^:',9COL8>#PJB<))EI$!Y1 $P#/(6F+@D2 E9O..PHA+<K)DYRPG8K7!8
M+I>JX?*@<VH8J$S6[;:*LC. V=(5[1'MUUCN+MS-+L/C("K9B9NLM15;?[PW
M=M*KD+1P8?^82KC?T:MSB@[VO>%=MG,G-K@:A@J+P.YAR!CO$PFO<OKR<H"M
ML.3;LYQ]]G5SX'$V:3N.N!S)LAT1RE6[-H:[F[/\ST?@:KQ/R[8Q3G95V5.\
M'PH [/2V+AV<+#6@TAS)MCQ4L4VQKM-7Y>>B/U9]6NCP;8O;+]+S:BWO994=
M#X@>PQJY<K_-.YBJ1F5+< C7Z4;<B052_6?2#<DA01^7%S&DA!1S)"SKX@_2
M\Q%-25.:>970DL#:(0C(_Q?.*B%_U>6W/D+M;/>MVD#52\ 8AF6=*Y^+J62G
MJVZ8S 0^:B/ K]P @2%^R2TB00K;/,O0<2)K)G%FEI:9?PK!/76P+?0^G]?L
MP!=E^^5-M805^OKLZT^.<[W;0FB]B1(+QMNUX6M[K38=JM?JTQI]<98VX&?#
MOUK+7#_"6=Y9.=>LOCBH">(+?S!E6+!K48<%Z)=+(95S)L8[6FM%%<D] &69
M%GBB3NJ>X-?$G&6;X04A#0<E=K*;05X9;A)_X[.NSG/&[0Z5%^-'F@9?,/%(
M:_"4-TB*N2+:@ZPI/C90H57U#5,M/5]<@MPV9<@+Z"O&(V%8?G$#W7)K<@TR
M.M-90G0_4Y#][58*Y4.\WH>%AP9WEG>DO_'G8>^'P+UX2DATPES0@F)O;&%5
MS-CXN)BA(.]A1RM,\2=TLH=)NTMLO4N.#T<9'['SE#[,*%>CUR\ =*'L!>J3
MER$"K]&J?5:8SGP%+C_00]LFB*BAACAU5CGL*BV(#%/YW<OY5A<LD<'.]KFQ
MK 6">J^Q[F94AY?Z&?S:RH\=%C:Y$W ."(?KOUA29KW#[!.2Y\*:EQ@KLOS@
MXT"7O!3AQU=":@!*6<?X0_)ZYNA;+'2>KHC"K402!3+#,<Y3CO":*2 &"8R5
M6=AY)D&A*56)( N-<Q6P-N@/]<SY0B5$=?J3?GJ4_++DM_^B5MT/+P39J[=R
MA-H61774HW9U5)WSVSC_PFSC[=?-?@ZMY]P(\E>6FZ'+68,@:_M+EX:JV258
MU- YW:H9FUL;W+3?W<C7X.GQ PZQ'HK]"J\8@*4K YE(^CWNO.Q[%[3D=NL3
MYN)5"[@2\ILMJIJ$@V] -20(DP&LQS_4?J-D?A-Z'7SRC0100B#QH$-NHO&C
M%9$3$2 *7X_O@F^ ;SCU C:F.F<4^$_%7R:QF;P^(9LE5UG5Z[V!>\+"08!X
M^*=P<)QH5*[$3F(WBP7T_V68,0Z_!;H1/GFN#<Y7PXZ(?"4HYL+>51E>Z10G
M'!JN TXK0I0*_[ML+V$YU0N<R!B_4?'4!Z1%WSDFK&H,2?)U%3#%]]1@U*F<
MQE*=+V2P2_S)?W8!R=ZF*7ZSXFF*]K]WZ>,F*B&)^R^ IG.@V>1@8G9?",3<
M0"<FDFPH5W?M08CBS?^I$YR%%W-8!'?G4*T,'BIB]B- "2SK*G2JV56U)?_:
MA:/Y]UZ\2Z_"UZ'+T#6MFW (S/T1VY#RSK+W'3[955:6<UM/*$HC Z4$V<\O
MUZ-@6U%N'_,JFZ*MJ_N)R>D;5]AIFYA;%1NN2U_:2'H<%*=0?H*+/")<HEV#
M,N6KTTBP9XEOL4+JR& R>>]'3-,3)GV0EEIE+C67K9%$I./8*#6!PV"I[G-C
MHY@S.;G>#$1"<!%O(TI%BE!\T^*4_)B&S9X2=4SIJ+[_PW8SM2&T+Q>8R*^\
MA$Z0V,MH?WB;)Z4^>6>5.^42_B4NMRX_QKWW:*.5'X,,^F AVLHV/ ZW<TG>
M&W[S6,;V^ ]M+&0L5@D)D.^6)\,]:3]*3K2R+(\5OIQ;FJ&:'+"]XH\RP^YQ
MER+I]NC3N*10%VKX0%SM>F->AO=M>YE-<VG$&%I%=E1>^0#X46)N^[44L?9<
M7G/VZ;)"5/<TU.N2)A+'<[S0VRB/-YM,!1?J\6.L5D+MJ9 :E]0$[Y9']S!W
MZ94JXI2C&0!'>Z8AR,0D:DSDHJK]IO50W8FE=PN6;P9H:6@7>93E+BQ'K>I(
M^NG>$D>7%]3%#GT&RS>ZJ8<^IH1DT=Q#T>_-68<.%UN6&ACZ=HM'\\*(+I,F
M"D,"O!Z^1;:1ADW5:^>9DF;E=DFS;N\RT8+YE#[&#%#476#8B*;'1Z3AVYT)
MZ#.OZ[L.IA1-7R(8WWJH&-6.J>*(&0YBVM&7SB?:8V]>7+% JH\'3%WWTX(%
MPUOD4SH=@J@Q4UJ$^5=:DW;S(V">0DM$7?F,+ W[+A,?#)TSY-<VWVCW+3":
M&_O0+_@8I?O8^TM7E(,(3 17[%9##A5Z17"G+(&JEQ4O:KN:A8X+/')8W@G"
M&^;.X<%=G^];M%L4CD65A/%64EM5)YPN_[0A=*79F6AMS3=H<H5#^K9?8)F^
MLLF0IS14;Q%<8^UP/5^8'F[U\S6#LT%[RPP79YDJ2SMUC<R%#8VL6P*8YN\I
MP#AFE\?9(L'FV/C@\"(W5^:F%U_91IP?J_2R%6<B%$K()26D'NG3_'"-?6R8
MU=6])C6WQEI0L1B8J<&Q*JMUPO9<_94CD4I(N!D7MK)6"1FM(\L<H/RL*ETE
MY#13]N=K)22J8,34LYSY7MBZLI:D^/XE:<[H[^+A-5^@"@WV4^8DZ.*OMP*"
M&T!M$A\$G7^B%9?_-NR]I"/6(ATD^$MMH M? ^,)L!I/]/P'=TI"WDI\^0-8
MD:UFC3OCIJ<'J8[M8/?D27?86OB+C%3#=M;-'*['[.29"Y;6FBZ=AK9)^>69
MEE'Z!<4'_ZO2H9F4__B>;O724&<E9.TODD<Y6!243W\RZSO8RW8*XCU8&RDJ
M*;0J=-130FX.HF7^C(Z=43*0:SV.09TQKY_?Z+HON< XP#S(7IIGW C&FO34
MZL^O8G$C;S/];U$^G;5N6I>LA>N(V>'5^^Z+$C)KC[<]4Q75R^UR[&%*9I82
MO4,+1GL=GYP:K:2@=>%]!>]:65N 8)NHONMEB,IR):2_(,/F056T/YOLF/D;
MQ8L;/K!@*P0J71T'=<KZ%.]*9N?R''N_5/4@8U2@]X=\+,='YN >CWCJDK'(
M74K(?$64SZ[78Y@>U+-XC>:479[1/-E25-VET#/W$:*[DA[H7_(0^[*N/16O
M:U>*C8HO8:%)7<B-PJ ^K?$'F&YJR;;EK8PT_OR<&K^O#KY%1QO^\U1M2++^
MJS7EGO1!*6=4/H1.'D<G4$/M@BAW.$+VR7RLK2E"H]"H#3YHC8[):VK '+L3
MYM3I/Q8SPUW8$>OQ<9A8?&_&MCZ4*U63G68(D*R3+5K7R^.%"RPZ<.NE,SJD
MM'A/B6MR)S$ S#7(MO(9M/;O&4:GG*^3>TY-VJ9:L IM+]DZQ?_COB8]_?]D
M0?_;1KMW3_/-UBNFT1IV!>,/?=[EV3^)084(\E!\SX2AS7B$H*$2G^9=0<WL
MVEK%UKG\LBBK0<UCW'-9"7E6H#:1H)\X!-VFA RE#6KS1U]/*=9VN-8G?'RX
MRP8I-!WS$Z'G;<'4N0STT2(L=\M.LRT-"!4+=8R]Y2]'[,NM$ /69?KIZ$H-
M6YGAO-OBIS5'^JU\3KKU6AEF:JEN:XS7!6)$P$]+W=(#I2N\'XQ8OSI,-7(L
M71AZ%+3_F>M]>LNXRHH]OKA6$(N&WP0&K$ FPEB:W=F6?4"V/R2+)39\W\9S
M9(T_O($0]6$(3%']4NM@^6T$;_\GNSM8RG)B&5+3)G3"[2[G<YAY%D=.L1L2
MIL"[?9;:7*]H' PJ+JJ-1!]PVNMJ6W' &=Z/FZ)6>5&=]KGZZ99'N@*O[_:U
M5S5]0(SMG6YL7W%H2:4(:TS$B"$J_#T[CJ ]O"UQ^(K79:M' 7D#4MTKG'(_
ML4[U)].!."[R>:YMO+51QL=[%=2GKM# P0*XPWMIYXS6"NXR^3!R/;5GEN/R
M-><,(+HG:<3P;1M7GN#OM!'\7%\:AN11W&N_."7*<M%R<DHGLU*(G-R6F-LS
MX[AET&G *@AS8CG&[<PO 3% 57XU7IA==Z X+%AU-D@0<9VO55\-JS4.:.&2
MU"Y_#0OOGRVMZ"G'1$LK>QX6*2%JOX8@CWK%AQ!:-6V'7T[0']<+%=/64Z<T
M[-!;0M+^IZJ^_Z3]< _]&EKZS7(_@L30JQ!@2C_KN<9'7TSB[CPOPBOR/GH(
MY1PF72)FSQR]BX^6Y.U_?)/O,R_;WT(A_71X+EGZ*^WU5R4D1,(<6,[K:BHD
MV]&^I+5\OC]\(,3)G_SBFR,I$GT)4,<;O\UO\S8.@XMPK8I2'[IY7"4@/8E/
M[?2\'1F'%_U\,K,U852\;),4IX2\F=_ZMS(X7V?@$GW$JR@ORL_"D$*3OK!Z
MZCK\+KWNTC0OH2YF3\M&'PZN3Z99N-DCLT_] ;;O2O7U\GUKRCZ-<N;0'SKG
MH>N)A\IBV[ ZN^.RBJ1_H.$<.A@=F3TTE8!X3T3R+<>4IY_CI1CI4GUDVH["
ML9C#S[V@A)5:A6>YX&G>&NG<GB<2[5%@M0A,P?VZD_9A0;#:^<AVR:UIUU.(
M^U-BZ)XF)83( <%+0;H2@DKM79KE>2W$, A9"CF!S[*)+4<<IEB>(POV<8@Y
MH>KE9:!//I($B1(M<ICT7Y:9O0I5&8"Q%UA2Q K<PG)6X(<%1\=G-WPF)Z6[
MMA-'*&%K#BK:GW/[DZZ/OKE-''KN034FP&=]!&AW20T?MPM1=Y&6ZXRRS3:;
M+F@C%+Z[A18S?*B*WE,A[T_AA3N^4<[FYS;/DM';[UO_&:816QISTTH/Z_U_
MI)K+7[]O^Q]I G9/G=Y\[/O5/Q$>)WK3B[$H2&<'+*MOP-VEZ8D$$Z<&YLOY
M/RFTTO$D0V\79_?K^]P_?^;H:RZ3I!ABVT,E1#L4C<_PWAK$V/HUZ[YF.] L
M9P]@D8I$@WD'A4CLQT,R__B::Q&@J\FK&Z[_<I!BXC$1];E+K8K:F7UC"2T1
M!LMO+S>AMS^R@M9<ME&]$>QCG?>^Q5EZ8$IH#,$M#]Y/I^+/^2>7\0J(O3YQ
MQJ6M\X%(BW05FX18 &N>.B/3C!)+#7[V)7IYYE?_H7T?A3SS5I+JNO1L_=CR
M;,(MH%RF67,%4'0>L:GRFX,E2!(PR*+#N3J$E&>%N6:?*QWR.@%/H.>56!31
M"<M.<'"'LBINY&X>?2]C^U<6S!7N'P A;I]"@A.X+*GVL$<:*%*X9%Z*.J;+
M^$K3_*4S8%$JK&/Z.X"0,'=!":E>,+[OX8YXUSI-&SR6HR]%#Y+?$=?RK[[@
MBUD[ B-*M,T*V^]X"-,B3S$CF56?_?OR,D<T'Z43V.<%.M'9TV4G4DJZD'Q*
MW4\8N_+M@; I%VA?A2]\="\(EP&V#"_X=/]^2&-70B3-0A#12(M0K.F\&D>3
M%%_I,-N2W-N+901 YWR^<!HJG4I#MKM[O!0-##"F][W#"\U%SST31MBDZ"-'
M-GL&L(!J5(/];R]O.EZ+I3;=NS5C\_1X.O$5P'(*!7=!V@*8.1C)2DCD:CF7
M]Q)K)>3<> )(@\U7)<\)T,U5&T,$)QM=K)_=V?>R=^8:N6D! S6Z5!Q2#%3D
M+$T1U27[AQ"_ VJ+S T$K\83+Q::?%UXO+"]359.PYX<K7FBCQ2(JE[IT?O^
M2<GT1^ZSHU6*3^()F1FI%KX"-65*IYB2)#@WGZ@&1HEE< J<*TI('7OB,^<[
M4XX&UL6D< BF7D:CH/%VWD>4$%R/_"7^^)BT@'/$D&K>2%Y38@RM1>WOLC@Y
MC!^XCMZ$4YOJI3*RL^2D@**3>A+M^[[+;)Z9M<C2_7/&'$8,_&4X\T )B96O
M@Y:N3D!G\>\34)WSX),4$2TPQ8J?0H]I9(98BW.!/5U457/+!WHJ9MR-4QO
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M+%O\GV/QJ_5("O?ZX8,*AGM@4N.R7QH7:-GY=W[MN,,M*0N_27]L%J7/#G=
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M=\4._E+LUIJ)%>RSPQU20HK(#S (KD(\H.#!;=/J",%QNR\5./0O+P_I_KP
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MU3;\A'.TB9!_13>/):=[4FGTT)#,M>&+[J1?'2MDUPRDCD9QE)!?%=L<>UD
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M,[XEU2YX/O&\Q(>::QS?2RGC?8RJM5Y0JL.,A':R_V?Q1.<)D\VU"2Y\!G#
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MS?G.%+2V[>"4,63*'F&92Z=E;T^%F](AOABX.!*O7TM;]-1+?T0 =3U['UZ
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MGG#@&0-FX=[>SX"7V8K3U?MMW5DV."4*CN.N1)0LPIZ;MOG*]QU;9;W^/1%
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M:\[-RW>&$!9K>T$+9D7GH^BE=5_L\HCGY-6"G^:5C0_6J]\>Y%#=5LO+-WD
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M*QZZ=9UTS2UD,CRYP<=:J^K97R('1EUY5U?[IHA&9QZ?G>]?FD#977\]!U5
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M.&0\.**;'/$,>'CMY:<64;PQ6"T06M>(7T(2KQ^6D$'SR'DF)DUO$$ ]^R
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MUBRL4)AV_NA.2(&;":D";,.9%5=45? YL66FI7=<OX*,5R"G\!1XTP*[ZH6
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MI)N70BHZT"S++9O]X=P1._*K?4VX_LHIG)6=>YX,8=&@)S-'\)U*_NQ(;?8
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M"VS7Z;*2/JWG^BT9,4/8LHOMVV/GW'B;?N=\20UUJ80L+?TX/ !KP2T$NV4
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MW<306)^9(LW80@G@[O),*;N/[%GU&>;9[R$&=%BNUXM)6WCY>6!W:&<LUXO
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M/]&BOB>+0.0[XX+;<I4!?"$MZ5>XS24T<.#W69!G/=2;WQZGEZ4+4V.QJB4
M>O7.3+NJ,NF]XK>LN2LI^<L*.)YWMG&P!MKNQ7VD,0WFR@K46=TEJ3Z43_*N
M7*IFM6PP=:E3A*S"]=(%^]P>VY_-Q9@'"CHCPVBPT0VW#3^8Z[1K823DPRDV
MU)GJ)BD1T^W=5N?KF >^!RG]IW-!IROZE.CJ@Q=63-O-Z)#NST"1B5>"1:I5
ML'O:79!U0[!\YP+*9&95*D:N62V?.)KG\_M5NJ[4 X<?6W(]I%%C^W66;CRN
M8\ WS;^M([#2$<@OC;]+C"A>JY$?4;(NN?O^:K3*F6>O;9=TQUQ)C3DEP\#M
M"<..P<EYZE!'I-UYZ0J+%RTW&7DSDYEII"EQ(MIMY:DIYE(4(B_1V[>'XQ:U
M&=++3Z3/UF+F7-;H7+J="7&A!1_K)69CS7-AS0N,8!J61(H00PTZ?E0&&]OS
M43F'&6C[SFJNX>W36Z>Y(7U-,//Z;$%QK?_8$^:G0?_:YNOLZ>%WDBXV@ZBS
MCKS6&1'X"?F;,Z=EWVF'8!Z:]C;"S\;&2.*/UPQ17B5&ESBQ]<C?\@>0^O2P
M S8?JJJ^0DY;(DC'T1T*%U[';#^_<U".G,0(]?OIZ9(51A9$72TYPSL^\?-9
M4DFIPE>MA6E+@2"UAO>1J#[V74J&(!E=JBV8,[$5%.PUUD 5^FQ2L*4W0=+1
MLWJGM.]?2I#\^:V-W;9KS]88HM,A3%X$8!P/@1?+!89KA#$GT(K;A1$Q<\I&
M5/ 9YB247\C"[1:I]J#GM2SP3KU#GW"P7&;I3(LU8S%W5\E,9LW.VBL[\[DV
MG"[:<28[XDMM?I39G-1W'<%I#29Y7A/I9\"8"Z$QA9_-<@:<_G)Q:X.H8<#B
M9J" 15Y=)V=-,H<(\48V-IS*:+J$[ZA \?<:9$1 !(;@13B6;91O*TE&F:MB
M\RW!CUL6"/ADZ9K:,;'KBD3*+G##6U[5*_VDV,^TE&2U\Y/].^"1VG%B6XLD
M'X\3_2>YO*+_-%34^WW*9X_T$_<O:MRV>=*RYF3K?<)6]\C!IBURT,3- .SY
M">Y\+#@V >-OR;EY3+C0X:Q')'.-5KMP@6+SW _I<IJF2_H%O];_KJIR]W5L
M3GA)W9*KU_N4?[47SX9NEHMWZ#+"/+JW\FEWW4A[5R[ZB=XZI: ]3"F"M0AW
M0@1M+8G'7 (Q'I23?M"JQ([F50]'42CU.J;27J[8'AQA'C\&GG-$S.6>%&YQ
M6Q#N4$>J_ - )CS )H0% TN4(GXO\^,TYAB,T+9B81WJ'-HAT K096Q<] 02
M]X.+-I8;Y-Y\NSM!7=B)B9@H_827/1G@6$X<8VDA2,L[I@+I(5\_OL<U,-R8
M<#BL72CA[TM:$X&.3".>^<]E1Z%\QEVO,EJY,0$:/ O-W6QR3[4M=P:W>#IZ
M*,_-[&<)F(^C/60K,"#\S  L=,',ZPW6T!U6=]L:KD1*,E:%Q-/($[/'4393
M4N*-L3#-P<_H=2$?GC!("T1D6BJ'Z:V'J<^PQ2_/Q,]K[%5L!KHYFA:IVYM;
M.SL;O#%:[A)-S XT!*SD6SA0_+H%F'O[1)8CYVZGA ;ZYL &F]S@T+BS155$
MM' 2.^!?8<#UD04)(KHEP/D.FF"%1_!&KZ]6SP\Y0>2KB8!C_&\H2$B5FU&-
MOL$#! 3H@O[*SP <$[!=!L<<&^;4T#<-B6.^WJN?+,?R3NG.PLB)_1=N6JPB
M%+NQXM)-"S?[74T9N#1#[Q>1TZC.&=A,#N@[>R\)! 1&A$%3"Q U"NG2;=F,
MV/NUU*4WS6-]U\A)49?I^LJ5.:8>F/OW5!S(@>CZ<OW1K!SK6X9;JY6^"89Z
M?+N.^)$T5G%\6X(ZRIAK#/NCT);;KV'G91L.KM*EK.WV.MKW)7YD&8+F5Q=<
M0"N4&% ?XH4#T4"O4.A],.MOX['*P]<M1PW6,S9^'@VRU$3/%'.20.K$Y"E*
MW(O#F.&6PJGR*4^LW,]KG6$&LP?>@VRD&HU9@]/JWW:!8_"!0KE8,"Q6=(WF
MMJA/,5*%*#12^-_10$EJGZ_4Z%9,%.*RW/YEQ%9>)3)_ -^B!^[!-AG4_!K
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M%;3"P%M2=.3Q*%,7O$P?QCK4_%8 \1%AX9= Q?=_^M&0_ZS]'U!+ P04
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MHKJ.%! JZ:7[@;0=&="#')V7KC"9I ]J0\[""DS*,V93_0D,QO<:B'?),'L
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MT%DA&'#\Q$T7'WPQU6S2_ 61,-067BC^WEO;( FJT_K9U*"?7RK!CO>.IL.
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MNZ7=N]>N1/F]F7'D\_"+,>*CE6>#)K6O,*(76F6!7@&J$W_!)3:VHF\*^G(
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MOX1Y%PL!?VD4[AK]W*4VL??)GM:\P^RVF9'B*Q]+7%<\=N<_JW1.CJH:=_;
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M%:?OSO'\4U9-PH<Z6ZB7"/RZ8;:KPQF&03=[THE+8?C69K))0M#K/I,5RV>
M4="BFN-V8 RE988;4<_>QY,]$_:A:2FPVG[!'D%OJ"HWX8_M/^A1F^]0:8CL
M-VO_44SBLL'APATI"\Y"MSY_>F"]PD_:I^^8*X5,ITQ5(0T?CRWM8"?'B)MY
MT@'I@B]T.V2JI5_8VV:=[-OB>7.2)K25.W)N*:I%.FJ3E#I;:YND4@5FVGC?
M"?>6DS!(].F4>_'>!BT\BGM_R"VSF3Y>X!ZQT%TF>0]</ZVZ$] *_B"SXYS
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MZW9+G6F[1V QMN0I-K8K\]*RI9[,[]X7IOX9>M(3KX]8IXAN[69.&K!.'/V
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M9E'RV2]%,9%/AXM\E&W'(D<(PRG.1?JXJ^R%V>8D%K X(K0R0R^RZ?WFJ>7
M6@;,!?#7PVV0O+#EO[/'T);,-+NI=S8W-$'QZZ,,WF?TB&;AS9CTG4?>BSA#
MAF\_MC6:&N8J<WD4V E5>!:."5<2 (RE#ID.73=EVIUO^'$_ QO]Y1XLCAWU
M('Y#Z]\@G!_^HSU6:FG@F>XL.DP5Q\N$\X33M+$6]/M'!I!4[<H.@[4LK)>
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M);YN&FU)YC\3LR7[-M,+@.]%E>)@%_%!)[5DD7_MBC>LQ90<E<868N)!*R\
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M\J5#21VMG0A*F0A](2H.C1KQHLYV!*2W"V-?S0!EK((0+[:TA(E)#5)52G>
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M&VP3RG-PI7852MS2PTG RB0OZE42J9HTX+^Y!)J?_!]%X)_^BL +_AZ!,ST
MM%;?&2PF!IY5Q3F><]_O5NDD!][[:@>2[#.]\C'=2LBJG_=[TO84[(";B:?Q
MR2"[HT;)LZ0IZK&=JV)#W6J1#1\+_3:RB"]FAFI _444#6%?(77WAG.\0LS/
M205K9^7^>%[GQ;A,#<MN,!,RSKM [%4] 3PZM63X\#"*$"M#A?_1H_[S;6A"
M(]]QSV71I\1X4OPX%OZO2[\R,)WE"R:L60=]825XE;X#/H)A>F1S H\KH*IZ
MK]?CUL2_P*>;CVD,O?3[*>8_;6LE0I?Q9-@UA]A^)W,IOW[=3G?'WC#7+EBX
M[P+FO$LRY+=M^) 5)@G>PM[4C41L]Q&U-?\R8490-L(>HP/<SZKT:LK%R#+$
M@]$CNM<S2I;@ M#5JN*<GG5Z3&GW1\71++HQ\40G2[E),JHM0VM$@:>>$VSL
MXR3=\SV.] ,$84]KAQH3#ZS?4]>^*5D[<1*3L>V8Z21'^?144T(%]@U&+,U=
M-@Z'L6T"IYPDV.JP^T!X/;A@NGB [,3:G]QK$N1Z!>&>*YQGO2C,7+_J@,[1
M9>7?RXI:YJ(<^\A%4K(&VWL$W.)./HJ$FC\>OHHXZ$Z0[P&N:6W?<DP2X)::
MV:[3? Z\G_Z52/!8/9_Q#B'B<ZV5FKMV2*$%Y3I#;?<S+&%Y],2X84.HX ):
MQN'9U$GHU-9/K^RR=7N$V<'&-QL!FM.Y6N3.M;(I0"UTLF.8H;S\-:==6K%R
MT;XL[9AI&)6!!='0\[,R"CT:ONU-=#%G/9[WJ<@"YY+WTD_*.@#HZ*1WX/G6
MN<GO*=66->/T3Z3T?PSZ:"JI](XPB.L +M@'W,]B<J^GOVK,Q#2:4@GIIRG2
MF5G,\E_TJ/&BW[[+F:CL@;V/OW/C'?0/VSNRG(9]%U9#:?EE4P4NBDHH7$$7
ML C*[5]6_[XLM?K6:C-=GY:]S5FRSV<S'VMO10VF1IP0!?E_*;OV7_V=R+E]
M126#9MKG"[&W_S$ >([GJG'NB"_M01FZ?ZBKL7[ 7\+VVEYBRU)]HERJKIQ=
MZ$+XU[H8HSJ(9PTM<OBS/EFN^9H2LWYJBZ5$MW'\IH8E(F;^L)4BB>]^E$B1
M+*SFZ2+M8;?1 T# #[ZN$*4_4)U^1K\O"+3W9G0<: UY1AAF-#C+!ARM,3?*
MY3L5W!RP7+6>-V*8@8?9U3/BQ81_%3I4U_4RDI=/]?"V%-.=4-G7/+KE%&O_
M7KF\SM)*HVUO],PUGPR'F;EU!V+A9'JZ:JH[,K&X[.CRE9[ 3F/[\#3PN+'I
MK!K3>IY$EI$?PD$X0AEC!2&+:?6H)$YH4L\FX)4U6K8]V1[(:9 =N',XNA\!
MT>VIZE_52IG7+0*@E#&/\L5:MUJ<EJB,*CI6E( +G8+1\,=5WBK&3/[N-ZY^
MGM/VM]*Y7@0C)Z\$J-UM]_NH@W[64*N_%/L6DZD]*CB]>[V\:*"<U,='GP7;
M&6P7]RKLR-"/M$R%65/[CO.E>3AL) _SMS1+/Q(MG7N[AD,)TKMI1C0(RKS>
M:ML/V.92@DD;%*=+?3^IJVO*CKED/:-E_L)KI/+TN.WSO7O'^@T(YS.$9VG<
MG6PI,;.DI44U'T%VJMC# ;Y, J;OMT06ZC/3/%_S_1B/HZJW=+GO-?QM5AD8
MM^+Z &#R)X+_B;M: VI@E!R<#M-R]GFP794CJ SPA]AKP+Z.%2RTLBPU]1J#
M:J>Z[8P,]@ PBQ]=;'X M&*3SM6^O:+QQ_2I?IY;6' FSN,5'1N5Y :[,10C
MVO?LHLEK,M#M$3O(BO-K!F\/WV*Z0"<')4CW]A"R+JUV7*^E?UX-':<"(:R<
MYJIR=O2%K-&4X.?:_C3YN/*KJ=OC\&;PF\$J[8^IW 6:4;WHC,0+'DRIG_;
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M-OP_6NA6[P,*;T/I$<&+#X#)V:Z$O"CA;U?FOU50DI4/@.V]/W@/@%Y"QP>
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M19$6J6H&2Z'$"N6_OG]&!UZ0JAF<E\^56PH;K*0^BZ7P<:YY6/A?4$L#!!0
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M?.Z 97\HDRI<H%O/'G]^^_(]I+&UI4;#UJ5W$PF)7O3S8'1E#*>S 5G0+<_
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MF=O7+DCQY3N^2 /LT3SIF%%(MHG5U%X(B=14$H05A8;5Y)>UZ"WY'A _?'?
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M,XMVT)/J:-N/1R0W*:!6P3)7+7Q=*,]W"W8>$' ]7B'-</3J0$-19GXXT\[
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MBQ1?>ND3DMM>M.%$WM ;XB$YP$GX[Z"8$?NG.R1_200" =VG>8R>GOL:P7<
MD<L3LY+!+-D"*:KU9]!&+E,Z-3S!WK#!GL&=^,^-%:C&NPM?*.YCSRJ-]P>8
M=\^' 5:W84A-4]R'NDI7N126RY3%C#8_@X-:BY>)5I1Z6%&BU!$0$7]RG)#8
MO6U>UI<@)".&6-2 #KZ%4*()_"($.E^Q7J*$5)(FWD=GW?Z:;[7%@'H3Y3'S
MU[[TUX@%W^ ZC:$O-&H[M0%P4/M<-KSP:='88I 0_[-#;@;K\QHK\X4E\_9F
M3]VO;2O6UG(6JC#=+G(;V+S68%;+XTE9B9Q"_N-/7EPLYL$S?9=!TC,'6V,>
MC\M@XQ"Y=SM3F"9!?B^&SKN7AJ2GR(AN*BHL%#ZP'WM)HJ..-93B[-9H/1[7
M;2U[=AY9B98%'KCTX*"($U):H[V@##RATE[1+)[V%7R1_BH\_MFJX2&W$5G3
MQ?#0M2BDJ5^&L5;T'3_WA,OCH\U6B"ORWMENNA73MY:WGVV>^R 99Z'06JJI
M>:UAD"*,>;P,^4^Q#N]-/_YZ*8V8QAL7PR,]K\O6ZICW0[SQBRL1[U^K',]F
M?*Z+1NVX^7HL>JC9U/D2C.0\[9'J21*EO20XY\P6]L5(J"4^*_G+0@!C\J-E
MRD012\*N;*D?-GO,B-.VK32&Y"V>SL5BX/Q<U7CB UG_.>):PTN["$J4]ZA\
M]!69L.\0,MNM1M!VZ.S4_%[KY\1]5@:F;VEBE3_XWY;167G(6</)829%VRE$
MT[;-RDO81BXR0I-#V41#:3W2G:\BNDFC:9>DQ6+;>L"4R@^#CN*ZG=@:+5;7
M.;1WCK10--D5)N8TYH/TOR):;81](UZ\L H.;1I!S6B'QG6HO,CHSD.M==:N
M+OX9?)N4,_R" GI1XS+OM-IPRW;."GI7TQ3ZA#X4/"4ALS:S@A=1+T][37X4
M>YMJ(>_'-?_1F?2,A84W5G9FT;.^B9/X=>]1CV?88'!JM"X0>(X#&,V5Q$"<
M3<ST?RXNLTAW_^CYG*<1+4ZW,9"/:+4;"/SD^2?[HZ$\,<SXIZ];,CP($,>"
M<=ZH_WUXV(-@O+Y!#K4:'.ZZ.6RY]<'[ZF+X]HCY'TE(Z=^R8_W[TG\+#B/Z
M' @4K\NFGFV)'& (!MBD"F[=MFL903N[R%M"</R>5>4/)NPTI,[FUE\K5#\-
MPHHTPP^W-V=&L4J1II*XKWPQFR1H ILP,W8B'OTPL<)9;(X;3'S:+6, 9U,*
M7VQ'\1#0?FQQ>>!^Z"D5Q7MS(7+1]L<[_/\DNZ&Y7OD8:'([+HKKR!DNE6(%
M7\GLB[X#OMO< 2X8EYT](GA-<A YYQY\N<+A6Q_'$I 1,3XMTG8M[3P>Z=K!
MCTAI_I^=2PU"XFN^E3IV!;/?J4.,W!\6WJ_\1%TAZ[U(XX*R+W]D%1J86SX7
M&X@8&4&M<<2'7M\!-Y;O+U^X#_^I9;GG#B X:[P#_'HUO17,1#Z.'>;4I,C1
MP[FK#2'UJG,;.E8MMK3/T5ZN8R617_%32@>VK3_O6R-$P/D]J\S^1+ASZJ^9
M,#]H_3\D^V6Y]Z1?=@SN@%[D=W> [700?$1@VM\6.?2\4Z&I:FQEW#P',V=1
M'&O93#.'V(J)4R*D+6.+,51  ;7LVZ-#$3@?\[5@_'#J\+57B\O8C<X:IKS_
M%<YY]6)?E$)+5\WH0L?4D\]F#I&?45VL&8)C/PE<X3)#P[KD)&F"1H5"FWEO
M&)3O:]\/,A8"WSZK*55*FD$;5MY@X#V]_0&]M_.(_I+D+H_[RH-H<>9M?IHC
M!.UG,)4>:F8H=DY9G!M3,GV<?-A'J1384TU0]G?T+RIBB7)]BBY%!M!!)YSV
M4BIC]3C_9=EI^-Q<IGJ1XK-0),-R*0K\T2UZ*0*6.(:D?1K;$=0*?_U]_CN@
M!9GZ[?+)PAVP_" [C *\+9^& ?]+$/8;:K_>S_];&-[^V&;KV'V&2+^)8O7"
M7_ CY)#"<:J6UUW?\?1G5:,SQ;>OSX9YYGWJOR8?UN,@B[5I!.,:(BX(#]/=
M,VGV#O# $!YFNKG8AK>5HL&<UW!PMY?QA=M76=\XU)I@-A:_ETWL8ZP(F((H
MHWQ-OQT@^EQG2A"F(&>CGMN-;2,/+?4OR8(^ZLX)+2V8G].XJ7RM1<HK15H%
M<))^>^&8^Q+J?4\;X:1KP2S=H;X[P%+QW!%A.'7ZUE.;S>CJ(NCPAK?0-5.S
ML:9YK-1LL2AK KDK;=!<L)0-W/.8];'J:]$>RW<LDW!LV( [@6QQ>UYQV^24
M?)5\B^A(#V\_;B"M\(HX)A:U_-+/#@\AWM^(4OPK+#RU&HOU8/F;%X+QK5OU
MO^S[:QO#WU)QBR>[O'"^IYVVW">U@4U2:R'LJXRQL0YCB?.+KS8Q2><V2<9C
MA_=*^K1P'0JS K.30F\MK41I1"_Q$5-%4C6]PBK[@QT7G$R)5MU1732+Y IW
MK_2+W<&?O.:^#T2I-?KJ@RZ)+GHB)2V58I0QDSQ' -$2]W8X,U3<N"$GK,@X
M(;I2.)B-78\\N4&RMM40(\B$C_%U!=L*41EX+2D!N'JQ=XQS:78'A&(H(F5F
M_0IQ)]3QJ\,DBS!0I].Z^H_:BYKI6N4'':"D?L;R=UV%A!3FA*\;U<5Z4 [.
M]K21F]ZW,!^5'%]\6 3U(7=W+P1NJD1RQUGO\R'B(]3"K&JK 0>M_Q%<_RS<
M)&L<NG^4.7<$WU[<FTPMSA)QJ47[#O@:M4KH5).>U5FP*%/4DFIGY3+L;&X6
M7CSQ^87Q@K],0-;'AZBT!CF&B-NME?VI9_<=U]USM?5D_@Z@)%H5QH/YV*!V
MRE,L+._R\N#D+BQ+96L9F\;QON);D63<8WRK:Z_3XW: OEK/RMLCS'P'^(#6
M>IN@$DM!A4:*\UJYB0[8\QE<+VN*AWA6)=_;>T8#GA/DP)4A2"#T$>!>]Z0#
M7;0MR1.^4HH(2US%P8,Y=*TICW/;"&4O^B5$@(;TCEF[=/2BNR_<U$@Y6QSU
M,4?(SY;]R+M;:B&8+$%Z=2$$KHVL$QEJO#W=I/&H.)%9!U0VHA3_SD!(6DE)
MUV.C$@ 1]L:<&JAI#)79FU'2)VP%E9N;CBP-2P3VUC1,UOGDM#+JYGX:7WN&
MX:ZE=\#10_FCXC8.65%2[:-O]WP<OE_AX C]<$+W#MW[:"@\?0? 4)E@RON$
M"#YW 'I(ZLWUO<U7*%,A4C>/>=Q/]MWO.6SM[F,^^O]"#Y0;K4&F$[+P,-<?
M7^\C<5(JY,-_Z:2X].:^^Y(0Y?O"'TY (7)YWGH'M/&+=(3=3^\.V)J[ ^X
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M3K70<36,4_AND[NHD>%?FA'0(=WO]68EAN\3.BHW<EA/,>=U3YPPM9SP?9;
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M9^FB\5$0=!+F)UL8'R>O)<ICBN?(NSIS-VC*/+-Y'4!H1B=JN8=)C4XGMJ*
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M'$$)]S07L4:!E(JX!+/DD/6$I9R&Q$608 [$Q?=)L&B[+%O[C#4?TC;X>.X
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MPB>-(;Z'&5',G8&?A61^- :;+5^K[:]$M3]O-Z<CC<(?"/=MO].+G:->@-/
M^['@O0>CR0?W^[Q^LTSC9+ 93UJ$QKE/'B)F.Z;$%^QUAKO!6>;ZC3!Q1FR9
M%%4T'TDV;B5:,95SSW=%[YKY"/QPS@*64YW$YG@M\N&<QEK$,NHE]3182:;%
MO74E/\_&]#N_D&3<A,[:-YH)$$U<60Y2PF#:O#Y0:93GR5L/_>M<%CTY>HM7
M=L<^K_.$(WGJX.W+-F4(KD[8ITB@I1M^3N>.CO[.2XLCJ4_:J^QVOL@DF(8Q
MYEQ:ETJFIKU*F),Y9:6[]]=;,S= R5&L=? !W@#8R<ZTBV#.U+=XWC/[8+ZW
MZ_8$O'76YE;$,NZWB?(+>4?Z;/JO%GBD5<LLM=#P'AI0UKNY?W,V8$YS>HLT
M^>T(5_=2$/^><1S@H^\@M=ULI.ZN]V.4X(3(4]3;<2$&2B!>?QWL99KCT]GG
M!9:47X^/_$UDJM0A=W>UU.9[L[<%XXMSVHZ"#O?WUBS6PBD*8IEQ,"*\N!2G
M<G/Z%KZ_9ZYUR,E=M!O:I_F<8$'1\WBJ<H%X:I_C9)>EZ?E9UZ[J"[;G]346
M2: .+&:<M8^^W<7NS@57KX$WE,BZ9?!=H-99=/\*#>@4[[EYT(-2XUD&^:6(
M&3+B#C5_*-LXQ'GC*SQN9[X-?R;G?,]U"CMO6Z'274N\"$EH-%JU-I8WZL10
MEV8>,F@X) 4L+1+C+*"T]DT3!KHH(^4*%I 274DY;<-Y5@N/'AW-;9W'[S\N
MQ@RORJ8NE1X/"W-9*9C.C;$Q:"'6I*JP$2K9/>%__'L,EG1+(Q56TA\BL=\C
MTE)SY9PRML>#F.)Y3#:%$C0POAJM6".T76C(IO:Y99V2PZE5_&2_^9*AXDM*
M!40BP[RK[ IP>6,G$MX6J<6&5DSTWR<TEEXT-O1;2O=SCPQK?.FPHE.52MV>
M1*IETLK!$PSCB5\J.61S+M@?4L)2A!\O\06+,-ZVOK"I<(;T7R=/)3_KX #S
M<,9>OP5<!$DQ;6LW:E L',U* Q_0/+=B?V6S7;55([1J_N2W(UFH*M(+CJ&.
M]%\&<1GX=0@R1M\KS!>)RVLM&$ T#?;Y.+.3^BA)O[:L-JHXJZ/Q\RH$NC>'
M+NMY "].*JF:1B7LG!YY]HP#(GYAKC+FK+Y@'$^#/2JER(U=<]]S\\;.R)G=
M8_%H%<&9O'F&3.L7&]GW'\IS7E>EK'[N@VO^29A,C#[I%P+2UI_^8&X;_@OH
MKARZUABW/R9**#]-3%\P2<GK=T+GI]O7Q-\?W?2.+K#PA6"P1>5%BO3HUDMY
MWU]:X S4$P1C WD(*:PZ.=_50_EFHG;<"6>!.O@#-H&IFL#LQ"0^>/GTQG?)
MB #YX\##J6)Z+=5ZWX]$0#9B*JKD%;D+8#-)N$K$1F_WMLQ" Z(6J,HCN2+B
M6U;! ^M_L'\37UO+'1XHI:O\E<[8:2H!L/ -]B3]J-0"6.J'N:._V%,:PCXE
MX'#F&-C&FJ$Y8&@%^,+ -'[Y.2/_3/-.!<$=X0"+<'<'D-1^;5Y@L:)4GRAQ
M_?'+I=_.VK&L])%&.N7 SKHQC@P@HU0]L5[M*Z[KGRA;O6KWLT)R;VS$$__]
MJKCIP%,%X&SV:W$P3W)A7\;'KYAFI<+,U]EL'HE7S.E]?V:!+2&L%8_"PF1M
M(8%"12<019(K77ET&KTPY03[>Z*Y*>?4+*-=<M%/XWLEX ,Q5N/JH-ZG& 4P
M@95(2^P)I93Q"BG6/^9!+!&24BOT0Y'2IY *G1CV3U>DR4^??@SD;T/X#;YM
M)IA>&S=2B928R"[5_K*QS:;?02?0GM#%"W<;Y #B&:Y?4=74L'"6"K]4PM:X
M9BF9]J:VHO+J"@3EN-T\;YSDGIC0Q,-[V=@35U\R5F<-<9-F&142OV(WLM#5
M;+)/JM"?M]3E32W$8ZA\KF.XWX<C-B2N1J#LWJ>=I%(>6S44XLI\RK[ZI&5Y
M^ 'L=^]4TH_P\!LWQ1N([% 4Y3PT$(HJ#W4CL(TA%M'DW[+2@%>7P[0GNJ(A
MU\D^B]977&[:;)5/D-UL/S>A9#65_E"'N/'4?5,6C!%5WRT6^]V?"PRE39^'
M=MMAQ55KB$3CZJ0AJ9CW& S1LOT  ?[\$L]G4!TKYWI05V!^:X$!8.K,7K>^
M_Y7P??;7B_XBKN?46:I>\1]!-%]O\\@)![DGU50C1PZ241SLYE'DFK1@&1!3
M;</.!A/@=3-SCUW,HRUVP%U*)U(HT+=$;%%E+>J]SI[J-W\6SPNNI[2+3K%+
M&N(I&'1@NK:V%.*Q$-&1[/AY0MK /\1_6@Q&2E8-[[E50?9 $E>,Y!9K+5<L
M%S@_EPH\/SQT%8F;1DHLY4)7E.^Y5G0DV!EL\PHR)ESG/4AX9$/71/UY7X;_
MR7&TDE-!J^&[]_#)'_WQG"Z+!T*;?QBA8!R%+5*P%#!=;.,]ZG3]/<G1_;WF
M6&-Y!?M2WY(U&N"SR9.8[ZJN-X:5V#)ZBD?D;@<\2]92%D*T??3LCOYYFOOC
MK=YK ZIHN5E(XM>'-&U?96+$*.E@3;3+T)\04E<T8(4M\HN-X]4BX9PRR=R@
M\.G7$&-_+8:S*#QS?XRZY]5"1E?"P\NT@22NY1MH@.JM=80C$LUY(UGM]9E+
M:3[6H0'JM3&D-#FV7-H*E-(D[^>JS/5?H]YMU_\0Y!A![/T!X6*)UOJ;N(+9
M[7,88XXYQ,$/#!1."6:=V:["Z46Q9)8C:5=#T0!"5S\=98)%*7#FA<D!=1"-
MP(UWLDJ)'D;LE@!/1;'22UXT(->^2/@33-7],>/O98:6WBIMH(LWZ5%NB/FD
MXUEU39K"%H@AA$)7@[6LS%;$AK\;N\I\%DG>4>/BPAOEZJ&1M@/C25K!V5LS
M]Z<PT_'!])%YFE;)7&JU_25?(ZQ.W^G5F=\OM0_NWG$V[0H-D]#5LK*JVJ:F
MN.IN$)C23?_JQ4:#$16*9DJ(-A-I=;'44%<[Z=C+\Z9!N5Q0[D/!L_ O6:68
M]DJ<24\LI/)K"G%4"OG[['39AD5O@7(+P:E*>%H=Q,O2#)1E1<Z7$.UV-@6'
M-<@)>:*V,LP2_'H*','W=@4/0UD;>4!Y0_7KDWTPAI31<L$>2"-.G^]$##_@
M4D,P2JOA5YQT5M7WTY'?\'=;O$P!6^Y[&BP?4BP@=;WN7J[J5;'5+XS-KR]D
MK Z\XQ@(Q,8?JS@AQ **,"+,T@.LBQAN9NOK'A58,I,Z>5]UO<X@D*/+4:[.
ML[$!8>]9%=@?[7IX#HAEG%&<9L.$6:82SL (22K""*:&JOI0/7CG?%/9V(<J
M-UVX?*=D],/7ZH"HGQ]"CN=%VZC.RO+U?VE;),6=[I=XCX+ EO0Q$GY^36+T
MWCRO.M22;%[SI)$0*7;*$QJ$>=["8G3;0*O],.!RN*.%K'7Y^MESA1EBN8_
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M)*3GU+7B1@H-.#M")1XW>5'"C59E AHIX6A 6Q(!U'$0S%B5+U4,PS0-%]D
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M+B!.P=)O]"+<"NMI]VF7O!1TQJNT&R5<EH!>?)TU29U=J2"+ R>@FP\.M3D
MKG!O"[>;YX@L(#K?ZDSKO)K7?EYWN\QM.E8R4<&1Z4[*&>5IT:J0<463^!.W
M;;GU;R[?8Z^FP8H0)7_63>)B)BSD^>GX>HOZ;76-[SU*@S-218NM:.<X?;=;
M9SHW7KF\XCK1)M2-Q'_5=C-C,U8!B#B7C^W6]%-%= =NCGX?HVES8W/4ZS&-
M)__&&6SD%J</P+&UQ>WT'#>'SW:XN*=N)%V:ZAC-6*(!L-C91<&?;7,OWG2M
M#HECWNDMT99[)!\X/^LW33,1KQ,0XUE\MCVMEI-BLFQC47Q8 T::;D7ZI#T;
M+1$%RI4X]H?6C)UJ3; Y7E3Q+;[A+JV-'##MI8>_.>(RH&V#1+C+M(>S+$O[
MY0-=W"WA-] ?Z0]UZ<%5&E]"*6RQA_B<]Z>?[*Z' BNP.M1FAQ#*)/<B9-.!
M=!A1XH\_\PMDIRWUVHX-OXPQMQ^DJ]8)WI$35G34^#E>S+AQ/<NP^1UX9,[V
M>*P8YV;?8QK<KR<Z2/O>U7PUX0O''@HC'UFC4SMQ:O3 *JFK!*$O?23'PO6H
M(M2;'W/_J2.UE#:\>Q]WB<W1E>3]1'$VO+I@&4RLX,X&<P._FTJX/\B%2V$>
MC//FC5W(Q=MYQ=,V/;V"),M4-?ZL]918'\ I$QEO<=[<5L(T+U48L8Z1GJQQ
M;74*R'7.2?-)N,G1#O%DOQ'2X^;3Z& 9+DNGGE*:_*(PMTB9422,((XC@*WH
MYFEU34%[B155^V[]4#)KM.[L(#4S3' 3\J;NA;?::Q9>Y8>N]J?> JY9XO5U
MC?!95Y-IV0C@#+WMN7V/#[WTN^J?JB$!FW>;M=BQAZCQ)DAFJ^23O@:;,Y3/
MR[+.M_?>[9&T;L\BVY+=4V2('PNO,P,;_?9E$N&52=%\'FV[W@QTXDPTH.5A
M9;*HSP(WW P-"&(:@1Z BZM8GI7+1"P30=S 1]?S:P"';J'I+$])Y/;R$W4I
MQ$:6^8I"D_1B!XRA.MEX:;,ZVG2,7BPYV\3['?OXY\:4Z3X1>RQV/?XMARY@
M)L+<ET<9$[:E)?C]9^FN,V[!S#>S8[ZV#M\&6D>X%% (GUQ#L4FO^;KX1IK;
MX;'D2WLIBQBMJ^D=]_.]701V^PW6N)G10V3G\Y&-6M-"5P65,?PU/@2HK9+]
M]2/UD<TG;Z85EVZA2_A3%*_8$\\XVT+=RKETAT^WZJ3%*H:PE/O E),4@\3:
M9Q5SM41P^LNVT7V48J$^\O/(+>!-&D<<QPL-6[T7U'-J[TN\>+H6M73#T^VV
M,QHP=_^,?J(?0X+H)1\;&I!SD:#\JM/8&">? <1C"(%W3RV0(L^7P/[UWM$Y
MEL2S0%VIEK"20_HKJ<37L.VC?%PAUO:U:-S5QZ@JF>7-#N@]Y&OPPUD@C>@M
MD>2U3B?45!BX@C5&%U84YF<;"S*^7G=;%YC8]8CJ7I@9K<T1O#^_Y\=J35EC
MYOXQ28$E9Q&BG) Q!=:18R++#84;T&YXF+<>AHM0P$7#*Y/[(W%GMQ_A80WZ
M'^08TY?/"ZEUJ<CV#5;&+:76'NJFX_$8!:;?$P+Q=-9$T$\EJ(]S5*Y-L57V
M/J?2D\WJ3=ZX2.PB<(9C2QA*9+C2:B"T CRE2K;+?L+ @<LAP VWM^6%S9W,
M+9V#'[!)ZJ1LE=W'=[[NR"ND[GX\O<@V?>!DQ4R0_2AB>]:L8M1RY-*9(Y*&
M%GX>WDQQBS*;X95^?))W]6,\:,!#_;<[X*=UIM%5-\[:73C#0EID")D5B#\C
M8B$9G&51O< ,%PVL_%;IQ8XOE^-/3<L=Z_F%=Z7CR'VE\48T #;00I#<5<X3
M5Q+ KCM&(CRB$)I(?J=#-<W(QJU$1?EQ</L!WI#+>]56536UL"HMO8O%FSM.
M%0^TF!AD9]X(UWO7C#MLI=_;7<"&3[=>FRQ*(\+3 QK-5V3G>4R=S(1R8;.L
M4N%U*F+#@ 8:\2+:F<@5)G\4G=<*&TDWB1RV_ZG%TY2]M\CZFJ]RC\1. =!5
MPQ?T<G=]9@ ?'&0/J?)%/G3; (WRQVU3S)@.16L[/W&%R]N'$:]I5E=/HX:A
MC3I7*JY<:K=^US.(F%^?K#*P&59'&(1(.A<YYZLQ4"[7%WK$%>L-PY3;LU8B
MOU11IS^R=(\,W*OR:)(,??)\A7(_7M9 YMO!8/P;'V:_Q^81+"MCRV*L8L-O
M%1G79QML6U??%&)_50E=C]V:VH5>6$= ]P?D&^2LQB^*(>2%(J5(N2L%W?9E
M?*5%0P1/54(H03W/LT)@/-<"P\ =WBZ_/F8)J!3^T4KCU=)A)XBOC9:Z47%E
M7EE%C_^0]90+:[*J+ES73?PHI(NK@NTSMO4I]%%9=?S-R@LV8SZN@05]U><'
MY@X_-3 *>,9<IY<C0T2H.S\N,(Y^&NV<>8[!E;GP_J-?90I1=)3;1N5E&DU*
M'@$X,B\AFI"S\WVXP*P\>!CJI9PM<A?E"#</1 D;%R#;.\F/D:DY353?K3B<
M1+_1*P:9:(@8XG2M_$SC+PD@#-+E:$^_BV*?/(60SNO-,'TYS#*ZWVES2)-K
MQAZD0!@%HO<Z$,-8:!:&Y_F?TE);J>E8OL3J[+#MMUVP[O/K#[?OIO=-P?!=
MJ/1T61:&M/'>/+Z93QX(U1BG:QD/A+W+!*6D9A NG:OJQ_;G*Q5_W7>I67"Z
M96[.+-2;V9)FO=TU+S+L;D)L0\N'VYRN\6!\(WW71\.2!N[4;I25N[5K;/00
MCL'/!'P$_'F>XM<9*!9(KNMZ93J1OJ%50C/-:%$1^T:-ZUK2 <S9C;+BW+7=
MF^=(Q=$:*XI38)5['=.WRZUK1/!*ZVW_B[R!9)102\^FV]2S[OC>DYT:1>^&
M=+6;*6_V\<56&HKJ\6+Z<6BCQ2BR1B] W&_#38'X)8V_7^UEK(X@[3Y&KBNX
M#0W K/QVBE<8SB)>FP0FLGR8^:M[&)_R@ZM]B^N=.:W0WUYN?,,&=SI-H7E5
MT5Q:GS9J5JVWS1=?L]6@I 2X.7 ]*3&@$#S0['ELZZ 4<2\VB\(HT?#\@EO*
MLYM(J3$/^(;!?-P<V>1M#@->R;O:S*Y  GA86AYMNUR2A1]DN1*D9NM+\!3$
M8[\_II(&#>CX,&=1 J8YEX9AA.UEV^F$2@W0^7";<<6IRJM!0UE#R\H+=GTW
MDD="I48V<4=?;6*JB5J%706R%S+;XC$C.H[5KZ/%&:C/=AI1C8,T+B&Q3?6+
MYNN;:U[1WV]&:/!&JD1Q9PU<2Y2)YF:0NL<2R1TN9Z]+ ];7-76>O'[<]9Z,
M_LFLV*#Q;GJE(^\4+1'->&?\XNQYTI.(].P=088O4T'[C\-N0TSA[H]?<QUV
M1LQ%T=PVDB%B^VDO-49+/5N'[21?UY,W'4*4SO=(ALK8='+R8O<2(-T.NPJ+
M, [)!J1XGK9E_51"SJ+4\N98%3X-&B"7Y)$<'.'R;4V+:+EW:(,2,U8=.;W:
MXE<%O>]ZL>=I[ I'1K8[3U%!_!?&I$*5DA@TS.;/Q46R%GF.->/@TX93*#(T
M %?8_\>\99ZZXA.ZX KN!/:&: W INC %-9I\5"REX.9$]ZL@5[?J"*F'SYU
M03L+H8HTX=AW 6\J=<^82=Y+EQ:3G*255>6%B'#=R^*XAC/AU:7T3B-\I.AR
M5V#.3LT^V .X&JKX2?O+NV40\?.BI0A^_M5BYR2F_9?+_5YJ0VB T21[54N9
MZ^6FIB]#<+:%XWF 9(3D_ C+ZU2_L68Y9]DARL_1AR%&/$JKC1^<-G,<W_?G
M:^9O+$!/!;8__4KB7L5A,%M# P:NJ AA;Z3+D,G+A0W#Y);U <'&X!^?#%C>
MU55S)F9]"'X6_:U'X<.2;?:G6C0 RWM$5SI\.?W+Z*Y[^%DQ>_ *=?^U(4S:
MC4)R]9S=H3V.OA0[E^6G)\LR2*8K87S&\BZNS?.:F'74]A@#T?<#<&(0Y<_M
MJ?('9?%MU:2KZ\/\/"FO]T3*6M8W;SX=\G7R#8-H$Y!ZJ.@S(32@$ARPBE@(
M93@/X9Z7D8\0EF.#GJ3>$JYC7FT8\[LNF4^?=J-2"+[7LM&MT(0;+RD'+1#4
M(U/S=[1TBU.3M7?/'^IC)6F'ND5E]#H]P-%/J]L,@=\VDB9H0-=EPW;]VW8>
MF#A#JTZ>;&"\GX/G@)B0\P]86F2^Q1G,JRO37/@K51BM147,QU_LSX?X\O*'
M*4FS$HQ7+D@;G+==9GO4!NW4;3SK@8L_:AQV#.A6 ]NO3;M(+!;H)G)$<"8\
M>;);'9C;.CHAY@$ =JZTPBCF\\\M5D^H#FA)Y@RLIFBHI@\\WUUV\+F7)/-,
MJ,UBXMZ_0W*/("3KOFLK-+(7YFI=NH-MI?R:+HK^P;QSA)P &K ;PA2G&E.9
MO9^W#1W.STQ=H6.@3S",O"R?6LBK1-$A$[.0D%6.D*I44]6;?C_=B@DVMM-D
M/;5'0VZ^,X)=KWO>+-ES&::@ 52-E )E(U A2Z<?G7R^!XT\+BMZA0*X>O')
M]F_R6+6>="F_.X6F"GG!I[61E@[&YB5-7[2F-5>68+KSK&,_B^[<U:"UC1)O
M+9'+#7O@]D-V/ZE@:6M%MWBP?MPFB7)\@%-;NY$["PH45=]C(U^M\1$2+I+(
MG0&J*M]'LL^*U4SSX NJ/U!OYZI@+7M&0.2+S>S%TB-DA]  HP$63VB[C&#5
MET6Z7IVQP@<)E@S?Y1Y+@N^'*:1_)8IQ@PK!E7T]Q1&$&H+@ ,>"JF+QYUS)
MKIQ1(6*L]F(_>PX5+)= FL=M5(?!MZ7_V(E"/ANX\;:\CI'O>'I?>&(CY96V
M%5?<PL[0OA,:P*5;%\!!AI-#+<7'8#8)1-)*6:63-;+E R&D>_O-] :6X)6&
M0I"$(N*U[I!W-['LT-1'PE0Q[!^(I&5/#T2DS&2+I0%MMZ#Z/,3,LN81"]O&
M,+M')@X>:P>!?;L0C2R4T#R(]-DT_@%+YH@0X0^D7[LAPS0K,>W>(F'[DZZ,
M8<:N]]$A):,H_1"Z+UE2 G6."H?EUP_23(,Z[-LXIU#S[KS#&8U2B :)L0_(
MRDO:<"@'%"57^,MH>_K1-K<:/1[O]K/>-4SU"'Z!E0;Q*SE7AD;%U8TQIV1\
MQE6UR:)3!0,C]7'SM(5EXGFBB2(I_5>V=FD$2E*>[\<SS,"OF--D^"]O*B=M
MA[1?+]DKN=]/-'/\6 SI+T<#Z&0W-;:;S6B;KQ<OTJ#?76<8D9L_D'DW)/?@
M1>/Z<_JZN]6Z#MR,TD)@/_J@%)(H>S=HIA#;*AC/M<( &0E9GC=P5 AJ)"C=
M67@Q;DVU(, A-&03<Z<'0".[>00-JLF/I<1J(M374EU& ^[O3B\0(F2"*F=0
MJ=2RVL83U7,4,U,ZO-_W:3UMA/$U6;#EORLGS7+L7M9$4[QK*W[)TS_HT=*>
MMW,N$H)PZ8;@6"4QA53V. 4[L<3#;R*S97X,8F!/?JJN.V;\ZM?3=L+6V^F8
MQG.=ZTWK&KN"'=@H03978+Y\^+"J(\F3=W_=*JK_H:I;S>-!$M-#!_^5YI>O
MOR\= &A2IJ:_-/)XK())+=,>CS7F350)=#SJY4XF2@VD% YL^G#4=U_H0-G\
M O*31Z>+'1S-ME>]-WNQ<^.E;'"=??-"U_6H7[*L?/HDW'EJ;&=CG2 Q5]EJ
MA"4-H[*H,]0\BG_05>5JTEQ]?'.T2J$?SZ?0P9)KMN_A&K8T\R_A"S(=]VEH
M0!85Z<33@TAR\J TYLH?[S5-L]  /<*K7=3N.9XD&A#%$WEM&XD&B),A/6@O
M?T$6C3:-:G694+Y%D-TOD$L<:/2*8H'G\ C_FQ7HT;6"S$$2JO:Z"0U86SN-
MO(3_\51(Q-^?"C%T(40#FD7A:$#TKITY*A0-V%^_X-ITOZ(^@XROUB YEYXH
MFL K'^VO /.KDHN]GAW3C_^\)QF>_?BLY_%)EP T I@)?@B$M?@[0A\DQ'@1
M+YSF5-00X7_?T']Y!S&!:.4Y0PZ\Z6A[I5;=DB7ZNM^.LVWRZSH-2/2]%T.A
MZ_A/0=& 1JQLF.X6>%G1M,-EU&JLJ5QX3M!JP2;(Y@I1@&GO]M0TQS%I./1D
M&-<*9I@#G4>*&>FYPN:0W@:X;/.98W(LSV(__#3(X6S9Z!FV0FX:C' TLA4O
M6%Q69?VRTK0VJ:V)I<XRGBF;SD?M")-(-",("L&YVYIJBSLD9=K%H'&''ELE
M *UR6RV- 6X7ZM+K!@(7)E3\-.YGYWAZU=BR=,&U#Z+3'XOM;B%U>B+K"C9$
M>.R\$HDO]#)_8+]M-A<>(UAI%GRUA%HCBM5I)FZ&"UU&^$P[WV*HQO-M/3!4
MJB[ 8J7ZBNFI"( 3O-TUE\:R^I*-ZB4-)4E_#"]S3SN6-HW6KS#-KN0E4:)=
M70^C[1N:21Y\88E/!V-=<L]^"J'Z<%9;<MZ5_[*:5S!"A4: 7W+'L32!I\Y=
MIB5VV-YT7M(&*?LX-:0RM5VF0<U6\'4'BR:+BV1^36J+IX37&=Y/H# 1/-:G
M#5X=O6V5@6 "EEU!YYJLU+>M)0>8*E)WV;7<%=8C7X9$X!$0KAI2H@$X&]GC
M,^+7R4YGR>M:E8%[>S3KRO.<86:^FQ3#\GH0_!V7=&L%T.N#S3UYPWWC:F?>
M'=S>J#M'2W[38_7//H>_%'#8_M1\GMFO3LL\5S ^R7VSOGTL\A..'5())44I
M(JKVIA>HQHI.FJ39!+N5*BK+_,TK=#Z*F"?R/\W'/)B-%XZ\6_^$27)L#\03
MNH@GLXSG@7/SO/=!@GOY3V,JRPC>Q&<NF#2O;1M7^3L]GYIJZ<=I&A(0X.SK
MO79MUTQN'7755<B\]DD(5-$3]EM/*1F;V4VMI2AQ3]1//F?*#5V+2!+H(/6Z
ME+]LNJS800,(E>'EBA[MK.'?PQ\@I[6!&ND?5'))SL!<0D'O4OD\FUA"KG.K
M$@]O\#T%RB8/4:(.*T"]:]E%\>7MYQ:KV)9O-3F^<NJ;8V#O&OT_U+UE6%S=
MUBU8"0&"!W<(%MS= WGQX*X5 @0I7 NMA 1(< D0/+A#"%6X:PC!I7 HW*E"
M"V_>V[?[^\[Y3I][^W8_3S_]8__8LM9<>ZPYQURC:NZ]1>7H5L+6,65L;P6U
M[7'F[:EH_47'M/ET2FEB_>HA.9=W3_N*0%Q?BS5F"_]4YI\^\.T!(UJK1;1P
M9WQGM!-A6NE\1S?OI/.ETF5VV4CGPRO!C4S\FYQOHAE5KQ! FMYJ,],1Q"\9
MS55Y@(E6U?$K%YQ)C+L+[,->IB>V^ S<&_+/T,8&R+!UBJ;>3^DN0[TM?@DJ
MG,!T3JQU=X45XA&8'9E>A03+90CC=&VL54XKSAU#SKK%B2GW1*F:^>$M4:,M
MRC(EH@1]W1U"/G4C2G\ #_6>AC)5W@UY^%-Q"Q!V.TJKKIQ)2 R]Y:T/AQ[-
M]AM0TBR%52SV(PI:?[Q)T;TT_MWYR>F[_Q!SPJ!@-T:T\8 0VMSP8]=T^GYZ
M4,*VGS@_B&!3&9ZE;(HMB8\MR\WQ'NB!(=?=JCBH;W6@58XTXO-OR5N6Y:7Q
M-3X\3#O/Z8&0SX"K^\UB*X/+MBFO\!]FRE6^EDZV,8%?IN1C^1M;N;7CCQ-9
M#9NU-VH>"'-(Q%67"O^GD>ZDE9F^M">*+*7W &<7NLR0BY#;6?;89-1<6;52
MQ^D0'V52-.D"D2NL^/RM$?2@?L7N]N?Z_%=QN7YTVBH0=X^&OR>.* RY/,,C
MPUVTY)AHIO3X]46O\1 W\_%(WU-Z;*<31@QPOS;2;;^[?,B-\(OX%[Z;ESSU
M3L]41'N,$E]%>!.< )[*"U1C=<5^I-I1%Z 2$U"AKF1*[1.YS<@QN%O#V8SU
M"<X/G:UN7;B.Z_.[HT;&=<_3PJ9/98UUQWUBF /QT(@:1>M?I"(>?XE_ZNPD
ML5U_ER+KI]*$[D5I&$S9(L^;JP;)A-#V=HL%JN<OC$X$63BC-2:DCWO\=H $
M964_N/)9YA+R3+'P;1B^#7E5E,V=W /,( D3M["?YTZ#-^FWVIY--,K-UX;S
M]M>4G>E!\#%HD7CD51?.$W^;S*?S'@<QN7&PP)'/14C+N*@6\G*-%Q_]2E_E
M@;Z 76F&>JH2PNM)>9[_I2;O;2.3,!3$-<-"M;//24P,^>1#]VBZOOR#CX6+
MW@ WW:F7DIK6Z82G'WP*DG"N$GZVC \N6NY*/ZU&.,@$!Z\T=SN[LH32VDT:
M.:ML%HEQ?SZI=[_9&VX',9+@9;DA6M?%FY0.BXO!(8RP>X#-MXVZV VVM[_)
M0RQL@Y<B)K#:@EG<.U\J["6DDW'ANV"TD^D-3DF5Y6<=0'I\:H&.2N,ZZN=3
M<M,/,78X\NQ&_=F-!FKD\S ,<3W$!\&0WFZ7(=H<^NS7S_4HQ64%82XK0455
M <3;DWO:AG+:\YK?%D;7771,BS]39*VO^[2<(N^P\;6?;-X7J5(99$(B>"-W
M>28'+0;Y,%Q>[-R4\^\W])JJ]QU)):6V/KE8'M%?"+(I=;QX$#!+J?Z4X:>T
M#D'7IGPB'B4]Y\+JI+QM=KI4BWWN @2!+UK9(]H18BC>Z;0RM),;C38"FOJJ
M?M+HCT+Q'WL;'EYF(K9UG)@*?\ C(%G9B\5<Y:755(<^,7Q[5N)I6&GJM1)9
ML:NA37K*N]R1 ,<3Z5.C4[D^%%_]R@R/W NSUJ48^BEXQ*G$&72<GF1I]<Q5
MH?'X\8H8Z9-]\HQKO=T[NHR.BY0 BJCO?$GD&[4.5Y6Q^<X3K.:"-<]CGGQ0
M910[5A4]MIJBIW25Y10HOS!VI,-W?WDU[3Y(QEI\('8/^'"G#/.*,,HLO1:I
MO@=@WXR4!Q&LW>(>(8@ZJXG0>1>ODUX!22R42LV&Z.P2,;$'A#P:#=H6ZE&$
MC54_\7)PU2K <OQ?2-!2P<%!:K[3]AK'<G_JF"F.,3L_8\[8SK]?N(+WS%@@
M!>?BF<N2<0546*B&R(5FAK5TLZKFKX_NK.E6U;F$PN;40+/F-W&E[;5N-Y9Y
M0:]&@S1+P1SHX0NMFL3._7=UH9@Q?)D_+R,?8\^/T!W,<8\_S^B*6-6.=JDH
M0K;&IHK&9N8@$[IY,T-G$R>\2D)?!OU:B/M61"N*C.UAP5396(;/C!^\QB^1
MV!;LR#.U%\N>T$:['7-1-Q6UAV?< R(>E,3\/<#>J["W!+W=*Q<=9)9N$T>P
M  +1S*7=+&>]3UK'UT]HGH17@)-Z0\B1-PQ24Q4J85NHF-1/T$N^H&_/4Z9@
MNDPG^#@QT9VJPYVQW&OAN!VA0D0E]P"9ZW&$6*PD-LO,6J6+.:!LTFL+=O"@
MC*-+WK4;%Y26N/R-^3T 8^&.QXFB]%IIFZ8XK%K$DF_7W$7LS'6-(T77BNJC
M*M -5]S]Y;9F8,B'7+1Y3SOU#4[9;@H-;TZ,:&",TEDEK5:[I6*7[3%=5-(D
MBS!A%H0+[1XV_UX Y\!<[AG*M72%-V39?+1*,[P8X$&WFUL7;EG\$1ZJI!34
M9LA$CK.;')F?KIRYP=FUJ]=X3I'C@2AQN^%EC"I"1J$KO5M]7 F3UH/37%I^
M\BK,?UK.:2(:,I"QJP!K6*)9<F=GG&A,49;5X2(U):T]"2UQ1>4Y4(5'[.O?
M;!.QAR+1DY\\]U>$A=VL8ZD2U=A/"CK8)0:&O8[V3"%VBYQ2Z?> [GM &K2V
MS1:Q#^>_$0<FG!,=$/'_33,0:S!$%3EIICF<:T_XI;*SS-RU7N419#(/AUQ
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M9BY,=F4[[72)+(H<N'5<#QJ,MW"7@^'=_&X,R:4@[*ZK5:#+->M/RK_^*"L
MCB_P41]&X<_Y6EBPN^N XEW]B#2DZNS38ZVRN4ZK&_\\S3MT=<H-]UJE5P<2
M1.R0FC.[9E1WS391X&2Y*OD[G(4[,W,%+D-,^83CUW;@-/'O]<)*36*XOF0Q
MV^'XY+6T(:HZ_/!.<,>*00!L*2/JAE#C,]N4>(.E ?]IQ[1.;_[\3<#UE!?*
M;.Y$'4T<7+JPW=0>MJRIR6A>Z[ "^FP?3S5PC&I5C&80$,+V M*7Z @HJP#[
M*G92CW=H"JMR03"^RB+3-5^=#JG,CQ\/,9U_]A:W_[QE_/OIQGEA5[6^@7M
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MGK5J]]"$)%/&!>G[R=18=!S#SK]6LZI'&M W9^NMU%,];N.*W5R5L*(J2I$
M'OV52&YT]=[=L9*[Q2'VCR'6,Q)5W8,=DY;* <_&G7L 9OM0?I'D'T>8Q 0<
M/L!].W"[U1(DB%8I<H3 _)'LG_?S)J&!@>6__I!DLHX]S<IS)2I:_MU*BF /
MOV, ;W7-U4?> Q 6O:66;3"&+/8([\\A$^?2AB\QN%K*#'YYODZ3D"U?UX99
M4#]$/51S*^X2M$E_*WA1F_WUQ^*@4^]*M@E]*H@JLY0%65GVAEUONN0P$>A[
M#_ ?>B58J*)MF^[2WN[6<-7?G4,80K\;0I#3=_!=P;$8+:3Y%FXT[CI_D>K<
M*,9LP9CVP4Y/85>VS!"MCY!'__7$$ZRB"<&6_ZA5<2<AS CER]-WCP'Z8C&N
MSV &Q?/1OTT435&*U<-/B&"RN/JQ#:$!0O^@J/"/,SS]_)5?U<H?;I%'#9;M
M[TI#@$C-%)"*GU+P("P.]N"5E%UW+,CI+R7!V0\^9'Q-%'$@.E^ZWM,DE[DM
M#\&^[F?*R-1OL4%&(7Z@ML*AM'%/%L&0UW+/-0RG;F"AP^?+@V]K_-M U!KQ
M!7+8%G3&O;R!TF[W +54_&8J:D)J2%.P"HS$:D&;A+5>[W?-/:#<E/4=SNG
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M @M"#GF1V.[#G)[!CAS?^=^P9D-UE2B?T7#DQ3^2S(L4U%KY[Q_T?4XI\V!
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MG^T23\E@D#' G]PGR9IT"*(UA:*T/[O-71C43L-H^PQ?R0Y!JS8,,'43I0
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M$,A_,GDEKX#&0VC0$A&!FPC>'EK*;5Y-:-2I@ >SM ^*./VX.;$$:=QP55
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M=0D44T<O,B;N6TY"Z]IVS3=F*L I_,?$ #)/QX_!GL^Q!<H=R)#BTZT>^#<
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M]G-IFB.^EPV46^J43K0*-T"9^Y-CFAV[F=GQ7#?M[SE'^1QX0ICY/V\MK=X
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M4"N<%A]%OTKRX;9TK\#N_EF_!SIR2=!B!XI8HC7[!>OL+%I"GF[*^<AI:!E
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MMCH?FU*!"U^*DXVZDVT;:F\+NO4\]-QAB<5;V)H=YA9ALF5HFR9ML?:SB!M
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MT-8!>Z+F2;R>KJT=Q!^9KI4Y$M-?T\IFDH/0E()O9*[(.[Q]6&!#@GJ:9'N
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M+THZ=ZTY:YQFFOM@J#9,?]B%5'4TV,$7Y@?JWS@H2?B.W@"Z"^&&UY@Z#"B
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MV"$K(YT\V=T  A YY20> ?YFE>&/OS$X:%LWH.."#LX)<'>(]:DN!)O.1DF
MKZ;Q$N 911AQQTQ3/TL"/+BW(H[K0DH '1!BP3@_>H,]M<42X*.TE5;VSH>)
M,Q3&YR0)\"K450*\0XI/6PL/:>!6#0,EP+J^!&CWEWV54\N&+L(1LU<')<"R
MM-637@FP36Y&I)!.$5^2 %P:,.M?%B-65NC>T# &A2D28++J_WSY/U_^YLO
MAG9-^(-Z9(5=@$X)^<K3JZIC]8$4SDDP]HY)84XB<.0/; 8C]>V 2[T$\#XA
M 6;5@I#450F@,$N,SL?';,DHH!5D6 P.U!]( &F!Q9/=Z\H$^@8W30*<P6=2
M)K)AVV^)#V)V4@E86]?!_14]MW3JO+3[0+VA>3#-9Q0$_?C^LK/VRNB5YBPE
M#EMX2'.Z]EKN;(RS!*B"%[B]6B>SWP]T0V[CZJ@M$J!)>GN;B;3OK=24:0EP
M2U0!K[@EYF?P@Z9!V-R/Z&)F]V(G@^4X=+IAV^K"X[.EAAH8QU&K&V27CV(#
M M/5S/EGB![.>1><:PF@DJJ7R<^*Q,DK 1+ ?[E: D1VK?,NR\^ZWC>/8; ?
MF9G-D_=0CY'.Y9\,%GCCS#HRR,5>!I@DADPHIY^'@X8+T*;-7*^6#?7,XM9L
MFAFMU8 ]*@'"(ZF>$R@:O-TCK;54MM';"'+7O0>[6EU74U4O_I#(!G_,R(S(
MD0"$,[ +O5:J@,,_62CY"ZX'=.Y<AF.PJ>.@.KP!E><IRID40]D[$Q.9Y'V8
MBU501JX$"'0/B&[+]*?/XUPJ!8ATRK@'RQ_X)U[Z9,]2[VP_DG-G^]$C78"!
MZLN\[$V)1_YBM>R=$N 7GQ;ZF@30$#\;H9Z[RH\'/QYGHC8D0)($L F>E:+G
MM_W]Q60SN3/"! ^V"-TI ;)=_%K!>!.Z>JQVT/AN4GU6$]6%(#!/4Z?'(OA!
M]NVX99T@RMHD7'S72PU =[>PAWG]3*6'YON#_9B*ULVQ^SG/6PV3F?OD'I<9
MC%U?QGU/Z9A?X#^K?2!ZLJH&^2+B/W(-*\0'TCRERR%%>-T#SH*Q[-<A07TL
M^UWE$@N?ZY^MM!_2X9@AXM*R/A\B*.T*U(9S71_IV(1KH9PN/ITZ[U6D_!JI
M]X::BDZ[R V/9]5SF#/>7*W\\IPQ]P7$L!F6C.-%W7K>D<3NK.<3UAYCKAG@
M[@1+ )049?:,Y-UEQ4SW8 *.U77*&%&%32"]&!;@UWW/P/P^S9YK"N8Z%6/+
M2%X\M1H<8]/+8L-S^J>\OAD!N_2Q'X/GO(N1F73.%7"XD^G7EAG$6./?]Q5X
M9VRF?/NLQ7XJ*M*1\LX B+TS]_.8E<\F[Z^)II?^E'K#*Y$E9OF[OA/O%+TD
M'QN&?"Y6#5'\[56LS=7+K2P:4N(*G;&4<%]!EY>9N,-C@+Z\"QKA;EH0U]#S
M*.)[53*K=A>6BOCI9 SJ0WLS'[F\BTMM4;05T/VYJ@1O^P^Z#-]?)( =<M>\
MKC@K7"!%4V6/?,-8T$9PVH;H4A]\8\',((K8AJ+M>XO;*I0I0<=[<Q73/I1^
MZ[L<K&L3HA,A*$RXVDI9W,>Y)+."-F4AUE8*QVRE/&3KAE &OX7?\_Z"HX[/
M:YSHM-C)=-O36C1\$)LS1H72P@%4;!M2VUR7VSZQA ME).1%A97S]#L]4T8,
MI.S"-5[5P5@(O@0;+6*UT7Z,)\E8OS?0PQ$DR;[*MB2 ED3K$D\/K@?U94S,
MM-O+(C(82C\XH!\.QBZE31H<UY$ =]:YF%69U0:UE7BA(>6Q]JYUC _'T2MD
M+':-?\_8#8]8]O9*=EGM'HED7*RSA>V>IZ7="9>R2IJ]QESH' 42%E5* .UL
MI5='RL FL5$/QN\&,7TGL6#!I:0^-=AR3M=>^'W=]E\Y,5EUK-@Y_^7GKJD7
MKIQ??YE.:CX#C>4'(50)].U[CSW3WZ?@^0L^MH]""?!V'I$ ,LL4[GR6?\M0
MBF9*[M$+B&WS3RBZ4C[-V/L!%[J%9,TC<K_!,^SOIVT\B2NR>>U-F,JL0UI5
M8FP-6B[28T0;*RA%X3<#EBK"&W6]QGAM>Z8$V-Z:;5M"M\5<CWE\/"=,?.3Y
M$H6OI^-]/.W8DXV]X5>M8*B]D7RP"1M3D<A![A /5&OF-Q3,;:0]-*8H9=[<
M%E)51%"S(R9I+MU8UR+E#Z\$8PEQ.>)AFF4Q*F?^&=JI15U[WZ"AXSOCD4<J
MB]QON@F1PI'J$#&BWHDU)P&.PX9K*.L\[%&^W3Z-9_K3R3N%6*Z=!& I,/%;
MWS&*9WJ#KQ.6#=6NB]K8IJ(#+O25\P)+)'/]J%@5D@!Y:/L)R_NEG;?+H'2V
MTX#?S_TY]5>P7VV 59?J8Y%I$(*=7DC](;$HU35/N@Z_EZ:\]E[6RN*:AY73
M]!=M9]G(PT)+:)J/V&>.+8'N63@UU[DD9],ZHPKF*<OS'<OL,.=US^]!3==L
MM"OOY<]#).O<N72B-'!%0^+FRCG7Z)\"JN><(RLP3[I4;JU76^QNN7#62:^E
M+PT.-ZV+H5U4!*:"VL2[,6A44J1#MP_CL4=S,_\+\R&SUF8K7M0@$C5J/4[A
MZ/&^F/3YUN7I"U_.3VI'.QXT9-H_RDH\DG]3K1L=*3ZG?5@"X"'*:NIXG>8,
MZ;0$V)^L E*%R U;U!DM156',W*_-;5)F)98=QQSP.N@<[(WI^LGE=.MABG,
MO>.#>,I"7-/2\DN0=@&9 05)5Z]?IIX5M%84:!;_J&RURWM9OSB?(RY5Z_.F
M6QU[\PM+_ZI%"=>*K\9R$LT#&_'_Q,*A9',)\%3?2^K>7G!U^VRA;)?E20R*
M0V_4VO2>[ZU!#46.EJ8\>9DW@LU96D8N66EP78V56,&<Y1G&,<JN6"HF_6M7
MW+!] 2%#FC<-Q"R<KP AE.:1ZZ1)WCOB ,:.>WJB_:'YJ4BE>',OR^+;A0'C
M!^OL3?01>O!,<_QZX!+%D+:^TLBU973OA4*;Q0=KXQW(/;'P=?)^[B;3#<.B
M<(M<DB-+ J1Z6DYW  +B!+N-O1,3U!]^U,A_34%AS# T",P+'*+XU1/2Q.FM
MWOM*T$\477DLCGHF[!Z*9&$05U99[UY;F7B$8#]FM=*RL((0[BR#0NRN+_!J
M(#K\WI,,PU<:\54UE'YW\CN>!,")4"DKHHZNNV(]&\%5C)1*XI(U'DR>+0@Z
MT"W>G6"8(7:WHG2M^,LN7OJ43B?$GPN-+!$U_6,DV]+9(C^]JU8[GQ^[^%C/
M9,J/KD*-L@)N!@RA"N:J>7VCW5%&-D26,BX+R<L(#NBU E0=K  I0HK/UU+#
M;!9+PSTSU=TO:"[U.N1)M<W=8M=S5L!MW$[S;?!FMI+U:\40">!)O!MQAM^I
M#O4+* <,(L*D4+DY3W/.)][DI<?]H,'#\U_5)OA>D/(?(<#AC/9N)N)#\00]
M >Y+MI?S1(/.D711+J/6MV_)%(S!UN>%FE$665R%1DUCX?@6:(KIFZ@?%3&7
M=3Q1\29]"4LW'O25:L>%.9J/(CWZ#D*#,H&C:&*L)O"T:C?R_J TDSK+_.?#
MV +7@-A.M2'VV*&OZ<<\R:S8GJ5Q0@?4S&#'FT<Q,L\U;XB?!Q0%F'+7G49(
MYV9@0F>T8GP"QDIP(-#!?]RPOIYKVJ3P<+F*KMHI&&F0%Z3R*>/W!142@'Y%
M9K4L-]]SP<14W?4[ZU#4=X]5RR_5IZ20EZEW9Q$5&O>-<(D>9,IM1K"L0-G3
MUJA_\5D7HM<O82K ]\HP(1)E+V V2 #[@<\';F77566=SK"A8AQ;1E+2!"-O
M.JJCC;_.W8NYL'K;^<@%AP)#;Y\V2B 87U?0 CXP)6OW'7-UK,M:[J*-O;XR
MFO#=#Q(@1I3RAOR%Z">A12@'U6JIQ,E_G =]SW:K1 L7;)T3-)&,L8J&QNI;
MZX5-TSE7?(Z&:O:WN^3M:?N)O#<4MD?X)?35AN\X+O0-YI"4N17-^D(-&TP?
M><2@7R^_C/1LG2;2I8HQ@GJ4TWX&2N(&\4 .\NZW' *!$N\1$S7%A8VDH3XP
M:U8BHI!@UWH$=8QZO-6BOOU O(O7#Z5"9QP#J3B7I=Q;&E:JW::@:#)H<A85
M4N^@(4IOGR=S%XXM%1RKS66'AEJ#89PU3OP/)'V!=9#9%"X>01">9MI9ON_
M7M#_)4<@>Y8R'89ZF38CWCX11K]G:<GA-\'CGWOX]XRB,YH\IH;R#B<;],6*
MM_G6K#LBZRDW"@=Y!RL.$"Q,ZI;$K(#% T^,TUT\VQ!^',LO!RQWH"4 \SV>
MJ\?V[,GFD"SW<U8];F:5HHE*GQ6^IS<,2X"*0=P#Y%9X6+**/]4LN7$NC.5C
M>\]53*WAPF@&?: ^:NEY%T@1SW36D>LNMT][OZA7B6 O]:ZA5T(U2=-5N4>6
MEUO6;2<BFQ'J_CCU?M<*3EYW<_<.VP X+^O%1H67Q[C7\77MK4^'72$RZKFH
M8^,7['M_ 6[1Z6=L8%'_XR/+62'Z:L>^KLU3CCZ20SAU[]]5PU+F/"I4Z2$;
MVGQ+^W-=7F;KLT[EJW-F#ZH=I?RU<LW/OF'?+?LT4?I"R;'5!F4M_4L$3[3+
M>[G$]_3(/S_58ZV#$\:=F.^YK?QFY .R'O>;EP%:XZ_RA@FM)%<94B9]'$LQ
M:15TB5D8!B>(^96X!UEE9%9=GPOY.?>+WX'PAVNGC^@(@C-+,P<<HL0A[#57
MY?42W%K''<O*?U3HKE97V<F(CY>HX$(;4K2I3@^8B#TB_)P3WQ:\R0#>&GTL
MFE"BC,W9XH?.(Z8)9CM7]%UTB(M4SG0_([/]SG4.X16GJR4+P\/7ATG79[?+
M<W84CN5:TGOF,XTF]@/MW=#)5[;Y:%?KY$O$FK3N3&%[JF<"2%ZBGS1&;\$S
MC'O!$#!^ R<\;);V"*RZM98F?E=?ZWZM3PI\C7?*\%$\7I\Y4\O902?R'S Y
MU(>4"I*M6G6EJ+[P\<E%:?I''36)Y8L]>N1I1@Y_H<__GZF]+)J+2'^?<=L'
M&ZPU]8);Y3324?_,2KS@DJDJLVS'>E(KT @\00_XT1N*GP@?J,<;S=[OCF0\
MIB\/Z8CUD6PXQ[4_5HN[\^6DXLY.]UY\]F!8,90:$U3O;MJJ!T9Y5+U^[)>0
MDN*U-Z+"&-/)M'\H/B!Z&2[%QQ[,L8HT-X[!0&DD'MHD3?Q7Z.WA^1+@M@2@
M:(P% AM/$B?)6ICS/>2CD&5GB[<FV<O:AH1\NK)2#"J;26MI.#^H/'MSJVK5
M91DKU<N;KO_@V/MW71 ZKB4!?FQ/H"R(X2(=8MG#W\*U1_Z<]"F9WYC\,TS$
M$T_8UGGM@[7<]WD3F7";_C+RL"$N6*V-]4L]S"<W) Q5AVLEDY)YP5R#-*%A
M,*HY@6O?ZOU%7?\M3>JBV?OX(-\;;)76:5&66XY=%VIZT9\2WX4/@O@,=ZE@
M %O-S,8^N-E%79_3FB[6MT*%T*.\QF*GZ6S7-K"RH"T9$)IP'S>0&X)+[:)>
M-QIFP!-72\\)0ILE0 "I;B7$,*\N0>/&<N>4O@2H>2'#)_X32'^[Z]![63Y%
M& B-Y NU^JL^/K<=,+?&+Y@>Z+3I-7KM6D=*0[ P;XI%TV6?BS]H*E*:7PK/
M8AGXW6Y!G*!M##9DI4.P9VTS5A?\6-!53FF@1- F$+>0.TV(7/8$R(M/-%:2
MA[Z?CQ$H9'I^C5M<.58JA6:W!#A&%(T-?HR(W4_N(_DP\@:$SEAF<KQ8#BI,
M#TY^M!:$JT*D&.!'4R?%'NN.Y*Y5&1ZR$??$!*<>8CQFXJ5TA8-+--KK:&!]
M=LA9KF4?]7OR1S_7"^)E:@J4X<'USA6@,%]64LU/[GR:0QM>.)HW_S3PZ'?\
MSBFK%2-/1+BS$*9(;5&BX2>#Z7'&'\N=.>+,/$-B@/+['[TQ;/'"B5*_Y@G4
M/C2"5P])I?>VR)93PHC*N8WN'Y_-/76/@M5);\Z3UP!L\A^@XX],OLOR-'26
MB7I -AR(/2C\_*Y?ZIJXEPG;?'K=9:-;9'R7,I72+39;FT=L)1^'(B?M'TH
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M8E'\H&[$#?86-\B3.38:,$$!T!YBI)+!/.7AFJ!S9-C +P63OUQ@1W:Z)9
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M;!57N]HSUA>2.)3[8B6T"F^$HQ[/:?^ZJM\XX[2BAT$@K;]K'1&68;I.$>@
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M'*4VU#8TJJENU0X%HFZ'\I(^?)[F1SN0\))7+<*U\_676/*3Q":DTFQT;$K
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MJVR*)0 !"4FE7K<&9[I,O ^X 3%O/M3R?S]?>@"LQBAHFP9Y,4*]N^ZY3QX
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M]UY^S/9U1O<B+G)2^,6%L9^Y(62\&LC"^M%3$06@?-X6H0UBR:6Z)L;EJP>
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MM_0*(UGP?^8W*.%W:BC-!IM=C2^N+(*SK^'ZSG'N+O2IC=5-(UJ2]X\]D$K
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MCX]8WT.TJKDG3[](,CD5KAIMY4 (NREQ74+[04UIH"Q$L$YZI671 F=B;$#
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M:,V^][)V9:O_TL8F*LJ(;]MJU5T9XB$!#76&\,B-UV!8;?14=NMG+\DRMV7
M539%.%G7RG.V<(IF)XBV=A )SK:;4Z+#F#-KY I<G-]7L:&H_^ >:D;X4H9"
M9@5 V$-FN Q?/23M#F^7F?Q\/GN:4S]2PDAA\/[@ \J23C]"YF!9><FDK)3.
M_IU'I,@>;\#,7DW-_KS&W6TZ((/(0VP=ZZG+BRXL7"USS8(@06GOW&7@4S(Y
MVE0V6?N?#%E(^$OZRDC];4_+Y'LH26"N>;TO0X'ENOL8^5"_CU/>M37%C*9-
MT\]]!SX(2U#H;AJ('2)0?4 &[KZ$\JUF5.]A>W?19G]S),1=IIO+@7=&5^>
M#"(%HY1)EY+S=.A23!R6,!_4R/&/D@NEE4R2&BE8:6/_?,W+]!3Q:HP+B/.&
MQ\SYOOVM+AH^HVY>>O+>I2K,6=@<HG;(4VY6T*%$;M?3BQEO6 0-KKF52&:L
MM-O[%GX93?1NA8?&","P7 !!Z1<F;8+$T?5;.^(G!CD<8VGI+FMH/2G-:9+2
M*4LQ &B\"R.DLWX>!=PII@Q<)IDZ7S@4GGTSQ5S"FH.CH]EK$4JV@PS?Y!-
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MVQ[C]B9HT<IV29#''%S'FRVM.<:5S_<&UK;(7"E@,&B5,\A]88'^_/CT(S_
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M\QZP$[G2NE;+?+ZJE@$UO!=[/*8WK0RU(O&C?L_ P1/&Z3 (T81XAR3W]]!
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MA1;<"S/=A]\Q9O_SG2&G,?7^F=>'_*I:K":@ZA]W<^:^'TO/[L5R'L&?EZ:
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M1DR-W'%_*!!Q^<)_=$&-.V>JM>,^ZJ")X3]%C3&<<IPO!K_3L0%O)6/4M-B
MT"#H]SV=Y_PJX-8>LRUG0KRZ^1%WDU957"\-8PT-0BC\3+X@\G<PM2JKJ2\7
M+FR8\-P?$Z"^*VJ--#YX+S)DI@'DR]=Y1?*X?4*TN 5"Y"50A9K9E\RCB,AL
M>:CLS/W\<T]3Q'O2C@)'C,!D6$#HEZ.Y'Q+7\9TL)W4CTXZ908=("PP>$A$+
MK*ESL61V=H4W+7@6>8ZYAY:#J^$T<Y5[C5Y>D!M.2T?R&*/87G@8_ .GIS^7
M5<()\LZ%H3!!)\W% 6PYBEF,K9B] F.@/V$&<< @CQ_\;UT"L(W:"RQ,'67
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M#-V4)C!=8 Q6#DQECSY5+C7$W\3DE<.,%M8</>]37S1QS9KJF;Z9/EDL1XA
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M8:<X#JHV!PQ?&BRHJL!R54!C-;3$&WMY?&I+]>)9PB^IT@$*D\:EHT?4ILD
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M^K;Q(N5\.V5H9VQ#.XMA/W>V_$Q9\;2=$33M:87PU.^0F FK?0\@RLUFWNC
M<:.&0>BH!DC!W!DQ2K>0 ,:(\_65*,04TC@*K[8*W@]3HS$>L-W;O#3 ^\A?
MY_?.Q60F'?@(O?/&G'#\;3*9F4&JK'V;K@KKZP9AG#*R'ABAD[#CRJQOV :L
M&_I11&.D;/C]ZQE[=5R5<E\-!CO?M6@%TU[/V>ALUG1@6V<4!SBKQDT+E+E$
M!B%P,[Y7%Y+=H,[V,F:#V]W\>1A6GY?H4_+:]>8\"F9+ZNR-YLQU640DUL(
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M$#)+V70Z8SY(T-\J$4*J9("(0WTR #Q/,HK?^F"IX R9#EA12%CPOD;<0$W
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M$\[S_W8?;IG,V=_(0V'+<2WR6(9>$O0;R\=RX:^LX0N+HLJ(%^1MD&&JL3B
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M5 ,5F&AL&8CNH3J=__L;Y6;@4C#?FALLR=DV"57\0KMQ7'X4N^H;00C6O78
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MI$I6K()E5J_9L&;-!@6933(*_]L/R6M ;OW*A)6?5JU0!U;*K5@EMT)2!R
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MKV<L8',Q7MP,EDOG]<B?@_ZU%6;<F7ER*9-+\C+N8IG]OR?HQK\-_=)#F)$
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MA_6[E0N890%N\Z[!2AH"GB^#.HLK78BC5^7>_H-:75SYRZ?6 -DE^'):DK&
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M;K]*L?3AUX[8^SZZ^_16-C15^IJ=H4]YOA0GK4FS#7$(?,<\I%-WH+&.XVA
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MMSZ]XUJ&B G<._0);MR,762$R$DI:NA.)WW^;'#EG2B"S]G*G$*Y(7]L8KI
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M;6?'@86F@TR/BJ09W0<[\DLIY!GC*[82(&S*T1@>$1_:@+.(,9=-' K7H3T
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MW[-+N H)\:#5.+CS^\%@F+"T<1S#6\) Z@3X];'EU[!GU:MK0;G^"+@/VV$
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M'<M6?,TO2BYR$:O]U8I4F'JG8<S2AF7JX_BN3!4XQO["H[B8_#=OVH2%9D@
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MXA_J.Y%<VQUZ=Z&;X 7U.$V552^V]V.MX.I+?2= 4<LG3KW(X*Z/U=@K<D_
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M#F<@_^E]<SOPC6^*$>G\<;(;_WFH6G)*VT]81A,YF5*(Q78M,J+![[G7>"G
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M^:@](*N/UJ2M$**H;4Y#TY^EBGB%BFD:/PE!CC#G.RIA.#=^5;?(!E:@H)0
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M?;Y<.@R1H[ZL796H*(3.Z6ZJ%TU 8!!ML1_@]V,4*8'Q;^ZO2E84E !TU5*
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MD">0THOW2I2P>X=ZPXD:0;&VE0/6B$LLFQ%<4HZUD0V>+O8!D:(Y'D)R$9M
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M,]ZE-GWCZ?.>B\MM96XW2),+P8:$B)9"0M@M^,I@>Q#33I";MW$0D(\.*\6
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MQS\OUXJLZI*NT**AG@\9 :0#QFZCG42!38S;F6UQ Y./M35\J<6#G2D!N\'
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M+FIP9]2\!U136]LN&GM!1%! 0< M(DK+5BE*RT8%!$0$A-"S4:DQ1*0+)#9
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MY#0F9@,V:6$WB7D!DC7@E)C>8:E=/FR:W8W0'!EJ?]-JI*H=*S_!4@0^CU%
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M$#XK<5:KE;T!+:5,56#.Q.;-Y]T0 >Y&K1S_/9YG7M^);^#DF)!%@%B=!5+
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MA&.FRKTQP<4!;FFOZY?7':7*%]V<9T>5Z5.)[#4A2[#FACZ,O*,)3!(!CFP
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MWSMH#TRW,*%B)ANJO<=L!=A@*\-JW+I11=1ZU/6)7&0V4[O)@2G<$S);GHH
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MK0J+D='(F)0[%<T[*'6@O;<\&;EZ%K3FA,KN2EJ#"&T ]\1*/E-!L>_J5:2
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M\-% 1;T(<[M5/5D-&LR?EUF J)$Z4.I:!45H%VD8V#-Y^IQ#6]PGQW:/22F
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M'MO@FF/#O"K?6751HL#>SV]=G)G'VY@,><@#7=?#LHR43Q)*)E4F72-IZU)
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M535@AQI P+5L_(OCY4R Q=^>Y_J[5(HOO-S^6?[4_U_#J"?^#5!+ P04
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MS--#Q\"_0>0!$;A6^(<+4:WPD34_>N"SV_OG[8 ]\#D8=6ZLZ3=KFJH5?A!
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MXZ1#;/O=!X*0,)C#FG):ZKHR5G9-83DWH++3INVVY6,G-CDJ+!I<;=)_$:O
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M34L= C0S?)7+&<]+X1Z0PG&EDSVW@L>4ZOKB*YVAM4G*/.\+5XY%=\!7.@T
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M <GH4,4VF4<&RU$S7>&(DG#D:3<O')&ZS=E']^&!.QDPDHZZPA(EH5+AIO)
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MK6EWV)G-N_/;^7CZ6[KMM#M/IZ'5+[#^-N>6"J ;!"@,Z/:<JJ ""^33.Y%
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M*SO/<1KK<K]+U@96HAMTM.OSYD;W ?HCHC/1>F)Q!*DZ CN\"HTD$0<'.8.
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MG$D,5M"Y I!6S0HW4B(0<-%IUD=)18M*8O0W3CXN,C9!_L24W^>7ST&PX_#
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M'6Z"5[;UWI[G0JLY$%8^ATH]>0)'*DQ_<+#"@[W[-#>BI4WI!2^BJE+$-&1
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MQ9FE!QN(-"B^[&=,WR;%X80LP8-G_+"G=6MF&R&S3N?C!LIPB<N#S&NC=9
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MT;I:=<V-EM8)*Z?MGLJ",=Z*]5_+?IB>HS\4>\*9=>2GR_UWU3 ]7;];?G0
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MK_: #2L89 [35]ABH3O)Y07KMB3OH*QSH.U0J";WDHUN@3,5+1A@&114WW,
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MJP?DR@GCH%KA^6QG,L/M<$;6!PG+[F2;$(\YWNSC^VB#68T2]4I^"#.L'CI
M<TELP$3PU7HE!'$IB(HI:[SX7J1+MM47=5W'NY H'6TBJBA_VZA*X6 [6,TS
MW62.W.*PK'W1_J%[4F-S$'&ZK\,"F0_3K8Y%FK*>*&JI43X1VV3>T%.P=LP4
M<%W0FBO3_:UWA.;%FWW"V3/.6J>*UVE.W\O=1JRV5SM#20#J %Y8,!NN>!\D
M7$+GB)26?Z7K6":$5H9>MW.RH)R$'CR<'G QC_=YO]%.ZKT4WX0%)G<&._%4
M])&]'=%!Q+:?J#;(DG1?7K-1;*Y(:&!!1*V@$.%R2E26F?>Y6])1^B;*UW%*
M=_G4L:V) 7"?J+4U=5##Z3MH;1(.6B=JQM0)@196+YD5U254= X"O697\/=
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M8\B"JF)"8</E9^+BN0:T](WJKJA( JLKE/JI\BJ"\#5BK[+D?,\^I]5XO%Z
M+#6;E(J59PDY,4F?X:)D -E#)FU5_57QH8H1$4Z_;BW:T/KC+Q'>3#_C]9Y>
M[9MM-D0W54J2D0-6C]FJ*[@X>N>$OGA%.5'-BDI>KYWV";\4P>XES:(UB49S
M>O#-]BD4/:8GA]5=5KJ**?<U$VJX$&&SZJ8C'E>9L^NP^"ZANXW]++Y.U",G
M=/:0B5;1UATT"14L@.A4%&^5,5I4$?N]8IY]"I)M^A(D+#%,T0-2*E@]H%-1
MN"^>H8JXS(?SNKNU?L'A/N:/J^V"Y/T>!WG[&KSABN9 ?EC==ICR0B132B'S
M("KE("8(M225=S5K65XZ>[;#M$)A\LS4H^4P>1V2(*Z?*%X$LO<@;1EA=>]
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M@NI]JN L*$IK70%'KJUED AKY2NF7^^#!54 D#T)PXZTXU\DSQED@YB,<46
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M/O<&H_%#;SA[-YVU/_5:D_[TIVFK/>RV!OV?'_O=_NS72FM2<D0?OYZC0$R
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MEMA>[XH2E[^A*3B ?ATKO&3%Y$OC*Y)UL&.!7&R'E/*A&?/J>9#J_$R*+I;
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M^J&=@56X6S[:P)Q!/^$&@;^*2;AA#Y[KKQSBUF]H(U32F1,Z.\#272%D[>T
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M^IO_#U!+ 0(4 Q0    ( $R)GEH[+SH(M (  &,.   *              "
M 0    !E>#(S+3$N:'1M4$L! A0#%     @ 3(F>6C5VC4J(TP0 B*DH  T
M             ( !W (  &9O<FUP;W-A;2YH=&U02P$"% ,4    " !,B9Y:
MU["_R3MF  "Q;   $0              @ &/U@0 9F]R;7!O<V%M7S Q,2YJ
M<&=02P$"% ,4    " !,B9Y:4T>H&\QU   N>0  $0              @ 'Y
M/ 4 9F]R;7!O<V%M7S Q,BYJ<&=02P$"% ,4    " !,B9Y:4&&<$-.S   ^
MNP  $0              @ 'TL@4 9F]R;7!O<V%M7S Q,RYJ<&=02P$"% ,4
M    " !,B9Y:QC\R=B8S 0!Q4@$ $0              @ 'V9@8 9F]R;7!O
M<V%M7S Q-"YJ<&=02P$"% ,4    " !,B9Y:P;&3MT8O  "E.0  $0
M        @ %+F@< 9F]R;7!O<V%M7S Q-BYJ<&=02P$"% ,4    " !,B9Y:
M.K%2X0J:  #7M   $0              @ ' R0< 9F]R;7!O<V%M7S Q-RYJ
M<&=02P$"% ,4    " !,B9Y:1-5/MDYN  #E@0  $0              @ 'Y
M8P@ 9F]R;7!O<V%M7S Q."YJ<&=02P$"% ,4    " !,B9Y:D>RZH4,F   $
M*   #P              @ %VT@@ 9F]R;7,M,5\P,#$N:G!G4$L! A0#%
M  @ 3(F>6F=K6Z<2*P$ 'F,!  T              ( !YO@( '!O<V%M7S P
M,2YJ<&=02P$"% ,4    " !,B9Y:"$U:]XB8  !3I   #0
M@ $C) H <&]S86U?,# R+FIP9U!+ 0(4 Q0    ( $R)GEH(CPBWDA,  )7,
M   1              "  =:\"@!T=F=N+3(P,C0Q,C,Q+GAS9%!+ 0(4 Q0
M   ( $R)GEJ;?4X=>Q<   HC 0 5              "  9?0"@!T=F=N+3(P
M,C0Q,C,Q7V-A;"YX;6Q02P$"% ,4    " !,B9Y:9L9^!ZE!  #86 0 %0
M            @ %%Z H ='9G;BTR,#(T,3(S,5]D968N>&UL4$L! A0#%
M  @ 3(F>6NUZ%U*\<   1UH& !4              ( !(2H+ '1V9VXM,C R
M-#$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( $R)GEH+W>J"]%(  #& !0 5
M          "  1";"P!T=F=N+3(P,C0Q,C,Q7W!R92YX;6Q02P4&     !$
,$0 J!   -^X+

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>formposam_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:TVGN="http://tevogen.com/20241231"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="tvgn-20241231.xsd" xlink:type="simple"/>
    <context id="From2024-01-01to2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_dei_BusinessContactMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-02-14_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-14</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TevogenBioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">TVGN:TevogenBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SemperParatusMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">TVGN:SemperParatusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-06-012024-06-30_custom_LoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_LoanAgreementMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputDiscountRateMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputDiscountRateMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ProbabilityOfFutureLiquidityMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">TVGN:ProbabilityOfFutureLiquidityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ProbabilityOfFutureLiquidityMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">TVGN:ProbabilityOfFutureLiquidityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputOptionVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputDiscountRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-02-14_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-14</instant>
        </period>
    </context>
    <context id="AsOf2024-02-14_us-gaap_FairValueInputsLevel3Member_us-gaap_CallOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:CallOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-14</instant>
        </period>
    </context>
    <context id="From2024-02-152024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-15</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-02-152024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_CallOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:CallOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-15</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_CallOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:CallOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-02-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
        </entity>
        <period>
            <instant>2024-02-14</instant>
        </period>
    </context>
    <context id="From2024-02-142024-02-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
        </entity>
        <period>
            <startDate>2024-02-14</startDate>
            <endDate>2024-02-14</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-14_custom_EarnoutSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-14</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TevogenBioCommonStockMember_custom_EarnoutSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:TevogenBioCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember_custom_EarnoutSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:TevogenBioCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_custom_EarnoutSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:TevogenBioCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_custom_EarnoutSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:TevogenBioCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:TevogenBioCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:TevogenBioCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:TevogenBioCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SponsorMember_custom_EarnoutSharesMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SponsorMember_custom_EarnoutSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ComputerAndSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">TVGN:ComputerAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ComputerAndSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">TVGN:ComputerAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-02-142024-02-14_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-14</startDate>
            <endDate>2024-02-14</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-06-012024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_ThePatelFamilyLLPMember_custom_LoanAgreementMember_us-gaap_UnsecuredDebtMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-02-28_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2024-06-012024-06-30_custom_ThePatelFamilyLLPMember_custom_LoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-06-012024-06-30_custom_ThePatelFamilyLLPMember_custom_LoanAgreementMember_custom_AdditionalAmountPurchaseOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">TVGN:AdditionalAmountPurchaseOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_custom_AdditionalAmountPurchaseOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">TVGN:AdditionalAmountPurchaseOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PolarMultiStrategyMasterFundMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:PolarMultiStrategyMasterFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TwoThousandTwentyFourPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">TVGN:TwoThousandTwentyFourPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-02-142024-02-14_custom_TwoThousandTwentyFourPlanMember_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">TVGN:TwoThousandTwentyFourPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-14</startDate>
            <endDate>2024-02-14</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_PerformanceBasedRSUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:PerformanceBasedRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-01-01_us-gaap_SubsequentEventMember_custom_PerformanceBasedRSUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:PerformanceBasedRSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-01</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-01-01_us-gaap_SubsequentEventMember_custom_ServiceBasedRestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:ServiceBasedRestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-01</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ServiceBasedRestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:ServiceBasedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PerformanceBasedRSUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:PerformanceBasedRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ServiceBasedRestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:ServiceBasedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ServiceBasedRestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:ServiceBasedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ServiceBasedRestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:ServiceBasedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ServiceBasedRestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:ServiceBasedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_PerformanceBasedRSUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:PerformanceBasedRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_PerformanceBasedRSUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:PerformanceBasedRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PerformanceBasedRSUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:PerformanceBasedRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2024-03-012024-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-03-262024-03-27_custom_SeriesAOnePreferredStockMember_custom_ThePatelFamilyLLPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TVGN:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-26</startDate>
            <endDate>2024-03-27</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-27_custom_SeriesAOnePreferredStockMember_custom_ThePatelFamilyLLPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TVGN:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-27</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SeriesAOnePreferredStockMember_custom_ThePatelFamilyLLPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TVGN:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-03-012024-03-31_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-08-212024-08-21_us-gaap_SeriesCPreferredStockMember_custom_ThePatelFamilyLLPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-21</startDate>
            <endDate>2024-08-21</endDate>
        </period>
    </context>
    <context id="AsOf2024-08-21_us-gaap_SeriesCPreferredStockMember_custom_ThePatelFamilyLLPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-21</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-11-30_custom_SemperParatusMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SemperParatusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="AsOf2021-11-30_custom_SemperParatusMember_custom_PublicWarrantsMember_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TVGN:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SemperParatusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="AsOf2021-11-30_custom_SemperParatusMember_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SemperParatusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="AsOf2021-11-30_custom_SemperParatusMember_custom_PublicWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TVGN:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SemperParatusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="From2021-11-012021-11-30_custom_SemperParatusMember_custom_PublicWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TVGN:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SemperParatusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SemperParatusMember_custom_PublicWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TVGN:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SemperParatusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SemperParatusMember_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SemperParatusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RestrictedStockMember74469375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_WarrantMember74469375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_ConvertibleDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_ConvertibleDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_EarnoutSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_EarnoutSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember74469500">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SponsorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SponsorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SponsorAdvisoryServicesFeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:SponsorAdvisoryServicesFeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-01-31_custom_PerformanceBasedRSUsMember_custom_WifeOfChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:WifeOfChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:PerformanceBasedRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-01-31_custom_MehtaphoricConsultingIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:MehtaphoricConsultingIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DrManmohanPatelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:DrManmohanPatelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DrManmohanPatelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:DrManmohanPatelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-01-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DrManmohanPatelMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:DrManmohanPatelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-31</instant>
        </period>
    </context>
    <context id="AsOf2025-02-28_us-gaap_RestrictedStockUnitsRSUMember_custom_DrManmohanPatelMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:DrManmohanPatelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="AsOf2025-01-31_us-gaap_SubsequentEventMember_custom_KRHPLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:KRHPLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-31</instant>
        </period>
    </context>
    <context id="AsOf2025-02-28_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-04-02_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-02</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Integer">
        <measure>TVGN:Integer</measure>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Segment">
        <measure>TVGN:Segment</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2024-01-01to2024-12-31" id="Fact000003">true</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="From2024-01-01to2024-12-31" id="Fact000004">0001860871</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0013">POS AM</dei:DocumentType>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl0054"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredCosts
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0065"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0090"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0092"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl0096"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0101"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0111"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0120"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0133"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0146"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0198"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0201"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:LossOnIssuanceOfCommitmentShares
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0207"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0236"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0237"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0238"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0244"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0246"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0248"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0252"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0253"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0254"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0255"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0256"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0260"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0261"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0262"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0268"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0270"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0272"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0276"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0277"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0278"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0284"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0286"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0288"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0293"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0294"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0295"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0296"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0297"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockIssuedDuringPeriodValueNewIssuesTwo
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0302"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockIssuedDuringPeriodValueNewIssuesTwo
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0303"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockIssuedDuringPeriodValueNewIssuesTwo
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0305"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockIssuedDuringPeriodValueNewIssuesTwo
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0306"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockIssuedDuringPeriodValueNewIssuesTwo
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0307"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockIssuedDuringPeriodValueNewIssuesOne
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0312"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockIssuedDuringPeriodValueNewIssuesOne
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0314"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockIssuedDuringPeriodValueNewIssuesOne
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0315"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockIssuedDuringPeriodValueNewIssuesOne
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0316"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockIssuedDuringPeriodValueNewIssuesOne
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0317"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0322"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0323"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0324"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0327"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:MergerNetOfRedemptionsAndTransactionCosts
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0332"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:MergerNetOfRedemptionsAndTransactionCosts
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0333"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:MergerNetOfRedemptionsAndTransactionCosts
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0334"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:MergerNetOfRedemptionsAndTransactionCosts
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0337"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0342"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0343"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0344"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0347"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0348"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0352"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0353"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0354"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0357"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0362"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0363"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0364"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0367"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0372"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0373"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0374"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0377"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0378"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockIssuedDuringPeriodValueContributionFromRelatedParty
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0382"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockIssuedDuringPeriodValueContributionFromRelatedParty
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0384"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockIssuedDuringPeriodValueContributionFromRelatedParty
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0385"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockIssuedDuringPeriodValueContributionFromRelatedParty
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0387"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockIssuedDuringPeriodValueContributionFromRelatedParty
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0388"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0392"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0393"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0394"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0395"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0397"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0400"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0401"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0402"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0405"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0406"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0410"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0411"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0412"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0413"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0415"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0418"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0419"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0420"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0421"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0422"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0427"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0436"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0443"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0452"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0471"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NoncashMergerRelatedCosts
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0477"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:LossOnPreferredStockIssuance
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0483"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:LossOnIssuanceOfCommitmentShares
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0486"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0489"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0518"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0521"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:CashAcquiredInConnectionWithReverseRecapitalization
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0528"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0531"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:ProceedsFromIssuanceOfSeriesCPreferredStock
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0534"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0537"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0540"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0542"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0545"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:ReverseRecapitalizationTransactionFeesIncludedInAccruedExpensesAndOtherLiabilities
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0563"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0567"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:RepurchaseOfSeriesBPreferredStock
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0570"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssued1
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0573"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0630"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2024-02-14_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      id="xdx2ixbrl0648"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2024-02-14_us-gaap_FairValueInputsLevel3Member_us-gaap_CallOptionMember"
      id="xdx2ixbrl0650"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_CallOptionMember"
      id="xdx2ixbrl0662"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0666"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0668"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2022-12-31_custom_ServiceBasedRestrictedStockMember"
      id="xdx2ixbrl0938"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2022-12-31_custom_ServiceBasedRestrictedStockMember"
      id="xdx2ixbrl0940"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2023-01-012023-12-31_custom_ServiceBasedRestrictedStockMember"
      id="xdx2ixbrl0942"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_custom_ServiceBasedRestrictedStockMember"
      id="xdx2ixbrl0944"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2023-01-012023-12-31_custom_ServiceBasedRestrictedStockMember"
      id="xdx2ixbrl0946"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_custom_ServiceBasedRestrictedStockMember"
      id="xdx2ixbrl0948"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2023-01-012023-12-31_custom_ServiceBasedRestrictedStockMember"
      id="xdx2ixbrl0950"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_custom_ServiceBasedRestrictedStockMember"
      id="xdx2ixbrl0952"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2023-12-31_custom_ServiceBasedRestrictedStockMember"
      id="xdx2ixbrl0954"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-12-31_custom_ServiceBasedRestrictedStockMember"
      id="xdx2ixbrl0956"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2024-01-012024-12-31_custom_ServiceBasedRestrictedStockMember"
      id="xdx2ixbrl0966"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-12-31_custom_ServiceBasedRestrictedStockMember"
      id="xdx2ixbrl0968"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2023-01-012023-12-31_custom_PerformanceBasedRSUsMember"
      id="xdx2ixbrl0982"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_custom_PerformanceBasedRSUsMember"
      id="xdx2ixbrl0984"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2024-01-012024-12-31_custom_PerformanceBasedRSUsMember"
      id="xdx2ixbrl0994"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-12-31_custom_PerformanceBasedRSUsMember"
      id="xdx2ixbrl0996"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2024-01-012024-12-31_custom_PerformanceBasedRSUsMember"
      id="xdx2ixbrl1002"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-12-31_custom_PerformanceBasedRSUsMember"
      id="xdx2ixbrl1004"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="From2023-01-012023-12-31_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1136"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockRepurchase
      contextRef="From2023-01-012023-12-31_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl1139"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockRepurchase
      contextRef="From2023-01-012023-12-31_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl1142"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="From2023-01-012023-12-31_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl1145"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="From2023-01-012023-12-31_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl1148"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockMember"
      id="xdx2ixbrl1159"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl1162"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_ConvertibleDebtSecuritiesMember"
      id="xdx2ixbrl1164"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_custom_EarnoutSharesMember"
      id="xdx2ixbrl1168"
      unitRef="Shares"
      xsi:nil="true"/>
    <TVGN:IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1186"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1199"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1202"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1204"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1207"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1208"
      unitRef="Pure"
      xsi:nil="true"/>
    <TVGN:DeferredTaxAssetsFixedAssets
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1228"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1231"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1257"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1258"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:EntityRegistrantName contextRef="From2024-01-01to2024-12-31" id="Fact000014">Tevogen Bio Holdings Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2024-01-01to2024-12-31" id="Fact000015">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2024-01-01to2024-12-31" id="Fact000016">98-1597194</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2024-01-01to2024-12-31" id="Fact000017">15 Independence Boulevard</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2024-01-01to2024-12-31" id="Fact000018">Suite #410</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2024-01-01to2024-12-31" id="Fact000019">Warren</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2024-01-01to2024-12-31" id="Fact000020">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2024-01-01to2024-12-31" id="Fact000021">07059</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2024-01-01to2024-12-31" id="Fact000022">877</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2024-01-01to2024-12-31" id="Fact000023">838-6436</dei:LocalPhoneNumber>
    <dei:ContactPersonnelName
      contextRef="From2024-01-012024-12-31_dei_BusinessContactMember"
      id="Fact000024">Ryan Saadi</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1
      contextRef="From2024-01-012024-12-31_dei_BusinessContactMember"
      id="Fact000025">15 Independence Boulevard</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="From2024-01-012024-12-31_dei_BusinessContactMember"
      id="Fact000026">Suite #410</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="From2024-01-012024-12-31_dei_BusinessContactMember"
      id="Fact000027">Warren</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="From2024-01-012024-12-31_dei_BusinessContactMember"
      id="Fact000028">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="From2024-01-012024-12-31_dei_BusinessContactMember"
      id="Fact000029">07059</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="From2024-01-012024-12-31_dei_BusinessContactMember"
      id="Fact000030">877</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="From2024-01-012024-12-31_dei_BusinessContactMember"
      id="Fact000031">838-6436</dei:LocalPhoneNumber>
    <dei:EntityFilerCategory contextRef="From2024-01-01to2024-12-31" id="Fact000032">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2024-01-01to2024-12-31" id="Fact000033">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2024-01-01to2024-12-31" id="Fact000034">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2024-01-01to2024-12-31" id="Fact000035">false</dei:EntityExTransitionPeriod>
    <dei:AmendmentDescription contextRef="From2024-01-01to2024-12-31" id="Fact000039">On
June 21, 2024, the registrant filed a Registration Statement on Form S-1 (Registration No. 333-280414), which was subsequently amended
on July 23, 2024, and August 1, 2024, and declared effective by the U.S. Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on
August 2, 2024 (the &#x201c;Registration Statement&#x201d;).&#160;The
Registration Statement registered the issuance by the registrant (i) up to 17,974,978 shares of common stock, par value $0.001 per share
(the &#x201c;Common Stock&#x201d;), upon the exercise of outstanding warrants to purchase Common Stock (the &#x201c;Warrants&#x201d;) originally
issued by Semper Paratus Acquisition Corporation (&#x201c;Semper Paratus&#x201d;), a Cayman Islands exempted company (n/k/a Tevogen Bio Holdings Inc., a Delaware corporation), as part of Semper Paratus&#x2019;
(a) initial public offering and (b) concurrent private placement (the &#x201c;Private Placement&#x201d;) of units at a price of $10.00
per unit, with each unit consisting of one Class A ordinary share of Semper Paratus and one-half of a warrant, and (ii) up to 24,500,000
shares of Common Stock issuable upon the achievement of certain earnout triggering events as described in prospectus below. The Registration
Statement also registered for resale by the securityholders identified in this prospectus (each a &#x201c;Registered Holder&#x201d; and,
collectively, the &#x201c;Registered Holders&#x201d;) up to 24,551,308 shares of Common Stock (the &#x201c;Total Resale Shares&#x201d;) and
725,000 of our outstanding Warrants, originally issued as part of units sold in the Private Placement (the &#x201c;Private Placement Warrants&#x201d;).

&#160;

This
post-effective amendment is being filed to update the Registration Statement to include information contained in the
registrant&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the SEC on April 2, 2025 (the
&#x201c;2024 Form 10-K&#x201d;), and update certain other information in the Registration Statement.

&#160;

The
information included in this filing amends the Registration Statement and the prospectus contained therein. No additional securities
are being registered under this post-effective amendment. All applicable registration fees were paid at the time of the original filing
of the Registration Statement.


&#160;</dei:AmendmentDescription>
    <us-gaap:Cash
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000047"
      unitRef="USD">1282995</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000048"
      unitRef="USD">1052397</us-gaap:Cash>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000050"
      unitRef="USD">919088</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000051"
      unitRef="USD">670582</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000053"
      unitRef="USD">158819</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000056"
      unitRef="USD">2360902</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000057"
      unitRef="USD">1722979</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000059"
      unitRef="USD">296442</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000060"
      unitRef="USD">458651</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000062"
      unitRef="USD">228490</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000063"
      unitRef="USD">469862</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredCosts
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000066"
      unitRef="USD">2582870</us-gaap:DeferredCosts>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000068"
      unitRef="USD">575841</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000069"
      unitRef="USD">271141</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000071"
      unitRef="USD">3461675</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000072"
      unitRef="USD">5505503</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000080"
      unitRef="USD">5200245</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000081"
      unitRef="USD">3418378</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000083"
      unitRef="USD">1712396</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000084"
      unitRef="USD">1096450</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000086"
      unitRef="USD">229063</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000087"
      unitRef="USD">252714</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000089"
      unitRef="USD">1651000</us-gaap:NotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000093"
      unitRef="USD">80712000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000095"
      unitRef="USD">250000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000098"
      unitRef="USD">9042704</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000099"
      unitRef="USD">85479542</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000102"
      unitRef="USD">14220000</us-gaap:ConvertibleLongTermNotesPayable>
    <TVGN:LoanAgreementNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000104"
      unitRef="USD">1000000</TVGN:LoanAgreementNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000107"
      unitRef="USD">5796</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000108"
      unitRef="USD">234858</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000110"
      unitRef="USD">87180</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000113"
      unitRef="USD">10135680</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000114"
      unitRef="USD">99934400</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000122"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000124"
      unitRef="Shares">2000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000126"
      unitRef="Shares">500</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000128"
      unitRef="Shares">500</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockLiquidationPreferenceValue
      contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact000130"
      unitRef="USD">2076712</us-gaap:PreferredStockLiquidationPreferenceValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact000119"
      unitRef="USD">2799990</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000135"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000137"
      unitRef="Shares">600</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000139"
      unitRef="Shares">600</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000141"
      unitRef="Shares">600</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockLiquidationPreferenceValue
      contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000143"
      unitRef="USD">6082603</us-gaap:PreferredStockLiquidationPreferenceValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000132"
      unitRef="USD">6000000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000145"
      unitRef="USD">6000000</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000151"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000153"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000155"
      unitRef="Shares">800000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000157"
      unitRef="Shares">800000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000159"
      unitRef="Shares">177991365</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000161"
      unitRef="Shares">177991365</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000163"
      unitRef="Shares">119999989</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000165"
      unitRef="Shares">119999989</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000148"
      unitRef="USD">17800</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000149"
      unitRef="USD">12000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000167"
      unitRef="USD">97893322</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000168"
      unitRef="USD">5216840</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000170"
      unitRef="USD">-113385117</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000171"
      unitRef="USD">-99657737</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000173"
      unitRef="USD">-6674005</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000174"
      unitRef="USD">-94428897</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000176"
      unitRef="USD">3461675</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000177"
      unitRef="USD">5505503</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000182"
      unitRef="USD">31033276</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000183"
      unitRef="USD">4403526</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000185"
      unitRef="USD">22531212</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000186"
      unitRef="USD">4439499</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000188"
      unitRef="USD">53564488</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000189"
      unitRef="USD">8843025</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000191"
      unitRef="USD">-53564488</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000192"
      unitRef="USD">-8843025</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000194"
      unitRef="USD">184037</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000195"
      unitRef="USD">1206352</us-gaap:InterestExpense>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000197"
      unitRef="USD">7499353</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000200"
      unitRef="USD">58180</us-gaap:FairValueAdjustmentOfWarrants>
    <TVGN:ChangeInFairValueOfConvertiblePromissoryNotes
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000203"
      unitRef="USD">48468678</TVGN:ChangeInFairValueOfConvertiblePromissoryNotes>
    <TVGN:ChangeInFairValueOfConvertiblePromissoryNotes
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000204"
      unitRef="USD">-50428303</TVGN:ChangeInFairValueOfConvertiblePromissoryNotes>
    <TVGN:LossOnIssuanceOfCommitmentShares
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000206"
      unitRef="USD">890000</TVGN:LossOnIssuanceOfCommitmentShares>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000209"
      unitRef="USD">-13727380</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000210"
      unitRef="USD">-60477680</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000212"
      unitRef="USD">-10273695</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000214"
      unitRef="USD">-10273695</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000216"
      unitRef="USD">-60477680</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000218"
      unitRef="USD">-60477680</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000220"
      unitRef="USDPShares">-0.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000222"
      unitRef="USDPShares">-0.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000224"
      unitRef="USDPShares">-2.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000226"
      unitRef="USDPShares">-2.44</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000228"
      unitRef="Shares">146672534</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000230"
      unitRef="Shares">146672534</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000232"
      unitRef="Shares">24752000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000234"
      unitRef="Shares">24752000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000250"
      unitRef="Shares">119999989</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000239"
      unitRef="USD">12000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000240"
      unitRef="USD">5216840</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000241"
      unitRef="USD">-39180057</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000242"
      unitRef="USD">-33951217</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000257"
      unitRef="USD">-60477680</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000258"
      unitRef="USD">-60477680</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000274"
      unitRef="Shares">119999989</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000263"
      unitRef="USD">12000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000264"
      unitRef="USD">5216840</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000265"
      unitRef="USD">-99657737</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000266"
      unitRef="USD">-94428897</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000290"
      unitRef="Shares">119999989</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000279"
      unitRef="USD">12000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000280"
      unitRef="USD">5216840</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000281"
      unitRef="USD">-99657737</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000282"
      unitRef="USD">-94428897</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000300"
      unitRef="Shares">500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact000292"
      unitRef="USD">2799990</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000298"
      unitRef="USD">2799990</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <TVGN:StockIssuedDuringPeriodSharesNewIssuesTwo
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000310"
      unitRef="Shares">600</TVGN:StockIssuedDuringPeriodSharesNewIssuesTwo>
    <TVGN:StockIssuedDuringPeriodValueNewIssuesTwo
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000304"
      unitRef="USD">6000000</TVGN:StockIssuedDuringPeriodValueNewIssuesTwo>
    <TVGN:StockIssuedDuringPeriodValueNewIssuesTwo
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000308"
      unitRef="USD">6000000</TVGN:StockIssuedDuringPeriodValueNewIssuesTwo>
    <TVGN:StockIssuedDuringPeriodSharesNewIssuesOne
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000320"
      unitRef="Shares">3613</TVGN:StockIssuedDuringPeriodSharesNewIssuesOne>
    <TVGN:StockIssuedDuringPeriodValueNewIssuesOne
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      id="Fact000313"
      unitRef="USD">3613000</TVGN:StockIssuedDuringPeriodValueNewIssuesOne>
    <TVGN:StockIssuedDuringPeriodValueNewIssuesOne
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000318"
      unitRef="USD">3613000</TVGN:StockIssuedDuringPeriodValueNewIssuesOne>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000330"
      unitRef="Shares">10337419</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000325"
      unitRef="USD">1034</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000326"
      unitRef="USD">46621593</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000328"
      unitRef="USD">46622627</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000340"
      unitRef="Shares">14778056</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <TVGN:MergerNetOfRedemptionsAndTransactionCosts
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000335"
      unitRef="USD">-1478</TVGN:MergerNetOfRedemptionsAndTransactionCosts>
    <TVGN:MergerNetOfRedemptionsAndTransactionCosts
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000336"
      unitRef="USD">2885459</TVGN:MergerNetOfRedemptionsAndTransactionCosts>
    <TVGN:MergerNetOfRedemptionsAndTransactionCosts
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000338"
      unitRef="USD">2883981</TVGN:MergerNetOfRedemptionsAndTransactionCosts>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000350"
      unitRef="Shares">19348954</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000345"
      unitRef="USD">1935</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000346"
      unitRef="USD">-1935</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000360"
      unitRef="Shares">150000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000355"
      unitRef="USD">15</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000356"
      unitRef="USD">676485</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000358"
      unitRef="USD">676500</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <TVGN:StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithLoanAgreement
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000370"
      unitRef="Shares">1000000</TVGN:StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithLoanAgreement>
    <TVGN:StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000365"
      unitRef="USD">100</TVGN:StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement>
    <TVGN:StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000366"
      unitRef="USD">889900</TVGN:StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement>
    <TVGN:StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000368"
      unitRef="USD">890000</TVGN:StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000380"
      unitRef="Shares">1500000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000375"
      unitRef="USD">150</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000376"
      unitRef="USD">-150</us-gaap:StockIssuedDuringPeriodValueOther>
    <TVGN:StockIssuedDuringPeriodSharesContributionFromRelatedParty
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000390"
      unitRef="Shares">-3613</TVGN:StockIssuedDuringPeriodSharesContributionFromRelatedParty>
    <TVGN:StockIssuedDuringPeriodValueContributionFromRelatedParty
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      id="Fact000383"
      unitRef="USD">-3613000</TVGN:StockIssuedDuringPeriodValueContributionFromRelatedParty>
    <TVGN:StockIssuedDuringPeriodValueContributionFromRelatedParty
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000386"
      unitRef="USD">3613000</TVGN:StockIssuedDuringPeriodValueContributionFromRelatedParty>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000396"
      unitRef="USD">3000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000398"
      unitRef="USD">3000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket>
    <TVGN:StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000408"
      unitRef="Shares">10876947</TVGN:StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits>
    <TVGN:StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000403"
      unitRef="USD">1088</TVGN:StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits>
    <TVGN:StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000404"
      unitRef="USD">-1088</TVGN:StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000414"
      unitRef="USD">40764136</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000416"
      unitRef="USD">40764136</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000423"
      unitRef="USD">-13727380</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000424"
      unitRef="USD">-13727380</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000434"
      unitRef="Shares">500</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact000426"
      unitRef="USD">2799990</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000438"
      unitRef="Shares">600</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000428"
      unitRef="USD">6000000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000440"
      unitRef="Shares">177991365</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000429"
      unitRef="USD">17800</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000430"
      unitRef="USD">97893322</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000431"
      unitRef="USD">-113385117</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000432"
      unitRef="USD">-6674005</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000450"
      unitRef="Shares">500</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact000442"
      unitRef="USD">2799990</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000454"
      unitRef="Shares">600</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000444"
      unitRef="USD">6000000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000456"
      unitRef="Shares">177991365</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000445"
      unitRef="USD">17800</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000446"
      unitRef="USD">97893322</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000447"
      unitRef="USD">-113385117</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000448"
      unitRef="USD">-6674005</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000461"
      unitRef="USD">-13727380</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000462"
      unitRef="USD">-60477680</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000467"
      unitRef="USD">162209</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000468"
      unitRef="USD">163300</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000470"
      unitRef="USD">40764136</us-gaap:ShareBasedCompensation>
    <us-gaap:PaidInKindInterest
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000473"
      unitRef="USD">187575</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000474"
      unitRef="USD">1206697</us-gaap:PaidInKindInterest>
    <us-gaap:NoncashMergerRelatedCosts
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000476"
      unitRef="USD">7099353</us-gaap:NoncashMergerRelatedCosts>
    <TVGN:ChangeInFairValueOfConvertiblePromissoryNotes
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000479"
      unitRef="USD">48468678</TVGN:ChangeInFairValueOfConvertiblePromissoryNotes>
    <TVGN:ChangeInFairValueOfConvertiblePromissoryNotes
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000480"
      unitRef="USD">-50428303</TVGN:ChangeInFairValueOfConvertiblePromissoryNotes>
    <TVGN:LossOnPreferredStockIssuance
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000482"
      unitRef="USD">799990</TVGN:LossOnPreferredStockIssuance>
    <TVGN:LossOnIssuanceOfCommitmentShares
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000485"
      unitRef="USD">890000</TVGN:LossOnIssuanceOfCommitmentShares>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000488"
      unitRef="USD">58180</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000491"
      unitRef="USD">241372</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000492"
      unitRef="USD">215057</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000497"
      unitRef="USD">246005</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000498"
      unitRef="USD">317605</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000500"
      unitRef="USD">511011</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000501"
      unitRef="USD">-323742</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000503"
      unitRef="USD">1685692</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000504"
      unitRef="USD">1114261</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000506"
      unitRef="USD">-681450</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000507"
      unitRef="USD">-603832</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000509"
      unitRef="USD">-252713</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000510"
      unitRef="USD">-223361</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000512"
      unitRef="USD">-11998730</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000513"
      unitRef="USD">-8171118</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000519"
      unitRef="USD">133000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000522"
      unitRef="USD">-133000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <TVGN:CashAcquiredInConnectionWithReverseRecapitalization
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000527"
      unitRef="USD">229328</TVGN:CashAcquiredInConnectionWithReverseRecapitalization>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000530"
      unitRef="USD">2000000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <TVGN:ProceedsFromIssuanceOfSeriesCPreferredStock
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000533"
      unitRef="USD">6000000</TVGN:ProceedsFromIssuanceOfSeriesCPreferredStock>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000536"
      unitRef="USD">1000000</us-gaap:ProceedsFromLinesOfCredit>
    <TVGN:NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000539"
      unitRef="USD">3000000</TVGN:NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000543"
      unitRef="USD">127750</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000546"
      unitRef="USD">4000000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000548"
      unitRef="USD">12229328</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000549"
      unitRef="USD">3872250</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000551"
      unitRef="USD">230598</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000552"
      unitRef="USD">-4431868</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000554"
      unitRef="USD">1052397</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000555"
      unitRef="USD">5484265</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000557"
      unitRef="USD">1282995</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000558"
      unitRef="USD">1052397</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <TVGN:ReverseRecapitalizationTransactionFeesIncludedInAccruedExpensesAndOtherLiabilities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000564"
      unitRef="USD">2455120</TVGN:ReverseRecapitalizationTransactionFeesIncludedInAccruedExpensesAndOtherLiabilities>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000566"
      unitRef="USD">46622627</us-gaap:DebtConversionOriginalDebtAmount1>
    <TVGN:RepurchaseOfSeriesBPreferredStock
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000569"
      unitRef="USD">3613000</TVGN:RepurchaseOfSeriesBPreferredStock>
    <us-gaap:StockIssued1
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000572"
      unitRef="USD">3113309</us-gaap:StockIssued1>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000575">&lt;p id="xdx_804_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zCNaGI6GbMM7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
1. &lt;span id="xdx_82B_zN9tcoyn3jBc"&gt;NATURE OF BUSINESS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Tevogen
Bio Holdings Inc., a Delaware corporation (the &#x201c;Company&#x201d;), is a clinical-stage specialty immunotherapy company harnessing
the power of CD8+ cytotoxic T lymphocytes to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases,
cancers, and other disorders. The Company&#x2019;s precision T cell technology, ExacTcell, is a set of processes and methodologies to
develop, enrich, and expand single human leukocyte antigen-restricted CTL therapies with proactively selected, precisely defined targets.
The Company has completed a Phase 1 proof-of-concept trial for the first clinical product of ExacTcell, TVGN 489, for the treatment of
ambulatory, high-risk adult COVID-19 patients, and has other product candidates in its pipeline.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 14, 2024 (the &#x201c;Closing Date&#x201d;), pursuant to the Agreement and Plan of Merger dated June 28, 2023 (the &#x201c;Merger
Agreement&#x201d;) by and among Semper Paratus Acquisition Corporation (&#x201c;Semper Paratus&#x201d;), Semper Merger Sub, Inc., a wholly
owned subsidiary of Semper Paratus (&#x201c;Merger Sub&#x201d;), SSVK Associates, LLC (the &#x201c;Sponsor&#x201d;), Tevogen Bio Inc (n/k/a
Tevogen Bio Inc.) (&#x201c;Tevogen Bio&#x201d;), and Dr. Ryan Saadi, in his capacity as seller representative, Merger Sub merged with and
into Tevogen Bio, with Tevogen Bio being the surviving entity and a wholly owned subsidiary of Semper Paratus (the &#x201c;Merger&#x201d;
and together with the other transactions contemplated by the Merger Agreement, the &#x201c;Business Combination&#x201d;) and Semper Paratus
was renamed Tevogen Bio Holdings Inc.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the closing of the Business Combination (the &#x201c;Closing&#x201d;), the then-outstanding shares of common stock of Tevogen
Bio, were converted into shares of the common stock of the Company at an exchange ratio of approximately&#160;&lt;span id="xdx_908_ecustom--BusinessCombinationSharesExchangeRatio_iI_c20240214__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXBingLPzREg" title="Business combination shares"&gt;4.85&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;shares
of Company common stock for each share of Tevogen Bio common stock (the &#x201c;Exchange Ratio&#x201d;). See Note 4 for more information
on the Business Combination.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
discussed in Note 4, the Merger was accounted for as a reverse recapitalization under which the historical financial statements of the
Company prior to the Merger are those of Tevogen Bio. All information related to the common stock of Tevogen Bio prior to the Closing
and presented in the consolidated financial statements and notes thereto has been retroactively adjusted to reflect the Exchange Ratio.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Following
the Merger, the former equity holders and holders of convertible promissory notes of Tevogen Bio held&#160;&lt;span id="xdx_904_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TevogenBioMember_z8YaQSRt0PL"&gt;91.0&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
of the outstanding shares of common stock of the Company and the former shareholders, creditors, and other contractual counterparties
of Semper Paratus held&#160;&lt;span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SemperParatusMember_zwafqri8gW67" title="Equity ownership percentage"&gt;9.0&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
of the Company.&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <TVGN:BusinessCombinationSharesExchangeRatio
      contextRef="AsOf2024-02-14_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000577"
      unitRef="Pure">4.85</TVGN:BusinessCombinationSharesExchangeRatio>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2024-12-31_custom_TevogenBioMember"
      decimals="INF"
      id="Fact000578"
      unitRef="Pure">0.910</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2024-12-31_custom_SemperParatusMember"
      decimals="INF"
      id="Fact000580"
      unitRef="Pure">0.090</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <TVGN:DevelopmentStageRisksAndLiquidityTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000582">&lt;p id="xdx_80E_ecustom--DevelopmentStageRisksAndLiquidityTextBlock_zSEL1kYFLT55" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
2. &lt;span id="xdx_825_zdaGSlgqJht8"&gt;DEVELOPMENT-STAGE RISKS AND LIQUIDITY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has generally incurred losses and negative cash flows from operations since inception. The Company anticipates incurring additional
losses until such time, if ever, that it can generate significant sales from its product candidates currently in development. Management
believes that cash of $&lt;span id="xdx_90E_eus-gaap--Cash_iI_c20241231_z54gFr7yqmm9" title="Cash"&gt;1,282,995&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;as
of December 31, 2024, the amounts available under the Loan Agreement entered into in June 2024 (as defined in Note 8), and the commitment
for an $&lt;span id="xdx_906_eus-gaap--ProceedsFromRelatedPartyDebt_c20240601__20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zz9m7Wc2CT43" title="Grant received"&gt;8,000,000
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;grant from KRHP LLC, a New Jersey limited
liability company (&#x201c;KRHP&#x201d;), will allow the Company to have adequate cash and financial resources to operate for at least
the next 12 months from the date of issuance of these consolidated financial statements. Subsequent to December 31, 2024, the Company
received a grant of $&lt;span id="xdx_90F_eus-gaap--ProceedsFromRelatedPartyDebt_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z3YVJ23ouYca" title="Grant received"&gt;2,000,000
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;from KRHP and drew $&lt;span id="xdx_907_ecustom--GrantDrewFromRelatedParty_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zHn5lQn3Qp5b" title="Grant drew from related party"&gt;1,000,000
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;in each of February 2025 and in March
2025 under the Loan Agreement. The grant funding may not be used for repayment of existing debt obligations and does not include any
requirement to repay the investor or to issue equity in consideration of the funding. KRHP has committed to provide an additional $&lt;span id="xdx_90D_eus-gaap--ProceedsFromRelatedPartyDebt_c20240601__20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zy6KwBSPcvhf" title="Grant received"&gt;8,000,000
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;of grant funding to the Company to be
used towards the Company&#x2019;s ongoing operational expenses. The grant funding will be used to satisfy the Company&#x2019;s obligations
as they come due through March 31, 2026. The Company does not plan to initiate a clinical trial until additional funding is received.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
regularly evaluates different strategies to obtain funding for operations for subsequent periods. These strategies may include but are
not limited to private placements of securities, licensing and/or marketing arrangements, partnerships with other pharmaceutical or biotechnology
companies, and public offerings of securities. The Company may not be able to obtain financing on acceptable terms and the Company may
not be able to enter into strategic alliances or other arrangements on favorable terms. The terms of any financing may adversely affect
the holdings or the rights of the Company&#x2019;s stockholders. If the Company is unable to obtain sufficient funding, the Company could
be required to delay, reduce or eliminate research and development programs, product portfolio expansion, or future commercialization
efforts, which could adversely affect its business prospects.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operations
since inception have consisted primarily of organizing the Company, securing financing, developing licensed technologies, performing
research, conducting pre-clinical studies and a clinical trial, and pursuing and completing the Business Combination. The Company is
subject to risks associated with any specialty biotechnology company that requires considerable expenditures for research and development.
The Company&#x2019;s research and development projects may not be successful, products developed may not obtain necessary regulatory approval,
and any approved product may not be commercially viable. In addition, the Company operates in an environment of rapid technological change
and is largely dependent on the services of its employees and consultants.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;b&gt;TEVOGEN BIO HOLDINGS
INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;b&gt;NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


</TVGN:DevelopmentStageRisksAndLiquidityTextBlock>
    <us-gaap:Cash
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000584"
      unitRef="USD">1282995</us-gaap:Cash>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2024-06-012024-06-30_custom_LoanAgreementMember"
      decimals="0"
      id="Fact000586"
      unitRef="USD">8000000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2025-01-012025-03-31_custom_LoanAgreementMember_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact000588"
      unitRef="USD">2000000</us-gaap:ProceedsFromRelatedPartyDebt>
    <TVGN:GrantDrewFromRelatedParty
      contextRef="From2025-01-012025-03-31_custom_LoanAgreementMember_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact000590"
      unitRef="USD">1000000</TVGN:GrantDrewFromRelatedParty>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2024-06-012024-06-30_custom_LoanAgreementMember"
      decimals="0"
      id="Fact000592"
      unitRef="USD">8000000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000594">&lt;p id="xdx_804_eus-gaap--SignificantAccountingPoliciesTextBlock_zFtpcnRqHCDf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
3. &lt;span id="xdx_82D_zIoAw2Lo0PA"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zEjozw92zT9b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_869_z6zGIDk7hIo2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basis
of Presentation&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;These
consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (&#x201c;GAAP&#x201d;).
Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;)
and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--UseOfEstimates_zh4v7xeUIyE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_86C_z9OsFUUKNFM7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Use
of Estimates&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
preparing the consolidated financial statements in conformity with GAAP, management is required to make estimates and assumptions that
affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts of
expenses. Actual results could differ from those estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions
are reflected in the consolidated financial statements in the period they are determined to be necessary.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Significant
areas that require management&#x2019;s estimates include the fair value of the common stock and convertible promissory notes prior to
the Merger, the fair value of the Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock, fair value of the
purchase options under the Loan Agreement, stock-based compensation assumptions, and accrued research and development expenses.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_ecustom--FreestandingAndEmbeddedCommonStockOptionsPolicyTextBlock_zU1Yg00Ynoqa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_86B_zjZOTYXrYvW1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Freestanding
and Embedded Common Stock Purchase Options&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity-linked
purchase options issued in connection with the Company&#x2019;s debt agreements are assessed to determine whether they are freestanding
or embedded with the host instrument under ASC 815,&#160;&lt;i&gt;Derivatives and Hedging Contracts in Entity&#x2019;s Own Equity&#160;&lt;/i&gt;(&#x201c;ASC
815&#x201d;). Each type of purchase option is then assessed for equity or liability classification under ASC 815. The Company&#x2019;s
embedded and freestanding purchase options were determined to be liability-classified derivative instruments and are measured at fair
value both on the date of issuance and at each subsequent balance sheet date, with changes in fair value recorded to &#x2018;Change in
fair value of written call option derivative liabilities&#x2019; within the consolidated statements of operations and consolidated statements
of cash flows.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_zaVX69hJqaGj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_860_zBYIf29m4TMl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Concentrations
of Credit Risk&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash. The Company
maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced
any losses in such accounts and believes it is not exposed to significant risk on its cash.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zGavjTbsGjld" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_86B_zqy1DxfGgale" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Segment
Reporting&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
segments are defined as components of an entity for which discrete financial information is both available and regularly reviewed by
its chief operating decision maker or decision-making group. The Company views its operations and manages its business in &lt;span id="xdx_905_eus-gaap--NumberOfOperatingSegments_pid_dc_uSegment_c20240101__20241231_zQCkR43qaf21" title="Number of operating segments"&gt;one
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;segment.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;b&gt;TEVOGEN BIO HOLDINGS
INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;b&gt;NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p id="xdx_84C_eus-gaap--DerivativesPolicyTextBlock_zD1xmE1CP1Z1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_860_zTyoPxhDqOEb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
the result of the Merger, the Company accounts for its warrants originally sold as part of Semper Paratus&#x2019;s initial public offering
(the &#x201c;IPO&#x201d;) in accordance with ASC 815, &lt;i&gt;Derivatives and Hedging Contracts in Entity&#x2019;s Own Equity &lt;/i&gt;(&#x201c;ASC
815&#x201d;) and ASC 480,&#160;&lt;i&gt;Distinguishing Liabilities from Equity&lt;/i&gt;&#160;(&#x201c;ASC 480&#x201d;). The assessment considers whether
the warrants are freestanding financial instruments and meet the definition of a liability pursuant to ASC 480 and meet all of the conditions
for equity classification under ASC 815, including whether the warrants are indexed to the Company&#x2019;s own shares of common stock,
among other conditions. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance
and as of each subsequent quarterly period end date while the warrants are outstanding. For issued or modified warrants that meet all
of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the
time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required
to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter until settlement. Changes
in the estimated fair value of the warrants are recognized as a non-cash loss on the consolidated statements of operations. Under these
standards, the Company&#x2019;s private placement warrants sold at the time of the IPO do not meet the criteria for equity classification
and must be recorded as liabilities while the public warrants sold in connection with the IPO do meet the criteria for equity classification
and must be recorded as equity.&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zrhlYragtHG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_867_zPsHFdIWiME8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Fair
Value Measurements&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Certain
assets and liabilities are carried at fair value under GAAP. Fair value is defined as the price that would be received for an asset or
paid to transfer a liability (exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction
between market participants on the measurement date. The Company utilizes valuation techniques that maximize the use of observable inputs
and minimize the use of unobservable inputs to the extent possible. When considering market participant assumptions in fair value measurements,
the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following
levels:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 0.5in; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unadjusted
    quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Observable
    inputs other than Level 1 prices, such as quoted prices for similar, but not identical, assets or liabilities in active markets;
    quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable
    or can be corroborated by observable market data;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unobservable
    inputs in which there is little or no market data available and which require the Company to develop its own assumptions that market
    participants would use in pricing an asset or liability.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments recognized at historical amounts in the balance sheets consist of accounts payable and notes payable. The Company believes
that the carrying value of accounts payable and notes payable approximates their fair values due to the short-term nature of these instruments.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s recurring fair value measurements consist of the convertible promissory notes prior to the Merger, for which the Company
elected the fair value option to reduce accounting complexity, and private warrants after the Merger. Such fair value measurements are
Level 3 inputs. The following table provides a roll-forward of the aggregate fair values of the Company&#x2019;s convertible promissory
notes.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zvQIcfKfBw7b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_8B4_zLwMSvweVTPg" style="display: none"&gt;SCHEDULE
OF FAIR VALUE MEASUREMENT&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;Balance at January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zmPdTyoWTo8e" style="width: 16%; text-align: right" title="Fair value beginning balance"&gt;&lt;span style="-sec-ix-redline: true"&gt;39,297,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Initial fair value at issuance&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zn2RHV15r6Be" style="text-align: right" title="Initial fair value at issuance"&gt;&lt;span style="-sec-ix-redline: true"&gt;4,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Accrued interest expense&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zPFQwSUZCOQj" style="text-align: right" title="Accrued interest expense"&gt;&lt;span style="-sec-ix-redline: true"&gt;1,206,697&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zNzncNEjVShd" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"&gt;&lt;span style="-sec-ix-redline: true"&gt;50,428,303&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z4rCEr5QVgp4" style="text-align: right" title="Fair value beginning balance"&gt;&lt;span style="-sec-ix-redline: true"&gt;94,932,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Accrued interest expense&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zt6aGeiPKPWa" style="text-align: right" title="Accrued interest expense"&gt;&lt;span style="-sec-ix-redline: true"&gt;159,305&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zyjBGFf91vbi" style="text-align: right" title="Change in fair value"&gt;&lt;span style="-sec-ix-redline: true"&gt;(48,468,678&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Derecognition upon conversion of convertible promissory
    notes&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5YwVfhmAdXj" style="border-bottom: Black 1pt solid; text-align: right" title="Derecognition upon conversion of convertible promissory notes"&gt;&lt;span style="-sec-ix-redline: true"&gt;(46,622,627&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2ME1DbWt72e" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value beginning balance"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0630"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zqcgjNCAyIG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;b&gt;TEVOGEN BIO HOLDINGS
INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;b&gt;NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were no transfers between levels during the years ended December 31, 2024 and 2023.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company used the probability weighted expected return method valuation methodology to determine the fair value of the convertible promissory
notes prior to the Merger. Significant assumptions and ranges used in determining the fair value of convertible promissory notes prior
to the Merger include volatility (&lt;span id="xdx_903_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zF3lzBx4NxE3" title="Volatility"&gt;80&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%),
discount rate (&lt;span id="xdx_90D_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember__srt--RangeAxis__srt--MinimumMember_zI7cdoSRgYZf" title="Volatility"&gt;35&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
- &lt;span id="xdx_90C_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember__srt--RangeAxis__srt--MaximumMember_z3CE1sVwC9l8" title="Volatility"&gt;36&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%),
and probability of a future liquidity event (&lt;span id="xdx_90F_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__custom--ProbabilityOfFutureLiquidityMember__srt--RangeAxis__srt--MinimumMember_zWLtQzBOBiyb" title="Volatility"&gt;85&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
- &lt;span id="xdx_906_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__custom--ProbabilityOfFutureLiquidityMember__srt--RangeAxis__srt--MaximumMember_ztX9pqLKBk9j" title="Volatility"&gt;95&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%).
The Company used its stock price on the Closing Date to determine the fair value for the derecognition of the convertible promissory
notes upon conversion on the Closing Date.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon
the Closing, the Company acquired private warrants, the fair value of which increased by $&lt;span id="xdx_900_eus-gaap--FairValueAdjustmentOfWarrants_iN_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCyhs8Yly2tg" title="Fair value adjustment of warrants"&gt;58,180&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;between
the Closing Date and December 31, 2024 primarily due to changes in the market value of the Company&#x2019;s common shares. In June 2024,
the Company issued written call options in connection with the Loan Agreement, the fair value of which decreased by $&lt;span id="xdx_903_eus-gaap--FairValueAdjustmentOfWarrants_iN_di_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zK0pZpXRMYP3" title="Fair value adjustment of warrants"&gt;375,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;between
the issuance and December 31, 2024. Such fair value measurements are Level 3 inputs. The following table provides a roll-forward of the
aggregate fair values of the warrants and the written call option derivative liabilities.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zVFlWWOtgvBk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_8BC_zKxxJeSEy77b" style="display: none"&gt;SCHEDULE
OF FAIR VALUES OF WARRANTS&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Derivative&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;warrant
                                            liabilities&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Written
                                            call option&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;derivative
                                            liabilities&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;Balance at February 15, 2024&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DerivativeLiabilitiesNoncurrent_iS_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHBI9UhFXWzg" style="text-align: right" title="Derivative warrant liabilities, Balance"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0648"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DerivativeLiabilitiesNoncurrent_iS_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zNojA057WR65" style="text-align: right" title="Derivative warrant liabilities, Balance"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0650"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Initial fair value at issuance&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_ecustom--DerivativeLiabilitiesFairValueIssuance_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziWiAcw0clR" style="width: 16%; text-align: right" title="Initial fair value at issuance"&gt;&lt;span style="-sec-ix-redline: true"&gt;29,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--DerivativeLiabilitiesFairValueIssuance_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zh8O4BbAP9Vc" style="width: 16%; text-align: right" title="Initial fair value at issuance"&gt;&lt;span style="-sec-ix-redline: true"&gt;375,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FairValueAdjustmentOfWarrants_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQUdk6IQWDg1" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"&gt;&lt;span style="-sec-ix-redline: true"&gt;58,180&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FairValueAdjustmentOfWarrants_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zhTcXjj4WLil" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"&gt;&lt;span style="-sec-ix-redline: true"&gt;(375,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--DerivativeLiabilitiesNoncurrent_iE_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeYQcoChW2m" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrant liabilities, Balance"&gt;&lt;span style="-sec-ix-redline: true"&gt;87,180&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--DerivativeLiabilitiesNoncurrent_iE_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zfSJPgabLkfk" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrant liabilities, Balance"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0662"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zoiLz4vJKfVi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zUKPgDAmlig6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents information about the Company&#x2019;s liabilities that are measured at fair value on a recurring basis at December
31, 2024, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_8B2_zMdNzDoPK375" style="display: none"&gt;SCHEDULE
OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;Level&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;Quoted Prices
    in &lt;br/&gt; Active Markets &lt;br/&gt; (Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;Significant
    Other &lt;br/&gt; Observable Inputs &lt;br/&gt; (Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;Significant
    Other &lt;br/&gt; Unobservable &lt;br/&gt; Inputs (Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 44%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Derivative warrant liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zTFE3aAAK2o2" style="width: 10%; text-align: right" title="Derivative warrant liabilities"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0666"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zI5XpHzeno74" style="width: 10%; text-align: right" title="Derivative warrant liabilities"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0668"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zT3vY3M4tuw6" style="width: 10%; text-align: right" title="Derivative warrant liabilities"&gt;&lt;span style="-sec-ix-redline: true"&gt;87,180&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zfdgPue2UFzb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s nonrecurring fair value measurements consist of Series A Preferred Stock. Such fair value measurements are Level 3 inputs.
The Company determined the fair value of Series A Preferred Stock using a Monte Carlo Simulation (&#x201c;MCS&#x201d;). Key inputs utilized
in the MCS to estimate fair value of Series A Preferred Stock included a range of volatility between&#160;&lt;span id="xdx_90E_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zBQCgsFYWXy" title="Stock, measurement input"&gt;75&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
to&#160;&lt;span id="xdx_90B_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zY07bkVh1tTi"&gt;85&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%,
a holding period to a deemed liquidation event, as defined in the Series A Preferred Stock agreement, ranging from&#160;&lt;span id="xdx_900_ecustom--EquitySecuritiesTerm_dtY_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--RangeAxis__srt--MinimumMember_zJ7WOdTcTrch" title="Holding period"&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;to&#160;&lt;span id="xdx_900_ecustom--EquitySecuritiesTerm_dtY_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--RangeAxis__srt--MaximumMember_zx3jOtbTc9Kk" title="Range in years"&gt;10.0&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;years,
and a risk-free interest rate between&#160;&lt;span id="xdx_90D_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zIZeBBxGPA83" title="Risk-free interest rate percentage"&gt;4.3&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
and&#160;&lt;span id="xdx_90B_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zBXxOkIGk7N7" title="Stock, measurement input"&gt;5.3&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%.
The difference between the cash received of $&lt;span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zgMvkcSAG6bc" title="Cash received upon issuance of preferred stock"&gt;2,000,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;upon
issuance of the Series A Preferred Stock and its estimated fair value was recognized as general and administrative expense on the consolidated
statements of operations during the three months ended March 31, 2024.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company used a MCS valuation methodology to determine the fair value of the freestanding $&lt;span id="xdx_905_ecustom--FreeStandingPurchaseOptions_c20240101__20241231_zMcIwfI14nab" title="Free standing purchase options"&gt;14,000,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;purchase
option and remaining embedded $&lt;span id="xdx_90A_ecustom--EmbeddedOptions_c20240101__20241231_zJt3WvksQt6c" title="Embedded options shares"&gt;30,000,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;purchase
option associated with the Loan Agreement as of December 31, 2024. The MCS methodology simulates the Company&#x2019;s future stock price
to estimate if and when the Trailing VWAP (as defined below) will reach $&lt;span id="xdx_90A_eus-gaap--SharePrice_iI_uUSDPShares_c20241231_zDGajU2DphH" title="Share price"&gt;10.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;per
share, and discounts the resulting payoff back to each valuation date using a present value factor. Significant assumptions used in determining
the fair value of these options include volatility of&#160;&lt;span id="xdx_905_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zO4ZtR8xaGD7"&gt;78.3&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
and discount rate of&#160;&lt;span id="xdx_900_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember_zA5hPt9cSmoa" title="Discount rate"&gt;4.3&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%.
At December 31, 2024, the MCS produced a fair value of $&lt;span id="xdx_901_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20241231_zCSBpPO94ljd" title="Fair value"&gt;0
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;relating to these freestanding and embedded
options.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;b&gt;TEVOGEN BIO HOLDINGS
INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;b&gt;NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zDD1mMrYTiic" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_863_zfPQfeKGxXZ1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Cash&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers all highly liquid financial instruments with a maturity date of 90 days or less when purchased to be cash equivalents.
There were &lt;span id="xdx_900_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_do_c20241231_zjoGF4P7HdTl" title="Cash equivalents"&gt;&lt;span id="xdx_902_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_do_c20231231_zSAdcokKBeoe" title="Cash equivalents"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;cash
equivalents as of December 31, 2024 and 2023 as all amounts consisted of bank deposits.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zdqI5jkunLD6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_864_zoqVO2hfbssd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Property
and Equipment, Net&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_ecustom--PropertyAndEquipmentUsefulLifeTableTextBlock_zHN0wr1ikGj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment is recorded at cost. Depreciation and amortization is provided using straight-line methods over their respective estimated
useful lives. Repairs and maintenance, which do not extend the useful lives of the related assets, are expensed as incurred.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_8B5_zJYD2SpYrHLa" style="display: none"&gt;SCHEDULE
OF PROPERTY AND EQUIPMENT USEFUL LIFE&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;Estimated Useful Lives&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 83%; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 14%; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zYycrtiHNlDj" title="Property, plant and equipment, useful life"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_zDnZQPBSz9v3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="Property, plant and equipment, useful life"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zLHnEO71cT9d" title="Property, plant and equipment, useful life"&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zSUqkMCooCEj" title="Property, plant and equipment, useful life"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zSoNNhiJr9od" title="Property, plant and equipment, useful life"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zl5Ugxi1eSE3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company reviews the carrying value of property and equipment whenever events and circumstances indicate that the carrying value of an
asset may not be recoverable from the estimated future cash flows expected to result from its eventual use and disposition. Based on
this assessment, management has determined that there was no impairment during the years ended December 31, 2024 and 2023.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--LesseeLeasesPolicyTextBlock_zfKTy2QrYHCk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_862_z4mqZGMPTzPj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determines whether an arrangement is or contains a lease, its classification, and its term at the lease commencement date. Leases
with a term greater than one year will be recognized on the balance sheet as right-of-use (&#x201c;ROU&#x201d;) assets, current lease liabilities,
and if applicable, long-term lease liabilities. The Company includes renewal options to extend the lease term where it is reasonably
certain that it will exercise these options. Lease liabilities and the corresponding ROU assets are recorded based on the present values
of lease payments over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such,
the Company utilizes the appropriate incremental borrowing rates, which are the rates that would be incurred to borrow on a collateralized
basis, over similar terms, amounts equal to the lease payments in a similar economic environment. If significant events, changes in circumstances,
or other events indicate that the lease term or other inputs have changed, the Company would reassess lease classification, remeasure
the lease liability using revised inputs as of the reassessment date, and adjust the ROU assets. Lease expense is recognized on a straight-line
basis over the expected lease term for operating classified leases.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leases
with an initial term of &lt;span id="xdx_902_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dc_c20241231_zDnUbmG7pY6j" title="Leases initial term"&gt;12 months&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;
&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;or less and without a purchase option that the Company is reasonably
certain of exercising are not included within the lease ROU assets and lease liabilities on the balance sheet.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_zIdxFuVgTZNh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_868_z51STCTlamK2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Research
and Development Expenses&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development activities are expensed as incurred. Costs for clinical trials and manufacturing activities are recognized based on an
evaluation of our vendors&#x2019; progress towards completion of specific tasks, using data such as participant enrollment, clinical site
activations, or information provided to us by vendors regarding their actual costs incurred. Payments for these activities are based
on the terms of individual contracts and payment timing may differ significantly from the period in which the services were performed.
The Company determines accrual estimates through reports from and discussions with applicable personnel and outside service providers
as to the progress or state of completion of studies, or the services completed. The Company estimates accrued expenses as of each balance
sheet date based on the facts and circumstances known at the time. Costs that are paid in advance of performance are deferred as a prepaid
expense and amortized over the service period as the services are provided.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;b&gt;TEVOGEN BIO HOLDINGS
INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;b&gt;NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p id="xdx_840_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zlWE40LQEnBa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_867_zN8KNyRNRiS1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Stock-Based
Compensation&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Compensation
cost is measured at the grant date fair value of the award and is recognized over the vesting period of the award. The Company uses the
straight-line method to record compensation expense of awards with service-based vesting conditions. The Company accounts for forfeitures
of awards as they occur rather than applying an estimated forfeiture rate to stock-based compensation expense. The Company recognizes
compensation expense for awards with performance conditions when it is probable that the condition will be met, and the award will vest.
Prior to the Merger, the Company estimated the fair value of the Company&#x2019;s common stock on the date of grant in accordance with
the guidance outlined in the American Institute of Certified Public Accountants&#x2019; &lt;i&gt;Accounting and Valuation Guide, Valuation of
Privately-Held-Company Equity Securities Issued as Compensation&lt;/i&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zoWCJBw0vlYh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_866_zldsYnnmPWEb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Income
Taxes&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes using the asset and liability method in accordance with ASC Topic 740, &lt;i&gt;Income Taxes &lt;/i&gt;(&#x201c;ASC
740&#x201d;), which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events
that have been recognized in the consolidated financial statements or in the Company&#x2019;s tax returns. Deferred tax assets and liabilities
are determined on the basis of the differences between the financial statement and tax basis of assets and liabilities using enacted
tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are
recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future
taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all
or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense.
Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent
and feasible tax planning strategies. At December 31, 2024 and 2023, the Company has concluded that a full valuation allowance is necessary
for its net deferred tax assets.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--EarningsPerSharePolicyTextBlock_zPrUSe34nzZ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_869_znCeJn71YSG1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Net
Loss Per Share&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company computes basic net loss per share by dividing net loss by the weighted-average common stock outstanding during the period. Given
the Company&#x2019;s net loss, basic and diluted net loss per share for the years ended December 31, 2024 and 2023 are the same.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zWIqaAo2igS8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_862_zOYer4WwVUw5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Recently
Issued Accounting Standards&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
August 2020, the FASB issued ASU No. 2020-06, &lt;i&gt;Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and
Hedging - Contracts in Entity&#x2019;s Own Equity (Subtopic 815 -40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s
Own Equity &lt;/i&gt;(&#x201c;ASU 2020-06&#x201d;), which simplifies the accounting for convertible instruments by reducing the number of accounting
models available for convertible debt instruments. ASU 2020-06 also eliminates the treasury stock method to calculate diluted earnings
per share for convertible instruments and requires the use of the if-converted method. Effective January 1, 2024, the Company adopted
ASU 2020-06 and that adoption did not have an impact on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2023, the FASB issued ASU No. 2023-07,&#160;&lt;i&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&#160;&lt;/i&gt;(&#x201c;ASU
2023-07&#x201d;). ASU 2023-07 enhances reportable segment disclosures by requiring disclosures such as significant segment expenses. The
main provisions of this update require companies to disclose, on an annual and interim basis, significant segment expenses, segment profit
and loss, and other segments items that are regularly provided to the chief operating decision maker (&#x201c;CODM&#x201d;). This update
also requires companies to disclose the title and position of the CODM and to explain how the CODM uses the reported segment measures
in assessing segment performance and deciding how to allocate resources. The update also requires companies with a single reportable
segment to provide all required segment reporting disclosures. This new standard is effective for fiscal years beginning after December
15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company adopted this standard on January 1,
2024 for annual reporting and interim periods beginning in 2025. See Note 16 for additional disclosures.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;b&gt;TEVOGEN BIO HOLDINGS
INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;b&gt;NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the FASB issued ASU 2024-03, &lt;i&gt;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures,
(Subtopic 220-40) &lt;/i&gt;(&#x201c;ASU 2024-03&#x201d;). ASU 2024-03 improves disclosures regarding the types of expenses included in commonly
presented expense captions, including disaggregating the amounts of employee compensation, depreciation and amortization included within
each income statement expense caption. This standard is effective for fiscal years beginning after December 15, 2026, and interim periods
within fiscal years beginning after December 15, 2027. The Company is currently evaluating the impact of the standard on its consolidated
financial statements and disclosures.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_853_znCRnm9LZro" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000596">&lt;p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zEjozw92zT9b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_869_z6zGIDk7hIo2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basis
of Presentation&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;These
consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (&#x201c;GAAP&#x201d;).
Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;)
and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2024-01-01to2024-12-31" id="Fact000598">&lt;p id="xdx_84E_eus-gaap--UseOfEstimates_zh4v7xeUIyE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_86C_z9OsFUUKNFM7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Use
of Estimates&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
preparing the consolidated financial statements in conformity with GAAP, management is required to make estimates and assumptions that
affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts of
expenses. Actual results could differ from those estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions
are reflected in the consolidated financial statements in the period they are determined to be necessary.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Significant
areas that require management&#x2019;s estimates include the fair value of the common stock and convertible promissory notes prior to
the Merger, the fair value of the Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock, fair value of the
purchase options under the Loan Agreement, stock-based compensation assumptions, and accrued research and development expenses.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <TVGN:FreestandingAndEmbeddedCommonStockOptionsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000600">&lt;p id="xdx_84C_ecustom--FreestandingAndEmbeddedCommonStockOptionsPolicyTextBlock_zU1Yg00Ynoqa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_86B_zjZOTYXrYvW1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Freestanding
and Embedded Common Stock Purchase Options&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity-linked
purchase options issued in connection with the Company&#x2019;s debt agreements are assessed to determine whether they are freestanding
or embedded with the host instrument under ASC 815,&#160;&lt;i&gt;Derivatives and Hedging Contracts in Entity&#x2019;s Own Equity&#160;&lt;/i&gt;(&#x201c;ASC
815&#x201d;). Each type of purchase option is then assessed for equity or liability classification under ASC 815. The Company&#x2019;s
embedded and freestanding purchase options were determined to be liability-classified derivative instruments and are measured at fair
value both on the date of issuance and at each subsequent balance sheet date, with changes in fair value recorded to &#x2018;Change in
fair value of written call option derivative liabilities&#x2019; within the consolidated statements of operations and consolidated statements
of cash flows.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

</TVGN:FreestandingAndEmbeddedCommonStockOptionsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2024-01-01to2024-12-31" id="Fact000602">&lt;p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_zaVX69hJqaGj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_860_zBYIf29m4TMl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Concentrations
of Credit Risk&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash. The Company
maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced
any losses in such accounts and believes it is not exposed to significant risk on its cash.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000604">&lt;p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zGavjTbsGjld" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_86B_zqy1DxfGgale" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Segment
Reporting&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
segments are defined as components of an entity for which discrete financial information is both available and regularly reviewed by
its chief operating decision maker or decision-making group. The Company views its operations and manages its business in &lt;span id="xdx_905_eus-gaap--NumberOfOperatingSegments_pid_dc_uSegment_c20240101__20241231_zQCkR43qaf21" title="Number of operating segments"&gt;one
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;segment.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;b&gt;TEVOGEN BIO HOLDINGS
INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;b&gt;NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000606"
      unitRef="Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:DerivativesPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000608">&lt;p id="xdx_84C_eus-gaap--DerivativesPolicyTextBlock_zD1xmE1CP1Z1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_860_zTyoPxhDqOEb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
the result of the Merger, the Company accounts for its warrants originally sold as part of Semper Paratus&#x2019;s initial public offering
(the &#x201c;IPO&#x201d;) in accordance with ASC 815, &lt;i&gt;Derivatives and Hedging Contracts in Entity&#x2019;s Own Equity &lt;/i&gt;(&#x201c;ASC
815&#x201d;) and ASC 480,&#160;&lt;i&gt;Distinguishing Liabilities from Equity&lt;/i&gt;&#160;(&#x201c;ASC 480&#x201d;). The assessment considers whether
the warrants are freestanding financial instruments and meet the definition of a liability pursuant to ASC 480 and meet all of the conditions
for equity classification under ASC 815, including whether the warrants are indexed to the Company&#x2019;s own shares of common stock,
among other conditions. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance
and as of each subsequent quarterly period end date while the warrants are outstanding. For issued or modified warrants that meet all
of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the
time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required
to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter until settlement. Changes
in the estimated fair value of the warrants are recognized as a non-cash loss on the consolidated statements of operations. Under these
standards, the Company&#x2019;s private placement warrants sold at the time of the IPO do not meet the criteria for equity classification
and must be recorded as liabilities while the public warrants sold in connection with the IPO do meet the criteria for equity classification
and must be recorded as equity.&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000610">&lt;p id="xdx_840_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zrhlYragtHG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_867_zPsHFdIWiME8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Fair
Value Measurements&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Certain
assets and liabilities are carried at fair value under GAAP. Fair value is defined as the price that would be received for an asset or
paid to transfer a liability (exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction
between market participants on the measurement date. The Company utilizes valuation techniques that maximize the use of observable inputs
and minimize the use of unobservable inputs to the extent possible. When considering market participant assumptions in fair value measurements,
the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following
levels:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 0.5in; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unadjusted
    quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Observable
    inputs other than Level 1 prices, such as quoted prices for similar, but not identical, assets or liabilities in active markets;
    quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable
    or can be corroborated by observable market data;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unobservable
    inputs in which there is little or no market data available and which require the Company to develop its own assumptions that market
    participants would use in pricing an asset or liability.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments recognized at historical amounts in the balance sheets consist of accounts payable and notes payable. The Company believes
that the carrying value of accounts payable and notes payable approximates their fair values due to the short-term nature of these instruments.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s recurring fair value measurements consist of the convertible promissory notes prior to the Merger, for which the Company
elected the fair value option to reduce accounting complexity, and private warrants after the Merger. Such fair value measurements are
Level 3 inputs. The following table provides a roll-forward of the aggregate fair values of the Company&#x2019;s convertible promissory
notes.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zvQIcfKfBw7b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_8B4_zLwMSvweVTPg" style="display: none"&gt;SCHEDULE
OF FAIR VALUE MEASUREMENT&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;Balance at January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zmPdTyoWTo8e" style="width: 16%; text-align: right" title="Fair value beginning balance"&gt;&lt;span style="-sec-ix-redline: true"&gt;39,297,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Initial fair value at issuance&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zn2RHV15r6Be" style="text-align: right" title="Initial fair value at issuance"&gt;&lt;span style="-sec-ix-redline: true"&gt;4,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Accrued interest expense&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zPFQwSUZCOQj" style="text-align: right" title="Accrued interest expense"&gt;&lt;span style="-sec-ix-redline: true"&gt;1,206,697&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zNzncNEjVShd" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"&gt;&lt;span style="-sec-ix-redline: true"&gt;50,428,303&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z4rCEr5QVgp4" style="text-align: right" title="Fair value beginning balance"&gt;&lt;span style="-sec-ix-redline: true"&gt;94,932,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Accrued interest expense&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zt6aGeiPKPWa" style="text-align: right" title="Accrued interest expense"&gt;&lt;span style="-sec-ix-redline: true"&gt;159,305&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zyjBGFf91vbi" style="text-align: right" title="Change in fair value"&gt;&lt;span style="-sec-ix-redline: true"&gt;(48,468,678&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Derecognition upon conversion of convertible promissory
    notes&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5YwVfhmAdXj" style="border-bottom: Black 1pt solid; text-align: right" title="Derecognition upon conversion of convertible promissory notes"&gt;&lt;span style="-sec-ix-redline: true"&gt;(46,622,627&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2ME1DbWt72e" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value beginning balance"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0630"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zqcgjNCAyIG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;b&gt;TEVOGEN BIO HOLDINGS
INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;b&gt;NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were no transfers between levels during the years ended December 31, 2024 and 2023.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company used the probability weighted expected return method valuation methodology to determine the fair value of the convertible promissory
notes prior to the Merger. Significant assumptions and ranges used in determining the fair value of convertible promissory notes prior
to the Merger include volatility (&lt;span id="xdx_903_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zF3lzBx4NxE3" title="Volatility"&gt;80&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%),
discount rate (&lt;span id="xdx_90D_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember__srt--RangeAxis__srt--MinimumMember_zI7cdoSRgYZf" title="Volatility"&gt;35&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
- &lt;span id="xdx_90C_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember__srt--RangeAxis__srt--MaximumMember_z3CE1sVwC9l8" title="Volatility"&gt;36&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%),
and probability of a future liquidity event (&lt;span id="xdx_90F_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__custom--ProbabilityOfFutureLiquidityMember__srt--RangeAxis__srt--MinimumMember_zWLtQzBOBiyb" title="Volatility"&gt;85&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
- &lt;span id="xdx_906_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__custom--ProbabilityOfFutureLiquidityMember__srt--RangeAxis__srt--MaximumMember_ztX9pqLKBk9j" title="Volatility"&gt;95&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%).
The Company used its stock price on the Closing Date to determine the fair value for the derecognition of the convertible promissory
notes upon conversion on the Closing Date.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon
the Closing, the Company acquired private warrants, the fair value of which increased by $&lt;span id="xdx_900_eus-gaap--FairValueAdjustmentOfWarrants_iN_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCyhs8Yly2tg" title="Fair value adjustment of warrants"&gt;58,180&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;between
the Closing Date and December 31, 2024 primarily due to changes in the market value of the Company&#x2019;s common shares. In June 2024,
the Company issued written call options in connection with the Loan Agreement, the fair value of which decreased by $&lt;span id="xdx_903_eus-gaap--FairValueAdjustmentOfWarrants_iN_di_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zK0pZpXRMYP3" title="Fair value adjustment of warrants"&gt;375,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;between
the issuance and December 31, 2024. Such fair value measurements are Level 3 inputs. The following table provides a roll-forward of the
aggregate fair values of the warrants and the written call option derivative liabilities.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zVFlWWOtgvBk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_8BC_zKxxJeSEy77b" style="display: none"&gt;SCHEDULE
OF FAIR VALUES OF WARRANTS&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Derivative&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;warrant
                                            liabilities&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Written
                                            call option&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;derivative
                                            liabilities&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;Balance at February 15, 2024&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DerivativeLiabilitiesNoncurrent_iS_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHBI9UhFXWzg" style="text-align: right" title="Derivative warrant liabilities, Balance"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0648"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DerivativeLiabilitiesNoncurrent_iS_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zNojA057WR65" style="text-align: right" title="Derivative warrant liabilities, Balance"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0650"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Initial fair value at issuance&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_ecustom--DerivativeLiabilitiesFairValueIssuance_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziWiAcw0clR" style="width: 16%; text-align: right" title="Initial fair value at issuance"&gt;&lt;span style="-sec-ix-redline: true"&gt;29,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--DerivativeLiabilitiesFairValueIssuance_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zh8O4BbAP9Vc" style="width: 16%; text-align: right" title="Initial fair value at issuance"&gt;&lt;span style="-sec-ix-redline: true"&gt;375,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FairValueAdjustmentOfWarrants_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQUdk6IQWDg1" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"&gt;&lt;span style="-sec-ix-redline: true"&gt;58,180&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FairValueAdjustmentOfWarrants_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zhTcXjj4WLil" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"&gt;&lt;span style="-sec-ix-redline: true"&gt;(375,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--DerivativeLiabilitiesNoncurrent_iE_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeYQcoChW2m" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrant liabilities, Balance"&gt;&lt;span style="-sec-ix-redline: true"&gt;87,180&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--DerivativeLiabilitiesNoncurrent_iE_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zfSJPgabLkfk" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrant liabilities, Balance"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0662"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zoiLz4vJKfVi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zUKPgDAmlig6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents information about the Company&#x2019;s liabilities that are measured at fair value on a recurring basis at December
31, 2024, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_8B2_zMdNzDoPK375" style="display: none"&gt;SCHEDULE
OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;Level&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;Quoted Prices
    in &lt;br/&gt; Active Markets &lt;br/&gt; (Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;Significant
    Other &lt;br/&gt; Observable Inputs &lt;br/&gt; (Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;Significant
    Other &lt;br/&gt; Unobservable &lt;br/&gt; Inputs (Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 44%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Derivative warrant liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zTFE3aAAK2o2" style="width: 10%; text-align: right" title="Derivative warrant liabilities"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0666"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zI5XpHzeno74" style="width: 10%; text-align: right" title="Derivative warrant liabilities"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0668"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zT3vY3M4tuw6" style="width: 10%; text-align: right" title="Derivative warrant liabilities"&gt;&lt;span style="-sec-ix-redline: true"&gt;87,180&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zfdgPue2UFzb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s nonrecurring fair value measurements consist of Series A Preferred Stock. Such fair value measurements are Level 3 inputs.
The Company determined the fair value of Series A Preferred Stock using a Monte Carlo Simulation (&#x201c;MCS&#x201d;). Key inputs utilized
in the MCS to estimate fair value of Series A Preferred Stock included a range of volatility between&#160;&lt;span id="xdx_90E_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zBQCgsFYWXy" title="Stock, measurement input"&gt;75&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
to&#160;&lt;span id="xdx_90B_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zY07bkVh1tTi"&gt;85&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%,
a holding period to a deemed liquidation event, as defined in the Series A Preferred Stock agreement, ranging from&#160;&lt;span id="xdx_900_ecustom--EquitySecuritiesTerm_dtY_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--RangeAxis__srt--MinimumMember_zJ7WOdTcTrch" title="Holding period"&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;to&#160;&lt;span id="xdx_900_ecustom--EquitySecuritiesTerm_dtY_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--RangeAxis__srt--MaximumMember_zx3jOtbTc9Kk" title="Range in years"&gt;10.0&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;years,
and a risk-free interest rate between&#160;&lt;span id="xdx_90D_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zIZeBBxGPA83" title="Risk-free interest rate percentage"&gt;4.3&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
and&#160;&lt;span id="xdx_90B_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zBXxOkIGk7N7" title="Stock, measurement input"&gt;5.3&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%.
The difference between the cash received of $&lt;span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zgMvkcSAG6bc" title="Cash received upon issuance of preferred stock"&gt;2,000,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;upon
issuance of the Series A Preferred Stock and its estimated fair value was recognized as general and administrative expense on the consolidated
statements of operations during the three months ended March 31, 2024.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company used a MCS valuation methodology to determine the fair value of the freestanding $&lt;span id="xdx_905_ecustom--FreeStandingPurchaseOptions_c20240101__20241231_zMcIwfI14nab" title="Free standing purchase options"&gt;14,000,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;purchase
option and remaining embedded $&lt;span id="xdx_90A_ecustom--EmbeddedOptions_c20240101__20241231_zJt3WvksQt6c" title="Embedded options shares"&gt;30,000,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;purchase
option associated with the Loan Agreement as of December 31, 2024. The MCS methodology simulates the Company&#x2019;s future stock price
to estimate if and when the Trailing VWAP (as defined below) will reach $&lt;span id="xdx_90A_eus-gaap--SharePrice_iI_uUSDPShares_c20241231_zDGajU2DphH" title="Share price"&gt;10.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;per
share, and discounts the resulting payoff back to each valuation date using a present value factor. Significant assumptions used in determining
the fair value of these options include volatility of&#160;&lt;span id="xdx_905_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zO4ZtR8xaGD7"&gt;78.3&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
and discount rate of&#160;&lt;span id="xdx_900_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember_zA5hPt9cSmoa" title="Discount rate"&gt;4.3&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%.
At December 31, 2024, the MCS produced a fair value of $&lt;span id="xdx_901_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20241231_zCSBpPO94ljd" title="Fair value"&gt;0
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;relating to these freestanding and embedded
options.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;b&gt;TEVOGEN BIO HOLDINGS
INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;b&gt;NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000612">&lt;p id="xdx_89D_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zvQIcfKfBw7b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_8B4_zLwMSvweVTPg" style="display: none"&gt;SCHEDULE
OF FAIR VALUE MEASUREMENT&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;Balance at January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zmPdTyoWTo8e" style="width: 16%; text-align: right" title="Fair value beginning balance"&gt;&lt;span style="-sec-ix-redline: true"&gt;39,297,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Initial fair value at issuance&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zn2RHV15r6Be" style="text-align: right" title="Initial fair value at issuance"&gt;&lt;span style="-sec-ix-redline: true"&gt;4,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Accrued interest expense&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zPFQwSUZCOQj" style="text-align: right" title="Accrued interest expense"&gt;&lt;span style="-sec-ix-redline: true"&gt;1,206,697&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zNzncNEjVShd" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"&gt;&lt;span style="-sec-ix-redline: true"&gt;50,428,303&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z4rCEr5QVgp4" style="text-align: right" title="Fair value beginning balance"&gt;&lt;span style="-sec-ix-redline: true"&gt;94,932,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Accrued interest expense&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zt6aGeiPKPWa" style="text-align: right" title="Accrued interest expense"&gt;&lt;span style="-sec-ix-redline: true"&gt;159,305&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zyjBGFf91vbi" style="text-align: right" title="Change in fair value"&gt;&lt;span style="-sec-ix-redline: true"&gt;(48,468,678&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Derecognition upon conversion of convertible promissory
    notes&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5YwVfhmAdXj" style="border-bottom: Black 1pt solid; text-align: right" title="Derecognition upon conversion of convertible promissory notes"&gt;&lt;span style="-sec-ix-redline: true"&gt;(46,622,627&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2ME1DbWt72e" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value beginning balance"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0630"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000614"
      unitRef="USD">39297000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000616"
      unitRef="USD">4000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <TVGN:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000618"
      unitRef="USD">1206697</TVGN:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000620"
      unitRef="USD">50428303</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000622"
      unitRef="USD">94932000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <TVGN:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest
      contextRef="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000624"
      unitRef="USD">159305</TVGN:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000626"
      unitRef="USD">-48468678</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <TVGN:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable
      contextRef="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000628"
      unitRef="USD">-46622627</TVGN:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      id="Fact000632"
      unitRef="Pure">80</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputDiscountRateMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000634"
      unitRef="Pure">35</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputDiscountRateMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000636"
      unitRef="Pure">36</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-12-31_custom_ProbabilityOfFutureLiquidityMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000638"
      unitRef="Pure">85</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-12-31_custom_ProbabilityOfFutureLiquidityMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000640"
      unitRef="Pure">95</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember"
      decimals="0"
      id="Fact000642"
      unitRef="USD">-58180</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000644"
      unitRef="USD">-375000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000646">&lt;p id="xdx_89E_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zVFlWWOtgvBk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_8BC_zKxxJeSEy77b" style="display: none"&gt;SCHEDULE
OF FAIR VALUES OF WARRANTS&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Derivative&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;warrant
                                            liabilities&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Written
                                            call option&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;derivative
                                            liabilities&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;Balance at February 15, 2024&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DerivativeLiabilitiesNoncurrent_iS_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHBI9UhFXWzg" style="text-align: right" title="Derivative warrant liabilities, Balance"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0648"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DerivativeLiabilitiesNoncurrent_iS_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zNojA057WR65" style="text-align: right" title="Derivative warrant liabilities, Balance"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0650"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Initial fair value at issuance&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_ecustom--DerivativeLiabilitiesFairValueIssuance_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziWiAcw0clR" style="width: 16%; text-align: right" title="Initial fair value at issuance"&gt;&lt;span style="-sec-ix-redline: true"&gt;29,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--DerivativeLiabilitiesFairValueIssuance_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zh8O4BbAP9Vc" style="width: 16%; text-align: right" title="Initial fair value at issuance"&gt;&lt;span style="-sec-ix-redline: true"&gt;375,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FairValueAdjustmentOfWarrants_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQUdk6IQWDg1" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"&gt;&lt;span style="-sec-ix-redline: true"&gt;58,180&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FairValueAdjustmentOfWarrants_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zhTcXjj4WLil" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"&gt;&lt;span style="-sec-ix-redline: true"&gt;(375,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--DerivativeLiabilitiesNoncurrent_iE_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeYQcoChW2m" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrant liabilities, Balance"&gt;&lt;span style="-sec-ix-redline: true"&gt;87,180&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--DerivativeLiabilitiesNoncurrent_iE_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zfSJPgabLkfk" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrant liabilities, Balance"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0662"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <TVGN:DerivativeLiabilitiesFairValueIssuance
      contextRef="From2024-02-152024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      decimals="0"
      id="Fact000652"
      unitRef="USD">29000</TVGN:DerivativeLiabilitiesFairValueIssuance>
    <TVGN:DerivativeLiabilitiesFairValueIssuance
      contextRef="From2024-02-152024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_CallOptionMember"
      decimals="0"
      id="Fact000654"
      unitRef="USD">375000</TVGN:DerivativeLiabilitiesFairValueIssuance>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-02-152024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      decimals="0"
      id="Fact000656"
      unitRef="USD">58180</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-02-152024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_CallOptionMember"
      decimals="0"
      id="Fact000658"
      unitRef="USD">-375000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      decimals="0"
      id="Fact000660"
      unitRef="USD">87180</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000664">&lt;p id="xdx_895_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zUKPgDAmlig6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents information about the Company&#x2019;s liabilities that are measured at fair value on a recurring basis at December
31, 2024, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_8B2_zMdNzDoPK375" style="display: none"&gt;SCHEDULE
OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;Level&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;Quoted Prices
    in &lt;br/&gt; Active Markets &lt;br/&gt; (Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;Significant
    Other &lt;br/&gt; Observable Inputs &lt;br/&gt; (Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;Significant
    Other &lt;br/&gt; Unobservable &lt;br/&gt; Inputs (Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 44%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Derivative warrant liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zTFE3aAAK2o2" style="width: 10%; text-align: right" title="Derivative warrant liabilities"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0666"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zI5XpHzeno74" style="width: 10%; text-align: right" title="Derivative warrant liabilities"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0668"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zT3vY3M4tuw6" style="width: 10%; text-align: right" title="Derivative warrant liabilities"&gt;&lt;span style="-sec-ix-redline: true"&gt;87,180&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact000670"
      unitRef="USD">87180</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:EquitySecuritiesFvNiMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000672"
      unitRef="Pure">75</us-gaap:EquitySecuritiesFvNiMeasurementInput>
    <us-gaap:EquitySecuritiesFvNiMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000673"
      unitRef="Pure">85</us-gaap:EquitySecuritiesFvNiMeasurementInput>
    <TVGN:EquitySecuritiesTerm
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember_srt_MinimumMember"
      id="Fact000675">P0Y6M</TVGN:EquitySecuritiesTerm>
    <TVGN:EquitySecuritiesTerm
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember_srt_MaximumMember"
      id="Fact000677">P10Y</TVGN:EquitySecuritiesTerm>
    <us-gaap:EquitySecuritiesFvNiMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000679"
      unitRef="Pure">4.3</us-gaap:EquitySecuritiesFvNiMeasurementInput>
    <us-gaap:EquitySecuritiesFvNiMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000681"
      unitRef="Pure">5.3</us-gaap:EquitySecuritiesFvNiMeasurementInput>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact000683"
      unitRef="USD">2000000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <TVGN:FreeStandingPurchaseOptions
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000685"
      unitRef="Shares">14000000</TVGN:FreeStandingPurchaseOptions>
    <TVGN:EmbeddedOptions
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000687"
      unitRef="Shares">30000000</TVGN:EmbeddedOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000689"
      unitRef="USDPShares">10.00</us-gaap:SharePrice>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputOptionVolatilityMember"
      decimals="INF"
      id="Fact000690"
      unitRef="Pure">78.3</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputDiscountRateMember"
      decimals="INF"
      id="Fact000692"
      unitRef="Pure">4.3</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000694"
      unitRef="USD">0</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000696">&lt;p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zDD1mMrYTiic" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_863_zfPQfeKGxXZ1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Cash&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers all highly liquid financial instruments with a maturity date of 90 days or less when purchased to be cash equivalents.
There were &lt;span id="xdx_900_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_do_c20241231_zjoGF4P7HdTl" title="Cash equivalents"&gt;&lt;span id="xdx_902_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_do_c20231231_zSAdcokKBeoe" title="Cash equivalents"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;cash
equivalents as of December 31, 2024 and 2023 as all amounts consisted of bank deposits.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000698"
      unitRef="USD">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000700"
      unitRef="USD">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000702">&lt;p id="xdx_84C_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zdqI5jkunLD6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_864_zoqVO2hfbssd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Property
and Equipment, Net&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_ecustom--PropertyAndEquipmentUsefulLifeTableTextBlock_zHN0wr1ikGj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment is recorded at cost. Depreciation and amortization is provided using straight-line methods over their respective estimated
useful lives. Repairs and maintenance, which do not extend the useful lives of the related assets, are expensed as incurred.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_8B5_zJYD2SpYrHLa" style="display: none"&gt;SCHEDULE
OF PROPERTY AND EQUIPMENT USEFUL LIFE&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;Estimated Useful Lives&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 83%; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 14%; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zYycrtiHNlDj" title="Property, plant and equipment, useful life"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_zDnZQPBSz9v3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="Property, plant and equipment, useful life"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zLHnEO71cT9d" title="Property, plant and equipment, useful life"&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zSUqkMCooCEj" title="Property, plant and equipment, useful life"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zSoNNhiJr9od" title="Property, plant and equipment, useful life"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zl5Ugxi1eSE3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company reviews the carrying value of property and equipment whenever events and circumstances indicate that the carrying value of an
asset may not be recoverable from the estimated future cash flows expected to result from its eventual use and disposition. Based on
this assessment, management has determined that there was no impairment during the years ended December 31, 2024 and 2023.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <TVGN:PropertyAndEquipmentUsefulLifeTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000704">&lt;p id="xdx_893_ecustom--PropertyAndEquipmentUsefulLifeTableTextBlock_zHN0wr1ikGj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment is recorded at cost. Depreciation and amortization is provided using straight-line methods over their respective estimated
useful lives. Repairs and maintenance, which do not extend the useful lives of the related assets, are expensed as incurred.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_8B5_zJYD2SpYrHLa" style="display: none"&gt;SCHEDULE
OF PROPERTY AND EQUIPMENT USEFUL LIFE&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;Estimated Useful Lives&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 83%; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 14%; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zYycrtiHNlDj" title="Property, plant and equipment, useful life"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_zDnZQPBSz9v3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="Property, plant and equipment, useful life"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zLHnEO71cT9d" title="Property, plant and equipment, useful life"&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zSUqkMCooCEj" title="Property, plant and equipment, useful life"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zSoNNhiJr9od" title="Property, plant and equipment, useful life"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</TVGN:PropertyAndEquipmentUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_ComputerEquipmentMember"
      id="Fact000706">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember_srt_MinimumMember"
      id="Fact000708">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember_srt_MaximumMember"
      id="Fact000710">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_OfficeEquipmentMember"
      id="Fact000712">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember"
      id="Fact000714">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000716">&lt;p id="xdx_84A_eus-gaap--LesseeLeasesPolicyTextBlock_zfKTy2QrYHCk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_862_z4mqZGMPTzPj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determines whether an arrangement is or contains a lease, its classification, and its term at the lease commencement date. Leases
with a term greater than one year will be recognized on the balance sheet as right-of-use (&#x201c;ROU&#x201d;) assets, current lease liabilities,
and if applicable, long-term lease liabilities. The Company includes renewal options to extend the lease term where it is reasonably
certain that it will exercise these options. Lease liabilities and the corresponding ROU assets are recorded based on the present values
of lease payments over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such,
the Company utilizes the appropriate incremental borrowing rates, which are the rates that would be incurred to borrow on a collateralized
basis, over similar terms, amounts equal to the lease payments in a similar economic environment. If significant events, changes in circumstances,
or other events indicate that the lease term or other inputs have changed, the Company would reassess lease classification, remeasure
the lease liability using revised inputs as of the reassessment date, and adjust the ROU assets. Lease expense is recognized on a straight-line
basis over the expected lease term for operating classified leases.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leases
with an initial term of &lt;span id="xdx_902_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dc_c20241231_zDnUbmG7pY6j" title="Leases initial term"&gt;12 months&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;
&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;or less and without a purchase option that the Company is reasonably
certain of exercising are not included within the lease ROU assets and lease liabilities on the balance sheet.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="AsOf2024-12-31" id="Fact000718">P12M</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2024-01-01to2024-12-31" id="Fact000720">&lt;p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_zIdxFuVgTZNh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_868_z51STCTlamK2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Research
and Development Expenses&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development activities are expensed as incurred. Costs for clinical trials and manufacturing activities are recognized based on an
evaluation of our vendors&#x2019; progress towards completion of specific tasks, using data such as participant enrollment, clinical site
activations, or information provided to us by vendors regarding their actual costs incurred. Payments for these activities are based
on the terms of individual contracts and payment timing may differ significantly from the period in which the services were performed.
The Company determines accrual estimates through reports from and discussions with applicable personnel and outside service providers
as to the progress or state of completion of studies, or the services completed. The Company estimates accrued expenses as of each balance
sheet date based on the facts and circumstances known at the time. Costs that are paid in advance of performance are deferred as a prepaid
expense and amortized over the service period as the services are provided.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;b&gt;TEVOGEN BIO HOLDINGS
INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;b&gt;NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000722">&lt;p id="xdx_840_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zlWE40LQEnBa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_867_zN8KNyRNRiS1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Stock-Based
Compensation&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Compensation
cost is measured at the grant date fair value of the award and is recognized over the vesting period of the award. The Company uses the
straight-line method to record compensation expense of awards with service-based vesting conditions. The Company accounts for forfeitures
of awards as they occur rather than applying an estimated forfeiture rate to stock-based compensation expense. The Company recognizes
compensation expense for awards with performance conditions when it is probable that the condition will be met, and the award will vest.
Prior to the Merger, the Company estimated the fair value of the Company&#x2019;s common stock on the date of grant in accordance with
the guidance outlined in the American Institute of Certified Public Accountants&#x2019; &lt;i&gt;Accounting and Valuation Guide, Valuation of
Privately-Held-Company Equity Securities Issued as Compensation&lt;/i&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000724">&lt;p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zoWCJBw0vlYh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_866_zldsYnnmPWEb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Income
Taxes&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes using the asset and liability method in accordance with ASC Topic 740, &lt;i&gt;Income Taxes &lt;/i&gt;(&#x201c;ASC
740&#x201d;), which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events
that have been recognized in the consolidated financial statements or in the Company&#x2019;s tax returns. Deferred tax assets and liabilities
are determined on the basis of the differences between the financial statement and tax basis of assets and liabilities using enacted
tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are
recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future
taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all
or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense.
Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent
and feasible tax planning strategies. At December 31, 2024 and 2023, the Company has concluded that a full valuation allowance is necessary
for its net deferred tax assets.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000726">&lt;p id="xdx_84B_eus-gaap--EarningsPerSharePolicyTextBlock_zPrUSe34nzZ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_869_znCeJn71YSG1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Net
Loss Per Share&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company computes basic net loss per share by dividing net loss by the weighted-average common stock outstanding during the period. Given
the Company&#x2019;s net loss, basic and diluted net loss per share for the years ended December 31, 2024 and 2023 are the same.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000728">&lt;p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zWIqaAo2igS8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_862_zOYer4WwVUw5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Recently
Issued Accounting Standards&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
August 2020, the FASB issued ASU No. 2020-06, &lt;i&gt;Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and
Hedging - Contracts in Entity&#x2019;s Own Equity (Subtopic 815 -40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s
Own Equity &lt;/i&gt;(&#x201c;ASU 2020-06&#x201d;), which simplifies the accounting for convertible instruments by reducing the number of accounting
models available for convertible debt instruments. ASU 2020-06 also eliminates the treasury stock method to calculate diluted earnings
per share for convertible instruments and requires the use of the if-converted method. Effective January 1, 2024, the Company adopted
ASU 2020-06 and that adoption did not have an impact on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2023, the FASB issued ASU No. 2023-07,&#160;&lt;i&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&#160;&lt;/i&gt;(&#x201c;ASU
2023-07&#x201d;). ASU 2023-07 enhances reportable segment disclosures by requiring disclosures such as significant segment expenses. The
main provisions of this update require companies to disclose, on an annual and interim basis, significant segment expenses, segment profit
and loss, and other segments items that are regularly provided to the chief operating decision maker (&#x201c;CODM&#x201d;). This update
also requires companies to disclose the title and position of the CODM and to explain how the CODM uses the reported segment measures
in assessing segment performance and deciding how to allocate resources. The update also requires companies with a single reportable
segment to provide all required segment reporting disclosures. This new standard is effective for fiscal years beginning after December
15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company adopted this standard on January 1,
2024 for annual reporting and interim periods beginning in 2025. See Note 16 for additional disclosures.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;b&gt;TEVOGEN BIO HOLDINGS
INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;b&gt;NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the FASB issued ASU 2024-03, &lt;i&gt;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures,
(Subtopic 220-40) &lt;/i&gt;(&#x201c;ASU 2024-03&#x201d;). ASU 2024-03 improves disclosures regarding the types of expenses included in commonly
presented expense captions, including disaggregating the amounts of employee compensation, depreciation and amortization included within
each income statement expense caption. This standard is effective for fiscal years beginning after December 15, 2026, and interim periods
within fiscal years beginning after December 15, 2027. The Company is currently evaluating the impact of the standard on its consolidated
financial statements and disclosures.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000730">&lt;p id="xdx_802_eus-gaap--BusinessCombinationDisclosureTextBlock_zqNIOxtWAU41" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
4.&#160;&lt;span id="xdx_82A_zDbQ2iMDygAd"&gt;BUSINESS COMBINATION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
the Closing Date, the Company completed the Business Combination described in Note 1. The Merger was accounted for as a reverse recapitalization
under GAAP because Tevogen Bio was determined to be the accounting acquirer based upon the terms of the Merger and other factors, including
that following the Merger, former Tevogen Bio (i) equity holders and holders of convertible promissory notes owned approximately&#160;&lt;span id="xdx_90A_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TevogenBioMember_zpb728IdYnI5" title="Ownership percentage"&gt;91.0&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
of the Company, (ii) directors constituted the majority (six of seven) of the directors of the Company, and (iii) management held all
key positions of management of the Company. Accordingly, the Merger was treated as the equivalent of Tevogen Bio issuing stock to acquire
the net assets of Semper Paratus. As a result of the Merger, the net liabilities of Semper Paratus were recorded at their acquisition-date
fair value in the consolidated financial statements and the reported operating results prior to the Merger are those of Tevogen Bio.
Immediately after the Merger, there were&#160;&lt;span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_c20240214_zm7oVlVJKBmh" title="Common stock, shares outstanding"&gt;164,614,418&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;shares
of the Company&#x2019;s common stock outstanding.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_zJzX1OzWkW2l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table shows the net liabilities acquired in the Merger:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_8BF_zCTQj89vyov1" style="display: none"&gt;SCHEDULE OF NET LIABILITIES
ACQUIRED IN MERGER&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20240214_zbcnrScvqKR1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;February&#160;14,&#160;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_maBCRIAzgn3_z9Io3A3mnHy3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;&lt;span style="-sec-ix-redline: true"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;229,328&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_iI_maBCRIAzgn3_z0mQ6Jgtmb0h" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Due from Sponsor&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;158,819&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_iI_maBCRIAzgn3_zl4ektKvznGj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Prepaid expenses and other assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;2,501&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iNI_di_msBCRIAzgn3_zQnadgn4rRHk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(96,175&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_iNI_di_msBCRIAzgn3_zY1HfC6433le" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(1,269,126&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_iNI_di_msBCRIAzgn3_zZRAK9OX6HM8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Notes payable&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(1,651,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_iNI_di_msBCRIAzgn3_zPRMCGucTFN8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Derivative warrant liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(29,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iTI_mtBCRIAzgn3_maBCRIAzidu_ztgwK4PBMIHb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Total net liabilities acquired&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(2,654,653&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--MergerTransactionCostsLimitedToCashAcquired_iI_maBCRIAzidu_z4zGz7PO8Sa4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Plus: Merger transaction costs limited to cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(229,328&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts_iTI_mtBCRIAzidu_z3Z0rZNtOiEc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Total net liabilities acquired plus transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(2,883,981&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zqlUY39z45fd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
transaction costs of $&lt;span id="xdx_906_eus-gaap--BusinessCombinationAcquisitionRelatedCosts_c20240214__20240214_zcK3LwHoWqu5" title="Transaction costs"&gt;7,728,681&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;were
incurred in relation to the Business Combination through the Closing Date, of which $&lt;span id="xdx_903_eus-gaap--BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_iI_c20240214_z0JxgTGn9CSj" title="Transaction costs charged to equity"&gt;229,328&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;were
charged directly to equity to the extent of the cash received from the Business Combination, with the balance of $&lt;span id="xdx_909_eus-gaap--BusinessCombinationAcquisitionRelatedCosts_c20240101__20241231_zOJEgRME5SF6" title="Merger transaction costs"&gt;7,499,353&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;charged
to Merger transaction costs for the year ended December 31, 2024.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Former
holders of Tevogen Bio common stock and the Sponsor are eligible to receive up to an aggregate of&#160;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20240214__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_ztQMKkaGXToh" title="Earnout shares issuable"&gt;24,500,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;shares
of common stock (&#x201c;Earnout Shares&#x201d;) if the volume-weighted average price (the &#x201c;VWAP&#x201d;) of the Company&#x2019;s common
stock reaches specified threshold levels during the three-year period commencing on the Closing Date. Refer to Note 5, Earnout Shares,
for further details of the earnout arrangement.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the Merger, the Company issued Series B Preferred Stock to the Sponsor in return for the Sponsor assuming $&lt;span id="xdx_90B_ecustom--StockIssuedDuringPeriodValueNewIssuesOne_c20240214__20240214_zhmT0tkR4K6g" title="New issuance value"&gt;3,613,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;of
liabilities and obligations (&#x201c;Assumed Liabilities&#x201d;) of Semper Paratus and Tevogen Bio. The issuance date fair value of the
Series B Preferred Stock was recorded to Merger transaction costs within the consolidated statements of operations. All of the issued
Series B Preferred Stock was repurchased by the Company during the three months ended June 30, 2024 in exchange for the Sponsor being
released from their obligation to repay the Assumed Liabilities. See Note 12 for additional information.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;b&gt;TEVOGEN BIO HOLDINGS
INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;b&gt;NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2024-12-31_custom_TevogenBioMember"
      decimals="INF"
      id="Fact000732"
      unitRef="Pure">0.910</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-02-14"
      decimals="INF"
      id="Fact000734"
      unitRef="Shares">164614418</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000736">&lt;p id="xdx_892_eus-gaap--ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_zJzX1OzWkW2l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table shows the net liabilities acquired in the Merger:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_8BF_zCTQj89vyov1" style="display: none"&gt;SCHEDULE OF NET LIABILITIES
ACQUIRED IN MERGER&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20240214_zbcnrScvqKR1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;February&#160;14,&#160;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_maBCRIAzgn3_z9Io3A3mnHy3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;&lt;span style="-sec-ix-redline: true"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;229,328&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_iI_maBCRIAzgn3_z0mQ6Jgtmb0h" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Due from Sponsor&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;158,819&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_iI_maBCRIAzgn3_zl4ektKvznGj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Prepaid expenses and other assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;2,501&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iNI_di_msBCRIAzgn3_zQnadgn4rRHk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(96,175&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_iNI_di_msBCRIAzgn3_zY1HfC6433le" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(1,269,126&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_iNI_di_msBCRIAzgn3_zZRAK9OX6HM8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Notes payable&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(1,651,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_iNI_di_msBCRIAzgn3_zPRMCGucTFN8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Derivative warrant liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(29,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iTI_mtBCRIAzgn3_maBCRIAzidu_ztgwK4PBMIHb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Total net liabilities acquired&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(2,654,653&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--MergerTransactionCostsLimitedToCashAcquired_iI_maBCRIAzidu_z4zGz7PO8Sa4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Plus: Merger transaction costs limited to cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(229,328&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts_iTI_mtBCRIAzidu_z3Z0rZNtOiEc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Total net liabilities acquired plus transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(2,883,981&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="AsOf2024-02-14"
      decimals="0"
      id="Fact000738"
      unitRef="USD">229328</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="AsOf2024-02-14"
      decimals="0"
      id="Fact000740"
      unitRef="USD">158819</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="AsOf2024-02-14"
      decimals="0"
      id="Fact000742"
      unitRef="USD">2501</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="AsOf2024-02-14"
      decimals="0"
      id="Fact000744"
      unitRef="USD">96175</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <TVGN:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses
      contextRef="AsOf2024-02-14"
      decimals="0"
      id="Fact000746"
      unitRef="USD">1269126</TVGN:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt
      contextRef="AsOf2024-02-14"
      decimals="0"
      id="Fact000748"
      unitRef="USD">1651000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther
      contextRef="AsOf2024-02-14"
      decimals="0"
      id="Fact000750"
      unitRef="USD">29000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="AsOf2024-02-14"
      decimals="0"
      id="Fact000752"
      unitRef="USD">-2654653</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <TVGN:MergerTransactionCostsLimitedToCashAcquired
      contextRef="AsOf2024-02-14"
      decimals="0"
      id="Fact000754"
      unitRef="USD">-229328</TVGN:MergerTransactionCostsLimitedToCashAcquired>
    <TVGN:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts
      contextRef="AsOf2024-02-14"
      decimals="0"
      id="Fact000756"
      unitRef="USD">-2883981</TVGN:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="From2024-02-142024-02-14"
      decimals="0"
      id="Fact000758"
      unitRef="USD">7728681</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="AsOf2024-02-14"
      decimals="0"
      id="Fact000760"
      unitRef="USD">229328</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000762"
      unitRef="USD">7499353</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-02-14_custom_EarnoutSharesMember"
      decimals="INF"
      id="Fact000764"
      unitRef="Shares">24500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <TVGN:StockIssuedDuringPeriodValueNewIssuesOne
      contextRef="From2024-02-142024-02-14"
      decimals="0"
      id="Fact000766"
      unitRef="USD">3613000</TVGN:StockIssuedDuringPeriodValueNewIssuesOne>
    <TVGN:EarnoutSharesDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000768">&lt;p id="xdx_806_ecustom--EarnoutSharesDisclosureTextBlock_zagX6b1RQoS5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
5.&#160;&lt;span id="xdx_82B_znlZKg6laZk7"&gt;EARNOUT SHARES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Following
the Closing, former holders of Tevogen Bio common stock may receive up to&#160;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20241231__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_zt67oQ3JkOM2" title="Earnout shares"&gt;20,000,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;Earnout
Shares in tranches of&#160;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20241231__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_zRX8DRXnEewa" title="Earnout shares"&gt;6,666,667&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,&#160;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20241231__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_zAC3jlxHCxN5" title="Earnout shares"&gt;6,666,667&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
and&#160;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20241231__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_zuvEsTKHrt37" title="Earnout shares"&gt;6,666,666&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;shares
of common stock per tranche, respectively. The first, second, and third tranches are issuable if the VWAP per share of the Company&#x2019;s
common stock is greater or equal to $&lt;span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241231__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQfktJPCqMR7" title="Shares issued, price per share"&gt;15.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
$&lt;span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241231__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zslYvEivslpf" title="Shares issued, price per share"&gt;17.50&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
and $&lt;span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241231__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLC8ZTppmgR3" title="Shares issued, price per share"&gt;20.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
respectively, over any twenty trading days within any thirty consecutive day trading period during the three-year period after the Closing.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Sponsor received the right to Earnout Shares with the same terms above, except that each of the Sponsor&#x2019;s three earnout tranches
are for&#160;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20241231__srt--TitleOfIndividualAxis__custom--SponsorMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember_zZt0gzpM7SQf" title="Earnout shares"&gt;1,500,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;shares
of common stock, for an aggregate of&#160;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20241231__srt--TitleOfIndividualAxis__custom--SponsorMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_ziei3aO7tYy8" title="Earnout shares"&gt;4,500,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;shares
of common stock across the entire Sponsor earnout. The Earnout Shares are a form of dividend for holders of Tevogen Bio common stock,
and the Earnout Shares earnable by the Sponsor are treated as contingent consideration in a reverse recapitalization. In accordance with
ASC 815, the Earnout Shares were considered to be indexed to the Company&#x2019;s common stock and are classified within permanent equity.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

</TVGN:EarnoutSharesDisclosureTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-12-31_custom_TevogenBioCommonStockMember_custom_EarnoutSharesMember"
      decimals="INF"
      id="Fact000770"
      unitRef="Shares">20000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-12-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember_custom_EarnoutSharesMember"
      decimals="INF"
      id="Fact000772"
      unitRef="Shares">6666667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-12-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_custom_EarnoutSharesMember"
      decimals="INF"
      id="Fact000774"
      unitRef="Shares">6666667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-12-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_custom_EarnoutSharesMember"
      decimals="INF"
      id="Fact000776"
      unitRef="Shares">6666666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-12-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000778"
      unitRef="USDPShares">15.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-12-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000780"
      unitRef="USDPShares">17.50</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-12-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000782"
      unitRef="USDPShares">20.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-12-31_custom_SponsorMember_custom_EarnoutSharesMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember"
      decimals="INF"
      id="Fact000784"
      unitRef="Shares">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-12-31_custom_SponsorMember_custom_EarnoutSharesMember"
      decimals="INF"
      id="Fact000786"
      unitRef="Shares">4500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000788">&lt;p id="xdx_805_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_z8VPehfYwEia" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
6. &lt;span id="xdx_823_zklmFykksWod"&gt;PROPERTY AND EQUIPMENT, NET&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--PropertyPlantAndEquipmentTextBlock_zyTLeod1iAYg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment consists of the following:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_8B7_zL4gRjUr8gL8" style="display: none"&gt;SCHEDULE
OF PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20241231_z2fTAjjPcK87" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20231231_zafoUtjWTt3c" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerAndSoftwareMember_zLcF9UHhLe03" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;292,341&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;292,341&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zWEzRTWh31K3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;263,217&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;263,217&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zOA54W6JoE32" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;132,468&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;132,468&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zAxeUorRM0F7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;33,743&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;33,743&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzFLE_z9CL68pLllfg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property and equipment, gross&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;721,769&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;721,769&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzFLE_zDXDRLq09mIh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(425,327&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(263,118&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzFLE_zd2iNvK6JHzf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total property and
    equipment, net&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;296,442&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;458,651&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zsRWGRsOH3c1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
expense for the years ended December 31, 2024 and 2023 was $&lt;span id="xdx_905_eus-gaap--Depreciation_c20240101__20241231_zi2l51PiBoSk" title="Depreciation expense"&gt;162,209
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and $&lt;span id="xdx_900_eus-gaap--Depreciation_c20230101__20231231_zpc6SRupOUdg" title="Depreciation expense"&gt;163,300&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
respectively.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000790">&lt;p id="xdx_895_eus-gaap--PropertyPlantAndEquipmentTextBlock_zyTLeod1iAYg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment consists of the following:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_8B7_zL4gRjUr8gL8" style="display: none"&gt;SCHEDULE
OF PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20241231_z2fTAjjPcK87" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20231231_zafoUtjWTt3c" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerAndSoftwareMember_zLcF9UHhLe03" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;292,341&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;292,341&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zWEzRTWh31K3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;263,217&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;263,217&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zOA54W6JoE32" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;132,468&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;132,468&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zAxeUorRM0F7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;33,743&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;33,743&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzFLE_z9CL68pLllfg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property and equipment, gross&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;721,769&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;721,769&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzFLE_zDXDRLq09mIh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(425,327&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(263,118&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzFLE_zd2iNvK6JHzf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total property and
    equipment, net&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;296,442&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;458,651&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_custom_ComputerAndSoftwareMember"
      decimals="0"
      id="Fact000792"
      unitRef="USD">292341</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_custom_ComputerAndSoftwareMember"
      decimals="0"
      id="Fact000793"
      unitRef="USD">292341</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      id="Fact000795"
      unitRef="USD">263217</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      id="Fact000796"
      unitRef="USD">263217</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_us-gaap_OfficeEquipmentMember"
      decimals="0"
      id="Fact000798"
      unitRef="USD">132468</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_us-gaap_OfficeEquipmentMember"
      decimals="0"
      id="Fact000799"
      unitRef="USD">132468</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      id="Fact000801"
      unitRef="USD">33743</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      id="Fact000802"
      unitRef="USD">33743</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000804"
      unitRef="USD">721769</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000805"
      unitRef="USD">721769</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000807"
      unitRef="USD">425327</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000808"
      unitRef="USD">263118</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000810"
      unitRef="USD">296442</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000811"
      unitRef="USD">458651</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000813"
      unitRef="USD">162209</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000815"
      unitRef="USD">163300</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000817">&lt;p id="xdx_804_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_z6RfvuWeYq5f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
7. &lt;span id="xdx_827_zRrSDVU9XqN4"&gt;ACCRUED EXPENSES AND OTHER LIABILITIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zRlUj4VqPk4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
expenses and other liabilities consisted of the following:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_8BE_zB2Az3kYPDPi" style="display: none"&gt;SCHEDULE
OF ACCRUED EXPENSES AND OTHER LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20241231_zjOO0oCsnLwg" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20231231_z9WXnm6jsJTl" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
    31,&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AccruedProfessionalFeesCurrent_iI_maALCzC3I_zGgDsihN9oXg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 62%; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Professional
    services&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 16%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,309,163&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 16%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;976,301&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maALCzC3I_zrCYjFa3Avbi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;403,233&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;120,149&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzC3I_zmG7bIjIJOo2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,712,396&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,096,450&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A2_z7WvcneI6UYf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000819">&lt;p id="xdx_892_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zRlUj4VqPk4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
expenses and other liabilities consisted of the following:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_8BE_zB2Az3kYPDPi" style="display: none"&gt;SCHEDULE
OF ACCRUED EXPENSES AND OTHER LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20241231_zjOO0oCsnLwg" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20231231_z9WXnm6jsJTl" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
    31,&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AccruedProfessionalFeesCurrent_iI_maALCzC3I_zGgDsihN9oXg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 62%; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Professional
    services&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 16%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,309,163&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 16%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;976,301&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maALCzC3I_zrCYjFa3Avbi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;403,233&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;120,149&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzC3I_zmG7bIjIJOo2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,712,396&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,096,450&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000821"
      unitRef="USD">1309163</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000822"
      unitRef="USD">976301</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000824"
      unitRef="USD">403233</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000825"
      unitRef="USD">120149</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000827"
      unitRef="USD">1712396</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000828"
      unitRef="USD">1096450</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000830">&lt;p id="xdx_800_eus-gaap--DebtDisclosureTextBlock_zw2kLZQBNkj1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
8.&#160;&lt;span id="xdx_823_zgdJfRsQOU48"&gt;DEBT&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 14, 2024, in connection with the consummation of the Business Combination, previously issued promissory notes and accrued interest
were automatically converted into an aggregate of &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20240214__20240214__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlWQrcXAraJ8" title="Converted shares"&gt;10,337,419
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock. These debt obligations
were retired upon conversion.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;b&gt;TEVOGEN BIO HOLDINGS
INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;b&gt;NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Loan
Agreement&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
June 2024, the Company entered into a Loan Agreement (the &#x201c;Loan Agreement&#x201d;) with The Patel Family, LLP (the &#x201c;Patel
Family&#x201d;), a related party of the Company, providing for an unsecured line of credit facility (the &#x201c;Facility&#x201d;) for term
loans of up to an initial total of $&lt;span id="xdx_90B_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_z3rwGeRKyp6c" title="Line of credit maximum borrowing capacity"&gt;36,000,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
Under the Facility, the Company may draw up to $&lt;span id="xdx_903_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_ztPZbIxcq55h" title="Line of credit borrowing capacity"&gt;1,000,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;in
term loans per calendar month over a draw period of 36 months. Each term loan draw will have a maturity date of&#160;&lt;span id="xdx_90C_eus-gaap--DebtInstrumentTerm_dtM_c20240601__20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zJMa7xPDymH5" title="Debt maturity date"&gt;48&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;months
and will accrue interest at the lower of (i) daily SOFR plus&#160;&lt;span id="xdx_903_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zhr7Tpjltdag" title="Debt instrument variable rate"&gt;2.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
and (ii)&#160;&lt;span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zc06Lxl0USuj" title="Debt instrument interest rate"&gt;7.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%.
Interest accrues quarterly and is payable on the three-month anniversary of the draw date. Interest is payable in shares of common stock
at an effective price of $&lt;span id="xdx_90F_eus-gaap--SharePrice_iI_c20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zrMQbfykxT5d" title="Share price"&gt;1.50&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;per
share. Interest payable through December 31, 2024 relating to the first two draws on the Facility were settled in February 2025 through
issuance of &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zKfL1dDXu1S2" title="Shares issued"&gt;18,847
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock. Principal may
be prepaid at any time without penalty, and repayments or prepayments may be made in cash or common stock at the Company&#x2019;s election.
Payments of principal in common stock would be made at an effective price of the greater of $&lt;span id="xdx_90F_eus-gaap--SharePrice_iI_c20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember__srt--RangeAxis__srt--MaximumMember_zK5gCn2eQJfc" title="Share price"&gt;1.50&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;per
share and the ten-day trailing volume weighted average price per share of the common stock (the &#x201c;Trailing VWAP&#x201d;) as of the
trading day prior to payment. As an inducement to enter into the Loan Agreement, the Company issued&#160;&lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240601__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zhosEAWuDlCb" title="Issuance of shares"&gt;1,000,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;shares
of common stock to the Patel Family during June 2024. As of December 31, 2024, the Company has drawn $&lt;span id="xdx_907_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zhqC3Y2o57Ij" title="Line of credit borrowing capacity"&gt;1,000,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;from
the Facility, with maturity dates in July and August 2028, with a remaining $&lt;span id="xdx_900_eus-gaap--LineOfCreditFacilityRemainingBorrowingCapacity_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zKEoY04aRsli" title="Line of credit remaining capacity"&gt;30,000,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;available
for future financing over the remaining&#160;&lt;span id="xdx_908_eus-gaap--DebtInstrumentTerm_dtM_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zPMZFpcBxoJi" title="Debt maturity date"&gt;30&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;months.
The Company drew an additional $&lt;span id="xdx_90A_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20250228__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zHXGIGQ17x75" title="Line of credit borrowing capacity"&gt;&lt;span id="xdx_905_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20250331__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zYqwI2uqfct5" title="Line of credit borrowing capacity"&gt;1,000,000&lt;/span&gt;
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;in each of February and March 2025, with
maturity dates in February and March 2029, respectively (see Note 17).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Loan Agreement includes a purchase option whereby the Patel Family has the option to purchase up to $&lt;span id="xdx_909_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensationGross_c20240601__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zN5WdCriU1oh" title="Option to purchase common stock, value"&gt;14,000,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;of
shares of common stock at a purchase price equal to&#160;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_pid_dp_uPure_c20240601__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zs03c8p9FpJ1" title="Percentage of price of common stock purchased"&gt;70&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
of the Trailing VWAP per share (the &#x201c;$&lt;span id="xdx_905_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensationGross_pn6n6_c20240601__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zNZq2yLBs2Ic" title="Option to purchase common stock, value"&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;million
Purchase Option&#x201d;). The $&lt;span id="xdx_900_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensationGross_pn6n6_c20240601__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zbmPytDfLmsj" title="Option to purchase common stock, value"&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;million
Purchase Option only becomes exercisable once Trailing VWAP reaches $&lt;span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_c20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_zoP8P3O1Mj0h" title="Purchase, price per share"&gt;10.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;per
share. The $&lt;span id="xdx_90A_eus-gaap--DerivativeLiabilities_iI_pn6n6_c20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zvcNqi4vgof3" title="Derivative liability"&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;million
Purchase Option was determined to be a freestanding derivative liability under ASC 815 and is carried at fair value, with changes in
fair value recorded to change in fair value of written call option derivatives liabilities within the consolidated statements of operations
and consolidated statements of cash flows.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Loan Agreement also includes a purchase option (the &#x201c;Additional Amount Purchase Option&#x201d;) that is identical to the $&lt;span id="xdx_90E_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensationGross_pn6n6_c20240601__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AdditionalAmountPurchaseOptionMember_zztYjOylm645" title="Option to purchase common stock, value"&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;million
Purchase Option, except that the option is exercisable for an amount up to the then-remaining undrawn term loan amount under the Loan
Agreement at the time Trailing VWAP reaches $&lt;span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_c20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AdditionalAmountPurchaseOptionMember_zVJdG09Z1zMj" title="Purchase, price per share"&gt;10.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;per
share. The Additional Amount Purchase Option was determined to be an embedded derivative within the written loan commitment that requires
bifurcation under ASC 815, and thus is carried at fair value with changes in fair value recorded to change in fair value of written call
option derivatives liabilities within the consolidated statements of operations and consolidated statements of cash flows.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
$&lt;span id="xdx_909_eus-gaap--DerivativeLiabilities_iI_pn6n6_c20240630_zFmdl79XH6Bg" title="Derivative liability"&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;million
Purchase Option and the Additional Amount Purchase Option are recorded to written call option derivative liabilities within the consolidated
balance sheet and have a fair value of $&lt;span id="xdx_906_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20241231_zSuuARFpSgrh" title="Derivative liabilities"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;
&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;as of December 31, 2024.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Loan Agreement is a written loan commitment that is not eligible for the fair value option under ASC 825,&#160;&lt;i&gt;Financial Instruments&lt;/i&gt;.
However, management intends to elect the fair value option for future draws under this commitment, and therefore has expensed all issuance
costs associated with the Loan Agreement, which are comprised of the fair value of the&#160;&lt;span id="xdx_90C_ecustom--StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility_c20240601__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_z2m85ELBeYTc" title="Line of credit facility shares"&gt;1,000,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;shares
of common stock issued to the Patel Family as well as the issuance date fair value of the $&lt;span id="xdx_90F_eus-gaap--DerivativeLiabilities_iI_pn6n6_c20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zqXtJwOpLcnc" title="Derivative liability"&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;million
Purchase Option and Additional Amount Purchase Option.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Notes
Payable&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
a result of the Merger, the Company assumed notes payable held by Polar Multi-Strategy Master Fund (&#x201c;Polar&#x201d;) for which the
proceeds were to be used for working capital purposes by Semper Paratus with an outstanding balance of $&lt;span id="xdx_902_eus-gaap--NotesPayableCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PolarMultiStrategyMasterFundMember_z3rY3o5uyHX6" title="Notes payable"&gt;1,651,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;on
the Closing Date and remain outstanding at December 31, 2024. The notes payable do not accrue interest. The outstanding balance of the
notes was required to be repaid in full within five business days of the Merger, and the Company is therefore in default of its obligations
at December 31, 2024. The notes&#x2019; default provisions do not require the Company to transfer any shares or pay any amounts to Polar.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;b&gt;TEVOGEN BIO HOLDINGS
INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;b&gt;NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2024-02-142024-02-14_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000832"
      unitRef="Shares">10337419</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember"
      decimals="0"
      id="Fact000834"
      unitRef="USD">36000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember"
      decimals="0"
      id="Fact000836"
      unitRef="USD">1000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm
      contextRef="From2024-06-012024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember"
      id="Fact000838">P48M</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember"
      decimals="INF"
      id="Fact000840"
      unitRef="Pure">0.0200</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember"
      decimals="INF"
      id="Fact000842"
      unitRef="Pure">0.0700</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:SharePrice
      contextRef="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember"
      decimals="INF"
      id="Fact000844"
      unitRef="USDPShares">1.50</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-12-31_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember"
      decimals="INF"
      id="Fact000846"
      unitRef="Shares">18847</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="AsOf2024-06-30_custom_ThePatelFamilyLLPMember_custom_LoanAgreementMember_us-gaap_UnsecuredDebtMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000848"
      unitRef="USDPShares">1.50</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-06-012024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember"
      decimals="INF"
      id="Fact000850"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="AsOf2024-12-31_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember"
      decimals="0"
      id="Fact000852"
      unitRef="USD">1000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="AsOf2024-12-31_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember"
      decimals="0"
      id="Fact000854"
      unitRef="USD">30000000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm
      contextRef="From2024-01-012024-12-31_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember"
      id="Fact000856">P30M</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="AsOf2025-02-28_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact000858"
      unitRef="USD">1000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="AsOf2025-03-31_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact000860"
      unitRef="USD">1000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross
      contextRef="From2024-06-012024-06-30_custom_ThePatelFamilyLLPMember_custom_LoanAgreementMember"
      decimals="0"
      id="Fact000862"
      unitRef="USD">14000000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="From2024-06-012024-06-30_custom_ThePatelFamilyLLPMember_custom_LoanAgreementMember"
      decimals="INF"
      id="Fact000864"
      unitRef="Pure">0.70</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross
      contextRef="From2024-06-012024-06-30_custom_ThePatelFamilyLLPMember_custom_LoanAgreementMember"
      decimals="-6"
      id="Fact000866"
      unitRef="USD">14000000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross
      contextRef="From2024-06-012024-06-30_custom_ThePatelFamilyLLPMember_custom_LoanAgreementMember"
      decimals="-6"
      id="Fact000868"
      unitRef="USD">14000000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember"
      decimals="INF"
      id="Fact000870"
      unitRef="USDPShares">10.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember"
      decimals="-6"
      id="Fact000872"
      unitRef="USD">14000000</us-gaap:DerivativeLiabilities>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross
      contextRef="From2024-06-012024-06-30_custom_ThePatelFamilyLLPMember_custom_LoanAgreementMember_custom_AdditionalAmountPurchaseOptionMember"
      decimals="-6"
      id="Fact000874"
      unitRef="USD">14000000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_custom_AdditionalAmountPurchaseOptionMember"
      decimals="INF"
      id="Fact000876"
      unitRef="USDPShares">10.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2024-06-30"
      decimals="-6"
      id="Fact000878"
      unitRef="USD">14000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000880"
      unitRef="USD">0</us-gaap:DerivativeLiabilitiesCurrent>
    <TVGN:StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility
      contextRef="From2024-06-012024-06-30_custom_ThePatelFamilyLLPMember_custom_LoanAgreementMember"
      decimals="INF"
      id="Fact000882"
      unitRef="Shares">1000000</TVGN:StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember"
      decimals="-6"
      id="Fact000884"
      unitRef="USD">14000000</us-gaap:DerivativeLiabilities>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2024-12-31_custom_PolarMultiStrategyMasterFundMember"
      decimals="0"
      id="Fact000886"
      unitRef="USD">1651000</us-gaap:NotesPayableCurrent>
    <us-gaap:OperatingLeasesOfLessorDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000888">&lt;p id="xdx_80E_eus-gaap--OperatingLeasesOfLessorDisclosureTextBlock_zc3CeCOj6qU6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
9. &lt;span id="xdx_82C_zArk9wUoyvf7"&gt;LEASES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
2022, the Company entered into leases for office and laboratory space in Warren Township, New Jersey and Philadelphia, Pennsylvania under
operating leases expiring in February 2026 and July 2025, respectively. The leases require fixed monthly payments of rent, as well as
a share of operating costs. The leases are classified as operating leases and the lease liabilities were calculated using incremental
borrowing rates ranging from &lt;span id="xdx_901_ecustom--OperatingLeasesIncrementalBorrowingRates_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_zM9BKtznH8Yg" title="Operating leases incremental borrowing rates"&gt;11.0&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
to &lt;span id="xdx_902_ecustom--OperatingLeasesIncrementalBorrowingRates_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zWk0ioLAECGb" title="Operating leases incremental borrowing rates"&gt;11.2&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%,
which was determined using a synthetic credit rating model. Lease expense for the year ended December 31, 2024 was $&lt;span id="xdx_907_eus-gaap--OperatingLeaseExpense_c20240101__20241231_z0wILeVXmThd" title="Operating lease expense"&gt;1,065,784&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
which consisted of $&lt;span id="xdx_908_eus-gaap--OperatingLeaseExpense_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentArrangementMember_zZO81HfiBvi3" title="Operating lease expense"&gt;897,958
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and $&lt;span id="xdx_906_eus-gaap--OperatingLeaseExpense_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zKHxjj4OAQvc" title="Operating lease expense"&gt;167,826
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;recognized as a component of research
and development expense and general and administrative expense, respectively. This amount included $&lt;span id="xdx_903_eus-gaap--ShortTermLeasePayments_c20240101__20241231_zyfKBUXNg9Tg" title="Short term lease"&gt;785,424
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;of expense under short-term leases.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
weighted average remaining lease term for the Company&#x2019;s operating leases as of December 31, 2024 was &lt;span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_zflP0svOdGRa" title="Operating leases weighted average remaining lease term"&gt;0.93
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;years. The weighted average discount rate
for the Company&#x2019;s operating leases for the year ended December 31, 2024 was &lt;span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20241231_zZUuLFURavl6" title="Operating leases weighted average discount rate"&gt;11.1&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_ecustom--ScheduleOfCompanyLeaseLiabilitiesTableTextBlock_z5Amd0mc7FH6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Future
aggregate minimum rental payments under the operating leases as of December 31, 2024 were as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_8B5_z56qhGR4fHig" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SCHEDULE
OF MINIMUM RENTAL PAYMENTS UNDER THE OPERATING LEASES&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Years Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20241231_ziRvYQE54ivl" style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maOLLzALR_zmGsqaMQdUM" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;230,471&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maOLLzALR_zGr95ElDsClh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;13,975&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtOLLzALR_zrMvbdd8G9Lh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;244,446&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zS0rZ8shQAB6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(9,587&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OperatingLeaseLiability_iTI_zj9oIpfMdBmb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;234,859&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zNODONkrSBx2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
cash payments related to leases for the years ended December 31, 2024 and 2023 were $&lt;span id="xdx_90F_eus-gaap--OperatingLeasePayments_c20240101__20241231_zbQfrmSDpMK" title="Cash payments"&gt;1,077,127
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and $&lt;span id="xdx_909_eus-gaap--OperatingLeasePayments_c20230101__20231231_zj7JgaiK49mk" title="Cash payments"&gt;1,058,754&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
respectively.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OperatingLeasesOfLessorDisclosureTextBlock>
    <TVGN:OperatingLeasesIncrementalBorrowingRates
      contextRef="From2024-01-012024-12-31_srt_MinimumMember"
      decimals="INF"
      id="Fact000890"
      unitRef="Pure">0.110</TVGN:OperatingLeasesIncrementalBorrowingRates>
    <TVGN:OperatingLeasesIncrementalBorrowingRates
      contextRef="From2024-01-012024-12-31_srt_MaximumMember"
      decimals="INF"
      id="Fact000892"
      unitRef="Pure">0.112</TVGN:OperatingLeasesIncrementalBorrowingRates>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000894"
      unitRef="USD">1065784</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentArrangementMember"
      decimals="0"
      id="Fact000896"
      unitRef="USD">897958</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact000898"
      unitRef="USD">167826</us-gaap:OperatingLeaseExpense>
    <us-gaap:ShortTermLeasePayments
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000900"
      unitRef="USD">785424</us-gaap:ShortTermLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2024-12-31" id="Fact000902">P0Y11M4D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000904"
      unitRef="Pure">0.111</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <TVGN:ScheduleOfCompanyLeaseLiabilitiesTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000906">&lt;p id="xdx_895_ecustom--ScheduleOfCompanyLeaseLiabilitiesTableTextBlock_z5Amd0mc7FH6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Future
aggregate minimum rental payments under the operating leases as of December 31, 2024 were as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_8B5_z56qhGR4fHig" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SCHEDULE
OF MINIMUM RENTAL PAYMENTS UNDER THE OPERATING LEASES&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Years Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20241231_ziRvYQE54ivl" style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maOLLzALR_zmGsqaMQdUM" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;230,471&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maOLLzALR_zGr95ElDsClh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;13,975&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtOLLzALR_zrMvbdd8G9Lh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;244,446&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zS0rZ8shQAB6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(9,587&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OperatingLeaseLiability_iTI_zj9oIpfMdBmb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;234,859&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</TVGN:ScheduleOfCompanyLeaseLiabilitiesTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000908"
      unitRef="USD">230471</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000910"
      unitRef="USD">13975</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000912"
      unitRef="USD">244446</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000914"
      unitRef="USD">9587</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000916"
      unitRef="USD">234859</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeasePayments
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000918"
      unitRef="USD">1077127</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000920"
      unitRef="USD">1058754</us-gaap:OperatingLeasePayments>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000922">&lt;p id="xdx_80E_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zHq3GNNa6Zf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
10. &lt;span id="xdx_821_zsWcklDknXOc"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Employment
contracts&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has entered into employment contracts with its officers and certain employees that provide for severance and continuation of
benefits in the event of termination of employment either by the Company without cause or by the employee for good reason, both as defined
in the applicable agreement.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Contingencies&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Liabilities
for loss contingencies arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is probable
that a liability has been incurred and the amount of the assessment and/or remediation can be reasonably estimated.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000924">&lt;p id="xdx_808_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zyMCODyWWnya" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
11. &lt;span id="xdx_827_z4dAxgKik4m6"&gt;STOCK-BASED COMPENSATION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the Closing, the Company adopted the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan (the &#x201c;2024 Plan&#x201d;)
and no longer grants awards pursuant to the 2020 Equity Incentive Plan (the &#x201c;2020 Plan&#x201d;). Each RSU award granted under the
2020 Plan that was outstanding and unvested as of the Closing Date was automatically canceled and converted into an award under the 2024
Plan with respect to the common stock of the Company (the &#x201c;Rollover RSUs&#x201d;). Such Rollover RSUs remain subject to the same
terms and conditions as set forth under the applicable award agreement prior to the Closing.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
addition to covering the Rollover RSUs, under the 2024 Plan, the Company is authorized to grant awards up to an aggregate&#160;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourPlanMember_zkaAUew16Z37" title="Granted shares"&gt;40,000,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;shares
of common stock. The 2024 Plan provides for the grant of options, stock appreciation rights, Restricted Stock, RSUs, and other equity-based
awards. As of December 31, 2024, awards for &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourPlanMember_z7HKfBKy4zE6" title="Shares available for granted"&gt;10,670,118
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares remained available to be granted
under the 2024 Plan.&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has issued RSUs that are subject to either service-based vesting conditions or service-based and performance-based vesting conditions.
Compensation expense for service-based RSUs are recognized on a straight-line basis over the vesting period of the award. Compensation
expense for service-based and performance-based RSUs (&#x201c;Performance-Based RSUs&#x201d;) are recognized when the performance condition,
which is based on a liquidity event condition being satisfied, is deemed probable of achievement.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;b&gt;TEVOGEN BIO HOLDINGS
INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;b&gt;NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
the Closing Date, the Company issued an aggregate of&#160;&lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240214__20240214__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourPlanMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z84ak8g02yQ4" title="Number of shares issued for RSUs"&gt;19,348,954&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;RSUs
under the 2024 Plan to the Company&#x2019;s Chief Executive Officer, Dr. Ryan Saadi (the &#x201c;Special RSU Award&#x201d;). Such RSUs immediately
converted into shares of Restricted Stock, the restrictions on which lapse in four equal annual installments beginning on February 14,
2031 (&#x201c;Vesting Period&#x201d;). Pursuant to the terms of the Special RSU Award, Dr. Saadi will be entitled to vote the Restricted
Stock, but the shares may not be sold, assigned, transferred, pledged, hypothecated, or otherwise encumbered, subject to forfeit. Dr.
Saadi will automatically forfeit all unvested Restricted Stock in the event he departs the Company. The fair value per share for the
Special RSU Award was determined to be $&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20240214__20240214__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourPlanMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_ziRYnY7CEYVf" title="Fair value per share for award"&gt;4.51&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;per
share, equivalent to the Company&#x2019;s stock price on the Closing Date, resulting in a total grant date fair value of $&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20240214__20240214__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourPlanMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zs7oTBLqaQu3" title="Grant date fair value of shares"&gt;87,263,783&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
In accordance with ASC 718,&#160;&lt;i&gt;Compensation - Stock Compensation&#160;&lt;/i&gt;(&#x201c;ASC 718&#x201d;), the Company will recognize compensation
expense on a straight-line basis from the Closing Date until the completion of the Vesting Period.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zg71PxSY1j3d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Restricted
Stock and RSU activity was as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_8BB_zKiyxUa8Uqya" style="display: none"&gt;SCHEDULE
OF RESTRICTED STOCK AND RSU ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;Service-Based Restricted Stock and
    RSUs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;Weighted average grant-date fair
    value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;Nonvested as of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zYkbcEwtskV6" style="text-align: right" title="Nonvested Shares, Beginning"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0938"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zTw0SUr5swm" style="text-align: right" title="Nonvested weighted average grant-date fair value, Beginning"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0940"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zSMKKQsYVatk" style="text-align: right" title="Nonvested Shares, Granted"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0942"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zfQCmYSGg127" style="text-align: right" title="Nonvested weighted average grant-date fair value, Granted"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0944"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zYGORBC0qyr8" style="text-align: right" title="Nonvested Shares, Vested"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0946"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zgzleRueiFa5" style="text-align: right" title="Nonvested weighted average grant-date fair value, Vested"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0948"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_z0nVoVud6em5" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested Shares, Forfeited"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0950"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zxUFVKPP1Mf5" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested weighted average grant-date fair value, Forfeited"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0952"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;Nonvested as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zl7TdslQqUz7" style="text-align: right" title="Nonvested Shares, Beginning"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0954"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zVjv6BEq74j5" style="text-align: right" title="Nonvested weighted average grant-date fair value, Beginning"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0956"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%"&gt;&lt;span style="-sec-ix-redline: true"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zmhyAJn6R25k" style="width: 16%; text-align: right" title="Nonvested Shares, Granted"&gt;&lt;span style="-sec-ix-redline: true"&gt;29,329,882&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zIVhFVfiUd26" style="width: 16%; text-align: right" title="Nonvested weighted average grant-date fair value, Granted"&gt;&lt;span style="-sec-ix-redline: true"&gt;3.31&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zb4N3FdAt0F4" style="text-align: right" title="Nonvested Shares, Vested"&gt;&lt;span style="-sec-ix-redline: true"&gt;(2,639,628&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zjmY3Ryy46re" style="text-align: right" title="Nonvested weighted average grant-date fair value, Vested"&gt;&lt;span style="-sec-ix-redline: true"&gt;0.96&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zOT6oxpXsWYh" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested Shares, Forfeited"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0966"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zVr3GW8f4fFg" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested weighted average grant-date fair value, Forfeited"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0968"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Nonvested as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zAbeEL3jQWA2" style="border-bottom: Black 2.5pt double; text-align: right" title="Nonvested Shares, Beginning"&gt;&lt;span style="-sec-ix-redline: true"&gt;26,690,254&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zpPP7ynEpTU" style="border-bottom: Black 2.5pt double; text-align: right" title="Nonvested weighted average grant-date fair value, Beginning"&gt;&lt;span style="-sec-ix-redline: true"&gt;3.54&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;Performance-Based RSUs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;Weighted average grant-date fair
    value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;&lt;span style="-sec-ix-redline: true"&gt;Nonvested as of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z1rlz6ZIH2E1" style="width: 16%; text-align: right" title="Nonvested Shares, Beginning"&gt;&lt;span style="-sec-ix-redline: true"&gt;9,894,958&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zYEBRUUa4fS6" style="width: 16%; text-align: right" title="Nonvested weighted average grant-date fair value, Beginning"&gt;&lt;span style="-sec-ix-redline: true"&gt;2.85&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zXzXs5LuVewk" style="text-align: right" title="Nonvested Shares, Granted"&gt;&lt;span style="-sec-ix-redline: true"&gt;1,027,796&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zU5QwhOVtKKh" style="text-align: right" title="Nonvested weighted average grant-date fair value, Granted"&gt;&lt;span style="-sec-ix-redline: true"&gt;4.16&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zNihbNDgoJlj" style="text-align: right" title="Nonvested Shares, Vested"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0982"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zRtEuhMXxxY2" style="text-align: right" title="Nonvested weighted average grant-date fair value, Vested"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0984"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z4WNux4psgFf" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested Shares, Forfeited"&gt;&lt;span style="-sec-ix-redline: true"&gt;(22,626&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zCwJ89xod5X9" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested weighted average grant-date fair value, Forfeited"&gt;&lt;span style="-sec-ix-redline: true"&gt;4.39&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;Nonvested as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zVTTQ5j3Vxe1" style="text-align: right" title="Nonvested Shares, Beginning"&gt;&lt;span style="-sec-ix-redline: true"&gt;10,900,128&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z4tOtcsDbQrk" style="text-align: right" title="Nonvested weighted average grant-date fair value, Ending"&gt;&lt;span style="-sec-ix-redline: true"&gt;2.97&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zmsRkYvAG8l3" style="text-align: right" title="Nonvested Shares, Granted"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0994"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zf55dHhm3mC2" style="text-align: right" title="Nonvested weighted average grant-date fair value, Granted"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0996"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zaPBEe7jGmH7" style="text-align: right" title="Nonvested Shares, Vested"&gt;&lt;span style="-sec-ix-redline: true"&gt;(9,610,540&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z3qi8eJlnIoj" style="text-align: right" title="Nonvested weighted average grant-date fair value, Vested"&gt;&lt;span style="-sec-ix-redline: true"&gt;2.87&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zDVaCo8Kj5x6" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested Shares, Forfeited"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1002"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zZJSQQVnys22" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested weighted average grant-date fair value, Forfeited"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1004"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Nonvested as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z6DRsiRRodBh" style="border-bottom: Black 2.5pt double; text-align: right" title="Nonvested Shares, Beginning"&gt;&lt;span style="-sec-ix-redline: true"&gt;1,289,578&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_znTBbMTO9Iii" style="border-bottom: Black 2.5pt double; text-align: right" title="Nonvested weighted average grant-date fair value, Ending"&gt;&lt;span style="-sec-ix-redline: true"&gt;3.70&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_z4eThjaJVWS9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
a result of the Merger, the liquidity event performance condition was achieved and therefore compensation cost of $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensation_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zf9pjdTt3KNe" title="Compensation cost recognized"&gt;25,233,487&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;for
the year ended December 31, 2024 was recognized for the Performance-Based RSUs, of which&#160;&lt;span id="xdx_907_ecustom--StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zSX8nT5zA3p8" title="Number of shares issued and outstading RSU"&gt;8,237,319
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares were issued and outstanding as
of December 31, 2024, and&#160;&lt;span id="xdx_90C_ecustom--VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing_iI_c20250101__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zX2rnjABA6Je" title="Number of shares issuable"&gt;1,373,221&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;shares
will be issued subsequent to December 31, 2024. There was $&lt;span id="xdx_90C_eus-gaap--EmployeeStockOwnershipPlanESOPCompensationExpense_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z83Wk1gYbvT1" title="Compensation cost"&gt;11,410,921
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;compensation cost related to Service-Based
Restricted Stock and RSUs, for the year ended December 31, 2024, and &lt;span id="xdx_90D_ecustom--VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing_iI_c20250101__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zRLZER3wPQl7" title="Number of shares issuable"&gt;2,639,628
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares were issued and outstanding. There
was $&lt;span id="xdx_902_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zCzwJ6CqfhDd" title="Unrecognized compensation cost"&gt;85,601,786&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;of
unrecognized compensation cost related to Service-Based Restricted Stock and RSUs as of December 31, 2024, which will be expensed over
a weighted average period of&#160;&lt;span id="xdx_901_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zQygHX4CHgMl" title="Weighted average period"&gt;7.0&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;years.
There was $&lt;span id="xdx_906_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zapiN8fpwYak" title="Unrecognized compensation cost"&gt;2,984,909&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;of
unrecognized compensation cost related to Performance-Based RSUs as of December 31, 2024, which will be expensed over a weighted average
period of&#160;&lt;span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zO72HDdRqff6" title="Weighted average period for recognition"&gt;1.1&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;years.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;b&gt;TEVOGEN BIO HOLDINGS
INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;b&gt;NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p id="xdx_89F_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zqQ6C3RkJXLh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recorded stock-based compensation expense in the following expense categories in the accompanying consolidated statements of
operations:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_8B4_z0T6x9S9R0nc" style="display: none"&gt;SCHEDULE OF STOCK-BASED
COMPENSATION EXPENSE&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20240101__20241231_zDU36E9nUsml" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;Year ended&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
                                            31,&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zYTqU2Y6qIUa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;27,019,781&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z2XZFhW9Nmak" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;13,744,355&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AllocatedShareBasedCompensationExpense_zwdTtZqbiUNb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;40,764,136&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zolbzGpD9Gyc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_do_c20230101__20231231_ze91l903pZjd"&gt;No
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;stock-based compensation expense was recognized
in 2023.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyFourPlanMember"
      decimals="INF"
      id="Fact000926"
      unitRef="Shares">40000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyFourPlanMember"
      decimals="INF"
      id="Fact000928"
      unitRef="Shares">10670118</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2024-02-142024-02-14_custom_TwoThousandTwentyFourPlanMember_srt_ChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact000930"
      unitRef="Shares">19348954</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-02-142024-02-14_custom_TwoThousandTwentyFourPlanMember_srt_ChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact000932"
      unitRef="USDPShares">4.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2024-02-142024-02-14_custom_TwoThousandTwentyFourPlanMember_srt_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact000934"
      unitRef="USD">87263783</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000936">&lt;p id="xdx_89E_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zg71PxSY1j3d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Restricted
Stock and RSU activity was as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_8BB_zKiyxUa8Uqya" style="display: none"&gt;SCHEDULE
OF RESTRICTED STOCK AND RSU ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;Service-Based Restricted Stock and
    RSUs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;Weighted average grant-date fair
    value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;Nonvested as of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zYkbcEwtskV6" style="text-align: right" title="Nonvested Shares, Beginning"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0938"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zTw0SUr5swm" style="text-align: right" title="Nonvested weighted average grant-date fair value, Beginning"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0940"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zSMKKQsYVatk" style="text-align: right" title="Nonvested Shares, Granted"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0942"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zfQCmYSGg127" style="text-align: right" title="Nonvested weighted average grant-date fair value, Granted"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0944"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zYGORBC0qyr8" style="text-align: right" title="Nonvested Shares, Vested"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0946"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zgzleRueiFa5" style="text-align: right" title="Nonvested weighted average grant-date fair value, Vested"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0948"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_z0nVoVud6em5" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested Shares, Forfeited"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0950"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zxUFVKPP1Mf5" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested weighted average grant-date fair value, Forfeited"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0952"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;Nonvested as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zl7TdslQqUz7" style="text-align: right" title="Nonvested Shares, Beginning"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0954"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zVjv6BEq74j5" style="text-align: right" title="Nonvested weighted average grant-date fair value, Beginning"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0956"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%"&gt;&lt;span style="-sec-ix-redline: true"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zmhyAJn6R25k" style="width: 16%; text-align: right" title="Nonvested Shares, Granted"&gt;&lt;span style="-sec-ix-redline: true"&gt;29,329,882&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zIVhFVfiUd26" style="width: 16%; text-align: right" title="Nonvested weighted average grant-date fair value, Granted"&gt;&lt;span style="-sec-ix-redline: true"&gt;3.31&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zb4N3FdAt0F4" style="text-align: right" title="Nonvested Shares, Vested"&gt;&lt;span style="-sec-ix-redline: true"&gt;(2,639,628&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zjmY3Ryy46re" style="text-align: right" title="Nonvested weighted average grant-date fair value, Vested"&gt;&lt;span style="-sec-ix-redline: true"&gt;0.96&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zOT6oxpXsWYh" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested Shares, Forfeited"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0966"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zVr3GW8f4fFg" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested weighted average grant-date fair value, Forfeited"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0968"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Nonvested as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zAbeEL3jQWA2" style="border-bottom: Black 2.5pt double; text-align: right" title="Nonvested Shares, Beginning"&gt;&lt;span style="-sec-ix-redline: true"&gt;26,690,254&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zpPP7ynEpTU" style="border-bottom: Black 2.5pt double; text-align: right" title="Nonvested weighted average grant-date fair value, Beginning"&gt;&lt;span style="-sec-ix-redline: true"&gt;3.54&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;Performance-Based RSUs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;Weighted average grant-date fair
    value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;&lt;span style="-sec-ix-redline: true"&gt;Nonvested as of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z1rlz6ZIH2E1" style="width: 16%; text-align: right" title="Nonvested Shares, Beginning"&gt;&lt;span style="-sec-ix-redline: true"&gt;9,894,958&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zYEBRUUa4fS6" style="width: 16%; text-align: right" title="Nonvested weighted average grant-date fair value, Beginning"&gt;&lt;span style="-sec-ix-redline: true"&gt;2.85&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zXzXs5LuVewk" style="text-align: right" title="Nonvested Shares, Granted"&gt;&lt;span style="-sec-ix-redline: true"&gt;1,027,796&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zU5QwhOVtKKh" style="text-align: right" title="Nonvested weighted average grant-date fair value, Granted"&gt;&lt;span style="-sec-ix-redline: true"&gt;4.16&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zNihbNDgoJlj" style="text-align: right" title="Nonvested Shares, Vested"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0982"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zRtEuhMXxxY2" style="text-align: right" title="Nonvested weighted average grant-date fair value, Vested"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0984"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z4WNux4psgFf" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested Shares, Forfeited"&gt;&lt;span style="-sec-ix-redline: true"&gt;(22,626&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zCwJ89xod5X9" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested weighted average grant-date fair value, Forfeited"&gt;&lt;span style="-sec-ix-redline: true"&gt;4.39&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;Nonvested as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zVTTQ5j3Vxe1" style="text-align: right" title="Nonvested Shares, Beginning"&gt;&lt;span style="-sec-ix-redline: true"&gt;10,900,128&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z4tOtcsDbQrk" style="text-align: right" title="Nonvested weighted average grant-date fair value, Ending"&gt;&lt;span style="-sec-ix-redline: true"&gt;2.97&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zmsRkYvAG8l3" style="text-align: right" title="Nonvested Shares, Granted"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0994"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zf55dHhm3mC2" style="text-align: right" title="Nonvested weighted average grant-date fair value, Granted"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0996"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zaPBEe7jGmH7" style="text-align: right" title="Nonvested Shares, Vested"&gt;&lt;span style="-sec-ix-redline: true"&gt;(9,610,540&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z3qi8eJlnIoj" style="text-align: right" title="Nonvested weighted average grant-date fair value, Vested"&gt;&lt;span style="-sec-ix-redline: true"&gt;2.87&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zDVaCo8Kj5x6" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested Shares, Forfeited"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1002"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zZJSQQVnys22" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested weighted average grant-date fair value, Forfeited"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1004"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Nonvested as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z6DRsiRRodBh" style="border-bottom: Black 2.5pt double; text-align: right" title="Nonvested Shares, Beginning"&gt;&lt;span style="-sec-ix-redline: true"&gt;1,289,578&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_znTBbMTO9Iii" style="border-bottom: Black 2.5pt double; text-align: right" title="Nonvested weighted average grant-date fair value, Ending"&gt;&lt;span style="-sec-ix-redline: true"&gt;3.70&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2024-01-012024-12-31_custom_ServiceBasedRestrictedStockMember"
      decimals="INF"
      id="Fact000958"
      unitRef="Shares">29329882</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-12-31_custom_ServiceBasedRestrictedStockMember"
      decimals="INF"
      id="Fact000960"
      unitRef="USDPShares">3.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2024-01-012024-12-31_custom_ServiceBasedRestrictedStockMember"
      decimals="INF"
      id="Fact000962"
      unitRef="Shares">2639628</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-12-31_custom_ServiceBasedRestrictedStockMember"
      decimals="INF"
      id="Fact000964"
      unitRef="USDPShares">0.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-12-31_custom_ServiceBasedRestrictedStockMember"
      decimals="INF"
      id="Fact000970"
      unitRef="Shares">26690254</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-12-31_custom_ServiceBasedRestrictedStockMember"
      decimals="INF"
      id="Fact000972"
      unitRef="USDPShares">3.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2022-12-31_custom_PerformanceBasedRSUsMember"
      decimals="INF"
      id="Fact000974"
      unitRef="Shares">9894958</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2022-12-31_custom_PerformanceBasedRSUsMember"
      decimals="INF"
      id="Fact000976"
      unitRef="USDPShares">2.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2023-01-012023-12-31_custom_PerformanceBasedRSUsMember"
      decimals="INF"
      id="Fact000978"
      unitRef="Shares">1027796</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_custom_PerformanceBasedRSUsMember"
      decimals="INF"
      id="Fact000980"
      unitRef="USDPShares">4.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2023-01-012023-12-31_custom_PerformanceBasedRSUsMember"
      decimals="INF"
      id="Fact000986"
      unitRef="Shares">22626</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_custom_PerformanceBasedRSUsMember"
      decimals="INF"
      id="Fact000988"
      unitRef="USDPShares">4.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2023-12-31_custom_PerformanceBasedRSUsMember"
      decimals="INF"
      id="Fact000990"
      unitRef="Shares">10900128</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-12-31_custom_PerformanceBasedRSUsMember"
      decimals="INF"
      id="Fact000992"
      unitRef="USDPShares">2.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2024-01-012024-12-31_custom_PerformanceBasedRSUsMember"
      decimals="INF"
      id="Fact000998"
      unitRef="Shares">9610540</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-12-31_custom_PerformanceBasedRSUsMember"
      decimals="INF"
      id="Fact001000"
      unitRef="USDPShares">2.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-12-31_custom_PerformanceBasedRSUsMember"
      decimals="INF"
      id="Fact001006"
      unitRef="Shares">1289578</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-12-31_custom_PerformanceBasedRSUsMember"
      decimals="INF"
      id="Fact001008"
      unitRef="USDPShares">3.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-12-31_custom_PerformanceBasedRSUsMember"
      decimals="0"
      id="Fact001010"
      unitRef="USD">25233487</us-gaap:ShareBasedCompensation>
    <TVGN:StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits
      contextRef="From2024-01-012024-12-31_custom_PerformanceBasedRSUsMember"
      decimals="INF"
      id="Fact001012"
      unitRef="Shares">8237319</TVGN:StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits>
    <TVGN:VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing
      contextRef="AsOf2025-01-01_us-gaap_SubsequentEventMember_custom_PerformanceBasedRSUsMember"
      decimals="INF"
      id="Fact001014"
      unitRef="Shares">1373221</TVGN:VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing>
    <us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockMember"
      decimals="0"
      id="Fact001016"
      unitRef="USD">11410921</us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense>
    <TVGN:VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing
      contextRef="AsOf2025-01-01_us-gaap_SubsequentEventMember_custom_ServiceBasedRestrictedStockMember"
      decimals="INF"
      id="Fact001018"
      unitRef="Shares">2639628</TVGN:VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2024-12-31_custom_ServiceBasedRestrictedStockMember"
      decimals="0"
      id="Fact001020"
      unitRef="USD">85601786</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockMember"
      id="Fact001022">P7Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2024-12-31_custom_PerformanceBasedRSUsMember"
      decimals="0"
      id="Fact001024"
      unitRef="USD">2984909</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="From2024-01-012024-12-31_custom_PerformanceBasedRSUsMember"
      id="Fact001026">P1Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001028">&lt;p id="xdx_89F_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zqQ6C3RkJXLh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recorded stock-based compensation expense in the following expense categories in the accompanying consolidated statements of
operations:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_8B4_z0T6x9S9R0nc" style="display: none"&gt;SCHEDULE OF STOCK-BASED
COMPENSATION EXPENSE&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20240101__20241231_zDU36E9nUsml" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;Year ended&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
                                            31,&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zYTqU2Y6qIUa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;27,019,781&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z2XZFhW9Nmak" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;13,744,355&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AllocatedShareBasedCompensationExpense_zwdTtZqbiUNb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;40,764,136&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact001030"
      unitRef="USD">27019781</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact001032"
      unitRef="USD">13744355</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001034"
      unitRef="USD">40764136</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001035"
      unitRef="USD">0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001037">&lt;p id="xdx_800_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zqa4HQO38Ad3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
12.&#160;&lt;span id="xdx_823_zPEUk6aDyaG5"&gt;STOCKHOLDERS&#x2019; DEFICIT&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;Common
Stock&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of February 15, 2024, the Company&#x2019;s common stock and warrants began trading on The Nasdaq Stock Market LLC under the symbols &#x201c;TVGN&#x201d;
and &#x201c;TVGNW&#x201d;, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, the Company had&#160;&lt;span id="xdx_90C_eus-gaap--CommonStockSharesIssued_iI_c20241231_zMwByKIdp1T5" title="Common shares, shares issued"&gt;&lt;span id="xdx_905_eus-gaap--CommonStockSharesOutstanding_iI_c20241231_z3wxrw4IG9ql" title="Common shares, shares outstanding"&gt;177,991,365&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;shares
of common stock issued and outstanding. For accounting purposes related to earnings per share, only shares that are fully vested are
considered issued and outstanding.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfStockholdersEquityTableTextBlock_zSOL5mLD6Ex8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Below
is a reconciliation of shares of common stock issued and outstanding:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_8BF_zBobVkOAVlrc" style="display: none"&gt;SCHEDULE OF RECONCILIATION
OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Total shares of common stock issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_c20241231_zyN8CCKLMVr8" title="Total shares of common stock legally issued"&gt;&lt;span id="xdx_909_eus-gaap--CommonStockSharesOutstanding_iI_c20241231_z5LoyIQAfSeg" title="Total shares of common stock legally outstanding"&gt;177,991,365&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Plus: shares to be issued:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Vested RSUs not yet legally settled into common stock (a)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing_iI_c20241231_fKGEp_zCbHItSD0oN5" style="text-align: right" title="Vested Performance-Based RSUs from satisfaction of liquidity condition upon the Closing"&gt;&lt;span style="-sec-ix-redline: true"&gt;1,373,221&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Less: Shares subject to future vesting:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Issuance of restricted common stock subject to forfeiture
    (b)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture_iI_c20241231_fKGIp_zAWe8GbZVlj2" style="border-bottom: Black 1pt solid; text-align: right" title="Issuance of restricted common stock subject to forfeiture"&gt;&lt;span style="-sec-ix-redline: true"&gt;(19,348,954&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Total shares, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_ecustom--CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture_iI_c20241231_zTEH5atUDVxk" style="border-bottom: Black 2.5pt double; text-align: right" title="Total shares issued and outstanding"&gt;&lt;span style="-sec-ix-redline: true"&gt;160,015,632&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_F0C_zk3ugD4zYWK3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_F1B_z37YHzlQJlp4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
    of December 31, 2024, there were RSUs that had vested but had not been legally settled into common stock. See Note 11 for additional
    information.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_F03_zRtXAoAo4a1b" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(b)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_F1E_zYoDAP8O7hp2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dr.
    Saadi will automatically forfeit all unvested Restricted Stock granted pursuant to the Special RSU Award in the event he departs
    the Company. See Note 11 for additional information on the Special RSU Award.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A5_zFXyPlOcKyif" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prior
to the Merger, Tevogen Bio had outstanding shares of voting and non-voting common stock. Upon the Closing, Tevogen Bio&#x2019;s common
stockholders received shares of the Company&#x2019;s common stock in an amount determined by application of the Exchange Ratio, as discussed
in Note 1.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;b&gt;TEVOGEN BIO HOLDINGS
INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;b&gt;NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Preferred
Stock&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is authorized to issue up to&#160;&lt;span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_c20241231_zeKFUrWx9AP2" title="Preferred shares, shares authorized"&gt;20,000,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;shares
of preferred stock, par value $&lt;span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20241231_zoEeMt6zvnV4" title="Preferred shares, par value"&gt;0.0001&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;per
share.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Series
A Preferred Stock&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
March 2024, the Company authorized and issued&#160;&lt;span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zOLmDBCk46lb" title="Preferred stock, shares authorized"&gt;2,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;and&#160;&lt;span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zbMqeQf9Qm6a" title="Preferred stock, shares issued"&gt;500&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;shares,
respectively, of Series A Preferred Stock (the &#x201c;Series A&#x201d;) to the Patel Family at a price of $&lt;span id="xdx_908_eus-gaap--SharePrice_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_z3XSZLyE1g57" title="Original issue price per share"&gt;4,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;per
share (the &#x201c;Series A Original Issue Price&#x201d;), for gross proceeds of $&lt;span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20240301__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zfEFg1tPo3j9" title="Proceeds from issuance of preferred stock"&gt;2,000,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
The Company recorded an expense of $&lt;span id="xdx_900_ecustom--LossOnPreferredStockIssuance_c20240301__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zsNErM7B6u37" title="Loss on preferred stock issuance"&gt;799,990&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;in
its consolidated statements of operations related to issuance of the Series A equal to the fair value of the Series A when issued of
$&lt;span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zJiiIEZtR32" title="Price per share"&gt;5,600&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;per
share less the purchase price of $&lt;span id="xdx_90A_eus-gaap--SharePrice_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zQ5BTtvcEdja" title="Share price"&gt;4,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;per
share.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Dividends&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Holders
of Series A are entitled to receive dividends accruing daily on a cumulative basis payable at a fixed rate of&#160;&lt;span id="xdx_903_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zEXAZXeTMRm2" title="Dividend rate, percentage"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
per annum per share on&#160;&lt;span id="xdx_90A_eus-gaap--PreferredStockDividendPaymentRateVariable_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zRwbc71eB8U1" title="Dividend variable rate, description"&gt;the
Series A Original Issue Price, which rate will automatically increase by 2% every year that the Series A remains outstanding (the &#x201c;Series
A Accruing Dividends&#x201d;). These dividends become payable when and if declared by the Company. The Series A Preferred Stock will also
participate on an as-converted basis in any regular or special dividends paid to holders of the common stock&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Liquidation&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Series A ranks senior to common stock and Series C Preferred Stock in liquidation priority. In the event of a liquidation of the Company,
or certain deemed liquidation events, the Series A is redeemable for a price equal to the greater of the Series A Original Issue Price
plus all Series A Accruing Dividends that are unpaid through the redemption date, or such amount that would have been payable had the
Series A converted into shares of common stock immediately before the liquidation or deemed liquidation event.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Voting&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Series A does not have any voting rights.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Redemption&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
holders of Series A are not entitled to redeem their shares outside of the liquidation of the Company or the occurrence of a deemed liquidation
event. The Company is entitled to redeem the Series A at a price equal to the Series A Original Issue Price plus any Series A Accruing
Dividends accrued but unpaid thereon, if the VWAP of the Company&#x2019;s common stock exceeds $&lt;span id="xdx_904_eus-gaap--PreferredStockRedemptionPricePerShare_iI_pid_uUSDPShares_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zuAfldtfHc62" title="Redemption price per share"&gt;5.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;per
share for&#160;&lt;span id="xdx_907_eus-gaap--PreferredStockRedemptionTerms_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zf3mfbHmCfG8" title="Redemption term"&gt;the
twenty days immediately prior to the Company&#x2019;s call election&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;i&gt;Conversion&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
holders of Series A have the option to convert the Series A into shares of common stock at a ratio equal to the Series A Original Issue
Price divided by the Series A Conversion Price, which is initially $&lt;span id="xdx_902_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_uUSDPShares_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zQIYF4ixkDGa" title="Conversion price per share"&gt;4.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;per
share and is subject to standard antidilution adjustments.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span style="text-decoration: underline"&gt;Series
A-1 Preferred Stock&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 27, 2024, the Company entered into an Amended and Restated Securities Purchase Agreement with the Patel Family covering the issuance
of&#160;&lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240326__20240327__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_zoxKHXWMgXH3"&gt;600&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;shares
of Series A-1 Preferred Stock for a gross purchase price of $&lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240326__20240327__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_zil4uC88XYqb"&gt;6,000,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.&#160;&lt;span id="xdx_900_eus-gaap--PreferredStockDividendPaymentRateVariable_c20240326__20240327__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_z0EexvHdNfP4" title="Dividend variable rate, description"&gt;The
terms of the Series A-1 Preferred Stock are identical to the Series A, except that the cumulative dividends are capped at 15% per annum,
and the Series A-1 Issuance Price is defined as $&lt;span id="xdx_90C_eus-gaap--SharePrice_iI_c20240327__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_zNLrJD98P3cf" title="Share price"&gt;10,000&lt;/span&gt;&#160;per share&lt;/span&gt;. As of December 31, 2024, the investor had paid a non-refundable
deposit of $&lt;span id="xdx_903_eus-gaap--Deposits_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_zGLhxcx8NeVb" title="Non refundable deposist paid"&gt;3,000,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;towards
the Series A-1 purchase price, and no shares of Series A-1 Preferred Stock were issued or outstanding.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;b&gt;TEVOGEN BIO HOLDINGS
INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;b&gt;NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Series
B Preferred Stock&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the Closing, the Company entered into an agreement to issue shares of Series B to the Sponsor in return for the Sponsor
assuming certain liabilities and obligations of Semper Paratus and Tevogen Bio. In March 2024,&#160;&lt;span id="xdx_90C_ecustom--StockIssuedDuringPeriodSharesConversionOfLiabilities_c20240301__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zzKEiMAM1kA" title="Conversion of certain liabilities into Series B preferred stock, shares"&gt;3,613&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;shares
of Series B were issued in return for the assumption of the Assumed Liabilities. The issuance date fair value of the Series B was determined
to be $&lt;span id="xdx_90E_ecustom--StockIssuedDuringPeriodValueConversionOfLiabilities_c20240301__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z0w4NNJx0206" title="Conversion of certain liabilities into Series B preferred stock"&gt;3,613,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;and
was recorded within Merger transaction costs in the consolidated statements of operations. The Series B was classified as permanent equity.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 15, 2024, the Company and the Sponsor entered into the Preferred Stock Repurchase Agreement, pursuant to which the Company repurchased
all outstanding Series B in exchange for the release of the Sponsor from its obligations related to the Assumed Liabilities, but no cash
consideration. The repurchase was recorded as a deemed contribution from a related party and recorded to additional paid-in capital.
As of June 30, 2024, there were&#160;&lt;span id="xdx_909_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20240630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zjMKJrpQOGJ7" title="Preferred stock shares outstanding"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;shares
of Series B outstanding, and on August 9, 2024, the Company filed a Certificate of Elimination to eliminate the Series B. Although the
Company was not legally released by the creditors, the Company has made payments towards the Assumed Liabilities and approximately $&lt;span id="xdx_901_eus-gaap--LiabilitiesAssumed1_pn5n6_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zyMnhtgkwDqa" title="Liabilities assumed"&gt;2.6&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;million
remains on the Company&#x2019;s balance sheet at December 31, 2024.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span style="text-decoration: underline"&gt;Series
C Preferred Stock&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 21, 2024, the Company entered into a securities purchase agreement (the &#x201c;Series C Agreement&#x201d;) with an investor, pursuant
to which the Patel Family purchased&#160;&lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240821__20240821__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_zSPnuzVFW8I3"&gt;600&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;shares
of Series C Preferred Stock (the &#x201c;Series C&#x201d;) of the Company at a price of $&lt;span id="xdx_909_eus-gaap--SharePrice_iI_c20240821__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_zDTaVGWAeBdf" title="Share price"&gt;10,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;per
share (the &#x201c;Series C Original Issue Price&#x201d;), for gross proceeds of $&lt;span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20240821__20240821__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_zAEFpmxITdxc" title="Gross proceeds"&gt;6,000,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Series C is subject to a call right providing the Company the right to call the stock at any time after the fifth anniversary of the
date of issuance. The Company also agreed that so long as the Series C is outstanding, the Company will not, without the written consent
of the holders of 50.1% of the Series C, amend, alter, or repeal any provision of the Company&#x2019;s certificate of incorporation or
bylaws in a manner adverse to the Series C. Assessed under accounting guidance within ASC 480 and ASC 815, as the Series C is unregistered
and without mandatory redemption features, the Series C is classified within equity at issued face value as of December 31, 2024.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Dividends&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Series C carries an annual&#160;&lt;span id="xdx_90E_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zOfmBzQmYJh5" title="Dividend rate, percentage"&gt;7.5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
cumulative dividend, compounded annually, beginning on the later of (1) September 30, 2024 and (2)&#160;the date on which the investor
has paid the entirety of the purchase price under the Series C Agreement and ending on the last business day of the calendar quarter
ending September 30, 2034 (the &#x201c;Series C Accruing Dividends&#x201d;). Dividends will be payable in shares of Series C or, at the
election of the Company, in cash.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Liquidation&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Series C ranks subordinate to the Series A and Series A-1 Preferred Stock and ranks senior to common stock in liquidation priority. In
&lt;span id="xdx_90E_eus-gaap--PreferredStockDividendPaymentRateVariable_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zLJfTgOGcgV4" title="Dividend variable rate, description"&gt;the
event of a liquidation of the Company, or certain deemed liquidation events, the Series C is redeemable for a price equal to the greater
of the Series C Original Issue Price plus all Series C Accruing Dividends that are unpaid through the redemption date, or such asset
amount as would have been payable had the Series C converted into shares of common stock immediately before the liquidation or deemed
liquidation event&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Voting&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Series C does not have any voting rights.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;b&gt;TEVOGEN BIO HOLDINGS
INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;b&gt;NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Redemption&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
holders of Series C are not entitled to redeem their shares outside of the liquidation of the Company or the occurrence of a deemed liquidation
event. The Company is entitled to redeem that Series C at a price equal to the Series C Original Issue Price plus any Series C Accruing
Dividends accrued but unpaid thereon, subject to the conversion right described below.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Conversion&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
shares of Series C will be convertible at the election of the holder, beginning six months after the date of issuance, into shares of
common stock at a conversion price equal to the volume-weighted average price of the Common Stock for the 30 trading days immediately
prior to the exercise of the holder&#x2019;s conversion option, subject to a floor price of $&lt;span id="xdx_903_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_uUSDPShares_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zv0yGDL9ogud" title="Floor price"&gt;0.6172&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Warrants&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon
the Closing,&#160;&lt;span id="xdx_907_ecustom--ClassOfWarrantOrRightIssued_iI_c20211130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SemperParatusMember_zzjSEoZrAQV6" title="Number of warrants issued"&gt;17,975,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;warrants
initially issued by Semper Paratus in November 2021, comprising&#160;&lt;span id="xdx_901_ecustom--ClassOfWarrantOrRightIssued_iI_c20211130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SemperParatusMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zC20OblgOKeb" title="Number of warrants issued"&gt;17,250,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;public
warrants sold in the IPO and&#160;&lt;span id="xdx_90C_ecustom--ClassOfWarrantOrRightIssued_iI_c20211130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SemperParatusMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zTabAw0W3unb" title="Number of warrants issued"&gt;725,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;warrants
issued in a concurrent private placement, were assumed.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Public
Warrants&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
public warrants have an exercise price of $&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SemperParatusMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_z9sHJ50LAX11" title="Exercise price"&gt;11.50&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;per
share, became exercisable on&#160;&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20211101__20211130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SemperParatusMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zjAflArab5ke" title="Exercisable date"&gt;March
15, 2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;, and will expire at 5:00 p.m.,
New York City time, on February 14, 2029, or earlier upon redemption or liquidation. Warrant holders may, until such time as there is
an effective registration statement and during any period when the Company has failed to maintain an effective registration statement
covering the shares of the Company&#x2019;s common stock issuable upon exercise of the warrants, exercise warrants on a &#x201c;cashless
basis&#x201d; in accordance with Section 3(a)(9) of the Securities Act of 1933, as amended, or another exception.&#160;&lt;span id="xdx_900_ecustom--WarrantsRedemptionDescription_c20211101__20211130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SemperParatusMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_za1vBJ9LJ5e" title="Warrants redemption description"&gt;The
Company may redeem the public warrants if the Company&#x2019;s common stock equals or exceeds $18.00 per share for 20 trading days within
a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the
holders of public warrants&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.&#160;As of
December 31, 2024, there are&#160;&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SemperParatusMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zwCbzd7uy8J7" title="Number of warrants outstanding"&gt;17,386,580&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;public
warrants outstanding.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;i&gt;Private
Placement Warrants&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Each
private placement warrant is identical to the public warrants, except that the private placement warrants, so long as they are held by
the initial purchasers or their permitted transferees, (i) will not be redeemable by the Company and (ii) may be exercised by the holders
on a cashless basis. As of December 31, 2024, there are&#160;&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SemperParatusMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zDLTpTVdl9I7" title="Number of warrants outstanding"&gt;588,398
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;private placement warrants outstanding.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;See
Note 3 for additional information on the Company&#x2019;s warrant accounting policy.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;b&gt;TEVOGEN BIO HOLDINGS
INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;b&gt;NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001039"
      unitRef="Shares">177991365</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001041"
      unitRef="Shares">177991365</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ScheduleOfStockholdersEquityTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001043">&lt;p id="xdx_897_eus-gaap--ScheduleOfStockholdersEquityTableTextBlock_zSOL5mLD6Ex8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Below
is a reconciliation of shares of common stock issued and outstanding:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_8BF_zBobVkOAVlrc" style="display: none"&gt;SCHEDULE OF RECONCILIATION
OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Total shares of common stock issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_c20241231_zyN8CCKLMVr8" title="Total shares of common stock legally issued"&gt;&lt;span id="xdx_909_eus-gaap--CommonStockSharesOutstanding_iI_c20241231_z5LoyIQAfSeg" title="Total shares of common stock legally outstanding"&gt;177,991,365&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Plus: shares to be issued:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Vested RSUs not yet legally settled into common stock (a)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing_iI_c20241231_fKGEp_zCbHItSD0oN5" style="text-align: right" title="Vested Performance-Based RSUs from satisfaction of liquidity condition upon the Closing"&gt;&lt;span style="-sec-ix-redline: true"&gt;1,373,221&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Less: Shares subject to future vesting:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Issuance of restricted common stock subject to forfeiture
    (b)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture_iI_c20241231_fKGIp_zAWe8GbZVlj2" style="border-bottom: Black 1pt solid; text-align: right" title="Issuance of restricted common stock subject to forfeiture"&gt;&lt;span style="-sec-ix-redline: true"&gt;(19,348,954&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Total shares, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_ecustom--CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture_iI_c20241231_zTEH5atUDVxk" style="border-bottom: Black 2.5pt double; text-align: right" title="Total shares issued and outstanding"&gt;&lt;span style="-sec-ix-redline: true"&gt;160,015,632&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_F0C_zk3ugD4zYWK3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_F1B_z37YHzlQJlp4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
    of December 31, 2024, there were RSUs that had vested but had not been legally settled into common stock. See Note 11 for additional
    information.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_F03_zRtXAoAo4a1b" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(b)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_F1E_zYoDAP8O7hp2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dr.
    Saadi will automatically forfeit all unvested Restricted Stock granted pursuant to the Special RSU Award in the event he departs
    the Company. See Note 11 for additional information on the Special RSU Award.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfStockholdersEquityTableTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001045"
      unitRef="Shares">177991365</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001047"
      unitRef="Shares">177991365</us-gaap:CommonStockSharesOutstanding>
    <TVGN:VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001049"
      unitRef="Shares">1373221</TVGN:VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing>
    <TVGN:SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001051"
      unitRef="Shares">-19348954</TVGN:SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture>
    <TVGN:CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001053"
      unitRef="Shares">160015632</TVGN:CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001057"
      unitRef="Shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001059"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001061"
      unitRef="Shares">2000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_InvestorMember"
      decimals="INF"
      id="Fact001063"
      unitRef="Shares">500</us-gaap:PreferredStockSharesIssued>
    <us-gaap:SharePrice
      contextRef="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_InvestorMember"
      decimals="INF"
      id="Fact001065"
      unitRef="USDPShares">4000</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="From2024-03-012024-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_InvestorMember"
      decimals="0"
      id="Fact001067"
      unitRef="USD">2000000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <TVGN:LossOnPreferredStockIssuance
      contextRef="From2024-03-012024-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_InvestorMember"
      decimals="0"
      id="Fact001069"
      unitRef="USD">799990</TVGN:LossOnPreferredStockIssuance>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_InvestorMember"
      decimals="INF"
      id="Fact001071"
      unitRef="USDPShares">5600</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharePrice
      contextRef="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_InvestorMember"
      decimals="INF"
      id="Fact001073"
      unitRef="USDPShares">4000</us-gaap:SharePrice>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001075"
      unitRef="Pure">0.05</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockDividendPaymentRateVariable
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember"
      id="Fact001077">the
Series A Original Issue Price, which rate will automatically increase by 2% every year that the Series A remains outstanding (the &#x201c;Series
A Accruing Dividends&#x201d;). These dividends become payable when and if declared by the Company. The Series A Preferred Stock will also
participate on an as-converted basis in any regular or special dividends paid to holders of the common stock</us-gaap:PreferredStockDividendPaymentRateVariable>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001079"
      unitRef="USDPShares">5.00</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionTerms
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember"
      id="Fact001081">the
twenty days immediately prior to the Company&#x2019;s call election</us-gaap:PreferredStockRedemptionTerms>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001083"
      unitRef="USDPShares">4.00</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-03-262024-03-27_custom_SeriesAOnePreferredStockMember_custom_ThePatelFamilyLLPMember"
      decimals="INF"
      id="Fact001084"
      unitRef="Shares">600</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-03-262024-03-27_custom_SeriesAOnePreferredStockMember_custom_ThePatelFamilyLLPMember"
      decimals="0"
      id="Fact001085"
      unitRef="USD">6000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PreferredStockDividendPaymentRateVariable
      contextRef="From2024-03-262024-03-27_custom_SeriesAOnePreferredStockMember_custom_ThePatelFamilyLLPMember"
      id="Fact001087">The
terms of the Series A-1 Preferred Stock are identical to the Series A, except that the cumulative dividends are capped at 15% per annum,
and the Series A-1 Issuance Price is defined as $10,000&#160;per share</us-gaap:PreferredStockDividendPaymentRateVariable>
    <us-gaap:SharePrice
      contextRef="AsOf2024-03-27_custom_SeriesAOnePreferredStockMember_custom_ThePatelFamilyLLPMember"
      decimals="INF"
      id="Fact001089"
      unitRef="USDPShares">10000</us-gaap:SharePrice>
    <us-gaap:Deposits
      contextRef="AsOf2024-12-31_custom_SeriesAOnePreferredStockMember_custom_ThePatelFamilyLLPMember"
      decimals="0"
      id="Fact001091"
      unitRef="USD">3000000</us-gaap:Deposits>
    <TVGN:StockIssuedDuringPeriodSharesConversionOfLiabilities
      contextRef="From2024-03-012024-03-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001093"
      unitRef="Shares">3613</TVGN:StockIssuedDuringPeriodSharesConversionOfLiabilities>
    <TVGN:StockIssuedDuringPeriodValueConversionOfLiabilities
      contextRef="From2024-03-012024-03-31_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      id="Fact001095"
      unitRef="USD">3613000</TVGN:StockIssuedDuringPeriodValueConversionOfLiabilities>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-06-30_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001097"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:LiabilitiesAssumed1
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="-5"
      id="Fact001099"
      unitRef="USD">2600000</us-gaap:LiabilitiesAssumed1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-08-212024-08-21_us-gaap_SeriesCPreferredStockMember_custom_ThePatelFamilyLLPMember"
      decimals="INF"
      id="Fact001100"
      unitRef="Shares">600</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="AsOf2024-08-21_us-gaap_SeriesCPreferredStockMember_custom_ThePatelFamilyLLPMember"
      decimals="INF"
      id="Fact001102"
      unitRef="USDPShares">10000</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="From2024-08-212024-08-21_us-gaap_SeriesCPreferredStockMember_custom_ThePatelFamilyLLPMember"
      decimals="0"
      id="Fact001104"
      unitRef="USD">6000000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact001106"
      unitRef="Pure">0.075</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockDividendPaymentRateVariable
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesCPreferredStockMember"
      id="Fact001108">the
event of a liquidation of the Company, or certain deemed liquidation events, the Series C is redeemable for a price equal to the greater
of the Series C Original Issue Price plus all Series C Accruing Dividends that are unpaid through the redemption date, or such asset
amount as would have been payable had the Series C converted into shares of common stock immediately before the liquidation or deemed
liquidation event</us-gaap:PreferredStockDividendPaymentRateVariable>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact001110"
      unitRef="USDPShares">0.6172</us-gaap:PreferredStockConvertibleConversionPrice>
    <TVGN:ClassOfWarrantOrRightIssued
      contextRef="AsOf2021-11-30_custom_SemperParatusMember"
      decimals="INF"
      id="Fact001112"
      unitRef="Shares">17975000</TVGN:ClassOfWarrantOrRightIssued>
    <TVGN:ClassOfWarrantOrRightIssued
      contextRef="AsOf2021-11-30_custom_SemperParatusMember_custom_PublicWarrantsMember_us-gaap_IPOMember"
      decimals="INF"
      id="Fact001114"
      unitRef="Shares">17250000</TVGN:ClassOfWarrantOrRightIssued>
    <TVGN:ClassOfWarrantOrRightIssued
      contextRef="AsOf2021-11-30_custom_SemperParatusMember_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact001116"
      unitRef="Shares">725000</TVGN:ClassOfWarrantOrRightIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-11-30_custom_SemperParatusMember_custom_PublicWarrantsMember"
      decimals="INF"
      id="Fact001118"
      unitRef="USDPShares">11.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="From2021-11-012021-11-30_custom_SemperParatusMember_custom_PublicWarrantsMember"
      id="Fact001120">2024-03-15</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <TVGN:WarrantsRedemptionDescription
      contextRef="From2021-11-012021-11-30_custom_SemperParatusMember_custom_PublicWarrantsMember"
      id="Fact001122">The
Company may redeem the public warrants if the Company&#x2019;s common stock equals or exceeds $18.00 per share for 20 trading days within
a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the
holders of public warrants</TVGN:WarrantsRedemptionDescription>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_SemperParatusMember_custom_PublicWarrantsMember"
      decimals="INF"
      id="Fact001124"
      unitRef="Shares">17386580</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_SemperParatusMember_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact001126"
      unitRef="Shares">588398</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001128">&lt;p id="xdx_80D_eus-gaap--EarningsPerShareTextBlock_ze736zl6POZi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
13.&#160;&lt;span id="xdx_825_zqPN9q60Q2sd"&gt;NET LOSS PER SHARE&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_zrMhznhcADK1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
below table is a reconciliation of net loss to net loss attributable to common stockholders.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_8B2_zqvjlw0tPPPc" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SCHEDULE
OF RECONCILIATION OF NET LOSS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20240101__20241231_zewavYKYmcO9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20230101__20231231_z5LV02lxoR03" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;Year ended&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--NetIncomeLoss_maNILATzLnk_z0EjB95kvWd5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(13,727,380&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(60,477,680&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--PreferredStockDividendsIncomeStatementImpact_iN_di_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_msNILATzLnk_ziuy4AAZlZpa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Series A cumulative preferred stock dividend&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(76,712&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1136"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--StockRepurchase_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_msNILATzLnk_zMbcnuDaiYHe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Series B stock repurchase&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;3,613,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1139"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--StockRepurchase_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zsFxVRhsUdRd" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Stock repurchase&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;3,613,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1142"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--PreferredStockDividendsIncomeStatementImpact_iN_di_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_msNILATzLnk_zXXqhExT8Qp9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Series C cumulative preferred stock dividend&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(82,603&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1145"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PreferredStockDividendsIncomeStatementImpact_iN_di_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zYSKuDF6E6f7" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Cumulative preferred stock dividend&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(82,603&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1148"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iT_mtNILATzLnk_zCi7OAkiAonl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(10,273,695&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(60,477,680&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zG3z9K9LYeO2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company excluded the following potential shares from the computation of diluted net loss per share because including them would have
had an anti-dilutive effect:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zMKW3hz6iji8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_8B5_zdSENhIO9rV3" style="display: none"&gt;SCHEDULE
OF ANTI-DILUTIVE NET LOSS PER SHARE&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20240101__20241231_zsfIgTckdztj" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20230101__20231231_z3pWLbJFR0Ba" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zF2EpHKswSyc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Outstanding RSUs &lt;span id="xdx_F4D_z07FvddSvL6a"&gt;(a)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;8,623,225&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;10,900,128&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_z059N4sxVyL8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Restricted Stock&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;19,348,954&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1159"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zs04JFRW2k1j" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;17,974,978&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1162"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zvxNYvig3f4k" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Convertible promissory notes &lt;span id="xdx_F41_zy3oX7MkW0ga"&gt;(b)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1164"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;891,298&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--EarnoutSharesMember_zQdxAkjI4TOe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Earnout Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;24,500,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1168"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zQ4P6OqK2bi6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;70,447,157&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;11,791,426&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 0.25in; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_F0D_zlr7PY4CNPL7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_F18_zLgqOEX8aBr1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
    of December 31, 2024 there were an additional&#160;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFOVEktRElMVVRJVkUgTkVUIExPU1MgUEVSIFNIQVJFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8EyIlRCBIqc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="Stock option vested"&gt;1,373,221&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;RSUs
    that had vested but had not been legally settled into common stock and therefore were included in the basic net income per share.
    See Note 11 for additional information.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_F0D_zYhkL5W3VIKi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(b)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_F17_zDwYlBaiVt58" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    numbers of shares were determined based on the conversion upon maturity provisions in the convertible promissory note agreements,
    dividing the conversion amount (principal plus accrued interest) by three times the estimated fair value of the Company&#x2019;s common
    stock derived from the Company&#x2019;s most recently completed convertible promissory notes valuation as of the balance sheet date.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A5_ztzzjDJRdhf4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
above table excludes any potentially anti-dilutive shares as a result of the $&lt;span id="xdx_90E_eus-gaap--DerivativeLiabilities_iI_pn6n6_c20241231_zSEHCi9gIi7b" title="Derivative liability"&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;million
Purchase Option and the Additional Amount Purchase Option (see Note 8). These are excluded as the number of shares issuable cannot be
determined until the conditions for issuance are met and the share prices are known upon exercise.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001130">&lt;p id="xdx_891_eus-gaap--ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_zrMhznhcADK1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
below table is a reconciliation of net loss to net loss attributable to common stockholders.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_8B2_zqvjlw0tPPPc" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SCHEDULE
OF RECONCILIATION OF NET LOSS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20240101__20241231_zewavYKYmcO9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20230101__20231231_z5LV02lxoR03" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;Year ended&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--NetIncomeLoss_maNILATzLnk_z0EjB95kvWd5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(13,727,380&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(60,477,680&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--PreferredStockDividendsIncomeStatementImpact_iN_di_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_msNILATzLnk_ziuy4AAZlZpa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Series A cumulative preferred stock dividend&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(76,712&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1136"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--StockRepurchase_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_msNILATzLnk_zMbcnuDaiYHe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Series B stock repurchase&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;3,613,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1139"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--StockRepurchase_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zsFxVRhsUdRd" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Stock repurchase&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;3,613,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1142"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--PreferredStockDividendsIncomeStatementImpact_iN_di_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_msNILATzLnk_zXXqhExT8Qp9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Series C cumulative preferred stock dividend&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(82,603&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1145"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PreferredStockDividendsIncomeStatementImpact_iN_di_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zYSKuDF6E6f7" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Cumulative preferred stock dividend&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(82,603&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1148"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iT_mtNILATzLnk_zCi7OAkiAonl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(10,273,695&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(60,477,680&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001132"
      unitRef="USD">-13727380</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001133"
      unitRef="USD">-60477680</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact001135"
      unitRef="USD">76712</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <TVGN:StockRepurchase
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      id="Fact001138"
      unitRef="USD">3613000</TVGN:StockRepurchase>
    <TVGN:StockRepurchase
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      id="Fact001141"
      unitRef="USD">3613000</TVGN:StockRepurchase>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact001144"
      unitRef="USD">82603</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact001147"
      unitRef="USD">82603</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001150"
      unitRef="USD">-10273695</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001151"
      unitRef="USD">-60477680</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001153">&lt;p id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zMKW3hz6iji8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_8B5_zdSENhIO9rV3" style="display: none"&gt;SCHEDULE
OF ANTI-DILUTIVE NET LOSS PER SHARE&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20240101__20241231_zsfIgTckdztj" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20230101__20231231_z3pWLbJFR0Ba" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zF2EpHKswSyc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Outstanding RSUs &lt;span id="xdx_F4D_z07FvddSvL6a"&gt;(a)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;8,623,225&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;10,900,128&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_z059N4sxVyL8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Restricted Stock&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;19,348,954&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1159"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zs04JFRW2k1j" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;17,974,978&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1162"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zvxNYvig3f4k" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Convertible promissory notes &lt;span id="xdx_F41_zy3oX7MkW0ga"&gt;(b)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1164"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;891,298&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--EarnoutSharesMember_zQdxAkjI4TOe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Earnout Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;24,500,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1168"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zQ4P6OqK2bi6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;70,447,157&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;11,791,426&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 0.25in; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_F0D_zlr7PY4CNPL7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_F18_zLgqOEX8aBr1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
    of December 31, 2024 there were an additional&#160;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFOVEktRElMVVRJVkUgTkVUIExPU1MgUEVSIFNIQVJFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8EyIlRCBIqc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="Stock option vested"&gt;1,373,221&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;RSUs
    that had vested but had not been legally settled into common stock and therefore were included in the basic net income per share.
    See Note 11 for additional information.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_F0D_zYhkL5W3VIKi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(b)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_F17_zDwYlBaiVt58" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    numbers of shares were determined based on the conversion upon maturity provisions in the convertible promissory note agreements,
    dividing the conversion amount (principal plus accrued interest) by three times the estimated fair value of the Company&#x2019;s common
    stock derived from the Company&#x2019;s most recently completed convertible promissory notes valuation as of the balance sheet date.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001155"
      unitRef="Shares">8623225</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001156"
      unitRef="Shares">10900128</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockMember74469375"
      decimals="INF"
      id="Fact001158"
      unitRef="Shares">19348954</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember74469375"
      decimals="INF"
      id="Fact001161"
      unitRef="Shares">17974978</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_ConvertibleDebtSecuritiesMember"
      decimals="INF"
      id="Fact001165"
      unitRef="Shares">891298</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_custom_EarnoutSharesMember"
      decimals="INF"
      id="Fact001167"
      unitRef="Shares">24500000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001170"
      unitRef="Shares">70447157</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001171"
      unitRef="Shares">11791426</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember74469500"
      decimals="INF"
      id="Fact001174"
      unitRef="Shares">1373221</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2024-12-31"
      decimals="-6"
      id="Fact001177"
      unitRef="USD">14000000</us-gaap:DerivativeLiabilities>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001179">&lt;p id="xdx_80B_eus-gaap--IncomeTaxDisclosureTextBlock_zOH3qqx6CUEg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
14. &lt;span id="xdx_82E_zVru2JBQBEJ"&gt;INCOME TAXES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Due
to the Company&#x2019;s net losses for 2024 and 2023, as well as the full valuation allowance on its net deferred tax assets as discussed
below, the Company did not record any income tax expense or benefit for the years ended December 31, 2024 and 2023.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zzuUunQjL2f1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of income tax benefit at the federal statutory income tax rate to the income tax expense at the Company&#x2019;s effective
income tax rate is as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_8B0_zfqHypT5TS0f" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SCHEDULE
OF RECONCILIATION OF INCOME TAX BENEFIT AT THE FEDERAL STATUTORY INCOME TAX RATE&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240101__20241231_zFaKKRbw9Jgg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20230101__20231231_zNiY81lgme86" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_uPure_ma123_zUDNJ7EwY67a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Federal benefit at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;21.0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;21.0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest_dp_uPure_ma123_zW5cTaPDNid4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Convertible note interest&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1186"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(0.4&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_dp_uPure_ma123_z5fy4lkgWl6j" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;29.2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(17.4&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_uPure_ma123_z93Oyuc8PpGh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;12.3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;2.2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_uPure_ma123_z8l8k4IRndd6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(66.5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(5.4&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_dp_uPure_ma123_zdjWGnsqB8jb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Stock based compensation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1199"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_iN_dpi_uPure_ms123_zV87CPJluAad" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(0.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1202"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_dp_ms123_zZEC2coYO4Ze" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1204"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;0.1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_dp_uPure_mt123_zpKTAJJeo2Ik" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Income Tax Expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1207"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1208"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zI1V4O0T35ek" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
income taxes reflect the net tax effects of temporary differences between carrying amounts of assets and liabilities for financial reporting
purposes and the amounts used for income tax purposes. Realization of net deferred tax assets is dependent upon future earnings, if any,
the timing and amount of which are uncertain.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;b&gt;TEVOGEN BIO HOLDINGS
INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;b&gt;NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p id="xdx_89D_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zVwD84JmqhR9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following items comprise the Company&#x2019;s net deferred tax assets and liabilities as of December&#160;31, 2024 and December 31, 2023:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B1_zDJj32uxJhO7" style="display: none"&gt;SCHEDULE
OF DEFERRED TAX ASSETS AND LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20241231_zGc3SqzUGCkk" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20231231_zhmEz9hnVLok" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsGrossAbstract_iB_z6v0y1kTSMR1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzJ64_zOmUptAXUjeg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Net operating loss&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;6,808,826&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;3,755,008&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DeferredTaxAssetsAccruedExpensesAndOther_iI_maDTAGzJ64_zbnWptSsezM2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Accrued expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;385,801&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;42,330&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--DeferredTaxAssetsOperatingLeaseLiabilities_iI_maDTAGzJ64_zbPtKvCafCgc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;61,380&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;127,427&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGzJ64_z4vJKSUIuMtd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;6,110,942&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;718,425&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--DeferredTaxAssetsFixedAssets_iI_maDTAGzJ64_z9o5LRtyj6Wf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;33,834&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1228"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsOther_iI_maDTAGzJ64_zRoN4unq5yVf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;30,823&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1231"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures_iI_maDTAGzJ64_zzXlwd8COPvd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Capitalized research and development expenditures&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;2,944,801&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;2,589,105&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTAGzJ64_zTLvRLdgkjH8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;234,478&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;317,455&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzJ64_maDTANz2Fd_zCuir0pCfzL2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 20pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;16,610,885&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;7,549,750&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANz2Fd_zxaKCulwpvQ7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(16,551,169&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(7,426,952&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANz2Fd_maDTALNz6fV_zBQC16G4WuN8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;59,716&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;122,798&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_zwH9JPsFaUL4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--DeferredTaxLiabilitiesRightOfUseAsset_iNI_di_maDITLzmly_zrkAHcCoXP54" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Right of use asset&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(59,716&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(122,798&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_di_mtDITLzmly_msDTALNz6fV_zHWdAIwKT5s5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(59,716&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(122,798&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNz6fV_zsuFt7LrE58b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1257"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1258"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zlBeaG0lqf3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company continually evaluates the likelihood of the realization of deferred tax assets and adjusts the carrying amount of the deferred
tax assets by the valuation allowance to the extent the future realization of the deferred tax assets is more likely than not. The Company
considers many factors when assessing the likelihood of future realization of its deferred tax assets, including its recent cumulative
earnings experience by taxing jurisdiction, expectation of future taxable income or loss, the carryforward periods available to the Company
for tax reporting purposes, and other relevant factors.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, based on the Company&#x2019;s history of earnings and its assessment of future earnings, management believes that
it is more likely than not that future taxable income will not be sufficient to realize the deferred tax assets. Therefore, a valuation
allowance has been applied to deferred tax assets.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of the year ended December 31, 2024, the Company has federal and state net operating loss carryforwards of approximately $&lt;span id="xdx_905_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn5n6_c20241231_zcC2rR17KDnk" title="Federal  net operating loss carryforwards"&gt;25.6
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million and $&lt;span id="xdx_90A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pn5n6_c20241231_zjbEu68R0teg" title="State net operating loss carryforwards"&gt;27.8
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Federal
net operating loss (&#x201c;NOL&#x201d;) carryforwards in the amount of $&lt;span id="xdx_902_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn5n6_c20241231_zSWtVs0fo31a" title="Federal  net operating loss carryforwards"&gt;25.6
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million have an indefinite life. Federal
NOL carryforwards generated after tax year 2017 are subject to an &lt;span id="xdx_907_ecustom--TaxableIncomeLimitationPercentage_dp_uPure_c20240101__20241231_zK3J71d5c3v2" title="Limitation percentage"&gt;80&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
limitation on taxable income, do not expire and will carryforward indefinitely.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;State
net operating loss carryforwards in the amount of $&lt;span id="xdx_90B_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pn5n6_c20241231_zqE47Zt8h4jl" title="State net operating loss carryforwards"&gt;27.8
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million begin expiring in 2040.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
utilization of the Company&#x2019;s net operating losses may be subject to a U.S. federal limitation due to the &#x201c;change in ownership
provisions&#x201d; under Section 382 of the Internal Revenue Code and other similar limitations in various state jurisdictions. Such limitations
may result in a reduction of the amount of net operating loss carryforwards in future years and possibly the expiration of certain net
operating loss carryforwards before their utilization.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business,
the Company is subject to examinations by federal, state and local jurisdictions, where applicable. There are currently no pending tax
examinations. The Company&#x2019;s tax years are still open under statute from 2021 to the present in the United States. To the extent
the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination
by the Internal Revenue Service and state and local tax authorities to the extent utilized in a future period.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
required by the uncertain tax position guidance in ASC No. 740, Income Tax, the Company recognizes the financial statement benefit of
a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit.
For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit
that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company applied
the uncertain tax position guidance in ASC No. 740 to all tax positions for which the statute of limitations remained open. Any estimates
of tax contingencies contain assumptions and judgments about potential actions by taxing jurisdictions. Any interest and penalties related
to uncertain tax positions would be included as part of the income tax provision.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;b&gt;TEVOGEN BIO HOLDINGS
INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;b&gt;NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p id="xdx_89A_ecustom--ScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock_zWnNsTHpLs3g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of changes in the valuation allowance for net deferred tax assets during the year ended December 31, 2024 and 2023 were as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B2_zf0aPlttrYT4" style="display: none"&gt;SCHEDULE
OF VALUATION ALLOWANCE FOR NET DEFERRED TAX ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20240101__20241231_z9U4XQUAmYQd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230101__20231231_zSNRXftI7Xx" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsValuationAllowance_iS_zdHNImCfERul" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;7,426,952&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;4,175,241&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--IncreasesRecordedToIncomeTaxProvision_zSpem9g5uypc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Increases recorded to income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;9,124,217&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;3,251,711&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsValuationAllowance_iE_z3yEnVjWbsEh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;16,551,169&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;7,426,952&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zp0wzhbf7Lr4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company applies the authoritative guidance on accounting for and disclosure of uncertainty in tax positions, which requires the Company
to determine whether a tax position of the Company is more likely than not to be sustained upon examination, including resolution of
any related appeals of litigation processes, based on the technical merits of the position. For tax positions meeting the more likely
than not threshold, the tax amount recognized in the consolidated financial statements is reduced by the largest benefit that has a greater
than 50% likelihood of being realized upon the ultimate settlement with the relevant taxing authority. There were no material uncertain
tax positions as of December 31, 2024.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes interest and penalties related to uncertain tax positions in income tax expense when in a taxable income position.
As of December 31, 2024, the Company had &lt;span id="xdx_90F_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestAccrued_iI_do_c20241231_zBNPAu47Q8Q6" title="Income tax penalties and interest accrued"&gt;no
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;accrued interest or penalties related
to uncertain tax positions and no amounts have been recognized in the Company&#x2019;s statements of operations and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001181">&lt;p id="xdx_891_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zzuUunQjL2f1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of income tax benefit at the federal statutory income tax rate to the income tax expense at the Company&#x2019;s effective
income tax rate is as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_8B0_zfqHypT5TS0f" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SCHEDULE
OF RECONCILIATION OF INCOME TAX BENEFIT AT THE FEDERAL STATUTORY INCOME TAX RATE&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240101__20241231_zFaKKRbw9Jgg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20230101__20231231_zNiY81lgme86" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_uPure_ma123_zUDNJ7EwY67a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Federal benefit at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;21.0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;21.0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest_dp_uPure_ma123_zW5cTaPDNid4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Convertible note interest&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1186"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(0.4&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_dp_uPure_ma123_z5fy4lkgWl6j" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;29.2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(17.4&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_uPure_ma123_z93Oyuc8PpGh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;12.3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;2.2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_uPure_ma123_z8l8k4IRndd6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(66.5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(5.4&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_dp_uPure_ma123_zdjWGnsqB8jb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Stock based compensation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1199"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_iN_dpi_uPure_ms123_zV87CPJluAad" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(0.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1202"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_dp_ms123_zZEC2coYO4Ze" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1204"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;0.1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_dp_uPure_mt123_zpKTAJJeo2Ik" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Income Tax Expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1207"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1208"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001183"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001184"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <TVGN:IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001187"
      unitRef="Pure">-0.004</TVGN:IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001189"
      unitRef="Pure">0.292</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001190"
      unitRef="Pure">-0.174</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001192"
      unitRef="Pure">0.123</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001193"
      unitRef="Pure">0.022</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001195"
      unitRef="Pure">-0.665</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001196"
      unitRef="Pure">-0.054</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001198"
      unitRef="Pure">0.046</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001201"
      unitRef="Pure">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001205"
      unitRef="Pure">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001210">&lt;p id="xdx_89D_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zVwD84JmqhR9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following items comprise the Company&#x2019;s net deferred tax assets and liabilities as of December&#160;31, 2024 and December 31, 2023:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B1_zDJj32uxJhO7" style="display: none"&gt;SCHEDULE
OF DEFERRED TAX ASSETS AND LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20241231_zGc3SqzUGCkk" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20231231_zhmEz9hnVLok" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsGrossAbstract_iB_z6v0y1kTSMR1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzJ64_zOmUptAXUjeg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Net operating loss&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;6,808,826&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;3,755,008&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DeferredTaxAssetsAccruedExpensesAndOther_iI_maDTAGzJ64_zbnWptSsezM2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Accrued expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;385,801&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;42,330&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--DeferredTaxAssetsOperatingLeaseLiabilities_iI_maDTAGzJ64_zbPtKvCafCgc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;61,380&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;127,427&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGzJ64_z4vJKSUIuMtd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;6,110,942&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;718,425&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--DeferredTaxAssetsFixedAssets_iI_maDTAGzJ64_z9o5LRtyj6Wf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;33,834&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1228"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsOther_iI_maDTAGzJ64_zRoN4unq5yVf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;30,823&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1231"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures_iI_maDTAGzJ64_zzXlwd8COPvd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Capitalized research and development expenditures&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;2,944,801&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;2,589,105&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTAGzJ64_zTLvRLdgkjH8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;234,478&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;317,455&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzJ64_maDTANz2Fd_zCuir0pCfzL2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 20pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;16,610,885&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;7,549,750&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANz2Fd_zxaKCulwpvQ7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(16,551,169&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(7,426,952&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANz2Fd_maDTALNz6fV_zBQC16G4WuN8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;59,716&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;122,798&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_zwH9JPsFaUL4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--DeferredTaxLiabilitiesRightOfUseAsset_iNI_di_maDITLzmly_zrkAHcCoXP54" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Right of use asset&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(59,716&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(122,798&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_di_mtDITLzmly_msDTALNz6fV_zHWdAIwKT5s5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(59,716&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;(122,798&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNz6fV_zsuFt7LrE58b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1257"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1258"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001215"
      unitRef="USD">6808826</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001216"
      unitRef="USD">3755008</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <TVGN:DeferredTaxAssetsAccruedExpensesAndOther
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001218"
      unitRef="USD">385801</TVGN:DeferredTaxAssetsAccruedExpensesAndOther>
    <TVGN:DeferredTaxAssetsAccruedExpensesAndOther
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001219"
      unitRef="USD">42330</TVGN:DeferredTaxAssetsAccruedExpensesAndOther>
    <TVGN:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001221"
      unitRef="USD">61380</TVGN:DeferredTaxAssetsOperatingLeaseLiabilities>
    <TVGN:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001222"
      unitRef="USD">127427</TVGN:DeferredTaxAssetsOperatingLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001224"
      unitRef="USD">6110942</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001225"
      unitRef="USD">718425</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <TVGN:DeferredTaxAssetsFixedAssets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001227"
      unitRef="USD">33834</TVGN:DeferredTaxAssetsFixedAssets>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001230"
      unitRef="USD">30823</us-gaap:DeferredTaxAssetsOther>
    <TVGN:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001233"
      unitRef="USD">2944801</TVGN:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures>
    <TVGN:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001234"
      unitRef="USD">2589105</TVGN:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001236"
      unitRef="USD">234478</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001237"
      unitRef="USD">317455</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001239"
      unitRef="USD">16610885</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001240"
      unitRef="USD">7549750</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001242"
      unitRef="USD">16551169</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001243"
      unitRef="USD">7426952</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001245"
      unitRef="USD">59716</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001246"
      unitRef="USD">122798</us-gaap:DeferredTaxAssetsNet>
    <TVGN:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001251"
      unitRef="USD">59716</TVGN:DeferredTaxLiabilitiesRightOfUseAsset>
    <TVGN:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001252"
      unitRef="USD">122798</TVGN:DeferredTaxLiabilitiesRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001254"
      unitRef="USD">59716</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001255"
      unitRef="USD">122798</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact001260"
      unitRef="USD">25600000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact001262"
      unitRef="USD">27800000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact001264"
      unitRef="USD">25600000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <TVGN:TaxableIncomeLimitationPercentage
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001266"
      unitRef="Pure">0.80</TVGN:TaxableIncomeLimitationPercentage>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact001268"
      unitRef="USD">27800000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <TVGN:ScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001270">&lt;p id="xdx_89A_ecustom--ScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock_zWnNsTHpLs3g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of changes in the valuation allowance for net deferred tax assets during the year ended December 31, 2024 and 2023 were as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B2_zf0aPlttrYT4" style="display: none"&gt;SCHEDULE
OF VALUATION ALLOWANCE FOR NET DEFERRED TAX ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20240101__20241231_z9U4XQUAmYQd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230101__20231231_zSNRXftI7Xx" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsValuationAllowance_iS_zdHNImCfERul" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;7,426,952&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;4,175,241&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--IncreasesRecordedToIncomeTaxProvision_zSpem9g5uypc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Increases recorded to income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;9,124,217&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;3,251,711&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsValuationAllowance_iE_z3yEnVjWbsEh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;16,551,169&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;7,426,952&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</TVGN:ScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001272"
      unitRef="USD">7426952</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001273"
      unitRef="USD">4175241</us-gaap:DeferredTaxAssetsValuationAllowance>
    <TVGN:IncreasesRecordedToIncomeTaxProvision
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001275"
      unitRef="USD">9124217</TVGN:IncreasesRecordedToIncomeTaxProvision>
    <TVGN:IncreasesRecordedToIncomeTaxProvision
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001276"
      unitRef="USD">3251711</TVGN:IncreasesRecordedToIncomeTaxProvision>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001278"
      unitRef="USD">16551169</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001279"
      unitRef="USD">7426952</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001281"
      unitRef="USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001283">&lt;p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zrerlloKSUG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
15. &lt;span id="xdx_826_zuwxRamozzMf"&gt;RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Transactions
with Sponsor&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the Merger Agreement, the Company incurred $&lt;span id="xdx_90F_eus-gaap--SponsorFees_c20240101__20241231_zFnqLSQtv1d" title="Sponsor advisory service fee"&gt;2,000,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;in
fees to the Sponsor for advisory services (the &#x201c;Sponsor Advisory Service Fee&#x201d;). In connection with the Merger and thereafter,
the Company and Sponsor agreed that $&lt;span id="xdx_906_ecustom--SponsorFeesPayable_iI_c20241231_ztCWpzk26Dm6" title="Sponsor advisory services fee payable"&gt;250,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;of
the Sponsor Advisory Service Fee is payable in cash, $&lt;span id="xdx_900_eus-gaap--OtherLiabilities_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zLCUmLigY3f7" title="Sponsor fee payable offset"&gt;250,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;would
be offset against amounts due from the Sponsor, and the remainder of the Sponsor Advisory Service Fee was paid with the issuance of&#160;&lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--SponsorAdvisoryServicesFeeMember_zCMhICFCUQWh" title="Number of shares issued for sponsor fees"&gt;150,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;shares
of the Company&#x2019;s common stock at Closing. The Sponsor Advisory Service Fee payable in cash is presented on the consolidated balance
sheets under the line item &#x201c;Due to related party.&#x201d;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, the Sponsor owes the Company $&lt;span id="xdx_906_eus-gaap--OtherReceivables_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zjPvxlc8Yh34" title="Due from related party"&gt;158,819&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;to
cover working capital expenses, which is presented on the consolidated balance sheets under the line item &#x201c;Due from related party.&#x201d;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;See
Note 12 for additional information on the Series B issued to the Sponsor.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Stock-Based
Compensation&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
January 2023, the Company issued&#160;&lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20230131__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember__srt--TitleOfIndividualAxis__custom--WifeOfChiefExecutiveOfficerMember_zydIjts291zk" title="Isssued shares to related party"&gt;40,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;Performance-Based
RSUs to the wife of the Company&#x2019;s chair and chief executive officer for advisory services provided to the Company, and&#160;&lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20230131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MehtaphoricConsultingIncMember_zQFiNPfzRHKj" title="Shares issued to related party"&gt;20,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;Performance-Based
RSUs to Mehtaphoric Consulting Inc, a company controlled by the daughter of the Company&#x2019;s chief financial officer, for information
technology services provided to the Company. In connection with the Closing, the performance condition was achieved and therefore compensation
cost of $&lt;span id="xdx_904_eus-gaap--EmployeeStockOwnershipPlanESOPCompensationExpense_c20240101__20241231_zZgPukrSpgSj" title="Compensation cost recognized"&gt;800,396&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;has
been recognized.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Loan
Agreement&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;See
Note 8 for additional information on the Loan Agreement with the Patel Family, which provides for an unsecured line of credit facility
for term loans of up to an initial amount of $&lt;span id="xdx_906_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_z17ANZk39xOl" title="Line of credit maximum borrowing capacity"&gt;36,000,000
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;in the aggregate. As of December 31, 2024,
the facility has remaining available capacity of $&lt;span id="xdx_905_eus-gaap--LineOfCreditFacilityRemainingBorrowingCapacity_iI_c20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zqzsSLMY6ME8" title="Line of credit remaining borrowing capacity"&gt;30,000,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Preferred
Stock&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;See
Note 12 for additional information on the Series A, Series A-1, and Series C Preferred Stock, which were purchased by the Patel Family.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;b&gt;TEVOGEN BIO HOLDINGS
INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;b&gt;NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Consulting
Agreement&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2024, the Company contracted with Dr. Manmohan Patel of The Patel Family LLP to provide advisory services to the Company in
support of the Company&#x2019;s manufacturing development, including but not limited to identifying and developing real estate, establishing
quality management processes, attracting and hiring an executive to lead operations, providing medical advice, and addressing government
affairs and regulatory matters. In exchange for his consultation services, Dr. Patel was granted &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrManmohanPatelMember_zhI5kz6Iu5r4" title="Granted, shares"&gt;6,000,000
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;RSUs, of which &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrManmohanPatelMember_zZbyZm2qdgt3" title="Vested shares"&gt;2,000,000
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;immediately vested, and &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20250131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrManmohanPatelMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zXrgChRsVMTb" title="Vested shares"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20250228__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrManmohanPatelMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zBB0HEnVRZH4"&gt;2,000,000&lt;/span&gt;
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;RSUs vested in both January 2025 and February
2025.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:SponsorFees
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001285"
      unitRef="USD">2000000</us-gaap:SponsorFees>
    <TVGN:SponsorFeesPayable
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001287"
      unitRef="USD">250000</TVGN:SponsorFeesPayable>
    <us-gaap:OtherLiabilities
      contextRef="AsOf2024-12-31_custom_SponsorMember"
      decimals="0"
      id="Fact001289"
      unitRef="USD">250000</us-gaap:OtherLiabilities>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-01-012024-12-31_custom_SponsorAdvisoryServicesFeeMember"
      decimals="INF"
      id="Fact001291"
      unitRef="Shares">150000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:OtherReceivables
      contextRef="AsOf2024-12-31_custom_SponsorMember"
      decimals="0"
      id="Fact001293"
      unitRef="USD">158819</us-gaap:OtherReceivables>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-01-012023-01-31_custom_PerformanceBasedRSUsMember_custom_WifeOfChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact001295"
      unitRef="Shares">40000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-01-012023-01-31_custom_MehtaphoricConsultingIncMember"
      decimals="INF"
      id="Fact001297"
      unitRef="Shares">20000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001299"
      unitRef="USD">800396</us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember"
      decimals="0"
      id="Fact001301"
      unitRef="USD">36000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember"
      decimals="0"
      id="Fact001303"
      unitRef="USD">30000000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DrManmohanPatelMember"
      decimals="INF"
      id="Fact001305"
      unitRef="Shares">6000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DrManmohanPatelMember"
      decimals="INF"
      id="Fact001307"
      unitRef="Shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2025-01-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DrManmohanPatelMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001309"
      unitRef="Shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2025-02-28_us-gaap_RestrictedStockUnitsRSUMember_custom_DrManmohanPatelMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001310"
      unitRef="Shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001312">&lt;p id="xdx_805_eus-gaap--SegmentReportingDisclosureTextBlock_zjViOtEdXFwc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
16. &lt;span id="xdx_824_zz8eWF3pcbLk"&gt;SEGMENT REPORTING&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company operates in one operating segment, and therefore one reportable segment, and is focused on the global discovery, development
and commercialization of proprietary therapeutics. The Company&#x2019;s business activities are managed on a consolidated basis through
the development and potential commercialization of pharmaceutical products, which are aimed at the global market in the event that products
are successful in receiving regulatory approvals. Our determination that we operate as a single operating segment is consistent with
the financial information regularly reviewed by the chief operating decision maker for purposes of evaluating performance, allocating
resources, setting incentive compensation targets, and planning and forecasting for future periods. Our chief operating decision maker
is the Chief Executive Officer.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accounting policies for our single operating segment are the same as those described in the summary of significant accounting policies.
Our single operating segment incurs expenses from the development of TVGN 489, which is developed by our research and development department,
designed to target various disease indications. The Company has not yet generated revenue in its operating history.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the segment, the chief operating decision maker uses net loss, which is reported on the consolidated statements of operations as consolidated
net income (loss), to allocate resources (including employees, property, and financial resources), predominantly during the annual budget
and forecasting process. The chief operating decision maker also uses consolidated net loss, along with non-financial inputs and qualitative
information, to evaluate our performance, establish compensation, monitor budget versus actual results, and decide the level of investment
in our various research activities. The measure of segment assets is reported on the consolidated balance sheet as total consolidated
assets.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001314">&lt;p id="xdx_800_eus-gaap--SubsequentEventsTextBlock_zcq2drwDeQt5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
17. &lt;span id="xdx_823_zySUOK5HYSp2"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has evaluated subsequent events and transactions for potential recognition or disclosure from the balance sheet date through
April 2, 2025, the issuance date of these the consolidated financial statements, and has not identified any additional items requiring
disclosure except as noted below.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
January 2025, the Company executed an agreement with KRHP to receive a grant for $&lt;span id="xdx_90C_eus-gaap--OtherReceivablesNetCurrent_iI_c20250131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KRHPLLCMember_zotOYpqGdIo8" title="Grant"&gt;2,000,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
KRHP is affiliated with the Patel Family. The grant is specified for use toward the Company&#x2019;s ongoing operational expenses, may
not be used for repayment of existing debt obligations, and does not include any requirement to repay the investor or to issue equity
in response. Cash payment was received by the Company in January 2025.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
February 2025, the Company executed a draw on the Loan Agreement for an additional $&lt;span id="xdx_907_eus-gaap--LineOfCredit_iI_c20250228__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zajpY7rBcYEg" title="Line of credit Facility additional"&gt;1,000,000
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;to be utilized for operational expenses.
An additional draw of $&lt;span id="xdx_909_eus-gaap--LineOfCredit_iI_c20250331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zYH65LGJr0Ak" title="Line of credit Facility additional"&gt;1,000,000
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;was completed in March 2025. As of the
date of filing, the facility has a remaining capacity of $&lt;span id="xdx_90B_eus-gaap--LineOfCreditFacilityRemainingBorrowingCapacity_iI_c20250402__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zTexk7tGogP7" title="Line of credit Facility remaining capacity"&gt;26,000,000
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and remains effective for the next 26
months.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2025-01-31_us-gaap_SubsequentEventMember_custom_KRHPLLCMember"
      decimals="0"
      id="Fact001316"
      unitRef="USD">2000000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:LineOfCredit
      contextRef="AsOf2025-02-28_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact001318"
      unitRef="USD">1000000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="AsOf2025-03-31_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact001320"
      unitRef="USD">1000000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="AsOf2025-04-02_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact001322"
      unitRef="USD">26000000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact001049"
          xlink:label="Fact001049"
          xlink:type="locator"/>
        <link:footnote id="Footnote001054" xlink:label="Footnote001054" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">As
    of December 31, 2024, there were RSUs that had vested but had not been legally settled into common stock. See Note 11 for additional
    information.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001049"
          xlink:to="Footnote001054"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001051"
          xlink:label="Fact001051"
          xlink:type="locator"/>
        <link:footnote id="Footnote001055" xlink:label="Footnote001055" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Dr.
    Saadi will automatically forfeit all unvested Restricted Stock granted pursuant to the Special RSU Award in the event he departs
    the Company. See Note 11 for additional information on the Special RSU Award.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001051"
          xlink:to="Footnote001055"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001155"
          xlink:label="Fact001155"
          xlink:type="locator"/>
        <link:footnote id="Footnote001172" xlink:label="Footnote001172" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">As
    of December 31, 2024 there were an additional&#160;</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001155"
          xlink:to="Footnote001172"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001156"
          xlink:label="Fact001156"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001156"
          xlink:to="Footnote001172"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1164"
          xlink:label="xdx2ixbrl1164"
          xlink:type="locator"/>
        <link:footnote id="Footnote001175" xlink:label="Footnote001175" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The
    numbers of shares were determined based on the conversion upon maturity provisions in the convertible promissory note agreements,
    dividing the conversion amount (principal plus accrued interest) by three times the estimated fair value of the Company&#x2019;s common
    stock derived from the Company&#x2019;s most recently completed convertible promissory notes valuation as of the balance sheet date.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1164"
          xlink:to="Footnote001175"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001165"
          xlink:label="Fact001165"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001165"
          xlink:to="Footnote001175"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">POS AM<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">On
June 21, 2024, the registrant filed a Registration Statement on Form S-1 (Registration No. 333-280414), which was subsequently amended
on July 23, 2024, and August 1, 2024, and declared effective by the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) on
August 2, 2024 (the &#8220;Registration Statement&#8221;).&#160;The
Registration Statement registered the issuance by the registrant (i) up to 17,974,978 shares of common stock, par value $0.001 per share
(the &#8220;Common Stock&#8221;), upon the exercise of outstanding warrants to purchase Common Stock (the &#8220;Warrants&#8221;) originally
issued by Semper Paratus Acquisition Corporation (&#8220;Semper Paratus&#8221;), a Cayman Islands exempted company (n/k/a Tevogen Bio Holdings Inc., a Delaware corporation), as part of Semper Paratus&#8217;
(a) initial public offering and (b) concurrent private placement (the &#8220;Private Placement&#8221;) of units at a price of $10.00
per unit, with each unit consisting of one Class A ordinary share of Semper Paratus and one-half of a warrant, and (ii) up to 24,500,000
shares of Common Stock issuable upon the achievement of certain earnout triggering events as described in prospectus below. The Registration
Statement also registered for resale by the securityholders identified in this prospectus (each a &#8220;Registered Holder&#8221; and,
collectively, the &#8220;Registered Holders&#8221;) up to 24,551,308 shares of Common Stock (the &#8220;Total Resale Shares&#8221;) and
725,000 of our outstanding Warrants, originally issued as part of units sold in the Private Placement (the &#8220;Private Placement Warrants&#8221;).

&#160;

This
post-effective amendment is being filed to update the Registration Statement to include information contained in the
registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the SEC on April 2, 2025 (the
&#8220;2024 Form 10-K&#8221;), and update certain other information in the Registration Statement.

&#160;

The
information included in this filing amends the Registration Statement and the prospectus contained therein. No additional securities
are being registered under this post-effective amendment. All applicable registration fees were paid at the time of the original filing
of the Registration Statement.


&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Tevogen
Bio Holdings Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001860871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1597194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">15
Independence Boulevard<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite #410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Warren<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07059<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">838-6436<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">15
Independence Boulevard<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite #410<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Warren<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07059<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">877<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">838-6436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Ryan
Saadi<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 1,282,995<span></span>
</td>
<td class="nump">$ 1,052,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other assets</a></td>
<td class="nump">919,088<span></span>
</td>
<td class="nump">670,582<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">2,360,902<span></span>
</td>
<td class="nump">1,722,979<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">296,442<span></span>
</td>
<td class="nump">458,651<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets - operating leases</a></td>
<td class="nump">228,490<span></span>
</td>
<td class="nump">469,862<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Deferred transaction costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,582,870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">575,841<span></span>
</td>
<td class="nump">271,141<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">3,461,675<span></span>
</td>
<td class="nump">5,505,503<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">5,200,245<span></span>
</td>
<td class="nump">3,418,378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">1,712,396<span></span>
</td>
<td class="nump">1,096,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">229,063<span></span>
</td>
<td class="nump">252,714<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable</a></td>
<td class="nump">1,651,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible promissory notes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">80,712,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">9,042,704<span></span>
</td>
<td class="nump">85,479,542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible promissory notes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">14,220,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_LoanAgreementNoncurrent', window );">Loan agreement</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">5,796<span></span>
</td>
<td class="nump">234,858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative warrant liabilities</a></td>
<td class="nump">87,180<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">10,135,680<span></span>
</td>
<td class="nump">99,934,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 800,000,000 shares authorized; 177,991,365 and 119,999,989 shares issued and outstanding at December 31, 2024 and December 31, 2023</a></td>
<td class="nump">17,800<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">97,893,322<span></span>
</td>
<td class="nump">5,216,840<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(113,385,117)<span></span>
</td>
<td class="num">(99,657,737)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; deficit</a></td>
<td class="num">(6,674,005)<span></span>
</td>
<td class="num">(94,428,897)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; deficit</a></td>
<td class="nump">3,461,675<span></span>
</td>
<td class="nump">5,505,503<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, value</a></td>
<td class="nump">2,799,990<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, value</a></td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Due from related party</a></td>
<td class="nump">158,819<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to related party</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_LoanAgreementNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loan agreement non current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_LoanAgreementNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, shares authorized</a></td>
<td class="nump">800,000,000<span></span>
</td>
<td class="nump">800,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued</a></td>
<td class="nump">177,991,365<span></span>
</td>
<td class="nump">119,999,989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding</a></td>
<td class="nump">177,991,365<span></span>
</td>
<td class="nump">119,999,989<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Preferred stock, liquidation preference, value</a></td>
<td class="nump">$ 2,076,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Preferred stock, liquidation preference, value</a></td>
<td class="nump">$ 6,082,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreferenceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of the difference between preference in liquidation and the par or stated values of the preferred shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreferenceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 31,033,276<span></span>
</td>
<td class="nump">$ 4,403,526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">22,531,212<span></span>
</td>
<td class="nump">4,439,499<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">53,564,488<span></span>
</td>
<td class="nump">8,843,025<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(53,564,488)<span></span>
</td>
<td class="num">(8,843,025)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense, net</a></td>
<td class="num">(184,037)<span></span>
</td>
<td class="num">(1,206,352)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Merger transaction costs</a></td>
<td class="num">(7,499,353)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrants</a></td>
<td class="num">(58,180)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_ChangeInFairValueOfConvertiblePromissoryNotes', window );">Change in fair value of convertible promissory notes</a></td>
<td class="nump">48,468,678<span></span>
</td>
<td class="num">(50,428,303)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_LossOnIssuanceOfCommitmentShares', window );">Loss on issuance of commitment shares</a></td>
<td class="num">(890,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(13,727,380)<span></span>
</td>
<td class="num">(60,477,680)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders, basic</a></td>
<td class="num">(10,273,695)<span></span>
</td>
<td class="num">(60,477,680)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common stockholders, diluted</a></td>
<td class="num">$ (10,273,695)<span></span>
</td>
<td class="num">$ (60,477,680)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders, basic</a></td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="num">$ (2.44)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders, diluted</a></td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="num">$ (2.44)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common stock outstanding, basic</a></td>
<td class="nump">146,672,534<span></span>
</td>
<td class="nump">24,752,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common stock outstanding, diluted</a></td>
<td class="nump">146,672,534<span></span>
</td>
<td class="nump">24,752,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_ChangeInFairValueOfConvertiblePromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of convertible promissory notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_ChangeInFairValueOfConvertiblePromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_LossOnIssuanceOfCommitmentShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss on issuance of commitment shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_LossOnIssuanceOfCommitmentShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479405/805-10-25-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Deficit - USD ($)<br></strong></div></th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Series A Preferred Stock [Member]</div>
</th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Series B Preferred Stock [Member]</div>
</th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Series C Preferred Stock [Member]</div>
</th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="nump">$ 5,216,840<span></span>
</td>
<td class="num">$ (39,180,057)<span></span>
</td>
<td class="num">$ (33,951,217)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">119,999,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(60,477,680)<span></span>
</td>
<td class="num">(60,477,680)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="nump">5,216,840<span></span>
</td>
<td class="num">(99,657,737)<span></span>
</td>
<td class="num">(94,428,897)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">119,999,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(13,727,380)<span></span>
</td>
<td class="num">(13,727,380)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series A preferred stock</a></td>
<td class="nump">$ 2,799,990<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,799,990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of preferred stock, shares</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_StockIssuedDuringPeriodValueNewIssuesTwo', window );">Issuance of Series C preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_StockIssuedDuringPeriodSharesNewIssuesTwo', window );">Issuance of preferred stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_StockIssuedDuringPeriodValueNewIssuesOne', window );">Issuance of Series B preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,613,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,613,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_StockIssuedDuringPeriodSharesNewIssuesOne', window );">Issuance of Series B preferred stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible promissory notes into common stock in connection with merger</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,034<span></span>
</td>
<td class="nump">46,621,593<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">46,622,627<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible promissory notes into common stock in connection with merger, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,337,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_MergerNetOfRedemptionsAndTransactionCosts', window );">Merger, net of redemptions and transaction costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,478<span></span>
</td>
<td class="num">(2,885,459)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,883,981)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Merger, net of redemptions and transaction costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,778,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Issuance of restricted common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,935<span></span>
</td>
<td class="num">(1,935)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of restricted common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,348,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for Sponsor advisory service fee</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">676,485<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">676,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for Sponsor advisory service fee, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement', window );">Issuance of commitment shares in connection with the loan agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">889,900<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">890,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithLoanAgreement', window );">Issuance of commitment shares in connection with the loan agreement, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common stock in connection with Polar note</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
<td class="num">(150)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common stock in connection with Polar Note, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_StockIssuedDuringPeriodValueContributionFromRelatedParty', window );">Contribution from related party</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (3,613,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,613,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_StockIssuedDuringPeriodSharesContributionFromRelatedParty', window );">Contribution from related party, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,613)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket', window );">Nonrefundable prepaid proceeds towards anticipated Series A-1 preferred stock issuance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits', window );">Issuance of common stock in settlement of vested restricted stock units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,088<span></span>
</td>
<td class="num">(1,088)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits', window );">Issuance of common stock in settlement of vested restricted stock units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,876,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">40,764,136<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">40,764,136<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 2,799,990<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="nump">$ 17,800<span></span>
</td>
<td class="nump">$ 97,893,322<span></span>
</td>
<td class="num">$ (113,385,117)<span></span>
</td>
<td class="num">$ (6,674,005)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2024</a></td>
<td class="nump">500<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="nump">177,991,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_MergerNetOfRedemptionsAndTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Merger net of redemptions and transaction costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_MergerNetOfRedemptionsAndTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithLoanAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares commitment shares in connection with loan agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithLoanAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_StockIssuedDuringPeriodSharesContributionFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares contribution from related party</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_StockIssuedDuringPeriodSharesContributionFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_StockIssuedDuringPeriodSharesNewIssuesOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_StockIssuedDuringPeriodSharesNewIssuesOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_StockIssuedDuringPeriodSharesNewIssuesTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares new issues two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_StockIssuedDuringPeriodSharesNewIssuesTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares settlement of vested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value commitment shares in connection with loan agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_StockIssuedDuringPeriodValueContributionFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value contribution from related party</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_StockIssuedDuringPeriodValueContributionFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_StockIssuedDuringPeriodValueNewIssuesOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value new issues one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_StockIssuedDuringPeriodValueNewIssuesOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_StockIssuedDuringPeriodValueNewIssuesTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value new issues two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_StockIssuedDuringPeriodValueNewIssuesTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value settlement of vested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to additional paid in capital (APIC) resulting from changes in fair value of common and preferred stock issued to employee benefit trust but unearned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong> Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (13,727,380)<span></span>
</td>
<td class="num">$ (60,477,680)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">162,209<span></span>
</td>
<td class="nump">163,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">40,764,136<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense</a></td>
<td class="nump">187,575<span></span>
</td>
<td class="nump">1,206,697<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashMergerRelatedCosts', window );">Merger transaction costs</a></td>
<td class="nump">7,099,353<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_ChangeInFairValueOfConvertiblePromissoryNotes', window );">Change in fair value of convertible promissory notes</a></td>
<td class="num">(48,468,678)<span></span>
</td>
<td class="nump">50,428,303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_LossOnPreferredStockIssuance', window );">Loss on Series A Preferred Stock issuance</a></td>
<td class="nump">799,990<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_LossOnIssuanceOfCommitmentShares', window );">Loss on issuance of commitment shares</a></td>
<td class="nump">890,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrants</a></td>
<td class="nump">58,180<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of right-of-use asset</a></td>
<td class="nump">241,372<span></span>
</td>
<td class="nump">215,057<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(246,005)<span></span>
</td>
<td class="num">(317,605)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(511,011)<span></span>
</td>
<td class="nump">323,742<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="nump">1,685,692<span></span>
</td>
<td class="nump">1,114,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="num">(681,450)<span></span>
</td>
<td class="num">(603,832)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(252,713)<span></span>
</td>
<td class="num">(223,361)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(11,998,730)<span></span>
</td>
<td class="num">(8,171,118)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(133,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(133,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_CashAcquiredInConnectionWithReverseRecapitalization', window );">Cash acquired in connection with the reverse recapitalization</a></td>
<td class="nump">229,328<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of Series A Preferred Stock</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_ProceedsFromIssuanceOfSeriesCPreferredStock', window );">Proceeds from issuance of Series C Preferred Stock</a></td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from loan agreement</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance', window );">Nonrefundable prepaid proceeds towards anticipated Series A-1 Preferred Stock Issuance</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Payments of deferred transaction costs</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(127,750)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible promissory notes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">12,229,328<span></span>
</td>
<td class="nump">3,872,250<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash</a></td>
<td class="nump">230,598<span></span>
</td>
<td class="num">(4,431,868)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash &#8211; beginning of period</a></td>
<td class="nump">1,052,397<span></span>
</td>
<td class="nump">5,484,265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash &#8211; end of period</a></td>
<td class="nump">1,282,995<span></span>
</td>
<td class="nump">1,052,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplementary disclosure of noncash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_ReverseRecapitalizationTransactionFeesIncludedInAccruedExpensesAndOtherLiabilities', window );">Reverse recapitalization transaction fees included in accrued expenses and other liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,455,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of convertible promissory notes into common stock in connection with Merger</a></td>
<td class="nump">46,622,627<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_RepurchaseOfSeriesBPreferredStock', window );">Repurchase of Series B preferred stock</a></td>
<td class="nump">3,613,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of common stock for net liabilities upon reverse recapitalization, net of transaction costs</a></td>
<td class="nump">$ 3,113,309<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_CashAcquiredInConnectionWithReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash acquired in connection with the reverse recapitalization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_CashAcquiredInConnectionWithReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_ChangeInFairValueOfConvertiblePromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of convertible promissory notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_ChangeInFairValueOfConvertiblePromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_LossOnIssuanceOfCommitmentShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss on issuance of commitment shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_LossOnIssuanceOfCommitmentShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_LossOnPreferredStockIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss on preferred stock issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_LossOnPreferredStockIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nonrefundable prepaid proceeds towards anticipated Series A-1 Preferred Stock Issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_ProceedsFromIssuanceOfSeriesCPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of series c preferred stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_ProceedsFromIssuanceOfSeriesCPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_RepurchaseOfSeriesBPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repurchase of series B preferred stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_RepurchaseOfSeriesBPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_ReverseRecapitalizationTransactionFeesIncludedInAccruedExpensesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reverse recapitalization transaction fees included in accrued expenses and other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_ReverseRecapitalizationTransactionFeesIncludedInAccruedExpensesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashMergerRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to the increase (decrease) in reserve for business combination costs. Includes, but is not limited to, legal, accounting, and other costs incurred to consummate the merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashMergerRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentOfFinancingAndStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">NATURE OF BUSINESS</a></td>
<td class="text"><p id="xdx_804_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zCNaGI6GbMM7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1. <span id="xdx_82B_zN9tcoyn3jBc">NATURE OF BUSINESS</span></b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tevogen
Bio Holdings Inc., a Delaware corporation (the &#8220;Company&#8221;), is a clinical-stage specialty immunotherapy company harnessing
the power of CD8+ cytotoxic T lymphocytes to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases,
cancers, and other disorders. The Company&#8217;s precision T cell technology, ExacTcell, is a set of processes and methodologies to
develop, enrich, and expand single human leukocyte antigen-restricted CTL therapies with proactively selected, precisely defined targets.
The Company has completed a Phase 1 proof-of-concept trial for the first clinical product of ExacTcell, TVGN 489, for the treatment of
ambulatory, high-risk adult COVID-19 patients, and has other product candidates in its pipeline.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 14, 2024 (the &#8220;Closing Date&#8221;), pursuant to the Agreement and Plan of Merger dated June 28, 2023 (the &#8220;Merger
Agreement&#8221;) by and among Semper Paratus Acquisition Corporation (&#8220;Semper Paratus&#8221;), Semper Merger Sub, Inc., a wholly
owned subsidiary of Semper Paratus (&#8220;Merger Sub&#8221;), SSVK Associates, LLC (the &#8220;Sponsor&#8221;), Tevogen Bio Inc (n/k/a
Tevogen Bio Inc.) (&#8220;Tevogen Bio&#8221;), and Dr. Ryan Saadi, in his capacity as seller representative, Merger Sub merged with and
into Tevogen Bio, with Tevogen Bio being the surviving entity and a wholly owned subsidiary of Semper Paratus (the &#8220;Merger&#8221;
and together with the other transactions contemplated by the Merger Agreement, the &#8220;Business Combination&#8221;) and Semper Paratus
was renamed Tevogen Bio Holdings Inc.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the closing of the Business Combination (the &#8220;Closing&#8221;), the then-outstanding shares of common stock of Tevogen
Bio, were converted into shares of the common stock of the Company at an exchange ratio of approximately&#160;<span id="xdx_908_ecustom--BusinessCombinationSharesExchangeRatio_iI_c20240214__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXBingLPzREg" title="Business combination shares">4.85</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;shares
of Company common stock for each share of Tevogen Bio common stock (the &#8220;Exchange Ratio&#8221;). See Note 4 for more information
on the Business Combination.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed in Note 4, the Merger was accounted for as a reverse recapitalization under which the historical financial statements of the
Company prior to the Merger are those of Tevogen Bio. All information related to the common stock of Tevogen Bio prior to the Closing
and presented in the consolidated financial statements and notes thereto has been retroactively adjusted to reflect the Exchange Ratio.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the Merger, the former equity holders and holders of convertible promissory notes of Tevogen Bio held&#160;<span id="xdx_904_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TevogenBioMember_z8YaQSRt0PL">91.0</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the outstanding shares of common stock of the Company and the former shareholders, creditors, and other contractual counterparties
of Semper Paratus held&#160;<span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SemperParatusMember_zwafqri8gW67" title="Equity ownership percentage">9.0</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the Company.&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEVELOPMENT-STAGE RISKS AND LIQUIDITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_DisclosureDevelopmentstageRisksAndLiquidityAbstract', window );"><strong>Development-stage Risks And Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_DevelopmentStageRisksAndLiquidityTextBlock', window );">DEVELOPMENT-STAGE RISKS AND LIQUIDITY</a></td>
<td class="text"><p id="xdx_80E_ecustom--DevelopmentStageRisksAndLiquidityTextBlock_zSEL1kYFLT55" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2. <span id="xdx_825_zdaGSlgqJht8">DEVELOPMENT-STAGE RISKS AND LIQUIDITY</span></b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has generally incurred losses and negative cash flows from operations since inception. The Company anticipates incurring additional
losses until such time, if ever, that it can generate significant sales from its product candidates currently in development. Management
believes that cash of $<span id="xdx_90E_eus-gaap--Cash_iI_c20241231_z54gFr7yqmm9" title="Cash">1,282,995</span></span></span> <span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
of December 31, 2024, the amounts available under the Loan Agreement entered into in June 2024 (as defined in Note 8), and the commitment
for an $<span id="xdx_906_eus-gaap--ProceedsFromRelatedPartyDebt_c20240601__20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zz9m7Wc2CT43" title="Grant received">8,000,000
</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">grant from KRHP LLC, a New Jersey limited
liability company (&#8220;KRHP&#8221;), will allow the Company to have adequate cash and financial resources to operate for at least
the next 12 months from the date of issuance of these consolidated financial statements. Subsequent to December 31, 2024, the Company
received a grant of $<span id="xdx_90F_eus-gaap--ProceedsFromRelatedPartyDebt_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z3YVJ23ouYca" title="Grant received">2,000,000
</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">from KRHP and drew $<span id="xdx_907_ecustom--GrantDrewFromRelatedParty_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zHn5lQn3Qp5b" title="Grant drew from related party">1,000,000
</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in each of February 2025 and in March
2025 under the Loan Agreement. The grant funding may not be used for repayment of existing debt obligations and does not include any
requirement to repay the investor or to issue equity in consideration of the funding. KRHP has committed to provide an additional $<span id="xdx_90D_eus-gaap--ProceedsFromRelatedPartyDebt_c20240601__20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zy6KwBSPcvhf" title="Grant received">8,000,000
</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of grant funding to the Company to be
used towards the Company&#8217;s ongoing operational expenses. The grant funding will be used to satisfy the Company&#8217;s obligations
as they come due through March 31, 2026. The Company does not plan to initiate a clinical trial until additional funding is received.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
regularly evaluates different strategies to obtain funding for operations for subsequent periods. These strategies may include but are
not limited to private placements of securities, licensing and/or marketing arrangements, partnerships with other pharmaceutical or biotechnology
companies, and public offerings of securities. The Company may not be able to obtain financing on acceptable terms and the Company may
not be able to enter into strategic alliances or other arrangements on favorable terms. The terms of any financing may adversely affect
the holdings or the rights of the Company&#8217;s stockholders. If the Company is unable to obtain sufficient funding, the Company could
be required to delay, reduce or eliminate research and development programs, product portfolio expansion, or future commercialization
efforts, which could adversely affect its business prospects.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operations
since inception have consisted primarily of organizing the Company, securing financing, developing licensed technologies, performing
research, conducting pre-clinical studies and a clinical trial, and pursuing and completing the Business Combination. The Company is
subject to risks associated with any specialty biotechnology company that requires considerable expenditures for research and development.
The Company&#8217;s research and development projects may not be successful, products developed may not obtain necessary regulatory approval,
and any approved product may not be commercially viable. In addition, the Company operates in an environment of rapid technological change
and is largely dependent on the services of its employees and consultants.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-redline: true"><b>TEVOGEN BIO HOLDINGS
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-redline: true"><b>NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_DevelopmentStageRisksAndLiquidityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development Stage Risks And Liquidity [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_DevelopmentStageRisksAndLiquidityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_DisclosureDevelopmentstageRisksAndLiquidityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_DisclosureDevelopmentstageRisksAndLiquidityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_804_eus-gaap--SignificantAccountingPoliciesTextBlock_zFtpcnRqHCDf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3. <span id="xdx_82D_zIoAw2Lo0PA">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zEjozw92zT9b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_869_z6zGIDk7hIo2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
of Presentation</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (&#8220;GAAP&#8221;).
Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;)
and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p id="xdx_84E_eus-gaap--UseOfEstimates_zh4v7xeUIyE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_86C_z9OsFUUKNFM7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use
of Estimates</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preparing the consolidated financial statements in conformity with GAAP, management is required to make estimates and assumptions that
affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts of
expenses. Actual results could differ from those estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions
are reflected in the consolidated financial statements in the period they are determined to be necessary.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
areas that require management&#8217;s estimates include the fair value of the common stock and convertible promissory notes prior to
the Merger, the fair value of the Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock, fair value of the
purchase options under the Loan Agreement, stock-based compensation assumptions, and accrued research and development expenses.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p id="xdx_84C_ecustom--FreestandingAndEmbeddedCommonStockOptionsPolicyTextBlock_zU1Yg00Ynoqa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_86B_zjZOTYXrYvW1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Freestanding
and Embedded Common Stock Purchase Options</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity-linked
purchase options issued in connection with the Company&#8217;s debt agreements are assessed to determine whether they are freestanding
or embedded with the host instrument under ASC 815,&#160;<i>Derivatives and Hedging Contracts in Entity&#8217;s Own Equity&#160;</i>(&#8220;ASC
815&#8221;). Each type of purchase option is then assessed for equity or liability classification under ASC 815. The Company&#8217;s
embedded and freestanding purchase options were determined to be liability-classified derivative instruments and are measured at fair
value both on the date of issuance and at each subsequent balance sheet date, with changes in fair value recorded to &#8216;Change in
fair value of written call option derivative liabilities&#8217; within the consolidated statements of operations and consolidated statements
of cash flows.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_zaVX69hJqaGj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_860_zBYIf29m4TMl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Concentrations
of Credit Risk</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash. The Company
maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced
any losses in such accounts and believes it is not exposed to significant risk on its cash.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zGavjTbsGjld" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_86B_zqy1DxfGgale" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Segment
Reporting</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are defined as components of an entity for which discrete financial information is both available and regularly reviewed by
its chief operating decision maker or decision-making group. The Company views its operations and manages its business in <span id="xdx_905_eus-gaap--NumberOfOperatingSegments_pid_dc_uSegment_c20240101__20241231_zQCkR43qaf21" title="Number of operating segments">one
</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">segment.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-redline: true"><b>TEVOGEN BIO HOLDINGS
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-redline: true"><b>NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>


<p id="xdx_84C_eus-gaap--DerivativesPolicyTextBlock_zD1xmE1CP1Z1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span id="xdx_860_zTyoPxhDqOEb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the result of the Merger, the Company accounts for its warrants originally sold as part of Semper Paratus&#8217;s initial public offering
(the &#8220;IPO&#8221;) in accordance with ASC 815, <i>Derivatives and Hedging Contracts in Entity&#8217;s Own Equity </i>(&#8220;ASC
815&#8221;) and ASC 480,&#160;<i>Distinguishing Liabilities from Equity</i>&#160;(&#8220;ASC 480&#8221;). The assessment considers whether
the warrants are freestanding financial instruments and meet the definition of a liability pursuant to ASC 480 and meet all of the conditions
for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s own shares of common stock,
among other conditions. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance
and as of each subsequent quarterly period end date while the warrants are outstanding. For issued or modified warrants that meet all
of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the
time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required
to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter until settlement. Changes
in the estimated fair value of the warrants are recognized as a non-cash loss on the consolidated statements of operations. Under these
standards, the Company&#8217;s private placement warrants sold at the time of the IPO do not meet the criteria for equity classification
and must be recorded as liabilities while the public warrants sold in connection with the IPO do meet the criteria for equity classification
and must be recorded as equity.&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<p id="xdx_840_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zrhlYragtHG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_867_zPsHFdIWiME8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair
Value Measurements</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
assets and liabilities are carried at fair value under GAAP. Fair value is defined as the price that would be received for an asset or
paid to transfer a liability (exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction
between market participants on the measurement date. The Company utilizes valuation techniques that maximize the use of observable inputs
and minimize the use of unobservable inputs to the extent possible. When considering market participant assumptions in fair value measurements,
the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following
levels:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 0.5in; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unadjusted
    quoted prices in active markets for identical assets or liabilities;</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Observable
    inputs other than Level 1 prices, such as quoted prices for similar, but not identical, assets or liabilities in active markets;
    quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable
    or can be corroborated by observable market data;</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unobservable
    inputs in which there is little or no market data available and which require the Company to develop its own assumptions that market
    participants would use in pricing an asset or liability.</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments recognized at historical amounts in the balance sheets consist of accounts payable and notes payable. The Company believes
that the carrying value of accounts payable and notes payable approximates their fair values due to the short-term nature of these instruments.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s recurring fair value measurements consist of the convertible promissory notes prior to the Merger, for which the Company
elected the fair value option to reduce accounting complexity, and private warrants after the Merger. Such fair value measurements are
Level 3 inputs. The following table provides a roll-forward of the aggregate fair values of the Company&#8217;s convertible promissory
notes.</span></span></p>

<p id="xdx_89D_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zvQIcfKfBw7b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_8B4_zLwMSvweVTPg" style="display: none">SCHEDULE
OF FAIR VALUE MEASUREMENT</span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; font-weight: bold"><span style="-sec-ix-redline: true">Balance at January 1, 2023</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zmPdTyoWTo8e" style="width: 16%; text-align: right" title="Fair value beginning balance"><span style="-sec-ix-redline: true">39,297,000</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="-sec-ix-redline: true">Initial fair value at issuance</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zn2RHV15r6Be" style="text-align: right" title="Initial fair value at issuance"><span style="-sec-ix-redline: true">4,000,000</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="-sec-ix-redline: true">Accrued interest expense</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_98C_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zPFQwSUZCOQj" style="text-align: right" title="Accrued interest expense"><span style="-sec-ix-redline: true">1,206,697</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="-sec-ix-redline: true">Change in fair value</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zNzncNEjVShd" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"><span style="-sec-ix-redline: true">50,428,303</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold"><span style="-sec-ix-redline: true">Balance at December 31, 2023</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z4rCEr5QVgp4" style="text-align: right" title="Fair value beginning balance"><span style="-sec-ix-redline: true">94,932,000</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="-sec-ix-redline: true">Accrued interest expense</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_98A_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zt6aGeiPKPWa" style="text-align: right" title="Accrued interest expense"><span style="-sec-ix-redline: true">159,305</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="-sec-ix-redline: true">Change in fair value</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zyjBGFf91vbi" style="text-align: right" title="Change in fair value"><span style="-sec-ix-redline: true">(48,468,678</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="-sec-ix-redline: true">Derecognition upon conversion of convertible promissory
    notes</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_988_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5YwVfhmAdXj" style="border-bottom: Black 1pt solid; text-align: right" title="Derecognition upon conversion of convertible promissory notes"><span style="-sec-ix-redline: true">(46,622,627</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">Balance at December 31, 2024</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2ME1DbWt72e" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value beginning balance"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0630">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  </table>

<p id="xdx_8A4_zqcgjNCAyIG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-redline: true"><b>TEVOGEN BIO HOLDINGS
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-redline: true"><b>NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no transfers between levels during the years ended December 31, 2024 and 2023.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company used the probability weighted expected return method valuation methodology to determine the fair value of the convertible promissory
notes prior to the Merger. Significant assumptions and ranges used in determining the fair value of convertible promissory notes prior
to the Merger include volatility (<span id="xdx_903_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zF3lzBx4NxE3" title="Volatility">80</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%),
discount rate (<span id="xdx_90D_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember__srt--RangeAxis__srt--MinimumMember_zI7cdoSRgYZf" title="Volatility">35</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
- <span id="xdx_90C_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember__srt--RangeAxis__srt--MaximumMember_z3CE1sVwC9l8" title="Volatility">36</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%),
and probability of a future liquidity event (<span id="xdx_90F_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__custom--ProbabilityOfFutureLiquidityMember__srt--RangeAxis__srt--MinimumMember_zWLtQzBOBiyb" title="Volatility">85</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
- <span id="xdx_906_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__custom--ProbabilityOfFutureLiquidityMember__srt--RangeAxis__srt--MaximumMember_ztX9pqLKBk9j" title="Volatility">95</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%).
The Company used its stock price on the Closing Date to determine the fair value for the derecognition of the convertible promissory
notes upon conversion on the Closing Date.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the Closing, the Company acquired private warrants, the fair value of which increased by $<span id="xdx_900_eus-gaap--FairValueAdjustmentOfWarrants_iN_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCyhs8Yly2tg" title="Fair value adjustment of warrants">58,180</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;between
the Closing Date and December 31, 2024 primarily due to changes in the market value of the Company&#8217;s common shares. In June 2024,
the Company issued written call options in connection with the Loan Agreement, the fair value of which decreased by $<span id="xdx_903_eus-gaap--FairValueAdjustmentOfWarrants_iN_di_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zK0pZpXRMYP3" title="Fair value adjustment of warrants">375,000</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;between
the issuance and December 31, 2024. Such fair value measurements are Level 3 inputs. The following table provides a roll-forward of the
aggregate fair values of the warrants and the written call option derivative liabilities.</span></span></p>

<p id="xdx_89E_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zVFlWWOtgvBk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_8BC_zKxxJeSEy77b" style="display: none">SCHEDULE
OF FAIR VALUES OF WARRANTS</span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Derivative</b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>warrant
                                            liabilities</b></span></span></p></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Written
                                            call option</b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>derivative
                                            liabilities</b></span></span></p></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold"><span style="-sec-ix-redline: true">Balance at February 15, 2024</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_98A_eus-gaap--DerivativeLiabilitiesNoncurrent_iS_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHBI9UhFXWzg" style="text-align: right" title="Derivative warrant liabilities, Balance"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0648">&#8212;</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_98B_eus-gaap--DerivativeLiabilitiesNoncurrent_iS_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zNojA057WR65" style="text-align: right" title="Derivative warrant liabilities, Balance"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0650">&#8212;</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-left: 10pt"><span style="-sec-ix-redline: true">Initial fair value at issuance</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_983_ecustom--DerivativeLiabilitiesFairValueIssuance_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziWiAcw0clR" style="width: 16%; text-align: right" title="Initial fair value at issuance"><span style="-sec-ix-redline: true">29,000</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_985_ecustom--DerivativeLiabilitiesFairValueIssuance_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zh8O4BbAP9Vc" style="width: 16%; text-align: right" title="Initial fair value at issuance"><span style="-sec-ix-redline: true">375,000</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="-sec-ix-redline: true">Change in fair value</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_986_eus-gaap--FairValueAdjustmentOfWarrants_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQUdk6IQWDg1" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"><span style="-sec-ix-redline: true">58,180</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_986_eus-gaap--FairValueAdjustmentOfWarrants_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zhTcXjj4WLil" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"><span style="-sec-ix-redline: true">(375,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">Balance at December 31, 2024</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_984_eus-gaap--DerivativeLiabilitiesNoncurrent_iE_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeYQcoChW2m" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrant liabilities, Balance"><span style="-sec-ix-redline: true">87,180</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_989_eus-gaap--DerivativeLiabilitiesNoncurrent_iE_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zfSJPgabLkfk" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrant liabilities, Balance"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0662">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  </table>

<p id="xdx_8AA_zoiLz4vJKfVi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p id="xdx_895_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zUKPgDAmlig6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information about the Company&#8217;s liabilities that are measured at fair value on a recurring basis at December
31, 2024, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_8B2_zMdNzDoPK375" style="display: none">SCHEDULE
OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS</span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span style="-sec-ix-redline: true">&#160;</span></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">Level</span></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">Quoted Prices
    in <br/> Active Markets <br/> (Level 1)</span></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">Significant
    Other <br/> Observable Inputs <br/> (Level 2)</span></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">Significant
    Other <br/> Unobservable <br/> Inputs (Level 3)</span></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">Liabilities:</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 44%; text-align: left"><span style="-sec-ix-redline: true">Derivative warrant liabilities</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="width: 10%; text-align: right"><span style="-sec-ix-redline: true">3</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_98F_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zTFE3aAAK2o2" style="width: 10%; text-align: right" title="Derivative warrant liabilities"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0666">&#8212;</span></span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_984_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zI5XpHzeno74" style="width: 10%; text-align: right" title="Derivative warrant liabilities"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0668">&#8212;</span></span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_98A_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zT3vY3M4tuw6" style="width: 10%; text-align: right" title="Derivative warrant liabilities"><span style="-sec-ix-redline: true">87,180</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  </table>

<p id="xdx_8A8_zfdgPue2UFzb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s nonrecurring fair value measurements consist of Series A Preferred Stock. Such fair value measurements are Level 3 inputs.
The Company determined the fair value of Series A Preferred Stock using a Monte Carlo Simulation (&#8220;MCS&#8221;). Key inputs utilized
in the MCS to estimate fair value of Series A Preferred Stock included a range of volatility between&#160;<span id="xdx_90E_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zBQCgsFYWXy" title="Stock, measurement input">75</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
to&#160;<span id="xdx_90B_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zY07bkVh1tTi">85</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%,
a holding period to a deemed liquidation event, as defined in the Series A Preferred Stock agreement, ranging from&#160;<span id="xdx_900_ecustom--EquitySecuritiesTerm_dtY_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--RangeAxis__srt--MinimumMember_zJ7WOdTcTrch" title="Holding period">0.5</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;to&#160;<span id="xdx_900_ecustom--EquitySecuritiesTerm_dtY_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--RangeAxis__srt--MaximumMember_zx3jOtbTc9Kk" title="Range in years">10.0</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;years,
and a risk-free interest rate between&#160;<span id="xdx_90D_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zIZeBBxGPA83" title="Risk-free interest rate percentage">4.3</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
and&#160;<span id="xdx_90B_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zBXxOkIGk7N7" title="Stock, measurement input">5.3</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%.
The difference between the cash received of $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zgMvkcSAG6bc" title="Cash received upon issuance of preferred stock">2,000,000</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;upon
issuance of the Series A Preferred Stock and its estimated fair value was recognized as general and administrative expense on the consolidated
statements of operations during the three months ended March 31, 2024.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company used a MCS valuation methodology to determine the fair value of the freestanding $<span id="xdx_905_ecustom--FreeStandingPurchaseOptions_c20240101__20241231_zMcIwfI14nab" title="Free standing purchase options">14,000,000</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;purchase
option and remaining embedded $<span id="xdx_90A_ecustom--EmbeddedOptions_c20240101__20241231_zJt3WvksQt6c" title="Embedded options shares">30,000,000</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;purchase
option associated with the Loan Agreement as of December 31, 2024. The MCS methodology simulates the Company&#8217;s future stock price
to estimate if and when the Trailing VWAP (as defined below) will reach $<span id="xdx_90A_eus-gaap--SharePrice_iI_uUSDPShares_c20241231_zDGajU2DphH" title="Share price">10.00</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;per
share, and discounts the resulting payoff back to each valuation date using a present value factor. Significant assumptions used in determining
the fair value of these options include volatility of&#160;<span id="xdx_905_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zO4ZtR8xaGD7">78.3</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
and discount rate of&#160;<span id="xdx_900_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember_zA5hPt9cSmoa" title="Discount rate">4.3</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%.
At December 31, 2024, the MCS produced a fair value of $<span id="xdx_901_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20241231_zCSBpPO94ljd" title="Fair value">0
</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">relating to these freestanding and embedded
options.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-redline: true"><b>TEVOGEN BIO HOLDINGS
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-redline: true"><b>NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>


<p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zDD1mMrYTiic" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_863_zfPQfeKGxXZ1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid financial instruments with a maturity date of 90 days or less when purchased to be cash equivalents.
There were <span id="xdx_900_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_do_c20241231_zjoGF4P7HdTl" title="Cash equivalents"><span id="xdx_902_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_do_c20231231_zSAdcokKBeoe" title="Cash equivalents">no</span></span></span></span> <span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cash
equivalents as of December 31, 2024 and 2023 as all amounts consisted of bank deposits.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p id="xdx_84C_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zdqI5jkunLD6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_864_zoqVO2hfbssd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Property
and Equipment, Net</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<p id="xdx_893_ecustom--PropertyAndEquipmentUsefulLifeTableTextBlock_zHN0wr1ikGj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment is recorded at cost. Depreciation and amortization is provided using straight-line methods over their respective estimated
useful lives. Repairs and maintenance, which do not extend the useful lives of the related assets, are expensed as incurred.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_8B5_zJYD2SpYrHLa" style="display: none">SCHEDULE
OF PROPERTY AND EQUIPMENT USEFUL LIFE</span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"><span style="-sec-ix-redline: true">Estimated Useful Lives</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">Years</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 83%; text-align: justify"><span style="-sec-ix-redline: true">Computer software</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 14%; text-align: center"><span style="-sec-ix-redline: true"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zYycrtiHNlDj" title="Property, plant and equipment, useful life">5</span></span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="-sec-ix-redline: true">Leasehold improvements</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: center"><span style="-sec-ix-redline: true"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_zDnZQPBSz9v3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="Property, plant and equipment, useful life">3</span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zLHnEO71cT9d" title="Property, plant and equipment, useful life">4</span></span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-sec-ix-redline: true">Office equipment</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: center"><span style="-sec-ix-redline: true"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zSUqkMCooCEj" title="Property, plant and equipment, useful life">5</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="-sec-ix-redline: true">Furniture and fixtures</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: center"><span style="-sec-ix-redline: true"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zSoNNhiJr9od" title="Property, plant and equipment, useful life">7</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  </table>

<p id="xdx_8A7_zl5Ugxi1eSE3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews the carrying value of property and equipment whenever events and circumstances indicate that the carrying value of an
asset may not be recoverable from the estimated future cash flows expected to result from its eventual use and disposition. Based on
this assessment, management has determined that there was no impairment during the years ended December 31, 2024 and 2023.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p id="xdx_84A_eus-gaap--LesseeLeasesPolicyTextBlock_zfKTy2QrYHCk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_862_z4mqZGMPTzPj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Leases</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines whether an arrangement is or contains a lease, its classification, and its term at the lease commencement date. Leases
with a term greater than one year will be recognized on the balance sheet as right-of-use (&#8220;ROU&#8221;) assets, current lease liabilities,
and if applicable, long-term lease liabilities. The Company includes renewal options to extend the lease term where it is reasonably
certain that it will exercise these options. Lease liabilities and the corresponding ROU assets are recorded based on the present values
of lease payments over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such,
the Company utilizes the appropriate incremental borrowing rates, which are the rates that would be incurred to borrow on a collateralized
basis, over similar terms, amounts equal to the lease payments in a similar economic environment. If significant events, changes in circumstances,
or other events indicate that the lease term or other inputs have changed, the Company would reassess lease classification, remeasure
the lease liability using revised inputs as of the reassessment date, and adjust the ROU assets. Lease expense is recognized on a straight-line
basis over the expected lease term for operating classified leases.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases
with an initial term of <span id="xdx_902_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dc_c20241231_zDnUbmG7pY6j" title="Leases initial term">12 months</span></span></span>
<span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">or less and without a purchase option that the Company is reasonably
certain of exercising are not included within the lease ROU assets and lease liabilities on the balance sheet.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_zIdxFuVgTZNh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_868_z51STCTlamK2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and Development Expenses</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development activities are expensed as incurred. Costs for clinical trials and manufacturing activities are recognized based on an
evaluation of our vendors&#8217; progress towards completion of specific tasks, using data such as participant enrollment, clinical site
activations, or information provided to us by vendors regarding their actual costs incurred. Payments for these activities are based
on the terms of individual contracts and payment timing may differ significantly from the period in which the services were performed.
The Company determines accrual estimates through reports from and discussions with applicable personnel and outside service providers
as to the progress or state of completion of studies, or the services completed. The Company estimates accrued expenses as of each balance
sheet date based on the facts and circumstances known at the time. Costs that are paid in advance of performance are deferred as a prepaid
expense and amortized over the service period as the services are provided.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-redline: true"><b>TEVOGEN BIO HOLDINGS
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-redline: true"><b>NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>


<p id="xdx_840_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zlWE40LQEnBa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_867_zN8KNyRNRiS1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock-Based
Compensation</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation
cost is measured at the grant date fair value of the award and is recognized over the vesting period of the award. The Company uses the
straight-line method to record compensation expense of awards with service-based vesting conditions. The Company accounts for forfeitures
of awards as they occur rather than applying an estimated forfeiture rate to stock-based compensation expense. The Company recognizes
compensation expense for awards with performance conditions when it is probable that the condition will be met, and the award will vest.
Prior to the Merger, the Company estimated the fair value of the Company&#8217;s common stock on the date of grant in accordance with
the guidance outlined in the American Institute of Certified Public Accountants&#8217; <i>Accounting and Valuation Guide, Valuation of
Privately-Held-Company Equity Securities Issued as Compensation</i>.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zoWCJBw0vlYh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_866_zldsYnnmPWEb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Income
Taxes</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes using the asset and liability method in accordance with ASC Topic 740, <i>Income Taxes </i>(&#8220;ASC
740&#8221;), which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events
that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities
are determined on the basis of the differences between the financial statement and tax basis of assets and liabilities using enacted
tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are
recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future
taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all
or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense.
Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent
and feasible tax planning strategies. At December 31, 2024 and 2023, the Company has concluded that a full valuation allowance is necessary
for its net deferred tax assets.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p id="xdx_84B_eus-gaap--EarningsPerSharePolicyTextBlock_zPrUSe34nzZ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_869_znCeJn71YSG1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net
Loss Per Share</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company computes basic net loss per share by dividing net loss by the weighted-average common stock outstanding during the period. Given
the Company&#8217;s net loss, basic and diluted net loss per share for the years ended December 31, 2024 and 2023 are the same.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zWIqaAo2igS8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_862_zOYer4WwVUw5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recently
Issued Accounting Standards</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, the FASB issued ASU No. 2020-06, <i>Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and
Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815 -40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s
Own Equity </i>(&#8220;ASU 2020-06&#8221;), which simplifies the accounting for convertible instruments by reducing the number of accounting
models available for convertible debt instruments. ASU 2020-06 also eliminates the treasury stock method to calculate diluted earnings
per share for convertible instruments and requires the use of the if-converted method. Effective January 1, 2024, the Company adopted
ASU 2020-06 and that adoption did not have an impact on its consolidated financial statements and related disclosures.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the FASB issued ASU No. 2023-07,&#160;<i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&#160;</i>(&#8220;ASU
2023-07&#8221;). ASU 2023-07 enhances reportable segment disclosures by requiring disclosures such as significant segment expenses. The
main provisions of this update require companies to disclose, on an annual and interim basis, significant segment expenses, segment profit
and loss, and other segments items that are regularly provided to the chief operating decision maker (&#8220;CODM&#8221;). This update
also requires companies to disclose the title and position of the CODM and to explain how the CODM uses the reported segment measures
in assessing segment performance and deciding how to allocate resources. The update also requires companies with a single reportable
segment to provide all required segment reporting disclosures. This new standard is effective for fiscal years beginning after December
15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company adopted this standard on January 1,
2024 for annual reporting and interim periods beginning in 2025. See Note 16 for additional disclosures.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-redline: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-redline: true"><b>TEVOGEN BIO HOLDINGS
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-redline: true"><b>NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU 2024-03, <i>Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures,
(Subtopic 220-40) </i>(&#8220;ASU 2024-03&#8221;). ASU 2024-03 improves disclosures regarding the types of expenses included in commonly
presented expense captions, including disaggregating the amounts of employee compensation, depreciation and amortization included within
each income statement expense caption. This standard is effective for fiscal years beginning after December 15, 2026, and interim periods
within fiscal years beginning after December 15, 2027. The Company is currently evaluating the impact of the standard on its consolidated
financial statements and disclosures.</span></span></p>

<p id="xdx_853_znCRnm9LZro" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS COMBINATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">BUSINESS COMBINATION</a></td>
<td class="text"><p id="xdx_802_eus-gaap--BusinessCombinationDisclosureTextBlock_zqNIOxtWAU41" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4.&#160;<span id="xdx_82A_zDbQ2iMDygAd">BUSINESS COMBINATION</span></b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the Closing Date, the Company completed the Business Combination described in Note 1. The Merger was accounted for as a reverse recapitalization
under GAAP because Tevogen Bio was determined to be the accounting acquirer based upon the terms of the Merger and other factors, including
that following the Merger, former Tevogen Bio (i) equity holders and holders of convertible promissory notes owned approximately&#160;<span id="xdx_90A_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TevogenBioMember_zpb728IdYnI5" title="Ownership percentage">91.0</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the Company, (ii) directors constituted the majority (six of seven) of the directors of the Company, and (iii) management held all
key positions of management of the Company. Accordingly, the Merger was treated as the equivalent of Tevogen Bio issuing stock to acquire
the net assets of Semper Paratus. As a result of the Merger, the net liabilities of Semper Paratus were recorded at their acquisition-date
fair value in the consolidated financial statements and the reported operating results prior to the Merger are those of Tevogen Bio.
Immediately after the Merger, there were&#160;<span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_c20240214_zm7oVlVJKBmh" title="Common stock, shares outstanding">164,614,418</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;shares
of the Company&#8217;s common stock outstanding.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p id="xdx_892_eus-gaap--ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_zJzX1OzWkW2l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the net liabilities acquired in the Merger:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span id="xdx_8BF_zCTQj89vyov1" style="display: none">SCHEDULE OF NET LIABILITIES
ACQUIRED IN MERGER</span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" id="xdx_494_20240214_zbcnrScvqKR1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">February&#160;14,&#160;2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_maBCRIAzgn3_z9Io3A3mnHy3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%"><span style="-sec-ix-redline: true">Cash</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="width: 16%; text-align: right"><span style="-sec-ix-redline: true">229,328</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_iI_maBCRIAzgn3_z0mQ6Jgtmb0h" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Due from Sponsor</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">158,819</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_iI_maBCRIAzgn3_zl4ektKvznGj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Prepaid expenses and other assets</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">2,501</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iNI_di_msBCRIAzgn3_zQnadgn4rRHk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Accounts payable</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">(96,175</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">)</span></td></tr>
  <tr id="xdx_40D_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_iNI_di_msBCRIAzgn3_zY1HfC6433le" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Accrued expenses</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">(1,269,126</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">)</span></td></tr>
  <tr id="xdx_404_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_iNI_di_msBCRIAzgn3_zZRAK9OX6HM8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Notes payable</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">(1,651,000</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">)</span></td></tr>
  <tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_iNI_di_msBCRIAzgn3_zPRMCGucTFN8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="-sec-ix-redline: true">Derivative warrant liabilities</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true">(29,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">)</span></td></tr>
  <tr id="xdx_402_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iTI_mtBCRIAzgn3_maBCRIAzidu_ztgwK4PBMIHb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Total net liabilities acquired</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">(2,654,653</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">)</span></td></tr>
  <tr id="xdx_40D_ecustom--MergerTransactionCostsLimitedToCashAcquired_iI_maBCRIAzidu_z4zGz7PO8Sa4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="-sec-ix-redline: true">Plus: Merger transaction costs limited to cash acquired</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true">(229,328</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">)</span></td></tr>
  <tr id="xdx_40A_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts_iTI_mtBCRIAzidu_z3Z0rZNtOiEc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">Total net liabilities acquired plus transaction costs</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-redline: true">(2,883,981</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline: true">)</span></td></tr>
  </table>

<p id="xdx_8A2_zqlUY39z45fd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
transaction costs of $<span id="xdx_906_eus-gaap--BusinessCombinationAcquisitionRelatedCosts_c20240214__20240214_zcK3LwHoWqu5" title="Transaction costs">7,728,681</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;were
incurred in relation to the Business Combination through the Closing Date, of which $<span id="xdx_903_eus-gaap--BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_iI_c20240214_z0JxgTGn9CSj" title="Transaction costs charged to equity">229,328</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;were
charged directly to equity to the extent of the cash received from the Business Combination, with the balance of $<span id="xdx_909_eus-gaap--BusinessCombinationAcquisitionRelatedCosts_c20240101__20241231_zOJEgRME5SF6" title="Merger transaction costs">7,499,353</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;charged
to Merger transaction costs for the year ended December 31, 2024.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Former
holders of Tevogen Bio common stock and the Sponsor are eligible to receive up to an aggregate of&#160;<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20240214__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_ztQMKkaGXToh" title="Earnout shares issuable">24,500,000</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;shares
of common stock (&#8220;Earnout Shares&#8221;) if the volume-weighted average price (the &#8220;VWAP&#8221;) of the Company&#8217;s common
stock reaches specified threshold levels during the three-year period commencing on the Closing Date. Refer to Note 5, Earnout Shares,
for further details of the earnout arrangement.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Merger, the Company issued Series B Preferred Stock to the Sponsor in return for the Sponsor assuming $<span id="xdx_90B_ecustom--StockIssuedDuringPeriodValueNewIssuesOne_c20240214__20240214_zhmT0tkR4K6g" title="New issuance value">3,613,000</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;of
liabilities and obligations (&#8220;Assumed Liabilities&#8221;) of Semper Paratus and Tevogen Bio. The issuance date fair value of the
Series B Preferred Stock was recorded to Merger transaction costs within the consolidated statements of operations. All of the issued
Series B Preferred Stock was repurchased by the Company during the three months ended June 30, 2024 in exchange for the Sponsor being
released from their obligation to repay the Assumed Liabilities. See Note 12 for additional information.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-redline: true"><b>TEVOGEN BIO HOLDINGS
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-redline: true"><b>NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNOUT SHARES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_DisclosureEarnoutSharesAbstract', window );"><strong>Earnout Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_EarnoutSharesDisclosureTextBlock', window );">EARNOUT SHARES</a></td>
<td class="text"><p id="xdx_806_ecustom--EarnoutSharesDisclosureTextBlock_zagX6b1RQoS5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5.&#160;<span id="xdx_82B_znlZKg6laZk7">EARNOUT SHARES</span></b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the Closing, former holders of Tevogen Bio common stock may receive up to&#160;<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20241231__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_zt67oQ3JkOM2" title="Earnout shares">20,000,000</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Earnout
Shares in tranches of&#160;<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20241231__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_zRX8DRXnEewa" title="Earnout shares">6,666,667</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,&#160;<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20241231__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_zAC3jlxHCxN5" title="Earnout shares">6,666,667</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
and&#160;<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20241231__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_zuvEsTKHrt37" title="Earnout shares">6,666,666</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;shares
of common stock per tranche, respectively. The first, second, and third tranches are issuable if the VWAP per share of the Company&#8217;s
common stock is greater or equal to $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241231__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQfktJPCqMR7" title="Shares issued, price per share">15.00</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
$<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241231__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zslYvEivslpf" title="Shares issued, price per share">17.50</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
and $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241231__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLC8ZTppmgR3" title="Shares issued, price per share">20.00</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively, over any twenty trading days within any thirty consecutive day trading period during the three-year period after the Closing.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Sponsor received the right to Earnout Shares with the same terms above, except that each of the Sponsor&#8217;s three earnout tranches
are for&#160;<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20241231__srt--TitleOfIndividualAxis__custom--SponsorMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember_zZt0gzpM7SQf" title="Earnout shares">1,500,000</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;shares
of common stock, for an aggregate of&#160;<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20241231__srt--TitleOfIndividualAxis__custom--SponsorMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_ziei3aO7tYy8" title="Earnout shares">4,500,000</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;shares
of common stock across the entire Sponsor earnout. The Earnout Shares are a form of dividend for holders of Tevogen Bio common stock,
and the Earnout Shares earnable by the Sponsor are treated as contingent consideration in a reverse recapitalization. In accordance with
ASC 815, the Earnout Shares were considered to be indexed to the Company&#8217;s common stock and are classified within permanent equity.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_DisclosureEarnoutSharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_DisclosureEarnoutSharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_EarnoutSharesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Earnout Shares [Disclosure Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_EarnoutSharesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT, NET</a></td>
<td class="text"><p id="xdx_805_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_z8VPehfYwEia" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6. <span id="xdx_823_zklmFykksWod">PROPERTY AND EQUIPMENT, NET</span></b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<p id="xdx_895_eus-gaap--PropertyPlantAndEquipmentTextBlock_zyTLeod1iAYg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment consists of the following:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_8B7_zL4gRjUr8gL8" style="display: none">SCHEDULE
OF PROPERTY AND EQUIPMENT</span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" id="xdx_496_20241231_z2fTAjjPcK87" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" id="xdx_493_20231231_zafoUtjWTt3c" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">December 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerAndSoftwareMember_zLcF9UHhLe03" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="-sec-ix-redline: true">Computer software</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="width: 16%; text-align: right"><span style="-sec-ix-redline: true">292,341</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="width: 16%; text-align: right"><span style="-sec-ix-redline: true">292,341</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zWEzRTWh31K3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Leasehold improvements</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">263,217</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">263,217</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zOA54W6JoE32" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Office equipment</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">132,468</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">132,468</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zAxeUorRM0F7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="-sec-ix-redline: true">Furniture and fixtures</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true">33,743</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true">33,743</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzFLE_z9CL68pLllfg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-sec-ix-redline: true"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, gross</span></span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">721,769</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">721,769</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzFLE_zDXDRLq09mIh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="-sec-ix-redline: true">Less: accumulated depreciation</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true">(425,327</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">)</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true">(263,118</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">)</span></td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzFLE_zd2iNvK6JHzf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total property and
    equipment, net</span></span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-redline: true">296,442</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-redline: true">458,651</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  </table>

<p id="xdx_8AE_zsRWGRsOH3c1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense for the years ended December 31, 2024 and 2023 was $<span id="xdx_905_eus-gaap--Depreciation_c20240101__20241231_zi2l51PiBoSk" title="Depreciation expense">162,209
</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_900_eus-gaap--Depreciation_c20230101__20231231_zpc6SRupOUdg" title="Depreciation expense">163,300</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED EXPENSES AND OTHER LIABILITIES</a></td>
<td class="text"><p id="xdx_804_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_z6RfvuWeYq5f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
7. <span id="xdx_827_zRrSDVU9XqN4">ACCRUED EXPENSES AND OTHER LIABILITIES</span></b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<p id="xdx_892_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zRlUj4VqPk4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses and other liabilities consisted of the following:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_8BE_zB2Az3kYPDPi" style="display: none">SCHEDULE
OF ACCRUED EXPENSES AND OTHER LIABILITIES</span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td colspan="2" id="xdx_496_20241231_zjOO0oCsnLwg" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td colspan="2" id="xdx_49B_20231231_z9WXnm6jsJTl" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td colspan="6" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
    31,</b></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td></tr>
  <tr id="xdx_403_eus-gaap--AccruedProfessionalFeesCurrent_iI_maALCzC3I_zGgDsihN9oXg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 62%; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Professional
    services</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 16%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,309,163</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 16%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">976,301</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td></tr>
  <tr id="xdx_40E_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maALCzC3I_zrCYjFa3Avbi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">403,233</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">120,149</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td></tr>
  <tr id="xdx_408_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzC3I_zmG7bIjIJOo2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,712,396</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,096,450</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td></tr>
  </table>
<p id="xdx_8A2_z7WvcneI6UYf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT</a></td>
<td class="text"><p id="xdx_800_eus-gaap--DebtDisclosureTextBlock_zw2kLZQBNkj1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
8.&#160;<span id="xdx_823_zgdJfRsQOU48">DEBT</span></b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 14, 2024, in connection with the consummation of the Business Combination, previously issued promissory notes and accrued interest
were automatically converted into an aggregate of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20240214__20240214__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlWQrcXAraJ8" title="Converted shares">10,337,419
</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock. These debt obligations
were retired upon conversion.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-redline: true"><b>TEVOGEN BIO HOLDINGS
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-redline: true"><b>NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Loan
Agreement</i></b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2024, the Company entered into a Loan Agreement (the &#8220;Loan Agreement&#8221;) with The Patel Family, LLP (the &#8220;Patel
Family&#8221;), a related party of the Company, providing for an unsecured line of credit facility (the &#8220;Facility&#8221;) for term
loans of up to an initial total of $<span id="xdx_90B_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_z3rwGeRKyp6c" title="Line of credit maximum borrowing capacity">36,000,000</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
Under the Facility, the Company may draw up to $<span id="xdx_903_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_ztPZbIxcq55h" title="Line of credit borrowing capacity">1,000,000</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;in
term loans per calendar month over a draw period of 36 months. Each term loan draw will have a maturity date of&#160;<span id="xdx_90C_eus-gaap--DebtInstrumentTerm_dtM_c20240601__20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zJMa7xPDymH5" title="Debt maturity date">48</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;months
and will accrue interest at the lower of (i) daily SOFR plus&#160;<span id="xdx_903_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zhr7Tpjltdag" title="Debt instrument variable rate">2.00</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
and (ii)&#160;<span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zc06Lxl0USuj" title="Debt instrument interest rate">7.00</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%.
Interest accrues quarterly and is payable on the three-month anniversary of the draw date. Interest is payable in shares of common stock
at an effective price of $<span id="xdx_90F_eus-gaap--SharePrice_iI_c20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zrMQbfykxT5d" title="Share price">1.50</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;per
share. Interest payable through December 31, 2024 relating to the first two draws on the Facility were settled in February 2025 through
issuance of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zKfL1dDXu1S2" title="Shares issued">18,847
</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock. Principal may
be prepaid at any time without penalty, and repayments or prepayments may be made in cash or common stock at the Company&#8217;s election.
Payments of principal in common stock would be made at an effective price of the greater of $<span id="xdx_90F_eus-gaap--SharePrice_iI_c20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember__srt--RangeAxis__srt--MaximumMember_zK5gCn2eQJfc" title="Share price">1.50</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;per
share and the ten-day trailing volume weighted average price per share of the common stock (the &#8220;Trailing VWAP&#8221;) as of the
trading day prior to payment. As an inducement to enter into the Loan Agreement, the Company issued&#160;<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240601__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zhosEAWuDlCb" title="Issuance of shares">1,000,000</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;shares
of common stock to the Patel Family during June 2024. As of December 31, 2024, the Company has drawn $<span id="xdx_907_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zhqC3Y2o57Ij" title="Line of credit borrowing capacity">1,000,000</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;from
the Facility, with maturity dates in July and August 2028, with a remaining $<span id="xdx_900_eus-gaap--LineOfCreditFacilityRemainingBorrowingCapacity_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zKEoY04aRsli" title="Line of credit remaining capacity">30,000,000</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;available
for future financing over the remaining&#160;<span id="xdx_908_eus-gaap--DebtInstrumentTerm_dtM_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zPMZFpcBxoJi" title="Debt maturity date">30</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;months.
The Company drew an additional $<span id="xdx_90A_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20250228__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zHXGIGQ17x75" title="Line of credit borrowing capacity"><span id="xdx_905_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20250331__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zYqwI2uqfct5" title="Line of credit borrowing capacity">1,000,000</span>
</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in each of February and March 2025, with
maturity dates in February and March 2029, respectively (see Note 17).</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Loan Agreement includes a purchase option whereby the Patel Family has the option to purchase up to $<span id="xdx_909_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensationGross_c20240601__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zN5WdCriU1oh" title="Option to purchase common stock, value">14,000,000</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;of
shares of common stock at a purchase price equal to&#160;<span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_pid_dp_uPure_c20240601__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zs03c8p9FpJ1" title="Percentage of price of common stock purchased">70</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the Trailing VWAP per share (the &#8220;$<span id="xdx_905_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensationGross_pn6n6_c20240601__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zNZq2yLBs2Ic" title="Option to purchase common stock, value">14</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;million
Purchase Option&#8221;). The $<span id="xdx_900_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensationGross_pn6n6_c20240601__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zbmPytDfLmsj" title="Option to purchase common stock, value">14</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;million
Purchase Option only becomes exercisable once Trailing VWAP reaches $<span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_c20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_zoP8P3O1Mj0h" title="Purchase, price per share">10.00</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;per
share. The $<span id="xdx_90A_eus-gaap--DerivativeLiabilities_iI_pn6n6_c20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zvcNqi4vgof3" title="Derivative liability">14</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;million
Purchase Option was determined to be a freestanding derivative liability under ASC 815 and is carried at fair value, with changes in
fair value recorded to change in fair value of written call option derivatives liabilities within the consolidated statements of operations
and consolidated statements of cash flows.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Loan Agreement also includes a purchase option (the &#8220;Additional Amount Purchase Option&#8221;) that is identical to the $<span id="xdx_90E_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensationGross_pn6n6_c20240601__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AdditionalAmountPurchaseOptionMember_zztYjOylm645" title="Option to purchase common stock, value">14</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;million
Purchase Option, except that the option is exercisable for an amount up to the then-remaining undrawn term loan amount under the Loan
Agreement at the time Trailing VWAP reaches $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_c20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AdditionalAmountPurchaseOptionMember_zVJdG09Z1zMj" title="Purchase, price per share">10.00</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;per
share. The Additional Amount Purchase Option was determined to be an embedded derivative within the written loan commitment that requires
bifurcation under ASC 815, and thus is carried at fair value with changes in fair value recorded to change in fair value of written call
option derivatives liabilities within the consolidated statements of operations and consolidated statements of cash flows.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
$<span id="xdx_909_eus-gaap--DerivativeLiabilities_iI_pn6n6_c20240630_zFmdl79XH6Bg" title="Derivative liability">14</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;million
Purchase Option and the Additional Amount Purchase Option are recorded to written call option derivative liabilities within the consolidated
balance sheet and have a fair value of $<span id="xdx_906_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20241231_zSuuARFpSgrh" title="Derivative liabilities">0</span></span></span>
<span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as of December 31, 2024.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Loan Agreement is a written loan commitment that is not eligible for the fair value option under ASC 825,&#160;<i>Financial Instruments</i>.
However, management intends to elect the fair value option for future draws under this commitment, and therefore has expensed all issuance
costs associated with the Loan Agreement, which are comprised of the fair value of the&#160;<span id="xdx_90C_ecustom--StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility_c20240601__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_z2m85ELBeYTc" title="Line of credit facility shares">1,000,000</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;shares
of common stock issued to the Patel Family as well as the issuance date fair value of the $<span id="xdx_90F_eus-gaap--DerivativeLiabilities_iI_pn6n6_c20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zqXtJwOpLcnc" title="Derivative liability">14</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;million
Purchase Option and Additional Amount Purchase Option.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Notes
Payable</i></b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the Merger, the Company assumed notes payable held by Polar Multi-Strategy Master Fund (&#8220;Polar&#8221;) for which the
proceeds were to be used for working capital purposes by Semper Paratus with an outstanding balance of $<span id="xdx_902_eus-gaap--NotesPayableCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PolarMultiStrategyMasterFundMember_z3rY3o5uyHX6" title="Notes payable">1,651,000</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;on
the Closing Date and remain outstanding at December 31, 2024. The notes payable do not accrue interest. The outstanding balance of the
notes was required to be repaid in full within five business days of the Merger, and the Company is therefore in default of its obligations
at December 31, 2024. The notes&#8217; default provisions do not require the Company to transfer any shares or pay any amounts to Polar.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-redline: true"><b>TEVOGEN BIO HOLDINGS
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-redline: true"><b>NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock', window );">LEASES</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--OperatingLeasesOfLessorDisclosureTextBlock_zc3CeCOj6qU6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9. <span id="xdx_82C_zArk9wUoyvf7">LEASES</span></b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2022, the Company entered into leases for office and laboratory space in Warren Township, New Jersey and Philadelphia, Pennsylvania under
operating leases expiring in February 2026 and July 2025, respectively. The leases require fixed monthly payments of rent, as well as
a share of operating costs. The leases are classified as operating leases and the lease liabilities were calculated using incremental
borrowing rates ranging from <span id="xdx_901_ecustom--OperatingLeasesIncrementalBorrowingRates_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_zM9BKtznH8Yg" title="Operating leases incremental borrowing rates">11.0</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
to <span id="xdx_902_ecustom--OperatingLeasesIncrementalBorrowingRates_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zWk0ioLAECGb" title="Operating leases incremental borrowing rates">11.2</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%,
which was determined using a synthetic credit rating model. Lease expense for the year ended December 31, 2024 was $<span id="xdx_907_eus-gaap--OperatingLeaseExpense_c20240101__20241231_z0wILeVXmThd" title="Operating lease expense">1,065,784</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
which consisted of $<span id="xdx_908_eus-gaap--OperatingLeaseExpense_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentArrangementMember_zZO81HfiBvi3" title="Operating lease expense">897,958
</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_906_eus-gaap--OperatingLeaseExpense_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zKHxjj4OAQvc" title="Operating lease expense">167,826
</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recognized as a component of research
and development expense and general and administrative expense, respectively. This amount included $<span id="xdx_903_eus-gaap--ShortTermLeasePayments_c20240101__20241231_zyfKBUXNg9Tg" title="Short term lease">785,424
</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of expense under short-term leases.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average remaining lease term for the Company&#8217;s operating leases as of December 31, 2024 was <span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_zflP0svOdGRa" title="Operating leases weighted average remaining lease term">0.93
</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years. The weighted average discount rate
for the Company&#8217;s operating leases for the year ended December 31, 2024 was <span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20241231_zZUuLFURavl6" title="Operating leases weighted average discount rate">11.1</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p id="xdx_895_ecustom--ScheduleOfCompanyLeaseLiabilitiesTableTextBlock_z5Amd0mc7FH6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
aggregate minimum rental payments under the operating leases as of December 31, 2024 were as follows:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_8B5_z56qhGR4fHig" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF MINIMUM RENTAL PAYMENTS UNDER THE OPERATING LEASES</span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Years Ending December 31,</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" id="xdx_49D_20241231_ziRvYQE54ivl" style="text-align: right"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maOLLzALR_zmGsqaMQdUM" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left"><span style="-sec-ix-redline: true">2025</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="width: 16%; text-align: right"><span style="-sec-ix-redline: true">230,471</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maOLLzALR_zGr95ElDsClh" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">2026</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true">13,975</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtOLLzALR_zrMvbdd8G9Lh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Total</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">244,446</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zS0rZ8shQAB6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="-sec-ix-redline: true">Less: imputed interest</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true">(9,587</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">)</span></td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiability_iTI_zj9oIpfMdBmb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">Operating lease liability</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-redline: true">234,859</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  </table>

<p id="xdx_8AB_zNODONkrSBx2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
cash payments related to leases for the years ended December 31, 2024 and 2023 were $<span id="xdx_90F_eus-gaap--OperatingLeasePayments_c20240101__20241231_zbQfrmSDpMK" title="Cash payments">1,077,127
</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_909_eus-gaap--OperatingLeasePayments_c20230101__20231231_zj7JgaiK49mk" title="Cash payments">1,058,754</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessor's operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLessorDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zHq3GNNa6Zf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10. <span id="xdx_821_zsWcklDknXOc">COMMITMENTS AND CONTINGENCIES</span></b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employment
contracts</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered into employment contracts with its officers and certain employees that provide for severance and continuation of
benefits in the event of termination of employment either by the Company without cause or by the employee for good reason, both as defined
in the applicable agreement.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contingencies</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities
for loss contingencies arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is probable
that a liability has been incurred and the amount of the assessment and/or remediation can be reasonably estimated.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text"><p id="xdx_808_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zyMCODyWWnya" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
11. <span id="xdx_827_z4dAxgKik4m6">STOCK-BASED COMPENSATION</span></b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Closing, the Company adopted the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan (the &#8220;2024 Plan&#8221;)
and no longer grants awards pursuant to the 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;). Each RSU award granted under the
2020 Plan that was outstanding and unvested as of the Closing Date was automatically canceled and converted into an award under the 2024
Plan with respect to the common stock of the Company (the &#8220;Rollover RSUs&#8221;). Such Rollover RSUs remain subject to the same
terms and conditions as set forth under the applicable award agreement prior to the Closing.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to covering the Rollover RSUs, under the 2024 Plan, the Company is authorized to grant awards up to an aggregate&#160;<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourPlanMember_zkaAUew16Z37" title="Granted shares">40,000,000</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;shares
of common stock. The 2024 Plan provides for the grant of options, stock appreciation rights, Restricted Stock, RSUs, and other equity-based
awards. As of December 31, 2024, awards for <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourPlanMember_z7HKfBKy4zE6" title="Shares available for granted">10,670,118
</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares remained available to be granted
under the 2024 Plan.&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has issued RSUs that are subject to either service-based vesting conditions or service-based and performance-based vesting conditions.
Compensation expense for service-based RSUs are recognized on a straight-line basis over the vesting period of the award. Compensation
expense for service-based and performance-based RSUs (&#8220;Performance-Based RSUs&#8221;) are recognized when the performance condition,
which is based on a liquidity event condition being satisfied, is deemed probable of achievement.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-redline: true"><b>TEVOGEN BIO HOLDINGS
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-redline: true"><b>NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the Closing Date, the Company issued an aggregate of&#160;<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240214__20240214__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourPlanMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z84ak8g02yQ4" title="Number of shares issued for RSUs">19,348,954</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;RSUs
under the 2024 Plan to the Company&#8217;s Chief Executive Officer, Dr. Ryan Saadi (the &#8220;Special RSU Award&#8221;). Such RSUs immediately
converted into shares of Restricted Stock, the restrictions on which lapse in four equal annual installments beginning on February 14,
2031 (&#8220;Vesting Period&#8221;). Pursuant to the terms of the Special RSU Award, Dr. Saadi will be entitled to vote the Restricted
Stock, but the shares may not be sold, assigned, transferred, pledged, hypothecated, or otherwise encumbered, subject to forfeit. Dr.
Saadi will automatically forfeit all unvested Restricted Stock in the event he departs the Company. The fair value per share for the
Special RSU Award was determined to be $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20240214__20240214__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourPlanMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_ziRYnY7CEYVf" title="Fair value per share for award">4.51</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;per
share, equivalent to the Company&#8217;s stock price on the Closing Date, resulting in a total grant date fair value of $<span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20240214__20240214__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourPlanMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zs7oTBLqaQu3" title="Grant date fair value of shares">87,263,783</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
In accordance with ASC 718,&#160;<i>Compensation - Stock Compensation&#160;</i>(&#8220;ASC 718&#8221;), the Company will recognize compensation
expense on a straight-line basis from the Closing Date until the completion of the Vesting Period.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zg71PxSY1j3d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
Stock and RSU activity was as follows:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_8BB_zKiyxUa8Uqya" style="display: none">SCHEDULE
OF RESTRICTED STOCK AND RSU ACTIVITY</span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">Service-Based Restricted Stock and
    RSUs</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">Weighted average grant-date fair
    value</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-sec-ix-redline: true">Nonvested as of January 1, 2023</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zYkbcEwtskV6" style="text-align: right" title="Nonvested Shares, Beginning"><span style="-sec-ix-redline: true"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0938">-</span></span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zTw0SUr5swm" style="text-align: right" title="Nonvested weighted average grant-date fair value, Beginning"><span style="-sec-ix-redline: true"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0940">-</span></span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-sec-ix-redline: true">Granted</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zSMKKQsYVatk" style="text-align: right" title="Nonvested Shares, Granted"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0942">&#8212;</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zfQCmYSGg127" style="text-align: right" title="Nonvested weighted average grant-date fair value, Granted"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0944">&#8212;</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-sec-ix-redline: true">Vested</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zYGORBC0qyr8" style="text-align: right" title="Nonvested Shares, Vested"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0946">&#8212;</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zgzleRueiFa5" style="text-align: right" title="Nonvested weighted average grant-date fair value, Vested"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0948">&#8212;</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">Forfeited</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_z0nVoVud6em5" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested Shares, Forfeited"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0950">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zxUFVKPP1Mf5" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested weighted average grant-date fair value, Forfeited"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0952">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-sec-ix-redline: true">Nonvested as of December 31, 2023</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zl7TdslQqUz7" style="text-align: right" title="Nonvested Shares, Beginning"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0954">&#8212;</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zVjv6BEq74j5" style="text-align: right" title="Nonvested weighted average grant-date fair value, Beginning"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0956">&#8212;</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%"><span style="-sec-ix-redline: true">Granted</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zmhyAJn6R25k" style="width: 16%; text-align: right" title="Nonvested Shares, Granted"><span style="-sec-ix-redline: true">29,329,882</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zIVhFVfiUd26" style="width: 16%; text-align: right" title="Nonvested weighted average grant-date fair value, Granted"><span style="-sec-ix-redline: true">3.31</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-sec-ix-redline: true">Vested</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zb4N3FdAt0F4" style="text-align: right" title="Nonvested Shares, Vested"><span style="-sec-ix-redline: true">(2,639,628</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">)</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zjmY3Ryy46re" style="text-align: right" title="Nonvested weighted average grant-date fair value, Vested"><span style="-sec-ix-redline: true">0.96</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">Forfeited</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zOT6oxpXsWYh" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested Shares, Forfeited"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0966">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zVr3GW8f4fFg" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested weighted average grant-date fair value, Forfeited"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0968">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">Nonvested as of December 31, 2024</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zAbeEL3jQWA2" style="border-bottom: Black 2.5pt double; text-align: right" title="Nonvested Shares, Beginning"><span style="-sec-ix-redline: true">26,690,254</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zpPP7ynEpTU" style="border-bottom: Black 2.5pt double; text-align: right" title="Nonvested weighted average grant-date fair value, Beginning"><span style="-sec-ix-redline: true">3.54</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">Performance-Based RSUs</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">Weighted average grant-date fair
    value</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%"><span style="-sec-ix-redline: true">Nonvested as of January 1, 2023</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z1rlz6ZIH2E1" style="width: 16%; text-align: right" title="Nonvested Shares, Beginning"><span style="-sec-ix-redline: true">9,894,958</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zYEBRUUa4fS6" style="width: 16%; text-align: right" title="Nonvested weighted average grant-date fair value, Beginning"><span style="-sec-ix-redline: true">2.85</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-sec-ix-redline: true">Granted</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zXzXs5LuVewk" style="text-align: right" title="Nonvested Shares, Granted"><span style="-sec-ix-redline: true">1,027,796</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zU5QwhOVtKKh" style="text-align: right" title="Nonvested weighted average grant-date fair value, Granted"><span style="-sec-ix-redline: true">4.16</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-sec-ix-redline: true">Vested</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zNihbNDgoJlj" style="text-align: right" title="Nonvested Shares, Vested"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0982">&#8212;</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zRtEuhMXxxY2" style="text-align: right" title="Nonvested weighted average grant-date fair value, Vested"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0984">&#8212;</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">Forfeited</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z4WNux4psgFf" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested Shares, Forfeited"><span style="-sec-ix-redline: true">(22,626</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">)</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zCwJ89xod5X9" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested weighted average grant-date fair value, Forfeited"><span style="-sec-ix-redline: true">4.39</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-sec-ix-redline: true">Nonvested as of December 31, 2023</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zVTTQ5j3Vxe1" style="text-align: right" title="Nonvested Shares, Beginning"><span style="-sec-ix-redline: true">10,900,128</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z4tOtcsDbQrk" style="text-align: right" title="Nonvested weighted average grant-date fair value, Ending"><span style="-sec-ix-redline: true">2.97</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-sec-ix-redline: true">Granted</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zmsRkYvAG8l3" style="text-align: right" title="Nonvested Shares, Granted"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0994">&#8212;</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zf55dHhm3mC2" style="text-align: right" title="Nonvested weighted average grant-date fair value, Granted"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0996">&#8212;</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-sec-ix-redline: true">Vested</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zaPBEe7jGmH7" style="text-align: right" title="Nonvested Shares, Vested"><span style="-sec-ix-redline: true">(9,610,540</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">)</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z3qi8eJlnIoj" style="text-align: right" title="Nonvested weighted average grant-date fair value, Vested"><span style="-sec-ix-redline: true">2.87</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">Forfeited</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zDVaCo8Kj5x6" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested Shares, Forfeited"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1002">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zZJSQQVnys22" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested weighted average grant-date fair value, Forfeited"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1004">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">Nonvested as of December 31, 2024</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z6DRsiRRodBh" style="border-bottom: Black 2.5pt double; text-align: right" title="Nonvested Shares, Beginning"><span style="-sec-ix-redline: true">1,289,578</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_znTBbMTO9Iii" style="border-bottom: Black 2.5pt double; text-align: right" title="Nonvested weighted average grant-date fair value, Ending"><span style="-sec-ix-redline: true">3.70</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  </table>

<p id="xdx_8A3_z4eThjaJVWS9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the Merger, the liquidity event performance condition was achieved and therefore compensation cost of $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zf9pjdTt3KNe" title="Compensation cost recognized">25,233,487</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;for
the year ended December 31, 2024 was recognized for the Performance-Based RSUs, of which&#160;<span id="xdx_907_ecustom--StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zSX8nT5zA3p8" title="Number of shares issued and outstading RSU">8,237,319
</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares were issued and outstanding as
of December 31, 2024, and&#160;<span id="xdx_90C_ecustom--VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing_iI_c20250101__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zX2rnjABA6Je" title="Number of shares issuable">1,373,221</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;shares
will be issued subsequent to December 31, 2024. There was $<span id="xdx_90C_eus-gaap--EmployeeStockOwnershipPlanESOPCompensationExpense_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z83Wk1gYbvT1" title="Compensation cost">11,410,921
</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">compensation cost related to Service-Based
Restricted Stock and RSUs, for the year ended December 31, 2024, and <span id="xdx_90D_ecustom--VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing_iI_c20250101__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zRLZER3wPQl7" title="Number of shares issuable">2,639,628
</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares were issued and outstanding. There
was $<span id="xdx_902_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zCzwJ6CqfhDd" title="Unrecognized compensation cost">85,601,786</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;of
unrecognized compensation cost related to Service-Based Restricted Stock and RSUs as of December 31, 2024, which will be expensed over
a weighted average period of&#160;<span id="xdx_901_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zQygHX4CHgMl" title="Weighted average period">7.0</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;years.
There was $<span id="xdx_906_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zapiN8fpwYak" title="Unrecognized compensation cost">2,984,909</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;of
unrecognized compensation cost related to Performance-Based RSUs as of December 31, 2024, which will be expensed over a weighted average
period of&#160;<span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zO72HDdRqff6" title="Weighted average period for recognition">1.1</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;years.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-redline: true"><b>TEVOGEN BIO HOLDINGS
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-redline: true"><b>NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>


<p id="xdx_89F_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zqQ6C3RkJXLh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded stock-based compensation expense in the following expense categories in the accompanying consolidated statements of
operations:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span id="xdx_8B4_z0T6x9S9R0nc" style="display: none">SCHEDULE OF STOCK-BASED
COMPENSATION EXPENSE</span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" id="xdx_494_20240101__20241231_zDU36E9nUsml" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">Year ended</span></td><td style="font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></span></p></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zYTqU2Y6qIUa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left"><span style="-sec-ix-redline: true">Research and development</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="width: 18%; text-align: right"><span style="-sec-ix-redline: true">27,019,781</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z2XZFhW9Nmak" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="-sec-ix-redline: true">General and administrative</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true">13,744,355</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--AllocatedShareBasedCompensationExpense_zwdTtZqbiUNb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt"><span style="-sec-ix-redline: true">Total</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-redline: true">40,764,136</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  </table>

<p id="xdx_8AF_zolbzGpD9Gyc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_do_c20230101__20231231_ze91l903pZjd">No
</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">stock-based compensation expense was recognized
in 2023.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; DEFICIT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; DEFICIT</a></td>
<td class="text"><p id="xdx_800_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zqa4HQO38Ad3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
12.&#160;<span id="xdx_823_zPEUk6aDyaG5">STOCKHOLDERS&#8217; DEFICIT</span></b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;Common
Stock</i></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of February 15, 2024, the Company&#8217;s common stock and warrants began trading on The Nasdaq Stock Market LLC under the symbols &#8220;TVGN&#8221;
and &#8220;TVGNW&#8221;, respectively.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the Company had&#160;<span id="xdx_90C_eus-gaap--CommonStockSharesIssued_iI_c20241231_zMwByKIdp1T5" title="Common shares, shares issued"><span id="xdx_905_eus-gaap--CommonStockSharesOutstanding_iI_c20241231_z3wxrw4IG9ql" title="Common shares, shares outstanding">177,991,365</span></span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;shares
of common stock issued and outstanding. For accounting purposes related to earnings per share, only shares that are fully vested are
considered issued and outstanding.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p id="xdx_897_eus-gaap--ScheduleOfStockholdersEquityTableTextBlock_zSOL5mLD6Ex8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below
is a reconciliation of shares of common stock issued and outstanding:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span id="xdx_8BF_zBobVkOAVlrc" style="display: none">SCHEDULE OF RECONCILIATION
OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING</span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">December 31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left"><span style="-sec-ix-redline: true">Total shares of common stock issued and outstanding</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="width: 16%; text-align: right"><span style="-sec-ix-redline: true"><span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_c20241231_zyN8CCKLMVr8" title="Total shares of common stock legally issued"><span id="xdx_909_eus-gaap--CommonStockSharesOutstanding_iI_c20241231_z5LoyIQAfSeg" title="Total shares of common stock legally outstanding">177,991,365</span></span></span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Plus: shares to be issued:</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="-sec-ix-redline: true">Vested RSUs not yet legally settled into common stock (a)</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_98E_ecustom--VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing_iI_c20241231_fKGEp_zCbHItSD0oN5" style="text-align: right" title="Vested Performance-Based RSUs from satisfaction of liquidity condition upon the Closing"><span style="-sec-ix-redline: true">1,373,221</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Less: Shares subject to future vesting:</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="-sec-ix-redline: true">Issuance of restricted common stock subject to forfeiture
    (b)</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_982_ecustom--SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture_iI_c20241231_fKGIp_zAWe8GbZVlj2" style="border-bottom: Black 1pt solid; text-align: right" title="Issuance of restricted common stock subject to forfeiture"><span style="-sec-ix-redline: true">(19,348,954</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">Total shares, net</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_981_ecustom--CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture_iI_c20241231_zTEH5atUDVxk" style="border-bottom: Black 2.5pt double; text-align: right" title="Total shares issued and outstanding"><span style="-sec-ix-redline: true">160,015,632</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_F0C_zk3ugD4zYWK3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_F1B_z37YHzlQJlp4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of December 31, 2024, there were RSUs that had vested but had not been legally settled into common stock. See Note 11 for additional
    information.</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_F03_zRtXAoAo4a1b" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_F1E_zYoDAP8O7hp2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Saadi will automatically forfeit all unvested Restricted Stock granted pursuant to the Special RSU Award in the event he departs
    the Company. See Note 11 for additional information on the Special RSU Award.</span></span></td></tr>
  </table>
<p id="xdx_8A5_zFXyPlOcKyif" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the Merger, Tevogen Bio had outstanding shares of voting and non-voting common stock. Upon the Closing, Tevogen Bio&#8217;s common
stockholders received shares of the Company&#8217;s common stock in an amount determined by application of the Exchange Ratio, as discussed
in Note 1.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-redline: true"><b>TEVOGEN BIO HOLDINGS
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-redline: true"><b>NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Preferred
Stock</i></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue up to&#160;<span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_c20241231_zeKFUrWx9AP2" title="Preferred shares, shares authorized">20,000,000</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;shares
of preferred stock, par value $<span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20241231_zoEeMt6zvnV4" title="Preferred shares, par value">0.0001</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;per
share.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Series
A Preferred Stock</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2024, the Company authorized and issued&#160;<span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zOLmDBCk46lb" title="Preferred stock, shares authorized">2,000</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;and&#160;<span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zbMqeQf9Qm6a" title="Preferred stock, shares issued">500</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;shares,
respectively, of Series A Preferred Stock (the &#8220;Series A&#8221;) to the Patel Family at a price of $<span id="xdx_908_eus-gaap--SharePrice_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_z3XSZLyE1g57" title="Original issue price per share">4,000</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;per
share (the &#8220;Series A Original Issue Price&#8221;), for gross proceeds of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20240301__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zfEFg1tPo3j9" title="Proceeds from issuance of preferred stock">2,000,000</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The Company recorded an expense of $<span id="xdx_900_ecustom--LossOnPreferredStockIssuance_c20240301__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zsNErM7B6u37" title="Loss on preferred stock issuance">799,990</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;in
its consolidated statements of operations related to issuance of the Series A equal to the fair value of the Series A when issued of
$<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zJiiIEZtR32" title="Price per share">5,600</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;per
share less the purchase price of $<span id="xdx_90A_eus-gaap--SharePrice_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zQ5BTtvcEdja" title="Share price">4,000</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;per
share.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dividends</i></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of Series A are entitled to receive dividends accruing daily on a cumulative basis payable at a fixed rate of&#160;<span id="xdx_903_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zEXAZXeTMRm2" title="Dividend rate, percentage">5</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
per annum per share on&#160;<span id="xdx_90A_eus-gaap--PreferredStockDividendPaymentRateVariable_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zRwbc71eB8U1" title="Dividend variable rate, description">the
Series A Original Issue Price, which rate will automatically increase by 2% every year that the Series A remains outstanding (the &#8220;Series
A Accruing Dividends&#8221;). These dividends become payable when and if declared by the Company. The Series A Preferred Stock will also
participate on an as-converted basis in any regular or special dividends paid to holders of the common stock</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidation</i></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series A ranks senior to common stock and Series C Preferred Stock in liquidation priority. In the event of a liquidation of the Company,
or certain deemed liquidation events, the Series A is redeemable for a price equal to the greater of the Series A Original Issue Price
plus all Series A Accruing Dividends that are unpaid through the redemption date, or such amount that would have been payable had the
Series A converted into shares of common stock immediately before the liquidation or deemed liquidation event.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Voting</i></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series A does not have any voting rights.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Redemption</i></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of Series A are not entitled to redeem their shares outside of the liquidation of the Company or the occurrence of a deemed liquidation
event. The Company is entitled to redeem the Series A at a price equal to the Series A Original Issue Price plus any Series A Accruing
Dividends accrued but unpaid thereon, if the VWAP of the Company&#8217;s common stock exceeds $<span id="xdx_904_eus-gaap--PreferredStockRedemptionPricePerShare_iI_pid_uUSDPShares_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zuAfldtfHc62" title="Redemption price per share">5.00</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;per
share for&#160;<span id="xdx_907_eus-gaap--PreferredStockRedemptionTerms_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zf3mfbHmCfG8" title="Redemption term">the
twenty days immediately prior to the Company&#8217;s call election</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<i>Conversion</i></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of Series A have the option to convert the Series A into shares of common stock at a ratio equal to the Series A Original Issue
Price divided by the Series A Conversion Price, which is initially $<span id="xdx_902_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_uUSDPShares_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zQIYF4ixkDGa" title="Conversion price per share">4.00</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;per
share and is subject to standard antidilution adjustments.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="text-decoration: underline">Series
A-1 Preferred Stock</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 27, 2024, the Company entered into an Amended and Restated Securities Purchase Agreement with the Patel Family covering the issuance
of&#160;<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240326__20240327__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_zoxKHXWMgXH3">600</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;shares
of Series A-1 Preferred Stock for a gross purchase price of $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240326__20240327__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_zil4uC88XYqb">6,000,000</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.&#160;<span id="xdx_900_eus-gaap--PreferredStockDividendPaymentRateVariable_c20240326__20240327__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_z0EexvHdNfP4" title="Dividend variable rate, description">The
terms of the Series A-1 Preferred Stock are identical to the Series A, except that the cumulative dividends are capped at 15% per annum,
and the Series A-1 Issuance Price is defined as $<span id="xdx_90C_eus-gaap--SharePrice_iI_c20240327__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_zNLrJD98P3cf" title="Share price">10,000</span>&#160;per share</span>. As of December 31, 2024, the investor had paid a non-refundable
deposit of $<span id="xdx_903_eus-gaap--Deposits_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_zGLhxcx8NeVb" title="Non refundable deposist paid">3,000,000</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;towards
the Series A-1 purchase price, and no shares of Series A-1 Preferred Stock were issued or outstanding.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-redline: true"><b>TEVOGEN BIO HOLDINGS
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-redline: true"><b>NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Series
B Preferred Stock</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Closing, the Company entered into an agreement to issue shares of Series B to the Sponsor in return for the Sponsor
assuming certain liabilities and obligations of Semper Paratus and Tevogen Bio. In March 2024,&#160;<span id="xdx_90C_ecustom--StockIssuedDuringPeriodSharesConversionOfLiabilities_c20240301__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zzKEiMAM1kA" title="Conversion of certain liabilities into Series B preferred stock, shares">3,613</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;shares
of Series B were issued in return for the assumption of the Assumed Liabilities. The issuance date fair value of the Series B was determined
to be $<span id="xdx_90E_ecustom--StockIssuedDuringPeriodValueConversionOfLiabilities_c20240301__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z0w4NNJx0206" title="Conversion of certain liabilities into Series B preferred stock">3,613,000</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;and
was recorded within Merger transaction costs in the consolidated statements of operations. The Series B was classified as permanent equity.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 15, 2024, the Company and the Sponsor entered into the Preferred Stock Repurchase Agreement, pursuant to which the Company repurchased
all outstanding Series B in exchange for the release of the Sponsor from its obligations related to the Assumed Liabilities, but no cash
consideration. The repurchase was recorded as a deemed contribution from a related party and recorded to additional paid-in capital.
As of June 30, 2024, there were&#160;<span id="xdx_909_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20240630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zjMKJrpQOGJ7" title="Preferred stock shares outstanding">no</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;shares
of Series B outstanding, and on August 9, 2024, the Company filed a Certificate of Elimination to eliminate the Series B. Although the
Company was not legally released by the creditors, the Company has made payments towards the Assumed Liabilities and approximately $<span id="xdx_901_eus-gaap--LiabilitiesAssumed1_pn5n6_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zyMnhtgkwDqa" title="Liabilities assumed">2.6</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;million
remains on the Company&#8217;s balance sheet at December 31, 2024.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="text-decoration: underline">Series
C Preferred Stock</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 21, 2024, the Company entered into a securities purchase agreement (the &#8220;Series C Agreement&#8221;) with an investor, pursuant
to which the Patel Family purchased&#160;<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240821__20240821__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_zSPnuzVFW8I3">600</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;shares
of Series C Preferred Stock (the &#8220;Series C&#8221;) of the Company at a price of $<span id="xdx_909_eus-gaap--SharePrice_iI_c20240821__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_zDTaVGWAeBdf" title="Share price">10,000</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;per
share (the &#8220;Series C Original Issue Price&#8221;), for gross proceeds of $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20240821__20240821__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_zAEFpmxITdxc" title="Gross proceeds">6,000,000</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series C is subject to a call right providing the Company the right to call the stock at any time after the fifth anniversary of the
date of issuance. The Company also agreed that so long as the Series C is outstanding, the Company will not, without the written consent
of the holders of 50.1% of the Series C, amend, alter, or repeal any provision of the Company&#8217;s certificate of incorporation or
bylaws in a manner adverse to the Series C. Assessed under accounting guidance within ASC 480 and ASC 815, as the Series C is unregistered
and without mandatory redemption features, the Series C is classified within equity at issued face value as of December 31, 2024.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dividends</i></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series C carries an annual&#160;<span id="xdx_90E_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zOfmBzQmYJh5" title="Dividend rate, percentage">7.5</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
cumulative dividend, compounded annually, beginning on the later of (1) September 30, 2024 and (2)&#160;the date on which the investor
has paid the entirety of the purchase price under the Series C Agreement and ending on the last business day of the calendar quarter
ending September 30, 2034 (the &#8220;Series C Accruing Dividends&#8221;). Dividends will be payable in shares of Series C or, at the
election of the Company, in cash.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidation</i></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series C ranks subordinate to the Series A and Series A-1 Preferred Stock and ranks senior to common stock in liquidation priority. In
<span id="xdx_90E_eus-gaap--PreferredStockDividendPaymentRateVariable_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zLJfTgOGcgV4" title="Dividend variable rate, description">the
event of a liquidation of the Company, or certain deemed liquidation events, the Series C is redeemable for a price equal to the greater
of the Series C Original Issue Price plus all Series C Accruing Dividends that are unpaid through the redemption date, or such asset
amount as would have been payable had the Series C converted into shares of common stock immediately before the liquidation or deemed
liquidation event</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Voting</i></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series C does not have any voting rights.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-redline: true"><b>TEVOGEN BIO HOLDINGS
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-redline: true"><b>NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Redemption</i></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of Series C are not entitled to redeem their shares outside of the liquidation of the Company or the occurrence of a deemed liquidation
event. The Company is entitled to redeem that Series C at a price equal to the Series C Original Issue Price plus any Series C Accruing
Dividends accrued but unpaid thereon, subject to the conversion right described below.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Conversion</i></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of Series C will be convertible at the election of the holder, beginning six months after the date of issuance, into shares of
common stock at a conversion price equal to the volume-weighted average price of the Common Stock for the 30 trading days immediately
prior to the exercise of the holder&#8217;s conversion option, subject to a floor price of $<span id="xdx_903_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_uUSDPShares_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zv0yGDL9ogud" title="Floor price">0.6172</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Warrants</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the Closing,&#160;<span id="xdx_907_ecustom--ClassOfWarrantOrRightIssued_iI_c20211130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SemperParatusMember_zzjSEoZrAQV6" title="Number of warrants issued">17,975,000</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;warrants
initially issued by Semper Paratus in November 2021, comprising&#160;<span id="xdx_901_ecustom--ClassOfWarrantOrRightIssued_iI_c20211130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SemperParatusMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zC20OblgOKeb" title="Number of warrants issued">17,250,000</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;public
warrants sold in the IPO and&#160;<span id="xdx_90C_ecustom--ClassOfWarrantOrRightIssued_iI_c20211130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SemperParatusMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zTabAw0W3unb" title="Number of warrants issued">725,000</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;warrants
issued in a concurrent private placement, were assumed.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Public
Warrants</i></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
public warrants have an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SemperParatusMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_z9sHJ50LAX11" title="Exercise price">11.50</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;per
share, became exercisable on&#160;<span id="xdx_901_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20211101__20211130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SemperParatusMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zjAflArab5ke" title="Exercisable date">March
15, 2024</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, and will expire at 5:00 p.m.,
New York City time, on February 14, 2029, or earlier upon redemption or liquidation. Warrant holders may, until such time as there is
an effective registration statement and during any period when the Company has failed to maintain an effective registration statement
covering the shares of the Company&#8217;s common stock issuable upon exercise of the warrants, exercise warrants on a &#8220;cashless
basis&#8221; in accordance with Section 3(a)(9) of the Securities Act of 1933, as amended, or another exception.&#160;<span id="xdx_900_ecustom--WarrantsRedemptionDescription_c20211101__20211130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SemperParatusMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_za1vBJ9LJ5e" title="Warrants redemption description">The
Company may redeem the public warrants if the Company&#8217;s common stock equals or exceeds $18.00 per share for 20 trading days within
a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the
holders of public warrants</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.&#160;As of
December 31, 2024, there are&#160;<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SemperParatusMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zwCbzd7uy8J7" title="Number of warrants outstanding">17,386,580</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;public
warrants outstanding.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<i>Private
Placement Warrants</i></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
private placement warrant is identical to the public warrants, except that the private placement warrants, so long as they are held by
the initial purchasers or their permitted transferees, (i) will not be redeemable by the Company and (ii) may be exercised by the holders
on a cashless basis. As of December 31, 2024, there are&#160;<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SemperParatusMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zDLTpTVdl9I7" title="Number of warrants outstanding">588,398
</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">private placement warrants outstanding.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 3 for additional information on the Company&#8217;s warrant accounting policy.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-redline: true"><b>TEVOGEN BIO HOLDINGS
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-redline: true"><b>NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET LOSS PER SHARE</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--EarningsPerShareTextBlock_ze736zl6POZi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
13.&#160;<span id="xdx_825_zqPN9q60Q2sd">NET LOSS PER SHARE</span></b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p id="xdx_891_eus-gaap--ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_zrMhznhcADK1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
below table is a reconciliation of net loss to net loss attributable to common stockholders.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_8B2_zqvjlw0tPPPc" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF RECONCILIATION OF NET LOSS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" id="xdx_499_20240101__20241231_zewavYKYmcO9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">2024</span></td><td style="font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" id="xdx_493_20230101__20231231_z5LV02lxoR03" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">2023</span></td><td style="font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">Year ended</span></td><td style="font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">December 31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">2024</span></td><td style="font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">2023</span></td><td style="font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_maNILATzLnk_z0EjB95kvWd5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="-sec-ix-redline: true">Net loss</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="width: 16%; text-align: right"><span style="-sec-ix-redline: true">(13,727,380</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">)</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="width: 16%; text-align: right"><span style="-sec-ix-redline: true">(60,477,680</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">)</span></td></tr>
  <tr id="xdx_407_eus-gaap--PreferredStockDividendsIncomeStatementImpact_iN_di_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_msNILATzLnk_ziuy4AAZlZpa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Series A cumulative preferred stock dividend</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">(76,712</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">)</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1136">&#8212;</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_40D_ecustom--StockRepurchase_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_msNILATzLnk_zMbcnuDaiYHe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Series B stock repurchase</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">3,613,000</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1139">&#8212;</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_400_ecustom--StockRepurchase_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zsFxVRhsUdRd" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Stock repurchase</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">3,613,000</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1142">&#8212;</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
<tr id="xdx_404_eus-gaap--PreferredStockDividendsIncomeStatementImpact_iN_di_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_msNILATzLnk_zXXqhExT8Qp9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Series C cumulative preferred stock dividend</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true">(82,603</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">)</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1145">&#8212;</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--PreferredStockDividendsIncomeStatementImpact_iN_di_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zYSKuDF6E6f7" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Cumulative preferred stock dividend</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true">(82,603</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">)</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1148">&#8212;</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
<tr id="xdx_406_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iT_mtNILATzLnk_zCi7OAkiAonl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Net loss attributable to common stockholders</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-redline: true">(10,273,695</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">)</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-redline: true">(60,477,680</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">)</span></td></tr>
  </table>

<p id="xdx_8A2_zG3z9K9LYeO2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: center"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company excluded the following potential shares from the computation of diluted net loss per share because including them would have
had an anti-dilutive effect:</span></span></p>

<p id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zMKW3hz6iji8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_8B5_zdSENhIO9rV3" style="display: none">SCHEDULE
OF ANTI-DILUTIVE NET LOSS PER SHARE</span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" id="xdx_499_20240101__20241231_zsfIgTckdztj" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" id="xdx_493_20230101__20231231_z3pWLbJFR0Ba" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">December 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zF2EpHKswSyc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="-sec-ix-redline: true">Outstanding RSUs <span id="xdx_F4D_z07FvddSvL6a">(a)</span></span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="width: 16%; text-align: right"><span style="-sec-ix-redline: true">8,623,225</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="width: 16%; text-align: right"><span style="-sec-ix-redline: true">10,900,128</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_z059N4sxVyL8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Restricted Stock</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">19,348,954</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1159">&#8212;</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zs04JFRW2k1j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Warrants</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">17,974,978</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1162">&#8212;</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zvxNYvig3f4k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Convertible promissory notes <span id="xdx_F41_zy3oX7MkW0ga">(b)</span></span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1164">&#8212;</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">891,298</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--EarnoutSharesMember_zQdxAkjI4TOe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">Earnout Shares</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true">24,500,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1168">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zQ4P6OqK2bi6" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">Total</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-redline: true">70,447,157</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-redline: true">11,791,426</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 0.25in; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_F0D_zlr7PY4CNPL7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_F18_zLgqOEX8aBr1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of December 31, 2024 there were an additional&#160;</span></span><span style="-sec-ix-redline: true"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFOVEktRElMVVRJVkUgTkVUIExPU1MgUEVSIFNIQVJFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8EyIlRCBIqc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="Stock option vested">1,373,221</span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;RSUs
    that had vested but had not been legally settled into common stock and therefore were included in the basic net income per share.
    See Note 11 for additional information.</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_F0D_zYhkL5W3VIKi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_F17_zDwYlBaiVt58" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    numbers of shares were determined based on the conversion upon maturity provisions in the convertible promissory note agreements,
    dividing the conversion amount (principal plus accrued interest) by three times the estimated fair value of the Company&#8217;s common
    stock derived from the Company&#8217;s most recently completed convertible promissory notes valuation as of the balance sheet date.</span></span></td></tr>
  </table>
<p id="xdx_8A5_ztzzjDJRdhf4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
above table excludes any potentially anti-dilutive shares as a result of the $<span id="xdx_90E_eus-gaap--DerivativeLiabilities_iI_pn6n6_c20241231_zSEHCi9gIi7b" title="Derivative liability">14</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;million
Purchase Option and the Additional Amount Purchase Option (see Note 8). These are excluded as the number of shares issuable cannot be
determined until the conditions for issuance are met and the share prices are known upon exercise.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--IncomeTaxDisclosureTextBlock_zOH3qqx6CUEg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
14. <span id="xdx_82E_zVru2JBQBEJ">INCOME TAXES</span></b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the Company&#8217;s net losses for 2024 and 2023, as well as the full valuation allowance on its net deferred tax assets as discussed
below, the Company did not record any income tax expense or benefit for the years ended December 31, 2024 and 2023.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p id="xdx_891_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zzuUunQjL2f1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of income tax benefit at the federal statutory income tax rate to the income tax expense at the Company&#8217;s effective
income tax rate is as follows:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_8B0_zfqHypT5TS0f" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF RECONCILIATION OF INCOME TAX BENEFIT AT THE FEDERAL STATUTORY INCOME TAX RATE</span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20240101__20241231_zFaKKRbw9Jgg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20230101__20231231_zNiY81lgme86" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">Year Ended December 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_uPure_ma123_zUDNJ7EwY67a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="-sec-ix-redline: true">Federal benefit at statutory rate</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="width: 16%; text-align: right"><span style="-sec-ix-redline: true">21.0</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">%</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="width: 16%; text-align: right"><span style="-sec-ix-redline: true">21.0</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">%</span></td></tr>
  <tr id="xdx_40A_ecustom--IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest_dp_uPure_ma123_zW5cTaPDNid4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Convertible note interest</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1186">&#8212;</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">(0.4</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">)</span></td></tr>
  <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_dp_uPure_ma123_z5fy4lkgWl6j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Permanent differences</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">29.2</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">(17.4</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">)</span></td></tr>
  <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_uPure_ma123_z93Oyuc8PpGh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline: true">State taxes, net of federal benefit</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">12.3</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">2.2</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_uPure_ma123_z8l8k4IRndd6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Change in valuation allowance</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">(66.5</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">)</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">(5.4</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">)</span></td></tr>
  <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_dp_uPure_ma123_zdjWGnsqB8jb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Stock based compensation</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">4.6</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1199">&#8212;</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_iN_dpi_uPure_ms123_zV87CPJluAad" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-sec-ix-redline: true">Other</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">(0.6</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">)</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1202">&#8212;</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_dp_ms123_zZEC2coYO4Ze" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="-sec-ix-redline: true">Tax credits</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1204">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true">0.1</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_dp_uPure_mt123_zpKTAJJeo2Ik" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">Income Tax Expense</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1207">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline: true">%</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1208">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline: true">%</span></td></tr>
  </table>

<p id="xdx_8AD_zI1V4O0T35ek" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
income taxes reflect the net tax effects of temporary differences between carrying amounts of assets and liabilities for financial reporting
purposes and the amounts used for income tax purposes. Realization of net deferred tax assets is dependent upon future earnings, if any,
the timing and amount of which are uncertain.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-redline: true"><b>TEVOGEN BIO HOLDINGS
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-redline: true"><b>NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>


<p id="xdx_89D_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zVwD84JmqhR9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following items comprise the Company&#8217;s net deferred tax assets and liabilities as of December&#160;31, 2024 and December 31, 2023:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zDJj32uxJhO7" style="display: none">SCHEDULE
OF DEFERRED TAX ASSETS AND LIABILITIES</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" id="xdx_49D_20241231_zGc3SqzUGCkk" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" id="xdx_492_20231231_zhmEz9hnVLok" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">December 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsGrossAbstract_iB_z6v0y1kTSMR1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Deferred tax assets</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzJ64_zOmUptAXUjeg" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-left: 10pt"><span style="-sec-ix-redline: true">Net operating loss</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="width: 16%; text-align: right"><span style="-sec-ix-redline: true">6,808,826</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="width: 16%; text-align: right"><span style="-sec-ix-redline: true">3,755,008</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_40F_ecustom--DeferredTaxAssetsAccruedExpensesAndOther_iI_maDTAGzJ64_zbnWptSsezM2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="-sec-ix-redline: true">Accrued expenses and other</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">385,801</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">42,330</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_405_ecustom--DeferredTaxAssetsOperatingLeaseLiabilities_iI_maDTAGzJ64_zbPtKvCafCgc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="-sec-ix-redline: true">Lease liability</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">61,380</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">127,427</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGzJ64_z4vJKSUIuMtd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="-sec-ix-redline: true">Stock-based compensation</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">6,110,942</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">718,425</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_40E_ecustom--DeferredTaxAssetsFixedAssets_iI_maDTAGzJ64_z9o5LRtyj6Wf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="-sec-ix-redline: true">Fixed assets</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">33,834</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1228">&#8212;</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsOther_iI_maDTAGzJ64_zRoN4unq5yVf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt"><span style="-sec-ix-redline: true">Other</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">30,823</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1231">&#8212;</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_40E_ecustom--DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures_iI_maDTAGzJ64_zzXlwd8COPvd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="-sec-ix-redline: true">Capitalized research and development expenditures</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">2,944,801</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">2,589,105</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTAGzJ64_zTLvRLdgkjH8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="-sec-ix-redline: true">Research and development credits</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true">234,478</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true">317,455</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzJ64_maDTANz2Fd_zCuir0pCfzL2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt"><span style="-sec-ix-redline: true">Total deferred tax assets</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">16,610,885</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">7,549,750</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANz2Fd_zxaKCulwpvQ7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="-sec-ix-redline: true">Valuation allowance</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true">(16,551,169</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">)</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true">(7,426,952</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">)</span></td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANz2Fd_maDTALNz6fV_zBQC16G4WuN8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="-sec-ix-redline: true">Deferred tax assets</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true">59,716</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true">122,798</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_zwH9JPsFaUL4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Deferred tax liabilities:</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_40C_ecustom--DeferredTaxLiabilitiesRightOfUseAsset_iNI_di_maDITLzmly_zrkAHcCoXP54" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="-sec-ix-redline: true">Right of use asset</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true">(59,716</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">)</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true">(122,798</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">)</span></td></tr>
  <tr id="xdx_407_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_di_mtDITLzmly_msDTALNz6fV_zHWdAIwKT5s5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="-sec-ix-redline: true">Total deferred tax liabilities</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true">(59,716</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">)</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true">(122,798</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">)</span></td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNz6fV_zsuFt7LrE58b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"><span style="-sec-ix-redline: true">Net deferred tax assets</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1257">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1258">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  </table>

<p id="xdx_8AC_zlBeaG0lqf3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company continually evaluates the likelihood of the realization of deferred tax assets and adjusts the carrying amount of the deferred
tax assets by the valuation allowance to the extent the future realization of the deferred tax assets is more likely than not. The Company
considers many factors when assessing the likelihood of future realization of its deferred tax assets, including its recent cumulative
earnings experience by taxing jurisdiction, expectation of future taxable income or loss, the carryforward periods available to the Company
for tax reporting purposes, and other relevant factors.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, based on the Company&#8217;s history of earnings and its assessment of future earnings, management believes that
it is more likely than not that future taxable income will not be sufficient to realize the deferred tax assets. Therefore, a valuation
allowance has been applied to deferred tax assets.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the year ended December 31, 2024, the Company has federal and state net operating loss carryforwards of approximately $<span id="xdx_905_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn5n6_c20241231_zcC2rR17KDnk" title="Federal  net operating loss carryforwards">25.6
</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and $<span id="xdx_90A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pn5n6_c20241231_zjbEu68R0teg" title="State net operating loss carryforwards">27.8
</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, respectively.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal
net operating loss (&#8220;NOL&#8221;) carryforwards in the amount of $<span id="xdx_902_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn5n6_c20241231_zSWtVs0fo31a" title="Federal  net operating loss carryforwards">25.6
</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million have an indefinite life. Federal
NOL carryforwards generated after tax year 2017 are subject to an <span id="xdx_907_ecustom--TaxableIncomeLimitationPercentage_dp_uPure_c20240101__20241231_zK3J71d5c3v2" title="Limitation percentage">80</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
limitation on taxable income, do not expire and will carryforward indefinitely.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
net operating loss carryforwards in the amount of $<span id="xdx_90B_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pn5n6_c20241231_zqE47Zt8h4jl" title="State net operating loss carryforwards">27.8
</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million begin expiring in 2040.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
utilization of the Company&#8217;s net operating losses may be subject to a U.S. federal limitation due to the &#8220;change in ownership
provisions&#8221; under Section 382 of the Internal Revenue Code and other similar limitations in various state jurisdictions. Such limitations
may result in a reduction of the amount of net operating loss carryforwards in future years and possibly the expiration of certain net
operating loss carryforwards before their utilization.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business,
the Company is subject to examinations by federal, state and local jurisdictions, where applicable. There are currently no pending tax
examinations. The Company&#8217;s tax years are still open under statute from 2021 to the present in the United States. To the extent
the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination
by the Internal Revenue Service and state and local tax authorities to the extent utilized in a future period.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
required by the uncertain tax position guidance in ASC No. 740, Income Tax, the Company recognizes the financial statement benefit of
a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit.
For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit
that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company applied
the uncertain tax position guidance in ASC No. 740 to all tax positions for which the statute of limitations remained open. Any estimates
of tax contingencies contain assumptions and judgments about potential actions by taxing jurisdictions. Any interest and penalties related
to uncertain tax positions would be included as part of the income tax provision.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-redline: true"><b>TEVOGEN BIO HOLDINGS
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-redline: true"><b>NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>


<p id="xdx_89A_ecustom--ScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock_zWnNsTHpLs3g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of changes in the valuation allowance for net deferred tax assets during the year ended December 31, 2024 and 2023 were as follows:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zf0aPlttrYT4" style="display: none">SCHEDULE
OF VALUATION ALLOWANCE FOR NET DEFERRED TAX ASSETS</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" id="xdx_490_20240101__20241231_z9U4XQUAmYQd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" id="xdx_499_20230101__20231231_zSNRXftI7Xx" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">Year Ended December 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsValuationAllowance_iS_zdHNImCfERul" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="-sec-ix-redline: true">Valuation allowance</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="width: 16%; text-align: right"><span style="-sec-ix-redline: true">7,426,952</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="width: 16%; text-align: right"><span style="-sec-ix-redline: true">4,175,241</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_402_ecustom--IncreasesRecordedToIncomeTaxProvision_zSpem9g5uypc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="-sec-ix-redline: true">Increases recorded to income tax provision</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true">9,124,217</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true">3,251,711</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsValuationAllowance_iE_z3yEnVjWbsEh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">Valuation allowance</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-redline: true">16,551,169</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-redline: true">7,426,952</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  </table>

<p id="xdx_8AC_zp0wzhbf7Lr4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company applies the authoritative guidance on accounting for and disclosure of uncertainty in tax positions, which requires the Company
to determine whether a tax position of the Company is more likely than not to be sustained upon examination, including resolution of
any related appeals of litigation processes, based on the technical merits of the position. For tax positions meeting the more likely
than not threshold, the tax amount recognized in the consolidated financial statements is reduced by the largest benefit that has a greater
than 50% likelihood of being realized upon the ultimate settlement with the relevant taxing authority. There were no material uncertain
tax positions as of December 31, 2024.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes interest and penalties related to uncertain tax positions in income tax expense when in a taxable income position.
As of December 31, 2024, the Company had <span id="xdx_90F_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestAccrued_iI_do_c20241231_zBNPAu47Q8Q6" title="Income tax penalties and interest accrued">no
</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">accrued interest or penalties related
to uncertain tax positions and no amounts have been recognized in the Company&#8217;s statements of operations and comprehensive loss.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zrerlloKSUG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
15. <span id="xdx_826_zuwxRamozzMf">RELATED PARTY TRANSACTIONS</span></b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Transactions
with Sponsor</i></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Merger Agreement, the Company incurred $<span id="xdx_90F_eus-gaap--SponsorFees_c20240101__20241231_zFnqLSQtv1d" title="Sponsor advisory service fee">2,000,000</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;in
fees to the Sponsor for advisory services (the &#8220;Sponsor Advisory Service Fee&#8221;). In connection with the Merger and thereafter,
the Company and Sponsor agreed that $<span id="xdx_906_ecustom--SponsorFeesPayable_iI_c20241231_ztCWpzk26Dm6" title="Sponsor advisory services fee payable">250,000</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;of
the Sponsor Advisory Service Fee is payable in cash, $<span id="xdx_900_eus-gaap--OtherLiabilities_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zLCUmLigY3f7" title="Sponsor fee payable offset">250,000</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;would
be offset against amounts due from the Sponsor, and the remainder of the Sponsor Advisory Service Fee was paid with the issuance of&#160;<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--SponsorAdvisoryServicesFeeMember_zCMhICFCUQWh" title="Number of shares issued for sponsor fees">150,000</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;shares
of the Company&#8217;s common stock at Closing. The Sponsor Advisory Service Fee payable in cash is presented on the consolidated balance
sheets under the line item &#8220;Due to related party.&#8221;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the Sponsor owes the Company $<span id="xdx_906_eus-gaap--OtherReceivables_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zjPvxlc8Yh34" title="Due from related party">158,819</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;to
cover working capital expenses, which is presented on the consolidated balance sheets under the line item &#8220;Due from related party.&#8221;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 12 for additional information on the Series B issued to the Sponsor.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock-Based
Compensation</i></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2023, the Company issued&#160;<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20230131__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember__srt--TitleOfIndividualAxis__custom--WifeOfChiefExecutiveOfficerMember_zydIjts291zk" title="Isssued shares to related party">40,000</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Performance-Based
RSUs to the wife of the Company&#8217;s chair and chief executive officer for advisory services provided to the Company, and&#160;<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20230131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MehtaphoricConsultingIncMember_zQFiNPfzRHKj" title="Shares issued to related party">20,000</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Performance-Based
RSUs to Mehtaphoric Consulting Inc, a company controlled by the daughter of the Company&#8217;s chief financial officer, for information
technology services provided to the Company. In connection with the Closing, the performance condition was achieved and therefore compensation
cost of $<span id="xdx_904_eus-gaap--EmployeeStockOwnershipPlanESOPCompensationExpense_c20240101__20241231_zZgPukrSpgSj" title="Compensation cost recognized">800,396</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;has
been recognized.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Loan
Agreement</i></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 8 for additional information on the Loan Agreement with the Patel Family, which provides for an unsecured line of credit facility
for term loans of up to an initial amount of $<span id="xdx_906_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_z17ANZk39xOl" title="Line of credit maximum borrowing capacity">36,000,000
</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in the aggregate. As of December 31, 2024,
the facility has remaining available capacity of $<span id="xdx_905_eus-gaap--LineOfCreditFacilityRemainingBorrowingCapacity_iI_c20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zqzsSLMY6ME8" title="Line of credit remaining borrowing capacity">30,000,000</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Preferred
Stock</i></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 12 for additional information on the Series A, Series A-1, and Series C Preferred Stock, which were purchased by the Patel Family.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-redline: true"><b>TEVOGEN BIO HOLDINGS
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-redline: true"><b>NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Consulting
Agreement</i></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2024, the Company contracted with Dr. Manmohan Patel of The Patel Family LLP to provide advisory services to the Company in
support of the Company&#8217;s manufacturing development, including but not limited to identifying and developing real estate, establishing
quality management processes, attracting and hiring an executive to lead operations, providing medical advice, and addressing government
affairs and regulatory matters. In exchange for his consultation services, Dr. Patel was granted <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrManmohanPatelMember_zhI5kz6Iu5r4" title="Granted, shares">6,000,000
</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RSUs, of which <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrManmohanPatelMember_zZbyZm2qdgt3" title="Vested shares">2,000,000
</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">immediately vested, and <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20250131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrManmohanPatelMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zXrgChRsVMTb" title="Vested shares"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20250228__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrManmohanPatelMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zBB0HEnVRZH4">2,000,000</span>
</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RSUs vested in both January 2025 and February
2025.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT REPORTING</a></td>
<td class="text"><p id="xdx_805_eus-gaap--SegmentReportingDisclosureTextBlock_zjViOtEdXFwc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
16. <span id="xdx_824_zz8eWF3pcbLk">SEGMENT REPORTING</span></b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates in one operating segment, and therefore one reportable segment, and is focused on the global discovery, development
and commercialization of proprietary therapeutics. The Company&#8217;s business activities are managed on a consolidated basis through
the development and potential commercialization of pharmaceutical products, which are aimed at the global market in the event that products
are successful in receiving regulatory approvals. Our determination that we operate as a single operating segment is consistent with
the financial information regularly reviewed by the chief operating decision maker for purposes of evaluating performance, allocating
resources, setting incentive compensation targets, and planning and forecasting for future periods. Our chief operating decision maker
is the Chief Executive Officer.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accounting policies for our single operating segment are the same as those described in the summary of significant accounting policies.
Our single operating segment incurs expenses from the development of TVGN 489, which is developed by our research and development department,
designed to target various disease indications. The Company has not yet generated revenue in its operating history.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the segment, the chief operating decision maker uses net loss, which is reported on the consolidated statements of operations as consolidated
net income (loss), to allocate resources (including employees, property, and financial resources), predominantly during the annual budget
and forecasting process. The chief operating decision maker also uses consolidated net loss, along with non-financial inputs and qualitative
information, to evaluate our performance, establish compensation, monitor budget versus actual results, and decide the level of investment
in our various research activities. The measure of segment assets is reported on the consolidated balance sheet as total consolidated
assets.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p id="xdx_800_eus-gaap--SubsequentEventsTextBlock_zcq2drwDeQt5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
17. <span id="xdx_823_zySUOK5HYSp2">SUBSEQUENT EVENTS</span></b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated subsequent events and transactions for potential recognition or disclosure from the balance sheet date through
April 2, 2025, the issuance date of these the consolidated financial statements, and has not identified any additional items requiring
disclosure except as noted below.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2025, the Company executed an agreement with KRHP to receive a grant for $<span id="xdx_90C_eus-gaap--OtherReceivablesNetCurrent_iI_c20250131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KRHPLLCMember_zotOYpqGdIo8" title="Grant">2,000,000</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
KRHP is affiliated with the Patel Family. The grant is specified for use toward the Company&#8217;s ongoing operational expenses, may
not be used for repayment of existing debt obligations, and does not include any requirement to repay the investor or to issue equity
in response. Cash payment was received by the Company in January 2025.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2025, the Company executed a draw on the Loan Agreement for an additional $<span id="xdx_907_eus-gaap--LineOfCredit_iI_c20250228__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zajpY7rBcYEg" title="Line of credit Facility additional">1,000,000
</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to be utilized for operational expenses.
An additional draw of $<span id="xdx_909_eus-gaap--LineOfCredit_iI_c20250331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zYH65LGJr0Ak" title="Line of credit Facility additional">1,000,000
</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">was completed in March 2025. As of the
date of filing, the facility has a remaining capacity of $<span id="xdx_90B_eus-gaap--LineOfCreditFacilityRemainingBorrowingCapacity_iI_c20250402__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zTexk7tGogP7" title="Line of credit Facility remaining capacity">26,000,000
</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and remains effective for the next 26
months.</span></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zEjozw92zT9b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_869_z6zGIDk7hIo2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
of Presentation</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (&#8220;GAAP&#8221;).
Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;)
and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--UseOfEstimates_zh4v7xeUIyE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_86C_z9OsFUUKNFM7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use
of Estimates</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preparing the consolidated financial statements in conformity with GAAP, management is required to make estimates and assumptions that
affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts of
expenses. Actual results could differ from those estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions
are reflected in the consolidated financial statements in the period they are determined to be necessary.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
areas that require management&#8217;s estimates include the fair value of the common stock and convertible promissory notes prior to
the Merger, the fair value of the Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock, fair value of the
purchase options under the Loan Agreement, stock-based compensation assumptions, and accrued research and development expenses.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_FreestandingAndEmbeddedCommonStockOptionsPolicyTextBlock', window );">Freestanding and Embedded Common Stock Purchase Options</a></td>
<td class="text"><p id="xdx_84C_ecustom--FreestandingAndEmbeddedCommonStockOptionsPolicyTextBlock_zU1Yg00Ynoqa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_86B_zjZOTYXrYvW1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Freestanding
and Embedded Common Stock Purchase Options</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity-linked
purchase options issued in connection with the Company&#8217;s debt agreements are assessed to determine whether they are freestanding
or embedded with the host instrument under ASC 815,&#160;<i>Derivatives and Hedging Contracts in Entity&#8217;s Own Equity&#160;</i>(&#8220;ASC
815&#8221;). Each type of purchase option is then assessed for equity or liability classification under ASC 815. The Company&#8217;s
embedded and freestanding purchase options were determined to be liability-classified derivative instruments and are measured at fair
value both on the date of issuance and at each subsequent balance sheet date, with changes in fair value recorded to &#8216;Change in
fair value of written call option derivative liabilities&#8217; within the consolidated statements of operations and consolidated statements
of cash flows.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_zaVX69hJqaGj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_860_zBYIf29m4TMl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Concentrations
of Credit Risk</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash. The Company
maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced
any losses in such accounts and believes it is not exposed to significant risk on its cash.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zGavjTbsGjld" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_86B_zqy1DxfGgale" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Segment
Reporting</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are defined as components of an entity for which discrete financial information is both available and regularly reviewed by
its chief operating decision maker or decision-making group. The Company views its operations and manages its business in <span id="xdx_905_eus-gaap--NumberOfOperatingSegments_pid_dc_uSegment_c20240101__20241231_zQCkR43qaf21" title="Number of operating segments">one
</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">segment.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-redline: true"><b>TEVOGEN BIO HOLDINGS
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-redline: true"><b>NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Warrants</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--DerivativesPolicyTextBlock_zD1xmE1CP1Z1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span id="xdx_860_zTyoPxhDqOEb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the result of the Merger, the Company accounts for its warrants originally sold as part of Semper Paratus&#8217;s initial public offering
(the &#8220;IPO&#8221;) in accordance with ASC 815, <i>Derivatives and Hedging Contracts in Entity&#8217;s Own Equity </i>(&#8220;ASC
815&#8221;) and ASC 480,&#160;<i>Distinguishing Liabilities from Equity</i>&#160;(&#8220;ASC 480&#8221;). The assessment considers whether
the warrants are freestanding financial instruments and meet the definition of a liability pursuant to ASC 480 and meet all of the conditions
for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s own shares of common stock,
among other conditions. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance
and as of each subsequent quarterly period end date while the warrants are outstanding. For issued or modified warrants that meet all
of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the
time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required
to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter until settlement. Changes
in the estimated fair value of the warrants are recognized as a non-cash loss on the consolidated statements of operations. Under these
standards, the Company&#8217;s private placement warrants sold at the time of the IPO do not meet the criteria for equity classification
and must be recorded as liabilities while the public warrants sold in connection with the IPO do meet the criteria for equity classification
and must be recorded as equity.&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p id="xdx_840_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zrhlYragtHG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_867_zPsHFdIWiME8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair
Value Measurements</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
assets and liabilities are carried at fair value under GAAP. Fair value is defined as the price that would be received for an asset or
paid to transfer a liability (exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction
between market participants on the measurement date. The Company utilizes valuation techniques that maximize the use of observable inputs
and minimize the use of unobservable inputs to the extent possible. When considering market participant assumptions in fair value measurements,
the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following
levels:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 0.5in; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unadjusted
    quoted prices in active markets for identical assets or liabilities;</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Observable
    inputs other than Level 1 prices, such as quoted prices for similar, but not identical, assets or liabilities in active markets;
    quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable
    or can be corroborated by observable market data;</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unobservable
    inputs in which there is little or no market data available and which require the Company to develop its own assumptions that market
    participants would use in pricing an asset or liability.</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments recognized at historical amounts in the balance sheets consist of accounts payable and notes payable. The Company believes
that the carrying value of accounts payable and notes payable approximates their fair values due to the short-term nature of these instruments.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s recurring fair value measurements consist of the convertible promissory notes prior to the Merger, for which the Company
elected the fair value option to reduce accounting complexity, and private warrants after the Merger. Such fair value measurements are
Level 3 inputs. The following table provides a roll-forward of the aggregate fair values of the Company&#8217;s convertible promissory
notes.</span></span></p>

<p id="xdx_89D_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zvQIcfKfBw7b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_8B4_zLwMSvweVTPg" style="display: none">SCHEDULE
OF FAIR VALUE MEASUREMENT</span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; font-weight: bold"><span style="-sec-ix-redline: true">Balance at January 1, 2023</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zmPdTyoWTo8e" style="width: 16%; text-align: right" title="Fair value beginning balance"><span style="-sec-ix-redline: true">39,297,000</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="-sec-ix-redline: true">Initial fair value at issuance</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zn2RHV15r6Be" style="text-align: right" title="Initial fair value at issuance"><span style="-sec-ix-redline: true">4,000,000</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="-sec-ix-redline: true">Accrued interest expense</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_98C_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zPFQwSUZCOQj" style="text-align: right" title="Accrued interest expense"><span style="-sec-ix-redline: true">1,206,697</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="-sec-ix-redline: true">Change in fair value</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zNzncNEjVShd" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"><span style="-sec-ix-redline: true">50,428,303</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold"><span style="-sec-ix-redline: true">Balance at December 31, 2023</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z4rCEr5QVgp4" style="text-align: right" title="Fair value beginning balance"><span style="-sec-ix-redline: true">94,932,000</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="-sec-ix-redline: true">Accrued interest expense</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_98A_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zt6aGeiPKPWa" style="text-align: right" title="Accrued interest expense"><span style="-sec-ix-redline: true">159,305</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="-sec-ix-redline: true">Change in fair value</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zyjBGFf91vbi" style="text-align: right" title="Change in fair value"><span style="-sec-ix-redline: true">(48,468,678</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="-sec-ix-redline: true">Derecognition upon conversion of convertible promissory
    notes</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_988_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5YwVfhmAdXj" style="border-bottom: Black 1pt solid; text-align: right" title="Derecognition upon conversion of convertible promissory notes"><span style="-sec-ix-redline: true">(46,622,627</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">Balance at December 31, 2024</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2ME1DbWt72e" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value beginning balance"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0630">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  </table>

<p id="xdx_8A4_zqcgjNCAyIG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-redline: true"><b>TEVOGEN BIO HOLDINGS
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-redline: true"><b>NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no transfers between levels during the years ended December 31, 2024 and 2023.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company used the probability weighted expected return method valuation methodology to determine the fair value of the convertible promissory
notes prior to the Merger. Significant assumptions and ranges used in determining the fair value of convertible promissory notes prior
to the Merger include volatility (<span id="xdx_903_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zF3lzBx4NxE3" title="Volatility">80</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%),
discount rate (<span id="xdx_90D_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember__srt--RangeAxis__srt--MinimumMember_zI7cdoSRgYZf" title="Volatility">35</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
- <span id="xdx_90C_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember__srt--RangeAxis__srt--MaximumMember_z3CE1sVwC9l8" title="Volatility">36</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%),
and probability of a future liquidity event (<span id="xdx_90F_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__custom--ProbabilityOfFutureLiquidityMember__srt--RangeAxis__srt--MinimumMember_zWLtQzBOBiyb" title="Volatility">85</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
- <span id="xdx_906_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__custom--ProbabilityOfFutureLiquidityMember__srt--RangeAxis__srt--MaximumMember_ztX9pqLKBk9j" title="Volatility">95</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%).
The Company used its stock price on the Closing Date to determine the fair value for the derecognition of the convertible promissory
notes upon conversion on the Closing Date.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the Closing, the Company acquired private warrants, the fair value of which increased by $<span id="xdx_900_eus-gaap--FairValueAdjustmentOfWarrants_iN_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCyhs8Yly2tg" title="Fair value adjustment of warrants">58,180</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;between
the Closing Date and December 31, 2024 primarily due to changes in the market value of the Company&#8217;s common shares. In June 2024,
the Company issued written call options in connection with the Loan Agreement, the fair value of which decreased by $<span id="xdx_903_eus-gaap--FairValueAdjustmentOfWarrants_iN_di_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zK0pZpXRMYP3" title="Fair value adjustment of warrants">375,000</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;between
the issuance and December 31, 2024. Such fair value measurements are Level 3 inputs. The following table provides a roll-forward of the
aggregate fair values of the warrants and the written call option derivative liabilities.</span></span></p>

<p id="xdx_89E_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zVFlWWOtgvBk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_8BC_zKxxJeSEy77b" style="display: none">SCHEDULE
OF FAIR VALUES OF WARRANTS</span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Derivative</b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>warrant
                                            liabilities</b></span></span></p></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Written
                                            call option</b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>derivative
                                            liabilities</b></span></span></p></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold"><span style="-sec-ix-redline: true">Balance at February 15, 2024</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_98A_eus-gaap--DerivativeLiabilitiesNoncurrent_iS_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHBI9UhFXWzg" style="text-align: right" title="Derivative warrant liabilities, Balance"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0648">&#8212;</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_98B_eus-gaap--DerivativeLiabilitiesNoncurrent_iS_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zNojA057WR65" style="text-align: right" title="Derivative warrant liabilities, Balance"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0650">&#8212;</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-left: 10pt"><span style="-sec-ix-redline: true">Initial fair value at issuance</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_983_ecustom--DerivativeLiabilitiesFairValueIssuance_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziWiAcw0clR" style="width: 16%; text-align: right" title="Initial fair value at issuance"><span style="-sec-ix-redline: true">29,000</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_985_ecustom--DerivativeLiabilitiesFairValueIssuance_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zh8O4BbAP9Vc" style="width: 16%; text-align: right" title="Initial fair value at issuance"><span style="-sec-ix-redline: true">375,000</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="-sec-ix-redline: true">Change in fair value</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_986_eus-gaap--FairValueAdjustmentOfWarrants_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQUdk6IQWDg1" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"><span style="-sec-ix-redline: true">58,180</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_986_eus-gaap--FairValueAdjustmentOfWarrants_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zhTcXjj4WLil" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"><span style="-sec-ix-redline: true">(375,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">Balance at December 31, 2024</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_984_eus-gaap--DerivativeLiabilitiesNoncurrent_iE_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeYQcoChW2m" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrant liabilities, Balance"><span style="-sec-ix-redline: true">87,180</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_989_eus-gaap--DerivativeLiabilitiesNoncurrent_iE_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zfSJPgabLkfk" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrant liabilities, Balance"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0662">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  </table>

<p id="xdx_8AA_zoiLz4vJKfVi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p id="xdx_895_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zUKPgDAmlig6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information about the Company&#8217;s liabilities that are measured at fair value on a recurring basis at December
31, 2024, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_8B2_zMdNzDoPK375" style="display: none">SCHEDULE
OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS</span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span style="-sec-ix-redline: true">&#160;</span></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">Level</span></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">Quoted Prices
    in <br/> Active Markets <br/> (Level 1)</span></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">Significant
    Other <br/> Observable Inputs <br/> (Level 2)</span></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">Significant
    Other <br/> Unobservable <br/> Inputs (Level 3)</span></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">Liabilities:</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 44%; text-align: left"><span style="-sec-ix-redline: true">Derivative warrant liabilities</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="width: 10%; text-align: right"><span style="-sec-ix-redline: true">3</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_98F_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zTFE3aAAK2o2" style="width: 10%; text-align: right" title="Derivative warrant liabilities"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0666">&#8212;</span></span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_984_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zI5XpHzeno74" style="width: 10%; text-align: right" title="Derivative warrant liabilities"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0668">&#8212;</span></span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_98A_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zT3vY3M4tuw6" style="width: 10%; text-align: right" title="Derivative warrant liabilities"><span style="-sec-ix-redline: true">87,180</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  </table>

<p id="xdx_8A8_zfdgPue2UFzb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s nonrecurring fair value measurements consist of Series A Preferred Stock. Such fair value measurements are Level 3 inputs.
The Company determined the fair value of Series A Preferred Stock using a Monte Carlo Simulation (&#8220;MCS&#8221;). Key inputs utilized
in the MCS to estimate fair value of Series A Preferred Stock included a range of volatility between&#160;<span id="xdx_90E_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zBQCgsFYWXy" title="Stock, measurement input">75</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
to&#160;<span id="xdx_90B_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zY07bkVh1tTi">85</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%,
a holding period to a deemed liquidation event, as defined in the Series A Preferred Stock agreement, ranging from&#160;<span id="xdx_900_ecustom--EquitySecuritiesTerm_dtY_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--RangeAxis__srt--MinimumMember_zJ7WOdTcTrch" title="Holding period">0.5</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;to&#160;<span id="xdx_900_ecustom--EquitySecuritiesTerm_dtY_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--RangeAxis__srt--MaximumMember_zx3jOtbTc9Kk" title="Range in years">10.0</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;years,
and a risk-free interest rate between&#160;<span id="xdx_90D_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zIZeBBxGPA83" title="Risk-free interest rate percentage">4.3</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
and&#160;<span id="xdx_90B_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zBXxOkIGk7N7" title="Stock, measurement input">5.3</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%.
The difference between the cash received of $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zgMvkcSAG6bc" title="Cash received upon issuance of preferred stock">2,000,000</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;upon
issuance of the Series A Preferred Stock and its estimated fair value was recognized as general and administrative expense on the consolidated
statements of operations during the three months ended March 31, 2024.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company used a MCS valuation methodology to determine the fair value of the freestanding $<span id="xdx_905_ecustom--FreeStandingPurchaseOptions_c20240101__20241231_zMcIwfI14nab" title="Free standing purchase options">14,000,000</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;purchase
option and remaining embedded $<span id="xdx_90A_ecustom--EmbeddedOptions_c20240101__20241231_zJt3WvksQt6c" title="Embedded options shares">30,000,000</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;purchase
option associated with the Loan Agreement as of December 31, 2024. The MCS methodology simulates the Company&#8217;s future stock price
to estimate if and when the Trailing VWAP (as defined below) will reach $<span id="xdx_90A_eus-gaap--SharePrice_iI_uUSDPShares_c20241231_zDGajU2DphH" title="Share price">10.00</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;per
share, and discounts the resulting payoff back to each valuation date using a present value factor. Significant assumptions used in determining
the fair value of these options include volatility of&#160;<span id="xdx_905_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zO4ZtR8xaGD7">78.3</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
and discount rate of&#160;<span id="xdx_900_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember_zA5hPt9cSmoa" title="Discount rate">4.3</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%.
At December 31, 2024, the MCS produced a fair value of $<span id="xdx_901_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20241231_zCSBpPO94ljd" title="Fair value">0
</span></span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">relating to these freestanding and embedded
options.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-redline: true"><b>TEVOGEN BIO HOLDINGS
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-redline: true"><b>NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash</a></td>
<td class="text"><p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zDD1mMrYTiic" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_863_zfPQfeKGxXZ1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid financial instruments with a maturity date of 90 days or less when purchased to be cash equivalents.
There were <span id="xdx_900_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_do_c20241231_zjoGF4P7HdTl" title="Cash equivalents"><span id="xdx_902_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_do_c20231231_zSAdcokKBeoe" title="Cash equivalents">no</span></span></span></span> <span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cash
equivalents as of December 31, 2024 and 2023 as all amounts consisted of bank deposits.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zdqI5jkunLD6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_864_zoqVO2hfbssd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Property
and Equipment, Net</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<p id="xdx_893_ecustom--PropertyAndEquipmentUsefulLifeTableTextBlock_zHN0wr1ikGj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment is recorded at cost. Depreciation and amortization is provided using straight-line methods over their respective estimated
useful lives. Repairs and maintenance, which do not extend the useful lives of the related assets, are expensed as incurred.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_8B5_zJYD2SpYrHLa" style="display: none">SCHEDULE
OF PROPERTY AND EQUIPMENT USEFUL LIFE</span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"><span style="-sec-ix-redline: true">Estimated Useful Lives</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">Years</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 83%; text-align: justify"><span style="-sec-ix-redline: true">Computer software</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 14%; text-align: center"><span style="-sec-ix-redline: true"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zYycrtiHNlDj" title="Property, plant and equipment, useful life">5</span></span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="-sec-ix-redline: true">Leasehold improvements</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: center"><span style="-sec-ix-redline: true"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_zDnZQPBSz9v3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="Property, plant and equipment, useful life">3</span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zLHnEO71cT9d" title="Property, plant and equipment, useful life">4</span></span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-sec-ix-redline: true">Office equipment</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: center"><span style="-sec-ix-redline: true"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zSUqkMCooCEj" title="Property, plant and equipment, useful life">5</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="-sec-ix-redline: true">Furniture and fixtures</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: center"><span style="-sec-ix-redline: true"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zSoNNhiJr9od" title="Property, plant and equipment, useful life">7</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  </table>

<p id="xdx_8A7_zl5Ugxi1eSE3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews the carrying value of property and equipment whenever events and circumstances indicate that the carrying value of an
asset may not be recoverable from the estimated future cash flows expected to result from its eventual use and disposition. Based on
this assessment, management has determined that there was no impairment during the years ended December 31, 2024 and 2023.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--LesseeLeasesPolicyTextBlock_zfKTy2QrYHCk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_862_z4mqZGMPTzPj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Leases</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines whether an arrangement is or contains a lease, its classification, and its term at the lease commencement date. Leases
with a term greater than one year will be recognized on the balance sheet as right-of-use (&#8220;ROU&#8221;) assets, current lease liabilities,
and if applicable, long-term lease liabilities. The Company includes renewal options to extend the lease term where it is reasonably
certain that it will exercise these options. Lease liabilities and the corresponding ROU assets are recorded based on the present values
of lease payments over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such,
the Company utilizes the appropriate incremental borrowing rates, which are the rates that would be incurred to borrow on a collateralized
basis, over similar terms, amounts equal to the lease payments in a similar economic environment. If significant events, changes in circumstances,
or other events indicate that the lease term or other inputs have changed, the Company would reassess lease classification, remeasure
the lease liability using revised inputs as of the reassessment date, and adjust the ROU assets. Lease expense is recognized on a straight-line
basis over the expected lease term for operating classified leases.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases
with an initial term of <span id="xdx_902_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dc_c20241231_zDnUbmG7pY6j" title="Leases initial term">12 months</span></span></span>
<span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">or less and without a purchase option that the Company is reasonably
certain of exercising are not included within the lease ROU assets and lease liabilities on the balance sheet.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_zIdxFuVgTZNh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_868_z51STCTlamK2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and Development Expenses</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development activities are expensed as incurred. Costs for clinical trials and manufacturing activities are recognized based on an
evaluation of our vendors&#8217; progress towards completion of specific tasks, using data such as participant enrollment, clinical site
activations, or information provided to us by vendors regarding their actual costs incurred. Payments for these activities are based
on the terms of individual contracts and payment timing may differ significantly from the period in which the services were performed.
The Company determines accrual estimates through reports from and discussions with applicable personnel and outside service providers
as to the progress or state of completion of studies, or the services completed. The Company estimates accrued expenses as of each balance
sheet date based on the facts and circumstances known at the time. Costs that are paid in advance of performance are deferred as a prepaid
expense and amortized over the service period as the services are provided.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-redline: true"><b>TEVOGEN BIO HOLDINGS
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-redline: true"><b>NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_840_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zlWE40LQEnBa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_867_zN8KNyRNRiS1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock-Based
Compensation</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation
cost is measured at the grant date fair value of the award and is recognized over the vesting period of the award. The Company uses the
straight-line method to record compensation expense of awards with service-based vesting conditions. The Company accounts for forfeitures
of awards as they occur rather than applying an estimated forfeiture rate to stock-based compensation expense. The Company recognizes
compensation expense for awards with performance conditions when it is probable that the condition will be met, and the award will vest.
Prior to the Merger, the Company estimated the fair value of the Company&#8217;s common stock on the date of grant in accordance with
the guidance outlined in the American Institute of Certified Public Accountants&#8217; <i>Accounting and Valuation Guide, Valuation of
Privately-Held-Company Equity Securities Issued as Compensation</i>.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zoWCJBw0vlYh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_866_zldsYnnmPWEb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Income
Taxes</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes using the asset and liability method in accordance with ASC Topic 740, <i>Income Taxes </i>(&#8220;ASC
740&#8221;), which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events
that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities
are determined on the basis of the differences between the financial statement and tax basis of assets and liabilities using enacted
tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are
recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future
taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all
or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense.
Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent
and feasible tax planning strategies. At December 31, 2024 and 2023, the Company has concluded that a full valuation allowance is necessary
for its net deferred tax assets.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--EarningsPerSharePolicyTextBlock_zPrUSe34nzZ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_869_znCeJn71YSG1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net
Loss Per Share</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company computes basic net loss per share by dividing net loss by the weighted-average common stock outstanding during the period. Given
the Company&#8217;s net loss, basic and diluted net loss per share for the years ended December 31, 2024 and 2023 are the same.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Standards</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zWIqaAo2igS8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_862_zOYer4WwVUw5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recently
Issued Accounting Standards</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, the FASB issued ASU No. 2020-06, <i>Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and
Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815 -40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s
Own Equity </i>(&#8220;ASU 2020-06&#8221;), which simplifies the accounting for convertible instruments by reducing the number of accounting
models available for convertible debt instruments. ASU 2020-06 also eliminates the treasury stock method to calculate diluted earnings
per share for convertible instruments and requires the use of the if-converted method. Effective January 1, 2024, the Company adopted
ASU 2020-06 and that adoption did not have an impact on its consolidated financial statements and related disclosures.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the FASB issued ASU No. 2023-07,&#160;<i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&#160;</i>(&#8220;ASU
2023-07&#8221;). ASU 2023-07 enhances reportable segment disclosures by requiring disclosures such as significant segment expenses. The
main provisions of this update require companies to disclose, on an annual and interim basis, significant segment expenses, segment profit
and loss, and other segments items that are regularly provided to the chief operating decision maker (&#8220;CODM&#8221;). This update
also requires companies to disclose the title and position of the CODM and to explain how the CODM uses the reported segment measures
in assessing segment performance and deciding how to allocate resources. The update also requires companies with a single reportable
segment to provide all required segment reporting disclosures. This new standard is effective for fiscal years beginning after December
15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company adopted this standard on January 1,
2024 for annual reporting and interim periods beginning in 2025. See Note 16 for additional disclosures.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-redline: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-redline: true"><b>TEVOGEN BIO HOLDINGS
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-redline: true"><b>NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU 2024-03, <i>Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures,
(Subtopic 220-40) </i>(&#8220;ASU 2024-03&#8221;). ASU 2024-03 improves disclosures regarding the types of expenses included in commonly
presented expense captions, including disaggregating the amounts of employee compensation, depreciation and amortization included within
each income statement expense caption. This standard is effective for fiscal years beginning after December 15, 2026, and interim periods
within fiscal years beginning after December 15, 2027. The Company is currently evaluating the impact of the standard on its consolidated
financial statements and disclosures.</span></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_FreestandingAndEmbeddedCommonStockOptionsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Freestanding And Embedded Common Stock Options [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_FreestandingAndEmbeddedCommonStockOptionsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">SCHEDULE OF FAIR VALUE MEASUREMENT</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zvQIcfKfBw7b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_8B4_zLwMSvweVTPg" style="display: none">SCHEDULE
OF FAIR VALUE MEASUREMENT</span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; font-weight: bold"><span style="-sec-ix-redline: true">Balance at January 1, 2023</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zmPdTyoWTo8e" style="width: 16%; text-align: right" title="Fair value beginning balance"><span style="-sec-ix-redline: true">39,297,000</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="-sec-ix-redline: true">Initial fair value at issuance</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zn2RHV15r6Be" style="text-align: right" title="Initial fair value at issuance"><span style="-sec-ix-redline: true">4,000,000</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="-sec-ix-redline: true">Accrued interest expense</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_98C_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zPFQwSUZCOQj" style="text-align: right" title="Accrued interest expense"><span style="-sec-ix-redline: true">1,206,697</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="-sec-ix-redline: true">Change in fair value</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zNzncNEjVShd" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"><span style="-sec-ix-redline: true">50,428,303</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold"><span style="-sec-ix-redline: true">Balance at December 31, 2023</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z4rCEr5QVgp4" style="text-align: right" title="Fair value beginning balance"><span style="-sec-ix-redline: true">94,932,000</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="-sec-ix-redline: true">Accrued interest expense</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_98A_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zt6aGeiPKPWa" style="text-align: right" title="Accrued interest expense"><span style="-sec-ix-redline: true">159,305</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="-sec-ix-redline: true">Change in fair value</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zyjBGFf91vbi" style="text-align: right" title="Change in fair value"><span style="-sec-ix-redline: true">(48,468,678</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="-sec-ix-redline: true">Derecognition upon conversion of convertible promissory
    notes</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_988_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5YwVfhmAdXj" style="border-bottom: Black 1pt solid; text-align: right" title="Derecognition upon conversion of convertible promissory notes"><span style="-sec-ix-redline: true">(46,622,627</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">Balance at December 31, 2024</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2ME1DbWt72e" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value beginning balance"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0630">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">SCHEDULE OF FAIR VALUES OF WARRANTS</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zVFlWWOtgvBk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_8BC_zKxxJeSEy77b" style="display: none">SCHEDULE
OF FAIR VALUES OF WARRANTS</span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Derivative</b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>warrant
                                            liabilities</b></span></span></p></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Written
                                            call option</b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>derivative
                                            liabilities</b></span></span></p></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold"><span style="-sec-ix-redline: true">Balance at February 15, 2024</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_98A_eus-gaap--DerivativeLiabilitiesNoncurrent_iS_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHBI9UhFXWzg" style="text-align: right" title="Derivative warrant liabilities, Balance"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0648">&#8212;</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_98B_eus-gaap--DerivativeLiabilitiesNoncurrent_iS_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zNojA057WR65" style="text-align: right" title="Derivative warrant liabilities, Balance"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0650">&#8212;</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-left: 10pt"><span style="-sec-ix-redline: true">Initial fair value at issuance</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_983_ecustom--DerivativeLiabilitiesFairValueIssuance_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziWiAcw0clR" style="width: 16%; text-align: right" title="Initial fair value at issuance"><span style="-sec-ix-redline: true">29,000</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_985_ecustom--DerivativeLiabilitiesFairValueIssuance_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zh8O4BbAP9Vc" style="width: 16%; text-align: right" title="Initial fair value at issuance"><span style="-sec-ix-redline: true">375,000</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="-sec-ix-redline: true">Change in fair value</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_986_eus-gaap--FairValueAdjustmentOfWarrants_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQUdk6IQWDg1" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"><span style="-sec-ix-redline: true">58,180</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_986_eus-gaap--FairValueAdjustmentOfWarrants_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zhTcXjj4WLil" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"><span style="-sec-ix-redline: true">(375,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">Balance at December 31, 2024</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_984_eus-gaap--DerivativeLiabilitiesNoncurrent_iE_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeYQcoChW2m" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrant liabilities, Balance"><span style="-sec-ix-redline: true">87,180</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_989_eus-gaap--DerivativeLiabilitiesNoncurrent_iE_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zfSJPgabLkfk" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrant liabilities, Balance"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0662">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zUKPgDAmlig6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information about the Company&#8217;s liabilities that are measured at fair value on a recurring basis at December
31, 2024, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_8B2_zMdNzDoPK375" style="display: none">SCHEDULE
OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS</span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span style="-sec-ix-redline: true">&#160;</span></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">Level</span></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">Quoted Prices
    in <br/> Active Markets <br/> (Level 1)</span></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">Significant
    Other <br/> Observable Inputs <br/> (Level 2)</span></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">Significant
    Other <br/> Unobservable <br/> Inputs (Level 3)</span></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">Liabilities:</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 44%; text-align: left"><span style="-sec-ix-redline: true">Derivative warrant liabilities</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="width: 10%; text-align: right"><span style="-sec-ix-redline: true">3</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_98F_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zTFE3aAAK2o2" style="width: 10%; text-align: right" title="Derivative warrant liabilities"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0666">&#8212;</span></span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_984_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zI5XpHzeno74" style="width: 10%; text-align: right" title="Derivative warrant liabilities"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0668">&#8212;</span></span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_98A_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zT3vY3M4tuw6" style="width: 10%; text-align: right" title="Derivative warrant liabilities"><span style="-sec-ix-redline: true">87,180</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_PropertyAndEquipmentUsefulLifeTableTextBlock', window );">SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE</a></td>
<td class="text"><p id="xdx_893_ecustom--PropertyAndEquipmentUsefulLifeTableTextBlock_zHN0wr1ikGj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment is recorded at cost. Depreciation and amortization is provided using straight-line methods over their respective estimated
useful lives. Repairs and maintenance, which do not extend the useful lives of the related assets, are expensed as incurred.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_8B5_zJYD2SpYrHLa" style="display: none">SCHEDULE
OF PROPERTY AND EQUIPMENT USEFUL LIFE</span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"><span style="-sec-ix-redline: true">Estimated Useful Lives</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">Years</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 83%; text-align: justify"><span style="-sec-ix-redline: true">Computer software</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 14%; text-align: center"><span style="-sec-ix-redline: true"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zYycrtiHNlDj" title="Property, plant and equipment, useful life">5</span></span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="-sec-ix-redline: true">Leasehold improvements</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: center"><span style="-sec-ix-redline: true"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_zDnZQPBSz9v3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="Property, plant and equipment, useful life">3</span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zLHnEO71cT9d" title="Property, plant and equipment, useful life">4</span></span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-sec-ix-redline: true">Office equipment</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: center"><span style="-sec-ix-redline: true"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zSUqkMCooCEj" title="Property, plant and equipment, useful life">5</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="-sec-ix-redline: true">Furniture and fixtures</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: center"><span style="-sec-ix-redline: true"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zSoNNhiJr9od" title="Property, plant and equipment, useful life">7</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_PropertyAndEquipmentUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property And Equipment Useful Life [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_PropertyAndEquipmentUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS COMBINATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">SCHEDULE OF NET LIABILITIES ACQUIRED IN MERGER</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_zJzX1OzWkW2l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the net liabilities acquired in the Merger:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span id="xdx_8BF_zCTQj89vyov1" style="display: none">SCHEDULE OF NET LIABILITIES
ACQUIRED IN MERGER</span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" id="xdx_494_20240214_zbcnrScvqKR1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">February&#160;14,&#160;2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_maBCRIAzgn3_z9Io3A3mnHy3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%"><span style="-sec-ix-redline: true">Cash</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="width: 16%; text-align: right"><span style="-sec-ix-redline: true">229,328</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_iI_maBCRIAzgn3_z0mQ6Jgtmb0h" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Due from Sponsor</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">158,819</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_iI_maBCRIAzgn3_zl4ektKvznGj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Prepaid expenses and other assets</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">2,501</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iNI_di_msBCRIAzgn3_zQnadgn4rRHk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Accounts payable</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">(96,175</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">)</span></td></tr>
  <tr id="xdx_40D_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_iNI_di_msBCRIAzgn3_zY1HfC6433le" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Accrued expenses</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">(1,269,126</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">)</span></td></tr>
  <tr id="xdx_404_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_iNI_di_msBCRIAzgn3_zZRAK9OX6HM8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Notes payable</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">(1,651,000</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">)</span></td></tr>
  <tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_iNI_di_msBCRIAzgn3_zPRMCGucTFN8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="-sec-ix-redline: true">Derivative warrant liabilities</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true">(29,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">)</span></td></tr>
  <tr id="xdx_402_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iTI_mtBCRIAzgn3_maBCRIAzidu_ztgwK4PBMIHb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Total net liabilities acquired</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">(2,654,653</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">)</span></td></tr>
  <tr id="xdx_40D_ecustom--MergerTransactionCostsLimitedToCashAcquired_iI_maBCRIAzidu_z4zGz7PO8Sa4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="-sec-ix-redline: true">Plus: Merger transaction costs limited to cash acquired</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true">(229,328</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">)</span></td></tr>
  <tr id="xdx_40A_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts_iTI_mtBCRIAzidu_z3Z0rZNtOiEc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">Total net liabilities acquired plus transaction costs</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-redline: true">(2,883,981</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline: true">)</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">SCHEDULE OF PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p id="xdx_895_eus-gaap--PropertyPlantAndEquipmentTextBlock_zyTLeod1iAYg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment consists of the following:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_8B7_zL4gRjUr8gL8" style="display: none">SCHEDULE
OF PROPERTY AND EQUIPMENT</span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" id="xdx_496_20241231_z2fTAjjPcK87" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" id="xdx_493_20231231_zafoUtjWTt3c" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">December 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerAndSoftwareMember_zLcF9UHhLe03" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="-sec-ix-redline: true">Computer software</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="width: 16%; text-align: right"><span style="-sec-ix-redline: true">292,341</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="width: 16%; text-align: right"><span style="-sec-ix-redline: true">292,341</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zWEzRTWh31K3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Leasehold improvements</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">263,217</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">263,217</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zOA54W6JoE32" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Office equipment</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">132,468</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">132,468</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zAxeUorRM0F7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="-sec-ix-redline: true">Furniture and fixtures</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true">33,743</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true">33,743</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzFLE_z9CL68pLllfg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-sec-ix-redline: true"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, gross</span></span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">721,769</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">721,769</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzFLE_zDXDRLq09mIh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="-sec-ix-redline: true">Less: accumulated depreciation</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true">(425,327</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">)</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true">(263,118</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">)</span></td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzFLE_zd2iNvK6JHzf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total property and
    equipment, net</span></span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-redline: true">296,442</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-redline: true">458,651</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zRlUj4VqPk4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses and other liabilities consisted of the following:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_8BE_zB2Az3kYPDPi" style="display: none">SCHEDULE
OF ACCRUED EXPENSES AND OTHER LIABILITIES</span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td colspan="2" id="xdx_496_20241231_zjOO0oCsnLwg" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td colspan="2" id="xdx_49B_20231231_z9WXnm6jsJTl" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td colspan="6" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
    31,</b></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td></tr>
  <tr id="xdx_403_eus-gaap--AccruedProfessionalFeesCurrent_iI_maALCzC3I_zGgDsihN9oXg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 62%; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Professional
    services</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 16%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,309,163</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 16%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">976,301</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td></tr>
  <tr id="xdx_40E_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maALCzC3I_zrCYjFa3Avbi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">403,233</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">120,149</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td></tr>
  <tr id="xdx_408_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzC3I_zmG7bIjIJOo2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,712,396</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,096,450</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_ScheduleOfCompanyLeaseLiabilitiesTableTextBlock', window );">SCHEDULE OF MINIMUM RENTAL PAYMENTS UNDER THE OPERATING LEASES</a></td>
<td class="text"><p id="xdx_895_ecustom--ScheduleOfCompanyLeaseLiabilitiesTableTextBlock_z5Amd0mc7FH6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
aggregate minimum rental payments under the operating leases as of December 31, 2024 were as follows:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_8B5_z56qhGR4fHig" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF MINIMUM RENTAL PAYMENTS UNDER THE OPERATING LEASES</span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Years Ending December 31,</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" id="xdx_49D_20241231_ziRvYQE54ivl" style="text-align: right"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maOLLzALR_zmGsqaMQdUM" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left"><span style="-sec-ix-redline: true">2025</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="width: 16%; text-align: right"><span style="-sec-ix-redline: true">230,471</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maOLLzALR_zGr95ElDsClh" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">2026</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true">13,975</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtOLLzALR_zrMvbdd8G9Lh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Total</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">244,446</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zS0rZ8shQAB6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="-sec-ix-redline: true">Less: imputed interest</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true">(9,587</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">)</span></td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiability_iTI_zj9oIpfMdBmb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">Operating lease liability</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-redline: true">234,859</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_ScheduleOfCompanyLeaseLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Company Lease Liabilities [TableTextBlock]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_ScheduleOfCompanyLeaseLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">SCHEDULE OF RESTRICTED STOCK AND RSU ACTIVITY</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zg71PxSY1j3d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
Stock and RSU activity was as follows:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_8BB_zKiyxUa8Uqya" style="display: none">SCHEDULE
OF RESTRICTED STOCK AND RSU ACTIVITY</span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">Service-Based Restricted Stock and
    RSUs</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">Weighted average grant-date fair
    value</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-sec-ix-redline: true">Nonvested as of January 1, 2023</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zYkbcEwtskV6" style="text-align: right" title="Nonvested Shares, Beginning"><span style="-sec-ix-redline: true"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0938">-</span></span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zTw0SUr5swm" style="text-align: right" title="Nonvested weighted average grant-date fair value, Beginning"><span style="-sec-ix-redline: true"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0940">-</span></span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-sec-ix-redline: true">Granted</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zSMKKQsYVatk" style="text-align: right" title="Nonvested Shares, Granted"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0942">&#8212;</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zfQCmYSGg127" style="text-align: right" title="Nonvested weighted average grant-date fair value, Granted"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0944">&#8212;</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-sec-ix-redline: true">Vested</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zYGORBC0qyr8" style="text-align: right" title="Nonvested Shares, Vested"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0946">&#8212;</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zgzleRueiFa5" style="text-align: right" title="Nonvested weighted average grant-date fair value, Vested"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0948">&#8212;</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">Forfeited</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_z0nVoVud6em5" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested Shares, Forfeited"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0950">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zxUFVKPP1Mf5" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested weighted average grant-date fair value, Forfeited"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0952">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-sec-ix-redline: true">Nonvested as of December 31, 2023</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zl7TdslQqUz7" style="text-align: right" title="Nonvested Shares, Beginning"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0954">&#8212;</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zVjv6BEq74j5" style="text-align: right" title="Nonvested weighted average grant-date fair value, Beginning"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0956">&#8212;</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%"><span style="-sec-ix-redline: true">Granted</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zmhyAJn6R25k" style="width: 16%; text-align: right" title="Nonvested Shares, Granted"><span style="-sec-ix-redline: true">29,329,882</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zIVhFVfiUd26" style="width: 16%; text-align: right" title="Nonvested weighted average grant-date fair value, Granted"><span style="-sec-ix-redline: true">3.31</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-sec-ix-redline: true">Vested</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zb4N3FdAt0F4" style="text-align: right" title="Nonvested Shares, Vested"><span style="-sec-ix-redline: true">(2,639,628</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">)</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zjmY3Ryy46re" style="text-align: right" title="Nonvested weighted average grant-date fair value, Vested"><span style="-sec-ix-redline: true">0.96</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">Forfeited</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zOT6oxpXsWYh" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested Shares, Forfeited"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0966">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zVr3GW8f4fFg" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested weighted average grant-date fair value, Forfeited"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0968">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">Nonvested as of December 31, 2024</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zAbeEL3jQWA2" style="border-bottom: Black 2.5pt double; text-align: right" title="Nonvested Shares, Beginning"><span style="-sec-ix-redline: true">26,690,254</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zpPP7ynEpTU" style="border-bottom: Black 2.5pt double; text-align: right" title="Nonvested weighted average grant-date fair value, Beginning"><span style="-sec-ix-redline: true">3.54</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">Performance-Based RSUs</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">Weighted average grant-date fair
    value</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%"><span style="-sec-ix-redline: true">Nonvested as of January 1, 2023</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z1rlz6ZIH2E1" style="width: 16%; text-align: right" title="Nonvested Shares, Beginning"><span style="-sec-ix-redline: true">9,894,958</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zYEBRUUa4fS6" style="width: 16%; text-align: right" title="Nonvested weighted average grant-date fair value, Beginning"><span style="-sec-ix-redline: true">2.85</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-sec-ix-redline: true">Granted</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zXzXs5LuVewk" style="text-align: right" title="Nonvested Shares, Granted"><span style="-sec-ix-redline: true">1,027,796</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zU5QwhOVtKKh" style="text-align: right" title="Nonvested weighted average grant-date fair value, Granted"><span style="-sec-ix-redline: true">4.16</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-sec-ix-redline: true">Vested</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zNihbNDgoJlj" style="text-align: right" title="Nonvested Shares, Vested"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0982">&#8212;</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zRtEuhMXxxY2" style="text-align: right" title="Nonvested weighted average grant-date fair value, Vested"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0984">&#8212;</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">Forfeited</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z4WNux4psgFf" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested Shares, Forfeited"><span style="-sec-ix-redline: true">(22,626</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">)</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zCwJ89xod5X9" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested weighted average grant-date fair value, Forfeited"><span style="-sec-ix-redline: true">4.39</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-sec-ix-redline: true">Nonvested as of December 31, 2023</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zVTTQ5j3Vxe1" style="text-align: right" title="Nonvested Shares, Beginning"><span style="-sec-ix-redline: true">10,900,128</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z4tOtcsDbQrk" style="text-align: right" title="Nonvested weighted average grant-date fair value, Ending"><span style="-sec-ix-redline: true">2.97</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-sec-ix-redline: true">Granted</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zmsRkYvAG8l3" style="text-align: right" title="Nonvested Shares, Granted"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0994">&#8212;</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zf55dHhm3mC2" style="text-align: right" title="Nonvested weighted average grant-date fair value, Granted"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl0996">&#8212;</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-sec-ix-redline: true">Vested</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zaPBEe7jGmH7" style="text-align: right" title="Nonvested Shares, Vested"><span style="-sec-ix-redline: true">(9,610,540</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">)</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z3qi8eJlnIoj" style="text-align: right" title="Nonvested weighted average grant-date fair value, Vested"><span style="-sec-ix-redline: true">2.87</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">Forfeited</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zDVaCo8Kj5x6" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested Shares, Forfeited"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1002">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zZJSQQVnys22" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested weighted average grant-date fair value, Forfeited"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1004">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">Nonvested as of December 31, 2024</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z6DRsiRRodBh" style="border-bottom: Black 2.5pt double; text-align: right" title="Nonvested Shares, Beginning"><span style="-sec-ix-redline: true">1,289,578</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_znTBbMTO9Iii" style="border-bottom: Black 2.5pt double; text-align: right" title="Nonvested weighted average grant-date fair value, Ending"><span style="-sec-ix-redline: true">3.70</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zqQ6C3RkJXLh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded stock-based compensation expense in the following expense categories in the accompanying consolidated statements of
operations:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span id="xdx_8B4_z0T6x9S9R0nc" style="display: none">SCHEDULE OF STOCK-BASED
COMPENSATION EXPENSE</span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" id="xdx_494_20240101__20241231_zDU36E9nUsml" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">Year ended</span></td><td style="font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></span></p></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zYTqU2Y6qIUa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left"><span style="-sec-ix-redline: true">Research and development</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="width: 18%; text-align: right"><span style="-sec-ix-redline: true">27,019,781</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z2XZFhW9Nmak" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="-sec-ix-redline: true">General and administrative</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true">13,744,355</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--AllocatedShareBasedCompensationExpense_zwdTtZqbiUNb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt"><span style="-sec-ix-redline: true">Total</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-redline: true">40,764,136</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; DEFICIT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock', window );">SCHEDULE OF RECONCILIATION OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfStockholdersEquityTableTextBlock_zSOL5mLD6Ex8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below
is a reconciliation of shares of common stock issued and outstanding:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="-sec-ix-redline: true"><span id="xdx_8BF_zBobVkOAVlrc" style="display: none">SCHEDULE OF RECONCILIATION
OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING</span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">December 31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left"><span style="-sec-ix-redline: true">Total shares of common stock issued and outstanding</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="width: 16%; text-align: right"><span style="-sec-ix-redline: true"><span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_c20241231_zyN8CCKLMVr8" title="Total shares of common stock legally issued"><span id="xdx_909_eus-gaap--CommonStockSharesOutstanding_iI_c20241231_z5LoyIQAfSeg" title="Total shares of common stock legally outstanding">177,991,365</span></span></span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Plus: shares to be issued:</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="-sec-ix-redline: true">Vested RSUs not yet legally settled into common stock (a)</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_98E_ecustom--VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing_iI_c20241231_fKGEp_zCbHItSD0oN5" style="text-align: right" title="Vested Performance-Based RSUs from satisfaction of liquidity condition upon the Closing"><span style="-sec-ix-redline: true">1,373,221</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Less: Shares subject to future vesting:</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="-sec-ix-redline: true">Issuance of restricted common stock subject to forfeiture
    (b)</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_982_ecustom--SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture_iI_c20241231_fKGIp_zAWe8GbZVlj2" style="border-bottom: Black 1pt solid; text-align: right" title="Issuance of restricted common stock subject to forfeiture"><span style="-sec-ix-redline: true">(19,348,954</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">Total shares, net</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td id="xdx_981_ecustom--CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture_iI_c20241231_zTEH5atUDVxk" style="border-bottom: Black 2.5pt double; text-align: right" title="Total shares issued and outstanding"><span style="-sec-ix-redline: true">160,015,632</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_F0C_zk3ugD4zYWK3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_F1B_z37YHzlQJlp4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of December 31, 2024, there were RSUs that had vested but had not been legally settled into common stock. See Note 11 for additional
    information.</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_F03_zRtXAoAo4a1b" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_F1E_zYoDAP8O7hp2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Saadi will automatically forfeit all unvested Restricted Stock granted pursuant to the Special RSU Award in the event he departs
    the Company. See Note 11 for additional information on the Special RSU Award.</span></span></td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock', window );">SCHEDULE OF RECONCILIATION OF NET LOSS</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_zrMhznhcADK1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
below table is a reconciliation of net loss to net loss attributable to common stockholders.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_8B2_zqvjlw0tPPPc" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF RECONCILIATION OF NET LOSS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" id="xdx_499_20240101__20241231_zewavYKYmcO9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">2024</span></td><td style="font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" id="xdx_493_20230101__20231231_z5LV02lxoR03" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">2023</span></td><td style="font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">Year ended</span></td><td style="font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">December 31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">2024</span></td><td style="font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">2023</span></td><td style="font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_maNILATzLnk_z0EjB95kvWd5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="-sec-ix-redline: true">Net loss</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="width: 16%; text-align: right"><span style="-sec-ix-redline: true">(13,727,380</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">)</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="width: 16%; text-align: right"><span style="-sec-ix-redline: true">(60,477,680</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">)</span></td></tr>
  <tr id="xdx_407_eus-gaap--PreferredStockDividendsIncomeStatementImpact_iN_di_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_msNILATzLnk_ziuy4AAZlZpa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Series A cumulative preferred stock dividend</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">(76,712</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">)</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1136">&#8212;</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_40D_ecustom--StockRepurchase_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_msNILATzLnk_zMbcnuDaiYHe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Series B stock repurchase</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">3,613,000</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1139">&#8212;</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_400_ecustom--StockRepurchase_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zsFxVRhsUdRd" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Stock repurchase</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">3,613,000</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1142">&#8212;</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
<tr id="xdx_404_eus-gaap--PreferredStockDividendsIncomeStatementImpact_iN_di_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_msNILATzLnk_zXXqhExT8Qp9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Series C cumulative preferred stock dividend</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true">(82,603</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">)</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1145">&#8212;</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--PreferredStockDividendsIncomeStatementImpact_iN_di_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zYSKuDF6E6f7" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Cumulative preferred stock dividend</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true">(82,603</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">)</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1148">&#8212;</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
<tr id="xdx_406_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iT_mtNILATzLnk_zCi7OAkiAonl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Net loss attributable to common stockholders</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-redline: true">(10,273,695</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">)</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-redline: true">(60,477,680</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">)</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zMKW3hz6iji8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_8B5_zdSENhIO9rV3" style="display: none">SCHEDULE
OF ANTI-DILUTIVE NET LOSS PER SHARE</span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" id="xdx_499_20240101__20241231_zsfIgTckdztj" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" id="xdx_493_20230101__20231231_z3pWLbJFR0Ba" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">December 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zF2EpHKswSyc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="-sec-ix-redline: true">Outstanding RSUs <span id="xdx_F4D_z07FvddSvL6a">(a)</span></span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="width: 16%; text-align: right"><span style="-sec-ix-redline: true">8,623,225</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="width: 16%; text-align: right"><span style="-sec-ix-redline: true">10,900,128</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_z059N4sxVyL8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Restricted Stock</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">19,348,954</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1159">&#8212;</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zs04JFRW2k1j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Warrants</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">17,974,978</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1162">&#8212;</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zvxNYvig3f4k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Convertible promissory notes <span id="xdx_F41_zy3oX7MkW0ga">(b)</span></span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1164">&#8212;</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">891,298</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--EarnoutSharesMember_zQdxAkjI4TOe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">Earnout Shares</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true">24,500,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1168">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zQ4P6OqK2bi6" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">Total</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-redline: true">70,447,157</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-redline: true">11,791,426</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 0.25in; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_F0D_zlr7PY4CNPL7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_F18_zLgqOEX8aBr1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of December 31, 2024 there were an additional&#160;</span></span><span style="-sec-ix-redline: true"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFOVEktRElMVVRJVkUgTkVUIExPU1MgUEVSIFNIQVJFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8EyIlRCBIqc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="Stock option vested">1,373,221</span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;RSUs
    that had vested but had not been legally settled into common stock and therefore were included in the basic net income per share.
    See Note 11 for additional information.</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_F0D_zYhkL5W3VIKi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="-sec-ix-redline: true"><span id="xdx_F17_zDwYlBaiVt58" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    numbers of shares were determined based on the conversion upon maturity provisions in the convertible promissory note agreements,
    dividing the conversion amount (principal plus accrued interest) by three times the estimated fair value of the Company&#8217;s common
    stock derived from the Company&#8217;s most recently completed convertible promissory notes valuation as of the balance sheet date.</span></span></td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effect of income (loss) on basic earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">SCHEDULE OF RECONCILIATION OF INCOME TAX BENEFIT AT THE FEDERAL STATUTORY INCOME TAX RATE</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zzuUunQjL2f1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of income tax benefit at the federal statutory income tax rate to the income tax expense at the Company&#8217;s effective
income tax rate is as follows:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span id="xdx_8B0_zfqHypT5TS0f" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF RECONCILIATION OF INCOME TAX BENEFIT AT THE FEDERAL STATUTORY INCOME TAX RATE</span></span><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20240101__20241231_zFaKKRbw9Jgg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20230101__20231231_zNiY81lgme86" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">Year Ended December 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_uPure_ma123_zUDNJ7EwY67a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="-sec-ix-redline: true">Federal benefit at statutory rate</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="width: 16%; text-align: right"><span style="-sec-ix-redline: true">21.0</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">%</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="width: 16%; text-align: right"><span style="-sec-ix-redline: true">21.0</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">%</span></td></tr>
  <tr id="xdx_40A_ecustom--IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest_dp_uPure_ma123_zW5cTaPDNid4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Convertible note interest</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1186">&#8212;</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">(0.4</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">)</span></td></tr>
  <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_dp_uPure_ma123_z5fy4lkgWl6j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Permanent differences</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">29.2</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">(17.4</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">)</span></td></tr>
  <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_uPure_ma123_z93Oyuc8PpGh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline: true">State taxes, net of federal benefit</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">12.3</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">2.2</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_uPure_ma123_z8l8k4IRndd6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Change in valuation allowance</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">(66.5</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">)</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">(5.4</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">)</span></td></tr>
  <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_dp_uPure_ma123_zdjWGnsqB8jb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Stock based compensation</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">4.6</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1199">&#8212;</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_iN_dpi_uPure_ms123_zV87CPJluAad" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-sec-ix-redline: true">Other</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">(0.6</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">)</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1202">&#8212;</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_dp_ms123_zZEC2coYO4Ze" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="-sec-ix-redline: true">Tax credits</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1204">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true">0.1</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_dp_uPure_mt123_zpKTAJJeo2Ik" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">Income Tax Expense</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1207">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline: true">%</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1208">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline: true">%</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zVwD84JmqhR9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following items comprise the Company&#8217;s net deferred tax assets and liabilities as of December&#160;31, 2024 and December 31, 2023:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zDJj32uxJhO7" style="display: none">SCHEDULE
OF DEFERRED TAX ASSETS AND LIABILITIES</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" id="xdx_49D_20241231_zGc3SqzUGCkk" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" id="xdx_492_20231231_zhmEz9hnVLok" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">December 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsGrossAbstract_iB_z6v0y1kTSMR1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Deferred tax assets</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzJ64_zOmUptAXUjeg" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-left: 10pt"><span style="-sec-ix-redline: true">Net operating loss</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="width: 16%; text-align: right"><span style="-sec-ix-redline: true">6,808,826</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="width: 16%; text-align: right"><span style="-sec-ix-redline: true">3,755,008</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_40F_ecustom--DeferredTaxAssetsAccruedExpensesAndOther_iI_maDTAGzJ64_zbnWptSsezM2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="-sec-ix-redline: true">Accrued expenses and other</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">385,801</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">42,330</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_405_ecustom--DeferredTaxAssetsOperatingLeaseLiabilities_iI_maDTAGzJ64_zbPtKvCafCgc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="-sec-ix-redline: true">Lease liability</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">61,380</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">127,427</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGzJ64_z4vJKSUIuMtd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="-sec-ix-redline: true">Stock-based compensation</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">6,110,942</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">718,425</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_40E_ecustom--DeferredTaxAssetsFixedAssets_iI_maDTAGzJ64_z9o5LRtyj6Wf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="-sec-ix-redline: true">Fixed assets</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">33,834</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1228">&#8212;</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsOther_iI_maDTAGzJ64_zRoN4unq5yVf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt"><span style="-sec-ix-redline: true">Other</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">30,823</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1231">&#8212;</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_40E_ecustom--DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures_iI_maDTAGzJ64_zzXlwd8COPvd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="-sec-ix-redline: true">Capitalized research and development expenditures</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">2,944,801</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">2,589,105</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTAGzJ64_zTLvRLdgkjH8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="-sec-ix-redline: true">Research and development credits</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true">234,478</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true">317,455</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzJ64_maDTANz2Fd_zCuir0pCfzL2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt"><span style="-sec-ix-redline: true">Total deferred tax assets</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">16,610,885</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">7,549,750</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANz2Fd_zxaKCulwpvQ7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="-sec-ix-redline: true">Valuation allowance</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true">(16,551,169</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">)</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true">(7,426,952</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">)</span></td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANz2Fd_maDTALNz6fV_zBQC16G4WuN8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="-sec-ix-redline: true">Deferred tax assets</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true">59,716</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true">122,798</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_zwH9JPsFaUL4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Deferred tax liabilities:</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_40C_ecustom--DeferredTaxLiabilitiesRightOfUseAsset_iNI_di_maDITLzmly_zrkAHcCoXP54" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="-sec-ix-redline: true">Right of use asset</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true">(59,716</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">)</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true">(122,798</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">)</span></td></tr>
  <tr id="xdx_407_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_di_mtDITLzmly_msDTALNz6fV_zHWdAIwKT5s5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="-sec-ix-redline: true">Total deferred tax liabilities</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true">(59,716</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">)</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true">(122,798</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">)</span></td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNz6fV_zsuFt7LrE58b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"><span style="-sec-ix-redline: true">Net deferred tax assets</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1257">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-redline: true"><span style="-sec-ix-hidden: xdx2ixbrl1258">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_ScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock', window );">SCHEDULE OF VALUATION ALLOWANCE FOR NET DEFERRED TAX ASSETS</a></td>
<td class="text"><p id="xdx_89A_ecustom--ScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock_zWnNsTHpLs3g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of changes in the valuation allowance for net deferred tax assets during the year ended December 31, 2024 and 2023 were as follows:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zf0aPlttrYT4" style="display: none">SCHEDULE
OF VALUATION ALLOWANCE FOR NET DEFERRED TAX ASSETS</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" id="xdx_490_20240101__20241231_z9U4XQUAmYQd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" id="xdx_499_20230101__20231231_zSNRXftI7Xx" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">Year Ended December 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline: true">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsValuationAllowance_iS_zdHNImCfERul" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="-sec-ix-redline: true">Valuation allowance</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="width: 16%; text-align: right"><span style="-sec-ix-redline: true">7,426,952</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="width: 16%; text-align: right"><span style="-sec-ix-redline: true">4,175,241</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_402_ecustom--IncreasesRecordedToIncomeTaxProvision_zSpem9g5uypc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="-sec-ix-redline: true">Increases recorded to income tax provision</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true">9,124,217</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="padding-bottom: 1pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true">3,251,711</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsValuationAllowance_iE_z3yEnVjWbsEh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">Valuation allowance</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-redline: true">16,551,169</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-redline: true">7,426,952</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_ScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Valuation Allowance For Net Deferred Tax Assets [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_ScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>NATURE OF BUSINESS (Details Narrative)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 14, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=TVGN_TevogenBioMember', window );">Tevogen Bio [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity ownership percentage</a></td>
<td class="nump">91.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=TVGN_SemperParatusMember', window );">Semper Paratus [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity ownership percentage</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_BusinessCombinationSharesExchangeRatio', window );">Business combination shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.85<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_BusinessCombinationSharesExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination shares exchange ratio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_BusinessCombinationSharesExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=TVGN_TevogenBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=TVGN_TevogenBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=TVGN_SemperParatusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=TVGN_SemperParatusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEVELOPMENT-STAGE RISKS AND LIQUIDITY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,282,995<span></span>
</td>
<td class="nump">$ 1,052,397<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=TVGN_LoanAgreementMember', window );">Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Grant received</a></td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=TVGN_LoanAgreementMember', window );">Loan Agreement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Grant received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_GrantDrewFromRelatedParty', window );">Grant drew from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_GrantDrewFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant drew from related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_GrantDrewFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=TVGN_LoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=TVGN_LoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF FAIR VALUE MEASUREMENT (Details) - Fair Value, Inputs, Level 3 [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value beginning balance</a></td>
<td class="nump">$ 94,932,000<span></span>
</td>
<td class="nump">$ 39,297,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Initial fair value at issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest', window );">Accrued interest expense</a></td>
<td class="nump">159,305<span></span>
</td>
<td class="nump">1,206,697<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in fair value</a></td>
<td class="num">(48,468,678)<span></span>
</td>
<td class="nump">50,428,303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable', window );">Derecognition upon conversion of convertible promissory notes</a></td>
<td class="num">(46,622,627)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value beginning balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 94,932,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable inputs reconciliation recurring basis liability accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable inputs reconciliation recurring basis liability derecognition upon conversion of note payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_PlatformOperatorCryptoAssetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.FF.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476188/405-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_PlatformOperatorCryptoAssetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF FAIR VALUES OF WARRANTS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative warrant liabilities, Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,180<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative warrant liabilities, Balance</a></td>
<td class="nump">$ 87,180<span></span>
</td>
<td class="nump">87,180<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(58,180)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(375,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Call Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative warrant liabilities, Balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_DerivativeLiabilitiesFairValueIssuance', window );">Initial fair value at issuance</a></td>
<td class="nump">375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value</a></td>
<td class="num">(375,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative warrant liabilities, Balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative warrant liabilities, Balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_DerivativeLiabilitiesFairValueIssuance', window );">Initial fair value at issuance</a></td>
<td class="nump">29,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value</a></td>
<td class="nump">58,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative warrant liabilities, Balance</a></td>
<td class="nump">$ 87,180<span></span>
</td>
<td class="nump">$ 87,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_DerivativeLiabilitiesFairValueIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative liabilities fair value issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_DerivativeLiabilitiesFairValueIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_PlatformOperatorCryptoAssetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.FF.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476188/405-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_PlatformOperatorCryptoAssetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_CallOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_CallOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative warrant liabilities</a></td>
<td class="nump">$ 87,180<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative warrant liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative warrant liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative warrant liabilities</a></td>
<td class="nump">$ 87,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_PlatformOperatorCryptoAssetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.FF.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476188/405-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_PlatformOperatorCryptoAssetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Segment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustment of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (58,180)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Cash received upon issuance of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_FreeStandingPurchaseOptions', window );">Free standing purchase options | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_EmbeddedOptions', window );">Embedded options shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNet', window );">Fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Leases initial term</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Cash received upon issuance of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustment of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustment of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustment of warrants</a></td>
<td class="num">$ (58,180)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_EquitySecuritiesTerm', window );">Range in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_EquitySecuritiesTerm', window );">Range in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Volatility</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | Minimum [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiMeasurementInput', window );">Stock, measurement input</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | Maximum [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiMeasurementInput', window );">Stock, measurement input</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Measurement Input, Discount Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Discount rate</a></td>
<td class="nump">4.3<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Measurement Input, Discount Rate [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Volatility</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Measurement Input, Discount Rate [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Volatility</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=TVGN_ProbabilityOfFutureLiquidityMember', window );">Probability of Future Liquidity [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Volatility</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=TVGN_ProbabilityOfFutureLiquidityMember', window );">Probability of Future Liquidity [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Volatility</a></td>
<td class="nump">95<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiMeasurementInput', window );">Stock, measurement input</a></td>
<td class="nump">4.3<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiMeasurementInput', window );">Stock, measurement input</a></td>
<td class="nump">5.3<span></span>
</td>
<td class="nump">5.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember', window );">Measurement Input, Option Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Discount rate</a></td>
<td class="nump">78.3<span></span>
</td>
<td class="nump">78.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_EmbeddedOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Embedded options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_EmbeddedOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_EquitySecuritiesTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity securities term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_EquitySecuritiesTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_FreeStandingPurchaseOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Free standing purchase options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_FreeStandingPurchaseOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AlternativeInvestmentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure alternative investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AlternativeInvestmentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of the assets less the liabilities of a derivative or group of derivatives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=TVGN_ProbabilityOfFutureLiquidityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=TVGN_ProbabilityOfFutureLiquidityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF NET LIABILITIES ACQUIRED IN MERGER (Details)<br></strong></div></th>
<th class="th">
<div>Feb. 14, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash</a></td>
<td class="nump">$ 229,328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Due from Sponsor</a></td>
<td class="nump">158,819<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">2,501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(96,175)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses', window );">Accrued expenses</a></td>
<td class="num">(1,269,126)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt', window );">Notes payable</a></td>
<td class="num">(1,651,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther', window );">Derivative warrant liabilities</a></td>
<td class="num">(29,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total net liabilities acquired</a></td>
<td class="num">(2,654,653)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_MergerTransactionCostsLimitedToCashAcquired', window );">Plus: Merger transaction costs limited to cash acquired</a></td>
<td class="num">(229,328)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts', window );">Total net liabilities acquired plus transaction costs</a></td>
<td class="num">$ (2,883,981)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination recognized identifiable assets acquired and liabilities assumed current liabilities accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination recognized identifiable assets acquired and liabilities assumed net plus transaction costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_MergerTransactionCostsLimitedToCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Merger transaction costs limited to cash acquired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_MergerTransactionCostsLimitedToCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS COMBINATION (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 14, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">164,614,418<span></span>
</td>
<td class="nump">177,991,365<span></span>
</td>
<td class="nump">119,999,989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Merger transaction costs</a></td>
<td class="nump">$ 7,728,681<span></span>
</td>
<td class="nump">$ 7,499,353<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Transaction costs charged to equity</a></td>
<td class="nump">229,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_StockIssuedDuringPeriodValueNewIssuesOne', window );">New issuance value</a></td>
<td class="nump">$ 3,613,000<span></span>
</td>
<td class="nump">$ 3,613,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=TVGN_EarnoutSharesMember', window );">Earnout Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Earnout shares issuable</a></td>
<td class="nump">24,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=TVGN_TevogenBioMember', window );">Tevogen Bio [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_StockIssuedDuringPeriodValueNewIssuesOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value new issues one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_StockIssuedDuringPeriodValueNewIssuesOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479405/805-10-25-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=TVGN_EarnoutSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=TVGN_EarnoutSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=TVGN_TevogenBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=TVGN_TevogenBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>EARNOUT SHARES (Details Narrative) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 14, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=TVGN_EarnoutSharesMember', window );">Earnout Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Earnout shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=TVGN_TevogenBioCommonStockMember', window );">Tevogen Bio Common Stock [Member] | Share-Based Payment Arrangement, Tranche One [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share</a></td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=TVGN_TevogenBioCommonStockMember', window );">Tevogen Bio Common Stock [Member] | Share-Based Payment Arrangement, Tranche Two [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share</a></td>
<td class="nump">17.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=TVGN_TevogenBioCommonStockMember', window );">Tevogen Bio Common Stock [Member] | Share-Based Payment Arrangement, Tranche Three [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share</a></td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=TVGN_TevogenBioCommonStockMember', window );">Tevogen Bio Common Stock [Member] | Earnout Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Earnout shares</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=TVGN_TevogenBioCommonStockMember', window );">Tevogen Bio Common Stock [Member] | Earnout Shares [Member] | Share-Based Payment Arrangement, Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Earnout shares</a></td>
<td class="nump">6,666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=TVGN_TevogenBioCommonStockMember', window );">Tevogen Bio Common Stock [Member] | Earnout Shares [Member] | Share-Based Payment Arrangement, Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Earnout shares</a></td>
<td class="nump">6,666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=TVGN_TevogenBioCommonStockMember', window );">Tevogen Bio Common Stock [Member] | Earnout Shares [Member] | Share-Based Payment Arrangement, Tranche Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Earnout shares</a></td>
<td class="nump">6,666,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=TVGN_SponsorMember', window );">Sponsor [Member] | Earnout Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Earnout shares</a></td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=TVGN_SponsorMember', window );">Sponsor [Member] | Earnout Shares [Member] | Share-Based Payment Arrangement, Tranche Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Earnout shares</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=TVGN_EarnoutSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=TVGN_EarnoutSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=TVGN_TevogenBioCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=TVGN_TevogenBioCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=TVGN_SponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=TVGN_SponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 721,769<span></span>
</td>
<td class="nump">$ 721,769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(425,327)<span></span>
</td>
<td class="num">(263,118)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">296,442<span></span>
</td>
<td class="nump">458,651<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=TVGN_ComputerAndSoftwareMember', window );">Computer And Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">292,341<span></span>
</td>
<td class="nump">292,341<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">263,217<span></span>
</td>
<td class="nump">263,217<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">132,468<span></span>
</td>
<td class="nump">132,468<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 33,743<span></span>
</td>
<td class="nump">$ 33,743<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=TVGN_ComputerAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=TVGN_ComputerAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 162,209<span></span>
</td>
<td class="nump">$ 163,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional services</a></td>
<td class="nump">$ 1,309,163<span></span>
</td>
<td class="nump">$ 976,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">403,233<span></span>
</td>
<td class="nump">120,149<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 1,712,396<span></span>
</td>
<td class="nump">$ 1,096,450<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 14, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Apr. 02, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Feb. 28, 2025</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000,000<span></span>
</td>
<td class="nump">$ 14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,651,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Line of credit remaining capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_PolarMultiStrategyMasterFundMember', window );">Polar Multi-Strategy Master Fund [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,651,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=TVGN_LoanAgreementMember', window );">Loan Agreement [Member] | The Patel Family LLP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross', window );">Option to purchase common stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of price of common stock purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility', window );">Line of credit facility shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=TVGN_LoanAgreementMember', window );">Loan Agreement [Member] | The Patel Family LLP [Member] | Additional Amount Purchase Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross', window );">Option to purchase common stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=TVGN_LoanAgreementMember', window );">Loan Agreement [Member] | The Patel Family LLP [Member] | Unsecured Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Line of credit borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">48 months<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">18,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Line of credit remaining capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=TVGN_LoanAgreementMember', window );">Loan Agreement [Member] | The Patel Family LLP [Member] | Unsecured Debt [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Line of credit borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=TVGN_LoanAgreementMember', window );">Loan Agreement [Member] | The Patel Family LLP [Member] | Unsecured Debt [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Converted shares</a></td>
<td class="nump">10,337,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,337,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares commitment shares in connection with unsecured equity line of credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 28: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, before forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_PolarMultiStrategyMasterFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_PolarMultiStrategyMasterFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=TVGN_LoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=TVGN_LoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_ThePatelFamilyLLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_ThePatelFamilyLLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=TVGN_AdditionalAmountPurchaseOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=TVGN_AdditionalAmountPurchaseOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF MINIMUM RENTAL PAYMENTS UNDER THE OPERATING LEASES (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 230,471<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">13,975<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">244,446<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(9,587)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">$ 234,859<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="nump">$ 1,065,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeasePayments', window );">Short term lease</a></td>
<td class="nump">$ 785,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases weighted average remaining lease term</a></td>
<td class="text">11 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases weighted average discount rate</a></td>
<td class="nump">11.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash payments</a></td>
<td class="nump">$ 1,077,127<span></span>
</td>
<td class="nump">$ 1,058,754<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentArrangementMember', window );">Research and Development Arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="nump">897,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="nump">$ 167,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_OperatingLeasesIncrementalBorrowingRates', window );">Operating leases incremental borrowing rates</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_OperatingLeasesIncrementalBorrowingRates', window );">Operating leases incremental borrowing rates</a></td>
<td class="nump">11.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_OperatingLeasesIncrementalBorrowingRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating leases incremental borrowing rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_OperatingLeasesIncrementalBorrowingRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term lease payment excluded from lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF RESTRICTED STOCK AND RSU ACTIVITY (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=TVGN_ServiceBasedRestrictedStockMember', window );">Service-Based Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested Shares, Beginning</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested weighted average grant-date fair value, Ending</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Nonvested Shares, Granted</a></td>
<td class="nump">29,329,882<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Nonvested weighted average grant-date fair value, Granted</a></td>
<td class="nump">$ 3.31<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Nonvested Shares, Vested</a></td>
<td class="num">(2,639,628)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Nonvested weighted average grant-date fair value, Vested</a></td>
<td class="nump">$ 0.96<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Nonvested Shares, Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Nonvested weighted average grant-date fair value, Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested Shares, Beginning</a></td>
<td class="nump">26,690,254<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested weighted average grant-date fair value, Ending</a></td>
<td class="nump">$ 3.54<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Nonvested Shares, Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=TVGN_PerformanceBasedRSUsMember', window );">Performance-Based RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested Shares, Beginning</a></td>
<td class="nump">10,900,128<span></span>
</td>
<td class="nump">9,894,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested weighted average grant-date fair value, Ending</a></td>
<td class="nump">$ 2.97<span></span>
</td>
<td class="nump">$ 2.85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Nonvested Shares, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,027,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Nonvested weighted average grant-date fair value, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4.16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Nonvested Shares, Vested</a></td>
<td class="num">(9,610,540)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Nonvested weighted average grant-date fair value, Vested</a></td>
<td class="nump">$ 2.87<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Nonvested Shares, Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">22,626<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Nonvested weighted average grant-date fair value, Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested Shares, Beginning</a></td>
<td class="nump">1,289,578<span></span>
</td>
<td class="nump">10,900,128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested weighted average grant-date fair value, Ending</a></td>
<td class="nump">$ 3.70<span></span>
</td>
<td class="nump">$ 2.97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Nonvested Shares, Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(22,626)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=TVGN_ServiceBasedRestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=TVGN_ServiceBasedRestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=TVGN_PerformanceBasedRSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=TVGN_PerformanceBasedRSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 40,764,136<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">27,019,781<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 13,744,355<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 14, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Compensation cost recognized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,764,136<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing', window );">Number of shares issuable</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,373,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense', window );">Compensation cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Share-Based Payment Arrangement, Amount Capitalized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=TVGN_PerformanceBasedRSUsMember', window );">Performance-Based RSUs [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Compensation cost recognized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,233,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits', window );">Number of shares issued and outstading RSU</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,237,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,984,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period for recognition</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=TVGN_PerformanceBasedRSUsMember', window );">Performance-Based RSUs [Member] | Subsequent Event [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing', window );">Number of shares issuable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,373,221<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense', window );">Compensation cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,410,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period for recognition</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=TVGN_ServiceBasedRestrictedStockMember', window );">Service-Based Restricted Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,601,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=TVGN_ServiceBasedRestrictedStockMember', window );">Service-Based Restricted Stock [Member] | Subsequent Event [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing', window );">Number of shares issuable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,639,628<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=TVGN_TwoThousandTwentyFourPlanMember', window );">2024 Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Granted shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,670,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=TVGN_TwoThousandTwentyFourPlanMember', window );">2024 Plan [Member] | Chief Executive Officer [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Number of shares issued for RSUs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19,348,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value per share for award</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Grant date fair value of shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 87,263,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As
    of December 31, 2024, there were RSUs that had vested but had not been legally settled into common stock. See Note 11 for additional
    information.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares settlement of vested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vested performance based restricted stock units from satisfaction of liquidity condition upon closing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of plan compensation cost recognized during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480489/718-40-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=TVGN_PerformanceBasedRSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=TVGN_PerformanceBasedRSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=TVGN_ServiceBasedRestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=TVGN_ServiceBasedRestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=TVGN_TwoThousandTwentyFourPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=TVGN_TwoThousandTwentyFourPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF RECONCILIATION OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 14, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Total shares of common stock legally issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">177,991,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,999,989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Total shares of common stock legally outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">177,991,365<span></span>
</td>
<td class="nump">164,614,418<span></span>
</td>
<td class="nump">119,999,989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing', window );">Vested Performance-Based RSUs from satisfaction of liquidity condition upon the Closing</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,373,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture', window );">Issuance of restricted common stock subject to forfeiture</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(19,348,954)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture', window );">Total shares issued and outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">160,015,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As
    of December 31, 2024, there were RSUs that had vested but had not been legally settled into common stock. See Note 11 for additional
    information.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Dr.
    Saadi will automatically forfeit all unvested Restricted Stock granted pursuant to the Special RSU Award in the event he departs
    the Company. See Note 11 for additional information on the Special RSU Award.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock shares issued and outstanding inclusion of shares to be issued and exclusion of shares subject to forfeiture.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares subject to future vesting issuance of restricted common stock subject to forfeiture.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vested performance based restricted stock units from satisfaction of liquidity condition upon closing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; DEFICIT (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 21, 2024</div></th>
<th class="th"><div>Mar. 27, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Feb. 14, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,991,365<span></span>
</td>
<td class="nump">119,999,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,991,365<span></span>
</td>
<td class="nump">119,999,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,614,418<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred shares, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_LossOnPreferredStockIssuance', window );">Loss on preferred stock issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">799,990<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,799,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_SemperParatusMember', window );">Semper Paratus [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_ClassOfWarrantOrRightIssued', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,975,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_SemperParatusMember', window );">Semper Paratus [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_ClassOfWarrantOrRightIssued', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">725,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">588,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_SemperParatusMember', window );">Semper Paratus [Member] | Public Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Exercisable date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 15,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_WarrantsRedemptionDescription', window );">Warrants redemption description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The
Company may redeem the public warrants if the Company&#8217;s common stock equals or exceeds $18.00 per share for 20 trading days within
a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the
holders of public warrants<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,386,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_SemperParatusMember', window );">Semper Paratus [Member] | Public Warrants [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_ClassOfWarrantOrRightIssued', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred shares, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Dividend rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendPaymentRateVariable', window );">Dividend variable rate, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the
Series A Original Issue Price, which rate will automatically increase by 2% every year that the Series A remains outstanding (the &#8220;Series
A Accruing Dividends&#8221;). These dividends become payable when and if declared by the Company. The Series A Preferred Stock will also
participate on an as-converted basis in any regular or special dividends paid to holders of the common stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionPricePerShare', window );">Redemption price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionTerms', window );">Redemption term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the
twenty days immediately prior to the Company&#8217;s call election<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Floor price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_LossOnPreferredStockIssuance', window );">Loss on preferred stock issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 799,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=TVGN_SeriesAOnePreferredStockMember', window );">Series A1 Preferred Stock [Member] | The Patel Family LLP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendPaymentRateVariable', window );">Dividend variable rate, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The
terms of the Series A-1 Preferred Stock are identical to the Series A, except that the cumulative dividends are capped at 15% per annum,
and the Series A-1 Issuance Price is defined as $10,000&#160;per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Deposits', window );">Non refundable deposist paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_StockIssuedDuringPeriodSharesConversionOfLiabilities', window );">Conversion of certain liabilities into Series B preferred stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_StockIssuedDuringPeriodValueConversionOfLiabilities', window );">Conversion of certain liabilities into Series B preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,613,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAssumed1', window );">Liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred shares, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Dividend rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendPaymentRateVariable', window );">Dividend variable rate, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the
event of a liquidation of the Company, or certain deemed liquidation events, the Series C is redeemable for a price equal to the greater
of the Series C Original Issue Price plus all Series C Accruing Dividends that are unpaid through the redemption date, or such asset
amount as would have been payable had the Series C converted into shares of common stock immediately before the liquidation or deemed
liquidation event<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Floor price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member] | The Patel Family LLP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Gross proceeds</a></td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_ClassOfWarrantOrRightIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_ClassOfWarrantOrRightIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_LossOnPreferredStockIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss on preferred stock issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_LossOnPreferredStockIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_StockIssuedDuringPeriodSharesConversionOfLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares conversion of liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_StockIssuedDuringPeriodSharesConversionOfLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_StockIssuedDuringPeriodValueConversionOfLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value conversion of liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_StockIssuedDuringPeriodValueConversionOfLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_WarrantsRedemptionDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants redemption description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_WarrantsRedemptionDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are exercisable, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Deposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Deposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of liabilities assumed in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendPaymentRateVariable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of basis of dividend, such as adjustable rate. Excludes percentage rate dividend payments or fixed dollar amounts per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendPaymentRateVariable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-5<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-11<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockRedemptionTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The redemption terms of preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity. The redemption features of this capital stock are solely within the control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-11<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockRedemptionTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_SemperParatusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_SemperParatusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=TVGN_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=TVGN_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=TVGN_SeriesAOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=TVGN_SeriesAOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_ThePatelFamilyLLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_ThePatelFamilyLLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF RECONCILIATION OF NET LOSS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (13,727,380)<span></span>
</td>
<td class="num">$ (60,477,680)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">(10,273,695)<span></span>
</td>
<td class="num">(60,477,680)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Cumulative preferred stock dividend</a></td>
<td class="num">(76,712)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_StockRepurchase', window );">Stock repurchase</a></td>
<td class="nump">3,613,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Cumulative preferred stock dividend</a></td>
<td class="num">$ (82,603)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_StockRepurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock repurchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_StockRepurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">70,447,157<span></span>
</td>
<td class="nump">11,791,426<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">8,623,225<span></span>
</td>
<td class="nump">10,900,128<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19,348,954<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17,974,978<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible Debt Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">891,298<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=TVGN_EarnoutSharesMember', window );">Earnout Shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">24,500,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As
    of December 31, 2024 there were an additional&#160;</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The
    numbers of shares were determined based on the conversion upon maturity provisions in the convertible promissory note agreements,
    dividing the conversion amount (principal plus accrued interest) by three times the estimated fair value of the Company&#8217;s common
    stock derived from the Company&#8217;s most recently completed convertible promissory notes valuation as of the balance sheet date.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=TVGN_EarnoutSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=TVGN_EarnoutSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details) (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Stock option vested</a></td>
<td class="nump">1,373,221<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>151
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>NET LOSS PER SHARE (Details Narrative) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 28: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF RECONCILIATION OF INCOME TAX BENEFIT AT THE FEDERAL STATUTORY INCOME TAX RATE (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal benefit at statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest', window );">Convertible note interest</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(0.40%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Permanent differences</a></td>
<td class="nump">29.20%<span></span>
</td>
<td class="num">(17.40%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="nump">12.30%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(66.50%)<span></span>
</td>
<td class="num">(5.40%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock based compensation</a></td>
<td class="nump">4.60%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther', window );">Other</a></td>
<td class="num">(0.60%)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income Tax Expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation income tax expense benefit convertible noteinterest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>153
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">$ 6,808,826<span></span>
</td>
<td class="nump">$ 3,755,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_DeferredTaxAssetsAccruedExpensesAndOther', window );">Accrued expenses and other</a></td>
<td class="nump">385,801<span></span>
</td>
<td class="nump">42,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_DeferredTaxAssetsOperatingLeaseLiabilities', window );">Lease liability</a></td>
<td class="nump">61,380<span></span>
</td>
<td class="nump">127,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">6,110,942<span></span>
</td>
<td class="nump">718,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_DeferredTaxAssetsFixedAssets', window );">Fixed assets</a></td>
<td class="nump">33,834<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">30,823<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures', window );">Capitalized research and development expenditures</a></td>
<td class="nump">2,944,801<span></span>
</td>
<td class="nump">2,589,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development credits</a></td>
<td class="nump">234,478<span></span>
</td>
<td class="nump">317,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">16,610,885<span></span>
</td>
<td class="nump">7,549,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(16,551,169)<span></span>
</td>
<td class="num">(7,426,952)<span></span>
</td>
<td class="num">$ (4,175,241)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">59,716<span></span>
</td>
<td class="nump">122,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_DeferredTaxLiabilitiesRightOfUseAsset', window );">Right of use asset</a></td>
<td class="num">(59,716)<span></span>
</td>
<td class="num">(122,798)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(59,716)<span></span>
</td>
<td class="num">(122,798)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_DeferredTaxAssetsAccruedExpensesAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets accrued expenses and other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_DeferredTaxAssetsAccruedExpensesAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets capitalized research and development expenditures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_DeferredTaxAssetsFixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets fixed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_DeferredTaxAssetsFixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_DeferredTaxLiabilitiesRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities right of use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_DeferredTaxLiabilitiesRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>154
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF VALUATION ALLOWANCE FOR NET DEFERRED TAX ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 7,426,952<span></span>
</td>
<td class="nump">$ 4,175,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_IncreasesRecordedToIncomeTaxProvision', window );">Increases recorded to income tax provision</a></td>
<td class="nump">9,124,217<span></span>
</td>
<td class="nump">3,251,711<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 16,551,169<span></span>
</td>
<td class="nump">$ 7,426,952<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_IncreasesRecordedToIncomeTaxProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increases recorded to income tax provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_IncreasesRecordedToIncomeTaxProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>155
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal net operating loss carryforwards</a></td>
<td class="nump">$ 25,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State net operating loss carryforwards</a></td>
<td class="nump">$ 27,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_TaxableIncomeLimitationPercentage', window );">Limitation percentage</a></td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Income tax penalties and interest accrued</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_TaxableIncomeLimitationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Taxable income limitation percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_TaxableIncomeLimitationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>156
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Apr. 02, 2025</div></th>
<th class="th"><div>Feb. 28, 2025</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SponsorFees', window );">Sponsor advisory service fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_TVGN_SponsorFeesPayable', window );">Sponsor advisory services fee payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense', window );">Compensation cost recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Line of credit remaining borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=TVGN_PerformanceBasedRSUsMember', window );">Performance-Based RSUs [Member] | Wife of Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued to related party</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=TVGN_SponsorAdvisoryServicesFeeMember', window );">Sponsor Advisory Services Fee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_SponsorMember', window );">Sponsor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Sponsor fee payable offset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Due from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_MehtaphoricConsultingIncMember', window );">Mehtaphoric Consulting Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued to related party</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_ThePatelFamilyLLPMember', window );">The Patel Family LLP [Member] | Loan Agreement [Member] | Unsecured Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Line of credit remaining borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_DrManmohanPatelMember', window );">Dr. Manmohan Patel [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_DrManmohanPatelMember', window );">Dr. Manmohan Patel [Member] | Restricted Stock Units (RSUs) [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_SponsorFeesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sponsor advisory services fee payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_SponsorFeesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of plan compensation cost recognized during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480489/718-40-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SponsorFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fees paid to advisors who provide certain management support and administrative oversight services including the organization and sale of stock, investment funds, limited partnerships and mutual funds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SponsorFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=TVGN_PerformanceBasedRSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=TVGN_PerformanceBasedRSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=TVGN_WifeOfChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=TVGN_WifeOfChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=TVGN_SponsorAdvisoryServicesFeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=TVGN_SponsorAdvisoryServicesFeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_SponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_SponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_MehtaphoricConsultingIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_MehtaphoricConsultingIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_ThePatelFamilyLLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_ThePatelFamilyLLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=TVGN_LoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=TVGN_LoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_DrManmohanPatelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_DrManmohanPatelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>157
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details Narrative) - Subsequent Event [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Apr. 02, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Feb. 28, 2025</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Line of credit Facility additional</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Line of credit Facility remaining capacity</a></td>
<td class="nump">$ 26,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">KRHP LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_KRHPLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_KRHPLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>158
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>178</ContextCount>
  <ElementCount>304</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>67</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/StatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Changes in Stockholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Deficit</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement -  Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName> Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>999007 - Disclosure - NATURE OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/NatureOfBusiness</Role>
      <ShortName>NATURE OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>999008 - Disclosure - DEVELOPMENT-STAGE RISKS AND LIQUIDITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/Development-stageRisksAndLiquidity</Role>
      <ShortName>DEVELOPMENT-STAGE RISKS AND LIQUIDITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>999009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>999010 - Disclosure - BUSINESS COMBINATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/BusinessCombination</Role>
      <ShortName>BUSINESS COMBINATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>999011 - Disclosure - EARNOUT SHARES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/EarnoutShares</Role>
      <ShortName>EARNOUT SHARES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>999012 - Disclosure - PROPERTY AND EQUIPMENT, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/PropertyAndEquipmentNet</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>999013 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/AccruedExpensesAndOtherLiabilities</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>999014 - Disclosure - DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/Debt</Role>
      <ShortName>DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>999015 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/Leases</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>999016 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>999017 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/Stock-basedCompensation</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>999018 - Disclosure - STOCKHOLDERS??? DEFICIT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/StockholdersDeficit</Role>
      <ShortName>STOCKHOLDERS??? DEFICIT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>999019 - Disclosure - NET LOSS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/NetLossPerShare</Role>
      <ShortName>NET LOSS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>999020 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>999021 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/RelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>999022 - Disclosure - SEGMENT REPORTING</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/SegmentReporting</Role>
      <ShortName>SEGMENT REPORTING</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>999023 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>999024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>999025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tevogen.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>999026 - Disclosure - BUSINESS COMBINATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/BusinessCombinationTables</Role>
      <ShortName>BUSINESS COMBINATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tevogen.com/role/BusinessCombination</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>999027 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/PropertyAndEquipmentNetTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tevogen.com/role/PropertyAndEquipmentNet</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>999028 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/AccruedExpensesAndOtherLiabilitiesTables</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tevogen.com/role/AccruedExpensesAndOtherLiabilities</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>999029 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/LeasesTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tevogen.com/role/Leases</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>999030 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/Stock-basedCompensationTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tevogen.com/role/Stock-basedCompensation</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>999031 - Disclosure - STOCKHOLDERS??? DEFICIT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/StockholdersDeficitTables</Role>
      <ShortName>STOCKHOLDERS??? DEFICIT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tevogen.com/role/StockholdersDeficit</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>999032 - Disclosure - NET LOSS PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/NetLossPerShareTables</Role>
      <ShortName>NET LOSS PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tevogen.com/role/NetLossPerShare</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>999033 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/IncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tevogen.com/role/IncomeTaxes</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>999034 - Disclosure - NATURE OF BUSINESS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/NatureOfBusinessDetailsNarrative</Role>
      <ShortName>NATURE OF BUSINESS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tevogen.com/role/NatureOfBusiness</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>999035 - Disclosure - DEVELOPMENT-STAGE RISKS AND LIQUIDITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative</Role>
      <ShortName>DEVELOPMENT-STAGE RISKS AND LIQUIDITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tevogen.com/role/Development-stageRisksAndLiquidity</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>999036 - Disclosure - SCHEDULE OF FAIR VALUE MEASUREMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails</Role>
      <ShortName>SCHEDULE OF FAIR VALUE MEASUREMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>999037 - Disclosure - SCHEDULE OF FAIR VALUES OF WARRANTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails</Role>
      <ShortName>SCHEDULE OF FAIR VALUES OF WARRANTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>999038 - Disclosure - SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>999039 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails</Role>
      <ShortName>SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>999040 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>999041 - Disclosure - SCHEDULE OF NET LIABILITIES ACQUIRED IN MERGER (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails</Role>
      <ShortName>SCHEDULE OF NET LIABILITIES ACQUIRED IN MERGER (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>999042 - Disclosure - BUSINESS COMBINATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/BusinessCombinationDetailsNarrative</Role>
      <ShortName>BUSINESS COMBINATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tevogen.com/role/BusinessCombinationTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>999043 - Disclosure - EARNOUT SHARES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/EarnoutSharesDetailsNarrative</Role>
      <ShortName>EARNOUT SHARES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tevogen.com/role/EarnoutShares</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>999044 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>SCHEDULE OF PROPERTY AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>999045 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/PropertyAndEquipmentNetDetailsNarrative</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tevogen.com/role/PropertyAndEquipmentNetTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>999046 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails</Role>
      <ShortName>SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>999047 - Disclosure - DEBT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/DebtDetailsNarrative</Role>
      <ShortName>DEBT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tevogen.com/role/Debt</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>999048 - Disclosure - SCHEDULE OF MINIMUM RENTAL PAYMENTS UNDER THE OPERATING LEASES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ScheduleOfMinimumRentalPaymentsUnderOperatingLeasesDetails</Role>
      <ShortName>SCHEDULE OF MINIMUM RENTAL PAYMENTS UNDER THE OPERATING LEASES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>999049 - Disclosure - LEASES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/LeasesDetailsNarrative</Role>
      <ShortName>LEASES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tevogen.com/role/LeasesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>999050 - Disclosure - SCHEDULE OF RESTRICTED STOCK AND RSU ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails</Role>
      <ShortName>SCHEDULE OF RESTRICTED STOCK AND RSU ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>999051 - Disclosure - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ScheduleOfStock-basedCompensationExpenseDetails</Role>
      <ShortName>SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>999052 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/Stock-basedCompensationDetailsNarrative</Role>
      <ShortName>STOCK-BASED COMPENSATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tevogen.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>999053 - Disclosure - SCHEDULE OF RECONCILIATION OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails</Role>
      <ShortName>SCHEDULE OF RECONCILIATION OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>999054 - Disclosure - STOCKHOLDERS??? DEFICIT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/StockholdersDeficitDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS??? DEFICIT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tevogen.com/role/StockholdersDeficitTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>999055 - Disclosure - SCHEDULE OF RECONCILIATION OF NET LOSS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ScheduleOfReconciliationOfNetLossDetails</Role>
      <ShortName>SCHEDULE OF RECONCILIATION OF NET LOSS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>999056 - Disclosure - SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails</Role>
      <ShortName>SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>999057 - Disclosure - SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical</Role>
      <ShortName>SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details) (Parenthetical)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>999058 - Disclosure - NET LOSS PER SHARE (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/NetLossPerShareDetailsNarrative</Role>
      <ShortName>NET LOSS PER SHARE (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tevogen.com/role/NetLossPerShareTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>999059 - Disclosure - SCHEDULE OF RECONCILIATION OF INCOME TAX BENEFIT AT THE FEDERAL STATUTORY INCOME TAX RATE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails</Role>
      <ShortName>SCHEDULE OF RECONCILIATION OF INCOME TAX BENEFIT AT THE FEDERAL STATUTORY INCOME TAX RATE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>999060 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>999061 - Disclosure - SCHEDULE OF VALUATION ALLOWANCE FOR NET DEFERRED TAX ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ScheduleOfValuationAllowanceForNetDeferredTaxAssetsDetails</Role>
      <ShortName>SCHEDULE OF VALUATION ALLOWANCE FOR NET DEFERRED TAX ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>999062 - Disclosure - INCOME TAXES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>INCOME TAXES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tevogen.com/role/IncomeTaxesTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>999063 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tevogen.com/role/RelatedPartyTransactions</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>999064 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>SUBSEQUENT EVENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tevogen.com/role/SubsequentEvents</ParentRole>
      <Position>64</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="POS AM" isDefinitelyFs="true" isUsgaap="true" original="formposam.htm">formposam.htm</File>
    <File>tvgn-20241231.xsd</File>
    <File>tvgn-20241231_cal.xml</File>
    <File>tvgn-20241231_def.xml</File>
    <File>tvgn-20241231_lab.xml</File>
    <File>tvgn-20241231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>formposam_011.jpg</File>
    <File>formposam_012.jpg</File>
    <File>formposam_013.jpg</File>
    <File>formposam_014.jpg</File>
    <File>formposam_016.jpg</File>
    <File>formposam_017.jpg</File>
    <File>formposam_018.jpg</File>
    <File>forms-1_001.jpg</File>
    <File>posam_001.jpg</File>
    <File>posam_002.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="617">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="26">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>160
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "formposam.htm": {
   "nsprefix": "TVGN",
   "nsuri": "http://tevogen.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "formposam.htm"
     ]
    },
    "schema": {
     "local": [
      "tvgn-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "tvgn-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "tvgn-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "tvgn-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "tvgn-20241231_pre.xml"
     ]
    }
   },
   "keyStandard": 248,
   "keyCustom": 56,
   "axisStandard": 22,
   "axisCustom": 0,
   "memberStandard": 40,
   "memberCustom": 21,
   "hidden": {
    "total": 170,
    "http://fasb.org/us-gaap/2024": 127,
    "http://tevogen.com/20241231": 40,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 178,
   "entityCount": 1,
   "segmentCount": 67,
   "elementCount": 510,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 617,
    "http://xbrl.sec.gov/dei/2024": 26
   },
   "report": {
    "R1": {
     "role": "http://tevogen.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "dei:AmendmentDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "dei:AmendmentDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://tevogen.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:Cash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://tevogen.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://tevogen.com/role/StatementsOfOperations",
     "longName": "00000004 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit",
     "longName": "00000005 - Statement - Consolidated Statements of Changes in Stockholders' Deficit",
     "shortName": "Consolidated Statements of Changes in Stockholders' Deficit",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows",
     "longName": "00000006 - Statement -  Consolidated Statements of Cash Flows",
     "shortName": " Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PaidInKindInterest",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://tevogen.com/role/NatureOfBusiness",
     "longName": "999007 - Disclosure - NATURE OF BUSINESS",
     "shortName": "NATURE OF BUSINESS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://tevogen.com/role/Development-stageRisksAndLiquidity",
     "longName": "999008 - Disclosure - DEVELOPMENT-STAGE RISKS AND LIQUIDITY",
     "shortName": "DEVELOPMENT-STAGE RISKS AND LIQUIDITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "TVGN:DevelopmentStageRisksAndLiquidityTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "TVGN:DevelopmentStageRisksAndLiquidityTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://tevogen.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "999009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://tevogen.com/role/BusinessCombination",
     "longName": "999010 - Disclosure - BUSINESS COMBINATION",
     "shortName": "BUSINESS COMBINATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://tevogen.com/role/EarnoutShares",
     "longName": "999011 - Disclosure - EARNOUT SHARES",
     "shortName": "EARNOUT SHARES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "TVGN:EarnoutSharesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "TVGN:EarnoutSharesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://tevogen.com/role/PropertyAndEquipmentNet",
     "longName": "999012 - Disclosure - PROPERTY AND EQUIPMENT, NET",
     "shortName": "PROPERTY AND EQUIPMENT, NET",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://tevogen.com/role/AccruedExpensesAndOtherLiabilities",
     "longName": "999013 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES",
     "shortName": "ACCRUED EXPENSES AND OTHER LIABILITIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://tevogen.com/role/Debt",
     "longName": "999014 - Disclosure - DEBT",
     "shortName": "DEBT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://tevogen.com/role/Leases",
     "longName": "999015 - Disclosure - LEASES",
     "shortName": "LEASES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://tevogen.com/role/CommitmentsAndContingencies",
     "longName": "999016 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://tevogen.com/role/Stock-basedCompensation",
     "longName": "999017 - Disclosure - STOCK-BASED COMPENSATION",
     "shortName": "STOCK-BASED COMPENSATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://tevogen.com/role/StockholdersDeficit",
     "longName": "999018 - Disclosure - STOCKHOLDERS\u2019 DEFICIT",
     "shortName": "STOCKHOLDERS\u2019 DEFICIT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://tevogen.com/role/NetLossPerShare",
     "longName": "999019 - Disclosure - NET LOSS PER SHARE",
     "shortName": "NET LOSS PER SHARE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://tevogen.com/role/IncomeTaxes",
     "longName": "999020 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://tevogen.com/role/RelatedPartyTransactions",
     "longName": "999021 - Disclosure - RELATED PARTY TRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://tevogen.com/role/SegmentReporting",
     "longName": "999022 - Disclosure - SEGMENT REPORTING",
     "shortName": "SEGMENT REPORTING",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://tevogen.com/role/SubsequentEvents",
     "longName": "999023 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "999024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "999025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://tevogen.com/role/BusinessCombinationTables",
     "longName": "999026 - Disclosure - BUSINESS COMBINATION (Tables)",
     "shortName": "BUSINESS COMBINATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://tevogen.com/role/PropertyAndEquipmentNetTables",
     "longName": "999027 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)",
     "shortName": "PROPERTY AND EQUIPMENT, NET (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://tevogen.com/role/AccruedExpensesAndOtherLiabilitiesTables",
     "longName": "999028 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)",
     "shortName": "ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://tevogen.com/role/LeasesTables",
     "longName": "999029 - Disclosure - LEASES (Tables)",
     "shortName": "LEASES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "TVGN:ScheduleOfCompanyLeaseLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "TVGN:ScheduleOfCompanyLeaseLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://tevogen.com/role/Stock-basedCompensationTables",
     "longName": "999030 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://tevogen.com/role/StockholdersDeficitTables",
     "longName": "999031 - Disclosure - STOCKHOLDERS\u2019 DEFICIT (Tables)",
     "shortName": "STOCKHOLDERS\u2019 DEFICIT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://tevogen.com/role/NetLossPerShareTables",
     "longName": "999032 - Disclosure - NET LOSS PER SHARE (Tables)",
     "shortName": "NET LOSS PER SHARE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://tevogen.com/role/IncomeTaxesTables",
     "longName": "999033 - Disclosure - INCOME TAXES (Tables)",
     "shortName": "INCOME TAXES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://tevogen.com/role/NatureOfBusinessDetailsNarrative",
     "longName": "999034 - Disclosure - NATURE OF BUSINESS (Details Narrative)",
     "shortName": "NATURE OF BUSINESS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_custom_TevogenBioMember",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_custom_SemperParatusMember",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative",
     "longName": "999035 - Disclosure - DEVELOPMENT-STAGE RISKS AND LIQUIDITY (Details Narrative)",
     "shortName": "DEVELOPMENT-STAGE RISKS AND LIQUIDITY (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:Cash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-06-012024-06-30_custom_LoanAgreementMember",
      "name": "us-gaap:ProceedsFromRelatedPartyDebt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "TVGN:DevelopmentStageRisksAndLiquidityTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails",
     "longName": "999036 - Disclosure - SCHEDULE OF FAIR VALUE MEASUREMENT (Details)",
     "shortName": "SCHEDULE OF FAIR VALUE MEASUREMENT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails",
     "longName": "999037 - Disclosure - SCHEDULE OF FAIR VALUES OF WARRANTS (Details)",
     "shortName": "SCHEDULE OF FAIR VALUES OF WARRANTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:FairValueAdjustmentOfWarrants",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-02-152024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_CallOptionMember",
      "name": "TVGN:DerivativeLiabilitiesFairValueIssuance",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
     "longName": "999038 - Disclosure - SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS (Details)",
     "shortName": "SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DerivativeLiabilitiesNoncurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember",
      "name": "us-gaap:DerivativeLiabilitiesNoncurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails",
     "longName": "999039 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE (Details)",
     "shortName": "SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_ComputerEquipmentMember",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "TVGN:PropertyAndEquipmentUsefulLifeTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_ComputerEquipmentMember",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "TVGN:PropertyAndEquipmentUsefulLifeTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "999040 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails",
     "longName": "999041 - Disclosure - SCHEDULE OF NET LIABILITIES ACQUIRED IN MERGER (Details)",
     "shortName": "SCHEDULE OF NET LIABILITIES ACQUIRED IN MERGER (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "AsOf2024-02-14",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-02-14",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://tevogen.com/role/BusinessCombinationDetailsNarrative",
     "longName": "999042 - Disclosure - BUSINESS COMBINATION (Details Narrative)",
     "shortName": "BUSINESS COMBINATION (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "AsOf2024-02-14",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-02-142024-02-14",
      "name": "us-gaap:BusinessCombinationAcquisitionRelatedCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://tevogen.com/role/EarnoutSharesDetailsNarrative",
     "longName": "999043 - Disclosure - EARNOUT SHARES (Details Narrative)",
     "shortName": "EARNOUT SHARES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "AsOf2024-02-14_custom_EarnoutSharesMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember_us-gaap_CommonStockMember",
      "name": "us-gaap:SharesIssuedPricePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "TVGN:EarnoutSharesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentDetails",
     "longName": "999044 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)",
     "shortName": "SCHEDULE OF PROPERTY AND EQUIPMENT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://tevogen.com/role/PropertyAndEquipmentNetDetailsNarrative",
     "longName": "999045 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative)",
     "shortName": "PROPERTY AND EQUIPMENT, NET (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R46": {
     "role": "http://tevogen.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails",
     "longName": "999046 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES (Details)",
     "shortName": "SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://tevogen.com/role/DebtDetailsNarrative",
     "longName": "999047 - Disclosure - DEBT (Details Narrative)",
     "shortName": "DEBT (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:SharePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DerivativeLiabilitiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://tevogen.com/role/ScheduleOfMinimumRentalPaymentsUnderOperatingLeasesDetails",
     "longName": "999048 - Disclosure - SCHEDULE OF MINIMUM RENTAL PAYMENTS UNDER THE OPERATING LEASES (Details)",
     "shortName": "SCHEDULE OF MINIMUM RENTAL PAYMENTS UNDER THE OPERATING LEASES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "TVGN:ScheduleOfCompanyLeaseLiabilitiesTableTextBlock",
       "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "TVGN:ScheduleOfCompanyLeaseLiabilitiesTableTextBlock",
       "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://tevogen.com/role/LeasesDetailsNarrative",
     "longName": "999049 - Disclosure - LEASES (Details Narrative)",
     "shortName": "LEASES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails",
     "longName": "999050 - Disclosure - SCHEDULE OF RESTRICTED STOCK AND RSU ACTIVITY (Details)",
     "shortName": "SCHEDULE OF RESTRICTED STOCK AND RSU ACTIVITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31_custom_ServiceBasedRestrictedStockMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_custom_ServiceBasedRestrictedStockMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://tevogen.com/role/ScheduleOfStock-basedCompensationExpenseDetails",
     "longName": "999051 - Disclosure - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details)",
     "shortName": "SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative",
     "longName": "999052 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)",
     "shortName": "STOCK-BASED COMPENSATION (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://tevogen.com/role/ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails",
     "longName": "999053 - Disclosure - SCHEDULE OF RECONCILIATION OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING (Details)",
     "shortName": "SCHEDULE OF RECONCILIATION OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "TVGN:SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://tevogen.com/role/StockholdersDeficitDetailsNarrative",
     "longName": "999054 - Disclosure - STOCKHOLDERS\u2019 DEFICIT (Details Narrative)",
     "shortName": "STOCKHOLDERS\u2019 DEFICIT (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-11-30_custom_SemperParatusMember",
      "name": "TVGN:ClassOfWarrantOrRightIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://tevogen.com/role/ScheduleOfReconciliationOfNetLossDetails",
     "longName": "999055 - Disclosure - SCHEDULE OF RECONCILIATION OF NET LOSS (Details)",
     "shortName": "SCHEDULE OF RECONCILIATION OF NET LOSS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember",
      "name": "us-gaap:PreferredStockDividendsIncomeStatementImpact",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails",
     "longName": "999056 - Disclosure - SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details)",
     "shortName": "SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical",
     "longName": "999057 - Disclosure - SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details) (Parenthetical)",
     "shortName": "SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details) (Parenthetical)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember74469500",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember74469500",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://tevogen.com/role/NetLossPerShareDetailsNarrative",
     "longName": "999058 - Disclosure - NET LOSS PER SHARE (Details Narrative)",
     "shortName": "NET LOSS PER SHARE (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DerivativeLiabilities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R59": {
     "role": "http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails",
     "longName": "999059 - Disclosure - SCHEDULE OF RECONCILIATION OF INCOME TAX BENEFIT AT THE FEDERAL STATUTORY INCOME TAX RATE (Details)",
     "shortName": "SCHEDULE OF RECONCILIATION OF INCOME TAX BENEFIT AT THE FEDERAL STATUTORY INCOME TAX RATE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
     "longName": "999060 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)",
     "shortName": "SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://tevogen.com/role/ScheduleOfValuationAllowanceForNetDeferredTaxAssetsDetails",
     "longName": "999061 - Disclosure - SCHEDULE OF VALUATION ALLOWANCE FOR NET DEFERRED TAX ASSETS (Details)",
     "shortName": "SCHEDULE OF VALUATION ALLOWANCE FOR NET DEFERRED TAX ASSETS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "TVGN:IncreasesRecordedToIncomeTaxProvision",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "TVGN:ScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://tevogen.com/role/IncomeTaxesDetailsNarrative",
     "longName": "999062 - Disclosure - INCOME TAXES (Details Narrative)",
     "shortName": "INCOME TAXES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
     "longName": "999063 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)",
     "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SponsorFees",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SponsorFees",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://tevogen.com/role/SubsequentEventsDetailsNarrative",
     "longName": "999064 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)",
     "shortName": "SUBSEQUENT EVENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31_us-gaap_SubsequentEventMember",
      "name": "us-gaap:LineOfCredit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31_us-gaap_SubsequentEventMember",
      "name": "us-gaap:LineOfCredit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://tevogen.com/role/AccruedExpensesAndOtherLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ACCRUED EXPENSES AND OTHER LIABILITIES",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r61",
      "r66",
      "r754"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r655"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://tevogen.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets",
      "http://tevogen.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses and other liabilities",
        "totalLabel": "Total",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Professional services",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r128",
      "r481"
     ]
    },
    "TVGN_AdditionalAmountPurchaseOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "AdditionalAmountPurchaseOptionMember",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Amount Purchase Option [Member]",
        "documentation": "Additional Amount Purchase Option [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r655",
      "r798"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r507",
      "r703",
      "r704",
      "r705",
      "r706",
      "r764",
      "r799"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalMarkToMarket",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonrefundable prepaid proceeds towards anticipated Series A-1 preferred stock issuance",
        "documentation": "Amount of increase (decrease) to additional paid in capital (APIC) resulting from changes in fair value of common and preferred stock issued to employee benefit trust but unearned."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r96"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40",
      "r317"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r352"
     ]
    },
    "us-gaap_AlternativeInvestmentMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AlternativeInvestmentMeasurementInput",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discount rate",
        "documentation": "Value of input used to measure alternative investment."
       }
      }
     },
     "auth_ref": [
      "r649",
      "r767",
      "r768",
      "r769"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r187"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets [Default Label]",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r111",
      "r130",
      "r152",
      "r192",
      "r200",
      "r213",
      "r216",
      "r228",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r394",
      "r396",
      "r423",
      "r471",
      "r550",
      "r627",
      "r628",
      "r655",
      "r667",
      "r723",
      "r724",
      "r782"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r135",
      "r152",
      "r228",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r394",
      "r396",
      "r423",
      "r655",
      "r723",
      "r724",
      "r782"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://tevogen.com/role/BusinessCombinationDetailsNarrative",
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical",
      "http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails",
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/BusinessCombinationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction costs charged to equity",
        "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BusinessCombinationDetailsNarrative",
      "http://tevogen.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Merger transaction costs",
        "verboseLabel": "Merger transaction costs",
        "label": "Business Combination, Acquisition Related Costs",
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://tevogen.com/role/BusinessCombination"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "BUSINESS COMBINATION",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r390"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Prepaid expenses and other assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due from Sponsor",
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts payable",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accrued expenses",
        "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed current liabilities accrued expenses.",
        "label": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Notes payable",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-Term Debt",
        "documentation": "Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails": {
       "parentTag": "TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total net liabilities acquired",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46"
     ]
    },
    "TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total net liabilities acquired plus transaction costs",
        "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed net plus transaction costs.",
        "label": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Derivative warrant liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other",
        "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "TVGN_BusinessCombinationSharesExchangeRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "BusinessCombinationSharesExchangeRatio",
     "presentation": [
      "http://tevogen.com/role/NatureOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business combination shares",
        "documentation": "Business combination shares exchange ratio."
       }
      }
     },
     "auth_ref": []
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r681",
      "r682"
     ]
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://tevogen.com/role/NatureOfBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NATURE OF BUSINESS",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r85",
      "r86"
     ]
    },
    "us-gaap_CallOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CallOptionMember",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Call Option [Member]",
        "documentation": "Financial contract between two parties, the buyer and the seller of the option, where the buyer has the right but not the obligation to buy an agreed quantity of a particular commodity or financial instrument (the underlying instrument) from the seller of the option for a certain price (the strike price). Seller is obligated to sell the asset to the buyer, if the buyer exercises the option."
       }
      }
     },
     "auth_ref": [
      "r596",
      "r597"
     ]
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Cash",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets",
      "http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r474",
      "r518",
      "r544",
      "r655",
      "r667",
      "r693"
     ]
    },
    "TVGN_CashAcquiredInConnectionWithReverseRecapitalization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "CashAcquiredInConnectionWithReverseRecapitalization",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash acquired in connection with the reverse recapitalization",
        "documentation": "Cash acquired in connection with the reverse recapitalization."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r126",
      "r617"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash \u2013 beginning of period",
        "periodEndLabel": "Cash \u2013 end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r82",
      "r147"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r82"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplementary disclosure of noncash investing and financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_ChangeInFairValueOfConvertiblePromissoryNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "ChangeInFairValueOfConvertiblePromissoryNotes",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 5.0
      },
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows",
      "http://tevogen.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of convertible promissory notes",
        "negatedLabel": "Change in fair value of convertible promissory notes",
        "documentation": "Change in fair value of convertible promissory notes."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://tevogen.com/role/BalanceSheets",
      "http://tevogen.com/role/BalanceSheetsParenthetical",
      "http://tevogen.com/role/ScheduleOfReconciliationOfNetLossDetails",
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r131",
      "r132",
      "r133",
      "r152",
      "r176",
      "r177",
      "r184",
      "r186",
      "r194",
      "r195",
      "r228",
      "r249",
      "r251",
      "r252",
      "r253",
      "r256",
      "r257",
      "r287",
      "r288",
      "r292",
      "r295",
      "r302",
      "r423",
      "r498",
      "r499",
      "r500",
      "r501",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r519",
      "r536",
      "r559",
      "r581",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r688",
      "r699",
      "r708"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r132",
      "r133",
      "r194",
      "r287",
      "r288",
      "r290",
      "r292",
      "r295",
      "r300",
      "r302",
      "r498",
      "r499",
      "r500",
      "r501",
      "r639",
      "r688",
      "r699"
     ]
    },
    "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable date",
        "documentation": "Date the warrants or rights are exercisable, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "TVGN_ClassOfWarrantOrRightIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "ClassOfWarrantOrRightIssued",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of warrants issued",
        "documentation": "Class of warrant or right issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of warrants outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://tevogen.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r241",
      "r242",
      "r613",
      "r717",
      "r722"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative",
      "http://tevogen.com/role/NatureOfBusinessDetailsNarrative",
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r657",
      "r658",
      "r659",
      "r661",
      "r662",
      "r663",
      "r664",
      "r703",
      "r704",
      "r706",
      "r764",
      "r795",
      "r799"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://tevogen.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common shares, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://tevogen.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common shares, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r536"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://tevogen.com/role/BalanceSheetsParenthetical",
      "http://tevogen.com/role/ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common shares, shares issued",
        "verboseLabel": "Total shares of common stock legally issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "TVGN_CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total shares issued and outstanding",
        "documentation": "Common stock shares issued and outstanding inclusion of shares to be issued and exclusion of shares subject to forfeiture."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://tevogen.com/role/BalanceSheetsParenthetical",
      "http://tevogen.com/role/BusinessCombinationDetailsNarrative",
      "http://tevogen.com/role/ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common shares, shares outstanding",
        "verboseLabel": "Common stock, shares outstanding",
        "terseLabel": "Total shares of common stock legally outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r72",
      "r536",
      "r556",
      "r799",
      "r800"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, $0.0001 par value; 800,000,000 shares authorized; 177,991,365 and 119,999,989 shares issued and outstanding at December 31, 2024 and December 31, 2023",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r476",
      "r655"
     ]
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r99"
     ]
    },
    "TVGN_ComputerAndSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "ComputerAndSoftwareMember",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer And Software [Member]",
        "documentation": "Computer And Software [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentrations of Credit Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r115"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtSecuritiesMember",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt Securities [Member]",
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "us-gaap_ConvertibleLongTermNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleLongTermNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Convertible promissory notes",
        "label": "Convertible Notes Payable, Noncurrent",
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ConvertibleNotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleNotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible promissory notes",
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtConversionOriginalDebtAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionOriginalDebtAmount1",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of convertible promissory notes into common stock in connection with Merger",
        "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r16"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://tevogen.com/role/Debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DEBT",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r149",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r247",
      "r248",
      "r258",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r274",
      "r281",
      "r282",
      "r284",
      "r432"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt instrument variable rate",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r285",
      "r432",
      "r433",
      "r653"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt instrument interest rate",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r260"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r265",
      "r270",
      "r271",
      "r272",
      "r273",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r283",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r653",
      "r700",
      "r774",
      "r775"
     ]
    },
    "us-gaap_DebtInstrumentMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentMeasurementInput",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Volatility",
        "documentation": "Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt."
       }
      }
     },
     "auth_ref": [
      "r767",
      "r768",
      "r769"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r31",
      "r35",
      "r55",
      "r94",
      "r95",
      "r157",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r265",
      "r270",
      "r271",
      "r272",
      "r273",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r283",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r653",
      "r700",
      "r774",
      "r775"
     ]
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt maturity date",
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCosts",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred transaction costs",
        "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r694"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r69",
      "r105",
      "r371"
     ]
    },
    "TVGN_DeferredTaxAssetsAccruedExpensesAndOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "DeferredTaxAssetsAccruedExpensesAndOther",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses and other",
        "documentation": "Deferred tax assets accrued expenses and other."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized research and development expenditures",
        "documentation": "Deferred tax assets capitalized research and development expenditures."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_DeferredTaxAssetsFixedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "DeferredTaxAssetsFixedAssets",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fixed assets",
        "documentation": "Deferred tax assets fixed assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGrossAbstract",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development credits",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "TVGN_DeferredTaxAssetsOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liability",
        "documentation": "Deferred tax assets operating lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
      "http://tevogen.com/role/ScheduleOfValuationAllowanceForNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "periodStartLabel": "Valuation allowance",
        "periodEndLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_DeferredTaxLiabilitiesRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "DeferredTaxLiabilitiesRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Right of use asset",
        "documentation": "Deferred tax liabilities right of use asset.",
        "label": "DeferredTaxLiabilitiesRightOfUseAsset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Deposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Deposits",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non refundable deposist paid",
        "documentation": "The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows",
      "http://tevogen.com/role/PropertyAndEquipmentNetDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation expense",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r24"
     ]
    },
    "us-gaap_DerivativeFairValueOfDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeFairValueOfDerivativeNet",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value",
        "documentation": "Fair value of the assets less the liabilities of a derivative or group of derivatives."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "us-gaap_DerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/NetLossPerShareDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative liability",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r137",
      "r409",
      "r410",
      "r419",
      "r422",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r551",
      "r553",
      "r554",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r618",
      "r767",
      "r768",
      "r769",
      "r796"
     ]
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative liabilities",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "TVGN_DerivativeLiabilitiesFairValueIssuance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "DerivativeLiabilitiesFairValueIssuance",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Initial fair value at issuance",
        "documentation": "Derivative liabilities fair value issuance.",
        "label": "DerivativeLiabilitiesFairValueIssuance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets",
      "http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative warrant liabilities",
        "periodStartLabel": "Derivative warrant liabilities, Balance",
        "periodEndLabel": "Derivative warrant liabilities, Balance",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r47",
      "r48",
      "r49",
      "r50",
      "r156",
      "r171"
     ]
    },
    "TVGN_DevelopmentStageRisksAndLiquidityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "DevelopmentStageRisksAndLiquidityTextBlock",
     "presentation": [
      "http://tevogen.com/role/Development-stageRisksAndLiquidity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DEVELOPMENT-STAGE RISKS AND LIQUIDITY",
        "documentation": "Development Stage Risks And Liquidity [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_DisclosureDevelopmentstageRisksAndLiquidityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "DisclosureDevelopmentstageRisksAndLiquidityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Development-stage Risks And Liquidity"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_DisclosureEarnoutSharesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "DisclosureEarnoutSharesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnout Shares"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_DisclosureLeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "DisclosureLeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "verboseLabel": "Schedule Of Minimum Rental Payments Under Operating Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://tevogen.com/role/Stock-basedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCK-BASED COMPENSATION",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r319",
      "r348",
      "r349",
      "r351",
      "r644"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r679",
      "r681",
      "r682"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "TVGN_DrManmohanPatelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "DrManmohanPatelMember",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dr. Manmohan Patel [Member]",
        "documentation": "Dr Manmohan Patel [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://tevogen.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share attributable to common stockholders, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r173",
      "r176",
      "r184",
      "r185",
      "r186",
      "r191",
      "r388",
      "r392",
      "r406",
      "r407",
      "r469",
      "r485",
      "r619"
     ]
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasicLineItems",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfReconciliationOfNetLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r177",
      "r184"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://tevogen.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share attributable to common stockholders, diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r176",
      "r184",
      "r185",
      "r186",
      "r191",
      "r388",
      "r392",
      "r406",
      "r407",
      "r469",
      "r485",
      "r619"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r188"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://tevogen.com/role/NetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NET LOSS PER SHARE",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r187",
      "r189",
      "r190"
     ]
    },
    "TVGN_EarnoutSharesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "EarnoutSharesDisclosureTextBlock",
     "presentation": [
      "http://tevogen.com/role/EarnoutShares"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "EARNOUT SHARES",
        "documentation": "Earnout Shares [Disclosure Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_EarnoutSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "EarnoutSharesMember",
     "presentation": [
      "http://tevogen.com/role/BusinessCombinationDetailsNarrative",
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative",
      "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnout Shares [Member]",
        "documentation": "Earnout Shares [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income Tax Expense",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r646"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal benefit at statutory rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r359",
      "r379",
      "r646"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r364",
      "r646",
      "r702",
      "r755"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Permanent differences",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r362",
      "r646",
      "r702",
      "r755"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock based compensation",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r646",
      "r702",
      "r755",
      "r756"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State taxes, net of federal benefit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r361",
      "r646",
      "r702",
      "r755"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax credits",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r363",
      "r365",
      "r702",
      "r755"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsOther",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits."
       }
      }
     },
     "auth_ref": [
      "r646",
      "r702",
      "r755",
      "r756"
     ]
    },
    "TVGN_EmbeddedOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "EmbeddedOptions",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Embedded options shares",
        "documentation": "Embedded options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Amount Capitalized",
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized compensation cost",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average period for recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOwnershipPlanESOPCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation cost",
        "verboseLabel": "Compensation cost recognized",
        "documentation": "The amount of plan compensation cost recognized during the period."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r684"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative",
      "http://tevogen.com/role/NatureOfBusinessDetailsNarrative",
      "http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails",
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r122",
      "r141",
      "r142",
      "r143",
      "r158",
      "r159",
      "r160",
      "r162",
      "r167",
      "r169",
      "r171",
      "r193",
      "r229",
      "r230",
      "r231",
      "r305",
      "r377",
      "r378",
      "r385",
      "r386",
      "r387",
      "r389",
      "r391",
      "r392",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r405",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r434",
      "r435",
      "r450",
      "r484",
      "r490",
      "r491",
      "r492",
      "r507",
      "r581"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://tevogen.com/role/BusinessCombinationDetailsNarrative",
      "http://tevogen.com/role/NatureOfBusinessDetailsNarrative"
     ],
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r384",
      "r689",
      "r690",
      "r691",
      "r760",
      "r761",
      "r762",
      "r763"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://tevogen.com/role/BusinessCombinationDetailsNarrative",
      "http://tevogen.com/role/NatureOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity ownership percentage",
        "verboseLabel": "Ownership percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNiMeasurementInput",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, measurement input",
        "documentation": "Value of input used to measure investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r412",
      "r413"
     ]
    },
    "TVGN_EquitySecuritiesTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "EquitySecuritiesTerm",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range in years",
        "documentation": "Equity securities term."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      },
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows",
      "http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails",
      "http://tevogen.com/role/StatementsOfOperations",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of warrants",
        "label": "Change in fair value of warrants",
        "verboseLabel": "Change in fair value",
        "negatedTerseLabel": "Fair value adjustment of warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r4"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails",
      "http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r408",
      "r410",
      "r411",
      "r412",
      "r413",
      "r418",
      "r419",
      "r421",
      "r462",
      "r463",
      "r464",
      "r635",
      "r636",
      "r640",
      "r641",
      "r642",
      "r647",
      "r649"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r410",
      "r411",
      "r413",
      "r647",
      "r768",
      "r772"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r307",
      "r312",
      "r410",
      "r419",
      "r462",
      "r640",
      "r641",
      "r642",
      "r647"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r307",
      "r312",
      "r410",
      "r411",
      "r419",
      "r463",
      "r635",
      "r636",
      "r640",
      "r641",
      "r642",
      "r647"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails",
      "http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r410",
      "r411",
      "r412",
      "r413",
      "r419",
      "r464",
      "r635",
      "r636",
      "r640",
      "r641",
      "r642",
      "r647",
      "r649"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF FAIR VALUES OF WARRANTS",
        "documentation": "Tabular disclosure of liabilities measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r410"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF FAIR VALUE MEASUREMENT",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r417",
      "r420"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r410",
      "r411",
      "r413",
      "r647",
      "r768",
      "r772"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued interest expense",
        "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis liability accrued interest."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derecognition upon conversion of convertible promissory notes",
        "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis liability derecognition upon conversion of note payable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial fair value at issuance",
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r420"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value",
        "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r770",
      "r771"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Fair value beginning balance",
        "periodEndLabel": "Fair value beginning balance",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r420"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails",
      "http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r408",
      "r410",
      "r411",
      "r412",
      "r413",
      "r418",
      "r419",
      "r421",
      "r462",
      "r463",
      "r464",
      "r635",
      "r636",
      "r640",
      "r641",
      "r642",
      "r647",
      "r649"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r647",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r772"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of right-of-use asset",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r442",
      "r654"
     ]
    },
    "TVGN_FreeStandingPurchaseOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "FreeStandingPurchaseOptions",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Free standing purchase options",
        "documentation": "Free standing purchase options."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_FreestandingAndEmbeddedCommonStockOptionsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "FreestandingAndEmbeddedCommonStockOptionsPolicyTextBlock",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Freestanding and Embedded Common Stock Purchase Options",
        "documentation": "Freestanding And Embedded Common Stock Options [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r561"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://tevogen.com/role/LeasesDetailsNarrative",
      "http://tevogen.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "TVGN_GrantDrewFromRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "GrantDrewFromRelatedParty",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant drew from related party",
        "documentation": "Grant drew from related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IPOMember",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://tevogen.com/role/LeasesDetailsNarrative",
      "http://tevogen.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r239",
      "r240",
      "r415",
      "r417",
      "r420",
      "r487",
      "r489",
      "r566",
      "r616",
      "r648",
      "r794"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://tevogen.com/role/LeasesDetailsNarrative",
      "http://tevogen.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r240",
      "r415",
      "r417",
      "r420",
      "r487",
      "r489",
      "r566",
      "r616",
      "r648",
      "r794"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://tevogen.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r356",
      "r359",
      "r366",
      "r367",
      "r368",
      "r369",
      "r375",
      "r380",
      "r381",
      "r382",
      "r383",
      "r503",
      "r646"
     ]
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax penalties and interest accrued",
        "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations."
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r357",
      "r358",
      "r369",
      "r370",
      "r374",
      "r376",
      "r497"
     ]
    },
    "TVGN_IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest": {
     "xbrltype": "percentItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible note interest",
        "documentation": "Income tax reconciliation income tax expense benefit convertible noteinterest."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses and other liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r692",
      "r698"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other assets",
        "label": "Increase (Decrease) in Other Operating Assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "TVGN_IncreasesRecordedToIncomeTaxProvision": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "IncreasesRecordedToIncomeTaxProvision",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfValuationAllowanceForNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increases recorded to income tax provision",
        "documentation": "Increases recorded to income tax provision."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense, net",
        "label": "Interest Expense, Operating and Nonoperating",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r200",
      "r201",
      "r202",
      "r216",
      "r431",
      "r627",
      "r628"
     ]
    },
    "us-gaap_InvestorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestorMember",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investor [Member]",
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value."
       }
      }
     },
     "auth_ref": [
      "r778",
      "r779"
     ]
    },
    "TVGN_KRHPLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "KRHPLLCMember",
     "presentation": [
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "KRHP LLC [Member]",
        "documentation": "KRHP LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r447"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfMinimumRentalPaymentsUnderOperatingLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfMinimumRentalPaymentsUnderOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfMinimumRentalPaymentsUnderOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfMinimumRentalPaymentsUnderOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfMinimumRentalPaymentsUnderOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfMinimumRentalPaymentsUnderOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfMinimumRentalPaymentsUnderOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases initial term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r777"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r60",
      "r61",
      "r62",
      "r65",
      "r66",
      "r67",
      "r70",
      "r152",
      "r228",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r395",
      "r396",
      "r397",
      "r423",
      "r535",
      "r620",
      "r667",
      "r723",
      "r782",
      "r783"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 deficit",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r108",
      "r478",
      "r655",
      "r701",
      "r716",
      "r773"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and stockholders\u2019 deficit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAssumed1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAssumed1",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities assumed",
        "documentation": "The fair value of liabilities assumed in noncash investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15",
      "r16"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r125",
      "r152",
      "r228",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r395",
      "r396",
      "r397",
      "r423",
      "r655",
      "r723",
      "r782",
      "r783"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of credit Facility additional",
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r107",
      "r791"
     ]
    },
    "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityCurrentBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of credit borrowing capacity",
        "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r64"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of credit maximum borrowing capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r64"
     ]
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of credit remaining capacity",
        "verboseLabel": "Line of credit remaining borrowing capacity",
        "terseLabel": "Line of credit Facility remaining capacity",
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r64",
      "r248"
     ]
    },
    "TVGN_LoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "LoanAgreementMember",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Agreement [Member]",
        "documentation": "Loan Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_LoanAgreementNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "LoanAgreementNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan agreement",
        "documentation": "Loan agreement non current."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r718",
      "r719",
      "r720"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r26",
      "r718",
      "r719",
      "r720"
     ]
    },
    "TVGN_LossOnIssuanceOfCommitmentShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "LossOnIssuanceOfCommitmentShares",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 6.0
      },
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows",
      "http://tevogen.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on issuance of commitment shares",
        "label": "Loss on issuance of commitment shares",
        "documentation": "Loss on issuance of commitment shares."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_LossOnPreferredStockIssuance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "LossOnPreferredStockIssuance",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on Series A Preferred Stock issuance",
        "verboseLabel": "Loss on preferred stock issuance",
        "documentation": "Loss on preferred stock issuance."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/LeasesDetailsNarrative",
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r243",
      "r244",
      "r245",
      "r246",
      "r314",
      "r353",
      "r413",
      "r467",
      "r486",
      "r488",
      "r495",
      "r527",
      "r528",
      "r589",
      "r591",
      "r594",
      "r595",
      "r605",
      "r614",
      "r615",
      "r633",
      "r639",
      "r643",
      "r649",
      "r650",
      "r651",
      "r652",
      "r656",
      "r725",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789"
     ]
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputDiscountRateMember",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Discount Rate [Member]",
        "documentation": "Measurement input using interest rate to determine present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r767",
      "r768",
      "r769"
     ]
    },
    "us-gaap_MeasurementInputOptionVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputOptionVolatilityMember",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Option Volatility [Member]",
        "documentation": "Measurement input using rate at which price of option increases (decreases) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r767",
      "r768",
      "r769"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r649",
      "r767",
      "r768",
      "r769"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r767",
      "r768",
      "r769"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r412",
      "r413",
      "r649"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r412",
      "r413",
      "r649"
     ]
    },
    "TVGN_MehtaphoricConsultingIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "MehtaphoricConsultingIncMember",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mehtaphoric Consulting Inc [Member]",
        "documentation": "Mehtaphoric Consulting Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_MergerNetOfRedemptionsAndTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "MergerNetOfRedemptionsAndTransactionCosts",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Merger, net of redemptions and transaction costs",
        "documentation": "Merger net of redemptions and transaction costs.",
        "label": "MergerNetOfRedemptionsAndTransactionCosts"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_MergerTransactionCostsLimitedToCashAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "MergerTransactionCostsLimitedToCashAcquired",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails": {
       "parentTag": "TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plus: Merger transaction costs limited to cash acquired",
        "documentation": "Merger transaction costs limited to cash acquired."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://tevogen.com/role/LeasesDetailsNarrative",
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r243",
      "r244",
      "r245",
      "r246",
      "r314",
      "r353",
      "r413",
      "r467",
      "r486",
      "r488",
      "r495",
      "r527",
      "r528",
      "r589",
      "r591",
      "r594",
      "r595",
      "r605",
      "r614",
      "r615",
      "r633",
      "r639",
      "r643",
      "r649",
      "r650",
      "r651",
      "r656",
      "r725",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r83",
      "r84"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://tevogen.com/role/ScheduleOfReconciliationOfNetLossDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 1.0
      },
      "http://tevogen.com/role/StatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows",
      "http://tevogen.com/role/ScheduleOfReconciliationOfNetLossDetails",
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://tevogen.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "label": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r84",
      "r109",
      "r123",
      "r138",
      "r139",
      "r143",
      "r152",
      "r161",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r170",
      "r171",
      "r182",
      "r228",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r388",
      "r392",
      "r407",
      "r423",
      "r483",
      "r558",
      "r579",
      "r580",
      "r665",
      "r723"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfReconciliationOfNetLossDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfReconciliationOfNetLossDetails",
      "http://tevogen.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss attributable to common stockholders, basic",
        "totalLabel": "Net loss attributable to common stockholders",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r163",
      "r164",
      "r165",
      "r166",
      "r173",
      "r174",
      "r183",
      "r186",
      "r392"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss attributable to common stockholders, diluted",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r175",
      "r178",
      "r179",
      "r180",
      "r181",
      "r183",
      "r186"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recently Issued Accounting Standards",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashMergerRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashMergerRelatedCosts",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Merger transaction costs",
        "documentation": "Amount of expense (income) related to the increase (decrease) in reserve for business combination costs. Includes, but is not limited to, legal, accounting, and other costs incurred to consummate the merger."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonrefundable prepaid proceeds towards anticipated Series A-1 Preferred Stock Issuance",
        "documentation": "Nonrefundable prepaid proceeds towards anticipated Series A-1 Preferred Stock Issuance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets",
      "http://tevogen.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes payable",
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r61"
     ]
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of operating segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r628",
      "r710"
     ]
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://tevogen.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r621",
      "r709",
      "r711",
      "r712",
      "r713",
      "r714"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfMinimumRentalPaymentsUnderOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating lease liability",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r439",
      "r443"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use assets - operating leases",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://tevogen.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating leases weighted average discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r654"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://tevogen.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating leases weighted average remaining lease term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r654"
     ]
    },
    "TVGN_OperatingLeasesIncrementalBorrowingRates": {
     "xbrltype": "percentItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "OperatingLeasesIncrementalBorrowingRates",
     "presentation": [
      "http://tevogen.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating leases incremental borrowing rates",
        "documentation": "Operating leases incremental borrowing rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeasesOfLessorDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasesOfLessorDisclosureTextBlock",
     "presentation": [
      "http://tevogen.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LEASES",
        "documentation": "The entire disclosure for lessor's operating leases."
       }
      }
     },
     "auth_ref": [
      "r449"
     ]
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OptionIndexedToIssuersEquityTypeAxis",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Indexed to Issuer's Equity, Type [Axis]",
        "documentation": "Information by type of freestanding contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r51",
      "r52",
      "r101"
     ]
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OptionIndexedToIssuersEquityTypeDomain",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "us-gaap_OtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sponsor fee payable offset",
        "documentation": "Amount of liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r472",
      "r531",
      "r532",
      "r667",
      "r792",
      "r797"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due to related party",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r655"
     ]
    },
    "us-gaap_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Due from related party",
        "label": "Other Receivables",
        "documentation": "Amount due from parties in nontrade transactions, classified as other."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r545",
      "r628",
      "r793"
     ]
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets",
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due from related party",
        "verboseLabel": "Grant",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "us-gaap_PaidInKindInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaidInKindInterest",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash interest expense",
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentOfFinancingAndStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments of deferred transaction costs",
        "label": "Payment of Financing and Stock Issuance Costs",
        "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "TVGN_PerformanceBasedRSUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "PerformanceBasedRSUsMember",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails",
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance-Based RSUs [Member]",
        "documentation": "Performance-Based RSUs [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753"
     ]
    },
    "srt_PlatformOperatorCryptoAssetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "PlatformOperatorCryptoAssetLineItems",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails",
      "http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Platform Operator, Crypto Asset [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "srt_PlatformOperatorCryptoAssetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "PlatformOperatorCryptoAssetTable",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails",
      "http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Platform Operator, Crypto Asset [Table]"
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "TVGN_PolarMultiStrategyMasterFundMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "PolarMultiStrategyMasterFundMember",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Polar Multi-Strategy Master Fund [Member]",
        "documentation": "Polar Multi-Strategy Master Fund [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "us-gaap_PreferredStockConvertibleConversionPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockConvertibleConversionPrice",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Floor price",
        "documentation": "Per share conversion price of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r289"
     ]
    },
    "us-gaap_PreferredStockDividendPaymentRateVariable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockDividendPaymentRateVariable",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend variable rate, description",
        "documentation": "Description of basis of dividend, such as adjustable rate. Excludes percentage rate dividend payments or fixed dollar amounts per share."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r31",
      "r71"
     ]
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockDividendRatePercentage",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend rate, percentage",
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r590",
      "r592",
      "r593",
      "r606"
     ]
    },
    "us-gaap_PreferredStockDividendsIncomeStatementImpact": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockDividendsIncomeStatementImpact",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfReconciliationOfNetLossDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfReconciliationOfNetLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cumulative preferred stock dividend",
        "label": "Preferred Stock Dividends, Income Statement Impact",
        "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockLiquidationPreferenceValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockLiquidationPreferenceValue",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, liquidation preference, value",
        "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r292",
      "r304"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r657",
      "r658",
      "r661",
      "r662",
      "r663",
      "r664",
      "r795",
      "r799"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://tevogen.com/role/BalanceSheetsParenthetical",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "verboseLabel": "Preferred shares, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r287"
     ]
    },
    "us-gaap_PreferredStockRedemptionPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockRedemptionPricePerShare",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redemption price per share",
        "documentation": "The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r34"
     ]
    },
    "us-gaap_PreferredStockRedemptionTerms": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockRedemptionTerms",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redemption term",
        "documentation": "The redemption terms of preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity. The redemption features of this capital stock are solely within the control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://tevogen.com/role/BalanceSheetsParenthetical",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r536"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://tevogen.com/role/BalanceSheetsParenthetical",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r287"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://tevogen.com/role/BalanceSheetsParenthetical",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "verboseLabel": "Preferred stock shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r536",
      "r556",
      "r799",
      "r800"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, value",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r475",
      "r655"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_ProbabilityOfFutureLiquidityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "ProbabilityOfFutureLiquidityMember",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Probability of Future Liquidity [Member]",
        "documentation": "Probability of Future Liquidity [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of convertible promissory notes",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of Series A Preferred Stock",
        "verboseLabel": "Cash received upon issuance of preferred stock",
        "terseLabel": "Gross proceeds",
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "TVGN_ProceedsFromIssuanceOfSeriesCPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "ProceedsFromIssuanceOfSeriesCPreferredStock",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of Series C Preferred Stock",
        "documentation": "Proceeds from issuance of series c preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromLinesOfCredit",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from loan agreement",
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r700"
     ]
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromRelatedPartyDebt",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant received",
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "TVGN_PropertyAndEquipmentUsefulLifeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "PropertyAndEquipmentUsefulLifeTableTextBlock",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE",
        "documentation": "Property And Equipment Useful Life [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r447"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://tevogen.com/role/PropertyAndEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PROPERTY AND EQUIPMENT, NET",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r116",
      "r119",
      "r120"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r127",
      "r482"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets",
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r447",
      "r470",
      "r482",
      "r655"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, Net",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r116",
      "r119",
      "r480"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://tevogen.com/role/PropertyAndEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF PROPERTY AND EQUIPMENT",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r447"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, plant and equipment, useful life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_PublicWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "PublicWarrantsMember",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Warrants [Member]",
        "documentation": "Public Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/LeasesDetailsNarrative",
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r243",
      "r244",
      "r245",
      "r246",
      "r306",
      "r314",
      "r342",
      "r343",
      "r344",
      "r353",
      "r413",
      "r465",
      "r466",
      "r467",
      "r486",
      "r488",
      "r495",
      "r527",
      "r528",
      "r589",
      "r591",
      "r594",
      "r595",
      "r605",
      "r614",
      "r615",
      "r633",
      "r639",
      "r643",
      "r649",
      "r650",
      "r651",
      "r652",
      "r656",
      "r659",
      "r721",
      "r725",
      "r768",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/LeasesDetailsNarrative",
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "auth_ref": [
      "r243",
      "r244",
      "r245",
      "r246",
      "r306",
      "r314",
      "r342",
      "r343",
      "r344",
      "r353",
      "r413",
      "r465",
      "r466",
      "r467",
      "r486",
      "r488",
      "r495",
      "r527",
      "r528",
      "r589",
      "r591",
      "r594",
      "r595",
      "r605",
      "r614",
      "r615",
      "r633",
      "r639",
      "r643",
      "r649",
      "r650",
      "r651",
      "r652",
      "r656",
      "r659",
      "r721",
      "r725",
      "r768",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://tevogen.com/role/BalanceSheets",
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative",
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r313",
      "r454",
      "r455",
      "r473",
      "r479",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r555",
      "r557",
      "r588"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r454",
      "r455",
      "r456",
      "r457",
      "r473",
      "r479",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r555",
      "r557",
      "r588"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r562",
      "r563",
      "r566"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://tevogen.com/role/BalanceSheets",
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative",
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r313",
      "r454",
      "r455",
      "r473",
      "r479",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r555",
      "r557",
      "r588",
      "r781"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTIONS",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r451",
      "r452",
      "r453",
      "r455",
      "r458",
      "r504",
      "r505",
      "r506",
      "r564",
      "r565",
      "r566",
      "r585",
      "r587"
     ]
    },
    "TVGN_RepurchaseOfSeriesBPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "RepurchaseOfSeriesBPreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repurchase of Series B preferred stock",
        "documentation": "Repurchase of series B preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementMember",
     "presentation": [
      "http://tevogen.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement [Member]",
        "documentation": "Contractual obligation to provide funding of research and development costs over periods that initially exceed one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r616",
      "r627",
      "r790"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expenses",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r354"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails",
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails",
      "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r96",
      "r477",
      "r493",
      "r494",
      "r502",
      "r537",
      "r655"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r158",
      "r159",
      "r160",
      "r162",
      "r167",
      "r169",
      "r171",
      "r229",
      "r230",
      "r231",
      "r377",
      "r378",
      "r385",
      "r386",
      "r387",
      "r389",
      "r391",
      "r392",
      "r398",
      "r400",
      "r401",
      "r403",
      "r405",
      "r434",
      "r435",
      "r490",
      "r492",
      "r507",
      "r799"
     ]
    },
    "TVGN_ReverseRecapitalizationTransactionFeesIncludedInAccruedExpensesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "ReverseRecapitalizationTransactionFeesIncludedInAccruedExpensesAndOtherLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse recapitalization transaction fees included in accrued expenses and other liabilities",
        "documentation": "Reverse recapitalization transaction fees included in accrued expenses and other liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://tevogen.com/role/AccruedExpensesAndOtherLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://tevogen.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "presentation": [
      "http://tevogen.com/role/BusinessCombinationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF NET LIABILITIES ACQUIRED IN MERGER",
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "TVGN_ScheduleOfCompanyLeaseLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "ScheduleOfCompanyLeaseLiabilitiesTableTextBlock",
     "presentation": [
      "http://tevogen.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF MINIMUM RENTAL PAYMENTS UNDER THE OPERATING LEASES",
        "documentation": "Schedule Of Company Lease Liabilities [TableTextBlock]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://tevogen.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfReconciliationOfNetLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]",
        "documentation": "Disclosure of information about basic earnings per share by class of stock. Includes, but is not limited to, two-class method."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r20",
      "r176",
      "r177",
      "r184"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTextBlock",
     "presentation": [
      "http://tevogen.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF RECONCILIATION OF NET LOSS",
        "documentation": "Tabular disclosure of the effect of income (loss) on basic earnings per share."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r20",
      "r707"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://tevogen.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF RECONCILIATION OF INCOME TAX BENEFIT AT THE FEDERAL STATUTORY INCOME TAX RATE",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r646",
      "r755"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://tevogen.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://tevogen.com/role/BusinessCombinationDetailsNarrative",
      "http://tevogen.com/role/NatureOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r384",
      "r689",
      "r690",
      "r691",
      "r760",
      "r761",
      "r762",
      "r763"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r765",
      "r766"
     ]
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://tevogen.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF RESTRICTED STOCK AND RSU ACTIVITY",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r447"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54",
      "r562",
      "r563",
      "r566"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical",
      "http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails",
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r318",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r31",
      "r32",
      "r33",
      "r35",
      "r92",
      "r94",
      "r95",
      "r96",
      "r131",
      "r132",
      "r133",
      "r194",
      "r287",
      "r288",
      "r290",
      "r292",
      "r295",
      "r300",
      "r302",
      "r498",
      "r499",
      "r500",
      "r501",
      "r639",
      "r688",
      "r699"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityTableTextBlock",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF RECONCILIATION OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING",
        "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "TVGN_ScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "ScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock",
     "presentation": [
      "http://tevogen.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF VALUATION ALLOWANCE FOR NET DEFERRED TAX ASSETS",
        "documentation": "Schedule Of Valuation Allowance For Net Deferred Tax Assets [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://tevogen.com/role/SegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEGMENT REPORTING",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r192",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r203",
      "r204",
      "r205",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r223",
      "r622",
      "r625",
      "r626",
      "r627",
      "r629",
      "r631",
      "r632"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r219",
      "r222",
      "r623",
      "r624",
      "r630"
     ]
    },
    "TVGN_SemperParatusMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "SemperParatusMember",
     "presentation": [
      "http://tevogen.com/role/NatureOfBusinessDetailsNarrative",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Semper Paratus [Member]",
        "documentation": "Semper Paratus [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_SeriesAOnePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "SeriesAOnePreferredStockMember",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A1 Preferred Stock [Member]",
        "documentation": "Series A1 Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://tevogen.com/role/BalanceSheets",
      "http://tevogen.com/role/BalanceSheetsParenthetical",
      "http://tevogen.com/role/ScheduleOfReconciliationOfNetLossDetails",
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r695",
      "r696",
      "r726"
     ]
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesBPreferredStockMember",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfReconciliationOfNetLossDetails",
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Preferred Stock [Member]",
        "documentation": "Series B preferred stock."
       }
      }
     },
     "auth_ref": [
      "r695",
      "r696",
      "r726"
     ]
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesCPreferredStockMember",
     "presentation": [
      "http://tevogen.com/role/BalanceSheets",
      "http://tevogen.com/role/BalanceSheetsParenthetical",
      "http://tevogen.com/role/ScheduleOfReconciliationOfNetLossDetails",
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C Preferred Stock [Member]",
        "documentation": "Series C preferred stock."
       }
      }
     },
     "auth_ref": [
      "r695",
      "r696",
      "r726"
     ]
    },
    "TVGN_ServiceBasedRestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "ServiceBasedRestrictedStockMember",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails",
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Service-Based Restricted Stock [Member]",
        "documentation": "Service-Based Restricted Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows",
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense",
        "verboseLabel": "Compensation cost recognized",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonvested Shares, Forfeited",
        "negatedLabel": "Nonvested Shares, Forfeited",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonvested weighted average grant-date fair value, Forfeited",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonvested Shares, Granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonvested weighted average grant-date fair value, Granted",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://tevogen.com/role/BusinessCombinationDetailsNarrative",
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative",
      "http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnout shares issuable",
        "verboseLabel": "Earnout shares",
        "periodStartLabel": "Nonvested Shares, Beginning",
        "periodEndLabel": "Nonvested Shares, Beginning",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r332"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Nonvested weighted average grant-date fair value, Ending",
        "periodEndLabel": "Nonvested weighted average grant-date fair value, Ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r332"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical",
      "http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Nonvested Shares, Vested",
        "label": "Stock option vested",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r335"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonvested weighted average grant-date fair value, Vested",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r335"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical",
      "http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails",
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r318",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted shares",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares available for granted",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted, shares",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value per share for award",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r337"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested shares",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://tevogen.com/role/BusinessCombinationDetailsNarrative",
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical",
      "http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails",
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "presentation": [
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche Three [Member]",
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant date fair value of shares",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of price of common stock purchased",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued, price per share",
        "verboseLabel": "Purchase, price per share",
        "terseLabel": "Price per share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "periodEndLabel": "Balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of restricted common stock subject to forfeiture",
        "documentation": "Shares subject to future vesting issuance of restricted common stock subject to forfeiture."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short term lease",
        "documentation": "Amount of cash outflow for short-term lease payment excluded from lease liability."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r148"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "TVGN_SponsorAdvisoryServicesFeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "SponsorAdvisoryServicesFeeMember",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sponsor Advisory Services Fee [Member]",
        "documentation": "Sponsor Advisory Services Fee [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SponsorFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SponsorFees",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sponsor advisory service fee",
        "documentation": "Fees paid to advisors who provide certain management support and administrative oversight services including the organization and sale of stock, investment funds, limited partnerships and mutual funds."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "TVGN_SponsorFeesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "SponsorFeesPayable",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sponsor advisory services fee payable",
        "documentation": "Sponsor advisory services fee payable."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_SponsorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "SponsorMember",
     "presentation": [
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sponsor [Member]",
        "documentation": "Sponsor [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://tevogen.com/role/BalanceSheets",
      "http://tevogen.com/role/BalanceSheetsParenthetical",
      "http://tevogen.com/role/ScheduleOfReconciliationOfNetLossDetails",
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r131",
      "r132",
      "r133",
      "r152",
      "r176",
      "r177",
      "r184",
      "r186",
      "r194",
      "r195",
      "r228",
      "r249",
      "r251",
      "r252",
      "r253",
      "r256",
      "r257",
      "r287",
      "r288",
      "r292",
      "r295",
      "r302",
      "r423",
      "r498",
      "r499",
      "r500",
      "r501",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r519",
      "r536",
      "r559",
      "r581",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r688",
      "r699",
      "r708"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative",
      "http://tevogen.com/role/NatureOfBusinessDetailsNarrative",
      "http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails",
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r72",
      "r75",
      "r76",
      "r122",
      "r141",
      "r142",
      "r143",
      "r158",
      "r159",
      "r160",
      "r162",
      "r167",
      "r169",
      "r171",
      "r193",
      "r229",
      "r230",
      "r231",
      "r305",
      "r377",
      "r378",
      "r385",
      "r386",
      "r387",
      "r389",
      "r391",
      "r392",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r405",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r434",
      "r435",
      "r450",
      "r484",
      "r490",
      "r491",
      "r492",
      "r507",
      "r581"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://tevogen.com/role/BalanceSheets",
      "http://tevogen.com/role/BalanceSheetsParenthetical",
      "http://tevogen.com/role/BusinessCombinationDetailsNarrative",
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative",
      "http://tevogen.com/role/LeasesDetailsNarrative",
      "http://tevogen.com/role/NatureOfBusinessDetailsNarrative",
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r159",
      "r160",
      "r193",
      "r435",
      "r468",
      "r496",
      "r519",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r536",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r546",
      "r547",
      "r548",
      "r549",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r557",
      "r560",
      "r561",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r581",
      "r660"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://tevogen.com/role/BalanceSheets",
      "http://tevogen.com/role/BalanceSheetsParenthetical",
      "http://tevogen.com/role/BusinessCombinationDetailsNarrative",
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative",
      "http://tevogen.com/role/LeasesDetailsNarrative",
      "http://tevogen.com/role/NatureOfBusinessDetailsNarrative",
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r159",
      "r160",
      "r193",
      "r224",
      "r435",
      "r468",
      "r496",
      "r519",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r536",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r546",
      "r547",
      "r548",
      "r549",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r557",
      "r560",
      "r561",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r581",
      "r660"
     ]
    },
    "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockGrantedDuringPeriodValueSharebasedCompensationGross",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option to purchase common stock, value",
        "documentation": "Value, before forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssued1",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock for net liabilities upon reverse recapitalization, net of transaction costs",
        "documentation": "The fair value of stock issued in noncash financing activities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15",
      "r16"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Merger, net of redemptions and transaction costs, shares",
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r72",
      "r96"
     ]
    },
    "TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithLoanAgreement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithLoanAgreement",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of commitment shares in connection with the loan agreement, shares",
        "documentation": "Stock issued during period shares commitment shares in connection with loan agreement."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of credit facility shares",
        "documentation": "Stock issued during period shares commitment shares in connection with unsecured equity line of credit facility."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_StockIssuedDuringPeriodSharesContributionFromRelatedParty": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesContributionFromRelatedParty",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contribution from related party, shares",
        "documentation": "Stock issued during period shares contribution from related party"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of convertible promissory notes into common stock in connection with merger, shares",
        "verboseLabel": "Converted shares",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r31",
      "r72",
      "r75",
      "r96",
      "r275"
     ]
    },
    "TVGN_StockIssuedDuringPeriodSharesConversionOfLiabilities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesConversionOfLiabilities",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of certain liabilities into Series B preferred stock, shares",
        "documentation": "Stock issued during period shares conversion of liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock for Sponsor advisory service fee, shares",
        "verboseLabel": "Shares issued to related party",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of preferred stock, shares",
        "verboseLabel": "Issuance of shares",
        "terseLabel": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r71",
      "r72",
      "r96",
      "r498",
      "r581",
      "r608"
     ]
    },
    "TVGN_StockIssuedDuringPeriodSharesNewIssuesOne": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesNewIssuesOne",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Series B preferred stock, shares",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_StockIssuedDuringPeriodSharesNewIssuesTwo": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesNewIssuesTwo",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of preferred stock, shares",
        "documentation": "Stock issued during period shares new issues two.",
        "label": "StockIssuedDuringPeriodSharesNewIssuesTwo"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock in connection with Polar Note, shares",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of restricted common stock, shares",
        "verboseLabel": "Number of shares issued for RSUs",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r96"
     ]
    },
    "TVGN_StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock in settlement of vested restricted stock units, shares",
        "verboseLabel": "Number of shares issued and outstading RSU",
        "documentation": "Stock issued during period shares settlement of vested restricted stock units."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of commitment shares in connection with the loan agreement",
        "documentation": "Stock issued during period value commitment shares in connection with loan agreement."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_StockIssuedDuringPeriodValueContributionFromRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "StockIssuedDuringPeriodValueContributionFromRelatedParty",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contribution from related party",
        "documentation": "Stock issued during period value contribution from related party"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of convertible promissory notes into common stock in connection with merger",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r72",
      "r75",
      "r76",
      "r96"
     ]
    },
    "TVGN_StockIssuedDuringPeriodValueConversionOfLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "StockIssuedDuringPeriodValueConversionOfLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of certain liabilities into Series B preferred stock",
        "documentation": "Stock issued during period value conversion of liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock for Sponsor advisory service fee",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Series A preferred stock",
        "verboseLabel": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r71",
      "r72",
      "r96",
      "r507",
      "r581",
      "r608",
      "r666"
     ]
    },
    "TVGN_StockIssuedDuringPeriodValueNewIssuesOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "StockIssuedDuringPeriodValueNewIssuesOne",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/BusinessCombinationDetailsNarrative",
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Series B preferred stock",
        "verboseLabel": "New issuance value",
        "documentation": "Stock issued during period value new issues one."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_StockIssuedDuringPeriodValueNewIssuesTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "StockIssuedDuringPeriodValueNewIssuesTwo",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Series C preferred stock",
        "documentation": "Stock issued during period value new issues two."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock in connection with Polar note",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of restricted common stock",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r71",
      "r72",
      "r96"
     ]
    },
    "TVGN_StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock in settlement of vested restricted stock units",
        "documentation": "Stock issued during period value settlement of vested restricted stock units."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_StockRepurchase": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "StockRepurchase",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfReconciliationOfNetLossDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfReconciliationOfNetLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock repurchase",
        "documentation": "Stock repurchase."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets",
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 deficit",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r75",
      "r76",
      "r87",
      "r538",
      "r556",
      "r582",
      "r583",
      "r655",
      "r667",
      "r701",
      "r716",
      "r773",
      "r799"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 deficit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS\u2019 DEFICIT",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r151",
      "r286",
      "r288",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r301",
      "r305",
      "r404",
      "r584",
      "r586",
      "r612"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r460"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative",
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r460"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r460"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative",
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r460"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative",
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r460"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://tevogen.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r461"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_TaxableIncomeLimitationPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "TaxableIncomeLimitationPercentage",
     "presentation": [
      "http://tevogen.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Limitation percentage",
        "documentation": "Taxable income limitation percentage."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_TevogenBioCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "TevogenBioCommonStockMember",
     "presentation": [
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tevogen Bio Common Stock [Member]",
        "documentation": "Tevogen Bio Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_TevogenBioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "TevogenBioMember",
     "presentation": [
      "http://tevogen.com/role/BusinessCombinationDetailsNarrative",
      "http://tevogen.com/role/NatureOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tevogen Bio [Member]",
        "documentation": "Tevogen Bio [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_ThePatelFamilyLLPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "ThePatelFamilyLLPMember",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The Patel Family LLP [Member]",
        "documentation": "The Patel Family LLP [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r715",
      "r780"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_TwoThousandTwentyFourPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "TwoThousandTwentyFourPlanMember",
     "presentation": [
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2024 Plan [Member]",
        "documentation": "2024 Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_UnsecuredDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnsecuredDebtMember",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unsecured Debt [Member]",
        "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r23",
      "r113",
      "r114",
      "r117",
      "r118"
     ]
    },
    "TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails",
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares issuable",
        "verboseLabel": "Vested Performance-Based RSUs from satisfaction of liquidity condition upon the Closing",
        "documentation": "Vested performance based restricted stock units from satisfaction of liquidity condition upon closing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingAxis",
     "presentation": [
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingDomain",
     "presentation": [
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails",
      "http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r657",
      "r658",
      "r661",
      "r662",
      "r663",
      "r664"
     ]
    },
    "TVGN_WarrantsRedemptionDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "WarrantsRedemptionDescription",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants redemption description",
        "documentation": "Warrants redemption description."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://tevogen.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average common stock outstanding, diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r186"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://tevogen.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average common stock outstanding, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r186"
     ]
    },
    "TVGN_WifeOfChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "WifeOfChiefExecutiveOfficerMember",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Wife of Chief Executive Officer [Member]",
        "documentation": "Wife of Chief Executive Officer [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "63",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-63"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-11"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480489/718-40-50-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "25",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-23"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "37",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-37"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-4"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805/tableOfContent"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-3"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.FF.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476188/405-10-S99-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-30/tableOfContent"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
